0000937556-24-000042.txt : 20240507 0000937556-24-000042.hdr.sgml : 20240507 20240507171142 ACCESSION NUMBER: 0000937556-24-000042 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 120 CONFORMED PERIOD OF REPORT: 20240330 FILED AS OF DATE: 20240507 DATE AS OF CHANGE: 20240507 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MASIMO CORP CENTRAL INDEX KEY: 0000937556 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 330368882 STATE OF INCORPORATION: DE FISCAL YEAR END: 1228 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-33642 FILM NUMBER: 24923151 BUSINESS ADDRESS: STREET 1: 52 DISCOVERY CITY: IRVINE STATE: CA ZIP: 92618 BUSINESS PHONE: 949-297-7000 MAIL ADDRESS: STREET 1: 52 DISCOVERY CITY: IRVINE STATE: CA ZIP: 92618 10-Q 1 masi-20240330.htm 10-Q masi-20240330
false2024Q10000937556December 28http://fasb.org/us-gaap/2023#OperatingExpenseshttp://fasb.org/us-gaap/2023#OperatingExpenseshttp://fasb.org/us-gaap/2023#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2023#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2023#AccruedLiabilitiesAndOtherLiabilitieshttp://fasb.org/us-gaap/2023#AccruedLiabilitiesAndOtherLiabilitieshttp://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2023#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2023#OtherAssetsNoncurrentP3YP3Yxbrli:sharesiso4217:USDiso4217:USDxbrli:sharesmasi:reportingUnitmasi:segmentutr:sqftxbrli:pureiso4217:CADiso4217:JPYmasi:planmasi:executiveOfficermasi:distributormasi:customermasi:patentmasi:complaint00009375562023-12-312024-03-3000009375562024-03-3000009375562023-12-3000009375562023-04-010000937556us-gaap:CustomerRelationshipsMember2024-03-300000937556us-gaap:CustomerRelationshipsMember2023-12-300000937556masi:AcquiredTechnologyMember2024-03-300000937556masi:AcquiredTechnologyMember2023-12-300000937556masi:OtherMiscellaneousIntangibleAssetsMember2024-03-300000937556masi:OtherMiscellaneousIntangibleAssetsMember2023-12-3000009375562023-01-012023-04-010000937556us-gaap:CommonStockMember2023-12-300000937556us-gaap:TreasuryStockCommonMember2023-12-300000937556us-gaap:AdditionalPaidInCapitalMember2023-12-300000937556us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-300000937556us-gaap:RetainedEarningsMember2023-12-300000937556us-gaap:CommonStockMember2023-12-312024-03-300000937556us-gaap:AdditionalPaidInCapitalMember2023-12-312024-03-300000937556us-gaap:RetainedEarningsMember2023-12-312024-03-300000937556us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-312024-03-300000937556us-gaap:CommonStockMember2024-03-300000937556us-gaap:TreasuryStockCommonMember2024-03-300000937556us-gaap:AdditionalPaidInCapitalMember2024-03-300000937556us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-300000937556us-gaap:RetainedEarningsMember2024-03-300000937556us-gaap:CommonStockMember2022-12-310000937556us-gaap:TreasuryStockCommonMember2022-12-310000937556us-gaap:AdditionalPaidInCapitalMember2022-12-310000937556us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310000937556us-gaap:RetainedEarningsMember2022-12-3100009375562022-12-310000937556us-gaap:CommonStockMember2023-01-012023-04-010000937556us-gaap:AdditionalPaidInCapitalMember2023-01-012023-04-010000937556us-gaap:RetainedEarningsMember2023-01-012023-04-010000937556us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-04-010000937556us-gaap:CommonStockMember2023-04-010000937556us-gaap:TreasuryStockCommonMember2023-04-010000937556us-gaap:AdditionalPaidInCapitalMember2023-04-010000937556us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-04-010000937556us-gaap:RetainedEarningsMember2023-04-010000937556us-gaap:FairValueMeasurementsRecurringMember2024-03-300000937556us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-03-300000937556us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-03-300000937556us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2024-03-300000937556us-gaap:CashFlowHedgingMemberus-gaap:FairValueMeasurementsRecurringMember2024-03-300000937556us-gaap:CashFlowHedgingMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-03-300000937556us-gaap:CashFlowHedgingMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-03-300000937556us-gaap:FairValueInputsLevel3Memberus-gaap:CashFlowHedgingMemberus-gaap:FairValueMeasurementsRecurringMember2024-03-300000937556us-gaap:WarrantMemberus-gaap:FairValueMeasurementsRecurringMember2024-03-300000937556us-gaap:WarrantMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-03-300000937556us-gaap:WarrantMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-03-300000937556us-gaap:FairValueInputsLevel3Memberus-gaap:WarrantMemberus-gaap:FairValueMeasurementsRecurringMember2024-03-300000937556us-gaap:FairValueMeasurementsRecurringMember2023-12-300000937556us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-300000937556us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-300000937556us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-300000937556us-gaap:CashFlowHedgingMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-300000937556us-gaap:CashFlowHedgingMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-300000937556us-gaap:CashFlowHedgingMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-300000937556us-gaap:FairValueInputsLevel3Memberus-gaap:CashFlowHedgingMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-300000937556us-gaap:WarrantMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-300000937556us-gaap:WarrantMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-300000937556us-gaap:WarrantMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-300000937556us-gaap:FairValueInputsLevel3Memberus-gaap:WarrantMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-300000937556us-gaap:LandBuildingsAndImprovementsMembersrt:MinimumMember2024-03-300000937556us-gaap:LandBuildingsAndImprovementsMembersrt:MaximumMember2024-03-300000937556us-gaap:ComputerEquipmentMembersrt:MinimumMember2024-03-300000937556us-gaap:ComputerEquipmentMembersrt:MaximumMember2024-03-300000937556masi:DemonstrationUnitsMembersrt:MinimumMember2024-03-300000937556masi:DemonstrationUnitsMembersrt:MaximumMember2024-03-300000937556masi:FurnitureandOfficeEquipmentMembersrt:MinimumMember2024-03-300000937556srt:MaximumMembermasi:FurnitureandOfficeEquipmentMember2024-03-300000937556us-gaap:MachineryAndEquipmentMembersrt:MinimumMember2024-03-300000937556srt:MaximumMemberus-gaap:MachineryAndEquipmentMember2024-03-300000937556us-gaap:TransportationEquipmentMembersrt:MinimumMember2024-03-300000937556us-gaap:TransportationEquipmentMembersrt:MaximumMember2024-03-300000937556us-gaap:PatentsMember2023-12-312024-03-300000937556us-gaap:TrademarksMember2023-12-312024-03-300000937556srt:MinimumMember2024-03-300000937556srt:MaximumMember2024-03-300000937556srt:MinimumMember2023-12-312024-03-300000937556srt:MaximumMember2023-12-312024-03-300000937556us-gaap:RestrictedStockUnitsRSUMembersrt:ChiefExecutiveOfficerMember2023-01-012023-04-010000937556us-gaap:RestrictedStockUnitsRSUMembersrt:ChiefExecutiveOfficerMember2023-12-312024-03-300000937556us-gaap:RelatedPartyMembersrt:MinimumMember2023-12-312024-03-300000937556us-gaap:RelatedPartyMembermasi:WillowLaboratoriesMember2023-12-312024-03-300000937556us-gaap:RelatedPartyMembermasi:WillowLaboratoriesMember2023-01-012023-04-010000937556masi:WillowLaboratoriesMember2023-01-012023-04-010000937556masi:WillowLaboratoriesMember2023-12-312024-03-300000937556masi:LeasedPropertyMember2023-12-312024-03-300000937556us-gaap:RelatedPartyMembermasi:WillowLaboratoriesMember2024-03-300000937556us-gaap:RelatedPartyMembermasi:WillowLaboratoriesMember2023-12-300000937556masi:NotforProfitOrganizationMember2023-01-012023-04-010000937556masi:NotforProfitOrganizationMember2023-12-312024-03-300000937556masi:LikeMindedEntertainmentMember2023-12-312024-03-300000937556masi:LikeMindedEntertainmentMember2023-01-012023-04-010000937556masi:LikeMindedEntertainmentMemberus-gaap:RelatedPartyMember2024-03-300000937556masi:LikeMindedEntertainmentMemberus-gaap:RelatedPartyMember2023-12-300000937556masi:LikeMindedLabsMember2021-07-030000937556us-gaap:PurchaseCommitmentMembermasi:VantrixCorpMember2021-07-012021-07-310000937556us-gaap:OptionMembermasi:VantrixCorpMember2021-07-012021-07-310000937556masi:ReimbursementFeeMembersrt:ChiefExecutiveOfficerMember2023-12-312024-03-300000937556masi:ReimbursementFeeMembersrt:ChiefExecutiveOfficerMember2023-01-012023-04-010000937556us-gaap:MachineryAndEquipmentMember2024-03-300000937556us-gaap:MachineryAndEquipmentMember2023-12-300000937556us-gaap:BuildingAndBuildingImprovementsMember2024-03-300000937556us-gaap:BuildingAndBuildingImprovementsMember2023-12-300000937556masi:OperatingLeaseAssetsMember2024-03-300000937556masi:OperatingLeaseAssetsMember2023-12-300000937556us-gaap:LandMember2024-03-300000937556us-gaap:LandMember2023-12-300000937556us-gaap:ComputerEquipmentMember2024-03-300000937556us-gaap:ComputerEquipmentMember2023-12-300000937556us-gaap:LeaseholdImprovementsMember2024-03-300000937556us-gaap:LeaseholdImprovementsMember2023-12-300000937556masi:AircraftAndVehiclesMember2024-03-300000937556masi:AircraftAndVehiclesMember2023-12-300000937556us-gaap:FurnitureAndFixturesMember2024-03-300000937556us-gaap:FurnitureAndFixturesMember2023-12-300000937556masi:DemonstrationUnitsMember2024-03-300000937556masi:DemonstrationUnitsMember2023-12-300000937556us-gaap:ConstructionInProgressMember2024-03-300000937556us-gaap:ConstructionInProgressMember2023-12-3000009375562022-02-142022-02-140000937556us-gaap:LicensingAgreementsMember2024-03-300000937556us-gaap:LicensingAgreementsMember2023-12-300000937556us-gaap:SoftwareAndSoftwareDevelopmentCostsMember2024-03-300000937556us-gaap:SoftwareAndSoftwareDevelopmentCostsMember2023-12-300000937556us-gaap:PatentsMember2024-03-300000937556us-gaap:PatentsMember2023-12-300000937556us-gaap:TrademarksMember2024-03-300000937556us-gaap:TrademarksMember2023-12-300000937556us-gaap:NoncompeteAgreementsMember2024-03-300000937556us-gaap:NoncompeteAgreementsMember2023-12-300000937556masi:WillowLaboratoriesMemberus-gaap:LicensingAgreementsMember2024-03-300000937556masi:WillowLaboratoriesMemberus-gaap:LicensingAgreementsMember2023-12-300000937556us-gaap:OtherIntangibleAssetsMember2024-03-300000937556us-gaap:OtherIntangibleAssetsMember2023-12-300000937556us-gaap:TrademarksMember2024-03-300000937556us-gaap:TrademarksMember2023-12-3000009375562023-01-012023-12-300000937556us-gaap:TrademarksMember2023-12-312024-03-300000937556us-gaap:TrademarksMember2023-01-012023-12-300000937556masi:PatentsAndTrademarksMember2023-01-012023-04-010000937556masi:PatentsAndTrademarksMember2023-12-312024-03-300000937556us-gaap:TrademarksMember2023-07-022023-09-300000937556us-gaap:TrademarksMember2023-10-012023-12-300000937556masi:HealthCareSegmentMember2023-12-300000937556masi:NonHealthcareMember2023-12-300000937556masi:HealthCareSegmentMember2023-12-312024-03-300000937556masi:NonHealthcareMember2023-12-312024-03-300000937556masi:HealthCareSegmentMember2024-03-300000937556masi:NonHealthcareMember2024-03-300000937556us-gaap:CashFlowHedgingMember2024-03-300000937556us-gaap:CashFlowHedgingMember2023-12-3000009375562024-03-312024-03-300000937556masi:TwelveMonthsAndThereafterMember2024-03-312024-03-300000937556masi:BowersAndWilkinsMember2020-10-310000937556masi:BowersAndWilkinsMember2024-03-300000937556us-gaap:NonrelatedPartyMember2024-03-300000937556us-gaap:NonrelatedPartyMember2023-12-300000937556us-gaap:RelatedPartyMember2024-03-300000937556us-gaap:RelatedPartyMember2023-12-300000937556masi:TermLoanMember2024-03-300000937556masi:TermLoanMember2023-12-300000937556masi:JapaneseLoansMember2024-03-300000937556masi:JapaneseLoansMember2023-12-300000937556masi:RevolverMember2024-03-300000937556masi:RevolverMember2023-12-300000937556masi:NewCreditFacilityAgreementMemberus-gaap:UnsecuredDebtMember2022-04-110000937556masi:NewCreditFacilityAgreementMemberus-gaap:RevolvingCreditFacilityMember2022-04-110000937556masi:NewCreditFacilityAgreementMember2022-04-110000937556masi:InitialLendersMemberus-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMember2022-04-110000937556masi:NewCreditFacilityAgreementMemberus-gaap:LetterOfCreditMember2022-04-110000937556masi:NewCreditFacilityAgreementMembermasi:AlternateBaseRateMembersrt:MinimumMember2022-04-112022-04-110000937556masi:NewCreditFacilityAgreementMembersrt:MaximumMembermasi:AlternateBaseRateMember2022-04-112022-04-110000937556masi:AdjustedSecuredOvernightFinancingRateSOFRMembermasi:NewCreditFacilityAgreementMembersrt:MinimumMember2022-04-112022-04-110000937556masi:AdjustedSecuredOvernightFinancingRateSOFRMembermasi:NewCreditFacilityAgreementMembersrt:MaximumMember2022-04-112022-04-110000937556masi:NewCreditFacilityAgreementMemberus-gaap:FederalFundsEffectiveSwapRateMember2022-04-112022-04-110000937556masi:AdjustedSecuredOvernightFinancingRateSOFRMembermasi:NewCreditFacilityAgreementMember2022-04-112022-04-110000937556masi:NewCreditFacilityAgreementMembermasi:AdjustedSecuredOvernightFinancingRateSOFROneMonthInterestPeriodMember2022-04-112022-04-110000937556masi:NewCreditFacilityAgreementMembermasi:AdjustedSecuredOvernightFinancingRateSOFRThreeMonthInterestPeriodMember2022-04-112022-04-110000937556masi:NewCreditFacilityAgreementMembermasi:AdjustedSecuredOvernightFinancingRateSOFRSixMonthInterestPeriodMember2022-04-112022-04-110000937556masi:NewCreditFacilityAgreementMembersrt:MinimumMember2022-04-112022-04-110000937556masi:NewCreditFacilityAgreementMembersrt:MaximumMember2022-04-112022-04-110000937556masi:NewCreditFacilityAgreementMemberus-gaap:RevolvingCreditFacilityMember2022-05-160000937556us-gaap:RevolvingCreditFacilityMember2023-12-312024-03-300000937556us-gaap:RevolvingCreditFacilityMember2023-01-012023-04-010000937556us-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMembermasi:JapaneseRevolvingLoanMember2020-03-310000937556us-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMembermasi:JapaneseRevolvingLoanMember2020-03-012020-03-310000937556us-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMembermasi:JapaneseRevolvingLoanMember2023-02-280000937556us-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMembermasi:JapaneseRevolvingLoanMember2023-02-282023-02-280000937556masi:JapaneseGovernmentLoansMember2020-06-300000937556masi:JapaneseEquipmentLoansMember2021-04-300000937556masi:JapaneseEquipmentLoansMember2021-05-310000937556us-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-03-300000937556us-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-312024-03-300000937556us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMemberus-gaap:OtherNoncurrentAssetsMember2024-03-300000937556us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMemberus-gaap:OtherNoncurrentAssetsMember2023-12-300000937556us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMemberus-gaap:OtherNoncurrentLiabilitiesMember2024-03-300000937556us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMemberus-gaap:OtherNoncurrentLiabilitiesMember2023-12-300000937556us-gaap:DesignatedAsHedgingInstrumentMember2024-03-300000937556us-gaap:DesignatedAsHedgingInstrumentMember2023-12-300000937556us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2023-12-312024-03-300000937556us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMemberus-gaap:NonoperatingIncomeExpenseMember2023-01-012023-04-010000937556us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2023-12-300000937556us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2022-12-310000937556us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2023-01-012023-04-010000937556us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2024-03-300000937556us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2023-04-010000937556srt:ScenarioForecastMemberus-gaap:InterestExpenseMember2024-03-312025-03-300000937556masi:SoundUnitedMember2022-04-110000937556masi:SoundUnitedMember2022-04-112022-04-110000937556masi:SoundUnitedMember2023-01-012023-04-010000937556masi:SoundUnitedMember2023-12-312024-03-300000937556masi:SoundUnitedMember2023-04-010000937556masi:SoundUnitedMember2024-03-300000937556masi:SoundUnitedMemberus-gaap:TrademarksAndTradeNamesMember2022-04-112022-04-110000937556masi:SoundUnitedMemberus-gaap:TrademarksAndTradeNamesMember2022-04-110000937556masi:SoundUnitedMemberus-gaap:CustomerRelationshipsMember2022-04-112022-04-110000937556masi:SoundUnitedMemberus-gaap:CustomerRelationshipsMember2022-04-110000937556us-gaap:DevelopedTechnologyRightsMembermasi:SoundUnitedMember2022-04-112022-04-110000937556us-gaap:DevelopedTechnologyRightsMembermasi:SoundUnitedMember2022-04-110000937556masi:SoundUnitedMemberus-gaap:LicensingAgreementsMember2022-04-112022-04-110000937556masi:SoundUnitedMemberus-gaap:LicensingAgreementsMember2022-04-110000937556masi:RightsToPurchaseSeriesAJuniorParticipatingPreferredStockMember2022-09-200000937556masi:RightsToPurchaseSeriesAJuniorParticipatingPreferredStockMembersrt:MinimumMember2022-09-200000937556masi:RightsToPurchaseSeriesAJuniorParticipatingPreferredStockMembersrt:MaximumMember2022-09-200000937556us-gaap:CommonStockMembermasi:A2022RepurchaseProgramMember2022-06-300000937556us-gaap:CommonStockMembermasi:A2022RepurchaseProgramMember2024-03-300000937556masi:A2017EquityIncentivePlanMembersrt:MinimumMember2017-06-010000937556masi:A2017EquityIncentivePlanMember2020-05-012020-05-310000937556srt:MaximumMembermasi:A2017EquityIncentivePlanMember2020-05-310000937556masi:A2007StockIncentivePlanMembersrt:MaximumMember2020-05-310000937556us-gaap:EmployeeStockOptionMember2023-12-312024-03-300000937556us-gaap:EmployeeStockOptionMember2023-01-012023-04-010000937556us-gaap:EmployeeStockOptionMember2024-03-300000937556us-gaap:RestrictedStockUnitsRSUMember2023-12-300000937556us-gaap:RestrictedStockUnitsRSUMember2023-12-312024-03-300000937556us-gaap:RestrictedStockUnitsRSUMember2024-03-300000937556us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-04-010000937556us-gaap:PerformanceSharesMember2023-12-300000937556us-gaap:PerformanceSharesMember2023-12-312024-03-300000937556us-gaap:PerformanceSharesMember2024-03-300000937556us-gaap:PerformanceSharesMember2024-02-280000937556us-gaap:PerformanceSharesMember2024-02-282024-02-280000937556masi:A2021PSUGrantMemberus-gaap:PerformanceSharesMembersrt:MinimumMember2023-12-312024-03-300000937556masi:A2021PSUGrantMemberus-gaap:PerformanceSharesMembersrt:MinimumMember2024-03-300000937556masi:A2021PSUGrantMemberus-gaap:PerformanceSharesMembersrt:MaximumMember2024-03-300000937556us-gaap:PerformanceSharesMember2023-01-012023-04-010000937556masi:MasimoRetirementSavingsPlanMember2023-12-312024-03-300000937556masi:MasimoRetirementSavingsPlanMember2023-01-012023-04-010000937556masi:MasimoRetirementSavingsPlanMemberus-gaap:ForeignPlanMember2023-12-312024-03-300000937556masi:MasimoRetirementSavingsPlanMemberus-gaap:ForeignPlanMember2023-01-012023-04-010000937556srt:ChiefExecutiveOfficerMember2017-07-012017-07-310000937556us-gaap:CashDistributionMembersrt:ChiefExecutiveOfficerMember2017-07-012017-07-310000937556us-gaap:RestrictedStockUnitsRSUMembersrt:ChiefExecutiveOfficerMember2017-07-012017-07-310000937556srt:ChiefExecutiveOfficerMember2023-12-312024-03-3000009375562024-02-010000937556masi:GPOMembersMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2023-12-312024-03-300000937556masi:GPOMembersMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2023-01-012023-04-010000937556us-gaap:SalesRevenueNetMember2023-12-312024-03-300000937556us-gaap:SalesRevenueNetMember2023-01-012023-04-010000937556masi:JustintimedistributoroneMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2023-12-312024-03-300000937556masi:JustintimedistributoroneMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2023-01-012023-04-010000937556us-gaap:AccountsReceivableMember2023-12-300000937556us-gaap:AccountsReceivableMember2024-03-300000937556masi:CustomerOneMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2024-03-300000937556masi:CustomerOneMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2023-12-300000937556masi:MasimoVsAppleIncMemberus-gaap:PendingLitigationMember2020-10-132020-10-130000937556masi:MasimoVsAppleIncMember2023-01-302023-01-300000937556masi:MasimoVsAppleIncMember2023-02-012023-02-280000937556us-gaap:PendingLitigationMembermasi:AppleIncPatentInfringementMember2022-10-200000937556us-gaap:IntersegmentEliminationMember2023-12-312024-03-300000937556us-gaap:IntersegmentEliminationMember2023-01-012023-04-010000937556us-gaap:OperatingSegmentsMembermasi:HealthCareSegmentMember2023-12-312024-03-300000937556us-gaap:OperatingSegmentsMembermasi:HealthCareSegmentMember2023-01-012023-04-010000937556us-gaap:OperatingSegmentsMembermasi:NonHealthcareMember2023-12-312024-03-300000937556us-gaap:OperatingSegmentsMembermasi:NonHealthcareMember2023-01-012023-04-010000937556us-gaap:OperatingSegmentsMember2023-12-312024-03-300000937556us-gaap:OperatingSegmentsMember2023-01-012023-04-010000937556us-gaap:MaterialReconcilingItemsMember2023-12-312024-03-300000937556us-gaap:MaterialReconcilingItemsMember2023-01-012023-04-010000937556masi:HealthCareSegmentMember2023-01-012023-04-010000937556masi:NonHealthcareMember2023-01-012023-04-01
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
________________________________________________
FORM 10-Q
________________________________________________
(Mark One)
☒
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 30, 2024
OR
☐
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from _________ to _________
Commission File Number 001-33642
masimologoq32019.jpg
________________________________________________
MASIMO CORPORATION
(Exact Name of Registrant as Specified in its Charter)
________________________________________________
Delaware33-0368882
(State or Other Jurisdiction of
Incorporation or Organization)		(I.R.S. Employer
Identification Number)
52 DiscoveryIrvine,California92618
(Address of Principal Executive Offices)(Zip Code)
(949)297-7000
(Registrant’s Telephone Number, Including Area Code)
Securities Registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $0.001 par value
MASI
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.        Yes☒
No
☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).      
Yes
☒
No
☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer☒Accelerated filer☐
Non-accelerated filer☐Smaller reporting company☐
Emerging growth company☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act.)     
Yes☐
No
☒
Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date:
Class
Number of Shares Outstanding as of
March 30, 2024
Common stock, $0.001 par value
53,085,556

MASIMO CORPORATION
FORM 10-Q FOR THE QUARTER ENDED MARCH 30, 2024
TABLE OF CONTENTS
 
Item 1.
Item 2.
Item 3.
Item 4.
Item 1.
Item 1A.
Item 5.
Item 6.

2
PART I. FINANCIAL INFORMATION
Item 1.     Financial Statements
MASIMO CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS
(unaudited, in millions, except par values)
March 30,
2024		December 30,
2023
ASSETS
Current assets
Cash and cash equivalents$157.6 $163.0 
Trade accounts receivable, net of allowance for credit losses of $4.7 million and $4.8 million at March 30, 2024 and December 30, 2023, respectively
330.7 355.5 
Inventories506.1 545.0 
Assets held for sale11.4 — 
Other current assets159.8 168.4 
Total current assets1,165.6 1,231.9 
Lease receivable, non-current70.3 71.4 
Deferred costs and other contract assets57.9 57.3 
Property and equipment, net415.0 424.4 
Customer relationships, net - (Note 9)169.3 177.7 
Acquired technologies, net - (Note 9)119.9 129.4 
Other intangible assets, net - (Note 9)124.0 112.8 
Trademarks - (Note 9)222.7 232.4 
Goodwill396.0 407.7 
Deferred tax assets107.1 107.2 
Other non-current assets109.9 89.3 
Total assets$2,957.7 $3,041.5 
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities
Accounts payable$203.1 $251.5 
Accrued compensation65.2 62.6 
Deferred revenue and other contract liabilities, current70.0 87.3 
Other current liabilities165.9 162.4 
Total current liabilities504.2 563.8 
Long-term debt841.4 871.7 
Deferred tax liabilities106.9 111.7 
Other non-current liabilities140.0 129.5 
Total liabilities1,592.5 1,676.7 
Commitments and contingencies - (Note 24)
Stockholders’ equity
Preferred stock, $0.001 par value; 5.0 million shares authorized; 0 shares issued and outstanding
— — 
Common stock, $0.001 par value; 100.0 million shares authorized; 53.1 million and 52.8 million shares issued and outstanding at March 30, 2024 and December 30, 2023, respectively
0.1 0.1 
Treasury stock, 19.5 million and 19.5 million shares at March 30, 2024 and December 30, 2023, respectively
(1,169.2)(1,169.2)
Additional paid-in capital794.9 783.4 
Accumulated other comprehensive loss(75.3)(45.3)
Retained earnings1,814.7 1,795.8 
Total stockholders’ equity1,365.2 1,364.8 
Total liabilities and stockholders’ equity$2,957.7 $3,041.5 
The accompanying notes are an integral part of these condensed consolidated financial statements.
3
MASIMO CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited, in millions, except per share amounts)
 
Three Months Ended
March 30,
2024		April 1,
2023
Revenue$492.8 $565.0 
Cost of goods sold251.1 280.2 
Gross profit241.7 284.8 
Operating expenses:
Selling, general and administrative159.9 196.3 
Research and development47.8 50.5 
Total operating expenses207.7 246.8 
Operating income34.0 38.0 
Non-operating loss(9.1)(11.8)
Income before provision for income taxes24.9 26.2 
Provision for income taxes6.0 4.9 
Net income$18.9 $21.3 
Net income per share:
Basic$0.36 $0.40 
Diluted$0.35 $0.39 
Weighted-average shares used in per share calculations:
Basic53.0 52.6 
Diluted54.2 54.4 
The accompanying notes are an integral part of these condensed consolidated financial statements.
4
MASIMO CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
(unaudited, in millions)
 
Three Months Ended
March 30,
2024		April 1,
2023
Net income$18.9 $21.3 
Other comprehensive loss, net of tax:
Unrealized losses from foreign currency translation adjustments(35.6)(22.8)
       Change in pension benefits0.7 (2.2)
       Unrealized gain (loss) on cash flow hedges4.9 (4.3)
Total comprehensive loss$(11.1)$(8.0)


The accompanying notes are an integral part of these condensed consolidated financial statements.
5

MASIMO CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(in millions)
Three Months Ended March 30, 2024
Common StockTreasury StockAdditional
Paid-In
Capital
Accumulated
Other
Comprehensive (Loss)
Retained
Earnings		Total
Stockholders’
Equity
SharesAmountSharesAmount
Balance at December 30, 202352.8 $0.1 19.5 $(1,169.2)$783.4 $(45.3)$1,795.8 $1,364.8 
Stock options exercised0.2 — — — 7.2 — — 7.2 
Restricted/Performance stock units vested0.1 — — — — — — — 
Shares paid for tax withholding— — — — (5.3)— — (5.3)
Stock-based compensation— — — — 9.6 — — 9.6 
Net income— — — — — — 18.9 18.9 
Foreign currency translation adjustment— — — — — (35.6)— (35.6)
Change in pension benefits— — — — — 0.7 — 0.7 
Unrealized gain on cash flow hedge— — — — — 4.9 — 4.9 
Balance at March 30, 202453.1 $0.1 19.5 $(1,169.2)$794.9 $(75.3)$1,814.7 $1,365.2 

Three Months Ended April 1, 2023
Common StockTreasury StockAdditional
Paid-In
Capital
Accumulated
Other
Comprehensive
Income (Loss)
Retained
Earnings		Total
Stockholders’
Equity
SharesAmountSharesAmount
Balance at December 31, 202252.5 $0.1 19.5 $(1,169.2)$782.2 $11.5 $1,714.3 $1,338.9 
Stock options exercised0.1 — — — 4.3 — — 4.3 
Restricted/Performance stock units vested0.2 — — — — — — — 
Shares paid for tax withholding— — — — (12.2)— — (12.2)
Stock-based compensation— — — — 7.3 — — 7.3 
Net income— — — — — — 21.3 21.3 
Foreign currency translation adjustment— — — — — (22.8)— (22.8)
Change in pension benefits— — — — — (2.2)— (2.2)
Unrealized loss on cash flow hedge— — — — — (4.3)— (4.3)
Balance at April 1, 202352.8 $0.1 19.5 $(1,169.2)$781.6 $(17.8)$1,735.6 $1,330.3 
The accompanying notes are an integral part of these condensed consolidated financial statements.
6
MASIMO CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited, in millions)
Three Months Ended
March 30,
2024		April 1,
2023
Cash flows from operating activities:
Net income$18.9 $21.3 
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization24.3 26.1 
Stock-based compensation expense9.6 7.3 
Provision for credit losses0.1 0.4 
Amortization of debt issuance cost0.5 0.5 
Changes in operating assets and liabilities:
Decrease (increase) in accounts receivable22.4 34.8 
Decrease (increase) in inventories23.9 (7.1)
Decrease (increase) in other current assets7.0 (5.9)
Decrease (increase) in lease receivable, net0.7 (8.8)
Decrease (increase) in deferred costs and other contract assets(0.6)(1.0)
Decrease (increase) in other non-current assets(0.8)(2.7)
Increase (decrease) in accounts payable(40.6)(27.1)
Increase (decrease) in accrued compensation3.2 (16.5)
Increase (decrease) in accrued liabilities2.3 (21.8)
Increase (decrease) in income tax payable(5.8)(8.3)
Increase (decrease) in deferred revenue and other contract-related liabilities(13.9)0.9 
Increase (decrease) in other non-current liabilities(5.4)8.3 
Net cash provided by (used in) operating activities45.8 0.4 
Cash flows from investing activities:
Purchases of property and equipment, net(8.2)(8.5)
Increase in intangible assets(10.6)(9.7)
Business combinations, net of cash acquired— 7.5 
Other strategic investing activities(0.1)(0.4)
Net cash (used in) provided by investing activities(18.9)(11.1)
Cash flows from financing activities:
Borrowings under line of credit64.0 44.4 
Repayments on line of credit(92.3)(72.4)
Proceeds from issuance of common stock7.1 4.9 
Payroll tax withholdings on behalf of employees for vested equity awards(5.3)(12.1)
Net cash (used in) provided by financing activities(26.5)(35.2)
Effect of foreign currency exchange rates on cash(4.6)17.4 
Net decrease in cash, cash equivalents and restricted cash(4.2)(28.5)
Cash, cash equivalents and restricted cash at beginning of period168.2 209.6 
Cash, cash equivalents and restricted cash at end of period$164.0 $181.1 
The accompanying notes are an integral part of these condensed consolidated financial statements.
7
MASIMO CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)

1. Description of the Company
Masimo Corporation is a global technology company that develops, manufactures and markets a wide array of patient monitoring technologies, as well as automation and connectivity solutions. The Company’s mission is to improve patient outcomes, reduce the cost of care and take noninvasive monitoring to new sites and applications. The Company operates two business segments: healthcare and non-healthcare.
The Company’s healthcare products and patient monitoring solutions generally incorporate a monitor or circuit board, proprietary single-patient use or reusable sensors, software and/or cables. The Company primarily sells its healthcare products to hospitals, emergency medical service providers, home care providers, physician offices, veterinarians, long-term care facilities and consumers through its direct sales force, distributors and original equipment manufacturer (OEM) partners.
On April 11, 2022, the Company acquired Viper Holdings Corporation, the parent company of DEI Sales, Inc., d/b/a Sound United (Sound United), via the Company’s wholly-owned subsidiary, Sonic Boom Acquisition Corp (Sonic) (Sound United Acquisition). For additional information on the Company’s acquisition of Sound United, see Note 18, “Business Combinations”.
The Company’s non-healthcare consumer products and home integration technologies are primarily sold or licensed direct-to-consumers, or through authorized retailers and wholesalers.
The terms “the Company” and “Masimo” refer to Masimo Corporation and, where applicable, its consolidated subsidiaries.
2. Summary of Significant Accounting Policies
Basis of Presentation
The accompanying unaudited condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (SEC). Certain information and note disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) have been condensed or omitted pursuant to such rules and regulations. The accompanying condensed consolidated financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments, including normal recurring accruals, necessary to present fairly the Company’s condensed consolidated financial statements. The accompanying condensed consolidated balance sheet as of December 30, 2023 was derived from the Company’s audited consolidated financial statements at that date. The accompanying condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes contained in the Company’s Annual Report on Form 10-K for the fiscal year ended December 30, 2023 (fiscal year 2023), filed with the SEC on February 28, 2024. The results for the three months ended March 30, 2024 are not necessarily indicative of the results to be expected for the fiscal year ending December 28, 2024 (fiscal year 2024) or for any other interim period or for any future year.
Fiscal Periods
The Company follows a conventional 52/53 week fiscal year. Under a conventional 52/53 week fiscal year, a 52 week fiscal year includes four quarters of 13 weeks while a 53 week fiscal year includes three 13 week fiscal quarters and one 14 week fiscal quarter. The Company’s last 53 week fiscal year was fiscal year 2020. Fiscal year 2024 is a 52 week fiscal year ending December 28, 2024. All references to years in these notes to condensed consolidated financial statements are fiscal years unless otherwise noted.
Reclassifications
Certain amounts in the accompanying condensed consolidated financial statements have been reclassified to conform to the current period presentation, including certain balance sheet asset accounts in the consolidated financial statements for the year ended December 30, 2023. There was no impact on previously reported total assets, liabilities, stockholders’ equity or net income.
8
MASIMO CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(unaudited)
Use of Estimates
The Company prepares its financial statements in conformity with GAAP, which requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Significant estimates include the determination of standalone selling prices, variable consideration, total consideration allocated to each performance obligation within a contract, inventory valuation, valuation of the Company’s equity awards, valuation of identifiable assets and liabilities connected with business combinations, impairment of long-lived assets, intangible assets and goodwill; derivative and equity instruments, deferred taxes and any associated valuation allowances, deferred revenue, accounting for pensions, uncertain income tax positions, litigation costs, and related accruals. See Note 24, “Commitments and Contingencies”. Actual results could differ from such estimates.
Business Combinations
The Company accounts for business combinations using the acquisition method of accounting in accordance with Accounting Standards Codification (ASC) Topic 805, Business Combinations, which requires that once control is obtained, assets acquired, liabilities assumed and noncontrolling interests in the acquired entity, if applicable, are recorded at their respective fair values at the date of acquisition, with the exception of acquired contract assets and contract liabilities (i.e., deferred revenue) from contracts with customers. These are recognized and measured in accordance with ASC Topic 606, Revenue from Contracts with Customers. The excess of the purchase price over fair values of identifiable assets, liabilities and noncontrolling interests in the acquired entity, if applicable, is recorded as goodwill.
Fair Value Measurements
The Company accounts for certain financial instruments at their fair values as either assets or liabilities on the balance sheet. The Company determines the fair value of its financial instruments using the framework prescribed by ASC Topic 820, Fair Value Measurements and Disclosures, and considers the estimated amount the Company would receive or pay to transfer these instruments at the reporting date with respect to current currency exchange rates, interest rates, the creditworthiness of the counterparty for unrealized gain positions and the Company’s creditworthiness for unrealized loss positions. In certain instances, the Company may utilize financial models to measure the fair value of its financial instruments. In doing so, the Company uses inputs that include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, other observable inputs for the asset or liability and inputs derived principally from, or corroborated by, observable market data by correlation or other means.
Recurring Fair Value Measurement
On a recurring basis, the Company measures certain financial assets and financial liabilities at fair value based upon quoted market prices. Where quoted market prices or other observable inputs are not available, the Company applies valuation techniques to estimate fair value. Authoritative guidance describes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value:
●    Level 1—Quoted prices in active markets for identical assets or liabilities.
●    Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active; or other inputs that can be corroborated by observable market data for substantially the full term of the assets or liabilities.
●    Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
9
MASIMO CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(unaudited)
The following tables represent the Company’s financial assets, measured at fair value on a recurring basis at March 30, 2024:
Total Carrying
Value		Fair Value Measurement Hierarchy
(in millions)Level 1Level 2Level 3
Assets
Cash and cash equivalents$81.9 $81.9 $— $— 
Money market funds75.7 75.7 — — 
Equity securities1.7 1.7 — — 
Pension assets22.9 16.6 6.3 — 
Derivative instruments - cash flow hedges(1)
14.4 — 14.4 — 
Derivative instruments - warrants0.9 0.9 — — 
Total assets$197.5 $176.8 $20.7 $— 
Liabilities
Derivative instruments - cash flow hedges
$— $— $— $— 
Pension benefit obligation32.1 32.1 — — 
Total liabilities$32.1 $32.1 $— $— 
______________
(1)     Includes accrued interest.
The following tables represent the Company’s financial assets, measured at fair value on a recurring basis at December 30, 2023:
Total Carrying
Value		Fair Value Measurement Hierarchy
(in millions)Level 1Level 2Level 3
Assets
Cash and cash equivalents$87.0 $87.0 $— $— 
Money market funds76.0 76.0 — — 
Pension assets
23.1 16.8 6.3 — 
Equity securities1.7 1.7 — — 
Derivative instruments - cash flow hedges(1)
11.6 — 11.6 — 
Derivative instruments - warrants1.0 1.0 — — 
Total assets$200.4 $182.5 $17.9 $— 
Liabilities
Derivative instruments - cash flow hedges$3.6 $3.6 $— $— 
Pension benefit obligation32.6 32.6 — — 
Total liabilities$36.2 $36.2 $— $— 
______________
(1)     Includes accrued interest.
The Company invests in checking, savings and money market fund accounts, which are classified within Level 1 of the fair value hierarchy as they are valued using quoted market prices. These investments are classified as cash and cash equivalents within the Company’s accompanying condensed consolidated balance sheets, in accordance with GAAP and its accounting policies.
10
MASIMO CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(unaudited)
The Company has certain strategic investments in privately-held companies (non-marketable equity securities) and companies that have completed initial public offerings (marketable equity securities). The Company’s marketable equity securities, whose price is based on quoted market price in an active market, are classified within Level 1 of the fair value hierarchy. Equity securities are classified as current, short-term investments, or non-current, recorded in other non-current assets, based on the nature of the securities and their availability for use in current operations. The changes in the fair value of those equity securities are measured at each reporting date and changes in the value of these investments between reporting dates are recorded within non-operating loss.
The Company’s pension assets consist of Level 1 and Level 2 investments. The fair value of Level 2 assets is based on observable inputs such as prices or quotes for similar assets, adjusted for any differences in terms or conditions that may affect the value of the instrument being valued. The valuation techniques used for Level 2 assets may include the use of models or other valuation techniques, but these methods are all based on observable market inputs.
The Company also has investments in certain derivative instruments, which are measured at fair value and classified within Level 1 of the fair value hierarchy.
Non-Recurring Fair Value Measurements
For certain other financial assets and liabilities, including restricted cash, accounts receivable, accounts payable and other current assets and liabilities, the carrying amounts approximate their fair value primarily due to the relatively short maturity of these balances. The Company also measures certain non-financial assets at fair value on a non-recurring basis, primarily goodwill, intangible assets and operating lease right-of-use assets, in connection with periodic evaluations for potential impairment.
Furthermore, the Company did not elect to apply the fair value option to specific assets or liabilities on a contract-by-contract basis. The Company did not have any transfers between Level 2 and Level 3 during the three months ended March 30, 2024.
Cash and Cash Equivalents
The Company considers all highly liquid investments with an original maturity from the date of purchase of three months or less, or highly liquid investments that are readily convertible into known amounts of cash, to be cash equivalents. The Company carries cash and cash equivalents at cost, which approximates fair value, and they are Level 1 under the fair value hierarchy.
Accounts Receivable and Allowance for Credit Losses
Accounts receivable consist of trade receivables recorded at the time of invoicing of product sales, reduced by reserves for estimated bad debts and returns. Trade accounts receivable are recorded at the invoiced amount and do not bear interest. Credit is extended based on an evaluation of the customer’s financial condition. Collateral is generally not required. The Company records an allowance for credit losses that it does not expect to collect based on relevant information, including historical experience, current conditions, and reasonable and supportable forecasts. Accounts are charged off against the allowance when the Company believes they are uncollectible. The allowance for credit losses is measured on a collective (pool) basis when similar risk characteristics exist. Based on the risk characteristics, the Company has identified U.S. and international customers as separate portfolios for both segments, and measures expected credit losses on such receivables using an aging methodology.
Inventories
Inventories are stated at the lower of cost or net realizable value. Cost is determined using a standard cost method, which approximates the first in, first out method, and includes material, labor and overhead costs. Inventory valuation adjustments are recorded for inventory items that have become excess or obsolete or are no longer used in current production and for inventory items that have a market price less than the carrying value in inventory. The Company generally determines inventory valuation adjustments based on an evaluation of the expected future use of its inventory on an item by item basis and applies historical obsolescence rates to estimate the loss on inventory expected to have a recovery value below cost. The Company also records other specific inventory valuation adjustments when it becomes aware of unique events or circumstances that result in an expected recovery value below cost. For inventory items that have been written down, the reduced value becomes the new cost basis.
11
MASIMO CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(unaudited)
Property and Equipment
Property and equipment are stated at cost. Depreciation is calculated using the straight-line method over estimated useful lives as follows:
Useful Lives
Buildings and building improvements
7 to 39 years
Computer equipment and software
2 to 12 years
Demonstration units
2 to 3 years
Furniture and office equipment
2 to 15 years
Leasehold improvementsLesser of useful life or term of lease
Machinery, equipment and tooling
3 to 20 years
Operating lease assetsLesser of useful life or term of lease
Transportation, vehicles and other
1 to 20 years
Land is not depreciated and construction-in-progress is not depreciated until placed in service. Normal repair and maintenance costs are expensed as incurred, whereas significant improvements that materially increase values or extend useful lives are capitalized and depreciated over the remaining estimated useful lives of the related assets. Upon sale or retirement of depreciable assets, the related cost and accumulated depreciation or amortization are removed from the accounts and any gain or loss on the sale or retirement is recognized in income.
Lessee Right-of-Use (ROU) Assets and Lease Liabilities
The Company determines if an arrangement contains a lease at inception. ROU assets represent the Company’s right to use an asset underlying an operating lease for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from an operating lease. ROU assets and lease liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. The Company generally estimates the applicable discount rate used to determine the net present value of lease payments based on available information at the lease commencement date. Many of the Company’s lessee agreements include options to extend the lease, which the Company does not include in its lease terms unless they are reasonably certain to be exercised. The Company utilizes a portfolio approach to account for the ROU assets and liabilities associated with certain equipment leases.
The Company has also made an accounting policy election not to separate lease and non-lease components for its real estate leases and to exclude short-term leases with a term of twelve months or less from its ROU assets and lease liabilities. Rental expense for lease payments related to operating leases is recognized on a straight-line basis over the lease term.
Intangible Assets
Intangible assets consist primarily of patents, trademarks, software development costs, customer relationships and acquired technology. Costs related to patents and trademarks, which include legal and application fees, are capitalized and amortized over the estimated useful lives using the straight-line method. Patent and trademark amortization commences once final approval of the patent or trademark has been obtained. Patent costs are amortized over the lesser of 10 years or the patent’s remaining legal life, which assumes renewals, and trademark costs are amortized over 17 years, and their associated amortization cost is included in selling, general and administrative expense in the accompanying condensed consolidated statements of operations. For intangibles purchased in an asset acquisition or business combination, which mainly include patents, trademarks, customer relationships and acquired technologies, the useful life is determined largely by valuation estimates of remaining economic life.
The Company’s policy is to renew its patents and trademarks. Costs to renew patents and trademarks are capitalized and amortized over the remaining useful life of the intangible asset. The Company periodically evaluates the amortization period and carrying basis of patents and trademarks to determine whether any events or circumstances warrant a revised estimated useful life or reduction in value. Capitalized application costs are charged to operations when it is determined that the patent or trademark will not be obtained or is abandoned.
12
MASIMO CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(unaudited)
Software development costs are accounted for in accordance with ASC Topic 985-20, Software - Costs of Software to be Sold, Leased, or Marketed. Once technological feasibility has been established, qualifying costs incurred in development are capitalized until available for general release to customers, and subsequently reported at the lower of unamortized cost or net realizable value.
Intangibles purchased as part of an asset acquisition or business combination historically have included patents, trademarks, customer relationships, developed technologies and contractual licenses. In certain circumstances the Company has also acquired non-compete agreements tied to certain employment relationships. The useful life for all of these is largely determined by valuation estimates of remaining economic life. In connection with the Sound United acquisition, the Company acquired certain trademarks/tradenames, which are intangible assets with indefinite useful lives. These brands are expected to maintain brand value for an indefinite period of time.
Impairment of Goodwill, Intangible Assets and Other Long-Lived Assets
Goodwill is recorded as the difference, if any, between the aggregate consideration paid for an acquisition and the fair value of the acquired net tangible and intangible assets. Goodwill is not amortized, but instead is tested annually for impairment, or more frequently when events or changes in circumstances indicate that goodwill might be impaired. In assessing goodwill impairment, the Company has the option to first assess the qualitative factors to determine whether the existence of events or circumstances leads to a determination that it is more likely than not that the fair value of a reporting unit is less than its carrying amount. The Company has two reporting units, healthcare and non-healthcare. The Company’s qualitative assessment of the recoverability of goodwill considers various macro-economic, industry-specific and Company-specific factors, including: (i) severe adverse industry or economic trends; (ii) significant Company-specific actions; (iii) current, historical or projected deterioration of the Company’s financial performance; or (iv) a sustained decrease in the Company’s market capitalization below its net book value. If the qualitative assessment indicates that it is more-likely-than-not that the fair value of a reporting unit is less than its carrying value, or if the Company elects to bypass the qualitative analysis, then the Company performs a quantitative analysis that compares the fair value of the reporting unit with its carrying amount, including goodwill. If the fair value of the reporting unit exceeds its carrying amount, goodwill is not considered impaired; otherwise, a goodwill impairment loss is recognized for the lesser of: (a) the amount that the carrying amount of such reporting unit exceeds its fair value; or (b) the amount of the goodwill allocated to such reporting unit. The annual impairment test is performed during the fourth fiscal quarter.
Similar to goodwill, indefinite-lived intangible assets are not amortized but instead are subject to annual impairment testing, unless circumstances dictate more frequent testing, if impairment indicators exist. Impairment for indefinite-lived assets exists if the carrying value of the indefinite-lived intangible asset exceeds its fair value. Determining whether impairment indicators exist and estimating the fair value of the Company’s indefinite-lived intangible assets if necessary for impairment testing require significant judgment. Qualitative factors considered in this assessment include industry and market conditions, overall financial performance, and other relevant events and factors.
The Company reviews finite lived intangible assets and long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted operating cash flows expected to be generated by the asset. If such asset is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount exceeds the fair value of the asset. Long-lived assets to be disposed of are reported at the lower of carrying amount or fair value less costs to sell.
Employee Defined Benefit Plans
The Company maintains noncontributory defined benefit plans that cover certain employees in certain international locations. The Company recognizes the funded status, or the difference between the fair value of plan assets and the projected benefit obligations of the pension plan on the condensed consolidated balance sheet, with a corresponding adjustment to accumulated other comprehensive (loss) income. If the projected benefit obligation exceeds the fair value of plan assets, the difference or underfunded status represents the pension liability. The Company records a net periodic pension cost in the condensed consolidated statement of operations. The liabilities and annual income or expense are determined using methodologies that involve several actuarial assumptions, the most significant of which are the discount rate and the expected long-term rate of asset return. The Company’s accounting policy includes an annual re-measurement of pension assets and obligations. In addition, the Company re-measures pension assets and obligations for significant events, as of the nearest month-end date on the calendar. The fair values of plan assets are determined based on prevailing market prices. See Note 21, “Employee Benefits”, for further details.
13
MASIMO CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(unaudited)
Income Taxes
The Company accounts for income taxes using the asset and liability method, under which the Company recognizes deferred tax assets and liabilities for the future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and for net operating loss and tax credit carryforwards. Tax positions that meet a more-likely-than-not recognition threshold are recognized in the first reporting period that it becomes more-likely-than-not such tax position will be sustained upon examination. A tax position that meets this more-likely-than-not recognition threshold is recorded at the largest amount of tax benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. Previously recognized income tax positions that fail to meet the recognition threshold in a subsequent period are derecognized in that period. Differences between actual results and the Company’s assumptions, or changes in the Company’s assumptions in future periods, are recorded in the period they become known. The Company records potential accrued interest and penalties related to unrecognized tax benefits in income tax expense.
As a multinational corporation, the Company is subject to complex tax laws and regulations in various jurisdictions. The application of tax laws and regulations is subject to legal and factual interpretation, judgment and uncertainty. Tax laws themselves are subject to change as a result of changes in fiscal policy, changes in legislation, evolution of regulations and court rulings. Therefore, the actual liability for U.S. or foreign taxes may be materially different from the Company’s estimates, which could result in the need to record additional liabilities or potentially to reverse previously recorded tax liabilities.
Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that includes the enactment date. A valuation allowance is recorded against any deferred tax assets when, in the judgment of management, it is more likely than not that all or part of a deferred tax asset will not be realized. In assessing the need for a valuation allowance, the Company considers all positive and negative evidence, including recent financial performance, scheduled reversals of temporary differences, projected future taxable income, availability of taxable income in carryback periods and tax planning strategies.
Income taxes are highly susceptible to changes from period to period, requiring management to make assumptions about the Company’s future income over the lives of its deferred tax assets and the impact of changes in valuation allowances. Any difference in the assumptions, judgments and estimates mentioned above could result in changes to the Company’s results of operations.
Revenue Recognition, Deferred Revenue and Other Contract Liabilities
The Company generally recognizes revenue following a single, principles-based five-step model to be applied to all contracts with customers and generally provides for the recognition of revenue in an amount that reflects the consideration to which the Company expects to be entitled, net of allowances for estimated returns, discounts or sales incentives, as well as taxes collected from customers that are remitted to government authorities, when control over the promised goods or services are transferred to the customer.
Healthcare segment
While the majority of the Company’s healthcare segment revenue contracts and transactions contain standard business terms and conditions, there are some transactions that contain non-standard business terms and conditions. As a result, contract interpretation, judgment and analysis are required to determine the appropriate accounting, including: (i) the amount of the total consideration, as well as variable consideration, (ii) whether the arrangement contains an embedded lease, and if so, whether such embedded lease is a sales-type lease or an operating lease, (iii) the identification of the distinct performance obligations contained within the arrangement, (iv) how the arrangement consideration should be allocated to each performance obligation when multiple performance obligations exist, including the determination of standalone selling price, and (v) when to recognize revenue on the performance obligations. Changes in judgments on these assumptions and estimates could materially impact the timing of revenue recognition. Revenue from fixed lease payments related to equipment supplied under sales-type lease arrangements is recognized once control over the equipment is transferred to the customer, while revenue from fixed lease payments related to equipment supplied under operating-type lease arrangements is generally recognized on a straight-line basis over the term of the lease and variable lease payments are recognized as they occur.
14
MASIMO CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(unaudited)
The Company derives the majority of its healthcare segment revenue from four primary sources: (i) direct sales under deferred equipment agreements with end-user hospitals where the Company provides up-front monitoring equipment at no up-front charge in exchange for a multi-year sensor purchase commitment; (ii) other direct sales of noninvasive monitoring solutions to end-user hospitals, emergency medical response organizations and other direct customers; (iii) sales of noninvasive monitoring solutions to distributors who then typically resell to end-user hospitals, emergency medical response organizations and other customers; and (iv) sales of integrated circuit boards to OEM customers who incorporate the Company’s embedded software technology into their multiparameter monitoring devices. Subject to customer credit considerations, the majority of such sales are made on open accounts using industry standard payment terms based on the geography within which the specific customer is located.
The Company enters into agreements to sell its monitoring solutions and services, sometimes as a part of arrangements with multiple performance obligations that include various combinations of product sales, equipment leases, software and services. In the case of contracts with multiple performance obligations, the authoritative guidance provides that the total consideration be allocated to each performance obligation on the basis of relative standalone selling prices. When a standalone selling price is not readily observable, the Company estimates the standalone selling price by considering multiple factors including, but not limited to, features and functionality of the product, geographies, type of customer, contractual prices pursuant to Group Purchasing Organization (GPO) contracts, the Company’s pricing and discount practices, and other market conditions.
Sales under deferred equipment agreements are generally structured such that the Company agrees to provide certain monitoring-related equipment, software, installation, training and/or warranty support at no up-front charge in exchange for the customer’s commitment to purchase sensors over the term of the agreement, which generally ranges from three years to six years. The Company allocates contract consideration under deferred equipment agreements containing fixed annual sensor purchase commitments to the underlying lease and non-lease components at contract inception. In determining whether any underlying lease components are related to a sales-type lease or an operating lease, the Company evaluates the customer’s rights and ability to control the use of the underlying equipment throughout the contract term, including any equipment substitution rights retained by the Company, as well as the Company’s expectations surrounding potential contract/lease extensions or renewals and the customer’s likelihood to exercise any purchase options. Beginning in 2022, for contracts that contain variable lease payments that are not dependent on an index or rate, the Company classifies as operating leases any lease components that would have otherwise been classified as sales-type leases that would result in a selling loss upon lease commencement. Revenue allocable to non-lease performance obligations is generally recognized as such non-lease performance obligations are satisfied. Revenue allocable to lease components under sales-type lease arrangements is generally recognized when control over the equipment is transferred to the customer. Revenue allocable to lease components under operating lease arrangements is generally recognized over the term of the operating lease. The Company generally does not expect to derive any significant value in excess of such asset’s unamortized book value from equipment underlying its operating lease arrangements after the end of the agreement.
Revenue from the sale of products and software to end-user hospitals, emergency medical response organizations, other direct customers, distributors and OEM customers, is recognized by the Company when control of the performance obligations thereunder transfers to the customer based upon the terms of the contract or underlying purchase order.
Revenue related to OEM rainbow® parameter software licenses is recognized by the Company upon the OEM’s shipment of its product to its customer, as reported to the Company by the OEM.
The Company provides certain customers with various sales incentives that may take the form of discounts or rebates. The Company records estimates related to these programs as a reduction to revenue at the time of sale. In general, customers do not have a right of return for credit or refund. However, the Company allows returns under certain circumstances. At the end of each period, the Company estimates and accrues for these returns as a reduction to revenue. The Company estimates the revenue constraints related to these forms of variable consideration based on various factors, including expected purchasing volumes, prior sales and returns history, and specific contractual terms and limitations.
Non-healthcare segment
Non-healthcare segment revenue is related to hardware and embedded software that is integrated into final products that are manufactured and sold by the Company. Products and related software are accounted for as a single performance obligation and all intended functionality is available to the customer upon purchase. Non-healthcare segment revenue is recognized upon transfer of control of promised products or service to customers, which is either upon shipment or upon delivery to the customers, depending on delivery terms.
15
MASIMO CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(unaudited)
The Company offers sales incentives and has customer programs consisting primarily of discounts and market development fund programs, and records them as contra revenue. Estimates for sales incentives are developed using the most likely amount and are included in the transaction price to the extent that a significant reversal of revenue would not result once the uncertainty is resolved. In developing these estimates, the Company also considers the susceptibility of the incentive to outside influences, the length of time until the uncertainty is resolved and the Company’s experience with similar contracts. Reductions in revenue related to discounts are allocated to products on a relative basis based on their respective standard selling price if there are undelivered products in a contract. Judgement is required to determine the timing and amount of recognition of marketing funds which the Company estimates based on past practice of providing similar funds.
Payment terms and conditions vary among the Company’s distribution channels although terms generally include a requirement of payment within 30 to 60 days of product shipment. Sales made directly to customers from the Company’s website are paid at the time of product shipment. Prior to determining payment terms for each customer, an evaluation of such customer’s credit risk is performed. Contractual allowances are an offset to accounts receivable.
Shipping and Handling Costs and Fees
All shipping and handling costs are expensed as incurred and are recorded as a component of cost of goods sold in the accompanying condensed consolidated statements of operations. Charges for shipping and handling billed to customers are included as a component of revenue.
Taxes Collected From Customers and Remitted to Governmental Authorities
The Company’s policy is to present revenue net of taxes collected from customers and remitted to governmental authorities.
Deferred Costs and Other Contract Assets
The costs of monitoring-related equipment provided to customers under operating lease arrangements within the Company’s deferred equipment agreements are generally deferred and amortized to cost of goods sold over the life of the underlying contracts. Some of the Company’s deferred equipment agreements also contain provisions for certain allowances to be made directly to the end-user hospital customer at the inception of the arrangement. These allowances are generally allocated to the lease and non-lease components and recognized as a reduction to revenue as the underlying performance obligations are satisfied.
The Company generally invoices its customers under deferred equipment agreements as sensors are provided to the customer. However, the Company may recognize revenue for certain non-lease performance obligations under deferred equipment agreements with fixed annual commitments at the time such performance obligations are satisfied and prior to the customer being invoiced. When this occurs, the Company records an unbilled contract receivable related to such revenue until the customer has been invoiced pursuant to the terms of the underlying deferred equipment agreement.
The incremental costs of obtaining a contract with a customer are capitalized and deferred if the Company expects such costs to be recoverable over the life of the contract and the contract term is greater than one year. Such deferred costs generally relate to certain incentive sales commissions earned by the Company’s internal sales team in connection with the execution of deferred equipment agreements and are amortized to expense over the expected term of the underlying contract.
The Company recognizes non-healthcare royalty revenue associated with certain prepaid license arrangements. The Company recognizes non-healthcare revenue from the prepaid license arrangements based upon sales-based royalties when a subsequent sale occurs.
Warranty
The Company generally provides a warranty against defects in material and workmanship for a period ranging from six months to forty-eight months, depending on the product type. In traditional sales activities, including direct and OEM sales, the Company establishes an accrued liability for the estimated warranty costs at the time of revenue recognition, with a corresponding provision to cost of goods sold. Customers may also purchase extended warranty coverage or service level upgrades separately or as part of a deferred equipment agreement. Revenue related to extended warranty coverage and service level upgrades is generally recognized over the life of the contract, which reasonably approximates the period over which such services will be provided. The related extended warranty and service level upgrade costs are expensed as incurred.
16
MASIMO CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(unaudited)
Changes in the product warranty accrual were as follows:
Three Months Ended
(in millions)March 30,
2024		April 1,
2023
Product warranty accrual, beginning of period$8.6 $10.6 
Accrual for warranties issued3.1 3.8 
Changes in pre-existing warranties (including changes in estimates)0.4 (3.5)
Settlements made(4.0)(0.7)
Product warranty accrual, end of period$8.1 $10.2 
Advertising Costs
Advertising costs include certain advertising, marketing and endorsement licensing fee agreements. Advertising and marketing costs are expensed as incurred. Licensing fees associated with product endorsers are expensed on a straight-line basis over the term of the agreement. Advertising costs are included in selling, general and administrative expense in the accompanying condensed consolidated statements of operations. Advertising costs for the three months ended March 30, 2024 and April 1, 2023 were $11.9 million and $14.4 million, respectively.
Litigation Costs and Contingencies
The Company records a charge equal to at least the minimum estimated liability for a loss contingency or litigation settlement when both of the following conditions are met: (i) information available prior to issuance of the financial statements indicates that it is probable that a liability had been incurred at the date of the financial statements, and (ii) the range of loss can be reasonably estimated. The determination of whether a loss contingency, litigation settlement or contingent fee is probable or reasonably possible involves a significant amount of management judgment, as does the estimation of the range of loss given the nature of contingencies or any associated contingent fees related to a settlement of a legal matter. Liabilities related to litigation settlements with multiple elements are recorded based on the fair value of each element. Legal and other litigation related expenses are recognized as the services are provided. Contingent legal fee expenses are recognized when probable and reasonably estimable. The Company records insurance and other indemnity recoveries for litigation expenses when both of the following conditions are met: (a) the recovery is probable, and (b) collectability is reasonably assured. Insurance recoveries are only recorded to the extent the litigation costs to which they relate have been incurred and recognized in the financial statements.
Foreign Currency Translation
The Company’s international headquarters is in Switzerland, and its functional currency is the U.S. Dollar. The Company has many other foreign subsidiaries, and the largest transactions in foreign currency translations occur in the Japanese Yen, the British Pound, the Chinese Yuan and the European Euro.
The Company records certain revenues and expenses in foreign currencies. These revenues and expenses are translated into U.S. Dollars based on the average exchange rate for the reporting period. Assets and liabilities denominated in foreign currencies are translated into U.S. Dollars at the exchange rate in effect as of the balance sheet date. Translation gains and losses related to foreign currency assets and liabilities of a subsidiary that are denominated in the functional currency of such subsidiary are included as a component of accumulated other comprehensive (loss) income within the accompanying condensed consolidated balance sheets. Realized and unrealized foreign currency gains and losses related to foreign currency assets and liabilities of the Company, or a subsidiary that are not denominated in the underlying functional currency are included as a component of non-operating (loss) income within the accompanying condensed consolidated statements of operations.
17
MASIMO CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(unaudited)
Derivatives Instruments and Hedging Activities
The Company addresses market risk from changes in interest rates risks through risk management programs, which include the use of derivative instruments. The Company’s exposure to a counterparty’s credit risk is generally limited to the amounts of the net obligation to the counterparty. The Company established policies to enter into contracts only with major investment-grade financial institutions to mitigate such counterparty credit risk. The Company also established a policy to further monitor the counterparty risks throughout the life of the instruments. None of the derivative instruments currently held by the Company were entered into for speculative trading purposes.
All derivative financial instruments are recognized as either assets or liabilities at fair value in the condensed consolidated balance sheets and are classified as short-term or long-term based on the tenor of the instrument. The Company has elected not to separate a derivative instrument into current and long-term portions. A derivative instrument whose fair value is a net liability is classified as current in total. A derivative instrument whose fair value is a net asset and whose current portion is an asset is classified as non-current in total. For a derivative instrument that meets the criteria to qualify for hedge accounting, the Company marks the fair value of the derivative instrument to market periodically through other comprehensive (loss) income. When the hedged items are recorded to income (loss), the associated deferred gains (losses) of the derivatives in accumulated other comprehensive (loss) income will be reclassified into earnings. Any fluctuation in the fair value of a derivative instrument that does not meet the criteria for hedge accounting is recorded to earnings (expense) in the period it occurs.
Comprehensive (Loss) Income
Comprehensive (loss) income includes foreign currency translation adjustments, changes to pension benefits, unrealized gains (losses) on cash flow hedges and any related tax benefits (expenses) that have been excluded from net income and reflected in stockholders’ equity.
Net Income Per Share
A computation of basic and diluted net income per share is as follows:
Three Months Ended
(in millions, except per share amounts)
March 30,
2024		April 1,
2023
Net income$18.9 $21.3 
Basic net income per share:
Weighted-average shares outstanding - basic53.0 52.6 
Net income per basic share$0.36 $0.40 
Diluted net income per share:
Weighted-average shares outstanding - basic53.0 52.6 
Diluted share equivalents: stock options, RSUs and PSUs1.3 1.8 
Weighted-average shares outstanding - diluted54.2 54.4 
Net income per diluted share$0.35 $0.39 
Basic net income per share is computed by dividing net income by the weighted-average number of shares outstanding during the period. Net income per diluted share is computed by dividing the net income by the weighted-average number of shares and potential shares outstanding during the period, if the effect of potential shares is dilutive. Potential shares include incremental shares of stock issuable upon the exercise of stock options and the vesting of both restricted share units (RSUs) and performance stock units (PSUs). For each of the three months ended March 30, 2024 and April 1, 2023, weighted options to purchase 1.4 million and 1.0 million shares of common stock, respectively, were outstanding but not included in the computation of diluted net income per share because the effect of including such shares would have been antidilutive in the applicable period. Certain RSUs were considered contingently issuable shares as their vesting is contingent upon the occurrence of certain future events. Since such events had not occurred and were not considered probable of occurring as of each of March 30, 2024 and April 1, 2023, 2.7 million weighted-average shares related to such RSUs have been excluded from the calculation of potential shares for the three month periods then ended. For additional information with respect to these RSUs, please see “Employment and Severance Agreements” in Note 24, “Commitments and Contingencies”.
18
MASIMO CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(unaudited)
Supplemental Cash Flow Information
Supplemental cash flow information includes the following:
Three Months Ended
(in millions)March 30,
2024		April 1,
2023
Cash paid during the year for:
Interest expense
$11.7 $11.7 
Income taxes
8.5 11.0 
Operating lease liabilities
5.7 5.3 
Non-cash operating activities:
ROU assets obtained in exchange for lease liabilities
$20.6 $0.6 
Non-cash investing activities:
Unpaid purchases of property and equipment$2.7 $0.7 
Unpaid strategic investments0.2 1.2 
Non-cash financing activities:
       Unsettled common stock proceeds from option exercises$0.1 $0.1 
Reconciliation of cash, cash equivalents and restricted cash:
Cash and cash equivalents
$157.6 $174.1 
Restricted cash
6.4 7.0 
Total cash, cash equivalents and restricted cash shown in the condensed consolidated statements of cash flows$164.0 $181.1 
Recently Adopted and Recently Announced Accounting Pronouncements
There have been no material changes to the accounting policies discussed in Note 2 to the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 30, 2023, filed with the SEC on February 28, 2024. other than the following update:
In November 2023, the Financial Accounting Standards Board issued Accounting Standards Update (ASU) No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The new standard is intended to improve reportable segment disclosure requirements primarily through enhanced disclosures about significant segment expenses. ASU No. 2023-07 is effective for annual reporting periods beginning after December 15, 2023 and interim periods in fiscal years beginning after December 15, 2024. Early adoption is permitted with retrospective application to all prior periods presented. Upon transition, the segment expense categories and amounts disclosed in the prior periods should be based on the significant segment expense categories identified and disclosed in the period of adoption. The Company is continuing to evaluate the impact of this standard on its consolidated financial statements upon adoption.
19
MASIMO CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(unaudited)
3. Related Party Transactions
The Company’s Chairman and Chief Executive Officer (CEO) is also the Chairman and CEO of Willow Laboratories, Inc. (Willow). The Company is a party to the following agreements with Willow:
•Cross-Licensing Agreement - The Company and Willow are parties to a cross-licensing agreement (Cross-Licensing Agreement), which governs each party’s rights to certain intellectual property held by the two companies. The Company is subject to certain annual minimum aggregate royalty obligations for use of the rainbow® licensed technology. The current annual minimum royalty obligation is $5.0 million. Aggregate liabilities payable to Willow arising under the Cross-Licensing Agreement were $4.8 million and $5.6 million for the three months ended March 30, 2024 and April 1, 2023, respectively.
•Administrative Services Agreement - The Company is a party to an administrative services agreement with Willow (G&A Services Agreement), which governs certain general and administrative services that the Company provides to Willow. Amounts charged by the Company pursuant to the G&A Services Agreement were $0.1 million for each of the three months ended March 30, 2024 and April 1, 2023.
•Lease Agreement - Effective December 2019, the Company entered into a lease agreement with Willow for approximately 34,000 square feet of office, research and development space at one of the Company’s owned facilities in Irvine (Willow Lease). The term of the Willow Lease expires on December 31, 2024. The Company recognized approximately $0.3 million of lease income for each of the three months ended March 30, 2024 and April 1, 2023.
Net amounts due to Willow at March 30, 2024 and December 30, 2023 were approximately $4.9 million and $4.1 million, respectively.
The Company’s CEO is also the Chairman of the Masimo Foundation for Ethics, Innovation and Competition in Healthcare (Masimo Foundation), a non-profit organization that was founded in 2010 to provide a platform for encouraging ethics, innovation, and competition in healthcare. In addition, the Company’s Executive Vice President (EVP), Chief Financial Officer (CFO) serves as the Treasurer of the Masimo Foundation and the Company’s EVP, General Counsel and Corporate Secretary serves as the Secretary for the Masimo Foundation. During each of the three months ended March 30, 2024 and April 1, 2023, the Company made cash contributions of approximately $1.0 million to the Masimo Foundation. During each of the three months ended March 30, 2024 and April 1, 2023, the Company made various in-kind contributions to the Masimo Foundation, mainly in the form of donated administrative services.
The Company’s CEO is also a co-founder and a member of the board of directors of Like Minded Media Ventures (LMMV), a team of storytellers that create content focused in the areas of true stories, social causes and science. LMMV creates stories with a multi-platform strategy, bridging the gap between film, television, digital and social media. The Company entered into a marketing service agreement with LMMV for audiovisual production services promoting brand awareness, including television commercials and digital advertising, during the second quarter of 2020. During each of the three months ended March 30, 2024, and April 1, 2023, the Company incurred no marketing expenses to LMMV under the marketing service agreement. At each of March 30, 2024 and December 30, 2023, there were no amounts due to LMMV for services rendered.
During the second quarter of 2021, the Company entered into a software license and professional services agreement with Like Minded Labs (LML), a subsidiary of LMMV. Pursuant to the software license agreement, LML granted the Company a perpetual, non-exclusive and fully paid-up right and license to integrate LML’s software into the Company’s products in exchange for a $3.0 million one-time license fee. Pursuant to the professional services agreement, LML will provide professional services to the Company, including the development of custom software intended to support the integration of the licensed software into the Company’s products, as well as future support services upon the Company’s acceptance of deliverables.
In July 2021, the Company entered into a patent purchase and option agreement with Vantrix Corporation (Vantrix), an acquiree of LML, for certain patents for $0.5 million, and the right to purchase two pools of additional patents from Vantrix for an exercise fee of up to $1.1 million. The agreements with LML and Vantrix include sublicensing provisions whereby the software and patents are licensed back to LML or Vantrix, respectively, for further advancement of the technologies.
20
MASIMO CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(unaudited)
The Company maintains an aircraft time share agreement, pursuant to which the Company has agreed from time to time to make its aircraft available to the Company’s CEO for lease on a time-sharing basis. The Company charges the Company’s CEO for personal use based on agreed upon reimbursement rates. For the three months ended March 30, 2024, the Company’s CEO did not incur charges pursuant to this agreement. For the three months ended April 1, 2023, the Company charged the Company’s CEO less than $0.1 million pursuant to this agreement.
4. Inventories
Inventories consist of the following:
(in millions)March 30,
2024		December 30,
2023
Raw materials$232.6 $229.7 
Work-in-process29.3 30.0 
Finished goods244.2 285.3 
     Total inventories$506.1 $545.0 
5. Other Current Assets
Other current assets consist of the following:
(in millions)March 30,
2024		December 30,
2023
Prepaid expenses$53.1 $58.3 
Lease receivable, current29.7 30.2 
Prepaid income taxes27.7 29.3 
Indirect taxes receivable23.1 28.6 
Other receivables10.3 6.8 
Contract assets, current7.2 6.7 
Prepaid rebates and royalties, current5.0 4.8 
Restricted cash(1)
3.0 3.0 
Other current assets0.7 0.7 
     Total other current assets$159.8 $168.4 
______________
(1)     Restricted cash includes funds received from the Bill and Melinda Gates Foundation. As the Company incurs costs associated with research and development related to this project, on a quarterly basis, the Company reclasses amounts from the grant to offset costs incurred.
6. Lease Receivable
For deferred equipment agreements that contain embedded operating leases, upon lease commencement, the Company defers and records the equipment cost of operating lease assets within property, plant and equipment, net of accumulated depreciation. These operating lease assets are subsequently amortized to cost of goods sold over the lease term on a straight-line basis.
For deferred equipment agreements that contain embedded sales-type leases, the Company recognizes lease revenue and costs, as well as a lease receivable, at the time the lease commences. Lease revenue related to both operating-type and sales-type leases are included within revenue in the accompanying condensed consolidated statements of operations. For the three months ended March 30, 2024 and April 1, 2023, lease revenue was approximately $16.0 million and $20.0 million, respectively. Costs related to embedded leases within the Company’s deferred equipment agreements are included in cost of goods sold in the accompanying condensed consolidated statements of operations.
21
MASIMO CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(unaudited)
Lease receivable from sales-type leases consists of the following:
(in millions)March 30,
2024		December 30,
2023
Lease receivable$100.3 $101.9 
Allowance for credit loss(0.3)(0.3)
     Lease receivable, net100.0 101.6 
Less: current portion of lease receivable(29.7)(30.2)
     Lease receivable, non-current$70.3 $71.4 
As of March 30, 2024, estimated future maturities of customer sales-type lease receivables and operating lease payments for each of the following fiscal years are as follows:
Future Lease Receivables/Payments
(in millions)
Fiscal yearSales-Type LeasesOperating Leases
2024 (balance of year)$22.9 $8.5 
202525.7 10.2 
202619.8 9.4 
202714.4 7.8 
20288.0 5.6 
Thereafter9.2 9.1 
     Total$100.0 $50.6 
Less: imputed interest(1)
— 
     Present value of total lease payments$100.0 
______________
(1)     The calculation of the rates implicit in the leases resulted in negative discount rates. Therefore, the Company as a lessor used a 0% discount rate to measure the net investment in the lease.
7. Deferred Costs and Other Contract Assets
Deferred costs and other contract assets consist of the following:
(in millions)March 30,
2024		December 30,
2023
Deferred commissions$21.3 $21.8 
Unbilled contract receivables18.8 17.0 
Prepaid contract allowances16.2 17.0 
Deferred equipment agreements, net1.6 1.5 
     Deferred costs and other contract assets$57.9 $57.3 

22
MASIMO CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(unaudited)
8. Property and Equipment, net
Property and equipment, net, consists of the following:
(in millions)March 30,
2024		December 30,
2023
Machinery, equipment and tooling$173.1 $169.7 
Building and building improvements150.5 151.0 
Operating lease assets108.1 92.2 
Land(1)
54.6 66.2 
Computer equipment and software45.4 45.5 
Leasehold improvements39.6 37.5 
Transportation, vehicles and other33.5 34.0 
Furniture and office equipment18.7 20.4 
Demonstration units11.3 11.1 
Construction-in-progress (CIP)58.0 59.2 
     Total property and equipment692.8 686.8 
Accumulated depreciation(277.8)(262.4)
     Property and equipment, net(1)
$415.0 $424.4 
______________
(1)    At March 30, 2024, property, plant and equipment, net, excluded $11.4 million of idle undeveloped land classified as held for sale within the healthcare segment. The sale of land is expected to be completed within the earlier of the next 12 months or upon the closing of customary escrow and due diligence procedures. Any gain on the sale of land transaction will be recorded at the time of disposal.
For the three months ended March 30, 2024 and April 1, 2023, depreciation expense of property and equipment was $10.5 million and $11.8 million, respectively.
For the three months ended March 30, 2024 and April 1, 2023, $6.4 million and $3.0 million of equipment leased to customers was amortized to cost of goods sold, respectively. As of March 30, 2024 and December 30, 2023, accumulated amortization of equipment leased to customers was $0.4 million and $1.5 million, respectively.
The balance in CIP at March 30, 2024 and December 30, 2023 related primarily to the capitalized implementation costs related to a new enterprise resource planning software system, costs related to facility improvements, the expansion of certain key manufacturing facilities globally, machinery and equipment at the Company’s corporate headquarters, as well as on-going development costs associated with a new research and development facility, the underlying assets for which have not been completed or placed into service.
On February 14, 2022, the Company’s wholly owned subsidiary, Masimo Canada ULC, entered into a Purchase and Sale Agreement (Purchase Agreement) with Keltic (Prior) Development Limited Partnership (Vendor) for the purchase of a property in Vancouver, British Columbia, Canada for a purchase price of CAD123.0 million, plus GST (Purchase Price), subject to certain adjustments. The Company paid CAD21.0 million as a deposit towards the purchase during the year ended December 31, 2022. The balance of the Purchase Price will be due and payable upon the closing of the transaction, which is currently expected to occur in mid-2025.

23
MASIMO CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(unaudited)
9. Intangible Assets, net
Intangible assets, net, consist of the following:
March 30,
2024		December 30,
2023
(in millions)Gross Carrying
Amount		Accumulated
Amortization		Net Carrying
Amount		Gross Carrying
Amount		Accumulated
Amortization		Net Carrying
Amount
Intangible assets subject to amortization:
Customer relationships$184.4 $(15.1)$169.3 $209.2 $(31.5)$177.7 
Acquired technologies138.5 (18.6)119.9 174.7 (45.3)129.4 
Licenses45.3 (5.0)40.3 39.7 (7.4)32.3 
Capitalized software development costs48.7 (6.9)41.8 53.9 (15.2)38.7 
Patents40.8 (15.8)25.0 39.2 (15.2)24.0 
Trademarks19.1 (6.8)12.3 20.1 (7.4)12.7 
Non-compete agreements3.8 (0.4)3.4 6.3 (2.6)3.7 
Licenses-related party7.5 (6.8)0.7 7.5 (6.7)0.8 
Other1.6 (1.1)0.5 1.7 (1.1)0.6 
Total intangible assets subject to amortization, net$489.7 $(76.5)$413.2 $552.3 $(132.4)$419.9 
Intangible assets not subject to amortization:
Trademarks$222.7 $242.4 
Impairment charge— (10.0)
Total trademarks222.7 232.4 
Intangible assets, net$635.9 $652.3 
Finite lived intangible assets have a weighted-average amortization period ranging from twelve years to fourteen years. Total amortization expense for the three months ended March 30, 2024 and April 1, 2023 was $13.8 million and $14.3 million, respectively.
Total renewal costs for patents and trademarks for each of the three months ended March 30, 2024 and April 1, 2023 were $0.3 million. As of March 30, 2024, the weighted-average number of years until the next renewal was two years for patents and six years for trademarks.
Estimated amortization expense for each of the next fiscal years is as follows:
Fiscal yearAmount
(in millions)
2024 (balance of year)$44.8 
202556.1 
202644.7 
202743.3 
202843.0 
Thereafter181.3 
     Total$413.2 
Indefinite-lived intangible assets are subject to annual impairment testing, unless circumstances dictate more frequent testing, if impairment indicators exist.
24
MASIMO CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(unaudited)
In the third quarter of 2023, declines in the Company’s stock price and certain worsening macro-economic market conditions, including continued slowing in demand for consumer audio products, contributed to a significant decline in the Company’s market capitalization, which led the Company to conclude a trigger event had occurred. As a result, the Company performed a quantitative impairment assessment, which resulted in recording a $7.0 million impairment charge for indefinite-lived trademarks in the non-healthcare reporting unit. In conjunction with this third quarter interim impairment quantitative assessment, the Company concluded that both the healthcare reporting unit’s and non-healthcare reporting unit’s respective estimated fair values exceeded their carrying values. Furthermore, recoverability tests performed for other long-lived assets with finite lives indicated no recoverability issues.
During the fourth quarter of 2023, the Company performed its annual impairment analysis by first electing to complete a qualitative assessment of its indefinite-lived intangible assets. Based on this assessment, the Company determined it was not more likely than not that the fair value of the indefinite lived intangibles within the non-healthcare reporting unit exceeded their carrying values. Accordingly, the Company proceeded to perform a quantitative impairment assessment, which resulted in recording a $3.0 million impairment charge for indefinite-lived trademarks. For purposes of the impairment test, the fair value of indefinite-lived assets were determined using the same methodology as described in Note 18, “Business Combinations.” The estimates and assumptions applied represent a Level 3 measurement because they are supported by limited or no market activity and reflect the Company’s assumptions in measuring fair value.
During the fourth quarter of 2023, the Company also performed its annual goodwill impairment analysis by first electing to complete a qualitative assessment for its healthcare and non-healthcare reporting units. Based on this assessment, the Company concluded that it was more likely than not that the fair value of the healthcare reporting unit was greater than its carrying value. Accordingly, no further testing was required for the healthcare reporting unit. However, the Company concluded that it was not more likely than not that the fair value of the non-healthcare reporting unit was greater than its carrying value. Therefore, the Company proceeded to perform a quantitative assessment for its non-healthcare reporting unit.
When a quantitative assessment is required for the impairment test for goodwill, the Company uses a combination of both an income and a market approach to determine the fair value of the reporting unit. The income approach utilized the estimated discounted cash flows for the reporting unit, while the market approach utilized comparable company information. Estimates and assumptions used in the income approach to calculate projected future discounted cash flows included revenue growth rates, operating margins and a discount rate for the reporting unit. Discount rates were determined using a weighted average cost of capital for risk factors specific to the reporting unit and other market and industry data. The assumptions used are inherently subject to uncertainty and the Company noted that slight changes in these assumptions could have a significant impact on the concluded value.
The estimates and assumptions applied represent a Level 3 measurement because they are supported by limited or no market activity and reflect the Company’s assumptions in measuring fair value.
10. Goodwill
Changes in goodwill were as follows:
Three Months Ended
March 30, 2024
(in millions)HealthcareNon-healthcareTotal
Goodwill, beginning of period$98.6 $309.1 $407.7 
Foreign currency translation adjustment(1.0)(10.7)(11.7)
Goodwill, end of period$97.6 $298.4 $396.0 
25
MASIMO CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(unaudited)
11. Lessee ROU Assets and Lease Liabilities
The Company leases certain facilities in North and South America, Europe, the Middle East and Asia-Pacific regions under operating lease agreements expiring at various dates through January 2032. In addition, the Company leases equipment in the U.S. and Europe pursuant to leases that are classified as operating leases and expire at various dates through November 2028. The majority of these leases are non-cancellable and generally do not contain any material restrictive covenants, material residual value guarantees, or other material guarantees. The Company recognizes lease costs under these agreements using a straight-line method based on total lease payments. Certain facility leases contain predetermined price escalations and in some cases renewal options, the longest of which is for five years.
The Company generally estimates the applicable discount rate used to determine the net present value of lease payments based on available information at the lease commencement date. As of March 30, 2024, the weighted-average discount rate used by the Company for all operating leases was approximately 4.2%.
The balance sheet classifications for amounts related to the Company’s operating leases for which it is the lessee are as follows:
(in millions)Balance sheet classificationMarch 30,
2024		December 30,
2023
Lessee ROU assetsOther non-current assets$75.1 $59.1 
Lessee current lease liabilitiesOther current liabilities19.3 18.2 
Lessee non-current lease liabilitiesOther non-current liabilities61.5 45.8 
     Total operating lease liabilities$80.8 $64.0 
As of March 30, 2024 and December 30, 2023, accumulated amortization for lessee ROU assets was $53.8 million and $48.9 million, respectively. The weighted-average remaining lease term for the Company’s operating leases was 5.4 years as of March 30, 2024.
As of March 30, 2024, estimated future operating lease payments for each of the following fiscal years were as follows:
Fiscal yearAmount
(in millions)
2024 (balance of year)$16.9 
202519.9 
202615.6 
202711.1 
202810.4 
Thereafter(1)
18.8 
   Total92.7 
   Imputed interest(11.9)
   Present value$80.8 
______________
(1)     Includes optional renewal period for certain leases.
During the three months ended March 30, 2024 and April 1, 2023, operating lease costs were approximately $5.8 million and $5.1 million, respectively.
During the three months ended March 30, 2024, as part of the Company’s on-going rationalization of its operational footprint of the non-healthcare business, one operating lease was identified as under-utilized and considered temporarily idled due to the inability to sublease the property timely while having three years remaining on the lease term. The ROU asset had a net carrying value of approximately $5.8 million and the undiscounted future expected cash flows total $1.5 million. The recoverability test failed due to the undiscounted cash flows being less than the carrying value of the ROU asset. As a result, the Company recorded an impairment charge of approximately $3.9 million during the three months ended March 30, 2024, which was recorded in selling, general, and administrative expenses in the condensed consolidated statement of operations.
26
MASIMO CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(unaudited)
12. Other Non-Current Assets
Other non-current assets consist of the following:
(in millions)March 30,
2024		December 30,
2023
Lessee ROU assets, net$75.1 $59.1 
Derivative assets - non-current(1)
14.3 11.4 
Prepaid deposits and other7.5 6.4 
Strategic investments6.9 7.2 
Restricted cash(2)
3.4 2.2 
Equity investments - fair value2.6 2.7 
Other non-current assets0.1 0.3 
  Total non-current assets$109.9 $89.3 
______________
(1)    Excludes accrued interest.
(2)    Restricted cash includes cash held in certain subsidiaries in jurisdictions outside of the U.S. such as China, which may be subject to transfer restrictions depending on jurisdictions.
13. Deferred Revenue and Other Contract Liabilities, Current
Deferred revenue and other contract liabilities, current, consist of the following:
(in millions)March 30,
2024		December 30,
2023
Deferred revenue$63.1 $63.8 
Accrued rebates and allowances23.0 37.5 
Accrued customer reimbursements10.3 12.4 
     Total deferred revenue and other contract liabilities96.4 113.7 
Less: Non-current portion of deferred revenue(26.4)(26.4)
     Deferred revenue and other contract liabilities, current$70.0 $87.3 
Deferred revenue relates to contracted amounts that have been invoiced to customers for which remaining performance obligations must be completed before the Company can recognize revenue. Generally, both healthcare and non-healthcare segments record deferred revenue when revenue is to be recognized subsequent to invoicing.
Healthcare Deferred Revenue
Healthcare deferred revenue primarily relates to undelivered equipment, sensors and services under deferred equipment agreements, extended warranty agreements, and maintenance agreements. Expected revenue from remaining contractual performance obligations (Unrecognized Contract Revenue) includes deferred revenue, as well as other amounts that will be invoiced and recognized as revenue in future periods when the Company completes its performance obligations. Unrecognized Contract Revenue excludes revenue allocable to monitoring-related equipment that is effectively leased to customers under deferred equipment agreements and other contractual obligations for which neither party has performed. The estimated timing of this revenue is based, in part, on management’s estimates and assumptions about when its performance obligations will be completed. As a result, the actual timing of this revenue in future periods may vary, possibly materially. As of March 30, 2024, the Company had approximately $1,508.3 million of Unrecognized Contract Revenue related to executed contracts with an original duration of one year or more. The Company expects to recognize approximately $395.8 million of this amount as revenue within the next twelve months and the remaining balance thereafter.
27
MASIMO CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(unaudited)
Non-Healthcare Deferred Revenue
In October 2020, the Company’s subsidiary, B&W Group Ltd. (B&W), entered into an amendment to a licensing agreement, whereby B&W received a $20.0 million royalty prepayment in relation to sound system units manufactured under the Bowers & Wilkins brand for various high-end car manufacturers with a total commitment of $35.0 million to be received by September 30, 2028. As of March 30, 2024, deferred revenue was $14.6 million.
Changes in deferred revenue were as follows:
(in millions)Three Months Ended
March 30,
2024
Deferred revenue, beginning of the period$63.8 
  Revenue deferred during the period8.4 
  Recognition of revenue deferred in prior periods(9.1)
     Deferred revenue, end of the period$63.1 
14. Other Current Liabilities
Other current liabilities consist of the following:
(in millions)March 30,
2024		December 30,
2023
Long-term debt, current$34.6 $34.3 
Accrued indirect taxes payable29.1 23.9 
Accrued expenses27.6 26.3 
Lessee lease liabilities, current 19.3 18.2 
Income tax payable10.5 16.1 
Other current liabilities(1)
9.6 6.7 
Accrued property taxes9.4 10.2 
Accrued warranty8.1 8.6 
Accrued legal fees7.7 9.9 
Related party payables5.0 4.2 
Accrued donations2.0 4.0 
Licensing agreement, current3.0 — 
     Total other current liabilities$165.9 $162.4 
__________________
(1)    At March 30, 2024, other current liabilities included approximately $0.5 million of refundable deposits during the due diligence period related to certain assets held for sale.
28
MASIMO CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(unaudited)
15. Debt
(in millions)March 30,
2024		December 30,
2023
Term loan - current portion$13.1 $11.3 
Japanese loans - current portion21.5 23.0 
Debt, current portion34.6 34.3 
Term loan - long-term268.1 271.4 
Revolver - long-term565.5 591.5 
Japanese loans - long-term7.8 8.8 
Debt, long-term841.4 871.7 
Total debt$876.0 $906.0 
Credit Facility
On April 11, 2022, the Company entered into a credit agreement (Credit Facility) with financial institutions party thereto as initial lenders (collectively, the Initial Lenders), Citibank, N.A., as Administrative Agent, Citibank, N.A., JPMorgan Chase Bank, N.A., Bank of the West and BofA Securities, Inc., as joint lead arrangers and joint bookrunners, and JPMorgan Chase Bank, N.A., Bank of the West and BofA Securities, Inc., as co-syndication agents.
The Credit Facility provides for an unsecured term loan of $300.0 million (Term Loan) and $500.0 million of ongoing unsecured revolving commitments (Revolver), with an option, subject to certain conditions, for the Company to increase the aggregate borrowing capacity by an additional $400.0 million (plus additional unlimited amounts if certain incurrence tests are met) in the future with the Initial Lenders and additional lenders, as required. Debt issuance costs of $8.4 million were recorded as a reduction to the carrying amount of the Credit Facility and are being amortized to interest expense using the effective interest method.
The Credit Facility also provides for a sublimit of up to $50.0 million for the issuance of letters of credit.
Borrowings under the Credit Facility will be deemed, at the Company’s election, either: (a) an Alternate Base Rate (ABR) Loan, which bears interest at the ABR, plus a spread of 0.000% to 0.750% based upon a Company leverage ratio, or (b) a Term SOFR Loan, which bears interest at the Adjusted Term SOFR Rate (as defined below), plus a spread of 1.000% to 1.750% based upon a Company net leverage ratio. Pursuant to the terms of the Credit Facility, the ABR is equal to the greatest of (i) the prime rate, (ii) the Federal Reserve Bank of New York effective rate plus 0.50%, and (iii) the one-month Adjusted Term SOFR plus 1.0%. The Adjusted Term SOFR Rate is equal to the Term SOFR Rate (as defined in the Credit Facility) for the applicable interest period plus a spread adjustment of 0.10%, 0.15% and 0.25% for the interest periods ending one, three and six months, respectively.
The Company is also obligated under the Credit Facility to pay an unused fee ranging from 0.150% to 0.275% per annum, based upon a Company leverage ratio, with respect to any non-utilized portion of the Credit Facility.
The Company is subject to certain covenants, including financial covenants related to a net leverage ratio and an interest charge coverage ratio, and other customary negative covenants. The Credit Facility also includes customary events of default which, upon the occurrence of any such event of default, provide the Initial Lenders (and any additional lenders) with the right to take either or both of the following actions: (a) immediately terminate the commitments, and (b) declare the loans then outstanding immediately due and payable in full. All unpaid principal under the Credit Facility will become due and payable on April 12, 2027.
On May 16, 2022, the Company entered into the First Amendment to the Credit Agreement (First Amendment) with the Initial Lenders and Citibank, N.A., as the administrative agent, which amended the Credit Facility. The First Amendment provides for an additional $205 million of unsecured revolving commitments, increasing the aggregate amount of the Revolver from $500 million to $705 million.
29
MASIMO CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(unaudited)
Borrowing rates, financial covenants, affirmative and negative covenants and other restricted terms remain unchanged from the Credit Facility. All unpaid principal under the First Amendment will become due and payable on April 12, 2027. The Company was in full compliance with all covenants contained in its debt agreements and Credit Facility agreements as of March 30, 2024.
For the three months ended March 30, 2024 and April 1, 2023, the Company incurred total interest expense of $11.2 million and $10.9 million under the Credit Facility, respectively.
Furthermore, in connection with the Sound United acquisition, the Company assumed three outstanding loans as follows:
Japanese Revolving Loan
In March 2020, the Company entered into a secured revolving loan (Japanese Revolving Loan) with Mizuho bank, which allows the Company to borrow up to ¥800 million (approximately $5.3 million). The Japanese Revolving Loan is an evergreen agreement that terminates upon request by either the financial institution or the borrower and is collateralized with land and buildings in Shirakawa-Shi owned by the borrower. Interest accrues at a rate equal to the Mizuho Tokyo Interbank Offered Rate (TIBOR) plus a fixed spread of 0.50% per annum. In connection with the execution of the Japanese Revolving Loan, the Company incurred debt issuance costs of ¥7.2 million (approximately $0.05 million).
On February 28, 2023, the Company and Mizuho Bank executed an amendment to the Japanese Revolving Loan, to increase the maximum aggregate revolving loan to ¥3.00 billion (approximately $19.8 million). Under the amendment, the facility accrues interest at a rate equal to the TIBOR plus a fixed spread of 0.75% per annum. The Company also paid an upfront fee of ¥22.0 million (approximately $0.1 million) on the incremental amount of the revolving Credit Facility.
The Japanese Revolving Loan agreement contains customary affirmative and negative covenants, such as financial reporting requirements and customary covenants that restrict the borrower’s ability to, among other things, provide collateral for obligations borne by the borrower, and determine the eligibility to declare, and amount of potential dividends to be paid during a given fiscal year. As of March 30, 2024, the Company was in compliance with all covenants under the Japanese Revolving Loan agreements.
Japanese Government Loans
In May and June 2020, the Company received ¥1.48 billion (approximately $9.8 million) in non-collateralized Japanese Government Loan facilities (Japanese Government Loans) as part of its local Japanese stimulus program. Interest accrues at a weighted average rate of 1.33% and is repayable in installments with various maturities through June 2035. The non-current portion of the Japanese Government Loans is presented under long-term debt and the current portion is presented under short-term debt on the accompanying condensed consolidated balance sheets. The Company incurred no debt issuance costs in connection with the Japanese Government Loans.
Japanese Equipment Loans
In April and May 2021, the Company entered into collateralized Japanese Equipment Loans of ¥150 million (approximately $1.0 million), payable in installments through March 2031 with an interest of 0.58%, and ¥80 million (approximately $0.5 million) payable in installments through April 2028 with interest of 1.2%. The non-current portion of the Japanese Equipment Loans is presented under long-term debt and the current portion is presented under short-term debt on the accompanying condensed consolidated balance sheets. The Company incurred no debt issuance costs in connection with these Japanese Equipment Loans.
30
MASIMO CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(unaudited)
As of March 30, 2024, the aggregate maturities of principal on all debt for each of the next five years and thereafter are as follows:
Fiscal yearAmount
(in millions)
2024 (balance of year)$30.5 
202516.6 
202616.6 
2027809.0 
20281.0 
Thereafter2.3 
Total$876.0 
16. Other Non-Current Liabilities
Other non-current liabilities consist of the following:
(in millions)March 30,
2024		December 30,
2023
Lessee non-current lease liabilities$61.5 $45.8 
Unrecognized tax benefits26.8 24.4 
Deferred revenue, non-current26.4 26.4 
Projected benefit obligation9.2 9.5 
Income tax payable, non-current7.1 7.1 
Licensing agreement, non-current
4.5 — 
Indirect tax payable, non-current— 8.4 
Other4.5 7.9 
     Total other non-current liabilities$140.0 $129.5 
Unrecognized tax benefits relate to the Company’s long-term portion of tax liability associated with uncertain tax positions. Authoritative guidance prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. See Note 23, “Income Taxes”, for further details.
17. Derivative Instruments and Hedging Activities
Derivative Instruments - Cash Flow Hedges
The Company’s cash flow hedges are designed to mitigate the risk of exposure to variability in expected future cash flows of recognized assets, liabilities or any unrecognized forecasted transactions. Since July 2022, the Company has entered into various interest rate swaps that are designated as cash flow hedges on a substantial portion of the Company’s outstanding debt. The interest rate swaps reduce the variability of cash flow payments for the Company by converting the variable interest rate on the Company’s long-term debt to an average fixed interest rate of 3.22%. These contracts, carried at fair value, have maturities of approximately three years. All hedging relationships were highly effective at achieving offsetting changes in cash flows attributable to the risk being hedged. The Company used a regression analysis at hedge inception to assess the effectiveness of cash flow hedge and periodically thereafter.
The Company records gains and losses from the changes in the fair value of these instruments as a component of other comprehensive (loss) income. Deferred gains or losses from these designated cash flow hedges are reclassified into earnings in the period that the hedged items affect earnings. The Company does not offset fair value amounts recognized for derivative instruments in its condensed consolidated balance sheets for presentation purposes. The following table summarizes the fair value of the hedging instruments, presented on a gross basis, as of March 30, 2024 and December 30, 2023.
31
MASIMO CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(unaudited)
Condensed Consolidated
Balance Sheets
(in millions)Balance sheet classificationMarch 30,
2024		December 30,
2023
Interest rate contracts, inclusive of accrued interest
Other non-current assets
$14.4 $11.6 
Interest rate contracts, inclusive of accrued interest
Other non-current liabilities
— (3.6)
Total$14.4 $8.0 
The following table summarizes the gains (losses) reclassified from accumulated other comprehensive (loss) income to the condensed consolidated financial statements for the three months ended March 30, 2024 and April 1, 2023.
Cash flow hedgesCondensed Consolidated
Statement of Operations
Three Months Ended
(in millions)Location of gains (losses)March 30,
2024		April 1,
2023
Interest rate contracts
Non-operating (loss)
$(4.3)$(3.0)
Total$(4.3)$(3.0)
The following tables summarize the changes in accumulated other comprehensive income (loss) related to the hedging instruments for the three months and three months ended March 30, 2024 and April 1, 2023.
Three Months Ended
(in millions)March 30,
2024		April 1,
2023
Beginning balance$7.8 $19.3 
Amount recognized in other comprehensive income (loss)
10.8 (2.7)
Amount reclassified into earnings(4.3)(3.0)
Ending balance$14.3 $13.6 
For the three months ended March 30, 2024, the unrealized gain, net of tax was $4.9 million. For the three months ended April 1, 2023, the unrealized loss, net of tax was $4.3 million.
The Company expects to reclassify a net amount of gains of $11.8 million from accumulated other comprehensive (loss) income to non-operating (loss) income within the next 12 months.
18. Business Combinations
Sound United Acquisition
On April 11, 2022, the Company completed the previously announced acquisition of Sound United, pursuant to a Merger Agreement dated as of February 15, 2022, by and among the Company, Sonic Boom Acquisition Corp., a wholly-owned subsidiary of the Company (Merger Sub), Viper Holdings Corporation (Sound United), and, solely in its capacity as the Seller Representative, Viper Holdings, LLC, pursuant to which Merger Sub merged with and into Sound United, with Sound United continuing as a wholly-owned subsidiary of the Company (Merger).
Sound United is a leading innovator of premium, high-performance audio products for consumers around the world, which operates iconic consumer brands: Bowers & Wilkins®, Denon™, Marantz™, HEOS™, Classé™, Polk Audio™, Boston Acoustics™ and Definitive Technology™. The brands are linked by a commitment to the highest production standards and a focus on unparalleled audio quality and audio performance. Sound United delivers significant competitive benefits through its platform advantages including global distribution across online, retail, and custom installation channels; a cloud-connected home ecosystem; and a state-of-the-art research and development function focused on creating the highest-quality consumer products with world-class industrial design.
32
MASIMO CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(unaudited)
The Company acquired 100% of the equity interests of Sound United for $1.0575 billion in cash, subject to adjustments based on Sound United’s net working capital, transaction expenses, cash and debt as of the closing of the Merger, payable by the Company in cash. The transaction was primarily funded with the proceeds from the Credit Facility. See Note 15, “Debt”, for additional information about the Credit Facility. There was no contingent consideration resulting from the transaction.
The results of operations of Sound United subsequent to the acquisition date and the acquired assets and assumed liabilities, including the allocation of goodwill and intangible assets, are included in the non-healthcare segment. For the three months ended April 1, 2023, the Company recorded revenue of $216.6 million and a net loss of $3.3 million from Sound United, respectively. For the three months ended March 30, 2024, the Company recorded revenue of $152.4 million and a net loss of $11.6 million from Sound United, respectively.
Acquisition Costs
The Company recognized no transaction costs related to the Sound United acquisition for the three months ended March 30, 2024 and April 1, 2023, respectively.
Purchase Price Allocations
The purchase price allocation for the Sound United acquisition is final. Goodwill was calculated as the excess of the consideration transferred over the fair value of the identifiable net assets acquired in a business combination and represents the future economic benefits expected to arise from intangible assets acquired that do not qualify for separate recognition, including the assembled workforce. Goodwill is not expected to be deductible for tax purposes.
The measurement period adjustments resulted primarily from valuation inputs pertaining to certain acquired assets based on facts and circumstances that existed as of the acquisition date and did not result from events subsequent to the acquisition date.
The table below summarizes the final allocation of fair value of assets acquired and liabilities assumed.
(in millions)Sound United
Cash consideration
$1,057.5 
Purchase price$1,057.5 
Assets acquired:
Cash and cash equivalents$82.6 
Accounts receivables108.5 
Inventories238.6 
Prepaid expenses and other current assets30.0 
Property, plant and equipment113.2 
Intangible assets
649.0 
Goodwill
318.0 
Long-term other assets7.4 
Total assets acquired$1,547.3 
Liabilities assumed:
Accounts payable$(118.8)
Accrued liabilities and other current liabilities(148.9)
Deferred tax liabilities(145.1)
Other long-term liabilities(77.0)
Total liabilities assumed$(489.8)
33
MASIMO CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(unaudited)
Identifiable Intangible Assets
The following table sets forth the components of identifiable intangible assets acquired and the weighted average amortization period as of the acquisition date:
Weighted average
amortization period
(in years)		April 11,
 2022
(in millions)
Trademarks/tradenames10$6.0 
Customer relationships17196.0 
Developed technology8156.0 
Contractual license agreements1529.0 
Subtotal14 years$387.0 
Indefinite trademarks/tradenamesN/A262.0 
Total$649.0 
In determining the fair value of the identifiable intangible assets, the Company utilized various forms of the income approach, depending on the asset being valued. The estimation of fair value requires significant judgment related to cash flow forecasts, discount rates reflecting the risk inherent in each cash flow stream, competitive trends, market comparables and other factors. Other inputs included historical data, current and anticipated market conditions, and growth rates. Contractual license agreements have a weighted-average amortization period of five years until the next renewal term.
The intangible assets were valued using the following valuation approaches:
Customer relationships
The fair value of customer relationships was determined using the multi-period excess earnings method. The multi-period excess earnings method involves forecasting the net earnings expected to be generated by the asset, reducing them by appropriate returns on contributory assets, and then discounting the resulting net cash flows to a present value using an appropriate discount rate.
Trademarks/tradenames
The fair values of the trademark/tradenames were determined using the relief-from-royalty method under the income approach. This involves forecasting avoided royalties, reducing them by taxes, and discounting the resulting net cash flows to a present value using an appropriate discount rate. Judgment was applied for a number of assumptions in valuing the identified intangible assets, including revenue and cash flow forecasts, survival rates, technology life, royalty rate, obsolescence and discount rate.
Developed technology
The fair values of the developed technology were determined using the relief-from-royalty method under the income approach. This involves forecasting avoided royalties, reducing them by taxes, and discounting the resulting net cash flows to a present value using an appropriate discount rate. Judgment was applied for a number of assumptions in valuing the identified intangible assets including revenue and cash flow forecasts, survival rates, technology life, royalty rate, obsolescence and discount rate.
Contractual licensing agreements
The fair value of the contractual license agreements was determined using a variation of the multi-period excess earnings method. This method involves forecasting the net earnings expected to be generated by the asset and then discounting the resulting net cash flows to a present value using an appropriate discount rate.
34
MASIMO CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(unaudited)
19. Equity
Series A Junior Participating Preferred Stock and Stockholder Rights Plan
In September 2022, the Company authorized and declared a dividend of one preferred stock purchase right (Right) for each outstanding share of its common stock to stockholders of record at the close of business on September 20, 2022 (the Record Date) pursuant to a Rights Agreement, dated as of September 9, 2022 (Rights Agreement), with Broadridge Corporate Issuer Solutions, Inc. as Rights Agent. In addition, one Right was issued with each share of common stock that became outstanding after the Record Date. Each Right entitled the registered holder to purchase from the Company one thousandth of one share of the Company’s Series A junior participating preferred stock, par value $0.001 per share, at a purchase price equal to $1,000.00 per Right, subject to adjustment. Generally, the Rights were to become exercisable in the event any person or group of affiliated or associated persons acquires beneficial ownership of 10% (20% in the case of a passive institutional investor), subject to certain exceptions.
On March 22, 2023, the Company and the Rights Agent entered into an amendment (Rights Agreement Amendment) to the Rights Agreement. The Rights Agreement Amendment accelerated the expiration of the Rights to 5:00 P.M., New York time, on March 22, 2023, and the Rights Agreement terminated at such time. At the time of the termination of the Rights Agreement, all Rights distributed to holders of the Company’s common stock pursuant to the Rights Agreement expired.
Stock Repurchase Program
In June 2022, the Board approved a stock repurchase program, authorizing the Company to purchase up to 5.0 million shares of its common stock on or before December 31, 2027 (2022 Repurchase Program). The 2022 Repurchase Program became effective in July 2022. The Company expects to fund the 2022 Repurchase Program through its available cash, cash expected to be generated from future operations, the Credit Facility and other potential sources of capital. The 2022 Repurchase Program can be carried out at the discretion of a committee comprised of the Company’s CEO and CFO through open market purchases, one or more Rule 10b5-1 trading plans, block trades and privately negotiated transactions. No shares were repurchased pursuant to the 2022 Repurchase Program during the three months ended March 30, 2024. As of March 30, 2024, 5.0 million shares remained available for repurchase pursuant to the 2022 Repurchase Program.
20. Stock-Based Compensation
Total stock-based compensation expense for the three months ended March 30, 2024 and April 1, 2023 was $9.6 million and $7.3 million, respectively. The stock-based compensation expense amounts for the three months ended March 30, 2024 reflect adjustments for the expected life-to-date achievement of certain PSUs. The Company reassesses the expected achievement of such PSU awards based upon the achievement of certain pre-established multi-year performance criteria approved by the Board at the date of grant.
As of March 30, 2024, an aggregate of 9.7 million shares of common stock were reserved for future issuance under the Company’s equity plans, of which 3.1 million shares were available for future grant under the Masimo Corporation 2017 Equity Incentive Plan (2017 Equity Plan). Additional information related to the Company’s current equity incentive plans, stock-based award activity and valuation of stock-based awards is included below.
Equity Incentive Plans
2017 Equity Incentive Plan
On June 1, 2017, the Company’s stockholders ratified and approved the 2017 Equity Plan. The 2017 Equity Plan permits the grant of stock options, restricted stock, RSUs, stock appreciation rights, PSUs, performance shares, performance bonus awards and other stock or cash awards to employees, directors and consultants of the Company and employees and consultants of any parent or subsidiary of the Company. Upon effectiveness, an aggregate of 5.0 million shares were available for issuance under the 2017 Equity Plan. In May 2020, the Company’s stockholders approved an increase of 2.5 million shares to the 2017 Equity Plan. The aggregate number of shares that may be awarded under the 2017 Equity Plan is 7.5 million shares. The 2017 Equity Plan provides that at least 95% of the equity awards issued under the 2017 Equity Plan must vest over a period of not less than one year following the date of grant. The exercise price per share of each option granted under the 2017 Equity Plan may not be less than the fair market value of a share of the Company’s common stock on the date of grant, which is generally equal to the closing price of the Company’s common stock on the Nasdaq Global Select Market on the grant date.
35
MASIMO CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(unaudited)
2007 Stock Incentive Plan
Effective June 1, 2017, upon the approval and ratification of the 2017 Equity Plan, the Company’s 2007 Stock Incentive Plan (2007 Equity Plan) terminated, provided that awards outstanding under the 2007 Equity Plan will continue to be governed by the terms of that plan. In addition, upon the effectiveness of the 2017 Equity Plan, an aggregate of 5.0 million shares of the Company’s common stock registered under prior registration statements for issuance pursuant to the 2007 Equity Plan were deregistered and concurrently registered under the 2017 Equity Plan.
Stock-Based Award Activity
Stock Options
The number and weighted-average exercise price of options issued and outstanding under all of the Company’s equity plans are as follows:
Three Months Ended
March 30, 2024
(in millions, except for weighted-average exercise prices)
SharesWeighted-Average
Exercise Price
Options outstanding, beginning of period2.8 $87.79 
Granted0.1 126.49 
Canceled— 162.00 
Exercised(0.2)44.11 
Options outstanding, end of period2.7 $91.51 
Options exercisable, end of period2.3 $80.43 
Total stock option expense for the three months ended March 30, 2024 and April 1, 2023 was $2.1 million and $2.4 million, respectively. As of March 30, 2024, the Company had $19.6 million of unrecognized compensation cost related to non-vested stock options that are expected to vest over a weighted-average period of approximately 3.1 years.
RSUs
The number of RSUs issued and outstanding under all of the Company’s equity plans are as follows:
Three Months Ended
March 30, 2024
(in millions, except for weighted-average grant date fair value amounts)
UnitsWeighted-Average Grant
 Date Fair Value
RSUs outstanding, beginning of period3.5 $105.87 
Granted0.2 126.36 
Expired— 157.76 
Vested(0.1)178.68 
RSUs outstanding, end of period3.6 $104.94 
Total RSU expense for the three months ended March 30, 2024 and April 1, 2023 was $7.2 million and $4.2 million, respectively. As of March 30, 2024, the Company had $106.4 million of unrecognized compensation cost related to non-vested RSU awards expected to be recognized and vest over a weighted-average period of approximately 3.7 years.
36
MASIMO CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(unaudited)
PSUs
The number of PSUs outstanding under all of the Company’s equity plans are as follows:
Three Months Ended
March 30, 2024
(in millions, except for weighted-average grant date fair value amounts)UnitsWeighted-Average Grant
 Date Fair Value
PSUs outstanding, beginning of period0.3 $190.04 
Granted(1)
0.1 164.19 
Expired— 250.73 
Vested— 250.73 
PSUs outstanding, end of period0.4 $170.69 
______________
(1)     On February 28, 2024, the Audit Committee approved the weighted payout percentage of 28% for the 2021 PSU awards (three-year performance period), which were based upon the actual fiscal 2023 performance against pre-established performance objectives. Included in the granted amount are those additional PSUs earned based on actual performance achieved. These PSUs were originally awarded at target.
During the three months ended March 30, 2024, the Company awarded 155,156 PSUs that will vest three years from the award date, based on the achievement of certain pre-established multi-year performance criteria approved by the Board. Estimates of stock-based compensation expense for an award with performance conditions are based on the probable outcome of the performance conditions and the cumulative effect of any changes in the probability outcomes is recorded in the period in which the changes occur. If earned, the PSUs granted will vest upon achievement of the performance criteria, which include a relative total shareholder return (TSR) component, in the year following the evaluation and confirmation of the performance achievement criteria. The Company’s TSR is based on the Company’s common stock percentile ranking relative to the constituents of the Nasdaq Composite Index for the performance period beginning on January 1, 2024 and ending on December 31, 2026. The number of shares that may be earned can range from 0% to 200% of the target amount. The fair value of market-based RSUs is determined using a Monte Carlo simulation model, which uses multiple input variables to determine the probability of satisfying the market condition requirements. The fair value of performance-based PSUs is determined using the closing price of the Company’s common stock on the grant date. Based on management’s estimate of the number of units expected to vest, total PSU expense for the three months ended March 30, 2024 and April 1, 2023 was $0.3 million and $0.7 million, respectively. The PSU expense amounts for the three months ended March 30, 2024 relate to adjustments for the expected life-to-date performance of the PSU. As of March 30, 2024, the Company had $40.4 million of unrecognized compensation cost related to non-vested PSU awards expected to be recognized and vest over a weighted-average period of approximately 1.9 years.
Valuation of Stock-Based Award Activity
The fair value of each RSU and PSU is determined based on the closing price of the Company’s common stock on the grant date.
The Black-Scholes option pricing model is used to estimate the fair value of options granted under the Company’s stock-based compensation plans. The range of assumptions used and the resulting weighted-average fair value of options granted at the date of grant were as follows:
Three Months Ended
March 30,
2024
April 1,
2023
Risk-free interest rate4.2%4.2%
Expected term (in years)5.95.9
Estimated volatility42.6%36.7%
Expected dividends—%—%
Weighted-average fair value of options granted$59.60$75.08
37
MASIMO CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(unaudited)
The aggregate intrinsic value of options is calculated as the positive difference, if any, between the market value of the Company’s common stock on the date of exercise or the respective period end, as appropriate, and the exercise price of the options. The aggregate intrinsic value of options outstanding with an exercise price less than the closing price of the Company’s common stock as of March 30, 2024 was $169.8 million. The aggregate intrinsic value of options exercisable with an exercise price less than the closing price of the Company’s common stock as of March 30, 2024 was $167.4 million.
21. Employee Benefits
Defined Contribution Plans
In the U.S. the Company sponsors one qualified defined contribution plan or 401(k) plan, the Masimo Retirement Savings Plan (MRSP), covering the Company’s full-time U.S. employees who meet certain eligibility requirements. On April 11, 2022, in connection with the Sound United acquisition, the MRSP was amended to allow for participation by eligible Sound United employees.
The MRSP matches 100% of a participant’s salary deferral, up to 3% of each participant’s compensation for the pay period, subject to a maximum amount. The Company may also contribute to the MRSP on a discretionary basis. The Company contributed $1.3 million and $2.3 million to the MRSP for the three months ended March 30, 2024 and April 1, 2023, respectively, all in the form of matching contributions.
In addition, some of the Company’s international subsidiaries also have defined contribution plans to which both the employee and employers are eligible to make contributions. The Company contributed $1.6 million and $0.8 million to these plans for the three months ended March 30, 2024 and April 1, 2023, respectively.
Defined Benefit Plans
The Company sponsors several international noncontributory defined benefit plans. In connection with the Sound United acquisition, the Company assumed sponsorship of several international defined benefit plans and post-retirement benefit plans. All defined benefit plans and post-retirement benefit plans assumed by the Company were closed to new participants prior to the Sound United acquisition.
The service cost component for the defined benefit plans are recorded in operating expenses in the condensed consolidated statement of operations. All other cost components are recorded in other income (expense), net in the condensed consolidated statement of operations.
The Company’s net periodic defined benefit costs for each of the three months ended March 30, 2024, and April 1, 2023 were immaterial.
22. Non-operating Loss
Non-operating loss consists of the following:
Three Months Ended
(in millions)March 30,
2024		April 1,
2023
Realized and unrealized foreign currency gains (losses)1.9 (0.7)
Interest income$1.2 $0.8 
Interest expense(12.0)(11.9)
Other(0.2)— 
Total non-operating loss$(9.1)$(11.8)
38
MASIMO CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(unaudited)
23. Income Taxes
The Company has provided for income taxes in fiscal year 2024 interim periods based on the estimated effective income tax rate for the complete fiscal year, as adjusted for discrete tax events, including excess tax benefits or deficiencies related to stock-based compensation, in the period such events occur. The estimated annual effective tax rate is computed based on the expected annual pretax income of the consolidated entities located within each taxing jurisdiction based on legislation enacted as of the balance sheet date. For the three months ended March 30, 2024 and April 1, 2023, the Company recorded discrete tax benefits of approximately $1.3 million and $2.4 million, respectively, related to excess tax benefits realized from stock-based compensation.
Deferred tax assets and liabilities are determined based on the future tax consequences associated with temporary differences between income and expenses reported for accounting and tax purposes. A valuation allowance for deferred tax assets is recorded to the extent that the Company cannot determine that the ultimate realization of the net deferred tax assets is more likely than not. Realization of deferred tax assets is principally dependent upon the achievement of future taxable income, the estimation of which requires significant judgment by the Company’s management. The judgment of the Company’s management regarding future profitability may change due to many factors, including future market conditions and the Company’s ability to successfully execute its business plans or tax planning strategies. These changes, if any, may require material adjustments to these deferred tax asset balances.
As of March 30, 2024, the liability for income taxes associated with uncertain tax positions was approximately $35.3 million. If fully recognized, approximately $32.7 million (net of federal benefit on state taxes) would impact the Company’s effective tax rate. It is reasonably possible that the amount of unrecognized tax benefits in various jurisdictions may change in the next twelve months due to the expiration of statutes of limitation and audit settlements. However, due to the uncertainty surrounding the timing of these events, an estimate of the change within the next twelve months cannot currently be made.
The Company conducts business in multiple jurisdictions and, as a result, one or more of the Company’s subsidiaries files income tax returns in U.S. federal, various state, local and foreign jurisdictions. The Company has concluded all U.S. federal income tax matters through fiscal year 2019. All material state, local and foreign income tax matters have been concluded through fiscal year 2016. The Company does not believe that the results of any tax authority examination would have a significant impact on its consolidated financial statements.
24. Commitments and Contingencies
Employment and Severance Agreements
In July 2017, the Company entered into the First Amendment to that certain Amended and Restated Employment Agreement entered into between the Company and Mr. Kiani on November 4, 2015 (as amended, the Amended Employment Agreement). Pursuant to the terms of the Amended Employment Agreement, upon a “Qualifying Termination” (as defined in the Amended Employment Agreement), Mr. Kiani will be entitled to receive a cash severance benefit equal to two times the sum of his then-current base salary and the average annual bonus paid to Mr. Kiani during the immediately preceding three years, the full amount of the “Award Shares” (as defined in the Amended Employment Agreement) and the full amount of the “Cash Payment” (as defined in the Amended Employment Agreement). In addition, in the event of a “Change-in-Control” (as defined in the Amended Employment Agreement) prior to a Qualifying Termination, on each of the first and second anniversaries of the Change-in-Control, 50% of the Cash Payment and 50% of the Award Shares will vest, subject in each case to Mr. Kiani’s continuous employment through each such anniversary date; however, in the event of a Qualifying Termination or a termination of Mr. Kiani’s employment due to death or disability prior to either of such anniversaries, any unvested amount of the Cash Payment and all of the unvested Award Shares shall vest and be paid in full. Additionally, in the event of a Change-in-Control prior to a Qualifying Termination, Mr. Kiani’s stock options and any other equity awards will vest in accordance with their terms, but in no event later than in two equal installments on each of the one year and two year anniversaries of the Change-in- Control, subject in each case to Mr. Kiani’s continuous employment through each such anniversary date.
On January 14, 2022, the Company entered into the Second Amendment to the Amended Employment Agreement (Second Amendment) with Mr. Kiani. The Second Amendment provides that the RSUs granted to Mr. Kiani pursuant to the Amended Employment Agreement will vest in full upon the termination of Mr. Kiani’s employment with the Company pursuant to Mr. Kiani’s death or disability.
39
MASIMO CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(unaudited)
On February 8, 2023, Mr. Kiani agreed that the valid election to the Company’s Board of Directors (Board) at the Company’s 2023 Annual Meeting of Stockholders (2023 Annual Meeting) of any two individuals nominated by the Company’s stockholders in lieu of two of the Company’s then-current Board members would not be deemed to constitute a “Change in Control” for purposes of Section 9(iii) of the Amended Employment Agreement.
On March 22, 2023, in connection with the Board’s unanimous selection of H Michael Cohen as Lead Independent Director, Mr. Kiani voluntarily irrevocably and permanently waived his right to treat the appointment of any lead independent director as “Good Reason”, to terminate his employment under the Amended Employment Agreement, and his right to receive contractual separation payments on this basis.
On June 5, 2023, Mr. Kiani, pursuant to a Limited Waiver (Waiver), unconditionally, irrevocably and permanently waived his right, pursuant to the Amended Employment Agreement, to assert that a “Change in Control” has occurred pursuant to Section 9(iii) of the Amended Employment Agreement unless the individuals who constituted the Board at the beginning of the twelve (12) month period immediately preceding such change, as defined in Section 9(iii) of the Amended Employment Agreement, cease for any reason to constitute one-half or more of the directors then in office. In addition, Mr. Kiani agreed that, for purposes of determining whether such a “Change in Control” has occurred, any individual elected to the Board at the Company’s 2023 Annual Meeting will be treated as a member of the Board at the beginning of the twelve (12) month period.
As a result of Mr. Kiani’s execution of the Waiver on June 5, 2023, which waived certain of the “Change in Control” provisions in the Amended Employment Agreement, the Company remeasured the expense related to the Award Shares and Cash Payment that would be recognized in the Company’s condensed consolidated financial statements upon the occurrence of a Qualifying Termination under the Amended Employment Agreement, as amended by the Second Amendment, and the expense was determined to be approximately $479.7 million.
As of March 30, 2024, the Company had severance plan participation agreements with six executive officers. The participation agreements (the Agreements) are governed by the terms and conditions of the Company’s 2007 Severance Protection Plan (the Severance Plan), which became effective on July 19, 2007 and which was amended effective December 31, 2008.
Under each of the Agreements, the applicable executive officer may be entitled to receive certain salary, equity, medical and life insurance benefits if he is terminated by the Company without cause or if he terminates his employment for good reason under certain circumstances. Each executive officer is also required to give the Company six months’ advance notice of his resignation under certain circumstances.
Willow Cross-Licensing Agreement Provisions
The Company’s Cross-Licensing Agreement with Willow contains annual minimum aggregate royalty obligations for use of the rainbow® licensed technology. The current annual minimum royalty obligation is $5.0 million. Upon a change in control (as defined in the Willow Licensing Agreement) of the Company or Willow: (i) all rights to the “Masimo” trademark will be assigned to Willow if the surviving or acquiring entity ceases to use “Masimo” as a company name and trademark; (ii) the option to license technology developed by Willow for use in blood glucose monitoring will be deemed automatically exercised and a $2.5 million license fee for this technology will become immediately payable to Willow; and (iii) the minimum aggregate annual royalties payable to Willow for carbon monoxide, methemoglobin, fractional arterial oxygen saturation, hemoglobin and/or glucose measurements will increase to $15.0 million per year until the exclusivity period of the agreement ends, plus up to $2.0 million for each additional vital sign measurement with no maximum ceiling for non-vital sign measurements.
Purchase Commitments
Pursuant to contractual obligations with vendors, the Company had $267.2 million of purchase commitments as of March 30, 2024 that are expected to be purchased within one year. These purchase commitments have been made for certain inventory items in order to secure sufficient levels of those items, other critical inventory and manufacturing supplies, and to achieve better pricing.
Other Contractual Commitments
In the normal course of business, the Company may provide bank guarantees to support government hospital tenders in certain foreign jurisdictions. As of March 30, 2024, the Company had approximately $5.1 million in outstanding unsecured bank guarantees.
40
MASIMO CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(unaudited)
In certain circumstances, the Company also provides limited indemnification within its various customer contracts whereby the Company indemnifies the parties to whom it sells its products with respect to potential infringement of intellectual property, and against bodily injury caused by a defective Company product. It is not possible to predict the maximum potential amount of future payments under these or similar agreements, due to the conditional nature of the Company’s obligations and the unique facts and circumstances involved. As of March 30, 2024, the Company had not incurred any significant costs related to contractual indemnification of its customers.
Fee Agreements
On January 1, 2024, the Company entered into a one year alternative fee agreement (Fee Agreement) with respect to certain on-going legal fees and costs charged by a vendor. The Fee Agreement imposes certain limits on a quarterly and annual basis for actual legal fees incurred by the vendor that are payable based on work performed related to litigation matters against Apple (see Note 24, “Litigation” for further details). If the vendor is successful in obtaining a favorable judgement for the Company on any claim or counterclaim after exhaustion or dismissal of any appeals, or upon settlement resulting in monetary consideration to the Company, the vendor will be paid a success fee equal to three times the amount of the excess of the annual legal fee limit within 60 days after entry of a judgement or the effective date of any settlement. Amounts due to the vendor under this Fee Agreement will be recognized when probable and reasonably estimable.
In connection with the potential separation of the Company’s consumer business, the Company entered into contingent or discretionary fee agreements with various service providers, advisors and consultants. The Company is unable to reasonably estimate the contingent fees due under these agreements at this time. Amounts due will be recognized when probable and reasonably estimable.
Licensing Agreement
On February 1, 2024, the Company entered into a three-year licensing agreement for approximately $9.0 million, plus applicable taxes. As of March 30, 2024, the outstanding obligation under the licensing agreement was $7.5 million, with $3.0 million payable within 12 months.
Concentrations of Risk
The Company is exposed to credit loss for the amount of its cash deposits with financial institutions in excess of federally insured limits. The Company invests a portion of its excess cash with major financial institutions. As of March 30, 2024, the Company had $157.6 million of bank balances, of which $8.1 million was covered by either the U.S. Federal Deposit Insurance Corporation limit or foreign countries’ deposit insurance organizations.
The Company’s ability to sell its healthcare products to U.S. hospitals depends in part on its relationships with GPOs. Many existing and potential healthcare customers for the Company’s products become members of GPOs. GPOs negotiate pricing arrangements and contracts, sometimes exclusively, with medical supply manufacturers and distributors, and these negotiated prices are made available to a GPO’s affiliated hospitals and other members. During the three months ended March 30, 2024 and April 1, 2023, revenue from the sale of the Company’s healthcare products to customers that are members of GPOs approximated 55.7% and 51.0% of healthcare revenue, respectively.
For each of the three months ended March 30, 2024 and April 1, 2023, the Company had sales through one just-in-time healthcare distributor that represented 16.1% and 8.9% of consolidated revenue, respectively.
During the three months ended March 30, 2024 and April 1, 2023, there were no revenue concentrations for the Company’s non-healthcare business.
As of March 30, 2024 and December 30, 2023, one healthcare customer represented 11.3% and 18.1%, respectively, of the Company’s consolidated accounts receivable balance. The receivable balance related to such healthcare customer is fully secured by a letter of credit.
As of March 30, 2024 and December 30, 2023, there were no customer concentration risks associated with the Company’s non-healthcare business.
41
MASIMO CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(unaudited)
Litigation
On January 9, 2020, the Company filed a complaint against Apple Inc. (Apple) in the United States District Court for the Central District of California for infringement of a number of patents, for trade secret misappropriation, and for ownership and correction of inventorship of a number of Apple patents listing one of its former employees as an inventor. The Company is seeking damages, injunctive relief, and declaratory judgment regarding ownership of the Apple patents. Apple filed petitions for Inter Partes review (IPR) of the asserted patents in the U.S. Patent and Trademark Office (PTO). The PTO instituted IPR of the asserted patents. On October 13, 2020, the District Court stayed the patent infringement claims pending completion of the IPR proceedings. In the IPR proceedings, one or more of the challenged claims of three of the asserted patents were found valid. The challenged claims of nine of the asserted patents were found invalid. On appeal, the U.S. Court of Appeals for the Federal Circuit affirmed all the IPR decisions except it reversed a finding of invalidity for certain dependent claims of one Masimo patent. From April 4, 2023 through May 1, 2023, the District Court held a jury trial on the trade secret, ownership, and inventorship claims. The District Court granted Apple’s motion for judgment as a matter of law on certain trade secrets and denied the remainder of Apple’s motion. On May 1, 2023, the District Court declared a mistrial because the jury was unable to reach a unanimous verdict. The stay of the patent infringement claims has been lifted and the District Court scheduled a trial on all remaining claims beginning on November 5, 2024.
On June 30, 2021, the Company filed a complaint with the U.S. International Trade Commission (ITC) against Apple for infringement of a number of other patents. The Company filed an amended complaint on July 12, 2021. On August 13, 2021, the ITC issued a Notice of Institution of Investigation on the asserted patents. From June 6, 2022 to June 10, 2022, the ITC conducted an evidentiary hearing. In July and August 2022, Apple filed petitions for IPR of the asserted patents in the PTO. On January 10, 2023, a United States Administrative Law Judge in Washington, D.C. ruled that Apple violated Section 337 of the Tariff Act of 1930 (Section 337), as amended, by importing and selling within the United States certain Apple Watches with light-based pulse oximetry functionality and components, which infringe one of the Company’s pulse oximeter patents. On January 24, 2023, the United States Administrative Law Judge further recommended that the ITC issue an exclusion order and a cease and desist order on certain Apple Watches. On October 26, 2023, the ITC issued a Notice of Final Determination finding a violation of Section 337 by Apple. The ITC determined that the appropriate form of relief is a Limited Exclusion Order (LEO) prohibiting the unlicensed entry of infringing wearable electronic devices with light-based pulse oximetry functionality manufactured by or on behalf of Apple, and a Cease and Desist Order (CDO). The LEO and CDO went into effect after the 60-day Presidential review period expired. The LEO and CDO are currently in effect. Apple’s appeal to the Federal Circuit is pending. On January 30, 2023, the PTO denied institution of IPR proceedings for the Company’s pulse oximeter patents that the ITC ruled were infringed. With respect to the other patents asserted at the ITC, the PTO denied institution of IPR proceedings for two patents and instituted IPR proceedings for two patents in January and February 2023. In the IPR proceedings, one or more of the challenged claims were found valid, while others were found invalid. The time period for the appeal is pending.
On October 20, 2022, Apple filed two complaints against the Company in the U.S. District Court for the District of Delaware alleging that the Masimo W1™ watch infringes six utility and four design patents. Apple is seeking damages and injunctive relief. On December 12, 2022, the Company counterclaimed for monopolization, attempted monopolization, false advertising (and related causes of action) and infringement of ten patents. The Company is seeking damages and injunctive relief. On May 5, 2023, the Court ordered that the two cases be coordinated through the pre-trial stage. The Court held a case management conference in March 2024, but has not yet issued an order to address the scope of claims and counterclaims for trial or to set a trial date. The Company intends to vigorously pursue all of its claims against Apple and believes the Company has good and substantial defenses to Apple’s claims, but there is no guarantee that the Company will be successful in these efforts.
On August 22, 2023, a putative class action complaint was filed by Sergio Vazquez against the Company and members of its management alleging violations of the federal securities laws. On November 14, 2023, the court appointed Boston Retirement System, Central Pennsylvania Teamsters Pension Fund-Defined Benefit Plan, and Central Pennsylvania Teamsters Pension Fund-Retirement Income Plan 1987 as lead plaintiffs. The lead plaintiffs filed an amended complaint on February 12, 2024. The amended complaint alleges that the Company and members of its management, from May 4, 2022 through August 8, 2023, disseminated materially false and misleading statements and/or concealed material adverse facts relating to the performance of its healthcare business and the success of the Company’s legacy Sound United business. The Company moved to dismiss the amended complaint on April 29, 2024. Briefing on the motion is scheduled to conclude by July 26, 2024. The Company believes it has good and substantial defenses to the claims in the amended complaint, but there is no guarantee that the Company will be successful in these efforts. The Company is unable to determine whether any loss ultimately will occur or to estimate the range of such loss; therefore, no amount of loss has been accrued by the Company in the accompanying condensed consolidated financial statements.
42
MASIMO CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(unaudited)
On May 1, 2024, a purported stockholder, Linda McClellan filed a derivative action in the U.S. District Court for the Southern District of California against certain of the Company’s current and former executives and directors, and the Company as nominal defendant. The complaint alleges, among other things, that the defendants breached their fiduciary duties owed to the Company by allowing or permitting false or misleading statements to be disseminated regarding the performance of the Company’s healthcare business and the success of the Company’s legacy Sound United business. The complaint also asserts causes of action for violations of Section 10(b) of the Securities Exchange Act of 1934 (15 U.S.C.§ 78j(b)) and Rule 10b-5 promulgated thereunder, aiding and abetting breach of fiduciary duty, unjust enrichment, abuse of control, gross mismanagement, and waste of corporate assets. The Company believes it has good and substantial defenses to the claims in the complaint, but there is no guarantee that the Company will be successful in these efforts. The Company is unable to determine whether any loss ultimately will occur or to estimate the range of such loss; therefore, no amount of loss has been accrued by the Company in the accompanying condensed consolidated financial statements.
The Company received a subpoena from the Department of Justice (DOJ) dated February 21, 2024 seeking documents and information related to the Company’s Rad-G® and Rad-97® products, including information relating to complaints surrounding the products and the Company’s decision to recall select Rad-G® products in 2024.
The Company received a civil investigative demand from the DOJ pursuant to the False Claims Act, 31 U.S.C. §§ 3729-3733, dated March 25, 2024, seeking documents and information related to customer returns of the Company’s Rad-G® and Rad-97® products, including returns related to the Company’s recall of select Rad-G® products in 2024.
The Company received a subpoena from the Securities and Exchange Commission dated March 26, 2024 seeking documents and information relating to allegations of potential accounting irregularities and internal control deficiencies from employees within the Company’s accounting department.
With respect to each of the subpoenas and the investigative demand described above, the Company is cooperating with the government and may expend significant financial and managerial resources in connection with responding to the subpoenas and investigative demand and any related investigation or any other future requests for information.
From time to time, the Company may be involved in other litigation and investigations relating to claims and matters arising out of its operations in the normal course of business. The Company believes that it currently is not a party to any other legal proceedings which, individually or in the aggregate, would have a material adverse effect on its consolidated financial position, results of operations or cash flows.
25. Segment and Enterprise Reporting
The Company’s reportable segments are determined based upon the Company’s organizational structure and the way in which the Company’s Chief Operating Decision Maker (CODM), the CEO, makes operating decisions and assesses financial performance. The CODM considered several factors including, but not limited to, customer base, technology, and homogeneity of products. The two segments are:
•Healthcare - develops, manufactures, and markets a variety of noninvasive monitoring technologies and hospital automation solutions and therapeutics. This segment includes the Company’s core legacy hospital business and new Masimo-technology-enabled consumer products that are distributed through many channels including e-commerce sites, leading national retailers and specialty chains globally.
•Non-healthcare - designs, develops, manufactures, markets and sells a broad portfolio of premium, high-performance audio products and services.
Income from operations for each segment includes all geographic revenues, related cost of net revenues and operating expenses directly attributable to the segment. The Company uses gross profit, as presented in the Company’s financial reports, as the primary measure of segment profitability. The Company uses the same accounting policies to generate segment results as the Company does for consolidated results. Segment information presented herein reflects the impact of these changes for all periods presented. For the three months ended March 30, 2024, intercompany revenues between the Healthcare and Non-healthcare segments were $0.6 million. For the three months ended April 1, 2023, there was no intercompany revenue between healthcare and non-healthcare. All inter-segment transactions and balances are eliminated in consolidation for all periods presented below.
43
MASIMO CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(unaudited)
Selected information by reportable segment is presented below for each of the three months ended March 30, 2024 and April 1, 2023:
Three Months Ended
(in millions)March 30,
2024		April 1,
2023
Revenues by segment:
Healthcare$339.6 $346.7 
Non-healthcare153.2 218.3 
Total revenue by segment$492.8 $565.0 
Gross profit:
Healthcare$211.4 $214.8 
Non-healthcare44.5 77.8 
Other(1)
(14.2)(7.8)
Gross profit$241.7 $284.8 
____________________________
(1)     Management excludes certain corporate expenses from segment gross profit. In addition, certain amounts that management considers to be non-recurring or non-operational are excluded from segment gross profit because management evaluates the operating results of the segments excluding such items.
The Company’s depreciation and amortization by segment are as follows:
Three Months Ended
(in millions)March 30,
2024		April 1,
2023
Total depreciation and amortization by segment:
Healthcare$10.0 $9.0 
Non-healthcare14.3 17.1 
Total depreciation and amortization by segment$24.3 $26.1 


44
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
This Quarterly Report on Form 10-Q contains “forward-looking statements” as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, in connection with the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties, as well as assumptions that, if they never materialize or prove incorrect, could cause our results to differ materially and adversely from those expressed or implied by such forward-looking statements. Such forward-looking statements include any expectation of earnings, revenues or other financial items; any statements of the plans, strategies and objectives of management for future operations; factors that may affect our operating results or financial condition; statements concerning new products, technologies or services; statements related to future capital expenditures; statements related to future economic conditions or performance; statements related to our stock repurchase program; statements as to industry trends and other matters that do not relate strictly to historical facts or statements of assumptions underlying any of the foregoing. These statements are often identified by the use of words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may” or “will,” the negative versions of these terms and similar expressions or variations. These statements are based on the beliefs and assumptions of our management based on information currently available to management. Such forward-looking statements are subject to risks, uncertainties and other factors that could cause actual results and the timing of certain events to differ materially and adversely from future results expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those identified below, and those discussed in the section titled “Risk Factors” included elsewhere in this Quarterly Report on Form 10-Q and in our other Securities and Exchange Commission (SEC) filings, including our Annual Report on Form 10-K for the fiscal year ended December 30, 2023, which we filed with the SEC on February 28, 2024. Furthermore, such forward-looking statements speak only as of the date of this report. We undertake no obligation to update any forward-looking statements to reflect events or circumstances occurring after the date of such statements.
Executive Overview
We are a global technology company dedicated to improving lives. We seek to accelerate our growth strategies and strengthen our focus on patient care via two business segments: healthcare and non-healthcare.
Healthcare
Our healthcare business develops, manufactures and markets a variety of noninvasive patient monitoring technologies, hospital automation and connectivity solutions, remote monitoring devices and consumer health products. Our healthcare products and patient monitoring solutions generally incorporate a monitor or circuit board, proprietary single-patient use or reusable sensors, software, cables and other services. We primarily sell our healthcare products to hospitals, emergency medical service (EMS) providers, home care providers, physician offices, veterinarians, long-term care facilities and consumers through our direct sales force, distributors and original equipment manufacturer (OEM) partners, such as GE Healthcare, Hillrom, Mindray, Philips, Physio-Control, and Zoll, among others.
Our core measurement technologies are our breakthrough Measure-through Motion and Low Perfusion™ pulse oximetry, known as Masimo Signal Extraction Technology® (SET®) pulse oximetry, and advanced rainbow® Pulse CO-Oximetry parameters such as noninvasive hemoglobin (SpHb®), alongside many other modalities, including brain function monitoring, hemodynamic monitoring, regional oximetry, acoustic respiration rate monitoring, capnography and gas monitoring, nasal high-flow respiratory support therapy, patient position and activity tracking, neuromodulation technology, an opioid overdose prevention and alert solution, and telehealth solutions.
Our measurement technologies are available on many types of devices, from bedside hospital monitors like the Root® Patient Monitoring and Connectivity Hub, to various handheld and portable devices, and to the tetherless Radius-PPG®, Radius-VSM® and Masimo SafetyNet™ remote patient surveillance solution. The Masimo Hospital Automation™ Platform facilitates data integration, connectivity, and interoperability through solutions like Patient SafetyNet™, Iris™, iSirona™, Replica® and UniView™ to facilitate more efficient clinical workflows and to help clinicians provide the best possible care, both in-person and remotely. Leveraging our expertise in hospital-grade technologies, we have expanded our suite of products intended for use outside the hospital and products for home wellness, to include Masimo Sleep™, a sleep quality solution; the Masimo Radius Tº®, a wireless wearable continuous thermometer; Radius PCG®, a wireless tetherless capnograph; Masimo W1™ and upcoming Masimo Freedom™ biosensing health and smart watches; Masimo Opioid Halo™, an opioid overdose prevention and alert system, and the Masimo Stork™ a baby monitoring system.
45
Non-healthcare
Our non-healthcare business develops, manufactures, markets, sells and licenses premium sound and home integration technologies and accessories under iconic consumer brands such as Bowers & Wilkins™, Denon™, Marantz™, HEOS™, Classé™, Polk Audio™, Boston Acoustics™ and Definitive Technology™, which offer products with unparalleled quality and performance to consumers, professional sound studios and audiophiles worldwide. Our products are sold direct-to-consumers, or through authorized retailers, distributors and wholesalers. We also license our audio technology to select luxury automotive manufacturers such as Aston Martin®, BMW®, Maserati®, McLaren®, Polestar® and Volvo®. We continue to expand our collaborations and brand partnerships, which include certain airlines for bespoke headphones allowing for the best in-flight audio experience; certain computer and laptop manufacturers by delivering a new experience within computer audio; and certain high-performance TV manufacturers, allowing for delivery of a range of integrated discreet audio devices and enclosures.
Recent Product Developments and Releases by Segment
Healthcare
In February 2024, we announced FDA 510(k) clearance of MightySat® Medical, making it the first and only FDA-cleared medical fingertip pulse oximeter available Over-The-Counter (OTC) direct to consumers without a prescription. This clearance brings consumers a pulse oximeter medical device powered by Masimo SET® pulse oximetry, the same technology relied on by hospitals and clinics around the world to monitor more than 200 million patients every year.
Economic Trends and Developments Effecting Our Business
Economic Trends
The healthcare and non-healthcare markets we operate in are highly competitive and dynamic, and have experienced a number of headwinds in 2023, including but not limited to inflationary pressures, interest rates volatility, rising energy costs, recessionary trends, and foreign currency fluctuations. All of these have affected the global economic environment, along with the healthcare facility spending trends and consumer spending behaviors which ultimately affect the Company’s performance. While we have experienced some short-term volatility in both our healthcare and non-healthcare segments, we are optimistic about long-term growth across both segments due to our new product launches, our continued investment in expanding markets and embedding our improved technologies into our product portfolio.
In an effort to bolster our long-term financial position, during the first quarter of 2023, we initiated various cost reduction actions to better optimize our cost structure with near-term revenue to enhance our operating cash flow, and improve our profitability for both segments going forward. Our initial focus was on a reduction of variable costs, with specific attention to eliminating cost inefficiencies in our supply chain and reducing variable labor spend and overhead costs in our production facilities by shifting manufacturing of certain products to lower cost locations. Through the second and third quarter of 2023, we expanded these actions by streamlining operations, including the consolidation and rationalization of business activities and facilities, workforce reductions, suspension of incentive bonus compensation and annual salary adjustments, transfers of product lines between manufacturing facilities, and the transfer of other business activities between sites. At the same time, we also revisited our revenue forecasts to reflect the current lower than expected U.S. hospital inpatient census, elevated sensor inventory levels at some customers due to discounting in prior quarters, and other factors that negatively affected revenues.
Compared to the prior year period, healthcare revenues were close to flat. Encouragingly, unrecognized contract revenue grew 11% over the same period, and grew 1% sequentially over fourth quarter 2023. Our success in winning new customers is apparent and these contracts are expected to translate into a meaningful source of revenue growth this year.
Non-healthcare revenues were in-line with our guidance as this business has stabilized despite difficult conditions that are affecting discretionary consumer spending.
Seasonality
Each of our business segments is individually influenced by many factors, including but not limited to: new product releases, acquisitions, regulatory approvals, holiday schedules, hospital census, clinicians, nurses and hospital personnel, the timing of the influenza season, holiday seasons, consumer pressures, fluctuations in interest rates, inflationary and recessionary pressures, consumer demand and preferences, competitors’ marketing promotions and sales incentives; among many other factors.
Our healthcare revenues in the third quarter of our fiscal years have historically represented a lower percentage of segment revenues due to the seasonality of the U.S., European and Japanese markets, where summer vacation schedules normally result in fewer elective procedures utilizing our healthcare products.
46
Our non-healthcare revenues in the fourth quarter of a fiscal year historically produce a higher percentage of our segment revenues than the other quarters of our fiscal year due to the holiday shopping season and our corresponding promotional activities. Our promotional discounting activity may negatively impact our gross margin during the holiday periods and into the trailing period (depending on our annual 52/53 week fiscal year end calendar).
On-Going Russian-Ukraine Conflict, Israel-Palestine-Iran War
We continue to monitor the uncertainty from conflicts and wars in Russia, the Ukraine, Israel and Iran, with respect to ongoing business in such regions, and are continuing to support existing patient populations while remaining compliant with all applicable U.S. and EU sanctions and regulations, where applicable. While none of Russia, the Ukraine or Israel constitute a material portion of our business, a significant escalation or expansion of economic disruption or the current scope of the conflicts in either geographic region, including the Middle East, could have an impact on our business. In the interim, order acceptance for Russia has been halted. For the three months ended March 30, 2024, sales derived from customers based in Russia represented an immaterial percentage of our total revenue.
Related Party Transactions
Willow Laboratories, Inc.
Willow Laboratories, Inc. (Willow), formerly known as Cercacor Laboratories, Inc., is an independent entity spun off from us to our stockholders in 1998. Joe Kiani, our Chairman and Chief Executive Officer (CEO), is also the Chairman and CEO of Willow. We are a party to a cross-licensing agreement with Willow, which was amended and restated effective January 1, 2007 (the Cross-Licensing Agreement), which governs each party’s rights to certain intellectual property held by the two companies. See Note 3, “Related Party Transactions”, to our accompanying condensed consolidated financial statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q for additional information related to Willow.
Results of Operations
The following table sets forth, for the periods indicated, our results of operations expressed as U.S. Dollar amounts and as a percentage of revenue.
Three Months Ended
(in millions, except percentages)
March 30,
2024		Percentage
of Revenue		April 1,
2023		Percentage
of Revenue
Revenue$492.8 100.0 %$565.0 100.0 %
Cost of goods sold251.1 51.0 280.2 49.6 
Gross profit241.7 49.0 284.8 50.4 
Operating expenses:
Selling, general and administrative159.9 32.4 196.3 34.7 
Research and development47.8 9.7 50.5 8.9 
Total operating expenses207.7 42.1 246.8 43.7 
Operating income34.0 6.9 38.0 6.7 
Non-operating loss(9.1)(1.8)(11.8)(2.1)
Income before provision for income taxes24.9 5.1 26.2 4.5 
Provision for income taxes6.0 1.2 4.9 0.9 
Net income$18.9 3.8 %$21.3 3.7 %
47
Comparison of the Three Months ended March 30, 2024 to the Three Months ended April 1, 2023
Revenue. Revenue decreased $72.2 million, or 12.8%, to $492.8 million for the three months ended March 30, 2024 from $565.0 million for the three months ended April 1, 2023.
Revenue by segment: Revenue by segment is comprised of healthcare and non-healthcare segments. The healthcare segment consists of hospital products and services. The non-healthcare segment consists of consumer audio visual and sound related products. The following table details our revenues by segment for each of the three months ended March 30, 2024 and April 1, 2023:
Three Months Ended
(in millions, except percentage)
March 30,
2024		April 1,
2023		Increase/
(Decrease)		Percentage
Change
Healthcare$339.6 68.9 %$346.7 61.4 %$(7.1)(2.0)%
Non-healthcare153.2 31.1 218.3 38.6 (65.1)(29.8)
Revenue by segment$492.8 100.0 %$565.0 100.0 %$(72.2)(12.8)%
Healthcare segment revenue for the three months ended March 30, 2024 decreased slightly year over year due to a challenging comparison to the three months ended April 1, 2023. Revenues were unfavorably impacted by approximately $1.5 million of foreign exchange rate movements from the prior year period that decreased the U.S. Dollar translation of foreign sales that were denominated in various foreign currencies.
Revenue generated through our direct and distribution sales channels decreased $4.0 million, or 1.3%, to $310.9 million for the three months ended March 30, 2024 compared to $314.9 million for the three months ended April 1, 2023. Revenues from our OEM channel decreased $3.1 million, or 9.7%, to $28.7 million for the three months ended March 30, 2024 as compared to $31.8 million for the three months ended April 1, 2023.
During the three months ended March 30, 2024, we shipped approximately 50,400 noninvasive technology boards and instruments. Unrecognized Contract Revenues grew 11% over the prior year and also increased by 1% sequentially to reach $1.5 billion. Our success in winning new customers is apparent and these contracts are expected to translate into a meaningful source of revenue growth this year.
For the three months ended March 30, 2024, non-healthcare revenue decreased $65.1 million, or 29.8%, compared to the three months ended April 1, 2023. Non-healthcare revenues were in-line with our guidance as this business has stabilized despite difficult conditions that are affecting discretionary consumer spending.
Gross Profit. Gross profit consists of revenue less cost of goods sold. Cost of goods sold includes labor, material, overhead and other similar costs related to the production, supply, distribution and support of our products. Our gross profit for the three months ended March 30, 2024 and April 1, 2023 was as follows:
Gross Profit
(in millions, except percentages)
Three Months Ended
March 30, 2024		Percentage of
 Net Revenues		Three Months Ended
April 1, 2023		Percentage of
Net Revenues		Increase/
(Decrease)		Percentage
Change
$241.749.0%$284.850.4%$(43.1)(15.1)%
Cost of goods sold decreased $29.1 million for the three months ended March 30, 2024, compared to the three months ended April 1, 2023, primarily due to decreased sales volumes in both the healthcare and non-healthcare segments. Gross profit decreased to 49.0% for the three months ended March 30, 2024, compared to 50.4% for the three months ended April 1, 2023, primarily due to product mix volumes and certain manufacturing transition expenses. Additionally, cost of goods sold for the three months ended March 30, 2024 includes approximately $3.1 million for certain product recall expenses.
Selling, General and Administrative. Selling, general and administrative expenses consist primarily of salaries, stock-based compensation and related expenses for sales, marketing and administrative personnel, sales commissions, advertising, marketing, promotion costs, licensing fees, professional fees related to legal, accounting and other outside services, public company costs and other corporate expenses. Selling, general and administrative expenses for the three months ended March 30, 2024 and April 1, 2023 were as follows:
48
Selling, General and Administrative
(in millions, except percentages)
Three Months Ended
March 30, 2024		Percentage of
 Net Revenues		Three Months Ended
April 1, 2023		Percentage of
Net Revenues		Increase/
(Decrease)		Percentage
Change
$159.932.4%$196.334.7%$(36.4)(18.5)%
Selling, general and administrative expenses decreased $36.4 million, or 18.5%, for the three months ended March 30, 2024, compared to the three months ended April 1, 2023. The decrease was primarily attributable to lower legal and professional fees of approximately $23.4 million, lower compensation and other employee-related costs of approximately $6.4 million, insurance recoveries of approximately $5.0 million, lower advertising and marketing-related costs of approximately $3.4 million and lower amortization expense of approximately $0.2 million, which were offset by an ROU asset impairment charge of approximately $3.9 million and higher other office-related costs of approximately $1.9 million.
Research and Development. Research and development expenses consist primarily of salaries, stock-based compensation and related expenses for engineers and other personnel engaged in the design and development of our products. These expenses also include third-party fees paid to consultants, prototype and engineering supply expenses and the costs of clinical trials. Research and development expenses for the three months ended March 30, 2024 and April 1, 2023 were as follows:
Research and Development
(in millions, except percentages)
Three Months Ended
March 30, 2024		Percentage of
 Net Revenues		Three Months Ended
April 1, 2023		Percentage of
Net Revenues		Increase/
(Decrease)		Percentage
Change
$47.89.7%$50.58.9%$(2.7)(5.3)%
Research and development expenses decreased $2.7 million, or 5.3%, for the three months ended March 30, 2024, compared to the three months ended April 1, 2023. The decrease was primarily attributable to lower compensation and other employee-related costs of approximately $1.8 million, lower engineering project costs of approximately $0.9 million, lower amortization expense of approximately $0.4 million and lower professional fees of approximately $0.3 million, which were offset by higher other office-related costs of approximately $0.8 million.
Non-operating Loss. Non-operating loss consists primarily of interest income, interest expense and foreign exchange gains and losses. Non-operating loss for the three months ended March 30, 2024 and April 1, 2023 was as follows:
Non-operating Loss
(in millions, except percentages)
Three Months Ended
March 30, 2024		Percentage of
 Net Revenues		Three Months Ended
April 1, 2023		Percentage of
Net Revenues		Increase/
(Decrease)		Percentage
Change
$(9.1)(1.8)%$(11.8)(2.1)%$2.7(22.9)%
Non-operating loss was $9.1 million for the three months ended March 30, 2024, as compared to $11.8 million of non-operating loss for the three months ended April 1, 2023. This net increase of approximately $2.7 million was primarily due to interest expense incurred under our credit facility of approximately $12.0 million, offset by the net realized and unrealized foreign currency denominated transactions of approximately $1.9 million and interest income on cash deposits of approximately $1.2 million.
Provision for Income Taxes. Our provision for income taxes for the three months ended March 30, 2024 and April 1, 2023 was as follows:
Provision for Income Taxes
(in millions, except percentages)
Three Months Ended
March 30, 2024		Percentage of
 Net Revenues		Three Months Ended
April 1, 2023		Percentage of
Net Revenues		Increase/
(Decrease)		Percentage
Change
$6.01.2%$4.90.9%$1.122.4%
For the three months ended March 30, 2024, we recorded a provision for income taxes of approximately $6.0 million, or an effective tax provision rate of 24.1%, as compared to a provision for income taxes of approximately $4.9 million, or an effective tax provision rate of 18.7%, for the three months ended April 1, 2023. The increase in our income tax rate for the three months ended March 30, 2024 resulted primarily a decrease in the amount of excess tax benefits realized from stock-based compensation of approximately $1.1 million compared to the three months ended April 1, 2023.
49
Liquidity and Capital Resources
Our principal sources of liquidity consist of our existing cash and cash equivalent balances, future funds expected to be generated from operations and available borrowing capacity under our Credit Facility. As of March 30, 2024, we had approximately $661.4 million in working capital, of which approximately $157.6 million was in cash and cash equivalents. In addition to net working capital, as of March 30, 2024, we had approximately $135.8 million of available borrowing capacity (net of outstanding letters of credit) under our Credit Facility.
We currently maintain a Credit Facility which provides for $705.0 million of unsecured borrowings. The Credit Facility also provides for a sublimit of up to $50.0 million for the issuance of letters of credit. Proceeds from the Credit Facility are being used for general corporate, capital investment and expenditures and working capital needs. For additional information regarding the Credit Facility, see Note 15, “Debt”, to our accompanying condensed consolidated financial statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q.
In managing our day-to-day liquidity and capital structure, we generally do not rely on foreign earnings as a source of funds. As of March 30, 2024, we had cash totaling $62.4 million held outside of the U.S., of which approximately $25.5 million was accessible without additional tax cost and approximately $36.9 million was accessible at an incremental estimated tax cost of up to $0.3 million. We currently have sufficient funds on-hand and cash held outside the U.S. that is available without additional tax cost to fund our global operations. In the event funds that are treated as permanently reinvested are repatriated, we may be required to accrue and pay additional U.S. taxes to repatriate these funds.
Our cash requirements depend on numerous factors, including, but not limited to, market acceptance of our technologies, our continued ability to commercialize new products and to create or improve our technologies and applications, expansion of our global footprint through acquisitions and/or strategic investments in technologies or technology companies, hedging and derivative activities, investments in property and equipment, the renewal of our Credit Facility, the impact of disruptions to the manufacturing industry supply chain for key components, inflation, repurchases of our stock under our authorized stock repurchase program, costs related to our domestic and international regulatory requirements and other long-term commitment and contingencies. For further details regarding our commitment and contingencies, see Note 24 to our accompanying condensed consolidated financial statements included in Part IV, Item 15(a) of this Quarterly Report on Form 10-Q.
Our total cash and cash equivalents and related cash flows may be affected by certain discretionary actions we may take with customers and suppliers to accelerate or delay certain cash receipts or payments to manage liquidity for our strategic business requirements. These actions can include, among others, negotiating with suppliers to optimize our payment terms and conditions, adjusting the timing of cash flows associated with customer sales programs and collections, managing inventory levels and purchasing practices, and selling certain of our accounts receivables on a non-recourse basis to third party financial institutions.
Despite recent acquisitions and strategic investment expenditures, we anticipate that our existing cash and cash equivalents, amounts available under our Credit Facility, and cash provided by operations, taken together, provide adequate resources to fund ongoing operating and capital expenditures, working capital requirements, and other operational funding needs for the next 12 months.
Should we require additional funds in the future to support our working capital requirements or for other purposes, we may seek to raise such additional funds through debt financing, as well as from other sources such as through our effective automatic shelf registration statement on Form S-3 (File No. 333-262770) on file with the SEC, pursuant to which we may offer an unspecified amount of debt, equity, and other securities. No assurance can be given that additional financing will be available in the future or that if available, such financing will be obtainable on terms favorable when required.
50
Cash Flows
The following table summarizes our cash flows:
Three Months Ended
March 30, 2024
(in millions)
March 30,
2024		April 1,
2023
Net cash provided by (used in):
Operating activities$45.8 $0.4 
Investing activities(18.9)(11.1)
Financing activities(26.5)(35.2)
Effect of foreign currency exchange rates on cash(4.6)17.4 
Decrease in cash, cash equivalents and restricted cash$(4.2)$(28.5)
Operating Activities. Cash provided by operating activities was approximately $45.8 million for the three months ended March 30, 2024, generated primarily from net income from operations of $18.9 million. Non-cash activity included depreciation and amortization of approximately $24.3 million and stock-based benefit of approximately $9.6 million.
Other major changes in operating assets and liabilities include a decrease in accounts payable, inventories, accounts receivable, deferred revenue and other contract-related liabilities and other non-current liabilities of approximately$40.6 million, $23.9 million, $22.4 million, $13.9 million and $5.4 million, respectively, primarily due to the timing of payments and inventory build-up; an increase in accrued compensation and accrued liabilities of approximately $3.2 million and $2.3 million, respectively, primarily due to the timing of payments and the Company’s costs reduction strategies.
For the three months ended April 1, 2023, cash provided by operating activities was approximately $0.4 million, generated primarily from net income from operations of $21.3 million. Non-cash activity included depreciation and amortization of approximately $26.1 million and stock-based compensation of approximately $7.3 million. Other changes in operating assets and liabilities include a decrease in accounts payable, accrued liabilities, accrued compensation and income tax payables of approximately $27.1 million, $21.8 million, $16.5 million and $8.3 million, primarily due to the timing of payments; an increase in lease receivables, net, inventories, other current assets, deferred costs and other contract assets of approximately $8.8 million, $7.1 million, $5.9 million and $1.0 million, respectively.
Investing Activities. Cash used in investing activities for the three months ended March 30, 2024 was approximately $18.9 million, consisting primarily of approximately $8.2 million for purchases of property and equipment, approximately $10.6 million of capitalized intangible asset costs related primarily to patent and trademark costs and license fees, and approximately $0.1 million of strategic investments.
For the three months ended April 1, 2023, cash used in investing activities was approximately $11.1 million, consisting primarily of approximately $9.7 million of capitalized intangible asset costs related primarily to patent and trademark costs and license fees, approximately $8.5 million for purchases of property and equipment, approximately $0.4 million of strategic investments which were offset by approximately $7.5 million from return of escrow funds associated with a business combination.
Financing Activities. Cash used in financing activities for the three months ended March 30, 2024 was approximately $26.5 million, consisting primarily of repayment on the line of credit of approximately $92.3 million, and withholding of shares for employee payroll taxes for vested equity awards of approximately $5.3 million, which were offset by proceeds from borrowings under the line of credit of approximately $64.0 million and the issuance of common stock related to employee equity awards of approximately $7.1 million.
For the three months ended April 1, 2023, cash used in financing activities was approximately $35.2 million, consisting primarily of repayment on the line of credit of approximately $72.4 million, withholding of shares for employee payroll taxes for vested equity awards of approximately $12.1 million, which were offset by proceeds from borrowings under the line of credit of approximately $44.4 million and the issuance of common stock related to employee equity awards of approximately $4.9 million.
51
Capital Resources and Prospective Capital Requirements
We expect to fund our future operating, investing and financing activities through our available cash, future cash from operations, our Credit Facility and other potential sources of capital. In addition to funding our working capital requirements, we anticipate additional capital expenditures primarily related to investments in infrastructure growth. Possible additional uses of cash may include acquisitions of and/or strategic investments in technologies or technology companies, investments in property, repurchases of common stock under our authorized stock repurchase program and continued legal defense of our intellectual property. However, any repurchases of common stock will be subject to numerous factors, including the availability of our common stock, general market conditions, the trading price of our common stock, availability of capital, alternative uses for capital and our financial performance. In addition, the amount and timing of our actual investing activities will vary significantly depending on numerous factors, including the timing and amount of capital expenditures, costs of product development efforts, our timetable for infrastructure expansion, any stock repurchase activity and costs related to our domestic and international regulatory requirements. Despite these strategic investment requirements and potential expenditures, we anticipate that our existing cash and cash equivalents, amounts available under our Credit Facility and cash provided by operations, taken together, provide adequate resources to fund ongoing operating and capital expenditures, working capital requirements, and other operational funding needs for the next 12 months. We may require additional funds in the future to support our working capital requirements or for other purposes and may seek to raise such additional funds through debt financing, as well as from other sources. No assurance can be given that additional financing will be available in the future or that if available, such financing will be obtainable on terms favorable when required. For additional information related to our Credit Facility, please see Note 15, “Debt”, to our accompanying condensed consolidated financial statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q.
Critical Accounting Policies and Estimates
The discussion and analysis of our financial condition and results of operations is based on our condensed consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these condensed consolidated financial statements requires management to make estimates and judgments that affect the reported amounts of net revenues, expenses, assets and liabilities. We regularly evaluate our estimates and assumptions related to our critical accounting policies, including revenue recognition, inventory valuation, stock-based compensation, impairment of long-lived assets, intangible assets and goodwill; business combinations, deferred taxes and related valuation allowances, uncertain tax positions, tax contingencies, litigation costs and loss contingencies.
These estimates and judgments are based on historical experience and on various other factors that we believe to be reasonable under the circumstances, and form the basis for making management’s most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effects of matters that are inherently uncertain. Although we regularly evaluate these estimates and assumptions, changes in judgments and uncertainties relating to these estimates could potentially result in materially different results under different assumptions and conditions. If these estimates differ significantly from actual results, the impact on the condensed consolidated financial statements may be material.
There have been no material changes to any of our critical accounting policies during the three months ended March 30, 2024.
For a description of our critical accounting policies, please refer to “Critical Accounting Estimates” in Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” of our Annual Report on Form 10-K for the fiscal year ended December 30, 2023, which was filed with the SEC on February 28, 2024.
Recent Accounting Pronouncements
For details regarding any recently adopted and recently issued accounting standards, see Note 2, “Summary of Significant Accounting Policies”, to our accompanying condensed consolidated financial statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q.
Item 3. Quantitative and Qualitative Disclosures About Market Risk
We are exposed to various market risks that may arise from adverse changes in market rates and prices, such as interest rates, foreign exchange fluctuations and inflation. We do maintain a derivative instrument for cash flow hedging, but do not enter into derivatives or other financial instruments for trading or speculative purposes.
Interest Rate Risk
Our exposure to market risk for changes in interest rates relates to the increase or decrease in the amount of interest income we can earn on our cash and cash equivalents and on the increase or decrease in the amount of interest expense we must pay with respect to our various outstanding debt instruments. As of March 30, 2024, the carrying value of our cash equivalents
52
approximated fair value. We manage our risk associated with interest rates fluctuations related to interest expenses under our Credit Facility by engaging in hedging activities. Since July 2022, we entered into various interest rate swap contracts to hedge our exposure to changes in cash flows associated with our outstanding debt with variable interest rates. The interest rate swap contracts have maturities averaging five years or less. See Note 17, “Derivative Instruments and Hedging Activities”, to our accompanying condensed consolidated financial statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q for further details.
A hypothetical 100 basis point change in interest rates along the entire interest rate yield curve would increase or decrease our interest rate yields on our investments, interest income and credit facilities by approximately $0.1 million for each $10.0 million in interest-bearing investments and by $0.1 million for each additional $10.0 million of debt.
Our ultimate realized gain or loss with respect to interest rate fluctuations will depend on interest rates, the exposures that arise during the period and our hedging strategies at that time. A hypothetical 100 basis point change in interest rates would increase or decrease our annual interest expense by approximately $0.2 million based on average debt outstanding, after consideration of our interest rate swap contracts, for the quarter ended March 30, 2024 and approximately $2.0 million based on average debt outstanding, after consideration of our interest rate swap contracts, for the three months ended March 30, 2024.
We sponsor multiple defined benefit pension plans covering certain international employees. The aggregate fair value of the plans’ investments was $22.9 million as of March 30, 2024. The plans’ assets may be subject to market risk, interest rate risk, and credit risk, which may affect the value of the plans’ assets and the funding of the plans.
Increases in interest rates globally may impact the value of pension plan assets held by us. When interest rates increase, the value of fixed income securities, such as bonds, may decrease, which can negatively impact the fair value of the pension plan assets. However, interest rate increases may also improve the funded status of plan by increasing the discount rate used to measure the present value of the pension obligations and potentially decreasing our requirement to make contributions to the plan. The most significant actuarial assumption affecting pension expense and pension obligations is discount rates. A hypothetical increase of 100 basis point in discount rates would result in a decrease of approximately $0.3 million in the projected benefit obligation. The impact of interest rate increases on the pension plan assets and funded status may not be predictable and may vary from period to period.
Foreign Currency Exchange Rate Risk
A majority of our assets and liabilities are maintained in the United States in U.S. Dollars and a majority of our sales and expenditures are transacted in U.S. Dollars. However, we also transact with foreign customers in currencies other than the U.S. Dollar. These foreign currency revenues, when converted into U.S. Dollars, can vary depending on average exchange rates during a respective period. In addition, certain of our foreign subsidiaries transact in their respective country’s local currency, which is also their functional currency. As a result, expenses of these foreign subsidiaries, when converted into U.S. Dollars can also vary depending on average monthly exchange rates during a respective period.
We are exposed to foreign currency gains or losses on outstanding foreign currency denominated receivables and payables, as well as our foreign currency denominated cash balances and certain intercompany transactions. In addition, other transactions between us or our subsidiaries and a third-party, denominated in a currency different from the functional currency, are foreign currency transactions. Realized and unrealized foreign currency gains or losses on these transactions are also included in our statements of operations as incurred.
The balance sheets of each of our foreign subsidiaries whose functional currency is not the U.S. Dollar are translated into U.S. Dollars at the rate of exchange at the balance sheet date and the statements of comprehensive income and cash flows are translated into U.S. Dollars using an approximation of the average monthly exchange rates applicable during the period. Any foreign exchange gain or loss as a result of translating the balance sheets of our foreign subsidiaries whose functional currency is not the U.S. Dollar is included in equity as a component of accumulated other comprehensive income Our foreign currency exchange rate exposures are primarily with the Canadian Dollar, Euro, Japanese Yen, Swedish Krona, the British Pound, Mexican Peso, Turkish Lira, Australian Dollar and the Chinese Yuan. Foreign currency exchange rates may experience significant volatility from one period to the next.
We do not use derivatives or financial instruments for trading or speculative purposes. The effect of additional changes in foreign currency exchange rates could have a material effect on our future operating results or cash flows, depending on which foreign currency exchange rates change and depending on the directional change (either a strengthening or weakening against the U.S. Dollar). We estimate that the potential impact of a hypothetical 10% adverse change in all applicable foreign currency exchange rates from the rates in effect as of March 30, 2024 would have resulted in an estimated reduction of $9.7 million in
53
reported pre-tax income for the three months ended March 30, 2024. As our foreign operations continue to grow, our exposure to foreign currency exchange rate risk may become more significant.
Inflation Risk
Inflation has continued to increase in the first quarter of 2024 and is expected to continue to increase for the near future. Consumer demand and discretionary spending continue to be impacted by inflationary pressures, which could materially impact our financial results, in particular, our consumer products and non-healthcare business segment. We are unable to determine the exact impact of inflation on our global business, financial condition or results of operations during the periods presented.
If our costs were to become subject to significant inflationary pressures, we may not be able to fully offset such higher costs through price increases. Our inability or failure to do so could have a material adverse effect on our business, financial condition and results of operations.
Item 4. Controls and Procedures
We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports filed under the Securities Exchange Act of 1934, as amended (the Exchange Act), is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s (SEC) regulations, rules and forms and that such information is accumulated and communicated to our management, including our CEO and Chief Financial Officer (CFO), as appropriate, to allow for timely decisions regarding required disclosure.
In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. As required by Rule 13a-15(b) or Rule 15d-15(b) promulgated by the SEC under the Exchange Act, we carried out an evaluation, under the supervision and with the participation of our management, including our CEO and CFO, of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on the foregoing, our CEO and CFO concluded that our disclosure controls and procedures were effective as of the end of the period covered by this Quarterly Report on Form 10-Q.
During the three months ended March 30, 2024, there were no changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
PART II. OTHER INFORMATION
Item 1. Legal Proceedings
The information set forth in Note 24, “Commitments and Contingencies”, to our accompanying condensed consolidated financial statements under the caption “Litigation” included in Part I, Item 1 of this Quarterly Report on Form 10-Q is incorporated herein by reference.
Item 1A. Risk Factors
The following risk factors and other information included in this Quarterly Report on Form 10-Q should be carefully considered. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties not presently known to us or that we presently deem less significant may also impair our business operations. If any of the following risks come to fruition, our business, financial condition, results of operations and future growth prospects would likely be materially and adversely affected. In these circumstances, the market price of our common stock could decline, and you could lose all or part of your investment. Risk factors marked with an asterisk (*) below include a substantive change from or an update to the risk factors included in our Annual Report on Form 10-K for the fiscal year ended December 30, 2023, filed with the SEC on February 28, 2024.
54
Summary of Material Risk Factors
Below is a summary of the principal factors that make an investment in our securities speculative or risky. This summary does not address all of the risks that we face. Additional discussion of the risks summarized in this summary, and other risks that we face, can be found following this summary and should be carefully considered together with all of the other information appearing in this Quarterly Report on Form 10-Q.
•We currently derive a significant portion of our revenue from our Masimo SET® platform, Masimo rainbow SET® platform and related products. If these technologies and related products do not continue to achieve market acceptance, our business, financial condition and results of operations would be adversely affected.
•Some of our products are in development or have been recently introduced into the market and may not achieve market acceptance, which could limit our growth and adversely affect our business, financial condition and results of operations.
•Our ability to commercialize new products, new or improved technologies and additional applications for Masimo SET® and our licensed rainbow® technology is limited to certain markets by our Cross-Licensing Agreement with Willow Laboratories, Inc. (Willow), formerly known as Cercacor Laboratories, Inc., which may impair our growth and adversely affect our business, financial condition and results of operations.
•We depend on our domestic and international original equipment manufacturer (OEM) partners for a portion of our revenue. If they do not devote sufficient resources to the promotion of products that use our technologies, our business would be harmed.
•If we fail to maintain or develop relationships with GPOs, sales of our healthcare products would decline.
•Inadequate levels of coverage or reimbursement from governmental or other third-party payers for our healthcare products, or for procedures using our healthcare products, may cause our revenue to decline or prevent us from realizing revenues from future products.
•*The loss of any large customer or distributor, or any cancellation or delay of a significant purchase by a large customer, could reduce our net sales and harm our operating results.
•Counterfeit Masimo sensors and third-party reprocessed single-patient-use Masimo sensors may harm our reputation and adversely affect our business, financial condition and results of operations.
•Competition and other conflicts with our non-healthcare distribution partners could harm our business and operating results.
•If the patents we own or license, or our other intellectual property rights, do not adequately protect our technologies, we may lose market share to our competitors and be unable to operate our business profitably.
•If third-parties claim that we infringe their intellectual property rights, we may incur liabilities and costs and may have to redesign or discontinue selling certain products.
•*We believe competitors may currently be violating and may in the future violate our intellectual property rights. As a result, we may initiate litigation to protect and enforce our intellectual property rights, which may result in substantial expense and may divert management’s attention from implementing our business strategy.
•Our failure to obtain and maintain FDA clearances or approvals on a timely basis, or at all, would prevent us from commercializing our current, upgraded or new healthcare products in the U.S., which could severely harm our business.
•If our healthcare products cause or contribute to a death or serious injury, or malfunction in a way that would likely cause or contribute to a death or serious injury, we will be subject to medical device reporting regulations and other applicable laws, and may need to initiate voluntary or mandatory corrective actions, such as the recall of our healthcare products.
•Promotion of our healthcare products using claims that are off-label, unsubstantiated, false or misleading could subject us to substantial penalties.
•The regulatory environment governing information, data security and privacy is increasingly demanding and evolving. Many of the laws and regulations in this area are subject to uncertain interpretation, and our failure to comply could result in claims, penalties or increased costs or otherwise harm our business.
•We may be subject to or otherwise affected by federal and state healthcare laws, including fraud and abuse laws, and could face substantial penalties if we are unable to fully comply with these laws.
•We may experience conflicts of interest with Willow with respect to business opportunities and other matters.
55
•We will be required to assign to Willow and pay Willow for the right to use certain products and technologies we develop that relate to the monitoring of non-vital sign parameters, including improvements to Masimo SET®.
•In the event that the Cross-Licensing Agreement is terminated for any reason, or Willow grants a license to rainbow® technology to a third-party, our business would be adversely affected.
•Rights provided to Willow in the Cross-Licensing Agreement may impede a change in control of our company.
•If we are unable to obtain key materials and components from sole or limited source suppliers, we will not be able to deliver our products to customers.
•Future strategic initiatives, including acquisitions of businesses and strategic investments, could negatively affect our business, financial condition and results of operations if we fail to integrate the acquired businesses and their employees successfully into our existing operations or achieve the desired results of our initiatives.
•Our new products and changes to existing products, including as a result of our acquisition of Sound United could fail to attract or retain users or generate revenue and profits. Further, we may not be successful in our non-healthcare expansion, which could adversely affect our business, reputation or financial results.
•Our Credit Facility contains certain covenants and restrictions that may limit our flexibility in operating our business.
•We have incurred impairment charges for other intangible assets, and may incur further impairment charges in the future, which would negatively impact our operating results.
•We may need additional capital and failure to raise additional capital on terms favorable to us, or at all, could limit our ability to grow our business and develop or enhance our service offerings to respond to market demand or competitive challenges.
•Concentration of ownership of our stock among our existing directors, executive officers and principal stockholders may prevent new investors from influencing significant corporate decisions.
•We may be unable to accurately forecast our financial and operating results and appropriately plan our expenses in the future or we may fail to meet our publicly announced guidance about our business and future operating results.
•Our corporate documents, and Delaware law contain provisions that could discourage, delay or prevent a change in control of our company, prevent attempts to replace or remove current management and reduce the market price of our stock.
•*Shareholder activism could cause us to incur significant expense, disrupt our business, result in a proxy contest or litigation and impact our stock price.
•Exclusive forum provisions in our bylaws could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.
56
Risks Related to Our Revenues
We currently derive a significant portion of our revenue from our Masimo SET® platform, Masimo rainbow SET® platform and related products. If these technologies and related products do not continue to achieve market acceptance, our business, financial condition and results of operations would be adversely affected.
Our healthcare business is highly dependent upon the continued success and market acceptance of our proprietary Masimo SET® and Masimo rainbow SET® technologies that serve as the basis of our primary healthcare product offerings. Continued market acceptance of products incorporating these technologies will depend upon us continuing to provide evidence to the medical community that our products are cost-effective and offer significantly improved performance compared to conventional pulse oximeters. Healthcare providers that currently have significant investments in competitive pulse oximetry products may be reluctant to purchase our products. If hospitals and other healthcare providers do not believe our Masimo SET® and Masimo rainbow SET® platforms are cost-effective, safe or more accurate or reliable than competitive pulse oximetry products, they may not buy our healthcare products in sufficient quantities to enable us to generate revenue growth from the sale of these products. In addition, allegations regarding the safety and effectiveness of our products, whether or not substantiated, may impair or impede the acceptance of our products.
Some of our products are in development or have been recently introduced into the market and may not achieve market acceptance, which could limit our growth and adversely affect our business, financial condition and results of operations.
Many of our noninvasive measurement technologies are considered disruptive. These technologies have performance levels that we believe are acceptable for many clinical environments but may be insufficient in others. In addition, these technologies may perform better in some patients and settings than others. Over time, we hope to continue to improve the performance of these technologies and educate the clinical community on how to properly evaluate them. If we are successful in these endeavors, we expect these technologies will become more useful in more environments and will become more widely adopted. Our product portfolio continues to expand, and we are investing significant resources to enter into, and in some cases create, new markets for our products. For example, our acquisition of Sound United expanded our business and product strategy to additionally focus on non-healthcare products to integrate with our successful medical technology. See the risk factor with the heading “Our new products and changes to existing products, including as a result of our acquisition of Sound United could fail to attract or retain users or generate revenue and profits. Further, we may not be successful in our non-healthcare expansion, which could adversely affect our business, reputation or financial results” for additional risks related to this expansion of our business.
We are continuing to invest in sales and marketing resources to achieve market acceptance of our products, but are unable to guarantee that our technologies will achieve general market acceptance.
The degree of market acceptance of our healthcare products will depend on a number of factors, including but not limited to:
•perceived clinical benefits from our products;
•perceived cost effectiveness of our products;
•perceived safety and effectiveness of our products;
•reimbursement available through government and private healthcare programs for using some of our products; and
•introduction and acceptance of competing products or technologies.
Further, market acceptance of our non-healthcare products will depend on certain additional factors, including but not limited to:
•perceived quality of our non-healthcare brands and technology;
•our ability to accurately forecast consumer demand and maintain manufacturing capacity to meet such demand;
•our ability to introduce new innovative products that align with rapidly changing consumer tastes; and
•implementation of pricing and marketing strategies that drive consumer adoption without eroding our premium market position.
If our products do not gain market acceptance or if our customers prefer our competitors’ products, our potential revenue growth would be limited, which would adversely affect our business, financial condition and results of operations.

57
Our ability to commercialize new products, new or improved technologies and additional applications for Masimo SET® and our licensed rainbow® technology is limited to certain markets by our Cross-Licensing Agreement with Willow Laboratories, Inc. (Willow), formerly known as Cercacor Laboratories, Inc., which may impair our growth and adversely affect our business, financial condition and results of operations.
Since 1998, we have been a party to a cross-licensing agreement with Willow (as amended, the Cross-Licensing Agreement), under which we granted Willow:
•an exclusive, perpetual and worldwide license, with sublicense rights, to use all Masimo SET® technology owned by us, including all improvements to this technology, for the monitoring of non-vital signs parameters and to develop and sell devices incorporating Masimo SET® for monitoring non-vital signs parameters in any product market in which a product is intended to be used by a patient or pharmacist rather than by a professional medical caregiver, which we refer to as the “Willow Market”; and
•a non-exclusive, perpetual and worldwide license, with sublicense rights, to use all Masimo SET® technology owned by us for measurement of vital signs in the “Willow Market”.
Non-vital signs measurements consist of body fluid constituents other than vital signs measurements, including, but not limited to, carbon monoxide, methemoglobin, blood glucose, hemoglobin and bilirubin. Under the Cross-Licensing Agreement, we are only permitted to sell devices utilizing Masimo SET® for the monitoring of non-vital signs parameters in markets where the product is intended to be used by a professional medical caregiver, including, but not limited to, hospital caregivers and alternate care facility caregivers, rather than by a patient or pharmacist, which we refer to as the “Masimo Market”. Accordingly, our ability to commercialize new products, new or improved technologies and additional applications for Masimo SET® is limited. In particular, our inability to expand beyond the “Masimo Market” may limit our ability to maintain or increase our revenue and impair our growth.
Pursuant to the Cross-Licensing Agreement, we have licensed from Willow the right to make and distribute products in the “Masimo Market” that utilize rainbow® technology for certain noninvasive measurements. As a result, the opportunity to expand the market for our products incorporating rainbow® technology is also limited, which could limit our ability to maintain or increase our revenue and impair our growth.
We depend on our domestic and international original equipment manufacturer (OEM) partners for a portion of our revenue. If they do not devote sufficient resources to the promotion of products that use our technologies, our business would be harmed.
We are, and will continue to be, dependent upon our domestic and international OEM partners for a portion of our revenue through their marketing, selling and distribution of certain of their products that incorporate our technologies. Although we expect that our OEM partners will accept and actively market, sell and distribute products that incorporate our technologies, they may not do so. Because products that incorporate our technologies may represent a relatively small percentage of business for some of our OEM partners, they may have less incentive to promote these products over other products that do not incorporate these technologies.
In addition, some of our OEM partners offer products that compete with ours and also may be involved in intellectual property disputes with us. Therefore, we cannot guarantee that our OEM partners, or any company that may acquire any of our OEM partners, will vigorously promote products incorporating our technologies. The failure of our OEM partners to successfully market, sell or distribute products incorporating our technologies, the termination of OEM agreements, the loss of OEM partners or the inability to enter into future OEM partnership agreements would have a material adverse effect on our business, financial condition and results of operations.
If we fail to maintain or develop relationships with GPOs, sales of our healthcare products would decline.
Our ability to sell our healthcare products to hospitals depends, in part, on our relationships with GPOs. Many existing and potential customers for our products are members of GPOs. GPOs negotiate pricing arrangements and contracts with medical supply manufacturers and distributors that may include provisions for sole sourcing and bundling, which generally reduce the choices available to member hospitals.
58
These negotiated prices are made available to a GPO’s members. If we are not one of the providers selected by a GPO, the GPO’s members may be less likely or unlikely to purchase our products. If a GPO has negotiated a strict sole source, market share compliance or bundling contract for another manufacturer’s products, we may be prohibited from making sales to members of such GPO for the duration of such contractual arrangement. Shipments of our pulse oximetry products to customers that are members of GPOs represent approximately 94% of our U.S. healthcare product sales. Our failure to renew our contracts with GPOs may cause us to lose market share in our healthcare business and could have a material adverse effect on our business, financial condition and results of operations. In addition, if we are unable to develop new relationships with GPOs, our competitive position would likely suffer and our opportunities to grow our revenues and business would be harmed.
Inadequate levels of coverage or reimbursement from governmental or other third-party payers for our healthcare products, or for procedures using our healthcare products, may cause our revenue to decline or prevent us from realizing revenues from future products.
Sales of our healthcare products depend in part on the reimbursement and coverage policies of governmental and private healthcare payers. The lack of adequate coverage and reimbursement for our healthcare products or the procedures in which our healthcare products are used may deter customers from purchasing our products.
We cannot guarantee that governmental or third-party payers will reimburse or begin reimbursing a customer for the cost of our healthcare products or the procedures in which our healthcare products are used. For example, some insurance carriers have issued policies denying coverage for transcutaneous hemoglobin measurement on the grounds that the technology is investigational in the outpatient setting. Other payers are continuing to investigate our products to determine if they will provide reimbursement for the use of such products. In addition, we may incur significant expenses to generate clinical data to demonstrate not only the safety and efficacy, but also the cost-effectiveness of our products in order to obtain favorable reimbursement policies from payers.
These trends could lead to pressure to reduce prices for our current and future healthcare products, hinder our ability to obtain market adoption, cause a decrease in the size of the market or potentially increase competition, any of which could have a material adverse effect on our business, financial condition and results of operations.
We do not control payer decision-making with respect to coverage and payment levels for our products. Additionally, we expect many payers to continue to explore cost-containment strategies (e.g., comparative and cost-effectiveness analyses, so-called “pay-for-performance” programs implemented by various public government healthcare programs and private third-party payers, and expansion of payment bundling initiatives, and other such methods that shift medical cost risk to providers) that may potentially impact coverage and/or payment levels for our current products or products we develop in the future.
Outside of the U.S., reimbursement systems vary by country. These systems are often subject to the same pressures to curb rising healthcare costs and control healthcare expenditures as those in the U.S. In addition, as economies of emerging markets develop, these countries may implement changes in their healthcare delivery and payment systems. If adequate levels of reimbursement from third-party payers outside of the U.S. are not obtained, sales of our products outside of the U.S. may be adversely affected.
*Our healthcare customers may reduce, delay or cancel purchases due to a variety of factors, such as lower hospital census levels or third-party guidelines, which could adversely affect our business, financial condition and results of operations.
Our healthcare customers are facing growing levels of uncertainties, including variations in overall hospital census for paying patients and the impact of such census variations on hospital budgets. As a result, many hospitals are reevaluating their entire cost structure, including the amount of capital they allocate to medical device technologies and products. In addition, certain of our products, including our rainbow® measurements such as carbon monoxide, methemoglobin and hemoglobin, that are sold with upfront license fees and more complex and expensive sensors, could also be impacted by hospital budget reductions. Any reductions in capital spending budgets by hospitals could have a significant negative impact on our OEM customers who, due to their traditionally larger capital equipment sales model, could see declines in purchases from their hospital customers. This, in turn, could reduce our board sales to our OEM customers.
From time to time, states and other local regulatory authorities may issue guidelines regarding the appropriate scope and use of our products. For example, some of our noninvasive monitoring devices may be subject to authorization by individual states as part of the Emergency Medical Services (EMS) scope of practice procedures. A lack of inclusion into scope of practice procedures may limit adoption of our products.
59
Additionally, increases in demand resulting from global medical crises, such as the increase in demand we experienced during the COVID-19 pandemic, may be short lived. If the increased demand results in a stockpiling of our healthcare products by, or excess inventory at, our customers, future orders may be delayed or canceled until such on-hand inventory is consumed. We may be unable to accurately forecast our financial and operating results and appropriately plan our expenses in the future or we may fail to meet our publicly announced guidance about our business and future operating results. For example, during the second half of 2023, customers maintained elevated levels of single-patient use sensors and consumables in inventory due to the softer demand and lower hospital census, which had an adverse impact on our second half of 2023 healthcare revenue. Continued stockpiling or excess inventory as a result of lower hospital census in future quarters could also negatively impact our healthcare revenue.
*The loss of any large customer or distributor, or any cancellation or delay of a significant purchase by a large customer, could reduce our net sales and harm our operating results.
Our healthcare business has a concentration of OEM, distributor and direct customers. For example, sales to one just-in-time distributor represented 10% or more of our consolidated revenue for the first quarter of 2024. There were no revenue concentrations for our non-healthcare business, which represented 10% or more of our consolidated revenue for the first quarter of 2024.
We cannot provide any assurances that we will retain our current customers, groups of customers or distributors, that they will maintain their current or forecasted demand for our products, or that we will be able to attract and retain additional customers in the future. If for any reason we were to lose our ability to sell to a specific group or class of customers or through a distributor, we could experience a significant reduction in revenue or loss of market share, which would adversely impact our operating results.
Our revenues could also be negatively affected by any rebates, discounts or fees that are required by, or offered to, GPOs and customers, including wholesalers or distributors. Additionally, one just-in-time distributor of our healthcare products has demanded higher fees, which we may be obligated to pay in order to continue to offer products to our customers through this distributor or which may obligate us to distribute our products directly to our customers. Specifically, in February 2024, we were notified by this just-in-time distributor of its intent to terminate our distribution agreement as a result of our refusal to increase distribution fees. The loss of this or any large customer or distributor, an increase in distributor fees, or the risks associated with selling directly to our customers could have a material adverse effect on our business, financial condition and results of operations.
Counterfeit Masimo sensors and third-party reprocessed single-patient-use Masimo sensors may harm our reputation and adversely affect our business, financial condition and results of operations.
We believe that other entities are manufacturing and selling counterfeit Masimo sensors. In addition, certain medical device reprocessors have been collecting our used single-patient-use sensors from hospitals and then reprocessing, repackaging and reselling those sensors to hospitals. These counterfeit and third-party reprocessed sensors are sold at lower prices than new Masimo sensors. Our experience with both these counterfeit sensors and third-party reprocessed sensors is that they provide inferior performance, increased sensor consumption, reduced comfort and a number of monitoring problems. Notwithstanding these limitations, some of our customers have indicated a willingness to purchase some of their sensor requirements from these counterfeit manufacturers and third-party reprocessors in an effort to reduce their sensor costs.
These counterfeit and reprocessed sensors have led and may continue to lead to confusion with our genuine Masimo products, have reduced and may continue to reduce our revenue, and, in some cases, have harmed and may continue to harm our reputation if customers conclude incorrectly that these counterfeit or reprocessed sensors are original Masimo sensors.
In addition, we have expended a significant amount of time and expense investigating issues caused by counterfeit and reprocessed sensors, troubleshooting problems stemming from such sensors, educating customers about why counterfeit and reprocessed sensors do not perform to their expectations, enforcing our proprietary rights against the counterfeit manufacturers and reprocessors, and enforcing our contractual rights.
In response to these counterfeit sensors and third-party reprocessors, we have incorporated X-Cal® technology into certain products to ensure our customers get the performance they expect by using genuine Masimo sensors and that such sensors do not continue to be used beyond their useful life. However, some customers may object to the X-Cal® technology, potentially resulting in the loss of customers and revenues.
We also offer our own Masimo reprocessed sensors, which meet the same performance specifications as our new Masimo sensors, to our customers. Reprocessed sensors sold by us are also offered at a lower price and, therefore, may reduce certain customer demand for our new sensors. As a result, increased sales of our own Masimo reprocessed sensors may result in lower revenues, which could negatively impact our business, financial condition and results of operations.
60
Competition and other conflicts with our non-healthcare distribution partners could harm our business and operating results.
Several of our existing non-healthcare products compete, and future products may compete, with the product offerings of some of our significant channel and distribution partners. These partners may choose to market and promote their own products over ours or could cease or reduce selling or promoting our products. Any reduction in our ability to place and promote our non-healthcare products, or increased competition from our distribution partners for available shelf or website placement, especially during peak retail sales periods, could adversely affect our non-healthcare business. In addition, the expansion of our direct-to-consumer channel in our non-healthcare business through our brand websites could increase our competition with our channel partners and cause these partners to reduce their purchases of our non-healthcare products. Conflicts in our sales channels could arise and cause channel partners to divert resources away from the promotion and sale of our products. Any of these situations could adversely impact our business, financial condition and results of operations.
Risks Related to Our Intellectual Property
If the patents we own or license, or our other intellectual property rights, do not adequately protect our technologies, we may lose market share to our competitors and be unable to operate our business profitably.
Our success depends significantly on our ability to protect our rights to the technologies used in our products. Our utilization of patent protection, trade secrets and a combination of copyright and trademark laws, as well as nondisclosure, confidentiality and other contractual arrangements, to protect our intellectual property afford us only limited protection and may not adequately protect our rights or permit us to gain or maintain any competitive advantage.
Certain of our patents related to our technologies have begun to expire. Upon the expiration of our issued or licensed patents, we generally lose some of our rights to exclude competitors from making, using, selling or importing products using the technology based on the expired patents.
Furthermore, in recent years, the U.S. Supreme Court has ruled on several patent cases and several laws have been enacted that, in certain situations, potentially narrow the scope of patent protection available and weaken the rights of patent owners. As a result, we believe large technology companies may be pursuing an “efficient infringement” strategy, having concluded that it is cheaper to infringe third-party intellectual property rights than to acquire, license or otherwise respect them. There can be no assurance that we will be successful in securing additional patents on commercially desirable improvements, that such additional patents will adequately protect our innovations or offset the effect of expiring patents, or that competitors will not be able to design around our patents.
In addition, third-parties have challenged, and may continue to challenge, our issued patents through procedures such as Inter-Partes Review (IPR). In many IPR challenges, the U.S. Patent and Trademark Office (PTO) cancels or significantly narrows issued patent claims. IPR challenges could increase the uncertainties and costs associated with the maintenance, enforcement and defense of our issued and future patents and could have a material adverse effect on our business, financial condition and results of operations. Similarly, changes in patent law and regulations in other countries or jurisdictions or changes in the governmental bodies that enforce them or changes in how the relevant governmental authority enforces patent laws or regulations may weaken our ability to obtain new patents or to enforce patents that we have licensed or that we may obtain in the future. For example, the complexity and uncertainty of European patent laws have also increased in recent years. In Europe, in June 2023, a new unitary patent system was introduced, which will significantly impact European patents, including those granted before the introduction of the system. Under the unitary patent system, after a European patent is granted, the patent proprietor can request unitary effect, thereby getting a European patent with unitary effect (Unitary Patent). Each Unitary Patent is subject to the jurisdiction of the Unitary Patent Court (UPC). As the UPC is a new court system, there is no precedent for the court, increasing the uncertainty of any litigation. Patents granted before the implementation of the UPC will have the option of opting out of the jurisdiction of the UPC and remaining as national patents in the UPC countries. Patents that remain under the jurisdiction of the UPC may be potentially vulnerable to a single UPC-based revocation challenge that, if successful, could invalidate the patent in all countries who are signatories to the UPC. We cannot predict with certainty the long-term effects of the new unitary patent system.
We also utilize unpatented proprietary technology and know-how and often rely on confidentiality agreements and intellectual property assignment agreements with our employees, OEM partners, independent distributors and consultants to protect such unpatented proprietary technology and know-how. However, such agreements may not be enforceable or may not provide meaningful protection for our proprietary information in the event of unauthorized use or disclosure or other breaches of the agreements, or in the event that our competitors discover or independently develop similar or identical designs or other proprietary information.
61
We rely on the use of registered and common law trademarks with respect to our brands and the names of some of our products. Common law trademarks provide less protection than registered trademarks. Loss of rights in our trademarks could adversely affect our business, financial condition and results of operations.
If third-parties claim that we infringe their intellectual property rights, we may incur liabilities and costs and may have to redesign or discontinue selling certain products.
Searching for existing intellectual property rights may not reveal important intellectual property and our competitors may also have filed for patent protection, which may not be publicly-available information, or claimed trademark rights that have not been revealed through our searches. In addition, some of our employees were previously employed at our competitors. We may be subject to claims that our employees have disclosed, or that we have used, trade secrets or other proprietary information of our employees’ former employers. Our efforts to identify and avoid infringing on third-parties’ intellectual property rights may not always be successful. Any claims of patent or other intellectual property infringement against us, even those without merit, could:
•be expensive and time-consuming to defend and result in payment of significant damages to third-parties;
•force us to stop making or selling products that incorporate the intellectual property;
•require us to redesign, reengineer or rebrand our products, product candidates and technologies;
•require us to enter into royalty agreements that would increase the costs of our products;
•require us to indemnify third-parties pursuant to contracts in which we have agreed to provide indemnification for intellectual property infringement claims;
•divert the attention of our management and other key employees; and
•result in our customers or potential customers deferring or limiting their purchase or use of the affected products impacted by the claims until the claims are resolved;
any of which could have a material adverse effect on our business, financial condition and results of operations. In addition, new patents obtained by our competitors could threaten the continued commercialization of our products in the market even after they have already been introduced.
*We believe competitors may currently be violating and may in the future violate our intellectual property rights. As a result, we may initiate litigation to protect and enforce our intellectual property rights, which may result in substantial expense and may divert management’s attention from implementing our business strategy.
We believe that the success of our business depends, in part, on obtaining patent protection for our products and technologies, defending our patents and preserving our trade secrets. We were previously involved in significant litigation to protect our patent positions related to some of our pulse oximetry signal processing patents that resulted in various settlements. We believe some of the new market entrants in the healthcare and monitoring space, including some of the world’s largest technology companies, and some consumer audio companies may be infringing our intellectual property, and we may be required to engage in additional litigation to protect our intellectual property in the future. In addition, we believe that certain individuals who previously held high level technical and clinical positions with us misappropriated our intellectual property for the benefit of themselves and other companies. For example, on January 9, 2020, we initiated litigation against Apple Inc. for infringement of a number of patents, for trade secret misappropriation and for ownership and correction of inventorship of a number of Apple Inc. patents that list one of our former employees as an inventor. For additional information on the current status of our litigation with Apple Inc., please see Note 24, “Commitments and Contingencies”, to our accompanying condensed consolidated financial statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q. Our ongoing and future litigation could result in significant additional costs and further divert the attention of our management and key personnel from our business operations and the implementation of our business strategy and may not be successful or adequate to protect our intellectual property rights. Furthermore, in January 2024, we entered into a one year alternative fee agreement (Fee Agreement) with respect to certain on-going legal fees and costs incurred by a vendor. The Fee Agreement imposes certain limits on a quarterly and annual basis for actual legal fees incurred by the vendor that are payable based on work performed related to litigation matters against Apple. If the vendor is successful in obtaining a favorable judgement for us on any claim or counterclaim after exhaustion or dismissal of any appeals, or upon settlement resulting in monetary consideration to us, the vendor will be paid a success fee equal to three times the amount of the excess of the annual legal fee limit within 60 days after entry of a judgement or the effective date of any settlement. Therefore, to the extent that we may be successful in our litigation against Apple, we could be required to make a payments to this vendor in excess of the actual amount of fees incurred in connection with our litigation against Apple.
62
Risks Related to Our Regulatory Environment
Our failure to obtain and maintain FDA clearances or approvals on a timely basis, or at all, would prevent us from commercializing our current, upgraded or new healthcare products in the U.S., which could severely harm our business.
Unless an exemption applies, each medical device that we market in the U.S. must first undergo premarket review pursuant to the Federal Food, Drug, and Cosmetic Act (FDCA) by receiving clearance of a 510(k) premarket notification, receiving clearance through the de novo classification review process or obtaining approval of a premarket approval (PMA) application. Even if regulatory clearance or approval of a product is granted, the U.S. Food and Drug Administration (FDA) may clear or approve our products only for limited indications for use. Additionally, the FDA may not grant 510(k) clearance on a timely basis, if at all, for new products or new uses that we propose for Masimo SET® or licensed rainbow® technology.
The traditional FDA 510(k) clearance process for our medical devices has generally taken between four to nine months. However, our more recent experience and interactions with the FDA, along with information we have received from other medical device manufacturers, suggests that, in some cases, the FDA is requiring applicants to provide additional or different information and data for 510(k) clearance than it had previously required, and that the FDA may not rely on approaches that it had previously accepted to support 510(k) clearance. As a result, FDA 510(k) clearance can be delayed for our products in some cases.
To support our product applications to the FDA, we frequently are required to conduct clinical testing of our products. Such clinical testing must be conducted in compliance with FDA requirements pertaining to human research. Among other requirements, we must obtain informed consent from study subjects and approval by institutional review boards before such studies may begin. We must also comply with other FDA requirements such as monitoring, record-keeping, reporting and the submission of information regarding certain clinical trials to a public database maintained by the National Institutes of Health. In addition, if the study involves a significant risk device, we are required to obtain the FDA’s approval of the study under an Investigational Device Exemption (IDE). Compliance with these requirements can require significant time and resources. In addition, public health emergencies and other extraordinary circumstances may disrupt the conduct of our clinical trials. If the FDA determines that we have not complied with such requirements, the FDA may refuse to consider the data to support our applications or may initiate enforcement actions.
Even though 510(k) clearances have been obtained, if safety or effectiveness problems are identified with our products, we may need to initiate a recall of such products. Furthermore, our new products or significantly modified marketed products could be denied 510(k) clearance and be required to undergo the more burdensome PMA or de novo classification review processes. The process of obtaining a de novo classification or PMA approval is much more costly, lengthy and uncertain than the process for obtaining 510(k) clearance.
De novo classification review generally takes six months to one year from the time of submission of the de novo request, although it can take longer. Approval of a PMA generally takes one year from the time of submission of the PMA, but may be longer.
Some of our products or product features may not be subject to the 510(k) process and/or other regulatory requirements in accordance with specific FDA guidance and policies, such as the FDA guidance related to mobile medical applications. In additions, some of our products or product features may not be subject to device regulation pursuant to Section 520(o) of the FDCA, which excludes certain software functions from the statutory definition of a device. If the FDA changes its policies or concludes that our marketing of these products is not in accordance with its current policies and/or Section 520(o) of the FDCA, we may be required to seek clearance or approval of these devices through the 510(k), de novo classification review or PMA processes.
The failure of our OEM partners to obtain required FDA clearances or approvals for products that incorporate our healthcare technologies could have a negative impact on our revenue.
Our healthcare OEM partners are required to obtain their own FDA clearances in the U.S. for most products incorporating our technologies. The FDA clearances we have obtained may not make it easier for our OEM partners to obtain clearances of products incorporating these technologies, or the FDA may not grant clearances on a timely basis, if at all, for any future products incorporating our technologies that our OEM partners propose to market.
63
Failure to obtain regulatory authorizations in foreign jurisdictions may prevent us from marketing our products abroad.
We currently market and intend to continue to market our products internationally. Outside of the U.S., we can generally market our healthcare products only if we receive a marketing authorization (and/or meet certain pre-marketing requirements) and, in some cases, pricing approval, from the appropriate regulatory authorities. The regulatory registration/licensing process varies among international jurisdictions and may require additional or different product testing than required to obtain FDA clearance. FDA clearance does not ensure new product registration/licensing by foreign regulatory authorities, and we may be unable to obtain foreign regulatory registration/licensing on a timely basis, if at all.
In addition, clearance by one foreign regulatory authority does not ensure clearance by any other foreign regulatory authority or by the FDA. If we fail to receive necessary approvals to commercialize our products in foreign jurisdictions on a timely basis, or at all, our business, financial condition and results of operations could be adversely affected.
Furthermore, foreign regulatory requirements may change from time to time, which could adversely affect our ability to market new products, and/or continue to market existing products, internationally. Certain significant changes in the international regulatory landscape have recently taken place or will take place in the near future. These include the new EU Medical Devices Regulation (EU) 2017/745 (MDR), which came into effect on May 26, 2021 and a regulatory regime in the UK effective since January 1, 2021 as a result of the UK’s exit from the EU (Brexit).
Modifications to our marketed medical devices may require new regulatory clearances or premarket approvals, or may require us to cease marketing or to recall the modified devices until clearances or approvals are obtained.
We have made modifications to our medical devices in the past and we may make additional modifications in the future. Any modification to a medical device that is cleared by the FDA that could significantly affect its safety or effectiveness or that could constitute a major change in its intended use would require a new clearance or approval and certain modifications to devices cleared or approved by foreign regulatory authorities may also require a new clearance or approval.
We may not be able to obtain such clearances or approvals in a timely fashion, or at all. Delays in obtaining future clearances would adversely affect our ability to introduce new or enhanced products in a timely manner, which in turn would have an adverse effect on our business, financial condition and results of operations.
For device modifications that we conclude do not require a new regulatory clearance or approval, we may be required to recall and to stop marketing the modified devices if the government agency disagrees with our conclusion and requires new clearances or approvals for the modifications. This could have an adverse effect on our business, financial condition and results of operations.
If our healthcare products cause or contribute to a death or serious injury, or malfunction in a way that would likely cause or contribute to a death or serious injury, we will be subject to medical device reporting regulations and other applicable laws, and may need to initiate voluntary or mandatory corrective actions, such as the recall of our healthcare products.
Regulatory agencies in many countries require us to report anytime our healthcare products cause or contribute to a death or serious injury, or malfunction in a way that would likely cause or contribute to a death or serious injury. For example, under the FDA medical device reporting regulations, we are required to report to the FDA any incident in which a product of ours may have caused or contributed to a death or serious injury or in which a product of ours malfunctioned and, if the malfunction were to recur, would be likely to cause or contribute to death or serious injury. In addition, all manufacturers placing medical devices on the market in the EU are legally required to report any serious or potentially serious incidents involving devices produced or sold by the manufacturer to the relevant authority in those jurisdictions where any such incident occurred.
The FDA and similar foreign regulatory authorities have the authority to require the recall of our commercialized healthcare products in the event of material deficiencies or defects in, for example, design, labeling or manufacture. The FDA must find that there is a reasonable probability that the device would cause serious adverse health consequences or death in order to require a recall. The standard for recalling deficient products may be different in foreign jurisdictions. Manufacturers may, under their own initiative, recall a product if any material deficiency is found in a device or they become aware of a safety issue involving a marketed product. A government-mandated or voluntary recall by us or by one of our distributors could occur as a result of component failures, manufacturing errors, design or labeling defects or other deficiencies and issues.
64
We may initiate certain field actions, such as a product correction or removal of our products in the future. In addition, third- parties that commercialize products incorporating our technologies may initiate similar actions or product corrections. Any correction or removal initiated by us to reduce a health risk posed by our device, or to remedy a violation of the FDCA or other regulations caused by the device that may present a risk to health, must be reported to the FDA. If the FDA subsequently determines that a report was required for a correction or removal of our products that we did not believe required a report, we could be subject to enforcement actions.
In addition, our non-healthcare products, including components we source from third parties, may be found to have design or manufacturing defects. Such defects may result in additional costs for product modifications, voluntary or mandated product recalls or other liabilities resulting from product malfunctions. For example, defects in our audio products may result in overheating or electrical shock, creating a risk of personal injury or property damage.
Any recalls or corrections of our products or third-party products that incorporate our technologies, or enforcement actions would divert managerial and financial resources and could have an adverse effect on our financial condition and results of operations. In addition, given our dependence upon patient, physician and consumer perceptions, any negative publicity associated with any recalls could materially and adversely affect our business, financial condition, results of operations and growth prospects.
In August 2023, we determined to initiate a voluntary recall of select Rad-G® products in connection with an issue that can result in an unintentional change in the power state of the device. On February 14, 2024, we initiated the voluntary recall. On February 21, 2024, we received a subpoena from the Department of Justice (DOJ) seeking documents and information related to our Rad-G® and Rad-97® products, including information relating to complaints surrounding the products and our decision to recall the Rad-G®. Additionally, on March 25, 2024, we received a civil investigative demand from the DOJ seeking documents and information related to customer returns of our Rad-G® and Rad-97® products, including returns related our recall of select Rad-G® products in 2024. We are investigating the reasons for the delay between August 2023 and February 2024 when the recall was initiated. We are cooperating with the government and may expend significant financial and managerial resources in connection with responding to the subpoena and the investigative demand and any related investigation or any other future requests for information.
Promotion of our healthcare products using claims that are off-label, unsubstantiated, false or misleading could subject us to substantial penalties.
Obtaining 510(k) clearance permits us to promote our products for the uses cleared by the FDA. Use of a device outside its cleared or approved indications is known as “off-label” use. Physicians may use our products off-label because the FDA does not restrict or regulate a physician’s choice of treatment within the practice of medicine, but we may not promote our products “off-label”. While we may request additional cleared indications for our current products, the FDA may deny those requests, require additional expensive clinical data to support any additional indications or impose limitations on the intended use of any cleared product as a condition of clearance. If the FDA determines that our products were promoted for off-label use or that false, misleading or inadequately substantiated promotional claims have been made by us or our OEM partners, it could request that we or our OEM partners modify those promotional materials or it could take regulatory or enforcement actions, including the issuance of an untitled letter, warning letter, injunction, seizure, civil fine and criminal penalties. While certain U.S. courts have held that truthful, non-misleading, off-label information is protected under the First Amendment under certain circumstances, the FDA continues to take the position that off-label promotion is subject to enforcement action.
It is also possible that other federal, state or foreign enforcement authorities may take action if they consider our communications, including promotional or training materials, to constitute promotion of an uncleared or unapproved use. If not successfully defended, enforcement actions related to off-label promotion could result in significant fines or penalties under other statutory authorities, such as laws prohibiting false claims for reimbursement. In any such event, our reputation could be damaged, adoption of our products could be impaired and we could be subject to extensive fines and penalties.
Additionally, we must have adequate substantiation for the claims we make for our products. If any of our claims are determined to be false, misleading or deceptive, our products could be considered misbranded under the FDCA or in violation of the Federal Trade Commission Act. We could also face lawsuits from our competitors under the Lanham Act alleging that our marketing materials are false or misleading.
Government agencies in the EU, UK, Japan and other countries and jurisdictions have similar regulations on the advertising and promotion of medical devices. If we fail to comply with any of these regulations, our reputation could be damaged, adoption of our products could be impaired and we could be subject to extensive fines and penalties.

65
The regulatory environment governing information, data security and privacy is increasingly demanding and evolving. Many of the laws and regulations in this area are subject to uncertain interpretation, and our failure to comply could result in claims, penalties or increased costs or otherwise harm our business.
Personal privacy and data security have become significant issues in the U.S., Europe, the Middle East, Canada, China and many other jurisdictions where we offer our products. The regulatory framework for privacy and security issues worldwide is rapidly evolving and is likely to remain uncertain for the foreseeable future.
Several U.S. states have passed comprehensive privacy laws. For example, the California Consumer Privacy Rights Act (CPRA) amended and expanded the California Consumer Privacy Act (CCPA) effective January 1, 2023. Other states have also enacted data privacy laws that took effect in 2023, including the Virginia Consumer Data Protection Act, the Colorado Privacy Act, Utah’s Consumer Privacy Act, and the Connecticut Data Privacy Act. Further, Delaware, Florida, Indiana, Iowa, Montana, Oregon, Tennessee and Texas also adopted privacy laws, which take effect from July 1, 2024 through 2026. These state laws govern the processing of residents’ personal information. Among many new requirements, some of the state privacy laws expand consumers’ rights (such as opting out of certain data sales to third parties and targeted advertising, restricting certain uses and disclosures of sensitive data, and requesting access, deletion, or correction of personal information). These state laws also minimize what data that can be collected from consumers and how businesses may use and disclose it. These state privacy laws also require businesses to make disclosures to consumers about data collection, use and sharing practices. In addition, some of these laws (including the CPRA) subject health-related information to additional safeguards and disclosures and some specifically regulate consumer health data, such as the Washington My Health My Data Act, which will become effective in 2024. There is significant uncertainty regarding how regulators will interpret and enforce this patchwork of new laws, particularly to the extent there are inconsistencies or differences in their requirements.
We continue to be subject to federal privacy laws such as the Health Insurance Portability and Accountability Act of 1996 (HIPAA), in certain circumstances, in connection with any personal health information or medical information that we may obtain or have access to in connection with the operation of our business. Moreover, a comprehensive federal data privacy legislation has been proposed and, if passed, will further change the privacy and data security compliance landscape. In addition, on July 26, 2023, the SEC adopted rules requiring registrants to disclose material cybersecurity incidents they experience and to disclose on an annual basis material information regarding their cybersecurity risk management, strategy and governance.
All 50 U.S. states have data breach notification laws that, if violated, could result in penalties, fines and litigation. In addition, many states have implemented or are in the process of implementing related legislation, including state-specific biometric privacy laws that have resulted in class-action lawsuits against businesses. The full impact of these laws on our business is yet to be determined, but it could result in increased operating expenses as well as additional exposure to the risk of litigation by or on behalf of consumers.
Internationally, the European Data Protection Board continues to release guidelines for industries and impose fines related to the General Data Protection Regulation (GDPR), some of which have been very significant. To improve coordination among EU supervisory authorities, the European Commission has proposed a new regulation that would help to streamline enforcement of the GDPR in cross-border cases. Meanwhile, there continues to be persistent uncertainty relating to the transfer of personal data from Europe to the U.S., or other non-adequate countries, following the Schrems II decision. On July 10, 2023, the European Commission adopted its adequacy decision on the EU-U.S. Data Privacy Framework (DPF). The decision, which took effect on the day of its adoption, concludes that the United States ensures an adequate level of protection for personal data transferred from the EEA to companies certified to the DPF. However, it remains too soon to tell how the future of Privacy Shield 2.0 will evolve and what impact it will have on our international activities. At least one challenge to the DPF is pending before the Court of Justice of the European Union.
Further, Brexit has led and could also lead to legislative and regulatory changes that may increase our compliance costs. As of January 1, 2021 and the expiry of transitional arrangements agreed to between the UK and the EU, data processing in the UK is governed by a UK version of the GDPR (combining the GDPR and the Data Protection Act 2018), exposing us to two parallel regimes, each of which authorizes similar fines and other potentially divergent enforcement actions for certain violations. On June 28, 2021, the European Commission adopted an Adequacy Decision for the UK, allowing for the relatively free exchange of personal information between the EU and the UK, (as the UK correspondingly allows transfers back to the EU). However, the European Commission may suspend the Adequacy Decision if it considers that the UK no longer provides for an adequate level of data protection. A bill to amend the existing UK framework is now pending, but is not expected to be passed before the new UK election.
Other international jurisdictions, including Canada, China, India, Saudi Arabia, South Africa, the UAE, Singapore, South Korea, Mexico, Australia, Argentina, India and Brazil, among others, have also implemented, or are in the process of implementing laws relating to data privacy and protection that are all already in effect or are anticipated to go into effect soon,
66
or are amending existing laws. In addition, several jurisdictions such as South Korea have shown increased enforcement of their existing data privacy and security laws. Although we believe that we are complying with the GDPR and similar laws, these laws are still relatively new. Therefore, as international data privacy and protection laws continue to evolve, and as new regulations, interpretive guidance and enforcement information become available, we may incur additional costs to modify our business practices to comply with these requirements.
We may be required to make costly system modifications to comply with applicable data privacy and security laws. Violations of these laws, or allegations of such violations, could subject us to criminal or civil, monetary or and non-monetary penalties, disrupt our operations, involve significant management distraction, negatively impact our brand image, subject us to class action lawsuits and result in a material adverse effect on our business, financial condition and results of operations.
We may be subject to or otherwise affected by federal and state healthcare laws, including fraud and abuse laws, and could face substantial penalties if we are unable to fully comply with these laws.
Healthcare fraud and abuse laws potentially applicable to our operations include, but are not limited to:
•the federal Anti-Kickback Statute, which prohibits, among other things, knowingly and willfully offering, paying, soliciting or receiving any bribe, kickback or other remuneration intended to induce the purchase, order or recommendation of an item or service reimbursable under a federal healthcare program (such as the Medicare or Medicaid programs);
•the federal False Claims Act and other federal laws which prohibit, among other things, knowingly and willfully presenting, or causing to be presented, claims for payment from Medicare, Medicaid, other government payers or other third-party payers that are false or fraudulent;
•the Physician Payments Sunshine Act, which requires medical device companies to track and publicly report, with limited exceptions, all payments and transfers of value to certain healthcare professionals and teaching hospitals in the U.S.; and
•state laws analogous to each of the above federal laws, such as state anti-kickback and false claims laws that may apply to items or services reimbursed by governmental programs and non-governmental third-party payers, including commercial insurers.
If we are found to have violated any such laws or other similar governmental regulations, including their foreign counterparts, that are directly or indirectly applicable to us, we may be subject to penalties, including civil and criminal penalties, damages, fines, exclusion of our products from reimbursement under Medicare, Medicaid and other federal healthcare programs, and the curtailment or restructuring of our operations. Any penalties could adversely affect our ability to operate our business and our financial results. Any action against us for violation of these laws, even if we successfully defend against such action, could cause us to incur significant legal expenses and divert our management’s attention from the operation of our business.
Risks Related to Our Business and Operations
We may experience conflicts of interest with Willow with respect to business opportunities and other matters.
Prior to our initial public offering in August 2007, our stockholders owned 99% of the outstanding shares of capital stock of Willow, and we believe that a number of our stockholders, including certain of our directors and executive officers, continue to own shares of Willow stock. Joe Kiani, our Chairman and Chief Executive Officer (CEO), is also the Chairman and CEO of Willow.
Due to the interrelated nature of Willow with us, conflicts of interest may arise with respect to transactions involving business dealings between us and Willow, potential acquisitions of businesses or products, the development and ownership of technologies and products, the sale of products, markets and other matters in which our best interests and the best interests of our stockholders may conflict with the best interests of the stockholders of Willow. In addition, we and Willow may disagree regarding the interpretation of certain terms in the Cross-Licensing Agreement. We cannot guarantee that any conflict of interest will be resolved in our favor, or that, with respect to our transactions with Willow, we will negotiate terms that are as favorable to us as if such transactions were with another third-party.
We will be required to assign to Willow and pay Willow for the right to use certain products and technologies we develop that relate to the monitoring of non-vital sign parameters, including improvements to Masimo SET®.
Under the Cross-Licensing Agreement, if we develop certain products or technologies that relate to the noninvasive monitoring of non-vital sign parameters, including improvements to Masimo SET® for the noninvasive monitoring of non-vital sign parameters, we would be required to assign these developments to Willow and then license the technology back from Willow in consideration for upfront payments and royalty obligations to Willow. Therefore, these products and technologies would be deemed to have been developed or improved exclusively by Willow.
67
In addition, we will not be reimbursed by Willow for our expenses relating to the development or improvement of any such products or technologies, which expenses may be significant. As a result of these terms, we may not generate any revenue from the further development of certain products and technologies for the monitoring of non-vital sign parameters, including improvements to Masimo SET®, which could adversely affect our business, financial condition and results of operations.
In the event that the Cross-Licensing Agreement is terminated for any reason, or Willow grants a license to rainbow® technology to a third-party, our business would be adversely affected.
Willow owns all of the proprietary rights to certain rainbow® technology developed with our proprietary Masimo SET® for products intended to be used in the “Willow Market”, and all rights to any non-vital signs measurement for which we do not exercise an option pursuant to the Cross-Licensing Agreement. In addition, Willow has the right to terminate the Cross-Licensing Agreement or grant licenses covering rainbow® technology to third-parties if we breach certain terms of the agreement, including any failure to meet our minimum royalty payment obligations or failure to use commercially reasonable efforts to develop or market products incorporating licensed rainbow® technology. If we lose our exclusive license to rainbow® technology, we would lose the ability to prevent others from making, using, selling or importing products using rainbow® technology in our market. As a result, we would likely be subject to increased competition within our market, and Willow or competitors who obtain a license to rainbow® technology from Willow would be able to offer related products.
We may not be able to commercialize our products incorporating licensed rainbow® technology cost-effectively or successfully.
As a result of the royalties that we must pay to Willow, it is generally more expensive for us to make products that incorporate licensed rainbow® technology than products that do not include licensed rainbow® technology.
Accordingly, we may not be able to sell products incorporating licensed rainbow® technology at a price the market is willing to accept. If we cannot commercialize our products incorporating licensed rainbow® technology successfully, we may not be able to generate sufficient revenue from these products to be profitable, which could adversely affect our business, financial condition and results of operations.
Rights provided to Willow in the Cross-Licensing Agreement may impede a change in control of our company.
Under the Cross-Licensing Agreement, a change in control includes the resignation or termination of Joe Kiani from his position as CEO of either Masimo or Willow. A change in control also includes other customary events, such as the sale or merger of Masimo or Willow to a non-affiliated third-party or the acquisition of 50% or more of the voting power of Masimo or Willow by a non-affiliated third-party.
Among other things, the Cross-Licensing Agreement provides that if the surviving or acquiring entity ceases to use “Masimo” as a company name and trademark following a change in control, all rights to the “Masimo” trademark will automatically be assigned to Willow. This could delay or discourage transactions involving an actual or potential change in control of us, including transactions in which our stockholders might otherwise receive a premium for their shares over our then-current trading price. In addition, our requirement to assign all future improvements for non-vital signs to Willow could impede a change in control of our company.
If we are unable to obtain key materials and components from sole or limited source suppliers, we will not be able to deliver our products to customers.
We depend on certain sole or limited source suppliers for certain key materials and components, including digital signal processor chips and analog-to-digital converter chips for certain products. These suppliers are located around the world, and the production and shipment of such materials and components may be constrained globally due to freight carrier delays and other disruptions to the supply chain. We may experience manufacturing problems related to these suppliers and other outside sources if such suppliers fail to develop, manufacture or ship products and components to us on a timely basis, or provide us with products and components that do not meet our quality standards and required quantities. We previously experienced supply constraints with regard to certain digital signal processor chips and other components during the COVID-19 pandemic, which affected our sales during 2022. In addition, from time to time there have been industry-wide shortages of certain components that we use in certain products. We may also experience price increases for materials, components and shipping with no guarantee that such increases can be passed along to our customers, which could adversely impact our gross margins.
If any of these problems occur, we may be unable to obtain substitute sources for these products and components on a timely basis or on terms acceptable to us, which could harm our ability to manufacture our own products and components profitably or on time.
68
Future strategic initiatives, including acquisitions of businesses and strategic investments, could negatively affect our business, financial condition and results of operations if we fail to integrate the acquired businesses and their employees successfully into our existing operations or achieve the desired results of our initiatives.
We have acquired several businesses since our inception and we may acquire additional businesses in the future. For example, on April 11, 2022, we completed our acquisition of Sound United. In connection with the Sound United acquisition, on April 11, 2022, we entered into a Credit Facility to partially fund the acquisition. Future acquisitions may require additional debt or equity financing, which could be dilutive to our existing stockholders or reduce our earnings per share or other financial metrics. Even if we complete acquisitions, there are many factors that could affect whether such acquisition, including our acquisition of Sound United, will be beneficial to our business, including, without limitation:
•payment of above-market prices for acquisitions and higher than anticipated acquisition costs;
•issuance of common stock as part of the acquisition price or a need to issue stock options or other equity-based compensation to newly-hired employees of target companies, resulting in dilution of ownership to our existing stockholders;
•reduced profitability if an acquisition is not accretive to our business over either the short-term or the long-term;
•difficulties in integrating any acquired companies, personnel, products and other assets into our existing business;
•delays in realizing the benefits of the acquired company, products or other assets;
•regulatory challenges and becoming subject to additional regulatory requirements;
•cybersecurity and compliance-related issues;
•diversion of our management’s time and attention from other business concerns;
•limited or no direct prior experience in new markets or countries we may enter;
•unanticipated issues dealing with unfamiliar suppliers, service providers or other collaborators of the acquired company;
•higher costs of integration than we anticipated;
•write-downs or impairments of goodwill or other intangible assets associated with the acquired company;
•difficulties in retaining key employees of the acquired business who are necessary to manage these acquisitions;
•negative impacts on our relationships with our employees, clients, customers or collaborators;
•intellectual property and other litigation, other claims or liabilities in connection with the acquisition; and
•changes in the overall financial model as certain acquired companies may have a different revenue, gross profit margin or operating expense profile.
Further, our ability to benefit from future acquisitions and/or external strategic investments depends on our ability to successfully conduct due diligence, negotiate acceptable terms, evaluate prospective opportunities and bring acquired technologies and/or products to market at acceptable margins and operating expense levels.
We may also discover deficiencies in internal controls, data adequacy and integrity, product quality, regulatory compliance, product liabilities or other undisclosed liabilities that we did not uncover prior to our acquisition or investment, which could result in us becoming subject to penalties, other liabilities or asset impairments. In addition, if we do not achieve the anticipated benefits of an acquisition or other external investment as rapidly as expected, or at all, investors or analysts may downgrade our stock.
We also expect to continue to carry out internal strategic initiatives that we believe are necessary to grow our revenues and expand our business, both in the U.S. and abroad. For example, we have continued to invest in international expansion programs designed to increase our worldwide presence and take advantage of market expansion opportunities around the world. Although we believe our investments in these initiatives continue to be in the long-term best interests of Masimo and our stockholders, there are no assurances that such initiatives will yield favorable results for us. Accordingly, if these initiatives are not successful, our business, financial condition and results of operations could be adversely affected.
If these risks materialize, our stock price could be materially adversely affected. Any difficulties in the integration of acquired businesses or unexpected penalties, liabilities or asset impairments in connection with such acquisitions or investments could have a material adverse effect on our business, financial condition and results of operations.
69
Our new products and changes to existing products, including as a result of our acquisition of Sound United could fail to attract or retain users or generate revenue and profits. Further, we may not be successful in our non-healthcare expansion, which could adversely affect our business, reputation or financial results.
In connection with the Sound United acquisition, we have expanded our business and product strategy to additionally focus on non-healthcare consumer products to integrate with our successful medical technology businesses. Further, we may introduce certain changes to our existing healthcare products or introduce new and unproven products. Prior to the Sound United acquisition, we did not have significant experience with consumer hardware products, and Sound United does not have experience with healthcare products, which may adversely affect our ability to successfully develop and market these products and technologies and integrate them with our existing products and platforms. We expect this will be a complex, evolving, and long-term strategic initiative that will involve the development of new and emerging technologies, continued investment in medical technology and consumer products, and collaboration with other companies, developers, partners and other participants. However, our non-healthcare business may not develop in accordance with our vision and expectations, and market acceptance of features, products or services we build for our consumer business may be uncertain. We may be unsuccessful in our research and product development efforts, including if we are unable to develop relationships with key participants in the consumer products business. Our new strategic efforts may also divert resources and management attention from other areas of our business. In addition, as our non-healthcare business continues to evolve, we may be subject to a variety of laws and regulations in the U.S. and international jurisdictions, which we were not previously affected by, including in the areas of privacy, which may delay or impede the development of our products and services, increase our operating costs, require significant management time and attention, or otherwise harm our business. As a result of these or other factors, our non-healthcare expansion and investments may not be successful in the foreseeable future, or at all, which could adversely affect our business, reputation, or financial results.
Our Credit Facility contains certain covenants and restrictions that may limit our flexibility in operating our business.
Our Credit Facility contains various affirmative covenants and restrictions that limit our ability to engage in specified types of transactions, including:
•incurring specified types of additional indebtedness, there can be no assurance that we will be able to obtain any additional debt or equity financing at the time needed or that such financing will be available on terms that are favorable or acceptable to us (including guarantees or other contingent obligations);
•paying dividends on, repurchasing or making distributions in respect of our common stock or making other restricted payments, subject to specified exceptions;
•making specified investments (including loans and advances);
•selling or transferring certain assets;
•creating certain liens;
•consolidating, merging, selling or otherwise disposing of all or substantially all of our assets; and
•entering into certain transactions with any of our affiliates.
In addition, under our Credit Facility, we are required to satisfy and maintain specified financial ratios and other customary affirmative and negative covenants. Our ability to meet those financial ratios and affirmative and negative covenants could be affected by events beyond our control and, therefore, we cannot be assured that we will be able to continue to satisfy these requirements. A breach of any of these ratios or covenants could result in a default under our Credit Facility. Upon the occurrence of an event of default, the Lenders could elect to declare all amounts outstanding under our Credit Facility immediately due and payable, terminate all commitments to extend further credit and pursue legal remedies for recovery, all of which could adversely affect our business and financial condition. See Note 15, “Debt”, to our accompanying condensed consolidated financial statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q for additional information on our Credit Facility.
Further, if we do not achieve the anticipated benefits from the Sound United acquisition, our ability to service our indebtedness may be adversely impacted. Even if we achieve the anticipated benefits from the acquisition, we may be required to raise substantial additional financing to fund working capital, capital expenditures, acquisitions, or other general corporate purposes. Our ability to arrange additional financing and make payments of principal and interest on our indebtedness will depend on our future performance, which will be subject to general economic, financial, and business conditions as well as other factors affecting our operations, many of which are beyond our control.
70
We have incurred impairment charges for other intangible assets, and may incur further impairment charges in the future, which would negatively impact our operating results.
During the third quarter of 2023, we experienced continued declines in our stock price and certain worsening macro-economic market conditions, including continued slowing in demand for consumer audio products, which contributed to a significant decline in our market capitalization. Based on these factors, we determined that there was a triggering event for the three months ended September 30, 2023, which required an interim impairment assessment. Accordingly, we performed an interim impairment test of goodwill and indefinite-lived intangibles, and a recoverability test for other long lived assets with finite lives. This quantitative assessment indicated that the carrying value of certain trademarks in the non-healthcare reporting unit were impaired by approximately $7.0 million. No impairment of goodwill was identified, as the fair value of each reporting unit exceeded its carrying value as of September 30, 2023.
During the fourth quarter of 2023, although we experienced a recovery in our stock price and stabilization in our market capitalization, we also experienced continued softening in customer demand for our non-healthcare core audio products and additional supply chain inefficiencies. Based on these factors and further quantitative assessment, we determined the carrying value of certain trademarks in the non-healthcare reporting unit were impaired by approximately $3.0 million.
We review goodwill, other intangibles and other long-lived assets with finite lives for impairment at least annually in the fourth quarter of the year or more frequently if an event occurs indicating the potential for impairment. In the event we are required to record additional non-cash impairment charges to our goodwill, other intangibles and other long-lived assets with finite lives in the future, such a non-cash charge could have a material adverse effect on our consolidated statements of operations and balance sheets in the reporting period in which we record the charge.
We may need additional capital and failure to raise additional capital on terms favorable to us, or at all, could limit our ability to grow our business and develop or enhance our service offerings to respond to market demand or competitive challenges.
We anticipate that our existing cash and cash equivalents, amounts available under our Credit Facility, and cash provided by operations, taken together, provide adequate resources to fund ongoing operating and capital expenditures, working capital requirements, and other operational funding needs for the next 12 months. However, we may require additional cash resources due to changed business conditions or other future developments. If our existing resources are insufficient to satisfy cash requirements, we may seek to obtain one or more additional credit facilities, sell equity or debt securities or pursue other forms of financing. The incurrence of indebtedness would result in increased debt service obligations and could require us to agree to operating and financing covenants that could potentially restrict our operations. The sale of additional equity securities, or securities convertible into equity securities, could result in dilution to stockholders. In addition, actual events involving limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions, transactional counterparties or other companies in the financial services industry or the financial services industry generally, or concerns or rumors about any events of these kinds or other similar risks, have in the past and may in the future lead to market-wide liquidity problems and could increase our costs of borrowing.
Our ability to obtain additional capital on acceptable terms is subject to a variety of uncertainties, including investors’ perception of, and demand for, our securities, conditions in the capital markets in which we may seek to raise funds, our future results of operations and financial condition, and general economic, macro-economic, political and geopolitical conditions. In addition, even if debt financing is available, the cost of additional financing may be significantly higher than those provided for in our current Credit Facility. Moreover, financing may not be available in amounts or on terms acceptable to us, or at all, or at times when we require it, each of which could limit our ability to grow and expand our business and operations and develop or enhance our products and offerings to respond to market demand or competitive or other business challenges.
*The potential separation of our consumer business is subject to various risks and uncertainties, and may not be completed on the terms currently contemplated, if at all, and, if completed, may not achieve the intended benefits.
On March 22, 2024, we announced that our Board has authorized management to evaluate a proposed separation of our consumer business. Our Board and management are currently evaluating the proposed structure of the proposed separation, but we currently expect the proposed separation will include our consumer audio and consumer health products, including the Stork baby monitor and the Freedom smart watch and band. The proposed separation is complex, and completion of the proposed separation and the timing of its completion will be subject to a number of factors and conditions, including the finalization of the structure of the proposed separation and final approval by our Board, as well as the satisfaction of conditions to completing the proposed separation, among other things. The uncertainties associated with this process, foreseen and unforeseen costs incurred, and efforts involved, may negatively affect our operating results, business and our relationships with employees, customers, suppliers and vendors. Unanticipated developments could delay, prevent or otherwise adversely affect the proposed separation, including, but not limited to, changes in general economic and financial market conditions and material adverse
71
changes in business or industry conditions. There can be no assurances that we will be able to complete the proposed separation or that the proposed separation will maximize shareholder value or be the best path for success. In addition, we cannot assure that we will be able to complete the proposed separation within any specified timeline, or at all. Delays or failure to consummate the proposed separation could negatively affect our business, financial condition and results of operations. The execution of the proposed separation has required and may continue to require significant time and attention from our senior management and employees, which could cause disruption in business processes and adversely affect our financial results and our results of operations, and our employees may be distracted due to uncertainty regarding the future state of our company. Additionally, foreseen and unforeseen costs may be incurred with the proposed separation, including fees such as advisory, accounting, tax, legal, reorganization, restructuring, and various other fees, some of which may be incurred regardless if the proposed separation occurs. Furthermore, if the proposed separation is completed, we may not be able to achieve the full strategic and financial benefits that are expected to result from the proposed separation.
Risks Related to Our Stock
Concentration of ownership of our stock among our existing directors, executive officers and principal stockholders may prevent new investors from influencing significant corporate decisions.
As of March 30, 2024, our current directors and executive officers and their affiliates, in the aggregate, beneficially owned approximately 18.6% of our outstanding stock. Subject to any fiduciary duties owed to our other stockholders under Delaware law, these stockholders may be able to exercise significant influence over matters requiring stockholder approval, including the election of directors and approval of significant corporate transactions, and will have some control over our management and policies in their roles as stockholders. Some of these persons or entities may have interests that are different from yours. For example, these stockholders may support proposals and actions with which you may disagree or which are not in your best interests.
The concentration of ownership could delay or prevent a change in control of us, or otherwise discourage a potential acquirer from attempting to obtain control of us, which in turn could reduce the price of our stock.
In addition, these stockholders could use their voting influence to maintain our existing management and directors in office or support or reject other management and Board proposals that are subject to stockholder approval, such as amendments to our employee stock plans and approvals of significant financing transactions.
We may be unable to accurately forecast our financial and operating results and appropriately plan our expenses in the future or we may fail to meet our publicly announced guidance about our business and future operating results.
From time to time, we release earnings guidance or other financial guidance in our quarterly and annual earnings conference calls or otherwise, regarding our future performance that represents our management’s estimates as of the date of release. Our guidance includes forward-looking statements based on projections prepared by our management. Projections are based upon a number of assumptions and estimates that are based on information known when they are issued, and, while presented with numerical specificity, are inherently subject to significant business, economic, and competitive uncertainties and contingencies relating to our business, many of which are beyond our control and are based upon specific assumptions with respect to future business decisions, some of which will change. Some of those key assumptions include broader macro-economic conditions and the resulting impact of these factors on future consumer spending patterns and our business. These assumptions are inherently difficult to predict, particularly in the long term. Additionally, forecasted financial and operating results may differ materially from actual results, which may materially adversely affect our financial condition and stock price. For example, if certain of our assumptions or estimates prove to be wrong, including any of the economic trends and developments affecting our business discussed in Part I, Item 2 of this Quarterly Report on Form 10-Q, this could cause us to miss our earnings guidance or negatively impact the results we report, either of which could negatively impact our stock price and expose us to potential shareholder litigation.
We generally state possible outcomes as high and low ranges which are intended to provide a sensitivity analysis as variables are changed but are not intended to imply that actual results could not fall outside of the suggested ranges. Furthermore, analysts and investors may develop and publish their own projections of our business, which may form a consensus about our future performance. Our actual business results may vary significantly from such guidance or estimates or that consensus due to a number of factors, many of which are outside of our control, including global economic uncertainty and financial market conditions, geopolitical events, rising inflation, and rising interest rates, potential recessionary factors, and foreign exchange rate volatility, which could adversely affect our business and future operating results. We use the reports and models of economic experts in making assumptions relating to consumer discretionary spending and predictions as to timing and pace of any future economic impacts. If these models are incorrect or incomplete, or if we fail to accurately predict the full impact of certain factors, such as macro-economic factors, the guidance and other forward-looking statements we provide may also be
72
incorrect or incomplete. Furthermore, if we make downward revisions of our previously announced guidance, or if our publicly announced guidance of future operating results fails to meet expectations of analysts, investors, or other interested parties, the price of our common stock could decline. Guidance is necessarily speculative in nature, and it can be expected that some or all of the assumptions underlying the guidance furnished by us will not materialize or will vary significantly from actual results. In light of the foregoing, investors are urged not to rely upon our guidance in making an investment decision regarding our common stock.
Our corporate documents, and Delaware law contain provisions that could discourage, delay or prevent a change in control of our company, prevent attempts to replace or remove current management and reduce the market price of our stock.
Provisions in our certificate of incorporation and bylaws may discourage, delay or prevent a merger or acquisition involving us that our stockholders may consider favorable. For example, our certificate of incorporation authorizes our Board to issue up to 5.0 million shares of “blank check” preferred stock. As a result, without further stockholder approval, our Board has the authority to attach special rights, including voting and dividend rights, to this preferred stock, including pursuant to a stockholder rights plan, such as those underlying the Rights Agreement we previously adopted on September 9, 2022, which we terminated in accordance with the terms of the Amendment to the Rights Agreement we entered into effective as of March 22, 2023. However, we may implement a new stockholder rights plan in the future, which may have the effect of discouraging or preventing a change in control by, among other things, making it uneconomical for a third party to acquire us without the consent of our Board. With such rights, preferred stockholders could make it more difficult for a third-party to acquire us.
In addition, our certificate of incorporation previously provided for a staggered Board, whereby directors serve for three-year terms, with one-third of the directors coming up for reelection each year. However, at our 2023 annual meeting of stockholders held on June 26, 2023, our stockholders approved an amendment to our certificate of incorporation, pursuant to which we will phase-in the declassification of our Board over four years, whereby all members of our Board that are elected after our 2023 annual meeting of stockholders would be elected for annual terms. Accordingly, the three-year term for the Class I directors elected at our 2023 annual meeting of stockholders will expire at our 2026 annual meeting of stockholders, the three-year term for the Class II directors elected at our 2021 annual meeting of stockholders will expire as originally scheduled at our 2024 annual meeting of stockholders and the three-year term for the Class III directors elected at our 2022 annual meeting of stockholders will expire as originally scheduled at our 2025 annual meeting of stockholders. The implementation of the declassification of our Board will commence at our 2024 annual meeting of stockholders. Director nominees standing for election at our 2024 annual meeting of stockholders and each annual meeting of stockholders thereafter will be elected to serve a one-year term. Beginning with our 2026 annual meeting of stockholders, all directors would stand for annual elections.
We are also subject to anti-takeover provisions under the General Corporation Law of the State of Delaware (DGCL). Under these provisions, if anyone becomes an “interested stockholder,” we may not enter into a “business combination” with that person for three years without special approval, which could discourage a third-party from making a takeover offer and could delay or prevent a change in control of us. For purposes of these provisions, an “interested stockholder” generally means someone owning 15% or more of our outstanding voting stock or an affiliate of ours that owned 15% or more of our outstanding voting stock during the past three years, subject to certain exceptions as described in the DGCL.
*Shareholder activism could cause us to incur significant expense, disrupt our business, result in a proxy contest or litigation and impact our stock price.
We have been subject to shareholder activism and may be subject to such activism in the future, which as before could result in substantial costs and divert management’s and our Board’s attention and resources from our business. Such shareholder activism could give rise to perceived uncertainties as to our future, adversely affect our relationships with our employees, customers, suppliers, or business partners, make it more difficult to attract and retain key personnel, and result in a change in control pursuant to the employment agreement between us and Joe Kiani, our Chairman and CEO.
73
We value input from investors and regularly engage in dialogue with our stockholders regarding strategy and performance. Activist shareholders who disagree with the composition of our Board, our strategy or the way our Company is managed may seek to effect change through various strategies and channels, such as through commencing another proxy contest, making public statements critical of our performance or business or engaging in other similar activities. Responding to shareholder activism can be costly and time-consuming, disrupt our operations, and divert the attention of management and our employees from our strategic initiatives, and we may be required to incur significant fees and other expenses related to activist shareholder matters, including for third-party advisors. For example, in 2022, Politan Capital Management LP and Politan Capital NY LLC and certain of their affiliates (Politan), acquired a material portion of our outstanding shares and filed a proxy statement with the SEC seeking an election of two of its nominees to our Board at our 2023 Annual Meeting. At the 2023 Annual Meeting held on June 26, 2023, our stockholders voted to elect both nominees designated by Politan to serve on our Board. As a result of the contested director election, we incurred significant costs, as well as Board and management distraction during the fourth quarter of 2022 and majority of the 2023 fiscal year. In March 2024, Politan nominated two additional persons for election to our Board at our upcoming 2024 Annual Meeting. As a result of the contested director election, we expect to again incur significant costs, as well as endure Board and management distractions during the first and second quarters of 2024 and possibly through the remainder of 2024.
Responding to the upcoming proxy contest from Politan or proxy contests from any other activist shareholders will be costly and time-consuming and will again divert management’s and our Board’s attention and resources from our business activities. This could have a material adverse effect on us for at least the following reasons:
•shareholders may attempt to effect changes in our strategic direction and governance or to acquire control over our Board or our Company;
•while we welcome the opinions of all shareholders, responding to proxy contests is likely to be costly and time-consuming, disrupt our operations, and potentially divert the attention of our Board, management team and other employees away from their regular duties and the pursuit of business opportunities to enhance shareholder value;
•perceived uncertainties as to our future direction as a result of potential changes to the composition of our Board may lead to the perception of a change in the strategic direction of the business, the loss of key employees, including our executive officers, instability or lack of continuity, particularly if the activism campaign results in the appointment of one or more activist shareholders on the Board, which may cause concern to our existing or potential collaboration partners, employees and shareholders; may be exploited by our competitors; may result in the loss of potential business opportunities or limit our ability to timely initiate or advance clinical trials; and may make it more difficult to attract and retain qualified personnel and business partners;
•if additional individuals are elected to our Board who may have a specific agenda, including a plan to terminate our Chief Executive Officer or other executive officers, initiate a hostile takeover, or sell our healthcare or non-healthcare business, it may result in operational disruptions and adversely affect our ability to effectively implement our strategic plans in a timely manner and create additional value for our shareholders;
•activist directors may make overly burdensome demands of Company management and materially and unnecessarily increase management’s workload; and
•proxy contests and related litigation by shareholders could cause significant fluctuations in our share price based on temporary or speculative market perceptions or other factors that do not necessarily reflect the underlying fundamentals and prospects of our business.
The occurrence of any of the foregoing could adversely affect our business, financial condition and results of operations.
74
Exclusive forum provisions in our bylaws could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.
Our bylaws provide that the state or federal courts located within the State of Delaware are the sole and exclusive forum for: (i) any derivative action or proceeding brought on our behalf, (ii) any action asserting a claim of breach of fiduciary duty owed by any of our directors, officers or other employees or stockholders to our stockholders, (iii) any action asserting a claim against us arising pursuant to the DGCL, our certificate of incorporation or our bylaws or as to which the DGCL confers jurisdiction on the Court of Chancery of the State of Delaware, or (iv) any action asserting a claim governed by the internal affairs doctrine. However, this choice of forum provision does not apply to (a) actions in which the Court of Chancery in the State of Delaware concludes that an indispensable party is not subject to the jurisdiction of Delaware courts, or (b) actions in which a federal court has assumed exclusive jurisdiction to a proceeding. This choice of forum provision is not intended to apply to any actions brought under the Securities Act of 1933, as amended (the Securities Act), or the Securities Exchange Act of 1934, as amended (the Exchange Act). Section 27 of the Exchange Act creates exclusive federal jurisdiction over all suits brought to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder. As a result, the exclusive forum provision will not apply to suits brought to enforce any duty or liability created by the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction. This choice of forum provision may limit a stockholder’s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees or stockholders, which may discourage such lawsuits against us and our directors, officers and other employees or stockholders.
Furthermore, the enforceability of similar choice of forum provisions in other companies’ certificates of incorporation has been challenged in legal proceedings, and it is possible that a court could find these types of provisions to be inapplicable or unenforceable. If a court were to find the choice of forum provision in our bylaws to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could adversely affect our business, financial condition and results of operations.
General Risk Factors
We may experience significant fluctuations in our periodic financial results and may not maintain our current levels of profitability in the future.
Our operating results have fluctuated in the past and are likely to fluctuate in the future. Many of the countries in which we operate, including the U.S. and several of the members of the EU, have experienced and continue to experience uncertain economic conditions resulting from global as well as local factors. In addition, continuing uncertainty in the U.S. economy may result in continued inflationary pressures globally and in the U.S. in particular, which may contribute to future interest rate volatility.
Our business or financial results may be adversely impacted by these uncertain economic conditions, including: adverse changes in interest rates, foreign currency exchange rates, tax laws or tax rates; inflation; contraction in the availability of credit in the marketplace due to legislation or other economic conditions, which may potentially impair our ability to access the capital markets on terms acceptable to us or at all; changes in consumer spending during a recession; and the effects of government initiatives to manage economic conditions.
We are also unable to predict how changing global economic conditions or potential global health concerns will affect our critical customers, suppliers and distributors. Any negative impact of such matters on our critical customers, suppliers or distributors may also have an adverse impact on our results of operations or financial condition. Our expense levels are based, in part, on our expectations regarding future revenue levels and are relatively fixed in the short-term.
As a result, if our revenue for a particular period was below our expectations, we would not be able to proportionately reduce our operating expenses for that period. Any revenue shortfall would have a disproportionately negative effect on our operating results for the period.
In addition, the methods, estimates and judgments that we use in applying our accounting policies are, by their nature, subject to substantial risks, uncertainties and assumptions. Factors may arise over time that lead us to change our methods, estimates and judgments, the impact of which could significantly affect our results of operations. See “Critical Accounting Policies and Estimates” contained in Part I, Item 2 of this Quarterly Report on Form 10-Q.
Recent accounting changes related to our embedded leases within certain deferred equipment agreements have also resulted in the acceleration of the timing related to our recognition of revenue and expenses associated with certain equipment provided to healthcare customers at no up-front charge. Since we cannot control the timing of when our customers will request us to deliver such equipment, our revenue and costs with respect to leased equipment could vary substantially in any given quarter or year, which could further increase quarterly or annual fluctuations within our financial results.
75
Due to these and other factors, you should not rely on our results for any one quarter as an indication of our future performance. If our operating results fail to meet or exceed the expectations of securities analysts or investors, our stock price could drop suddenly and significantly.
Adverse developments affecting the financial services industry, such as actual events or concerns involving liquidity, defaults or non-performance by financial institutions or transactional counterparties, could adversely affect our current and projected business operations and its financial condition and results of operations.
Actual events involving limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions, transactional counterparties or other companies in the financial services industry or the financial services industry generally, or concerns or rumors about any events of these kinds or other similar risks, have in the past and may in the future lead to market-wide liquidity problems. For example, on March 10, 2023, Silicon Valley Bank (SVB) was closed by the California Department of Financial Protection and Innovation, which appointed the Federal Deposit Insurance Corporation (FDIC) as receiver. Similarly, on March 12, 2023, Signature Bank and Silvergate Capital Corp. were each swept into receivership. Although a statement by the Department of the Treasury, the Federal Reserve and the FDIC stated all depositors of SVB would have access to all of their money after only one business day of closure, including funds held in uninsured deposit accounts, borrowers under credit agreements, letters of credit and certain other financial instruments with SVB, Signature Bank or any other financial institution that is placed into receivership by the FDIC may be unable to access undrawn amounts thereunder. Although we are not a borrower or party to any such instruments with SVB, Signature or any other financial institution currently in receivership, if any of our lenders or counterparties to any such instruments were to be placed into receivership, we may be unable to access such funds. In addition, counterparties to SVB credit agreements and arrangements, and third parties such as beneficiaries of letters of credit (among others), may experience direct impacts from the closure of SVB and uncertainty remains over liquidity concerns in the broader financial services industry. Similar impacts have occurred in the past, such as during the 2008-2010 financial crisis.
Although we assess our banking relationships as we believe necessary or appropriate, our access to funding sources and other credit arrangements in amounts adequate to finance or capitalize our current and projected future business operations could be significantly impaired by factors that affect us, the financial institutions with which we have credit agreements or arrangements directly, or the financial services industry or economy in general. These factors could include, among others, events such as liquidity constraints or failures, the ability to perform obligations under various types of financial, credit or liquidity agreements or arrangements, disruptions or instability in the financial services industry or financial markets, or concerns or negative expectations about the prospects for companies in the financial services industry. These factors could involve financial institutions or financial services industry companies with which we have financial or business relationships, but could also include factors involving financial markets or the financial services industry generally.
The results of events or concerns that involve one or more of these factors could include a variety of material and adverse impacts on our current and projected business operations and our financial condition and results of operations. These could include, but may not be limited to, the following:
•delayed access to deposits or other financial assets or the uninsured loss of deposits or other financial assets;
•loss of access to revolving existing credit facilities or other working capital sources and/or the inability to refund, roll over or extend the maturity of, or enter into new credit facilities or other working capital resources;
•potential or actual breach of contractual obligations that require us to maintain letters or credit or other credit support arrangements;
•potential or actual breach of financial covenants in our credit agreements or credit arrangements;
•potential or actual cross-defaults in other credit agreements, credit arrangements or operating or financing agreements; or
•termination of cash management arrangements and/or delays in accessing or actual loss of funds subject to cash management arrangements.
Any decline in available funding or access to our cash and liquidity resources could, among other risks, adversely impact our ability to meet our operating expenses, financial obligations or fulfill our other obligations, result in breaches of our financial and/or contractual obligations or result in violations of federal or state wage and hour laws. Any of these impacts, or any other impacts resulting from the factors described above or other related or similar factors not described above, could have material adverse impacts on our liquidity and our current and/or projected business operations and financial condition and results of operations.
76
In addition, any further deterioration in the macro-economic economy or financial services industry could lead to losses or defaults by our customers or suppliers, which in turn, could have a material adverse effect on our current and/or projected business operations and results of operations and financial condition. For example, a customer may fail to make payments when due, default under their agreements with us, become insolvent or declare bankruptcy, or a supplier may determine that it will no longer deal with us as a customer. In addition, a customer or supplier could be adversely affected by any of the liquidity or other risks that are described above as factors that could result in material adverse impacts on our company, including but not limited to delayed access or loss of access to uninsured deposits or loss of the ability to draw on existing credit facilities involving a troubled or failed financial institution. Any customer or supplier bankruptcy or insolvency, or the failure of any customer to make payments when due, or any breach or default by a customer or supplier, or the loss of any significant supplier relationships, could result in material losses to our company and may have material adverse impacts on our business.
A regional or global recession and other negative macro-economic trends could adversely affect our consumer business.
Our consumer products are generally considered non-essential, discretionary products. As such, many of these products can be especially sensitive to general downturns in the economy. Negative macro-economic conditions, such as high inflation, recession, changes to monetary policy, increasing interest rates and decreasing consumer confidence can adversely impact demand for these products, which could negatively impact our business, financial condition and results of operations.
Future changes in accounting pronouncements and tax laws, or the interpretation thereof, could have a significant impact on our reported results, and may affect our historical reporting of previous transactions.
New accounting pronouncements or taxation rules, and evolving interpretations thereof, have occurred and are likely to occur in the future. Future changes made by new accounting standards may apply prospectively or retrospectively, depending on the method of adoption, and may recast previously reported results. For additional information related to the impact of new accounting pronouncements, please see Note 2, “Summary of Significant Accounting Policies”, to our accompanying condensed consolidated financial statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q.
In addition, future changes to the U.S. tax code and its regulations could have a material impact on our effective tax rate and the implementation of these changes could require us to make substantial changes to our business practices, allocate resources, and increase our costs, which could negatively affect our business, results of operations and financial condition.
The OECD (Organization for Economic Co-operation and Development) has proposed a global minimum tax of 15% of reported profits (Pillar Two) that has been agreed upon in principle by over 140 countries. The OECD continues to release additional guidance, including administrative guidance on how Pillar Two rules should be interpreted and applied by jurisdictions as they adopt Pillar Two. A number of countries have utilized the administrative guidance as a starting point for legislation that is effective January 1, 2024. The Company is continuing to evaluate the potential impact on future periods of Pillar Two, pending legislative adoption by individual countries.
Our retirement and post-retirement pension benefit plans are subject to financial market risks that could adversely affect our future results of operations and cash flows.
We sponsor several defined benefit plans with post-retirement benefits to certain employees in certain international markets. These defined benefit plans are funded with trust assets invested in a diversified portfolio of securities and other investments. Changes in interest rates, mortality rates, early retirement rates, investment returns, discount rates and the market value of plan assets could affect the funded status of our defined benefit plan and post-retirement benefit obligations, causing volatility in the net periodic benefit cost and future funding requirements of the plans. A significant increase in our obligations or future funding requirements could have a negative impact on our results of operations and cash flows from operations.
77
If we lose the services of our key personnel, or if we are unable to attract and retain other key personnel, we may not be able to manage our operations or meet our growth objectives.
We are highly dependent on our senior management, especially Joe Kiani, our CEO, and other key officers. We are also heavily dependent on our engineers and field sales team, including sales representatives and clinical specialists. We believe certain of our competitors with greater financial resources than us have targeted our key personnel for recruitment and will likely continue to do so in the future. To the extent that key personnel depart, we may be required to bring on new hires that require training and take time before they achieve full productivity. New employees may not become as productive as we expect, and we may be unable to hire or retain sufficient numbers of qualified individuals. The loss of the services of members of our key personnel or the inability to attract and retain qualified personnel in the future could prevent the implementation and completion of our objectives, including the development and introduction of our products. In general, our key personnel may terminate their employment at any time and for any reason without notice, unless the individual is a participant in our 2007 Severance Protection Plan, in which case the individual has agreed to provide us with six months’ notice if such individual decides to voluntarily resign. In addition, Politan Capital Management LP and Politan Capital NY LLC, which are managed by Quentin Koffey, a member of our Board, previously filed a lawsuit against us and members of our Board seeking to invalidate the employment agreement of Mr. Kiani, our Chief Executive Officer. Although Politan subsequently filed a motion to dismiss the complaint without prejudice, which was approved by the court in September 2023, Politan can refile this or any other complaint against us, our Board or any individual director at any time. We do not maintain any “key person” life insurance policies with respect to any of our key personnel.
In addition, regulation or legislation impacting the workforce, such as the proposed rule published by the Federal Trade Commission which would, if issued, generally prevent employers from entering into non-competition agreements with employees and require employers to rescind existing non-competition agreements, may lead to increased uncertainty in hiring and competition for talent.
We are involved, and may become involved in the future, in disputes and other legal or regulatory proceedings that, if adversely decided or settled, could materially and adversely affect our business, financial condition and results of operations.
We are, and may in the future become, party to litigation, regulatory proceedings or other disputes. In general, claims made by or against us in disputes and other legal or regulatory proceedings can be expensive and time-consuming to bring or defend against, requiring us to expend significant resources and divert the efforts and attention of our management and other personnel from our business operations. These potential claims may include, but are not limited to personal injury and class action lawsuits, intellectual property claims and regulatory investigations relating to the advertising and promotional claims about our products and employee claims against us based on, among other things, discrimination, harassment or wrongful termination. In addition, we may become subject to claims against companies we acquire based on circumstances arising prior to the acquisition, and the sellers of the acquired company may have no obligation to reimburse us for any resulting damages or expenses.
Due to the complexity of our business and the variety of risks that we face, our internal risk mitigation policies and procedures may not always be sufficient to allow us to identify issues and take corrective action before a claim, lawsuit or regulatory action is initiated against us. Failure to detect and remediate issues at an early stage could have a material adverse effect on our business and result in increased liability in any ensuing proceeding.
Any litigation, proceedings or dispute, even those without merit, may divert our financial and management resources that would otherwise be used to benefit the future performance of our operations. Any adverse determination against us in these proceedings, or even the allegations contained in the claims, regardless of whether they are ultimately found to be without merit, may also result in settlements, injunctions or damages that could have a material adverse effect on our business, financial condition and results of operations.
Changes to government immigration regulations may materially affect our workforce and limit our supply of qualified professionals, or increase our cost of securing workers.
We recruit professionals on a global basis and must comply with the immigration laws in the countries in which we operate, including the U.S. Some of our employees are working under Masimo-sponsored temporary work visas, including H1-B visas. Statutory law limits the number of new H1-B temporary work permit petitions that may be approved in a fiscal year. Furthermore, there is a possibility that the current U.S. immigration visa program may be significantly overhauled, and the number of H1-B visas available, as well as the process to obtain them, may be subject to significant change. Any resulting changes to this visa program could impact our ability to recruit, hire and retain qualified skilled personnel. If we are unable to obtain work visas in sufficient quantities or at a sufficient rate for a significant period of time, our business, operating results and financial condition could be adversely affected.
78
The risks inherent in operating internationally, including the purchase, sale and shipment of our components and products across international borders, may adversely impact our business, financial condition and results of operations.
We currently derive approximately 45% of our net sales from international operations. In addition, we purchase a portion of our raw materials and components from international sources. The sale and shipment of our products across international borders, as well as the purchase of materials and components from international sources, subject us to extensive U.S. and foreign governmental trade regulations, including those related to duties, tariffs and conflict minerals. Compliance with such regulations is costly and we could be exposed to potentially significant penalties, fines and interest if we are found not to be in compliance with such regulations. Any failure to comply with applicable legal and regulatory obligations could impact us in a variety of ways that include, but are not limited to, significant criminal, civil and administrative penalties, including imprisonment of individuals, fines and penalties, denial of export privileges, seizure of shipments, restrictions on certain business activities, and exclusion or debarment from government contracting. We have historically engaged in transactions with entities related to or located in countries subject to certain U.S. export restrictions. For example, we have had sales of medical products destined for Iran.
In addition, changes in policy in the U.S. and other countries regarding international trade, including import and export regulation and international trade agreements, could negatively impact our business. In recent years, the U.S. has imposed tariffs on goods imported from China and certain other countries, which has resulted in retaliatory tariffs by China and other countries. Changes or uncertainty in tariffs or further retaliatory trade measures taken by China or other countries in response could affect the demand for our products and services, impact the competitive position of our products, prevent us from being able to sell products in certain countries or otherwise adversely impact our results of operations. The implementation of more restrictive trade policies, such as more detailed inspections, higher tariffs or new barriers to entry, could negatively impact our business, results of operations and financial condition.
In addition, our international operations expose us and our representatives, agents and distributors to risks inherent in operating in foreign jurisdictions. These risks include, but are not limited to:
•the imposition of additional U.S. and foreign governmental controls or regulations;
•the imposition of costly and lengthy new export licensing requirements;
•a shortage of high-quality sales people and distributors;
•the loss of any key personnel who possess proprietary knowledge, or who are otherwise important to our success in certain international markets;
•changes in duties and tariffs, license obligations and other non-tariff barriers to trade;
•the imposition of new trade restrictions;
•the imposition of restrictions on the activities of foreign agents, representatives and distributors;
•compliance with foreign tax laws, regulations and requirements;
•pricing pressure;
•changes in foreign currency exchange rates;
•laws and business practices favoring local companies;
•political instability and actual or anticipated military or political conflicts, including the ongoing conflict between Ukraine and Russia, the global impact of restrictions and sanctions imposed on Russia and the Israel-Palestine-Iran war;
•financial and civil unrest worldwide;
•outbreaks of illnesses, pandemics or other local or global health issues;
•the inability to collect amounts paid by foreign government customers to our appointed foreign agents;
•longer payment cycles, increased credit risk and different collection remedies with respect to receivables; and
•difficulties in enforcing or defending intellectual property rights.
The U.S. government initiated substantial changes in U.S. trade policy and U.S. trade agreements, including tariffs on certain foreign goods. In response to these tariffs, certain foreign governments instituted or are considering imposing tariffs on certain U.S. goods. In addition, the U.S. has negotiated new trade agreements that could impact us, including the United States-Mexico-Canada Agreement (USMCA), which went into force on July 1, 2020 and replaced the North American Free Trade Agreement. A trade war, trade barriers or other governmental actions related to tariffs, international trade agreements, import or export restrictions or other trade policies could adversely impact demand for our products, our costs, customers, suppliers and/or the U.S. economy or certain sectors thereof and, therefore, adversely affect our business, financial condition and results of operations.
79
The U.S. Foreign Corrupt Practices Act and similar worldwide anti-bribery laws in non-U.S. jurisdictions generally prohibit companies and their intermediaries from promising or making improper payments to foreign officials for the purpose of obtaining an advantage to secure or retain business. Because of the predominance of government-sponsored healthcare systems around the world, many of our customer relationships outside of the U.S. are with governmental entities and are therefore subject to such anti-bribery laws. We have adopted policies and practices that help us ensure compliance with these anti-bribery laws. However, such policies and practice may require us to invest in additional monitoring resources or forgo certain business opportunities in order to ensure global compliance with these laws. Additionally, any alleged or actual violation could subject us to government scrutiny, severe criminal or civil fines, or sanctions on our ability to export product outside the U.S., which could adversely affect our reputation and financial condition.
Although these activities have not been financially material to our business, financial condition or results of operations, and were undertaken in accordance with general licenses authorizing such activities issued by the U.S. Treasury Department’s Office of Foreign Assets Control, we may not be successful in ensuring compliance with limitations or restrictions on business in Iran or any other countries subject to economic sanctions and embargoes imposed by the U.S. Additionally, the export of U.S. technology or goods manufactured in the U.S. to some jurisdictions requires special U.S. export authorization or local market controls that may be influenced by factors, including political dynamics, outside our control. Also, the failure to comply with applicable legal and regulatory obligations could result in the disruption of our shipping, manufacturing and sales activities. Any material decrease in our international sales would adversely affect our business, financial condition and results of operations.
The laws of foreign countries may not adequately protect our intellectual property rights.
Intellectual property protection laws in foreign countries differ substantially from those in the U.S. If we fail to apply for intellectual property protection in foreign countries, or if we cannot adequately protect our intellectual property rights in these foreign countries, our competitors may be able to compete more effectively against us, which could adversely affect our competitive position, as well as our business, financial condition and results of operations.
Our operations may be adversely impacted by our exposure to risks related to foreign currency exchange rates.
We market our products in certain foreign markets through our subsidiaries and other international distributors. As a result, events that result in global economic uncertainty could significantly affect our results of operations in the form of gains and losses on foreign currency transactions and potential devaluation of the local currencies of our customers relative to the U.S. Dollar.
While a majority of our sales are transacted in U.S. Dollars, some of our sales agreements with foreign customers provide for payment in currencies other than the U.S. Dollar. These foreign currency revenues, when converted into U.S. Dollars, can vary depending on the approximation of the exchange rates applied during a respective period. Similarly, certain of our foreign subsidiaries transact business in their respective country’s local currency, which is also their functional currency. In addition, certain production costs related to our manufacturing operations are denominated in local currency. As a result, expenses of these foreign subsidiaries and certain production costs, when converted into U.S. Dollars, can vary depending on average monthly exchange rates during a respective period.
We are also exposed to foreign currency gains or losses on outstanding foreign currency denominated receivables and payables, as well as cash deposits. When converted to U.S. Dollars, these receivables, payables and cash deposits can vary depending on the monthly exchange rates at the end of the period. In addition, certain intercompany transactions may give rise to realized and unrealized foreign currency gains or losses based on the currency underlying such intercompany transactions. Accordingly, our operating results are subject to fluctuations in foreign currency exchange rates.
The balance sheets of our foreign subsidiaries whose functional currency is not the U.S. Dollar are translated into U.S. Dollars at the rate of exchange at the balance sheet date and the statements of operations and cash flows are translated into U.S. Dollars using an approximation of the average monthly exchange rates applicable during the period. Any foreign currency exchange gain or loss as a result of translating the balance sheets of our foreign subsidiaries whose functional currency is not the U.S. Dollar is included in equity as a component of accumulated other comprehensive income (loss).
We currently do not hedge our foreign currency exchange rate risk. As a result, changes in foreign exchange rates could have a material adverse effect on our business, financial condition and results of operations. For additional information related to our foreign currency exchange rate risk, please see “Quantitative and Qualitative Disclosures about Market Risk” in Part I, Item 3 of this Quarterly Report on Form 10-Q.
80
We currently manufacture our products at a limited number of locations and any disruption to, expansion of, or changes in trade programs related to such manufacturing operations could adversely affect our business, financial condition and results of operations.
We rely on manufacturing facilities in the U.S., Mexico, Asia and Europe that may be affected by natural or man-made disasters. Earthquakes are of particular significance since some of our facilities are located in earthquake-prone areas. We are also vulnerable to damage from other types of disasters, including power loss, attacks from extremist or terrorist organizations, epidemics, communication failures, fire, floods, hurricanes and similar events. Our facilities and the manufacturing equipment we use to produce our products would be difficult to replace and could require substantial time to repair if significant damage were to result from any of these occurrences.
If one of our manufacturing facilities was affected by a natural or man-made disaster, we would be forced to rely on third-party manufacturers if we could not shift production to our other manufacturing facilities. Furthermore, our insurance for damage to our property and the disruption of our business from casualties may not be sufficient to cover all of our potential losses and may not continue to be available to us on acceptable terms, or at all. If the lease for any of our leased facilities is terminated, we are unable to renew any of our leases or we are otherwise forced to seek alternative facilities, or if we voluntarily expand one or more of our manufacturing operations to new locations, we may incur additional transition costs and experience a disruption in the supply of our products until the new facilities are available and operating. Additionally, we have occasionally experienced seasonality and other shortages among our manufacturing workforce, and if we continue to experience such seasonality or other workforce shortages or otherwise have issues retaining employees or contractors at our manufacturing facilities, we may not be able to meet our customers’ demands.
Our global manufacturing and distribution are dependent upon our manufacturing facilities in multiple countries, and the expedient importation of raw materials and exportation of finished goods between these facilities. Undue delays and/or closures of cross-border transit facilities, or any restrictions by local governments related to the movement of goods to or from the U.S., may adversely affect our ability to fulfill orders and supply our customers, as well as adversely impact our business, operating results and financial condition.
In addition, delays and closures of shipping ports, or ports of entry into and out of the U.S., including as a result of labor strikes or shortages, may delay our ability to fulfill order and supply of our non-healthcare consumer products, which could also adversely impact our business, operating results and financial condition.
Our manufacturing facilities in Mexico are authorized to operate under the Mexican Maquiladora (IMMEX) program. The IMMEX program allows us to import certain items from the U.S. into Mexico duty-free, provided that such items, after processing, are exported from Mexico within a stipulated timeframe. Maquiladora status, which is renewed periodically, is subject to various restrictions and requirements, including compliance with the terms of the IMMEX program and other local regulations. Failure to comply with the IMMEX program regulations, including any changes thereto, could increase our manufacturing costs and adversely affect our business, operating results and financial condition.
If we do not accurately forecast customer demand, we may hold suboptimal inventory levels that could adversely affect our business, financial condition and results of operations.
If we are unable to meet the demand of our customers, our customers may cancel orders or purchase products from our competitors, which could reduce our revenue and gross profit margin. Conversely, if product demand decreases, we may be unable to timely adjust our manufacturing cost structure, resulting in excess capacity, which would lower gross product margins. Similarly, if we are unable to forecast demand accurately, we could be required to record charges related to excess or obsolete inventory, which would also lower our gross margin. Each of our business segments is individually influenced by many factors, including but not limited to: new product releases, acquisitions, regulatory approvals, holiday schedules, hospital census, the timing of the influenza season, holiday seasons, consumer pressures, inflationary and recessionary pressures, consumer demand and preferences, and competitors’ marketing promotions and sales incentives; among many other factors.
81
In addition, we may experience seasonal demand for our products and demand for such products could decrease significantly during a recession. For example, healthcare revenues in the third quarter of our fiscal years have generally historically represented a lower percentage of segment revenues due to the seasonality of the U.S., European and Japanese markets, where summer vacation schedules normally result in fewer elective procedures utilizing our healthcare products. The flu season concluded abnormally early and faded quickly in the first quarter of 2023, resulting in reduced inpatient census. In addition, some customers held elevated sensor inventory levels due to discounting in prior quarters, which was discontinued during the second quarter. Healthcare facilities and hospitals experienced fewer flu-related hospitalizations and medical office visits, which decreased consumption of our single-patient use sensors and consumables. The corresponding delays in reordering for our single-patient use sensors and consumables had an adverse impact on our second,third and fourth quarter 2023 healthcare revenue. Similarly, our non-healthcare revenues in the fourth quarter of a fiscal year generally produce a higher percentage of our segment revenues than the other quarters of our fiscal year due to the holiday shopping season and our corresponding promotional activities. Our promotional discounting activity may negatively impact our gross margin during the holiday periods. Any shortfalls in expected revenue due to a mismatch in supply of and demand for our products, could cause our operating results to suffer significantly, and seasonal or similar variances may also result in fluctuations in our revenues.
If we fail to comply with the reporting obligations of the Exchange Act or if we fail to maintain adequate internal control over financial reporting, our business, results of operations and financial condition and investors’ confidence in us could be adversely affected.
We are required to prepare and disclose certain information under the Exchange Act, in a timely manner and meet our reporting obligations in their entirety, and our failure to do so could subject us to penalties under federal securities laws and regulations of The Nasdaq Stock Market LLC, expose us to lawsuits and restrict our ability to access financing on favorable terms, or at all.
If we fail to maintain adequate internal controls over financial reporting, we may not be able to conclude on an ongoing basis that we have effective internal control over financial reporting in accordance with the Sarbanes-Oxley Act. Moreover, any material weakness in our internal control environment could result in the loss of investor confidence in the reliability of our financial statements, which in turn could harm our business, negatively impact the trading price of our stock, and adversely affect investors’ confidence in our company and our ability to access capital markets for financing.
Changing laws and increasingly complex corporate governance and public disclosure requirements could have an adverse effect on our business and operating results.
Changing laws, regulations and standards relating to corporate governance and public disclosure, including the Dodd-Frank Wall Street Reform and Consumer Protection Act (Dodd-Frank Act), the California Transparency in Supply Chains Act, the UK Modern Slavery Act and new regulations issued by the SEC and The Nasdaq Stock Market LLC, have created, and will create, additional compliance requirements for us. For example, the Dodd-Frank Act includes provisions regarding, among other things, advisory votes on named executive officer compensation and “conflict minerals” reporting. Complying with these rules and regulations has increased and will increase our legal and financial compliance costs, make some activities more difficult, time-consuming or costly and increase demand on our systems and resources. As a result, management’s attention may be diverted from other business concerns, which could adversely affect our business, financial condition and results of operations.
We may also need to hire additional employees or engage outside consultants to comply with these requirements, which will increase our costs and expenses. To maintain high standards of corporate governance and public disclosure, we have invested in, and intend to continue to invest in, reasonably necessary resources to comply with evolving standards.
In addition, stockholder litigation surrounding executive compensation and disclosure of executive compensation has increased with the passage of the Dodd-Frank Act. Furthermore, our stockholders in certain instances have not approved our advisory vote on named executive officer compensation that is being voted on by our stockholders annually pursuant to the Dodd-Frank Act. If we are involved in a lawsuit related to compensation matters or any other matters not covered by our directors’ and officers’ liability insurance, we may incur significant expenses in defending against such lawsuits, or be subject to significant fines or required to take significant remedial actions, each of which could adversely affect our business, financial condition and results of operations.
82
If product liability claims are brought against us, we could face substantial liability and costs.
Our products expose us to product liability claims and product recalls, including, but not limited to, those that may arise from unauthorized off-label use, malfunctions, design flaws or manufacturing defects related to our products or the use of our products with incompatible components or systems. In addition, as we continue to expand our product portfolio, we may enter or create new markets, including consumer markets, which may expose us to additional product liability risks. For example, with our previous acquisition of TNI®, we added softFlow® technology to our product portfolio. While this technology provides efficient, quiet and comfortable respiratory support to patients, it may present increased risk of infection to caregivers. In addition, with the Sound United Acquisition, we added multiple broadly distributed premium audio brands to our product portfolio and significantly expanded our consumer base worldwide, which could expose us to increased product liability claims.
We cannot be certain that our product liability insurance will be sufficient to cover any or all damages for product liability claims that may be brought against us in the future. Furthermore, we may not be able to obtain or maintain insurance in the future at satisfactory rates or in adequate amounts to protect us against any product liability claims.
Additionally, the laws and regulations regarding product liability are constantly evolving, both through the passage of new legislation at the state and federal levels and through new interpretations of existing legislation. For example, in February 2017, the Washington Supreme Court determined that, under the Washington Product Liability Act, medical device manufacturers have a duty to warn hospitals of any potential risks posed by their products. As the legal and regulatory landscape surrounding product liability change, we may become exposed to greater liability than currently anticipated.
Any losses that we may suffer from product liability claims, and the effect that any product liability litigation may have upon the reputation and marketability of our technology and products, together with the corresponding diversion of the attention of our key employees, may subject us to significant damages and could adversely affect our business, financial condition and results of operations.
We may incur environmental and personal injury liabilities related to certain hazardous materials used in our operations.
Certain manufacturing processes for our products may involve the storage, use, generation and disposal of certain hazardous materials and wastes, including silicone adhesives, solder and solder paste, sealants, epoxies and various solvents such as methyl ethyl ketone, acetone and isopropyl alcohol. As a result, we are subject to certain environmental laws, as well as certain other laws and regulations, that restrict the materials that can be used in our products or in our manufacturing processes. For example, products that we sell in Europe are subject to regulation in the EU markets under the Restriction of the Use of Hazardous Substances Directive (RoHS). RoHS prohibits companies from selling products that contain certain hazardous materials in EU member states. In addition, the EU’s Registration, Evaluation, Authorization, and Restriction of Chemicals Directive also restricts substances of very high concern in products. Compliance with such regulations may be costly and, therefore, we may incur significant costs to comply with these laws and regulations.
In addition, new environmental laws may further affect how we manufacture our products, how we use, generate or dispose of hazardous materials and waste, or further affect what materials can be used in our products. Any required changes to our operations or products may increase our manufacturing costs, detrimentally impact the performance of our products, add greater testing lead-times for product introductions or have other similar effects.
In connection with our research and manufacturing activities, we use, and our employees may be exposed to, materials that are hazardous to human health, safety or the environment. The risk of accidental injury to our employees or contamination from these materials cannot be eliminated, and we could be held liable for any resulting damages, the related liability for which could exceed our reserves. We do not specifically insure against environmental liabilities. If an enforcement action were to occur, our reputation and our business and financial condition may be harmed, even if we were to prevail or settle the action on terms favorable to us.
We rely significantly on information technology and any failure, inadequacy, interruption or security lapse of that technology, including any cybersecurity incidents, could harm our ability to operate our business effectively.
Increased global cybersecurity vulnerabilities, cybersecurity threats and sophisticated and targeted cybersecurity attacks pose a risk to the security of our systems and networks, including the confidentiality, availability and integrity of any underlying information and data, and those of our customers, partners, suppliers and third-party service providers. Our ability to effectively manage and maintain our internal business information, and to ship products to customers and invoice them on a timely basis, depends significantly on our enterprise resource planning system and other information systems.
83
Portions of our information technology systems may experience interruptions, delays or cessations of service or produce errors in connection with ongoing systems implementation work. In addition, interfaces between our products and our customers’ computer networks could provide additional opportunities for cybersecurity attacks on us and our customers. The techniques used to attack computer systems are sophisticated, change frequently and may originate from less regulated and remote areas of the world. We have experienced cybersecurity incidents in the past and expect that we will continue to be subject to cybersecurity attacks in the future. Cybersecurity attacks in particular are evolving and include, but are not limited to: threats, malicious software, ransomware, attempts to gain unauthorized access to data and other electronic security breaches that could lead to disruptions in systems, misappropriation of confidential or otherwise protected information and corruption of data. As a result, there can be no assurance that our protective measures will prevent or detect security breaches that could have a significant impact on our business, reputation, financial condition and results of operations.
The failure of these systems to operate or integrate effectively with other internal, customer, supplier or third-party service provider systems and to protect the underlying information technology system and data integrity, including from cyber-attacks, intrusions or other breaches or unauthorized access of these systems, or any failure by us to remediate any such attacks or breaches, may also result in damage to our reputation or competitiveness, delays in product fulfillment and reduced efficiency of our operations, and could require significant capital investments to remediate any such failure, problem or breach, all of which could adversely affect our business, financial condition and results of operations.
The impact of the Russian invasion of Ukraine, and the war in Israel, on the global economy, energy supplies and raw materials is uncertain, but may prove to negatively impact our business and operations.
The short and long-term implications of Russia’s invasion of Ukraine, and the war in Israel are difficult to predict at this time. We continue to monitor any adverse impact that the outbreak of war in Ukraine and the subsequent institution of sanctions against Russia by the U.S. and several European and Asian countries; along with the war in Israel, may have on the global economy in general, on our business and operations and on the businesses and operations of our suppliers and customers. For example, a prolonged conflict may result in challenges associated with timely receipt of customer payments and banking transactions in Russia, increased inflation, escalating energy prices and constrained availability, and thus increasing costs, of raw materials. In addition, as a result of the current conflict, we have stopped selling non-healthcare products in Russia indefinitely. Furthermore, the Israel-Palestine-Iran war could result in disruption in the Middle East more broadly and negatively impact our operations in that region. We will continue to monitor these fluid situations and develop contingency plans as necessary to address any disruptions to our business operations as they develop. To the extent the wars in Ukraine or Israel may adversely affect our business as discussed above, it may also have the effect of heightening many of the other risks described herein. Such risks include, but are not limited to, adverse effects on macro-economic conditions, including inflation; disruptions to our global technology infrastructure, including through cyberattack, ransom attack, or cyber-intrusion; adverse changes in international trade policies and relations; our ability to maintain or increase our product prices; disruptions in global supply chains; our exposure to foreign currency fluctuations; and constraints, volatility, or disruption in the capital markets, any of which could negatively affect our business and financial condition.
*Our stock price may be volatile, and your investment in our stock could suffer a decline in value.
There has been and could continue to be significant volatility in the market price and trading volume of equity securities. For example, our closing stock price ranged from $109.17 to $146.85 per share from December 31, 2023 to March 30, 2024. Factors contributing to our stock price volatility may include our financial performance, as well as broader economic, political and market factors. In addition to the other risk factors previously discussed in this Quarterly Report on Form 10-Q, there are many other factors that we may not be able to control that could have a significant effect on our stock price. These include, but are not limited to:
•actual or anticipated fluctuations in our operating results or future prospects;
•our announcements or our competitors’ announcements of new products;
•the public’s reaction to our press releases, including those relating to our earnings or financial guidance, our other public announcements and our filings with the SEC;
•strategic actions by us or our competitors, such as acquisitions or restructurings;
•new laws or regulations or new interpretations of existing laws or regulations applicable to our business;
•changes in accounting standards, policies, guidance, interpretations or principles;
•changes in our growth rates or our competitors’ growth rates;
•developments regarding our patents or proprietary rights or those of our competitors;
•ongoing legal proceedings;
84
•our inability to raise additional capital as needed;
•concerns or allegations as to the safety or efficacy of our products;
•changes in financial markets or general economic conditions, including the effects of recession or slow economic growth in the U.S. and abroad;
•effects of public health crises, epidemics and pandemics, such as the COVID-19 pandemic;
•sales of stock by us or members of our management team, our Board or certain institutional stockholders;
•shareholder activism;
•changes in stock market analyst recommendations or earnings estimates regarding our stock, other comparable companies or our industry generally; and
•short selling or other hedging activity in our stock.
Therefore, you may not be able to resell your shares at or above the price you paid for them.
*Our investors could experience substantial dilution of their investments as a result of subsequent exercises of our outstanding options, vesting of outstanding restricted stock units (RSUs) and performance stock units (PSUs), or the grant of future equity awards by us.
As of March 30, 2024, approximately 9.7 million shares of our common stock were reserved for issuance under our equity incentive plans, of which approximately 2.7 million shares were subject to options outstanding at such date at a weighted-average exercise price of $91.51 per share, approximately 3.6 million shares were subject to outstanding RSUs, approximately 0.4 million shares were subject to outstanding PSUs and approximately 3.1 million shares were available for future awards under our 2017 Equity Incentive Plan. Over the past 48 months, we have experienced higher rates of stock option exercises compared to many earlier periods, and this trend may continue. To the extent outstanding options are exercised or outstanding RSUs or PSUs vest, our existing stockholders may incur dilution.
We rely on equity awards to motivate current employees and to attract new employees. The grant of future equity awards by us to our employees and other service providers may further dilute our stockholders.
Future resales of our stock, including those by our insiders and a few investment funds, may cause our stock price to decline.
A significant portion of our outstanding shares are held by our directors, our executive officers and a few investment funds. Resales by these stockholders of a substantial number of such shares, announcements of any proposed resale of substantial amounts of our stock or the perception that substantial resales may be made, could significantly reduce the market price of our stock. Some of our directors and executive officers have entered into Rule 10b5-1 trading plans pursuant to which they have arranged to sell shares of our stock from time to time in the future. Generally, these sales require public filings. Actual or potential sales by these insiders, including those under a pre-arranged Rule 10b5-1 trading plan, could be interpreted by the market as an indication that the insider has lost confidence in our stock and reduce the market price of our stock.
We have registered and expect to continue to register shares reserved under our incentive equity plans pursuant to Registration Statements on Form S-8. All shares issued pursuant to a Registration Statement on Form S-8 can be freely sold in the public market upon issuance, subject to restrictions on our affiliates under Rule 144. If a large number of these shares are sold in the public market, the sales could reduce the trading price of our stock.
We may elect not to declare cash dividends on our stock, may elect to only pay dividends on an infrequent or irregular basis, or may elect not to make any additional stock repurchases. As a result, any return on your investment may be limited to the value of our stock. In addition, the payment of any future dividends or the repurchase of our stock might limit our ability to pursue other growth opportunities.
Our Board may from time to time declare, and we may pay, dividends on our outstanding shares in the manner and upon the terms and conditions permitted under applicable law. However, we may elect to retain all future earnings for the operation and expansion of our business, rather than paying cash dividends on our stock. In addition, under certain circumstances, our Credit Facility may limit our ability to pay cash dividends, repurchase our common stock or make other distributions to stockholders. Any payment of cash dividends on our stock will be at the discretion of our Board and will depend upon our results of operations, earnings, capital requirements, financial condition, business prospects, contractual restrictions and other factors deemed relevant by our Board. In addition, our Credit Facility places limitations on our ability to pay dividends. In the event our Board declares any dividends, there is no assurance with respect to the amount, timing or frequency of any such dividends.
85
Any repurchase of our common stock under the stock repurchase plan authorized by our Board in June 2022 (Repurchase Program) will be at the discretion of a committee comprised of our CEO and Chief Financial Officer, and will depend on several factors, including, but not limited to, results of operations, capital requirements, financial conditions, available capital from operations or other sources, including debt, and the market price of our common stock. In addition, on August 16, 2022, the U.S. enacted the Inflation Reduction Act of 2022, which, among other things, imposes an excise tax of 1% tax on the fair market value of net stock repurchases made after December 31, 2022. Therefore, there is no assurance with respect to the amount, price or timing of any such repurchases. We may elect to retain all future earnings for the operation and expansion of our business, rather than repurchasing additional outstanding shares. For additional information related to our Repurchase Program, please see Note 19, “Equity”, to our accompanying condensed consolidated financial statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q.
In the event we pay dividends, or make any stock repurchases in the future, our ability to finance any material expansion of our business, including through acquisitions, investments or increased capital spending, or to fund our operations, may be limited. In addition, any repurchases we may make in the future may not prove to be at optimal prices. Our Board may modify or amend the Repurchase Program, or adopt a new stock repurchase program, at any time at its discretion without stockholder approval.
Environmental, social and corporate governance (ESG) regulations, global climate change, corporate citizenship and related matters may adversely affect our business.
There is an increasing focus on ESG risks. Our customers, including distributors and retail partners have adopted, or may adopt, procurement policies that include ESG provisions that their suppliers or manufacturers must comply with, or they may seek to include such provisions in their terms and conditions. An increasing number of participants in our industries are also joining voluntary ESG groups or organizations. These ESG provisions and initiatives are subject to change, can be unpredictable, and may be difficult and expensive for us to comply with, given the complexity of our supply chain and the outsourced manufacturing of certain components of our products. If we are unable to comply, or are unable to cause our suppliers to comply, with such policies or provisions, a customer may cease purchasing products from us, and may take legal action against us, which could harm our reputation, revenue and results of operations.
Further, increased public awareness and concern regarding global climate change may result in new or enhanced legal requirements. There continues to be a lack of consistent climate legislation, which creates economic and regulatory uncertainty. Such uncertainty may have an impact on our business, from the demand for our products to our costs of compliance in the manufacturing and servicing of our products, all of which may impact our results of operations. In addition, climate change initiatives and legislation could also disrupt our operations by impacting the availability and cost of materials within our supply chain, and could also increase insurance and other operating costs. In addition, on March 6, 2024, the SEC finalized new rules for public companies that will require extensive climate-related disclosures and significant analysis of the impact of climate-related issues on our business strategy, results of operations, and financial condition (the SEC Climate Disclosure Rules), and extensive attestation requirements. The new rules require disclosure of, among other things, our material climate-related risks and opportunities, greenhouse gas emissions inventory, climate-related targets and goals, and financial impacts of physical and transition risks. Subsequently, in April 2024, the SEC issued an order staying implementation of the SEC Climate Disclosure Rules pending the resolution of certain challenges. Nonetheless, our legal, accounting, and other compliance expenses may increase significantly, and compliance efforts may divert management time and attention as we prepare for the potential implementation of the SEC Climate Disclosure Rules, and such expenses, efforts and diversions of management time and attention may be even greater if the SEC Climate Disclosure Rules ultimately go into effect. We may also be exposed to legal or regulatory action or claims as a result of these new regulations. Separately, the SEC has also announced that it is scrutinizing existing climate-change related disclosures in public filings, increasing the potential for enforcement if the SEC were to allege our existing climate disclosures are misleading or deficient. All of these risks could have a material adverse effect on our business, financial position, and/or stock price.
Investors, stockholders, consumers, customers, suppliers and other third-parties are increasingly focusing on ESG and corporate social responsibility endeavors and reporting and transparency. Certain institutional investors, investment funds, other influential investors, customers, suppliers and other third-parties are also increasingly focused on ESG practices. If we do not adapt to or comply with evolving investor or stakeholder expectations and standards, or if we are perceived to have not responded appropriately, we may suffer from reputational damage and our business, financial condition and/or stock price may be materially and adversely affected. Further, this increased focus on ESG issues may result in new regulations and/or third-party requirements that could adversely impact our business, or certain shareholders reducing or eliminating their holdings of our stock, causing our stock price to decline.
86
*Loss of or inability to continue to obtain or maintain high-quality endorsers of our consumer audio products could harm our business.
From time to time, we have established, and expect to continue to establish, relationships with public figures, music artists, automotive designers, sound studios, social media influencers and other endorsers, to develop, evaluate and promote our consumer audio products, as well as establish product authenticity with consumers. However, as competition in our consumer segment has increased, the costs associated with establishing and retaining such relationships have increased, and competition to attract and retain high-quality endorsers has also increased. If we are unable to maintain our current associations with public figures, music artists, automotive designers, sound studios, social media influencers or other endorsers, or to do so at a reasonable cost, we could lose the high visibility associated with our products, and we may be required to modify and substantially increase our marketing investments. As a result, our brands, consumer product revenues, expenses and profitability could be harmed. Furthermore, if certain public figures, music artists, automotive designers, sound studios, social media influencers or other endorsers, were to stop using our products contrary to their agreements, our business could be adversely affected. In addition, certain negative actions taken or statements made by those associated with our products or brands, could impact or harm the reputations of our consumer products, and our decisions to cease collaborating with certain endorsers in light of actions that may be taken or statements that may be made by them, could impact have an adverse effect on our sales and financial condition. Poor or non-performance by those associated with our products, a failure to continue to correctly identify promising public figures, music artists, automotive designers, sound studios, social media influencers or other endorsers to use our products and brands or a failure to enter into cost-effective fee arrangements with any of such endorsers could adversely affect our brands, reputation, sales and profitability.
Item 5. Other Information
During the fiscal quarter ended March 30, 2024, none of our directors or officers (as defined in Section 16 of the Securities Exchange Act of 1934, as amended) adopted or terminated any contract, instruction or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any “non-Rule 10b5-1 trading arrangement,” as defined in Item 408(a) of Regulation S-K.
On May 3, 2024, Rolf Classon notified our Board of Directors (the “Board”) of his decision to resign from the Board and the Audit Committee of the Board, effective as of May 10, 2024.









87
Item 6. Exhibits
EXHIBIT INDEX
Exhibit
Number
Description of Document
3.1
3.2
3.3
3.4
4.1
4.2#+
31.1*
31.2*
32.1**
101.INS*
Inline XBRL Instance Document - The instance document does not appear in the interactive data file because its XBRL tags are embedded within the inline XBRL document.
101.SCH*
Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents
104Cover Page Interactive Data File (embedded within the inline XBRL document)
Attached as Exhibit 101 to this report are the following formatted in iXBRL (Inline eXtensible Business Reporting Language): (i) Condensed Consolidated Balance Sheets as of March 30, 2024 and December 30, 2023, (ii) Condensed Consolidated Statements of Operations for the three months ended March 30, 2024 and April 1, 2023, respectively, (iii) Condensed Consolidated Statements of Comprehensive (Loss) for the three months ended March 30, 2024 and April 1, 2023, respectively, (iv) Condensed Consolidated Statements of Cash Flows for the three months ended March 30, 2024 and April 1, 2023, respectively, and (v) Notes to Condensed Consolidated Financial Statements.
 ______________
#     Indicates management or compensatory plan.
*    Filed herewith.
**    Furnished herewith.
+    Non-material schedules and exhibits have been omitted pursuant to Item 601(b)(2) of Regulation S-K. The Registrant hereby undertakes to furnish supplemental copies of any of the omitted schedules and exhibits upon request by the SEC.

88
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
MASIMO CORPORATION
Date: May 7, 2024By:
/s/ JOE KIANI
Joe Kiani
Chief Executive Officer and Chairman
Date: May 7, 2024By:
/s/ MICAH YOUNG
Micah Young
Executive Vice President and Chief Financial Officer
89
 EX-31.1 2 masi-20240330x10qex311.htm EX-31.1 Document

Exhibit 31.1
CERTIFICATION OF CHIEF EXECUTIVE OFFICER
I, Joe Kiani, certify that:
1. I have reviewed this Quarterly Report on Form 10-Q of Masimo Corporation;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)    Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)    Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)    Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)    Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a)     All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)     Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
/s/ JOE KIANI
Date: May 7, 2024Joe Kiani
Chairman of the Board and Chief Executive Officer
(Principal Executive Officer)


 EX-31.2 3 masi-20240330x10qex312.htm EX-31.2 Document

Exhibit 31.2
CERTIFICATION OF CHIEF FINANCIAL OFFICER
I, Micah Young, certify that:
1. I have reviewed this Quarterly Report on Form 10-Q of Masimo Corporation;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)    Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)    Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)    Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)    Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a)     All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)     Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
/s/ MICAH YOUNG
Date: May 7, 2024Micah Young
Executive Vice President and Chief Financial Officer
(Principal Financial Officer)


 EX-32.1 4 masi-20240330x10qex321.htm EX-32.1 Document

Exhibit 32.1

CERTIFICATIONS OF
CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER
PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
I, Joe Kiani, Chief Executive Officer of Masimo Corporation (the “Company”), certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that to my knowledge:
1. The Quarterly Report on Form 10-Q of the Company for the period ended March 30, 2024 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
/s/ JOE KIANI
Date: May 7, 2024Joe Kiani
Chairman of the Board and Chief Executive Officer
(Principal Executive Officer)
I, Micah Young, Executive Vice President and Chief Financial Officer of Masimo Corporation (the “Company”), certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that to my knowledge:
1. The Quarterly Report on Form 10-Q of the Company for the period ended March 30, 2024 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
/s/ MICAH YOUNG
Date: May 7, 2024Micah Young
Executive Vice President and Chief Financial Officer
(Principal Financial Officer)
A signed original of these certifications has been provided to Masimo Corporation and will be retained by Masimo Corporation and furnished to the Securities and Exchange Commission or its staff upon request.
These certifications are being furnished solely to accompany this Quarterly Report pursuant to 18 U.S.C. Section 1350, and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934 and are not to be incorporated by reference into any filing of Masimo Corporation, whether made before or after the date hereof, regardless of any general incorporation language in such filing.


GRAPHIC 5 masi-20240330_g1.jpg GRAPHIC begin 644 masi-20240330_g1.jpg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end EX-101.SCH 6 masi-20240330.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 0000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 0000008 - Disclosure - Description of the Company link:presentationLink link:calculationLink link:definitionLink 0000009 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 0000010 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - Other Current Assets link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - Lease Receivable link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - Deferred Costs and Other Contract Assets link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - Property and Equipment, net link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - Intangible Assets, net link:presentationLink link:calculationLink link:definitionLink 0000017 - Disclosure - Goodwill link:presentationLink link:calculationLink link:definitionLink 0000018 - Disclosure - Lessee ROU Assets and Lease Liabilities link:presentationLink link:calculationLink link:definitionLink 0000019 - Disclosure - Other Non-Current Assets link:presentationLink link:calculationLink link:definitionLink 0000020 - Disclosure - Deferred Revenue and Other Contract Liabilities, Current link:presentationLink link:calculationLink link:definitionLink 0000021 - Disclosure - Other Current Liabilities link:presentationLink link:calculationLink link:definitionLink 0000022 - Disclosure - Debt link:presentationLink link:calculationLink link:definitionLink 0000023 - Disclosure - Other Non-Current Liabilities link:presentationLink link:calculationLink link:definitionLink 0000024 - Disclosure - Derivative Instruments and Hedging Activities link:presentationLink link:calculationLink link:definitionLink 0000025 - Disclosure - Business Combinations link:presentationLink link:calculationLink link:definitionLink 0000026 - Disclosure - Equity link:presentationLink link:calculationLink link:definitionLink 0000027 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 0000028 - Disclosure - Employee Benefits link:presentationLink link:calculationLink link:definitionLink 0000029 - Disclosure - Non-operating Loss link:presentationLink link:calculationLink link:definitionLink 0000030 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 0000031 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 0000032 - Disclosure - Segment and Enterprise Reporting link:presentationLink link:calculationLink link:definitionLink 9954471 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 9954472 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 9954473 - Disclosure - Inventories (Tables) link:presentationLink link:calculationLink link:definitionLink 9954474 - Disclosure - Other Current Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 9954475 - Disclosure - Lease Receivable (Tables) link:presentationLink link:calculationLink link:definitionLink 9954476 - Disclosure - Deferred Costs and Other Contract Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 9954477 - Disclosure - Property and Equipment, net (Tables) link:presentationLink link:calculationLink link:definitionLink 9954478 - Disclosure - Intangible Assets, net (Tables) link:presentationLink link:calculationLink link:definitionLink 9954479 - Disclosure - Goodwill (Tables) link:presentationLink link:calculationLink link:definitionLink 9954480 - Disclosure - Lessee ROU Assets and Lease Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 9954481 - Disclosure - Other Non-Current Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 9954482 - Disclosure - Deferred Revenue and Other Contract Liabilities, Current (Tables) link:presentationLink link:calculationLink link:definitionLink 9954483 - Disclosure - Other Current Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 9954484 - Disclosure - Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 9954485 - Disclosure - Other Non-Current Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 9954486 - Disclosure - Derivative Instruments and Hedging Activities (Tables) link:presentationLink link:calculationLink link:definitionLink 9954487 - Disclosure - Business Combinations (Tables) link:presentationLink link:calculationLink link:definitionLink 9954488 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 9954489 - Disclosure - Non-operating Loss (Tables) link:presentationLink link:calculationLink link:definitionLink 9954490 - Disclosure - Segment and Enterprise Reporting (Tables) link:presentationLink link:calculationLink link:definitionLink 9954491 - Disclosure - Summary of Significant Accounting Policies - Schedule of Fair Value, Assets Measured on Recurring Basis (Detail) link:presentationLink link:calculationLink link:definitionLink 9954492 - Disclosure - Summary of Significant Accounting Policies - Schedule of Property and Equipment (Detail) link:presentationLink link:calculationLink link:definitionLink 9954493 - Disclosure - Summary of Significant Accounting Policies - Narrative (Detail) link:presentationLink link:calculationLink link:definitionLink 9954494 - Disclosure - Summary of Significant Accounting Policies - Schedule of Changes in Product Warranty Accrual (Detail) link:presentationLink link:calculationLink link:definitionLink 9954495 - Disclosure - Summary of Significant Accounting Policies - Schedule of Reconciliation of Basic and Diluted Net Income Per Share (Detail) link:presentationLink link:calculationLink link:definitionLink 9954496 - Disclosure - Summary of Significant Accounting Policies - Schedule of Supplemental Cash Flow Information (Detail) link:presentationLink link:calculationLink link:definitionLink 9954497 - Disclosure - Related Party Transactions (Details) link:presentationLink link:calculationLink link:definitionLink 9954498 - Disclosure - Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 9954499 - Disclosure - Other Current Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9954500 - Disclosure - Lease Receivable - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954501 - Disclosure - Lease Receivable - Schedule of Sale-Type Lease Receivable (Details) link:presentationLink link:calculationLink link:definitionLink 9954501 - Disclosure - Lease Receivable - Schedule of Sale-Type Lease Receivable (Details) link:presentationLink link:calculationLink link:definitionLink 9954502 - Disclosure - Lease Receivable - Schedule of Sales-type Lease, Lease Receivable, Maturity (Details) link:presentationLink link:calculationLink link:definitionLink 9954503 - Disclosure - Deferred Costs and Other Contract Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9954504 - Disclosure - Property and Equipment, net - Schedule of Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 9954505 - Disclosure - Property and Equipment, net - Narrative (Detail) link:presentationLink link:calculationLink link:definitionLink 9954506 - Disclosure - Intangible Assets, net - Schedule of Finite-Lived Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9954507 - Disclosure - Intangible Assets, net - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954508 - Disclosure - Intangible Assets, net - Schedule of Finite-Lived Intangible Assets, Future Amortization Expense (Details) link:presentationLink link:calculationLink link:definitionLink 9954509 - Disclosure - Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 9954510 - Disclosure - Lessee ROU Assets and Lease Liabilities - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954511 - Disclosure - Lessee ROU Assets and Lease Liabilities - Schedule of Lessee Operating Lease Balance Sheet Classification (Details) link:presentationLink link:calculationLink link:definitionLink 9954512 - Disclosure - Lessee ROU Assets and Lease Liabilities - Schedule of Lessee, Operating Lease, Liability, Maturity (Details) link:presentationLink link:calculationLink link:definitionLink 9954512 - Disclosure - Lessee ROU Assets and Lease Liabilities - Schedule of Lessee, Operating Lease, Liability, Maturity (Details) link:presentationLink link:calculationLink link:definitionLink 9954513 - Disclosure - Other Non-Current Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9954514 - Disclosure - Deferred Revenue and Other Contract Liabilities, Current - Schedule of Deferred Revenue and Other Contract Liabilities, Current (Details) link:presentationLink link:calculationLink link:definitionLink 9954515 - Disclosure - Deferred Revenue and Other Contract Liabilities, Current - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954515 - Disclosure - Deferred Revenue and Other Contract Liabilities, Current - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954516 - Disclosure - Deferred Revenue and Other Contract Liabilities, Current - Schedule of Changes in Deferred Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 9954517 - Disclosure - Other Current Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954518 - Disclosure - Debt - Schedule of Debt (Details) link:presentationLink link:calculationLink link:definitionLink 9954519 - Disclosure - Debt - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954520 - Disclosure - Debt - Schedule of Maturities of Long-term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 9954521 - Disclosure - Other Non-Current Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954522 - Disclosure - Derivative Instruments and Hedging Activities - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954523 - Disclosure - Derivative Instruments and Hedging Activities - Schedule of Derivative Instruments in Statement of Financial Position, Fair Value (Details) link:presentationLink link:calculationLink link:definitionLink 9954524 - Disclosure - Derivative Instruments and Hedging Activities - Schedule of Reclassification out of Accumulated Other Comprehensive Income (Details) link:presentationLink link:calculationLink link:definitionLink 9954525 - Disclosure - Derivative Instruments and Hedging Activities - Schedule of Accumulated Other Comprehensive Income (Loss) (Details) link:presentationLink link:calculationLink link:definitionLink 9954526 - Disclosure - Business Combinations - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954527 - Disclosure - Business Combinations - Fair Value of Assets Acquired and Liabilities Assumed (Details) link:presentationLink link:calculationLink link:definitionLink 9954528 - Disclosure - Business Combinations - Schedule of Acquired Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9954529 - Disclosure - Equity (Details) link:presentationLink link:calculationLink link:definitionLink 9954530 - Disclosure - Stock-Based Compensation - Narrative (Detail) link:presentationLink link:calculationLink link:definitionLink 9954531 - Disclosure - Stock-Based Compensation - Schedule of Number and Weighted Average Exercise Price of Options Issued and Outstanding under all Stock Option Plans (Detail) link:presentationLink link:calculationLink link:definitionLink 9954532 - Disclosure - Stock-Based Compensation - Schedule of Stock Units Activity (Detail) link:presentationLink link:calculationLink link:definitionLink 9954533 - Disclosure - Stock-Based Compensation - Schedule of Range of Assumptions Used and Resulting Weighted-Average Fair Value of Options Granted at Date of Grant (Detail) link:presentationLink link:calculationLink link:definitionLink 9954534 - Disclosure - Employee Benefits (Details) link:presentationLink link:calculationLink link:definitionLink 9954535 - Disclosure - Non-operating Loss (Details) link:presentationLink link:calculationLink link:definitionLink 9954536 - Disclosure - Income Taxes - Narrative (Detail) link:presentationLink link:calculationLink link:definitionLink 9954537 - Disclosure - Commitments and Contingencies (Detail) link:presentationLink link:calculationLink link:definitionLink 9954538 - Disclosure - Segment and Enterprise Reporting - Schedule of Segment Reporting Information, by Segment (Detail) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 masi-20240330_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 masi-20240330_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 masi-20240330_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Accrued expenses Accrued Liabilities, Current Schedule of Other Current Liabilities Schedule of Accrued Liabilities [Table Text Block] Other non-current liabilities Other Noncurrent Liabilities [Member] Maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Research and development Research and Development Expense Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Related Party Transaction [Line Items] Related Party Transaction [Line Items] Interest income Interest Income, Other Licensing agreement, current Licensing Agreement, Current Licensing Agreement, Current Award Type [Domain] Award Type [Domain] Fair Value as of Grant Date Award Grant Date Fair Value Revenue remaining performance obligation, expected timing of satisfaction Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period Employee Defined Benefit Plans Pension and Other Postretirement Plans, Policy [Policy Text Block] Cash consideration Payments to Acquire Businesses, Gross Schedule of Recognized Identified Assets Acquired and Liabilities Assumed Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Deferred tax liabilities Deferred Income Tax Liabilities, Net Accounts payable Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable Insider Trading Policies and Procedures [Line Items] Options exercisable, end of period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Share-based compensation arrangement by share-based payment award, range of percentage payout Share-based compensation arrangement by share-based payment award, range of percentage payout Share-based compensation arrangement by share-based payment award, range of percentage payout Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Number of complaints Loss Contingency, Number Of Complaints Loss Contingency, Number Of Complaints Equity Equity [Text Block] Decrease (increase) in other non-current assets Increase (Decrease) in Other Noncurrent Assets Other Other Accrued Liabilities, Noncurrent Settlements made Standard and Extended Product Warranty Accrual, Decrease for Payments Expected dividends Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate 2028 Sales-Type and Direct Financing Leases, Payment to be Received, Year Four Impairment, Intangible Asset, Indefinite-Lived (Excluding Goodwill), Statement of Income or Comprehensive Income [Extensible Enumeration] Impairment, Intangible Asset, Indefinite-Lived (Excluding Goodwill), Statement of Income or Comprehensive Income [Extensible Enumeration] Customer [Axis] Customer [Axis] Current liabilities Liabilities, Current [Abstract] Intersegment Intersegment Eliminations [Member] Diluted (in dollars per share) Net income per diluted share (in dollars per share) Earnings Per Share, Diluted Trade accounts receivable, net of allowance for credit losses of $4.7 million and $4.8 million at March 30, 2024 and December 30, 2023, respectively Accounts Receivable, after Allowance for Credit Loss, Current Unrealized gain (loss) on cash flow hedges Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent Qualifying termination Employment Agreement, Severance Benefits, Special Payment, Qualifying Termination Employment Agreement, Severance Benefits, Special Payment, Qualifying Termination Line of Credit Line of Credit [Member] Amount recognized in other comprehensive income (loss) Other Comprehensive Income (Loss), before Reclassifications, before Tax Litigation Case [Axis] Litigation Case [Axis] Trading Symbol Trading Symbol Non-compete agreements Noncompete Agreements [Member] Granted (in usd per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Transportation, vehicles and other Transportation Equipment [Member] Impairment of Goodwill, Intangible Assets and Other Long-Lived Assets Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block] Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-Lived Intangible Assets, Major Class Name [Domain] Machinery, equipment and tooling Machinery and Equipment [Member] Total Lessor, Operating Lease, Payment to be Received Prepaid income taxes Prepaid Taxes Purchase Commitment Purchase Commitment [Member] Other non-current assets Other Assets, Miscellaneous, Noncurrent Deferred revenue Deferred revenue, beginning of the period Deferred revenue, end of the period Contract with Customer, Liability 2027 Sales-Type and Direct Financing Leases, Payment to be Received, Year Three Other Other Intangible Assets [Member] Schedule of Reconciliation of Basic and Diluted Net Income Per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Related party transaction, amounts of transaction (less than) Related Party Transaction, Amounts of Transaction Executive Category: Executive Category [Axis] 2022 Repurchase Program 2022 Repurchase Program [Member] 2022 Repurchase Program 2028 Lessor, Operating Lease, Payment to be Received, Year Four Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Exercised (in usd per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Level 1 Fair Value, Inputs, Level 1 [Member] Change in pension benefits Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent Schedule of Property and Equipment Schedule of Property, Plant and Equipment Property, Plant and Equipment [Table Text Block] Equity Components [Axis] Equity Components [Axis] Other Current Liabilities [Line Items] Other Current Liabilities [Line Items] Other Current Liabilities [Line Items] Royalty prepayment Accrued Royalties Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Increase (decrease) in accrued liabilities Increase (Decrease) in Accrued Liabilities Cash Distribution Cash Distribution [Member] Options available for grant, end of period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant 2026 Long-Term Debt, Maturity, Year Two Prepaid expenses and other current assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets Smaller Reporting Company Entity Small Business 2028 Finite-Lived Intangible Asset, Expected Amortization, Year Four Payment for administrative fees Payment for Administrative Fees Local Phone Number Local Phone Number Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Letter of Credit Letter of Credit [Member] Litigation Costs and Contingencies Legal Costs, Policy [Policy Text Block] Accounts Receivable Accounts Receivable [Member] Changes in pre-existing warranties (including changes in estimates) Standard and Extended Product Warranty Accrual, Increase (Decrease) for Preexisting Warranties Measurement Frequency [Axis] Measurement Frequency [Axis] Restricted Stock Units (RSUs) Restricted Stock Units (RSUs) [Member] Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Depreciation Depreciation Trademarks Trademarks [Member] Other strategic investing activities Payments to Acquire Long-Term Investments Shares paid for tax withholding Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation Income tax payable Accrued Income Taxes, Current Finite-lived intangible assets, cost incurred to renew or extend Finite-Lived Intangible Assets, Cost Incurred to Renew or Extend Interest expense Interest Expense, Debt Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Lease receivable, net Sales-Type Lease, Net Investment in Lease, before Allowance for Credit Loss Options to purchase of shares of common stock Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Award Type [Axis] Award Type [Axis] Share-based compensation arrangement, grants in period (in shares) Granted (in units) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Document Quarterly Report Document Quarterly Report Non-cash investing activities: Noncash Investing and Financing Items [Abstract] Fair Value Hierarchy [Domain] Fair Value Hierarchy and NAV [Domain] Hedging Designation [Axis] Hedging Designation [Axis] Goodwill [Line Items] Goodwill [Line Items] Total property and equipment Property, Plant and Equipment, Gross ROU assets obtained in exchange for lease liabilities Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Payments for royalties Payments for Royalties Schedule of Sale-Type Lease Receivable Sale-Type Lease Receivable [Table Text Block] Sale-Type Lease Receivable [Table Text Block] Related Party Transactions Related Party Transactions Disclosure [Text Block] Imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Lessee lease liabilities, current Operating Lease, Liability, Current Prepaid expenses Prepaid Expense, Current Schedule of Other Non-Current Assets Schedule of Other Non-Current Assets Schedule of Other Assets [Table Text Block] Preferred stock, $0.001 par value; 5.0 million shares authorized; 0 shares issued and outstanding Preferred Stock, Value, Outstanding 2027 Lessee, Operating Lease, Liability, to be Paid, Year Three Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Recently Adopted and Recently Announced Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Finite-lived intangible assets, net Net Carrying Amount Finite-Lived Intangible Assets, Net Total assets acquired Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets Acquired Including Goodwill Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets Acquired Including Goodwill Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization 2026 Lessee, Operating Lease, Liability, to be Paid, Year Two Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Award vesting period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights Purchase price Business Combination, Consideration Transferred Gross profit Gross profit: Gross Profit Deferred revenue and other contract liabilities, current Contract with Customer, Liability, Current Schedule of Range of Assumptions Used and Resulting Weighted-Average Fair Value of Options Granted at Date of Grant Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Security Exchange Name Security Exchange Name Selling, general and administrative Selling, General and Administrative Expense Employee Stock Option Employee Stock Option [Member] Derivative Instruments and Hedging Activities Derivative Instruments and Hedging Activities Disclosure [Text Block] Thereafter Long-Term Debt, Maturity, after Year Four Long-Term Debt, Maturity, after Year Four Purchase price per each right (in dollars per share) Preferred Stock, Preferred Stock Purchase Right, Purchase Price Per Right Preferred Stock, Preferred Stock Purchase Right, Purchase Price Per Right Maximum Maximum [Member] Document Type Document Type Tabular List, Table Tabular List [Table Text Block] Inventories Inventory, Policy [Policy Text Block] Chief Executive Officer Chief Executive Officer [Member] Stock-Based Compensation Share-Based Payment Arrangement [Text Block] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] 2024 (balance of year) Lessor, Operating Lease, Payment to be Received, Remainder of Fiscal Year Business Acquisition [Axis] Business Acquisition [Axis] Allowance for credit losses Accounts Receivable, Allowance for Credit Loss, Current Trademarks/tradenames Trademarks and Trade Names [Member] 2017 Equity Incentive Plan 2017 Equity Incentive Plan [Member] 2017 Equity Incentive Plan [Domain] Customer Concentration Risk Customer Concentration Risk [Member] Restricted cash Restricted Cash, Noncurrent Lease Receivable Lessor, Sales-type Leases [Text Block] Vantrix Corp Vantrix Corp [Member] Vantrix Corp [Member] Variable Rate [Axis] Variable Rate [Axis] Thereafter Lessor, Operating Lease, Payment to be Received, after Year Four Lessor, Operating Lease, Payment to be Received, after Year Four 2024 (balance of year) Lessor, Operating Lease, Payment to be Received, Year One Raw materials Inventory, Raw Materials, Net of Reserves Canceled (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Indirect taxes receivable Value Added Tax Receivable, Current Title of 12(b) Security Title of 12(b) Security Other long-term liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other Demonstration units Demonstration Units [Member] Demonstration units. Sublease income Sublease Income Related Party [Domain] Related Party, Type [Domain] Business Combinations Business Combination Disclosure [Text Block] License agreement term (in year) License Agreement Term License Agreement Term Income tax payable, non-current Income Tax Payable, Noncurrent Income Tax Payable, Noncurrent Trademarks - (Note 9) Trademarks Indefinite-Lived Intangible Assets (Excluding Goodwill) Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Operating Segments Operating Segments [Member] Beginning of period (in dollars per share) End of period, fair value (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Entity Tax Identification Number Entity Tax Identification Number Foreign currency translation adjustment Goodwill, Foreign Currency Translation Gain (Loss) Japanese Revolving Loan Japanese Revolving Loan [Member] Japanese Revolving Loan 2024 (balance of year) Sales-Type and Direct Financing Leases, Payment to be Received, Remainder of Fiscal Year Change in control Royalty Guarantees, Commitments, Change in Control Royalty Guarantees, Commitments, Change in Control Statistical Measurement [Axis] Statistical Measurement [Axis] Decrease (increase) in other current assets Increase (Decrease) in Other Current Assets Balance Sheet Location [Domain] Balance Sheet Location [Domain] Entity Interactive Data Current Entity Interactive Data Current Adjusted Secured Overnight Financing Rate (SOFR), Three-Month Interest Period Adjusted Secured Overnight Financing Rate (SOFR), Three-Month Interest Period [Member] Adjusted Secured Overnight Financing Rate (SOFR), Three-Month Interest Period Related and Nonrelated Party Status [Axis] Related and Nonrelated Party Status [Axis] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Bank balance covered by federal deposit insurance corporation limit Cash, FDIC Insured Amount Measure: Measure [Axis] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Name Outstanding Recovery, Individual Name Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Adjusted Secured Overnight Financing Rate (SOFR), One-Month Interest Period Adjusted Secured Overnight Financing Rate (SOFR), One-Month Interest Period [Member] Adjusted Secured Overnight Financing Rate (SOFR), One-Month Interest Period Advertising expense Advertising Expense Equity investments - fair value Equity Securities, FV-NI Revenue Business Acquisitions, Revenue Business Acquisitions, Revenue Derivatives Instruments and Hedging Activities Derivatives, Policy [Policy Text Block] Schedule of Related Party Transactions, by Related Party [Table] Schedule of Related Party Transactions, by Related Party [Table] 2025 Finite-Lived Intangible Asset, Expected Amortization, Year One Operating lease liabilities Operating Lease, Payments Common stock, shares, outstanding (in shares) Beginning balance (in shares) Ending balance (in shares) Common Stock, Shares, Outstanding PEO PEO [Member] AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward] AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward] Non-healthcare Non-Healthcare [Member] Non-Healthcare Defined Contribution Plan Disclosure [Line Items] Defined Contribution Plan Disclosure [Line Items] Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Net cash (used in) provided by investing activities Net Cash Provided by (Used in) Investing Activities Gains (losses) reclassified from accumulated other comprehensive income Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax Interest rate contracts, inclusive of accrued interest Interest Rate Swap [Member] Debt Instrument [Axis] Debt Instrument [Axis] Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Aggregate intrinsic value of options exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value Credit Facility [Axis] Credit Facility [Axis] Prepaid rebates and royalties, current Prepaid Royalties Schedule of Maturities of Long-term Debt Schedule of Maturities of Long-Term Debt [Table Text Block] Total liabilities Liabilities Estimated volatility Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] Common stock, capital shares reserved for future issuance (in shares) Common Stock, Capital Shares Reserved for Future Issuance Measurement Frequency [Domain] Measurement Frequency [Domain] Property and Equipment, net Property, Plant and Equipment Disclosure [Text Block] 2027 Lessor, Operating Lease, Payment to be Received, Year Three Title of Individual [Axis] Title of Individual [Axis] Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Japanese Loans Japanese Loans [Member] Japanese Loans Related Party Transaction [Domain] Related Party Transaction [Domain] Property, Plant and Equipment, Type [Domain] Long-Lived Tangible Asset [Domain] Canceled (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Expired, Weighed Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Expired, Weighed Average Grant Date Fair Value Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Total current assets Assets, Current Total deferred revenue and other contract liabilities Other Liabilities and Deferred Revenue, Noncurrent Impairment charge Asset Impairment Charges Cash paid during the year for: Supplemental Cash Flow Information [Abstract] Acquired technologies Acquired Technology [Member] Acquired Technology [Member] Net Income Per Share Earnings Per Share, Policy [Policy Text Block] Concentration risk, percentage Concentration Risk, Percentage Schedule of Accumulated Other Comprehensive Income (Loss) Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Accumulated amortization for lessee ROU assets Operating Lease, Right-of-Use Asset, Accumulated Amortization Operating Lease, Right-of-Use Asset, Accumulated Amortization Accounts Receivable and Allowance for Credit Losses Accounts Receivable [Policy Text Block] Net cash provided by (used in) operating activities Net Cash Provided by (Used in) Operating Activities Schedule of Finite-Lived Intangible Assets, Future Amortization Expense Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Class of Stock [Axis] Class of Stock [Axis] Other comprehensive loss, net of tax: Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent [Abstract] Money market funds Money Market Funds, Fair Value Disclosure Money Market Funds, Fair Value Disclosure Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Depreciation and amortization Depreciation, Depletion and Amortization Furniture and office equipment Furniture and Fixtures [Member] Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Postemployment Benefits [Abstract] Business Combination and Asset Acquisition [Abstract] Consolidation Items [Axis] Consolidation Items [Axis] Reimbursement Fee Reimbursement Fee [Member] Reimbursement Fee [Member] Increase (decrease) in deferred revenue and other contract-related liabilities Increase (Decrease) in Deferred Revenue Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Recognition of revenue deferred in prior periods Contract with Customer, Liability, Revenue Recognized Deferred tax liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Net income per share: Earnings Per Share Reconciliation [Abstract] Property, Plant and Equipment, Type [Axis] Long-Lived Tangible Asset [Axis] Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Total liabilities assumed Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities Other Non-Current Assets Other Assets Disclosure [Text Block] Total other non-current liabilities Deferred Credits and Other Liabilities Range of assumptions used and resulting weighted-average fair value of options granted at the date of grant Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract] Emerging Growth Company Entity Emerging Growth Company Debt issuance costs Debt Issuance Costs, Net 2007 Stock Incentive Plan 2007 Stock Incentive Plan [Member] 2007 Stock Incentive Plan [Domain] Intangible assets, net Intangible Assets, Net (Excluding Goodwill) Other non-current assets Other Noncurrent Assets [Member] Warranty Standard Product Warranty, Policy [Policy Text Block] Finite lived intangible assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles 2025 Lessee, Operating Lease, Liability, to be Paid, Year One Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Title Trading Arrangement, Individual Title Common Stock Common Stock [Member] Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures Individual: Individual [Axis] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Income Statement Location [Domain] Income Statement Location [Domain] Finite-lived license agreements, gross Finite-Lived License Agreements, Gross Undiscounted future expected cash flows totaling Effect on Future Cash Flows, Amount Derivative assets - non-current Derivative Asset, Noncurrent Beginning balance Ending balance Equity, Including Portion Attributable to Noncontrolling Interest Average interest rate Debt, Weighted Average Interest Rate Lease receivable Total Sales-Type and Direct Financing Leases, Payment to be Received Minimum Minimum [Member] Property and equipment, net Property and equipment, net Property, Plant and Equipment, Net Unpaid strategic investments Investments Expenditures Incurred but Not yet Paid Investments Expenditures Incurred but Not yet Paid Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Projected benefit obligation Defined Benefit Plan, Benefit Obligation Accrued indirect taxes payable Accrual for Taxes Other than Income Taxes, Current ASSETS Assets [Abstract] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Assets acquired: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract] Allowance for credit loss Sales-Type Lease, Allowance For Credit Loss Sales-Type Lease, Allowance For Credit Loss Realized and unrealized foreign currency gains (losses) Gain (Loss), Foreign Currency Transaction, before Tax Schedule of Derivative Instruments in Statement of Financial Position, Fair Value Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block] Payroll tax withholdings on behalf of employees for vested equity awards Payment, Tax Withholding, Share-Based Payment Arrangement Net cash (used in) provided by financing activities Net Cash Provided by (Used in) Financing Activities Deferred tax assets Deferred Income Tax Assets, Net Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Percentage of voting interests acquired Business Acquisition, Percentage of Voting Interests Acquired Retained Earnings Retained Earnings [Member] Masimo Vs. Apple Inc Masimo Vs. Apple Inc [Member] Masimo Vs. Apple Inc Long-term debt, current Long-Term Debt, Current Maturities Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Nonoperating Income (Expense) [Abstract] Nonoperating Income (Expense) [Abstract] Net of tax gain (loss) on derivatives Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax Basic (in dollars per share) Net income per basic share (in dollars per share) Earnings Per Share, Basic Share-based payment arrangement, cost not yet recognized, amount Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Accounting Policies [Abstract] Accounting Policies [Abstract] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Summary Of Significant Accounting Policies [Table] Summary Of Significant Accounting Policies [Table] Summary Of Significant Accounting Policies [Table] Pending Litigation Pending Litigation [Member] Income taxes Income Taxes Paid Operating Lease, Liability, Current, Statement of Financial Position [Extensible List] Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Document Transition Report Document Transition Report Award Timing Predetermined Award Timing Predetermined [Flag] Interest Expense Interest Expense [Member] Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Unsecured Debt Unsecured Debt [Member] Increase (decrease) in accounts payable Increase (Decrease) in Accounts Payable Leased Property Leased Property [Member] Leased Property [Member] Taxes Collected From Customers and Remitted to Governmental Authorities Taxes Collected From Customers And Remitted To Governmental Authorities Policy [Policy Text Block] Disclosure of accounting policy for taxes collected from customers and remitted to government authorities. Repayments on line of credit Repayments of Lines of Credit Adjusted Secured Overnight Financing Rate (SOFR), Six-Month Interest Period Adjusted Secured Overnight Financing Rate (SOFR), Six-Month Interest Period [Member] Adjusted Secured Overnight Financing Rate (SOFR), Six-Month Interest Period Accrued Liabilities [Abstract] Accrued Liabilities [Abstract] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Property, Plant and Equipment [Abstract] Property, Plant and Equipment [Abstract] Other Liabilities Disclosure [Abstract] Derivative Instrument [Axis] Derivative Instrument [Axis] All Trading Arrangements All Trading Arrangements [Member] All Adjustments to Compensation All Adjustments to Compensation [Member] Timing of Transfer of Good or Service [Domain] Timing of Transfer of Good or Service [Domain] Common stock, $0.001 par value; 100.0 million shares authorized; 53.1 million and 52.8 million shares issued and outstanding at March 30, 2024 and December 30, 2023, respectively Common Stock, Value, Outstanding Twelve Months and Thereafter Twelve Months and Thereafter [Member] Twelve Months and Thereafter Compensation Amount Outstanding Recovery Compensation Amount Deferred commissions Deferred Sales Commissions Deferred Sales Commissions Provision for credit losses Accounts Receivable, Credit Loss Expense (Reversal) Derivative instruments Derivative Asset Proceeds from issuance of common stock Proceeds from Stock Options Exercised Property plant and equipment, occupied square feet Property Plant And Equipment, Occupied Square Feet The amount of square feet occupied. License fee License Fee, Change In Control License Fee, Change In Control Term Loan Term Loan [Member] Term Loan Canceled (in usd per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Masimo Retirement Savings Plan Masimo Retirement Savings Plan [Member] Masimo Retirement Savings Plan Percent of employees' gross pay Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay Other Current Assets Other Current Assets [Text Block] 2025 Long-Term Debt, Maturity, Year One Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Diluted share equivalent: stock options, RSUs and PSUs (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements Rights to Purchase Series A Junior Participating Preferred Stock Rights to Purchase Series A Junior Participating Preferred Stock [Member] Rights to Purchase Series A Junior Participating Preferred Stock Deferred costs and other contract assets Deferred Costs and Other Assets Shipping and Handling Costs and Fees Shipping And Handling Costs And Fees [Policy Text Block] Shipping and Handling costs and Fees [Policy Text Block] Document Period End Date Document Period End Date Adoption Date Trading Arrangement Adoption Date Treasury Stock Treasury Stock, Common [Member] Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Diluted net income per share: Net Income (Loss) Available to Common Stockholders, Diluted [Abstract] Provision for income taxes Income Tax Expense (Benefit) Defined contribution plan, number of plans Defined Contribution Plan, Number Of Plans Defined Contribution Plan, Number Of Plans Share-based compensation arrangement outstanding, weighted average remaining contractual terms (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms Designated as Hedging Instrument Designated as Hedging Instrument [Member] Number of operating segments Number of Operating Segments Weighted payout percentage Share-Based Compensation Arrangement by Share-Based Payment Award, Weighted Payout Percentage Share-Based Compensation Arrangement by Share-Based Payment Award, Weighted Payout Percentage Lender Name [Axis] Lender Name [Axis] Summary Of Significant Accounting Policies [Line Items] Summary Of Significant Accounting Policies [Line Items] Summary Of Significant Accounting Policies [Line Items] Equity [Abstract] Equity [Abstract] Inventories Inventory Disclosure [Text Block] Weighted average remaining lease term Operating Lease, Weighted Average Remaining Lease Term Other receivables Other Receivables, Net, Current Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] 2026 Lessor, Operating Lease, Payment to be Received, Year Two Cash and cash equivalents Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Business combinations, net of cash acquired Payments to Acquire Businesses, Net of Cash Acquired Payment terms Revenue, Performance Obligation, Payment Terms Revenue, Performance Obligation, Payment Terms Credit Facility [Domain] Credit Facility [Domain] Repurchase of common stock (in shares) Treasury Stock, Shares, Acquired Pension benefit obligation Obligations, Fair Value Disclosure Intangible Assets Intangible Assets, Finite-Lived, Policy [Policy Text Block] Variable rate Debt Instrument, Basis Spread on Variable Rate Property and equipment, useful life Property, Plant and Equipment, Useful Life Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Basic net income per share: Net Income (Loss) Available to Common Stockholders, Basic [Abstract] Contingencies And Commitments [Line Items] Contingencies And Commitments [Line Items] Contingencies And Commitments [Line Items] Revenue deferred during the period Contract with Customer, Liability, Deferred Revenue, Additions Contract with Customer, Liability, Deferred Revenue, Additions Intangible assets Total Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill Other commitment Other Commitment Schedule of Contract with Customer, Asset and Liability Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] Payable Lease amount (in month) Term Of The Agreement Term Of The Agreement Intangible Assets, Net (Excluding Goodwill) [Abstract] Intangible Assets, Net (Excluding Goodwill) [Abstract] Accrued rebates and allowances Accrued Rebates And Allowances Accrued Rebates And Allowances Deferred Revenue and Other Contract Liabilities, Current Revenue from Contract with Customer [Text Block] Lease receivable, non-current Net Investment in Lease, before Allowance for Credit Loss, Noncurrent Additional Paid-In Capital Additional Paid-in Capital [Member] Balance Sheet Location [Axis] Balance Sheet Location [Axis] Cover [Abstract] Amortization of debt issuance cost Amortization of Debt Issuance Costs Recurring Fair Value, Recurring [Member] Other non-current liabilities Other Liabilities, Noncurrent Total Lessee, Operating Lease, Liability, to be Paid Schedule of Supplemental Cash Flow Information Schedule of Cash Flow, Supplemental Disclosures [Table Text Block] Unrecognized contract revenue Revenue, Remaining Performance Obligation, Amount Employee Benefits Compensation and Employee Benefit Plans [Text Block] Cash Flow Hedges Cash Flow Hedging [Member] Total operating expenses Operating Expenses Segment and Enterprise Reporting Segment Reporting Disclosure [Text Block] Net decrease in cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Thereafter Lessee, Operating Lease, Liability, to be Paid, after Year Four Lessee, Operating Lease, Liability, to be Paid, after Year Four Lessee, operating lease, renewal term Lessee, Operating Lease, Renewal Term Equity Component [Domain] Equity Component [Domain] Work-in-process Inventory, Work in Process, Net of Reserves Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Pension assets Pension Asset, Fair Value Disclosure Pension Asset, Fair Value Disclosure Entity Current Reporting Status Entity Current Reporting Status Concentration Risk Type [Domain] Concentration Risk Type [Domain] Operating income Operating Income (Loss) Number of reporting units Number of Reporting Units Less: imputed interest Sales-type and Direct Financing Leases, Lease Receivable, Undiscounted Excess Amount Deferred Costs and Other Contract Assets Deferred Costs and Other Contract Assets [Policy Text Block] Deferred Costs and Other Contract Assets [Policy Text Block] Segments [Axis] Segments [Axis] Property and Equipment Property, Plant and Equipment, Policy [Policy Text Block] Schedule of Nonvested Performance-based Units Activity Schedule of Nonvested Performance-Based Units Activity [Table Text Block] Scenario [Domain] Scenario [Domain] Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Customer relationships Customer Relationships [Member] Average fixed interest rate related to derivative contracts Derivative, Average Swaption Interest Rate Stockholders’ equity Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] Variable Rate [Domain] Variable Rate [Domain] Property, plant and equipment, additions Property, Plant and Equipment, Additions Pay vs Performance Disclosure [Line Items] Statistical Measurement [Domain] Statistical Measurement [Domain] Underlying Security Market Price Change Underlying Security Market Price Change, Percent Cash and cash equivalents Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents Beginning of period (in shares) End of period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Asserted patents found invalid Gain Contingency, Patents Found Not Infringed upon, Number Debt Debt Disclosure [Text Block] Distributors Concentration Risk, Just-In-Time Distributors Concentration Risk, Just-In-Time Distributors Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Company's contribution to employee retirement savings plan Defined Contribution Plan, Employer Discretionary Contribution Amount Revolving Credit Facility Revolving Credit Facility [Member] Effect of foreign currency exchange rates on cash Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Percentage of accounts receivable balance Percentage of Accounts Receivable Balance Percentage of Accounts Receivable Balance MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Performance Shares Performance Shares [Member] Segment Reporting [Abstract] Segment Reporting [Abstract] Accounts payable Accounts Payable, Current Computer equipment and software Computer Equipment [Member] Restatement Determination Date: Restatement Determination Date [Axis] Non-operating loss Total non-operating loss Nonoperating Income (Expense) Commitments and contingencies - (Note 24) Commitments and Contingencies Impairment charge Impairment charge Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill) Willow Laboratories Willow Laboratories [Member] Willow Laboratories Deferred revenue and other contract liabilities, current Deferred Revenue, Current Schedule of Goodwill [Table] Schedule of Goodwill [Table] Foreign Plan Foreign Plan [Member] Finite lived intangible asset useful life Finite Lived Intangible Asset Useful Life Maximum Finite Lived Intangible Asset Useful Life Maximum Income Taxes Income Tax Disclosure [Text Block] Accrual for warranties issued Standard and Extended Product Warranty Accrual, Increase for Warranties Issued Other current assets Other Assets, Miscellaneous, Current Lessee Right-of-Use (ROU) Assets and Lease Liabilities Lessee, Leases [Policy Text Block] Property, plant and equipment Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment Revenue Recognition, Deferred Revenue and Other Contract Liabilities Revenue [Policy Text Block] Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Business Acquisition [Line Items] Business Acquisition [Line Items] Weighted-Average Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] PEO Total Compensation Amount PEO Total Compensation Amount 2026 Sales-Type and Direct Financing Leases, Payment to be Received, Year Two Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Operating Leases Lessor, Operating Lease, Payment to be Received, Fiscal Year Maturity [Abstract] Other current liability Customer Refund Liability, Current Goodwill [Roll Forward] Goodwill [Roll Forward] Severance terms Employment Agreement, Severance Terms Employment Agreement, Severance Terms Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Level 3 Fair Value, Inputs, Level 3 [Member] Treasury stock, shares (in shares) Beginning balance (in shares) Ending balance (in shares) Treasury Stock, Common, Shares Options outstanding, beginning of period (in shares) Options outstanding, end of period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Building and building improvements Building and Building Improvements [Member] Stock options exercised Stock Issued During Period, Value, Stock Options Exercised Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Weighted-average fair value of options granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Accrued liabilities and other current liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Liabilities And Other Liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Liabilities And Other Liabilities Net income Net income Net Income (Loss) Total current liabilities Liabilities, Current Derivative Contract [Domain] Derivative Contract [Domain] Foreign Currency Translation Foreign Currency Transactions and Translations Policy [Policy Text Block] Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Company Selected Measure Name Company Selected Measure Name Licensing agreement, non-current Licensing Agreement, Noncurrent Licensing Agreement, Noncurrent Lessee ROU Assets and Lease Liabilities Lessee, Operating Leases [Text Block] Expired (in units) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Expired in Period Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Expired in Period Total debt Debt and Lease Obligation LIABILITIES AND STOCKHOLDERS’ EQUITY Liabilities and Equity [Abstract] Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Fed Funds Effective Rate Overnight Index Swap Rate Fed Funds Effective Rate Overnight Index Swap Rate [Member] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Stock options exercised (in shares) Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Cost of goods sold Cost of Goods and Services Sold Award vesting period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Litigation Status [Domain] Litigation Status [Domain] Prepaid deposits and other Deposits Assets, Noncurrent Acquired finite-lived intangible assets, weighted average useful life Weighted average amortization period (in years) Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life Comprehensive (Loss) Income Comprehensive Income, Policy [Policy Text Block] Name Measure Name Patents Patents [Member] Name Forgone Recovery, Individual Name Goodwill Goodwill, beginning of period Goodwill, end of period Goodwill Underlying Securities Award Underlying Securities Amount Accrued donations Accrued Donations, Current Accrued Donations, Current Decrease (increase) in accounts receivable Increase (Decrease) in Accounts Receivable Forecast Forecast [Member] 2024 (balance of year) Long-Term Debt, Maturity, Remainder of Fiscal Year Deferred costs and other contract assets Deferred Costs, Noncurrent Warrants Warrant [Member] Lessee non-current lease liabilities Operating Lease, Liability, Noncurrent Not for Profit Organization Not for Profit Organization [Member] Not for Profit Organization [Member] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Operating lease assets Operating Lease Assets [Member] Operating Lease Assets Amount reclassified into earnings Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax Income Statement Location [Axis] Income Statement Location [Axis] Schedule of Lessee, Operating Lease, Liability, Maturity Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Discount rate used to measure the net investment in lease Sales-type and Direct Financing Leases, Lease Receivable, Discount Rate Sales-type and Direct Financing Leases, Lease Receivable, Discount Rate Sound United Sound United [Member] Sound United Healthcare Health Care Segment [Member] Health Care Segment Cash and Cash Equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Defined Contribution Plan [Table] Defined Contribution Plan [Table] Alternate Base Rate Alternate Base Rate [Member] Alternate Base Rate Other Performance Measure, Amount Other Performance Measure, Amount Decrease (increase) in inventories Increase (Decrease) in Inventories Contract assets, current Contract with Customer, Asset, after Allowance for Credit Loss, Current Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Litigation Status [Axis] Litigation Status [Axis] Derivative Instruments and Hedging Activities Disclosure [Abstract] Plan Name [Domain] Plan Name [Domain] Interest expense Interest Expense Share-based payment arrangement, nonvested award, cost not yet recognized, amount Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Unpaid purchases of property and equipment Capital Expenditures Incurred but Not yet Paid 2024 (balance of year) Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year Trading Arrangement: Trading Arrangement [Axis] Use of Estimates Use of Estimates, Policy [Policy Text Block] Timing of Transfer of Good or Service [Axis] Timing of Transfer of Good or Service [Axis] Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Entity File Number Entity File Number Like Minded Labs Like Minded Labs [Member] Like Minded Labs [Member] Schedule of Share-based Compensation, Restricted Stock Units Award Activity Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block] Maturities of derivative contracts Derivative, Term of Contract 2027 Long-Term Debt, Maturity, Year Three Accrued warranty Product Warranty Accrual, Current Amortization of intangible assets Amortization of Intangible Assets Entity Shell Company Entity Shell Company Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Restatement Determination Date Restatement Determination Date Award Date [Domain] Award Date [Domain] Increase (decrease) in income tax payable Increase (Decrease) in Income Taxes Payable Increase (decrease) in other non-current liabilities Increase (Decrease) in Other Operating Liabilities Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Cash, cash equivalents and restricted cash at beginning of period Cash, cash equivalents and restricted cash at end of period Total cash, cash equivalents and restricted cash shown in the condensed consolidated statements of cash flows Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Deferred Costs and Other Contract Assets Deferred Costs and Other Contract Assets [Text Block] Deferred Costs and Other Contract Assets [Text Block] Operating lease, cost Operating Lease, Cost Weighted-average shares used in per share calculations: Weighted Average Number of Shares Outstanding Reconciliation [Abstract] Common stock, shares, issued (in shares) Common Stock, Shares, Issued Vested (in units) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Treasury stock, 19.5 million and 19.5 million shares at March 30, 2024 and December 30, 2023, respectively Treasury Stock, Common, Value Total Long-Term Debt Total assets Assets, Fair Value Disclosure 2028 Long-Term Debt, Maturity, Year Four Percent of match Defined Contribution Plan, Employer Matching Contribution, Percent of Match Share-based payment arrangement, period for recognition (in years) Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Total comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Entity Address, Address Line One Entity Address, Address Line One Other current liabilities Total other current liabilities Accrued Liabilities and Other Liabilities Remaining commitment Purchase Commitment, Remaining Minimum Amount Committed Movement in Standard and Extended Product Warranty Accrual, Increase (Decrease) [Roll Forward] Movement in Standard and Extended Product Warranty Accrual, Increase (Decrease) [Roll Forward] Weighted-Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Accrued property taxes Taxes Payable, Current Accrued customer reimbursements Accounts Payable, Other Schedule of Sales-type Lease, Lease Receivable, Maturity Sales-Type and Direct Financing Leases, Payment to be Received, Maturity [Table Text Block] Schedule of Finite-Lived Intangible Assets Schedule of Finite-Lived Intangible Assets [Table Text Block] Income Statement [Abstract] Income Statement [Abstract] Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Cash and cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Derivative instruments - cash flow hedges Derivative Liability Non-operating (loss) Nonoperating Income (Expense) [Member] Like Minded Media Ventures Like Minded Entertainment [Member] Like Minded Entertainment [Member] Other current assets Total other current assets Other Assets, Current Class of Stock [Line Items] Class of Stock [Line Items] Strategic investments Equity Method Investments Inventories Total inventories Inventory, Net Furniture and office equipment Furniture and Office Equipment [Member] Furniture and Office Equipment [Member] Land Land [Member] Long-term other assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets Advertising Costs Advertising Cost [Policy Text Block] New Credit Facility Agreement New Credit Facility Agreement [Member] New Credit Facility Agreement Royalty obligation Royalty Guarantees, Commitments, Amount Sales-Type Leases Sales-type Lease, Lease Income [Abstract] Total Shareholder Return Amount Total Shareholder Return Amount Reconciliation of cash, cash equivalents and restricted cash: Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract] Threshold percentage to exercise purchase right Preferred Stock Purchase Right, Threshold Percentage of Purchase Right Trigger Preferred Stock Purchase Right, Threshold Percentage of Purchase Right Trigger Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Inventory Disclosure [Abstract] Inventory Disclosure [Abstract] Segments [Domain] Segments [Domain] Fair Value Hierarchy [Axis] Fair Value Hierarchy and NAV [Axis] Schedule of Non-operating Loss Schedule of Other Nonoperating Income (Expense) [Table Text Block] Consolidation Items [Domain] Consolidation Items [Domain] Revenue Recognition and Deferred Revenue [Abstract] Revenue Recognition and Deferred Revenue [Abstract] Retained earnings Retained Earnings (Accumulated Deficit) Restricted/Performance stock units vested (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Gross Debt instrument face amount Debt Instrument, Face Amount Bowers and Wilkins Bowers and Wilkins [Member] Bowers and Wilkins Current assets Assets, Current [Abstract] Leases [Abstract] Leases [Abstract] Decrease (increase) in lease receivable, net Proceeds from Lease Payment, Operating Activity Entity Address, State or Province Entity Address, State or Province Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Transportation, vehicles and other Aircraft And Vehicles [Member] Aircraft And Vehicles Fair value of hedging instruments Derivative Asset, Subject to Master Netting Arrangement, before Offset Unrealized losses from foreign currency translation adjustments Foreign currency translation adjustment Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent Class of Stock [Domain] Class of Stock [Domain] Customer [Domain] Customer [Domain] Schedule of Reclassification out of Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income [Table Text Block] Schedule of Components of Inventory Schedule of Inventory, Current [Table Text Block] Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Net loss Business Acquisitions, Net Income (Loss) Business Acquisitions, Net Income (Loss) Total operating lease liabilities Present value Operating Lease, Liability Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Inventories Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory Accumulated Other Comprehensive Income (Loss) AOCI Attributable to Parent [Member] Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis] All Executive Categories All Executive Categories [Member] Customer One Customer One [Member] Customer One Less: Non-current portion of deferred revenue Deferred revenue, non-current Contract with Customer, Liability, Noncurrent Plan Name [Axis] Plan Name [Axis] Other Current Liabilities Accounts Payable and Accrued Liabilities Disclosure [Text Block] Debt Disclosure [Abstract] Debt Disclosure [Abstract] Accrued legal fees Accrued Professional Fees Number of reportable segments Number of Reportable Segments Lease receivable, net Lease receivable, net Sales-type Lease, Lease Receivable Units Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward] GPO Members GPO Members [Member] GPO Members Retirement Plan Sponsor Location [Domain] Retirement Plan Sponsor Location [Domain] Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List] Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Just in time distributor one Just in time distributor one [Member] Just in time distributor one [Member] Restricted cash Restricted Cash All Individuals All Individuals [Member] Deferred equipment agreements, net Deferred Equipment Agreements, Net Deferred Equipment Agreements, Net Litigation Case [Domain] Litigation Case [Domain] Other Other Nonoperating Income (Expense) Entity Filer Category Entity Filer Category Depreciation and amortization Cost, Depreciation and Amortization Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Statement [Table] Statement [Table] Current Fiscal Year End Date Current Fiscal Year End Date Derivative Instruments and Hedging Activities Disclosures [Line Items] Derivative Instruments and Hedging Activities Disclosures [Line Items] Gross unrecognized tax benefit Unrecognized Tax Benefits PEO Name PEO Name Other Assets Long Term [Table] Schedule of Product Information [Table] Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Restricted cash Restricted Cash, Current Schedule of Goodwill Schedule of Goodwill [Table Text Block] Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Thereafter Finite-Lived Intangible Asset, Expected Amortization, after Year Four Finite-Lived Intangible Asset, Expected Amortization, after Year Four Non-operating Loss Other Nonoperating Income and Expense [Text Block] Schedule of Deferred Costs and Other Contract Assets Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block] Other Current Liabilities [Table] Other Current Liabilities [Table] Other Current Liabilities [Table] Required notice of resignation Supplemental Unemployment Benefits, Severance Benefits, Required Notice of Resignation Supplemental Unemployment Benefits, Severance Benefits, Required Notice of Resignation Other current liabilities, related party Other current liabilities, related party payables Other Accrued Liabilities, Current Description of the Company Nature of Operations [Text Block] Severance payment period Employee Agreement, Severance Payment Period Employee Agreement, Severance Payment Period Japanese Government Loans Japanese Government Loans [Member] Japanese Government Loans Product warranty accrual, beginning of period Product warranty accrual, end of period Standard and Extended Product Warranty Accrual Increase (decrease) in accrued compensation Increase (Decrease) in Employee Related Liabilities Other intangible assets, net - (Note 9) Other Miscellaneous Intangible Assets [Member] Other Miscellaneous Intangible Assets Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Total stockholders’ equity Beginning balance Ending balance Equity, Attributable to Parent Assets held for sale Disposal Group, Including Discontinued Operation, Assets, Current Unrecognized tax benefit that would affect effective tax rate Unrecognized Tax Benefits that Would Impact Effective Tax Rate Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Japanese Equipment Loans Japanese Equipment Loans [Member] Japanese Equipment Loans Concentration Risk Type [Axis] Concentration Risk Type [Axis] Expected term (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Income before provision for income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Increase in intangible assets Payments to Acquire Intangible Assets Accumulated amortization of deferred cost of goods sold Deferred Cost of Goods Sold, Accumulated Amortization Deferred Cost of Goods Sold, Accumulated Amortization Unbilled contract receivables Unbilled Contracts Receivable Bank balances Bank Balances Lease receivable, current Less: current portion of lease receivable Net Investment in Lease, before Allowance for Credit Loss, Current Hedging Designation [Domain] Hedging Designation [Domain] Level 2 Fair Value, Inputs, Level 2 [Member] Royalty guarantees, commitments, additional, change in control Royalty Guarantees, Commitments, Additional, Change in Control Royalty Guarantees, Commitments, Additional, Change in Control Other tax benefit Other Tax Expense (Benefit) Schedule of Changes in Product Warranty Accrual Schedule of Product Warranty Liability [Table Text Block] Number of patents found infringed Loss Contingency, Patents Found Infringed, Number Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Patents And Trademarks Patents And Trademarks [Member] Patents and Trademarks. Document Fiscal Period Focus Document Fiscal Period Focus 2028 Lessee, Operating Lease, Liability, to be Paid, Year Four Options outstanding, beginning of period (in usd per share) Options outstanding, end of period (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Stock-based compensation expense Share-Based Payment Arrangement, Noncash Expense Unrecognized tax benefits Unrecognized Tax Benefits Liabilities Noncurrent Unrecognized tax benefits liabilities noncurrent. Indirect tax payable, non-current Accrued Income Taxes, Noncurrent 2021 PSU Grant 2021 PSU Grant [Member] 2021 PSU Grant City Area Code City Area Code Document Fiscal Year Focus Document Fiscal Year Focus Capitalized software development costs Software and Software Development Costs [Member] Idle undeveloped land held for sale Undeveloped Land, Held-For-Sale Undeveloped Land, Held-For-Sale Total trademarks Indefinite-Lived Intangible Assets, Net (Excluding Goodwill) Indefinite-Lived Intangible Assets, Net (Excluding Goodwill) Share Repurchase Program [Domain] Share Repurchase Program [Domain] Severance plan participation agreements Severance Plan Participation Agreements Severance plan participation agreements. Schedule of Number and Weighted Average Exercise Price of Options Issued and Outstanding under all Stock Option Plans Share-Based Payment Arrangement, Option, Activity [Table Text Block] Exercise Price Award Exercise Price Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Total liabilities Liabilities, Fair Value Disclosure Nonrelated Party Nonrelated Party [Member] Fiscal Periods Fiscal Period, Policy [Policy Text Block] Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Liabilities assumed: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities [Abstract] Schedule of Fair Value, Assets Measured on Recurring Basis Fair Value, Assets Measured on Recurring Basis [Table Text Block] Developed technology Developed Technology Rights [Member] Total liabilities and stockholders’ equity Liabilities and Equity Other non-current assets Total non-current assets Other Assets, Noncurrent Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Deferred Revenue Arrangement, by Type [Table] Deferred Revenue Arrangement, by Type [Table] Risk-free interest rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Lessee ROU assets Lessee ROU assets, net Operating Lease, Right-of-Use Asset Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Non-cash operating activities: NonCash Operating Items [Abstract] NonCash Operating Items Indefinite-Lived Intangible Assets [Line Items] Indefinite-Lived Intangible Assets [Line Items] 2024 (balance of year) Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Arrangement Duration Trading Arrangement Duration Entity Address, City or Town Entity Address, City or Town Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Related Party Related Party [Member] Schedule of Segment Reporting Information, by Segment Schedule of Segment Reporting Information, by Segment [Table Text Block] Non-cash financing activities: Non-cash Financing Activities [Abstract] Non-cash Financing Activities Schedule of Components Of Other Liabilities Long Term Table Components Of Other Liabilities Long Term Table [Table Text Block] This element may be used as a single block of text to encapsulate the entire disclosure for other liabilities including data and tables. Unpaid purchases of intangible assets Unpaid Purchases Of Intangible Assets Unpaid Purchases Of Intangible Assets Prepaid contract allowances Prepaid Discount Prepaid Discount Fair Value Measurements Fair Value of Financial Instruments, Policy [Policy Text Block] Derivative Instruments and Hedging Activities Disclosures [Table] Derivative Instruments and Hedging Activities Disclosures [Table] Termination Date Trading Arrangement Termination Date Transaction costs Business Acquisition, Transaction Costs Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax Common stock, shares authorized (in shares) Common Stock, Shares Authorized Buildings and building improvements Land, Buildings and Improvements [Member] Line of Credit Facility, Lender [Domain] Line of Credit Facility, Lender [Domain] Indefinite-lived Intangible Assets [Axis] Indefinite-Lived Intangible Assets [Axis] Adjustments to reconcile net income to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Related Party Transactions [Abstract] Related Party Transactions [Abstract] Unsettled common stock proceeds from option exercises Proceeds From Stock Options Exercised, Unsettled At Period End Proceeds From Stock Options Exercised, Unsettled At Period End Award Timing Disclosures [Line Items] Preferred stock purchase right declared for each share of common stock Dividends, Preferred Stock, Preferred Stock Purchase Right For Each Share Dividends, Preferred Stock, Preferred Stock Purchase Right For Each Share Title of Individual [Domain] Title of Individual [Domain] Asserted patents found valid Gain Contingency, Patents Found Infringed upon, Number Initial Lenders Initial Lenders [Member] Initial Lenders Schedule of Lessee Operating Lease Balance Sheet Classification Lessee Operating Lease Balance Sheet Classification [Table Text Block] [Table Text Block] for Lessee Operating Lease Balance Sheet Classification [Table] Escrow deposit Escrow Deposit Licensing agreement outstanding obligation Licensing Agreement Licensing Agreement Additional paid-in capital Additional Paid in Capital Debt, current portion Debt, Current Income Taxes Income Tax, Policy [Policy Text Block] 2027 Finite-Lived Intangible Asset, Expected Amortization, Year Three Insider Trading Arrangements [Line Items] Stock repurchase program, remaining number of shares available for repurchase (in shares) Stock Repurchase Program, Remaining Number of Shares Authorized to be Repurchased Related Party [Axis] Related Party, Type [Axis] Aggregate intrinsic value of options outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Entity Registrant Name Entity Registrant Name Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Award Timing Method Award Timing Method [Text Block] 2026 Finite-Lived Intangible Asset, Expected Amortization, Year Two Intangible assets not subject to amortization: Indefinite-Lived Intangible Assets (Excluding Goodwill) [Abstract] Revolver Revolver [Member] Revolver Options Held Options Held [Member] Adjustment to Compensation, Amount Adjustment to Compensation Amount Borrowings under line of credit Proceeds from Lines of Credit Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Options exercisable, end of period (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Entity Central Index Key Entity Central Index Key Liabilities Liabilities, Fair Value Disclosure [Abstract] Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Gross Carrying Amount Finite-Lived Intangible Assets, Gross Finished goods Inventory, Finished Goods, Net of Reserves Accounts receivables Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables Accrued compensation Employee-related Liabilities, Current Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest [Member] Revenue Benchmark Revenue Benchmark [Member] Name Trading Arrangement, Individual Name Award Date [Axis] Award Date [Axis] Thereafter Sales-Type and Direct Financing Leases, Lease Receivable, to be Received, after Year Four Sales-Type and Direct Financing Leases, Lease Receivable, to be Received, after Year Four Revenue Total revenue by segment Revenue from Contract with Customer, Excluding Assessed Tax Entity [Domain] Entity [Domain] Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Amendment Flag Amendment Flag Indefinite intangible assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets Intangible Assets, net Intangible Assets Disclosure [Text Block] Legal Entity [Axis] Legal Entity [Axis] Intangible assets subject to amortization: Finite-Lived Intangible Assets, Net [Abstract] Principal amount of license agreement Principal Amount Of License Agreement Principal Amount Of License Agreement Movement in Deferred Revenue [Roll Forward] Movement in Deferred Revenue [Roll Forward] Operating lease, weighted average discount rate Operating Lease, Weighted Average Discount Rate, Percent Licenses Contractual license agreements Licensing Agreements [Member] Interest expense Interest Paid, Excluding Capitalized Interest, Operating Activities Assets Assets, Fair Value Disclosure [Abstract] Business Combinations Business Combinations Policy [Policy Text Block] Goodwill Goodwill Disclosure [Text Block] Long-term debt Debt, long-term Long-Term Debt, Excluding Current Maturities Leasehold improvements Leasehold Improvements [Member] Related and Nonrelated Party Status [Domain] Related and Nonrelated Party Status [Domain] Diluted (in shares) Weighted-average shares outstanding - diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Equity securities Equity Securities, Fair Value Disclosure Equity Securities, Fair Value Disclosure Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Retirement Plan Sponsor Location [Axis] Retirement Plan Sponsor Location [Axis] Revenue Recognition, Multiple-deliverable Arrangements [Line Items] Revenue Recognition, Multiple-deliverable Arrangements [Line Items] 2025 Sales-Type and Direct Financing Leases, Payment to be Received, Year One Share-based compensation, number of additional shares authorized (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized Operating expenses: Operating Expenses [Abstract] Variable lease income Operating Lease, Variable Lease Income Purchases of property and equipment, net Payments to Acquire Property, Plant, and Equipment Company Selected Measure Amount Company Selected Measure Amount Accordion feature, increase limit Line Of Credit Facility, Accordion Feature, Increase Limit Line Of Credit Facility, Accordion Feature, Increase Limit Total assets Assets Name Awards Close in Time to MNPI Disclosures, Individual Name Share Repurchase Program [Axis] Share Repurchase Program [Axis] Adjusted Secured Overnight Financing Rate (SOFR) Adjusted Secured Overnight Financing Rate (SOFR) [Member] Adjusted Secured Overnight Financing Rate (SOFR) Stock-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Segment Reconciling Items Segment Reconciling Items [Member] Contingencies And Commitments [Table] Contingencies And Commitments [Table] Contingencies And Commitments [Table] Other Non-Current Liabilities Other Liabilities Disclosure [Text Block] Decrease (increase) in deferred costs and other contract assets Increase (Decrease) in Deferred Charges Amortization of deferred cost of goods sold Deferred Cost of Goods Sold, Amortization Deferred Cost of Goods Sold, Amortization Vested (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Non-NEOs Non-NEOs [Member] Construction-in-progress (CIP) Construction in Progress [Member] Related party transaction, purchases from related party Related Party Transaction, Purchases from Related Party Number of sources of product revenue Number Of Sources Of Product Revenue Number Of Sources Of Product Revenue Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Non-PEO NEO Non-PEO NEO [Member] Adjustment to Compensation: Adjustment to Compensation [Axis] Weighted average number of years until the next renewal Finite-Lived Intangible Asset, Weighted Average Period before Next Renewal or Extension Scenario [Axis] Scenario [Axis] Debt Instrument [Line Items] Debt Instrument [Line Items] Basic (in shares) Weighted-average shares outstanding - basic (in shares) Weighted Average Number of Shares Outstanding, Basic Reclassifications Reclassification, Comparability Adjustment [Policy Text Block] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Schedule of Indefinite-Lived Intangible Assets [Table] Schedule of Indefinite-Lived Intangible Assets [Table] Other Assets Long Term [Line Items] Product Information [Line Items] Related Party Transaction [Axis] Related Party Transaction [Axis] Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Commitment fee percentage Line of Credit Facility, Unused Capacity, Commitment Fee Percentage Statement [Line Items] Statement [Line Items] Warranty period for defects in material and workmanship Warranty Period For Defects In Material And Workmanship Warranty period for defects in material and workmanship. Apple, Inc. Patent Infringement Apple, Inc. Patent Infringement [Member] Apple, Inc. Patent Infringement Stock compensation (benefit) expense Share-Based Payment Arrangement, Expensed and Capitalized, Amount Schedule of Debt Schedule of Debt [Table Text Block] Concentration risk, AR balance one customer Concentration Risk AR Customer Concentration Risk, Customer, Percentage of Receivable Balance ROU asset had a net carrying value Right-of-Use Asset, Net Carrying Value Right-of-Use Asset, Net Carrying Value Number of common shares authorized to be repurchased under new stock repurchase program Stock Repurchase Program, Number of Shares Authorized to be Repurchased EX-101.PRE 10 masi-20240330_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 12 R1.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Cover
 3 Months Ended
Mar. 30, 2024
shares
Cover [Abstract]  
Document Type 10-Q
Document Quarterly Report true
Document Period End Date Mar. 30, 2024
Document Transition Report false
Entity File Number 001-33642
Entity Registrant Name MASIMO CORP
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 33-0368882
Entity Address, Address Line One 52 Discovery
Entity Address, City or Town Irvine,
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92618
City Area Code (949)
Local Phone Number 297-7000
Title of 12(b) Security Common Stock, $0.001 par value
Trading Symbol MASI
Security Exchange Name NASDAQ
Entity Current Reporting Status Yes
Entity Interactive Data Current Yes
Entity Filer Category Large Accelerated Filer
Smaller Reporting Company false
Emerging Growth Company false
Entity Shell Company false
Entity Common Stock, Shares Outstanding 53,085,556
Amendment Flag false
Document Fiscal Year Focus 2024
Document Fiscal Period Focus Q1
Entity Central Index Key 0000937556
Current Fiscal Year End Date --12-28
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.24.1.u1
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Millions
Mar. 30, 2024
Dec. 30, 2023
Apr. 01, 2023
Current assets      
Cash and cash equivalents $ 157.6 $ 163.0 $ 174.1
Trade accounts receivable, net of allowance for credit losses of $4.7 million and $4.8 million at March 30, 2024 and December 30, 2023, respectively 330.7 355.5  
Inventories 506.1 545.0  
Assets held for sale 11.4   0.0
Other current assets 159.8 168.4  
Total current assets 1,165.6 1,231.9  
Lease receivable, non-current 70.3 71.4  
Deferred costs and other contract assets 57.9 57.3  
Property and equipment, net 415.0 424.4  
Finite-lived intangible assets, net 413.2 419.9  
Trademarks - (Note 9) 222.7 232.4  
Goodwill 396.0 407.7  
Deferred tax assets 107.1 107.2  
Other non-current assets 109.9 89.3  
Total assets 2,957.7 3,041.5  
Current liabilities      
Accounts payable 203.1 251.5  
Accrued compensation 65.2 62.6  
Deferred revenue and other contract liabilities, current 70.0 87.3  
Other current liabilities 165.9 162.4  
Total current liabilities 504.2 563.8  
Long-term debt 841.4 871.7  
Deferred tax liabilities 106.9 111.7  
Other non-current liabilities 140.0 129.5  
Total liabilities 1,592.5 1,676.7  
Commitments and contingencies - (Note 24)  
Stockholders’ equity      
Preferred stock, $0.001 par value; 5.0 million shares authorized; 0 shares issued and outstanding 0.0 0.0  
Common stock, $0.001 par value; 100.0 million shares authorized; 53.1 million and 52.8 million shares issued and outstanding at March 30, 2024 and December 30, 2023, respectively 0.1 0.1  
Treasury stock, 19.5 million and 19.5 million shares at March 30, 2024 and December 30, 2023, respectively (1,169.2) (1,169.2)  
Additional paid-in capital 794.9 783.4  
Accumulated other comprehensive loss (75.3) (45.3)  
Retained earnings 1,814.7 1,795.8  
Total stockholders’ equity 1,365.2 1,364.8 $ 1,330.3
Total liabilities and stockholders’ equity 2,957.7 3,041.5  
Customer relationships      
Current assets      
Finite-lived intangible assets, net 169.3 177.7  
Acquired technologies      
Current assets      
Finite-lived intangible assets, net 119.9 129.4  
Other intangible assets, net - (Note 9)      
Current assets      
Finite-lived intangible assets, net $ 124.0 $ 112.8  
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.24.1.u1
CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)
shares in Millions, $ in Millions
Mar. 30, 2024
Dec. 30, 2023
Statement of Financial Position [Abstract]    
Allowance for credit losses $ 4.7 $ 4.8
Preferred stock, par value (in dollars per share) $ 0.001 $ 0.001
Preferred stock, shares authorized (in shares) 5.0 5.0
Preferred stock, shares issued (in shares) 0.0 0.0
Preferred stock, shares outstanding (in shares) 0.0 0.0
Common stock, par value (in dollars per share) $ 0.001 $ 0.001
Common stock, shares authorized (in shares) 100.0 100.0
Common stock, shares, issued (in shares) 53.1 52.8
Common stock, shares, outstanding (in shares) 53.1 52.8
Treasury stock, shares (in shares) 19.5 19.5
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.24.1.u1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Millions, $ in Millions
 3 Months Ended
Mar. 30, 2024
Apr. 01, 2023
Income Statement [Abstract]    
Revenue $ 492.8 $ 565.0
Cost of goods sold 251.1 280.2
Gross profit 241.7 284.8
Operating expenses:    
Selling, general and administrative 159.9 196.3
Research and development 47.8 50.5
Total operating expenses 207.7 246.8
Operating income 34.0 38.0
Non-operating loss (9.1) (11.8)
Income before provision for income taxes 24.9 26.2
Provision for income taxes 6.0 4.9
Net income $ 18.9 $ 21.3
Net income per share:    
Basic (in dollars per share) $ 0.36 $ 0.40
Diluted (in dollars per share) $ 0.35 $ 0.39
Weighted-average shares used in per share calculations:    
Basic (in shares) 53.0 52.6
Diluted (in shares) 54.2 54.4
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.24.1.u1
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)
$ in Millions
 3 Months Ended
Mar. 30, 2024
Apr. 01, 2023
Income Statement [Abstract]    
Net income $ 18.9 $ 21.3
Other comprehensive loss, net of tax:    
Unrealized losses from foreign currency translation adjustments (35.6) (22.8)
Change in pension benefits 0.7 (2.2)
Unrealized gain (loss) on cash flow hedges 4.9 (4.3)
Total comprehensive loss $ (11.1) $ (8.0)
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.24.1.u1
CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY - USD ($)
shares in Millions, $ in Millions
Total
Common Stock
Treasury Stock
Additional Paid-In Capital
Accumulated Other Comprehensive Income (Loss)
Retained Earnings
Beginning balance (in shares) at Dec. 31, 2022   52.5        
Beginning balance at Dec. 31, 2022 $ 1,338.9 $ 0.1 $ (1,169.2) $ 782.2 $ 11.5 $ 1,714.3
Beginning balance (in shares) at Dec. 31, 2022     19.5      
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Stock options exercised (in shares)   0.1        
Stock options exercised 4.3     4.3    
Restricted/Performance stock units vested (in shares)   0.2        
Shares paid for tax withholding (12.2)     (12.2)    
Stock-based compensation 7.3     7.3    
Net income 21.3         21.3
Foreign currency translation adjustment (22.8)       (22.8)  
Change in pension benefits (2.2)       (2.2)  
Unrealized gain (loss) on cash flow hedges (4.3)       (4.3)  
Ending balance (in shares) at Apr. 01, 2023   52.8        
Ending balance at Apr. 01, 2023 $ 1,330.3 $ 0.1 $ (1,169.2) 781.6 (17.8) 1,735.6
Ending balance (in shares) at Apr. 01, 2023     19.5      
Beginning balance (in shares) at Dec. 30, 2023 52.8 52.8        
Beginning balance at Dec. 30, 2023 $ 1,364.8 $ 0.1 $ (1,169.2) 783.4 (45.3) 1,795.8
Beginning balance (in shares) at Dec. 30, 2023 19.5   19.5      
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Stock options exercised (in shares) 0.2 0.2        
Stock options exercised $ 7.2     7.2    
Restricted/Performance stock units vested (in shares)   0.1        
Shares paid for tax withholding (5.3)     (5.3)    
Stock-based compensation 9.6     9.6    
Net income 18.9         18.9
Foreign currency translation adjustment (35.6)       (35.6)  
Change in pension benefits 0.7       0.7  
Unrealized gain (loss) on cash flow hedges $ 4.9       4.9  
Ending balance (in shares) at Mar. 30, 2024 53.1 53.1        
Ending balance at Mar. 30, 2024 $ 1,365.2 $ 0.1 $ (1,169.2) $ 794.9 $ (75.3) $ 1,814.7
Ending balance (in shares) at Mar. 30, 2024 19.5   19.5      
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.24.1.u1
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Millions
 3 Months Ended
Mar. 30, 2024
Apr. 01, 2023
Cash flows from operating activities:    
Net income $ 18.9 $ 21.3
Adjustments to reconcile net income to net cash provided by operating activities:    
Depreciation and amortization 24.3 26.1
Stock-based compensation expense 9.6 7.3
Provision for credit losses 0.1 0.4
Amortization of debt issuance cost 0.5 0.5
Changes in operating assets and liabilities:    
Decrease (increase) in accounts receivable 22.4 34.8
Decrease (increase) in inventories 23.9 (7.1)
Decrease (increase) in other current assets 7.0 (5.9)
Decrease (increase) in lease receivable, net 0.7 (8.8)
Decrease (increase) in deferred costs and other contract assets (0.6) (1.0)
Decrease (increase) in other non-current assets (0.8) (2.7)
Increase (decrease) in accounts payable (40.6) (27.1)
Increase (decrease) in accrued compensation 3.2 (16.5)
Increase (decrease) in accrued liabilities 2.3 (21.8)
Increase (decrease) in income tax payable (5.8) (8.3)
Increase (decrease) in deferred revenue and other contract-related liabilities (13.9) 0.9
Increase (decrease) in other non-current liabilities (5.4) 8.3
Net cash provided by (used in) operating activities 45.8 0.4
Cash flows from investing activities:    
Purchases of property and equipment, net (8.2) (8.5)
Increase in intangible assets (10.6) (9.7)
Business combinations, net of cash acquired 0.0 7.5
Other strategic investing activities (0.1) (0.4)
Net cash (used in) provided by investing activities (18.9) (11.1)
Cash flows from financing activities:    
Borrowings under line of credit 64.0 44.4
Repayments on line of credit (92.3) (72.4)
Proceeds from issuance of common stock 7.1 4.9
Payroll tax withholdings on behalf of employees for vested equity awards (5.3) (12.1)
Net cash (used in) provided by financing activities (26.5) (35.2)
Effect of foreign currency exchange rates on cash (4.6) 17.4
Net decrease in cash, cash equivalents and restricted cash (4.2) (28.5)
Cash, cash equivalents and restricted cash at beginning of period 168.2 209.6
Cash, cash equivalents and restricted cash at end of period $ 164.0 $ 181.1
XML 19 R8.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Description of the Company
 3 Months Ended
Mar. 30, 2024
Accounting Policies [Abstract]  
Description of the Company
1. Description of the Company
Masimo Corporation is a global technology company that develops, manufactures and markets a wide array of patient monitoring technologies, as well as automation and connectivity solutions. The Company’s mission is to improve patient outcomes, reduce the cost of care and take noninvasive monitoring to new sites and applications. The Company operates two business segments: healthcare and non-healthcare.
The Company’s healthcare products and patient monitoring solutions generally incorporate a monitor or circuit board, proprietary single-patient use or reusable sensors, software and/or cables. The Company primarily sells its healthcare products to hospitals, emergency medical service providers, home care providers, physician offices, veterinarians, long-term care facilities and consumers through its direct sales force, distributors and original equipment manufacturer (OEM) partners.
On April 11, 2022, the Company acquired Viper Holdings Corporation, the parent company of DEI Sales, Inc., d/b/a Sound United (Sound United), via the Company’s wholly-owned subsidiary, Sonic Boom Acquisition Corp (Sonic) (Sound United Acquisition). For additional information on the Company’s acquisition of Sound United, see Note 18, “Business Combinations”.
The Company’s non-healthcare consumer products and home integration technologies are primarily sold or licensed direct-to-consumers, or through authorized retailers and wholesalers.
The terms “the Company” and “Masimo” refer to Masimo Corporation and, where applicable, its consolidated subsidiaries.
XML 20 R9.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Summary of Significant Accounting Policies
 3 Months Ended
Mar. 30, 2024
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies
2. Summary of Significant Accounting Policies
Basis of Presentation
The accompanying unaudited condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (SEC). Certain information and note disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) have been condensed or omitted pursuant to such rules and regulations. The accompanying condensed consolidated financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments, including normal recurring accruals, necessary to present fairly the Company’s condensed consolidated financial statements. The accompanying condensed consolidated balance sheet as of December 30, 2023 was derived from the Company’s audited consolidated financial statements at that date. The accompanying condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes contained in the Company’s Annual Report on Form 10-K for the fiscal year ended December 30, 2023 (fiscal year 2023), filed with the SEC on February 28, 2024. The results for the three months ended March 30, 2024 are not necessarily indicative of the results to be expected for the fiscal year ending December 28, 2024 (fiscal year 2024) or for any other interim period or for any future year.
Fiscal Periods
The Company follows a conventional 52/53 week fiscal year. Under a conventional 52/53 week fiscal year, a 52 week fiscal year includes four quarters of 13 weeks while a 53 week fiscal year includes three 13 week fiscal quarters and one 14 week fiscal quarter. The Company’s last 53 week fiscal year was fiscal year 2020. Fiscal year 2024 is a 52 week fiscal year ending December 28, 2024. All references to years in these notes to condensed consolidated financial statements are fiscal years unless otherwise noted.
Reclassifications
Certain amounts in the accompanying condensed consolidated financial statements have been reclassified to conform to the current period presentation, including certain balance sheet asset accounts in the consolidated financial statements for the year ended December 30, 2023. There was no impact on previously reported total assets, liabilities, stockholders’ equity or net income.
Use of Estimates
The Company prepares its financial statements in conformity with GAAP, which requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Significant estimates include the determination of standalone selling prices, variable consideration, total consideration allocated to each performance obligation within a contract, inventory valuation, valuation of the Company’s equity awards, valuation of identifiable assets and liabilities connected with business combinations, impairment of long-lived assets, intangible assets and goodwill; derivative and equity instruments, deferred taxes and any associated valuation allowances, deferred revenue, accounting for pensions, uncertain income tax positions, litigation costs, and related accruals. See Note 24, “Commitments and Contingencies”. Actual results could differ from such estimates.
Business Combinations
The Company accounts for business combinations using the acquisition method of accounting in accordance with Accounting Standards Codification (ASC) Topic 805, Business Combinations, which requires that once control is obtained, assets acquired, liabilities assumed and noncontrolling interests in the acquired entity, if applicable, are recorded at their respective fair values at the date of acquisition, with the exception of acquired contract assets and contract liabilities (i.e., deferred revenue) from contracts with customers. These are recognized and measured in accordance with ASC Topic 606, Revenue from Contracts with Customers. The excess of the purchase price over fair values of identifiable assets, liabilities and noncontrolling interests in the acquired entity, if applicable, is recorded as goodwill.
Fair Value Measurements
The Company accounts for certain financial instruments at their fair values as either assets or liabilities on the balance sheet. The Company determines the fair value of its financial instruments using the framework prescribed by ASC Topic 820, Fair Value Measurements and Disclosures, and considers the estimated amount the Company would receive or pay to transfer these instruments at the reporting date with respect to current currency exchange rates, interest rates, the creditworthiness of the counterparty for unrealized gain positions and the Company’s creditworthiness for unrealized loss positions. In certain instances, the Company may utilize financial models to measure the fair value of its financial instruments. In doing so, the Company uses inputs that include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, other observable inputs for the asset or liability and inputs derived principally from, or corroborated by, observable market data by correlation or other means.
Recurring Fair Value Measurement
On a recurring basis, the Company measures certain financial assets and financial liabilities at fair value based upon quoted market prices. Where quoted market prices or other observable inputs are not available, the Company applies valuation techniques to estimate fair value. Authoritative guidance describes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value:
●    Level 1—Quoted prices in active markets for identical assets or liabilities.
●    Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active; or other inputs that can be corroborated by observable market data for substantially the full term of the assets or liabilities.
●    Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
The following tables represent the Company’s financial assets, measured at fair value on a recurring basis at March 30, 2024:
Total Carrying
Value		Fair Value Measurement Hierarchy
(in millions)Level 1Level 2Level 3
Assets
Cash and cash equivalents$81.9 $81.9 $— $— 
Money market funds75.7 75.7 — — 
Equity securities1.7 1.7 — — 
Pension assets22.9 16.6 6.3 — 
Derivative instruments - cash flow hedges(1)
14.4 — 14.4 — 
Derivative instruments - warrants0.9 0.9 — — 
Total assets$197.5 $176.8 $20.7 $— 
Liabilities
Derivative instruments - cash flow hedges
$— $— $— $— 
Pension benefit obligation32.1 32.1 — — 
Total liabilities$32.1 $32.1 $— $— 
______________
(1)     Includes accrued interest.
The following tables represent the Company’s financial assets, measured at fair value on a recurring basis at December 30, 2023:
Total Carrying
Value		Fair Value Measurement Hierarchy
(in millions)Level 1Level 2Level 3
Assets
Cash and cash equivalents$87.0 $87.0 $— $— 
Money market funds76.0 76.0 — — 
Pension assets
23.1 16.8 6.3 — 
Equity securities1.7 1.7 — — 
Derivative instruments - cash flow hedges(1)
11.6 — 11.6 — 
Derivative instruments - warrants1.0 1.0 — — 
Total assets$200.4 $182.5 $17.9 $— 
Liabilities
Derivative instruments - cash flow hedges$3.6 $3.6 $— $— 
Pension benefit obligation32.6 32.6 — — 
Total liabilities$36.2 $36.2 $— $— 
______________
(1)     Includes accrued interest.
The Company invests in checking, savings and money market fund accounts, which are classified within Level 1 of the fair value hierarchy as they are valued using quoted market prices. These investments are classified as cash and cash equivalents within the Company’s accompanying condensed consolidated balance sheets, in accordance with GAAP and its accounting policies.
The Company has certain strategic investments in privately-held companies (non-marketable equity securities) and companies that have completed initial public offerings (marketable equity securities). The Company’s marketable equity securities, whose price is based on quoted market price in an active market, are classified within Level 1 of the fair value hierarchy. Equity securities are classified as current, short-term investments, or non-current, recorded in other non-current assets, based on the nature of the securities and their availability for use in current operations. The changes in the fair value of those equity securities are measured at each reporting date and changes in the value of these investments between reporting dates are recorded within non-operating loss.
The Company’s pension assets consist of Level 1 and Level 2 investments. The fair value of Level 2 assets is based on observable inputs such as prices or quotes for similar assets, adjusted for any differences in terms or conditions that may affect the value of the instrument being valued. The valuation techniques used for Level 2 assets may include the use of models or other valuation techniques, but these methods are all based on observable market inputs.
The Company also has investments in certain derivative instruments, which are measured at fair value and classified within Level 1 of the fair value hierarchy.
Non-Recurring Fair Value Measurements
For certain other financial assets and liabilities, including restricted cash, accounts receivable, accounts payable and other current assets and liabilities, the carrying amounts approximate their fair value primarily due to the relatively short maturity of these balances. The Company also measures certain non-financial assets at fair value on a non-recurring basis, primarily goodwill, intangible assets and operating lease right-of-use assets, in connection with periodic evaluations for potential impairment.
Furthermore, the Company did not elect to apply the fair value option to specific assets or liabilities on a contract-by-contract basis. The Company did not have any transfers between Level 2 and Level 3 during the three months ended March 30, 2024.
Cash and Cash Equivalents
The Company considers all highly liquid investments with an original maturity from the date of purchase of three months or less, or highly liquid investments that are readily convertible into known amounts of cash, to be cash equivalents. The Company carries cash and cash equivalents at cost, which approximates fair value, and they are Level 1 under the fair value hierarchy.
Accounts Receivable and Allowance for Credit Losses
Accounts receivable consist of trade receivables recorded at the time of invoicing of product sales, reduced by reserves for estimated bad debts and returns. Trade accounts receivable are recorded at the invoiced amount and do not bear interest. Credit is extended based on an evaluation of the customer’s financial condition. Collateral is generally not required. The Company records an allowance for credit losses that it does not expect to collect based on relevant information, including historical experience, current conditions, and reasonable and supportable forecasts. Accounts are charged off against the allowance when the Company believes they are uncollectible. The allowance for credit losses is measured on a collective (pool) basis when similar risk characteristics exist. Based on the risk characteristics, the Company has identified U.S. and international customers as separate portfolios for both segments, and measures expected credit losses on such receivables using an aging methodology.
Inventories
Inventories are stated at the lower of cost or net realizable value. Cost is determined using a standard cost method, which approximates the first in, first out method, and includes material, labor and overhead costs. Inventory valuation adjustments are recorded for inventory items that have become excess or obsolete or are no longer used in current production and for inventory items that have a market price less than the carrying value in inventory. The Company generally determines inventory valuation adjustments based on an evaluation of the expected future use of its inventory on an item by item basis and applies historical obsolescence rates to estimate the loss on inventory expected to have a recovery value below cost. The Company also records other specific inventory valuation adjustments when it becomes aware of unique events or circumstances that result in an expected recovery value below cost. For inventory items that have been written down, the reduced value becomes the new cost basis.
Property and Equipment
Property and equipment are stated at cost. Depreciation is calculated using the straight-line method over estimated useful lives as follows:
Useful Lives
Buildings and building improvements
7 to 39 years
Computer equipment and software
2 to 12 years
Demonstration units
2 to 3 years
Furniture and office equipment
2 to 15 years
Leasehold improvementsLesser of useful life or term of lease
Machinery, equipment and tooling
3 to 20 years
Operating lease assetsLesser of useful life or term of lease
Transportation, vehicles and other
1 to 20 years
Land is not depreciated and construction-in-progress is not depreciated until placed in service. Normal repair and maintenance costs are expensed as incurred, whereas significant improvements that materially increase values or extend useful lives are capitalized and depreciated over the remaining estimated useful lives of the related assets. Upon sale or retirement of depreciable assets, the related cost and accumulated depreciation or amortization are removed from the accounts and any gain or loss on the sale or retirement is recognized in income.
Lessee Right-of-Use (ROU) Assets and Lease Liabilities
The Company determines if an arrangement contains a lease at inception. ROU assets represent the Company’s right to use an asset underlying an operating lease for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from an operating lease. ROU assets and lease liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. The Company generally estimates the applicable discount rate used to determine the net present value of lease payments based on available information at the lease commencement date. Many of the Company’s lessee agreements include options to extend the lease, which the Company does not include in its lease terms unless they are reasonably certain to be exercised. The Company utilizes a portfolio approach to account for the ROU assets and liabilities associated with certain equipment leases.
The Company has also made an accounting policy election not to separate lease and non-lease components for its real estate leases and to exclude short-term leases with a term of twelve months or less from its ROU assets and lease liabilities. Rental expense for lease payments related to operating leases is recognized on a straight-line basis over the lease term.
Intangible Assets
Intangible assets consist primarily of patents, trademarks, software development costs, customer relationships and acquired technology. Costs related to patents and trademarks, which include legal and application fees, are capitalized and amortized over the estimated useful lives using the straight-line method. Patent and trademark amortization commences once final approval of the patent or trademark has been obtained. Patent costs are amortized over the lesser of 10 years or the patent’s remaining legal life, which assumes renewals, and trademark costs are amortized over 17 years, and their associated amortization cost is included in selling, general and administrative expense in the accompanying condensed consolidated statements of operations. For intangibles purchased in an asset acquisition or business combination, which mainly include patents, trademarks, customer relationships and acquired technologies, the useful life is determined largely by valuation estimates of remaining economic life.
The Company’s policy is to renew its patents and trademarks. Costs to renew patents and trademarks are capitalized and amortized over the remaining useful life of the intangible asset. The Company periodically evaluates the amortization period and carrying basis of patents and trademarks to determine whether any events or circumstances warrant a revised estimated useful life or reduction in value. Capitalized application costs are charged to operations when it is determined that the patent or trademark will not be obtained or is abandoned.
Software development costs are accounted for in accordance with ASC Topic 985-20, Software - Costs of Software to be Sold, Leased, or Marketed. Once technological feasibility has been established, qualifying costs incurred in development are capitalized until available for general release to customers, and subsequently reported at the lower of unamortized cost or net realizable value.
Intangibles purchased as part of an asset acquisition or business combination historically have included patents, trademarks, customer relationships, developed technologies and contractual licenses. In certain circumstances the Company has also acquired non-compete agreements tied to certain employment relationships. The useful life for all of these is largely determined by valuation estimates of remaining economic life. In connection with the Sound United acquisition, the Company acquired certain trademarks/tradenames, which are intangible assets with indefinite useful lives. These brands are expected to maintain brand value for an indefinite period of time.
Impairment of Goodwill, Intangible Assets and Other Long-Lived Assets
Goodwill is recorded as the difference, if any, between the aggregate consideration paid for an acquisition and the fair value of the acquired net tangible and intangible assets. Goodwill is not amortized, but instead is tested annually for impairment, or more frequently when events or changes in circumstances indicate that goodwill might be impaired. In assessing goodwill impairment, the Company has the option to first assess the qualitative factors to determine whether the existence of events or circumstances leads to a determination that it is more likely than not that the fair value of a reporting unit is less than its carrying amount. The Company has two reporting units, healthcare and non-healthcare. The Company’s qualitative assessment of the recoverability of goodwill considers various macro-economic, industry-specific and Company-specific factors, including: (i) severe adverse industry or economic trends; (ii) significant Company-specific actions; (iii) current, historical or projected deterioration of the Company’s financial performance; or (iv) a sustained decrease in the Company’s market capitalization below its net book value. If the qualitative assessment indicates that it is more-likely-than-not that the fair value of a reporting unit is less than its carrying value, or if the Company elects to bypass the qualitative analysis, then the Company performs a quantitative analysis that compares the fair value of the reporting unit with its carrying amount, including goodwill. If the fair value of the reporting unit exceeds its carrying amount, goodwill is not considered impaired; otherwise, a goodwill impairment loss is recognized for the lesser of: (a) the amount that the carrying amount of such reporting unit exceeds its fair value; or (b) the amount of the goodwill allocated to such reporting unit. The annual impairment test is performed during the fourth fiscal quarter.
Similar to goodwill, indefinite-lived intangible assets are not amortized but instead are subject to annual impairment testing, unless circumstances dictate more frequent testing, if impairment indicators exist. Impairment for indefinite-lived assets exists if the carrying value of the indefinite-lived intangible asset exceeds its fair value. Determining whether impairment indicators exist and estimating the fair value of the Company’s indefinite-lived intangible assets if necessary for impairment testing require significant judgment. Qualitative factors considered in this assessment include industry and market conditions, overall financial performance, and other relevant events and factors.
The Company reviews finite lived intangible assets and long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted operating cash flows expected to be generated by the asset. If such asset is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount exceeds the fair value of the asset. Long-lived assets to be disposed of are reported at the lower of carrying amount or fair value less costs to sell.
Employee Defined Benefit Plans
The Company maintains noncontributory defined benefit plans that cover certain employees in certain international locations. The Company recognizes the funded status, or the difference between the fair value of plan assets and the projected benefit obligations of the pension plan on the condensed consolidated balance sheet, with a corresponding adjustment to accumulated other comprehensive (loss) income. If the projected benefit obligation exceeds the fair value of plan assets, the difference or underfunded status represents the pension liability. The Company records a net periodic pension cost in the condensed consolidated statement of operations. The liabilities and annual income or expense are determined using methodologies that involve several actuarial assumptions, the most significant of which are the discount rate and the expected long-term rate of asset return. The Company’s accounting policy includes an annual re-measurement of pension assets and obligations. In addition, the Company re-measures pension assets and obligations for significant events, as of the nearest month-end date on the calendar. The fair values of plan assets are determined based on prevailing market prices. See Note 21, “Employee Benefits”, for further details.
Income Taxes
The Company accounts for income taxes using the asset and liability method, under which the Company recognizes deferred tax assets and liabilities for the future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and for net operating loss and tax credit carryforwards. Tax positions that meet a more-likely-than-not recognition threshold are recognized in the first reporting period that it becomes more-likely-than-not such tax position will be sustained upon examination. A tax position that meets this more-likely-than-not recognition threshold is recorded at the largest amount of tax benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. Previously recognized income tax positions that fail to meet the recognition threshold in a subsequent period are derecognized in that period. Differences between actual results and the Company’s assumptions, or changes in the Company’s assumptions in future periods, are recorded in the period they become known. The Company records potential accrued interest and penalties related to unrecognized tax benefits in income tax expense.
As a multinational corporation, the Company is subject to complex tax laws and regulations in various jurisdictions. The application of tax laws and regulations is subject to legal and factual interpretation, judgment and uncertainty. Tax laws themselves are subject to change as a result of changes in fiscal policy, changes in legislation, evolution of regulations and court rulings. Therefore, the actual liability for U.S. or foreign taxes may be materially different from the Company’s estimates, which could result in the need to record additional liabilities or potentially to reverse previously recorded tax liabilities.
Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that includes the enactment date. A valuation allowance is recorded against any deferred tax assets when, in the judgment of management, it is more likely than not that all or part of a deferred tax asset will not be realized. In assessing the need for a valuation allowance, the Company considers all positive and negative evidence, including recent financial performance, scheduled reversals of temporary differences, projected future taxable income, availability of taxable income in carryback periods and tax planning strategies.
Income taxes are highly susceptible to changes from period to period, requiring management to make assumptions about the Company’s future income over the lives of its deferred tax assets and the impact of changes in valuation allowances. Any difference in the assumptions, judgments and estimates mentioned above could result in changes to the Company’s results of operations.
Revenue Recognition, Deferred Revenue and Other Contract Liabilities
The Company generally recognizes revenue following a single, principles-based five-step model to be applied to all contracts with customers and generally provides for the recognition of revenue in an amount that reflects the consideration to which the Company expects to be entitled, net of allowances for estimated returns, discounts or sales incentives, as well as taxes collected from customers that are remitted to government authorities, when control over the promised goods or services are transferred to the customer.
Healthcare segment
While the majority of the Company’s healthcare segment revenue contracts and transactions contain standard business terms and conditions, there are some transactions that contain non-standard business terms and conditions. As a result, contract interpretation, judgment and analysis are required to determine the appropriate accounting, including: (i) the amount of the total consideration, as well as variable consideration, (ii) whether the arrangement contains an embedded lease, and if so, whether such embedded lease is a sales-type lease or an operating lease, (iii) the identification of the distinct performance obligations contained within the arrangement, (iv) how the arrangement consideration should be allocated to each performance obligation when multiple performance obligations exist, including the determination of standalone selling price, and (v) when to recognize revenue on the performance obligations. Changes in judgments on these assumptions and estimates could materially impact the timing of revenue recognition. Revenue from fixed lease payments related to equipment supplied under sales-type lease arrangements is recognized once control over the equipment is transferred to the customer, while revenue from fixed lease payments related to equipment supplied under operating-type lease arrangements is generally recognized on a straight-line basis over the term of the lease and variable lease payments are recognized as they occur.
The Company derives the majority of its healthcare segment revenue from four primary sources: (i) direct sales under deferred equipment agreements with end-user hospitals where the Company provides up-front monitoring equipment at no up-front charge in exchange for a multi-year sensor purchase commitment; (ii) other direct sales of noninvasive monitoring solutions to end-user hospitals, emergency medical response organizations and other direct customers; (iii) sales of noninvasive monitoring solutions to distributors who then typically resell to end-user hospitals, emergency medical response organizations and other customers; and (iv) sales of integrated circuit boards to OEM customers who incorporate the Company’s embedded software technology into their multiparameter monitoring devices. Subject to customer credit considerations, the majority of such sales are made on open accounts using industry standard payment terms based on the geography within which the specific customer is located.
The Company enters into agreements to sell its monitoring solutions and services, sometimes as a part of arrangements with multiple performance obligations that include various combinations of product sales, equipment leases, software and services. In the case of contracts with multiple performance obligations, the authoritative guidance provides that the total consideration be allocated to each performance obligation on the basis of relative standalone selling prices. When a standalone selling price is not readily observable, the Company estimates the standalone selling price by considering multiple factors including, but not limited to, features and functionality of the product, geographies, type of customer, contractual prices pursuant to Group Purchasing Organization (GPO) contracts, the Company’s pricing and discount practices, and other market conditions.
Sales under deferred equipment agreements are generally structured such that the Company agrees to provide certain monitoring-related equipment, software, installation, training and/or warranty support at no up-front charge in exchange for the customer’s commitment to purchase sensors over the term of the agreement, which generally ranges from three years to six years. The Company allocates contract consideration under deferred equipment agreements containing fixed annual sensor purchase commitments to the underlying lease and non-lease components at contract inception. In determining whether any underlying lease components are related to a sales-type lease or an operating lease, the Company evaluates the customer’s rights and ability to control the use of the underlying equipment throughout the contract term, including any equipment substitution rights retained by the Company, as well as the Company’s expectations surrounding potential contract/lease extensions or renewals and the customer’s likelihood to exercise any purchase options. Beginning in 2022, for contracts that contain variable lease payments that are not dependent on an index or rate, the Company classifies as operating leases any lease components that would have otherwise been classified as sales-type leases that would result in a selling loss upon lease commencement. Revenue allocable to non-lease performance obligations is generally recognized as such non-lease performance obligations are satisfied. Revenue allocable to lease components under sales-type lease arrangements is generally recognized when control over the equipment is transferred to the customer. Revenue allocable to lease components under operating lease arrangements is generally recognized over the term of the operating lease. The Company generally does not expect to derive any significant value in excess of such asset’s unamortized book value from equipment underlying its operating lease arrangements after the end of the agreement.
Revenue from the sale of products and software to end-user hospitals, emergency medical response organizations, other direct customers, distributors and OEM customers, is recognized by the Company when control of the performance obligations thereunder transfers to the customer based upon the terms of the contract or underlying purchase order.
Revenue related to OEM rainbow® parameter software licenses is recognized by the Company upon the OEM’s shipment of its product to its customer, as reported to the Company by the OEM.
The Company provides certain customers with various sales incentives that may take the form of discounts or rebates. The Company records estimates related to these programs as a reduction to revenue at the time of sale. In general, customers do not have a right of return for credit or refund. However, the Company allows returns under certain circumstances. At the end of each period, the Company estimates and accrues for these returns as a reduction to revenue. The Company estimates the revenue constraints related to these forms of variable consideration based on various factors, including expected purchasing volumes, prior sales and returns history, and specific contractual terms and limitations.
Non-healthcare segment
Non-healthcare segment revenue is related to hardware and embedded software that is integrated into final products that are manufactured and sold by the Company. Products and related software are accounted for as a single performance obligation and all intended functionality is available to the customer upon purchase. Non-healthcare segment revenue is recognized upon transfer of control of promised products or service to customers, which is either upon shipment or upon delivery to the customers, depending on delivery terms.
The Company offers sales incentives and has customer programs consisting primarily of discounts and market development fund programs, and records them as contra revenue. Estimates for sales incentives are developed using the most likely amount and are included in the transaction price to the extent that a significant reversal of revenue would not result once the uncertainty is resolved. In developing these estimates, the Company also considers the susceptibility of the incentive to outside influences, the length of time until the uncertainty is resolved and the Company’s experience with similar contracts. Reductions in revenue related to discounts are allocated to products on a relative basis based on their respective standard selling price if there are undelivered products in a contract. Judgement is required to determine the timing and amount of recognition of marketing funds which the Company estimates based on past practice of providing similar funds.
Payment terms and conditions vary among the Company’s distribution channels although terms generally include a requirement of payment within 30 to 60 days of product shipment. Sales made directly to customers from the Company’s website are paid at the time of product shipment. Prior to determining payment terms for each customer, an evaluation of such customer’s credit risk is performed. Contractual allowances are an offset to accounts receivable.
Shipping and Handling Costs and Fees
All shipping and handling costs are expensed as incurred and are recorded as a component of cost of goods sold in the accompanying condensed consolidated statements of operations. Charges for shipping and handling billed to customers are included as a component of revenue.
Taxes Collected From Customers and Remitted to Governmental Authorities
The Company’s policy is to present revenue net of taxes collected from customers and remitted to governmental authorities.
Deferred Costs and Other Contract Assets
The costs of monitoring-related equipment provided to customers under operating lease arrangements within the Company’s deferred equipment agreements are generally deferred and amortized to cost of goods sold over the life of the underlying contracts. Some of the Company’s deferred equipment agreements also contain provisions for certain allowances to be made directly to the end-user hospital customer at the inception of the arrangement. These allowances are generally allocated to the lease and non-lease components and recognized as a reduction to revenue as the underlying performance obligations are satisfied.
The Company generally invoices its customers under deferred equipment agreements as sensors are provided to the customer. However, the Company may recognize revenue for certain non-lease performance obligations under deferred equipment agreements with fixed annual commitments at the time such performance obligations are satisfied and prior to the customer being invoiced. When this occurs, the Company records an unbilled contract receivable related to such revenue until the customer has been invoiced pursuant to the terms of the underlying deferred equipment agreement.
The incremental costs of obtaining a contract with a customer are capitalized and deferred if the Company expects such costs to be recoverable over the life of the contract and the contract term is greater than one year. Such deferred costs generally relate to certain incentive sales commissions earned by the Company’s internal sales team in connection with the execution of deferred equipment agreements and are amortized to expense over the expected term of the underlying contract.
The Company recognizes non-healthcare royalty revenue associated with certain prepaid license arrangements. The Company recognizes non-healthcare revenue from the prepaid license arrangements based upon sales-based royalties when a subsequent sale occurs.
Warranty
The Company generally provides a warranty against defects in material and workmanship for a period ranging from six months to forty-eight months, depending on the product type. In traditional sales activities, including direct and OEM sales, the Company establishes an accrued liability for the estimated warranty costs at the time of revenue recognition, with a corresponding provision to cost of goods sold. Customers may also purchase extended warranty coverage or service level upgrades separately or as part of a deferred equipment agreement. Revenue related to extended warranty coverage and service level upgrades is generally recognized over the life of the contract, which reasonably approximates the period over which such services will be provided. The related extended warranty and service level upgrade costs are expensed as incurred.
Changes in the product warranty accrual were as follows:
Three Months Ended
(in millions)March 30,
2024		April 1,
2023
Product warranty accrual, beginning of period$8.6 $10.6 
Accrual for warranties issued3.1 3.8 
Changes in pre-existing warranties (including changes in estimates)0.4 (3.5)
Settlements made(4.0)(0.7)
Product warranty accrual, end of period$8.1 $10.2 
Advertising Costs
Advertising costs include certain advertising, marketing and endorsement licensing fee agreements. Advertising and marketing costs are expensed as incurred. Licensing fees associated with product endorsers are expensed on a straight-line basis over the term of the agreement. Advertising costs are included in selling, general and administrative expense in the accompanying condensed consolidated statements of operations. Advertising costs for the three months ended March 30, 2024 and April 1, 2023 were $11.9 million and $14.4 million, respectively.
Litigation Costs and Contingencies
The Company records a charge equal to at least the minimum estimated liability for a loss contingency or litigation settlement when both of the following conditions are met: (i) information available prior to issuance of the financial statements indicates that it is probable that a liability had been incurred at the date of the financial statements, and (ii) the range of loss can be reasonably estimated. The determination of whether a loss contingency, litigation settlement or contingent fee is probable or reasonably possible involves a significant amount of management judgment, as does the estimation of the range of loss given the nature of contingencies or any associated contingent fees related to a settlement of a legal matter. Liabilities related to litigation settlements with multiple elements are recorded based on the fair value of each element. Legal and other litigation related expenses are recognized as the services are provided. Contingent legal fee expenses are recognized when probable and reasonably estimable. The Company records insurance and other indemnity recoveries for litigation expenses when both of the following conditions are met: (a) the recovery is probable, and (b) collectability is reasonably assured. Insurance recoveries are only recorded to the extent the litigation costs to which they relate have been incurred and recognized in the financial statements.
Foreign Currency Translation
The Company’s international headquarters is in Switzerland, and its functional currency is the U.S. Dollar. The Company has many other foreign subsidiaries, and the largest transactions in foreign currency translations occur in the Japanese Yen, the British Pound, the Chinese Yuan and the European Euro.
The Company records certain revenues and expenses in foreign currencies. These revenues and expenses are translated into U.S. Dollars based on the average exchange rate for the reporting period. Assets and liabilities denominated in foreign currencies are translated into U.S. Dollars at the exchange rate in effect as of the balance sheet date. Translation gains and losses related to foreign currency assets and liabilities of a subsidiary that are denominated in the functional currency of such subsidiary are included as a component of accumulated other comprehensive (loss) income within the accompanying condensed consolidated balance sheets. Realized and unrealized foreign currency gains and losses related to foreign currency assets and liabilities of the Company, or a subsidiary that are not denominated in the underlying functional currency are included as a component of non-operating (loss) income within the accompanying condensed consolidated statements of operations.
Derivatives Instruments and Hedging Activities
The Company addresses market risk from changes in interest rates risks through risk management programs, which include the use of derivative instruments. The Company’s exposure to a counterparty’s credit risk is generally limited to the amounts of the net obligation to the counterparty. The Company established policies to enter into contracts only with major investment-grade financial institutions to mitigate such counterparty credit risk. The Company also established a policy to further monitor the counterparty risks throughout the life of the instruments. None of the derivative instruments currently held by the Company were entered into for speculative trading purposes.
All derivative financial instruments are recognized as either assets or liabilities at fair value in the condensed consolidated balance sheets and are classified as short-term or long-term based on the tenor of the instrument. The Company has elected not to separate a derivative instrument into current and long-term portions. A derivative instrument whose fair value is a net liability is classified as current in total. A derivative instrument whose fair value is a net asset and whose current portion is an asset is classified as non-current in total. For a derivative instrument that meets the criteria to qualify for hedge accounting, the Company marks the fair value of the derivative instrument to market periodically through other comprehensive (loss) income. When the hedged items are recorded to income (loss), the associated deferred gains (losses) of the derivatives in accumulated other comprehensive (loss) income will be reclassified into earnings. Any fluctuation in the fair value of a derivative instrument that does not meet the criteria for hedge accounting is recorded to earnings (expense) in the period it occurs.
Comprehensive (Loss) Income
Comprehensive (loss) income includes foreign currency translation adjustments, changes to pension benefits, unrealized gains (losses) on cash flow hedges and any related tax benefits (expenses) that have been excluded from net income and reflected in stockholders’ equity.
Net Income Per Share
A computation of basic and diluted net income per share is as follows:
Three Months Ended
(in millions, except per share amounts)
March 30,
2024		April 1,
2023
Net income$18.9 $21.3 
Basic net income per share:
Weighted-average shares outstanding - basic53.0 52.6 
Net income per basic share$0.36 $0.40 
Diluted net income per share:
Weighted-average shares outstanding - basic53.0 52.6 
Diluted share equivalents: stock options, RSUs and PSUs1.3 1.8 
Weighted-average shares outstanding - diluted54.2 54.4 
Net income per diluted share$0.35 $0.39 
Basic net income per share is computed by dividing net income by the weighted-average number of shares outstanding during the period. Net income per diluted share is computed by dividing the net income by the weighted-average number of shares and potential shares outstanding during the period, if the effect of potential shares is dilutive. Potential shares include incremental shares of stock issuable upon the exercise of stock options and the vesting of both restricted share units (RSUs) and performance stock units (PSUs). For each of the three months ended March 30, 2024 and April 1, 2023, weighted options to purchase 1.4 million and 1.0 million shares of common stock, respectively, were outstanding but not included in the computation of diluted net income per share because the effect of including such shares would have been antidilutive in the applicable period. Certain RSUs were considered contingently issuable shares as their vesting is contingent upon the occurrence of certain future events. Since such events had not occurred and were not considered probable of occurring as of each of March 30, 2024 and April 1, 2023, 2.7 million weighted-average shares related to such RSUs have been excluded from the calculation of potential shares for the three month periods then ended. For additional information with respect to these RSUs, please see “Employment and Severance Agreements” in Note 24, “Commitments and Contingencies”.
Supplemental Cash Flow Information
Supplemental cash flow information includes the following:
Three Months Ended
(in millions)March 30,
2024		April 1,
2023
Cash paid during the year for:
Interest expense
$11.7 $11.7 
Income taxes
8.5 11.0 
Operating lease liabilities
5.7 5.3 
Non-cash operating activities:
ROU assets obtained in exchange for lease liabilities
$20.6 $0.6 
Non-cash investing activities:
Unpaid purchases of property and equipment$2.7 $0.7 
Unpaid strategic investments0.2 1.2 
Non-cash financing activities:
       Unsettled common stock proceeds from option exercises$0.1 $0.1 
Reconciliation of cash, cash equivalents and restricted cash:
Cash and cash equivalents
$157.6 $174.1 
Restricted cash
6.4 7.0 
Total cash, cash equivalents and restricted cash shown in the condensed consolidated statements of cash flows$164.0 $181.1 
Recently Adopted and Recently Announced Accounting Pronouncements
There have been no material changes to the accounting policies discussed in Note 2 to the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 30, 2023, filed with the SEC on February 28, 2024. other than the following update:
In November 2023, the Financial Accounting Standards Board issued Accounting Standards Update (ASU) No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The new standard is intended to improve reportable segment disclosure requirements primarily through enhanced disclosures about significant segment expenses. ASU No. 2023-07 is effective for annual reporting periods beginning after December 15, 2023 and interim periods in fiscal years beginning after December 15, 2024. Early adoption is permitted with retrospective application to all prior periods presented. Upon transition, the segment expense categories and amounts disclosed in the prior periods should be based on the significant segment expense categories identified and disclosed in the period of adoption. The Company is continuing to evaluate the impact of this standard on its consolidated financial statements upon adoption.
XML 21 R10.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Related Party Transactions
 3 Months Ended
Mar. 30, 2024
Related Party Transactions [Abstract]  
Related Party Transactions
3. Related Party Transactions
The Company’s Chairman and Chief Executive Officer (CEO) is also the Chairman and CEO of Willow Laboratories, Inc. (Willow). The Company is a party to the following agreements with Willow:
•Cross-Licensing Agreement - The Company and Willow are parties to a cross-licensing agreement (Cross-Licensing Agreement), which governs each party’s rights to certain intellectual property held by the two companies. The Company is subject to certain annual minimum aggregate royalty obligations for use of the rainbow® licensed technology. The current annual minimum royalty obligation is $5.0 million. Aggregate liabilities payable to Willow arising under the Cross-Licensing Agreement were $4.8 million and $5.6 million for the three months ended March 30, 2024 and April 1, 2023, respectively.
•Administrative Services Agreement - The Company is a party to an administrative services agreement with Willow (G&A Services Agreement), which governs certain general and administrative services that the Company provides to Willow. Amounts charged by the Company pursuant to the G&A Services Agreement were $0.1 million for each of the three months ended March 30, 2024 and April 1, 2023.
•Lease Agreement - Effective December 2019, the Company entered into a lease agreement with Willow for approximately 34,000 square feet of office, research and development space at one of the Company’s owned facilities in Irvine (Willow Lease). The term of the Willow Lease expires on December 31, 2024. The Company recognized approximately $0.3 million of lease income for each of the three months ended March 30, 2024 and April 1, 2023.
Net amounts due to Willow at March 30, 2024 and December 30, 2023 were approximately $4.9 million and $4.1 million, respectively.
The Company’s CEO is also the Chairman of the Masimo Foundation for Ethics, Innovation and Competition in Healthcare (Masimo Foundation), a non-profit organization that was founded in 2010 to provide a platform for encouraging ethics, innovation, and competition in healthcare. In addition, the Company’s Executive Vice President (EVP), Chief Financial Officer (CFO) serves as the Treasurer of the Masimo Foundation and the Company’s EVP, General Counsel and Corporate Secretary serves as the Secretary for the Masimo Foundation. During each of the three months ended March 30, 2024 and April 1, 2023, the Company made cash contributions of approximately $1.0 million to the Masimo Foundation. During each of the three months ended March 30, 2024 and April 1, 2023, the Company made various in-kind contributions to the Masimo Foundation, mainly in the form of donated administrative services.
The Company’s CEO is also a co-founder and a member of the board of directors of Like Minded Media Ventures (LMMV), a team of storytellers that create content focused in the areas of true stories, social causes and science. LMMV creates stories with a multi-platform strategy, bridging the gap between film, television, digital and social media. The Company entered into a marketing service agreement with LMMV for audiovisual production services promoting brand awareness, including television commercials and digital advertising, during the second quarter of 2020. During each of the three months ended March 30, 2024, and April 1, 2023, the Company incurred no marketing expenses to LMMV under the marketing service agreement. At each of March 30, 2024 and December 30, 2023, there were no amounts due to LMMV for services rendered.
During the second quarter of 2021, the Company entered into a software license and professional services agreement with Like Minded Labs (LML), a subsidiary of LMMV. Pursuant to the software license agreement, LML granted the Company a perpetual, non-exclusive and fully paid-up right and license to integrate LML’s software into the Company’s products in exchange for a $3.0 million one-time license fee. Pursuant to the professional services agreement, LML will provide professional services to the Company, including the development of custom software intended to support the integration of the licensed software into the Company’s products, as well as future support services upon the Company’s acceptance of deliverables.
In July 2021, the Company entered into a patent purchase and option agreement with Vantrix Corporation (Vantrix), an acquiree of LML, for certain patents for $0.5 million, and the right to purchase two pools of additional patents from Vantrix for an exercise fee of up to $1.1 million. The agreements with LML and Vantrix include sublicensing provisions whereby the software and patents are licensed back to LML or Vantrix, respectively, for further advancement of the technologies.
The Company maintains an aircraft time share agreement, pursuant to which the Company has agreed from time to time to make its aircraft available to the Company’s CEO for lease on a time-sharing basis. The Company charges the Company’s CEO for personal use based on agreed upon reimbursement rates. For the three months ended March 30, 2024, the Company’s CEO did not incur charges pursuant to this agreement. For the three months ended April 1, 2023, the Company charged the Company’s CEO less than $0.1 million pursuant to this agreement.
XML 22 R11.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Inventories
 3 Months Ended
Mar. 30, 2024
Inventory Disclosure [Abstract]  
Inventories
4. Inventories
Inventories consist of the following:
(in millions)March 30,
2024		December 30,
2023
Raw materials$232.6 $229.7 
Work-in-process29.3 30.0 
Finished goods244.2 285.3 
     Total inventories$506.1 $545.0 
XML 23 R12.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Other Current Assets
 3 Months Ended
Mar. 30, 2024
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]  
Other Current Assets
5. Other Current Assets
Other current assets consist of the following:
(in millions)March 30,
2024		December 30,
2023
Prepaid expenses$53.1 $58.3 
Lease receivable, current29.7 30.2 
Prepaid income taxes27.7 29.3 
Indirect taxes receivable23.1 28.6 
Other receivables10.3 6.8 
Contract assets, current7.2 6.7 
Prepaid rebates and royalties, current5.0 4.8 
Restricted cash(1)
3.0 3.0 
Other current assets0.7 0.7 
     Total other current assets$159.8 $168.4 
______________
(1)     Restricted cash includes funds received from the Bill and Melinda Gates Foundation. As the Company incurs costs associated with research and development related to this project, on a quarterly basis, the Company reclasses amounts from the grant to offset costs incurred.
XML 24 R13.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Lease Receivable
 3 Months Ended
Mar. 30, 2024
Leases [Abstract]  
Lease Receivable
6. Lease Receivable
For deferred equipment agreements that contain embedded operating leases, upon lease commencement, the Company defers and records the equipment cost of operating lease assets within property, plant and equipment, net of accumulated depreciation. These operating lease assets are subsequently amortized to cost of goods sold over the lease term on a straight-line basis.
For deferred equipment agreements that contain embedded sales-type leases, the Company recognizes lease revenue and costs, as well as a lease receivable, at the time the lease commences. Lease revenue related to both operating-type and sales-type leases are included within revenue in the accompanying condensed consolidated statements of operations. For the three months ended March 30, 2024 and April 1, 2023, lease revenue was approximately $16.0 million and $20.0 million, respectively. Costs related to embedded leases within the Company’s deferred equipment agreements are included in cost of goods sold in the accompanying condensed consolidated statements of operations.
Lease receivable from sales-type leases consists of the following:
(in millions)March 30,
2024		December 30,
2023
Lease receivable$100.3 $101.9 
Allowance for credit loss(0.3)(0.3)
     Lease receivable, net100.0 101.6 
Less: current portion of lease receivable(29.7)(30.2)
     Lease receivable, non-current$70.3 $71.4 
As of March 30, 2024, estimated future maturities of customer sales-type lease receivables and operating lease payments for each of the following fiscal years are as follows:
Future Lease Receivables/Payments
(in millions)
Fiscal yearSales-Type LeasesOperating Leases
2024 (balance of year)$22.9 $8.5 
202525.7 10.2 
202619.8 9.4 
202714.4 7.8 
20288.0 5.6 
Thereafter9.2 9.1 
     Total$100.0 $50.6 
Less: imputed interest(1)
— 
     Present value of total lease payments$100.0 
______________
(1)     The calculation of the rates implicit in the leases resulted in negative discount rates. Therefore, the Company as a lessor used a 0% discount rate to measure the net investment in the lease.
XML 25 R14.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Deferred Costs and Other Contract Assets
 3 Months Ended
Mar. 30, 2024
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]  
Deferred Costs and Other Contract Assets
7. Deferred Costs and Other Contract Assets
Deferred costs and other contract assets consist of the following:
(in millions)March 30,
2024		December 30,
2023
Deferred commissions$21.3 $21.8 
Unbilled contract receivables18.8 17.0 
Prepaid contract allowances16.2 17.0 
Deferred equipment agreements, net1.6 1.5 
     Deferred costs and other contract assets$57.9 $57.3 
XML 26 R15.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Property and Equipment, net
 3 Months Ended
Mar. 30, 2024
Property, Plant and Equipment [Abstract]  
Property and Equipment, net
8. Property and Equipment, net
Property and equipment, net, consists of the following:
(in millions)March 30,
2024		December 30,
2023
Machinery, equipment and tooling$173.1 $169.7 
Building and building improvements150.5 151.0 
Operating lease assets108.1 92.2 
Land(1)
54.6 66.2 
Computer equipment and software45.4 45.5 
Leasehold improvements39.6 37.5 
Transportation, vehicles and other33.5 34.0 
Furniture and office equipment18.7 20.4 
Demonstration units11.3 11.1 
Construction-in-progress (CIP)58.0 59.2 
     Total property and equipment692.8 686.8 
Accumulated depreciation(277.8)(262.4)
     Property and equipment, net(1)
$415.0 $424.4 
______________
(1)    At March 30, 2024, property, plant and equipment, net, excluded $11.4 million of idle undeveloped land classified as held for sale within the healthcare segment. The sale of land is expected to be completed within the earlier of the next 12 months or upon the closing of customary escrow and due diligence procedures. Any gain on the sale of land transaction will be recorded at the time of disposal.
For the three months ended March 30, 2024 and April 1, 2023, depreciation expense of property and equipment was $10.5 million and $11.8 million, respectively.
For the three months ended March 30, 2024 and April 1, 2023, $6.4 million and $3.0 million of equipment leased to customers was amortized to cost of goods sold, respectively. As of March 30, 2024 and December 30, 2023, accumulated amortization of equipment leased to customers was $0.4 million and $1.5 million, respectively.
The balance in CIP at March 30, 2024 and December 30, 2023 related primarily to the capitalized implementation costs related to a new enterprise resource planning software system, costs related to facility improvements, the expansion of certain key manufacturing facilities globally, machinery and equipment at the Company’s corporate headquarters, as well as on-going development costs associated with a new research and development facility, the underlying assets for which have not been completed or placed into service.
On February 14, 2022, the Company’s wholly owned subsidiary, Masimo Canada ULC, entered into a Purchase and Sale Agreement (Purchase Agreement) with Keltic (Prior) Development Limited Partnership (Vendor) for the purchase of a property in Vancouver, British Columbia, Canada for a purchase price of CAD123.0 million, plus GST (Purchase Price), subject to certain adjustments. The Company paid CAD21.0 million as a deposit towards the purchase during the year ended December 31, 2022. The balance of the Purchase Price will be due and payable upon the closing of the transaction, which is currently expected to occur in mid-2025.
XML 27 R16.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Intangible Assets, net
 3 Months Ended
Mar. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangible Assets, net
9. Intangible Assets, net
Intangible assets, net, consist of the following:
March 30,
2024		December 30,
2023
(in millions)Gross Carrying
Amount		Accumulated
Amortization		Net Carrying
Amount		Gross Carrying
Amount		Accumulated
Amortization		Net Carrying
Amount
Intangible assets subject to amortization:
Customer relationships$184.4 $(15.1)$169.3 $209.2 $(31.5)$177.7 
Acquired technologies138.5 (18.6)119.9 174.7 (45.3)129.4 
Licenses45.3 (5.0)40.3 39.7 (7.4)32.3 
Capitalized software development costs48.7 (6.9)41.8 53.9 (15.2)38.7 
Patents40.8 (15.8)25.0 39.2 (15.2)24.0 
Trademarks19.1 (6.8)12.3 20.1 (7.4)12.7 
Non-compete agreements3.8 (0.4)3.4 6.3 (2.6)3.7 
Licenses-related party7.5 (6.8)0.7 7.5 (6.7)0.8 
Other1.6 (1.1)0.5 1.7 (1.1)0.6 
Total intangible assets subject to amortization, net$489.7 $(76.5)$413.2 $552.3 $(132.4)$419.9 
Intangible assets not subject to amortization:
Trademarks$222.7 $242.4 
Impairment charge— (10.0)
Total trademarks222.7 232.4 
Intangible assets, net$635.9 $652.3 
Finite lived intangible assets have a weighted-average amortization period ranging from twelve years to fourteen years. Total amortization expense for the three months ended March 30, 2024 and April 1, 2023 was $13.8 million and $14.3 million, respectively.
Total renewal costs for patents and trademarks for each of the three months ended March 30, 2024 and April 1, 2023 were $0.3 million. As of March 30, 2024, the weighted-average number of years until the next renewal was two years for patents and six years for trademarks.
Estimated amortization expense for each of the next fiscal years is as follows:
Fiscal yearAmount
(in millions)
2024 (balance of year)$44.8 
202556.1 
202644.7 
202743.3 
202843.0 
Thereafter181.3 
     Total$413.2 
Indefinite-lived intangible assets are subject to annual impairment testing, unless circumstances dictate more frequent testing, if impairment indicators exist.
In the third quarter of 2023, declines in the Company’s stock price and certain worsening macro-economic market conditions, including continued slowing in demand for consumer audio products, contributed to a significant decline in the Company’s market capitalization, which led the Company to conclude a trigger event had occurred. As a result, the Company performed a quantitative impairment assessment, which resulted in recording a $7.0 million impairment charge for indefinite-lived trademarks in the non-healthcare reporting unit. In conjunction with this third quarter interim impairment quantitative assessment, the Company concluded that both the healthcare reporting unit’s and non-healthcare reporting unit’s respective estimated fair values exceeded their carrying values. Furthermore, recoverability tests performed for other long-lived assets with finite lives indicated no recoverability issues.
During the fourth quarter of 2023, the Company performed its annual impairment analysis by first electing to complete a qualitative assessment of its indefinite-lived intangible assets. Based on this assessment, the Company determined it was not more likely than not that the fair value of the indefinite lived intangibles within the non-healthcare reporting unit exceeded their carrying values. Accordingly, the Company proceeded to perform a quantitative impairment assessment, which resulted in recording a $3.0 million impairment charge for indefinite-lived trademarks. For purposes of the impairment test, the fair value of indefinite-lived assets were determined using the same methodology as described in Note 18, “Business Combinations.” The estimates and assumptions applied represent a Level 3 measurement because they are supported by limited or no market activity and reflect the Company’s assumptions in measuring fair value.
During the fourth quarter of 2023, the Company also performed its annual goodwill impairment analysis by first electing to complete a qualitative assessment for its healthcare and non-healthcare reporting units. Based on this assessment, the Company concluded that it was more likely than not that the fair value of the healthcare reporting unit was greater than its carrying value. Accordingly, no further testing was required for the healthcare reporting unit. However, the Company concluded that it was not more likely than not that the fair value of the non-healthcare reporting unit was greater than its carrying value. Therefore, the Company proceeded to perform a quantitative assessment for its non-healthcare reporting unit.
When a quantitative assessment is required for the impairment test for goodwill, the Company uses a combination of both an income and a market approach to determine the fair value of the reporting unit. The income approach utilized the estimated discounted cash flows for the reporting unit, while the market approach utilized comparable company information. Estimates and assumptions used in the income approach to calculate projected future discounted cash flows included revenue growth rates, operating margins and a discount rate for the reporting unit. Discount rates were determined using a weighted average cost of capital for risk factors specific to the reporting unit and other market and industry data. The assumptions used are inherently subject to uncertainty and the Company noted that slight changes in these assumptions could have a significant impact on the concluded value.
The estimates and assumptions applied represent a Level 3 measurement because they are supported by limited or no market activity and reflect the Company’s assumptions in measuring fair value.
XML 28 R17.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Goodwill
 3 Months Ended
Mar. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill
10. Goodwill
Changes in goodwill were as follows:
Three Months Ended
March 30, 2024
(in millions)HealthcareNon-healthcareTotal
Goodwill, beginning of period$98.6 $309.1 $407.7 
Foreign currency translation adjustment(1.0)(10.7)(11.7)
Goodwill, end of period$97.6 $298.4 $396.0 
XML 29 R18.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Lessee ROU Assets and Lease Liabilities
 3 Months Ended
Mar. 30, 2024
Leases [Abstract]  
Lessee ROU Assets and Lease Liabilities
11. Lessee ROU Assets and Lease Liabilities
The Company leases certain facilities in North and South America, Europe, the Middle East and Asia-Pacific regions under operating lease agreements expiring at various dates through January 2032. In addition, the Company leases equipment in the U.S. and Europe pursuant to leases that are classified as operating leases and expire at various dates through November 2028. The majority of these leases are non-cancellable and generally do not contain any material restrictive covenants, material residual value guarantees, or other material guarantees. The Company recognizes lease costs under these agreements using a straight-line method based on total lease payments. Certain facility leases contain predetermined price escalations and in some cases renewal options, the longest of which is for five years.
The Company generally estimates the applicable discount rate used to determine the net present value of lease payments based on available information at the lease commencement date. As of March 30, 2024, the weighted-average discount rate used by the Company for all operating leases was approximately 4.2%.
The balance sheet classifications for amounts related to the Company’s operating leases for which it is the lessee are as follows:
(in millions)Balance sheet classificationMarch 30,
2024		December 30,
2023
Lessee ROU assetsOther non-current assets$75.1 $59.1 
Lessee current lease liabilitiesOther current liabilities19.3 18.2 
Lessee non-current lease liabilitiesOther non-current liabilities61.5 45.8 
     Total operating lease liabilities$80.8 $64.0 
As of March 30, 2024 and December 30, 2023, accumulated amortization for lessee ROU assets was $53.8 million and $48.9 million, respectively. The weighted-average remaining lease term for the Company’s operating leases was 5.4 years as of March 30, 2024.
As of March 30, 2024, estimated future operating lease payments for each of the following fiscal years were as follows:
Fiscal yearAmount
(in millions)
2024 (balance of year)$16.9 
202519.9 
202615.6 
202711.1 
202810.4 
Thereafter(1)
18.8 
   Total92.7 
   Imputed interest(11.9)
   Present value$80.8 
______________
(1)     Includes optional renewal period for certain leases.
During the three months ended March 30, 2024 and April 1, 2023, operating lease costs were approximately $5.8 million and $5.1 million, respectively.
During the three months ended March 30, 2024, as part of the Company’s on-going rationalization of its operational footprint of the non-healthcare business, one operating lease was identified as under-utilized and considered temporarily idled due to the inability to sublease the property timely while having three years remaining on the lease term. The ROU asset had a net carrying value of approximately $5.8 million and the undiscounted future expected cash flows total $1.5 million. The recoverability test failed due to the undiscounted cash flows being less than the carrying value of the ROU asset. As a result, the Company recorded an impairment charge of approximately $3.9 million during the three months ended March 30, 2024, which was recorded in selling, general, and administrative expenses in the condensed consolidated statement of operations.
XML 30 R19.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Other Non-Current Assets
 3 Months Ended
Mar. 30, 2024
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]  
Other Non-Current Assets
12. Other Non-Current Assets
Other non-current assets consist of the following:
(in millions)March 30,
2024		December 30,
2023
Lessee ROU assets, net$75.1 $59.1 
Derivative assets - non-current(1)
14.3 11.4 
Prepaid deposits and other7.5 6.4 
Strategic investments6.9 7.2 
Restricted cash(2)
3.4 2.2 
Equity investments - fair value2.6 2.7 
Other non-current assets0.1 0.3 
  Total non-current assets$109.9 $89.3 
______________
(1)    Excludes accrued interest.
(2)    Restricted cash includes cash held in certain subsidiaries in jurisdictions outside of the U.S. such as China, which may be subject to transfer restrictions depending on jurisdictions.
XML 31 R20.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Deferred Revenue and Other Contract Liabilities, Current
 3 Months Ended
Mar. 30, 2024
Revenue Recognition and Deferred Revenue [Abstract]  
Deferred Revenue and Other Contract Liabilities, Current
13. Deferred Revenue and Other Contract Liabilities, Current
Deferred revenue and other contract liabilities, current, consist of the following:
(in millions)March 30,
2024		December 30,
2023
Deferred revenue$63.1 $63.8 
Accrued rebates and allowances23.0 37.5 
Accrued customer reimbursements10.3 12.4 
     Total deferred revenue and other contract liabilities96.4 113.7 
Less: Non-current portion of deferred revenue(26.4)(26.4)
     Deferred revenue and other contract liabilities, current$70.0 $87.3 
Deferred revenue relates to contracted amounts that have been invoiced to customers for which remaining performance obligations must be completed before the Company can recognize revenue. Generally, both healthcare and non-healthcare segments record deferred revenue when revenue is to be recognized subsequent to invoicing.
Healthcare Deferred Revenue
Healthcare deferred revenue primarily relates to undelivered equipment, sensors and services under deferred equipment agreements, extended warranty agreements, and maintenance agreements. Expected revenue from remaining contractual performance obligations (Unrecognized Contract Revenue) includes deferred revenue, as well as other amounts that will be invoiced and recognized as revenue in future periods when the Company completes its performance obligations. Unrecognized Contract Revenue excludes revenue allocable to monitoring-related equipment that is effectively leased to customers under deferred equipment agreements and other contractual obligations for which neither party has performed. The estimated timing of this revenue is based, in part, on management’s estimates and assumptions about when its performance obligations will be completed. As a result, the actual timing of this revenue in future periods may vary, possibly materially. As of March 30, 2024, the Company had approximately $1,508.3 million of Unrecognized Contract Revenue related to executed contracts with an original duration of one year or more. The Company expects to recognize approximately $395.8 million of this amount as revenue within the next twelve months and the remaining balance thereafter.
Non-Healthcare Deferred Revenue
In October 2020, the Company’s subsidiary, B&W Group Ltd. (B&W), entered into an amendment to a licensing agreement, whereby B&W received a $20.0 million royalty prepayment in relation to sound system units manufactured under the Bowers & Wilkins brand for various high-end car manufacturers with a total commitment of $35.0 million to be received by September 30, 2028. As of March 30, 2024, deferred revenue was $14.6 million.
Changes in deferred revenue were as follows:
(in millions)Three Months Ended
March 30,
2024
Deferred revenue, beginning of the period$63.8 
  Revenue deferred during the period8.4 
  Recognition of revenue deferred in prior periods(9.1)
     Deferred revenue, end of the period$63.1 
XML 32 R21.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Other Current Liabilities
 3 Months Ended
Mar. 30, 2024
Accrued Liabilities [Abstract]  
Other Current Liabilities
14. Other Current Liabilities
Other current liabilities consist of the following:
(in millions)March 30,
2024		December 30,
2023
Long-term debt, current$34.6 $34.3 
Accrued indirect taxes payable29.1 23.9 
Accrued expenses27.6 26.3 
Lessee lease liabilities, current 19.3 18.2 
Income tax payable10.5 16.1 
Other current liabilities(1)
9.6 6.7 
Accrued property taxes9.4 10.2 
Accrued warranty8.1 8.6 
Accrued legal fees7.7 9.9 
Related party payables5.0 4.2 
Accrued donations2.0 4.0 
Licensing agreement, current3.0 — 
     Total other current liabilities$165.9 $162.4 
__________________
(1)    At March 30, 2024, other current liabilities included approximately $0.5 million of refundable deposits during the due diligence period related to certain assets held for sale.
XML 33 R22.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Debt
 3 Months Ended
Mar. 30, 2024
Debt Disclosure [Abstract]  
Debt
15. Debt
(in millions)March 30,
2024		December 30,
2023
Term loan - current portion$13.1 $11.3 
Japanese loans - current portion21.5 23.0 
Debt, current portion34.6 34.3 
Term loan - long-term268.1 271.4 
Revolver - long-term565.5 591.5 
Japanese loans - long-term7.8 8.8 
Debt, long-term841.4 871.7 
Total debt$876.0 $906.0 
Credit Facility
On April 11, 2022, the Company entered into a credit agreement (Credit Facility) with financial institutions party thereto as initial lenders (collectively, the Initial Lenders), Citibank, N.A., as Administrative Agent, Citibank, N.A., JPMorgan Chase Bank, N.A., Bank of the West and BofA Securities, Inc., as joint lead arrangers and joint bookrunners, and JPMorgan Chase Bank, N.A., Bank of the West and BofA Securities, Inc., as co-syndication agents.
The Credit Facility provides for an unsecured term loan of $300.0 million (Term Loan) and $500.0 million of ongoing unsecured revolving commitments (Revolver), with an option, subject to certain conditions, for the Company to increase the aggregate borrowing capacity by an additional $400.0 million (plus additional unlimited amounts if certain incurrence tests are met) in the future with the Initial Lenders and additional lenders, as required. Debt issuance costs of $8.4 million were recorded as a reduction to the carrying amount of the Credit Facility and are being amortized to interest expense using the effective interest method.
The Credit Facility also provides for a sublimit of up to $50.0 million for the issuance of letters of credit.
Borrowings under the Credit Facility will be deemed, at the Company’s election, either: (a) an Alternate Base Rate (ABR) Loan, which bears interest at the ABR, plus a spread of 0.000% to 0.750% based upon a Company leverage ratio, or (b) a Term SOFR Loan, which bears interest at the Adjusted Term SOFR Rate (as defined below), plus a spread of 1.000% to 1.750% based upon a Company net leverage ratio. Pursuant to the terms of the Credit Facility, the ABR is equal to the greatest of (i) the prime rate, (ii) the Federal Reserve Bank of New York effective rate plus 0.50%, and (iii) the one-month Adjusted Term SOFR plus 1.0%. The Adjusted Term SOFR Rate is equal to the Term SOFR Rate (as defined in the Credit Facility) for the applicable interest period plus a spread adjustment of 0.10%, 0.15% and 0.25% for the interest periods ending one, three and six months, respectively.
The Company is also obligated under the Credit Facility to pay an unused fee ranging from 0.150% to 0.275% per annum, based upon a Company leverage ratio, with respect to any non-utilized portion of the Credit Facility.
The Company is subject to certain covenants, including financial covenants related to a net leverage ratio and an interest charge coverage ratio, and other customary negative covenants. The Credit Facility also includes customary events of default which, upon the occurrence of any such event of default, provide the Initial Lenders (and any additional lenders) with the right to take either or both of the following actions: (a) immediately terminate the commitments, and (b) declare the loans then outstanding immediately due and payable in full. All unpaid principal under the Credit Facility will become due and payable on April 12, 2027.
On May 16, 2022, the Company entered into the First Amendment to the Credit Agreement (First Amendment) with the Initial Lenders and Citibank, N.A., as the administrative agent, which amended the Credit Facility. The First Amendment provides for an additional $205 million of unsecured revolving commitments, increasing the aggregate amount of the Revolver from $500 million to $705 million.
Borrowing rates, financial covenants, affirmative and negative covenants and other restricted terms remain unchanged from the Credit Facility. All unpaid principal under the First Amendment will become due and payable on April 12, 2027. The Company was in full compliance with all covenants contained in its debt agreements and Credit Facility agreements as of March 30, 2024.
For the three months ended March 30, 2024 and April 1, 2023, the Company incurred total interest expense of $11.2 million and $10.9 million under the Credit Facility, respectively.
Furthermore, in connection with the Sound United acquisition, the Company assumed three outstanding loans as follows:
Japanese Revolving Loan
In March 2020, the Company entered into a secured revolving loan (Japanese Revolving Loan) with Mizuho bank, which allows the Company to borrow up to ¥800 million (approximately $5.3 million). The Japanese Revolving Loan is an evergreen agreement that terminates upon request by either the financial institution or the borrower and is collateralized with land and buildings in Shirakawa-Shi owned by the borrower. Interest accrues at a rate equal to the Mizuho Tokyo Interbank Offered Rate (TIBOR) plus a fixed spread of 0.50% per annum. In connection with the execution of the Japanese Revolving Loan, the Company incurred debt issuance costs of ¥7.2 million (approximately $0.05 million).
On February 28, 2023, the Company and Mizuho Bank executed an amendment to the Japanese Revolving Loan, to increase the maximum aggregate revolving loan to ¥3.00 billion (approximately $19.8 million). Under the amendment, the facility accrues interest at a rate equal to the TIBOR plus a fixed spread of 0.75% per annum. The Company also paid an upfront fee of ¥22.0 million (approximately $0.1 million) on the incremental amount of the revolving Credit Facility.
The Japanese Revolving Loan agreement contains customary affirmative and negative covenants, such as financial reporting requirements and customary covenants that restrict the borrower’s ability to, among other things, provide collateral for obligations borne by the borrower, and determine the eligibility to declare, and amount of potential dividends to be paid during a given fiscal year. As of March 30, 2024, the Company was in compliance with all covenants under the Japanese Revolving Loan agreements.
Japanese Government Loans
In May and June 2020, the Company received ¥1.48 billion (approximately $9.8 million) in non-collateralized Japanese Government Loan facilities (Japanese Government Loans) as part of its local Japanese stimulus program. Interest accrues at a weighted average rate of 1.33% and is repayable in installments with various maturities through June 2035. The non-current portion of the Japanese Government Loans is presented under long-term debt and the current portion is presented under short-term debt on the accompanying condensed consolidated balance sheets. The Company incurred no debt issuance costs in connection with the Japanese Government Loans.
Japanese Equipment Loans
In April and May 2021, the Company entered into collateralized Japanese Equipment Loans of ¥150 million (approximately $1.0 million), payable in installments through March 2031 with an interest of 0.58%, and ¥80 million (approximately $0.5 million) payable in installments through April 2028 with interest of 1.2%. The non-current portion of the Japanese Equipment Loans is presented under long-term debt and the current portion is presented under short-term debt on the accompanying condensed consolidated balance sheets. The Company incurred no debt issuance costs in connection with these Japanese Equipment Loans.
As of March 30, 2024, the aggregate maturities of principal on all debt for each of the next five years and thereafter are as follows:
Fiscal yearAmount
(in millions)
2024 (balance of year)$30.5 
202516.6 
202616.6 
2027809.0 
20281.0 
Thereafter2.3 
Total$876.0 
XML 34 R23.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Other Non-Current Liabilities
 3 Months Ended
Mar. 30, 2024
Other Liabilities Disclosure [Abstract]  
Other Non-Current Liabilities
16. Other Non-Current Liabilities
Other non-current liabilities consist of the following:
(in millions)March 30,
2024		December 30,
2023
Lessee non-current lease liabilities$61.5 $45.8 
Unrecognized tax benefits26.8 24.4 
Deferred revenue, non-current26.4 26.4 
Projected benefit obligation9.2 9.5 
Income tax payable, non-current7.1 7.1 
Licensing agreement, non-current
4.5 — 
Indirect tax payable, non-current— 8.4 
Other4.5 7.9 
     Total other non-current liabilities$140.0 $129.5 
Unrecognized tax benefits relate to the Company’s long-term portion of tax liability associated with uncertain tax positions. Authoritative guidance prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. See Note 23, “Income Taxes”, for further details.
XML 35 R24.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Derivative Instruments and Hedging Activities
 3 Months Ended
Mar. 30, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Derivative Instruments and Hedging Activities
17. Derivative Instruments and Hedging Activities
Derivative Instruments - Cash Flow Hedges
The Company’s cash flow hedges are designed to mitigate the risk of exposure to variability in expected future cash flows of recognized assets, liabilities or any unrecognized forecasted transactions. Since July 2022, the Company has entered into various interest rate swaps that are designated as cash flow hedges on a substantial portion of the Company’s outstanding debt. The interest rate swaps reduce the variability of cash flow payments for the Company by converting the variable interest rate on the Company’s long-term debt to an average fixed interest rate of 3.22%. These contracts, carried at fair value, have maturities of approximately three years. All hedging relationships were highly effective at achieving offsetting changes in cash flows attributable to the risk being hedged. The Company used a regression analysis at hedge inception to assess the effectiveness of cash flow hedge and periodically thereafter.
The Company records gains and losses from the changes in the fair value of these instruments as a component of other comprehensive (loss) income. Deferred gains or losses from these designated cash flow hedges are reclassified into earnings in the period that the hedged items affect earnings. The Company does not offset fair value amounts recognized for derivative instruments in its condensed consolidated balance sheets for presentation purposes. The following table summarizes the fair value of the hedging instruments, presented on a gross basis, as of March 30, 2024 and December 30, 2023.
Condensed Consolidated
Balance Sheets
(in millions)Balance sheet classificationMarch 30,
2024		December 30,
2023
Interest rate contracts, inclusive of accrued interest
Other non-current assets
$14.4 $11.6 
Interest rate contracts, inclusive of accrued interest
Other non-current liabilities
— (3.6)
Total$14.4 $8.0 
The following table summarizes the gains (losses) reclassified from accumulated other comprehensive (loss) income to the condensed consolidated financial statements for the three months ended March 30, 2024 and April 1, 2023.
Cash flow hedgesCondensed Consolidated
Statement of Operations
Three Months Ended
(in millions)Location of gains (losses)March 30,
2024		April 1,
2023
Interest rate contracts
Non-operating (loss)
$(4.3)$(3.0)
Total$(4.3)$(3.0)
The following tables summarize the changes in accumulated other comprehensive income (loss) related to the hedging instruments for the three months and three months ended March 30, 2024 and April 1, 2023.
Three Months Ended
(in millions)March 30,
2024		April 1,
2023
Beginning balance$7.8 $19.3 
Amount recognized in other comprehensive income (loss)
10.8 (2.7)
Amount reclassified into earnings(4.3)(3.0)
Ending balance$14.3 $13.6 
For the three months ended March 30, 2024, the unrealized gain, net of tax was $4.9 million. For the three months ended April 1, 2023, the unrealized loss, net of tax was $4.3 million.
The Company expects to reclassify a net amount of gains of $11.8 million from accumulated other comprehensive (loss) income to non-operating (loss) income within the next 12 months.
XML 36 R25.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Business Combinations
 3 Months Ended
Mar. 30, 2024
Business Combination and Asset Acquisition [Abstract]  
Business Combinations
18. Business Combinations
Sound United Acquisition
On April 11, 2022, the Company completed the previously announced acquisition of Sound United, pursuant to a Merger Agreement dated as of February 15, 2022, by and among the Company, Sonic Boom Acquisition Corp., a wholly-owned subsidiary of the Company (Merger Sub), Viper Holdings Corporation (Sound United), and, solely in its capacity as the Seller Representative, Viper Holdings, LLC, pursuant to which Merger Sub merged with and into Sound United, with Sound United continuing as a wholly-owned subsidiary of the Company (Merger).
Sound United is a leading innovator of premium, high-performance audio products for consumers around the world, which operates iconic consumer brands: Bowers & Wilkins®, Denon™, Marantz™, HEOS™, Classé™, Polk Audio™, Boston Acoustics™ and Definitive Technology™. The brands are linked by a commitment to the highest production standards and a focus on unparalleled audio quality and audio performance. Sound United delivers significant competitive benefits through its platform advantages including global distribution across online, retail, and custom installation channels; a cloud-connected home ecosystem; and a state-of-the-art research and development function focused on creating the highest-quality consumer products with world-class industrial design.
The Company acquired 100% of the equity interests of Sound United for $1.0575 billion in cash, subject to adjustments based on Sound United’s net working capital, transaction expenses, cash and debt as of the closing of the Merger, payable by the Company in cash. The transaction was primarily funded with the proceeds from the Credit Facility. See Note 15, “Debt”, for additional information about the Credit Facility. There was no contingent consideration resulting from the transaction.
The results of operations of Sound United subsequent to the acquisition date and the acquired assets and assumed liabilities, including the allocation of goodwill and intangible assets, are included in the non-healthcare segment. For the three months ended April 1, 2023, the Company recorded revenue of $216.6 million and a net loss of $3.3 million from Sound United, respectively. For the three months ended March 30, 2024, the Company recorded revenue of $152.4 million and a net loss of $11.6 million from Sound United, respectively.
Acquisition Costs
The Company recognized no transaction costs related to the Sound United acquisition for the three months ended March 30, 2024 and April 1, 2023, respectively.
Purchase Price Allocations
The purchase price allocation for the Sound United acquisition is final. Goodwill was calculated as the excess of the consideration transferred over the fair value of the identifiable net assets acquired in a business combination and represents the future economic benefits expected to arise from intangible assets acquired that do not qualify for separate recognition, including the assembled workforce. Goodwill is not expected to be deductible for tax purposes.
The measurement period adjustments resulted primarily from valuation inputs pertaining to certain acquired assets based on facts and circumstances that existed as of the acquisition date and did not result from events subsequent to the acquisition date.
The table below summarizes the final allocation of fair value of assets acquired and liabilities assumed.
(in millions)Sound United
Cash consideration
$1,057.5 
Purchase price$1,057.5 
Assets acquired:
Cash and cash equivalents$82.6 
Accounts receivables108.5 
Inventories238.6 
Prepaid expenses and other current assets30.0 
Property, plant and equipment113.2 
Intangible assets
649.0 
Goodwill
318.0 
Long-term other assets7.4 
Total assets acquired$1,547.3 
Liabilities assumed:
Accounts payable$(118.8)
Accrued liabilities and other current liabilities(148.9)
Deferred tax liabilities(145.1)
Other long-term liabilities(77.0)
Total liabilities assumed$(489.8)
Identifiable Intangible Assets
The following table sets forth the components of identifiable intangible assets acquired and the weighted average amortization period as of the acquisition date:
Weighted average
amortization period
(in years)		April 11,
 2022
(in millions)
Trademarks/tradenames10$6.0 
Customer relationships17196.0 
Developed technology8156.0 
Contractual license agreements1529.0 
Subtotal14 years$387.0 
Indefinite trademarks/tradenamesN/A262.0 
Total$649.0 
In determining the fair value of the identifiable intangible assets, the Company utilized various forms of the income approach, depending on the asset being valued. The estimation of fair value requires significant judgment related to cash flow forecasts, discount rates reflecting the risk inherent in each cash flow stream, competitive trends, market comparables and other factors. Other inputs included historical data, current and anticipated market conditions, and growth rates. Contractual license agreements have a weighted-average amortization period of five years until the next renewal term.
The intangible assets were valued using the following valuation approaches:
Customer relationships
The fair value of customer relationships was determined using the multi-period excess earnings method. The multi-period excess earnings method involves forecasting the net earnings expected to be generated by the asset, reducing them by appropriate returns on contributory assets, and then discounting the resulting net cash flows to a present value using an appropriate discount rate.
Trademarks/tradenames
The fair values of the trademark/tradenames were determined using the relief-from-royalty method under the income approach. This involves forecasting avoided royalties, reducing them by taxes, and discounting the resulting net cash flows to a present value using an appropriate discount rate. Judgment was applied for a number of assumptions in valuing the identified intangible assets, including revenue and cash flow forecasts, survival rates, technology life, royalty rate, obsolescence and discount rate.
Developed technology
The fair values of the developed technology were determined using the relief-from-royalty method under the income approach. This involves forecasting avoided royalties, reducing them by taxes, and discounting the resulting net cash flows to a present value using an appropriate discount rate. Judgment was applied for a number of assumptions in valuing the identified intangible assets including revenue and cash flow forecasts, survival rates, technology life, royalty rate, obsolescence and discount rate.
Contractual licensing agreements
The fair value of the contractual license agreements was determined using a variation of the multi-period excess earnings method. This method involves forecasting the net earnings expected to be generated by the asset and then discounting the resulting net cash flows to a present value using an appropriate discount rate.
XML 37 R26.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Equity
 3 Months Ended
Mar. 30, 2024
Equity [Abstract]  
Equity
19. Equity
Series A Junior Participating Preferred Stock and Stockholder Rights Plan
In September 2022, the Company authorized and declared a dividend of one preferred stock purchase right (Right) for each outstanding share of its common stock to stockholders of record at the close of business on September 20, 2022 (the Record Date) pursuant to a Rights Agreement, dated as of September 9, 2022 (Rights Agreement), with Broadridge Corporate Issuer Solutions, Inc. as Rights Agent. In addition, one Right was issued with each share of common stock that became outstanding after the Record Date. Each Right entitled the registered holder to purchase from the Company one thousandth of one share of the Company’s Series A junior participating preferred stock, par value $0.001 per share, at a purchase price equal to $1,000.00 per Right, subject to adjustment. Generally, the Rights were to become exercisable in the event any person or group of affiliated or associated persons acquires beneficial ownership of 10% (20% in the case of a passive institutional investor), subject to certain exceptions.
On March 22, 2023, the Company and the Rights Agent entered into an amendment (Rights Agreement Amendment) to the Rights Agreement. The Rights Agreement Amendment accelerated the expiration of the Rights to 5:00 P.M., New York time, on March 22, 2023, and the Rights Agreement terminated at such time. At the time of the termination of the Rights Agreement, all Rights distributed to holders of the Company’s common stock pursuant to the Rights Agreement expired.
Stock Repurchase Program
In June 2022, the Board approved a stock repurchase program, authorizing the Company to purchase up to 5.0 million shares of its common stock on or before December 31, 2027 (2022 Repurchase Program). The 2022 Repurchase Program became effective in July 2022. The Company expects to fund the 2022 Repurchase Program through its available cash, cash expected to be generated from future operations, the Credit Facility and other potential sources of capital. The 2022 Repurchase Program can be carried out at the discretion of a committee comprised of the Company’s CEO and CFO through open market purchases, one or more Rule 10b5-1 trading plans, block trades and privately negotiated transactions. No shares were repurchased pursuant to the 2022 Repurchase Program during the three months ended March 30, 2024. As of March 30, 2024, 5.0 million shares remained available for repurchase pursuant to the 2022 Repurchase Program.
XML 38 R27.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Stock-Based Compensation
 3 Months Ended
Mar. 30, 2024
Share-Based Payment Arrangement [Abstract]  
Stock-Based Compensation
20. Stock-Based Compensation
Total stock-based compensation expense for the three months ended March 30, 2024 and April 1, 2023 was $9.6 million and $7.3 million, respectively. The stock-based compensation expense amounts for the three months ended March 30, 2024 reflect adjustments for the expected life-to-date achievement of certain PSUs. The Company reassesses the expected achievement of such PSU awards based upon the achievement of certain pre-established multi-year performance criteria approved by the Board at the date of grant.
As of March 30, 2024, an aggregate of 9.7 million shares of common stock were reserved for future issuance under the Company’s equity plans, of which 3.1 million shares were available for future grant under the Masimo Corporation 2017 Equity Incentive Plan (2017 Equity Plan). Additional information related to the Company’s current equity incentive plans, stock-based award activity and valuation of stock-based awards is included below.
Equity Incentive Plans
2017 Equity Incentive Plan
On June 1, 2017, the Company’s stockholders ratified and approved the 2017 Equity Plan. The 2017 Equity Plan permits the grant of stock options, restricted stock, RSUs, stock appreciation rights, PSUs, performance shares, performance bonus awards and other stock or cash awards to employees, directors and consultants of the Company and employees and consultants of any parent or subsidiary of the Company. Upon effectiveness, an aggregate of 5.0 million shares were available for issuance under the 2017 Equity Plan. In May 2020, the Company’s stockholders approved an increase of 2.5 million shares to the 2017 Equity Plan. The aggregate number of shares that may be awarded under the 2017 Equity Plan is 7.5 million shares. The 2017 Equity Plan provides that at least 95% of the equity awards issued under the 2017 Equity Plan must vest over a period of not less than one year following the date of grant. The exercise price per share of each option granted under the 2017 Equity Plan may not be less than the fair market value of a share of the Company’s common stock on the date of grant, which is generally equal to the closing price of the Company’s common stock on the Nasdaq Global Select Market on the grant date.
2007 Stock Incentive Plan
Effective June 1, 2017, upon the approval and ratification of the 2017 Equity Plan, the Company’s 2007 Stock Incentive Plan (2007 Equity Plan) terminated, provided that awards outstanding under the 2007 Equity Plan will continue to be governed by the terms of that plan. In addition, upon the effectiveness of the 2017 Equity Plan, an aggregate of 5.0 million shares of the Company’s common stock registered under prior registration statements for issuance pursuant to the 2007 Equity Plan were deregistered and concurrently registered under the 2017 Equity Plan.
Stock-Based Award Activity
Stock Options
The number and weighted-average exercise price of options issued and outstanding under all of the Company’s equity plans are as follows:
Three Months Ended
March 30, 2024
(in millions, except for weighted-average exercise prices)
SharesWeighted-Average
Exercise Price
Options outstanding, beginning of period2.8 $87.79 
Granted0.1 126.49 
Canceled— 162.00 
Exercised(0.2)44.11 
Options outstanding, end of period2.7 $91.51 
Options exercisable, end of period2.3 $80.43 
Total stock option expense for the three months ended March 30, 2024 and April 1, 2023 was $2.1 million and $2.4 million, respectively. As of March 30, 2024, the Company had $19.6 million of unrecognized compensation cost related to non-vested stock options that are expected to vest over a weighted-average period of approximately 3.1 years.
RSUs
The number of RSUs issued and outstanding under all of the Company’s equity plans are as follows:
Three Months Ended
March 30, 2024
(in millions, except for weighted-average grant date fair value amounts)
UnitsWeighted-Average Grant
 Date Fair Value
RSUs outstanding, beginning of period3.5 $105.87 
Granted0.2 126.36 
Expired— 157.76 
Vested(0.1)178.68 
RSUs outstanding, end of period3.6 $104.94 
Total RSU expense for the three months ended March 30, 2024 and April 1, 2023 was $7.2 million and $4.2 million, respectively. As of March 30, 2024, the Company had $106.4 million of unrecognized compensation cost related to non-vested RSU awards expected to be recognized and vest over a weighted-average period of approximately 3.7 years.
PSUs
The number of PSUs outstanding under all of the Company’s equity plans are as follows:
Three Months Ended
March 30, 2024
(in millions, except for weighted-average grant date fair value amounts)UnitsWeighted-Average Grant
 Date Fair Value
PSUs outstanding, beginning of period0.3 $190.04 
Granted(1)
0.1 164.19 
Expired— 250.73 
Vested— 250.73 
PSUs outstanding, end of period0.4 $170.69 
______________
(1)     On February 28, 2024, the Audit Committee approved the weighted payout percentage of 28% for the 2021 PSU awards (three-year performance period), which were based upon the actual fiscal 2023 performance against pre-established performance objectives. Included in the granted amount are those additional PSUs earned based on actual performance achieved. These PSUs were originally awarded at target.
During the three months ended March 30, 2024, the Company awarded 155,156 PSUs that will vest three years from the award date, based on the achievement of certain pre-established multi-year performance criteria approved by the Board. Estimates of stock-based compensation expense for an award with performance conditions are based on the probable outcome of the performance conditions and the cumulative effect of any changes in the probability outcomes is recorded in the period in which the changes occur. If earned, the PSUs granted will vest upon achievement of the performance criteria, which include a relative total shareholder return (TSR) component, in the year following the evaluation and confirmation of the performance achievement criteria. The Company’s TSR is based on the Company’s common stock percentile ranking relative to the constituents of the Nasdaq Composite Index for the performance period beginning on January 1, 2024 and ending on December 31, 2026. The number of shares that may be earned can range from 0% to 200% of the target amount. The fair value of market-based RSUs is determined using a Monte Carlo simulation model, which uses multiple input variables to determine the probability of satisfying the market condition requirements. The fair value of performance-based PSUs is determined using the closing price of the Company’s common stock on the grant date. Based on management’s estimate of the number of units expected to vest, total PSU expense for the three months ended March 30, 2024 and April 1, 2023 was $0.3 million and $0.7 million, respectively. The PSU expense amounts for the three months ended March 30, 2024 relate to adjustments for the expected life-to-date performance of the PSU. As of March 30, 2024, the Company had $40.4 million of unrecognized compensation cost related to non-vested PSU awards expected to be recognized and vest over a weighted-average period of approximately 1.9 years.
Valuation of Stock-Based Award Activity
The fair value of each RSU and PSU is determined based on the closing price of the Company’s common stock on the grant date.
The Black-Scholes option pricing model is used to estimate the fair value of options granted under the Company’s stock-based compensation plans. The range of assumptions used and the resulting weighted-average fair value of options granted at the date of grant were as follows:
Three Months Ended
March 30,
2024
April 1,
2023
Risk-free interest rate4.2%4.2%
Expected term (in years)5.95.9
Estimated volatility42.6%36.7%
Expected dividends—%—%
Weighted-average fair value of options granted$59.60$75.08
The aggregate intrinsic value of options is calculated as the positive difference, if any, between the market value of the Company’s common stock on the date of exercise or the respective period end, as appropriate, and the exercise price of the options. The aggregate intrinsic value of options outstanding with an exercise price less than the closing price of the Company’s common stock as of March 30, 2024 was $169.8 million. The aggregate intrinsic value of options exercisable with an exercise price less than the closing price of the Company’s common stock as of March 30, 2024 was $167.4 million.
XML 39 R28.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Employee Benefits
 3 Months Ended
Mar. 30, 2024
Postemployment Benefits [Abstract]  
Employee Benefits
21. Employee Benefits
Defined Contribution Plans
In the U.S. the Company sponsors one qualified defined contribution plan or 401(k) plan, the Masimo Retirement Savings Plan (MRSP), covering the Company’s full-time U.S. employees who meet certain eligibility requirements. On April 11, 2022, in connection with the Sound United acquisition, the MRSP was amended to allow for participation by eligible Sound United employees.
The MRSP matches 100% of a participant’s salary deferral, up to 3% of each participant’s compensation for the pay period, subject to a maximum amount. The Company may also contribute to the MRSP on a discretionary basis. The Company contributed $1.3 million and $2.3 million to the MRSP for the three months ended March 30, 2024 and April 1, 2023, respectively, all in the form of matching contributions.
In addition, some of the Company’s international subsidiaries also have defined contribution plans to which both the employee and employers are eligible to make contributions. The Company contributed $1.6 million and $0.8 million to these plans for the three months ended March 30, 2024 and April 1, 2023, respectively.
Defined Benefit Plans
The Company sponsors several international noncontributory defined benefit plans. In connection with the Sound United acquisition, the Company assumed sponsorship of several international defined benefit plans and post-retirement benefit plans. All defined benefit plans and post-retirement benefit plans assumed by the Company were closed to new participants prior to the Sound United acquisition.
The service cost component for the defined benefit plans are recorded in operating expenses in the condensed consolidated statement of operations. All other cost components are recorded in other income (expense), net in the condensed consolidated statement of operations.
The Company’s net periodic defined benefit costs for each of the three months ended March 30, 2024, and April 1, 2023 were immaterial.
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Non-operating Loss
 3 Months Ended
Mar. 30, 2024
Nonoperating Income (Expense) [Abstract]  
Non-operating Loss
22. Non-operating Loss
Non-operating loss consists of the following:
Three Months Ended
(in millions)March 30,
2024		April 1,
2023
Realized and unrealized foreign currency gains (losses)1.9 (0.7)
Interest income$1.2 $0.8 
Interest expense(12.0)(11.9)
Other(0.2)— 
Total non-operating loss$(9.1)$(11.8)
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Income Taxes
 3 Months Ended
Mar. 30, 2024
Income Tax Disclosure [Abstract]  
Income Taxes
23. Income Taxes
The Company has provided for income taxes in fiscal year 2024 interim periods based on the estimated effective income tax rate for the complete fiscal year, as adjusted for discrete tax events, including excess tax benefits or deficiencies related to stock-based compensation, in the period such events occur. The estimated annual effective tax rate is computed based on the expected annual pretax income of the consolidated entities located within each taxing jurisdiction based on legislation enacted as of the balance sheet date. For the three months ended March 30, 2024 and April 1, 2023, the Company recorded discrete tax benefits of approximately $1.3 million and $2.4 million, respectively, related to excess tax benefits realized from stock-based compensation.
Deferred tax assets and liabilities are determined based on the future tax consequences associated with temporary differences between income and expenses reported for accounting and tax purposes. A valuation allowance for deferred tax assets is recorded to the extent that the Company cannot determine that the ultimate realization of the net deferred tax assets is more likely than not. Realization of deferred tax assets is principally dependent upon the achievement of future taxable income, the estimation of which requires significant judgment by the Company’s management. The judgment of the Company’s management regarding future profitability may change due to many factors, including future market conditions and the Company’s ability to successfully execute its business plans or tax planning strategies. These changes, if any, may require material adjustments to these deferred tax asset balances.
As of March 30, 2024, the liability for income taxes associated with uncertain tax positions was approximately $35.3 million. If fully recognized, approximately $32.7 million (net of federal benefit on state taxes) would impact the Company’s effective tax rate. It is reasonably possible that the amount of unrecognized tax benefits in various jurisdictions may change in the next twelve months due to the expiration of statutes of limitation and audit settlements. However, due to the uncertainty surrounding the timing of these events, an estimate of the change within the next twelve months cannot currently be made.
The Company conducts business in multiple jurisdictions and, as a result, one or more of the Company’s subsidiaries files income tax returns in U.S. federal, various state, local and foreign jurisdictions. The Company has concluded all U.S. federal income tax matters through fiscal year 2019. All material state, local and foreign income tax matters have been concluded through fiscal year 2016. The Company does not believe that the results of any tax authority examination would have a significant impact on its consolidated financial statements.
XML 42 R31.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Commitments and Contingencies
 3 Months Ended
Mar. 30, 2024
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies
24. Commitments and Contingencies
Employment and Severance Agreements
In July 2017, the Company entered into the First Amendment to that certain Amended and Restated Employment Agreement entered into between the Company and Mr. Kiani on November 4, 2015 (as amended, the Amended Employment Agreement). Pursuant to the terms of the Amended Employment Agreement, upon a “Qualifying Termination” (as defined in the Amended Employment Agreement), Mr. Kiani will be entitled to receive a cash severance benefit equal to two times the sum of his then-current base salary and the average annual bonus paid to Mr. Kiani during the immediately preceding three years, the full amount of the “Award Shares” (as defined in the Amended Employment Agreement) and the full amount of the “Cash Payment” (as defined in the Amended Employment Agreement). In addition, in the event of a “Change-in-Control” (as defined in the Amended Employment Agreement) prior to a Qualifying Termination, on each of the first and second anniversaries of the Change-in-Control, 50% of the Cash Payment and 50% of the Award Shares will vest, subject in each case to Mr. Kiani’s continuous employment through each such anniversary date; however, in the event of a Qualifying Termination or a termination of Mr. Kiani’s employment due to death or disability prior to either of such anniversaries, any unvested amount of the Cash Payment and all of the unvested Award Shares shall vest and be paid in full. Additionally, in the event of a Change-in-Control prior to a Qualifying Termination, Mr. Kiani’s stock options and any other equity awards will vest in accordance with their terms, but in no event later than in two equal installments on each of the one year and two year anniversaries of the Change-in- Control, subject in each case to Mr. Kiani’s continuous employment through each such anniversary date.
On January 14, 2022, the Company entered into the Second Amendment to the Amended Employment Agreement (Second Amendment) with Mr. Kiani. The Second Amendment provides that the RSUs granted to Mr. Kiani pursuant to the Amended Employment Agreement will vest in full upon the termination of Mr. Kiani’s employment with the Company pursuant to Mr. Kiani’s death or disability.
On February 8, 2023, Mr. Kiani agreed that the valid election to the Company’s Board of Directors (Board) at the Company’s 2023 Annual Meeting of Stockholders (2023 Annual Meeting) of any two individuals nominated by the Company’s stockholders in lieu of two of the Company’s then-current Board members would not be deemed to constitute a “Change in Control” for purposes of Section 9(iii) of the Amended Employment Agreement.
On March 22, 2023, in connection with the Board’s unanimous selection of H Michael Cohen as Lead Independent Director, Mr. Kiani voluntarily irrevocably and permanently waived his right to treat the appointment of any lead independent director as “Good Reason”, to terminate his employment under the Amended Employment Agreement, and his right to receive contractual separation payments on this basis.
On June 5, 2023, Mr. Kiani, pursuant to a Limited Waiver (Waiver), unconditionally, irrevocably and permanently waived his right, pursuant to the Amended Employment Agreement, to assert that a “Change in Control” has occurred pursuant to Section 9(iii) of the Amended Employment Agreement unless the individuals who constituted the Board at the beginning of the twelve (12) month period immediately preceding such change, as defined in Section 9(iii) of the Amended Employment Agreement, cease for any reason to constitute one-half or more of the directors then in office. In addition, Mr. Kiani agreed that, for purposes of determining whether such a “Change in Control” has occurred, any individual elected to the Board at the Company’s 2023 Annual Meeting will be treated as a member of the Board at the beginning of the twelve (12) month period.
As a result of Mr. Kiani’s execution of the Waiver on June 5, 2023, which waived certain of the “Change in Control” provisions in the Amended Employment Agreement, the Company remeasured the expense related to the Award Shares and Cash Payment that would be recognized in the Company’s condensed consolidated financial statements upon the occurrence of a Qualifying Termination under the Amended Employment Agreement, as amended by the Second Amendment, and the expense was determined to be approximately $479.7 million.
As of March 30, 2024, the Company had severance plan participation agreements with six executive officers. The participation agreements (the Agreements) are governed by the terms and conditions of the Company’s 2007 Severance Protection Plan (the Severance Plan), which became effective on July 19, 2007 and which was amended effective December 31, 2008.
Under each of the Agreements, the applicable executive officer may be entitled to receive certain salary, equity, medical and life insurance benefits if he is terminated by the Company without cause or if he terminates his employment for good reason under certain circumstances. Each executive officer is also required to give the Company six months’ advance notice of his resignation under certain circumstances.
Willow Cross-Licensing Agreement Provisions
The Company’s Cross-Licensing Agreement with Willow contains annual minimum aggregate royalty obligations for use of the rainbow® licensed technology. The current annual minimum royalty obligation is $5.0 million. Upon a change in control (as defined in the Willow Licensing Agreement) of the Company or Willow: (i) all rights to the “Masimo” trademark will be assigned to Willow if the surviving or acquiring entity ceases to use “Masimo” as a company name and trademark; (ii) the option to license technology developed by Willow for use in blood glucose monitoring will be deemed automatically exercised and a $2.5 million license fee for this technology will become immediately payable to Willow; and (iii) the minimum aggregate annual royalties payable to Willow for carbon monoxide, methemoglobin, fractional arterial oxygen saturation, hemoglobin and/or glucose measurements will increase to $15.0 million per year until the exclusivity period of the agreement ends, plus up to $2.0 million for each additional vital sign measurement with no maximum ceiling for non-vital sign measurements.
Purchase Commitments
Pursuant to contractual obligations with vendors, the Company had $267.2 million of purchase commitments as of March 30, 2024 that are expected to be purchased within one year. These purchase commitments have been made for certain inventory items in order to secure sufficient levels of those items, other critical inventory and manufacturing supplies, and to achieve better pricing.
Other Contractual Commitments
In the normal course of business, the Company may provide bank guarantees to support government hospital tenders in certain foreign jurisdictions. As of March 30, 2024, the Company had approximately $5.1 million in outstanding unsecured bank guarantees.
In certain circumstances, the Company also provides limited indemnification within its various customer contracts whereby the Company indemnifies the parties to whom it sells its products with respect to potential infringement of intellectual property, and against bodily injury caused by a defective Company product. It is not possible to predict the maximum potential amount of future payments under these or similar agreements, due to the conditional nature of the Company’s obligations and the unique facts and circumstances involved. As of March 30, 2024, the Company had not incurred any significant costs related to contractual indemnification of its customers.
Fee Agreements
On January 1, 2024, the Company entered into a one year alternative fee agreement (Fee Agreement) with respect to certain on-going legal fees and costs charged by a vendor. The Fee Agreement imposes certain limits on a quarterly and annual basis for actual legal fees incurred by the vendor that are payable based on work performed related to litigation matters against Apple (see Note 24, “Litigation” for further details). If the vendor is successful in obtaining a favorable judgement for the Company on any claim or counterclaim after exhaustion or dismissal of any appeals, or upon settlement resulting in monetary consideration to the Company, the vendor will be paid a success fee equal to three times the amount of the excess of the annual legal fee limit within 60 days after entry of a judgement or the effective date of any settlement. Amounts due to the vendor under this Fee Agreement will be recognized when probable and reasonably estimable.
In connection with the potential separation of the Company’s consumer business, the Company entered into contingent or discretionary fee agreements with various service providers, advisors and consultants. The Company is unable to reasonably estimate the contingent fees due under these agreements at this time. Amounts due will be recognized when probable and reasonably estimable.
Licensing Agreement
On February 1, 2024, the Company entered into a three-year licensing agreement for approximately $9.0 million, plus applicable taxes. As of March 30, 2024, the outstanding obligation under the licensing agreement was $7.5 million, with $3.0 million payable within 12 months.
Concentrations of Risk
The Company is exposed to credit loss for the amount of its cash deposits with financial institutions in excess of federally insured limits. The Company invests a portion of its excess cash with major financial institutions. As of March 30, 2024, the Company had $157.6 million of bank balances, of which $8.1 million was covered by either the U.S. Federal Deposit Insurance Corporation limit or foreign countries’ deposit insurance organizations.
The Company’s ability to sell its healthcare products to U.S. hospitals depends in part on its relationships with GPOs. Many existing and potential healthcare customers for the Company’s products become members of GPOs. GPOs negotiate pricing arrangements and contracts, sometimes exclusively, with medical supply manufacturers and distributors, and these negotiated prices are made available to a GPO’s affiliated hospitals and other members. During the three months ended March 30, 2024 and April 1, 2023, revenue from the sale of the Company’s healthcare products to customers that are members of GPOs approximated 55.7% and 51.0% of healthcare revenue, respectively.
For each of the three months ended March 30, 2024 and April 1, 2023, the Company had sales through one just-in-time healthcare distributor that represented 16.1% and 8.9% of consolidated revenue, respectively.
During the three months ended March 30, 2024 and April 1, 2023, there were no revenue concentrations for the Company’s non-healthcare business.
As of March 30, 2024 and December 30, 2023, one healthcare customer represented 11.3% and 18.1%, respectively, of the Company’s consolidated accounts receivable balance. The receivable balance related to such healthcare customer is fully secured by a letter of credit.
As of March 30, 2024 and December 30, 2023, there were no customer concentration risks associated with the Company’s non-healthcare business.
Litigation
On January 9, 2020, the Company filed a complaint against Apple Inc. (Apple) in the United States District Court for the Central District of California for infringement of a number of patents, for trade secret misappropriation, and for ownership and correction of inventorship of a number of Apple patents listing one of its former employees as an inventor. The Company is seeking damages, injunctive relief, and declaratory judgment regarding ownership of the Apple patents. Apple filed petitions for Inter Partes review (IPR) of the asserted patents in the U.S. Patent and Trademark Office (PTO). The PTO instituted IPR of the asserted patents. On October 13, 2020, the District Court stayed the patent infringement claims pending completion of the IPR proceedings. In the IPR proceedings, one or more of the challenged claims of three of the asserted patents were found valid. The challenged claims of nine of the asserted patents were found invalid. On appeal, the U.S. Court of Appeals for the Federal Circuit affirmed all the IPR decisions except it reversed a finding of invalidity for certain dependent claims of one Masimo patent. From April 4, 2023 through May 1, 2023, the District Court held a jury trial on the trade secret, ownership, and inventorship claims. The District Court granted Apple’s motion for judgment as a matter of law on certain trade secrets and denied the remainder of Apple’s motion. On May 1, 2023, the District Court declared a mistrial because the jury was unable to reach a unanimous verdict. The stay of the patent infringement claims has been lifted and the District Court scheduled a trial on all remaining claims beginning on November 5, 2024.
On June 30, 2021, the Company filed a complaint with the U.S. International Trade Commission (ITC) against Apple for infringement of a number of other patents. The Company filed an amended complaint on July 12, 2021. On August 13, 2021, the ITC issued a Notice of Institution of Investigation on the asserted patents. From June 6, 2022 to June 10, 2022, the ITC conducted an evidentiary hearing. In July and August 2022, Apple filed petitions for IPR of the asserted patents in the PTO. On January 10, 2023, a United States Administrative Law Judge in Washington, D.C. ruled that Apple violated Section 337 of the Tariff Act of 1930 (Section 337), as amended, by importing and selling within the United States certain Apple Watches with light-based pulse oximetry functionality and components, which infringe one of the Company’s pulse oximeter patents. On January 24, 2023, the United States Administrative Law Judge further recommended that the ITC issue an exclusion order and a cease and desist order on certain Apple Watches. On October 26, 2023, the ITC issued a Notice of Final Determination finding a violation of Section 337 by Apple. The ITC determined that the appropriate form of relief is a Limited Exclusion Order (LEO) prohibiting the unlicensed entry of infringing wearable electronic devices with light-based pulse oximetry functionality manufactured by or on behalf of Apple, and a Cease and Desist Order (CDO). The LEO and CDO went into effect after the 60-day Presidential review period expired. The LEO and CDO are currently in effect. Apple’s appeal to the Federal Circuit is pending. On January 30, 2023, the PTO denied institution of IPR proceedings for the Company’s pulse oximeter patents that the ITC ruled were infringed. With respect to the other patents asserted at the ITC, the PTO denied institution of IPR proceedings for two patents and instituted IPR proceedings for two patents in January and February 2023. In the IPR proceedings, one or more of the challenged claims were found valid, while others were found invalid. The time period for the appeal is pending.
On October 20, 2022, Apple filed two complaints against the Company in the U.S. District Court for the District of Delaware alleging that the Masimo W1™ watch infringes six utility and four design patents. Apple is seeking damages and injunctive relief. On December 12, 2022, the Company counterclaimed for monopolization, attempted monopolization, false advertising (and related causes of action) and infringement of ten patents. The Company is seeking damages and injunctive relief. On May 5, 2023, the Court ordered that the two cases be coordinated through the pre-trial stage. The Court held a case management conference in March 2024, but has not yet issued an order to address the scope of claims and counterclaims for trial or to set a trial date. The Company intends to vigorously pursue all of its claims against Apple and believes the Company has good and substantial defenses to Apple’s claims, but there is no guarantee that the Company will be successful in these efforts.
On August 22, 2023, a putative class action complaint was filed by Sergio Vazquez against the Company and members of its management alleging violations of the federal securities laws. On November 14, 2023, the court appointed Boston Retirement System, Central Pennsylvania Teamsters Pension Fund-Defined Benefit Plan, and Central Pennsylvania Teamsters Pension Fund-Retirement Income Plan 1987 as lead plaintiffs. The lead plaintiffs filed an amended complaint on February 12, 2024. The amended complaint alleges that the Company and members of its management, from May 4, 2022 through August 8, 2023, disseminated materially false and misleading statements and/or concealed material adverse facts relating to the performance of its healthcare business and the success of the Company’s legacy Sound United business. The Company moved to dismiss the amended complaint on April 29, 2024. Briefing on the motion is scheduled to conclude by July 26, 2024. The Company believes it has good and substantial defenses to the claims in the amended complaint, but there is no guarantee that the Company will be successful in these efforts. The Company is unable to determine whether any loss ultimately will occur or to estimate the range of such loss; therefore, no amount of loss has been accrued by the Company in the accompanying condensed consolidated financial statements.
On May 1, 2024, a purported stockholder, Linda McClellan filed a derivative action in the U.S. District Court for the Southern District of California against certain of the Company’s current and former executives and directors, and the Company as nominal defendant. The complaint alleges, among other things, that the defendants breached their fiduciary duties owed to the Company by allowing or permitting false or misleading statements to be disseminated regarding the performance of the Company’s healthcare business and the success of the Company’s legacy Sound United business. The complaint also asserts causes of action for violations of Section 10(b) of the Securities Exchange Act of 1934 (15 U.S.C.§ 78j(b)) and Rule 10b-5 promulgated thereunder, aiding and abetting breach of fiduciary duty, unjust enrichment, abuse of control, gross mismanagement, and waste of corporate assets. The Company believes it has good and substantial defenses to the claims in the complaint, but there is no guarantee that the Company will be successful in these efforts. The Company is unable to determine whether any loss ultimately will occur or to estimate the range of such loss; therefore, no amount of loss has been accrued by the Company in the accompanying condensed consolidated financial statements.
The Company received a subpoena from the Department of Justice (DOJ) dated February 21, 2024 seeking documents and information related to the Company’s Rad-G® and Rad-97® products, including information relating to complaints surrounding the products and the Company’s decision to recall select Rad-G® products in 2024.
The Company received a civil investigative demand from the DOJ pursuant to the False Claims Act, 31 U.S.C. §§ 3729-3733, dated March 25, 2024, seeking documents and information related to customer returns of the Company’s Rad-G® and Rad-97® products, including returns related to the Company’s recall of select Rad-G® products in 2024.
The Company received a subpoena from the Securities and Exchange Commission dated March 26, 2024 seeking documents and information relating to allegations of potential accounting irregularities and internal control deficiencies from employees within the Company’s accounting department.
With respect to each of the subpoenas and the investigative demand described above, the Company is cooperating with the government and may expend significant financial and managerial resources in connection with responding to the subpoenas and investigative demand and any related investigation or any other future requests for information.
From time to time, the Company may be involved in other litigation and investigations relating to claims and matters arising out of its operations in the normal course of business. The Company believes that it currently is not a party to any other legal proceedings which, individually or in the aggregate, would have a material adverse effect on its consolidated financial position, results of operations or cash flows.
XML 43 R32.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Segment and Enterprise Reporting
 3 Months Ended
Mar. 30, 2024
Segment Reporting [Abstract]  
Segment and Enterprise Reporting
25. Segment and Enterprise Reporting
The Company’s reportable segments are determined based upon the Company’s organizational structure and the way in which the Company’s Chief Operating Decision Maker (CODM), the CEO, makes operating decisions and assesses financial performance. The CODM considered several factors including, but not limited to, customer base, technology, and homogeneity of products. The two segments are:
•Healthcare - develops, manufactures, and markets a variety of noninvasive monitoring technologies and hospital automation solutions and therapeutics. This segment includes the Company’s core legacy hospital business and new Masimo-technology-enabled consumer products that are distributed through many channels including e-commerce sites, leading national retailers and specialty chains globally.
•Non-healthcare - designs, develops, manufactures, markets and sells a broad portfolio of premium, high-performance audio products and services.
Income from operations for each segment includes all geographic revenues, related cost of net revenues and operating expenses directly attributable to the segment. The Company uses gross profit, as presented in the Company’s financial reports, as the primary measure of segment profitability. The Company uses the same accounting policies to generate segment results as the Company does for consolidated results. Segment information presented herein reflects the impact of these changes for all periods presented. For the three months ended March 30, 2024, intercompany revenues between the Healthcare and Non-healthcare segments were $0.6 million. For the three months ended April 1, 2023, there was no intercompany revenue between healthcare and non-healthcare. All inter-segment transactions and balances are eliminated in consolidation for all periods presented below.
Selected information by reportable segment is presented below for each of the three months ended March 30, 2024 and April 1, 2023:
Three Months Ended
(in millions)March 30,
2024		April 1,
2023
Revenues by segment:
Healthcare$339.6 $346.7 
Non-healthcare153.2 218.3 
Total revenue by segment$492.8 $565.0 
Gross profit:
Healthcare$211.4 $214.8 
Non-healthcare44.5 77.8 
Other(1)
(14.2)(7.8)
Gross profit$241.7 $284.8 
____________________________
(1)     Management excludes certain corporate expenses from segment gross profit. In addition, certain amounts that management considers to be non-recurring or non-operational are excluded from segment gross profit because management evaluates the operating results of the segments excluding such items.
The Company’s depreciation and amortization by segment are as follows:
Three Months Ended
(in millions)March 30,
2024		April 1,
2023
Total depreciation and amortization by segment:
Healthcare$10.0 $9.0 
Non-healthcare14.3 17.1 
Total depreciation and amortization by segment$24.3 $26.1 
XML 44 R33.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Pay vs Performance Disclosure - USD ($)
$ in Millions
 3 Months Ended
Mar. 30, 2024
Apr. 01, 2023
Pay vs Performance Disclosure    
Net income $ 18.9 $ 21.3
XML 45 R34.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Insider Trading Arrangements
 3 Months Ended
Mar. 30, 2024
Trading Arrangements, by Individual  
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
XML 46 R35.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Summary of Significant Accounting Policies (Policies)
 3 Months Ended
Mar. 30, 2024
Accounting Policies [Abstract]  
Basis of Presentation
Basis of Presentation
The accompanying unaudited condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (SEC). Certain information and note disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) have been condensed or omitted pursuant to such rules and regulations. The accompanying condensed consolidated financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments, including normal recurring accruals, necessary to present fairly the Company’s condensed consolidated financial statements. The accompanying condensed consolidated balance sheet as of December 30, 2023 was derived from the Company’s audited consolidated financial statements at that date. The accompanying condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes contained in the Company’s Annual Report on Form 10-K for the fiscal year ended December 30, 2023 (fiscal year 2023), filed with the SEC on February 28, 2024. The results for the three months ended March 30, 2024 are not necessarily indicative of the results to be expected for the fiscal year ending December 28, 2024 (fiscal year 2024) or for any other interim period or for any future year.
Fiscal Periods
Fiscal Periods
The Company follows a conventional 52/53 week fiscal year. Under a conventional 52/53 week fiscal year, a 52 week fiscal year includes four quarters of 13 weeks while a 53 week fiscal year includes three 13 week fiscal quarters and one 14 week fiscal quarter. The Company’s last 53 week fiscal year was fiscal year 2020. Fiscal year 2024 is a 52 week fiscal year ending December 28, 2024. All references to years in these notes to condensed consolidated financial statements are fiscal years unless otherwise noted.
Reclassifications
Reclassifications
Certain amounts in the accompanying condensed consolidated financial statements have been reclassified to conform to the current period presentation, including certain balance sheet asset accounts in the consolidated financial statements for the year ended December 30, 2023. There was no impact on previously reported total assets, liabilities, stockholders’ equity or net income.
Use of Estimates
Use of Estimates
The Company prepares its financial statements in conformity with GAAP, which requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Significant estimates include the determination of standalone selling prices, variable consideration, total consideration allocated to each performance obligation within a contract, inventory valuation, valuation of the Company’s equity awards, valuation of identifiable assets and liabilities connected with business combinations, impairment of long-lived assets, intangible assets and goodwill; derivative and equity instruments, deferred taxes and any associated valuation allowances, deferred revenue, accounting for pensions, uncertain income tax positions, litigation costs, and related accruals. See Note 24, “Commitments and Contingencies”. Actual results could differ from such estimates.
Business Combinations
Business Combinations
The Company accounts for business combinations using the acquisition method of accounting in accordance with Accounting Standards Codification (ASC) Topic 805, Business Combinations, which requires that once control is obtained, assets acquired, liabilities assumed and noncontrolling interests in the acquired entity, if applicable, are recorded at their respective fair values at the date of acquisition, with the exception of acquired contract assets and contract liabilities (i.e., deferred revenue) from contracts with customers. These are recognized and measured in accordance with ASC Topic 606, Revenue from Contracts with Customers. The excess of the purchase price over fair values of identifiable assets, liabilities and noncontrolling interests in the acquired entity, if applicable, is recorded as goodwill.
Fair Value Measurements
Fair Value Measurements
The Company accounts for certain financial instruments at their fair values as either assets or liabilities on the balance sheet. The Company determines the fair value of its financial instruments using the framework prescribed by ASC Topic 820, Fair Value Measurements and Disclosures, and considers the estimated amount the Company would receive or pay to transfer these instruments at the reporting date with respect to current currency exchange rates, interest rates, the creditworthiness of the counterparty for unrealized gain positions and the Company’s creditworthiness for unrealized loss positions. In certain instances, the Company may utilize financial models to measure the fair value of its financial instruments. In doing so, the Company uses inputs that include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, other observable inputs for the asset or liability and inputs derived principally from, or corroborated by, observable market data by correlation or other means.
Recurring Fair Value Measurement
On a recurring basis, the Company measures certain financial assets and financial liabilities at fair value based upon quoted market prices. Where quoted market prices or other observable inputs are not available, the Company applies valuation techniques to estimate fair value. Authoritative guidance describes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value:
●    Level 1—Quoted prices in active markets for identical assets or liabilities.
●    Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active; or other inputs that can be corroborated by observable market data for substantially the full term of the assets or liabilities.
●    Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
The following tables represent the Company’s financial assets, measured at fair value on a recurring basis at March 30, 2024:
Total Carrying
Value		Fair Value Measurement Hierarchy
(in millions)Level 1Level 2Level 3
Assets
Cash and cash equivalents$81.9 $81.9 $— $— 
Money market funds75.7 75.7 — — 
Equity securities1.7 1.7 — — 
Pension assets22.9 16.6 6.3 — 
Derivative instruments - cash flow hedges(1)
14.4 — 14.4 — 
Derivative instruments - warrants0.9 0.9 — — 
Total assets$197.5 $176.8 $20.7 $— 
Liabilities
Derivative instruments - cash flow hedges
$— $— $— $— 
Pension benefit obligation32.1 32.1 — — 
Total liabilities$32.1 $32.1 $— $— 
______________
(1)     Includes accrued interest.
The following tables represent the Company’s financial assets, measured at fair value on a recurring basis at December 30, 2023:
Total Carrying
Value		Fair Value Measurement Hierarchy
(in millions)Level 1Level 2Level 3
Assets
Cash and cash equivalents$87.0 $87.0 $— $— 
Money market funds76.0 76.0 — — 
Pension assets
23.1 16.8 6.3 — 
Equity securities1.7 1.7 — — 
Derivative instruments - cash flow hedges(1)
11.6 — 11.6 — 
Derivative instruments - warrants1.0 1.0 — — 
Total assets$200.4 $182.5 $17.9 $— 
Liabilities
Derivative instruments - cash flow hedges$3.6 $3.6 $— $— 
Pension benefit obligation32.6 32.6 — — 
Total liabilities$36.2 $36.2 $— $— 
______________
(1)     Includes accrued interest.
The Company invests in checking, savings and money market fund accounts, which are classified within Level 1 of the fair value hierarchy as they are valued using quoted market prices. These investments are classified as cash and cash equivalents within the Company’s accompanying condensed consolidated balance sheets, in accordance with GAAP and its accounting policies.
The Company has certain strategic investments in privately-held companies (non-marketable equity securities) and companies that have completed initial public offerings (marketable equity securities). The Company’s marketable equity securities, whose price is based on quoted market price in an active market, are classified within Level 1 of the fair value hierarchy. Equity securities are classified as current, short-term investments, or non-current, recorded in other non-current assets, based on the nature of the securities and their availability for use in current operations. The changes in the fair value of those equity securities are measured at each reporting date and changes in the value of these investments between reporting dates are recorded within non-operating loss.
The Company’s pension assets consist of Level 1 and Level 2 investments. The fair value of Level 2 assets is based on observable inputs such as prices or quotes for similar assets, adjusted for any differences in terms or conditions that may affect the value of the instrument being valued. The valuation techniques used for Level 2 assets may include the use of models or other valuation techniques, but these methods are all based on observable market inputs.
The Company also has investments in certain derivative instruments, which are measured at fair value and classified within Level 1 of the fair value hierarchy.
Non-Recurring Fair Value Measurements
For certain other financial assets and liabilities, including restricted cash, accounts receivable, accounts payable and other current assets and liabilities, the carrying amounts approximate their fair value primarily due to the relatively short maturity of these balances. The Company also measures certain non-financial assets at fair value on a non-recurring basis, primarily goodwill, intangible assets and operating lease right-of-use assets, in connection with periodic evaluations for potential impairment.
Furthermore, the Company did not elect to apply the fair value option to specific assets or liabilities on a contract-by-contract basis. The Company did not have any transfers between Level 2 and Level 3 during the three months ended March 30, 2024.
Cash and Cash Equivalents
Cash and Cash Equivalents
The Company considers all highly liquid investments with an original maturity from the date of purchase of three months or less, or highly liquid investments that are readily convertible into known amounts of cash, to be cash equivalents. The Company carries cash and cash equivalents at cost, which approximates fair value, and they are Level 1 under the fair value hierarchy.
Accounts Receivable and Allowance for Credit Losses
Accounts Receivable and Allowance for Credit Losses
Accounts receivable consist of trade receivables recorded at the time of invoicing of product sales, reduced by reserves for estimated bad debts and returns. Trade accounts receivable are recorded at the invoiced amount and do not bear interest. Credit is extended based on an evaluation of the customer’s financial condition. Collateral is generally not required. The Company records an allowance for credit losses that it does not expect to collect based on relevant information, including historical experience, current conditions, and reasonable and supportable forecasts. Accounts are charged off against the allowance when the Company believes they are uncollectible. The allowance for credit losses is measured on a collective (pool) basis when similar risk characteristics exist. Based on the risk characteristics, the Company has identified U.S. and international customers as separate portfolios for both segments, and measures expected credit losses on such receivables using an aging methodology.
Inventories
Inventories
Inventories are stated at the lower of cost or net realizable value. Cost is determined using a standard cost method, which approximates the first in, first out method, and includes material, labor and overhead costs. Inventory valuation adjustments are recorded for inventory items that have become excess or obsolete or are no longer used in current production and for inventory items that have a market price less than the carrying value in inventory. The Company generally determines inventory valuation adjustments based on an evaluation of the expected future use of its inventory on an item by item basis and applies historical obsolescence rates to estimate the loss on inventory expected to have a recovery value below cost. The Company also records other specific inventory valuation adjustments when it becomes aware of unique events or circumstances that result in an expected recovery value below cost. For inventory items that have been written down, the reduced value becomes the new cost basis.
Property and Equipment
Property and Equipment
Property and equipment are stated at cost. Depreciation is calculated using the straight-line method over estimated useful lives as follows:
Useful Lives
Buildings and building improvements
7 to 39 years
Computer equipment and software
2 to 12 years
Demonstration units
2 to 3 years
Furniture and office equipment
2 to 15 years
Leasehold improvementsLesser of useful life or term of lease
Machinery, equipment and tooling
3 to 20 years
Operating lease assetsLesser of useful life or term of lease
Transportation, vehicles and other
1 to 20 years
Land is not depreciated and construction-in-progress is not depreciated until placed in service. Normal repair and maintenance costs are expensed as incurred, whereas significant improvements that materially increase values or extend useful lives are capitalized and depreciated over the remaining estimated useful lives of the related assets. Upon sale or retirement of depreciable assets, the related cost and accumulated depreciation or amortization are removed from the accounts and any gain or loss on the sale or retirement is recognized in income.
Lessee Right-of-Use (ROU) Assets and Lease Liabilities
Lessee Right-of-Use (ROU) Assets and Lease Liabilities
The Company determines if an arrangement contains a lease at inception. ROU assets represent the Company’s right to use an asset underlying an operating lease for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from an operating lease. ROU assets and lease liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. The Company generally estimates the applicable discount rate used to determine the net present value of lease payments based on available information at the lease commencement date. Many of the Company’s lessee agreements include options to extend the lease, which the Company does not include in its lease terms unless they are reasonably certain to be exercised. The Company utilizes a portfolio approach to account for the ROU assets and liabilities associated with certain equipment leases.
The Company has also made an accounting policy election not to separate lease and non-lease components for its real estate leases and to exclude short-term leases with a term of twelve months or less from its ROU assets and lease liabilities. Rental expense for lease payments related to operating leases is recognized on a straight-line basis over the lease term.
Intangible Assets
Intangible Assets
Intangible assets consist primarily of patents, trademarks, software development costs, customer relationships and acquired technology. Costs related to patents and trademarks, which include legal and application fees, are capitalized and amortized over the estimated useful lives using the straight-line method. Patent and trademark amortization commences once final approval of the patent or trademark has been obtained. Patent costs are amortized over the lesser of 10 years or the patent’s remaining legal life, which assumes renewals, and trademark costs are amortized over 17 years, and their associated amortization cost is included in selling, general and administrative expense in the accompanying condensed consolidated statements of operations. For intangibles purchased in an asset acquisition or business combination, which mainly include patents, trademarks, customer relationships and acquired technologies, the useful life is determined largely by valuation estimates of remaining economic life.
The Company’s policy is to renew its patents and trademarks. Costs to renew patents and trademarks are capitalized and amortized over the remaining useful life of the intangible asset. The Company periodically evaluates the amortization period and carrying basis of patents and trademarks to determine whether any events or circumstances warrant a revised estimated useful life or reduction in value. Capitalized application costs are charged to operations when it is determined that the patent or trademark will not be obtained or is abandoned.
Software development costs are accounted for in accordance with ASC Topic 985-20, Software - Costs of Software to be Sold, Leased, or Marketed. Once technological feasibility has been established, qualifying costs incurred in development are capitalized until available for general release to customers, and subsequently reported at the lower of unamortized cost or net realizable value.
Intangibles purchased as part of an asset acquisition or business combination historically have included patents, trademarks, customer relationships, developed technologies and contractual licenses. In certain circumstances the Company has also acquired non-compete agreements tied to certain employment relationships. The useful life for all of these is largely determined by valuation estimates of remaining economic life. In connection with the Sound United acquisition, the Company acquired certain trademarks/tradenames, which are intangible assets with indefinite useful lives. These brands are expected to maintain brand value for an indefinite period of time.
Impairment of Goodwill, Intangible Assets and Other Long-Lived Assets
Impairment of Goodwill, Intangible Assets and Other Long-Lived Assets
Goodwill is recorded as the difference, if any, between the aggregate consideration paid for an acquisition and the fair value of the acquired net tangible and intangible assets. Goodwill is not amortized, but instead is tested annually for impairment, or more frequently when events or changes in circumstances indicate that goodwill might be impaired. In assessing goodwill impairment, the Company has the option to first assess the qualitative factors to determine whether the existence of events or circumstances leads to a determination that it is more likely than not that the fair value of a reporting unit is less than its carrying amount. The Company has two reporting units, healthcare and non-healthcare. The Company’s qualitative assessment of the recoverability of goodwill considers various macro-economic, industry-specific and Company-specific factors, including: (i) severe adverse industry or economic trends; (ii) significant Company-specific actions; (iii) current, historical or projected deterioration of the Company’s financial performance; or (iv) a sustained decrease in the Company’s market capitalization below its net book value. If the qualitative assessment indicates that it is more-likely-than-not that the fair value of a reporting unit is less than its carrying value, or if the Company elects to bypass the qualitative analysis, then the Company performs a quantitative analysis that compares the fair value of the reporting unit with its carrying amount, including goodwill. If the fair value of the reporting unit exceeds its carrying amount, goodwill is not considered impaired; otherwise, a goodwill impairment loss is recognized for the lesser of: (a) the amount that the carrying amount of such reporting unit exceeds its fair value; or (b) the amount of the goodwill allocated to such reporting unit. The annual impairment test is performed during the fourth fiscal quarter.
Similar to goodwill, indefinite-lived intangible assets are not amortized but instead are subject to annual impairment testing, unless circumstances dictate more frequent testing, if impairment indicators exist. Impairment for indefinite-lived assets exists if the carrying value of the indefinite-lived intangible asset exceeds its fair value. Determining whether impairment indicators exist and estimating the fair value of the Company’s indefinite-lived intangible assets if necessary for impairment testing require significant judgment. Qualitative factors considered in this assessment include industry and market conditions, overall financial performance, and other relevant events and factors.
The Company reviews finite lived intangible assets and long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted operating cash flows expected to be generated by the asset. If such asset is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount exceeds the fair value of the asset. Long-lived assets to be disposed of are reported at the lower of carrying amount or fair value less costs to sell.
Employee Defined Benefit Plans
Employee Defined Benefit Plans
The Company maintains noncontributory defined benefit plans that cover certain employees in certain international locations. The Company recognizes the funded status, or the difference between the fair value of plan assets and the projected benefit obligations of the pension plan on the condensed consolidated balance sheet, with a corresponding adjustment to accumulated other comprehensive (loss) income. If the projected benefit obligation exceeds the fair value of plan assets, the difference or underfunded status represents the pension liability. The Company records a net periodic pension cost in the condensed consolidated statement of operations. The liabilities and annual income or expense are determined using methodologies that involve several actuarial assumptions, the most significant of which are the discount rate and the expected long-term rate of asset return. The Company’s accounting policy includes an annual re-measurement of pension assets and obligations. In addition, the Company re-measures pension assets and obligations for significant events, as of the nearest month-end date on the calendar. The fair values of plan assets are determined based on prevailing market prices. See Note 21, “Employee Benefits”, for further details.
Income Taxes
Income Taxes
The Company accounts for income taxes using the asset and liability method, under which the Company recognizes deferred tax assets and liabilities for the future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and for net operating loss and tax credit carryforwards. Tax positions that meet a more-likely-than-not recognition threshold are recognized in the first reporting period that it becomes more-likely-than-not such tax position will be sustained upon examination. A tax position that meets this more-likely-than-not recognition threshold is recorded at the largest amount of tax benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. Previously recognized income tax positions that fail to meet the recognition threshold in a subsequent period are derecognized in that period. Differences between actual results and the Company’s assumptions, or changes in the Company’s assumptions in future periods, are recorded in the period they become known. The Company records potential accrued interest and penalties related to unrecognized tax benefits in income tax expense.
As a multinational corporation, the Company is subject to complex tax laws and regulations in various jurisdictions. The application of tax laws and regulations is subject to legal and factual interpretation, judgment and uncertainty. Tax laws themselves are subject to change as a result of changes in fiscal policy, changes in legislation, evolution of regulations and court rulings. Therefore, the actual liability for U.S. or foreign taxes may be materially different from the Company’s estimates, which could result in the need to record additional liabilities or potentially to reverse previously recorded tax liabilities.
Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that includes the enactment date. A valuation allowance is recorded against any deferred tax assets when, in the judgment of management, it is more likely than not that all or part of a deferred tax asset will not be realized. In assessing the need for a valuation allowance, the Company considers all positive and negative evidence, including recent financial performance, scheduled reversals of temporary differences, projected future taxable income, availability of taxable income in carryback periods and tax planning strategies.
Income taxes are highly susceptible to changes from period to period, requiring management to make assumptions about the Company’s future income over the lives of its deferred tax assets and the impact of changes in valuation allowances. Any difference in the assumptions, judgments and estimates mentioned above could result in changes to the Company’s results of operations.
Revenue Recognition, Deferred Revenue and Other Contract Liabilities
Revenue Recognition, Deferred Revenue and Other Contract Liabilities
The Company generally recognizes revenue following a single, principles-based five-step model to be applied to all contracts with customers and generally provides for the recognition of revenue in an amount that reflects the consideration to which the Company expects to be entitled, net of allowances for estimated returns, discounts or sales incentives, as well as taxes collected from customers that are remitted to government authorities, when control over the promised goods or services are transferred to the customer.
Healthcare segment
While the majority of the Company’s healthcare segment revenue contracts and transactions contain standard business terms and conditions, there are some transactions that contain non-standard business terms and conditions. As a result, contract interpretation, judgment and analysis are required to determine the appropriate accounting, including: (i) the amount of the total consideration, as well as variable consideration, (ii) whether the arrangement contains an embedded lease, and if so, whether such embedded lease is a sales-type lease or an operating lease, (iii) the identification of the distinct performance obligations contained within the arrangement, (iv) how the arrangement consideration should be allocated to each performance obligation when multiple performance obligations exist, including the determination of standalone selling price, and (v) when to recognize revenue on the performance obligations. Changes in judgments on these assumptions and estimates could materially impact the timing of revenue recognition. Revenue from fixed lease payments related to equipment supplied under sales-type lease arrangements is recognized once control over the equipment is transferred to the customer, while revenue from fixed lease payments related to equipment supplied under operating-type lease arrangements is generally recognized on a straight-line basis over the term of the lease and variable lease payments are recognized as they occur.
The Company derives the majority of its healthcare segment revenue from four primary sources: (i) direct sales under deferred equipment agreements with end-user hospitals where the Company provides up-front monitoring equipment at no up-front charge in exchange for a multi-year sensor purchase commitment; (ii) other direct sales of noninvasive monitoring solutions to end-user hospitals, emergency medical response organizations and other direct customers; (iii) sales of noninvasive monitoring solutions to distributors who then typically resell to end-user hospitals, emergency medical response organizations and other customers; and (iv) sales of integrated circuit boards to OEM customers who incorporate the Company’s embedded software technology into their multiparameter monitoring devices. Subject to customer credit considerations, the majority of such sales are made on open accounts using industry standard payment terms based on the geography within which the specific customer is located.
The Company enters into agreements to sell its monitoring solutions and services, sometimes as a part of arrangements with multiple performance obligations that include various combinations of product sales, equipment leases, software and services. In the case of contracts with multiple performance obligations, the authoritative guidance provides that the total consideration be allocated to each performance obligation on the basis of relative standalone selling prices. When a standalone selling price is not readily observable, the Company estimates the standalone selling price by considering multiple factors including, but not limited to, features and functionality of the product, geographies, type of customer, contractual prices pursuant to Group Purchasing Organization (GPO) contracts, the Company’s pricing and discount practices, and other market conditions.
Sales under deferred equipment agreements are generally structured such that the Company agrees to provide certain monitoring-related equipment, software, installation, training and/or warranty support at no up-front charge in exchange for the customer’s commitment to purchase sensors over the term of the agreement, which generally ranges from three years to six years. The Company allocates contract consideration under deferred equipment agreements containing fixed annual sensor purchase commitments to the underlying lease and non-lease components at contract inception. In determining whether any underlying lease components are related to a sales-type lease or an operating lease, the Company evaluates the customer’s rights and ability to control the use of the underlying equipment throughout the contract term, including any equipment substitution rights retained by the Company, as well as the Company’s expectations surrounding potential contract/lease extensions or renewals and the customer’s likelihood to exercise any purchase options. Beginning in 2022, for contracts that contain variable lease payments that are not dependent on an index or rate, the Company classifies as operating leases any lease components that would have otherwise been classified as sales-type leases that would result in a selling loss upon lease commencement. Revenue allocable to non-lease performance obligations is generally recognized as such non-lease performance obligations are satisfied. Revenue allocable to lease components under sales-type lease arrangements is generally recognized when control over the equipment is transferred to the customer. Revenue allocable to lease components under operating lease arrangements is generally recognized over the term of the operating lease. The Company generally does not expect to derive any significant value in excess of such asset’s unamortized book value from equipment underlying its operating lease arrangements after the end of the agreement.
Revenue from the sale of products and software to end-user hospitals, emergency medical response organizations, other direct customers, distributors and OEM customers, is recognized by the Company when control of the performance obligations thereunder transfers to the customer based upon the terms of the contract or underlying purchase order.
Revenue related to OEM rainbow® parameter software licenses is recognized by the Company upon the OEM’s shipment of its product to its customer, as reported to the Company by the OEM.
The Company provides certain customers with various sales incentives that may take the form of discounts or rebates. The Company records estimates related to these programs as a reduction to revenue at the time of sale. In general, customers do not have a right of return for credit or refund. However, the Company allows returns under certain circumstances. At the end of each period, the Company estimates and accrues for these returns as a reduction to revenue. The Company estimates the revenue constraints related to these forms of variable consideration based on various factors, including expected purchasing volumes, prior sales and returns history, and specific contractual terms and limitations.
Non-healthcare segment
Non-healthcare segment revenue is related to hardware and embedded software that is integrated into final products that are manufactured and sold by the Company. Products and related software are accounted for as a single performance obligation and all intended functionality is available to the customer upon purchase. Non-healthcare segment revenue is recognized upon transfer of control of promised products or service to customers, which is either upon shipment or upon delivery to the customers, depending on delivery terms.
The Company offers sales incentives and has customer programs consisting primarily of discounts and market development fund programs, and records them as contra revenue. Estimates for sales incentives are developed using the most likely amount and are included in the transaction price to the extent that a significant reversal of revenue would not result once the uncertainty is resolved. In developing these estimates, the Company also considers the susceptibility of the incentive to outside influences, the length of time until the uncertainty is resolved and the Company’s experience with similar contracts. Reductions in revenue related to discounts are allocated to products on a relative basis based on their respective standard selling price if there are undelivered products in a contract. Judgement is required to determine the timing and amount of recognition of marketing funds which the Company estimates based on past practice of providing similar funds.
Payment terms and conditions vary among the Company’s distribution channels although terms generally include a requirement of payment within 30 to 60 days of product shipment. Sales made directly to customers from the Company’s website are paid at the time of product shipment. Prior to determining payment terms for each customer, an evaluation of such customer’s credit risk is performed. Contractual allowances are an offset to accounts receivable.
Shipping and Handling Costs and Fees
Shipping and Handling Costs and Fees
All shipping and handling costs are expensed as incurred and are recorded as a component of cost of goods sold in the accompanying condensed consolidated statements of operations. Charges for shipping and handling billed to customers are included as a component of revenue.
Taxes Collected From Customers and Remitted to Governmental Authorities
Taxes Collected From Customers and Remitted to Governmental Authorities
The Company’s policy is to present revenue net of taxes collected from customers and remitted to governmental authorities.
Deferred Costs and Other Contract Assets
Deferred Costs and Other Contract Assets
The costs of monitoring-related equipment provided to customers under operating lease arrangements within the Company’s deferred equipment agreements are generally deferred and amortized to cost of goods sold over the life of the underlying contracts. Some of the Company’s deferred equipment agreements also contain provisions for certain allowances to be made directly to the end-user hospital customer at the inception of the arrangement. These allowances are generally allocated to the lease and non-lease components and recognized as a reduction to revenue as the underlying performance obligations are satisfied.
The Company generally invoices its customers under deferred equipment agreements as sensors are provided to the customer. However, the Company may recognize revenue for certain non-lease performance obligations under deferred equipment agreements with fixed annual commitments at the time such performance obligations are satisfied and prior to the customer being invoiced. When this occurs, the Company records an unbilled contract receivable related to such revenue until the customer has been invoiced pursuant to the terms of the underlying deferred equipment agreement.
The incremental costs of obtaining a contract with a customer are capitalized and deferred if the Company expects such costs to be recoverable over the life of the contract and the contract term is greater than one year. Such deferred costs generally relate to certain incentive sales commissions earned by the Company’s internal sales team in connection with the execution of deferred equipment agreements and are amortized to expense over the expected term of the underlying contract.
The Company recognizes non-healthcare royalty revenue associated with certain prepaid license arrangements. The Company recognizes non-healthcare revenue from the prepaid license arrangements based upon sales-based royalties when a subsequent sale occurs.
Warranty
Warranty
The Company generally provides a warranty against defects in material and workmanship for a period ranging from six months to forty-eight months, depending on the product type. In traditional sales activities, including direct and OEM sales, the Company establishes an accrued liability for the estimated warranty costs at the time of revenue recognition, with a corresponding provision to cost of goods sold. Customers may also purchase extended warranty coverage or service level upgrades separately or as part of a deferred equipment agreement. Revenue related to extended warranty coverage and service level upgrades is generally recognized over the life of the contract, which reasonably approximates the period over which such services will be provided. The related extended warranty and service level upgrade costs are expensed as incurred.
Changes in the product warranty accrual were as follows:
Three Months Ended
(in millions)March 30,
2024		April 1,
2023
Product warranty accrual, beginning of period$8.6 $10.6 
Accrual for warranties issued3.1 3.8 
Changes in pre-existing warranties (including changes in estimates)0.4 (3.5)
Settlements made(4.0)(0.7)
Product warranty accrual, end of period$8.1 $10.2 
Advertising Costs
Advertising Costs
Advertising costs include certain advertising, marketing and endorsement licensing fee agreements. Advertising and marketing costs are expensed as incurred. Licensing fees associated with product endorsers are expensed on a straight-line basis over the term of the agreement. Advertising costs are included in selling, general and administrative expense in the accompanying condensed consolidated statements of operations. Advertising costs for the three months ended March 30, 2024 and April 1, 2023 were $11.9 million and $14.4 million, respectively.
Litigation Costs and Contingencies
Litigation Costs and Contingencies
The Company records a charge equal to at least the minimum estimated liability for a loss contingency or litigation settlement when both of the following conditions are met: (i) information available prior to issuance of the financial statements indicates that it is probable that a liability had been incurred at the date of the financial statements, and (ii) the range of loss can be reasonably estimated. The determination of whether a loss contingency, litigation settlement or contingent fee is probable or reasonably possible involves a significant amount of management judgment, as does the estimation of the range of loss given the nature of contingencies or any associated contingent fees related to a settlement of a legal matter. Liabilities related to litigation settlements with multiple elements are recorded based on the fair value of each element. Legal and other litigation related expenses are recognized as the services are provided. Contingent legal fee expenses are recognized when probable and reasonably estimable. The Company records insurance and other indemnity recoveries for litigation expenses when both of the following conditions are met: (a) the recovery is probable, and (b) collectability is reasonably assured. Insurance recoveries are only recorded to the extent the litigation costs to which they relate have been incurred and recognized in the financial statements.
Foreign Currency Translation
Foreign Currency Translation
The Company’s international headquarters is in Switzerland, and its functional currency is the U.S. Dollar. The Company has many other foreign subsidiaries, and the largest transactions in foreign currency translations occur in the Japanese Yen, the British Pound, the Chinese Yuan and the European Euro.
The Company records certain revenues and expenses in foreign currencies. These revenues and expenses are translated into U.S. Dollars based on the average exchange rate for the reporting period. Assets and liabilities denominated in foreign currencies are translated into U.S. Dollars at the exchange rate in effect as of the balance sheet date. Translation gains and losses related to foreign currency assets and liabilities of a subsidiary that are denominated in the functional currency of such subsidiary are included as a component of accumulated other comprehensive (loss) income within the accompanying condensed consolidated balance sheets. Realized and unrealized foreign currency gains and losses related to foreign currency assets and liabilities of the Company, or a subsidiary that are not denominated in the underlying functional currency are included as a component of non-operating (loss) income within the accompanying condensed consolidated statements of operations.
Derivatives Instruments and Hedging Activities
Derivatives Instruments and Hedging Activities
The Company addresses market risk from changes in interest rates risks through risk management programs, which include the use of derivative instruments. The Company’s exposure to a counterparty’s credit risk is generally limited to the amounts of the net obligation to the counterparty. The Company established policies to enter into contracts only with major investment-grade financial institutions to mitigate such counterparty credit risk. The Company also established a policy to further monitor the counterparty risks throughout the life of the instruments. None of the derivative instruments currently held by the Company were entered into for speculative trading purposes.
All derivative financial instruments are recognized as either assets or liabilities at fair value in the condensed consolidated balance sheets and are classified as short-term or long-term based on the tenor of the instrument. The Company has elected not to separate a derivative instrument into current and long-term portions. A derivative instrument whose fair value is a net liability is classified as current in total. A derivative instrument whose fair value is a net asset and whose current portion is an asset is classified as non-current in total. For a derivative instrument that meets the criteria to qualify for hedge accounting, the Company marks the fair value of the derivative instrument to market periodically through other comprehensive (loss) income. When the hedged items are recorded to income (loss), the associated deferred gains (losses) of the derivatives in accumulated other comprehensive (loss) income will be reclassified into earnings. Any fluctuation in the fair value of a derivative instrument that does not meet the criteria for hedge accounting is recorded to earnings (expense) in the period it occurs.
Comprehensive (Loss) Income
Comprehensive (Loss) Income
Comprehensive (loss) income includes foreign currency translation adjustments, changes to pension benefits, unrealized gains (losses) on cash flow hedges and any related tax benefits (expenses) that have been excluded from net income and reflected in stockholders’ equity.
Net Income Per Share
Net Income Per Share
A computation of basic and diluted net income per share is as follows:
Three Months Ended
(in millions, except per share amounts)
March 30,
2024		April 1,
2023
Net income$18.9 $21.3 
Basic net income per share:
Weighted-average shares outstanding - basic53.0 52.6 
Net income per basic share$0.36 $0.40 
Diluted net income per share:
Weighted-average shares outstanding - basic53.0 52.6 
Diluted share equivalents: stock options, RSUs and PSUs1.3 1.8 
Weighted-average shares outstanding - diluted54.2 54.4 
Net income per diluted share$0.35 $0.39 
Basic net income per share is computed by dividing net income by the weighted-average number of shares outstanding during the period. Net income per diluted share is computed by dividing the net income by the weighted-average number of shares and potential shares outstanding during the period, if the effect of potential shares is dilutive. Potential shares include incremental shares of stock issuable upon the exercise of stock options and the vesting of both restricted share units (RSUs) and performance stock units (PSUs). For each of the three months ended March 30, 2024 and April 1, 2023, weighted options to purchase 1.4 million and 1.0 million shares of common stock, respectively, were outstanding but not included in the computation of diluted net income per share because the effect of including such shares would have been antidilutive in the applicable period. Certain RSUs were considered contingently issuable shares as their vesting is contingent upon the occurrence of certain future events. Since such events had not occurred and were not considered probable of occurring as of each of March 30, 2024 and April 1, 2023, 2.7 million weighted-average shares related to such RSUs have been excluded from the calculation of potential shares for the three month periods then ended. For additional information with respect to these RSUs, please see “Employment and Severance Agreements” in Note 24, “Commitments and Contingencies”.
Recently Adopted and Recently Announced Accounting Pronouncements
Recently Adopted and Recently Announced Accounting Pronouncements
There have been no material changes to the accounting policies discussed in Note 2 to the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 30, 2023, filed with the SEC on February 28, 2024. other than the following update:
XML 47 R36.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Summary of Significant Accounting Policies (Tables)
 3 Months Ended
Mar. 30, 2024
Accounting Policies [Abstract]  
Schedule of Fair Value, Assets Measured on Recurring Basis
The following tables represent the Company’s financial assets, measured at fair value on a recurring basis at March 30, 2024:
Total Carrying
Value		Fair Value Measurement Hierarchy
(in millions)Level 1Level 2Level 3
Assets
Cash and cash equivalents$81.9 $81.9 $— $— 
Money market funds75.7 75.7 — — 
Equity securities1.7 1.7 — — 
Pension assets22.9 16.6 6.3 — 
Derivative instruments - cash flow hedges(1)
14.4 — 14.4 — 
Derivative instruments - warrants0.9 0.9 — — 
Total assets$197.5 $176.8 $20.7 $— 
Liabilities
Derivative instruments - cash flow hedges
$— $— $— $— 
Pension benefit obligation32.1 32.1 — — 
Total liabilities$32.1 $32.1 $— $— 
______________
(1)     Includes accrued interest.
The following tables represent the Company’s financial assets, measured at fair value on a recurring basis at December 30, 2023:
Total Carrying
Value		Fair Value Measurement Hierarchy
(in millions)Level 1Level 2Level 3
Assets
Cash and cash equivalents$87.0 $87.0 $— $— 
Money market funds76.0 76.0 — — 
Pension assets
23.1 16.8 6.3 — 
Equity securities1.7 1.7 — — 
Derivative instruments - cash flow hedges(1)
11.6 — 11.6 — 
Derivative instruments - warrants1.0 1.0 — — 
Total assets$200.4 $182.5 $17.9 $— 
Liabilities
Derivative instruments - cash flow hedges$3.6 $3.6 $— $— 
Pension benefit obligation32.6 32.6 — — 
Total liabilities$36.2 $36.2 $— $— 
______________
(1)     Includes accrued interest.
Schedule of Property and Equipment
Property and equipment are stated at cost. Depreciation is calculated using the straight-line method over estimated useful lives as follows:
Useful Lives
Buildings and building improvements
7 to 39 years
Computer equipment and software
2 to 12 years
Demonstration units
2 to 3 years
Furniture and office equipment
2 to 15 years
Leasehold improvementsLesser of useful life or term of lease
Machinery, equipment and tooling
3 to 20 years
Operating lease assetsLesser of useful life or term of lease
Transportation, vehicles and other
1 to 20 years
Property and equipment, net, consists of the following:
(in millions)March 30,
2024		December 30,
2023
Machinery, equipment and tooling$173.1 $169.7 
Building and building improvements150.5 151.0 
Operating lease assets108.1 92.2 
Land(1)
54.6 66.2 
Computer equipment and software45.4 45.5 
Leasehold improvements39.6 37.5 
Transportation, vehicles and other33.5 34.0 
Furniture and office equipment18.7 20.4 
Demonstration units11.3 11.1 
Construction-in-progress (CIP)58.0 59.2 
     Total property and equipment692.8 686.8 
Accumulated depreciation(277.8)(262.4)
     Property and equipment, net(1)
$415.0 $424.4 
______________
(1)    At March 30, 2024, property, plant and equipment, net, excluded $11.4 million of idle undeveloped land classified as held for sale within the healthcare segment. The sale of land is expected to be completed within the earlier of the next 12 months or upon the closing of customary escrow and due diligence procedures. Any gain on the sale of land transaction will be recorded at the time of disposal.
Schedule of Changes in Product Warranty Accrual
Changes in the product warranty accrual were as follows:
Three Months Ended
(in millions)March 30,
2024		April 1,
2023
Product warranty accrual, beginning of period$8.6 $10.6 
Accrual for warranties issued3.1 3.8 
Changes in pre-existing warranties (including changes in estimates)0.4 (3.5)
Settlements made(4.0)(0.7)
Product warranty accrual, end of period$8.1 $10.2 
Schedule of Reconciliation of Basic and Diluted Net Income Per Share
A computation of basic and diluted net income per share is as follows:
Three Months Ended
(in millions, except per share amounts)
March 30,
2024		April 1,
2023
Net income$18.9 $21.3 
Basic net income per share:
Weighted-average shares outstanding - basic53.0 52.6 
Net income per basic share$0.36 $0.40 
Diluted net income per share:
Weighted-average shares outstanding - basic53.0 52.6 
Diluted share equivalents: stock options, RSUs and PSUs1.3 1.8 
Weighted-average shares outstanding - diluted54.2 54.4 
Net income per diluted share$0.35 $0.39 
Schedule of Supplemental Cash Flow Information
Supplemental cash flow information includes the following:
Three Months Ended
(in millions)March 30,
2024		April 1,
2023
Cash paid during the year for:
Interest expense
$11.7 $11.7 
Income taxes
8.5 11.0 
Operating lease liabilities
5.7 5.3 
Non-cash operating activities:
ROU assets obtained in exchange for lease liabilities
$20.6 $0.6 
Non-cash investing activities:
Unpaid purchases of property and equipment$2.7 $0.7 
Unpaid strategic investments0.2 1.2 
Non-cash financing activities:
       Unsettled common stock proceeds from option exercises$0.1 $0.1 
Reconciliation of cash, cash equivalents and restricted cash:
Cash and cash equivalents
$157.6 $174.1 
Restricted cash
6.4 7.0 
Total cash, cash equivalents and restricted cash shown in the condensed consolidated statements of cash flows$164.0 $181.1 
XML 48 R37.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Inventories (Tables)
 3 Months Ended
Mar. 30, 2024
Inventory Disclosure [Abstract]  
Schedule of Components of Inventory
Inventories consist of the following:
(in millions)March 30,
2024		December 30,
2023
Raw materials$232.6 $229.7 
Work-in-process29.3 30.0 
Finished goods244.2 285.3 
     Total inventories$506.1 $545.0 
XML 49 R38.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Other Current Assets (Tables)
 3 Months Ended
Mar. 30, 2024
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]  
Schedule of Other Non-Current Assets
Other current assets consist of the following:
(in millions)March 30,
2024		December 30,
2023
Prepaid expenses$53.1 $58.3 
Lease receivable, current29.7 30.2 
Prepaid income taxes27.7 29.3 
Indirect taxes receivable23.1 28.6 
Other receivables10.3 6.8 
Contract assets, current7.2 6.7 
Prepaid rebates and royalties, current5.0 4.8 
Restricted cash(1)
3.0 3.0 
Other current assets0.7 0.7 
     Total other current assets$159.8 $168.4 
______________
(1)     Restricted cash includes funds received from the Bill and Melinda Gates Foundation. As the Company incurs costs associated with research and development related to this project, on a quarterly basis, the Company reclasses amounts from the grant to offset costs incurred.
Other non-current assets consist of the following:
(in millions)March 30,
2024		December 30,
2023
Lessee ROU assets, net$75.1 $59.1 
Derivative assets - non-current(1)
14.3 11.4 
Prepaid deposits and other7.5 6.4 
Strategic investments6.9 7.2 
Restricted cash(2)
3.4 2.2 
Equity investments - fair value2.6 2.7 
Other non-current assets0.1 0.3 
  Total non-current assets$109.9 $89.3 
______________
(1)    Excludes accrued interest.
(2)    Restricted cash includes cash held in certain subsidiaries in jurisdictions outside of the U.S. such as China, which may be subject to transfer restrictions depending on jurisdictions.
XML 50 R39.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Lease Receivable (Tables)
 3 Months Ended
Mar. 30, 2024
Leases [Abstract]  
Schedule of Sale-Type Lease Receivable
Lease receivable from sales-type leases consists of the following:
(in millions)March 30,
2024		December 30,
2023
Lease receivable$100.3 $101.9 
Allowance for credit loss(0.3)(0.3)
     Lease receivable, net100.0 101.6 
Less: current portion of lease receivable(29.7)(30.2)
     Lease receivable, non-current$70.3 $71.4 
Schedule of Sales-type Lease, Lease Receivable, Maturity
As of March 30, 2024, estimated future maturities of customer sales-type lease receivables and operating lease payments for each of the following fiscal years are as follows:
Future Lease Receivables/Payments
(in millions)
Fiscal yearSales-Type LeasesOperating Leases
2024 (balance of year)$22.9 $8.5 
202525.7 10.2 
202619.8 9.4 
202714.4 7.8 
20288.0 5.6 
Thereafter9.2 9.1 
     Total$100.0 $50.6 
Less: imputed interest(1)
— 
     Present value of total lease payments$100.0 
______________
(1)     The calculation of the rates implicit in the leases resulted in negative discount rates. Therefore, the Company as a lessor used a 0% discount rate to measure the net investment in the lease.
XML 51 R40.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Deferred Costs and Other Contract Assets (Tables)
 3 Months Ended
Mar. 30, 2024
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]  
Schedule of Deferred Costs and Other Contract Assets
Deferred costs and other contract assets consist of the following:
(in millions)March 30,
2024		December 30,
2023
Deferred commissions$21.3 $21.8 
Unbilled contract receivables18.8 17.0 
Prepaid contract allowances16.2 17.0 
Deferred equipment agreements, net1.6 1.5 
     Deferred costs and other contract assets$57.9 $57.3 
XML 52 R41.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Property and Equipment, net (Tables)
 3 Months Ended
Mar. 30, 2024
Property, Plant and Equipment [Abstract]  
Schedule of Property, Plant and Equipment
Property and equipment are stated at cost. Depreciation is calculated using the straight-line method over estimated useful lives as follows:
Useful Lives
Buildings and building improvements
7 to 39 years
Computer equipment and software
2 to 12 years
Demonstration units
2 to 3 years
Furniture and office equipment
2 to 15 years
Leasehold improvementsLesser of useful life or term of lease
Machinery, equipment and tooling
3 to 20 years
Operating lease assetsLesser of useful life or term of lease
Transportation, vehicles and other
1 to 20 years
Property and equipment, net, consists of the following:
(in millions)March 30,
2024		December 30,
2023
Machinery, equipment and tooling$173.1 $169.7 
Building and building improvements150.5 151.0 
Operating lease assets108.1 92.2 
Land(1)
54.6 66.2 
Computer equipment and software45.4 45.5 
Leasehold improvements39.6 37.5 
Transportation, vehicles and other33.5 34.0 
Furniture and office equipment18.7 20.4 
Demonstration units11.3 11.1 
Construction-in-progress (CIP)58.0 59.2 
     Total property and equipment692.8 686.8 
Accumulated depreciation(277.8)(262.4)
     Property and equipment, net(1)
$415.0 $424.4 
______________
(1)    At March 30, 2024, property, plant and equipment, net, excluded $11.4 million of idle undeveloped land classified as held for sale within the healthcare segment. The sale of land is expected to be completed within the earlier of the next 12 months or upon the closing of customary escrow and due diligence procedures. Any gain on the sale of land transaction will be recorded at the time of disposal.
XML 53 R42.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Intangible Assets, net (Tables)
 3 Months Ended
Mar. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Finite-Lived Intangible Assets
Intangible assets, net, consist of the following:
March 30,
2024		December 30,
2023
(in millions)Gross Carrying
Amount		Accumulated
Amortization		Net Carrying
Amount		Gross Carrying
Amount		Accumulated
Amortization		Net Carrying
Amount
Intangible assets subject to amortization:
Customer relationships$184.4 $(15.1)$169.3 $209.2 $(31.5)$177.7 
Acquired technologies138.5 (18.6)119.9 174.7 (45.3)129.4 
Licenses45.3 (5.0)40.3 39.7 (7.4)32.3 
Capitalized software development costs48.7 (6.9)41.8 53.9 (15.2)38.7 
Patents40.8 (15.8)25.0 39.2 (15.2)24.0 
Trademarks19.1 (6.8)12.3 20.1 (7.4)12.7 
Non-compete agreements3.8 (0.4)3.4 6.3 (2.6)3.7 
Licenses-related party7.5 (6.8)0.7 7.5 (6.7)0.8 
Other1.6 (1.1)0.5 1.7 (1.1)0.6 
Total intangible assets subject to amortization, net$489.7 $(76.5)$413.2 $552.3 $(132.4)$419.9 
Intangible assets not subject to amortization:
Trademarks$222.7 $242.4 
Impairment charge— (10.0)
Total trademarks222.7 232.4 
Intangible assets, net$635.9 $652.3 
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense
Estimated amortization expense for each of the next fiscal years is as follows:
Fiscal yearAmount
(in millions)
2024 (balance of year)$44.8 
202556.1 
202644.7 
202743.3 
202843.0 
Thereafter181.3 
     Total$413.2 
XML 54 R43.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Goodwill (Tables)
 3 Months Ended
Mar. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Goodwill
Changes in goodwill were as follows:
Three Months Ended
March 30, 2024
(in millions)HealthcareNon-healthcareTotal
Goodwill, beginning of period$98.6 $309.1 $407.7 
Foreign currency translation adjustment(1.0)(10.7)(11.7)
Goodwill, end of period$97.6 $298.4 $396.0 
XML 55 R44.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Lessee ROU Assets and Lease Liabilities (Tables)
 3 Months Ended
Mar. 30, 2024
Leases [Abstract]  
Schedule of Lessee Operating Lease Balance Sheet Classification
The balance sheet classifications for amounts related to the Company’s operating leases for which it is the lessee are as follows:
(in millions)Balance sheet classificationMarch 30,
2024		December 30,
2023
Lessee ROU assetsOther non-current assets$75.1 $59.1 
Lessee current lease liabilitiesOther current liabilities19.3 18.2 
Lessee non-current lease liabilitiesOther non-current liabilities61.5 45.8 
     Total operating lease liabilities$80.8 $64.0 
Schedule of Lessee, Operating Lease, Liability, Maturity
As of March 30, 2024, estimated future operating lease payments for each of the following fiscal years were as follows:
Fiscal yearAmount
(in millions)
2024 (balance of year)$16.9 
202519.9 
202615.6 
202711.1 
202810.4 
Thereafter(1)
18.8 
   Total92.7 
   Imputed interest(11.9)
   Present value$80.8 
______________
(1)     Includes optional renewal period for certain leases.
XML 56 R45.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Other Non-Current Assets (Tables)
 3 Months Ended
Mar. 30, 2024
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]  
Schedule of Other Non-Current Assets
Other current assets consist of the following:
(in millions)March 30,
2024		December 30,
2023
Prepaid expenses$53.1 $58.3 
Lease receivable, current29.7 30.2 
Prepaid income taxes27.7 29.3 
Indirect taxes receivable23.1 28.6 
Other receivables10.3 6.8 
Contract assets, current7.2 6.7 
Prepaid rebates and royalties, current5.0 4.8 
Restricted cash(1)
3.0 3.0 
Other current assets0.7 0.7 
     Total other current assets$159.8 $168.4 
______________
(1)     Restricted cash includes funds received from the Bill and Melinda Gates Foundation. As the Company incurs costs associated with research and development related to this project, on a quarterly basis, the Company reclasses amounts from the grant to offset costs incurred.
Other non-current assets consist of the following:
(in millions)March 30,
2024		December 30,
2023
Lessee ROU assets, net$75.1 $59.1 
Derivative assets - non-current(1)
14.3 11.4 
Prepaid deposits and other7.5 6.4 
Strategic investments6.9 7.2 
Restricted cash(2)
3.4 2.2 
Equity investments - fair value2.6 2.7 
Other non-current assets0.1 0.3 
  Total non-current assets$109.9 $89.3 
______________
(1)    Excludes accrued interest.
(2)    Restricted cash includes cash held in certain subsidiaries in jurisdictions outside of the U.S. such as China, which may be subject to transfer restrictions depending on jurisdictions.
XML 57 R46.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Deferred Revenue and Other Contract Liabilities, Current (Tables)
 3 Months Ended
Mar. 30, 2024
Revenue Recognition and Deferred Revenue [Abstract]  
Schedule of Contract with Customer, Asset and Liability
Deferred revenue and other contract liabilities, current, consist of the following:
(in millions)March 30,
2024		December 30,
2023
Deferred revenue$63.1 $63.8 
Accrued rebates and allowances23.0 37.5 
Accrued customer reimbursements10.3 12.4 
     Total deferred revenue and other contract liabilities96.4 113.7 
Less: Non-current portion of deferred revenue(26.4)(26.4)
     Deferred revenue and other contract liabilities, current$70.0 $87.3 
Changes in deferred revenue were as follows:
(in millions)Three Months Ended
March 30,
2024
Deferred revenue, beginning of the period$63.8 
  Revenue deferred during the period8.4 
  Recognition of revenue deferred in prior periods(9.1)
     Deferred revenue, end of the period$63.1 
XML 58 R47.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Other Current Liabilities (Tables)
 3 Months Ended
Mar. 30, 2024
Accrued Liabilities [Abstract]  
Schedule of Other Current Liabilities
Other current liabilities consist of the following:
(in millions)March 30,
2024		December 30,
2023
Long-term debt, current$34.6 $34.3 
Accrued indirect taxes payable29.1 23.9 
Accrued expenses27.6 26.3 
Lessee lease liabilities, current 19.3 18.2 
Income tax payable10.5 16.1 
Other current liabilities(1)
9.6 6.7 
Accrued property taxes9.4 10.2 
Accrued warranty8.1 8.6 
Accrued legal fees7.7 9.9 
Related party payables5.0 4.2 
Accrued donations2.0 4.0 
Licensing agreement, current3.0 — 
     Total other current liabilities$165.9 $162.4 
__________________
(1)    At March 30, 2024, other current liabilities included approximately $0.5 million of refundable deposits during the due diligence period related to certain assets held for sale.
XML 59 R48.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Debt (Tables)
 3 Months Ended
Mar. 30, 2024
Debt Disclosure [Abstract]  
Schedule of Debt
(in millions)March 30,
2024		December 30,
2023
Term loan - current portion$13.1 $11.3 
Japanese loans - current portion21.5 23.0 
Debt, current portion34.6 34.3 
Term loan - long-term268.1 271.4 
Revolver - long-term565.5 591.5 
Japanese loans - long-term7.8 8.8 
Debt, long-term841.4 871.7 
Total debt$876.0 $906.0 
Schedule of Maturities of Long-term Debt
As of March 30, 2024, the aggregate maturities of principal on all debt for each of the next five years and thereafter are as follows:
Fiscal yearAmount
(in millions)
2024 (balance of year)$30.5 
202516.6 
202616.6 
2027809.0 
20281.0 
Thereafter2.3 
Total$876.0 
XML 60 R49.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Other Non-Current Liabilities (Tables)
 3 Months Ended
Mar. 30, 2024
Other Liabilities Disclosure [Abstract]  
Schedule of Components Of Other Liabilities Long Term Table
Other non-current liabilities consist of the following:
(in millions)March 30,
2024		December 30,
2023
Lessee non-current lease liabilities$61.5 $45.8 
Unrecognized tax benefits26.8 24.4 
Deferred revenue, non-current26.4 26.4 
Projected benefit obligation9.2 9.5 
Income tax payable, non-current7.1 7.1 
Licensing agreement, non-current
4.5 — 
Indirect tax payable, non-current— 8.4 
Other4.5 7.9 
     Total other non-current liabilities$140.0 $129.5 
XML 61 R50.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Derivative Instruments and Hedging Activities (Tables)
 3 Months Ended
Mar. 30, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Schedule of Derivative Instruments in Statement of Financial Position, Fair Value The following table summarizes the fair value of the hedging instruments, presented on a gross basis, as of March 30, 2024 and December 30, 2023.
Condensed Consolidated
Balance Sheets
(in millions)Balance sheet classificationMarch 30,
2024		December 30,
2023
Interest rate contracts, inclusive of accrued interest
Other non-current assets
$14.4 $11.6 
Interest rate contracts, inclusive of accrued interest
Other non-current liabilities
— (3.6)
Total$14.4 $8.0 
Schedule of Reclassification out of Accumulated Other Comprehensive Income
The following table summarizes the gains (losses) reclassified from accumulated other comprehensive (loss) income to the condensed consolidated financial statements for the three months ended March 30, 2024 and April 1, 2023.
Cash flow hedgesCondensed Consolidated
Statement of Operations
Three Months Ended
(in millions)Location of gains (losses)March 30,
2024		April 1,
2023
Interest rate contracts
Non-operating (loss)
$(4.3)$(3.0)
Total$(4.3)$(3.0)
Schedule of Accumulated Other Comprehensive Income (Loss)
The following tables summarize the changes in accumulated other comprehensive income (loss) related to the hedging instruments for the three months and three months ended March 30, 2024 and April 1, 2023.
Three Months Ended
(in millions)March 30,
2024		April 1,
2023
Beginning balance$7.8 $19.3 
Amount recognized in other comprehensive income (loss)
10.8 (2.7)
Amount reclassified into earnings(4.3)(3.0)
Ending balance$14.3 $13.6 
XML 62 R51.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Business Combinations (Tables)
 3 Months Ended
Mar. 30, 2024
Business Combination and Asset Acquisition [Abstract]  
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed
The table below summarizes the final allocation of fair value of assets acquired and liabilities assumed.
(in millions)Sound United
Cash consideration
$1,057.5 
Purchase price$1,057.5 
Assets acquired:
Cash and cash equivalents$82.6 
Accounts receivables108.5 
Inventories238.6 
Prepaid expenses and other current assets30.0 
Property, plant and equipment113.2 
Intangible assets
649.0 
Goodwill
318.0 
Long-term other assets7.4 
Total assets acquired$1,547.3 
Liabilities assumed:
Accounts payable$(118.8)
Accrued liabilities and other current liabilities(148.9)
Deferred tax liabilities(145.1)
Other long-term liabilities(77.0)
Total liabilities assumed$(489.8)
The following table sets forth the components of identifiable intangible assets acquired and the weighted average amortization period as of the acquisition date:
Weighted average
amortization period
(in years)		April 11,
 2022
(in millions)
Trademarks/tradenames10$6.0 
Customer relationships17196.0 
Developed technology8156.0 
Contractual license agreements1529.0 
Subtotal14 years$387.0 
Indefinite trademarks/tradenamesN/A262.0 
Total$649.0 
XML 63 R52.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Stock-Based Compensation (Tables)
 3 Months Ended
Mar. 30, 2024
Share-Based Payment Arrangement [Abstract]  
Schedule of Number and Weighted Average Exercise Price of Options Issued and Outstanding under all Stock Option Plans
The number and weighted-average exercise price of options issued and outstanding under all of the Company’s equity plans are as follows:
Three Months Ended
March 30, 2024
(in millions, except for weighted-average exercise prices)
SharesWeighted-Average
Exercise Price
Options outstanding, beginning of period2.8 $87.79 
Granted0.1 126.49 
Canceled— 162.00 
Exercised(0.2)44.11 
Options outstanding, end of period2.7 $91.51 
Options exercisable, end of period2.3 $80.43 
Schedule of Share-based Compensation, Restricted Stock Units Award Activity
The number of RSUs issued and outstanding under all of the Company’s equity plans are as follows:
Three Months Ended
March 30, 2024
(in millions, except for weighted-average grant date fair value amounts)
UnitsWeighted-Average Grant
 Date Fair Value
RSUs outstanding, beginning of period3.5 $105.87 
Granted0.2 126.36 
Expired— 157.76 
Vested(0.1)178.68 
RSUs outstanding, end of period3.6 $104.94 
Schedule of Nonvested Performance-based Units Activity
The number of PSUs outstanding under all of the Company’s equity plans are as follows:
Three Months Ended
March 30, 2024
(in millions, except for weighted-average grant date fair value amounts)UnitsWeighted-Average Grant
 Date Fair Value
PSUs outstanding, beginning of period0.3 $190.04 
Granted(1)
0.1 164.19 
Expired— 250.73 
Vested— 250.73 
PSUs outstanding, end of period0.4 $170.69 
______________
(1)     On February 28, 2024, the Audit Committee approved the weighted payout percentage of 28% for the 2021 PSU awards (three-year performance period), which were based upon the actual fiscal 2023 performance against pre-established performance objectives. Included in the granted amount are those additional PSUs earned based on actual performance achieved. These PSUs were originally awarded at target.
Schedule of Range of Assumptions Used and Resulting Weighted-Average Fair Value of Options Granted at Date of Grant The range of assumptions used and the resulting weighted-average fair value of options granted at the date of grant were as follows:
Three Months Ended
March 30,
2024
April 1,
2023
Risk-free interest rate4.2%4.2%
Expected term (in years)5.95.9
Estimated volatility42.6%36.7%
Expected dividends—%—%
Weighted-average fair value of options granted$59.60$75.08
XML 64 R53.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Non-operating Loss (Tables)
 3 Months Ended
Mar. 30, 2024
Nonoperating Income (Expense) [Abstract]  
Schedule of Non-operating Loss
Non-operating loss consists of the following:
Three Months Ended
(in millions)March 30,
2024		April 1,
2023
Realized and unrealized foreign currency gains (losses)1.9 (0.7)
Interest income$1.2 $0.8 
Interest expense(12.0)(11.9)
Other(0.2)— 
Total non-operating loss$(9.1)$(11.8)
XML 65 R54.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Segment and Enterprise Reporting (Tables)
 3 Months Ended
Mar. 30, 2024
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information, by Segment
Selected information by reportable segment is presented below for each of the three months ended March 30, 2024 and April 1, 2023:
Three Months Ended
(in millions)March 30,
2024		April 1,
2023
Revenues by segment:
Healthcare$339.6 $346.7 
Non-healthcare153.2 218.3 
Total revenue by segment$492.8 $565.0 
Gross profit:
Healthcare$211.4 $214.8 
Non-healthcare44.5 77.8 
Other(1)
(14.2)(7.8)
Gross profit$241.7 $284.8 
____________________________
(1)     Management excludes certain corporate expenses from segment gross profit. In addition, certain amounts that management considers to be non-recurring or non-operational are excluded from segment gross profit because management evaluates the operating results of the segments excluding such items.
The Company’s depreciation and amortization by segment are as follows:
Three Months Ended
(in millions)March 30,
2024		April 1,
2023
Total depreciation and amortization by segment:
Healthcare$10.0 $9.0 
Non-healthcare14.3 17.1 
Total depreciation and amortization by segment$24.3 $26.1 
XML 66 R55.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Summary of Significant Accounting Policies - Schedule of Fair Value, Assets Measured on Recurring Basis (Detail) - Recurring - USD ($)
$ in Millions
Mar. 30, 2024
Dec. 30, 2023
Assets    
Cash and cash equivalents $ 81.9 $ 87.0
Money market funds 75.7 76.0
Equity securities 1.7 1.7
Pension assets 22.9 23.1
Total assets 197.5 200.4
Liabilities    
Pension benefit obligation 32.1 32.6
Total liabilities 32.1 36.2
Cash Flow Hedges    
Assets    
Derivative instruments 14.4 11.6
Liabilities    
Derivative instruments - cash flow hedges 0.0 3.6
Warrants    
Assets    
Derivative instruments 0.9 1.0
Level 1    
Assets    
Cash and cash equivalents 81.9 87.0
Money market funds 75.7 76.0
Equity securities 1.7 1.7
Pension assets 16.6 16.8
Total assets 176.8 182.5
Liabilities    
Pension benefit obligation 32.1 32.6
Total liabilities 32.1 36.2
Level 1 | Cash Flow Hedges    
Assets    
Derivative instruments 0.0 0.0
Liabilities    
Derivative instruments - cash flow hedges 0.0 3.6
Level 1 | Warrants    
Assets    
Derivative instruments 0.9 1.0
Level 2    
Assets    
Cash and cash equivalents 0.0 0.0
Money market funds 0.0 0.0
Equity securities 0.0 0.0
Pension assets 6.3 6.3
Total assets 20.7 17.9
Liabilities    
Pension benefit obligation 0.0 0.0
Total liabilities 0.0 0.0
Level 2 | Cash Flow Hedges    
Assets    
Derivative instruments 14.4 11.6
Liabilities    
Derivative instruments - cash flow hedges 0.0 0.0
Level 2 | Warrants    
Assets    
Derivative instruments 0.0 0.0
Level 3    
Assets    
Cash and cash equivalents 0.0 0.0
Money market funds 0.0 0.0
Equity securities 0.0 0.0
Pension assets 0.0 0.0
Total assets 0.0 0.0
Liabilities    
Pension benefit obligation 0.0 0.0
Total liabilities 0.0 0.0
Level 3 | Cash Flow Hedges    
Assets    
Derivative instruments 0.0 0.0
Liabilities    
Derivative instruments - cash flow hedges 0.0 0.0
Level 3 | Warrants    
Assets    
Derivative instruments $ 0.0 $ 0.0
XML 67 R56.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Summary of Significant Accounting Policies - Schedule of Property and Equipment (Detail)
Mar. 30, 2024
Minimum | Buildings and building improvements  
Property, Plant and Equipment [Line Items]  
Property and equipment, useful life 7 years
Minimum | Computer equipment and software  
Property, Plant and Equipment [Line Items]  
Property and equipment, useful life 2 years
Minimum | Demonstration units  
Property, Plant and Equipment [Line Items]  
Property and equipment, useful life 2 years
Minimum | Furniture and office equipment  
Property, Plant and Equipment [Line Items]  
Property and equipment, useful life 2 years
Minimum | Machinery, equipment and tooling  
Property, Plant and Equipment [Line Items]  
Property and equipment, useful life 3 years
Minimum | Transportation, vehicles and other  
Property, Plant and Equipment [Line Items]  
Property and equipment, useful life 1 year
Maximum | Buildings and building improvements  
Property, Plant and Equipment [Line Items]  
Property and equipment, useful life 39 years
Maximum | Computer equipment and software  
Property, Plant and Equipment [Line Items]  
Property and equipment, useful life 12 years
Maximum | Demonstration units  
Property, Plant and Equipment [Line Items]  
Property and equipment, useful life 3 years
Maximum | Furniture and office equipment  
Property, Plant and Equipment [Line Items]  
Property and equipment, useful life 15 years
Maximum | Machinery, equipment and tooling  
Property, Plant and Equipment [Line Items]  
Property and equipment, useful life 20 years
Maximum | Transportation, vehicles and other  
Property, Plant and Equipment [Line Items]  
Property and equipment, useful life 20 years
XML 68 R57.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Summary of Significant Accounting Policies - Narrative (Detail)
shares in Millions, $ in Millions
 3 Months Ended
Mar. 30, 2024
USD ($)
segment
reportingUnit
shares
Apr. 01, 2023
USD ($)
shares
Summary Of Significant Accounting Policies [Line Items]    
Number of reporting units | reportingUnit 2  
Number of sources of product revenue | segment 4  
Advertising expense | $ $ 11.9 $ 14.4
Options to purchase of shares of common stock 1.4 1.0
Restricted Stock Units (RSUs)    
Summary Of Significant Accounting Policies [Line Items]    
Share-based compensation arrangement, grants in period (in shares) 0.2  
Chief Executive Officer | Restricted Stock Units (RSUs)    
Summary Of Significant Accounting Policies [Line Items]    
Share-based compensation arrangement, grants in period (in shares) 2.7 2.7
Minimum    
Summary Of Significant Accounting Policies [Line Items]    
Revenue remaining performance obligation, expected timing of satisfaction 3 years  
Payment terms 30 days  
Warranty period for defects in material and workmanship 6 months  
Maximum    
Summary Of Significant Accounting Policies [Line Items]    
Revenue remaining performance obligation, expected timing of satisfaction 6 years  
Payment terms 60 days  
Warranty period for defects in material and workmanship 48 months  
Patents    
Summary Of Significant Accounting Policies [Line Items]    
Finite lived intangible asset useful life 10 years  
Trademarks    
Summary Of Significant Accounting Policies [Line Items]    
Finite lived intangible asset useful life 17 years  
XML 69 R58.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Summary of Significant Accounting Policies - Schedule of Changes in Product Warranty Accrual (Detail) - USD ($)
$ in Millions
 3 Months Ended
Mar. 30, 2024
Apr. 01, 2023
Movement in Standard and Extended Product Warranty Accrual, Increase (Decrease) [Roll Forward]    
Product warranty accrual, beginning of period $ 8.6 $ 10.6
Accrual for warranties issued 3.1 3.8
Changes in pre-existing warranties (including changes in estimates) 0.4 (3.5)
Settlements made (4.0) (0.7)
Product warranty accrual, end of period $ 8.1 $ 10.2
XML 70 R59.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Summary of Significant Accounting Policies - Schedule of Reconciliation of Basic and Diluted Net Income Per Share (Detail) - USD ($)
$ / shares in Units, shares in Millions, $ in Millions
 3 Months Ended
Mar. 30, 2024
Apr. 01, 2023
Net income per share:    
Net income $ 18.9 $ 21.3
Basic net income per share:    
Weighted-average shares outstanding - basic (in shares) 53.0 52.6
Net income per basic share (in dollars per share) $ 0.36 $ 0.40
Diluted net income per share:    
Weighted-average shares outstanding - basic (in shares) 53.0 52.6
Diluted share equivalent: stock options, RSUs and PSUs (in shares) 1.3 1.8
Weighted-average shares outstanding - diluted (in shares) 54.2 54.4
Net income per diluted share (in dollars per share) $ 0.35 $ 0.39
XML 71 R60.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Summary of Significant Accounting Policies - Schedule of Supplemental Cash Flow Information (Detail) - USD ($)
$ in Millions
 3 Months Ended
Mar. 30, 2024
Apr. 01, 2023
Dec. 30, 2023
Dec. 31, 2022
Cash paid during the year for:        
Interest expense $ 11.7 $ 11.7    
Income taxes 8.5 11.0    
Operating lease liabilities 5.7 5.3    
Non-cash operating activities:        
ROU assets obtained in exchange for lease liabilities 20.6 0.6    
Non-cash investing activities:        
Unpaid purchases of property and equipment 2.7 0.7    
Unpaid strategic investments 0.2 1.2    
Non-cash financing activities:        
Unsettled common stock proceeds from option exercises 0.1 0.1    
Reconciliation of cash, cash equivalents and restricted cash:        
Cash and cash equivalents 157.6 174.1 $ 163.0  
Restricted cash 6.4 7.0    
Total cash, cash equivalents and restricted cash shown in the condensed consolidated statements of cash flows $ 164.0 $ 181.1 $ 168.2 $ 209.6
XML 72 R61.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Related Party Transactions (Details)
ft² in Thousands
 1 Months Ended 3 Months Ended
Jul. 31, 2021
USD ($)
Mar. 30, 2024
USD ($)
ft²
Apr. 01, 2023
USD ($)
Dec. 30, 2023
USD ($)
Jul. 03, 2021
USD ($)
Related Party          
Related Party Transaction [Line Items]          
Other current liabilities, related party   $ 5,000,000.0   $ 4,200,000  
Willow Laboratories          
Related Party Transaction [Line Items]          
Payment for administrative fees   100,000 $ 100,000    
Sublease income   300,000 300,000    
Willow Laboratories | Related Party          
Related Party Transaction [Line Items]          
Payments for royalties   4,800,000 5,600,000    
Other current liabilities, related party   $ 4,900,000   4,100,000  
Leased Property          
Related Party Transaction [Line Items]          
Property plant and equipment, occupied square feet | ft²   34      
Not for Profit Organization          
Related Party Transaction [Line Items]          
Related party transaction, amounts of transaction (less than)   $ 1,000,000 1,000,000    
Like Minded Media Ventures          
Related Party Transaction [Line Items]          
Related party transaction, amounts of transaction (less than)   0 0    
Like Minded Media Ventures | Related Party          
Related Party Transaction [Line Items]          
Other current liabilities, related party   0   $ 0  
Like Minded Labs          
Related Party Transaction [Line Items]          
Finite-lived license agreements, gross         $ 3,000,000
Vantrix Corp | Purchase Commitment          
Related Party Transaction [Line Items]          
Related party transaction, purchases from related party $ 500,000        
Vantrix Corp | Options Held          
Related Party Transaction [Line Items]          
Related party transaction, purchases from related party $ 1,100,000        
Reimbursement Fee | Chief Executive Officer          
Related Party Transaction [Line Items]          
Related party transaction, amounts of transaction (less than)   0 $ 100,000    
Minimum | Related Party          
Related Party Transaction [Line Items]          
Payments for royalties   $ 5,000,000      
XML 73 R62.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Inventories (Details) - USD ($)
$ in Millions
Mar. 30, 2024
Dec. 30, 2023
Inventory Disclosure [Abstract]    
Raw materials $ 232.6 $ 229.7
Work-in-process 29.3 30.0
Finished goods 244.2 285.3
Total inventories $ 506.1 $ 545.0
XML 74 R63.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Other Current Assets (Details) - USD ($)
$ in Millions
Mar. 30, 2024
Dec. 30, 2023
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]    
Prepaid expenses $ 53.1 $ 58.3
Lease receivable, current 29.7 30.2
Prepaid income taxes 27.7 29.3
Indirect taxes receivable 23.1 28.6
Other receivables 10.3 6.8
Contract assets, current 7.2 6.7
Prepaid rebates and royalties, current 5.0 4.8
Restricted cash 3.0 3.0
Other current assets 0.7 0.7
Total other current assets $ 159.8 $ 168.4
XML 75 R64.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Lease Receivable - Narrative (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 30, 2024
Apr. 01, 2023
Leases [Abstract]    
Variable lease income $ 16.0 $ 20.0
XML 76 R65.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Lease Receivable - Schedule of Sale-Type Lease Receivable (Details) - USD ($)
$ in Millions
Mar. 30, 2024
Dec. 30, 2023
Leases [Abstract]    
Lease receivable $ 100.3 $ 101.9
Allowance for credit loss (0.3) (0.3)
Lease receivable, net 100.0 101.6
Less: current portion of lease receivable (29.7) (30.2)
Lease receivable, non-current $ 70.3 $ 71.4
XML 77 R66.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Lease Receivable - Schedule of Sales-type Lease, Lease Receivable, Maturity (Details) - USD ($)
$ in Millions
Mar. 30, 2024
Dec. 30, 2023
Sales-Type Leases    
2024 (balance of year) $ 22.9  
2025 25.7  
2026 19.8  
2027 14.4  
2028 8.0  
Thereafter 9.2  
Lease receivable, net 100.0 $ 101.6
Total 100.3 $ 101.9
Less: imputed interest 0.0  
Lease receivable, net 100.0  
Operating Leases    
2024 (balance of year) 8.5  
2024 (balance of year) 10.2  
2026 9.4  
2027 7.8  
2028 5.6  
Thereafter 9.1  
Total $ 50.6  
Discount rate used to measure the net investment in lease 0.00%  
XML 78 R67.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Deferred Costs and Other Contract Assets (Details) - USD ($)
$ in Millions
Mar. 30, 2024
Dec. 30, 2023
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]    
Deferred commissions $ 21.3 $ 21.8
Unbilled contract receivables 18.8 17.0
Prepaid contract allowances 16.2 17.0
Deferred equipment agreements, net 1.6 1.5
Deferred costs and other contract assets $ 57.9 $ 57.3
XML 79 R68.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Property and Equipment, net - Schedule of Property and Equipment (Details) - USD ($)
$ in Millions
Mar. 30, 2024
Dec. 30, 2023
Property, Plant and Equipment [Line Items]    
Total property and equipment $ 692.8 $ 686.8
Accumulated depreciation (277.8) (262.4)
Property and equipment, net 415.0 424.4
Idle undeveloped land held for sale 11.4  
Machinery, equipment and tooling    
Property, Plant and Equipment [Line Items]    
Total property and equipment 173.1 169.7
Building and building improvements    
Property, Plant and Equipment [Line Items]    
Total property and equipment 150.5 151.0
Operating lease assets    
Property, Plant and Equipment [Line Items]    
Total property and equipment 108.1 92.2
Land    
Property, Plant and Equipment [Line Items]    
Total property and equipment 54.6 66.2
Computer equipment and software    
Property, Plant and Equipment [Line Items]    
Total property and equipment 45.4 45.5
Leasehold improvements    
Property, Plant and Equipment [Line Items]    
Total property and equipment 39.6 37.5
Transportation, vehicles and other    
Property, Plant and Equipment [Line Items]    
Total property and equipment 33.5 34.0
Furniture and office equipment    
Property, Plant and Equipment [Line Items]    
Total property and equipment 18.7 20.4
Demonstration units    
Property, Plant and Equipment [Line Items]    
Total property and equipment 11.3 11.1
Construction-in-progress (CIP)    
Property, Plant and Equipment [Line Items]    
Total property and equipment $ 58.0 $ 59.2
XML 80 R69.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Property and Equipment, net - Narrative (Detail)
$ in Millions, $ in Millions
 3 Months Ended
Feb. 14, 2022
CAD ($)
Mar. 30, 2024
USD ($)
Apr. 01, 2023
USD ($)
Dec. 31, 2022
CAD ($)
Property, Plant and Equipment [Line Items]        
Depreciation   $ 10.5 $ 11.8  
Amortization of deferred cost of goods sold   6.4 3.0  
Accumulated amortization of deferred cost of goods sold   $ 0.4 $ 1.5  
Property, plant and equipment, additions $ 123.0      
Escrow deposit       $ 21.0
XML 81 R70.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Intangible Assets, net - Schedule of Finite-Lived Intangible Assets (Details) - USD ($)
$ in Millions
 3 Months Ended 12 Months Ended
Mar. 30, 2024
Dec. 30, 2023
Sep. 30, 2023
Dec. 30, 2023
Intangible assets subject to amortization:        
Gross Carrying Amount $ 489.7 $ 552.3   $ 552.3
Accumulated Amortization (76.5) (132.4)   (132.4)
Net Carrying Amount $ 413.2 419.9   $ 419.9
Impairment, Intangible Asset, Indefinite-Lived (Excluding Goodwill), Statement of Income or Comprehensive Income [Extensible Enumeration] Operating Expenses     Operating Expenses
Intangible assets not subject to amortization:        
Trademarks $ 222.7 232.4   $ 232.4
Impairment, Intangible Asset, Indefinite-Lived (Excluding Goodwill), Statement of Income or Comprehensive Income [Extensible Enumeration] Operating Expenses     Operating Expenses
Intangible Assets, Net (Excluding Goodwill) [Abstract]        
Intangible assets, net $ 635.9 652.3   $ 652.3
Trademarks        
Intangible assets not subject to amortization:        
Trademarks 222.7 242.4   242.4
Impairment charge 0.0 (3.0) $ (7.0) (10.0)
Total trademarks 222.7 232.4   232.4
Customer relationships        
Intangible assets subject to amortization:        
Gross Carrying Amount 184.4 209.2   209.2
Accumulated Amortization (15.1) (31.5)   (31.5)
Net Carrying Amount 169.3 177.7   177.7
Acquired technologies        
Intangible assets subject to amortization:        
Gross Carrying Amount 138.5 174.7   174.7
Accumulated Amortization (18.6) (45.3)   (45.3)
Net Carrying Amount 119.9 129.4   129.4
Licenses        
Intangible assets subject to amortization:        
Gross Carrying Amount 45.3 39.7   39.7
Accumulated Amortization (5.0) (7.4)   (7.4)
Net Carrying Amount 40.3 32.3   32.3
Licenses | Willow Laboratories        
Intangible assets subject to amortization:        
Gross Carrying Amount 7.5 7.5   7.5
Accumulated Amortization (6.8) (6.7)   (6.7)
Net Carrying Amount 0.7 0.8   0.8
Patents        
Intangible assets subject to amortization:        
Gross Carrying Amount 40.8 39.2   39.2
Accumulated Amortization (15.8) (15.2)   (15.2)
Net Carrying Amount 25.0 24.0   24.0
Capitalized software development costs        
Intangible assets subject to amortization:        
Gross Carrying Amount 48.7 53.9   53.9
Accumulated Amortization (6.9) (15.2)   (15.2)
Net Carrying Amount 41.8 38.7   38.7
Trademarks        
Intangible assets subject to amortization:        
Gross Carrying Amount 19.1 20.1   20.1
Accumulated Amortization (6.8) (7.4)   (7.4)
Net Carrying Amount 12.3 12.7   12.7
Non-compete agreements        
Intangible assets subject to amortization:        
Gross Carrying Amount 3.8 6.3   6.3
Accumulated Amortization (0.4) (2.6)   (2.6)
Net Carrying Amount 3.4 3.7   3.7
Other        
Intangible assets subject to amortization:        
Gross Carrying Amount 1.6 1.7   1.7
Accumulated Amortization (1.1) (1.1)   (1.1)
Net Carrying Amount $ 0.5 $ 0.6   $ 0.6
XML 82 R71.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Intangible Assets, net - Narrative (Details) - USD ($)
$ in Millions
 3 Months Ended 12 Months Ended
Mar. 30, 2024
Dec. 30, 2023
Sep. 30, 2023
Apr. 01, 2023
Dec. 30, 2023
Finite-Lived Intangible Assets [Line Items]          
Amortization of intangible assets $ 13.8     $ 14.3  
Trademarks          
Finite-Lived Intangible Assets [Line Items]          
Impairment charge $ 0.0 $ 3.0 $ 7.0   $ 10.0
Minimum          
Finite-Lived Intangible Assets [Line Items]          
Acquired finite-lived intangible assets, weighted average useful life 12 years        
Maximum          
Finite-Lived Intangible Assets [Line Items]          
Acquired finite-lived intangible assets, weighted average useful life 14 years        
Patents And Trademarks          
Finite-Lived Intangible Assets [Line Items]          
Finite-lived intangible assets, cost incurred to renew or extend $ 0.3     $ 0.3  
Patents          
Finite-Lived Intangible Assets [Line Items]          
Weighted average number of years until the next renewal 2 years        
Trademarks          
Finite-Lived Intangible Assets [Line Items]          
Weighted average number of years until the next renewal 6 years        
XML 83 R72.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Intangible Assets, net - Schedule of Finite-Lived Intangible Assets, Future Amortization Expense (Details) - USD ($)
$ in Millions
Mar. 30, 2024
Dec. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]    
2024 (balance of year) $ 44.8  
2025 56.1  
2026 44.7  
2027 43.3  
2028 43.0  
Thereafter 181.3  
Net Carrying Amount $ 413.2 $ 419.9
XML 84 R73.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Goodwill (Details)
$ in Millions
 3 Months Ended
Mar. 30, 2024
USD ($)
Goodwill [Roll Forward]  
Goodwill, beginning of period $ 407.7
Foreign currency translation adjustment (11.7)
Goodwill, end of period 396.0
Healthcare  
Goodwill [Roll Forward]  
Goodwill, beginning of period 98.6
Foreign currency translation adjustment (1.0)
Goodwill, end of period 97.6
Non-healthcare  
Goodwill [Roll Forward]  
Goodwill, beginning of period 309.1
Foreign currency translation adjustment (10.7)
Goodwill, end of period $ 298.4
XML 85 R74.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Lessee ROU Assets and Lease Liabilities - Narrative (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 30, 2024
Apr. 01, 2023
Dec. 30, 2023
Leases [Abstract]      
Lessee, operating lease, renewal term 5 years    
Operating lease, weighted average discount rate 4.20%    
Accumulated amortization for lessee ROU assets $ 53.8   $ 48.9
Weighted average remaining lease term 5 years 4 months 24 days    
Operating lease, cost $ 5.8 $ 5.1  
ROU asset had a net carrying value 5.8    
Undiscounted future expected cash flows totaling 1.5    
Impairment charge $ 3.9    
XML 86 R75.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Lessee ROU Assets and Lease Liabilities - Schedule of Lessee Operating Lease Balance Sheet Classification (Details) - USD ($)
$ in Millions
Mar. 30, 2024
Dec. 30, 2023
Leases [Abstract]    
Lessee ROU assets $ 75.1 $ 59.1
Lessee lease liabilities, current 19.3 18.2
Lessee non-current lease liabilities 61.5 45.8
Total operating lease liabilities $ 80.8 $ 64.0
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Other non-current assets Other non-current assets
Operating Lease, Liability, Current, Statement of Financial Position [Extensible List] Other current liabilities Other current liabilities
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List] Other Liabilities, Noncurrent Other Liabilities, Noncurrent
XML 87 R76.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Lessee ROU Assets and Lease Liabilities - Schedule of Lessee, Operating Lease, Liability, Maturity (Details) - USD ($)
$ in Millions
Mar. 30, 2024
Dec. 30, 2023
Leases [Abstract]    
2024 (balance of year) $ 16.9  
2025 19.9  
2026 15.6  
2027 11.1  
2028 10.4  
Thereafter 18.8  
Total 92.7  
Imputed interest (11.9)  
Present value $ 80.8 $ 64.0
XML 88 R77.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Other Non-Current Assets (Details) - USD ($)
$ in Millions
Mar. 30, 2024
Dec. 30, 2023
Other Assets Long Term [Line Items]    
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Total non-current assets Total non-current assets
Lessee ROU assets, net $ 75.1 $ 59.1
Prepaid deposits and other 7.5 6.4
Strategic investments 6.9 7.2
Restricted cash 3.4 2.2
Equity investments - fair value 2.6 2.7
Other non-current assets 0.1 0.3
Total non-current assets 109.9 89.3
Cash Flow Hedges    
Other Assets Long Term [Line Items]    
Derivative assets - non-current $ 14.3 $ 11.4
XML 89 R78.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Deferred Revenue and Other Contract Liabilities, Current - Schedule of Deferred Revenue and Other Contract Liabilities, Current (Details) - USD ($)
$ in Millions
Mar. 30, 2024
Dec. 30, 2023
Revenue Recognition and Deferred Revenue [Abstract]    
Deferred revenue $ 63.1 $ 63.8
Accrued rebates and allowances 23.0 37.5
Accrued customer reimbursements 10.3 12.4
Total deferred revenue and other contract liabilities 96.4 113.7
Less: Non-current portion of deferred revenue (26.4) (26.4)
Deferred revenue and other contract liabilities, current $ 70.0 $ 87.3
XML 90 R79.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Deferred Revenue and Other Contract Liabilities, Current - Narrative (Details) - USD ($)
$ in Millions
Mar. 30, 2024
Dec. 30, 2023
Oct. 31, 2020
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]      
Deferred revenue $ 63.1 $ 63.8  
Bowers and Wilkins      
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]      
Royalty prepayment     $ 20.0
Deferred revenue 14.6   $ 35.0
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-03-31      
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]      
Unrecognized contract revenue $ 1,508.3    
Revenue remaining performance obligation, expected timing of satisfaction 1 year    
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-03-31 | Twelve Months and Thereafter      
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]      
Unrecognized contract revenue $ 395.8    
Revenue remaining performance obligation, expected timing of satisfaction 12 months    
XML 91 R80.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Deferred Revenue and Other Contract Liabilities, Current - Schedule of Changes in Deferred Revenue (Details)
$ in Millions
 3 Months Ended
Mar. 30, 2024
USD ($)
Movement in Deferred Revenue [Roll Forward]  
Deferred revenue, beginning of the period $ 63.8
Revenue deferred during the period 8.4
Recognition of revenue deferred in prior periods (9.1)
Deferred revenue, end of the period $ 63.1
XML 92 R81.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Other Current Liabilities (Details) - USD ($)
$ in Millions
Mar. 30, 2024
Dec. 30, 2023
Other Current Liabilities [Line Items]    
Long-term debt, current $ 34.6 $ 34.3
Accrued indirect taxes payable 29.1 23.9
Accrued expenses 27.6 26.3
Lessee lease liabilities, current 19.3 18.2
Income tax payable 10.5 16.1
Accrued property taxes 9.4 10.2
Accrued warranty 8.1 8.6
Accrued legal fees 7.7 9.9
Accrued donations 2.0 4.0
Licensing agreement, current 3.0 0.0
Total other current liabilities 165.9 162.4
Other current liability 0.5  
Nonrelated Party    
Other Current Liabilities [Line Items]    
Other current liabilities, related party payables 9.6 6.7
Related Party    
Other Current Liabilities [Line Items]    
Other current liabilities, related party payables $ 5.0 $ 4.2
XML 93 R82.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Debt - Schedule of Debt (Details) - USD ($)
$ in Millions
Mar. 30, 2024
Dec. 30, 2023
Debt Instrument [Line Items]    
Debt, current portion $ 34.6 $ 34.3
Debt, long-term 841.4 871.7
Total debt 876.0 906.0
Term Loan    
Debt Instrument [Line Items]    
Debt, current portion 13.1 11.3
Debt, long-term 268.1 271.4
Revolver    
Debt Instrument [Line Items]    
Debt, long-term 565.5 591.5
Japanese Loans    
Debt Instrument [Line Items]    
Debt, current portion 21.5 23.0
Debt, long-term $ 7.8 $ 8.8
XML 94 R83.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Debt - Narrative (Details)
 1 Months Ended 3 Months Ended
Feb. 28, 2023
USD ($)
Apr. 11, 2022
USD ($)
Mar. 31, 2020
USD ($)
Mar. 30, 2024
USD ($)
Apr. 01, 2023
USD ($)
Feb. 28, 2023
JPY (¥)
May 16, 2022
USD ($)
May 31, 2021
USD ($)
May 31, 2021
JPY (¥)
Apr. 30, 2021
USD ($)
Apr. 30, 2021
JPY (¥)
Jun. 30, 2020
USD ($)
Jun. 30, 2020
JPY (¥)
Mar. 31, 2020
JPY (¥)
New Credit Facility Agreement                            
Debt Instrument [Line Items]                            
Accordion feature, increase limit   $ 400,000,000                        
New Credit Facility Agreement | Adjusted Secured Overnight Financing Rate (SOFR)                            
Debt Instrument [Line Items]                            
Variable rate   1.00%                        
New Credit Facility Agreement | Fed Funds Effective Rate Overnight Index Swap Rate                            
Debt Instrument [Line Items]                            
Variable rate   0.50%                        
New Credit Facility Agreement | Adjusted Secured Overnight Financing Rate (SOFR), One-Month Interest Period                            
Debt Instrument [Line Items]                            
Variable rate   0.10%                        
New Credit Facility Agreement | Adjusted Secured Overnight Financing Rate (SOFR), Three-Month Interest Period                            
Debt Instrument [Line Items]                            
Variable rate   0.15%                        
New Credit Facility Agreement | Adjusted Secured Overnight Financing Rate (SOFR), Six-Month Interest Period                            
Debt Instrument [Line Items]                            
Variable rate   0.25%                        
New Credit Facility Agreement | Minimum                            
Debt Instrument [Line Items]                            
Commitment fee percentage   0.15%                        
New Credit Facility Agreement | Minimum | Alternate Base Rate                            
Debt Instrument [Line Items]                            
Variable rate   0.00%                        
New Credit Facility Agreement | Minimum | Adjusted Secured Overnight Financing Rate (SOFR)                            
Debt Instrument [Line Items]                            
Variable rate   1.00%                        
New Credit Facility Agreement | Maximum                            
Debt Instrument [Line Items]                            
Commitment fee percentage   0.275%                        
New Credit Facility Agreement | Maximum | Alternate Base Rate                            
Debt Instrument [Line Items]                            
Variable rate   0.75%                        
New Credit Facility Agreement | Maximum | Adjusted Secured Overnight Financing Rate (SOFR)                            
Debt Instrument [Line Items]                            
Variable rate   1.75%                        
Japanese Government Loans                            
Debt Instrument [Line Items]                            
Debt instrument face amount                       $ 9,800,000 ¥ 1,480,000,000  
Average interest rate                       1.33% 1.33%  
Japanese Equipment Loans                            
Debt Instrument [Line Items]                            
Debt instrument face amount               $ 500,000 ¥ 80,000,000 $ 1,000,000 ¥ 150,000,000      
Average interest rate               1.20% 1.20% 0.58% 0.58%      
Revolving Credit Facility                            
Debt Instrument [Line Items]                            
Interest expense       $ 11,200,000 $ 10,900,000                  
Revolving Credit Facility | New Credit Facility Agreement                            
Debt Instrument [Line Items]                            
Maximum borrowing capacity   $ 500,000,000         $ 705,000,000              
Accordion feature, increase limit             $ 205,000,000              
Revolving Credit Facility | Line of Credit | Japanese Revolving Loan                            
Debt Instrument [Line Items]                            
Maximum borrowing capacity $ 19,800,000   $ 5,300,000     ¥ 3,000,000,000               ¥ 800,000,000
Debt issuance costs $ 100,000   $ 50,000.00     ¥ 22,000,000               ¥ 7,200,000
Variable rate 0.75%   0.50%                      
Revolving Credit Facility | Line of Credit | Initial Lenders                            
Debt Instrument [Line Items]                            
Debt issuance costs   8,400,000                        
Unsecured Debt | New Credit Facility Agreement                            
Debt Instrument [Line Items]                            
Maximum borrowing capacity   300,000,000                        
Letter of Credit | New Credit Facility Agreement                            
Debt Instrument [Line Items]                            
Maximum borrowing capacity   $ 50,000,000                        
XML 95 R84.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Debt - Schedule of Maturities of Long-term Debt (Details)
$ in Millions
Mar. 30, 2024
USD ($)
Debt Disclosure [Abstract]  
2024 (balance of year) $ 30.5
2025 16.6
2026 16.6
2027 809.0
2028 1.0
Thereafter 2.3
Total $ 876.0
XML 96 R85.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Other Non-Current Liabilities (Details) - USD ($)
$ in Millions
Mar. 30, 2024
Dec. 30, 2023
Other Liabilities Disclosure [Abstract]    
Lessee non-current lease liabilities $ 61.5 $ 45.8
Deferred revenue, non-current 26.4 26.4
Unrecognized tax benefits 26.8 24.4
Projected benefit obligation 9.2 9.5
Income tax payable, non-current 7.1 7.1
Licensing agreement, non-current 4.5 0.0
Indirect tax payable, non-current 0.0 8.4
Other 4.5 7.9
Total other non-current liabilities $ 140.0 $ 129.5
XML 97 R86.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Derivative Instruments and Hedging Activities - Narrative (Details) - USD ($)
$ in Millions
 3 Months Ended 12 Months Ended
Mar. 30, 2024
Apr. 01, 2023
Mar. 30, 2025
Derivative Instruments and Hedging Activities Disclosures [Line Items]      
Net of tax gain (loss) on derivatives $ 4.9 $ (4.3)  
Forecast | Interest Expense      
Derivative Instruments and Hedging Activities Disclosures [Line Items]      
Net of tax gain (loss) on derivatives     $ 11.8
Designated as Hedging Instrument | Interest rate contracts, inclusive of accrued interest      
Derivative Instruments and Hedging Activities Disclosures [Line Items]      
Average fixed interest rate related to derivative contracts 3.22%    
Maturities of derivative contracts 3 years    
XML 98 R87.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Derivative Instruments and Hedging Activities - Schedule of Derivative Instruments in Statement of Financial Position, Fair Value (Details) - Designated as Hedging Instrument - USD ($)
$ in Millions
Mar. 30, 2024
Dec. 30, 2023
Derivative Instruments and Hedging Activities Disclosures [Line Items]    
Fair value of hedging instruments $ 14.4 $ 8.0
Interest rate contracts, inclusive of accrued interest | Other non-current assets    
Derivative Instruments and Hedging Activities Disclosures [Line Items]    
Fair value of hedging instruments 14.4 11.6
Interest rate contracts, inclusive of accrued interest | Other non-current liabilities    
Derivative Instruments and Hedging Activities Disclosures [Line Items]    
Fair value of hedging instruments $ 0.0 $ (3.6)
XML 99 R88.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Derivative Instruments and Hedging Activities - Schedule of Reclassification out of Accumulated Other Comprehensive Income (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 30, 2024
Apr. 01, 2023
Derivative Instruments and Hedging Activities Disclosures [Line Items]    
Gains (losses) reclassified from accumulated other comprehensive income $ (4.3) $ (3.0)
Designated as Hedging Instrument | Interest rate contracts, inclusive of accrued interest | Non-operating (loss)    
Derivative Instruments and Hedging Activities Disclosures [Line Items]    
Gains (losses) reclassified from accumulated other comprehensive income   $ (3.0)
XML 100 R89.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Derivative Instruments and Hedging Activities - Schedule of Accumulated Other Comprehensive Income (Loss) (Details) - Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest - USD ($)
$ in Millions
 3 Months Ended
Mar. 30, 2024
Apr. 01, 2023
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]    
Beginning balance $ 7.8 $ 19.3
Amount recognized in other comprehensive income (loss) 10.8 (2.7)
Amount reclassified into earnings (4.3) (3.0)
Ending balance $ 14.3 $ 13.6
XML 101 R90.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Business Combinations - Narrative (Details) - Sound United - USD ($)
$ in Millions
 3 Months Ended
Apr. 11, 2022
Mar. 30, 2024
Apr. 01, 2023
Business Acquisition [Line Items]      
Percentage of voting interests acquired 100.00%    
Cash consideration $ 1,057.5    
Revenue   $ 152.4 $ 216.6
Net loss   (11.6) 3.3
Transaction costs   $ 0.0 $ 0.0
XML 102 R91.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Business Combinations - Fair Value of Assets Acquired and Liabilities Assumed (Details) - USD ($)
$ in Millions
Apr. 11, 2022
Mar. 30, 2024
Dec. 30, 2023
Assets acquired:      
Goodwill   $ 396.0 $ 407.7
Sound United      
Business Acquisition [Line Items]      
Cash consideration $ 1,057.5    
Purchase price 1,057.5    
Assets acquired:      
Cash and cash equivalents 82.6    
Accounts receivables 108.5    
Inventories 238.6    
Prepaid expenses and other current assets 30.0    
Property, plant and equipment 113.2    
Intangible assets 649.0    
Goodwill 318.0    
Long-term other assets 7.4    
Total assets acquired 1,547.3    
Liabilities assumed:      
Accounts payable (118.8)    
Accrued liabilities and other current liabilities (148.9)    
Deferred tax liabilities (145.1)    
Other long-term liabilities (77.0)    
Total liabilities assumed $ (489.8)    
XML 103 R92.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Business Combinations - Schedule of Acquired Intangible Assets (Details) - Sound United
$ in Millions
Apr. 11, 2022
USD ($)
Business Acquisition [Line Items]  
Weighted average amortization period (in years) 14 years
Finite lived intangible assets $ 387.0
Indefinite intangible assets 262.0
Total $ 649.0
Trademarks/tradenames  
Business Acquisition [Line Items]  
Weighted average amortization period (in years) 10 years
Finite lived intangible assets $ 6.0
Customer relationships  
Business Acquisition [Line Items]  
Weighted average amortization period (in years) 17 years
Finite lived intangible assets $ 196.0
Developed technology  
Business Acquisition [Line Items]  
Weighted average amortization period (in years) 8 years
Finite lived intangible assets $ 156.0
Contractual license agreements  
Business Acquisition [Line Items]  
Weighted average amortization period (in years) 15 years
Finite lived intangible assets $ 29.0
XML 104 R93.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Equity (Details) - $ / shares
 3 Months Ended
Mar. 30, 2024
Dec. 30, 2023
Sep. 20, 2022
Jun. 30, 2022
Class of Stock [Line Items]        
Preferred stock, par value (in dollars per share) $ 0.001 $ 0.001    
Repurchase of common stock (in shares) 0      
Rights to Purchase Series A Junior Participating Preferred Stock        
Class of Stock [Line Items]        
Preferred stock purchase right declared for each share of common stock     1  
Preferred stock, par value (in dollars per share)     $ 0.001  
Purchase price per each right (in dollars per share)     $ 1,000  
Rights to Purchase Series A Junior Participating Preferred Stock | Minimum        
Class of Stock [Line Items]        
Threshold percentage to exercise purchase right     10.00%  
Rights to Purchase Series A Junior Participating Preferred Stock | Maximum        
Class of Stock [Line Items]        
Threshold percentage to exercise purchase right     20.00%  
Common Stock | 2022 Repurchase Program        
Class of Stock [Line Items]        
Number of common shares authorized to be repurchased under new stock repurchase program       5,000,000
Stock repurchase program, remaining number of shares available for repurchase (in shares) 5,000,000      
XML 105 R94.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Stock-Based Compensation - Narrative (Detail) - USD ($)
$ in Millions
 1 Months Ended 3 Months Ended
May 31, 2020
Mar. 30, 2024
Apr. 01, 2023
Jun. 01, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Stock compensation (benefit) expense   $ 9.6 $ 7.3  
Common stock, capital shares reserved for future issuance (in shares)   9,700,000    
Options available for grant, end of period (in shares)   3,100,000    
Award vesting period   three    
Aggregate intrinsic value of options outstanding   $ 169.8    
Aggregate intrinsic value of options exercisable   167.4    
Employee Stock Option        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Stock compensation (benefit) expense   2.1 2.4  
Share-based payment arrangement, cost not yet recognized, amount   $ 19.6    
Share-based payment arrangement, period for recognition (in years)   3 years 1 month 6 days    
Restricted Stock Units (RSUs)        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Stock compensation (benefit) expense   $ 7.2 4.2  
Share-based payment arrangement, nonvested award, cost not yet recognized, amount   $ 106.4    
Share-based compensation arrangement outstanding, weighted average remaining contractual terms (in years)   3 years 8 months 12 days    
Granted (in units)   200,000    
Performance Shares        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Stock compensation (benefit) expense   $ 0.3 $ 0.7  
Share-based payment arrangement, nonvested award, cost not yet recognized, amount   $ 40.4    
Share-based compensation arrangement outstanding, weighted average remaining contractual terms (in years)   1 year 10 months 24 days    
Granted (in units)   100,000    
Performance Shares | Minimum | 2021 PSU Grant        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Granted (in units)   155,156    
Share-based compensation arrangement by share-based payment award, range of percentage payout   0.00%    
Performance Shares | Maximum | 2021 PSU Grant        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Share-based compensation arrangement by share-based payment award, range of percentage payout   200.00%    
2017 Equity Incentive Plan        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Share-based compensation, number of additional shares authorized (in shares) 2,500,000      
2017 Equity Incentive Plan | Minimum        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Options available for grant, end of period (in shares)       5,000,000
2017 Equity Incentive Plan | Maximum        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Options available for grant, end of period (in shares) 7,500,000      
2007 Stock Incentive Plan | Maximum        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Options available for grant, end of period (in shares) 5,000,000      
XML 106 R95.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Stock-Based Compensation - Schedule of Number and Weighted Average Exercise Price of Options Issued and Outstanding under all Stock Option Plans (Detail)
shares in Millions
 3 Months Ended
Mar. 30, 2024
$ / shares
shares
Shares  
Options outstanding, beginning of period (in shares) | shares 2.8
Granted (in shares) | shares 0.1
Canceled (in shares) | shares 0.0
Exercised (in shares) | shares (0.2)
Options outstanding, end of period (in shares) | shares 2.7
Options exercisable, end of period (in shares) | shares 2.3
Weighted-Average Exercise Price  
Options outstanding, beginning of period (in usd per share) | $ / shares $ 87.79
Granted (in usd per share) | $ / shares 126.49
Canceled (in usd per share) | $ / shares 162.00
Exercised (in usd per share) | $ / shares 44.11
Options outstanding, end of period (in usd per share) | $ / shares 91.51
Options exercisable, end of period (in dollars per share) | $ / shares $ 80.43
XML 107 R96.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Stock-Based Compensation - Schedule of Stock Units Activity (Detail) - $ / shares
shares in Millions
 3 Months Ended
Feb. 28, 2024
Mar. 30, 2024
Dec. 30, 2023
Restricted Stock Units (RSUs)      
Units      
Beginning of period (in shares)   3.5  
Granted (in units)   0.2  
Expired (in units)   0.0  
Vested (in units)   (0.1)  
End of period (in shares)   3.6  
Weighted-Average Grant Date Fair Value      
Beginning of period (in dollars per share)   $ 104.94 $ 105.87
Granted (in dollars per share)   126.36  
Canceled (in dollars per share)   157.76  
Vested (in dollars per share)   178.68  
End of period, fair value (in dollars per share)   $ 104.94  
Performance Shares      
Units      
Beginning of period (in shares)   0.3  
Granted (in units)   0.1  
Expired (in units)   0.0  
Vested (in units)   0.0  
End of period (in shares)   0.4  
Weighted-Average Grant Date Fair Value      
Beginning of period (in dollars per share)   $ 170.69 $ 190.04
Granted (in dollars per share)   164.19  
Canceled (in dollars per share)   250.73  
Vested (in dollars per share)   250.73  
End of period, fair value (in dollars per share)   $ 170.69  
Weighted payout percentage 28.00%    
Award vesting period 3 years    
XML 108 R97.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Stock-Based Compensation - Schedule of Range of Assumptions Used and Resulting Weighted-Average Fair Value of Options Granted at Date of Grant (Detail) - $ / shares
 3 Months Ended
Mar. 30, 2024
Apr. 01, 2023
Range of assumptions used and resulting weighted-average fair value of options granted at the date of grant    
Risk-free interest rate 4.20% 4.20%
Expected term (in years) 5 years 10 months 24 days 5 years 10 months 24 days
Estimated volatility 42.60% 36.70%
Expected dividends 0.00% 0.00%
Weighted-average fair value of options granted (in dollars per share) $ 59.60 $ 75.08
XML 109 R98.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Employee Benefits (Details)
$ in Millions
 3 Months Ended
Mar. 30, 2024
USD ($)
plan
Apr. 01, 2023
USD ($)
Defined Contribution Plan Disclosure [Line Items]    
Defined contribution plan, number of plans | plan 1  
Masimo Retirement Savings Plan    
Defined Contribution Plan Disclosure [Line Items]    
Percent of employees' gross pay 100.00%  
Percent of match 3.00%  
Company's contribution to employee retirement savings plan $ 1.3 $ 2.3
Masimo Retirement Savings Plan | Foreign Plan    
Defined Contribution Plan Disclosure [Line Items]    
Company's contribution to employee retirement savings plan $ 1.6 $ 0.8
XML 110 R99.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Non-operating Loss (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 30, 2024
Apr. 01, 2023
Nonoperating Income (Expense) [Abstract]    
Realized and unrealized foreign currency gains (losses) $ 1.9 $ (0.7)
Interest income 1.2 0.8
Interest expense (12.0) (11.9)
Other (0.2) 0.0
Total non-operating loss $ (9.1) $ (11.8)
XML 111 R100.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Income Taxes - Narrative (Detail) - USD ($)
$ in Millions
 3 Months Ended
Mar. 30, 2024
Apr. 01, 2023
Income Tax Disclosure [Abstract]    
Other tax benefit $ 1.3 $ 2.4
Gross unrecognized tax benefit 35.3  
Unrecognized tax benefit that would affect effective tax rate $ 32.7  
XML 112 R101.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Commitments and Contingencies (Detail)
$ in Millions
 1 Months Ended 3 Months Ended
Jan. 30, 2023
patent
Oct. 13, 2020
patent
Feb. 28, 2023
patent
Jul. 31, 2017
Mar. 30, 2024
USD ($)
distributor
customer
executiveOfficer
Apr. 01, 2023
distributor
Feb. 01, 2024
USD ($)
Dec. 30, 2023
USD ($)
customer
Oct. 20, 2022
complaint
Contingencies And Commitments [Line Items]                  
Severance plan participation agreements | executiveOfficer         6        
Required notice of resignation         6 months        
Royalty obligation         $ 5.0        
License fee         2.5        
Change in control         15.0        
Royalty guarantees, commitments, additional, change in control         2.0        
Remaining commitment         267.2        
Other commitment         5.1        
License agreement term (in year)             3 years    
Principal amount of license agreement             $ 9.0    
Licensing agreement outstanding obligation         7.5        
Licensing agreement, current         $ 3.0     $ 0.0  
Payable Lease amount (in month)         12 months        
Bank balances         $ 157.6        
Bank balance covered by federal deposit insurance corporation limit         $ 8.1        
Masimo Vs. Apple Inc                  
Contingencies And Commitments [Line Items]                  
Number of patents found infringed | patent 2   2            
Masimo Vs. Apple Inc | Pending Litigation                  
Contingencies And Commitments [Line Items]                  
Asserted patents found valid | patent   3              
Asserted patents found invalid | patent   9              
Apple, Inc. Patent Infringement | Pending Litigation                  
Contingencies And Commitments [Line Items]                  
Number of complaints | complaint                 2
Revenue Benchmark                  
Contingencies And Commitments [Line Items]                  
Distributors | distributor         1 1      
Accounts Receivable                  
Contingencies And Commitments [Line Items]                  
Concentration risk, AR balance one customer | customer         1     1  
GPO Members | Revenue Benchmark | Customer Concentration Risk                  
Contingencies And Commitments [Line Items]                  
Concentration risk, percentage         55.70% 51.00%      
Just in time distributor one | Revenue Benchmark | Customer Concentration Risk                  
Contingencies And Commitments [Line Items]                  
Concentration risk, percentage         16.10% 8.90%      
Customer One | Accounts Receivable | Customer Concentration Risk                  
Contingencies And Commitments [Line Items]                  
Percentage of accounts receivable balance         11.30%     18.10%  
Chief Executive Officer                  
Contingencies And Commitments [Line Items]                  
Severance payment period       3 years          
Qualifying termination         $ 479.7        
Chief Executive Officer | Cash Distribution                  
Contingencies And Commitments [Line Items]                  
Severance terms       50.00%          
Chief Executive Officer | Restricted Stock Units (RSUs)                  
Contingencies And Commitments [Line Items]                  
Severance terms       50.00%          
XML 113 R102.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Segment and Enterprise Reporting - Schedule of Segment Reporting Information, by Segment (Detail)
$ in Millions
 3 Months Ended
Mar. 30, 2024
USD ($)
segment
Apr. 01, 2023
USD ($)
Segment Reporting [Abstract]    
Number of operating segments | segment 2  
Number of reportable segments | segment 2  
Segment Reporting Information [Line Items]    
Total revenue by segment $ 492.8 $ 565.0
Gross profit: 241.7 284.8
Depreciation and amortization 24.3 26.1
Intersegment    
Segment Reporting Information [Line Items]    
Total revenue by segment 0.6 0.0
Operating Segments    
Segment Reporting Information [Line Items]    
Total revenue by segment 492.8 565.0
Segment Reconciling Items    
Segment Reporting Information [Line Items]    
Gross profit: (14.2) (7.8)
Healthcare    
Segment Reporting Information [Line Items]    
Depreciation and amortization 10.0 9.0
Healthcare | Operating Segments    
Segment Reporting Information [Line Items]    
Total revenue by segment 339.6 346.7
Gross profit: 211.4 214.8
Non-healthcare    
Segment Reporting Information [Line Items]    
Depreciation and amortization 14.3 17.1
Non-healthcare | Operating Segments    
Segment Reporting Information [Line Items]    
Total revenue by segment 153.2 218.3
Gross profit: $ 44.5 $ 77.8
EXCEL 114 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( '")IU@'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " !PB:=8)A7V9^X K @ $0 &1O8U!R;W!S+V-O&ULS9+/ M2L0P$(=?17)O)^FN"J';B^))07!!\1:2V=U@\X=DI-VW-ZV[740?P&-F?OGF M&YA61ZE#PN<4(B:RF*]&U_LL==RP U&4 %D?T*E!S[%BZ "4:87/XNH%F(<_5/[-P!=DJ.V2ZI81CJ837GR@X"WIX>7^9U*^LS M*:^Q_,I6TC'BAITGOZ[N[K621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X M8-DOV]:[MR_>X%#BVR]*+ M41B1%G\@M MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7 MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V< M/!T3$LV4"P9!AI@S M&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0' MHYI9";V$5FJ?JH,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RSTS0LS0[=R2^JVE+ZU)CA* M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D* MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-# MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P MOFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2 MD 83 >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+ M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5 M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0 ( M '")IU@Z%B1T&@4 !T5 8 >&PO=V]R:W-H965T&UL MC9AK<^HV$(;_BL;M=,Z9";$MWT@[ %>&);KB1#^/== MV6!S4K/F"[[@??WHXG=7&FZ%?%=KSC7YB*-$75MKK=,KVU;^FL=,78J4)_#/ M4LB8:;B4*UNEDK,@#XHCFSI.UXY9F%BC87YO)D=#D>DH3/A,$I7%,9.[&QZ) M[;7E6H<;K^%JKS1,V8K/N?X]G4FXLDN5((QYHD*1$,F7U];8O;KQJ G( MG_@CY%MU=$Y,4Q9"O)N+:7!M.8:(1]S71H+!8<,G/(J,$G#\NQ>URG>:P./S M@_I]WGAHS((I/A'1GV&@U]=6WR(!7[(LTJ]B^RO?-ZAC]'P1J?R7;(MGVVV+ M^)G2(MX' T$<)L61?>P[XBC 3<2&RZ&M0>11)'JMR%T2\.#[ M>!L02@YZX+BAJ. CDY?$'A[M.ZP6AZ)04G?,H7C(F-9?1CKSR5$A=1X1+:9EQA*A;$G7/(YIQ&8K M3#,"\[NVBW"ED?NPXB3IRQ>U'_2N(;CN"W/Z[8IPC,H>0;G\+SR56@^/.BL)Q;7#AZN\SB> M3Q^?R>3Y=890N4YE=LXY7-/$%Q)&C)G!NR!S#3.+"$DF(DNTW,$QJ(5M4+^] MPR"/'-D]!_*-?9!I !,M7(9^3HH,;8.DY[4;R@W< MN<#0*L]W<=?^C%;.OYD4\!:_OO]PSTF5":1>2O,#W]4>"* M ]IU^QA;E1)BO6BQ<:2+B&+QFKH7_?D%^ M="XA,9"42;)A$9K;W2H[N+BM0^8,PF1%YKMX(:):QN:\@!6=54*@N&4?^HG< M??AKEJSXR435(/0TGM^.L5J,5OY/S_+_22:E*3.*VB+O+O")3-7"X8K?T%J: M5KY/S_+]:0(U8K&<,D49.Z#6DN&*#625V].SW-X40)#&P4Y7XG,>V?/@.@], MPAP8^SXL&Z$\X$$AB3%6MD]QBY['+#)XU8#"IY:RI)X3UVHJ'&GE^+3!\6,N M5P;F%PC5:Y0)5VIDJIR>XD:]'\WY&A;K*! NTPA4^3W%K?KP27YGC?-\D4J> M,PTY,C&&5LM8*'=R9;-'LAEU/*??Z72Z0WM31U5Y/L6=>@S+D"!?BMQ'K/[E MN$!C!U6.3G%#+A=%]U#$06K\QB%AW,/->KO"Q1H6:E[E[EY#0?Z):K^8/,G5 M(/?B8E25OWOG^3N 28":)@'_(+_QVAG>( 75@S/P>OE<.DU6^;N'N_$AY1P/ M(K;R;I!KM5S:HK7%GWVT8V4,*-^74\0W"[!B\ZJ\6^[]C8L=K^KQ8N,0%OC@ M7XI$? FASF4//C59[,45%UJD^?[70F@MXOQTS5G I7D _E\*H0\7Y@7ECNCH M/U!+ P04 " !PB:=8]HPV,9!:V5:@EZ#IML^,S,1" M98K'F2C>9GU;DK M.3_+MRI-,G$E2;%=K[E\?"_2_.%\1$=/)[XF=RM5GIC,SS;\3EP+]>?F2L*G M29-EF:Q%5B1Y1J2X/1]=T+>1%Y0%JHB_$O%0[!V34LI-GG\O/WQ8GH^/%Y<4FN_[B\_'9- M3LF?UQ'YY'>Y]_7EV#.7^\3EF+C."6$. M\RS%%WCQ2,1-<==2/,*+7VS@Z@ZU%9^ ;XUYK#&/5?G&Q.!]!IRV$O!>C^<\_T0I&6BVL4P55JG(4NY]3/QP'9Y/[?6_JJ' _*G#;,9$E M4^B-:1/5TN(U6CQ4RS?)EP*&KSC?@@ 8"F,!:FY2<4(R&+;S6\)3&%QY%@L" MPS2)I5@FBJ0YM)FB_/J--PZA9U<]JC(%3DSU"46@S\2KVONGGE/%06<0ZQLA M6U^Y)U"%8B.JX31]M!E:ZYGNV>"ZSCCL&&J)\OVQW[$4]:9G*_(;YWW4^0_9 M/;297";"VFY\0X#O!'MWNY991_G[45Y7)%J-GB*#1F2 BKRHAA:R$NFR:CX% M=!2;VL!02^G8ZXA%+W7L !(8SCGVGA0V4D-4ZA>U$M _#HZIH2G5GXVG':V6 MJ&#:=21":]3SUDX;O5-\Y,@53U^@=VJYM8%OC("6,.;2\:RC&*U33\6S1O$, M5?Q1 *&UA\@\.]TY8),^,S2%SK@SK"\L0=#TG;U_G4X?H;7LZ0%U-'$YJ N1 MN!6@&)Y^>0%=NQS*\[KIYYF2 ,)(6]BE;HUJ8?<>+^Q1W<9'JL3*@9( -3"=4]=2T*J?&>.-1ORN<&L(]YAF]'J]97^6:&BD*5_/? MDBQ1XC2%)_02<%KQ["Z!WK"[[<\[P$QQU!VSK@>VL)DQ#N!U[.N!)D"*(V"% M33#3_%[ Y.*7S[D29/:K5;5KR&&,&;AB"W.9>>?16O55K5F1XK#X>YXO'X#L MK$(]HX&[L^X@3TTL\YRPZT:$5Z.O3 UF%">S9H13_ "6-= MS:^!:51S&L5!K::7O><9)MQ":X[111>6L.G,',8'HKJV;@UM%*>VFF(0K2:( ML9EO--F%)F;R00?"K)TW0V:+ALK6 M=E S(,4A\.)IJKSACR4$6NTSF8XYKCDR6,)\2Y-Y#=YCFO<8SGL@6&XKW%MO M1%;PIKV3-=@QGN^8!( 7,T;?"!KE[/>B$ M(', 9H)?Z'1-,;EO:@(O7NF^INPM%N+8UY[?'AA F$EQY:2O^XBPAIG8@]>L MKW(->^P [+5FNH>4FR3G.Y[9#RQA@=M=!HCPFO55KH&/X<#W,<_N3I60:[(4 M-_;F;1+=U#.7;FQA,,WM@A]>G;YR-?BQ(\#OT'VV85U@MG!+&+4(?PWZ8YK^ MV+'T=TB]N7Q&/6-8LW BFQG/-[QN?;5K F0O(JVK=JRK96&+"\+ O-^O M@8%,8R##U^X6^7J=J'+!HE[ *9]J278GLACT-S-:YEFGM'AN>]V)=4-HH$11 MGT2'W=1(R&8H5%^K//Z^RM.ED,7//TT9#=]5*T+*NG_!!L*YG8=#9HN&RM;> M5M.HZ>*H>26?!N"BM/2$O''&CD,!M26YY^E6O"/^V&DVEXH5AUH0OE6K7";_ MBN4[XCR=3(JBA-8*W+:J4' #=RZ0><@.P&[W;F#(1&NK*]SFEA=G%C+#ETZ M\IQMU'%PXWR8GK2V\7RVMXV'FOH:FWRN2<2.,7]Z25"$&]?WQFAJ=G%J_B8% M+[;R\>G64'C^M7QNG7BZ,:]@J$G:IY0&,P-,7QH8X<+[&KNW!X]#^<5RF913 M47AV;WBR/$TR$O-- L]RJWP3M\.99]":+6SJ&O,1O&I]I6LJ=W$JAQGY=KU- MN1)Z5KJ&*ZW*]YGN1;4Y;S7!A/#3T#V>+"F6],Q_ Z]=6L,=W%,;U&U>(HW' M$.Y:%F;L M<9YI01W7>@VE? %#-X^V.,WA[I$<7HUW1XI]X6JM)_]UICN'L#T MZ@4ZZ-]2I-6Z6[%*-O:&/NB"[:#9HJ&RM4W4=.[B='[X+3=W4"(?-%LT5+;V MRV&:R#VS]44,XTVU*B3B59:G M^=TSBP1XGF/;T:#9HJ&RM3W4&.S]WU=-O4'?-1TT6S14MK9Y&G4]''7[=D(3 M9JGY)L7"%L9F!O/B=>SKP=YKJCCSUBN4=O$'7L' ,Q_=LH;,%@V5K>VJAFC/ M_[_=SB-]^V6==;6N]ZLNU_B62B;,@/&\1H>Z\!D M[W<8Y:]F/G%YEV0%2<4MI'?&(?@MZQ^BU!]4OJE^FG&3*^#4ZG E.*!Z&0#? MW^;0*W&PO=V]R:W-H965T&ULK9;;;MLX$(9?A= 610)DK8//J2W ML1VT0)L:==I>+/:"D<<6$4K4DK3=]NEW*"FJY,ARG-T;FQ1G?GTS&I(SV@OY MJ$( 37Y$/%9C*]0ZN;9M%8004=42"<2XLA8RHAJG3UW/.*06WQCL56E,3"@/0CR:R8?5V'(,$7 ( MM)&@^+>#*7!NE)#CGUS4*MYI',OC)_7;-'@,YH$JF K^G:UT.+8&%EG!FFZY M_B+V[R$/J&OT L%5^DOVN:UCD6"KM(AR9R2(6)S]TQ]Y(DH.;N>(@Y<[>"]U M:.<.[330C"P-:T8U]4=2[(DTUJAF!FEN4F^,AL7F,RZUQ%6&?MJ??KZ;S>^6 M\QG!T?+SQP^SR3U.;B8?)W?3.5F^G\_OE^1B027$.@3- LHOR9_DZW)&+MY< M$A7BBB(L)I\8Y_AAU!5Y4YZ.;(V8YF5VD"/=9$C>$:1/5+9(V[DBGN-U:MRG MS>XS" KW=M7=QN04&?**#'FI7ON(WE)3#5BXFH@UN64QC0-&.5D(Q=)"_&OR MH+3$U07^/XE5TM NTM!N M4O)-%!;I70/=> M! MBBC"\^8_%/;@185]RJH"/RS@AV? GUW5PV?)=)W#A#?;5*A=Y_?UZ)S-??7" MRLZE!^6=UFX=IKO.RCMV#KJE>]U]!?@9%9[KGZ*OL3I.__O.=1OO,O\>6U*U ME3\/"N84LO<,QAVV#L^_4U89LEWJJ4Q#BUW)AL6*<%BCF]/J8Z')K$?,)EHD M:9OU(#0V;>DPQ+X:I#' ];40^FEB.K>B4_?_!5!+ P04 " !PB:=8V29& MY+($ #4$0 & 'AL+W=O5>H+ MB<.]U^=<7]\39WRD[ ??8BS 6T9R/K&V0NQN'(?'6YPA;M,=SN4_:\HR).20 M;1R^8Q@EA5-&',]U(R=#:6Y-Q\6S)S8=T[T@:8Z?&.#[+$/LWUM,Z'%B0>OT MX#G=;(5ZX$S'.[3!*RR^[9Z8'#EUE"3-<,Y3F@.&UQ-K!F_F7N%06/R5XB-O MW0-%Y972'VIPGTPL5R'"!,="A4#RP:L 5/6,IJZ*7)3 M>$LV::Z6<268_#>5?F(Z?UPN[I:KNP60=ZO'/^\7LQ[Y]G+O30 U^#;:@$^?_H"^!8QS$&:@X>4$+DD_ I\:@_'CI U31.7(&Y M+<%X/6!\\$!SL>7@+D]PP4\UPLT>.9F]]E. MNKNPOC#%L M3>R%T(87\#160]?V] "C&F!D!/@[HYR#':/K5.B@1=U) V@/+J!IK(9!*[]G MT 8UM(&QCA]WF"&1YAN WZ2><,QO= @''UF_'Q3LC.^PYCLT+L5*JHQD>P4V M.)?,"4!Y E BVW&JMJ\2(AW_82?W,!S9HXL5TEB-(MO7K]"H1CSZGQW',6+Q MMD":R.U'Z$YU'!W,40= ,.CLP*Y1Z-H]6Q"ZC?BX1I@O5,ALTDXY::7#[9:R M.^@4O,XLB/HJ'K9T$AJA-C6?%EU<"[$,$;;F]H-+?!J;/G!> \XS@EO2_+K) M(I&-0PO/ZZ3F>M1I9CHK"'L3V&@?-$K,2?Q>L7SWQ*JO'=+B75 .JY0"@=YZ MUM[7+&IG)^FLHKXV#!OQ@F;U>GH?U*"SOM$ESJ"[XUIDSF$V>@;-@K:4[_R& MT@P[0@N'W0QVK3S8UXM@HV0P,NI% PW((BW?'+6* 8V2^%[)^*AHYZP;D81& M39K>(I[&X+-\(TXH(8CQAOP7+?DRG&I@=?9=V^]4C]8LZ%FC1N*@6>,6*=D+ MG+P'[U"+-[S$JS?KJ_=&X>#(6%3?BQ,:3J[103:^#3X=2/9
  •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end XML 115 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 116 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 118 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.u1 html 285 496 1 false 108 0 false 15 false false R1.htm 0000001 - Document - Cover Sheet http://www.masimo.com/role/Cover Cover Cover 1 false false R2.htm 0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://www.masimo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS CONDENSED CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 0000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.masimo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 0000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS Sheet http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS Statements 5 false false R6.htm 0000006 - Statement - CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY Sheet http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY Statements 6 false false R7.htm 0000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 7 false false R8.htm 0000008 - Disclosure - Description of the Company Sheet http://www.masimo.com/role/DescriptionoftheCompany Description of the Company Notes 8 false false R9.htm 0000009 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.masimo.com/role/SummaryofSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 9 false false R10.htm 0000010 - Disclosure - Related Party Transactions Sheet http://www.masimo.com/role/RelatedPartyTransactions Related Party Transactions Notes 10 false false R11.htm 0000011 - Disclosure - Inventories Sheet http://www.masimo.com/role/Inventories Inventories Notes 11 false false R12.htm 0000012 - Disclosure - Other Current Assets Sheet http://www.masimo.com/role/OtherCurrentAssets Other Current Assets Notes 12 false false R13.htm 0000013 - Disclosure - Lease Receivable Sheet http://www.masimo.com/role/LeaseReceivable Lease Receivable Notes 13 false false R14.htm 0000014 - Disclosure - Deferred Costs and Other Contract Assets Sheet http://www.masimo.com/role/DeferredCostsandOtherContractAssets Deferred Costs and Other Contract Assets Notes 14 false false R15.htm 0000015 - Disclosure - Property and Equipment, net Sheet http://www.masimo.com/role/PropertyandEquipmentnet Property and Equipment, net Notes 15 false false R16.htm 0000016 - Disclosure - Intangible Assets, net Sheet http://www.masimo.com/role/IntangibleAssetsnet Intangible Assets, net Notes 16 false false R17.htm 0000017 - Disclosure - Goodwill Sheet http://www.masimo.com/role/Goodwill Goodwill Notes 17 false false R18.htm 0000018 - Disclosure - Lessee ROU Assets and Lease Liabilities Sheet http://www.masimo.com/role/LesseeROUAssetsandLeaseLiabilities Lessee ROU Assets and Lease Liabilities Notes 18 false false R19.htm 0000019 - Disclosure - Other Non-Current Assets Sheet http://www.masimo.com/role/OtherNonCurrentAssets Other Non-Current Assets Notes 19 false false R20.htm 0000020 - Disclosure - Deferred Revenue and Other Contract Liabilities, Current Sheet http://www.masimo.com/role/DeferredRevenueandOtherContractLiabilitiesCurrent Deferred Revenue and Other Contract Liabilities, Current Notes 20 false false R21.htm 0000021 - Disclosure - Other Current Liabilities Sheet http://www.masimo.com/role/OtherCurrentLiabilities Other Current Liabilities Notes 21 false false R22.htm 0000022 - Disclosure - Debt Sheet http://www.masimo.com/role/Debt Debt Notes 22 false false R23.htm 0000023 - Disclosure - Other Non-Current Liabilities Sheet http://www.masimo.com/role/OtherNonCurrentLiabilities Other Non-Current Liabilities Notes 23 false false R24.htm 0000024 - Disclosure - Derivative Instruments and Hedging Activities Sheet http://www.masimo.com/role/DerivativeInstrumentsandHedgingActivities Derivative Instruments and Hedging Activities Notes 24 false false R25.htm 0000025 - Disclosure - Business Combinations Sheet http://www.masimo.com/role/BusinessCombinations Business Combinations Notes 25 false false R26.htm 0000026 - Disclosure - Equity Sheet http://www.masimo.com/role/Equity Equity Notes 26 false false R27.htm 0000027 - Disclosure - Stock-Based Compensation Sheet http://www.masimo.com/role/StockBasedCompensation Stock-Based Compensation Notes 27 false false R28.htm 0000028 - Disclosure - Employee Benefits Sheet http://www.masimo.com/role/EmployeeBenefits Employee Benefits Notes 28 false false R29.htm 0000029 - Disclosure - Non-operating Loss Sheet http://www.masimo.com/role/NonoperatingLoss Non-operating Loss Notes 29 false false R30.htm 0000030 - Disclosure - Income Taxes Sheet http://www.masimo.com/role/IncomeTaxes Income Taxes Notes 30 false false R31.htm 0000031 - Disclosure - Commitments and Contingencies Sheet http://www.masimo.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 31 false false R32.htm 0000032 - Disclosure - Segment and Enterprise Reporting Sheet http://www.masimo.com/role/SegmentandEnterpriseReporting Segment and Enterprise Reporting Notes 32 false false R33.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 33 false false R34.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 34 false false R35.htm 9954471 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.masimo.com/role/SummaryofSignificantAccountingPolicies 35 false false R36.htm 9954472 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://www.masimo.com/role/SummaryofSignificantAccountingPolicies 36 false false R37.htm 9954473 - Disclosure - Inventories (Tables) Sheet http://www.masimo.com/role/InventoriesTables Inventories (Tables) Tables http://www.masimo.com/role/Inventories 37 false false R38.htm 9954474 - Disclosure - Other Current Assets (Tables) Sheet http://www.masimo.com/role/OtherCurrentAssetsTables Other Current Assets (Tables) Tables http://www.masimo.com/role/OtherCurrentAssets 38 false false R39.htm 9954475 - Disclosure - Lease Receivable (Tables) Sheet http://www.masimo.com/role/LeaseReceivableTables Lease Receivable (Tables) Tables http://www.masimo.com/role/LeaseReceivable 39 false false R40.htm 9954476 - Disclosure - Deferred Costs and Other Contract Assets (Tables) Sheet http://www.masimo.com/role/DeferredCostsandOtherContractAssetsTables Deferred Costs and Other Contract Assets (Tables) Tables http://www.masimo.com/role/DeferredCostsandOtherContractAssets 40 false false R41.htm 9954477 - Disclosure - Property and Equipment, net (Tables) Sheet http://www.masimo.com/role/PropertyandEquipmentnetTables Property and Equipment, net (Tables) Tables http://www.masimo.com/role/PropertyandEquipmentnet 41 false false R42.htm 9954478 - Disclosure - Intangible Assets, net (Tables) Sheet http://www.masimo.com/role/IntangibleAssetsnetTables Intangible Assets, net (Tables) Tables http://www.masimo.com/role/IntangibleAssetsnet 42 false false R43.htm 9954479 - Disclosure - Goodwill (Tables) Sheet http://www.masimo.com/role/GoodwillTables Goodwill (Tables) Tables http://www.masimo.com/role/Goodwill 43 false false R44.htm 9954480 - Disclosure - Lessee ROU Assets and Lease Liabilities (Tables) Sheet http://www.masimo.com/role/LesseeROUAssetsandLeaseLiabilitiesTables Lessee ROU Assets and Lease Liabilities (Tables) Tables http://www.masimo.com/role/LesseeROUAssetsandLeaseLiabilities 44 false false R45.htm 9954481 - Disclosure - Other Non-Current Assets (Tables) Sheet http://www.masimo.com/role/OtherNonCurrentAssetsTables Other Non-Current Assets (Tables) Tables http://www.masimo.com/role/OtherNonCurrentAssets 45 false false R46.htm 9954482 - Disclosure - Deferred Revenue and Other Contract Liabilities, Current (Tables) Sheet http://www.masimo.com/role/DeferredRevenueandOtherContractLiabilitiesCurrentTables Deferred Revenue and Other Contract Liabilities, Current (Tables) Tables http://www.masimo.com/role/DeferredRevenueandOtherContractLiabilitiesCurrent 46 false false R47.htm 9954483 - Disclosure - Other Current Liabilities (Tables) Sheet http://www.masimo.com/role/OtherCurrentLiabilitiesTables Other Current Liabilities (Tables) Tables http://www.masimo.com/role/OtherCurrentLiabilities 47 false false R48.htm 9954484 - Disclosure - Debt (Tables) Sheet http://www.masimo.com/role/DebtTables Debt (Tables) Tables http://www.masimo.com/role/Debt 48 false false R49.htm 9954485 - Disclosure - Other Non-Current Liabilities (Tables) Sheet http://www.masimo.com/role/OtherNonCurrentLiabilitiesTables Other Non-Current Liabilities (Tables) Tables http://www.masimo.com/role/OtherNonCurrentLiabilities 49 false false R50.htm 9954486 - Disclosure - Derivative Instruments and Hedging Activities (Tables) Sheet http://www.masimo.com/role/DerivativeInstrumentsandHedgingActivitiesTables Derivative Instruments and Hedging Activities (Tables) Tables http://www.masimo.com/role/DerivativeInstrumentsandHedgingActivities 50 false false R51.htm 9954487 - Disclosure - Business Combinations (Tables) Sheet http://www.masimo.com/role/BusinessCombinationsTables Business Combinations (Tables) Tables http://www.masimo.com/role/BusinessCombinations 51 false false R52.htm 9954488 - Disclosure - Stock-Based Compensation (Tables) Sheet http://www.masimo.com/role/StockBasedCompensationTables Stock-Based Compensation (Tables) Tables http://www.masimo.com/role/StockBasedCompensation 52 false false R53.htm 9954489 - Disclosure - Non-operating Loss (Tables) Sheet http://www.masimo.com/role/NonoperatingLossTables Non-operating Loss (Tables) Tables http://www.masimo.com/role/NonoperatingLoss 53 false false R54.htm 9954490 - Disclosure - Segment and Enterprise Reporting (Tables) Sheet http://www.masimo.com/role/SegmentandEnterpriseReportingTables Segment and Enterprise Reporting (Tables) Tables http://www.masimo.com/role/SegmentandEnterpriseReporting 54 false false R55.htm 9954491 - Disclosure - Summary of Significant Accounting Policies - Schedule of Fair Value, Assets Measured on Recurring Basis (Detail) Sheet http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesScheduleofFairValueAssetsMeasuredonRecurringBasisDetail Summary of Significant Accounting Policies - Schedule of Fair Value, Assets Measured on Recurring Basis (Detail) Details 55 false false R56.htm 9954492 - Disclosure - Summary of Significant Accounting Policies - Schedule of Property and Equipment (Detail) Sheet http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentDetail Summary of Significant Accounting Policies - Schedule of Property and Equipment (Detail) Details 56 false false R57.htm 9954493 - Disclosure - Summary of Significant Accounting Policies - Narrative (Detail) Sheet http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetail Summary of Significant Accounting Policies - Narrative (Detail) Details 57 false false R58.htm 9954494 - Disclosure - Summary of Significant Accounting Policies - Schedule of Changes in Product Warranty Accrual (Detail) Sheet http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesScheduleofChangesinProductWarrantyAccrualDetail Summary of Significant Accounting Policies - Schedule of Changes in Product Warranty Accrual (Detail) Details 58 false false R59.htm 9954495 - Disclosure - Summary of Significant Accounting Policies - Schedule of Reconciliation of Basic and Diluted Net Income Per Share (Detail) Sheet http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesScheduleofReconciliationofBasicandDilutedNetIncomePerShareDetail Summary of Significant Accounting Policies - Schedule of Reconciliation of Basic and Diluted Net Income Per Share (Detail) Details 59 false false R60.htm 9954496 - Disclosure - Summary of Significant Accounting Policies - Schedule of Supplemental Cash Flow Information (Detail) Sheet http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesScheduleofSupplementalCashFlowInformationDetail Summary of Significant Accounting Policies - Schedule of Supplemental Cash Flow Information (Detail) Details 60 false false R61.htm 9954497 - Disclosure - Related Party Transactions (Details) Sheet http://www.masimo.com/role/RelatedPartyTransactionsDetails Related Party Transactions (Details) Details http://www.masimo.com/role/RelatedPartyTransactions 61 false false R62.htm 9954498 - Disclosure - Inventories (Details) Sheet http://www.masimo.com/role/InventoriesDetails Inventories (Details) Details http://www.masimo.com/role/InventoriesTables 62 false false R63.htm 9954499 - Disclosure - Other Current Assets (Details) Sheet http://www.masimo.com/role/OtherCurrentAssetsDetails Other Current Assets (Details) Details http://www.masimo.com/role/OtherCurrentAssetsTables 63 false false R64.htm 9954500 - Disclosure - Lease Receivable - Narrative (Details) Sheet http://www.masimo.com/role/LeaseReceivableNarrativeDetails Lease Receivable - Narrative (Details) Details 64 false false R65.htm 9954501 - Disclosure - Lease Receivable - Schedule of Sale-Type Lease Receivable (Details) Sheet http://www.masimo.com/role/LeaseReceivableScheduleofSaleTypeLeaseReceivableDetails Lease Receivable - Schedule of Sale-Type Lease Receivable (Details) Details 65 false false R66.htm 9954502 - Disclosure - Lease Receivable - Schedule of Sales-type Lease, Lease Receivable, Maturity (Details) Sheet http://www.masimo.com/role/LeaseReceivableScheduleofSalestypeLeaseLeaseReceivableMaturityDetails Lease Receivable - Schedule of Sales-type Lease, Lease Receivable, Maturity (Details) Details 66 false false R67.htm 9954503 - Disclosure - Deferred Costs and Other Contract Assets (Details) Sheet http://www.masimo.com/role/DeferredCostsandOtherContractAssetsDetails Deferred Costs and Other Contract Assets (Details) Details http://www.masimo.com/role/DeferredCostsandOtherContractAssetsTables 67 false false R68.htm 9954504 - Disclosure - Property and Equipment, net - Schedule of Property and Equipment (Details) Sheet http://www.masimo.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentDetails Property and Equipment, net - Schedule of Property and Equipment (Details) Details 68 false false R69.htm 9954505 - Disclosure - Property and Equipment, net - Narrative (Detail) Sheet http://www.masimo.com/role/PropertyandEquipmentnetNarrativeDetail Property and Equipment, net - Narrative (Detail) Details 69 false false R70.htm 9954506 - Disclosure - Intangible Assets, net - Schedule of Finite-Lived Intangible Assets (Details) Sheet http://www.masimo.com/role/IntangibleAssetsnetScheduleofFiniteLivedIntangibleAssetsDetails Intangible Assets, net - Schedule of Finite-Lived Intangible Assets (Details) Details 70 false false R71.htm 9954507 - Disclosure - Intangible Assets, net - Narrative (Details) Sheet http://www.masimo.com/role/IntangibleAssetsnetNarrativeDetails Intangible Assets, net - Narrative (Details) Details 71 false false R72.htm 9954508 - Disclosure - Intangible Assets, net - Schedule of Finite-Lived Intangible Assets, Future Amortization Expense (Details) Sheet http://www.masimo.com/role/IntangibleAssetsnetScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseDetails Intangible Assets, net - Schedule of Finite-Lived Intangible Assets, Future Amortization Expense (Details) Details 72 false false R73.htm 9954509 - Disclosure - Goodwill (Details) Sheet http://www.masimo.com/role/GoodwillDetails Goodwill (Details) Details http://www.masimo.com/role/GoodwillTables 73 false false R74.htm 9954510 - Disclosure - Lessee ROU Assets and Lease Liabilities - Narrative (Details) Sheet http://www.masimo.com/role/LesseeROUAssetsandLeaseLiabilitiesNarrativeDetails Lessee ROU Assets and Lease Liabilities - Narrative (Details) Details 74 false false R75.htm 9954511 - Disclosure - Lessee ROU Assets and Lease Liabilities - Schedule of Lessee Operating Lease Balance Sheet Classification (Details) Sheet http://www.masimo.com/role/LesseeROUAssetsandLeaseLiabilitiesScheduleofLesseeOperatingLeaseBalanceSheetClassificationDetails Lessee ROU Assets and Lease Liabilities - Schedule of Lessee Operating Lease Balance Sheet Classification (Details) Details 75 false false R76.htm 9954512 - Disclosure - Lessee ROU Assets and Lease Liabilities - Schedule of Lessee, Operating Lease, Liability, Maturity (Details) Sheet http://www.masimo.com/role/LesseeROUAssetsandLeaseLiabilitiesScheduleofLesseeOperatingLeaseLiabilityMaturityDetails Lessee ROU Assets and Lease Liabilities - Schedule of Lessee, Operating Lease, Liability, Maturity (Details) Details 76 false false R77.htm 9954513 - Disclosure - Other Non-Current Assets (Details) Sheet http://www.masimo.com/role/OtherNonCurrentAssetsDetails Other Non-Current Assets (Details) Details http://www.masimo.com/role/OtherNonCurrentAssetsTables 77 false false R78.htm 9954514 - Disclosure - Deferred Revenue and Other Contract Liabilities, Current - Schedule of Deferred Revenue and Other Contract Liabilities, Current (Details) Sheet http://www.masimo.com/role/DeferredRevenueandOtherContractLiabilitiesCurrentScheduleofDeferredRevenueandOtherContractLiabilitiesCurrentDetails Deferred Revenue and Other Contract Liabilities, Current - Schedule of Deferred Revenue and Other Contract Liabilities, Current (Details) Details 78 false false R79.htm 9954515 - Disclosure - Deferred Revenue and Other Contract Liabilities, Current - Narrative (Details) Sheet http://www.masimo.com/role/DeferredRevenueandOtherContractLiabilitiesCurrentNarrativeDetails Deferred Revenue and Other Contract Liabilities, Current - Narrative (Details) Details http://www.masimo.com/role/DeferredRevenueandOtherContractLiabilitiesCurrentTables 79 false false R80.htm 9954516 - Disclosure - Deferred Revenue and Other Contract Liabilities, Current - Schedule of Changes in Deferred Revenue (Details) Sheet http://www.masimo.com/role/DeferredRevenueandOtherContractLiabilitiesCurrentScheduleofChangesinDeferredRevenueDetails Deferred Revenue and Other Contract Liabilities, Current - Schedule of Changes in Deferred Revenue (Details) Details 80 false false R81.htm 9954517 - Disclosure - Other Current Liabilities (Details) Sheet http://www.masimo.com/role/OtherCurrentLiabilitiesDetails Other Current Liabilities (Details) Details http://www.masimo.com/role/OtherCurrentLiabilitiesTables 81 false false R82.htm 9954518 - Disclosure - Debt - Schedule of Debt (Details) Sheet http://www.masimo.com/role/DebtScheduleofDebtDetails Debt - Schedule of Debt (Details) Details 82 false false R83.htm 9954519 - Disclosure - Debt - Narrative (Details) Sheet http://www.masimo.com/role/DebtNarrativeDetails Debt - Narrative (Details) Details 83 false false R84.htm 9954520 - Disclosure - Debt - Schedule of Maturities of Long-term Debt (Details) Sheet http://www.masimo.com/role/DebtScheduleofMaturitiesofLongtermDebtDetails Debt - Schedule of Maturities of Long-term Debt (Details) Details 84 false false R85.htm 9954521 - Disclosure - Other Non-Current Liabilities (Details) Sheet http://www.masimo.com/role/OtherNonCurrentLiabilitiesDetails Other Non-Current Liabilities (Details) Details http://www.masimo.com/role/OtherNonCurrentLiabilitiesTables 85 false false R86.htm 9954522 - Disclosure - Derivative Instruments and Hedging Activities - Narrative (Details) Sheet http://www.masimo.com/role/DerivativeInstrumentsandHedgingActivitiesNarrativeDetails Derivative Instruments and Hedging Activities - Narrative (Details) Details 86 false false R87.htm 9954523 - Disclosure - Derivative Instruments and Hedging Activities - Schedule of Derivative Instruments in Statement of Financial Position, Fair Value (Details) Sheet http://www.masimo.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofDerivativeInstrumentsinStatementofFinancialPositionFairValueDetails Derivative Instruments and Hedging Activities - Schedule of Derivative Instruments in Statement of Financial Position, Fair Value (Details) Details 87 false false R88.htm 9954524 - Disclosure - Derivative Instruments and Hedging Activities - Schedule of Reclassification out of Accumulated Other Comprehensive Income (Details) Sheet http://www.masimo.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofReclassificationoutofAccumulatedOtherComprehensiveIncomeDetails Derivative Instruments and Hedging Activities - Schedule of Reclassification out of Accumulated Other Comprehensive Income (Details) Details 88 false false R89.htm 9954525 - Disclosure - Derivative Instruments and Hedging Activities - Schedule of Accumulated Other Comprehensive Income (Loss) (Details) Sheet http://www.masimo.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofAccumulatedOtherComprehensiveIncomeLossDetails Derivative Instruments and Hedging Activities - Schedule of Accumulated Other Comprehensive Income (Loss) (Details) Details 89 false false R90.htm 9954526 - Disclosure - Business Combinations - Narrative (Details) Sheet http://www.masimo.com/role/BusinessCombinationsNarrativeDetails Business Combinations - Narrative (Details) Details 90 false false R91.htm 9954527 - Disclosure - Business Combinations - Fair Value of Assets Acquired and Liabilities Assumed (Details) Sheet http://www.masimo.com/role/BusinessCombinationsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails Business Combinations - Fair Value of Assets Acquired and Liabilities Assumed (Details) Details 91 false false R92.htm 9954528 - Disclosure - Business Combinations - Schedule of Acquired Intangible Assets (Details) Sheet http://www.masimo.com/role/BusinessCombinationsScheduleofAcquiredIntangibleAssetsDetails Business Combinations - Schedule of Acquired Intangible Assets (Details) Details 92 false false R93.htm 9954529 - Disclosure - Equity (Details) Sheet http://www.masimo.com/role/EquityDetails Equity (Details) Details http://www.masimo.com/role/Equity 93 false false R94.htm 9954530 - Disclosure - Stock-Based Compensation - Narrative (Detail) Sheet http://www.masimo.com/role/StockBasedCompensationNarrativeDetail Stock-Based Compensation - Narrative (Detail) Details 94 false false R95.htm 9954531 - Disclosure - Stock-Based Compensation - Schedule of Number and Weighted Average Exercise Price of Options Issued and Outstanding under all Stock Option Plans (Detail) Sheet http://www.masimo.com/role/StockBasedCompensationScheduleofNumberandWeightedAverageExercisePriceofOptionsIssuedandOutstandingunderallStockOptionPlansDetail Stock-Based Compensation - Schedule of Number and Weighted Average Exercise Price of Options Issued and Outstanding under all Stock Option Plans (Detail) Details 95 false false R96.htm 9954532 - Disclosure - Stock-Based Compensation - Schedule of Stock Units Activity (Detail) Sheet http://www.masimo.com/role/StockBasedCompensationScheduleofStockUnitsActivityDetail Stock-Based Compensation - Schedule of Stock Units Activity (Detail) Details 96 false false R97.htm 9954533 - Disclosure - Stock-Based Compensation - Schedule of Range of Assumptions Used and Resulting Weighted-Average Fair Value of Options Granted at Date of Grant (Detail) Sheet http://www.masimo.com/role/StockBasedCompensationScheduleofRangeofAssumptionsUsedandResultingWeightedAverageFairValueofOptionsGrantedatDateofGrantDetail Stock-Based Compensation - Schedule of Range of Assumptions Used and Resulting Weighted-Average Fair Value of Options Granted at Date of Grant (Detail) Details 97 false false R98.htm 9954534 - Disclosure - Employee Benefits (Details) Sheet http://www.masimo.com/role/EmployeeBenefitsDetails Employee Benefits (Details) Details http://www.masimo.com/role/EmployeeBenefits 98 false false R99.htm 9954535 - Disclosure - Non-operating Loss (Details) Sheet http://www.masimo.com/role/NonoperatingLossDetails Non-operating Loss (Details) Details http://www.masimo.com/role/NonoperatingLossTables 99 false false R100.htm 9954536 - Disclosure - Income Taxes - Narrative (Detail) Sheet http://www.masimo.com/role/IncomeTaxesNarrativeDetail Income Taxes - Narrative (Detail) Details 100 false false R101.htm 9954537 - Disclosure - Commitments and Contingencies (Detail) Sheet http://www.masimo.com/role/CommitmentsandContingenciesDetail Commitments and Contingencies (Detail) Details http://www.masimo.com/role/CommitmentsandContingencies 101 false false R102.htm 9954538 - Disclosure - Segment and Enterprise Reporting - Schedule of Segment Reporting Information, by Segment (Detail) Sheet http://www.masimo.com/role/SegmentandEnterpriseReportingScheduleofSegmentReportingInformationbySegmentDetail Segment and Enterprise Reporting - Schedule of Segment Reporting Information, by Segment (Detail) Details 102 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 2 fact(s) appearing in ix:hidden were eligible for transformation: masi:LicenseAgreementTerm, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 - masi-20240330.htm 4 masi-20240330.htm masi-20240330.xsd masi-20240330_cal.xml masi-20240330_def.xml masi-20240330_lab.xml masi-20240330_pre.xml masi-20240330_g1.jpg http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 http://xbrl.sec.gov/ecd/2023 true true JSON 121 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "masi-20240330.htm": { "nsprefix": "masi", "nsuri": "http://www.masimo.com/20240330", "dts": { "inline": { "local": [ "masi-20240330.htm" ] }, "schema": { "local": [ "masi-20240330.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd" ] }, "calculationLink": { "local": [ "masi-20240330_cal.xml" ] }, "definitionLink": { "local": [ "masi-20240330_def.xml" ] }, "labelLink": { "local": [ "masi-20240330_lab.xml" ] }, "presentationLink": { "local": [ "masi-20240330_pre.xml" ] } }, "keyStandard": 426, "keyCustom": 70, "axisStandard": 37, "axisCustom": 0, "memberStandard": 62, "memberCustom": 43, "hidden": { "total": 17, "http://xbrl.sec.gov/dei/2023": 5, "http://fasb.org/us-gaap/2023": 11, "http://www.masimo.com/20240330": 1 }, "contextCount": 285, "entityCount": 1, "segmentCount": 108, "elementCount": 864, "unitCount": 15, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 989, "http://xbrl.sec.gov/dei/2023": 29, "http://xbrl.sec.gov/ecd/2023": 4 }, "report": { "R1": { "role": "http://www.masimo.com/role/Cover", "longName": "0000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "longName": "0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c-2", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-2", "name": "us-gaap:AccountsReceivableNetCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "unique": true } }, "R3": { "role": "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "longName": "0000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-2", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-2", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true } }, "R4": { "role": "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "longName": "0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CostOfGoodsAndServicesSold", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "unique": true } }, "R5": { "role": "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS", "longName": "0000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ComprehensiveIncomeNetOfTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "unique": true } }, "R6": { "role": "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY", "longName": "0000006 - Statement - CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY", "shortName": "CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-26", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-26", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true } }, "R7": { "role": "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "longName": "0000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DepreciationDepletionAndAmortization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "unique": true } }, "R8": { "role": "http://www.masimo.com/role/DescriptionoftheCompany", "longName": "0000008 - Disclosure - Description of the Company", "shortName": "Description of the Company", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.masimo.com/role/SummaryofSignificantAccountingPolicies", "longName": "0000009 - Disclosure - Summary of Significant Accounting Policies", "shortName": "Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.masimo.com/role/RelatedPartyTransactions", "longName": "0000010 - Disclosure - Related Party Transactions", "shortName": "Related Party Transactions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.masimo.com/role/Inventories", "longName": "0000011 - Disclosure - Inventories", "shortName": "Inventories", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.masimo.com/role/OtherCurrentAssets", "longName": "0000012 - Disclosure - Other Current Assets", "shortName": "Other Current Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherCurrentAssetsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherCurrentAssetsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.masimo.com/role/LeaseReceivable", "longName": "0000013 - Disclosure - Lease Receivable", "shortName": "Lease Receivable", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LessorSalesTypeLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LessorSalesTypeLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.masimo.com/role/DeferredCostsandOtherContractAssets", "longName": "0000014 - Disclosure - Deferred Costs and Other Contract Assets", "shortName": "Deferred Costs and Other Contract Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "masi:DeferredCostsandOtherContractAssetsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "masi:DeferredCostsandOtherContractAssetsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.masimo.com/role/PropertyandEquipmentnet", "longName": "0000015 - Disclosure - Property and Equipment, net", "shortName": "Property and Equipment, net", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.masimo.com/role/IntangibleAssetsnet", "longName": "0000016 - Disclosure - Intangible Assets, net", "shortName": "Intangible Assets, net", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.masimo.com/role/Goodwill", "longName": "0000017 - Disclosure - Goodwill", "shortName": "Goodwill", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.masimo.com/role/LesseeROUAssetsandLeaseLiabilities", "longName": "0000018 - Disclosure - Lessee ROU Assets and Lease Liabilities", "shortName": "Lessee ROU Assets and Lease Liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.masimo.com/role/OtherNonCurrentAssets", "longName": "0000019 - Disclosure - Other Non-Current Assets", "shortName": "Other Non-Current Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.masimo.com/role/DeferredRevenueandOtherContractLiabilitiesCurrent", "longName": "0000020 - Disclosure - Deferred Revenue and Other Contract Liabilities, Current", "shortName": "Deferred Revenue and Other Contract Liabilities, Current", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.masimo.com/role/OtherCurrentLiabilities", "longName": "0000021 - Disclosure - Other Current Liabilities", "shortName": "Other Current Liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.masimo.com/role/Debt", "longName": "0000022 - Disclosure - Debt", "shortName": "Debt", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.masimo.com/role/OtherNonCurrentLiabilities", "longName": "0000023 - Disclosure - Other Non-Current Liabilities", "shortName": "Other Non-Current Liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.masimo.com/role/DerivativeInstrumentsandHedgingActivities", "longName": "0000024 - Disclosure - Derivative Instruments and Hedging Activities", "shortName": "Derivative Instruments and Hedging Activities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.masimo.com/role/BusinessCombinations", "longName": "0000025 - Disclosure - Business Combinations", "shortName": "Business Combinations", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "25", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.masimo.com/role/Equity", "longName": "0000026 - Disclosure - Equity", "shortName": "Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "26", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.masimo.com/role/StockBasedCompensation", "longName": "0000027 - Disclosure - Stock-Based Compensation", "shortName": "Stock-Based Compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "27", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.masimo.com/role/EmployeeBenefits", "longName": "0000028 - Disclosure - Employee Benefits", "shortName": "Employee Benefits", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "28", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.masimo.com/role/NonoperatingLoss", "longName": "0000029 - Disclosure - Non-operating Loss", "shortName": "Non-operating Loss", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "29", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.masimo.com/role/IncomeTaxes", "longName": "0000030 - Disclosure - Income Taxes", "shortName": "Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "30", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.masimo.com/role/CommitmentsandContingencies", "longName": "0000031 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "31", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.masimo.com/role/SegmentandEnterpriseReporting", "longName": "0000032 - Disclosure - Segment and Enterprise Reporting", "shortName": "Segment and Enterprise Reporting", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "32", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true } }, "R33": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "33", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true }, "uniqueAnchor": null }, "R34": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "34", "firstAnchor": { "contextRef": "c-1", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ecd:NonRule10b51ArrTrmntdFlag", "ecd:Rule10b51ArrTrmntdFlag", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ecd:NonRule10b51ArrTrmntdFlag", "ecd:Rule10b51ArrTrmntdFlag", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesPolicies", "longName": "9954471 - Disclosure - Summary of Significant Accounting Policies (Policies)", "shortName": "Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "35", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesTables", "longName": "9954472 - Disclosure - Summary of Significant Accounting Policies (Tables)", "shortName": "Summary of Significant Accounting Policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "36", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.masimo.com/role/InventoriesTables", "longName": "9954473 - Disclosure - Inventories (Tables)", "shortName": "Inventories (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "37", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.masimo.com/role/OtherCurrentAssetsTables", "longName": "9954474 - Disclosure - Other Current Assets (Tables)", "shortName": "Other Current Assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "38", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfOtherAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:OtherCurrentAssetsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true }, "uniqueAnchor": null }, "R39": { "role": "http://www.masimo.com/role/LeaseReceivableTables", "longName": "9954475 - Disclosure - Lease Receivable (Tables)", "shortName": "Lease Receivable (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "39", "firstAnchor": { "contextRef": "c-1", "name": "masi:SaleTypeLeaseReceivableTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "masi:SaleTypeLeaseReceivableTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.masimo.com/role/DeferredCostsandOtherContractAssetsTables", "longName": "9954476 - Disclosure - Deferred Costs and Other Contract Assets (Tables)", "shortName": "Deferred Costs and Other Contract Assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "40", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "masi:DeferredCostsandOtherContractAssetsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "masi:DeferredCostsandOtherContractAssetsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.masimo.com/role/PropertyandEquipmentnetTables", "longName": "9954477 - Disclosure - Property and Equipment, net (Tables)", "shortName": "Property and Equipment, net (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "41", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true }, "uniqueAnchor": null }, "R42": { "role": "http://www.masimo.com/role/IntangibleAssetsnetTables", "longName": "9954478 - Disclosure - Intangible Assets, net (Tables)", "shortName": "Intangible Assets, net (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "42", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.masimo.com/role/GoodwillTables", "longName": "9954479 - Disclosure - Goodwill (Tables)", "shortName": "Goodwill (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "43", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:GoodwillDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:GoodwillDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true } }, "R44": { "role": "http://www.masimo.com/role/LesseeROUAssetsandLeaseLiabilitiesTables", "longName": "9954480 - Disclosure - Lessee ROU Assets and Lease Liabilities (Tables)", "shortName": "Lessee ROU Assets and Lease Liabilities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "44", "firstAnchor": { "contextRef": "c-1", "name": "masi:LesseeOperatingLeaseBalanceSheetClassificationTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "masi:LesseeOperatingLeaseBalanceSheetClassificationTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.masimo.com/role/OtherNonCurrentAssetsTables", "longName": "9954481 - Disclosure - Other Non-Current Assets (Tables)", "shortName": "Other Non-Current Assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "45", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfOtherAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:OtherCurrentAssetsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true }, "uniqueAnchor": null }, "R46": { "role": "http://www.masimo.com/role/DeferredRevenueandOtherContractLiabilitiesCurrentTables", "longName": "9954482 - Disclosure - Deferred Revenue and Other Contract Liabilities, Current (Tables)", "shortName": "Deferred Revenue and Other Contract Liabilities, Current (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "46", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true } }, "R47": { "role": "http://www.masimo.com/role/OtherCurrentLiabilitiesTables", "longName": "9954483 - Disclosure - Other Current Liabilities (Tables)", "shortName": "Other Current Liabilities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "47", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.masimo.com/role/DebtTables", "longName": "9954484 - Disclosure - Debt (Tables)", "shortName": "Debt (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "48", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true } }, "R49": { "role": "http://www.masimo.com/role/OtherNonCurrentLiabilitiesTables", "longName": "9954485 - Disclosure - Other Non-Current Liabilities (Tables)", "shortName": "Other Non-Current Liabilities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "49", "firstAnchor": { "contextRef": "c-1", "name": "masi:ComponentsOfOtherLiabilitiesLongTermTableTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:OtherLiabilitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "masi:ComponentsOfOtherLiabilitiesLongTermTableTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:OtherLiabilitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true } }, "R50": { "role": "http://www.masimo.com/role/DerivativeInstrumentsandHedgingActivitiesTables", "longName": "9954486 - Disclosure - Derivative Instruments and Hedging Activities (Tables)", "shortName": "Derivative Instruments and Hedging Activities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "50", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true } }, "R51": { "role": "http://www.masimo.com/role/BusinessCombinationsTables", "longName": "9954487 - Disclosure - Business Combinations (Tables)", "shortName": "Business Combinations (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "51", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true } }, "R52": { "role": "http://www.masimo.com/role/StockBasedCompensationTables", "longName": "9954488 - Disclosure - Stock-Based Compensation (Tables)", "shortName": "Stock-Based Compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "52", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true } }, "R53": { "role": "http://www.masimo.com/role/NonoperatingLossTables", "longName": "9954489 - Disclosure - Non-operating Loss (Tables)", "shortName": "Non-operating Loss (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "53", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true } }, "R54": { "role": "http://www.masimo.com/role/SegmentandEnterpriseReportingTables", "longName": "9954490 - Disclosure - Segment and Enterprise Reporting (Tables)", "shortName": "Segment and Enterprise Reporting (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "54", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true } }, "R55": { "role": "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesScheduleofFairValueAssetsMeasuredonRecurringBasisDetail", "longName": "9954491 - Disclosure - Summary of Significant Accounting Policies - Schedule of Fair Value, Assets Measured on Recurring Basis (Detail)", "shortName": "Summary of Significant Accounting Policies - Schedule of Fair Value, Assets Measured on Recurring Basis (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "c-41", "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-41", "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true } }, "R56": { "role": "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentDetail", "longName": "9954492 - Disclosure - Summary of Significant Accounting Policies - Schedule of Property and Equipment (Detail)", "shortName": "Summary of Significant Accounting Policies - Schedule of Property and Equipment (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "c-65", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-65", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true } }, "R57": { "role": "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetail", "longName": "9954493 - Disclosure - Summary of Significant Accounting Policies - Narrative (Detail)", "shortName": "Summary of Significant Accounting Policies - Narrative (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfReportingUnits", "unitRef": "reportingunit", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfReportingUnits", "unitRef": "reportingunit", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true } }, "R58": { "role": "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesScheduleofChangesinProductWarrantyAccrualDetail", "longName": "9954494 - Disclosure - Summary of Significant Accounting Policies - Schedule of Changes in Product Warranty Accrual (Detail)", "shortName": "Summary of Significant Accounting Policies - Schedule of Changes in Product Warranty Accrual (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:ProductWarrantyAccrual", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:ProductWarrantyAccrual", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true } }, "R59": { "role": "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesScheduleofReconciliationofBasicandDilutedNetIncomePerShareDetail", "longName": "9954495 - Disclosure - Summary of Significant Accounting Policies - Schedule of Reconciliation of Basic and Diluted Net Income Per Share (Detail)", "shortName": "Summary of Significant Accounting Policies - Schedule of Reconciliation of Basic and Diluted Net Income Per Share (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "unique": true } }, "R60": { "role": "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesScheduleofSupplementalCashFlowInformationDetail", "longName": "9954496 - Disclosure - Summary of Significant Accounting Policies - Schedule of Supplemental Cash Flow Information (Detail)", "shortName": "Summary of Significant Accounting Policies - Schedule of Supplemental Cash Flow Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:InterestPaidNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:InterestPaidNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true } }, "R61": { "role": "http://www.masimo.com/role/RelatedPartyTransactionsDetails", "longName": "9954497 - Disclosure - Related Party Transactions (Details)", "shortName": "Related Party Transactions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "c-162", "name": "us-gaap:OtherAccruedLiabilitiesCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-89", "name": "us-gaap:PaymentForAdministrativeFees", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "us-gaap:PaymentForAdministrativeFees", "span", "div", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "unique": true } }, "R62": { "role": "http://www.masimo.com/role/InventoriesDetails", "longName": "9954498 - Disclosure - Inventories (Details)", "shortName": "Inventories (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "c-2", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-2", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true } }, "R63": { "role": "http://www.masimo.com/role/OtherCurrentAssetsDetails", "longName": "9954499 - Disclosure - Other Current Assets (Details)", "shortName": "Other Current Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "c-2", "name": "us-gaap:PrepaidExpenseCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherAssetsTableTextBlock", "us-gaap:OtherCurrentAssetsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-2", "name": "us-gaap:PrepaidExpenseCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherAssetsTableTextBlock", "us-gaap:OtherCurrentAssetsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true } }, "R64": { "role": "http://www.masimo.com/role/LeaseReceivableNarrativeDetails", "longName": "9954500 - Disclosure - Lease Receivable - Narrative (Details)", "shortName": "Lease Receivable - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingLeaseVariableLeaseIncome", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "us-gaap:LessorSalesTypeLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingLeaseVariableLeaseIncome", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "us-gaap:LessorSalesTypeLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true } }, "R65": { "role": "http://www.masimo.com/role/LeaseReceivableScheduleofSaleTypeLeaseReceivableDetails", "longName": "9954501 - Disclosure - Lease Receivable - Schedule of Sale-Type Lease Receivable (Details)", "shortName": "Lease Receivable - Schedule of Sale-Type Lease Receivable (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "c-2", "name": "us-gaap:SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "masi:SaleTypeLeaseReceivableTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-2", "name": "masi:SalesTypeLeaseAllowanceForCreditLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "masi:SaleTypeLeaseReceivableTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "unique": true } }, "R66": { "role": "http://www.masimo.com/role/LeaseReceivableScheduleofSalestypeLeaseLeaseReceivableMaturityDetails", "longName": "9954502 - Disclosure - Lease Receivable - Schedule of Sales-type Lease, Lease Receivable, Maturity (Details)", "shortName": "Lease Receivable - Schedule of Sales-type Lease, Lease Receivable, Maturity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "c-2", "name": "us-gaap:SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:SalesTypeAndDirectFinancingLeasesLeaseReceivableMaturityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-2", "name": "us-gaap:SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:SalesTypeAndDirectFinancingLeasesLeaseReceivableMaturityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true } }, "R67": { "role": "http://www.masimo.com/role/DeferredCostsandOtherContractAssetsDetails", "longName": "9954503 - Disclosure - Deferred Costs and Other Contract Assets (Details)", "shortName": "Deferred Costs and Other Contract Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "c-2", "name": "masi:DeferredSalesCommissions", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "masi:DeferredCostsandOtherContractAssetsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-2", "name": "masi:DeferredSalesCommissions", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "masi:DeferredCostsandOtherContractAssetsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true } }, "R68": { "role": "http://www.masimo.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentDetails", "longName": "9954504 - Disclosure - Property and Equipment, net - Schedule of Property and Equipment (Details)", "shortName": "Property and Equipment, net - Schedule of Property and Equipment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "c-2", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-2", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true } }, "R69": { "role": "http://www.masimo.com/role/PropertyandEquipmentnetNarrativeDetail", "longName": "9954505 - Disclosure - Property and Equipment, net - Narrative (Detail)", "shortName": "Property and Equipment, net - Narrative (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:Depreciation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:Depreciation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true } }, "R70": { "role": "http://www.masimo.com/role/IntangibleAssetsnetScheduleofFiniteLivedIntangibleAssetsDetails", "longName": "9954506 - Disclosure - Intangible Assets, net - Schedule of Finite-Lived Intangible Assets (Details)", "shortName": "Intangible Assets, net - Schedule of Finite-Lived Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "c-2", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-2", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true } }, "R71": { "role": "http://www.masimo.com/role/IntangibleAssetsnetNarrativeDetails", "longName": "9954507 - Disclosure - Intangible Assets, net - Narrative (Details)", "shortName": "Intangible Assets, net - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "71", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AmortizationOfIntangibleAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AmortizationOfIntangibleAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true } }, "R72": { "role": "http://www.masimo.com/role/IntangibleAssetsnetScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseDetails", "longName": "9954508 - Disclosure - Intangible Assets, net - Schedule of Finite-Lived Intangible Assets, Future Amortization Expense (Details)", "shortName": "Intangible Assets, net - Schedule of Finite-Lived Intangible Assets, Future Amortization Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "72", "firstAnchor": { "contextRef": "c-2", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-2", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true } }, "R73": { "role": "http://www.masimo.com/role/GoodwillDetails", "longName": "9954509 - Disclosure - Goodwill (Details)", "shortName": "Goodwill (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "73", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:Goodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "us-gaap:GoodwillDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillForeignCurrencyTranslationGainLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "us-gaap:GoodwillDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "unique": true } }, "R74": { "role": "http://www.masimo.com/role/LesseeROUAssetsandLeaseLiabilitiesNarrativeDetails", "longName": "9954510 - Disclosure - Lessee ROU Assets and Lease Liabilities - Narrative (Details)", "shortName": "Lessee ROU Assets and Lease Liabilities - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "74", "firstAnchor": { "contextRef": "c-2", "name": "us-gaap:LesseeOperatingLeaseRenewalTerm", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-2", "name": "us-gaap:LesseeOperatingLeaseRenewalTerm", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true } }, "R75": { "role": "http://www.masimo.com/role/LesseeROUAssetsandLeaseLiabilitiesScheduleofLesseeOperatingLeaseBalanceSheetClassificationDetails", "longName": "9954511 - Disclosure - Lessee ROU Assets and Lease Liabilities - Schedule of Lessee Operating Lease Balance Sheet Classification (Details)", "shortName": "Lessee ROU Assets and Lease Liabilities - Schedule of Lessee Operating Lease Balance Sheet Classification (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "75", "firstAnchor": { "contextRef": "c-2", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:OtherAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true }, "uniqueAnchor": null }, "R76": { "role": "http://www.masimo.com/role/LesseeROUAssetsandLeaseLiabilitiesScheduleofLesseeOperatingLeaseLiabilityMaturityDetails", "longName": "9954512 - Disclosure - Lessee ROU Assets and Lease Liabilities - Schedule of Lessee, Operating Lease, Liability, Maturity (Details)", "shortName": "Lessee ROU Assets and Lease Liabilities - Schedule of Lessee, Operating Lease, Liability, Maturity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "76", "firstAnchor": { "contextRef": "c-2", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-2", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true } }, "R77": { "role": "http://www.masimo.com/role/OtherNonCurrentAssetsDetails", "longName": "9954513 - Disclosure - Other Non-Current Assets (Details)", "shortName": "Other Non-Current Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "77", "firstAnchor": { "contextRef": "c-2", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:OtherAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-2", "name": "us-gaap:DepositsAssetsNoncurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:OtherAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "unique": true } }, "R78": { "role": "http://www.masimo.com/role/DeferredRevenueandOtherContractLiabilitiesCurrentScheduleofDeferredRevenueandOtherContractLiabilitiesCurrentDetails", "longName": "9954514 - Disclosure - Deferred Revenue and Other Contract Liabilities, Current - Schedule of Deferred Revenue and Other Contract Liabilities, Current (Details)", "shortName": "Deferred Revenue and Other Contract Liabilities, Current - Schedule of Deferred Revenue and Other Contract Liabilities, Current (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "78", "firstAnchor": { "contextRef": "c-2", "name": "us-gaap:ContractWithCustomerLiability", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-2", "name": "masi:AccruedRebatesAndAllowances", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "unique": true } }, "R79": { "role": "http://www.masimo.com/role/DeferredRevenueandOtherContractLiabilitiesCurrentNarrativeDetails", "longName": "9954515 - Disclosure - Deferred Revenue and Other Contract Liabilities, Current - Narrative (Details)", "shortName": "Deferred Revenue and Other Contract Liabilities, Current - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "79", "firstAnchor": { "contextRef": "c-2", "name": "us-gaap:ContractWithCustomerLiability", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-158", "name": "us-gaap:AccruedRoyaltiesCurrentAndNoncurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "unique": true } }, "R80": { "role": "http://www.masimo.com/role/DeferredRevenueandOtherContractLiabilitiesCurrentScheduleofChangesinDeferredRevenueDetails", "longName": "9954516 - Disclosure - Deferred Revenue and Other Contract Liabilities, Current - Schedule of Changes in Deferred Revenue (Details)", "shortName": "Deferred Revenue and Other Contract Liabilities, Current - Schedule of Changes in Deferred Revenue (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "80", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:ContractWithCustomerLiability", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "masi:ContractWithCustomerLiabilityDeferredRevenueAdditions", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "unique": true } }, "R81": { "role": "http://www.masimo.com/role/OtherCurrentLiabilitiesDetails", "longName": "9954517 - Disclosure - Other Current Liabilities (Details)", "shortName": "Other Current Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "81", "firstAnchor": { "contextRef": "c-2", "name": "us-gaap:LongTermDebtCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-2", "name": "us-gaap:LongTermDebtCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true } }, "R82": { "role": "http://www.masimo.com/role/DebtScheduleofDebtDetails", "longName": "9954518 - Disclosure - Debt - Schedule of Debt (Details)", "shortName": "Debt - Schedule of Debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "82", "firstAnchor": { "contextRef": "c-2", "name": "us-gaap:DebtCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-2", "name": "us-gaap:DebtCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true } }, "R83": { "role": "http://www.masimo.com/role/DebtNarrativeDetails", "longName": "9954519 - Disclosure - Debt - Narrative (Details)", "shortName": "Debt - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "83", "firstAnchor": { "contextRef": "c-172", "name": "masi:LineOfCreditFacilityAccordionFeatureIncreaseLimit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-172", "name": "masi:LineOfCreditFacilityAccordionFeatureIncreaseLimit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true } }, "R84": { "role": "http://www.masimo.com/role/DebtScheduleofMaturitiesofLongtermDebtDetails", "longName": "9954520 - Disclosure - Debt - Schedule of Maturities of Long-term Debt (Details)", "shortName": "Debt - Schedule of Maturities of Long-term Debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "84", "firstAnchor": { "contextRef": "c-2", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-2", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true } }, "R85": { "role": "http://www.masimo.com/role/OtherNonCurrentLiabilitiesDetails", "longName": "9954521 - Disclosure - Other Non-Current Liabilities (Details)", "shortName": "Other Non-Current Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "85", "firstAnchor": { "contextRef": "c-2", "name": "us-gaap:OperatingLeaseLiabilityNoncurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "masi:LesseeOperatingLeaseBalanceSheetClassificationTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-2", "name": "masi:UnrecognizedTaxBenefitsLiabilitiesNoncurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "masi:ComponentsOfOtherLiabilitiesLongTermTableTableTextBlock", "us-gaap:OtherLiabilitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "unique": true } }, "R86": { "role": "http://www.masimo.com/role/DerivativeInstrumentsandHedgingActivitiesNarrativeDetails", "longName": "9954522 - Disclosure - Derivative Instruments and Hedging Activities - Narrative (Details)", "shortName": "Derivative Instruments and Hedging Activities - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "86", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true } }, "R87": { "role": "http://www.masimo.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofDerivativeInstrumentsinStatementofFinancialPositionFairValueDetails", "longName": "9954523 - Disclosure - Derivative Instruments and Hedging Activities - Schedule of Derivative Instruments in Statement of Financial Position, Fair Value (Details)", "shortName": "Derivative Instruments and Hedging Activities - Schedule of Derivative Instruments in Statement of Financial Position, Fair Value (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "87", "firstAnchor": { "contextRef": "c-202", "name": "us-gaap:DerivativeFairValueOfDerivativeAsset", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-202", "name": "us-gaap:DerivativeFairValueOfDerivativeAsset", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true } }, "R88": { "role": "http://www.masimo.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofReclassificationoutofAccumulatedOtherComprehensiveIncomeDetails", "longName": "9954524 - Disclosure - Derivative Instruments and Hedging Activities - Schedule of Reclassification out of Accumulated Other Comprehensive Income (Details)", "shortName": "Derivative Instruments and Hedging Activities - Schedule of Reclassification out of Accumulated Other Comprehensive Income (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "88", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true } }, "R89": { "role": "http://www.masimo.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofAccumulatedOtherComprehensiveIncomeLossDetails", "longName": "9954525 - Disclosure - Derivative Instruments and Hedging Activities - Schedule of Accumulated Other Comprehensive Income (Loss) (Details)", "shortName": "Derivative Instruments and Hedging Activities - Schedule of Accumulated Other Comprehensive Income (Loss) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "89", "firstAnchor": { "contextRef": "c-206", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-206", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true } }, "R90": { "role": "http://www.masimo.com/role/BusinessCombinationsNarrativeDetails", "longName": "9954526 - Disclosure - Business Combinations - Narrative (Details)", "shortName": "Business Combinations - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "90", "firstAnchor": { "contextRef": "c-212", "name": "us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-212", "name": "us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true } }, "R91": { "role": "http://www.masimo.com/role/BusinessCombinationsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails", "longName": "9954527 - Disclosure - Business Combinations - Fair Value of Assets Acquired and Liabilities Assumed (Details)", "shortName": "Business Combinations - Fair Value of Assets Acquired and Liabilities Assumed (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "91", "firstAnchor": { "contextRef": "c-2", "name": "us-gaap:Goodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "us-gaap:GoodwillDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-213", "name": "us-gaap:BusinessCombinationConsiderationTransferred1", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "unique": true } }, "R92": { "role": "http://www.masimo.com/role/BusinessCombinationsScheduleofAcquiredIntangibleAssetsDetails", "longName": "9954528 - Disclosure - Business Combinations - Schedule of Acquired Intangible Assets (Details)", "shortName": "Business Combinations - Schedule of Acquired Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "92", "firstAnchor": { "contextRef": "c-213", "name": "us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-213", "name": "us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true } }, "R93": { "role": "http://www.masimo.com/role/EquityDetails", "longName": "9954529 - Disclosure - Equity (Details)", "shortName": "Equity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "93", "firstAnchor": { "contextRef": "c-2", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "us-gaap:PreferredStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:TreasuryStockSharesAcquired", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "us-gaap:TreasuryStockSharesAcquired", "span", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "unique": true } }, "R94": { "role": "http://www.masimo.com/role/StockBasedCompensationNarrativeDetail", "longName": "9954530 - Disclosure - Stock-Based Compensation - Narrative (Detail)", "shortName": "Stock-Based Compensation - Narrative (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "94", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true } }, "R95": { "role": "http://www.masimo.com/role/StockBasedCompensationScheduleofNumberandWeightedAverageExercisePriceofOptionsIssuedandOutstandingunderallStockOptionPlansDetail", "longName": "9954531 - Disclosure - Stock-Based Compensation - Schedule of Number and Weighted Average Exercise Price of Options Issued and Outstanding under all Stock Option Plans (Detail)", "shortName": "Stock-Based Compensation - Schedule of Number and Weighted Average Exercise Price of Options Issued and Outstanding under all Stock Option Plans (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "95", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true } }, "R96": { "role": "http://www.masimo.com/role/StockBasedCompensationScheduleofStockUnitsActivityDetail", "longName": "9954532 - Disclosure - Stock-Based Compensation - Schedule of Stock Units Activity (Detail)", "shortName": "Stock-Based Compensation - Schedule of Stock Units Activity (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "96", "firstAnchor": { "contextRef": "c-238", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-238", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true } }, "R97": { "role": "http://www.masimo.com/role/StockBasedCompensationScheduleofRangeofAssumptionsUsedandResultingWeightedAverageFairValueofOptionsGrantedatDateofGrantDetail", "longName": "9954533 - Disclosure - Stock-Based Compensation - Schedule of Range of Assumptions Used and Resulting Weighted-Average Fair Value of Options Granted at Date of Grant (Detail)", "shortName": "Stock-Based Compensation - Schedule of Range of Assumptions Used and Resulting Weighted-Average Fair Value of Options Granted at Date of Grant (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "97", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true } }, "R98": { "role": "http://www.masimo.com/role/EmployeeBenefitsDetails", "longName": "9954534 - Disclosure - Employee Benefits (Details)", "shortName": "Employee Benefits (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "98", "firstAnchor": { "contextRef": "c-2", "name": "masi:DefinedContributionPlanNumberOfPlans", "unitRef": "plan", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "div", "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-2", "name": "masi:DefinedContributionPlanNumberOfPlans", "unitRef": "plan", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "div", "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true } }, "R99": { "role": "http://www.masimo.com/role/NonoperatingLossDetails", "longName": "9954535 - Disclosure - Non-operating Loss (Details)", "shortName": "Non-operating Loss (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "99", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ForeignCurrencyTransactionGainLossBeforeTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ForeignCurrencyTransactionGainLossBeforeTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true } }, "R100": { "role": "http://www.masimo.com/role/IncomeTaxesNarrativeDetail", "longName": "9954536 - Disclosure - Income Taxes - Narrative (Detail)", "shortName": "Income Taxes - Narrative (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "100", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherTaxExpenseBenefit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherTaxExpenseBenefit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true } }, "R101": { "role": "http://www.masimo.com/role/CommitmentsandContingenciesDetail", "longName": "9954537 - Disclosure - Commitments and Contingencies (Detail)", "shortName": "Commitments and Contingencies (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "101", "firstAnchor": { "contextRef": "c-2", "name": "masi:SeverancePlanParticipationAgreements", "unitRef": "executiveofficer", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-2", "name": "masi:SeverancePlanParticipationAgreements", "unitRef": "executiveofficer", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true } }, "R102": { "role": "http://www.masimo.com/role/SegmentandEnterpriseReportingScheduleofSegmentReportingInformationbySegmentDetail", "longName": "9954538 - Disclosure - Segment and Enterprise Reporting - Schedule of Segment Reporting Information, by Segment (Detail)", "shortName": "Segment and Enterprise Reporting - Schedule of Segment Reporting Information, by Segment (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "102", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "us-gaap:NumberOfReportableSegments", "span", "div", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "us-gaap:NumberOfReportableSegments", "span", "div", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "masi-20240330.htm", "first": true, "unique": true } } }, "tag": { "masi_A2007StockIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.masimo.com/20240330", "localname": "A2007StockIncentivePlanMember", "presentation": [ "http://www.masimo.com/role/StockBasedCompensationNarrativeDetail" ], "lang": { "en-us": { "role": { "terseLabel": "2007 Stock Incentive Plan", "label": "2007 Stock Incentive Plan [Member]", "documentation": "2007 Stock Incentive Plan [Domain]" } } }, "auth_ref": [] }, "masi_A2017EquityIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.masimo.com/20240330", "localname": "A2017EquityIncentivePlanMember", "presentation": [ "http://www.masimo.com/role/StockBasedCompensationNarrativeDetail" ], "lang": { "en-us": { "role": { "terseLabel": "2017 Equity Incentive Plan", "label": "2017 Equity Incentive Plan [Member]", "documentation": "2017 Equity Incentive Plan [Domain]" } } }, "auth_ref": [] }, "masi_A2021PSUGrantMember": { "xbrltype": "domainItemType", "nsuri": "http://www.masimo.com/20240330", "localname": "A2021PSUGrantMember", "presentation": [ "http://www.masimo.com/role/StockBasedCompensationNarrativeDetail" ], "lang": { "en-us": { "role": { "terseLabel": "2021 PSU Grant", "label": "2021 PSU Grant [Member]", "documentation": "2021 PSU Grant" } } }, "auth_ref": [] }, "masi_A2022RepurchaseProgramMember": { "xbrltype": "domainItemType", "nsuri": "http://www.masimo.com/20240330", "localname": "A2022RepurchaseProgramMember", "presentation": [ "http://www.masimo.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2022 Repurchase Program", "label": "2022 Repurchase Program [Member]", "documentation": "2022 Repurchase Program" } } }, "auth_ref": [] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Accounting Policies [Abstract]", "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "presentation": [ "http://www.masimo.com/role/OtherCurrentLiabilities" ], "lang": { "en-us": { "role": { "terseLabel": "Other Current Liabilities", "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period." } } }, "auth_ref": [ "r35" ] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Accounts Payable, Current", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r34", "r935" ] }, "us-gaap_AccountsPayableOtherCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableOtherCurrentAndNoncurrent", "crdr": "credit", "calculation": { "http://www.masimo.com/role/DeferredRevenueandOtherContractLiabilitiesCurrentScheduleofDeferredRevenueandOtherContractLiabilitiesCurrentDetails": { "parentTag": "us-gaap_OtherLiabilitiesAndDeferredRevenueNoncurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.masimo.com/role/DeferredRevenueandOtherContractLiabilitiesCurrentScheduleofDeferredRevenueandOtherContractLiabilitiesCurrentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued customer reimbursements", "label": "Accounts Payable, Other", "documentation": "Amount of obligations incurred and payable classified as other." } } }, "auth_ref": [ "r140" ] }, "us-gaap_AccountsReceivableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableMember", "presentation": [ "http://www.masimo.com/role/CommitmentsandContingenciesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts Receivable", "label": "Accounts Receivable [Member]", "documentation": "Due from customers or clients for goods or services that have been delivered or sold." } } }, "auth_ref": [ "r891" ] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Trade accounts receivable, net of allowance for credit losses of $4.7 million and $4.8 million at March\u00a030, 2024 and December\u00a030, 2023, respectively", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r370", "r371" ] }, "us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccrualForTaxesOtherThanIncomeTaxesCurrent", "crdr": "credit", "calculation": { "http://www.masimo.com/role/OtherCurrentLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.masimo.com/role/OtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued indirect taxes payable", "label": "Accrual for Taxes Other than Income Taxes, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for real and property taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r39", "r102", "r904" ] }, "masi_AccruedDonationsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.masimo.com/20240330", "localname": "AccruedDonationsCurrent", "crdr": "credit", "calculation": { "http://www.masimo.com/role/OtherCurrentLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.masimo.com/role/OtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued donations", "label": "Accrued Donations, Current", "documentation": "Accrued Donations, Current" } } }, "auth_ref": [] }, "us-gaap_AccruedIncomeTaxesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedIncomeTaxesCurrent", "crdr": "credit", "calculation": { "http://www.masimo.com/role/OtherCurrentLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.masimo.com/role/OtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income tax payable", "label": "Accrued Income Taxes, Current", "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations." } } }, "auth_ref": [ "r147", "r208" ] }, "us-gaap_AccruedIncomeTaxesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedIncomeTaxesNoncurrent", "crdr": "credit", "calculation": { "http://www.masimo.com/role/OtherNonCurrentLiabilitiesDetails": { "parentTag": "us-gaap_DeferredCreditsAndOtherLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.masimo.com/role/OtherNonCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Indirect tax payable, non-current", "label": "Accrued Income Taxes, Noncurrent", "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent." } } }, "auth_ref": [ "r148", "r208" ] }, "us-gaap_AccruedLiabilitiesAndOtherLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedLiabilitiesAndOtherLiabilities", "crdr": "credit", "calculation": { "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 }, "http://www.masimo.com/role/OtherCurrentLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.masimo.com/role/OtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other current liabilities", "totalLabel": "Total other current liabilities", "label": "Accrued Liabilities and Other Liabilities", "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other." } } }, "auth_ref": [] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.masimo.com/role/OtherCurrentLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.masimo.com/role/OtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses", "label": "Accrued Liabilities, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r39" ] }, "us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedLiabilitiesCurrentAndNoncurrentAbstract", "lang": { "en-us": { "role": { "terseLabel": "Accrued Liabilities [Abstract]", "label": "Accrued Liabilities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedProfessionalFeesCurrentAndNoncurrent", "crdr": "credit", "calculation": { "http://www.masimo.com/role/OtherCurrentLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://www.masimo.com/role/OtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued legal fees", "label": "Accrued Professional Fees", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received." } } }, "auth_ref": [ "r140" ] }, "masi_AccruedRebatesAndAllowances": { "xbrltype": "monetaryItemType", "nsuri": "http://www.masimo.com/20240330", "localname": "AccruedRebatesAndAllowances", "crdr": "credit", "calculation": { "http://www.masimo.com/role/DeferredRevenueandOtherContractLiabilitiesCurrentScheduleofDeferredRevenueandOtherContractLiabilitiesCurrentDetails": { "parentTag": "us-gaap_OtherLiabilitiesAndDeferredRevenueNoncurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.masimo.com/role/DeferredRevenueandOtherContractLiabilitiesCurrentScheduleofDeferredRevenueandOtherContractLiabilitiesCurrentDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Accrued rebates and allowances", "label": "Accrued Rebates And Allowances", "documentation": "Accrued Rebates And Allowances" } } }, "auth_ref": [] }, "us-gaap_AccruedRoyaltiesCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedRoyaltiesCurrentAndNoncurrent", "crdr": "credit", "presentation": [ "http://www.masimo.com/role/DeferredRevenueandOtherContractLiabilitiesCurrentNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Royalty prepayment", "label": "Accrued Royalties", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties." } } }, "auth_ref": [ "r140" ] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.masimo.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.masimo.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Accumulated depreciation", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": [ "r83", "r249", "r749" ] }, "us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember", "presentation": [ "http://www.masimo.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofAccumulatedOtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest", "label": "Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest [Member]", "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, including portion attributable to noncontrolling interest." } } }, "auth_ref": [ "r274", "r281", "r638", "r1039", "r1040" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax", "crdr": "credit", "calculation": { "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive loss", "label": "Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax", "documentation": "Accumulated adjustment, net of tax, that results from the process of translating subsidiary financial statements and foreign equity investments into the reporting currency from the functional currency of the reporting entity, net of reclassification of realized foreign currency translation gains or losses." } } }, "auth_ref": [ "r270", "r272", "r273", "r274", "r662" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss)", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r5", "r20", "r48", "r644", "r647", "r702", "r769", "r770", "r1038", "r1039", "r1040", "r1053", "r1054", "r1055" ] }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", "presentation": [ "http://www.masimo.com/role/BusinessCombinationsScheduleofAcquiredIntangibleAssetsDetails", "http://www.masimo.com/role/IntangibleAssetsnetNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Acquired finite-lived intangible assets, weighted average useful life", "terseLabel": "Weighted average amortization period (in years)", "label": "Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life", "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r178" ] }, "masi_AcquiredTechnologyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.masimo.com/20240330", "localname": "AcquiredTechnologyMember", "presentation": [ "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.masimo.com/role/IntangibleAssetsnetScheduleofFiniteLivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Acquired technologies", "label": "Acquired Technology [Member]", "documentation": "Acquired Technology [Member]" } } }, "auth_ref": [] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Additional 402(v) Disclosure", "label": "Additional 402(v) Disclosure [Text Block]" } } }, "auth_ref": [ "r987" ] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital", "label": "Additional Paid in Capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r152", "r935", "r1154" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Additional Paid-In Capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r605", "r606", "r607", "r787", "r1053", "r1054", "r1055", "r1127", "r1156" ] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation, Amount", "label": "Adjustment to Compensation Amount" } } }, "auth_ref": [ "r993" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation:", "label": "Adjustment to Compensation [Axis]" } } }, "auth_ref": [ "r993" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote", "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]" } } }, "auth_ref": [ "r993" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment To PEO Compensation, Footnote", "label": "Adjustment To PEO Compensation, Footnote [Text Block]" } } }, "auth_ref": [ "r993" ] }, "masi_AdjustedSecuredOvernightFinancingRateSOFRMember": { "xbrltype": "domainItemType", "nsuri": "http://www.masimo.com/20240330", "localname": "AdjustedSecuredOvernightFinancingRateSOFRMember", "presentation": [ "http://www.masimo.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Adjusted Secured Overnight Financing Rate (SOFR)", "label": "Adjusted Secured Overnight Financing Rate (SOFR) [Member]", "documentation": "Adjusted Secured Overnight Financing Rate (SOFR)" } } }, "auth_ref": [] }, "masi_AdjustedSecuredOvernightFinancingRateSOFROneMonthInterestPeriodMember": { "xbrltype": "domainItemType", "nsuri": "http://www.masimo.com/20240330", "localname": "AdjustedSecuredOvernightFinancingRateSOFROneMonthInterestPeriodMember", "presentation": [ "http://www.masimo.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Adjusted Secured Overnight Financing Rate (SOFR), One-Month Interest Period", "label": "Adjusted Secured Overnight Financing Rate (SOFR), One-Month Interest Period [Member]", "documentation": "Adjusted Secured Overnight Financing Rate (SOFR), One-Month Interest Period" } } }, "auth_ref": [] }, "masi_AdjustedSecuredOvernightFinancingRateSOFRSixMonthInterestPeriodMember": { "xbrltype": "domainItemType", "nsuri": "http://www.masimo.com/20240330", "localname": "AdjustedSecuredOvernightFinancingRateSOFRSixMonthInterestPeriodMember", "presentation": [ "http://www.masimo.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Adjusted Secured Overnight Financing Rate (SOFR), Six-Month Interest Period", "label": "Adjusted Secured Overnight Financing Rate (SOFR), Six-Month Interest Period [Member]", "documentation": "Adjusted Secured Overnight Financing Rate (SOFR), Six-Month Interest Period" } } }, "auth_ref": [] }, "masi_AdjustedSecuredOvernightFinancingRateSOFRThreeMonthInterestPeriodMember": { "xbrltype": "domainItemType", "nsuri": "http://www.masimo.com/20240330", "localname": "AdjustedSecuredOvernightFinancingRateSOFRThreeMonthInterestPeriodMember", "presentation": [ "http://www.masimo.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Adjusted Secured Overnight Financing Rate (SOFR), Three-Month Interest Period", "label": "Adjusted Secured Overnight Financing Rate (SOFR), Three-Month Interest Period [Member]", "documentation": "Adjusted Secured Overnight Financing Rate (SOFR), Three-Month Interest Period" } } }, "auth_ref": [] }, "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "debit", "presentation": [ "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Shares paid for tax withholding", "label": "Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation", "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r100", "r101", "r570" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AdvertisingCostsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdvertisingCostsPolicyTextBlock", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Advertising Costs", "label": "Advertising Cost [Policy Text Block]", "documentation": "Disclosure of accounting policy for advertising cost." } } }, "auth_ref": [ "r223" ] }, "us-gaap_AdvertisingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdvertisingExpense", "crdr": "debit", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Advertising expense", "label": "Advertising Expense", "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line." } } }, "auth_ref": [ "r608" ] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Amount", "label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r958", "r969", "r979", "r1004" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined", "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]" } } }, "auth_ref": [ "r961", "r972", "r982", "r1007" ] }, "masi_AircraftAndVehiclesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.masimo.com/20240330", "localname": "AircraftAndVehiclesMember", "presentation": [ "http://www.masimo.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Transportation, vehicles and other", "label": "Aircraft And Vehicles [Member]", "documentation": "Aircraft And Vehicles" } } }, "auth_ref": [] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Adjustments to Compensation", "label": "All Adjustments to Compensation [Member]" } } }, "auth_ref": [ "r993" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Executive Categories", "label": "All Executive Categories [Member]" } } }, "auth_ref": [ "r1000" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Individuals", "label": "All Individuals [Member]" } } }, "auth_ref": [ "r965", "r973", "r983", "r1000", "r1008", "r1012", "r1020" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "All Trading Arrangements", "label": "All Trading Arrangements [Member]" } } }, "auth_ref": [ "r1018" ] }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "crdr": "credit", "presentation": [ "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "verboseLabel": "Allowance for credit losses", "label": "Accounts Receivable, Allowance for Credit Loss, Current", "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current." } } }, "auth_ref": [ "r261", "r374", "r380" ] }, "masi_AlternateBaseRateMember": { "xbrltype": "domainItemType", "nsuri": "http://www.masimo.com/20240330", "localname": "AlternateBaseRateMember", "presentation": [ "http://www.masimo.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Alternate Base Rate", "label": "Alternate Base Rate [Member]", "documentation": "Alternate Base Rate" } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.masimo.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfFinancingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfFinancingCosts", "crdr": "debit", "calculation": { "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 17.0 } }, "presentation": [ "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of debt issuance cost", "label": "Amortization of Debt Issuance Costs", "documentation": "Amount of amortization expense attributable to debt issuance costs." } } }, "auth_ref": [ "r164", "r464", "r678", "r1045" ] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "presentation": [ "http://www.masimo.com/role/IntangibleAssetsnetNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of intangible assets", "label": "Amortization of Intangible Assets", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r11", "r74", "r79" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Options to purchase of shares of common stock", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r331" ] }, "masi_AppleIncPatentInfringementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.masimo.com/20240330", "localname": "AppleIncPatentInfringementMember", "presentation": [ "http://www.masimo.com/role/CommitmentsandContingenciesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Apple, Inc. Patent Infringement", "label": "Apple, Inc. Patent Infringement [Member]", "documentation": "Apple, Inc. Patent Infringement" } } }, "auth_ref": [] }, "us-gaap_AssetImpairmentCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetImpairmentCharges", "crdr": "debit", "presentation": [ "http://www.masimo.com/role/LesseeROUAssetsandLeaseLiabilitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment charge", "label": "Asset Impairment Charges", "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill." } } }, "auth_ref": [ "r11", "r81" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r206", "r253", "r299", "r341", "r356", "r362", "r377", "r429", "r430", "r432", "r433", "r434", "r436", "r438", "r440", "r441", "r636", "r639", "r664", "r743", "r829", "r935", "r949", "r1086", "r1087", "r1138" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": [ "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "ASSETS", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r244", "r266", "r299", "r377", "r429", "r430", "r432", "r433", "r434", "r436", "r438", "r440", "r441", "r636", "r639", "r664", "r935", "r1086", "r1087", "r1138" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": [ "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Current assets", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsFairValueDisclosure", "crdr": "debit", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesScheduleofFairValueAssetsMeasuredonRecurringBasisDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Total assets", "label": "Assets, Fair Value Disclosure", "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r130" ] }, "us-gaap_AssetsFairValueDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsFairValueDisclosureAbstract", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesScheduleofFairValueAssetsMeasuredonRecurringBasisDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Assets", "label": "Assets, Fair Value Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "crdr": "debit", "calculation": { "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Assets held for sale", "label": "Disposal Group, Including Discontinued Operation, Assets, Current", "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r4", "r144", "r145", "r183", "r185", "r242", "r243" ] }, "us-gaap_AwardDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardDateAxis", "presentation": [ "http://www.masimo.com/role/StockBasedCompensationNarrativeDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Award Date [Axis]", "label": "Award Date [Axis]", "documentation": "Information by date or year award under share-based payment arrangement is granted." } } }, "auth_ref": [ "r1096", "r1097", "r1098", "r1099", "r1100", "r1101", "r1102", "r1103", "r1104", "r1105", "r1106", "r1107", "r1108", "r1109", "r1110", "r1111", "r1112", "r1113", "r1114", "r1115", "r1116", "r1117", "r1118", "r1119", "r1120", "r1121" ] }, "us-gaap_AwardDateDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardDateDomain", "presentation": [ "http://www.masimo.com/role/StockBasedCompensationNarrativeDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Award Date [Domain]", "label": "Award Date [Domain]", "documentation": "Date or year award under share-based payment arrangement is granted." } } }, "auth_ref": [ "r1096", "r1097", "r1098", "r1099", "r1100", "r1101", "r1102", "r1103", "r1104", "r1105", "r1106", "r1107", "r1108", "r1109", "r1110", "r1111", "r1112", "r1113", "r1114", "r1115", "r1116", "r1117", "r1118", "r1119", "r1120", "r1121" ] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise Price", "label": "Award Exercise Price" } } }, "auth_ref": [ "r1015" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value as of Grant Date", "label": "Award Grant Date Fair Value" } } }, "auth_ref": [ "r1016" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]" } } }, "auth_ref": [ "r1011" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing, How MNPI Considered", "label": "Award Timing, How MNPI Considered [Text Block]" } } }, "auth_ref": [ "r1011" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Method", "label": "Award Timing Method [Text Block]" } } }, "auth_ref": [ "r1011" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Considered", "label": "Award Timing MNPI Considered [Flag]" } } }, "auth_ref": [ "r1011" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Disclosure", "label": "Award Timing MNPI Disclosure [Text Block]" } } }, "auth_ref": [ "r1011" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Predetermined", "label": "Award Timing Predetermined [Flag]" } } }, "auth_ref": [ "r1011" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardTypeAxis", "presentation": [ "http://www.masimo.com/role/CommitmentsandContingenciesDetail", "http://www.masimo.com/role/StockBasedCompensationNarrativeDetail", "http://www.masimo.com/role/StockBasedCompensationScheduleofStockUnitsActivityDetail", "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetail", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Axis]", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Securities", "label": "Award Underlying Securities Amount" } } }, "auth_ref": [ "r1014" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } }, "auth_ref": [ "r1013" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures", "label": "Awards Close in Time to MNPI Disclosures [Table]" } } }, "auth_ref": [ "r1012" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures, Table", "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]" } } }, "auth_ref": [ "r1012" ] }, "us-gaap_BalanceSheetLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BalanceSheetLocationAxis", "presentation": [ "http://www.masimo.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofDerivativeInstrumentsinStatementofFinancialPositionFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Location [Axis]", "label": "Balance Sheet Location [Axis]", "documentation": "Information by location on balance sheet (statement of financial position)." } } }, "auth_ref": [] }, "us-gaap_BalanceSheetLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BalanceSheetLocationDomain", "presentation": [ "http://www.masimo.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofDerivativeInstrumentsinStatementofFinancialPositionFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Location [Domain]", "label": "Balance Sheet Location [Domain]", "documentation": "Location in the balance sheet (statement of financial position)." } } }, "auth_ref": [ "r121", "r126" ] }, "masi_BankBalances": { "xbrltype": "monetaryItemType", "nsuri": "http://www.masimo.com/20240330", "localname": "BankBalances", "crdr": "debit", "presentation": [ "http://www.masimo.com/role/CommitmentsandContingenciesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Bank balances", "label": "Bank Balances" } } }, "auth_ref": [] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation", "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "masi_BowersAndWilkinsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.masimo.com/20240330", "localname": "BowersAndWilkinsMember", "presentation": [ "http://www.masimo.com/role/DeferredRevenueandOtherContractLiabilitiesCurrentNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Bowers and Wilkins", "label": "Bowers and Wilkins [Member]", "documentation": "Bowers and Wilkins" } } }, "auth_ref": [] }, "us-gaap_BuildingAndBuildingImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BuildingAndBuildingImprovementsMember", "presentation": [ "http://www.masimo.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Building and building improvements", "label": "Building and Building Improvements [Member]", "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and any addition, improvement, or renovation to the structure, for example, but not limited to, interior masonry, interior flooring, electrical, and plumbing." } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": [ "http://www.masimo.com/role/BusinessCombinationsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.masimo.com/role/BusinessCombinationsNarrativeDetails", "http://www.masimo.com/role/BusinessCombinationsScheduleofAcquiredIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition, Acquiree [Domain]", "label": "Business Acquisition, Acquiree [Domain]", "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "auth_ref": [ "r633", "r930", "r931" ] }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAxis", "presentation": [ "http://www.masimo.com/role/BusinessCombinationsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.masimo.com/role/BusinessCombinationsNarrativeDetails", "http://www.masimo.com/role/BusinessCombinationsScheduleofAcquiredIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition [Axis]", "label": "Business Acquisition [Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": [ "r104", "r106", "r633", "r930", "r931" ] }, "us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionCostOfAcquiredEntityTransactionCosts", "crdr": "debit", "presentation": [ "http://www.masimo.com/role/BusinessCombinationsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Transaction costs", "label": "Business Acquisition, Transaction Costs", "documentation": "Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition." } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionLineItems", "presentation": [ "http://www.masimo.com/role/BusinessCombinationsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.masimo.com/role/BusinessCombinationsNarrativeDetails", "http://www.masimo.com/role/BusinessCombinationsScheduleofAcquiredIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition [Line Items]", "label": "Business Acquisition [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r633" ] }, "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired", "presentation": [ "http://www.masimo.com/role/BusinessCombinationsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of voting interests acquired", "label": "Business Acquisition, Percentage of Voting Interests Acquired", "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination." } } }, "auth_ref": [ "r105" ] }, "masi_BusinessAcquisitionsNetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://www.masimo.com/20240330", "localname": "BusinessAcquisitionsNetIncomeLoss", "crdr": "credit", "presentation": [ "http://www.masimo.com/role/BusinessCombinationsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net loss", "label": "Business Acquisitions, Net Income (Loss)", "documentation": "Business Acquisitions, Net Income (Loss)" } } }, "auth_ref": [] }, "masi_BusinessAcquisitionsRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.masimo.com/20240330", "localname": "BusinessAcquisitionsRevenue", "crdr": "credit", "presentation": [ "http://www.masimo.com/role/BusinessCombinationsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue", "label": "Business Acquisitions, Revenue", "documentation": "Business Acquisitions, Revenue" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationAndAssetAcquisitionAbstract", "lang": { "en-us": { "role": { "label": "Business Combination and Asset Acquisition [Abstract]" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationConsiderationTransferred1", "crdr": "credit", "calculation": { "http://www.masimo.com/role/BusinessCombinationsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.masimo.com/role/BusinessCombinationsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Purchase price", "label": "Business Combination, Consideration Transferred", "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer." } } }, "auth_ref": [ "r1", "r2", "r18" ] }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationDisclosureTextBlock", "presentation": [ "http://www.masimo.com/role/BusinessCombinations" ], "lang": { "en-us": { "role": { "terseLabel": "Business Combinations", "label": "Business Combination Disclosure [Text Block]", "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)." } } }, "auth_ref": [ "r198", "r634" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract", "presentation": [ "http://www.masimo.com/role/BusinessCombinationsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Assets acquired:", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract]" } } }, "auth_ref": [] }, "masi_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://www.masimo.com/20240330", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill", "crdr": "debit", "calculation": { "http://www.masimo.com/role/BusinessCombinationsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.masimo.com/role/BusinessCombinationsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets acquired", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets Acquired Including Goodwill", "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets Acquired Including Goodwill" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "crdr": "debit", "calculation": { "http://www.masimo.com/role/BusinessCombinationsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "masi_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.masimo.com/role/BusinessCombinationsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r108" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets", "crdr": "debit", "calculation": { "http://www.masimo.com/role/BusinessCombinationsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "masi_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.masimo.com/role/BusinessCombinationsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other current assets", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date." } } }, "auth_ref": [ "r108" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables", "crdr": "debit", "calculation": { "http://www.masimo.com/role/BusinessCombinationsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "masi_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.masimo.com/role/BusinessCombinationsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivables", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables", "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date." } } }, "auth_ref": [ "r108" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable", "crdr": "credit", "calculation": { "http://www.masimo.com/role/BusinessCombinationsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.masimo.com/role/BusinessCombinationsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Accounts payable", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable", "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date." } } }, "auth_ref": [ "r108" ] }, "masi_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilitiesAndOtherLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.masimo.com/20240330", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilitiesAndOtherLiabilities", "crdr": "credit", "calculation": { "http://www.masimo.com/role/BusinessCombinationsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.masimo.com/role/BusinessCombinationsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Accrued liabilities and other current liabilities", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Liabilities And Other Liabilities", "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Liabilities And Other Liabilities" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities", "crdr": "credit", "calculation": { "http://www.masimo.com/role/BusinessCombinationsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.masimo.com/role/BusinessCombinationsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Deferred tax liabilities", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date." } } }, "auth_ref": [ "r108" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets", "crdr": "debit", "calculation": { "http://www.masimo.com/role/BusinessCombinationsScheduleofAcquiredIntangibleAssetsDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.masimo.com/role/BusinessCombinationsScheduleofAcquiredIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Indefinite intangible assets", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets", "documentation": "Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date." } } }, "auth_ref": [ "r108" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill", "crdr": "debit", "calculation": { "http://www.masimo.com/role/BusinessCombinationsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "masi_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill", "weight": 1.0, "order": 7.0 }, "http://www.masimo.com/role/BusinessCombinationsScheduleofAcquiredIntangibleAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.masimo.com/role/BusinessCombinationsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.masimo.com/role/BusinessCombinationsScheduleofAcquiredIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets", "totalLabel": "Total", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill", "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date." } } }, "auth_ref": [ "r108" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles", "crdr": "debit", "calculation": { "http://www.masimo.com/role/BusinessCombinationsScheduleofAcquiredIntangibleAssetsDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.masimo.com/role/BusinessCombinationsScheduleofAcquiredIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Finite lived intangible assets", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles", "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date." } } }, "auth_ref": [ "r107", "r108" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory", "crdr": "debit", "calculation": { "http://www.masimo.com/role/BusinessCombinationsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "masi_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.masimo.com/role/BusinessCombinationsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventories", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory", "documentation": "The amount of inventory recognized as of the acquisition date." } } }, "auth_ref": [ "r107", "r108" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "crdr": "credit", "calculation": { "http://www.masimo.com/role/BusinessCombinationsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.masimo.com/role/BusinessCombinationsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Total liabilities assumed", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities", "documentation": "Amount of liabilities assumed at the acquisition date." } } }, "auth_ref": [ "r108" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract", "presentation": [ "http://www.masimo.com/role/BusinessCombinationsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities assumed:", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther", "crdr": "credit", "calculation": { "http://www.masimo.com/role/BusinessCombinationsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.masimo.com/role/BusinessCombinationsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other long-term liabilities", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other", "documentation": "Amount of other liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date." } } }, "auth_ref": [ "r108" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets", "crdr": "debit", "calculation": { "http://www.masimo.com/role/BusinessCombinationsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "masi_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.masimo.com/role/BusinessCombinationsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term other assets", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets", "documentation": "Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date." } } }, "auth_ref": [ "r108" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment", "crdr": "debit", "calculation": { "http://www.masimo.com/role/BusinessCombinationsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "masi_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.masimo.com/role/BusinessCombinationsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, plant and equipment", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment", "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date." } } }, "auth_ref": [ "r107", "r108" ] }, "us-gaap_BusinessCombinationsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationsPolicy", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Business Combinations", "label": "Business Combinations Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy." } } }, "auth_ref": [ "r103" ] }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CapitalExpendituresIncurredButNotYetPaid", "crdr": "credit", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesScheduleofSupplementalCashFlowInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Unpaid purchases of property and equipment", "label": "Capital Expenditures Incurred but Not yet Paid", "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred." } } }, "auth_ref": [ "r57", "r58", "r59" ] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 }, "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesScheduleofSupplementalCashFlowInformationDetail": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesScheduleofSupplementalCashFlowInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "verboseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r54", "r247", "r899" ] }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsFairValueDisclosure", "crdr": "debit", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesScheduleofFairValueAssetsMeasuredonRecurringBasisDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth_ref": [ "r55" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesScheduleofSupplementalCashFlowInformationDetail": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesScheduleofSupplementalCashFlowInformationDetail" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period", "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period", "totalLabel": "Total cash, cash equivalents and restricted cash shown in the condensed consolidated statements of cash flows", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r54", "r172", "r295" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesScheduleofSupplementalCashFlowInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Reconciliation of cash, cash equivalents and restricted cash:", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net decrease in cash, cash equivalents and restricted cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r3", "r172" ] }, "us-gaap_CashDistributionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashDistributionMember", "presentation": [ "http://www.masimo.com/role/CommitmentsandContingenciesDetail", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Cash Distribution", "label": "Cash Distribution [Member]", "documentation": "Distribution of cash made by the entity based on a contractual agreement such as a partnership or employment agreement." } } }, "auth_ref": [] }, "us-gaap_CashFDICInsuredAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashFDICInsuredAmount", "crdr": "debit", "presentation": [ "http://www.masimo.com/role/CommitmentsandContingenciesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Bank balance covered by federal deposit insurance corporation limit", "label": "Cash, FDIC Insured Amount", "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation." } } }, "auth_ref": [] }, "us-gaap_CashFlowHedgingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashFlowHedgingMember", "presentation": [ "http://www.masimo.com/role/OtherNonCurrentAssetsDetails", "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesScheduleofFairValueAssetsMeasuredonRecurringBasisDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Cash Flow Hedges", "label": "Cash Flow Hedging [Member]", "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk." } } }, "auth_ref": [ "r119" ] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Changed Peer Group, Footnote", "label": "Changed Peer Group, Footnote [Text Block]" } } }, "auth_ref": [ "r991" ] }, "srt_ChiefExecutiveOfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ChiefExecutiveOfficerMember", "presentation": [ "http://www.masimo.com/role/CommitmentsandContingenciesDetail", "http://www.masimo.com/role/RelatedPartyTransactionsDetails", "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Chief Executive Officer", "label": "Chief Executive Officer [Member]" } } }, "auth_ref": [ "r1060" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.masimo.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://www.masimo.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Domain]", "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": [ "r238", "r258", "r259", "r260", "r299", "r322", "r326", "r328", "r330", "r335", "r336", "r377", "r429", "r432", "r433", "r434", "r440", "r441", "r472", "r473", "r476", "r479", "r486", "r664", "r777", "r778", "r779", "r780", "r787", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r795", "r796", "r797", "r798", "r817", "r838", "r862", "r884", "r885", "r886", "r887", "r888", "r1026", "r1047", "r1057" ] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockLineItems", "presentation": [ "http://www.masimo.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Line Items]", "label": "Class of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r258", "r259", "r260", "r335", "r472", "r473", "r474", "r476", "r479", "r484", "r486", "r777", "r778", "r779", "r780", "r924", "r1026", "r1047" ] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Amount", "label": "Company Selected Measure Amount" } } }, "auth_ref": [ "r992" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Name", "label": "Company Selected Measure Name" } } }, "auth_ref": [ "r992" ] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and contingencies - (Note 24)", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r44", "r141", "r745", "r816" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies Disclosure [Abstract]", "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://www.masimo.com/role/CommitmentsandContingencies" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r186", "r415", "r416", "r892", "r1078" ] }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "presentation": [ "http://www.masimo.com/role/StockBasedCompensationNarrativeDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, capital shares reserved for future issuance (in shares)", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "documentation": "Aggregate number of common shares reserved for future issuance." } } }, "auth_ref": [ "r45" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY", "http://www.masimo.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r937", "r938", "r939", "r941", "r942", "r943", "r946", "r1053", "r1054", "r1127", "r1152", "r1156" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, par value (in dollars per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r151" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares authorized (in shares)", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r151", "r817" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares, issued (in shares)", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r151" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares, outstanding (in shares)", "periodStartLabel": "Beginning balance (in shares)", "periodEndLabel": "Ending balance (in shares)", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r21", "r151", "r817", "r835", "r1156", "r1157" ] }, "us-gaap_CommonStockValueOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValueOutstanding", "crdr": "credit", "calculation": { "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, $0.001 par value; 100.0 million shares authorized; 53.1 million and 52.8 million shares issued and outstanding at March\u00a030, 2024 and December\u00a030, 2023, respectively", "label": "Common Stock, Value, Outstanding", "documentation": "Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares." } } }, "auth_ref": [ "r151", "r817" ] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Company Selected Measure", "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]" } } }, "auth_ref": [ "r997" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Net Income", "label": "Compensation Actually Paid vs. Net Income [Text Block]" } } }, "auth_ref": [ "r996" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Other Measure", "label": "Compensation Actually Paid vs. Other Measure [Text Block]" } } }, "auth_ref": [ "r998" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return", "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]" } } }, "auth_ref": [ "r995" ] }, "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CompensationAndEmployeeBenefitPlansTextBlock", "presentation": [ "http://www.masimo.com/role/EmployeeBenefits" ], "lang": { "en-us": { "role": { "terseLabel": "Employee Benefits", "label": "Compensation and Employee Benefit Plans [Text Block]", "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans." } } }, "auth_ref": [ "r192", "r193", "r194", "r195" ] }, "masi_ComponentsOfOtherLiabilitiesLongTermTableTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.masimo.com/20240330", "localname": "ComponentsOfOtherLiabilitiesLongTermTableTableTextBlock", "presentation": [ "http://www.masimo.com/role/OtherNonCurrentLiabilitiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Components Of Other Liabilities Long Term Table", "label": "Components Of Other Liabilities Long Term Table [Table Text Block]", "documentation": "This element may be used as a single block of text to encapsulate the entire disclosure for other liabilities including data and tables." } } }, "auth_ref": [] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" ], "lang": { "en-us": { "role": { "totalLabel": "Total comprehensive loss", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r49", "r277", "r279", "r285", "r738", "r754" ] }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Comprehensive (Loss) Income", "label": "Comprehensive Income, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for comprehensive income." } } }, "auth_ref": [] }, "us-gaap_ComputerEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComputerEquipmentMember", "presentation": [ "http://www.masimo.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentDetails", "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Computer equipment and software", "label": "Computer Equipment [Member]", "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems." } } }, "auth_ref": [] }, "masi_ConcentrationRiskARCustomer": { "xbrltype": "integerItemType", "nsuri": "http://www.masimo.com/20240330", "localname": "ConcentrationRiskARCustomer", "presentation": [ "http://www.masimo.com/role/CommitmentsandContingenciesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration risk, AR balance one customer", "label": "Concentration Risk AR Customer", "documentation": "Concentration Risk, Customer, Percentage of Receivable Balance" } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": [ "http://www.masimo.com/role/CommitmentsandContingenciesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark [Domain]", "label": "Concentration Risk Benchmark [Domain]", "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": [ "r62", "r64", "r131", "r132", "r369", "r891" ] }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": [ "http://www.masimo.com/role/CommitmentsandContingenciesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark [Axis]", "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": [ "r62", "r64", "r131", "r132", "r369", "r774", "r891" ] }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskByTypeAxis", "presentation": [ "http://www.masimo.com/role/CommitmentsandContingenciesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type [Axis]", "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth_ref": [ "r62", "r64", "r131", "r132", "r369", "r891", "r1030" ] }, "masi_ConcentrationRiskJustInTimeDistributors": { "xbrltype": "integerItemType", "nsuri": "http://www.masimo.com/20240330", "localname": "ConcentrationRiskJustInTimeDistributors", "presentation": [ "http://www.masimo.com/role/CommitmentsandContingenciesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Distributors", "label": "Concentration Risk, Just-In-Time Distributors", "documentation": "Concentration Risk, Just-In-Time Distributors" } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskPercentage1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskPercentage1", "presentation": [ "http://www.masimo.com/role/CommitmentsandContingenciesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration risk, percentage", "label": "Concentration Risk, Percentage", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division." } } }, "auth_ref": [ "r62", "r64", "r131", "r132", "r369" ] }, "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskTypeDomain", "presentation": [ "http://www.masimo.com/role/CommitmentsandContingenciesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type [Domain]", "label": "Concentration Risk Type [Domain]", "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": [ "r62", "r64", "r131", "r132", "r369", "r891" ] }, "srt_ConsolidationItemsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ConsolidationItemsAxis", "presentation": [ "http://www.masimo.com/role/SegmentandEnterpriseReportingScheduleofSegmentReportingInformationbySegmentDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidation Items [Axis]", "label": "Consolidation Items [Axis]" } } }, "auth_ref": [ "r305", "r343", "r354", "r355", "r356", "r357", "r358", "r360", "r364", "r429", "r430", "r431", "r432", "r434", "r435", "r437", "r439", "r440", "r1086", "r1087" ] }, "srt_ConsolidationItemsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ConsolidationItemsDomain", "presentation": [ "http://www.masimo.com/role/SegmentandEnterpriseReportingScheduleofSegmentReportingInformationbySegmentDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidation Items [Domain]", "label": "Consolidation Items [Domain]" } } }, "auth_ref": [ "r305", "r343", "r354", "r355", "r356", "r357", "r358", "r360", "r364", "r429", "r430", "r431", "r432", "r434", "r435", "r437", "r439", "r440", "r1086", "r1087" ] }, "us-gaap_ConstructionInProgressMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConstructionInProgressMember", "presentation": [ "http://www.masimo.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Construction-in-progress (CIP)", "label": "Construction in Progress [Member]", "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service." } } }, "auth_ref": [] }, "masi_ContingenciesAndCommitmentsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.masimo.com/20240330", "localname": "ContingenciesAndCommitmentsLineItems", "presentation": [ "http://www.masimo.com/role/CommitmentsandContingenciesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Contingencies And Commitments [Line Items]", "label": "Contingencies And Commitments [Line Items]", "documentation": "Contingencies And Commitments [Line Items]" } } }, "auth_ref": [] }, "masi_ContingenciesAndCommitmentsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.masimo.com/20240330", "localname": "ContingenciesAndCommitmentsTable", "presentation": [ "http://www.masimo.com/role/CommitmentsandContingenciesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Contingencies And Commitments [Table]", "label": "Contingencies And Commitments [Table]", "documentation": "Contingencies And Commitments [Table]" } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "presentation": [ "http://www.masimo.com/role/DeferredRevenueandOtherContractLiabilitiesCurrentTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Contract with Customer, Asset and Liability", "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]", "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability." } } }, "auth_ref": [ "r1090" ] }, "us-gaap_ContractWithCustomerAssetNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerAssetNetCurrent", "crdr": "debit", "calculation": { "http://www.masimo.com/role/OtherCurrentAssetsDetails": { "parentTag": "us-gaap_OtherAssetsCurrent", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.masimo.com/role/OtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contract assets, current", "label": "Contract with Customer, Asset, after Allowance for Credit Loss, Current", "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current." } } }, "auth_ref": [ "r488", "r490", "r501" ] }, "us-gaap_ContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerLiability", "crdr": "credit", "calculation": { "http://www.masimo.com/role/DeferredRevenueandOtherContractLiabilitiesCurrentScheduleofDeferredRevenueandOtherContractLiabilitiesCurrentDetails": { "parentTag": "us-gaap_OtherLiabilitiesAndDeferredRevenueNoncurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.masimo.com/role/DeferredRevenueandOtherContractLiabilitiesCurrentNarrativeDetails", "http://www.masimo.com/role/DeferredRevenueandOtherContractLiabilitiesCurrentScheduleofChangesinDeferredRevenueDetails", "http://www.masimo.com/role/DeferredRevenueandOtherContractLiabilitiesCurrentScheduleofDeferredRevenueandOtherContractLiabilitiesCurrentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred revenue", "periodStartLabel": "Deferred revenue, beginning of the period", "periodEndLabel": "Deferred revenue, end of the period", "label": "Contract with Customer, Liability", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r488", "r489", "r501" ] }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerLiabilityCurrent", "crdr": "credit", "presentation": [ "http://www.masimo.com/role/DeferredRevenueandOtherContractLiabilitiesCurrentScheduleofDeferredRevenueandOtherContractLiabilitiesCurrentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred revenue and other contract liabilities, current", "label": "Contract with Customer, Liability, Current", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current." } } }, "auth_ref": [ "r488", "r489", "r501" ] }, "masi_ContractWithCustomerLiabilityDeferredRevenueAdditions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.masimo.com/20240330", "localname": "ContractWithCustomerLiabilityDeferredRevenueAdditions", "crdr": "credit", "presentation": [ "http://www.masimo.com/role/DeferredRevenueandOtherContractLiabilitiesCurrentScheduleofChangesinDeferredRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue deferred during the period", "label": "Contract with Customer, Liability, Deferred Revenue, Additions", "documentation": "Contract with Customer, Liability, Deferred Revenue, Additions" } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.masimo.com/role/OtherNonCurrentLiabilitiesDetails": { "parentTag": "us-gaap_DeferredCreditsAndOtherLiabilities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.masimo.com/role/DeferredRevenueandOtherContractLiabilitiesCurrentScheduleofDeferredRevenueandOtherContractLiabilitiesCurrentDetails", "http://www.masimo.com/role/OtherNonCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Less: Non-current portion of deferred revenue", "terseLabel": "Deferred revenue, non-current", "label": "Contract with Customer, Liability, Noncurrent", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent." } } }, "auth_ref": [ "r488", "r489", "r501" ] }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerLiabilityRevenueRecognized", "crdr": "credit", "presentation": [ "http://www.masimo.com/role/DeferredRevenueandOtherContractLiabilitiesCurrentScheduleofChangesinDeferredRevenueDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Recognition of revenue deferred in prior periods", "label": "Contract with Customer, Liability, Revenue Recognized", "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due." } } }, "auth_ref": [ "r502" ] }, "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "calculation": { "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_GrossProfit", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of goods sold", "label": "Cost of Goods and Services Sold", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } }, "auth_ref": [ "r166", "r721" ] }, "us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfGoodsAndServicesSoldDepreciationAndAmortization", "crdr": "debit", "presentation": [ "http://www.masimo.com/role/SegmentandEnterpriseReportingScheduleofSegmentReportingInformationbySegmentDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation and amortization", "label": "Cost, Depreciation and Amortization", "documentation": "Amount of expense for allocation of cost of tangible and intangible assets over their useful lives directly used in production of good and rendering of service." } } }, "auth_ref": [ "r1041" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditFacilityAxis", "presentation": [ "http://www.masimo.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Axis]", "label": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditFacilityDomain", "presentation": [ "http://www.masimo.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Domain]", "label": "Credit Facility [Domain]", "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.masimo.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CustomerConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CustomerConcentrationRiskMember", "presentation": [ "http://www.masimo.com/role/CommitmentsandContingenciesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Customer Concentration Risk", "label": "Customer Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer." } } }, "auth_ref": [ "r63", "r369" ] }, "masi_CustomerOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.masimo.com/20240330", "localname": "CustomerOneMember", "presentation": [ "http://www.masimo.com/role/CommitmentsandContingenciesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Customer One", "label": "Customer One [Member]", "documentation": "Customer One" } } }, "auth_ref": [] }, "us-gaap_CustomerRefundLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CustomerRefundLiabilityCurrent", "crdr": "credit", "presentation": [ "http://www.masimo.com/role/OtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other current liability", "label": "Customer Refund Liability, Current", "documentation": "Current regulatory liabilities generally represent obligations to make refunds to customers for various reasons including overpayment." } } }, "auth_ref": [] }, "us-gaap_CustomerRelationshipsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CustomerRelationshipsMember", "presentation": [ "http://www.masimo.com/role/BusinessCombinationsScheduleofAcquiredIntangibleAssetsDetails", "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.masimo.com/role/IntangibleAssetsnetScheduleofFiniteLivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer relationships", "label": "Customer Relationships [Member]", "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships." } } }, "auth_ref": [ "r111" ] }, "us-gaap_DebtAndCapitalLeaseObligations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtAndCapitalLeaseObligations", "crdr": "credit", "calculation": { "http://www.masimo.com/role/DebtScheduleofDebtDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.masimo.com/role/DebtScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total debt", "label": "Debt and Lease Obligation", "documentation": "Amount of short-term and long-term debt and lease obligation." } } }, "auth_ref": [ "r212" ] }, "us-gaap_DebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtCurrent", "crdr": "credit", "calculation": { "http://www.masimo.com/role/DebtScheduleofDebtDetails": { "parentTag": "us-gaap_DebtAndCapitalLeaseObligations", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.masimo.com/role/DebtScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt, current portion", "label": "Debt, Current", "documentation": "Amount of debt and lease obligation, classified as current." } } }, "auth_ref": [ "r256" ] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Debt Disclosure [Abstract]", "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://www.masimo.com/role/Debt" ], "lang": { "en-us": { "role": { "terseLabel": "Debt", "label": "Debt Disclosure [Text Block]", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r187", "r297", "r442", "r448", "r449", "r450", "r451", "r452", "r453", "r458", "r465", "r466", "r468" ] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentAxis", "presentation": [ "http://www.masimo.com/role/DebtNarrativeDetails", "http://www.masimo.com/role/DebtScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Axis]", "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r32", "r146", "r147", "r207", "r209", "r305", "r443", "r444", "r445", "r446", "r447", "r449", "r454", "r455", "r456", "r457", "r459", "r460", "r461", "r462", "r463", "r464", "r679", "r919", "r920", "r921", "r922", "r923", "r1048" ] }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "presentation": [ "http://www.masimo.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable rate", "label": "Debt Instrument, Basis Spread on Variable Rate", "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": [ "http://www.masimo.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument face amount", "label": "Debt Instrument, Face Amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": [ "r134", "r136", "r443", "r679", "r920", "r921" ] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentLineItems", "presentation": [ "http://www.masimo.com/role/DebtNarrativeDetails", "http://www.masimo.com/role/DebtScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Line Items]", "label": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r305", "r443", "r444", "r445", "r446", "r447", "r449", "r454", "r455", "r456", "r457", "r459", "r460", "r461", "r462", "r463", "r464", "r467", "r679", "r919", "r920", "r921", "r922", "r923", "r1048" ] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://www.masimo.com/role/DebtNarrativeDetails", "http://www.masimo.com/role/DebtScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Name [Domain]", "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r42", "r305", "r443", "r444", "r445", "r446", "r447", "r449", "r454", "r455", "r456", "r457", "r459", "r460", "r461", "r462", "r463", "r464", "r679", "r919", "r920", "r921", "r922", "r923", "r1048" ] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentTable", "presentation": [ "http://www.masimo.com/role/DebtNarrativeDetails", "http://www.masimo.com/role/DebtScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-term Debt Instruments [Table]", "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r42", "r89", "r92", "r133", "r134", "r136", "r142", "r189", "r190", "r305", "r443", "r444", "r445", "r446", "r447", "r449", "r454", "r455", "r456", "r457", "r459", "r460", "r461", "r462", "r463", "r464", "r467", "r679", "r919", "r920", "r921", "r922", "r923", "r1048" ] }, "us-gaap_DebtWeightedAverageInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtWeightedAverageInterestRate", "presentation": [ "http://www.masimo.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Average interest rate", "label": "Debt, Weighted Average Interest Rate", "documentation": "Weighted average interest rate of debt outstanding." } } }, "auth_ref": [] }, "masi_DeferredCostofGoodsSoldAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://www.masimo.com/20240330", "localname": "DeferredCostofGoodsSoldAccumulatedAmortization", "crdr": "credit", "presentation": [ "http://www.masimo.com/role/PropertyandEquipmentnetNarrativeDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated amortization of deferred cost of goods sold", "label": "Deferred Cost of Goods Sold, Accumulated Amortization", "documentation": "Deferred Cost of Goods Sold, Accumulated Amortization" } } }, "auth_ref": [] }, "masi_DeferredCostofGoodsSoldAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://www.masimo.com/20240330", "localname": "DeferredCostofGoodsSoldAmortization", "crdr": "debit", "presentation": [ "http://www.masimo.com/role/PropertyandEquipmentnetNarrativeDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of deferred cost of goods sold", "label": "Deferred Cost of Goods Sold, Amortization", "documentation": "Deferred Cost of Goods Sold, Amortization" } } }, "auth_ref": [] }, "us-gaap_DeferredCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredCosts", "crdr": "debit", "calculation": { "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred costs and other contract assets", "label": "Deferred Costs, Noncurrent", "documentation": "Amount of deferred cost, excluding capitalized cost related to contract with customer; classified as noncurrent." } } }, "auth_ref": [ "r205", "r1035" ] }, "us-gaap_DeferredCostsAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredCostsAndOtherAssets", "crdr": "debit", "calculation": { "http://www.masimo.com/role/DeferredCostsandOtherContractAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.masimo.com/role/DeferredCostsandOtherContractAssetsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Deferred costs and other contract assets", "label": "Deferred Costs and Other Assets", "documentation": "Amount of deferred cost assets and assets classified as other." } } }, "auth_ref": [] }, "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]", "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "presentation": [ "http://www.masimo.com/role/DeferredCostsandOtherContractAssetsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Deferred Costs and Other Contract Assets", "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]", "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs." } } }, "auth_ref": [] }, "masi_DeferredCostsandOtherContractAssetsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.masimo.com/20240330", "localname": "DeferredCostsandOtherContractAssetsPolicyTextBlock", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred Costs and Other Contract Assets", "label": "Deferred Costs and Other Contract Assets [Policy Text Block]", "documentation": "Deferred Costs and Other Contract Assets [Policy Text Block]" } } }, "auth_ref": [] }, "masi_DeferredCostsandOtherContractAssetsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.masimo.com/20240330", "localname": "DeferredCostsandOtherContractAssetsTextBlock", "presentation": [ "http://www.masimo.com/role/DeferredCostsandOtherContractAssets" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred Costs and Other Contract Assets", "label": "Deferred Costs and Other Contract Assets [Text Block]", "documentation": "Deferred Costs and Other Contract Assets [Text Block]" } } }, "auth_ref": [] }, "us-gaap_DeferredCreditsAndOtherLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredCreditsAndOtherLiabilities", "crdr": "credit", "calculation": { "http://www.masimo.com/role/OtherNonCurrentLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.masimo.com/role/OtherNonCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total other non-current liabilities", "label": "Deferred Credits and Other Liabilities", "documentation": "Total carrying amount as of the balance sheet date of unearned revenue or income, not otherwise specified in the taxonomy, which is expected to be taken into income in future periods and obligations not separately disclosed in the balance sheet (other liabilities)." } } }, "auth_ref": [] }, "masi_DeferredEquipmentAgreementsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.masimo.com/20240330", "localname": "DeferredEquipmentAgreementsNet", "crdr": "debit", "calculation": { "http://www.masimo.com/role/DeferredCostsandOtherContractAssetsDetails": { "parentTag": "us-gaap_DeferredCostsAndOtherAssets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.masimo.com/role/DeferredCostsandOtherContractAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred equipment agreements, net", "label": "Deferred Equipment Agreements, Net", "documentation": "Deferred Equipment Agreements, Net" } } }, "auth_ref": [] }, "us-gaap_DeferredFinanceCostsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredFinanceCostsNet", "crdr": "debit", "presentation": [ "http://www.masimo.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt issuance costs", "label": "Debt Issuance Costs, Net", "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs." } } }, "auth_ref": [ "r135", "r1089" ] }, "us-gaap_DeferredIncomeTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxAssetsNet", "crdr": "debit", "calculation": { "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax assets", "label": "Deferred Income Tax Assets, Net", "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting." } } }, "auth_ref": [ "r615", "r616" ] }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxLiabilitiesNet", "crdr": "credit", "calculation": { "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax liabilities", "label": "Deferred Income Tax Liabilities, Net", "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting." } } }, "auth_ref": [ "r615", "r616", "r744" ] }, "us-gaap_DeferredRevenueArrangementByTypeTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredRevenueArrangementByTypeTable", "presentation": [ "http://www.masimo.com/role/DeferredRevenueandOtherContractLiabilitiesCurrentNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred Revenue Arrangement, by Type [Table]", "label": "Deferred Revenue Arrangement, by Type [Table]", "documentation": "Schedule of deferred revenue disclosure which includes the type of arrangements and the corresponding amount that comprise the current and noncurrent balance of deferred revenue as of the balance sheet date." } } }, "auth_ref": [] }, "us-gaap_DeferredRevenueCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredRevenueCurrent", "crdr": "credit", "calculation": { "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "verboseLabel": "Deferred revenue and other contract liabilities, current", "label": "Deferred Revenue, Current", "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current." } } }, "auth_ref": [ "r1036" ] }, "masi_DeferredSalesCommissions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.masimo.com/20240330", "localname": "DeferredSalesCommissions", "crdr": "debit", "calculation": { "http://www.masimo.com/role/DeferredCostsandOtherContractAssetsDetails": { "parentTag": "us-gaap_DeferredCostsAndOtherAssets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.masimo.com/role/DeferredCostsandOtherContractAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred commissions", "label": "Deferred Sales Commissions", "documentation": "Deferred Sales Commissions" } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanBenefitObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanBenefitObligation", "crdr": "credit", "calculation": { "http://www.masimo.com/role/OtherNonCurrentLiabilitiesDetails": { "parentTag": "us-gaap_DeferredCreditsAndOtherLiabilities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.masimo.com/role/OtherNonCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Projected benefit obligation", "label": "Defined Benefit Plan, Benefit Obligation", "documentation": "Amount of actuarial present value of benefits attributed to service rendered by employee for defined benefit plan." } } }, "auth_ref": [ "r504" ] }, "us-gaap_DefinedContributionPlanDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedContributionPlanDisclosureLineItems", "presentation": [ "http://www.masimo.com/role/EmployeeBenefitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Defined Contribution Plan Disclosure [Line Items]", "label": "Defined Contribution Plan Disclosure [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r565" ] }, "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount", "crdr": "debit", "presentation": [ "http://www.masimo.com/role/EmployeeBenefitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Company's contribution to employee retirement savings plan", "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount", "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan." } } }, "auth_ref": [] }, "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedContributionPlanEmployerMatchingContributionPercent", "presentation": [ "http://www.masimo.com/role/EmployeeBenefitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percent of employees' gross pay", "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay", "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan." } } }, "auth_ref": [] }, "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "presentation": [ "http://www.masimo.com/role/EmployeeBenefitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percent of match", "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match", "documentation": "Percentage employer matches of the employee's percentage contribution matched." } } }, "auth_ref": [] }, "masi_DefinedContributionPlanNumberOfPlans": { "xbrltype": "integerItemType", "nsuri": "http://www.masimo.com/20240330", "localname": "DefinedContributionPlanNumberOfPlans", "presentation": [ "http://www.masimo.com/role/EmployeeBenefitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Defined contribution plan, number of plans", "label": "Defined Contribution Plan, Number Of Plans", "documentation": "Defined Contribution Plan, Number Of Plans" } } }, "auth_ref": [] }, "us-gaap_DefinedContributionPlanTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedContributionPlanTable", "presentation": [ "http://www.masimo.com/role/EmployeeBenefitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Defined Contribution Plan [Table]", "label": "Defined Contribution Plan [Table]", "documentation": "Disclosure of information about defined contribution pension plans or defined contribution other postretirement plans, separately for pension plans and other postretirement benefit plans." } } }, "auth_ref": [ "r565" ] }, "masi_DemonstrationUnitsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.masimo.com/20240330", "localname": "DemonstrationUnitsMember", "presentation": [ "http://www.masimo.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentDetails", "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Demonstration units", "label": "Demonstration Units [Member]", "documentation": "Demonstration units." } } }, "auth_ref": [] }, "us-gaap_DepositsAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DepositsAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.masimo.com/role/OtherNonCurrentAssetsDetails": { "parentTag": "us-gaap_OtherAssetsNoncurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.masimo.com/role/OtherNonCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid deposits and other", "label": "Deposits Assets, Noncurrent", "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer." } } }, "auth_ref": [ "r1035" ] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Depreciation", "crdr": "debit", "presentation": [ "http://www.masimo.com/role/PropertyandEquipmentnetNarrativeDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation", "label": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r11", "r82" ] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "calculation": { "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation and amortization", "label": "Depreciation, Depletion and Amortization", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": [ "r11", "r346" ] }, "us-gaap_DerivativeAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeAssets", "crdr": "debit", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesScheduleofFairValueAssetsMeasuredonRecurringBasisDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative instruments", "label": "Derivative Asset", "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": [ "r268", "r269", "r663", "r799", "r800", "r801", "r802", "r803", "r804", "r805", "r806", "r807", "r808", "r823", "r824", "r874", "r878", "r879", "r880", "r881", "r882", "r908", "r939", "r1153" ] }, "us-gaap_DerivativeAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.masimo.com/role/OtherNonCurrentAssetsDetails": { "parentTag": "us-gaap_OtherAssetsNoncurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.masimo.com/role/OtherNonCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative assets - non-current", "label": "Derivative Asset, Noncurrent", "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": [ "r268" ] }, "us-gaap_DerivativeAverageSwaptionInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeAverageSwaptionInterestRate", "presentation": [ "http://www.masimo.com/role/DerivativeInstrumentsandHedgingActivitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Average fixed interest rate related to derivative contracts", "label": "Derivative, Average Swaption Interest Rate", "documentation": "Average fixed interest rate that will be received or paid upon exercise of a group of interest rate swaption contracts." } } }, "auth_ref": [] }, "us-gaap_DerivativeContractTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeContractTypeDomain", "presentation": [ "http://www.masimo.com/role/DerivativeInstrumentsandHedgingActivitiesNarrativeDetails", "http://www.masimo.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofDerivativeInstrumentsinStatementofFinancialPositionFairValueDetails", "http://www.masimo.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofReclassificationoutofAccumulatedOtherComprehensiveIncomeDetails", "http://www.masimo.com/role/OtherNonCurrentAssetsDetails", "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesScheduleofFairValueAssetsMeasuredonRecurringBasisDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Contract [Domain]", "label": "Derivative Contract [Domain]", "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "auth_ref": [ "r806", "r808", "r822", "r823", "r824", "r825", "r826", "r827", "r828", "r830", "r831", "r832", "r833", "r849", "r850", "r851", "r852", "r855", "r856", "r857", "r858", "r874", "r876", "r879", "r881", "r937", "r939" ] }, "us-gaap_DerivativeFairValueOfDerivativeAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeFairValueOfDerivativeAsset", "crdr": "debit", "presentation": [ "http://www.masimo.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofDerivativeInstrumentsinStatementofFinancialPositionFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value of hedging instruments", "label": "Derivative Asset, Subject to Master Netting Arrangement, before Offset", "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement." } } }, "auth_ref": [ "r30", "r124", "r160", "r267", "r908" ] }, "us-gaap_DerivativeInstrumentRiskAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentRiskAxis", "presentation": [ "http://www.masimo.com/role/DerivativeInstrumentsandHedgingActivitiesNarrativeDetails", "http://www.masimo.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofDerivativeInstrumentsinStatementofFinancialPositionFairValueDetails", "http://www.masimo.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofReclassificationoutofAccumulatedOtherComprehensiveIncomeDetails", "http://www.masimo.com/role/OtherNonCurrentAssetsDetails", "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesScheduleofFairValueAssetsMeasuredonRecurringBasisDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instrument [Axis]", "label": "Derivative Instrument [Axis]", "documentation": "Information by type of derivative contract." } } }, "auth_ref": [ "r122", "r125", "r127", "r128", "r806", "r808", "r822", "r823", "r824", "r825", "r826", "r827", "r828", "r830", "r831", "r832", "r833", "r849", "r850", "r851", "r852", "r855", "r856", "r857", "r858", "r874", "r876", "r879", "r881", "r908", "r937", "r939" ] }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "presentation": [ "http://www.masimo.com/role/DerivativeInstrumentsandHedgingActivities" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments and Hedging Activities", "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]", "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts." } } }, "auth_ref": [ "r202", "r642", "r649" ] }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems", "presentation": [ "http://www.masimo.com/role/DerivativeInstrumentsandHedgingActivitiesNarrativeDetails", "http://www.masimo.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofAccumulatedOtherComprehensiveIncomeLossDetails", "http://www.masimo.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofDerivativeInstrumentsinStatementofFinancialPositionFairValueDetails", "http://www.masimo.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofReclassificationoutofAccumulatedOtherComprehensiveIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments and Hedging Activities Disclosures [Line Items]", "label": "Derivative Instruments and Hedging Activities Disclosures [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable", "presentation": [ "http://www.masimo.com/role/DerivativeInstrumentsandHedgingActivitiesNarrativeDetails", "http://www.masimo.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofAccumulatedOtherComprehensiveIncomeLossDetails", "http://www.masimo.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofDerivativeInstrumentsinStatementofFinancialPositionFairValueDetails", "http://www.masimo.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofReclassificationoutofAccumulatedOtherComprehensiveIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments and Hedging Activities Disclosures [Table]", "label": "Derivative Instruments and Hedging Activities Disclosures [Table]", "documentation": "Disclosure of information about derivatives and hedging activities." } } }, "auth_ref": [] }, "us-gaap_DerivativeLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeLiabilities", "crdr": "credit", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesScheduleofFairValueAssetsMeasuredonRecurringBasisDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative instruments - cash flow hedges", "label": "Derivative Liability", "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": [ "r268", "r269", "r663", "r799", "r800", "r801", "r802", "r804", "r805", "r806", "r807", "r808", "r830", "r832", "r833", "r876", "r877", "r878", "r879", "r880", "r881", "r882", "r908", "r1153" ] }, "us-gaap_DerivativeTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeTermOfContract", "presentation": [ "http://www.masimo.com/role/DerivativeInstrumentsandHedgingActivitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maturities of derivative contracts", "label": "Derivative, Term of Contract", "documentation": "Period the derivative contract is outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_DerivativesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativesPolicyTextBlock", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Derivatives Instruments and Hedging Activities", "label": "Derivatives, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities." } } }, "auth_ref": [ "r22", "r117", "r118", "r120", "r129", "r304" ] }, "us-gaap_DesignatedAsHedgingInstrumentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DesignatedAsHedgingInstrumentMember", "presentation": [ "http://www.masimo.com/role/DerivativeInstrumentsandHedgingActivitiesNarrativeDetails", "http://www.masimo.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofDerivativeInstrumentsinStatementofFinancialPositionFairValueDetails", "http://www.masimo.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofReclassificationoutofAccumulatedOtherComprehensiveIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Designated as Hedging Instrument", "label": "Designated as Hedging Instrument [Member]", "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP)." } } }, "auth_ref": [ "r22" ] }, "us-gaap_DevelopedTechnologyRightsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DevelopedTechnologyRightsMember", "presentation": [ "http://www.masimo.com/role/BusinessCombinationsScheduleofAcquiredIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Developed technology", "label": "Developed Technology Rights [Member]", "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property." } } }, "auth_ref": [ "r200" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://www.masimo.com/role/StockBasedCompensation" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-Based Compensation", "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r568", "r573", "r601", "r602", "r604", "r933" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Share-based Payment Arrangement [Abstract]", "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "masi_DividendsPreferredStockPreferredStockPurchaseRightForEachShare": { "xbrltype": "sharesItemType", "nsuri": "http://www.masimo.com/20240330", "localname": "DividendsPreferredStockPreferredStockPurchaseRightForEachShare", "presentation": [ "http://www.masimo.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock purchase right declared for each share of common stock", "label": "Dividends, Preferred Stock, Preferred Stock Purchase Right For Each Share", "documentation": "Dividends, Preferred Stock, Preferred Stock Purchase Right For Each Share" } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.masimo.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.masimo.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.masimo.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://www.masimo.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r953" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://www.masimo.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r986" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.masimo.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": [ "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesScheduleofReconciliationofBasicandDilutedNetIncomePerShareDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Basic (in dollars per share)", "verboseLabel": "Net income per basic share (in dollars per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r286", "r311", "r312", "r313", "r314", "r315", "r320", "r322", "r328", "r329", "r330", "r332", "r652", "r653", "r739", "r755", "r912" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDiluted", "presentation": [ "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesScheduleofReconciliationofBasicandDilutedNetIncomePerShareDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted (in dollars per share)", "verboseLabel": "Net income per diluted share (in dollars per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r286", "r311", "r312", "r313", "r314", "r315", "r322", "r328", "r329", "r330", "r332", "r652", "r653", "r739", "r755", "r912" ] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerSharePolicyTextBlock", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Net Income Per Share", "label": "Earnings Per Share, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": [ "r60", "r61" ] }, "us-gaap_EarningsPerShareReconciliationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareReconciliationAbstract", "presentation": [ "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesScheduleofReconciliationofBasicandDilutedNetIncomePerShareDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Net income per share:", "label": "Earnings Per Share Reconciliation [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Effect of foreign currency exchange rates on cash", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r670" ] }, "us-gaap_EffectOnFutureCashFlowsAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectOnFutureCashFlowsAmount", "crdr": "debit", "presentation": [ "http://www.masimo.com/role/LesseeROUAssetsandLeaseLiabilitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Undiscounted future expected cash flows totaling", "label": "Effect on Future Cash Flows, Amount", "documentation": "The quantified amount of the future effect on cash flows." } } }, "auth_ref": [ "r84" ] }, "masi_EmployeeAgreementSeverancePaymentPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.masimo.com/20240330", "localname": "EmployeeAgreementSeverancePaymentPeriod", "presentation": [ "http://www.masimo.com/role/CommitmentsandContingenciesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Severance payment period", "label": "Employee Agreement, Severance Payment Period", "documentation": "Employee Agreement, Severance Payment Period" } } }, "auth_ref": [] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued compensation", "label": "Employee-related Liabilities, Current", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r39" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [ "http://www.masimo.com/role/StockBasedCompensationNarrativeDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based payment arrangement, period for recognition (in years)", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r603" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "crdr": "debit", "presentation": [ "http://www.masimo.com/role/StockBasedCompensationNarrativeDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based payment arrangement, nonvested award, cost not yet recognized, amount", "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount", "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r1122" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "crdr": "debit", "presentation": [ "http://www.masimo.com/role/StockBasedCompensationNarrativeDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based payment arrangement, cost not yet recognized, amount", "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "documentation": "Amount of cost to be recognized for option under share-based payment arrangement." } } }, "auth_ref": [ "r1122" ] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockOptionMember", "presentation": [ "http://www.masimo.com/role/StockBasedCompensationNarrativeDetail", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Employee Stock Option", "label": "Employee Stock Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "masi_EmploymentAgreementSeveranceBenefitsSpecialPaymentQualifyingTermination": { "xbrltype": "monetaryItemType", "nsuri": "http://www.masimo.com/20240330", "localname": "EmploymentAgreementSeveranceBenefitsSpecialPaymentQualifyingTermination", "crdr": "debit", "presentation": [ "http://www.masimo.com/role/CommitmentsandContingenciesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Qualifying termination", "label": "Employment Agreement, Severance Benefits, Special Payment, Qualifying Termination", "documentation": "Employment Agreement, Severance Benefits, Special Payment, Qualifying Termination" } } }, "auth_ref": [] }, "masi_EmploymentAgreementSeveranceTerms": { "xbrltype": "percentItemType", "nsuri": "http://www.masimo.com/20240330", "localname": "EmploymentAgreementSeveranceTerms", "presentation": [ "http://www.masimo.com/role/CommitmentsandContingenciesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Severance terms", "label": "Employment Agreement, Severance Terms", "documentation": "Employment Agreement, Severance Terms" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.masimo.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.masimo.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.masimo.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.masimo.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.masimo.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r951" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.masimo.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.masimo.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityDomain", "presentation": [ "http://www.masimo.com/role/DeferredRevenueandOtherContractLiabilitiesCurrentNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Entity [Domain]", "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.masimo.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r951" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.masimo.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://www.masimo.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r951" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.masimo.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.masimo.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r1025" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.masimo.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r951" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://www.masimo.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r951" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://www.masimo.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Smaller Reporting Company", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r951" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.masimo.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r951" ] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Equity [Abstract]", "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY", "http://www.masimo.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofAccumulatedOtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Component [Domain]", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r21", "r239", "r281", "r282", "r283", "r306", "r307", "r308", "r310", "r316", "r318", "r334", "r378", "r379", "r487", "r605", "r606", "r607", "r626", "r627", "r643", "r644", "r645", "r646", "r647", "r648", "r651", "r671", "r672", "r673", "r674", "r675", "r676", "r702", "r769", "r770", "r771", "r787", "r862" ] }, "us-gaap_EquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestments", "crdr": "debit", "calculation": { "http://www.masimo.com/role/OtherNonCurrentAssetsDetails": { "parentTag": "us-gaap_OtherAssetsNoncurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.masimo.com/role/OtherNonCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Strategic investments", "label": "Equity Method Investments", "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized." } } }, "auth_ref": [ "r351", "r376", "r1034", "r1061" ] }, "masi_EquitySecuritiesFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://www.masimo.com/20240330", "localname": "EquitySecuritiesFairValueDisclosure", "crdr": "debit", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesScheduleofFairValueAssetsMeasuredonRecurringBasisDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Equity securities", "label": "Equity Securities, Fair Value Disclosure", "documentation": "Equity Securities, Fair Value Disclosure" } } }, "auth_ref": [] }, "us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquitySecuritiesFvNiCurrentAndNoncurrent", "crdr": "debit", "calculation": { "http://www.masimo.com/role/OtherNonCurrentAssetsDetails": { "parentTag": "us-gaap_OtherAssetsNoncurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.masimo.com/role/OtherNonCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity investments - fair value", "label": "Equity Securities, FV-NI", "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)." } } }, "auth_ref": [ "r254", "r661", "r742" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Valuation Assumption Difference, Footnote", "label": "Equity Valuation Assumption Difference, Footnote [Text Block]" } } }, "auth_ref": [ "r994" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneous Compensation Analysis", "label": "Erroneous Compensation Analysis [Text Block]" } } }, "auth_ref": [ "r958", "r969", "r979", "r1004" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneously Awarded Compensation Recovery", "label": "Erroneously Awarded Compensation Recovery [Table]" } } }, "auth_ref": [ "r955", "r966", "r976", "r1001" ] }, "us-gaap_EscrowDeposit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EscrowDeposit", "crdr": "debit", "presentation": [ "http://www.masimo.com/role/PropertyandEquipmentnetNarrativeDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Escrow deposit", "label": "Escrow Deposit", "documentation": "The designation of funds furnished by a borrower to a lender to assure future payments of the borrower's real estate taxes and insurance obligations with respect to a mortgaged property. Escrow deposits may be made for a variety of other purposes such as earnest money and contingent payments. This element excludes replacement reserves which are an escrow separately provided for within the US GAAP taxonomy." } } }, "auth_ref": [ "r139", "r893" ] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Executive Category:", "label": "Executive Category [Axis]" } } }, "auth_ref": [ "r1000" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesScheduleofFairValueAssetsMeasuredonRecurringBasisDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r655", "r656", "r659" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesScheduleofFairValueAssetsMeasuredonRecurringBasisDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]", "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": [ "r655", "r656", "r659" ] }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Fair Value, Assets Measured on Recurring Basis", "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]", "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r130", "r204" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesScheduleofFairValueAssetsMeasuredonRecurringBasisDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy [Axis]", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r456", "r527", "r528", "r529", "r530", "r531", "r532", "r656", "r711", "r712", "r713", "r920", "r921", "r927", "r928", "r929" ] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesScheduleofFairValueAssetsMeasuredonRecurringBasisDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency [Axis]", "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": [ "r655", "r656", "r657", "r658", "r660" ] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesScheduleofFairValueAssetsMeasuredonRecurringBasisDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Level 1", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r456", "r527", "r532", "r656", "r711", "r927", "r928", "r929" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesScheduleofFairValueAssetsMeasuredonRecurringBasisDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Level 2", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r456", "r527", "r532", "r656", "r712", "r920", "r921", "r927", "r928", "r929" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesScheduleofFairValueAssetsMeasuredonRecurringBasisDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Level 3", "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r456", "r527", "r528", "r529", "r530", "r531", "r532", "r656", "r713", "r920", "r921", "r927", "r928", "r929" ] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisObligations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisObligations", "crdr": "credit", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesScheduleofFairValueAssetsMeasuredonRecurringBasisDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Pension benefit obligation", "label": "Obligations, Fair Value Disclosure", "documentation": "Fair value of obligations measured on a recurring basis." } } }, "auth_ref": [ "r130", "r204" ] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementFrequencyDomain", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesScheduleofFairValueAssetsMeasuredonRecurringBasisDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency [Domain]", "label": "Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesScheduleofFairValueAssetsMeasuredonRecurringBasisDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy [Domain]", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r456", "r527", "r528", "r529", "r530", "r531", "r532", "r711", "r712", "r713", "r920", "r921", "r927", "r928", "r929" ] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsRecurringMember", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesScheduleofFairValueAssetsMeasuredonRecurringBasisDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Recurring", "label": "Fair Value, Recurring [Member]", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": [ "r654", "r660" ] }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueOfFinancialInstrumentsPolicy", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurements", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments." } } }, "auth_ref": [ "r14", "r31" ] }, "us-gaap_FederalFundsEffectiveSwapRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FederalFundsEffectiveSwapRateMember", "presentation": [ "http://www.masimo.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fed Funds Effective Rate Overnight Index Swap Rate", "label": "Fed Funds Effective Rate Overnight Index Swap Rate [Member]", "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap having its variable-rate leg referenced to Federal Funds effective rate with no additional spread over Federal Funds effective rate on that variable-rate leg." } } }, "auth_ref": [ "r1126" ] }, "masi_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://www.masimo.com/20240330", "localname": "FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour", "crdr": "debit", "calculation": { "http://www.masimo.com/role/IntangibleAssetsnetScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.masimo.com/role/IntangibleAssetsnetScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Four", "documentation": "Finite-Lived Intangible Asset, Expected Amortization, after Year Four" } } }, "auth_ref": [] }, "masi_FiniteLivedIntangibleAssetUsefulLifeMaximum": { "xbrltype": "durationItemType", "nsuri": "http://www.masimo.com/20240330", "localname": "FiniteLivedIntangibleAssetUsefulLifeMaximum", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Finite lived intangible asset useful life", "label": "Finite Lived Intangible Asset Useful Life Maximum", "documentation": "Finite Lived Intangible Asset Useful Life Maximum" } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension", "presentation": [ "http://www.masimo.com/role/IntangibleAssetsnetNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average number of years until the next renewal", "label": "Finite-Lived Intangible Asset, Weighted Average Period before Next Renewal or Extension", "documentation": "Weighted average period before the next renewal or extension (both explicit and implicit) for intangible assets that have been renewed or extended, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r25" ] }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "calculation": { "http://www.masimo.com/role/IntangibleAssetsnetScheduleofFiniteLivedIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.masimo.com/role/IntangibleAssetsnetScheduleofFiniteLivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Accumulated Amortization", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r251", "r406" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "crdr": "debit", "calculation": { "http://www.masimo.com/role/IntangibleAssetsnetScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.masimo.com/role/IntangibleAssetsnetScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r180" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "crdr": "debit", "calculation": { "http://www.masimo.com/role/IntangibleAssetsnetScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.masimo.com/role/IntangibleAssetsnetScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2024 (balance of year)", "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "crdr": "debit", "calculation": { "http://www.masimo.com/role/IntangibleAssetsnetScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.masimo.com/role/IntangibleAssetsnetScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r180" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "crdr": "debit", "calculation": { "http://www.masimo.com/role/IntangibleAssetsnetScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.masimo.com/role/IntangibleAssetsnetScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r180" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "crdr": "debit", "calculation": { "http://www.masimo.com/role/IntangibleAssetsnetScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.masimo.com/role/IntangibleAssetsnetScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r180" ] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://www.masimo.com/role/BusinessCombinationsScheduleofAcquiredIntangibleAssetsDetails", "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.masimo.com/role/IntangibleAssetsnetNarrativeDetails", "http://www.masimo.com/role/IntangibleAssetsnetScheduleofFiniteLivedIntangibleAssetsDetails", "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": [ "r403", "r405", "r406", "r408", "r722", "r723" ] }, "us-gaap_FiniteLivedIntangibleAssetsCostIncurredToRenewOrExtend": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsCostIncurredToRenewOrExtend", "crdr": "debit", "presentation": [ "http://www.masimo.com/role/IntangibleAssetsnetNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-lived intangible assets, cost incurred to renew or extend", "label": "Finite-Lived Intangible Assets, Cost Incurred to Renew or Extend", "documentation": "The amount of capitalized costs incurred in the period to renew or extend the term of a recognized finite-lived (amortizing and amortizable) intangible asset." } } }, "auth_ref": [ "r80" ] }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsGross", "crdr": "debit", "calculation": { "http://www.masimo.com/role/IntangibleAssetsnetScheduleofFiniteLivedIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.masimo.com/role/IntangibleAssetsnetScheduleofFiniteLivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross Carrying Amount", "label": "Finite-Lived Intangible Assets, Gross", "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r179", "r723" ] }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsLineItems", "presentation": [ "http://www.masimo.com/role/IntangibleAssetsnetNarrativeDetails", "http://www.masimo.com/role/IntangibleAssetsnetScheduleofFiniteLivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets [Line Items]", "label": "Finite-Lived Intangible Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r722" ] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://www.masimo.com/role/BusinessCombinationsScheduleofAcquiredIntangibleAssetsDetails", "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.masimo.com/role/IntangibleAssetsnetNarrativeDetails", "http://www.masimo.com/role/IntangibleAssetsnetScheduleofFiniteLivedIntangibleAssetsDetails", "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": [ "r75", "r78" ] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "calculation": { "http://www.masimo.com/role/IntangibleAssetsnetScheduleofFiniteLivedIntangibleAssetsDetails": { "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0, "order": 1.0 }, "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 }, "http://www.masimo.com/role/IntangibleAssetsnetScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.masimo.com/role/IntangibleAssetsnetScheduleofFiniteLivedIntangibleAssetsDetails", "http://www.masimo.com/role/IntangibleAssetsnetScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Finite-lived intangible assets, net", "totalLabel": "Net Carrying Amount", "label": "Finite-Lived Intangible Assets, Net", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r179", "r722" ] }, "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsNetAbstract", "presentation": [ "http://www.masimo.com/role/IntangibleAssetsnetScheduleofFiniteLivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets subject to amortization:", "label": "Finite-Lived Intangible Assets, Net [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FiniteLivedLicenseAgreementsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedLicenseAgreementsGross", "crdr": "debit", "presentation": [ "http://www.masimo.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-lived license agreements, gross", "label": "Finite-Lived License Agreements, Gross", "documentation": "Gross carrying amount as of the balance sheet date of certain rights acquired to exercise a certain privilege or pursue a particular business or occupation and which is deemed to have a finite economic life." } } }, "auth_ref": [ "r179" ] }, "us-gaap_FiscalPeriod": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiscalPeriod", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Fiscal Periods", "label": "Fiscal Period, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for determining an entity's fiscal year or other fiscal period. This disclosure may include identification of the fiscal period end-date, the length of the fiscal period, any reporting period lag between the entity and its subsidiaries, or equity investees. If a reporting lag exists, the closing date of the entity having a different period end is generally noted, along with an explanation of the necessity for using different closing dates. Any intervening events that materially affect the entity's financial position or results of operations are generally also disclosed." } } }, "auth_ref": [ "r113" ] }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "crdr": "credit", "calculation": { "http://www.masimo.com/role/NonoperatingLossDetails": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.masimo.com/role/NonoperatingLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Realized and unrealized foreign currency gains (losses)", "label": "Gain (Loss), Foreign Currency Transaction, before Tax", "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction." } } }, "auth_ref": [ "r666", "r667", "r668", "r669", "r859" ] }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign Currency Translation", "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy." } } }, "auth_ref": [ "r665" ] }, "us-gaap_ForeignPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignPlanMember", "presentation": [ "http://www.masimo.com/role/EmployeeBenefitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign Plan", "label": "Foreign Plan [Member]", "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, not determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans." } } }, "auth_ref": [ "r1093", "r1094", "r1095" ] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r962", "r973", "r983", "r1008" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount", "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r962", "r973", "r983", "r1008" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount", "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r962", "r973", "r983", "r1008" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery, Explanation of Impracticability", "label": "Forgone Recovery, Explanation of Impracticability [Text Block]" } } }, "auth_ref": [ "r962", "r973", "r983", "r1008" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Forgone Recovery, Individual Name" } } }, "auth_ref": [ "r962", "r973", "r983", "r1008" ] }, "us-gaap_FurnitureAndFixturesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FurnitureAndFixturesMember", "presentation": [ "http://www.masimo.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Furniture and office equipment", "label": "Furniture and Fixtures [Member]", "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases." } } }, "auth_ref": [] }, "masi_FurnitureandOfficeEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.masimo.com/20240330", "localname": "FurnitureandOfficeEquipmentMember", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Furniture and office equipment", "label": "Furniture and Office Equipment [Member]", "documentation": "Furniture and Office Equipment [Member]" } } }, "auth_ref": [] }, "masi_GPOMembersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.masimo.com/20240330", "localname": "GPOMembersMember", "presentation": [ "http://www.masimo.com/role/CommitmentsandContingenciesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "GPO Members", "label": "GPO Members [Member]", "documentation": "GPO Members" } } }, "auth_ref": [] }, "us-gaap_GainContingencyPatentsFoundInfringedUponNumber": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainContingencyPatentsFoundInfringedUponNumber", "presentation": [ "http://www.masimo.com/role/CommitmentsandContingenciesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Asserted patents found valid", "label": "Gain Contingency, Patents Found Infringed upon, Number", "documentation": "Number of entity's patents that another entity was found to have infringed." } } }, "auth_ref": [ "r1082" ] }, "us-gaap_GainContingencyPatentsFoundNotInfringedUponNumber": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainContingencyPatentsFoundNotInfringedUponNumber", "presentation": [ "http://www.masimo.com/role/CommitmentsandContingenciesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Asserted patents found invalid", "label": "Gain Contingency, Patents Found Not Infringed upon, Number", "documentation": "Number of entity's patents that another entity was found not to have infringed." } } }, "auth_ref": [ "r1082" ] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Goodwill", "crdr": "debit", "calculation": { "http://www.masimo.com/role/BusinessCombinationsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "masi_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill", "weight": 1.0, "order": 4.0 }, "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.masimo.com/role/BusinessCombinationsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.masimo.com/role/GoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill", "periodStartLabel": "Goodwill, beginning of period", "periodEndLabel": "Goodwill, end of period", "label": "Goodwill", "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r250", "r389", "r737", "r918", "r935", "r1066", "r1073" ] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]", "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_GoodwillDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillDisclosureTextBlock", "presentation": [ "http://www.masimo.com/role/Goodwill" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill", "label": "Goodwill Disclosure [Text Block]", "documentation": "The entire disclosure for goodwill." } } }, "auth_ref": [ "r388", "r390", "r400", "r918" ] }, "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillForeignCurrencyTranslationGainLoss", "crdr": "credit", "presentation": [ "http://www.masimo.com/role/GoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency translation adjustment", "label": "Goodwill, Foreign Currency Translation Gain (Loss)", "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r396" ] }, "us-gaap_GoodwillLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillLineItems", "presentation": [ "http://www.masimo.com/role/GoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill [Line Items]", "label": "Goodwill [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r401", "r918" ] }, "us-gaap_GoodwillRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillRollForward", "presentation": [ "http://www.masimo.com/role/GoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill [Roll Forward]", "label": "Goodwill [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GrossProfit", "crdr": "credit", "calculation": { "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.masimo.com/role/SegmentandEnterpriseReportingScheduleofSegmentReportingInformationbySegmentDetail" ], "lang": { "en-us": { "role": { "totalLabel": "Gross profit", "terseLabel": "Gross profit:", "label": "Gross Profit", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } }, "auth_ref": [ "r165", "r299", "r341", "r355", "r361", "r364", "r377", "r429", "r430", "r432", "r433", "r434", "r436", "r438", "r440", "r441", "r664", "r914", "r1086" ] }, "masi_HealthCareSegmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.masimo.com/20240330", "localname": "HealthCareSegmentMember", "presentation": [ "http://www.masimo.com/role/GoodwillDetails", "http://www.masimo.com/role/SegmentandEnterpriseReportingScheduleofSegmentReportingInformationbySegmentDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Healthcare", "label": "Health Care Segment [Member]", "documentation": "Health Care Segment" } } }, "auth_ref": [] }, "us-gaap_HedgingDesignationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "HedgingDesignationAxis", "presentation": [ "http://www.masimo.com/role/DerivativeInstrumentsandHedgingActivitiesNarrativeDetails", "http://www.masimo.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofDerivativeInstrumentsinStatementofFinancialPositionFairValueDetails", "http://www.masimo.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofReclassificationoutofAccumulatedOtherComprehensiveIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Designation [Axis]", "label": "Hedging Designation [Axis]", "documentation": "Information by designation of purpose of derivative instrument." } } }, "auth_ref": [ "r22", "r641" ] }, "us-gaap_HedgingDesignationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "HedgingDesignationDomain", "presentation": [ "http://www.masimo.com/role/DerivativeInstrumentsandHedgingActivitiesNarrativeDetails", "http://www.masimo.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofDerivativeInstrumentsinStatementofFinancialPositionFairValueDetails", "http://www.masimo.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofReclassificationoutofAccumulatedOtherComprehensiveIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Designation [Domain]", "label": "Hedging Designation [Domain]", "documentation": "Designation of purpose of derivative instrument." } } }, "auth_ref": [ "r22" ] }, "us-gaap_ImpairmentOfIntangibleAssetIndefiniteLivedExcludingGoodwillStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ImpairmentOfIntangibleAssetIndefiniteLivedExcludingGoodwillStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration", "presentation": [ "http://www.masimo.com/role/IntangibleAssetsnetScheduleofFiniteLivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment, Intangible Asset, Indefinite-Lived (Excluding Goodwill), Statement of Income or Comprehensive Income [Extensible Enumeration]", "label": "Impairment, Intangible Asset, Indefinite-Lived (Excluding Goodwill), Statement of Income or Comprehensive Income [Extensible Enumeration]", "documentation": "Indicates line item in statement of income or comprehensive income that includes impairment of indefinite-lived intangible asset excluding goodwill." } } }, "auth_ref": [ "r409" ] }, "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill", "crdr": "debit", "presentation": [ "http://www.masimo.com/role/IntangibleAssetsnetNarrativeDetails", "http://www.masimo.com/role/IntangibleAssetsnetScheduleofFiniteLivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Impairment charge", "terseLabel": "Impairment charge", "label": "Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill)", "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value." } } }, "auth_ref": [ "r1045", "r1076" ] }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "verboseLabel": "Impairment of Goodwill, Intangible Assets and Other Long-Lived Assets", "label": "Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets." } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "totalLabel": "Income before provision for income taxes", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r0", "r162", "r213", "r341", "r355", "r361", "r364", "r740", "r751", "r914" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Statement [Abstract]", "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://www.masimo.com/role/DerivativeInstrumentsandHedgingActivitiesNarrativeDetails", "http://www.masimo.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofReclassificationoutofAccumulatedOtherComprehensiveIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Axis]", "label": "Income Statement Location [Axis]", "documentation": "Information by location in the income statement." } } }, "auth_ref": [ "r410", "r412", "r845" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://www.masimo.com/role/DerivativeInstrumentsandHedgingActivitiesNarrativeDetails", "http://www.masimo.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofReclassificationoutofAccumulatedOtherComprehensiveIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Domain]", "label": "Income Statement Location [Domain]", "documentation": "Location in the income statement." } } }, "auth_ref": [ "r412", "r845" ] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Tax Disclosure [Abstract]", "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://www.masimo.com/role/IncomeTaxes" ], "lang": { "en-us": { "role": { "terseLabel": "Income Taxes", "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information." } } }, "auth_ref": [ "r301", "r611", "r618", "r621", "r624", "r628", "r630", "r631", "r632", "r782" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Provision for income taxes", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r219", "r235", "r317", "r318", "r349", "r617", "r629", "r756" ] }, "masi_IncomeTaxPayableNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.masimo.com/20240330", "localname": "IncomeTaxPayableNoncurrent", "crdr": "credit", "calculation": { "http://www.masimo.com/role/OtherNonCurrentLiabilitiesDetails": { "parentTag": "us-gaap_DeferredCreditsAndOtherLiabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.masimo.com/role/OtherNonCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income tax payable, non-current", "label": "Income Tax Payable, Noncurrent", "documentation": "Income Tax Payable, Noncurrent" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxPolicyTextBlock", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Income Taxes", "label": "Income Tax, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": [ "r280", "r613", "r614", "r621", "r622", "r623", "r625", "r776" ] }, "us-gaap_IncomeTaxesPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxesPaid", "crdr": "credit", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesScheduleofSupplementalCashFlowInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Income taxes", "label": "Income Taxes Paid", "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income." } } }, "auth_ref": [ "r53", "r56" ] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "calculation": { "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (decrease) in accounts payable", "label": "Increase (Decrease) in Accounts Payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": [ "r10" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Decrease (increase) in accounts receivable", "label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r10" ] }, "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable", "crdr": "debit", "calculation": { "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 14.0 } }, "presentation": [ "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (decrease) in income tax payable", "label": "Increase (Decrease) in Income Taxes Payable", "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction." } } }, "auth_ref": [ "r10" ] }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccruedLiabilities", "crdr": "debit", "calculation": { "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (decrease) in accrued liabilities", "label": "Increase (Decrease) in Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid." } } }, "auth_ref": [ "r10" ] }, "us-gaap_IncreaseDecreaseInDeferredCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInDeferredCharges", "crdr": "credit", "calculation": { "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Decrease (increase) in deferred costs and other contract assets", "label": "Increase (Decrease) in Deferred Charges", "documentation": "The increase (decrease) during the reporting period in the value of expenditures made during the current reporting period for benefits that will be received over a period of years. Deferred charges differ from prepaid expenses in that they usually extend over a long period of time and may or may not be regularly recurring costs of operation." } } }, "auth_ref": [ "r10" ] }, "us-gaap_IncreaseDecreaseInDeferredRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInDeferredRevenue", "crdr": "debit", "calculation": { "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (decrease) in deferred revenue and other contract-related liabilities", "label": "Increase (Decrease) in Deferred Revenue", "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r896" ] }, "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities", "crdr": "debit", "calculation": { "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 15.0 } }, "presentation": [ "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (decrease) in accrued compensation", "label": "Increase (Decrease) in Employee Related Liabilities", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits." } } }, "auth_ref": [ "r10" ] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": { "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Decrease (increase) in inventories", "label": "Increase (Decrease) in Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r10" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in operating assets and liabilities:", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOtherCurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherCurrentAssets", "crdr": "credit", "calculation": { "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Decrease (increase) in other current assets", "label": "Increase (Decrease) in Other Current Assets", "documentation": "Amount of increase (decrease) in current assets classified as other." } } }, "auth_ref": [ "r1044" ] }, "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherNoncurrentAssets", "crdr": "credit", "calculation": { "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Decrease (increase) in other non-current assets", "label": "Increase (Decrease) in Other Noncurrent Assets", "documentation": "Amount of increase (decrease) in noncurrent assets classified as other." } } }, "auth_ref": [ "r1044" ] }, "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherOperatingLiabilities", "crdr": "debit", "calculation": { "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (decrease) in other non-current liabilities", "label": "Increase (Decrease) in Other Operating Liabilities", "documentation": "Amount of increase (decrease) in operating liabilities classified as other." } } }, "auth_ref": [ "r10" ] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": [ "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "calculation": { "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesScheduleofReconciliationofBasicandDilutedNetIncomePerShareDetail": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesScheduleofReconciliationofBasicandDilutedNetIncomePerShareDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted share equivalent: stock options, RSUs and PSUs (in shares)", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements", "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method." } } }, "auth_ref": [ "r323", "r324", "r325", "r330", "r572" ] }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://www.masimo.com/role/IntangibleAssetsnetNarrativeDetails", "http://www.masimo.com/role/IntangibleAssetsnetScheduleofFiniteLivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Indefinite-lived Intangible Assets [Axis]", "label": "Indefinite-Lived Intangible Assets [Axis]", "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit." } } }, "auth_ref": [ "r404", "r407" ] }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IndefiniteLivedIntangibleAssetsByMajorClassLineItems", "presentation": [ "http://www.masimo.com/role/IntangibleAssetsnetScheduleofFiniteLivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Indefinite-Lived Intangible Assets [Line Items]", "label": "Indefinite-Lived Intangible Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.masimo.com/role/IntangibleAssetsnetScheduleofFiniteLivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Trademarks - (Note 9)", "netLabel": "Trademarks", "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)", "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit." } } }, "auth_ref": [ "r181" ] }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract", "presentation": [ "http://www.masimo.com/role/IntangibleAssetsnetScheduleofFiniteLivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets not subject to amortization:", "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill) [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://www.masimo.com/role/IntangibleAssetsnetNarrativeDetails", "http://www.masimo.com/role/IntangibleAssetsnetScheduleofFiniteLivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]", "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company." } } }, "auth_ref": [ "r76", "r181" ] }, "masi_IndefiniteLivedIntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://www.masimo.com/20240330", "localname": "IndefiniteLivedIntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.masimo.com/role/IntangibleAssetsnetScheduleofFiniteLivedIntangibleAssetsDetails": { "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.masimo.com/role/IntangibleAssetsnetScheduleofFiniteLivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total trademarks", "label": "Indefinite-Lived Intangible Assets, Net (Excluding Goodwill)", "documentation": "Indefinite-Lived Intangible Assets, Net (Excluding Goodwill)" } } }, "auth_ref": [] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Individual:", "label": "Individual [Axis]" } } }, "auth_ref": [ "r965", "r973", "r983", "r1000", "r1008", "r1012", "r1020" ] }, "masi_InitialLendersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.masimo.com/20240330", "localname": "InitialLendersMember", "presentation": [ "http://www.masimo.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Initial Lenders", "label": "Initial Lenders [Member]", "documentation": "Initial Lenders" } } }, "auth_ref": [] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "auth_ref": [ "r1018" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": [ "r954", "r1024" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Adopted", "label": "Insider Trading Policies and Procedures Adopted [Flag]" } } }, "auth_ref": [ "r954", "r1024" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Not Adopted", "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]" } } }, "auth_ref": [ "r954", "r1024" ] }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsDisclosureTextBlock", "presentation": [ "http://www.masimo.com/role/IntangibleAssetsnet" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible Assets, net", "label": "Intangible Assets Disclosure [Text Block]", "documentation": "The entire disclosure for all or part of the information related to intangible assets." } } }, "auth_ref": [ "r402" ] }, "us-gaap_IntangibleAssetsFiniteLivedPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsFiniteLivedPolicy", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible Assets", "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets." } } }, "auth_ref": [ "r78", "r718", "r719", "r720", "r722", "r909" ] }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.masimo.com/role/IntangibleAssetsnetScheduleofFiniteLivedIntangibleAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.masimo.com/role/IntangibleAssetsnetScheduleofFiniteLivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Intangible assets, net", "label": "Intangible Assets, Net (Excluding Goodwill)", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": [ "r73", "r77" ] }, "us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsNetExcludingGoodwillAbstract", "presentation": [ "http://www.masimo.com/role/IntangibleAssetsnetScheduleofFiniteLivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible Assets, Net (Excluding Goodwill) [Abstract]", "label": "Intangible Assets, Net (Excluding Goodwill) [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpense", "crdr": "debit", "calculation": { "http://www.masimo.com/role/NonoperatingLossDetails": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.masimo.com/role/NonoperatingLossDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Interest expense", "label": "Interest Expense", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense." } } }, "auth_ref": [ "r135", "r215", "r284", "r345", "r677", "r846", "r947", "r1155" ] }, "us-gaap_InterestExpenseDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpenseDebt", "crdr": "debit", "presentation": [ "http://www.masimo.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest expense", "label": "Interest Expense, Debt", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt." } } }, "auth_ref": [ "r169", "r462", "r470", "r922", "r923" ] }, "us-gaap_InterestExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpenseMember", "presentation": [ "http://www.masimo.com/role/DerivativeInstrumentsandHedgingActivitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest Expense", "label": "Interest Expense [Member]", "documentation": "Primary financial statement caption encompassing interest expense." } } }, "auth_ref": [ "r29" ] }, "us-gaap_InterestIncomeOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestIncomeOther", "crdr": "credit", "calculation": { "http://www.masimo.com/role/NonoperatingLossDetails": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.masimo.com/role/NonoperatingLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest income", "label": "Interest Income, Other", "documentation": "Amount of interest income earned from interest bearing assets classified as other." } } }, "auth_ref": [] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesScheduleofSupplementalCashFlowInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Interest expense", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r291", "r293", "r294" ] }, "us-gaap_InterestRateSwapMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestRateSwapMember", "presentation": [ "http://www.masimo.com/role/DerivativeInstrumentsandHedgingActivitiesNarrativeDetails", "http://www.masimo.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofDerivativeInstrumentsinStatementofFinancialPositionFairValueDetails", "http://www.masimo.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofReclassificationoutofAccumulatedOtherComprehensiveIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest rate contracts, inclusive of accrued interest", "label": "Interest Rate Swap [Member]", "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period." } } }, "auth_ref": [ "r898", "r944", "r945" ] }, "us-gaap_IntersegmentEliminationMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntersegmentEliminationMember", "presentation": [ "http://www.masimo.com/role/SegmentandEnterpriseReportingScheduleofSegmentReportingInformationbySegmentDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Intersegment", "label": "Intersegment Eliminations [Member]", "documentation": "Eliminating entries used in operating segment consolidation." } } }, "auth_ref": [ "r343", "r354", "r355", "r356", "r357", "r358", "r360", "r364" ] }, "us-gaap_InventoryDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Inventory Disclosure [Abstract]", "label": "Inventory Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InventoryDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryDisclosureTextBlock", "presentation": [ "http://www.masimo.com/role/Inventories" ], "lang": { "en-us": { "role": { "terseLabel": "Inventories", "label": "Inventory Disclosure [Text Block]", "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory." } } }, "auth_ref": [ "r383" ] }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryFinishedGoodsNetOfReserves", "crdr": "debit", "calculation": { "http://www.masimo.com/role/InventoriesDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.masimo.com/role/InventoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finished goods", "label": "Inventory, Finished Goods, Net of Reserves", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale." } } }, "auth_ref": [ "r177", "r905" ] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 }, "http://www.masimo.com/role/InventoriesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.masimo.com/role/InventoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventories", "totalLabel": "Total inventories", "label": "Inventory, Net", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r263", "r900", "r935" ] }, "us-gaap_InventoryPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryPolicyTextBlock", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Inventories", "label": "Inventory, Policy [Policy Text Block]", "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost." } } }, "auth_ref": [ "r221", "r246", "r262", "r383", "r384", "r385", "r717", "r910" ] }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryRawMaterialsNetOfReserves", "crdr": "debit", "calculation": { "http://www.masimo.com/role/InventoriesDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.masimo.com/role/InventoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Raw materials", "label": "Inventory, Raw Materials, Net of Reserves", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process." } } }, "auth_ref": [ "r177", "r907" ] }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryWorkInProcessNetOfReserves", "crdr": "debit", "calculation": { "http://www.masimo.com/role/InventoriesDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.masimo.com/role/InventoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Work-in-process", "label": "Inventory, Work in Process, Net of Reserves", "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing." } } }, "auth_ref": [ "r177", "r906" ] }, "masi_InvestmentsExpendituresIncurredButNotYetPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://www.masimo.com/20240330", "localname": "InvestmentsExpendituresIncurredButNotYetPaid", "crdr": "credit", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesScheduleofSupplementalCashFlowInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Unpaid strategic investments", "label": "Investments Expenditures Incurred but Not yet Paid", "documentation": "Investments Expenditures Incurred but Not yet Paid" } } }, "auth_ref": [] }, "masi_JapaneseEquipmentLoansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.masimo.com/20240330", "localname": "JapaneseEquipmentLoansMember", "presentation": [ "http://www.masimo.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Japanese Equipment Loans", "label": "Japanese Equipment Loans [Member]", "documentation": "Japanese Equipment Loans" } } }, "auth_ref": [] }, "masi_JapaneseGovernmentLoansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.masimo.com/20240330", "localname": "JapaneseGovernmentLoansMember", "presentation": [ "http://www.masimo.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Japanese Government Loans", "label": "Japanese Government Loans [Member]", "documentation": "Japanese Government Loans" } } }, "auth_ref": [] }, "masi_JapaneseLoansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.masimo.com/20240330", "localname": "JapaneseLoansMember", "presentation": [ "http://www.masimo.com/role/DebtScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Japanese Loans", "label": "Japanese Loans [Member]", "documentation": "Japanese Loans" } } }, "auth_ref": [] }, "masi_JapaneseRevolvingLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.masimo.com/20240330", "localname": "JapaneseRevolvingLoanMember", "presentation": [ "http://www.masimo.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Japanese Revolving Loan", "label": "Japanese Revolving Loan [Member]", "documentation": "Japanese Revolving Loan" } } }, "auth_ref": [] }, "masi_JustintimedistributoroneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.masimo.com/20240330", "localname": "JustintimedistributoroneMember", "presentation": [ "http://www.masimo.com/role/CommitmentsandContingenciesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Just in time distributor one", "label": "Just in time distributor one [Member]", "documentation": "Just in time distributor one [Member]" } } }, "auth_ref": [] }, "us-gaap_LandBuildingsAndImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LandBuildingsAndImprovementsMember", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Buildings and building improvements", "label": "Land, Buildings and Improvements [Member]", "documentation": "Real estate held and additions or improvements to real estate held and structures used in the conduct of business." } } }, "auth_ref": [] }, "us-gaap_LandMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LandMember", "presentation": [ "http://www.masimo.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Land", "label": "Land [Member]", "documentation": "Part of earth's surface not covered by water." } } }, "auth_ref": [ "r1092" ] }, "masi_LeasedPropertyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.masimo.com/20240330", "localname": "LeasedPropertyMember", "presentation": [ "http://www.masimo.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Leased Property", "label": "Leased Property [Member]", "documentation": "Leased Property [Member]" } } }, "auth_ref": [] }, "us-gaap_LeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseholdImprovementsMember", "presentation": [ "http://www.masimo.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Leasehold improvements", "label": "Leasehold Improvements [Member]", "documentation": "Additions or improvements to assets held under a lease arrangement." } } }, "auth_ref": [ "r184" ] }, "us-gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeasesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Leases [Abstract]", "label": "Leases [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LegalCostsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LegalCostsPolicyTextBlock", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Litigation Costs and Contingencies", "label": "Legal Costs, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for legal costs incurred to protect or defend the entity's assets and rights, or to obtain assets, including monetary damages, or to obtain rights." } } }, "auth_ref": [ "r421" ] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LegalEntityAxis", "presentation": [ "http://www.masimo.com/role/DeferredRevenueandOtherContractLiabilitiesCurrentNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Legal Entity [Axis]", "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "us-gaap_LesseeLeasesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeLeasesPolicyTextBlock", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee Right-of-Use (ROU) Assets and Lease Liabilities", "label": "Lessee, Leases [Policy Text Block]", "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee." } } }, "auth_ref": [ "r685" ] }, "masi_LesseeOperatingLeaseBalanceSheetClassificationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.masimo.com/20240330", "localname": "LesseeOperatingLeaseBalanceSheetClassificationTableTextBlock", "presentation": [ "http://www.masimo.com/role/LesseeROUAssetsandLeaseLiabilitiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Lessee Operating Lease Balance Sheet Classification", "label": "Lessee Operating Lease Balance Sheet Classification [Table Text Block]", "documentation": "[Table Text Block] for Lessee Operating Lease Balance Sheet Classification [Table]" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": [ "http://www.masimo.com/role/LesseeROUAssetsandLeaseLiabilitiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Lessee, Operating Lease, Liability, Maturity", "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": [ "r1132" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://www.masimo.com/role/LesseeROUAssetsandLeaseLiabilitiesScheduleofLesseeOperatingLeaseLiabilityMaturityDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.masimo.com/role/LesseeROUAssetsandLeaseLiabilitiesScheduleofLesseeOperatingLeaseLiabilityMaturityDetails_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.masimo.com/role/LesseeROUAssetsandLeaseLiabilitiesScheduleofLesseeOperatingLeaseLiabilityMaturityDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Lessee, Operating Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": [ "r692" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.masimo.com/role/LesseeROUAssetsandLeaseLiabilitiesScheduleofLesseeOperatingLeaseLiabilityMaturityDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.masimo.com/role/LesseeROUAssetsandLeaseLiabilitiesScheduleofLesseeOperatingLeaseLiabilityMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r692" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "calculation": { "http://www.masimo.com/role/LesseeROUAssetsandLeaseLiabilitiesScheduleofLesseeOperatingLeaseLiabilityMaturityDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.masimo.com/role/LesseeROUAssetsandLeaseLiabilitiesScheduleofLesseeOperatingLeaseLiabilityMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r692" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://www.masimo.com/role/LesseeROUAssetsandLeaseLiabilitiesScheduleofLesseeOperatingLeaseLiabilityMaturityDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.masimo.com/role/LesseeROUAssetsandLeaseLiabilitiesScheduleofLesseeOperatingLeaseLiabilityMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r692" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://www.masimo.com/role/LesseeROUAssetsandLeaseLiabilitiesScheduleofLesseeOperatingLeaseLiabilityMaturityDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.masimo.com/role/LesseeROUAssetsandLeaseLiabilitiesScheduleofLesseeOperatingLeaseLiabilityMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r692" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "calculation": { "http://www.masimo.com/role/LesseeROUAssetsandLeaseLiabilitiesScheduleofLesseeOperatingLeaseLiabilityMaturityDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.masimo.com/role/LesseeROUAssetsandLeaseLiabilitiesScheduleofLesseeOperatingLeaseLiabilityMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2024 (balance of year)", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year." } } }, "auth_ref": [ "r1132" ] }, "masi_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://www.masimo.com/20240330", "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearFour", "crdr": "credit", "calculation": { "http://www.masimo.com/role/LesseeROUAssetsandLeaseLiabilitiesScheduleofLesseeOperatingLeaseLiabilityMaturityDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.masimo.com/role/LesseeROUAssetsandLeaseLiabilitiesScheduleofLesseeOperatingLeaseLiabilityMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Four", "documentation": "Lessee, Operating Lease, Liability, to be Paid, after Year Four" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "calculation": { "http://www.masimo.com/role/LesseeROUAssetsandLeaseLiabilitiesScheduleofLesseeOperatingLeaseLiabilityMaturityDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.masimo.com/role/LesseeROUAssetsandLeaseLiabilitiesScheduleofLesseeOperatingLeaseLiabilityMaturityDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Imputed interest", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": [ "r692" ] }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseRenewalTerm", "presentation": [ "http://www.masimo.com/role/LesseeROUAssetsandLeaseLiabilitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee, operating lease, renewal term", "label": "Lessee, Operating Lease, Renewal Term", "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r1131" ] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeasesTextBlock", "presentation": [ "http://www.masimo.com/role/LesseeROUAssetsandLeaseLiabilities" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee ROU Assets and Lease Liabilities", "label": "Lessee, Operating Leases [Text Block]", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": [ "r680" ] }, "masi_LessorOperatingLeasePaymentToBeReceivedAfterYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://www.masimo.com/20240330", "localname": "LessorOperatingLeasePaymentToBeReceivedAfterYearFour", "crdr": "debit", "calculation": { "http://www.masimo.com/role/LeaseReceivableScheduleofSalestypeLeaseLeaseReceivableMaturityDetails": { "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.masimo.com/role/LeaseReceivableScheduleofSalestypeLeaseLeaseReceivableMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Lessor, Operating Lease, Payment to be Received, after Year Four", "documentation": "Lessor, Operating Lease, Payment to be Received, after Year Four" } } }, "auth_ref": [] }, "us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LessorOperatingLeasePaymentsFiscalYearMaturityAbstract", "presentation": [ "http://www.masimo.com/role/LeaseReceivableScheduleofSalestypeLeaseLeaseReceivableMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Leases", "label": "Lessor, Operating Lease, Payment to be Received, Fiscal Year Maturity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LessorOperatingLeasePaymentsToBeReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LessorOperatingLeasePaymentsToBeReceived", "crdr": "debit", "calculation": { "http://www.masimo.com/role/LeaseReceivableScheduleofSalestypeLeaseLeaseReceivableMaturityDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.masimo.com/role/LeaseReceivableScheduleofSalestypeLeaseLeaseReceivableMaturityDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Lessor, Operating Lease, Payment to be Received", "documentation": "Amount of lease payments to be received by lessor for operating lease." } } }, "auth_ref": [ "r699" ] }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LessorOperatingLeasePaymentsToBeReceivedFourYears", "crdr": "debit", "calculation": { "http://www.masimo.com/role/LeaseReceivableScheduleofSalestypeLeaseLeaseReceivableMaturityDetails": { "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.masimo.com/role/LeaseReceivableScheduleofSalestypeLeaseLeaseReceivableMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Lessor, Operating Lease, Payment to be Received, Year Four", "documentation": "Amount of lease payment to be received by lessor for operating lease in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r699" ] }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths", "crdr": "debit", "calculation": { "http://www.masimo.com/role/LeaseReceivableScheduleofSalestypeLeaseLeaseReceivableMaturityDetails": { "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.masimo.com/role/LeaseReceivableScheduleofSalestypeLeaseLeaseReceivableMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2024 (balance of year)", "label": "Lessor, Operating Lease, Payment to be Received, Year One", "documentation": "Amount of lease payment to be received by lessor for operating lease in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r699" ] }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear", "crdr": "debit", "calculation": { "http://www.masimo.com/role/LeaseReceivableScheduleofSalestypeLeaseLeaseReceivableMaturityDetails": { "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.masimo.com/role/LeaseReceivableScheduleofSalestypeLeaseLeaseReceivableMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2024 (balance of year)", "label": "Lessor, Operating Lease, Payment to be Received, Remainder of Fiscal Year", "documentation": "Amount of lease payment to be received by lessor for operating lease in remainder of current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r1134" ] }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LessorOperatingLeasePaymentsToBeReceivedThreeYears", "crdr": "debit", "calculation": { "http://www.masimo.com/role/LeaseReceivableScheduleofSalestypeLeaseLeaseReceivableMaturityDetails": { "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.masimo.com/role/LeaseReceivableScheduleofSalestypeLeaseLeaseReceivableMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Lessor, Operating Lease, Payment to be Received, Year Three", "documentation": "Amount of lease payment to be received by lessor for operating lease in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r699" ] }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LessorOperatingLeasePaymentsToBeReceivedTwoYears", "crdr": "debit", "calculation": { "http://www.masimo.com/role/LeaseReceivableScheduleofSalestypeLeaseLeaseReceivableMaturityDetails": { "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.masimo.com/role/LeaseReceivableScheduleofSalestypeLeaseLeaseReceivableMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Lessor, Operating Lease, Payment to be Received, Year Two", "documentation": "Amount of lease payment to be received by lessor for operating lease in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r699" ] }, "us-gaap_LessorSalesTypeLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LessorSalesTypeLeasesTextBlock", "presentation": [ "http://www.masimo.com/role/LeaseReceivable" ], "lang": { "en-us": { "role": { "terseLabel": "Lease Receivable", "label": "Lessor, Sales-type Leases [Text Block]", "documentation": "The entire disclosure of lessor's sales-type leases." } } }, "auth_ref": [ "r693" ] }, "us-gaap_LetterOfCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LetterOfCreditMember", "presentation": [ "http://www.masimo.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Letter of Credit", "label": "Letter of Credit [Member]", "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit)." } } }, "auth_ref": [] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future." } } }, "auth_ref": [ "r38", "r299", "r377", "r429", "r430", "r432", "r433", "r434", "r436", "r438", "r440", "r441", "r637", "r639", "r640", "r664", "r815", "r913", "r949", "r1086", "r1138", "r1139" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and stockholders\u2019 equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r156", "r211", "r747", "r935", "r1049", "r1062", "r1128" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r41", "r245", "r299", "r377", "r429", "r430", "r432", "r433", "r434", "r436", "r438", "r440", "r441", "r637", "r639", "r640", "r664", "r935", "r1086", "r1138", "r1139" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Current liabilities", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesFairValueDisclosure", "crdr": "credit", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesScheduleofFairValueAssetsMeasuredonRecurringBasisDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Total liabilities", "label": "Liabilities, Fair Value Disclosure", "documentation": "Fair value of financial and nonfinancial obligations." } } }, "auth_ref": [ "r130" ] }, "us-gaap_LiabilitiesFairValueDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesFairValueDisclosureAbstract", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesScheduleofFairValueAssetsMeasuredonRecurringBasisDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities", "label": "Liabilities, Fair Value Disclosure [Abstract]" } } }, "auth_ref": [] }, "masi_LicenseAgreementTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.masimo.com/20240330", "localname": "LicenseAgreementTerm", "presentation": [ "http://www.masimo.com/role/CommitmentsandContingenciesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "License agreement term (in year)", "label": "License Agreement Term", "documentation": "License Agreement Term" } } }, "auth_ref": [] }, "masi_LicenseFeeChangeInControl": { "xbrltype": "monetaryItemType", "nsuri": "http://www.masimo.com/20240330", "localname": "LicenseFeeChangeInControl", "crdr": "credit", "presentation": [ "http://www.masimo.com/role/CommitmentsandContingenciesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "License fee", "label": "License Fee, Change In Control", "documentation": "License Fee, Change In Control" } } }, "auth_ref": [] }, "masi_LicensingAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.masimo.com/20240330", "localname": "LicensingAgreement", "crdr": "credit", "presentation": [ "http://www.masimo.com/role/CommitmentsandContingenciesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Licensing agreement outstanding obligation", "label": "Licensing Agreement", "documentation": "Licensing Agreement" } } }, "auth_ref": [] }, "masi_LicensingAgreementCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.masimo.com/20240330", "localname": "LicensingAgreementCurrent", "crdr": "credit", "calculation": { "http://www.masimo.com/role/OtherCurrentLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.masimo.com/role/CommitmentsandContingenciesDetail", "http://www.masimo.com/role/OtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Licensing agreement, current", "label": "Licensing Agreement, Current", "documentation": "Licensing Agreement, Current" } } }, "auth_ref": [] }, "masi_LicensingAgreementNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.masimo.com/20240330", "localname": "LicensingAgreementNoncurrent", "crdr": "credit", "calculation": { "http://www.masimo.com/role/OtherNonCurrentLiabilitiesDetails": { "parentTag": "us-gaap_DeferredCreditsAndOtherLiabilities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.masimo.com/role/OtherNonCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Licensing agreement, non-current", "label": "Licensing Agreement, Noncurrent", "documentation": "Licensing Agreement, Noncurrent" } } }, "auth_ref": [] }, "us-gaap_LicensingAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LicensingAgreementsMember", "presentation": [ "http://www.masimo.com/role/BusinessCombinationsScheduleofAcquiredIntangibleAssetsDetails", "http://www.masimo.com/role/IntangibleAssetsnetScheduleofFiniteLivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Licenses", "verboseLabel": "Contractual license agreements", "label": "Licensing Agreements [Member]", "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory)." } } }, "auth_ref": [ "r112", "r610", "r1123" ] }, "masi_LikeMindedEntertainmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.masimo.com/20240330", "localname": "LikeMindedEntertainmentMember", "presentation": [ "http://www.masimo.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Like Minded Media Ventures", "label": "Like Minded Entertainment [Member]", "documentation": "Like Minded Entertainment [Member]" } } }, "auth_ref": [] }, "masi_LikeMindedLabsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.masimo.com/20240330", "localname": "LikeMindedLabsMember", "presentation": [ "http://www.masimo.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Like Minded Labs", "label": "Like Minded Labs [Member]", "documentation": "Like Minded Labs [Member]" } } }, "auth_ref": [] }, "masi_LineOfCreditFacilityAccordionFeatureIncreaseLimit": { "xbrltype": "monetaryItemType", "nsuri": "http://www.masimo.com/20240330", "localname": "LineOfCreditFacilityAccordionFeatureIncreaseLimit", "crdr": "credit", "presentation": [ "http://www.masimo.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accordion feature, increase limit", "label": "Line Of Credit Facility, Accordion Feature, Increase Limit", "documentation": "Line Of Credit Facility, Accordion Feature, Increase Limit" } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityAxis", "presentation": [ "http://www.masimo.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lender Name [Axis]", "label": "Lender Name [Axis]", "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit." } } }, "auth_ref": [ "r36", "r1048" ] }, "us-gaap_LineOfCreditFacilityLenderDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityLenderDomain", "presentation": [ "http://www.masimo.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of Credit Facility, Lender [Domain]", "label": "Line of Credit Facility, Lender [Domain]", "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility." } } }, "auth_ref": [ "r36", "r1048" ] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": [ "http://www.masimo.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum borrowing capacity", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": [ "r36" ] }, "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage", "presentation": [ "http://www.masimo.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Commitment fee percentage", "label": "Line of Credit Facility, Unused Capacity, Commitment Fee Percentage", "documentation": "The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility." } } }, "auth_ref": [] }, "us-gaap_LineOfCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditMember", "presentation": [ "http://www.masimo.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of Credit", "label": "Line of Credit [Member]", "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars." } } }, "auth_ref": [] }, "srt_LitigationCaseAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "LitigationCaseAxis", "presentation": [ "http://www.masimo.com/role/CommitmentsandContingenciesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Litigation Case [Axis]", "label": "Litigation Case [Axis]" } } }, "auth_ref": [] }, "srt_LitigationCaseTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "LitigationCaseTypeDomain", "presentation": [ "http://www.masimo.com/role/CommitmentsandContingenciesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Litigation Case [Domain]", "label": "Litigation Case [Domain]" } } }, "auth_ref": [] }, "us-gaap_LitigationStatusAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LitigationStatusAxis", "presentation": [ "http://www.masimo.com/role/CommitmentsandContingenciesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Litigation Status [Axis]", "label": "Litigation Status [Axis]", "documentation": "Information by status of pending, threatened, or settled litigation." } } }, "auth_ref": [ "r1079" ] }, "us-gaap_LitigationStatusDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LitigationStatusDomain", "presentation": [ "http://www.masimo.com/role/CommitmentsandContingenciesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Litigation Status [Domain]", "label": "Litigation Status [Domain]", "documentation": "Status of pending, threatened, or settled litigation." } } }, "auth_ref": [ "r1079" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.masimo.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebt", "crdr": "credit", "calculation": { "http://www.masimo.com/role/DebtScheduleofMaturitiesofLongtermDebtDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.masimo.com/role/DebtScheduleofMaturitiesofLongtermDebtDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Long-Term Debt", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": [ "r32", "r209", "r455", "r469", "r920", "r921", "r1148" ] }, "us-gaap_LongTermDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtCurrent", "crdr": "credit", "calculation": { "http://www.masimo.com/role/OtherCurrentLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.masimo.com/role/OtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term debt, current", "label": "Long-Term Debt, Current Maturities", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation." } } }, "auth_ref": [ "r255" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.masimo.com/role/DebtScheduleofMaturitiesofLongtermDebtDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.masimo.com/role/DebtScheduleofMaturitiesofLongtermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Long-Term Debt, Maturity, Year One", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r13", "r305", "r460" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "crdr": "credit", "calculation": { "http://www.masimo.com/role/DebtScheduleofMaturitiesofLongtermDebtDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.masimo.com/role/DebtScheduleofMaturitiesofLongtermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Long-Term Debt, Maturity, Year Four", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r13", "r305", "r460" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "crdr": "credit", "calculation": { "http://www.masimo.com/role/DebtScheduleofMaturitiesofLongtermDebtDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.masimo.com/role/DebtScheduleofMaturitiesofLongtermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Long-Term Debt, Maturity, Year Three", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r13", "r305", "r460" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "crdr": "credit", "calculation": { "http://www.masimo.com/role/DebtScheduleofMaturitiesofLongtermDebtDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.masimo.com/role/DebtScheduleofMaturitiesofLongtermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Long-Term Debt, Maturity, Year Two", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r13", "r305", "r460" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "crdr": "credit", "calculation": { "http://www.masimo.com/role/DebtScheduleofMaturitiesofLongtermDebtDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.masimo.com/role/DebtScheduleofMaturitiesofLongtermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2024 (balance of year)", "label": "Long-Term Debt, Maturity, Remainder of Fiscal Year", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year." } } }, "auth_ref": [ "r1052" ] }, "masi_LongTermDebtMaturityAfterYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://www.masimo.com/20240330", "localname": "LongTermDebtMaturityAfterYearFour", "crdr": "credit", "calculation": { "http://www.masimo.com/role/DebtScheduleofMaturitiesofLongtermDebtDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.masimo.com/role/DebtScheduleofMaturitiesofLongtermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Long-Term Debt, Maturity, after Year Four", "documentation": "Long-Term Debt, Maturity, after Year Four" } } }, "auth_ref": [] }, "us-gaap_LongTermDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtNoncurrent", "crdr": "credit", "calculation": { "http://www.masimo.com/role/DebtScheduleofDebtDetails": { "parentTag": "us-gaap_DebtAndCapitalLeaseObligations", "weight": 1.0, "order": 1.0 }, "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.masimo.com/role/DebtScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term debt", "verboseLabel": "Debt, long-term", "label": "Long-Term Debt, Excluding Current Maturities", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation." } } }, "auth_ref": [ "r257" ] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeAxis", "presentation": [ "http://www.masimo.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Axis]", "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": [ "r42" ] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeDomain", "presentation": [ "http://www.masimo.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Domain]", "label": "Long-Term Debt, Type [Domain]", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r42", "r85" ] }, "masi_LossContingencyNumberOfComplaints": { "xbrltype": "integerItemType", "nsuri": "http://www.masimo.com/20240330", "localname": "LossContingencyNumberOfComplaints", "presentation": [ "http://www.masimo.com/role/CommitmentsandContingenciesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Number of complaints", "label": "Loss Contingency, Number Of Complaints", "documentation": "Loss Contingency, Number Of Complaints" } } }, "auth_ref": [] }, "us-gaap_LossContingencyPatentsFoundInfringedNumber": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingencyPatentsFoundInfringedNumber", "presentation": [ "http://www.masimo.com/role/CommitmentsandContingenciesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Number of patents found infringed", "label": "Loss Contingency, Patents Found Infringed, Number", "documentation": "Number of another entity's patents that the entity was found to have infringed." } } }, "auth_ref": [ "r1080", "r1081" ] }, "us-gaap_MachineryAndEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MachineryAndEquipmentMember", "presentation": [ "http://www.masimo.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentDetails", "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Machinery, equipment and tooling", "label": "Machinery and Equipment [Member]", "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment." } } }, "auth_ref": [] }, "srt_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MajorCustomersAxis", "presentation": [ "http://www.masimo.com/role/CommitmentsandContingenciesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Customer [Axis]", "label": "Customer [Axis]" } } }, "auth_ref": [ "r369", "r925", "r1091", "r1150", "r1151" ] }, "masi_MasimoRetirementSavingsPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.masimo.com/20240330", "localname": "MasimoRetirementSavingsPlanMember", "presentation": [ "http://www.masimo.com/role/EmployeeBenefitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Masimo Retirement Savings Plan", "label": "Masimo Retirement Savings Plan [Member]", "documentation": "Masimo Retirement Savings Plan" } } }, "auth_ref": [] }, "masi_MasimoVsAppleIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.masimo.com/20240330", "localname": "MasimoVsAppleIncMember", "presentation": [ "http://www.masimo.com/role/CommitmentsandContingenciesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Masimo Vs. Apple Inc", "label": "Masimo Vs. Apple Inc [Member]", "documentation": "Masimo Vs. Apple Inc" } } }, "auth_ref": [] }, "us-gaap_MaterialReconcilingItemsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MaterialReconcilingItemsMember", "presentation": [ "http://www.masimo.com/role/SegmentandEnterpriseReportingScheduleofSegmentReportingInformationbySegmentDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Reconciling Items", "label": "Segment Reconciling Items [Member]", "documentation": "Items used in reconciling reportable segments' amounts to consolidated amount. Excludes corporate-level activity." } } }, "auth_ref": [ "r71" ] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MaximumMember", "presentation": [ "http://www.masimo.com/role/DebtNarrativeDetails", "http://www.masimo.com/role/EquityDetails", "http://www.masimo.com/role/IntangibleAssetsnetNarrativeDetails", "http://www.masimo.com/role/StockBasedCompensationNarrativeDetail", "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetail", "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum", "label": "Maximum [Member]" } } }, "auth_ref": [ "r417", "r418", "r419", "r420", "r566", "r715", "r768", "r807", "r808", "r870", "r871", "r872", "r873", "r883", "r894", "r895", "r915", "r924", "r932", "r936", "r1088", "r1140", "r1141", "r1142", "r1143", "r1144", "r1145" ] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Measure:", "label": "Measure [Axis]" } } }, "auth_ref": [ "r992" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Measure Name" } } }, "auth_ref": [ "r992" ] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MinimumMember", "presentation": [ "http://www.masimo.com/role/DebtNarrativeDetails", "http://www.masimo.com/role/EquityDetails", "http://www.masimo.com/role/IntangibleAssetsnetNarrativeDetails", "http://www.masimo.com/role/RelatedPartyTransactionsDetails", "http://www.masimo.com/role/StockBasedCompensationNarrativeDetail", "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetail", "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum", "label": "Minimum [Member]" } } }, "auth_ref": [ "r417", "r418", "r419", "r420", "r566", "r715", "r768", "r807", "r808", "r870", "r871", "r872", "r873", "r883", "r894", "r895", "r915", "r924", "r932", "r936", "r1088", "r1140", "r1141", "r1142", "r1143", "r1144", "r1145" ] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "MNPI Disclosure Timed for Compensation Value", "label": "MNPI Disclosure Timed for Compensation Value [Flag]" } } }, "auth_ref": [ "r1011" ] }, "masi_MoneyMarketFundsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://www.masimo.com/20240330", "localname": "MoneyMarketFundsFairValueDisclosure", "crdr": "debit", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesScheduleofFairValueAssetsMeasuredonRecurringBasisDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Money market funds", "label": "Money Market Funds, Fair Value Disclosure", "documentation": "Money Market Funds, Fair Value Disclosure" } } }, "auth_ref": [] }, "us-gaap_MovementInDeferredRevenueRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MovementInDeferredRevenueRollForward", "presentation": [ "http://www.masimo.com/role/DeferredRevenueandOtherContractLiabilitiesCurrentScheduleofChangesinDeferredRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Movement in Deferred Revenue [Roll Forward]", "label": "Movement in Deferred Revenue [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesScheduleofChangesinProductWarrantyAccrualDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Movement in Standard and Extended Product Warranty Accrual, Increase (Decrease) [Roll Forward]", "label": "Movement in Standard and Extended Product Warranty Accrual, Increase (Decrease) [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Material Terms of Trading Arrangement", "label": "Material Terms of Trading Arrangement [Text Block]" } } }, "auth_ref": [ "r1019" ] }, "srt_NameOfMajorCustomerDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "NameOfMajorCustomerDomain", "presentation": [ "http://www.masimo.com/role/CommitmentsandContingenciesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Customer [Domain]", "label": "Customer [Domain]" } } }, "auth_ref": [ "r369", "r925", "r1091", "r1150", "r1151" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Named Executive Officers, Footnote", "label": "Named Executive Officers, Footnote [Text Block]" } } }, "auth_ref": [ "r993" ] }, "us-gaap_NatureOfOperations": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NatureOfOperations", "presentation": [ "http://www.masimo.com/role/DescriptionoftheCompany" ], "lang": { "en-us": { "role": { "terseLabel": "Description of the Company", "label": "Nature of Operations [Text Block]", "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward." } } }, "auth_ref": [ "r222", "r236" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash (used in) provided by financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r292" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from financing activities:", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash (used in) provided by investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r292" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from investing activities:", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by (used in) operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r172", "r173", "r174" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from operating activities:", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 2.0 }, "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 13.0 }, "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY", "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS", "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesScheduleofReconciliationofBasicandDilutedNetIncomePerShareDetail", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "totalLabel": "Net income", "terseLabel": "Net income", "label": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r163", "r174", "r214", "r243", "r276", "r278", "r283", "r299", "r309", "r311", "r312", "r313", "r314", "r317", "r318", "r327", "r341", "r355", "r361", "r364", "r377", "r429", "r430", "r432", "r433", "r434", "r436", "r438", "r440", "r441", "r653", "r664", "r752", "r837", "r860", "r861", "r914", "r947", "r1086" ] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesScheduleofReconciliationofBasicandDilutedNetIncomePerShareDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Basic net income per share:", "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAvailableToCommonStockholdersDilutedAbstract", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesScheduleofReconciliationofBasicandDilutedNetIncomePerShareDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted net income per share:", "label": "Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetInvestmentInLeaseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetInvestmentInLeaseCurrent", "crdr": "debit", "calculation": { "http://www.masimo.com/role/OtherCurrentAssetsDetails": { "parentTag": "us-gaap_OtherAssetsCurrent", "weight": 1.0, "order": 2.0 }, "http://www.masimo.com/role/LeaseReceivableScheduleofSaleTypeLeaseReceivableDetails": { "parentTag": "us-gaap_SalesTypeLeaseLeaseReceivable", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.masimo.com/role/LeaseReceivableScheduleofSaleTypeLeaseReceivableDetails", "http://www.masimo.com/role/OtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease receivable, current", "negatedTerseLabel": "Less: current portion of lease receivable", "label": "Net Investment in Lease, before Allowance for Credit Loss, Current", "documentation": "Amount, before allowance for credit loss, of net investment in sales-type and direct financing leases, classified as current." } } }, "auth_ref": [ "r694", "r695", "r1063" ] }, "us-gaap_NetInvestmentInLeaseNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetInvestmentInLeaseNoncurrent", "crdr": "debit", "calculation": { "http://www.masimo.com/role/LeaseReceivableScheduleofSaleTypeLeaseReceivableDetails": { "parentTag": "us-gaap_SalesTypeLeaseLeaseReceivable", "weight": 1.0, "order": 1.0 }, "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.masimo.com/role/LeaseReceivableScheduleofSaleTypeLeaseReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease receivable, non-current", "label": "Net Investment in Lease, before Allowance for Credit Loss, Noncurrent", "documentation": "Amount, before allowance for credit loss, of net investment in sales-type and direct financing leases, classified as noncurrent." } } }, "auth_ref": [ "r694", "r695", "r1063" ] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Recently Adopted and Recently Announced Accounting Pronouncements", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "masi_NewCreditFacilityAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.masimo.com/20240330", "localname": "NewCreditFacilityAgreementMember", "presentation": [ "http://www.masimo.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "New Credit Facility Agreement", "label": "New Credit Facility Agreement [Member]", "documentation": "New Credit Facility Agreement" } } }, "auth_ref": [] }, "masi_NonCashFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.masimo.com/20240330", "localname": "NonCashFinancingActivitiesAbstract", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesScheduleofSupplementalCashFlowInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Non-cash financing activities:", "label": "Non-cash Financing Activities [Abstract]", "documentation": "Non-cash Financing Activities" } } }, "auth_ref": [] }, "masi_NonCashOperatingItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.masimo.com/20240330", "localname": "NonCashOperatingItemsAbstract", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesScheduleofSupplementalCashFlowInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Non-cash operating activities:", "label": "NonCash Operating Items [Abstract]", "documentation": "NonCash Operating Items" } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-GAAP Measure Description", "label": "Non-GAAP Measure Description [Text Block]" } } }, "auth_ref": [ "r992" ] }, "masi_NonHealthcareMember": { "xbrltype": "domainItemType", "nsuri": "http://www.masimo.com/20240330", "localname": "NonHealthcareMember", "presentation": [ "http://www.masimo.com/role/GoodwillDetails", "http://www.masimo.com/role/SegmentandEnterpriseReportingScheduleofSegmentReportingInformationbySegmentDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Non-healthcare", "label": "Non-Healthcare [Member]", "documentation": "Non-Healthcare" } } }, "auth_ref": [] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-NEOs", "label": "Non-NEOs [Member]" } } }, "auth_ref": [ "r962", "r973", "r983", "r1000", "r1008" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount", "label": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r990" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Total Compensation Amount", "label": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r989" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO", "label": "Non-PEO NEO [Member]" } } }, "auth_ref": [ "r1000" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted", "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r1019" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated", "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r1019" ] }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncashInvestingAndFinancingItemsAbstract", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesScheduleofSupplementalCashFlowInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Non-cash investing activities:", "label": "Noncash Investing and Financing Items [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NoncompeteAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncompeteAgreementsMember", "presentation": [ "http://www.masimo.com/role/IntangibleAssetsnetScheduleofFiniteLivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-compete agreements", "label": "Noncompete Agreements [Member]", "documentation": "Agreement in which one party agrees not to pursue a similar trade in competition with another party." } } }, "auth_ref": [ "r110" ] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 }, "http://www.masimo.com/role/NonoperatingLossDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.masimo.com/role/NonoperatingLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-operating loss", "totalLabel": "Total non-operating loss", "label": "Nonoperating Income (Expense)", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [ "r168" ] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpenseAbstract", "lang": { "en-us": { "role": { "terseLabel": "Nonoperating Income (Expense) [Abstract]", "label": "Nonoperating Income (Expense) [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NonoperatingIncomeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpenseMember", "presentation": [ "http://www.masimo.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofReclassificationoutofAccumulatedOtherComprehensiveIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-operating (loss)", "label": "Nonoperating Income (Expense) [Member]", "documentation": "Primary financial statement caption encompassing nonoperating income (expense)." } } }, "auth_ref": [] }, "us-gaap_NonrelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonrelatedPartyMember", "presentation": [ "http://www.masimo.com/role/OtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Nonrelated Party", "label": "Nonrelated Party [Member]", "documentation": "Party not related to reporting entity." } } }, "auth_ref": [ "r1050", "r1051" ] }, "masi_NotforProfitOrganizationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.masimo.com/20240330", "localname": "NotforProfitOrganizationMember", "presentation": [ "http://www.masimo.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Not for Profit Organization", "label": "Not for Profit Organization [Member]", "documentation": "Not for Profit Organization [Member]" } } }, "auth_ref": [] }, "us-gaap_NumberOfOperatingSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NumberOfOperatingSegments", "presentation": [ "http://www.masimo.com/role/SegmentandEnterpriseReportingScheduleofSegmentReportingInformationbySegmentDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Number of operating segments", "label": "Number of Operating Segments", "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues." } } }, "auth_ref": [ "r1059" ] }, "us-gaap_NumberOfReportableSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NumberOfReportableSegments", "presentation": [ "http://www.masimo.com/role/SegmentandEnterpriseReportingScheduleofSegmentReportingInformationbySegmentDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Number of reportable segments", "label": "Number of Reportable Segments", "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements." } } }, "auth_ref": [ "r1059" ] }, "us-gaap_NumberOfReportingUnits": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NumberOfReportingUnits", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Number of reporting units", "label": "Number of Reporting Units", "documentation": "Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment." } } }, "auth_ref": [] }, "masi_NumberOfSourcesOfProductRevenue": { "xbrltype": "integerItemType", "nsuri": "http://www.masimo.com/20240330", "localname": "NumberOfSourcesOfProductRevenue", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Number of sources of product revenue", "label": "Number Of Sources Of Product Revenue", "documentation": "Number Of Sources Of Product Revenue" } } }, "auth_ref": [] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpensesAbstract", "presentation": [ "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Operating expenses:", "label": "Operating Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "totalLabel": "Operating income", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r341", "r355", "r361", "r364", "r914" ] }, "masi_OperatingLeaseAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.masimo.com/20240330", "localname": "OperatingLeaseAssetsMember", "presentation": [ "http://www.masimo.com/role/PropertyandEquipmentnetNarrativeDetail", "http://www.masimo.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease assets", "label": "Operating Lease Assets [Member]", "documentation": "Operating Lease Assets" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseCost", "crdr": "debit", "presentation": [ "http://www.masimo.com/role/LesseeROUAssetsandLeaseLiabilitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease, cost", "label": "Operating Lease, Cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": [ "r686", "r934" ] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiability", "crdr": "credit", "calculation": { "http://www.masimo.com/role/LesseeROUAssetsandLeaseLiabilitiesScheduleofLesseeOperatingLeaseLiabilityMaturityDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 }, "http://www.masimo.com/role/LesseeROUAssetsandLeaseLiabilitiesScheduleofLesseeOperatingLeaseBalanceSheetClassificationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.masimo.com/role/LesseeROUAssetsandLeaseLiabilitiesScheduleofLesseeOperatingLeaseBalanceSheetClassificationDetails", "http://www.masimo.com/role/LesseeROUAssetsandLeaseLiabilitiesScheduleofLesseeOperatingLeaseLiabilityMaturityDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total operating lease liabilities", "terseLabel": "Present value", "label": "Operating Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r682" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.masimo.com/role/LesseeROUAssetsandLeaseLiabilitiesScheduleofLesseeOperatingLeaseBalanceSheetClassificationDetails": { "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 1.0 }, "http://www.masimo.com/role/OtherCurrentLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.masimo.com/role/LesseeROUAssetsandLeaseLiabilitiesScheduleofLesseeOperatingLeaseBalanceSheetClassificationDetails", "http://www.masimo.com/role/OtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee lease liabilities, current", "label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r682" ] }, "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList", "presentation": [ "http://www.masimo.com/role/LesseeROUAssetsandLeaseLiabilitiesScheduleofLesseeOperatingLeaseBalanceSheetClassificationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]", "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes current operating lease liability." } } }, "auth_ref": [ "r683" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.masimo.com/role/LesseeROUAssetsandLeaseLiabilitiesScheduleofLesseeOperatingLeaseBalanceSheetClassificationDetails": { "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 2.0 }, "http://www.masimo.com/role/OtherNonCurrentLiabilitiesDetails": { "parentTag": "us-gaap_DeferredCreditsAndOtherLiabilities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.masimo.com/role/LesseeROUAssetsandLeaseLiabilitiesScheduleofLesseeOperatingLeaseBalanceSheetClassificationDetails", "http://www.masimo.com/role/OtherNonCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee non-current lease liabilities", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r682" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList", "presentation": [ "http://www.masimo.com/role/LesseeROUAssetsandLeaseLiabilitiesScheduleofLesseeOperatingLeaseBalanceSheetClassificationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]", "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability." } } }, "auth_ref": [ "r683" ] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesScheduleofSupplementalCashFlowInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liabilities", "label": "Operating Lease, Payments", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": [ "r684", "r688" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.masimo.com/role/OtherNonCurrentAssetsDetails": { "parentTag": "us-gaap_OtherAssetsNoncurrent", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.masimo.com/role/LesseeROUAssetsandLeaseLiabilitiesScheduleofLesseeOperatingLeaseBalanceSheetClassificationDetails", "http://www.masimo.com/role/OtherNonCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Lessee ROU assets", "terseLabel": "Lessee ROU assets, net", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r681" ] }, "masi_OperatingLeaseRightOfUseAssetAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://www.masimo.com/20240330", "localname": "OperatingLeaseRightOfUseAssetAccumulatedAmortization", "crdr": "credit", "presentation": [ "http://www.masimo.com/role/LesseeROUAssetsandLeaseLiabilitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated amortization for lessee ROU assets", "label": "Operating Lease, Right-of-Use Asset, Accumulated Amortization", "documentation": "Operating Lease, Right-of-Use Asset, Accumulated Amortization" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList", "presentation": [ "http://www.masimo.com/role/LesseeROUAssetsandLeaseLiabilitiesScheduleofLesseeOperatingLeaseBalanceSheetClassificationDetails", "http://www.masimo.com/role/OtherNonCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]", "label": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset." } } }, "auth_ref": [ "r683" ] }, "us-gaap_OperatingLeaseVariableLeaseIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseVariableLeaseIncome", "crdr": "credit", "presentation": [ "http://www.masimo.com/role/LeaseReceivableNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable lease income", "label": "Operating Lease, Variable Lease Income", "documentation": "Amount of operating lease income from variable lease payments paid and payable to lessor, excluding amount included in measurement of lease receivable." } } }, "auth_ref": [ "r333", "r700" ] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://www.masimo.com/role/LesseeROUAssetsandLeaseLiabilitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease, weighted average discount rate", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": [ "r691", "r934" ] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://www.masimo.com/role/LesseeROUAssetsandLeaseLiabilitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average remaining lease term", "label": "Operating Lease, Weighted Average Remaining Lease Term", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r690", "r934" ] }, "us-gaap_OperatingSegmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingSegmentsMember", "presentation": [ "http://www.masimo.com/role/SegmentandEnterpriseReportingScheduleofSegmentReportingInformationbySegmentDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Segments", "label": "Operating Segments [Member]", "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r354", "r355", "r356", "r357", "r358", "r364" ] }, "us-gaap_OptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OptionMember", "presentation": [ "http://www.masimo.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options Held", "label": "Options Held [Member]", "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific commodity, or financial or equity instrument, at a specified price during a specified period (an American option) or at a specified date (a European option) which were purchased or otherwise acquired, excluding options written (for which a premium was received)." } } }, "auth_ref": [ "r203", "r825", "r830", "r849", "r855", "r874", "r875", "r876", "r937", "r938" ] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.masimo.com/role/OtherCurrentLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.masimo.com/role/OtherCurrentLiabilitiesDetails", "http://www.masimo.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other current liabilities, related party", "verboseLabel": "Other current liabilities, related party payables", "label": "Other Accrued Liabilities, Current", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r39" ] }, "us-gaap_OtherAccruedLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAccruedLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.masimo.com/role/OtherNonCurrentLiabilitiesDetails": { "parentTag": "us-gaap_DeferredCreditsAndOtherLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.masimo.com/role/OtherNonCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other Accrued Liabilities, Noncurrent", "documentation": "Amount of expenses incurred but not yet paid classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r43" ] }, "us-gaap_OtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 }, "http://www.masimo.com/role/OtherCurrentAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.masimo.com/role/OtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other current assets", "totalLabel": "Total other current assets", "label": "Other Assets, Current", "documentation": "Amount of current assets classified as other." } } }, "auth_ref": [ "r265", "r935" ] }, "us-gaap_OtherAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsDisclosureTextBlock", "presentation": [ "http://www.masimo.com/role/OtherNonCurrentAssets" ], "lang": { "en-us": { "role": { "terseLabel": "Other Non-Current Assets", "label": "Other Assets Disclosure [Text Block]", "documentation": "The entire disclosure for other assets. This disclosure includes other current assets and other noncurrent assets." } } }, "auth_ref": [] }, "us-gaap_OtherAssetsMiscellaneousCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsMiscellaneousCurrent", "crdr": "debit", "calculation": { "http://www.masimo.com/role/OtherCurrentAssetsDetails": { "parentTag": "us-gaap_OtherAssetsCurrent", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.masimo.com/role/OtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other current assets", "label": "Other Assets, Miscellaneous, Current", "documentation": "Amount of other miscellaneous assets expected to be realized or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [] }, "us-gaap_OtherAssetsMiscellaneousNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsMiscellaneousNoncurrent", "crdr": "debit", "calculation": { "http://www.masimo.com/role/OtherNonCurrentAssetsDetails": { "parentTag": "us-gaap_OtherAssetsNoncurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.masimo.com/role/OtherNonCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other non-current assets", "label": "Other Assets, Miscellaneous, Noncurrent", "documentation": "Amount of other miscellaneous assets expected to be realized or consumed after one year or normal operating cycle, if longer." } } }, "auth_ref": [] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 }, "http://www.masimo.com/role/OtherNonCurrentAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.masimo.com/role/OtherNonCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other non-current assets", "totalLabel": "Total non-current assets", "label": "Other Assets, Noncurrent", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r252" ] }, "us-gaap_OtherCommitment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherCommitment", "crdr": "credit", "presentation": [ "http://www.masimo.com/role/CommitmentsandContingenciesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Other commitment", "label": "Other Commitment", "documentation": "Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions." } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent", "crdr": "debit", "calculation": { "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY", "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Change in pension benefits", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent", "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan, attributable to parent." } } }, "auth_ref": [ "r6", "r19", "r161", "r201" ] }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "crdr": "credit", "calculation": { "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY", "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized losses from foreign currency translation adjustments", "verboseLabel": "Foreign currency translation adjustment", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity." } } }, "auth_ref": [ "r8", "r19", "r201" ] }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParentAbstract", "presentation": [ "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive loss, net of tax:", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax", "crdr": "credit", "presentation": [ "http://www.masimo.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofAccumulatedOtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amount recognized in other comprehensive income (loss)", "label": "Other Comprehensive Income (Loss), before Reclassifications, before Tax", "documentation": "Amount before tax and reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": [ "r48", "r282", "r671", "r673", "r676", "r753", "r1038" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax", "crdr": "credit", "presentation": [ "http://www.masimo.com/role/DerivativeInstrumentsandHedgingActivitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Net of tax gain (loss) on derivatives", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax", "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r271", "r272" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent", "crdr": "credit", "calculation": { "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY", "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized gain (loss) on cash flow hedges", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent", "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent." } } }, "auth_ref": [ "r272" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax", "crdr": "debit", "presentation": [ "http://www.masimo.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofReclassificationoutofAccumulatedOtherComprehensiveIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gains (losses) reclassified from accumulated other comprehensive income", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax", "documentation": "Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r231", "r272", "r275" ] }, "us-gaap_OtherCurrentAssetsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherCurrentAssetsTextBlock", "presentation": [ "http://www.masimo.com/role/OtherCurrentAssets" ], "lang": { "en-us": { "role": { "terseLabel": "Other Current Assets", "label": "Other Current Assets [Text Block]", "documentation": "The entire disclosure for other current assets." } } }, "auth_ref": [] }, "masi_OtherCurrentLiabilitiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.masimo.com/20240330", "localname": "OtherCurrentLiabilitiesLineItems", "presentation": [ "http://www.masimo.com/role/OtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Current Liabilities [Line Items]", "label": "Other Current Liabilities [Line Items]", "documentation": "Other Current Liabilities [Line Items]" } } }, "auth_ref": [] }, "masi_OtherCurrentLiabilitiesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.masimo.com/20240330", "localname": "OtherCurrentLiabilitiesTable", "presentation": [ "http://www.masimo.com/role/OtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Current Liabilities [Table]", "label": "Other Current Liabilities [Table]", "documentation": "Other Current Liabilities [Table]" } } }, "auth_ref": [] }, "us-gaap_OtherIntangibleAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherIntangibleAssetsMember", "presentation": [ "http://www.masimo.com/role/IntangibleAssetsnetScheduleofFiniteLivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other Intangible Assets [Member]", "documentation": "Intangible assets classified as other." } } }, "auth_ref": [] }, "us-gaap_OtherLiabilitiesAndDeferredRevenueNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesAndDeferredRevenueNoncurrent", "crdr": "credit", "calculation": { "http://www.masimo.com/role/DeferredRevenueandOtherContractLiabilitiesCurrentScheduleofDeferredRevenueandOtherContractLiabilitiesCurrentDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.masimo.com/role/DeferredRevenueandOtherContractLiabilitiesCurrentScheduleofDeferredRevenueandOtherContractLiabilitiesCurrentDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total deferred revenue and other contract liabilities", "label": "Other Liabilities and Deferred Revenue, Noncurrent", "documentation": "Aggregate carrying amount, as of the balance sheet date, of noncurrent obligations and noncurrent portion of deferred revenue not separately disclosed in the balance sheet. Noncurrent liabilities are expected to be paid after one year (or the normal operating cycle, if longer). Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months." } } }, "auth_ref": [] }, "us-gaap_OtherLiabilitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Other Liabilities Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherLiabilitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesDisclosureTextBlock", "presentation": [ "http://www.masimo.com/role/OtherNonCurrentLiabilities" ], "lang": { "en-us": { "role": { "terseLabel": "Other Non-Current Liabilities", "label": "Other Liabilities Disclosure [Text Block]", "documentation": "The entire disclosure for other liabilities." } } }, "auth_ref": [ "r40" ] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "verboseLabel": "Other non-current liabilities", "label": "Other Liabilities, Noncurrent", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r43" ] }, "masi_OtherMiscellaneousIntangibleAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.masimo.com/20240330", "localname": "OtherMiscellaneousIntangibleAssetsMember", "presentation": [ "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Other intangible assets, net - (Note 9)", "label": "Other Miscellaneous Intangible Assets [Member]", "documentation": "Other Miscellaneous Intangible Assets" } } }, "auth_ref": [] }, "us-gaap_OtherNoncurrentAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNoncurrentAssetsMember", "presentation": [ "http://www.masimo.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofDerivativeInstrumentsinStatementofFinancialPositionFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other non-current assets", "label": "Other Noncurrent Assets [Member]", "documentation": "Primary financial statement caption encompassing other noncurrent assets." } } }, "auth_ref": [] }, "us-gaap_OtherNoncurrentLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNoncurrentLiabilitiesMember", "presentation": [ "http://www.masimo.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofDerivativeInstrumentsinStatementofFinancialPositionFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other non-current liabilities", "label": "Other Noncurrent Liabilities [Member]", "documentation": "Primary financial statement caption encompassing other noncurrent liabilities." } } }, "auth_ref": [] }, "us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncomeAndExpenseTextBlock", "presentation": [ "http://www.masimo.com/role/NonoperatingLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Non-operating Loss", "label": "Other Nonoperating Income and Expense [Text Block]", "documentation": "The entire disclosure for the components of non-operating income or non-operating expense, including, but not limited to, amounts earned from dividends, interest on securities, gain (loss) on securities sold, equity earnings of unconsolidated affiliates, gain (loss) on sales of business, interest expense and other miscellaneous income or expense items." } } }, "auth_ref": [ "r288", "r289" ] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.masimo.com/role/NonoperatingLossDetails": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.masimo.com/role/NonoperatingLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other Nonoperating Income (Expense)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r170" ] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Other Performance Measure, Amount", "label": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r992" ] }, "us-gaap_OtherReceivablesNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherReceivablesNetCurrent", "crdr": "debit", "calculation": { "http://www.masimo.com/role/OtherCurrentAssetsDetails": { "parentTag": "us-gaap_OtherAssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.masimo.com/role/OtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other receivables", "label": "Other Receivables, Net, Current", "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer." } } }, "auth_ref": [] }, "us-gaap_OtherTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherTaxExpenseBenefit", "crdr": "debit", "presentation": [ "http://www.masimo.com/role/IncomeTaxesNarrativeDetail" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other tax benefit", "label": "Other Tax Expense (Benefit)", "documentation": "Amount of other income tax expense (benefit)." } } }, "auth_ref": [ "r300", "r1124", "r1125" ] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount", "label": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r960", "r971", "r981", "r1006" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Amount", "label": "Outstanding Recovery Compensation Amount" } } }, "auth_ref": [ "r963", "r974", "r984", "r1009" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": [ "r963", "r974", "r984", "r1009" ] }, "masi_PatentsAndTrademarksMember": { "xbrltype": "domainItemType", "nsuri": "http://www.masimo.com/20240330", "localname": "PatentsAndTrademarksMember", "presentation": [ "http://www.masimo.com/role/IntangibleAssetsnetNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Patents And Trademarks", "label": "Patents And Trademarks [Member]", "documentation": "Patents and Trademarks." } } }, "auth_ref": [] }, "us-gaap_PatentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PatentsMember", "presentation": [ "http://www.masimo.com/role/IntangibleAssetsnetNarrativeDetails", "http://www.masimo.com/role/IntangibleAssetsnetScheduleofFiniteLivedIntangibleAssetsDetails", "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Patents", "label": "Patents [Member]", "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law." } } }, "auth_ref": [ "r200" ] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]" } } }, "auth_ref": [ "r988" ] }, "us-gaap_PaymentForAdministrativeFees": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentForAdministrativeFees", "crdr": "credit", "presentation": [ "http://www.masimo.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payment for administrative fees", "label": "Payment for Administrative Fees", "documentation": "Amount paid to managing member or general partner, affiliate of managing member or general partner, or affiliate of limited liability company (LLC) or limited partnership (LP) for administrative services provided to the LLC or LP, for example, but not limited to, salaries, rent, or overhead costs." } } }, "auth_ref": [ "r1043", "r1135" ] }, "us-gaap_PaymentsForRoyalties": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForRoyalties", "crdr": "credit", "presentation": [ "http://www.masimo.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payments for royalties", "label": "Payments for Royalties", "documentation": "The amount of cash paid for royalties during the current period." } } }, "auth_ref": [ "r9" ] }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "credit", "calculation": { "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payroll tax withholdings on behalf of employees for vested equity awards", "label": "Payment, Tax Withholding, Share-Based Payment Arrangement", "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [ "r290" ] }, "us-gaap_PaymentsToAcquireBusinessesGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireBusinessesGross", "crdr": "credit", "calculation": { "http://www.masimo.com/role/BusinessCombinationsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.masimo.com/role/BusinessCombinationsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.masimo.com/role/BusinessCombinationsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash consideration", "label": "Payments to Acquire Businesses, Gross", "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price." } } }, "auth_ref": [ "r50", "r635" ] }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "crdr": "credit", "calculation": { "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Business combinations, net of cash acquired", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase." } } }, "auth_ref": [ "r50" ] }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireIntangibleAssets", "crdr": "credit", "calculation": { "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Increase in intangible assets", "label": "Payments to Acquire Intangible Assets", "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill." } } }, "auth_ref": [ "r171" ] }, "us-gaap_PaymentsToAcquireLongtermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireLongtermInvestments", "crdr": "credit", "calculation": { "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other strategic investing activities", "label": "Payments to Acquire Long-Term Investments", "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, beyond the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the long-term." } } }, "auth_ref": [ "r1042" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchases of property and equipment, net", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r171" ] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Issuers, Footnote", "label": "Peer Group Issuers, Footnote [Text Block]" } } }, "auth_ref": [ "r991" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Total Shareholder Return Amount", "label": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r991" ] }, "us-gaap_PendingLitigationMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PendingLitigationMember", "presentation": [ "http://www.masimo.com/role/CommitmentsandContingenciesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Pending Litigation", "label": "Pending Litigation [Member]", "documentation": "Risk of loss associated with the outcome of pending litigation against the entity, for example, but not limited to, litigation in arbitration or within the trial process." } } }, "auth_ref": [ "r1079" ] }, "us-gaap_PensionAndOtherPostretirementPlansPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PensionAndOtherPostretirementPlansPolicy", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Employee Defined Benefit Plans", "label": "Pension and Other Postretirement Plans, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for pension and other postretirement benefit plans. This accounting policy may address (1) the types of plans sponsored by the entity, and the benefits provided by each plan (2) groups that participate in (or are covered by) each plan (3) how plan assets, liabilities and expenses are measured, including the use of any actuaries and (4) significant assumptions used by the entity to value plan assets and liabilities and how such assumptions are derived." } } }, "auth_ref": [ "r15", "r16", "r17", "r23", "r95" ] }, "masi_PensionAssetFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://www.masimo.com/20240330", "localname": "PensionAssetFairValueDisclosure", "crdr": "debit", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesScheduleofFairValueAssetsMeasuredonRecurringBasisDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Pension assets", "label": "Pension Asset, Fair Value Disclosure", "documentation": "Pension Asset, Fair Value Disclosure" } } }, "auth_ref": [] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Actually Paid Compensation Amount", "label": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r990" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO", "label": "PEO [Member]" } } }, "auth_ref": [ "r1000" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Name", "label": "PEO Name" } } }, "auth_ref": [ "r993" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Total Compensation Amount", "label": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r989" ] }, "masi_PercentageofAccountsReceivableBalance": { "xbrltype": "percentItemType", "nsuri": "http://www.masimo.com/20240330", "localname": "PercentageofAccountsReceivableBalance", "presentation": [ "http://www.masimo.com/role/CommitmentsandContingenciesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of accounts receivable balance", "label": "Percentage of Accounts Receivable Balance", "documentation": "Percentage of Accounts Receivable Balance" } } }, "auth_ref": [] }, "us-gaap_PerformanceSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PerformanceSharesMember", "presentation": [ "http://www.masimo.com/role/StockBasedCompensationNarrativeDetail", "http://www.masimo.com/role/StockBasedCompensationScheduleofStockUnitsActivityDetail", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Performance Shares", "label": "Performance Shares [Member]", "documentation": "Share-based payment arrangement awarded for meeting performance target." } } }, "auth_ref": [] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameAxis", "presentation": [ "http://www.masimo.com/role/EmployeeBenefitsDetails", "http://www.masimo.com/role/StockBasedCompensationNarrativeDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Plan Name [Axis]", "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": [ "r1096", "r1097", "r1098", "r1099", "r1100", "r1101", "r1102", "r1103", "r1104", "r1105", "r1106", "r1107", "r1108", "r1109", "r1110", "r1111", "r1112", "r1113", "r1114", "r1115", "r1116", "r1117", "r1118", "r1119", "r1120", "r1121" ] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameDomain", "presentation": [ "http://www.masimo.com/role/EmployeeBenefitsDetails", "http://www.masimo.com/role/StockBasedCompensationNarrativeDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Plan Name [Domain]", "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": [ "r1096", "r1097", "r1098", "r1099", "r1100", "r1101", "r1102", "r1103", "r1104", "r1105", "r1106", "r1107", "r1108", "r1109", "r1110", "r1111", "r1112", "r1113", "r1114", "r1115", "r1116", "r1117", "r1118", "r1119", "r1120", "r1121" ] }, "us-gaap_PostemploymentBenefitsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PostemploymentBenefitsAbstract", "lang": { "en-us": { "role": { "label": "Postemployment Benefits [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "http://www.masimo.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, par value (in dollars per share)", "label": "Preferred Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r150", "r472" ] }, "masi_PreferredStockPreferredStockPurchaseRightPurchasePricePerRight": { "xbrltype": "perShareItemType", "nsuri": "http://www.masimo.com/20240330", "localname": "PreferredStockPreferredStockPurchaseRightPurchasePricePerRight", "presentation": [ "http://www.masimo.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase price per each right (in dollars per share)", "label": "Preferred Stock, Preferred Stock Purchase Right, Purchase Price Per Right", "documentation": "Preferred Stock, Preferred Stock Purchase Right, Purchase Price Per Right" } } }, "auth_ref": [] }, "masi_PreferredStockPurchaseRightThresholdPercentageOfPurchaseRightTrigger": { "xbrltype": "percentItemType", "nsuri": "http://www.masimo.com/20240330", "localname": "PreferredStockPurchaseRightThresholdPercentageOfPurchaseRightTrigger", "presentation": [ "http://www.masimo.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Threshold percentage to exercise purchase right", "label": "Preferred Stock Purchase Right, Threshold Percentage of Purchase Right Trigger", "documentation": "Preferred Stock Purchase Right, Threshold Percentage of Purchase Right Trigger" } } }, "auth_ref": [] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares authorized (in shares)", "label": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r150", "r817" ] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesIssued", "presentation": [ "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares issued (in shares)", "label": "Preferred Stock, Shares Issued", "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt." } } }, "auth_ref": [ "r150", "r472" ] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares outstanding (in shares)", "label": "Preferred Stock, Shares Outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r150", "r817", "r835", "r1156", "r1157" ] }, "us-gaap_PreferredStockValueOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockValueOutstanding", "crdr": "credit", "calculation": { "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, $0.001 par value; 5.0 million shares authorized; 0 shares issued and outstanding", "label": "Preferred Stock, Value, Outstanding", "documentation": "Value of all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by shareholders, which is net of related treasury stock. May be all or a portion of the number of preferred shares authorized. These shares represent the ownership interest of the preferred shareholders." } } }, "auth_ref": [ "r150", "r817" ] }, "masi_PrepaidDiscount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.masimo.com/20240330", "localname": "PrepaidDiscount", "crdr": "debit", "calculation": { "http://www.masimo.com/role/DeferredCostsandOtherContractAssetsDetails": { "parentTag": "us-gaap_DeferredCostsAndOtherAssets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.masimo.com/role/DeferredCostsandOtherContractAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid contract allowances", "label": "Prepaid Discount", "documentation": "Prepaid Discount" } } }, "auth_ref": [] }, "us-gaap_PrepaidExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseCurrent", "crdr": "debit", "calculation": { "http://www.masimo.com/role/OtherCurrentAssetsDetails": { "parentTag": "us-gaap_OtherAssetsCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.masimo.com/role/OtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Prepaid expenses", "label": "Prepaid Expense, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r264", "r386", "r387", "r901" ] }, "us-gaap_PrepaidRoyalties": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidRoyalties", "crdr": "debit", "calculation": { "http://www.masimo.com/role/OtherCurrentAssetsDetails": { "parentTag": "us-gaap_OtherAssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.masimo.com/role/OtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid rebates and royalties, current", "label": "Prepaid Royalties", "documentation": "Amount of asset related to consideration paid in advance for royalties that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r903", "r917", "r1064" ] }, "us-gaap_PrepaidTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidTaxes", "crdr": "debit", "calculation": { "http://www.masimo.com/role/OtherCurrentAssetsDetails": { "parentTag": "us-gaap_OtherAssetsCurrent", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.masimo.com/role/OtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Prepaid income taxes", "label": "Prepaid Taxes", "documentation": "Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r902", "r916", "r1064" ] }, "masi_PrincipalAmountOfLicenseAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.masimo.com/20240330", "localname": "PrincipalAmountOfLicenseAgreement", "crdr": "debit", "presentation": [ "http://www.masimo.com/role/CommitmentsandContingenciesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Principal amount of license agreement", "label": "Principal Amount Of License Agreement", "documentation": "Principal Amount Of License Agreement" } } }, "auth_ref": [] }, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PriorPeriodReclassificationAdjustmentDescription", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Reclassifications", "label": "Reclassification, Comparability Adjustment [Policy Text Block]", "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error." } } }, "auth_ref": [ "r1032" ] }, "us-gaap_ProceedsFromLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromLeasePayments", "crdr": "debit", "calculation": { "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Decrease (increase) in lease receivable, net", "label": "Proceeds from Lease Payment, Operating Activity", "documentation": "Amount of cash inflow from lease payment, classified as operating activity." } } }, "auth_ref": [ "r696", "r697" ] }, "us-gaap_ProceedsFromLinesOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromLinesOfCredit", "crdr": "debit", "calculation": { "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowings under line of credit", "label": "Proceeds from Lines of Credit", "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements." } } }, "auth_ref": [ "r51", "r1048" ] }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "calculation": { "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from issuance of common stock", "label": "Proceeds from Stock Options Exercised", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth_ref": [ "r7", "r27" ] }, "masi_ProceedsFromStockOptionsExercisedUnsettledAtPeriodEnd": { "xbrltype": "monetaryItemType", "nsuri": "http://www.masimo.com/20240330", "localname": "ProceedsFromStockOptionsExercisedUnsettledAtPeriodEnd", "crdr": "debit", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesScheduleofSupplementalCashFlowInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Unsettled common stock proceeds from option exercises", "label": "Proceeds From Stock Options Exercised, Unsettled At Period End", "documentation": "Proceeds From Stock Options Exercised, Unsettled At Period End" } } }, "auth_ref": [] }, "us-gaap_ProductInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProductInformationLineItems", "presentation": [ "http://www.masimo.com/role/OtherNonCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Assets Long Term [Line Items]", "label": "Product Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_ProductWarrantyAccrual": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProductWarrantyAccrual", "crdr": "credit", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesScheduleofChangesinProductWarrantyAccrualDetail" ], "lang": { "en-us": { "role": { "periodStartLabel": "Product warranty accrual, beginning of period", "periodEndLabel": "Product warranty accrual, end of period", "label": "Standard and Extended Product Warranty Accrual", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers." } } }, "auth_ref": [ "r140", "r422", "r424", "r428" ] }, "us-gaap_ProductWarrantyAccrualClassifiedCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProductWarrantyAccrualClassifiedCurrent", "crdr": "credit", "calculation": { "http://www.masimo.com/role/OtherCurrentLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.masimo.com/role/OtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued warranty", "label": "Product Warranty Accrual, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers. For classified balance sheets, represents the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r39", "r1084", "r1085" ] }, "us-gaap_ProductWarrantyAccrualPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProductWarrantyAccrualPayments", "crdr": "debit", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesScheduleofChangesinProductWarrantyAccrualDetail" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Settlements made", "label": "Standard and Extended Product Warranty Accrual, Decrease for Payments", "documentation": "Amount of decrease in the standard and extended product warranty accrual from payments made in cash or in kind to satisfy claims under the terms of the standard and extended product warranty." } } }, "auth_ref": [ "r425" ] }, "us-gaap_ProductWarrantyAccrualPreexistingIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProductWarrantyAccrualPreexistingIncreaseDecrease", "crdr": "credit", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesScheduleofChangesinProductWarrantyAccrualDetail" ], "lang": { "en-us": { "role": { "negatedLabel": "Changes in pre-existing warranties (including changes in estimates)", "label": "Standard and Extended Product Warranty Accrual, Increase (Decrease) for Preexisting Warranties", "documentation": "Amount of increase (decrease) in the standard and extended product warranty accrual from changes in estimates attributable to preexisting product warranties." } } }, "auth_ref": [ "r427" ] }, "us-gaap_ProductWarrantyAccrualWarrantiesIssued": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProductWarrantyAccrualWarrantiesIssued", "crdr": "credit", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesScheduleofChangesinProductWarrantyAccrualDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Accrual for warranties issued", "label": "Standard and Extended Product Warranty Accrual, Increase for Warranties Issued", "documentation": "Amount of increase in the standard and extended product warranty accrual from warranties issued." } } }, "auth_ref": [ "r426" ] }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Abstract]", "label": "Property, Plant and Equipment [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentAdditions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentAdditions", "crdr": "debit", "presentation": [ "http://www.masimo.com/role/PropertyandEquipmentnetNarrativeDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Property, plant and equipment, additions", "label": "Property, Plant and Equipment, Additions", "documentation": "Amount of acquisition of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [ "http://www.masimo.com/role/PropertyandEquipmentnetNarrativeDetail", "http://www.masimo.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentDetails", "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment, Type [Axis]", "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r12" ] }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "presentation": [ "http://www.masimo.com/role/PropertyandEquipmentnet" ], "lang": { "en-us": { "role": { "terseLabel": "Property and Equipment, net", "label": "Property, Plant and Equipment Disclosure [Text Block]", "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r182", "r226", "r232", "r233" ] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "calculation": { "http://www.masimo.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.masimo.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total property and equipment", "label": "Property, Plant and Equipment, Gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r184", "r248", "r750" ] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": [ "http://www.masimo.com/role/PropertyandEquipmentnetNarrativeDetail", "http://www.masimo.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentDetails", "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Line Items]", "label": "Property, Plant and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 7.0 }, "http://www.masimo.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.masimo.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property and equipment, net", "totalLabel": "Property and equipment, net", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r12", "r741", "r750", "r935" ] }, "masi_PropertyPlantAndEquipmentOccupiedSquareFeet": { "xbrltype": "areaItemType", "nsuri": "http://www.masimo.com/20240330", "localname": "PropertyPlantAndEquipmentOccupiedSquareFeet", "presentation": [ "http://www.masimo.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property plant and equipment, occupied square feet", "label": "Property Plant And Equipment, Occupied Square Feet", "documentation": "The amount of square feet occupied." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Property and Equipment", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r12", "r226", "r232", "r748" ] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": [ "http://www.masimo.com/role/PropertyandEquipmentnetTables", "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Property and Equipment", "verboseLabel": "Schedule of Property, Plant and Equipment", "label": "Property, Plant and Equipment [Table Text Block]", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r12" ] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://www.masimo.com/role/PropertyandEquipmentnetNarrativeDetail", "http://www.masimo.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentDetails", "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment, Type [Domain]", "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r184" ] }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentUsefulLife", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentDetail" ], "lang": { "en-us": { "role": { "verboseLabel": "Property and equipment, useful life", "label": "Property, Plant and Equipment, Useful Life", "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment." } } }, "auth_ref": [] }, "us-gaap_ProvisionForDoubtfulAccounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProvisionForDoubtfulAccounts", "crdr": "debit", "calculation": { "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Provision for credit losses", "label": "Accounts Receivable, Credit Loss Expense (Reversal)", "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable." } } }, "auth_ref": [ "r287", "r381" ] }, "us-gaap_PurchaseCommitmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PurchaseCommitmentMember", "presentation": [ "http://www.masimo.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase Commitment", "label": "Purchase Commitment [Member]", "documentation": "Purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier. Excludes long-term commitments." } } }, "auth_ref": [ "r149", "r210" ] }, "us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PurchaseCommitmentRemainingMinimumAmountCommitted", "crdr": "credit", "presentation": [ "http://www.masimo.com/role/CommitmentsandContingenciesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Remaining commitment", "label": "Purchase Commitment, Remaining Minimum Amount Committed", "documentation": "Minimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional purchase obligations." } } }, "auth_ref": [ "r149", "r210" ] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure", "label": "Pay vs Performance Disclosure [Table]" } } }, "auth_ref": [ "r988" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure, Table", "label": "Pay vs Performance [Table Text Block]" } } }, "auth_ref": [ "r988" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": [ "http://www.masimo.com/role/DebtNarrativeDetails", "http://www.masimo.com/role/EquityDetails", "http://www.masimo.com/role/IntangibleAssetsnetNarrativeDetails", "http://www.masimo.com/role/RelatedPartyTransactionsDetails", "http://www.masimo.com/role/StockBasedCompensationNarrativeDetail", "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetail", "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Axis]", "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r417", "r418", "r419", "r420", "r525", "r566", "r596", "r597", "r598", "r714", "r715", "r768", "r807", "r808", "r870", "r871", "r872", "r873", "r883", "r894", "r895", "r915", "r924", "r932", "r936", "r939", "r1077", "r1088", "r1141", "r1142", "r1143", "r1144", "r1145" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeMember", "presentation": [ "http://www.masimo.com/role/DebtNarrativeDetails", "http://www.masimo.com/role/EquityDetails", "http://www.masimo.com/role/IntangibleAssetsnetNarrativeDetails", "http://www.masimo.com/role/RelatedPartyTransactionsDetails", "http://www.masimo.com/role/StockBasedCompensationNarrativeDetail", "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetail", "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Domain]", "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r417", "r418", "r419", "r420", "r525", "r566", "r596", "r597", "r598", "r714", "r715", "r768", "r807", "r808", "r870", "r871", "r872", "r873", "r883", "r894", "r895", "r915", "r924", "r932", "r936", "r939", "r1077", "r1088", "r1141", "r1142", "r1143", "r1144", "r1145" ] }, "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax", "crdr": "debit", "presentation": [ "http://www.masimo.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofAccumulatedOtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amount reclassified into earnings", "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax", "documentation": "Amount before tax of reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": [ "r48", "r282", "r671", "r675", "r676", "r753", "r1038" ] }, "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract", "presentation": [ "http://www.masimo.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofAccumulatedOtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]", "label": "AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock", "presentation": [ "http://www.masimo.com/role/DerivativeInstrumentsandHedgingActivitiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Reclassification out of Accumulated Other Comprehensive Income", "label": "Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]", "documentation": "Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss)." } } }, "auth_ref": [] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]" } } }, "auth_ref": [ "r955", "r966", "r976", "r1001" ] }, "masi_ReimbursementFeeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.masimo.com/20240330", "localname": "ReimbursementFeeMember", "presentation": [ "http://www.masimo.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reimbursement Fee", "label": "Reimbursement Fee [Member]", "documentation": "Reimbursement Fee [Member]" } } }, "auth_ref": [] }, "us-gaap_RelatedAndNonrelatedPartyStatusAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedAndNonrelatedPartyStatusAxis", "presentation": [ "http://www.masimo.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related and Nonrelated Party Status [Axis]", "label": "Related and Nonrelated Party Status [Axis]", "documentation": "Information by related and nonrelated party status." } } }, "auth_ref": [ "r302", "r303", "r706", "r707", "r708", "r709", "r810", "r811", "r812", "r813", "r814", "r834", "r836", "r940" ] }, "us-gaap_RelatedAndNonrelatedPartyStatusDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedAndNonrelatedPartyStatusDomain", "presentation": [ "http://www.masimo.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related and Nonrelated Party Status [Domain]", "label": "Related and Nonrelated Party Status [Domain]", "documentation": "Related and nonrelated party status." } } }, "auth_ref": [ "r302", "r303", "r706", "r707", "r708", "r709", "r810", "r811", "r812", "r813", "r814", "r834", "r836", "r940" ] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyDomain", "presentation": [ "http://www.masimo.com/role/OtherCurrentLiabilitiesDetails", "http://www.masimo.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party [Domain]", "label": "Related Party, Type [Domain]", "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r550", "r706", "r707", "r810", "r811", "r812", "r813", "r814", "r834", "r836", "r869" ] }, "us-gaap_RelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyMember", "presentation": [ "http://www.masimo.com/role/OtherCurrentLiabilitiesDetails", "http://www.masimo.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party", "label": "Related Party [Member]", "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family." } } }, "auth_ref": [ "r302", "r303", "r706", "r707", "r708", "r709", "r810", "r811", "r812", "r813", "r814", "r834", "r836", "r869" ] }, "us-gaap_RelatedPartyTransactionAmountsOfTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionAmountsOfTransaction", "crdr": "debit", "presentation": [ "http://www.masimo.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related party transaction, amounts of transaction (less than)", "label": "Related Party Transaction, Amounts of Transaction", "documentation": "Amount of transactions with related party during the financial reporting period." } } }, "auth_ref": [ "r138", "r706" ] }, "us-gaap_RelatedPartyTransactionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionAxis", "presentation": [ "http://www.masimo.com/role/IntangibleAssetsnetScheduleofFiniteLivedIntangibleAssetsDetails", "http://www.masimo.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party Transaction [Axis]", "label": "Related Party Transaction [Axis]", "documentation": "Information by type of related party transaction." } } }, "auth_ref": [ "r706", "r707", "r1137" ] }, "us-gaap_RelatedPartyTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionDomain", "presentation": [ "http://www.masimo.com/role/IntangibleAssetsnetScheduleofFiniteLivedIntangibleAssetsDetails", "http://www.masimo.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party Transaction [Domain]", "label": "Related Party Transaction [Domain]", "documentation": "Transaction between related party." } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionLineItems", "presentation": [ "http://www.masimo.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party Transaction [Line Items]", "label": "Related Party Transaction [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r841", "r842", "r845" ] }, "us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionPurchasesFromRelatedParty", "crdr": "debit", "presentation": [ "http://www.masimo.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related party transaction, purchases from related party", "label": "Related Party Transaction, Purchases from Related Party", "documentation": "Purchases during the period (excluding transactions that are eliminated in consolidated or combined financial statements) with related party." } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Related Party Transactions [Abstract]", "label": "Related Party Transactions [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [ "http://www.masimo.com/role/OtherCurrentLiabilitiesDetails", "http://www.masimo.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party [Axis]", "label": "Related Party, Type [Axis]", "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r550", "r706", "r707", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r810", "r811", "r812", "r813", "r814", "r834", "r836", "r869", "r1137" ] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": [ "http://www.masimo.com/role/RelatedPartyTransactions" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party Transactions", "label": "Related Party Transactions Disclosure [Text Block]", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r703", "r704", "r705", "r707", "r710", "r783", "r784", "r785", "r843", "r844", "r845", "r866", "r868" ] }, "us-gaap_RepaymentsOfLinesOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfLinesOfCredit", "crdr": "credit", "calculation": { "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Repayments on line of credit", "label": "Repayments of Lines of Credit", "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements." } } }, "auth_ref": [ "r52", "r1048" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "verboseLabel": "Research and development", "label": "Research and Development Expense", "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use." } } }, "auth_ref": [ "r143", "r609", "r1146" ] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date:", "label": "Restatement Determination Date [Axis]" } } }, "auth_ref": [ "r956", "r967", "r977", "r1002" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date", "label": "Restatement Determination Date" } } }, "auth_ref": [ "r957", "r968", "r978", "r1003" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement does not require Recovery", "label": "Restatement Does Not Require Recovery [Text Block]" } } }, "auth_ref": [ "r964", "r975", "r985", "r1010" ] }, "us-gaap_RestrictedCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedCash", "crdr": "debit", "calculation": { "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesScheduleofSupplementalCashFlowInformationDetail": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesScheduleofSupplementalCashFlowInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted cash", "label": "Restricted Cash", "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": [ "r1033", "r1046", "r1147", "r1149" ] }, "us-gaap_RestrictedCashCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedCashCurrent", "crdr": "debit", "calculation": { "http://www.masimo.com/role/OtherCurrentAssetsDetails": { "parentTag": "us-gaap_OtherAssetsCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.masimo.com/role/OtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted cash", "label": "Restricted Cash, Current", "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": [ "r1033", "r1046" ] }, "us-gaap_RestrictedCashNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedCashNoncurrent", "crdr": "debit", "calculation": { "http://www.masimo.com/role/OtherNonCurrentAssetsDetails": { "parentTag": "us-gaap_OtherAssetsNoncurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.masimo.com/role/OtherNonCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted cash", "label": "Restricted Cash, Noncurrent", "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": [ "r220", "r1035", "r1046" ] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockUnitsRSUMember", "presentation": [ "http://www.masimo.com/role/CommitmentsandContingenciesDetail", "http://www.masimo.com/role/StockBasedCompensationNarrativeDetail", "http://www.masimo.com/role/StockBasedCompensationScheduleofStockUnitsActivityDetail", "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetail", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted Stock Units (RSUs)", "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Retained earnings", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r153", "r191", "r746", "r772", "r773", "r781", "r818", "r935" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Retained Earnings", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r239", "r306", "r307", "r308", "r310", "r316", "r318", "r378", "r379", "r605", "r606", "r607", "r626", "r627", "r643", "r645", "r646", "r648", "r651", "r769", "r771", "r787", "r1156" ] }, "us-gaap_RetirementPlanSponsorLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetirementPlanSponsorLocationAxis", "presentation": [ "http://www.masimo.com/role/EmployeeBenefitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Retirement Plan Sponsor Location [Axis]", "label": "Retirement Plan Sponsor Location [Axis]", "documentation": "Information by location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans." } } }, "auth_ref": [ "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r1093", "r1094", "r1095" ] }, "us-gaap_RetirementPlanSponsorLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetirementPlanSponsorLocationDomain", "presentation": [ "http://www.masimo.com/role/EmployeeBenefitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Retirement Plan Sponsor Location [Domain]", "label": "Retirement Plan Sponsor Location [Domain]", "documentation": "Location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans." } } }, "auth_ref": [ "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r1093", "r1094", "r1095" ] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_GrossProfit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.masimo.com/role/SegmentandEnterpriseReportingScheduleofSegmentReportingInformationbySegmentDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue", "verboseLabel": "Total revenue by segment", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r342", "r343", "r354", "r359", "r360", "r366", "r368", "r369", "r499", "r500", "r721" ] }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerTextBlock", "presentation": [ "http://www.masimo.com/role/DeferredRevenueandOtherContractLiabilitiesCurrent" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred Revenue and Other Contract Liabilities, Current", "label": "Revenue from Contract with Customer [Text Block]", "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts." } } }, "auth_ref": [ "r237", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r503" ] }, "masi_RevenuePerformanceObligationPaymentTerms": { "xbrltype": "durationItemType", "nsuri": "http://www.masimo.com/20240330", "localname": "RevenuePerformanceObligationPaymentTerms", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Payment terms", "label": "Revenue, Performance Obligation, Payment Terms", "documentation": "Revenue, Performance Obligation, Payment Terms" } } }, "auth_ref": [] }, "us-gaap_RevenueRecognitionAndDeferredRevenueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRecognitionAndDeferredRevenueAbstract", "lang": { "en-us": { "role": { "terseLabel": "Revenue Recognition and Deferred Revenue [Abstract]", "label": "Revenue Recognition and Deferred Revenue [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRecognitionMultipleDeliverableArrangementsLineItems", "presentation": [ "http://www.masimo.com/role/DeferredRevenueandOtherContractLiabilitiesCurrentNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue Recognition, Multiple-deliverable Arrangements [Line Items]", "label": "Revenue Recognition, Multiple-deliverable Arrangements [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRecognitionPolicyTextBlock", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue Recognition, Deferred Revenue and Other Contract Liabilities", "label": "Revenue [Policy Text Block]", "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources." } } }, "auth_ref": [ "r839", "r897", "r911" ] }, "us-gaap_RevenueRemainingPerformanceObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRemainingPerformanceObligation", "crdr": "credit", "presentation": [ "http://www.masimo.com/role/DeferredRevenueandOtherContractLiabilitiesCurrentNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized contract revenue", "label": "Revenue, Remaining Performance Obligation, Amount", "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue." } } }, "auth_ref": [ "r229" ] }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1", "presentation": [ "http://www.masimo.com/role/DeferredRevenueandOtherContractLiabilitiesCurrentNarrativeDetails", "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue remaining performance obligation, expected timing of satisfaction", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period", "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r230" ] }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis", "presentation": [ "http://www.masimo.com/role/DeferredRevenueandOtherContractLiabilitiesCurrentNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]", "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in YYYY-MM-DD format." } } }, "auth_ref": [ "r230" ] }, "masi_RevolverMember": { "xbrltype": "domainItemType", "nsuri": "http://www.masimo.com/20240330", "localname": "RevolverMember", "presentation": [ "http://www.masimo.com/role/DebtScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revolver", "label": "Revolver [Member]", "documentation": "Revolver" } } }, "auth_ref": [] }, "us-gaap_RevolvingCreditFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevolvingCreditFacilityMember", "presentation": [ "http://www.masimo.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revolving Credit Facility", "label": "Revolving Credit Facility [Member]", "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount." } } }, "auth_ref": [] }, "masi_RightOfUseAssetNetCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.masimo.com/20240330", "localname": "RightOfUseAssetNetCarryingValue", "crdr": "debit", "presentation": [ "http://www.masimo.com/role/LesseeROUAssetsandLeaseLiabilitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "ROU asset had a net carrying value", "label": "Right-of-Use Asset, Net Carrying Value", "documentation": "Right-of-Use Asset, Net Carrying Value" } } }, "auth_ref": [] }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesScheduleofSupplementalCashFlowInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "ROU assets obtained in exchange for lease liabilities", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability." } } }, "auth_ref": [ "r689", "r934" ] }, "masi_RightsToPurchaseSeriesAJuniorParticipatingPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.masimo.com/20240330", "localname": "RightsToPurchaseSeriesAJuniorParticipatingPreferredStockMember", "presentation": [ "http://www.masimo.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Rights to Purchase Series A Junior Participating Preferred Stock", "label": "Rights to Purchase Series A Junior Participating Preferred Stock [Member]", "documentation": "Rights to Purchase Series A Junior Participating Preferred Stock" } } }, "auth_ref": [] }, "masi_RoyaltyGuaranteesCommitmentsAdditionalChangeinControl": { "xbrltype": "monetaryItemType", "nsuri": "http://www.masimo.com/20240330", "localname": "RoyaltyGuaranteesCommitmentsAdditionalChangeinControl", "crdr": "credit", "presentation": [ "http://www.masimo.com/role/CommitmentsandContingenciesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Royalty guarantees, commitments, additional, change in control", "label": "Royalty Guarantees, Commitments, Additional, Change in Control", "documentation": "Royalty Guarantees, Commitments, Additional, Change in Control" } } }, "auth_ref": [] }, "us-gaap_RoyaltyGuaranteesCommitmentsAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RoyaltyGuaranteesCommitmentsAmount", "crdr": "credit", "presentation": [ "http://www.masimo.com/role/CommitmentsandContingenciesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Royalty obligation", "label": "Royalty Guarantees, Commitments, Amount", "documentation": "The amount the entity has committed to make for future royalty guarantees." } } }, "auth_ref": [ "r724" ] }, "masi_RoyaltyGuaranteesCommitmentsChangeinControl": { "xbrltype": "monetaryItemType", "nsuri": "http://www.masimo.com/20240330", "localname": "RoyaltyGuaranteesCommitmentsChangeinControl", "crdr": "credit", "presentation": [ "http://www.masimo.com/role/CommitmentsandContingenciesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Change in control", "label": "Royalty Guarantees, Commitments, Change in Control", "documentation": "Royalty Guarantees, Commitments, Change in Control" } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Adopted", "label": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r1019" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Terminated", "label": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r1019" ] }, "masi_SaleTypeLeaseReceivableTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.masimo.com/20240330", "localname": "SaleTypeLeaseReceivableTableTextBlock", "presentation": [ "http://www.masimo.com/role/LeaseReceivableTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Sale-Type Lease Receivable", "label": "Sale-Type Lease Receivable [Table Text Block]", "documentation": "Sale-Type Lease Receivable [Table Text Block]" } } }, "auth_ref": [] }, "us-gaap_SalesRevenueNetMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SalesRevenueNetMember", "presentation": [ "http://www.masimo.com/role/CommitmentsandContingenciesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue Benchmark", "label": "Revenue Benchmark [Member]", "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation." } } }, "auth_ref": [ "r369", "r1029" ] }, "masi_SalesTypeAndDirectFinancingLeasesLeaseReceivableDiscountRate": { "xbrltype": "percentItemType", "nsuri": "http://www.masimo.com/20240330", "localname": "SalesTypeAndDirectFinancingLeasesLeaseReceivableDiscountRate", "presentation": [ "http://www.masimo.com/role/LeaseReceivableScheduleofSalestypeLeaseLeaseReceivableMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Discount rate used to measure the net investment in lease", "label": "Sales-type and Direct Financing Leases, Lease Receivable, Discount Rate", "documentation": "Sales-type and Direct Financing Leases, Lease Receivable, Discount Rate" } } }, "auth_ref": [] }, "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivableMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SalesTypeAndDirectFinancingLeasesLeaseReceivableMaturityTableTextBlock", "presentation": [ "http://www.masimo.com/role/LeaseReceivableTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Sales-type Lease, Lease Receivable, Maturity", "label": "Sales-Type and Direct Financing Leases, Payment to be Received, Maturity [Table Text Block]", "documentation": "Tabular disclosure of maturity of undiscounted cash flows to be received on annual basis for sales-type and direct financing leases receivable. Includes, but is not limited to, reconciliation to lease receivable recognized in statement of financial position." } } }, "auth_ref": [ "r698" ] }, "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived", "crdr": "debit", "calculation": { "http://www.masimo.com/role/LeaseReceivableScheduleofSaleTypeLeaseReceivableDetails_1": { "parentTag": "us-gaap_SalesTypeLeaseLeaseReceivable", "weight": 1.0, "order": 1.0 }, "http://www.masimo.com/role/LeaseReceivableScheduleofSalestypeLeaseLeaseReceivableMaturityDetails": { "parentTag": "us-gaap_SalesTypeLeaseNetInvestmentInLease", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.masimo.com/role/LeaseReceivableScheduleofSaleTypeLeaseReceivableDetails", "http://www.masimo.com/role/LeaseReceivableScheduleofSalestypeLeaseLeaseReceivableMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease receivable", "totalLabel": "Total", "label": "Sales-Type and Direct Financing Leases, Payment to be Received", "documentation": "Amount of undiscounted cash flows to be received by lessor for sales-type and direct financing leases." } } }, "auth_ref": [ "r698" ] }, "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFourYears": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFourYears", "crdr": "debit", "calculation": { "http://www.masimo.com/role/LeaseReceivableScheduleofSalestypeLeaseLeaseReceivableMaturityDetails": { "parentTag": "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.masimo.com/role/LeaseReceivableScheduleofSalestypeLeaseLeaseReceivableMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Sales-Type and Direct Financing Leases, Payment to be Received, Year Four", "documentation": "Amount of undiscounted cash flows to be received by lessor for sales-type and direct financing leases in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r698" ] }, "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedNextTwelveMonths", "crdr": "debit", "calculation": { "http://www.masimo.com/role/LeaseReceivableScheduleofSalestypeLeaseLeaseReceivableMaturityDetails": { "parentTag": "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.masimo.com/role/LeaseReceivableScheduleofSalestypeLeaseLeaseReceivableMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Sales-Type and Direct Financing Leases, Payment to be Received, Year One", "documentation": "Amount of undiscounted cash flows to be received by lessor for sales-type and direct financing leases in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r698" ] }, "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedRemainderOfFiscalYear", "crdr": "debit", "calculation": { "http://www.masimo.com/role/LeaseReceivableScheduleofSalestypeLeaseLeaseReceivableMaturityDetails": { "parentTag": "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.masimo.com/role/LeaseReceivableScheduleofSalestypeLeaseLeaseReceivableMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2024 (balance of year)", "label": "Sales-Type and Direct Financing Leases, Payment to be Received, Remainder of Fiscal Year", "documentation": "Amount of undiscounted cash flows to be received by lessor for sales-type and direct financing leases in remainder of current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r1133" ] }, "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThreeYears": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThreeYears", "crdr": "debit", "calculation": { "http://www.masimo.com/role/LeaseReceivableScheduleofSalestypeLeaseLeaseReceivableMaturityDetails": { "parentTag": "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.masimo.com/role/LeaseReceivableScheduleofSalestypeLeaseLeaseReceivableMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Sales-Type and Direct Financing Leases, Payment to be Received, Year Three", "documentation": "Amount of undiscounted cash flows to be received by lessor for sales-type and direct financing leases in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r698" ] }, "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedTwoYears": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedTwoYears", "crdr": "debit", "calculation": { "http://www.masimo.com/role/LeaseReceivableScheduleofSalestypeLeaseLeaseReceivableMaturityDetails": { "parentTag": "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.masimo.com/role/LeaseReceivableScheduleofSalestypeLeaseLeaseReceivableMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Sales-Type and Direct Financing Leases, Payment to be Received, Year Two", "documentation": "Amount of undiscounted cash flows to be received by lessor for sales-type and direct financing leases in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r698" ] }, "masi_SalesTypeAndDirectFinancingLeasesLeaseReceivableToBeReceivedAfterYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://www.masimo.com/20240330", "localname": "SalesTypeAndDirectFinancingLeasesLeaseReceivableToBeReceivedAfterYearFour", "crdr": "debit", "calculation": { "http://www.masimo.com/role/LeaseReceivableScheduleofSalestypeLeaseLeaseReceivableMaturityDetails": { "parentTag": "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.masimo.com/role/LeaseReceivableScheduleofSalestypeLeaseLeaseReceivableMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Sales-Type and Direct Financing Leases, Lease Receivable, to be Received, after Year Four", "documentation": "Sales-Type and Direct Financing Leases, Lease Receivable, to be Received, after Year Four" } } }, "auth_ref": [] }, "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivableUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SalesTypeAndDirectFinancingLeasesLeaseReceivableUndiscountedExcessAmount", "crdr": "debit", "calculation": { "http://www.masimo.com/role/LeaseReceivableScheduleofSalestypeLeaseLeaseReceivableMaturityDetails": { "parentTag": "us-gaap_SalesTypeLeaseNetInvestmentInLease", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.masimo.com/role/LeaseReceivableScheduleofSalestypeLeaseLeaseReceivableMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Less: imputed interest", "label": "Sales-type and Direct Financing Leases, Lease Receivable, Undiscounted Excess Amount", "documentation": "Amount of undiscounted lease receivable in excess of discounted receivable for sales-type and direct financing leases." } } }, "auth_ref": [ "r698" ] }, "masi_SalesTypeLeaseAllowanceForCreditLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://www.masimo.com/20240330", "localname": "SalesTypeLeaseAllowanceForCreditLoss", "crdr": "credit", "calculation": { "http://www.masimo.com/role/LeaseReceivableScheduleofSaleTypeLeaseReceivableDetails_1": { "parentTag": "us-gaap_SalesTypeLeaseLeaseReceivable", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.masimo.com/role/LeaseReceivableScheduleofSaleTypeLeaseReceivableDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Allowance for credit loss", "label": "Sales-Type Lease, Allowance For Credit Loss", "documentation": "Sales-Type Lease, Allowance For Credit Loss" } } }, "auth_ref": [] }, "us-gaap_SalesTypeLeaseLeaseIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SalesTypeLeaseLeaseIncomeAbstract", "presentation": [ "http://www.masimo.com/role/LeaseReceivableScheduleofSalestypeLeaseLeaseReceivableMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sales-Type Leases", "label": "Sales-type Lease, Lease Income [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SalesTypeLeaseLeaseReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SalesTypeLeaseLeaseReceivable", "crdr": "debit", "calculation": { "http://www.masimo.com/role/LeaseReceivableScheduleofSaleTypeLeaseReceivableDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.masimo.com/role/LeaseReceivableScheduleofSaleTypeLeaseReceivableDetails_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.masimo.com/role/LeaseReceivableScheduleofSaleTypeLeaseReceivableDetails", "http://www.masimo.com/role/LeaseReceivableScheduleofSalestypeLeaseLeaseReceivableMaturityDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Lease receivable, net", "terseLabel": "Lease receivable, net", "label": "Sales-type Lease, Lease Receivable", "documentation": "Present value of lease payments not yet received by lessor and amount expected to be derived from underlying asset, following end of lease term guaranteed by lessee or other third party unrelated to lessor, from sales-type lease." } } }, "auth_ref": [ "r701" ] }, "us-gaap_SalesTypeLeaseNetInvestmentInLease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SalesTypeLeaseNetInvestmentInLease", "crdr": "debit", "calculation": { "http://www.masimo.com/role/LeaseReceivableScheduleofSalestypeLeaseLeaseReceivableMaturityDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.masimo.com/role/LeaseReceivableScheduleofSalestypeLeaseLeaseReceivableMaturityDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Lease receivable, net", "label": "Sales-Type Lease, Net Investment in Lease, before Allowance for Credit Loss", "documentation": "Amount, before allowance for credit loss, of net investment in sales-type lease." } } }, "auth_ref": [ "r234", "r382", "r701", "r1063" ] }, "srt_ScenarioForecastMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScenarioForecastMember", "presentation": [ "http://www.masimo.com/role/DerivativeInstrumentsandHedgingActivitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Forecast", "label": "Forecast [Member]" } } }, "auth_ref": [ "r567", "r1056" ] }, "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScenarioUnspecifiedDomain", "presentation": [ "http://www.masimo.com/role/DerivativeInstrumentsandHedgingActivitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Scenario [Domain]", "label": "Scenario [Domain]" } } }, "auth_ref": [ "r319", "r567", "r1027", "r1056" ] }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "presentation": [ "http://www.masimo.com/role/OtherCurrentLiabilitiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Other Current Liabilities", "label": "Schedule of Accrued Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the components of accrued liabilities." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "presentation": [ "http://www.masimo.com/role/DerivativeInstrumentsandHedgingActivitiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Accumulated Other Comprehensive Income (Loss)", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r48", "r1129", "r1130" ] }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "presentation": [ "http://www.masimo.com/role/BusinessCombinationsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.masimo.com/role/BusinessCombinationsNarrativeDetails", "http://www.masimo.com/role/BusinessCombinationsScheduleofAcquiredIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities." } } }, "auth_ref": [ "r104", "r106", "r633" ] }, "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Supplemental Cash Flow Information", "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]", "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDebtTableTextBlock", "presentation": [ "http://www.masimo.com/role/DebtTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Debt", "label": "Schedule of Debt [Table Text Block]", "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "presentation": [ "http://www.masimo.com/role/DerivativeInstrumentsandHedgingActivitiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value", "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]", "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position." } } }, "auth_ref": [ "r123" ] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Reconciliation of Basic and Diluted Net Income Per Share", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": [ "r1058" ] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "presentation": [ "http://www.masimo.com/role/IntangibleAssetsnetNarrativeDetails", "http://www.masimo.com/role/IntangibleAssetsnetScheduleofFiniteLivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]", "label": "Schedule of Finite-Lived Intangible Assets [Table]", "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r75", "r78", "r722" ] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "presentation": [ "http://www.masimo.com/role/IntangibleAssetsnetTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Finite-Lived Intangible Assets", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment." } } }, "auth_ref": [ "r75", "r78" ] }, "us-gaap_ScheduleOfGoodwillTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfGoodwillTable", "presentation": [ "http://www.masimo.com/role/GoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Goodwill [Table]", "label": "Schedule of Goodwill [Table]", "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons." } } }, "auth_ref": [ "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r401", "r918" ] }, "us-gaap_ScheduleOfGoodwillTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfGoodwillTextBlock", "presentation": [ "http://www.masimo.com/role/GoodwillTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Goodwill", "label": "Schedule of Goodwill [Table Text Block]", "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule." } } }, "auth_ref": [ "r918", "r1065", "r1066", "r1067", "r1068", "r1069", "r1070", "r1071", "r1072", "r1073", "r1074", "r1075" ] }, "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTable", "presentation": [ "http://www.masimo.com/role/IntangibleAssetsnetScheduleofFiniteLivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Indefinite-Lived Intangible Assets [Table]", "label": "Schedule of Indefinite-Lived Intangible Assets [Table]", "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity." } } }, "auth_ref": [ "r28", "r181" ] }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": [ "http://www.masimo.com/role/InventoriesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Components of Inventory", "label": "Schedule of Inventory, Current [Table Text Block]", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": [ "r33", "r157", "r158", "r159" ] }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "presentation": [ "http://www.masimo.com/role/DebtTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Maturities of Long-term Debt", "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]", "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt." } } }, "auth_ref": [ "r13" ] }, "us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock", "presentation": [ "http://www.masimo.com/role/StockBasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Nonvested Performance-based Units Activity", "label": "Schedule of Nonvested Performance-Based Units Activity [Table Text Block]", "documentation": "Tabular disclosure of the changes in outstanding nonvested performance-based units." } } }, "auth_ref": [ "r99" ] }, "us-gaap_ScheduleOfOtherAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfOtherAssetsTableTextBlock", "presentation": [ "http://www.masimo.com/role/OtherCurrentAssetsTables", "http://www.masimo.com/role/OtherNonCurrentAssetsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Other Non-Current Assets", "verboseLabel": "Schedule of Other Non-Current Assets", "label": "Schedule of Other Assets [Table Text Block]", "documentation": "Tabular disclosure of the carrying amounts of other assets. This disclosure includes other current assets and other noncurrent assets." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "presentation": [ "http://www.masimo.com/role/NonoperatingLossTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Non-operating Loss", "label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]", "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfProductInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfProductInformationTable", "presentation": [ "http://www.masimo.com/role/OtherNonCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Assets Long Term [Table]", "label": "Schedule of Product Information [Table]", "documentation": "Schedule detailing quantitative information concerning products or product lines by product or product line." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfProductWarrantyLiabilityTableTextBlock", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Changes in Product Warranty Accrual", "label": "Schedule of Product Warranty Liability [Table Text Block]", "documentation": "Tabular disclosure of the changes in the guarantor's aggregate product warranty liability, including the beginning balance of the aggregate product warranty liability, the aggregate reductions in that liability for payments made (in cash or in kind) under the warranty, the aggregate changes in the liability for accruals related to product warranties issued during the reporting period, the aggregate changes in the liability for accruals related to preexisting warranties (including adjustments related to changes in estimates), and the ending balance of the aggregate product warranty liability." } } }, "auth_ref": [ "r423" ] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": [ "http://www.masimo.com/role/PropertyandEquipmentnetNarrativeDetail", "http://www.masimo.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentDetails", "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Table]", "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r12" ] }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "presentation": [ "http://www.masimo.com/role/BusinessCombinationsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed", "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]", "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree." } } }, "auth_ref": [ "r199" ] }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "presentation": [ "http://www.masimo.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]", "label": "Schedule of Related Party Transactions, by Related Party [Table]", "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r137", "r138", "r841", "r842", "r845" ] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "presentation": [ "http://www.masimo.com/role/SegmentandEnterpriseReportingScheduleofSegmentReportingInformationbySegmentDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss." } } }, "auth_ref": [ "r68", "r69", "r70", "r72" ] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "presentation": [ "http://www.masimo.com/role/SegmentandEnterpriseReportingTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Segment Reporting Information, by Segment", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss." } } }, "auth_ref": [ "r68", "r69", "r70", "r72" ] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://www.masimo.com/role/StockBasedCompensationNarrativeDetail", "http://www.masimo.com/role/StockBasedCompensationScheduleofStockUnitsActivityDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r569", "r571", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599" ] }, "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "presentation": [ "http://www.masimo.com/role/StockBasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Share-based Compensation, Restricted Stock Units Award Activity", "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]", "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year." } } }, "auth_ref": [ "r98" ] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [ "http://www.masimo.com/role/StockBasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Number and Weighted Average Exercise Price of Options Issued and Outstanding under all Stock Option Plans", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": [ "r24", "r26", "r98" ] }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": [ "http://www.masimo.com/role/StockBasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Range of Assumptions Used and Resulting Weighted-Average Fair Value of Options Granted at Date of Grant", "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": [ "r197" ] }, "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfStockByClassTable", "presentation": [ "http://www.masimo.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Stock by Class [Table]", "label": "Schedule of Stock by Class [Table]", "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity." } } }, "auth_ref": [ "r86", "r87", "r88", "r89", "r90", "r91", "r92", "r189", "r190", "r191", "r258", "r259", "r260", "r335", "r472", "r473", "r474", "r476", "r479", "r484", "r486", "r777", "r778", "r779", "r780", "r924", "r1026", "r1047" ] }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "presentation": [ "http://www.masimo.com/role/IntangibleAssetsnetTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense", "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]", "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets." } } }, "auth_ref": [ "r78" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.masimo.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r950" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.masimo.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r952" ] }, "us-gaap_SegmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentDomain", "presentation": [ "http://www.masimo.com/role/GoodwillDetails", "http://www.masimo.com/role/SegmentandEnterpriseReportingScheduleofSegmentReportingInformationbySegmentDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Segments [Domain]", "label": "Segments [Domain]", "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r338", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r364", "r369", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r413", "r414", "r757", "r758", "r759", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r918", "r1031", "r1150" ] }, "us-gaap_SegmentReportingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingAbstract", "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting [Abstract]", "label": "Segment Reporting [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SegmentReportingDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingDisclosureTextBlock", "presentation": [ "http://www.masimo.com/role/SegmentandEnterpriseReporting" ], "lang": { "en-us": { "role": { "terseLabel": "Segment and Enterprise Reporting", "label": "Segment Reporting Disclosure [Text Block]", "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments." } } }, "auth_ref": [ "r337", "r338", "r339", "r340", "r341", "r353", "r358", "r362", "r363", "r364", "r365", "r366", "r367", "r369" ] }, "us-gaap_SegmentReportingInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingInformationLineItems", "presentation": [ "http://www.masimo.com/role/SegmentandEnterpriseReportingScheduleofSegmentReportingInformationbySegmentDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting Information [Line Items]", "label": "Segment Reporting Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Selling, general and administrative", "label": "Selling, General and Administrative Expense", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": [ "r167" ] }, "masi_SeverancePlanParticipationAgreements": { "xbrltype": "integerItemType", "nsuri": "http://www.masimo.com/20240330", "localname": "SeverancePlanParticipationAgreements", "presentation": [ "http://www.masimo.com/role/CommitmentsandContingenciesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Severance plan participation agreements", "label": "Severance Plan Participation Agreements", "documentation": "Severance plan participation agreements." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 16.0 } }, "presentation": [ "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation expense", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r10" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": [ "http://www.masimo.com/role/StockBasedCompensationScheduleofStockUnitsActivityDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Award vesting period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": [ "r933" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights", "presentation": [ "http://www.masimo.com/role/StockBasedCompensationNarrativeDetail" ], "lang": { "en-us": { "role": { "verboseLabel": "Award vesting period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights", "documentation": "Description of service or performance condition required to be met for earning right to award under share-based payment arrangement. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": [ "r97" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": [ "http://www.masimo.com/role/StockBasedCompensationNarrativeDetail", "http://www.masimo.com/role/StockBasedCompensationScheduleofStockUnitsActivityDetail", "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation arrangement, grants in period (in shares)", "verboseLabel": "Granted (in units)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r588" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.masimo.com/role/StockBasedCompensationScheduleofStockUnitsActivityDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Granted (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r588" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": [ "http://www.masimo.com/role/StockBasedCompensationScheduleofStockUnitsActivityDetail" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning of period (in shares)", "periodEndLabel": "End of period (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": [ "r585", "r586" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": [ "http://www.masimo.com/role/StockBasedCompensationScheduleofStockUnitsActivityDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Beginning of period (in dollars per share)", "periodEndLabel": "End of period, fair value (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r585", "r586" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "presentation": [ "http://www.masimo.com/role/StockBasedCompensationScheduleofStockUnitsActivityDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-Average Grant Date Fair Value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms", "presentation": [ "http://www.masimo.com/role/StockBasedCompensationNarrativeDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation arrangement outstanding, weighted average remaining contractual terms (in years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms", "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r196" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": [ "http://www.masimo.com/role/StockBasedCompensationScheduleofStockUnitsActivityDetail" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Vested (in units)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": [ "r589" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.masimo.com/role/StockBasedCompensationScheduleofStockUnitsActivityDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Vested (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } }, "auth_ref": [ "r589" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract", "presentation": [ "http://www.masimo.com/role/StockBasedCompensationScheduleofRangeofAssumptionsUsedandResultingWeightedAverageFairValueofOptionsGrantedatDateofGrantDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Range of assumptions used and resulting weighted-average fair value of options granted at the date of grant", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": [ "http://www.masimo.com/role/StockBasedCompensationScheduleofRangeofAssumptionsUsedandResultingWeightedAverageFairValueofOptionsGrantedatDateofGrantDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Expected dividends", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": [ "r597" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": [ "http://www.masimo.com/role/StockBasedCompensationScheduleofRangeofAssumptionsUsedandResultingWeightedAverageFairValueofOptionsGrantedatDateofGrantDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated volatility", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [ "r596" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": [ "http://www.masimo.com/role/StockBasedCompensationScheduleofRangeofAssumptionsUsedandResultingWeightedAverageFairValueofOptionsGrantedatDateofGrantDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Risk-free interest rate", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [ "r598" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://www.masimo.com/role/StockBasedCompensationNarrativeDetail", "http://www.masimo.com/role/StockBasedCompensationScheduleofStockUnitsActivityDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r569", "r571", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward", "presentation": [ "http://www.masimo.com/role/StockBasedCompensationScheduleofStockUnitsActivityDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Units", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "presentation": [ "http://www.masimo.com/role/StockBasedCompensationNarrativeDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation, number of additional shares authorized (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized", "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": [ "http://www.masimo.com/role/StockBasedCompensationNarrativeDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Options available for grant, end of period (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": [ "r96" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": [ "http://www.masimo.com/role/StockBasedCompensationScheduleofNumberandWeightedAverageExercisePriceofOptionsIssuedandOutstandingunderallStockOptionPlansDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Options exercisable, end of period (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": [ "r579" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": [ "http://www.masimo.com/role/StockBasedCompensationScheduleofNumberandWeightedAverageExercisePriceofOptionsIssuedandOutstandingunderallStockOptionPlansDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Options exercisable, end of period (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": [ "r579" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": [ "http://www.masimo.com/role/StockBasedCompensationScheduleofNumberandWeightedAverageExercisePriceofOptionsIssuedandOutstandingunderallStockOptionPlansDetail" ], "lang": { "en-us": { "role": { "negatedLabel": "Canceled (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": [ "r583" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "presentation": [ "http://www.masimo.com/role/StockBasedCompensationScheduleofNumberandWeightedAverageExercisePriceofOptionsIssuedandOutstandingunderallStockOptionPlansDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures", "documentation": "Net number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r1103" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.masimo.com/role/StockBasedCompensationScheduleofRangeofAssumptionsUsedandResultingWeightedAverageFairValueofOptionsGrantedatDateofGrantDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average fair value of options granted (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": [ "r591" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.masimo.com/role/StockBasedCompensationNarrativeDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate intrinsic value of options outstanding", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": [ "r96" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://www.masimo.com/role/StockBasedCompensationScheduleofNumberandWeightedAverageExercisePriceofOptionsIssuedandOutstandingunderallStockOptionPlansDetail" ], "lang": { "en-us": { "role": { "periodStartLabel": "Options outstanding, beginning of period (in shares)", "periodEndLabel": "Options outstanding, end of period (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r577", "r578" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "presentation": [ "http://www.masimo.com/role/StockBasedCompensationScheduleofNumberandWeightedAverageExercisePriceofOptionsIssuedandOutstandingunderallStockOptionPlansDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Shares", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://www.masimo.com/role/StockBasedCompensationScheduleofNumberandWeightedAverageExercisePriceofOptionsIssuedandOutstandingunderallStockOptionPlansDetail" ], "lang": { "en-us": { "role": { "periodStartLabel": "Options outstanding, beginning of period (in usd per share)", "periodEndLabel": "Options outstanding, end of period (in usd per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r577", "r578" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "presentation": [ "http://www.masimo.com/role/StockBasedCompensationScheduleofNumberandWeightedAverageExercisePriceofOptionsIssuedandOutstandingunderallStockOptionPlansDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-Average Exercise\u00a0Price", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.masimo.com/role/StockBasedCompensationNarrativeDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate intrinsic value of options exercisable", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value", "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r594" ] }, "masi_ShareBasedCompensationArrangementByShareBasedPaymentAwardRangeOfPercentagePayout": { "xbrltype": "percentItemType", "nsuri": "http://www.masimo.com/20240330", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardRangeOfPercentagePayout", "presentation": [ "http://www.masimo.com/role/StockBasedCompensationNarrativeDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation arrangement by share-based payment award, range of percentage payout", "label": "Share-based compensation arrangement by share-based payment award, range of percentage payout", "documentation": "Share-based compensation arrangement by share-based payment award, range of percentage payout" } } }, "auth_ref": [] }, "masi_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedPayoutPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.masimo.com/20240330", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedPayoutPercentage", "presentation": [ "http://www.masimo.com/role/StockBasedCompensationScheduleofStockUnitsActivityDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted payout percentage", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Weighted Payout Percentage", "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Weighted Payout Percentage" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://www.masimo.com/role/CommitmentsandContingenciesDetail", "http://www.masimo.com/role/StockBasedCompensationNarrativeDetail", "http://www.masimo.com/role/StockBasedCompensationScheduleofStockUnitsActivityDetail", "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetail", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Domain]", "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.masimo.com/role/StockBasedCompensationScheduleofNumberandWeightedAverageExercisePriceofOptionsIssuedandOutstandingunderallStockOptionPlansDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Exercised (in usd per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": [ "r582" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.masimo.com/role/StockBasedCompensationScheduleofNumberandWeightedAverageExercisePriceofOptionsIssuedandOutstandingunderallStockOptionPlansDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Canceled (in usd per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": [ "r583" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.masimo.com/role/StockBasedCompensationScheduleofNumberandWeightedAverageExercisePriceofOptionsIssuedandOutstandingunderallStockOptionPlansDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Granted (in usd per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [ "r581" ] }, "us-gaap_ShareRepurchaseProgramAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareRepurchaseProgramAxis", "presentation": [ "http://www.masimo.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share Repurchase Program [Axis]", "label": "Share Repurchase Program [Axis]", "documentation": "Information by share repurchase program." } } }, "auth_ref": [] }, "us-gaap_ShareRepurchaseProgramDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareRepurchaseProgramDomain", "presentation": [ "http://www.masimo.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share Repurchase Program [Domain]", "label": "Share Repurchase Program [Domain]", "documentation": "Name of the share repurchase program." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1", "crdr": "debit", "presentation": [ "http://www.masimo.com/role/StockBasedCompensationNarrativeDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Stock compensation (benefit) expense", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount", "documentation": "Amount of cost expensed and capitalized for award under share-based payment arrangement." } } }, "auth_ref": [ "r600" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": [ "http://www.masimo.com/role/StockBasedCompensationScheduleofRangeofAssumptionsUsedandResultingWeightedAverageFairValueofOptionsGrantedatDateofGrantDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Expected term (in years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r595" ] }, "masi_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpiredWeighedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://www.masimo.com/20240330", "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpiredWeighedAverageGrantDateFairValue", "presentation": [ "http://www.masimo.com/role/StockBasedCompensationScheduleofStockUnitsActivityDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Canceled (in dollars per share)", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Expired, Weighed Average Grant Date Fair Value", "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Expired, Weighed Average Grant Date Fair Value" } } }, "auth_ref": [] }, "masi_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpiredinPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://www.masimo.com/20240330", "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpiredinPeriod", "presentation": [ "http://www.masimo.com/role/StockBasedCompensationScheduleofStockUnitsActivityDetail" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Expired (in units)", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Expired in Period", "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Expired in Period" } } }, "auth_ref": [] }, "masi_ShippingAndHandlingCostsAndFeesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.masimo.com/20240330", "localname": "ShippingAndHandlingCostsAndFeesPolicyTextBlock", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Shipping and Handling Costs and Fees", "label": "Shipping And Handling Costs And Fees [Policy Text Block]", "documentation": "Shipping and Handling costs and Fees [Policy Text Block]" } } }, "auth_ref": [] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Significant Accounting Policies", "label": "Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r175", "r296" ] }, "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SoftwareAndSoftwareDevelopmentCostsMember", "presentation": [ "http://www.masimo.com/role/IntangibleAssetsnetScheduleofFiniteLivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Capitalized software development costs", "label": "Software and Software Development Costs [Member]", "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use." } } }, "auth_ref": [] }, "masi_SoundUnitedMember": { "xbrltype": "domainItemType", "nsuri": "http://www.masimo.com/20240330", "localname": "SoundUnitedMember", "presentation": [ "http://www.masimo.com/role/BusinessCombinationsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.masimo.com/role/BusinessCombinationsNarrativeDetails", "http://www.masimo.com/role/BusinessCombinationsScheduleofAcquiredIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sound United", "label": "Sound United [Member]", "documentation": "Sound United" } } }, "auth_ref": [] }, "us-gaap_StandardProductWarrantyPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StandardProductWarrantyPolicy", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Warranty", "label": "Standard Product Warranty, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for standard warranties including the methodology for measuring the liability." } } }, "auth_ref": [ "r1083" ] }, "us-gaap_StatementBusinessSegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementBusinessSegmentsAxis", "presentation": [ "http://www.masimo.com/role/GoodwillDetails", "http://www.masimo.com/role/SegmentandEnterpriseReportingScheduleofSegmentReportingInformationbySegmentDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Segments [Axis]", "label": "Segments [Axis]", "documentation": "Information by business segments." } } }, "auth_ref": [ "r241", "r338", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r364", "r369", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r411", "r413", "r414", "r757", "r758", "r759", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r918", "r1031", "r1150" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://www.masimo.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Axis]", "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": [ "r238", "r258", "r259", "r260", "r299", "r322", "r326", "r328", "r330", "r335", "r336", "r377", "r429", "r432", "r433", "r434", "r440", "r441", "r472", "r473", "r476", "r479", "r486", "r664", "r777", "r778", "r779", "r780", "r787", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r795", "r796", "r797", "r798", "r817", "r838", "r862", "r884", "r885", "r886", "r887", "r888", "r1026", "r1047", "r1057" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY", "http://www.masimo.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofAccumulatedOtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Components [Axis]", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r21", "r46", "r239", "r281", "r282", "r283", "r306", "r307", "r308", "r310", "r316", "r318", "r334", "r378", "r379", "r487", "r605", "r606", "r607", "r626", "r627", "r643", "r644", "r645", "r646", "r647", "r648", "r651", "r671", "r672", "r673", "r674", "r675", "r676", "r702", "r769", "r770", "r771", "r787", "r862" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r306", "r307", "r308", "r334", "r721", "r775", "r798", "r809", "r810", "r811", "r812", "r813", "r814", "r817", "r820", "r821", "r822", "r823", "r824", "r825", "r826", "r827", "r828", "r830", "r831", "r832", "r833", "r834", "r836", "r839", "r840", "r847", "r848", "r849", "r850", "r851", "r852", "r853", "r854", "r855", "r856", "r857", "r858", "r862", "r940" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Cash Flows [Abstract]", "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position [Abstract]", "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Stockholders' Equity [Abstract]", "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StatementScenarioAxis", "presentation": [ "http://www.masimo.com/role/DerivativeInstrumentsandHedgingActivitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Scenario [Axis]", "label": "Scenario [Axis]" } } }, "auth_ref": [ "r319", "r567", "r1027", "r1028", "r1056" ] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r306", "r307", "r308", "r334", "r721", "r775", "r798", "r809", "r810", "r811", "r812", "r813", "r814", "r817", "r820", "r821", "r822", "r823", "r824", "r825", "r826", "r827", "r828", "r830", "r831", "r832", "r833", "r834", "r836", "r839", "r840", "r847", "r848", "r849", "r850", "r851", "r852", "r853", "r854", "r855", "r856", "r857", "r858", "r862", "r940" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Price or TSR Estimation Method", "label": "Stock Price or TSR Estimation Method [Text Block]" } } }, "auth_ref": [ "r959", "r970", "r980", "r1005" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Appreciation Rights (SARs)", "label": "Stock Appreciation Rights (SARs) [Member]", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "presentation": [ "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted/Performance stock units vested (in shares)", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross", "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards." } } }, "auth_ref": [ "r21", "r191" ] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY", "http://www.masimo.com/role/StockBasedCompensationScheduleofNumberandWeightedAverageExercisePriceofOptionsIssuedandOutstandingunderallStockOptionPlansDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Stock options exercised (in shares)", "negatedLabel": "Exercised (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r21", "r150", "r151", "r191", "r582" ] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": [ "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Stock options exercised", "label": "Stock Issued During Period, Value, Stock Options Exercised", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": [ "r21", "r46", "r191" ] }, "us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased", "presentation": [ "http://www.masimo.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of common shares authorized to be repurchased under new stock repurchase program", "label": "Stock Repurchase Program, Number of Shares Authorized to be Repurchased", "documentation": "The number of shares authorized to be repurchased by an entity's Board of Directors under a stock repurchase plan." } } }, "auth_ref": [] }, "us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased", "presentation": [ "http://www.masimo.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock repurchase program, remaining number of shares available for repurchase (in shares)", "label": "Stock Repurchase Program, Remaining Number of Shares Authorized to be Repurchased", "documentation": "The remaining number of shares authorized to be repurchased by an entity's Board of Directors under a stock repurchase plan." } } }, "auth_ref": [] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders\u2019 equity", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r151", "r154", "r155", "r176", "r819", "r835", "r863", "r864", "r935", "r949", "r1049", "r1062", "r1128", "r1156" ] }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "presentation": [ "http://www.masimo.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofAccumulatedOtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Equity, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r114", "r115", "r116", "r239", "r240", "r282", "r306", "r307", "r308", "r310", "r316", "r378", "r379", "r487", "r605", "r606", "r607", "r626", "r627", "r643", "r644", "r645", "r646", "r647", "r648", "r651", "r671", "r672", "r676", "r702", "r770", "r771", "r786", "r819", "r835", "r863", "r864", "r889", "r948", "r1049", "r1062", "r1128", "r1156" ] }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract", "presentation": [ "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders\u2019 equity", "label": "Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://www.masimo.com/role/Equity" ], "lang": { "en-us": { "role": { "terseLabel": "Equity", "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r188", "r298", "r471", "r473", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r485", "r487", "r650", "r865", "r867", "r890" ] }, "us-gaap_SubleaseIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubleaseIncome", "crdr": "credit", "presentation": [ "http://www.masimo.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sublease income", "label": "Sublease Income", "documentation": "Amount of sublease income excluding finance and operating lease expense." } } }, "auth_ref": [ "r687", "r934" ] }, "masi_SummaryOfSignificantAccountingPoliciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.masimo.com/20240330", "localname": "SummaryOfSignificantAccountingPoliciesLineItems", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Summary Of Significant Accounting Policies [Line Items]", "label": "Summary Of Significant Accounting Policies [Line Items]", "documentation": "Summary Of Significant Accounting Policies [Line Items]" } } }, "auth_ref": [] }, "masi_SummaryOfSignificantAccountingPoliciesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.masimo.com/20240330", "localname": "SummaryOfSignificantAccountingPoliciesTable", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Summary Of Significant Accounting Policies [Table]", "label": "Summary Of Significant Accounting Policies [Table]", "documentation": "Summary Of Significant Accounting Policies [Table]" } } }, "auth_ref": [] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesScheduleofSupplementalCashFlowInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Cash paid during the year for:", "label": "Supplemental Cash Flow Information [Abstract]" } } }, "auth_ref": [] }, "masi_SupplementalUnemploymentBenefitsSeveranceBenefitsRequiredNoticeofResignation": { "xbrltype": "durationItemType", "nsuri": "http://www.masimo.com/20240330", "localname": "SupplementalUnemploymentBenefitsSeveranceBenefitsRequiredNoticeofResignation", "presentation": [ "http://www.masimo.com/role/CommitmentsandContingenciesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Required notice of resignation", "label": "Supplemental Unemployment Benefits, Severance Benefits, Required Notice of Resignation", "documentation": "Supplemental Unemployment Benefits, Severance Benefits, Required Notice of Resignation" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Tabular List, Table", "label": "Tabular List [Table Text Block]" } } }, "auth_ref": [ "r999" ] }, "masi_TaxesCollectedFromCustomersAndRemittedToGovernmentalAuthoritiesPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.masimo.com/20240330", "localname": "TaxesCollectedFromCustomersAndRemittedToGovernmentalAuthoritiesPolicyPolicyTextBlock", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Taxes Collected From Customers and Remitted to Governmental Authorities", "label": "Taxes Collected From Customers And Remitted To Governmental Authorities Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for taxes collected from customers and remitted to government authorities." } } }, "auth_ref": [] }, "us-gaap_TaxesPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TaxesPayableCurrent", "crdr": "credit", "calculation": { "http://www.masimo.com/role/OtherCurrentLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.masimo.com/role/OtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued property taxes", "label": "Taxes Payable, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r37" ] }, "masi_TermLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.masimo.com/20240330", "localname": "TermLoanMember", "presentation": [ "http://www.masimo.com/role/DebtScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Term Loan", "label": "Term Loan [Member]", "documentation": "Term Loan" } } }, "auth_ref": [] }, "masi_TermOfTheAgreement": { "xbrltype": "durationItemType", "nsuri": "http://www.masimo.com/20240330", "localname": "TermOfTheAgreement", "presentation": [ "http://www.masimo.com/role/CommitmentsandContingenciesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Payable Lease amount (in month)", "label": "Term Of The Agreement", "documentation": "Term Of The Agreement" } } }, "auth_ref": [] }, "us-gaap_TimingOfTransferOfGoodOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TimingOfTransferOfGoodOrServiceAxis", "presentation": [ "http://www.masimo.com/role/DeferredRevenueandOtherContractLiabilitiesCurrentNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Timing of Transfer of Good or Service [Axis]", "label": "Timing of Transfer of Good or Service [Axis]", "documentation": "Information by timing of transfer of good or service to customer." } } }, "auth_ref": [ "r926", "r1091" ] }, "us-gaap_TimingOfTransferOfGoodOrServiceDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TimingOfTransferOfGoodOrServiceDomain", "presentation": [ "http://www.masimo.com/role/DeferredRevenueandOtherContractLiabilitiesCurrentNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Timing of Transfer of Good or Service [Domain]", "label": "Timing of Transfer of Good or Service [Domain]", "documentation": "Timing of transfer of good or service to customer. Includes, but is not limited to, at point in time or over time." } } }, "auth_ref": [ "r926", "r1091" ] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "TitleOfIndividualAxis", "presentation": [ "http://www.masimo.com/role/CommitmentsandContingenciesDetail", "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Title of Individual [Axis]", "label": "Title of Individual [Axis]" } } }, "auth_ref": [ "r1060", "r1136" ] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": [ "http://www.masimo.com/role/CommitmentsandContingenciesDetail", "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Title of Individual [Domain]", "label": "Title of Individual [Domain]" } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Amount", "label": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r991" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Vs Peer Group", "label": "Total Shareholder Return Vs Peer Group [Text Block]" } } }, "auth_ref": [ "r998" ] }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TradeAndOtherAccountsReceivablePolicy", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts Receivable and Allowance for Credit Losses", "label": "Accounts Receivable [Policy Text Block]", "documentation": "Disclosure of accounting policy for accounts receivable." } } }, "auth_ref": [ "r216", "r217", "r218", "r372", "r373", "r375" ] }, "us-gaap_TrademarksAndTradeNamesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TrademarksAndTradeNamesMember", "presentation": [ "http://www.masimo.com/role/BusinessCombinationsScheduleofAcquiredIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Trademarks/tradenames", "label": "Trademarks and Trade Names [Member]", "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style, or rights either acquired through registration of a business name to gain or protect exclusive use thereof." } } }, "auth_ref": [ "r109" ] }, "us-gaap_TrademarksMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TrademarksMember", "presentation": [ "http://www.masimo.com/role/IntangibleAssetsnetNarrativeDetails", "http://www.masimo.com/role/IntangibleAssetsnetScheduleofFiniteLivedIntangibleAssetsDetails", "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Trademarks", "label": "Trademarks [Member]", "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style." } } }, "auth_ref": [ "r109" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangement:", "label": "Trading Arrangement [Axis]" } } }, "auth_ref": [ "r1018" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangements, by Individual", "label": "Trading Arrangements, by Individual [Table]" } } }, "auth_ref": [ "r1020" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.masimo.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_TransportationEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TransportationEquipmentMember", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Transportation, vehicles and other", "label": "Transportation Equipment [Member]", "documentation": "Equipment used for the primary purpose of moving people and products from one place to another." } } }, "auth_ref": [] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Adoption Date", "label": "Trading Arrangement Adoption Date" } } }, "auth_ref": [ "r1021" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Arrangement Duration", "label": "Trading Arrangement Duration" } } }, "auth_ref": [ "r1022" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Trading Arrangement, Individual Name" } } }, "auth_ref": [ "r1020" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Title", "label": "Trading Arrangement, Individual Title" } } }, "auth_ref": [ "r1020" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Available", "label": "Trading Arrangement, Securities Aggregate Available Amount" } } }, "auth_ref": [ "r1023" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Termination Date", "label": "Trading Arrangement Termination Date" } } }, "auth_ref": [ "r1021" ] }, "us-gaap_TreasuryStockCommonMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockCommonMember", "presentation": [ "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury Stock", "label": "Treasury Stock, Common [Member]", "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r93" ] }, "us-gaap_TreasuryStockCommonShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockCommonShares", "presentation": [ "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury stock, shares (in shares)", "periodStartLabel": "Beginning balance (in shares)", "periodEndLabel": "Ending balance (in shares)", "label": "Treasury Stock, Common, Shares", "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r93" ] }, "us-gaap_TreasuryStockCommonValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockCommonValue", "crdr": "debit", "calculation": { "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Treasury stock, 19.5 million and 19.5 million shares at March\u00a030, 2024 and December\u00a030, 2023, respectively", "label": "Treasury Stock, Common, Value", "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r47", "r93", "r94" ] }, "us-gaap_TreasuryStockSharesAcquired": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockSharesAcquired", "presentation": [ "http://www.masimo.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Repurchase of common stock (in shares)", "label": "Treasury Stock, Shares, Acquired", "documentation": "Number of shares that have been repurchased during the period and are being held in treasury." } } }, "auth_ref": [ "r21", "r151", "r191" ] }, "masi_TwelveMonthsAndThereafterMember": { "xbrltype": "domainItemType", "nsuri": "http://www.masimo.com/20240330", "localname": "TwelveMonthsAndThereafterMember", "presentation": [ "http://www.masimo.com/role/DeferredRevenueandOtherContractLiabilitiesCurrentNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Twelve Months and Thereafter", "label": "Twelve Months and Thereafter [Member]", "documentation": "Twelve Months and Thereafter" } } }, "auth_ref": [] }, "us-gaap_UnbilledContractsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnbilledContractsReceivable", "crdr": "debit", "calculation": { "http://www.masimo.com/role/DeferredCostsandOtherContractAssetsDetails": { "parentTag": "us-gaap_DeferredCostsAndOtherAssets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.masimo.com/role/DeferredCostsandOtherContractAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unbilled contract receivables", "label": "Unbilled Contracts Receivable", "documentation": "Unbilled amounts due for services rendered or to be rendered, actions taken or to be taken, or a promise to refrain from taking certain actions in accordance with the terms of a legally binding agreement between the entity and, at a minimum, one other party. An example would be amounts associated with contracts or programs where the recognized revenue for performance thereunder exceeds the amounts billed under the terms thereof as of the date of the balance sheet." } } }, "auth_ref": [ "r716" ] }, "masi_UndevelopedLandHeldForSale": { "xbrltype": "monetaryItemType", "nsuri": "http://www.masimo.com/20240330", "localname": "UndevelopedLandHeldForSale", "crdr": "debit", "presentation": [ "http://www.masimo.com/role/PropertyandEquipmentnetScheduleofPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Idle undeveloped land held for sale", "label": "Undeveloped Land, Held-For-Sale", "documentation": "Undeveloped Land, Held-For-Sale" } } }, "auth_ref": [] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Security Market Price Change", "label": "Underlying Security Market Price Change, Percent" } } }, "auth_ref": [ "r1017" ] }, "masi_UnpaidPurchasesOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.masimo.com/20240330", "localname": "UnpaidPurchasesOfIntangibleAssets", "crdr": "credit", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesScheduleofSupplementalCashFlowInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Unpaid purchases of intangible assets", "label": "Unpaid Purchases Of Intangible Assets", "documentation": "Unpaid Purchases Of Intangible Assets" } } }, "auth_ref": [] }, "us-gaap_UnrecognizedTaxBenefits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefits", "crdr": "credit", "presentation": [ "http://www.masimo.com/role/IncomeTaxesNarrativeDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Gross unrecognized tax benefit", "label": "Unrecognized Tax Benefits", "documentation": "Amount of unrecognized tax benefits." } } }, "auth_ref": [ "r612", "r619" ] }, "masi_UnrecognizedTaxBenefitsLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.masimo.com/20240330", "localname": "UnrecognizedTaxBenefitsLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.masimo.com/role/OtherNonCurrentLiabilitiesDetails": { "parentTag": "us-gaap_DeferredCreditsAndOtherLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.masimo.com/role/OtherNonCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized tax benefits", "label": "Unrecognized Tax Benefits Liabilities Noncurrent", "documentation": "Unrecognized tax benefits liabilities noncurrent." } } }, "auth_ref": [] }, "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate", "crdr": "credit", "presentation": [ "http://www.masimo.com/role/IncomeTaxesNarrativeDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized tax benefit that would affect effective tax rate", "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate", "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate." } } }, "auth_ref": [ "r620" ] }, "us-gaap_UnsecuredDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnsecuredDebtMember", "presentation": [ "http://www.masimo.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unsecured Debt", "label": "Unsecured Debt [Member]", "documentation": "Debt obligation not collateralized by pledge of, mortgage of or other lien on the entity's assets." } } }, "auth_ref": [] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UseOfEstimates", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Use of Estimates", "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r65", "r66", "r67", "r224", "r225", "r227", "r228" ] }, "us-gaap_ValueAddedTaxReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ValueAddedTaxReceivableCurrent", "crdr": "debit", "calculation": { "http://www.masimo.com/role/OtherCurrentAssetsDetails": { "parentTag": "us-gaap_OtherAssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.masimo.com/role/OtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Indirect taxes receivable", "label": "Value Added Tax Receivable, Current", "documentation": "Carrying amount as of the balance sheet date of value added taxes due either from customers arising from sales on credit terms, or as previously overpaid to tax authorities. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r1037" ] }, "masi_VantrixCorpMember": { "xbrltype": "domainItemType", "nsuri": "http://www.masimo.com/20240330", "localname": "VantrixCorpMember", "presentation": [ "http://www.masimo.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vantrix Corp", "label": "Vantrix Corp [Member]", "documentation": "Vantrix Corp [Member]" } } }, "auth_ref": [] }, "us-gaap_VariableRateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableRateAxis", "presentation": [ "http://www.masimo.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Rate [Axis]", "label": "Variable Rate [Axis]", "documentation": "Information by type of variable rate." } } }, "auth_ref": [] }, "us-gaap_VariableRateDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableRateDomain", "presentation": [ "http://www.masimo.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Rate [Domain]", "label": "Variable Rate [Domain]", "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index." } } }, "auth_ref": [] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantMember", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesScheduleofFairValueAssetsMeasuredonRecurringBasisDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants", "label": "Warrant [Member]", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": [ "r937", "r938", "r941", "r942", "r943", "r946" ] }, "masi_WarrantyPeriodForDefectsInMaterialAndWorkmanship": { "xbrltype": "durationItemType", "nsuri": "http://www.masimo.com/20240330", "localname": "WarrantyPeriodForDefectsInMaterialAndWorkmanship", "presentation": [ "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Warranty period for defects in material and workmanship", "label": "Warranty Period For Defects In Material And Workmanship", "documentation": "Warranty period for defects in material and workmanship." } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "calculation": { "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesScheduleofReconciliationofBasicandDilutedNetIncomePerShareDetail": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesScheduleofReconciliationofBasicandDilutedNetIncomePerShareDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted (in shares)", "totalLabel": "Weighted-average shares outstanding - diluted (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r321", "r330" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "calculation": { "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesScheduleofReconciliationofBasicandDilutedNetIncomePerShareDetail": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.masimo.com/role/SummaryofSignificantAccountingPoliciesScheduleofReconciliationofBasicandDilutedNetIncomePerShareDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Basic (in shares)", "verboseLabel": "Weighted-average shares outstanding - basic (in shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r320", "r330" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract", "presentation": [ "http://www.masimo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average shares used in per share calculations:", "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]" } } }, "auth_ref": [] }, "masi_WillowLaboratoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.masimo.com/20240330", "localname": "WillowLaboratoriesMember", "presentation": [ "http://www.masimo.com/role/IntangibleAssetsnetScheduleofFiniteLivedIntangibleAssetsDetails", "http://www.masimo.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Willow Laboratories", "label": "Willow Laboratories [Member]", "documentation": "Willow Laboratories" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "SubTopic": "20", "Topic": "940", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "7", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-7" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "8", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-8" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-10" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(i-k)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-20" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(g)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "470", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-1" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "825", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-1" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "20", "Topic": "715", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "30", "Topic": "715", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481097/715-30-50-1" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "60", "Topic": "715", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480266/715-60-50-1" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c),(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "80", "Topic": "715", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-2" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "SubTopic": "30", "Topic": "350", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b),(d)", "SubTopic": "30", "Topic": "350", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-3" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(c)(2)", "SubTopic": "20", "Topic": "860", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4D" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "60", "Paragraph": "1", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482053/820-10-60-1" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19,20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19-26)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20,24)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.24)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.25)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.30)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "25", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "((a)(1),(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-4" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "420", "SubTopic": "10", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB TOPIC 5.P.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(CFRR 211.02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481549/505-30-45-1" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481520/505-30-50-4" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "70", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480794/715-70-50-1" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "720", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483384/720-30-45-1" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "05", "Paragraph": "4", "Subparagraph": "(a)-(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479515/805-10-05-4" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "55", "Paragraph": "37", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479303/805-10-55-37" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-14" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "14", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-14" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-20" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-31" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-12" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-15" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-16" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4I", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4I" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a),(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-7" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r136": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8" }, "r137": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r138": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r139": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.10)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r140": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.15(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r141": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.17)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r142": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3" }, "r143": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "985", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1" }, "r144": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-11" }, "r145": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B" }, "r146": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r147": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r148": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r149": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r150": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r151": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r152": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r153": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r154": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r155": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r156": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r157": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r158": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r159": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r160": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-7" }, "r161": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r162": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r163": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r164": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r165": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.1,2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r166": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r167": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r168": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r169": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.8)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r170": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r171": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r172": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r173": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r174": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r175": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//235/tableOfContent" }, "r176": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r177": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.BB)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480581/330-10-S99-2" }, "r178": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r179": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r180": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r181": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r182": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//360/tableOfContent" }, "r183": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-9" }, "r184": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r185": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r186": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//440/tableOfContent" }, "r187": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//470/tableOfContent" }, "r188": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//505/tableOfContent" }, "r189": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" }, "r190": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7" }, "r191": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r192": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "710", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//710/tableOfContent" }, "r193": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "712", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//712/tableOfContent" }, "r194": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "715", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//715/tableOfContent" }, "r195": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//718/tableOfContent" }, "r196": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r197": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(f)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r198": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//805/tableOfContent" }, "r199": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Paragraph": "1", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1" }, "r200": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "38", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-38" }, "r201": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r202": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//815/tableOfContent" }, "r203": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "15", "Paragraph": "83", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480647/815-10-15-83" }, "r204": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r205": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r206": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r207": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r208": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r209": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r210": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r211": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r212": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.13,16)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r213": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r214": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r215": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r216": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11B", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-11B" }, "r217": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-15" }, "r218": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "10", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-6" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "SubTopic": "210", "Topic": "954", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480632/954-210-45-5" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "270", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482989/270-10-45-6" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "35", "Topic": "720", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483406/720-35-50-1" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(1)", "SubTopic": "10", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "SubTopic": "10", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-7A" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//275/tableOfContent" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org//606/tableOfContent" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5C" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-10" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-15" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(210.5-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(n))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-22" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-23" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-28A" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482964/270-10-50-6A" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//280/tableOfContent" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-15" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-26" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-34" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-1" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-2" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-4" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-1" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481664/323-10-45-1" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//330/tableOfContent" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-1" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-4" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//350-20/tableOfContent" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1A" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//350-30/tableOfContent" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-3" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-2" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-4" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-8" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-8" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-8" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-8" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-8" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-8" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-2" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-3" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-15" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-9" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(10)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(8)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(8)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(q)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-3" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-3" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-4" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-8" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "70", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480794/715-70-50-1" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//718/tableOfContent" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480454/718-10-45-1" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "35", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483406/720-35-50-1" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//740/tableOfContent" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-10B" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-4" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4E" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-5C" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482736/825-10-45-1A" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482736/825-10-45-5A" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-10" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//830/tableOfContent" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481839/830-10-45-17" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482014/830-20-35-1" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481956/830-20-45-1" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481926/830-20-50-1" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//842-20/tableOfContent" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-2" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r690": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r692": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r693": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//842-30/tableOfContent" }, "r694": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479016/842-30-45-1" }, "r695": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479016/842-30-45-2" }, "r696": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479016/842-30-45-5" }, "r697": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479016/842-30-45-7" }, "r698": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-10" }, "r699": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-12" }, "r700": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-5" }, "r701": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-6" }, "r702": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r703": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//850/tableOfContent" }, "r704": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r705": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r706": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r707": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r708": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2" }, "r709": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r710": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6" }, "r711": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r712": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r713": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r714": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r715": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6" }, "r716": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482312/912-310-45-2" }, "r717": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "330", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482105/912-330-50-1" }, "r718": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "920", "SubTopic": "350", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-1" }, "r719": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "920", "SubTopic": "350", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-1" }, "r720": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "920", "SubTopic": "350", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-4" }, "r721": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r722": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5" }, "r723": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1" }, "r724": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483119/928-440-50-1" }, "r725": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15" }, "r726": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15" }, "r727": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r728": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r729": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r730": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r731": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r732": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r733": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r734": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r735": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r736": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r737": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r738": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r739": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r740": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1" }, "r741": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1" }, "r742": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r743": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r744": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r745": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r746": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r747": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r748": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r749": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r750": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r751": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r752": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r753": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r754": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r755": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r756": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r757": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r758": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r759": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r760": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r761": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r762": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r763": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r764": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r765": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r766": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column J))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r767": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column K))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r768": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A" }, "r769": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r770": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r771": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r772": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r773": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r774": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B" }, "r775": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r776": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r777": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r778": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r779": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r780": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r781": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r782": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13" }, "r783": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2" }, "r784": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5" }, "r785": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6" }, "r786": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3" }, "r787": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r788": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2" }, "r789": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27" }, "r790": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r791": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r792": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r793": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r794": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r795": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r796": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r797": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r798": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r799": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r800": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r801": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r802": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r803": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-12" }, "r804": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r805": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r806": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r807": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r808": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r809": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r810": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r811": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r812": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r813": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r814": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r815": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r816": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r817": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r818": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r819": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r820": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r821": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r822": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r823": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r824": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r825": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r826": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r827": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r828": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r829": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r830": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r831": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r832": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r833": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r834": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r835": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r836": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r837": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r838": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3" }, "r839": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r840": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r841": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r842": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r843": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r844": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r845": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r846": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r847": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r848": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r849": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r850": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r851": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r852": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r853": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r854": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r855": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r856": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r857": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r858": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r859": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r860": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r861": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r862": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r863": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r864": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r865": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r866": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r867": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r868": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r869": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r870": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r871": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r872": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r873": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r874": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r875": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r876": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r877": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r878": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5A", "Subparagraph": "(SX 210.12-13A(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5A" }, "r879": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B" }, "r880": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B" }, "r881": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C" }, "r882": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C" }, "r883": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r884": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1" }, "r885": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r886": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r887": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r888": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r889": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-3" }, "r890": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6" }, "r891": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2" }, "r892": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1" }, "r893": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1" }, "r894": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1" }, "r895": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1" }, "r896": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r897": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r898": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(1)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D" }, "r899": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r900": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r901": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r902": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r903": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r904": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "8", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-8" }, "r905": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r906": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r907": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r908": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22" }, "r909": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r910": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r911": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r912": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r913": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r914": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r915": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A" }, "r916": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5" }, "r917": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5" }, "r918": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24" }, "r919": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r920": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B" }, "r921": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C" }, "r922": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E" }, "r923": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F" }, "r924": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r925": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r926": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r927": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r928": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r929": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17" }, "r930": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11" }, "r931": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6" }, "r932": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8" }, "r933": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r934": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53" }, "r935": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r936": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F" }, "r937": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r938": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r939": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r940": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r941": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r942": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r943": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r944": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column A)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C" }, "r945": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column B)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C" }, "r946": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r947": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r948": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11" }, "r949": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r950": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r951": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r952": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r953": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r954": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r955": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r956": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r957": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r958": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r959": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r960": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r961": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r962": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r963": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r964": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r965": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii", "Section": "6" }, "r966": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r967": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r968": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r969": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r970": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r971": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r972": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r973": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r974": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r975": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r976": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r977": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r978": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r979": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r980": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r981": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r982": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r983": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r984": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r985": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r986": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r987": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r988": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r989": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r990": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r991": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r992": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r993": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r994": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r995": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r996": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r997": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r998": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r999": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r1000": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r1001": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r1002": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r1003": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r1004": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r1005": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r1006": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r1007": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r1008": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r1009": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r1010": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r1011": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r1012": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r1013": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r1014": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r1015": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r1016": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r1017": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r1018": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r1019": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r1020": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r1021": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r1022": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r1023": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r1024": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r1025": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r1026": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3" }, "r1027": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10" }, "r1028": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-3" }, "r1029": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r1030": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "SubTopic": "825", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B" }, "r1031": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4H", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H" }, "r1032": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "205", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483504/205-10-50-1" }, "r1033": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r1034": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r1035": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r1036": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r1037": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r1038": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r1039": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r1040": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r1041": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r1042": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r1043": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17" }, "r1044": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r1045": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r1046": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r1047": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r1048": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r1049": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r1050": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r1051": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r1052": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r1053": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r1054": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r1055": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r1056": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r1057": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55" }, "r1058": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r1059": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18" }, "r1060": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13" }, "r1061": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r1062": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r1063": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1" }, "r1064": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1" }, "r1065": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r1066": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r1067": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r1068": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r1069": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r1070": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r1071": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r1072": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r1073": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r1074": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1A" }, "r1075": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2" }, "r1076": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-3" }, "r1077": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10" }, "r1078": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//450/tableOfContent" }, "r1079": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1" }, "r1080": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r1081": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r1082": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483049/450-30-50-1" }, "r1083": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-8" }, "r1084": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-8" }, "r1085": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-8" }, "r1086": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r1087": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r1088": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r1089": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r1090": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10" }, "r1091": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r1092": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r1093": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480606/715-80-35-1" }, "r1094": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11" }, "r1095": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-9" }, "r1096": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1097": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1098": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1099": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1100": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1101": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1102": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1103": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1104": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1105": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1106": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1107": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1108": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1109": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1110": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1111": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1112": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1113": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1114": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1115": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1116": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1117": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1118": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1119": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1120": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1121": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1122": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1123": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "730", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1" }, "r1124": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10" }, "r1125": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r1126": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480682/815-20-25-6A" }, "r1127": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r1128": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r1129": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r1130": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r1131": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r1132": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r1133": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-10" }, "r1134": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-12" }, "r1135": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r1136": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2" }, "r1137": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r1138": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r1139": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r1140": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r1141": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r1142": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r1143": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r1144": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r1145": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r1146": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1" }, "r1147": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r1148": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r1149": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r1150": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B" }, "r1151": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r1152": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r1153": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r1154": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r1155": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r1156": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r1157": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" } } } ZIP 122 0000937556-24-000042-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000937556-24-000042-xbrl.zip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�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

  •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�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

    BY;C0GT),_(U#5;G#%#34K'OO$%2I!!GV^ MDZGR^C@D/-ZMD=!* GT(F@%AK<2V(@^,:23B)JSJ8EF)"%M"0S*#76P98 MKOU5,Z_%TO8;8,/)RQ7C\^I.%Q2L10?*EI=MEB;+]>AU(DC[;('\92^(+>D1[I<^*1UWG>CXFVL"$KR:J:U=A-<&+.\1_X/ FHIY5:CCM'@M.E-TP*H+V:FDJ:T* M7+4^J@-3Y.]BM:W@5M?%J. !R?XR=V+7$W?&Q@0M+1WUMF.[Z*W1?$!\HG:F MOR3V<.J35MQ>M6UU!:XMTOATJ1NG".O2L8C+-'#HZ^EJL3S=LW#,^ -G8Q+V M^ 311)739?BIIJI%UY2<#K$[I6P7JZF_2F_&-=YF-1TG$9E[UL?S94P* MFW TTT?SEM/48EFY)3_P':$>[-#0!TT82V'96G1#1 0#EB*V=YQ5+M1%ASC, MRBR :V-^=3EA$,=\HD@V;:=9]PVIZ]+9KGC+"/FW6+R&JQ'BXK*U$.(D]_;2 M-9H\Z"KVS)%1UNY*RM>^*KM:/3K"Q1O"F.C5: U1+6!;A53!/I1*^0H[VS(? M:OE,,R)^[8P2UR+U(Y;O\,EC1Q*_E:WN%LGGIJL\QP;$K]U%L:+K(P:SI6HA M@%\?>G%[-$M?OEPMFG\3<5B3(X[%(?YX3-Q5W$UU?PP(:]'!+GW"0>RZ$OHO M]62C@V[L0_>EXV#-Z_1#7.$KGMT YATQB>O*E:R'3C[ G/V&? MS84Q0+UOV!<8"+VQ(KZCG*2F1E\?D]DHXH'\?(,U\3EEI6L!V/*:6YQ_5L4E M )QX''E-3$SXE?WX$ ( %0 &UA?^)_93R]PG"9Y./[\UY_^.'X#[J?_ M_-N?_O0?_PO@OW[Y^.[%JTDZ.\'Q_,7+*88YYA??AO,O+^9?\,4_)]-_#;^& M%Q]&85XFTQ. ORW^V>+;[]ZT]?YO/3O_S\\[=OW_[\/4Y'?YY,/_\L&),_7W[ZI^7'O]_Y M_#>Y^#3WWO^\^.W51V?#^SY(C^4__]=O[SZE+W@28#B>S<,XU1?,AG^9+7[X M;I+"?+'K3]+UXL%/U._@\F-0?P1<@.1__C[+/_WM3R]>7&S'=#+"CUA>U#__ M^/CVQBM/PFQX,OESFIS\7'_]\\OWO[]Z_?NGUZ_H+Y_>OWO[ZNCX]:M?CMX= M_?[R]:>_OWY]_(E6L7CJ_/P4__H3_>O3$5[^[,L4RU]_JL^$RFXF):NT_.\U MGOKS-;TIC-+9:+$][^C[Y;,K>4U)Q^]S'!.\%CMU^>[1)-WXT*CR:3*]_)>C M$'&T^.G@; :?0S@=O!N&.!P-YT.&0&UT M_1^*H/C-+:O+FM&Z%OPM81873%Z^@I@MY,\XFL\N?U)W5RYV]F$J+G9T^W4= MI30Y&\]G'\)YB".\7!M3RKB$#.A/"4H7 ]'8"!HM"8,YWAR^>_+ M='+2% /S2?.MO^ RK6-7&+RF\STY1Q(@HRKQ[UFI19DSQP+UQ(-R$L$C)SC:,J093EYA07I]_HA?<7QVC5F=+#(6@)2G(%J4 MA\"] 6V5%,'YG)5I#([[*5D'$?)Y(J+!UC># 8FNZ=D-5!Z-\WNR$*VG:=KS7T[&<_*YR/=:,$$K69+DX$0A9T=%55>:@'ZDN4TZENP:+_<1 M]:7G4BFI PJ>#J?/&L(5FBPDIQC9,'Z6!I#XRGL M]\:X:H^('1G0A8 <<(V(@N2R<,J!$L*25K<,+ E_FY0P[0VJ#17D :RH]JS? M=LO;&5*S&"84P2[0 L1.CD>6QM,JP3LK.["[$L5 MJO1'9<[7,%J(V?G+,)V>DYC]1QB=X:"XH(HE=T5&XI4*=,RB\ H,F1W.9LQ& ML]:*;QW"^J0"M\?%'7W7G"$F M2Q+)@9-43X3*;+(-45DO0F,,K+Z_3VJP'<^WWN%F/%[XHS<7)(V.5J1 #*D& MEPED>6L>P&;M)&?H,VMM\=ZEHD]Q@7;\WG&W&YLZ[\NKX>QT,@NC7Z>3L].W MXS0ZJQ>1]-.T\,7.,+\_Q>EBCR[IS3Q(8S.#8ITGE))SYJ01$)RU* G#3MM. M[*)MJ%T'1?K9H6A/W&N,M@$O6J.)I+E8H26G*,%;K:%H[TM!)!'76JY'*"Q^'[Q6.KS,ZI,!."!'1(I[<8"3$6#R[%&'FR*MC6<;*'J>F?T;P1 MSQ\*LN^X[K"&+ MS0G/>21*6\<0'Z>H?V;R3G!HN/U=6$^_3\9I*60CY[J@(AU>,@E9S6HTG[X( M'K6*4B>N5'<&U#4A_;.9=P+ [IO=_.KUY61&B_(VYJ2E FT\02_K1,N3%GC2 MGD13\"2L.E(""P+Z9RLWD?N;;VY'H4">%?.!%>"2US"T(M'"*QU%1)%XL$ZV MENP;^T+[M6)WXN_VF]LPLI&Q/*Q/7G]?VM*_3B;YVW T&G =.,NJ0."%J$2R MV;W!!,PJYF0ISC2_!=J4QG508IX/2CIE43,@?9A.R,6:GW\8A?'\:)QK6/>T M7FA6DT2AD>3"2TAC-%C?:;\?O,,QPQ5+AG"$M3 "6R$%YY2"6%"#12C4+5AC?^J[E<8K6 81[ M/H!HN/W-('$EG8361=("@/-ZHZD4.:LQD["R14OMD$O1VH;81#'XY\/FK;:T MD\0 )#D2.'(@9U. XL*0R^D8&)W);/%.TKKVE1C0(*JU\NPJ0E-AQ!.T8%@, M-<9".UM(J<:4Z.PH'KAM?>'S!$E]BF]MBX,G@UP[<*%M6&.5D&LI*LB<*DHE MR(*3N\T4(U(X@N:H=$E2"-_:IGF8FCY%N%H!HM'>MQ-XD_'G8YR>O,(X7PV[ M)*=\0D?2EIQQ5:P@"2X\R.(*"R;RZ)O+OGLIZ5.0JQ4&&NQY%PKO*LW="DP: M-23,-=3J&2E>H8#;)$+((2#O,"&NAQ?$S?B^VUYWF08;9.;"DXE5)",]Q$,M M!]6N9B@D(XHDAZIU$5K[%/ /TZ6V73QZD6WU_FQ>2T5K)&%0K.6,9"B(8A/M M-2X2,!($I[,5!9G"UE?;CU/4)X-G1TS<]=Z;L:(9[(^GY#*>3<\7)-7<],GX M(B//<<,P,0V8-2G>B#47W3O(T:-S3E@16YO"#]&RHJ]A6,2 M&^/B::KZ9! U!DACEC2#R@56[Y=D3I,(R\Z#CX8(,D6#LT9 QA2]B$S&DAIC MY!%R^F0U-09'*R:TNT3,>5BW(8P^A"$Y^"_#Z7 >1@,;G5>1"Y)FF8/*/)!) M)ST@#PQ1R<)R\VSJ^TGIT\5B8S2TV/R6R?67SX5>\B/R\ MF\QF;R93VNEEKEXZ/YZ&\6S)C_S_SB[BVK_C_'TY#M\'+CDCDP]@>:X6DI<0 M@T'025?;R8J '13TMEY&GRXM6R/PP$R_A=[_^/GV%K^C[QNVK/ET3%]_>_W[ M\:?W;]Y_>/WQZ/@M_?8F-3OTKGG@\1TUL5EG,8VZV?PZ)11\F$X*62]!&6$) M5I T0[)>9 *OE02>2H@F87"AM4&Y\OK=+>9%-X0W=+)J+>\TI/D_A_,O+PG% M!/;IU95]O02B_^>*Z.)LB"1Y02A%*XY<0C#%0E*T!63):=<\*7@+,OODB&^+ ME[O&=+?<:FA=STC\U6N_1=4I3K\.$\X^D: >2"U($*.!X(@4Y4H!YYTEH2A0 MH11,VM9*\&%J>N6:MT))H\UO=S5U4=$P_OSZ^RFI4IP-(K=%(Y/ (B>+3@JB MH%Z86>5X5$)ZR9MGV]XF8N> *XY&-9<)Q_3@$6WT43X9CH>S>7W-5UR^9F"< ME"+0*HVJ-]Y.*X@\TFGD@DMCR0IPK0/OZU'6)_FX&T+N-"1HSYF&$:H9TF-J M2?$K$N:CR2+]Z9*D$M!Q9S)X4_L\:OI;,&0K.D$VBU4FQ=C:S7R4H#Y=UK;% M2#L^M$U%NW0Q!I[7XF&9:35*@"KD[X94$V\TK=-:HRRV[A=W@X#=TW67R1'+ M/?V%3F-5;*ID*T.M ,+:(P9KVZ3:G2D9E961067;.J/N 5(V%(#=ZO[MF7\W M"7?WC6^8M'WE,R]MUN'XC,[P59'C[!OZ6-FV1 M3E&MW=)JL;6S_Z1\VBVZS9![YYT&FY VU-21 H(A!/0J M%9D,<7-?T>V>Q"BVY/>=FH@M=[G#L)QQVI,83I"L6_1/CQ!#B;[;EA_R=O#E^]\^?'S]=_K,VW^\?O?^4S>7A'??LH>[PB>6 MUNC*\)ZKY*LKXN(S\I(%))YJL#]H\#YD\,4;:127O'G?RD?(:5*)5VOI5>RI%33O+8LY-! Z"L^B"_2NR,'8:G(*15I TQ?/ M1+%6&\YS:U_]D?#L81V&KO"S_8ZWK:I[( NHMH1],YI\^SOFS_AK&([K#X\* M>3H?,8W";#8LPXOQ54?C>A._!&_VF3$;)&3&$VE\+<%QI2 YY"HHIGCSQ/3V MJ^A3PO*^Q=>>>-\YAN_+8@OIDN;'D\V2!43TL>85T!*%MQ!L_5N,WNAB M!&L^A6*O"^Q3-O:^D7]XQ!S4!3KZ]/G]L F M^?AA.ODZI*?]49-&@4[W#J;U_0K0<.'<) M=1*FR-8EBNM3MW/I8CA?S$DYGARE_SX;3O'!]C>#PG3-*<@047-0VCKP(GO0 M(4H=3-:F?1GCVM3UREGI"%QW:AV[X5V[)E:WZ;O=;&L@E"K*"$]F1HTIS'WXN(W>6!2 M49B-A11J-JJITV)$,)!$8,)*GGALG8RT"7T;>B,_)JQ:\:\[A-46&>0AG5QW M_)H-C(Z*G"$-4A=;1^DQPK[SX*S0ECO.0_.8WCIT;6CE_YB(VI5?+4-O]VW MF^$XC-.M#2 X,U4\!,RUWTKA)$8#)]\BU='HEK'4NG1W?>H:=*Y,B'EQ+[^H M?'M_NKB/?_T=IVDXJP<]$L^#U) #(WU2N(7HZS OIB+G+(3V$[">)*I/E[@= M(>F>/I<-&=5<(B^'(A]/R#.O]4.U@)(63^[]IR_DD_\29K63\TF]HEQLZD!G M46(@A<'K@5=.UR&YT8#.ENE@4Y:Y*_V_*:W/P<1L#K=]\+5E_]VKP_&NFBQD MK)"1,JR-\P*R("W8D%CM&Q[!<=H-%Y/*W$JA2OMF/@\0TZ<(]P&DUO:,:5@J M<[K$]?MRDQQ!+V>L*/#62K)R3*W<\62)R.2UB")RIYN7R3Q S'.P%%L#I0UG MNC8/KY)M5E:-+DLIL/:.(*M8(09PR!R@/'GV_'=L?<#PPH*B:P.[V:UW3."J[TK+"N"RQ"%;9[@L Y=?L)!6,A;$Z ]XF4QNQ!/ N"C!%&BN#C;:#Z:./$/03D;7<[1K4/B=&3:0M)6$(QM(JN$')*0-2;A9$35.GSS M&#U]NNS?GZYJPYYNU=6"'E*C-9-@8(1T061%QJM5H*R3A&.+D+GDNHYDC;)U MWOJ31/6I3]LA%=76C.H0/Y<-_)?M= ;)<*-,)NE'BP>E!=9>_0BBYO1SY8S* M[2=%/4%4G[JL'0P_NS!J#_AY^25,/U<]&BRS7D;0EI%8U#Y#D$0E1^&2BTS9 MU$$E^N-$;3@YZ@>U=G;A5(< 6B3874\)6.8!Q,03RR*"-242<5K7<:@1@N)1 M1\FYXJV3H=8D;<.I4S\HF';G6M>0>GF#LIR<")$GD)*3>6]2@) X!YMDTM(+ M9G3W+OQ=NC:<;?4C@VE[?NW!NOZ("8=?%W9;=,KX7(@>4 M%Y%L\[#I.G2M%4ID/SR4=F18PPG+IU-,P\5>T=]'N,P,/SJIV=__3"BF6M^S^M0]=:4/K!PM+-^=6U>KO:@-7(9V;) M*,=\G2Y-/D$TC$RZ0M]RFX*(P0O;.F2T 7EKX>J'#UBWX5Y7I9PY1692 L]\ MHJ7R4I=J0$A,R@9G<]ACI[T'('+@5(/6$-F> ]W?@JWTM;F,6S$KLQ;UF@YK MSP=K#7A52X\S2J]DH65WT+1P7?+6 M /%J;NBGL=PNOUR>EHR"GSV87 M.!,08ITWD@BH7A%#J(.#+SA'D+P$AE97T:T-GH>HV+@J)QOOF#E4]^P.EPDN^*S>5(BM??TY%TM\7U:7_7Z\TP8/A+(N,UF[4&0$ MQ8(")^L$$^&R8:0+VJ=/=K",/F5=/B/ 'QI0'?9F^E2Y-3V?E$_#S^-%:[7Q M?'GK2?OX83(:)CK'G](7S&^ZLZI'IT<^" M:8.2DPZ"MD(XP4#%)"%HYJ XQBU:&YAL[6=O1&"?W,,NL79;8'?'Q;:W&+54 M+8R6L]H7Q-WLXW<=]%S6M1U-IU4!792XR:R*BM:#X=*1XJ"]BMP70"W06*(\ MV-8=7G:GND\NX3XAN6=^]\AD^'1V2NI^N?1E=]>WXS*9GBSS8_9E(:Q'R/X- M@BTVJ%7K_)U,6"Z0:W+A@%D60=D:1+<8P0DIG1*F%-UZ/G=#[V>[W:+GWWKJ M$3G#T^DYIAMHT#O>DO%#IFB3CC-/MLRF?)*M/BJ0]3!JQHSU. MW@S'PQGY&+].)OD6898P2PLW4)SQH+R1$(53$$JT,4I=LX.[PLG#9/7I.JX] M3AJQHT.CXF[AW ZVQ<,/V]W$6)/01I;&XFT7KUF^9-N@X?+^N<+M<(RM*F:09:*7J +!40UJK3DKZP(#&STI M-E\R!)8L>)0Q>U^;GK=NZ_$(.7VR+QH#HQ43&O:8PM,PS!\GYV%TT>W2>TW^ M1RKG7'CM9M&1'4?#K2?83TJ@@"Z=1&))$.=;2 M&D-KLBA)'!EO0O3<^]9!RM7W;]B8ZQER?/-M;E?!-!G/IR'-Z_2#EV>S^>1D MN;X5311Y%EY'!(W53R$ZP6?C01.=):B8(VL=5EJ#K U;;#TG6+1F2EN+\6*= MOPUG"4>C,,;)V=6BA= 8N22W)6JL90L"0G *&%FT@0NN4_,1>D^0M&'OK.>$ MDI;,Z##\N'!NKTWN^M#^P0G-SV5;N'+ILLLE%@L[YR=O7.6R\> ML.*MT%J"$4BH*,& PQQKWZO HA FY=:%98\2U$4\Z[KEX" 4+V0V"I+P!92L MX7<2CI YLT4P[;%Y*N_C%/4IW-D.*>L$N+;DREXBGR[ED!PZ**$.TO:V#O]F M".@*#YE$92S_II'/_6)D&W[T3W<-^!ZU%[WL8/KK]D+WH\$P& Q*0)VQ1=A@ M!6)Q9#AYU.AK[SW6.C^^4PUV]?"C6BPTQ32_*KE'M*#[&6G##5!WI\G-OCF\L\ZL\N'6 MAAR-1I-O1#2^F4POAI[?BC].)L_L#>_A?G9=#@_[\K36_O%'>O-[3:@D0Y]A[/99*6% M:*7@7KD2C6=2DWY MM':5FA$4_B^&Z4!&+8NL7DGFBDZPXE"GRP%F:S"9B-RU#GOO1'"?=&DGZ+NM M5O?'WF8^Z+HD_TY2X/@;CK[B;Y/Q_,MLX(QW*#,I?M15G>CJ8\7:-\T7+F/D M[=O/;4MKG[S77N%P)Z;N'8+'WR;UG!"5FNDD9 04OEY"RTQ4Z@(F<:6Y5M+E M>"#H7=+8IU2A7D%N*R;N'VH$&[R@TW(MD_4(1=:<;"%)*@OC(4E,,2I'KD[K MN\;-J>Q30E*_X+8=(_<.N#>3L^D%F9PA9D'.F0Y!5BL@0Y0N "LR!"U]:'^W MO3&1?4I[ZA79@E.HKT0MY'E5%/'DW2.A6*; M-S%O'O\]S-[=[QXB\LAX8!#0\8L(FR\8P62>74!IA6F= =W98OH4&=@[VKL( MQN\.F5Y)CSN.:7)*,,\9&"MD[6+(P*4B(7'NLY?,Z]2ZX+B+=?0I$O%#X'XG MH/0*\E>.L?89,Q<*&%O/#!R\YNDQO0WZ?(QP\!\:V T2]H M7SOA042MLQ> 3 5: U?@C;; !)I0BK."=Y;LUV0%?8JT_!CPW@XAG9^2'@O1TT&J?+K$G_PV&(5+Q+ M:!0(4?O4"5X@&,5K?]*B&!?V3K^?IW)J=B6I3[&C@P'U@%QN+W\O4K+O2<$= M9#HK6G,'198$*IL"G@@#5X3S-BO/4F>AI >IZH/>&62"A:SSYDO6^J)!F/=, M@+8"?H*"TZG=8KG M;#X+XWS1RVM9Q[ISU[$-GKY[3N>V2VF4N'GC]4?+UU^\=N"B\U([!&D"22:C M$'P6"#HGB2)PY7/K,J5'R-G)6EZ6OK]:HGI@F FL]K8@P5MQG#U$)PL87DKP M)>: MUL2S \D.?%$8GS&VRM",/92KV# MYUD021RTQ^K#I%H)R"UX$YPF !)%K6WC1\CI4UB\-3!:-.0BQ#F0,:)V34A?QI^'9-A=F \W=$MM0#_'=S5R>?MS M.\V0V>V5+0;.-%QT([WZR&LK9G/F6%AMTADM67623&^ON83D,8O E))!-A8, MCU.TJ\A\Y.D7@CR*G#P=24BF%E$R6X .A@)9N,U!ZRA\Z\ZP3]'4)_W:$"^W M95Q3UC33L8]0M2*45X7OP*:D@O&17):XN(DE6X#5IC\V1*FM\#&TOJ_8G,I> MZLHX?T)7AG()LZCH ,;ZWB4P;D MMB_O4TB_,[3LA3,]=$C>G,W/IKBJ/I;-S@_@J3Q)R^%$&R*C1C$%UQH%SPRFKE96Q=*'TPW^:>G;];^2(,+[6KEXQA,30>(02RM]"1 M) ^V>*5;QQ5WH[A/:K@AUC:Q8!NS=2]>TUV:KQ)(A1!1BYC(A& U.D5D!F4, MB* 8*8*4M6S=F&4[2ONDTWL#O:W8>$#('7^;#(S%XBUMAU2U7;V6"7P2$K0M M*)/C0>D]AGL>)K1/U_^] MRF3#P0WNZOK^;!<^%ES=G7D0X*"Q"<<_2M9+FH M6(1M/5VB =E]2DGH#19W9_ A)6&MH1MH],IKCE C7$ "6T&P00'G@4Z1%C7 M>GA96$GM4Y59;Q"X'2/;Q&0>IK02EVY%6&]6#1G%;T\_>D+XOSE*,QFPS),RYOT'3HW=TU4BZ[.>]VX5@/- M;]!P2>SY(#$MI"\$?%/O@U0N$)A 8+IVN8TIYMQ\JOG]I.P\?NS^QUX.#4$= ME7=("T540.:"HV-7%#"K6%;%*=_\^OUQBOH4+2\EHY3::""'[!"IP45US1G:M*RKDFMW1.N*R%:%]4K2=H.V^ M#KG=LK-KA3Q(SG@9'.D/87D=D%/[:W$/,0?T*+21LG6>REIFZ>$'%G2.GA8L M>88Z>-NQ?)U1TU\]W-%@O[71C8FP%JPBUR&*FGCOP0D5@$5>6$K)1]7%4**# M:^++]SP0'Y1%:^%+V:@[>1^2S5.:=PVYK M-AX&;=\F R>PY!S)%EF4+Z#DX'140#:L4O0KS+YU:\<-2>Q3DD'_D+8A"_>. ML[N97P$M\RQ!2:EF?AERCD*Q8)UD%IW@.AQ*N&V3RK?/^4.]0=Y.3&TW%^9! M4FN;N0]A>*L1I#7.,\'K*%]7R"T7O):Z)M#.&F.MB::L=Z6[^;O[E!K0*9+V MP9N#Z,H%E2HFYK,A%1[JCBA-]J/6!:)/QI>HM"VM^X)M2F.?<@9Z);.V8F*' MT9=%FYK?)^/E+=[.E>2//F_W",CZY+:Z9K]NX[-R?:4P87!,@4Y9UT$8'KQT M'+SGW(=DM2RM>T+<2\BNHN<53H=?B0E?\6!&^<5 MZB(6YDJ44+ @U+I@$E]"@!&2S# EO(ZMB[G7I:U/@8'VB.F$0XWQ\QO.OTSR M=1]=,L]U*5S+&GH@O:?('Z3%$J*5X%):SW-,K7-H'R"E3\Y\5^C8;?^;@>$C MO7XZK!F4+\/LR\H*4^&X:+3->&V#SW0 9Q."#<(KQ6,HJK45^Q M??*PV\.A M"0?:71!?K^^WX2SA:!3&.#E;7:PHWOBD$QA5:^>#"."9=<#09&M\1BM:%UL^ M356??.?V&&G,E69H>86GD]EP/KNS6".T*"@5>$5NF@IIX;4%*#(R#(P[%UOK MDH=HZ9.OVX5QVH #':67?*P[^K[\,;LPG >F&"]J8_ZH2B2UYC)9RPY!8%8H M?&*B>97VHP2M@PS[;)'1CA=[F%3P$;_B^ QO-_A?29U8VL_7&10;_],&(P_V M26:[V0D'V]R609Z55]8I'3?I6STRCC'%>02T7H$JU6I2FM"=' $[L9!N][9N M8YVL2=^N$O:2 _\*9V2 B9$+(4,B?Q(=2 (SV0%, M:8N-%_\H0;T+#'6!HMN"MQV+VER"':4T/:N+C&&^6/;1:#3Y5FNB9F0U%F5U M"B"":"2C1!G+T MD?1%!V?Q:<)VOE"?C#\?X_3D%<;Y976B-EDPPBJ=#$O>:O$$7Z%HK29K@=(: MV3Z9\2X9?3)7VF/DSIWXCGQH:IV\FHP7NW+I3PP29QE#,>!"=J"TUA!8"* 9 M6H=H%4>^B65R^P5]LDJZXW6S+>ZZ NF*)L*8R5*",2G5O L+WG$)3NB4D[.> ML]8>S.YEX_LR.[J7"0VYTRB#;YAP/"."KD8K7=)2L-Z.<@[165S&QE)6Y$V% MZ,G24L;+M03$@Z_HT[U3QR*BS3:W]%?J:M^.R4K#X_#]*LPT*-+0_ID$C"=2 M4(*T5.0.(:*.44?%M>U@W,O]Q/3ISJE[T="&)\T@\F$ZR6=I_L\PG8;Q_'Q! M71A=-GC!?-7W@J5:+JG M_9@TN:>&:*8\9A,,=IX!Z)4\5BB)GN)EJZM($,DD:,5J5=\0?19@%"2I)ZT"9PK1).U+@J9N&W>.&LG=<39 M#X..-DQIC1$RL HN!I*3@,,KFFY>$QCG29P5 T%AH66[!)Y;!<5P0=95LIZU M%B8;D+<6CGZ< &Q7C.LT7R?>R!*)NV75//2P%KDO:Q':Z$*G/I_X]3*<#N=A MM(B=O8^CX>>+>.L@:RW);(@0.'G)Q#L'WFI=:%&(]3U/(*9P6D M/!45,68P@0=06C (OGB(CNO"K$LBMU[G_93TZ2*G(38>N\'9D@T-4X%7;I&\ M*<)F\L-B32[4B0AP,@!S3B1G79"R=>D%K+;+1@EHUZ5HYX@.1E0OU3E8X0RZ(*QG(V$20W'%OZ(S; MYA5:J^]OJ36N]_(CGB[KK]^7#]/A. U/P^C^SDQ&>Z;(U*FX1E ^E-H_WD!) MW&29C%&IM5S9E>8^::*ML?28WNFT:.:Q/]=OQ=8,F218\EX:!0^5J&98B MGRX&$ME,:X_6"]=E:LKZE/9)[QT":MLR[8 ^S89E!R3%2X"+X:,M:2JL>8= M6&39E&"DEJW[Y&]#9Y_2( X(K@T9UB@'XBZ9YS<;X_#D3&3:UVP,#ZH&*'T@ M(PXF4G%AY.A5T<$)9K1-*"4Y&!LK(ZM*&VZW4P);8QR_;7WZIAR<"C#VW>Z6I/A0.7128OZ;]:]'W/A41- MQ?*Q6/!>&E)62D!P2/Z5U3&B92HW[^3_-%4[F3]_C*>8)I_'P__!?!R^_X)C M+/2:E<>OQCZE2 93)'-_46P3.41#"KLH;T0N27.Y7D';)F_MDY/?&"(W3*7. M.-%U(M<*60P-]R)@;1I)YKLOY!E:GB#D(CS/2F;627WP8T3UR7/O"#_=,*C# MA./51CPH4#O"+^G+VJ7+DM;T=3"I\C)G\@>M[B2!ZP%Z^N2*=XR69FQIXXA? MT;%,#5KMY*8P6,0 7MA<45OMJ>B@M@OE*+&4N)[>>?@=?7*]N]0RC7:YF6QX MM)Y_A3C4RD?KR7XWM9._)3*=I&]YT4FPY#W&O39?Z&=SK(XE1A?,VN,X3'1" MD6V4H5A+9(50(]B6@=16!L)\2J&7XS#WY35W;9TT95!7%7 KY&2I?6 L !I= MI[I&6W,-$ZE$G[Q*.8?;71K7+H+;# #[JC;H4O$TV^F&235E.,:\=+0^C,)X M^=?K)))!3*BY409PD1EH%8> CH'@P185C"NN=7'*&F3UJ:Z@8Z'1FDD=AMM^ M.2-XXVSV76":#QP*JSTI(^$"^M:DYX% M1*$V!F6[A1XMF14&]/IGK5_O I@OLU$[; , MJXMY\[P?W7?>;WZ$?-316293X=?))'\;CD8#]-K0(@0XQS0H*24$VCO XLDH M)/F>?%C+$MLCT;N>S9:DWA@90D_!X=?Z+PDVT958(SR.1U+-G'D(3$O05IG" MG4T&6]LW^UA7'V1$KP_);?G2.[ UL_);KJP.%!C3Z\X'7+%L9V^(+ 3]YWI]1.ZNJ ]70_^V9V5'@#4[-%<;DQ5+0?H, MWLER,0(@!%7JB"KC9&0VFM93>^^W+ ]S5_6L@+@5T_HI9U=MJP]3/ W#_/K[ M*8YG>!EYN_C=(%IN0QT *WF]B%D,J_!T3J04Q3*RO91I?=EQD(7VX?KM61V& M_L.QER?OPW1RBM/Y>0U!SY>:Z/1D<7E1#!IO/"W(U_!VJAGL6!.RN$F*FU!$ MZP3=O2RL#U>3_[8GJPW<>GF2WH[G8?QY>/7AJT915TQ0*HEB'(/"= ;ZCH2% M3@@<4=E,L@-%ZV2/O2ZP#W>^_[8GJRW\>GG"+O/GTZIZ'G#G@E&: 2>=2RJX MFL%(R\J$&RNM#>T+O#M?5!]NPO]M3]+N,.OEZ5E-72A:Z\1TS4.B+\H%!T'I M CK%4@36YE1]#F(U'"S1DJS+G)'C\'UUL[/B@ED70/":!<04>>=>12B.T5:C M==JV'F'8_:KZ,<48XRTD9T@.IYH1D$,$ M%XL3HEZW^5M5RGNX,]]R,7VXINKC(>H+?S8"6R^5_KT+7YT.-HA,6),C QEU M(/[40HF('C#;$%1F09O6W3WWNL ^7&_U\8SU'VV]/%#7?L'*[Q9R8^!XBL;G M0EX+1_(0:@0K2U[S=94U(8;8?&K$?E;6AXNY?Y\X'O^YW>.W>WPQ' M-1];[G@[G*].XP;ZH3&<"$@,V9!>>7!\:* J8#*%%E;A?98KFT8 MMCXT-W*M#"$9^&[X]2[M Y\#<]8EX#9I4+J6DEEI 9VP6J-#T[Q;\AZ7]Z,& M%=J>L6YO$=KAKY?VV_6*9@.>,!FTO/8!(&.4-"IXQA($GDOV'&U)?79]5I;R MHP82GM/!V0Y7'1IJ9$I.KFJ3)[-=3+"''K6[<;46D8W,IM5W732,6";U#"R3 M5ACD$&*I-P/!F\F4=G'98S"= M+THU0ZK[\FL8CJN(_04+?>8X?!\HZ5BQ/$/Q28$2L8Z>$C7HX6.*NC#F6AM M&Y#7I\AM-Z#IBE=M6^,]LG97R,(2DJRMVI)?N%#G]R(DX9)1G&<2=XWQ\SA% M?8I4=@.9AAQ9T_1<_KQ^B6&&?_O3_P=02P,$% @ <(FG6!"?7:DQA M=?0% !4 !M87-I+3(P,C0P,S,P7V1E9BYX;6SLO5ES6TF2+OA^?T5.S>MX M9>Q+67=?TUJE.THI1U)VWGF"Q>)!H1,$U "H97[]>&#A"H $0>@()65*2F2 MPOG"_3L1OH7[O_W/K^>#7S[C>-(?#?_];_SO[&^_X#"-C3]_&_;./TU\$$VKY:\N?CO^A"^<*F05N@P'% MC8=81('"%#.I")"T>+*>#L0P?]X5__ MJ'_$,,%?:'G#R>RO__ZWC]/IIW_\^NN7+U_^_C6.!W\?C<]^%8S)7Y>__;?% MKW^]\_M?Y.RWN??^U]E/+W]UTE_UB_2Q_-?__=OK]^DCG@?H#R?3,$Q7#Z#' MY^GE/[R.1O\Z_R']ZJ3_C\GLW[\>I3"=*>C>)?RR]C?JWV#Y:U"_!5R Y'__ M.LE_^X__\? M,/WV"?_];Y/^^:'\G_73?MT;TT<",DX7$8&^B\-* M\8885WWZ_I@O/PLREG QF#9$?/>SF^(=G8=^2P'?^>@&:&>!GCGZ>QJ=_SH#]^SMF^/_V]:OG3SZ\>/[T MR>LG;YZ]>/^O%R\^O+\?Z%)+@Q!Q,/MN[V("9R%\ZKV?T@E4#R/" MBJ_HRTDO<).+TAQ> .26159U#GE=%?'DR5G2IC$F987CR!M"_DK M#J:3Y7>J<.5,L.M1S 7:8%T?0AQ@+Y(ZK5+U1$P*5$@2 C,2E#&BZ("Q*-/5 MFF8(;J[GBB)/QLN5+=ZOG8Z),AZ=-]7G=-1,C'--$>B__3(:9QR3940_FKWT M_TB#T03SO_]M.K[ JV^.AE-B]8O![('T;N)9_6)?)KRLDL;7_<^87PW)@CCK MTTJ>3"8XG3S]]EOXK]'XV2!,)D^^]B<][YQ*7$0H7-"JM(S@E%*@46V M5&N:[ "O(8[%&$/I4AU1'I/TG]?],>8/V#Z M.!P-1F??%J!2SME&E\ :G4!ARN"<\Z!\4=R7$+FT][E/&Y]PFOIN)]2&F\$, MU-OI1QS_UI\D' S"$$<7DSM"F(,4TMM0L@1F."-HS(+#4LB!,)H,0!N<+5MI M?MLGGC 3.A'Z76:(?8^).98G<3(=AS3MQ1RBMEE %$* DL83&OJ#DSM9N#,D MA=;NT$T$AZ=$8_]Y#X$VW.)OHGEV,1[3 J] H119$*&CB89 18*G.!U#D95D M) I4LA,MWP)R>&7OHYV5BMY'M%U8?6'R\P.8\%'Y0AF,9K;UO;?-L".Q8>]E'C;WFNN M@0YH\B2ET07!>H<)"2*=26]PNI!"S]FDZ:4HP)6CER):27(0"8Q7->,8Z/^M MO8-->$Z!%,WDW8$%\&KXF5",QM\(4H_<$:U89:/PF;#0(KWB&7(4G,R4%&SV MC75__?FGH.L'R_.N;F6;X_]M>=Z??!I-PN"?X]'%IU?#-+BHI0KTW1J![P\O M,+_]A..9?[IDI5"&T ;:H1PG&PB9 1=9E8A7&F.B]>1.;(2'H#T%WAQ(5W=9 MIO9EV1,8NE,7ONHC@%5NPIV[O: MUDU=BIZ41FIO,\2@$B@2,@0"""GJ8@7WF;/0I2MQ"CI^N$3OJM?LJUXZM>H) M-IE6E_C5\#6&";X9#=,"'7(9$^.T1$6[C(HZ0>#%0$A>ZQ)$6X7,L2$#RL]%D.NDQRP.7VH+PD4P9GCD$] (<1[)296:2M][2;P#X MKA7]<%%V8!7^/AZ1!3']]OL@T XVS-5/_5096"W6&%+)$B5(%@@;:K(E,AJ0 MJ(KRD"1H?,A-U MF8"@F-1*.?)N6UU(AFJ*2)XC-FZ8@)# MW5TLYT0\O?U%>U??ODTHI\=+4E9P25L-LZ!L/3UBDS>WAG^U_T0^P,2&T[(PW@_':6_/HX&].&3ZFU,OUVNE4 Z6RQM)HP8 MI@I7$*) 2(870Y:F*JYU6F];;-]]T4)ON(O\."@-_#MYJ=7L:BO79>Q.!!2E%O M&7,'(=?TI46I.$N1Z>8GPTHD1R7$7KI:4PFPAZ [4/^+\T^#T3?$69$RYKMK M[PE?1/+90XQTUJE0Z*345@%9I&@*VN0%;\R$>T&=#"G:BK_#3, [_(S#BTO6 MID"&3RH.F-"$BKM(NV(RD+!$C%('T[Q:9#62DV%" T%W44:2TOCB!B_IC)QY M-->^U9,L9EUJ[8$A(UC9(B&F1$@Y>B9X":Z(]H?%_?<#Q^7.,TVO! M#<)BK(P.;&%D*?ML(6CN0<3B92C&E-+.M(U7HT)\J.1N+OUH#HA2@CC[0XIU1>Q,>]9."Y M9B@-8FI^4>FQ&(X'B4+M). .+(=GH_/S_JSXK:[WV:S ^0R'J4(S07+' H+, MHBZQU)"(CR#)P-7&JF!<\TM*Z^&<*!=:*:"#HH*[*[XLAO]]-)[)?CH=]^/% MM ;2/HSJ#D;X2<3TB6>OAE,>V,@VPY,5WK2,>=,."=S<4RQ5EH M7;/2=@4GRL CJKF# HK?QPNK:[:LV5V_MQ?3VL:R+J@7 L%#(\ ZQ6J=#@=O M,H?L3>36NZ!LZSUM,Z)C9-Z.I^\[Y9G-E-7%55[:FD?#U="2=UX4E\$859/. MFEZ]D ,4%$I[E4K2K2]G;8#S0Y.HE9HZ<,4_C#%,+L;?9N#F..>WCS4WFA=4 M(&M@4"F9R/Z3=+(;)XM/K/#F]9OKL/S0W&FBH"[B_3G/E! &OX=^?C5\%C[U MIV'08\XD$TT$IK*B/V&>=1J->CR>3E:(S]L\7=U?3MPS@,)_/66$_R?UW, MKT*]P>G;\B%\[;DLF;,.P7+DH)(39%DZ VB#\]Y%YD/S6\CME_%CL_7(M.@@ M;/$.IZ0$S"_">$CBFEQ;XG-2;NI/>\&G$&).D'FM)M,V@_=,0V&.ZVQXXJIU MN?3]J'YH'C96VD$B'CTC55*AT(*E-+2E!T,6)'? -!-%!JU%\ZJ\NRA^:-KL MJ90.8@SWA65ZSG"6R%X$IQU9CTS7H1^U]Z#+7$@OK6K>*/8^3"<:O&JJBK47 M.O[MUUM2>TU_;3@MX?T'^O.W%V\^O'WY_L/;9__WO]Z^?O[BW?L7_\\?KS[\ MOS?1[3$]8?-3NIFFL,/*NINN4 1'C3Y"L"Z \M& LUI"SC$5'I7@?L4$C<<] M78'[C");":E(#XJV/XC:9RC)TTN3@\F\]2WQ1S-=81=]WC-=81R.@1S)!82=% MK^/,W@+OHG+\)J9%V]QM0'4T&6$EH./,/VBHN-L%X\VD?C!*.!M0R2S Z^JR M!\Q EK('ZYD13%GTV/H4/" 5[IE1<&@F["+L;E-7BR[7)D=?D%PF[64!9;.& MD"RY3 R%DD:(PEI'CN^ .+P/TD YZ[--#Y!L!PVF5Z0PEHW-BU#>! U).%;K MT!TYW;1@DS"I+&3M>MI]DNET5-]&TEW<'5R=CEB BSH+]$6#%JG.N(@!(BL& M4"9D3K$B7/,&@9L G0(5VDF\BXD"]\?[%T ##\6:Q" Q[T!)B^!==F!-1FM, MX+'Y[+6MP9T$33K11 ?YYMNA^261178"G8?D+.UK/&GPW"1PB6O+A$=M6ON2 MJY&< AD:R+B#G#&QL!YK^!SG_WTUO!M$?3<:#%Z.QE_"./<*,\B%*6!F$Y,D MK\-1-:7U=^#'FQ0S)B3ZD?IB1RSM4>%]8XAKZN3H-* M@@BJ2P9M"T8LLD36NM)H+9C39D4;'71@ALX O9I,+C _OQC76@,<]T=Y#F[V MP[>?9B,<7WS%<>I/,->&?=9I01Y6\M7U=HEL,R; 6!T%UKJ"W/J V1WE:=.I M8ZUU8/2N03PK_5T-V*/5/-)QZ8.F73-9"YXE^JLTEC',PLGVZ=8=0?Z0+&ND MLPYJ%#>^%N]P,AWWTW1Q]>5)%<\_QZ/)I!>S"9C(.LLN6U F>7!>*^"U4Z+0 MV2C?R36YG9'^D'1KJ;T."ABO*G4GBU96'T8?PM<_^]./54JT#)+-; U/27ZY MAC=P.)D5^?98\B043SZJJAVN&(L0J_"*3T)J'Y3EL7F<^,%P3YM]A])C!\61 MUZ!_&*V)D\^0Q]O(WR')<-*?XGLTP]#YN,SHH.FW;,90LM;%+U8O#9U9I07-9XK M!$+P(JUE96_][ MF'6%48XS#(66Z.I=UB0<1(8"@G0FB%*<$:V3=0==X&D3]_%RI8N>Z.M66^_Y M##$_Q2%],:U3F2:[+IFAA2D1P!6F(%NK;'*>.]?)6,L.UO)C\OV@ M#%A![;T3&9NN4-:9XR\'HR__PGR&_R25U&\^*5,CZBZ;%@)F*Q0'ISTI,"JR %3A8$O(2KNH8SQ AY'KV;2&E^C> M7YR?A_&W47E/IM/L[1I.%WW]9Q=4!_W:/^U]^HCY8H"C\C+TQS-7<3XRYK<9 M3LS5P:P]%^G?/*4G3)[7"IW!S7=NN_MVW0+:^VK> >75Z!;?+02T<5Z[Z;G$ M\_8*#_W"F]%P? />Z\MJG!2MT4YY*"Z96J)MR!(N$G3RUG 6BDBM4\M-%[#W MJ-$&8.;7J'20RLGH:<&MR[^:@3_4C<7C,>YD-ENH MTU@O1Z)0BM*CT09FXT24M?06*>M!2TG^BO*9O+-3H!&#.Y MW(L7UPFXY((;M"!+;5Q8/FFE\FVVKJ;H.=?*M!1TB MO5G6U)NWM0NKF!5 20U"%,1@DR^J]8"C1\"M[>VGQT&M7;34):5>#3]=3"$KP3GHF<9;6I]&V #G!^-( _1PH%V$+F MEJ5TCF<+@K934-H5")Q98"I(C/2G4H<@B/PQ"?(0+70RB''<_QRFLUJ!R71\ M487PKC_Y:W;0>L68C2F!\='5V4ZY3J;(@+K4R29.T6G;F"&;\/S8GE8S375P M)_(*6QT.5AOF?J!_N7ASML'6D3NU"==QO*=V6EQ+CT8JZ. TVHC1T6[*"\$S M,=8>(PPAJJ1 !)=$D-87W=J@/3P][G& CL..723?11_ :Z5I5U%)U)A<0 ZI M^G>*Q5(KSR)@CLQH)6C5O'5QURH@A[=+VNGJ=NN-O07=@0OS9QB/PW"Z]*?J MY4.3#43.R,KR-H /EE=SF6QEQ5+[+M@W )R0MA\NV"ZZ_\TLITM#ZGE_4HLL MR&ZZ;+"/.@H?R/K-)94ZD)R#CQQA-EU6925L\RM)]X(ZHD]R]+*">23+IE .(3+:V,MR K[FTH&-61@M>1.L>HUN# M.SS%&BMVQ1G37BL-=Z1:=MK[;33$;[^%\5\X?7DQS"OQ88R1''YRSM"3%!AF M\'7$<>9(;U+Q6N"M9L1W2VZW?=BIL* 3X3:,>LSPS:O:W]<]<[:MKL+GF/4! M?093V_'3R3F;:FT!718F.*EUXELI?XN'G93R6PNW8;!BAN_WN2,:O!,K,>3R9X);+L+M0PQW J^F\BXPX:&ZU=;2\)9W@T$KRV]=IQ MB>!]41!M\BBRXD4U'T^[#LRIL:"-U#OH.73-B]JT=MJ+W&Q$J"^Q>LDN@>-9 M@G$6LRS*Q-*Z,'$[9#^R)]J![CJ-;5_#VR-GQA4E%&AI.:AB:MB%>4"T]$9( M9W3I[J2Y!N2HDQ6;:6WMF?-0D7>9<=_\NLS>C[=QT#^;7;J>]%R17@;:&W54 M@DO@2O7NF/4 Z&>))<.H;8.TO>;)=,KTB%CY%KI+,CP%F1_ M1<452(9,"Q((P]8)_,V(3I([#96PUMT]XL7TW\>C3SB>?@O#7+W[3S4I>;A; MZ!N>?O KY]M*HM']\N7C:@.:Z9-KS[RRJV)FSB59[:KJ97%)M$5AP9)U109W MTERT-ECO1[5W(XR%P-^6M<^:E]-8&T7(AMXL57OJ<5][Z@D)* K:P#(/LGES M_BVQ'>H>=V..W.DPVX4JCGWW>C*>]MZ%X1G.+^0)%6(6#++CM#V;8,%EFZ 4 MP1P)"Y%M]0K1IUXC$/WMBCPW'GBT6;.=J'*TKT@;FN"7("ZG%MT/8Y?"LVTT MW+Z,X/[:LCV$?UM]>TBN0T4&1"%L;99J4R8XUD&0-7/(4G*66W1EJ]J 8RMP M3?57>_WM(K#&>ON-)'5^<;Z<.VHPA,(S"-I4R/8-=61<8+7V1$I3K%!RJ]85 M]VCNQD,/YV/L)?91"YDUK*N8 0E?KP$INF2GO 16Y\6JJ 1X&Q+PY$T)"CF+ M6T7*[U/>]8=^A\I[L,PZB#ZM/=J??JME9?-!TDD:2>0'"&$#-O MDF7)<=VZTFH+6"=I%G6EE@XB2>M7?U6.N W$CBKYMX!WG(+^YJK=ECI[ZN60 MF\\UJ$:A8R$A<%,2'6[2@/,A@ M&ITQN:>"M>UD=C3KW%/L_!N;LHHX.&/,Z M#//3B_YL6$A-,;XZ_S0>?9[?Q%N6ISL;:B<2,+;4R]Y*0JSEZ'WHSI\&+NY,F_'L-MJHIL1KI\NICB^7/G25TU>95NO8]92!84B@TM6@F.8 M%$JOHF\]$F@-E--C10N9MZ[=?8[GHWHY:I: ^X,DO.2GC4%DYRW(V@Q"63+0 MG*XE)HRV31&+\?Q6F?>:TKUU3S@=_;839.OBW)<78T)R,4;:C]Z6TD]XFWNR MY)",TR"%)O<8N00OO :=2T+F>5;JWB34=H\Z,7VW%6T'MXA_"^EC?XCC;]=7 MOFQ2YK21S!A@CKQI%22K3<,C:+*#R$(2SK+6F>P-<$Z'&:UEWT'Y[FS S*?1 M>#K;J&Z#L\A4R;H9Q14.!1!,?)0A> M+XP(XJ(7DD,VO-;4^82W0]1K;+P='[R7Z;K=LQ;!Y))"E$1\5H*C(S6F.A0P MU_$GDF/4-MT.@^VUP(.4I'2NZ1O6;%?2/G9QRF5!:M4.OJ:7,K\:3L/PK$\K MF=?B/_WV6_BOT?A9'=LTBQ(:-*6H4B#S&$'59L&1^0 F, VU4;W-V@'JD1;E>JWYYBS?3V M".A6Y\GI8C/P[.DM='HV#,Q#TF1T^I3HW&O>CO QT.R^GKB/E&6[J*N+7&.8 M7DM-D&*3$XE!R(R<4%\R.*L29,&-8=RB;]ZH\ : (US/ZU)=MQV[!\NZ@S30 MAW'(2$?[7TL\@-@HR.7,M41E<1S"(KGPM![SSL( -W <-KJWTOB752% MSO:ZY)0I&B-8S7D=E*IH139 *=*Z[+5,VP5U'FO9]D&LV(>+M&'>YW8AWC8P M3J]L>R?AKRG[?8CD.BS;EK(D8Q*!,,LR#BX9#X5H*):VQ[5[1HY=MM]#? M+@+KM&P;#1T*14B(@C&@92#0\C0PGW6.BBFYW7"![Z-L>R>QKRW;WD5FG99M M(\25S[\9$V=_47= ML.IA): _^]./[W P;R[PL?_IP^@%K7^Z'$*P#=2&IM&.\ YO/C50Z"9Z=*"- MKC>/>R![+H1C,8)VA%MQU!#0&T!A)$L$/&\79/L>B+/!;#LN;W910F.^//O8 MQ_+B*Z:+FNZ=5X&-%V>@_(EC//E90,Z.$O21/@BO:J=X#F$'!T(;[QW9&BA:MUR_P: MD[0[]A=U!R5U[S^&,3X-$\RUPIOD$^9R'E?#>E;S__3;U>_\'K[5[\U6<+6, M8:Z%/M=BC-NLJ:-\81?K.4Y2<0^:W&[=\5ATW$'VIY.U6>%BCHF#*[R&M:LG M*7(&@]%IK-V@8NN+)-\/;^_)4CYRVNZBV@[H^@XGTW$_33&_GX[27[.[%N_> M_[&LH.5*5NL!,!I56Z,B^&0+V.2M"])DU*VO1&X$=/ALUO%U/NI*80V-MODE MCK6)OZLJVT5HJY>"LD:Q.F/.DL'JZXWU)#-DJ^ML4DUKV*Z*''HX\ARTW M[$KN'1CU;RZJP-Z6=UB+]DD,,_KV1)3,6TXO !,%5'$(&]E%CAC),'RNI4.502 M M.$DK9.F9C2\G;+ZS6;Q#T/.D&M-Y=O!VT]%C#>815973F.RVA\'H8)K]K8 MOOCZ">MA]Z%_3K]":Z'O3DI(]6?T#_JCS'M:995Y,;2IF4CK*"0@;HG2 KDN M0N<06@<'6F$_0>H=5;VM9[(L%K$2^\+8^X#CVD6^H"")((C$+1VL6H&S28)U M2K'@@T5GMMJKMGWB"3*G.XDWC%/-0"X&&'Z;4_3E:/P<"_%X\FKX6YC2]\* MC/X_1^._: $U7-N+7$LNG0>=90)EC(80ZE^=S"8HY5S:[E+-KD\^59ITJH$N MAK[DSTAFUX2D4/>\X01[Z#7GA18;A2<"*TE>(/4*KS/W!+-ER-8?LQ=IY&"%DA1"38\F+:!.V#@8V 7[*5#NX8N^RTW8>N5X7 MZ9H/UKL:"SYY._V(XP\?P_#MIUG"\I]UJZ:M>;Y9]Z+ ;$HN(%P]N1.K4P=* M 9D,N9TY*:=;E\4?:FTGS/%'28^[KX%K?A%_EG>O2QI/O\T:3LS=D\G\1OKD M)I3MKMS?]Y%[7Z[?"7.CF1!KGGG%/B(93Z0\X*FVYF*DXN@,@@Y)6Y^5++J] MG[X94[MY$.LD_O3;C9_,DO5:.&3"9/"HR!:-D;[RY+HXHW3(+-+.WWHTQH. M'FI21%/FK)\3T96*CGTO_V:U?PDR%^P1NOF,JT*M&BQOH1 M#8WH3*\KKR+M(M\.;[!L ^/TKB+M)/PU5UD>(KD.%>D%9TK7AI4Q:%!>!2*C MRT!;&OD#-D7R2[\'!6YU%:F%_G816+<3)'B*A5PV0,XS*$T;BA.U8U32P1M$ ME=T)39#82>SK)TCL(+,.$M!KCHH9-P7S1D>NH4[5HP4&8N?*I M]9C+#7!._UAMK9-.4I0KH2W*>+8!UU%5Z49@QRD/;:;&[>BQAPXZ*:/;!#*S M.HK5&T(E'(&,%IS4'EAD%G-(4OG6 :\C$.2>.LSC\&,7T;>N;_FS/QB,OKP. M<32NOS8;VSN_6L'H].-HP&0Z"56P!0*S!K+T03L6F"S;)8O7/>'P=9(-M3!J M+<+6A8ZO<1;B7/047=ZQYIFL(U[SSYG1"<@" 3(<.'(CT:@L1-Q*IZL^_63T MN;?HFM>@C:9E-"9 I3]].SX+P_[_-XMK+Z<)H(_(R=2UKEA0Q7HR:4P 9IW3 M/C"G;D_@7%>"MO$Y)Z/?AN)LW;[_=?\O)%\D8WXQG!+[:)W7>D4GQ4I" I6- M)@/6\P(1&?W!3$G6>QF,V.[UW?28D]%S.V&VKMBZ0D:GQO*T$#PZ*Y4#H;($ ME0*9%EQH8,%:)6.):#&>S#(=+_%R MHF5&CSXYB-+2ZDRJU[#(ZB^%88S*9ANWJX=;_?DGH\P&XNN@CFF[R-#;U7C):32>^-B"B4DY++I(\D.N[ MT/'V/;5V,=3-JYCF<9X]D"T0'B M;(\PN+:W_C;09 _A=QQ@6S:3UMXER3UP32Z$RCE!2(1,R@Z M/"R4=@ V["+SCEFP#!Y$$5&R %G3VE0P=!1:0J13X?4^0,;MRAT>R(+'8&\\ M1#<;5/T P3:/L&UT+W/(4IKH0!=5^UD:"?46(WT5:^5@<*BV#+4]7E]]#YTV MEF 7'=(OQNECF."ST?EY?WH-EP^^1,.0#!M'G@H&02O2MM_1U M6+Y;]3<5<@+W-A(C!ZN1 H@-*N#PLEC]3G3'\D(GIF(9;OLY_?0O*VQFEN*MH-> M78M5/AGF-Z/A^-J2WT_#]&(^^",%P8NHBQ5.@&*^@*\]#)UVSF'T10O6C7VV M"=8/Y_DWT]'A:;1X?[8!V6T48#/ HP8&VJEW-_KLH9ONW,-[P/I8=$E>@M:9 M3-Z$#*) "3P:ZQ2/M!\?>$KIAA9;JNC_2L(NL.Z@)7MQ5G+P([HH\9(@A"L@I8526)WF[_J<5#5;B.4TZ["_ZUE5A:^>%OTWI MXE,?\_O_O@CCBG/:RZI(]#8#T['VR3:Z9F45"!,8=\S0S^Z]#[SK0T^$!YW* MNH/0U?L+\L;"!%\-T^@<>R[*Q SQ4O!$;IE2!F+D C [*:WA@6'KT8XW$9P( M#1J(MX-$]*Q+P9.4QA>87_=#[ ]F33V>78S'1,Z>DRII92-$E6O+?:?(!A(9 M; PR.R$P26RL_,V(3HP,#<7?7G]U=J]L!;P3HTU7BNF@)=BUOKVO^ZGVIWIR-L9Y4^E_CD<3 M>$4*=_T7X9, B;$JMLR/W@CHQOK15PN%J[9;9O4EM+G7] M=WK%,I=4SI!=(+M9%G*DN2.3J1K.LCBFU(&VF[483XQ#G:IH;:.OAAV.EB9X MN&9]#W&Z3%:,RJI?V*/]T5[/V[LW4KO5-FJ>CD2A6RM#+(B C*LE]FU@Z!,@%@[7O*LHLVMDXU'H\X]^>C' MP)Q=U-$!8WX+Z2,=ZN-OU^$MAX%'+17C#&R(M8&U-1 D(ACK@G NVRUKZ79@ MR@8XA_?CFJMOU(WL.\A3/KWH#W)_>$;(EE^^.O\T'GV>!RN6(&5&@SZ!UQCI M&+9U#BB)@3&T:!A&)K<:SKX#0;8"=GI4::^/UEG,M[3^4!M!S[INS":"7;9/ M25P*HQ*8(FPM1K7@=+*0?4&41M9>^%LE+=<_XW0TWE*8'60E7X=A7M[T+C%$ M;A4D&V:%HAZBC!(TC\1#;L@>;QTFN'KZZ2A\3\EVD(RTS*17+G3<1 M#*N=-D*FA3&N(3L?N.=*\]PZ0[ &RNEIOX7,.T@]SO:?CZ-!7G':N,0D\\5# MUDH2-.05F@43O&!96*-UZ_M3&^"<'B5:R;YUEXTG?9)3*'7)_XD?^VEPV2=- MNAR\5Q%$-AF4+QQ<,I[T6(IW48GDMQNTNO81IZ/EAJ+L(!'X\F),@KT8UWG" M+_M?ZU=+9(&A\=9:0-2Q+K9&X<@UCLEJR^H@1]?ZV%^/YG3XT%CR#4?VS)CZ M',]'PWG)Y&@XF^:Z ,5D9DK2UI,#IYV(Q^JHA@!8@L:0BK.W^U*O>>?7/>%T M5-Q.D&LGT>QC],UFYLR2R:^&)((S(MX2FS=<<8P69*(S1T6IP4=TD A<=BFK M)$1SRV\]GM.A1'/IWV6&[RRH/"]9$2BT(LY""-[5_!_M2F1_0&V][H)).30W M SD3L:),O;:B #D*%3U*Z.+^8%9P\QT]C3/W9UD9?#W F]F%^)SYUM64$HR<*&9\-H*,JM;YC4UX3HY$S83?NCOO'\.,GW% Z'*- MNOT+!W6H[_LPP)XPEG.N%# 3Z\@0,K3)[Z*O%)JH'BYI2S7 MAC&[KSQ\4Z<[UYM@\[*[AC6&MS^YJVK"C2LX7-V@-J9(4V[" MD0?7#>ZBBN^I;M#4IDM6>,'-&;Y$QX+6J5Y.0MF[! M;>('.]V_@[K!KIFSBSH.6.N#F6E#&R[4BT6@(GH@1Y^!1B\2%TBG/]_*?_K> M:GUVTL>6M3Z["+.#R-[UR$]/Q*3)CY/ E" L1F<(7)=9&LH&EHJPH?'K?_WY MCTCI;8S9!PNW=?OCYUAP/,;\;#29CLH_1Z,\>3\:W CO]7).01MF08= Y):< M+*C:]A,=T='Y4M"$K=[J+1YV,IKN1+JMM_)U^*[BOS>@FHAH)-%3%UGO)].. MY++2P)7U7$96N/1[$6'U0<5GVLE\23GF1*J)+SE3B=(OFY:(B X M%SUH827FE!+M[(-:/@X4->^.6^[7. M%[=_;X^K_?L^CU"1KH_4M26>9M;)W\W1[=H0+V MS;FR/F3?5"&/)6B_85%/O_T6_FLT?C8(DWECXT!>'+."@0PND8^G:-,WC -W M2CLL+FO>NA/T#O".'\1O2Y#UG9>:*JJ#6.P&J%= WX3S9>!I&[@=A?9WA'J< M,']GJM^>8LWT]@CHQCDK&KD#RUCM7644A(0.1+#DE0896&A=I?SCF351?W8_[2,;BO)"_,E@4\Z@\):*HULUEXAY6QE MTK'Y=<+U< [O+7:JRMOUY8WTT#KX_"21BSS&_ '3Q^%H,#I;MND70ON$NHZ1 M=J;F[!.XNF+!4F$\)&_*=H'&=4\X37VW$VH'F\&\YV7M8G#9]7*9Z K"%2DX M1)\C4= +",0ZVA8M-RFHVO^B\5:P%LQI$J.M#KH(,X?I]?NM,@ID20"6Q$!9 MS!!J'MTF1 Q%6DRMG:4; $Z;! ^7=0=!X_>C,OT29O<=EU\^GU<45W;6',E5 M>Q-O"XL:;,[U3FR=!*/J11>I?0[2>MU\O/O6X$Z;,-WHJ(-^!1_&(>-Y&/^U MQ).8(IT&0;R6L69$R,RQ+(#W04C.D[6W$Y9[<^8VAM.FQEX2[Z#1^9M1'>CP M":=XYX2SR=7D>@;I.<$+B3:Z2 >>D#V:B' M.^M?7+!7*D13&V1'+4$5[<&KPH$H+;0L')EK/B!X/9S39D@K/31L=+"$MFZL M0XW=E%1*,+S.(ZR#ZBVY4&0O2\!LBQ(EHW*M;WEL@'/B4?M6BNC 75D#;?%B M; .NV_&QJX$==6SL_FK)H7'^M?]7VB=:5"N$II4X& M"5Q#T,X!8BHQN>C][1X(:\*>ZY[P:*:A/$0+H]8B[*!H_M5P(=0MDT$^!8]8 M1]$F1%"851VW;D!FCI(YKJ)IW4YK1X@G;F1TJ; .PF7WP%UIIV\#N2-SY %P MCV.D=$J#W2C73(<=F#,/@:ZL+\HX#LZE>O]6.7+L(NWV1J)C3$35O'O8HZ'= M/:;/8V?=+JKK@&UW@HM2AIJ;<*!H8P;(2=":;3W$"&&*P( ,9@BP'I]D! M"RRO(7M4@;S73>IZ.U#)88FS&+>I@Y'D24).]>:=+P4BHS^"\$IEJ2/FU@,L M[L/TJ,CR8%UN3Y?=%7'8(LAUM_*X(6?2A0*>N5QS718\TMMC?;8^9>:E/N - MBD=S;_*X9&JAK Z"Q9N%TBO*!5Z4 J2=ERP[[R$&XR!:BZA$-,RVGCBY&=&/ M1IM=E="%6W_^*?3'-4_ZMMR"=\O\>_$U#2[J *!Z[ZXSU/GT=-C2Y2G6 M]XJ^NSQ(>[+LF0O916F/)!B]#>3'F@LYC(2<12=-5$#;6UD2B'QQF951@G,A M5>L!P4>0S)T@)PM&6.$X%%XCG8+V^O@(&H\?.G#'=P] MG9W!DN@4%,D02O)^/-.F3K'3.DE'+]Z!:Q_N8'QT=&ND_3TIMY/JNCCYC^/[ MNN(X8SZ3?ZX$*,,\'9+1@7^L@6XR8$Y-.M^Y!OP_>GT1NJ]*&H>]9&><]TGJ# MT[MX&=.,#A@-!FNW7!W)A:L&5G2<%V7I!5*WKNFL*9)]P,-/G$\'T MFI+3JN/@G8_MHJO@9NR'[!SHL_')*7)L=+V^A]I"1%\S9H)4K[5U>.*= [FF M8]MX0=RFQ=-V62!R6]\K44+4=1QGZUN"WVGGP%VXLD?GP%T4\CUV#N2"2\U] M;0VN;"V_(TLQ:UIDL*Y@M+'HUGF:T^HDF6[ MJ*OU_C]H+M('EPLR=5<=H$[2U(7J^%YEH/["*M-VC*>] M=[34^<"\P P+(F; $.H,+%[ ^^@@,Q:==%*3E;Z-VNE3KZF<_G:E[AL//%&_ MY>%"[4*S2X)M 6,73V,;';=_D^_W'/80_FWU[2&YAIOT;3A1*AY2T"!\[2 K M(G$SF00YRI)""0)QJU#$L16XQB9OK[]=!-98;[^1I,XOSA= LH_*%6' )J5I M9^>&+#OR)(PW049$E;9KGGF/YFX\]'#'Z%YB'[6064.3> 8D?+T.I);5.V/! M"U_G>B4Z".KH)YWIU*X#94/8*NA^G_*N/_0[5-Z#97;<>PJSS49G8]$61AIA M=,+;[,$C)B@\B6*<%TD=N$G"#Q;H[5)ACZ0/S#:0'VOM\V/M [,3#1ITY'B( M#A])Z;WTQBDC&.A @!66"([7UF[.2Y;IY=2^=8.&1T.[QGU@#LVZ751WB!B1 MT1B+]QQ0IMHV#FM[DQ(@Y&D'QNR#]U%%(%\WJ>@XF/JZH-ZU;A)W*RQ[,2O%$QF:H491E4R2[$Z7@&DL MMD3/2$:MR;41T2G2IYT*#IL,K^,Q7@W311WY_F'T#H?XY>UX5AB>>TH$)R5& M,#7.I%ARX%1(P .GKT4--!VP9]4&I"=(J .H[*"]9&YMGK_CN#_*3[&,QO@& MOTYGJPB#Q3JJ5=H32OHZ_D6"+SBYK!3RR:FC6?DV*C-CHC2X8A>2B>;^.[^J22>=,/)CZ#G$9 M8 ELC\+_VQ^Q=Y'_1DR-"OJ7S[BBA,[!9ILU:&_JM>18*P9L@5 ,+](6&W-K M>^,.B':E^LN/G@=_O>"TRP5>KUP[6ALR\"$:L%9%J7)(1K6^F;8&RJ&*\/?3 M[_J*^X?+];&4UU_>SGQZ,2'A3";OYY^[[**<07%C&=, M:6.:,V43H.-G5O;0^&T6-9-\!U[: LME2_7[P724#KD!Y#B)CH:*NDV!O:7< MN>I+R-G+.A5$*3*.G39DG)"1E#.A$D4CVM:C ^@\GN2#(?2^"[";5TY_B\, M@^G'9V&,"TS+ZF;'N.&) 9>7EL2[T6#P&UFXK#4@G*'F380ZU3K[HW' M"[[LK8@UBMU)BAV^NK0F[)\-G]7P]S#-A[8-9GF7?Y)X7M=^_0V.$]>1"931F &88D%,A5&NUAC&FR TR[4 M>/]?!Y-9S0 ^MGONM/_II?[.8QL'K)P!O:RE4@#\!)43=U1@OC MQ9KF]6R;\!P_(-E$\Z..--"![76%[1G1K_;O^D#_C1U#O!]%4FL[.@FQF=1:C60&.=QV+&+ MY#M@Q;,P^?AR,/KR+\QG_>'9(A!DLQ$S'S(5HT#5.4E1:PE26%^"D$+PUIW: M5@(YO#O63E>CUH+N( CS]M.LK^SP[#6&";ZK=4)ORQ^3>;'&M3:U+_O#,$S] M,/A]-)DIX*HY[>O^9-I33*608@">.7EP(7KP3.5Z^9$9EYS.H741:R/HAV=8 M5Z;O,71Y:$KVN-"8).HZD9; \6C!QTB[LHCLEHFIJ!AX%!(8"S)+DWQHGHY=C^9TZ-!(XAV$#9_C MI[IQ3>[@4M(+GI"L,UNG%QGI:X>S#)%';S-7J'/KTIQU6$Z)!PVDW4&-\(O_ MONA/O_V&TX^C_&KX&2?363E"KY -IFEAX*(54%LP0$Q% @HA9$8TROC&)%@# MY70XT$+6:VMU'TZ!=P1DW$]3S-6VOD9-P;2)S-+B:#LB7"% ""4#5S8*;@47 MS4=MK,-R.B1H(NV[+-!M-H+W2'!(LCAY^?E-?YG.&.9K.$WAT@3RK6*.$51Q M$ASY[L L-X)9G;SJ9F>X']OIL*03;=QEC=G;RZB)K\7=Y_XDX6 0ACBZN&'F M",6$\\1F6X>Z:9?(-;<%N).^B.2\Q]8WG.Y'=3I,::R!NQRQ#3ER#12YPDDI M5BLK:H%SJ9Z0C@4$F<#D!W$G3.N.ZBN!G"03'BCGN\IWS1/[S[%@O=/Y#C_C M\ +#,,]P+Z.$K_LA]@>S/6^QW[68&;+_0_T[F3$C9/ MNS\<[?[.\@WM77O&TV\UL#W/C**2.:.H[ZRJ7=/(D _.:W+PL]-*TY$L6QO, M6P$[5#7"@=ATU[=NK9S'4K!P*=!ZL/2'9[_C>'9H#!.^C8/^69C'G3]A]2<^ M],_I5]Z6]_3=2:$]A7[V?AK&T^=A.N^FJ4U.3@H%FJ?:D0U#E2_]02:CCZ)H MU]RI;[N"8Q5%=,"P.V[AT33=1;.H!WX/8X_]],<(KJH%7(! MAK$Z2$$J"+HV<3#5]\U,JM Z!;$%K--E6&N==!"2O@?B(GN\#H)IC^?C;Z_"M]]'PWH"^N-H$5#SP]M//:PYL+?X1PUEUW"'OH/'H8T$QX)5L?;6 ML@%B0 TVZR1Y80KSIO#38]#AFA.Y,Q7N(K+6A^O3T1<F2K!&F=N:W'-F;KZ\P]WE.XG[%%;27503KA5?*(7 M4DJ1I01&:U'G8DEPR!-@MHXQ5^L<6M]!W@K8X4VJ(X5"VZOI6%S:%.N:MU[D M/>^3]4XHR%$$4#&1/Y(CO6-6YH(I,=.\H70K[#\9V:6R.P@I/$EI?$$&\^A; M&%S+TMVLQBBL*,.X!^9J^K9P.J:+]N0G83(L<;?ED* ="+D-KA^&;,V5U$&0 M-XF?W]UD,6A$&R\5PIMM8".K+Q2H&2F1+:2B9XZ[*( MC8!^&.JT4\M:#_8Q55'T;L$]4!U%CS^"2HK;:_]92_&SEN)G+<6IUU+\S$D_ MGB#QX7+2!THE_LQ)/]ZL_L4W;_BT1[YDDGIG1:YYW118Z,.CW[F&M?COB?MY3>M^?!Y?(:,-B'K$'@1D):@N0-7FUEE%Y/T M-G',<9\E'"0)VUY;-]RI9@)\++G5=S@(9"K]'L;3^824N9DT>?KM^D]F48- MCJ:WM0N)50H4\YJ61YM8+#G:I!++LO5TBNW1'3KTV9@-=\S<3K32@2%['<\B M5K$-HHXRJG?1'"=]VI7^-M!D#^$?AA8\,J>XUA"SBJ ("P3C&7@1?/8YZ=2\ MP?ZAZ'!/,O1X;-A%YAVP@-RD\3505PDZRU04X#S]H2PWM#Q&9C9:Y[50AC;' MQD18">08SLA^&AJU%F\GX;@[B%0H1=9T7PY<@U*Y6ELZ09*:UJA53MA:X7=1 M?/?:WE.P';S>KT?#LP\X/G^.<;JP@GHR*RYMT2!9(J0/*.^VD(WO( MZ\:Z7@'C<,KNSM]H)>4.WO%98"S4 8L?PE>K.Y'6 ,^9SJZ M-&UEWA2B=4[6<$/6#\IN MYWP9P<-_:6> ?1ZYLC-RX#I$MTG!6C,'"0RB H MCG1<"J. %:>MB4Y&UGJPWV9$IT2*AK+O8+K!@K(K=B^ML2@R;B")6#-W&, C M[5Y)(->>EQ)#ZUFY:\&<$A_:2+R#*0?S[LCKM[#(#-E"$BR2):T"G6N.![** MA#&9#&H6F@_-W8SHE$C14/8=3#Z8L?3W\*W&6Y>02O'$4!M!HZ1]2RL&SM . M1B+P/ M#&U?K*HX5,$Z) _M*N8/A!8M&['_6ZZ'#Z;>%[?ML$":3?NECOH2I M;(Q<:4!18_"<+!MG4P'A$\.QYB,:+V+[ #OE,C3E5;63D1X8.I\ M@?,Y 9P%[Y>D=O18M-*"]*4.BRRN#LA%,HZRES86J=DM\V--UGS- TY!U\T$ M>%>I?B^EONZGFL,9GCTY&^,LL7ZY5SDTJK;A3KS:O"EZ",'4*;6ZR*P-B[>+ M0=>H=>TC3D:Q;82X(M#4)DYYPW!]LF@Y<>U;/98="B\$V%+(EF'DY 9B'AB, M6CKK<["M>^MO!>P4"-*=)E;P9?]1X(M*O7=8+H;Y3DC$6>6SL@6BQDS'CZL3 MT(.!I()S$JUCO'4&>S.B4V)(0]FOH(;HH(]/G+Y/'S%?#'!4ZM_VFG*T[L,: M]-S9"F>C3CKU\U\-)]/QQ?F,)$MF<,Z=\\@A.NM(?=I"#'6NF>3&6JMMQ/:3 M:5="V;\'SO6/G9=ZZ:"S*%Q#\8Y,&,SU(E40$ OGJ(L/(K8>_KX"QJ'ZV[30 M\=WF-?M)];&44]Y,LA#\6 7.3?O^H+C\]>C,+R\ M9AW0IL(A83T262I0Z[\@TN&H4U IQW2?;;CBPI*VT-2K=^T_Q4^ MA2%.L')HV=5 V:BD,0YRJ-4L' 5XEQED%H7BN7"\71JP1G,K/OP4U+>OS#JH M +I1U>A]#DED,$X@&88\@.=90BZZ"(8\M;_O?)2:T:X=J8?(LX,JT>N%J]>3 M."S0(I(#6AP'Y7FBG9Z9.N RL,0]*M5:RZN1G(;"&TBY(R/XR3 _"Y_ZTS"8 M59A=]6>8]!B:PD5"H%W7@#(J0F2(9/PI:1G3F3>_2K@9T6EPH:'4UV[UC4.H M;6;$K_B<)H'3@TQR7\<$)9PQG&7@I7;I,AS!^5H]8;)6+KI(]O+W&S.E0XCV M(F100C5BO"P0?8ADA@C!)7HB?NMDRB.,F>ZBXVUBIKM(];'$3)^-,?>G+T.: M)7QF<0&'*&OG%$!-CJ!"VK-<[;^!Z*Q0Z+4)K6\1W47QF&*F.^GU=F9M/_EV M8!W<1'39XNY^3!W%2U?A.4ZL=%]=;53]'H(^% E0E"P,>2ODG]0R8IW!27)M MA9N(M(!5: M4J[Q)Y%KC3"S#*)R!FQ1W&O-%6>MB[%6P#@!S>\KW"[NB^-T6MO!S]>ZP(06 MK2]>0H@\UXX7CES=8(B2*#0:*V1J?F%\!8X3T/C>XNT@O%NC4]-%=*IV@I^= M:D(ZQU5AQ#L9"),+X*(1M0>U5U:)9)J[?JMPG(I]O[>,#Z#W!;VW0=61C;\: MT7&L_/TU=@\%]A!W1WU"5J CXU8KE1R8:"+M=5R!9V2""-H$%2KKO&A]D?>0 M)+C'VC\4!W:1\L$M?I\4#[7,VQ3Z0V4A(#+/( L9:RHR^-*^I>"CLOA;:&TG MFW\7D7>1%.P/\9:)HIT*QA'IB?BTUJ(9>%44B!248SQ:.@E;[P-W4)R$YO<4 M;A=;_S5$-R(;]&#EBC&@6>*@T&2(PEO(R@1D01ODK?V\=5A.Q@YL(>L.6GFL MPO6Z)L[&"\IO@Z\KJ_ >;$>R#YMH<@MZ[*V& VT9-W#*K%(HD4$*G/8U>BUH MA\P&1# ^JNRLS:V[ AV')O=9D$=AR2[2;UWS]ZI*M18V5#S+ C8=K6=61()1 M4Z@N*7 FD$&CN,TV<,-O]WA84_2WZM./8!8T5<"HI?0Z, =7U(23Q1-+3@RP M=B-3JDB(BA9IN5*>$W\Y;SWUZ7'?E]G')MA3OAUTJJR+K^6KJ('.K@"1*PZB9&Z%5=JXUFV#'_M]F4YXL(N<6Y_H M;_#++0-FV4-B69[.7.U#F($VP-K-NDX(=I(#*N&L4O6\VVY,\GU/.G8%Z$,5 M,NI*FJUOV2PO'UR&IZ[=_L%LC9#.0*85DA62(X3"+' 3/"\NE^"W&SVSX2&G MH.!6,NSJ,LX_1Y]Q/)R5.%Z[8L*"]\%Y,EM*X#6JC776'MFN#HNUDLB7MWN' M-S[FE/2[OQP;YO1N('OQWQ?]3[>!H:K=QY6'E"*M%VN#>\X4>%MK"EQRS.[V M^JYZRBGI=V\I-@S33<;3WKLZ_FYF89!Q81AM%[6GFB+O4B'$Z&JV0$7/$HL! MMXK+TJ=>,[CH;U?&UHT'?N^.UL.EU[ ?ZB6(!9.V@;&+*[6-,MN_I/=[3'L( M_[;Z]I!R0Q(^'H-2"DUS:H8)"O(S7;!0Q!1@D0MO DLJ[#5S:O[E'?] MH=^A\AXLLPZB2/\9QOUZB+\+T\5N(@0+T68@:XS^X-Z 8[-KCQ)#SMD%W3J, M?!O#]V[;-)%M!]V_K^-96.3;(.HH>'P7S7'"QOMI:8/*]Q!QQR_Z AFQV=M, M>'@PY!?7^35!H8%ZSUVBL8K+ULVZ#Z7T>T+$7>M\%\FVCBD]&4QQ/"0L3\-D MAFEQT!A3+ZIC@%*G&JHD,UD)R1+$E TO/J+:KLG+F@<R6!5L&0' M9@_>,@16LB\><\EY2PWO]N#O7/,=2KF#??PETN>$P (I--:SH:CT=?Z@6?\(E^,OW64TD9I;0 5N\.*Y_( M[>-%T>L@=:[!4\];-Z#?!=^Q4[>OF_1;ZDPCK?VM54"?I$2?33)_B6%*;\6K M81K/Y[Z>]Z<].H^E)HL.O.'D'6(,$#B!3SK2>\8RB\BVVGUV?O3W38T#B+N3 MBLN"8X([WP_QV6@RG;S!:8]KQK&6DCOCR",LB4PS;Q"*]M[D@.0MMN_*N!+* M]\V*EG+NJ.7NU5*?$H4G[S\1._/;X?53F/>C<]K8ZBI>(I(9E>BK<(8]IK*2 MLA0PB5G;."ABG08Q]Y=N!CW-SF<16?'(^ MNAA.>SE;QYQ5X-'5.V[:@Z-S$H*@$],D1=M@ZZ90Z["?#W+<@RUXV%6N8X%41)\#4-KINH(425Y[J('\@9(I\.' M5G*_2PO;0:OP;K+-9 M9_(5:)ZL0/.\/ZD=H\G1O38-E+B"9+"/9P'=,/Q;V[ M>^,A]/A8NJ\O5O4<)_VS^63V62$1M]&8Z N@Y&09"LO %?(]N9!2,><$+:DQ M)51,\@[4Z"VERT:%U/[?#DN&>HLQ#229@#(B=BLL!X MM5LN\JC"1YUK)9&.D=8M+0>7:D;5V^ 3R\+F]OU<[H5U>#>NC0[OV"IM%=!) MBY^[!^F[_N2OV4OA71 E206LA#K*,)"=YK('F4/,IN2,L;U_OQ[/CV5L---, M)TFJ);9G9/>.0[K>(W,;;)VU"EJ/ZUCM@EII<2T]&JF@DP-H \;(F&,"!5AI M2QUMRB%:QDBDS$2'NAC5.OET>'K1F[Q_BLDWG])>0LH^>\F<:,\D<&V,@-;JOKG MT8_ IO)V$YCK=4OJ/\@_6?K8@ ^7"".#4XMEEI4=*!P;0!UY-'X5%@IW$I5%-C.WH M+H^/@91:\""% )]+D2J.(+TC"%=3O-HDKYEO93><-T'V.!5.PX\NHN_1J;"* MGUP=A($:E4/)-S0*#T+')5AA;"E,;RVCD36X$,[U*HJ*S'(U4/D'2O MSQBK>+GB[2@3_BENS@0ELRUF5J *A# 432*O@%F&QI?7VO#:B7BM@)W2XW2Z M^)U:FNJ53I_3]/I]7KOE\(#3R8;$0%I3.\[WW)/$8J-7GK/QE/;LV/)J^R^]W5AV:VP/?&C:?_ M<%GBVRS!-3R#X\D##[@HN8@JF/J91$\R M"#W(J).1 K<&@79Z( DM=K2O@Q+1,Y.]E+6K*%YX$'H7[M4+0N^BQS,/0L^N ME" V!I)2.!6O KC@?$EXLCYPZWBNO7@O)0B]$PO:!:%WT<:0\<9MB= M]-8V\/@0H0\:A,X$A<='A"$WD4!0P>A4ZHS M<=H (8MD9QW*BZPY"[ZS%+F'& MAZA@Z"!TI4S(FFL\8E/"C94*<,I[T"$1(I@ER;0*/#UK>AP3A-X;.[I(?K@@ M=&,XXY(&W"%+84BN6"D#Q\%8;V+IT6!)_0"")Q"$WDE;[8+0NXBZ!YOCI;LJ M9?\^?4WIYQ )Z0U15(A2_C&#B(:5VJ ..!&$4LZ$V&R7>30%=F'YM6R-*AKI MH;[>-EQKN[P%LIZLC-VH3F-CU-%>"TH<(?H>SI%'$%JE5+1) U[< VYP48 1 M7D"FU&N1C7&#;"0GM"R&YD07B?<5#?"NF82;Z11WS!>S69JOVP?+Y(0T>-IQ M1PD(AM=X2V@$C]=K9U1(CM5^OWD$SO#612VM;7N(KR#R'@R,#6A_C)TOY3[Q MU%PW?6+,!$9*BQ]&2V?'8@!Q"Q3U8:*W0LI6[6,/I\0#3)?*B^.$W^NE]/:5 M_OV]-_X%CT<<;6W.58! '0-AA :7-0,70LB2)B9U[=%3:( M^BT;+CIHIPOWZ@7M=-'CF0?M^"QX"C&!]!R-8J<,^(2B3$0GJB*U(=:FY*4$ M[71B0;N@G2[:&#(^HPVN7SEHIY/>V@9J'"+T(4FA)67>& J.Q!*G'B18W&XA M1&9%UM[G5+L:W%,(VNF%"UUD?:J@':NRU;*DGMN2\4 M1-!.)VVU"]KI(NJ!*TOIB(:/\K&4R&1X8D8.: !EX"()%1C:7+2VR7%1E:6. ML3AJZ:6'Z)W'"Z&T ?=<6:JS&CM5#CI$!X-7EHH$-TOE-6BF<"]-CH&+I?VF MQ%43F1-,#E2W[DPK2_7'CRZB[X$7[YI)@QLP(BIW\ +TY\I'.KL@HV7E7D_Q M2"P1K3)8""8K$RWUC-:V1O= .K=J4YT4V/0G_;Z"?+H4 ME\#GZ97FIQL/VJU7-Q%WS))Z M41XDFJNKQ<5]^9BP;GE)*"VQ,6"%+A$SCH$ED8/4W@468R"J]GM-%>##7W(K MD* YM09[\+IL7JC?H.!:W*=>+9.!/N!AW\1W:?X^XQW\A9\M2PDKG;.0/@!1 M$J5J#0S2?.P&5C0'G. MHI,E]'%(9_@^O,^D'4[=/00EUA#FW61$3I&8P('YTK#5VP@VHOWO@M=+FS@(QZZ6GWNT6]5W=%7>FY:#_PBH"IG M:]RK:T"266KE. CB\02P"I>'U!&HTM$8K@BQM6L=/(;GZ#6W>N=[G[>,,GOY MX][?EGYD);P/F6A@E. >H61IR>TR&")D9%*('&LW?^F*<:BGH6H\>6!7]ZF4 M>&DYUT**6+T:U78HIWKDZ5?]FU6J M*JBACW)E6V"5/T[3.FB\#<"^2MKM W>BRG8U5-F"'L?KX22$"80ZHIB!Z$/I M78V;L3/"@Q-94H%;,K>UK^HG(LJ^:G/.),1N\R',J]IG!VS_Z!*7)ZLJ^J2:X/JKA/IPK MWF(#VB/N"QZ8_VCF]RY4LY48XHA+KZ3@";+%2ZU(BQ3GD("K7'K0)\)I[?+9 MAR$]"_;4L6('4%4/!/O@?BS>A3XW*T3K::39[]-F-AN98$5Q)8"CI06%-+A? M2H9K2<6F $LF)(I;&S=S.'0?*(X-<@)ZKRK&BAWTGKG=I?O<^,-(T9B49 :L$GGZ) M2O#XC=+D)O*<%>5<'JSEGX:Z9%T?+M,^JJ8_!/BJF@%4&E)9#SDF!O', MWQ9N;?*R//1Z3FX2[]4%QI_=7*=8V7U_V."]^/@KR&&(AP!+ RFEN<$+(T $ MCH:()QRRIB9*0Y6J'DYZ5@\!,;$4A4V9T3JGR_)_D M0T 7GAS]$-!%*>?^$&"2-M(9!SF6V$WOT1+DQ$-.,MK$1/*9/S\$'*[^E@\! M7=1P$K]N&X#/#P&=5=G9P7N('DY"&,ISD(%ZD%SKD@JEP)1VHMEKQ2/:AMH, M8+F?\4- OSSI(O[^'P)D4%+&@)/S'F\&/CHP.690KK21$Y[3S1R/I_P0T$GV MCS\$=!'<*?RTGMCL2CTQ*1;%/(@ 'TJ476FG0Z3)5-2V3Y^8G_88R[2J^'M\ M)[IWL7R%-M,X+DJTH+U4/ 0Y3?%:24(IX83$_@E7:3:73<]3J+R'S(&:,RMYF/B# M$NC\W5V54V"4$Y4IX:TVT>+#]RF#I]) X"D'(J*@U:-"^YW1Z4A]:N[UN"2. M),Z9[_&O[K=VQ$]).$G\E[.1DL1&+LN[0Q&_)!&,UQXXS9$2J[BIWLIFB'D] M+Y%S)=&9GQ]O)]_Q]YOICU'*246ZB"/+'H1P$7R.#$BFD;BDB''VC%?&[42> ME\+9T*3'"('JZ_O#-'USX[@J%(J_O\C76_YLE*2/SN0 1AF\_0A=REQ+#9*: M;!FN=E,]SNPD$WU>.T^&9CLC(\YC;7V8E@J\\Q\?KAQ.?6EG?BM>JI'QP:*E MZ M; F?O[K)[TT3_S6^NAH9Y=BB3#5.*H,($@]='34DGDRPRC,GSWG-[)W@\]HY M>UH]7$/JV#5TB\-ISD5)=DJ;@:[#F=%O>_L]:!S,X[HA2$TIM(.); NL !]> H8?A3KH\C2UB\AV?^LGE?1&;/HS&VY.X_$O9\M-H91C(D02P5H MS_"@%?C%Y[(Y*.M0&TQIUE>:7K\S>UXO9\ZF,W^.OK\5$"UED'A0,ELB6#0C MX ASP'WR2G#B1&_UIRI/Y7E5G!M?=KXT]UROXGZ+T+6K[N?7O\HU*MH/V$M= MB@/G.T0M"F,-ISQ(9$HN$:++!A-#:4I<+SM7G(M"HLW#V=YPO5A* AK M.>!?"7!N=&(V^I!JVR!/LA9%%YX<78NBBU+.OA:%)1YEA%NQ*J51#;5XY<4_ M26^3=)R6UN[/M2@.5W_;6A0=U'":6A0M #[7HNBLRNZU* [0PVFJF..NFR(I M_38=[LA!XY\H"9!D)-8$E[P98F,YXUH4O?*DB_C[KT5!HV'2D0S)ES?W% T8 MC@>UMD(YJ4T@PN\SG)].+8I.LG^\%D47P?50;.!-D6;Z8_S]X97@Y8\_W7\V MTU>E2]."SSR::%6TB*W$VY=X'BNE!Y^M4@DO>L+6SI3M .^7L"[Z4ETI5DUO/=@K76'C3BVF4N/ AK>9.I5G4U?NNC!GGIU,YLW MUVGZ,5TM7:]?Q]_6T+2REF1:^H_0 HB4NN&1@B)&1IR]Y[2VJ^\1.)=-DEIZ MZ&$O^2U]3U?-MQ0_I_!UTEPU7WY\''_Y.K^%Q[Q0E)9.TL[AMJH5"H!%X$[G M$DH?DJZ=WK,'TF53I:8^>K"C_QB'6Z%3"OHZ7$:XBDY*/1 MK, GPR$Z$QWCMC23K4R4G6 NFR)U=-!#H,SZ.>\18?Q'*F1.\<7W-'5?TE^S ME&^N_ACG--+<">J8!!Y*NZ+2=M&C*0="**N$B[*^V7(,WK-P!-5YD!I,;<.4 MIZR0WK&$\(20D7O-2A1O%;&L IY2$(J9DR+@=[SD&&>Z;WS/7>27'F<>C[ MZR;P'(FG04/.)068T 36"X'7+VV9BDE2=XI+T/G^:-^&?=PQR1JB@>0;#C041J $;2TM# MZHDT3I34@-J.JFU Z@7C+3[WY8_%*,M7.&I)3D1$R)8@]U1YG.<"I\P8FM&< MIYC[ZP'U ,Y0(7;'ZWMW;-UQ,CZ7,+I/.TBFQ.%B!ZL-&JY. MLQ+8G"!FX:.A"@_MZI&:N\"<_K'[2&UOLJB*U'NX*=S'LW(DM4'4TT/U0S2G M>8NNI*Y-GWT=60_# BF(S&A2@5\V^R4&'.,>#9BDG3&$^^IQZT-I?\\3\6#* M[R+BVA%NRQ> S\V'FVGXZF;I4YH6R_;?;R;C9OK!3>?C,/[F2AOX#]-5"N4" M^LHMG*W29M&GB"R>F!)%27B.*XN;[&-,^*U6X7#'X1C^9G*L&IO3Z*"/E^#F M^KJ9W =D*1%:>E$"_&QI"J-0)(8 55ZH%#Q/K+:__0&()\N(.F*MN$W,IO/1 M1[S@IL76)Z,WG&D+:#%'-*%++(R1> >7600O<;[M&B7@I][3*_[M3J<_#7@I M!N#A4JSH%KL%L>X/UP)&%PNOC5+K+\_]YMP1PM]4WQ&2ZV--KH.!B G), XD M2(YP\'9K8D"K))K )!,BJU97ME,K<(=%5E]_701666]_HJ2N;ZY70%24@GK* MP>=2K]HR!MYI!T9R84,.+K)6/N,]FOMIT.'.QJ/$WM20646#9P'$_7T/B$W. M)"U*@1U?GOBT!Q]E!JYH)%S03(6LH;S[@SY!Y1TLLQYNN)^^NFGZF+ZM3.T/ MT^;+U%TO]I5LLC:"&LC&%#N:1K Y!\@N2$T59;IZ >#=:"[%[JDL]QY"B[8C M6UGP;;#UY -[#->)O&&5=-B*&D&H,[I,L M1FZ#IJYVBL7PY-CG+#L!-[K(O;;?[ 6JA#T MCKC$(ZUBB$2A[=]$24%S[," MXST/BGO!Q48"X0ZOV&.C#._AJ*>,I@])5C3U%L!^&W\?QS2)LY^];AM_6\%> M^/#>--/7+GQ=R&F$!V5DDG@D.Y7%VN'@$EI/1BHT5&V*5(16)#@.QVD=87\< M]?8ZM!IZ\(YNP'33]]/%NT+\A[NZ21_2=(E24D(<&E'@I!8@DI?@C->@8C;$ M92(1;>4CI!VRITR?'G50^SAIS>T/M]OD.!3HBV^.RGEJ=9 @24D!8T: ,27* MB"KEB#5&R'8'SG$XGC)9AE9#1;?N-NCWP7Y&E<^^-E<1@88TF;LO>+W[^3>F MXR]?BEM34SRYA00CO -A IZTB!MB<)09[KUC[9[S:J"Y-#;UKY(^;L<%^@/K M[-U-$21*JFRWC,0XRC3%**2N(<*NWB?Q&G84@,D91)M ML-3)VD6:CP+\E"DWO,9Z*.[Z>9K<[&;Z8S&)%=95[.V(,6\%T19RT+@2E"FY M%#'CM9+@"N%$T.J=J!^!R'1-6W^^"CH^T/P%\I"G^AZ01";CL G 5(XU4&L)J5^D^'G7%^/Y]6&:[P"R? M<%PP+#&E00;F<1'CKFY8:=-F2%:*)D4H[2\;X#CP0^4.#,S21Q(-!E3VN:0E ME([>I9C!,M(#Y60(9\#PJ &ARY._8A9<\EJ8J- >K7UZWQ__#-Y@AV3 IM?L M4$WT\/RVQK*.JVR!IJ=7V9^1G.8=]G#-[%#Q$6+M7]G<,*>]CQ!DB7&FDH%1 M7H!V+)+$J5"R=E;M$$K>\Y[:EXZ[2+.'-U.JE[F>;R?%ZX769H&W>NMC,GHE M0\134E*@8#J!%<)#UD)EDD02I/5[^.YAGK1B*TFOA^UX:4[@+R]3GZ17 M5&<+?O',SQ&')]P S?@-;HV/H7:LRT\ ?FV;['!=]%!<66:0T204D:X9SPVW;.I_!Z9ALDH'2 M/+A_ZFQXN\?F/7/:=E%M#W1]??WMJOF1TL).>/^M3&A=N%.3&$O '8T*)66, M *^Y ^8(EZ7N/HVU;T@[P9PH*O&DNF[Z4%0/L6@?TVP^'8?Y*B"AM.>8??ST MUPJQW6CK1ZC'J">62G^#N>+C,*X:3;>82MH%Q>9GG MG82_(W/Y$,GUF'D>!0[(O868'0=1(L>,+YV>#(W2:LT\ MUYH22J1<.('Q)D'0]DN: D_:*;0)?7:M7L:?1N;YP;P.G)Q?X M!I03>J\/4\XN-1\AV3YW@A4L)T2.5N).%)4 D;,":R,'+C*U7%GB:.W ]D$4 MW<;=VXN>NPBTC\1P^N'37[_C/C9?G3P\F6PS&@O$(PJ!&Q/88 .$[)64CJ<@ M-EPBC^2#;WSX\$Z.HZ2]F?E]C*AZ<)$N#AR_/_;3;YY)]W_]53.;TQ%#NT(Q M'5 B2&-AK0,?2_B.#WAR!4]B]<:;]="?H>NLYZC;TRB^WWJ&WE W]WXJACX.,'%P8"&/M%6$PXZE"/!B0PNX"%# MO(PV^V"RZF4C[6$NOQR+SX(4IXA]VC>O%S$N-+]>UG?I;R-/C'>:,^"6T5+S M)J )Y#+(&%U,+AOOSR;%:?]TGBE_(FKT4 S@-K(!3Z#QZD7Q82)A,_F>9J6C M8YG4['.#1]>FD?2NF?__-+_KN'0O5 )O@M1$Z7D %+0%02,!GU(&3[2G3(5$ M:.VLGT$F]LNMA/.C2P_>N]XF^2%-QTTQ\U;?*K]'1SI2)Y,S$'7"RP61>+GP MC@(U29%D P^\=I3.L#-\7B7G0Z >ZCKTMR?K-X;=NK9C*?NC"_<5>?TQ15F*CG(F@+CA>'5S"H3,TR4(I? M4PHVD%Y*:)^+ 'ZY=7=6TN]$OX=K49_O6ESX/&9O)\LC?21#=@95!I2( $*K M""Y8 ]9'J6BV@$_4WP@U3]DL3WJ:?_@>2QBV=[GNUJ? M^,/F9CY2694T#8Y"S:Y$X:=2UX$!L8QD(D4I\-DJ+J VLE^&HJ?7ZY:7N#I1 M#(=,Z*'M]19-K/%D-@Z+6MFCI)FRPA!(:$^!,,Z DX2#LCXG$Y00HE6X]Q [ M[[[)_#(D/R]:;"'\Z=Z>5S/[Q](M,(FO__Z62K[=YZ9\Z_7?N++'L_+P^.++ MEVGZXN9I8^;9)2&D1%N*HVDE?,;+APP)C(DQD\1,B+6]2B>;[/.".4M:;5E0 M;*"BI^MH[B;?):B^"//Q=[R9U*Z#VF*LGDJC=IWE^51+Q3N?33)ZL$EY$(P3 ML(1)X#$R:KVV:$F?R^[TQ_E52]7)YYP-7IEE:5A(/=IQT@:\-PL2@W36;E8D M>ZZ6VC-+^ZN6VD79YU(M]>>**8(IZI)QP#E>B_'X,&"B*4TV/8HW,:E=[=5^ M8;6Y.G'@T=I<773Q5&H;M9G3C.()\/;3K6YSH^V'53; UT?+]039;#@@S7<"194=I5Y]RM45NJD\TZ5E;HHK(^>D3N*]CAB*;&XUERV!H1)M 0Y M(D"B3(A.$FI291Y==F6E8QA40TEGE873K-Z-'[XKW[E]/S975V^::?G]D9#" M&9HE1%W*30O!P+)H@+N@*>,HPU [:WFPR9TAOWN^1I\E;?I*\.TEW.(VNG"9 MQS%"@X@H:P1$*S@>(JE4 R<44G+1Z=)=K7[OPZ$F]X361[\$'2R8YQAVG=,Q MTS5J240=N<6#.2>-1W30$3(#7-0:""@*&> M2 M,):$(Y*ILXEEZCBWYQ4T]-%R!+=Z2$H=S@[E7#F)^P+X4JI)9#Q-3ZY9RE%C928Q8&3BG-]<:-IXM(HOLKAPJNI,H>C+8!=_?21LZ4 M %56?)K9FD2>X(VTBPB>T+YX8K_.&5#P25U;VXMCI*CWT8: JR7BV2!*!G:F M$6(,T;&H4_9/<,O<.^\GM/;.@?QGN) [,?=)K=Z?'0/[!1%D-LH& 9'07#H] M2K">H^DC;0R$4,GHV22@U9[\\SH^SW7<)X>?G/=K,?W'9D_*?A6M A8\:HZ3 M!-:6V@W:VE)CRRBFS\,KMF\JS^OQD/5X'KKK1,,G[&O;OQL9;X@Q(H#4IK1X M"!PW(NH O\M=RCQZV:H;R5F[Q_5(>R_V4CJ**E"H302>)^Z6, M$2R5&8BDVN>@LS-G4]A["_Y?ALHG5_Y.R[=B@O.Z@N#+-,%/F\^6B;VS0_*7 M=WW4T>G)K3!6RC[^K2 LFBZ)Z?ZF0"W1T[^-9R7!\6::[CBEA0M.4 $DL7*) M202,**UJG=>2:.^-K-T_HCVZ8W>\'2,M\P43%5D[FH 25D*\.06?E$(SUG-O MJ*"1UB[5_AB>H7)^>^+&YGY33?3GDJZ[3C]8Y%#A_=Y$R0PH&4N1((F'N @) M D]XWXFZ#_GF;1!TU/B[#FDO!ZNF1TJ M/D*L_2M;LYBMM0G0)$##)LL$-HB22Z:IB8Y&3VM[LLX@/[0O'7>19NU6?G\N MS*^/:3Z>+LZ!3^X[&K"S@G#=4M9I&KF6D POB8*,@I4EQSUIL M-]3PEXUC%-'T)L4>4H+NH!5,G[XUDUDS_:/\LR+?PF>:J$H&9TPTGDB"2PN& M:0U*NZP4EY*HVL^]>T%=W/E=5PT]^#X>!;A:)6T@]G32MX!WFN._LF*[T.8( MK?12): %U)QC##1 5F)1^,V#DU26YI&>Y$"5#[5K5)R,.'M,BC/@30=E],"7 M-\TTC;],[IV447.1&.ZO,:L$0D4/)AL'1%K&@Z=:L]HI"P] #&^)5%=54U/. M%2V2A;VTXX!==X;AZ_K1ACKGR_?BD;>)R\$\6"I);@,K /'F$6C M+'OAGO/1,H\IJF\ETW_7'_EUY<-S>XFJ)V@7(B %>- M+7%%&JPW&<]VJX/*N@0>#4O&/8A_52;65.00[\:OFNOK\7P1/N0FBUGA,DJ3 M,$ZSPRM@[__0H]^2.^(^\E5Y87']-,B+,N@MA#MJH?D>\(1CD$)"0B74KRLU M&@R)U/*4C:'M+-LVHQUEJ#\RP-(;)FSIN90%:%9ZE!L9P?QO%0D?CN)X^_C>..N%AX+Q4.R+,G2 M>-6#$ K/S])]U?!(F:-*9-WJ&,(1[AU!^+>[XV?GX$-[C'O0:U-3OA6-YJV M_F,\__HQ72V\%+.OXV^?F]B#=0NKN*NE'@/6CC MQ 2BC'LI-:Y!22B(*"0XZ3,HQ!W0'J?EYTT4)E?GRZNLXY==_ MIX#F\7?$G,YHK3$966^90/Y[R8L-IL#'X*)F:)[QVE$H)^T%T9^Q M<;Q\3Q&'?T@YY#9S>N[OT*F_0R>:#%$H_Q =/Y7^#J&DSB8G0"II\/*I37D. MSI YSYKO4>.6>FH I1 M0 E] J=I!F,YM<(R1F3MN+#M2,XP%:EW+3?55=1+;.%C?28XLY9+JD'F4LJ0 MHK%HHV20J,_!YZRSJ)T^\BLT!CF&1O445OFV]Z?[SV;ZZF8V;Z[3=+;8I;/- MB0GRYY#T>^'..^@F0KEN4H: J/RY/K M/4PK6KRFM\-SBE2Y5J]:.YZ7S1[QZ@ZB\BU1K)Y?\_N']\E!9-P["H\EISCCDY-'F=D2!HQ&/ M+F<(X2[Z*#>,@1VOA9N?/*PGKI*TFUJBJAV>^>\W)8U]CB2.:VNSF3:3M'8" M2N>-#AKP*&)H;Y92R%&5:C!X_!":+16DE18?'^?)Z[2B&&NOS/44W]^B$9)( MY;0%KFGQ[)I%4%Y OA%',X_:;C;PV_60O_G13UZ/QPFK!\\HFHDE:FVZN$A\ M',_^^?+'2[09OUZ[Z3^7+T/:I,!P;DYG D*6Z 3\"CIDF5-6RN3:GO%]F"[' MGNY%"SW4RGJ(;XUNO2!:X.O)%[X/VVG\VG4UNI<&:SE"J1T(6G&0G2UPTQ/0Y<][N33LJ6+%OIXW'!7:?8Q?4^3F_0NS5?G M8I(Y:.82,$H#;J>"XMSQ#L.%E$44PLG:W5NW AG>R5=77YO/#4<+NX^W^!!* ML#+B"FG\O9RFZYN+,+%D)@+CU((0C('GRD.DE-L@@U>IU3V^R[/\#BP7QH,J M(A_DR/AQ^\SF4E),XU2)"\A2)T5\[1) C\#Y):S0@V3_D!:R M.BT*L-4R: -M*-OS#M;9F)V'J7 ?-8Z4_Q [QSV(S!"N4S80LL?[.L4_.6T< MY&")U";P6+T!Q>#4Z&YB]LZ,+F+O@Q$K9\L#B.NCSL3H+1&0!.53T]W^-U&TP57X9W MX1C^8?A8_>Q4]9'"K?PNO!,;ER'PP!FP2 F(P!*X$!D>>S$D%@2SIOXR/]&Y M/Y2^N\BTGXJ#_YB]^/;M*KV=A'40&^5$9E7F6#HK!,G !IN!+AHJ:$V9V9M2 M_,CG#_L(54?P#RL,'B6UVJ_$:R@?W!Q/H;>3/!VO MK6%89"D"KE#,R4!L%. M%P=5R""E892Q%/5F[?L=*MTWTE-7;E5)]F"3W\WXT]S-;Y:A*B%'[LNF%%4H MI0E*4I!(&K3&V:<2)FAJU^G:AN-RC+%JTG[( %V; >LHU!:H>O+B;$=T&@?. M\1K;0X$CQ#W =K!"9_ .F!RAD(*5I7JN 1^\ JMCD)00RMKE_9\I"?:X:H;B M0!6W=F>?%EFI95KE-I%38):96SL&Q[,XIX-5&"1DA(;S16 MT!:R3%#@3A ?C0V!T%9F7\L!AU/X #5B^A!R/T189*D\0/DY3;GE7;O+!3>?C,/ZV3)I;SVDV,D:A$64),!5+U5JOP9;RQ8QQ M)W40D>IVJ01M1KLHBE07;\7LL"7 F^(/*3CFCM):$*50K%$A0+0V>,E2 M8*1ZHY2]J"Z%4#WIH6)PTV+^?R!O)[/T)J577TL6]]O)HHIKE$4Z$O8%;W@>W&^B'&A '>UB5@D'9C/ MNES82A$V3L!P2H'9('5T3A/9SAERT/"_#%'J*. A9^4LU%('1O\.:EN..&VX3_5_>D=@5Y M*;P:1DL/:66/I=7[^=<2IK=&.R)18^00N!:&I5/CSVD;I M!H1+H\0Q$M[B>3O.X[HRDV[OY\53,Z(J1B_0]I7*HX7$@@7'\=)$8LC&O^W3+T6==<2W1:''^5(_3,>3XG6Y6NXK[_,FQ!%N*S(C$F R2H2',S;6 M:OQK#LQQ9A-KY]_:.]1%J;JN8+?H_3C7YA(-3O\.3W(F)!4)A*SP)+$ M'-A2Z8-G9&)JI^B'GWU1FCU2=%M4>9R7\B&>5S?3:8%%HS3>2+RZYE*<&QD% M7A$)5A(:C>*&^78/'#N'N'#%'B+(+?H]V!NX@%4.B??Y\]=[6X?E3DB6%(AL M%IWR\/HIO<>[A*0Y>XMWTW8U4AY^]D5I]$C1;5'E<>ZZEV[RSY?NJOB@9R,J MM:3>&3#)%+]ACF"5=T 7\9G.6>;:=:RY_ZD7I;Z#Q;5%<0<[XN[7/'WSV]M7 M;R>E/5=<.7]+4;187@BX2FB-VXC&6R8> EKC/"ICG:]=570KD$O1>SUI;^' MT=&G#_+15FW[W)=$1T3R)#/:M?74?T96ZJV]G7P>7Z??[NJMS4:"ZBR]8)!I=FA%Z N(LBD J5> MLDRL;+7AMQSP4AC0FY"W,.%@A]AVD"\^KE-91]3XK#F)$/ 80\.#:S!4&U!& M6S0[I!&NW?7JD4$N6^,'"G-+5-!Q3K"[C:?)#RNAK R6D<<[0U*X&SFT6DJN M' .\U)=4F6RX22P1:EOIN]5P%Z7Y^@+>PH&C(]!_=\O'G:4E+)DZR:+_28$LO5\J35C%L-J@\VCSHAO!2*#2 M?K;0Z>A:FH_ ?=?,MR%FQG.K \J%9P/"! [.:P&).8Y[H.:^^MVC,\A?B%05 MM+2%5P?[!F^30IK9;-\R6$&560@7K0%I)2X!;=">5I&A%/*>'E6@G+W'EM MB?71.N H"Q1%%. <+N^H%?54,$XV\P>/%T5WF'WWH^^-/0^*R_:LHFUI:$,V MJK^=YQR/^D5>PLT,!3>;K6:TS-36V0;A@X-,B2H%&S1XI@Q$9K462BIKJJ^_ MQP -7=9B,#9LLJ^:5OHH7>59\E M3=2F )%HW%\3(O,F9""6!^&HX(R0IZ?R/14MAM)X%^'6SFG^O\E=S;^^1V*'#+AS]9Y1TK MJ,HE'_$6/FNNQG%A4RP,V<7.PD4D1%D&I88QB(P7<2]4@%+Y0"0OLU6M-ML] M!1^WCW[I=E1>Y]F!:ORV^NM6E_O75 M>%UR9-W5QN*14TK:.&8C;FJEJUXJKHPH!37"J^QJ>W\>!31L;=$Z.FOZ$G@/ M;83>XR'I%O[:U>UB!,4LF3J9)-"I$--X M1%^[F]CCB"Z "15%7M$&O"W[L>QQ]@;EL,C?=F'^'V.\;J[BSU[_':YN2EW$ M%[-9PO_B9_?W2/(L0RPEL*/@(*PUI6(,@U8R4DI1_>SP!#0LN:08C_7#>.Z&OT ^ M'"K<7MI*S>;O\^]-$TO\P*M)27! 8?SWLO:4 ME"H0(Q)0PF6Y3U.\3W,!G/JJ-JFYT% +Y [_2MLYVEU8)S& VTOY)E2 MO/ZWUR5N8#;V5^GUY.8Z35=RFLUG^^,N.C"J##B[HU09NEM(184I5 J1*$?$ M?/;"SQ:G2.4UMO'A-2IO+#_R'5I0JWS1K6,,ONJW:V5KH8Q= NFE^KSS M:+?.QVFVRA/NB3>/#'1\Z]SI38KW!L"=;2''>]^JO0I:C7F"VNG[M+FE"6Y[ MX>WDWX&[_F*ZLQ3^]Y?F^[^E$/_MQ;_<-)8>,.\G5S\Z;N_W/V>IP1#O%/?S M)W?:V+N@K!7D]M5-TTN'9GX)I,2S8WE@3Z=NU^L2@\O8-UB0S66 MBK3OW/6Z]5;E%_4^(!Y]X2TY=&&>XJ=Y$_[YUZ241_WTUY\_K9IJM];'QAK> MINR1,0^OJBW$W$,YV0]INC"4)R$MIC+K1;&[1KEHE>X1;<6*K_=SXV]S7N_> M!RI?"+X0+A (04**24T_^//WY#)S"0A MF7";(:/G^;[YYNB<]RSO[[SO[WV/+-_TD9L^<>2'!MU^]\A%%U]TT6,O>NR1 M(S=]\[&19 M?!R&P_0*8QF9UA6+*(!+(X;1*Q#XR)57E[&Q\*SLJ&FMW/"J8]?_^5N.'767 M5QW3"!$1X[;EN%R=6$H]5!>UMV"6QZX^<>F5Y?$RB ,K,XZ6@1^FQ\NKCAT( M/P[^WA7#QXX>5,F\JXXU=S>.ZJ)TM!TEUM'&%=@5V.4+A,2/$O@5.(&16..Q M1S$$H6&$@G'DO*&[^YZ.^X;X>JJ8^7E2\LV('N='J^AQI@_T M="6\KWZ:LDIW=O4 M!+Z]?&<%X*TTZO6#U6TW7,%NL+KERH-VQ]N)9611HD:1?V(/O+[OYVF6[$J/ MMI7&E?#IU(R\$?"'**D'W-TV2(T=*U MJ]-EH 1H>AS!Y_OFIU0ZO3G804LC,[Z30=RB[FER5"*G MM#HLNZUFAW =2)W>S>UNB>&SMCM _0F86<.-9G.L>/.!O&JVFJM.4VFV^LTF M"U/C9CKI.<6RQ]1&C]GV63$7F\W&V/.'30AI'ERM)JB_NSK-1SZ\;/YT<[QK M#*YQLP5#C2;K=3T3&_C-GKIO8,-FLP]NKL:=5G/2::TFW=;*Z[7<%[N^JU M5BN!;49\>QOQ!P+95E-DF]O=SYAM-J1.DQZQ+5'MML9JI]R:O3)=<"5M?_MG MV^%:V\60;2(ST,.LYTSDKAP=W#L0>(O*=_ 'IL%$QZNF"Z;;W';D_92;?;DY M%F4PM4[3.)@]U]S-;MQIWGR-N\UMOP>6A6LW/3 ]<&_59T^O=[B&S3:8+5B7 M1;\]C@1PNPTZ8)NK<1N4@14!@D(1*$N4P?IW^W*_'$\[O0[6<1>SSD2,>TZK MU,JQ*[4.!$XRSA'+N4NWY6I5=/QQ+:O>AJ]FN-0>3L:A1X[JH;.)01:1#-873+_/ML8 +N-9IPT 8>[6S.FPK79'$2>= M[D0>.OW5O%S-.]6!P,CDMEV1DQO*L-V=#MQ%T:D'K,RN'$.95)H[HX1V"Y>4 MH37HK,KEQ-NN#J8\6,^[/7?I+;L3G-Z,ZFVUB@\$(I!4.P/%RT1U0DBROYQI MT]C4NZBEH[(_#Y:1H<6)V4-S$[N]Z1\(A%A_H&D^X;#5EER08J8 , C=TAHK.#&$LWF4EC0W7UFH!,#A[)"[I+#/=3!@)D?NN5 MN)9ZK;+JE1K>VN0X3224-9HHE5Y9"<53K0K4&+4ZV@9RB43<]SH<""0Z<$^0WC%RI#8.$-F-0*)VW2S+"%$=A,:6F@JP\(# M">9[1@O&ZD2%O6T@=$?I% BZ^1<1P<2!P(JD&[BACSQHDACSB%I&ZTTO INJ M-:@6Y99'1Q7-#27/9KO].0'7ZP&1%T,;;K:);F(KV7!)"HOAW)7K:7 @T&DD M W8"$_U9),T7DRZ)G]KOJ;\L'MZR(T4B L7H1J0US02_820;>FY0_A@Q>LB! MP 'OM4-J4K9TH@GUJU 0(@I.A;$E2.7 5CD*QJ2 Q]TJ9IK;K8PLK%;=+Z?H MNC2=+LE":A%":N43:X7?3]GK(^I$TWAH'#; BH+BVL7I4U(R&Q611BI9G"Z M,A)V(4.TDTM2!4EXD70ZG>8*;9&K-Z=[8<1"F='UHC:Z7)>[[)KZPZ>82[QA*#&_R:&8G MY2%L,+X82M!BO92AV/9;B=U!O+S8,&D(2TI#]>$ML+#EE!XWTI#D(,6&)B+" MPEFHA4 Q,[7KAAJ?EU,,_#H0>/#7E#9V"SZA4IQ(E)7G"3-L.[&:41DS1*EP M$0FX&=?2!0W_UU\Z\I3^>446<# MJB*]SC0SY6PH\;@\D95:-*QFKQEXI:L8G%BL (:(*(>'85!/EG9NH <"BX$[ MF]5PGG=MQUW#&-]D"<+%+8J<8LM8=DNW2?+=@DM%W9XUHK)3";[L;AQ1:\CZ M0EZI*KF!!T*M885U(%"9]1-7#6U#LS<+0II$4=(NDT:^V4F$VUF3 ?\&%+325'4 ;* M".C')^:Y:ZF<&O5#LS2ZK4X),:(F"(NIU8-I8D&Z,ZG?"S ^6.M!W*\M\D#@ M>%MUUO JT(%%&/1X_?8T>:C$S4Z)>NB3%EO+$51L'"C1#P1FD2GCY$K!J!2" M5YHRF4 :/P;F).S4XT'"5:Q%)F+1(3,K17JXUL,G\@I0AGZ-MMS8PAO1S9OS M0. I>U4[V*M2?,]#M'8%\AAW!@4[6"[[6+YB!],C1G7;\JIM2:S07/0H/B&U7*F M\ZF[B.2&L^+GG,MJ2W7=BJJU7;2=H:D#;A$>"'2M?L9XHU@KJL1MMS$Y[.E] MC!D" [NP8+&%P'4$!2.T/]0=8Q2::#2>]VMX*XFVZ@Q[KU BLI).'G*RD/RIE/%L @ MY\!3()Z'LEHQP%;C3":P<.;Z:A5ZKKN6S+@TB_V4/2FPN\)W8N8WN@$3"T2H MV9A *(WJ"1.AGPZD<:A[T=):LP<"\S;/@*W$IT*[0J#:29->2P";V>LLND4G MFG9D>.0AT M3$HQ3$V+^38B8B6AF_I06KJ+BIXQ?;MC(2GLDNN!5'AVH3K^U.?39A7.5M1J M/BC-P>& MML:E@8C.Q&851*-&G^S,AR6^VS'?M@S *!P(/+0,- ^/"E7:<&$NKW@9]]F56/:$ <&O1C'8[Q/169%)'0 M90$LAJ(=)X 15"8=D7-F,RJ[7AVCW1D1"QG)6)OFM%2@.3TI$,"'!N"G)BO0]P&.X/6PX M49-SV6(HMJ1';2G,R[Q29_-.H<_ZL1M%HDLTV@8T78JP$@:ZDHT:M)]3>6^ M2JJ+K-@IC T7K2XU$I(]68*=V:"&@W( E:M+J:MJ ':2UJCOKZEF0.!VY$-N+X =YNBL-L M[,&D3 #-!V$?$KF937:72UCDH& -94'APQ-*F Z[*065LV)>ET[4 Z'&V&PB M_=9^+ZN#;;^/+85-VJ&!>1W $S:G]3,IWF#8M(R=X5![@2M,"EZ+0!B)1XO. M@&XCK<$ (F<' @$<@A >]4>QT"5*M%!=P]:2IKIAU05&5XE*(,&(]QE]%ME# MV*@BCCE=#"ZW580LQ:'0]V;,O M>YP*O4&:Q;@^;^=I0H0;#.F4C]R4*W30V MO;'MF02%%G5!#$PMFVM="^ X+V1*1XC9AD^P^ M>(0CX.=T+9MX2\%$@6,>C?K-2NF.YB,>V.P$T>B\(8R0,*>&/8:@],)LES$!9H:]Q*C5@4K&T:U<)""=,6UJ2\<,;FBZG-PX&YPV5)4[BV MCY='L ]A639$2A8BW&#-6'.4LZ; 7R<-?EATF)T"=QQ'!:0SRJ2ZE0Y,A7:5 MFBXQOD5M\'5"+M+Y4-H+=-A.IN0UKUA#N2A]HM) MO8"6#:'/-81>O9ZL0=0Z#P^!W?87I>CDL@W6J#?:+D:^6!!(S00XB?O6V$KM MJ4WT\'DN50A2:D,MPT)GP#@B)3!5*E:+ 68/)&/-;?>$D[3#;0C/G!4P.8#2 M\!UC"&-(":-L-3?(Y@ P%8^)([MJ$1PZ"IB\0&<97(99A,<@Y/#$*0M 'O:2 M";R/4W0B)Z<]519(GL@"J78,V2XLD>TJ$"9.I%" 0TY6-P610K8MRAM&]\=2 M;K2IHNY;J'@<&FV^JL:4N.8"F ML9[1\[FT-*V^&U:$LH)EP(A"BHZ6TY%O!TMB7C2M/K0G2UO@ UJ"4XS!+FAH MXT8L4"2P[B&8AE#4LF"0K0CV\U95D$I@D?EV1$^S<3^Q:@78!VS$CQVI&L!] MH?(/I^SW@&&VC$0DG:7A TY'30E.X?EV/.WQ91H.PKB"^MX$!!I=14]@7Z(W MQ8#SA2D53FT!79F]1MZPQX&\-PYS;LTO5EA5B0P[M3">6^_"L& *;UNB V.T M#94@0)@[0 &-&,S"2W2X.<+6N^"QTZ=Y!=T1HYTOZ[B#PUDA LKP*E[36:21C!-L@ B*M /:FS)REL,=BWVV6 M(L$%FF0'*@%6'$S4)FPB_'FC<,S9WD!\^0^S3(: MPVKE4^L:UN@,)LH(B>$$RPV/7-C*VLTF,\;(ZQ$)RZ2!5@F;FU;"9(M&0[3$ MI3*W(P[WJ3I0(+M8[Y5"UTNU%T,VL\S1P5Q*U&U44DE+Z:KT1J;F3@?3,3M5 M6PUM799PA-,,C*2S[0BQ51T>29VM!PN,QR[6[#Y>5OMRH[-9(R 4ZR4^Q'JV M!6D0UC%0GZ%;D.\6M^31!Q1:+P2G9X=4O,W!$JPH;;%AH?4^K(C1JFV8BU7: ME>%*BMV5%(1TNE1AV29<2Z,:@2L;:[,] 9KOFM5F#?YMIPM-MJT\PV%20@RX M &6^E^U3IC'XCS?MZ33; (;& [Y2=O5KC!+2--R&Q@?TX0C9.0[46A#=CW1EA!LW1B#&2MI7S M^HH+!QV$I=%LQ@RMCA:2Z%!H;YBH07GY:I]I[TJ8 <(K: 6H@KEJ1'9? L;! M#SMX/;X("C@4$SCV) A? ZOC @$U"X== :ZF"5@B4\XE""@S$NH0 M#OMKU4DD M7V_#"HS0VT=OI ,5HSCSLC=.0%$,1K(["'6=K<@,A(7"!<689TJ1Y.5Q5A8YJ )9WICF98II[G0QO:B\$,Y6G;H MG)Q'=+]=DK:QQ;9[I0!U\U[;@Q59[[J0:4.+[;*MM*,@LFJS'2EREN*DNTY!7;4@ MEHN1@D'QR"9:+4 JQ2W7(";B5BA$'=CZL *6W$9%C%[! 47H-*FGC!-[^W0? M:N)B1T^Z0M;WB+AJAPZY\'QKT$\\QVL-A[8AS0)3&7>(8."J&@K'S7GIX6H\ M( QZ@XU6JI$R<1IL]'UHAI+974JFAQ V M"+?VQW!BR%:V6)@JW&OL-GX)Y[%HG1F;";JWJNT:C6MC#-XVF:1L]0!UR87N "!CQHR@S=X>^L!WE5W6UKOH@B,':IME$!#;@;G> M6A*77M%0!S](1'($GX[YQ,#TA(ND_4Y1251DI&891>S>:ZB#$VC8) MJ1K!1*Z3Z3*B#'1J^^389,Q9S))S>,#I_>4,!D$AL9"SRL"S3AK+.(N%U.H@ MEYCG?&]QF,<&)!=:5 44C&'* CX9XQLQ*P(B,BG %(%QV;(W&Y=N4?="01>G2+FL)F M.2F6P%*'PH81=1"!S0W>Z!'H:!ATY4G"M7B%M\E:<"-K;[YLFNA@!:K6>N3' M")20K9B>LF-XQB88I/$.HT"*V3" ;GHKG(@5A"XPCT@0>(DI$LP"@ !3UJ93 M#-7WW&8+"UG&6W*^G&2V-@L7FSDZKVER6LZ[T"H0N@T;@)A8&-8 KAB$9#B, M4B?1UF84K3$.,2UFUJK("Z0>$8O MOV2 '0>)38(/MVJ^RA [*PT8ZW9'F$\#*5X2U&@F==!< MM&NUM 6;PBL]$*$B!S1,W&671PB_=_30>, U^R+*B%2'J3IKU20[%=Q)>8G4@#GZJV5D'J ]K$-]N=Z7:)K=O1BY]RS)0)L6T>/5PD65YE'[ZA'(6/E ME)@"IB\8E@.9W7+GY4!L:2KP(G9AP@<[BP1!>'NQ#WRDQ"8T:TH8:(.T618$ M(@N "K@7\%QM C'+N;(%#H0;;:4VA9!MF<6@+M&O)*A3*F"UB1((8_DU8NJ# M_4[A>[%"FZS&=8(P+Z'>"$14M#13^:;$S-@2[+R$Z[)$ A,U#Y-S8,D:0*NS MQ/7$+1"G .,PT, ,AUGO0& #;CB7N;I"-QRDRX1EY.EA#&,URF[Y8KP-%\'_A4\R@:)!9 NM;LMWJT M:(1VR4R0E^,VK%?MYLP:7GEQ-ID534-I!89$N@%&?4 MVR=U.7M68>W2]4=P:8+ 1\2)M@;O,G"%I7F1JEB*VK **F_+< [MG(*.3]W2 MFAZD_J8961!C(QZ,0[+8A[>&,N6,;.L!SKJU>*=!P+4[M(==:#:*M?D!2"MY M Q:^UX@;;F&%F&9V!]8XS2V[:!99(A4S@Z$-F35"5S_26;D+&<'^#&BR= M#8=S9XRS>"=CM8P5R14%];5\/NJ8DE=DJM?(EE+5D>%TO#>PYN[<]99'KIEE MLQBP_U2(NC M!+;K]28DFJQQ'*S79-AT9Q(?I'@UZ+1Y.MIR31)H58!Q>C&1,D&E1J,J%8P: M4!(AQURE.\(08[^&,I1T61K_]E%\L[T+% "/OCFG81-S7L !]V5K>#,T FPU MC$9;N.A/2 XP7KR"PC_5*!2!L$/R(']V!/ M0_>GM^W&C)N:(CP=JDVJEE<3#R;(_ABO-R-,Z!+RCE7X8 G4OLT4')R"&*HW MVR4F>:"L 0\4QV81#KQ?J[T'=K@+8UDH6I5*_H MYVW(<)GZQD2QJ$F6 MRADM#D $*0YVAB'=G9D8'1TVQ0R,Q". !Y9F]K"3R""(R;9ILZT22X08PJU& MU)7V;I2>2,T"6BPD>%!#>@&!2'S3"H&79PJ@X5""1V,::-M"&V6%Q&0\G/5PN((=&--Z@RC/F7C(-2!?=!A-0FTV80)X:T^QN4JX MD 'FZ&;[XV HA98-L\,UA#:R2U4V^ZD_JW:<99($ V]8">02V+7 M2U0;LZ[/=$U=8>VBG9J=*:VOS6X?P$RCI_6F"-4JB]:<;ZRGC3CGG+V6UZ65 M6T!0GC?MI>L5!=YUX:'9]KW1X&/G_;WO-\&/C\:)^PW+.OLV4M MUQ*QLXG)5/(E>-TR[20L%9K:+4F4B!KXUQRB?+<)99B?B&I6R)*R,?:1%#W; MF(U-3X8TBH9F=EW PL)?U5KN:'UON%S171_P,263UDGF;B: ),YL2!V[0"@V M-V$Z'"RF+ K7,^"N]H?^;MWLMH M8&(G&C(.UU3LJ,=S#HC$APMB#8^D,=)L M=2K=[81IRU *(+0%X) !2U]3-!"LC0YRCG5_+S!T8\>9<+A%N%.9&8SX NPI MEBB=];*H%VEO,FUK*%)S6R[R;=2;Q<(N6LRRSC A:F2M>>JZNQEZ,VZQGW*F M8*DS&#!0IV))L4RWN.53[0KR2FK-4.4&](VAW,,#9J MD(X_',OT>M5?NNTV+^U'6&1X)1#!FJZM239$8T6:Y#.9F4T-&X326R7)8']C M1_7 X;>0PD3DF+1!9(!S)K[D*A^:82D[M24KUS?[A.1&6E9R"938@3P';G1; M@;"DB@T^@X1M)JP=6 :1#AS/B+I0*ILDUX8LAQSO1'?;V[XT:K9;8IUD[>[;46=6QWX MC&C F4A@4^A[+3?;ZV#GA$0.,"QI$ -''JB 3,"JW"5R1)JL,BF9KI"6Y)K6 M/("G$J"N8T!="P0G*#):CF%"$S?G7< ?U!K.XX_I$-E M *@T,M+&B#P4,VW&&$V-]';/!!' K(T9-;5P"#C3K".-V*PP>5\_^#$7 \- MP57XQ7C$HA2%EJKB0Z9.$(#%N:0ZUSK06B87)K^H8]&C%,_Q^*XUD%MX*W$S M2=V%ONR&80U]'R^':4Z+#(#YMKF>>+M]Z@-[@4Q=I]':^>0I[",^'*52J&Q= M&,%52^S%M)PS&VH"XNL>X2XW($!DTHFSW\N P 31<&8'@$B&6J:CO3:.T8)? MC"4'\TI%3^TS3R^:9S^].!!XZ\:@#(%NR*IM+0'GD=$0060NAO/ DC>[4$+O MCGT0GHE.B HT!H+FB;\']J87**VFHI;*L$\M)G2+MGC_X-A\"[;@()*!P:Y MA#52O9QW*'.S3$W056_:+[4--#4MW=RZJ;>C5GO8= %00N#E!F4CZ$A$">E< MK"4X/X%12IGS,(B1@= *^O+*H2]O#$[72"*37L,JY0 @:;\WU6B<&C,A)'AE M[4H;K\\UZ (I>NM1G>I+MQ:-M!PJBA6/QC'%BYO%7)S0*D+!(6>/6>!4F;V3 M(M#$)*4VLRTE%>6X6%X3<$?CH,2+VH0TA! H:0R'6S8447HTMZA7L< M5FS=BI=$C'3]A=3W@%5.R0IU%U'97SN^OAD6;CG7T> 1'-J521BY+8YB M/ A5;!HA1A4;E DL^$Q0"H:9RPJ" MP?A4*"$0%RXF749M1.->04JF@4969,B+U;"UZ1;"/EY6ICCFCQ-@;]%R2K V?K1.4D/,MJL^!NS:LC@EE0RGJW M".O135B%NUS_/JR?2+OFN%>D'V>)\9DV&,)ALKP$&1:\6&GHI^L1@@A%QM)@M;V6?:9VVA M/5-$I3V:V2%!Q'2.%[Y=2QMMA1<,'-/4F"8[+:2U\58)MFSWN'2Q=4$PJ7FU MNY#[RXG$"IFWTLW9/B'I#K.D,EJ!T1N7OF\,W3B>&S'R7C9,DO\6TZ;6PZ0*:4F2+F;X_Y$(AI-_DQ[S-N JHF*9Y MR1IXG6 N6JR-M<,A6PR2=$;?6M'<(%L-0(S.<,P@P-HYYCUL^)$QA6L0LN_" M,!"RUP?6>@&\+@%-@DAM6:K6+4V]3WEV(;=5!BG+B2CNN.*(&;:-*>&CXMJR M+"S;)S%&&!Y%5!#@-NKHW8$MCWB.2&9IB!'$-HNNI:J9EH;MMPASGVG'H5$/A%V139$-SZ=L$N(W.$%JX]U#G70] M]J8-+ IBL G+OH?:46.V@99@7X==GH82./ 00*LT9I3WC?W6,Q%CI 7P+I*G M />CNN68ZNK;:=1I%5+M(1#?IPN-WI8M36\XY9!D*XQJFHV8!''IR7VX;>.[ M!Z7WR;3-+IX&+A92,AL^B*5O]JQ0-H$F,"1V,RBWN_S!DVFZ[\VE?N#A(%;' MH#CIE=VE[Z_\H;H_L(XUD3W[8U\-&[ M7'7@=&&L%G:&>*0T-AQ"09H.>UG!GW3T6)E)8,C1P:E*"8N"2A1 *QFY\0R/ M4QD5RC7 7$BS:A. /\H^7BH011D--S<-GG!,GQVYE9PU-HT]MVG"BYUCEN!0 M!/#H%H2)S-5I:#6*@:Q'W7994A8\H"?.$(868Z9C8'1(E@D;EZ,(WVS+,$>6 M"9?:?ATL3D92!0#*"MC5B4[HE>''I+5<\@X!+#+X,RFC(9XY3&"L0-B3]<"T M0TSG1624Y% UU+?AEEBL*X8B[#ULO'ZUZI)YAY05A>!Q?NU-9<')\IXEF8[VS"&)EY&NFW/A.%JK^5I MK*,F"". ]L3Q8N(SY;1K3/$>P=7EV./"NC9GU@3FK8@D+"7I"5JW-C=E=SZH M8H8?CJUX7I",.+7[)_DANRXB!$OM@(C%]70I<&@"$0NX8^-&AU?41I4'8"WZ M.W-5 -".\?L]>XL8]H=H_T[[Q,5E.PBDW5=5-.NE,6=!C-]BEEO6=J=IAF MZ3>=&0.[;H."AKNP;/>< 5O;'+&!10SR4D+2T^6H32[GHD.TRK8R[VFA[HL4 MTB?=W2;1FL!5>(VJDJM[#6N>PZOL8G\WZ# MZ&-K;R+U&GR^;G8ZG4F_+TVX[MBPA8+8 JQB9#C#O7U6)(,4DT7N]PU/,)#A5QW_7EA&#,5@E"-D+W5U(+;F339 MG>Y,H6"%5XNQ6BWL"1,WZ#X^#/?&@:58VH7DC*4#@^U&D%?";6F=FSYIQ1*_ MBYLETD&:6,VO>^%ZJ6\(8I=1I7IC8E#JL\VIGU7;I_N^_8$UJX8T0,,7"/!E M[$&*%,GYCFYIZ1*?UU@:,OA"+D#\W=SD\01.RJEK$R-R($0A,;=T9KBGQ!-! MX$PK[K>TD%\"X1-V,Q>G<]]-:#355#* I8KI[!Y_6X/]J_6;MIMC"":M-:>1 MS(L^X'1\)$Y:5!;M!<:,BFC;C%_8&R9CNTK8"]NB@%#+4; M"':MSJ 9P]%;0V?,+.'Y>E@(F^&FCCH^,P_:(WK>TJ+9)$'+,;<",>3<'O:* M_2<76&Z#;7!LDSJQ&2_Q#EI-!=-N#GJ&(V6NSQP<%0TE0L-Q7Y>%4,_FCMA+ MC>U&Z)HC7FH9":TX><.0U_ND[MQ"6R"X7*634\_9Z.9ASJUV?9@ M@0Z"+'' MZW*LB7#0@LD#$[)M'W( 95H:C_"H3VQJYBNM6I KH5YL "Q!$13@J2%&;#\ MDP$'UVLI3GT?FEA!I0A;@PERTVNZ#A],RHT-F$('\&N_X1PFTP W)X; %&7! M[D-#U<('5N 4/@";/024D\Z,GO!%B%?+&(2+%: N.H70G1R!%W5S*DXJSM\_ MJ=L'%F0Z,Z'^!EC=CI9H>DC1^=(HLH$7Y@R7SWVC-Z^O)+(RL MW1-,;1TM7 =FO*MN_MSZ_D/I9WP6_PZ\ZN'L'_:_*]_B((JW_3J&(#CKJQS2 MK%-DM]TRW;UC #[YBH%.8879P\\N2K;L.R(*5'_XZ>^'$,7CG)MF45*=Y8T( MBK6Y:]Z(<##KX\;B8,T745A8268MKX1O47[K#4$_1F!E5I*>L),H.&K$L>\N MC%TK.([2;*^WHUETBSM%N#Q<$O?F-UZ<[/,4D=\9SNZ2J:=&<0>F[89I9H0+ MJ\^> )JZPG67QQ&41E"4:B 4AI TBC(-@FJS-$H@%(MA.'U2]BE-;UW^UK'" MW=LTT,L1YG(44U'J>(,^WD!/ODWCE%JW+B2-[&QK)%9S!7!Z:V\8.5O56Q>Y M<(QP92U/P"<;GBPXKS2%?=Z4IK#+ M$: L\D!3V'&4NARA+VCJG#5%GZ8IIM%N-5"$0FF*0EK=.ZLI_'*,5E'L.(X? M)Z@+>^J[X:>(;J?-=!B&0E $;=SI/=6X'&54%#V.-8X#2WA!4Q?(U%T)4A1A MNL"D4!2.M]O,G7/1M_9JLO,4I/O26P8"!^'560.'PXB"M1(7Z*:[@]=WIM\K M#X*9.VM)3FMZ-LG+:)'OWD]X*'EY!R2?TO1LDJ/$7;FAX;,W5\MS(+[!-FF2 M;5(4W2%0E&TSC0;5!KZJB;#-)D-W3HH_2_NS=9-8X=+=8;SM&VEZ(DZB""SL MTCXIYK3[9VKK%*6A%NM?V9J/H.5'C&#CZCZ1EB^W?& M,)S1]+N085"EVWGC8P;'JUM]7^3MO2SR[!D%U@V^DXP"J&:%*9A&>D9" 8SZ MN+(ULH732Z(\/MN+%N^RM,)NGL=7NVZ&P/^<8/=O"3VZ[_[H0?_[I-(IE6Y; MSJ[7$\BIC0Y*;K51._*CQ BS,QW?[S$YSW,PZ'/XIQ;11NZ,HARVS6UFPTUHN*B,\@5R!'%R'30_* MOH.Q&CN?9YS>^F3Q[0NH+-^/MJ>W/RR]_>8'+YX]O?6^\-;5?&L\Z.8:=RD0 M6ON7XUX PFT*N$N @")W;RBT'2-91(9_ 0VW(^ N00-%W*W!T$N,^(*/^+\% M!O*P>>/N"89FZES P>T(N$MPT+A[&P4EB+P+%N'V!-PE2, /FV-W3R0(1G8^ M^0;TM-6\@U# \%LVO\-8P/'OX1"B;<3Y8N&&T7F$!^(*9G>1=PX/.'6.MH&@ MOX?Q($8+QSC/ (%CY^0K&O0Y H(BSRVT9/9XIN_&B#A_P-# SLDZ$-@Y@H$^ M1^I W[W- Y!P5-Z=R)TO>,"([.'\\HRG%N$>0$*9QG8*5J7\B#VW/"> H?3,\(7T'#+Y-,F-^XY>4CB M@FDX8V"G@B$/4\<-SZ,4U+G!X732<0$.IWF*Q#HZ.YC1/041%^S#&0,[%1!6 MXBZC[/P!PSE&%1?0<,; 3CVM<+/,MXXJ<1+EV=%>8EGG$:D\G0E<0,9=B(R! ML3R/.,1Y#H6[>1I*=,/LZ"#WK?C\0<3I,>,%1-R5B.@$5F+XYU$^Z@Q]G&]A MQMT<$(IEG&_TX3\=$J<[K>\M1+2-Q#5-RPB/MOS\/*(2_^FP.%W ]Q2M/,A' MM,&*WG, <>%#%J<-[!2=<\;6<-T+-N(")FY6NKIU?=]=.=D]#!3G?+#QO0P* M)3.2I#HZO ?BXIQ//[^7<<%:5GQT%WS<%R MPQD#._7)2B,U+4 OSQ\X_*<_:ON]#(>#')6X7Y'S!Q(7#,0M:MRUG_GW(]/P M[^QG,^Z\8C,WS,Y4S4'I=PV&=PLP?6\_6W$(ISO_W.X]#E$7'OH]'X^!8UOAN0 M.N=#@'L@K"X$?&<,[*YX^>-YB*3SV3S=W=\<>0Y9I'L(\"$(U>@#(E>X.*G#.QL:"+H"VBZC1X/44.B5Z 4 M2=SYU]PQY!4TB5$(^CT-)IJ\ *;;Z/$N\W,T>DZFJ7%>H F[IYBF!GX%BE,8 MP]S)IW[(*Q"*;EQ@34=O"TP4>@^Q3:>_*/F./IG.7.#@MQS8V=#$W$-,$PG0 M &CTG7X@\0J$H.D+6#IZ&UC"2>P>@R4:P9D[^Z;I_^RSE=-VPMT,31<.?6^_ MQ[L)D,X/L[2+Y2;W!+-T(98[_?:M?-G:80^W_GUM=_#K+V_C:^ZN/+PM^49F M[7!W![\#[^:T^ZU,]V2]DV;S=JH=G@;=X>F==?PG)R<:I02&J;BU]9U_Q2?K M!LQMU;DO8J+"2.-D9 MC:[AIV<3=7.-2T]5X%WP?9/QTC[[%S^"&S!Z!0[?XGL>0>%Q*8F6^<)*#K^F M5F*[1WW73(RD.KJ+PJZ$;U'I-L>[+Y79[HE+P:1W7U\96+=CA>ZRZT(G%SJY MT,F%3BYTBFCQ]YTI&+OO/KXINO2[Y]G;QWW+]7_Y*+ M+CMR\64777+913>]_:(7@ '>Y^)++CKR[>O[[GN?>]_K?I=<>O%%1[X?%-]G MU_.W;X);EWS?Q?>]Z'Y'+OW^'SIR\467W.NB2R[9C>7B^]POO^CB2^YUV;W_ MRWT>]GWW/W;DON@#FMC#'WB_<>N'C4?@/R)O?O%!YF_^9/OYK_J71S:22W_T M+_^6>-0G%?*7OOQ;+V#5M-.E>HN?FDRU!U_SUO?_[Z\L?SG[[2=9?_CJMWW@ M4X^F[:_FCV&.<_V!/INO''==;,NJ?O)3GOHK3_O5W_G=9_S>,Y_U[#]ZX8M> M_)*7ONPUKWW=Z__L#=>^_1U_]L+EOZQFO_S;W6PWWHF53ZDG/?E@P%]]](-_YX]>\_8/?OI??_>%KWW' MAS[SM9_J:39=/.49+WK=7_W==5]?;9_Z>R]^_3L__-D;.-TI?^69+_FS=WWD M__P;TY^YU=.>]=(W_/5'/_>-QQP?S-?UKS[[9=>^^V.?__>;/G;D_P'JN?BR M2RX[\^MI/O81\ M4?L)7W_=C1_]5G#-EX]]X\<_].;M3SS*^V^/?M ['_'2![SAOW[H9W_\02_Y MW8=%/]9\SV\]\&'J^,U/W'Q\W\(EU3U_;_\GJ\UG_B()WZ2?]Q]Z^>N_QGN??%_ MO?4;Q)^]]!'/?< K__+]/_&Z+SSUV<]Y8_+VC[^E_)O^&Q[U Y??F(Z_^/F/ MS<;\'[]P\",_^+/IY$E7O>Z3+XQ^;_T?'WC>1U[\QV__].C/GG?MC>]^:?[> M]*,^^=B+/O"P?W_YLW_LES_QUK<^[.F/N>&G/O&)EQ OI(OHQD=_]KJ_^_RS MG?J=+[OV_B][5?3HNEI_^2&O_%.J<=GGK^T\\F<>_0;T(;7UMV][Z"?>]9[J MP;_PW'>]Z+HO?/T_WO'PSC>__Z'_\HLW7OON7_C9_[C^^K4_>=PSJ1__[.;/ M7M1Z(_GEAS[W24_[]$/A#U]]_%\G7WGB^S[[C9=_YI%/GX]^\R._?_'1^&_, MX[T7V$^1W_L2_/=O^)GK/G])]ZJ'"[]Z^=?N]=4O7I*27Q'9/WC"KSSO,\H' M_W!U _3--_S%L^V/O/#WGT>]Y>\O>NA7G_YY]'G/_-SV-6_Y9/NA[_E"]->C M1RZN^?_?ZKWO8E](:??XO\NH\_X5O/>L1U#_GX4XZ]N?WY M!V^:GY%&+[U*?RK_Q+>^X(8//K#Q.\][V)NO^*+PWA][\@__^=4?>,@KT=<] MQKWW!_Z:>.3?_M,/_/D+WO6\*R/?_6/_OO[/__ AW_H M?@]]UX=OO*KU7S_\K;]_//NJU[SQ_WO/%AV<>-#UG^RW-V\;19_XW:^\Z_5/ M?/7+/_-OK[[Q']_\?3__VN<]]$D?>=,[^M=0U_7_[C$_][HO/;@\_M7M!S_( M_>*G_O =XL_^C/::UU^>_MKC7O6T=VOO::"/^>&W/^V/7_^M5]SXY%_]?Z]Y MWEN_]>*O?.7JW[S*>.(;KLZCQU_URE^[?OLG+[R>Y-XA_L/3*.G(#WP_/;G_ M6]_XTR]Z"O&N![[B^*M'JZL6K[^#H#]K 7O3D6\\^8D?O?CG__=-1]YQ]3?@ MFXZ\^7'U-V_XN2]\\M>O_X?'O_+QX*]__-:'K[WA+?F7GO$F[\W8$Q8?^?@E MU\3/?_KJE=O7?>B?'O0;OWWIEKGJQ<_Y@_=)]W[.\U^J/^A#TD_^_CN/*O_K M&:_]]6MO>%S]]_=)?_0-?ZK_[%\_^:7SOR<_\?9/O?J9SW[[O>57_N@S_O I M;_ZE%[:/_.7JA2_I'OGJ O3VXNB.S^.KK[_IR)/?6KCONN&A?_&#SW[Z$Z!7 M__O[WOCGY"N>]8C?J$:++SWGEU^[^>H'W_K0=SSJXT]_^ M?1GH[$_N_ZW3Y7W@^O^X3+GI2'C-]>^[\7'_\8&;CGPB_[>7[ZJ^Y0GGMLAW M1<'D;V]\_TU'GO4CHYN.0%?_RO_XU*>O7[_SQB=>/CH6_,0??.$Q\P_^P?_\ M^ON"ZU[R\I>1?_6>/_SC\K,/>N.\\^O/>]@SW_6@Z^@;KWJ@\.6WC8^_C;\: MZ.1AKWSNX][SV>N>^M6'_O,?O\6X\?E?"M[[AE=]:/(!-7C%2]_VZ:^4PV=_ MX6/WIW[K?SSPFN.??_ WXF=^Z$6_]O#>*YZS3E[[YD?4U[[L:>K5 Q/_Y&O M_.)_5(^#KO[=YT7!??_;/W[S;:\Y\9/:=>B_7O4G7WY;_-G'O/HAU/_PCW_F@S_][*=6^:_[_O_/WGO'-=5M>[]14*P@ J*T**!($T&: M($1%>@D=Z=)$NDB34**B(" @O8-("1UIH8."$*KT&@+2"2%!(! @)'G#?N4=<,>8@)](-6:Y@<$N0N%'78- MQ]56"M'RS=W71,7=C:SS(F&5V_K..:K@R(*\CH>+3F4Q*DNYQP*&DZ]6%TMZ MQD M6T&K/+LV*TMC;L1K!+%E"Q\5WZAIPU3[I83LZ[4F%M,BP'??+N7[IR@Z M/'X>JE^<[A"T);N4V4D!),G.NW[;9T7*5E9L9S@6B.K[0G9#G%U,(%VTL39P MU\$LY@8WAX73.B^?\3\Q/C5^H^;Z^TNXW>4M\,6E'JG^5T2Z8_M>(ZX/=Y$Q MI-JIX,&N5*^FB)*3<,7BBNAO>D M9+A6KVLTF6N9TH1]^'Q/SJ\9IG8X,WY[^--C?CZ3PT?W.<7?]]KN0N$>PN3I M1Z[^IFYS-A]!GZ>5)Z.W,,Q-:\14HBENT<,UX78IXD?D:5;O\OQ((XFK*-/S MHGUZ"='^_/UI.8 FUYI?#2NS")'T!LX:(S77;Z2Y=MUA]289A'N*F9NULV^A M^">R1%!D7HZ!M5U:7!"?\G4E^:S7BHG=%4HQAI,-QKCREPDE,_+7I>V(RK!> MFU)I(F)=N380L:'@M"(+WCS].-ROLUHNM_,*Z>Z9,.DKSVQ/"YR+&S(('=FU M'Y'Z9U8F$P6PS$(!V)[>#J< F"F Q1;R?@#F*%X$'[&AZ8\C1S.JI=NH*K,> ME,#Z]59G?D%,Y?6,O>A!YKJ#.@M?WD*4K%O9;5-3KQ'Q>,WK&ADN/>\*G_S M?6=/A(X$C-=_:?G[![E53(T*(;M6LZ ^##&G^J(JJX;_$W1@D_B2K4K!FH?Q M^4VD;L5)V)N[O"F9E=>$N:O&CVFW9". ]023DO\X\-_^$MCL(3>,C+*;S=QK M(<$H@*^832-J9Z:!Q#^^\D]N_2\W-(,S?Q4Q++/&[(<<=A) CUS\-U#XD%;0 M?+H(_-FS(HV]7IAKES '"5N_=E5WL#TI&Q6GX^*MW?OY?$7,3:44;>K\C@G^ M8>8&$\F,OMLS+8&>*WX4@(CP3IIC8Z;RJ,A+O+F$'3@F5P;AOQPI6^7=1\NG M$L14Y]9J-SE&@7/R3F/H[8.B_PJ"JN=,,MW^\CNV9, ^I M^Y4J8K.^+N?Z$R5;]L+6H?SQ/7IVSK-@X^@N6X$9:7[T7$1@#BKIG?;C5\^V M>%5L/[Z[+Z#Z4\:R&NN70*AMJW*YH.Y1;]99WL[L:(R:&!#([^(CQ496<9)= M6_I3OY MQG'0J!86L;J9JKTZCOA:N?9ZAT#,Z1;B/&U^PIG0"H-C$AY"Q,/D,[)"T(A#-^2C??R3:/P*AV$-*VC# M8A6LSL@__%:; NCH/[Q/O5(_>G]'7KKETQ=RRSCJ-%I7>61BGOQF=@'W%E]@ MLV:B2*(C KWX=CT/$$29N'*HI5<9#%P) MAF4;M_T2W4;"(%/V=J+]FCK,!1)<8%9+&G$)?2\=354CFBH]95[G;HN:NHPQ MNPQ4MP:,%EK$,\(!E'^_7Q1;YY8AR1[Y>!DC+;++GC/,*U:BOQ],JQ,],ACS M2)#7F89'$ "9"=HWADIK!FW[7(EJW?.OCFZVI-U0U@KF=&R_)91OBJ>/F_JB%)B3V<'QEK24I MOT0:2L@F?O*@J_ 1\[ 7.$T .O/&$M4<,[Z6'[-I& *(5G**FKUBB;BH'<.\ MZ8JXM\SQHW+2 MHP[CR-)S&7DRQ2':&UKXM>GLHJ]#2K^\9]9F:\,*)%,!;?0H 6=Q 7:&L%$ 5 M!;#'&2APQ&"WV7\O'!1#EFLZBRV_N[V'7B=KV7T7^S88P#/)F:BH("M0ZB17 MO0M7OP:77'_ZD(=8TE/'DX-HY2B\4JA_1V ZBDIP5F*LN[U/\'R_*VHPH;3? MU64XI=M5N#VMZ\>.L="8CY2Y/%@DH=- 12->8I+CG7ZL.L_%?IX87WGJT[?[ MPT@\9G]E N-T#S7);L#S4NV:/I-8U];U]_(@M[<)WGF?\I%-.YHB)CHC=G:& MVDFDNH;*B<:>2]P2_HZ5!P^.VIAT^AVQ]E]E&/+Q<<66?)&$S\T09Y_/[2;\ MF'KL'SPW3>.J%Z#X!^.ELSZUHS@$VU%3-S9;THY(Y@2_#Q%CG+YM%^0!ZO?7,S@Y:>G&#:YF#3$EO/?*IV&@')"7B.XVK[O)#Z'J4%40&#@ M !+Y".]R+N"FP]Q/=PJ G0(XAJTX G?Z?-@8P(.\0_W)+'3XPV^HWMF=E!-4 MH0#N) MU$F:ZXK)WU9NCU9+3\.!(A$%D96V+SQ:#2X.;@TN9$ZY\]HJYRRSV\;[\ M;N1@;8R80I"VTBF>UW2=^%'YP>#@:T,E M705^V@LJW.EN"H>9+:GGZ7I+:L"#30NQ[?/R8!_"IPK5RXYK*F-I^FV*0B_&16^M (?,/XJ,0)M>+X-R M0!<..P3HSC;O03V+HIY*W5@I50HS;BIK3*Q[@85KK!]OX[EH7))CDS?SM-/Q M@>"5>U(9.W+AD&]<_X!T"Z4 ML]0 !6T^^T40!ATRY("\&_>.5K(;< _MZ0M MU2SW'L$Q[X*WM/-Y"ASQ,5&QM8%O8:39[1QEZY!JV[O4;Z7#$7&2"">Y3 M8;2-LF1\CG68I1ZUC?K,OS^T[*GZ?UL?Q;4DS-XDQML3<[$MT0'(R2*]Q4BW M6G/BI%^JU^G#P7OEZLM7S$WBDTT(M)$!Q#)/<[G_-E45)QIJZKR^X0 )WY=S M)84JF^Y6S_(2A_,.;(O%Q R;!9EBNWT"S3^+RO1Q<@QZ'NB.M.S#P\I:#S58 MJ!%J_^%_5/\9DKO0.]5W]N2&:\18+D>TP2LO]Y+/"JMT5S_N_<$&/Q"?RZWOOD[>WW-H29 MD>^XE&L7?**_6Z<*U+OVNNSP'>5760J_,\;^LP83J@>TOH:FG;?O,M](W=/; M1'AT9G+5;\CM-E4V/C?H_>)C2 %\&Y51#+'#89E\AQT#N9U\8-Y-%0G\Y]9;?PZ4BW-XV3 M/BPNUNZITAQ6W=%(#[%-$+,.D.'<5IE)M\XW_"Z+S9COPPQS@=6?\&@WPFRF M"]-@%2,>EOMF-LI%='7^\N8V^N!RB>M="@"R.RAW12D._>,R=,'^@.B==6B!9$6B8O AQ)0C0%J9=?B F"4G]&C-T]T4=1H_-Y03M>O%KTL!/" C M4*HP-0,YF9CH8V0^E.H.>B>R2>5Q%Z$0?]!!QU59;(')IT\_Y5_?S313"-8Z M18(8.*LHKA8 M_K/%B/8KQN!H8)+XU3?',*O"AZ4M2<&3^YM#C$9+IL"@C=(&&,**&&ZOQWB. MR5"=O3UR%ODT/:EN*K5V6&7^EFW'6,Y(I/G%,V')F8F$6D*J6O6)>6T9"N!U M2%=+=#Z>;R5HPXCP'!6XD89WP3Z*)4+K[G35F,%5M!UW8S. .F[:$D\T&57C M!,6CV^TM^@_:2_]+M:_K#@5P*@1KWW98N-\T.._UF,BPL&&Y6ZEWP4N#)#$Q MY,*<)I6L+RQ#:.#GDN3MEE.W!E+[RO[[-/EJ\V'5^MP0E"50@R!:Z,@X @7Z MI59&.*K\:KH\8>Y1)Z53:)Q=TJ'*1 7BF;$KC@[=T>Z\T'R_,J]?H7_65WZW M\'SF0 &DXW96$(/5^UH#.*$%[88*K9&5*^=95KOY3/$NC09Z+"T5NK? M(G7E"%O?#]-IWZ=.V4KNG]0P!EHZC\W[M ASK%?USGYZ?C-8]K&K"B_(H_?"<+^)1CLIF(P%)I2=&BX M9O.+ LBN8=<]?+>A6:.-7) +*11=A"3"7G091!3G!Y=F**9>:6J@>U25-!_2 MKQBIEO+%*G[U^O/QV[A,=8:AA] .WBN@UI85>4NA Z_D3,],&PJ@C.,KE5Q) M\Z/=#;8+WY0X:Z0,9B[U$2F M00P''^ 72 M41>E.&R#X[&=U[>XP5^2GJ%QA<4.:J+W)W1ZNB/G(]'L*K%3/ MHG;"S(7DR]W,A7@%BV35'+21^9"V^'KI@Q=A(K]6D+;D'PF?O>2EL;B<\76T MB3(U\8^.W?GIER6?+J"_9J*\1X."Z);O9^0*!:Z!8>!"IK80XU:_<>0P!@@S M'N.&\#VG2Q__4JCB%P%, >26)L^?"H-I>^^V8LL#V0G-O1NW M:O-]BK\:E-Q80L;H=X'#9]G%X,^@C::@VSK7C\<*JE\05;.)+A!8",YE[CKC M9PEWO8,U"O5U:]=2CA5)R:S99P/>^DP!^,IE+;5 2"U-B[>>WK]:JZFMP7QG M:CI?_GRO+^=@.<[D-:_=O$UNOZ52\^L-^:9]_F$B4P.D02@Y(+GERT<[Z@4B M31T&;T8F YJ2W_!?5[NWB^IY(,'B+).DK$?SRMBYP[.B\0UY]!:VS]I=9VN' M;IF>H;\L> ,'RFP,&!6%38L% DP*84+)U+=&WH M\FYB$8K19$<[IL$,AW,>L$G%O'A_>C2+VL#!T-]7%2WH(3,S3;J-S'8E[K_! MQ14Z2G;C/=.?V1F?LQNN]PD<0W?QJQ\_;;)*F'Q;-OC]'9CNB/!7P'^VNB%/ M 1N8GD,QK^YF3B*S^ M&HZ0!F+\#T.SK,HPL >?_UL#JW=^N@(\$$3W;$M3#U'J\HT7.YE"SJ*GX$4W#:7'>X>% MUJ%,#1=QT\:328OXD,_!N[M)&2%?E-MR YA9:[BF^+*3>,K4NE4"TZ#@7?*D MS> (XR^T ICJUD ,M(044('(5LE&SUQN3G/? XY3F6W#$2"C^)L*!57F#L*T M1#L 5&#VP[O*U'FB>G?$I#>Z* 7"H"%H NU5XL6'/D>25U37GRYS^*(D(0" M-T2]?D9<<6 C)"::B?>!X1-!-P 2H%?<H#AEMV6\L+T]0)@J1 MPI-CY#,W/BQQRD^DP#_= MGLDDR^1;2-W_BB*"\;B&"^7-B_'E:[:G>=1W4R MN#&U22)^%D<,(@N*(CZW'-N7HMG.VL&D9\Z<)GB"W>N82%Z^U@#?\<222=B9 M)H*IX^BBGI;(,_5IY64;J5,2=Y1.KF;%8HWM8S+NT6,+Q#KJ&Z.#'Y9>SJ8* MO]V.O\\#''NHPNO4>MY$2]=6C5.H./W*_MTA.<<>!Y"7NR=QO-8_,$PM_I)K M_ODUB!ZM;4?#&T=$UC+W,\Z#,B"I(1\SMMC'*OV MQ+N(1ZB?,'#K=(O]-:;?IO6XC4713/P";^DG\?!S5J&GX-3;P65_/&L[$&H\ M"Z8 D*G>EF0A.C\H;IOUB*V9OP.6_2L,EK*@/1W"-@LT'LH?TDZNZ0]84?0W MZK5]OL]_\ZE1QX;%KFA/Q,S^-J\8<\GGB2^5V(.+Z)>%-ET]3/05#8_?C"_@8%8%;SLFK[%CX,8QDF*"3.KV:5 M!RK=[TXR>/6LWP0WV'8 G8!V- 7W&Q>X =7/7*;Z=;$<$=!7MF?>!.KH%W MK;:*HW](K\L-4 "W$CHR*PO*$?L@;!-<,_!' K=1P2:"%#"2XEER,8D#DA!* MHJO/U!NJBBIPN #4ZB7=Y-IY M^!*_JBVS2->B35_*G,'YX@RX19^^Y--.IQ(41MP@1$%&9&9>CZE\+Y=19[KW M0@G#^T*IG4OJX15.3A4[+ZOGRE>),X6V7LOOS-6D3YS*HM6_\/*-G,PL!;"O MXH\$W0F\-2\@Y:HC*%M4P!9NM5NA>:O^<.3+4&QU#;ZP=TC&[9ZF+%LH_<=) M$Y.!PO)""Y>E@ 5"\_2YX!IW[Y8"O-MN6Q3^-6:9L)&USGK0[EKCM$"I7YKO6W.=9GZ&%KR_IK>7?H M?.9A(@4P*])T)"Q^(?YLW1QFC5O/^#J#E VT4OOPHPLEZ^=CK8Z\WX5MK+[Q M]!4\)]HSK)"W:?1=RV]B#(+*JA>577# !F!>Q\.^N9(:WJ(N&Z>U6CAK_>P8 MMBL?*H>E?$ZKBO-Z!HY45L]4OUTNCT'=_#LRS1(J\(+6RR/0(J_,I6-0-9D. M!!^[_N-5]OWB9+<@).ADU1LQ+CHD:F?K9-,:FXNMS.CY'X6L*C>M;JQHTU ! M=O=/:JUC5'$H'%623=8@>>D9@'DOV#4,-[^XC.8 5,?IX#K=P3KG0QN=/G: M&9N:W*6.M/Z+WPG$_AF#'O0'=&44M$7:4VR1PLUV"P.]=AU'O$"/]+Y;.W9K M;M>)CCZM]#ME5FZB58_[Z!OJL5A M^S X<(I!'L;0L $7QD75PAO,AQR7,#)F,TPFEVVL5)PPLO&1\;1*ME[=7EOS MU.1[*ADCR)=26EKJX%A86&@7 TE)20D1Z]>YMU6I*KZMTIZ>E/"4-T:5<(4) M@RB=G/P:_2D"H*\- &@#;@-H7N$Y9/0&%%](4P"F*(:'9U\>& ]\"[@7(%=Q M!$W,4',DUXD0XL)1;DVEYN+IH90$=H!P/_SR>/9[O5?H7:K<>PZ: <-#5X=X MT6,WL5V[DVA_!Z),.C,TEMR&.HUVY--B1.#>#N?F9R@4Y"?^](/UXLMY2.D: M*E\/Z*%E];&8H9S(1IF$:+\"<2+$,/K Z[H^@U?7PO#RA5Y(2W1X%4+9A@/Z:[C$D1RRBY?1Q^T58VW&1\P/O^8U"9B*+ M[?=-#[_E[SEM]=BYG6O67#TH"^AA,/<^O"BUS^&G+&=\7!?G&Q_T?FEBOQK6 ME/V*8!J<9"=D0U!/1M?LAWW_$?GNZUMML6#2-9+>9][Z!+O3^I4<; W/'%L)LSSZ;##OYO!Z)\BL" M_NTNL:U. ;RKV'W9=[BVES5R812APV#N;Y0_>^<;"O!U>7AP=4A&7%7C!WL:79C H!Y__7O"D:H76G]X* _ZO]A@F3R;K2%EJ M$20[3;ZIZ*P$-L\T@.[A^RP+1P559"4>*SQYA!DSY6Z267 M^YJC3]@*(QN:SUX*-JY@KWCMSMC/=(]%^I!%:#!515V9G;0Q9AFG]]@:"W2; M!]4 GW!Z$7"YV,(M*?@ +C$Z;I90(J7GR&SW/@@_"!FTMN&G/6F4//+!2QGO M_N)$"XPXM_Y^)P$^B*_\%(+?)(%FH5'P";R?:YJ,\4 ;7I*:NU( W+L]7%'" MV6@CY?/K+M1<4QD;+,=EBE@92DD1@0$W@%C2%T3V>Q[TVF5RQA3?+MZ>S7.! MS9)DA7N[[UDOCNZX28)KRIBS^=++:47*3OAE[6RCG=UW9*2Q7RF "&()U$W] MH@PI73,2U,6U"OZX,%0%GAQY!8(UZ::]Q!^4?<3(/ */DZ4V%)MD?/4*SKP* ME!N'M4)V>D6:/']:U+TCK'D]3W]Q=F-B;4YF@ZHKO=P82O%$%!6)3;"90AE" MR!B^I8MUJ0K*(\]C7;_M;MMG^?3PA32NH3]7@VPRG=#Y4@!83& \9P(^]FU0 M_;UU[Y"<$IV1UP:[[PV7[E[\',HY(2#R$U\6AGD! -#6Z[,,0.K UC-?U/_%*O'_2:W@ MU-3JDW?RNMMBV<#+TX[RRY5Y#4Q-]16EAF+WOG(-].\:2F;XQ'QVL;0/6@][ M;'VF7$ /P?86CX%2II.#/S]O &;A?O,P:I9=9_7N,,'2#9/!#H MY_WU.3)G"A42EQ=B8*[QG)3Q# S**>*_%<^&],B7 MED;*TO;"?[4TZH8^I0"46KA]$A]KFEQ,S_L<5 >9#_AA(Z0_IJQNI#/$&"+P MZ,:C#ZH8T:/;EY?^Q*^1%$ W0U&A##4N0T5F&DN#'9U+!>>-E)<\JKQ.;?8] MJ"4$MK5M"'=%1MOF%\B43Z*^Z9QH.^'&.:JCHDBP6.OX-V\T_;,&XY:^A>4T M2UIY.A\I#^LMU0>3QL5/UL@)#X1T1KNF4G:>[I:#>MM0O' M7)>_H$+]IJG%U_\JQ+!/P%6VD<)[*.[G5C+>279@A))!N. J-?0.1J]%* MT'].HH,_Q@>X =6ZI6N!U,S:'2O+%8E=0"MJLM)$[;,>NB'/0>Z^$QVN,/6_&#'HTI5$M1+>'159I&)^F%TM&!29(E8("!3DP:L^L=S,..5($S7NN2*?4W;O(=A+_V2S0,C!^'!#P/"8IKMY0D2:@-] M/\OI[F.@+1YEEG=(__K"WV^&'+=#[CMP5HE-AN4H9;;X&*VZ??9*HCK6/Z[D M^CW.GK$X/UU^?T?Y VG'IZM=GLD,[Y*!'32G5:G->/_M)]LMF4 K_),V-:"4 MV>VS,X,_1O5C_>&XIO+P0I.47T8).\4EQ_OVK M%^Y3/;B*].=:_CT?J-2GZHXSMGL$D4[+Q;ZMJ5CVR%B>.AD/UJK AR[4!R,L MJZTXTE#)DC)K?/&]P5M/E)[DSS$*0&4P//4=S]%D 8'_H>6!GLW^O.U,[L#[ M>)_[V/CD&@;O78*9E^3EKUFY4=N/X.-^TVO#OD)IE&=]GAP CLH(Z^_F"8R+3>:DSAT;^#HCWSY02099[^OV]P=B6!%F&>?FQ[N1=^PZYVKHF]/GKQA 9 M\MQZ8Z"L\#V6YVT0QP+OP#8-9VW9.ZJ:>G%E;PLEOWREMV_<++LT*'_J'?B M&K5NP[!R7C0XRTX:N\6>R)>-:I:XK=7W\=U(T\J;67>/&U?'G+QB$UH9YL2@ MR'H&A"32>Z5+=D4/]0,9T L'?@Y1#\]ZS@W-!+,_1B*%!WXF+%-+%.&V0TU@ZYDL$CLRS*E(/!M]1,%$*@5S!6(", #/+,,6 M>]W!X]2+F;JJ^G^_-P.9.Y;^J>!!,A7O+0.NXU(Y(.I$;IB6>'%^+RB6-]U"$3#/]EQ MGR-FIZ&,YOI):U-CA<4SX0Y?,N_:OR"A*]MEV7YD*U >6;ZAQ,Z+?+-3^3W MY >BGLH19^I2-=B_I4TDE"&^_ZE 0CCCVXYQNZWXR)C.N*1U M%Z'JZE%-#L:>>^%@S;-W]0U?G'C%%T4=G__%!E:(K1_/%Y]QZZ<2YYI),Z:9 M$#N:1MW:3EP:ROM%@_X7/9T'/ %]'N8QES]F/+R)C_+"1?_9W@^H&4:K !0[ M9KY/ 5#Y/P4]I&]A.9J2FHU_;YZ6XV:]SEDVA0IH/FCPMTD4K6C@>XH+"&H4 MI<>RV4DV;[8:N:"^13JPCH2;AW;V,?)\9",?G=^T]*_<0S>2N0]3-J ? E[3 M#KK^B, *+XS?90M] O'L?5!SAT7\942/(OLK4Z;Z+T7@F,\?(78Y11&(#^0<. S@RIO:I9#E_C MY)-'S,3N0G5VR)AUX:^&C\(@'[Q'VPSMECYEBQTOB^ZJOIF7IWXIYK.^(NV7 M$P7+ZB\M?.5I=<&+,C)+?6&$9 +QECE2T:VLU.:U'(W*G!=PM<1+=$L;;'GU MUC36?'96KF$R?;P%HZ4 V6TFHN3>U0M4JPQR_%CO,WR*L_559@XRSJN?JFLB;R,P-MH M?Z[:OJJ?P1NC!=809[0$$QD\Y>A+]$+4/_B#8%2QF2<'1,+H$ZINDS/DJ DT MQG9NJ#4," .^QLIF1&&S2>D"#M9?@!O-&H^;5:M,R/H@US?GV,3 EI-2-.8+BX^Q.T/0"N"7E.7T<<-YS[ MSQ^+Z5FJNT+(JI(=^S0M\E(K8O+"3:@&%P+7<%Z&SD)X.?R$G*)G%=Z]2\B! MR1[^J(XNW^X\;TE8GNEC,X9].O=?(HO(-'):CP$%H%5'=C*A '(Y7Q"( W(P MCG9L A+7C&+QT;)HN&#VY8JD5''^E?>TF2?7'UY@.\%Z,65D ">,,\.\;?I/ M%Y GF )(,B)]Y/LA\'?[@MWPZ"9.YHC/P^$JA M_%A4GY^'5Y'UM$2.2J_D']3 MVKKZG@(0U^J1DSV$DR'>9GHE$H&#>T%;[-?>QKZ>+)#O6 MLY#F"ELQJ5<>FOV4>LJ59@V!5;^( L3H14SOG;)"LHQ>?%^PNE;^,NF;K],> M=1H5_K"M;&DBLJ>>N#7>=7B6;!$G%S69&J@![&1(FCPGXKZ1PG;@ZU I:U3* M7QZKYPG_UO7M=J0:I#=PMGO,WC$K1GJ-WZF&&1]K-BS<-%X_:?H[F)U_PF!" ME5^M,+)AC>ZAT$0+V^TKC.!Z>=V-50H@JHVYW=ZB<,UX4[9('M8F -::E-LV MKK'276C748MWGVPR/+NM.?O.%EZTJ39) :C5@7YD]A>W$E->&&WT/W>]6[%T MNG(2VW!>=$?J6K86=X@&]PN'>!MVB-'*K"*0)XHPNP5Z\N#UN"%6[Q7:/BHD M?H%$.-1#F69Q5CQ'>SPX_XH"L,(FR %-^=1E3D'!P&&R(!5E;R\-XK]\#G]- M!FVTS#3EV0R2J%=K@H$#4%,J=JC@ZV2")=D<0!]@/SL,YJ@2(2_"9*DJ2FX@ M4T3^ [=6VN=("@#CYYSB:7,Q< 8F0 (0+*[<@SPN,J/GU(P0/]*+;_$%K 5G MFG>& IX^3BL'@K4' MB-K=MLZZYJI9=H^7@ZTQC8(6M1KIL)P^ M:X'B*&Z&6L18Q^$=^I=\F V>:\FWKJG.2T2,W 9Q"X"B,8N529)RB 0I#,YD MAJD-M8OI*H&!YU).L_$;7>4:5^*@H^?D)S4,*O^CM&2$1!42HGQV+;K7M)JS M0OB:B'1RRG!XLPSDM3J+MW5CQ9#NE>[:"%BT9]G)]?N'5!*NROQQ5X9W#S_) MFLN ]W,I !%<1WZ1R3E7D:5$-2N/G8W;;V0XRYIJFOEL7.N[;&^/6+"9U]0) MY'@.G0O+5;@F,TYE)WSE;Q)L^:QD9N)DSYAEUYWE*\$P; 7J-5#;*Y+#=R$( M9^I-L+2\,9>W7)K@6[U>*)0U>"$Y%5QZYU1\(K65CPQ_L8/?:Z7RR/"1E#B6 M#IU.AS;*%%5[!\ZNT]>NGV^)F6H8ML,5N\A;NN$T6Q)A$+-@$?ZH0N5@B.]< M(,.Y#S191@96U ?4K[RR<<@#;'E.BJ^5"ME:QT;6S: >9/08VHJ:/T"EAHA6 M-K"7HHN>.CQ!)J6O)05\@SV>KO'$BW*.I(@L6?(R;!%>E&!%DJ9N3JE'2>MU,QHUGL=<8;.TK7J)Y>7MX M+T_0H$^5Y]CWLH(,ZF6")B\,R ]N0CM"@8GFOL3\+:LE2X=B',Q&H62X5G[:=P M_":> O#][23B8SS4.1GMHL Z'.60AK\&UXH?<2>!)J =I#R;@3? GKBF^_IYLZ9@F&47@ ,!@;3%VUWTQ<^'6UGATEY S,(U M?'?$>&OX4*IE:H,R"46X)L%':P^ODT:CU.(=1EX)8YO3CJ=3)VCV[YC"QK(M MX8VY:1#=+U,>/A,!*>7[..<:D[&<#WU&M\;SK>IV%3W?+%V*Y#"TT-"_-.0Y M;[(0H2FQI4@!C*X7G06.O@X#XELN9DYX1N&;_->A+Q'PS!%PHUS_[2EEF/VR MD\K&P.NI6ZR'%EBZC&Q>]>>''B]N^K_K];OL]=K\+XYK$$2VLMR]GRG=L@DF MJU, &XDS1UIKSX;*@K4?+3&]HOI0R;*E8=I-Y7M,AXWHRT^#;8VY4_BEX,*\ M88^GQ50YWG\7^_C@)(+:WJ.&Q43#KL$6[H;MW!N1SYZB<6BL?$D"VVN!$44^ M2[/D9>/H*V_JFP_[ 6.T#FY0RK?EC]J/B7,"ZY"UQ55F%\6<(8_L^U39E\*,>54P\-)6#/U0KVU6O$T&2"3$T_9+ MS"L,[Y/<=0X>!FJ(L ON7RT$O1QX;_W'3'O3N5\/ MHLJFV6N6:CK 49Y[_A.I3-&.W<9P@M>2H-4;_OSK$N*G1=*S@]4H*_],,J\S[UU&/12*!0+^B%A^!G"2+M#72QL1H7.D2O0I6KLDR*??[PP?G M1GU3NA^CKVD_\'UJP)'I;/8#/K;Q?/;,-;<)07!_%IV ,RO':"\1*FPR H;Z MG@-0 SOUW*;O].6[].,(XH\7-/(% "*F!W@VOBV+F"XR>>&FS?.K'AY>W&; M&,5GD-2[>./>C,ETA&V,%%$/Z'[AJ;?8W2)17A*L=',=&0!'VM#//LT2OAK* MHPA\Q_BPD/0*()/\@%60W#8;NFKU+/W6YN9SZ=UASVLU%@E[JR\M,8A#Y4,P M_#+^:K46I_!-ZP,J)&= LPP.9GANJD4 396L7VBFO*E)?"Y$>QAAA8WQKY=Y M)SI?L[ZEV75?7I3^_>713<@*%,^J)L M-U.@>5IS%,"5T7')ED8,,KJ7W#FYC2VVJJ$WF1Y,+] 5%JE":ASCJN'NBW!7 MY(N00;%.MX\?E_F'*IRCF=#K(*(?=&N)FK-^7=T@X42/BI1,H+G[32;I?*>V MJ=7\Q[.##3],(JK*QNYK0T5<\ (VQ070,$[9JA?Q[HWT AXHAZI5F7%W33[D MG0>7_-=U72;T\)9@16]=R]+<<-6P@PF'96=& M3]^W0H7ENR;-N5-("Q=YB=# ":O*LP&N?4L'5P$MU(SM[%&,V)4_OO.Z@*QN MV=]6M^9@H,3J3 '2;!8R0W7.)@WL<1%7EL<9\FY'=1,.NF M@63K1 PT)WU4[UQWCUBK1^TYSO,/RRX.+W))-;IV?RMUJ+N-;661&ZH%?L2! M>H_M[\3/>LP8F&^C>)JUJN%30HMQ0!$VMX$/C&T_?=,@8L?%1+?+/D M_U!6?V[H1Z2@*8E Q 7D>@P$3\KHZR*>@&8]R)M86:ZHDF$:V![/ 8,+T\K@ M].G(]"QUY-$/6A_FM=(87>\3+&A6AA9-,A/U!EV>R WGYC>I*I(S\)HRC\,U M=O@50^"A9>#7*^.!._\OGK(^ARR$=/KG78QZL2##7KU8T/$<(TX^,;D'2.DP=X.$-?+W#MWD2]?THB=E$\+2NN>2N9GT%[@_=':_ M?=?427?@YU)R:\#@\T>&E,QM3R>G_GNQ 7Q!=HTN>IIJ:/5:C@%W<>/3>4H0 M15MW8XU[&,V$CO'Y-8OKZ?Q;XE[,>HWG-MAZR_41S!%,JDPWGPBI1>_0(84B M@R-/@42UWEZJ@?L,)A?;A3T+TJX0JSWY:B">U_ MFWL65Y,4L4P-\A>76!9L M(=%U48:A^<"O;K-9*;5$EM71=2WE&8Y>F2FT9Z@_K:VIR>+<&+.^KFI.\&:O MYT?GAWWUV&*WN48+TEVMGL\<;< MN- M[Z[^6;%$*8>%UJ8LMUF*1R$)H6VW&:]CN/ B3K^.P\OY?.&9>K95GH*< MPG?%$HHZ8('ZS$[Y+0ECC^(.=,Z9[ M-C(*BO)N+70(%+B3_)1P[YW+^]BY+(]J8'E_XK4E?(>\;=6@(9$M" MOWY,SPSXJY*KVWSN<)0::&V&51TM=(H>0W/9@7PB)QEW/TF3,%FQ(H'70@@729B!FTGT( MP\F*/BJYAB.%(!=,8.HIITI@I!#BQN[,4-VJJF.:S&,=!!X8'D6(*JM:AUPP MY5,+TS^ UAR].R/]:%,?O4O[$ZI')AX0;3,BL\"WTGDTKS)XSCLM#7YP M? M3L6T4@"9GC>:A",@">&X1AE3-B_A2VU(9Z>A7$X/@D7)_TV)I>=%C<_MFK(& M?1]6-8WK77Q6_GA*^H&#X]85MJ3\5?1GG1Y5N4?=A2!>8@6/RMP%@U! "RG M9AR.=(E#1F#>KV/G?7EMONDP5XKNGZ#-:$[G=*N\"5DHW66UL!&'GI_P$W%R M[H5&>/)-8/TYZ>EC'TXX@&NR3!F^$F*\?Y4T-7IC?GT6B"J_#US$+-Y)(1 S MG);3>U)$!'?\$N;ZQMWO](Y2 ,XKN;":^JN_/4TEV_J5,@]1S9.65NN] MQ2P73SM>ZW+QO^ZIU\V[%?HTLC!8/^'!S=&"US)U!T2[$NRTSN"I_7S0XNK! M<$K=YV]CIIS=Y"L7=#1\+F8=C_LD\/.UAK:O3[53"G>XO5_W4B"<[]YS4H=T2P)\T61$A M,WX;K'!X4>#+Y81K08&E2S[2^7.A2Q\==DP0>^C&0?O\!-R_!8DUNAQXRH<@CK&?(W[-F_4W;H%:)0 M4K.!(!1-Y0O[MFX66&)+BF]);Y:-F*A;QCMI'4\_QAZ^?QXJXC\ G6LPK82' MW@RCGUE?[]-*4+4P]"+O/JC[YJ#SUL6O]-V)^T[E"GP\S@R_B@MV[U)77+47 M#Q8ZHTK(1*)W?%(5=\&[1'_U[\? FS9NK_Q"TE4+N%^QHOHH@-,#>]7ZZMA; MF(U&^A(^1'H!!MO/)AIC^%%QUU3028U[DUG_'*Y;/\%^U.X!7TV#,;G;81P[ M,/O38$U]"MH$GE$Y(=5LN524XMM: U_\J5N/PYUPTGT&D "9CUZN+_+*?0$>64=Y>TYUL:0)-GJU@@DS>S?BAH)%CJ/?I;@EX[!'^*^#] M1(SFP]=ZU71MY\NGV-GGQU76Z56-G&V>%3[UT1')L*>7"";1"0 8L_' @A2;XPY(+H$N?PBYBM8T*!9POJ<[:5; I.\=3&/!XX;O2P-&/* MT[XI:8?I'SK<5TS_54;6$0,&#UL:JA/ MR+3<#&C9HBG<'K46!KF1IKN\@K%3GANBZ8TMOB1TGUA^J'_@R>NICT]3[WP; M^,?X7MV@ $Z]PTKV'%KL=PU9NA= B,T'LU7MPHND!-RMQI(I39V<$7$%G++2 MB=K0RWMU/L<>4B-NXU_>%_B#80]-#<&Q#<*RX/WQP^5>O5%AQ9.3,^;0L3@= MQ-48 2D,?1JF*3PY]\.;*5-BUYN2& .^X7N1T@<,7KC\_J--S?MILX^AGRF M/06XZ^F?CU\TX,++&D!":U]>ZY!VR78!?A^1V[$7@Y^2EQ$?'MK:^V6Q&IP) M/2K?_\F!M]_Y;O#_),,6/]DZ?9O<2^AGB"TV#[??L#&':L MKV>]WKX&.;])ES,D$BI%,O"18_G@#Z4&=CB#GN9GSWH$@AJ6FW\KW2?AN6LL M;R4FK;8<%::XJ[42Q1DGJ-X3@#@TFC*2.RT]PO94L&$I) M <'VB%J(K!,5GL0S@5 8/'1UF1?=P5M' 1S#A1Q/%XEPRH!])L+4;2QR.UHR M";,88C970N&^5RI*QN/_L_ C5[:F,6[XRNV&^;&^9QF?,TG"6"S*4NO-?#;+ M& 7@/C$)\14ZS;P]OYO3Q7_)ZHKU*<"OV^ NB"(EB:H M)%2W&<>QU'+RK A.%1L=-1=#U/R@ MA8Z!-HXRB# * +P+VCSZ1JQF)1DZ#MJPF4%P-0T+@P=_J&'__Q?,Q3)D]6@N[L4P%(/576_'IPE M3EL?W=W,<"A\MHC5FP(0*DU;[S:!WE OD#=SSBO*YQ:K(AH%["#L7:8_!^UN M2,<$]--?.*O*86=0?=*-*Y.:6SSA^F.X>(GL/2ISH !H]RM_>^G@8ZMUZ ?I MR*.7#C*;=)-SL)PUK]_<#$3D';U_%II,!7;NFVZ=A6B#.0K$:9AJ_4R]%K_\TKWG-2G=W!'+JG-. MF[8@_1*S=H7,*P0UT0LX:J) :MMIC8 &[ZG2IFOJT,9-TC?O)1[6PCN>WGV$ M$73EL/?QUPMQ[Q;V?>$U M_)NQ$Y>60$,3FM)["7? 56$,R\H*_4[[T(-1W(V>+V+!P0ON;U5.Y8L*AJ1R M07/*MG:NVI=%"U\T*SM8F%:_@# ?^*)!G["WBC.*0B,:,MX9A@YM< +1"UMR M%8@LEHI%ST9$^]'+#&K^4,.:"@,-@<: Z_(M&Q9#Y:NJSFDR1CJ(HTL:M\F; MV#L9;PT+VG*%!:#MB2P=B\N/./ M[ E/34]4Y3^Y5_HN\41T]UU7S86S;@8C[IV2Y%M;PQF,#Q';ULQ0;I1'"+'? MMXP@\N62?PTC*6 EL"8BY/#&U-U2L\/.9.%V4(ZFNT)]5%U4*> O'T Q!U*5 MY&/J,(ZJ^8(DT 0%\/UHMTZRGYK9FU'M47X<$()&-4B!7$[-YKA(HW1NP%$!/(@7 M2I/=0JAM/[H?3=5F9S37LI'0+KT5>NXS2@5=+N?3R_V,V(7<-<6K>(ID[:TV M/BR9.1Q7>9A>\*Y305 L+O**>5*^N1.U;83>'__%SC94+0_&\F&B5HPWV\[M MB.DN-/@\]8$9+G%:>$4^RE_3'&VYC1]E_-K6SVFX.J'/6%C?Z"3(\[&>!D95 M3&9_]BV#__? J.F,>3@#& ][[CT*#L$>-!3YT93;$Z/V&.8F9<$B=7;;DW%[ MGC;TI?24VOCI!A-$K',DPKG?S.S<';M163K._YXD1^NV' 2 M=EOVFV[1[=0;XK$\:(\( M\"ID?T+[>C<1\.D3ID12\/40ADI$$ 9:4RY_B#J#U>,4*2\//-)B?E91#P6I M3-SF! Z3"'M^&BM9UPL]J[*H*%TA$8B(JE((XQ1,K5O\ $@506!"E,,TGK<: M+!]75> $?44!^/Y6^+%%3S'7M> )"NC!-'6S'3FZ>O\#<[8=T4NM9*3-4#NG M+<&B[$\\:0P)_96*J[E,ANU?1\:TGG7]T3HEYZ-\A\=V__A[KVCFMRVO>&XL6)AJZ @ BH@TD2ZTJ(B(""]=^DU($H M"1!1Z0+2!02D0RBA]Q"5$CK2.Q'I'4()(2%YG^SW[/OMN]W[G/O>[]PQWN_[ M@S$829[US#777'/^?G/-M=:!0HW>>)V/6+RX[59K'AG' Y^9*>* >V%%#_4D M<*GL&18=CC4-YL8781*?8UD1?*:QWQG[@U>L!9Z+&R?^_=C4_L/G 1(-Z!W M@7^#9("O(*G;9 #"PECW[NZN)SCX!AY:DG>DB8ASTC<78O.6V9/AVD*9^130 M\;!!#+&=.#(]>'!))W;01&4P1BB2H'OYQ&&0#. G?]JU^=_,8Q-/>B\O]^S, M;28!GS^AU2E(JFBX@\>8:M[O."V(G#PTJ;US=\E<](+L&:CV[F!OVQG_F:UV MQ)>!5XW ^_TC_MSQ8K4YZ3'THC(AR?OXZJBMH;'[! '2>]Z9-N#7JE#[!>)% MFLHJ6,Y$EYIJV5GDA_RM\J@;O"-QZKFCL@@S.Z9+ZO-G28U5CEH M*RKSN[2<:UD9X;EA<*9$>V]/6B(N(5U0:Z"-/B #=LO@%^2[9*^9JD@?@.K^ MMM0\#(X,U!-X1@&)8^<6RF;]'6ZD$42+85<\68Y&=JCU0X7QQQX];QFD[^#@ M/][\=-D@IO"+XHFU*L!O*V[L:WL<5FU2AC;<71.L0;VZ>S>:&;.X*[ MTO"@%(@V!30\*]Y!;9UN0FQ=A^I MDYT1:I'BI\P2(U0KF# "[(+2Y_[[7HD[(=[=KEI8-$7ML6T@W9W_W?+\^ M"HB9;8EZFJC,B/-;]]#&K,FC[J?)Q$/\\&]<5B]068*1_ 9H(M7^PP[G;S47 M[-_A#3-C-M(GU[1 .QE^3ADDGU+/'3BMNE:.?MQGNI6ULI1WEJ;9\N@--!9N M!K54C4__!N4=-Y$Y]M?5"E7C9.5D9]0+4MV!JJ*]OYA6,=>43V1Q/@2P?=*B$CB1[(3P,^8:)")&^@%,58' M8N\V;<9*V?BEH:]2PVI^$.8G:!X311FP#,>N@VG3H7G.WP]([P';;@1Q&) G M'=U_&$&B7@W1[T0!I>[V$$?P)1BD6X?6#GB%#9^V,:GNNL1OLNNR&T%2J!,X MA_P6[9=+_"AW-+Y&_RC_H8MJ"PU\2T:2F&-X5<(#OU[U?U;$UH..2CU$H0G/ M*: ?W]T\R'A&:O&]3Q&UD)%]3KS--'SS$'UP98,\NYQZK'": E+P M":W>"PP88Z^*V)=&*QW*O%D"%/V)YH]EQFM^7;-[W2_.UMRIX)=+&"VXL/O37.&=([9V]HE0^IJC91]F^.[U517C39<@?QO5#5+W=2D@FZ)& M\A.6_(JP1\]2EM?#7Z]PAC59(\89&I:(T6O3 FK"?"$H)6O.*S=[+YZU5E0 MGIL=IWJ=9 "]W3 QAM$0.IQ81O?6Q _H%IWWUR[>P B'/(@;U_;AQ9_KU5)] MG\^*W7*(3'MH37NUCN\Y-7W(1N*1)$]H;"=10/S WQNZ&>JR7,/]GTI6EO 4 MT,D\"JC*P&.!+$ ! 7:U*4'2H09A[$\__K\)*_U_ZX,&<_1F>M&P;S\9PG;] MUG2NZ-WPO"9HH-9T:FNI9S_-\#[?^G0.;5;<>1447D9'Y+5:CD9?IX[%ND5\ MRY05ZV,&A=DCX,Z4VAF\[JA\_^KZ^'7Z1)SB.MMA?7<0_&Y&!)DG64M&U,4% MC^T?=7F_PE<03Y-V\5+\:?)G-FI6S3[>[M52=X-G8:<'/H\G6O"V-< MRHDG-W(._5%9+[Y%#7JZE::KGB!N;.[%'EP @%WMH^_P8M9^@ 4[?&"Y]51Y MG"1=JJ907"3A^F ]5>:=A?&N*,!M/PSLE"@8'Z[D_^Q:HFYEI>A_>LU],\7^ MPBWSX"N*UG'RIZYJR+^JCWH\>TS]%,<(;/-HXCEIG[I)8<66I\%(]]N0!,Z4 MX(2Y&J&ZRQQ1:O61)567XM3'(G;NQL*GM.EP4)SPNH((6@KFW[ =\\ZDRN0' M;CU3Z_+E"TJ"^_?/@8SM0;= M&Z\1)UO G\_=(N'= >8PQ6@5QIF2V0,^1K@ MJI8JX3T'"X>KL)&9X5KKO-_\YS?\>N[=G;BB@ZH##)E],CY0;\FL= %GB7C* ME>B%*29'=ERY2P%%-\+25I0;LP#,U?!O8\AK4&I+87#2K20$!=1[8CN=L%'9 M%YNWA#_A:$[43"COO %\_F3R99FD12GBU,TH%Z%*K9>J4?20TT(2H$0W@5J\ M-O(GY[#N=7FEE"SN<3:#V0^J&Y+JTXTN[)>[/*[H])Z\8B\*,.0 M^+C2#*XRSI<3QUJP7U[Z.5>,//A8C#J W\0C LEQ8 #_EMW(2A^60 M\?"XEZ,;_W0G0FOWM0Y]4+W@WCQI@KG($/J^.N%25JTB(R)/5_"7)@;J37>C M960&X%'G6X0N@%4!?U\"MZ@I/;-K9G^VU__^Z0A#][)#4KAM4_2_OSXY99^= M,'0W+414@*.T=4[S[HP!GF7Q1J\0J5445Q#7&)M0'9 M*94!E2E7:B7:%3/RLO*S\L)LL[K\N MY:R0T8#?1CE7$+: 2Q3P%]*D1'<6W1E0$QS\/+!SWE4[7ELF*VP$9^?@II!7K2YT*^RON=ZW#AH%%:844"#M_BF %3=O4D 4D)(9 (*)HM2^^P_!>N%,;O'(\4# M-3<.\T:(!LM#M^8==":8)?D3FBH>-O+<>R#VJ>!L@0*@3'^Z?[G5C7X/8,\[ M<$Q7:=)P S$>X25KTZ9]RW(2A1Z!*12Z=PR50WAZLV$OY^]49R,$KYLSQIN^ M5RF0!IYDVL%WT_FG7L)K?O1\+'E".Y!1*2TDH [U>\4,<&G5;&M[7S5 M7\6[ZPT*1"/5@],7V6*%+:3Z)>3#7VSN6'TX+W_E0=&G@<-Z1W=;VE.L*Y,& M@2UTJ>#3OG;?5$RVS&8WGN"]!V+R3:(^KX9M!!5,>2J)]Z?G/%N5R%L2+YKT M[S PK'W]\>*S>T?IH.MAP__UR1YQHM.TEV5ZFV:.S55!/58;E82[6.W1(*;_ M-OU(X 2, @)'-SYX4A:7;,_MJO-K\Z_/C>5#&*-?K#/7Q&,:XN SD1&SBCDF M'7OCMI)TG&O,O+^P]D,J@_,QVL_2*^SG]2_8AVPN7FT16,*7-;(H#RE_BPA1 M]J> G.!3J%),FDGZYN*C%LP.M9@H8LQ6^M3:91;^K:U#(#YZ2P- )*[WKM=. M:;I:/[GQ<"9U/]7>>(>S'.!?]EH[6V29_JJ'RM9+Y&.E$5M[O8OK#)^7O1UW M\/(B+(SRY2Q*>\-*=_]Z2*]@7T^ZD.-E+$DV*P1NT\HW]R:9SWG/\=S.CG?Z M7E:>%.KFYQ:IISK1-,@BIU18] !$%!E9(R,]*U_'ZB8X[M'HDN_OGCZR_Q>D MJ[^A)64P05\<6L3-U?9*X/.+/FU1.;"_+PLNU[.%$3$D7+!)STWRWXD MBIZU[DM9F72P_PE8E)AM1A8-2X>2$FJQ]HG5RT;IL$;405JD84)F!I/*Z&4H M1E']Z4WS:X'5NG(7QQ[0!YU8\SP$5%;F\;?F_)&.Q#]3%F TI_>5-8&8_:*X M06;OA.T5=O:8')::D=XU#>WBQ%'VL'SPMX2'7Q-O_ "=B5HZ35>+-_SM.J\E M/0!8Q*U<]-\'XV:J9K.CF"1/S[%*/FV4>OV(P4U:;Q"F)4Y?S/N^5*O9:&Q7 MD$!OD*FG'/66BG-2*2#:<( ZT7O/ ^JSH8"^-^X3J1*]__F4R?]NO>0<$$II M),+7$ ![ 1U3P4[%*%W@S%;LP-P:('%JS9ROK M[8>MB_;R/HTEA$#JJBOW?"N14EA6(::0#T\S5LG5##=SK@>/[2=B<+:;VDZW MEG.S8DL")"S@/PN]I!H2P1E6D-5J64I?OCO L"-Z7J=73T.G*9:^ M(@:JO<'!(%)QYS'R:E!G^+N3'-2E):7_FO?U(2C@XM,;&'><#PA,.##\AQ<6 M(8%GQA,Z]Y[45XC&:HD'7JZJ7+^98-6Z+CU8S6M@7[*__'@.D9_[+"@G"@CP M!!^X.'A?*[Y3;9XF:9+%8&M!LE:&RUL^*KV.2:Z\TL;!6,'%/>77XARE]:G5 M,YQ*>GT:\9&SW/+?KQ+$:2[V^OE;Y#$"E"W]4M+$L!_?AL \8K^%&SS/=_7] 9PY//5U% +L\FX/NY+!T4$*I*G?K=\E^> M%%LH!IY6Q_:\\2+=;)GQ/>DM-E4&48NN Z!WO[/ITMJ[8P_#OO3Z.";GO(<< M5I0M]W*03X]-!JH:%EC1<-I@O_+IB+3RE&KKE,L @GT39OK8\*/#JFS\#6]4 MMZVPZ*"!5(NCH(E.=(?U M8H(!$P3_;0XEOY\ #/^=ADJROMF9.O"9N0]V5'O/UL79 MSO&BM5,NS^NZOM[.'1VF,\D/^:(TS5UW8T]=15YH(@.JX\2N+=7ZO " M<%+::OVP^4;!H8[9YIA28F)N94KC9S4#46O6MI7"TEWA;Y"S28'"L3D9.7/C MVOWU@T+*4H"7OO1$QE:@ZOG(Q!ZV?;;X9:"5XI'7\9W).>\SDXI MU8H,3R@%1MV9 OHOP9=T/"YT3N^^M\ 29!Q'-XNQ@9 1R\D)JFS M!RM[A".OHT-F7'81(EV7#_>X<[TI2I&ZED3U@3QBNOBI9$CMIN1&497OXHCD MC*/5C0Y(V%QI&0%26+LWKYNJ_H;+;T)?HO9, _OUDY;I#B\S(IV=J-ZHH0=W M#U"YJ;70:%?AEAXAS[G>^6/FP,CM:D*TGHIR8$A<"2:0N8HLJVF9][U%05F/ M^_'UR8%>K2Q).Z-34--0D M^(I[CO8**X@(RW^)C8FUOO;&!1#7YG?'8<;6646(\78GZU) S,+4$_:L>7A2 M#(/%-O2A<<<-X1M5SNY'!UX,SNR%CP:D;_;V8\Z%6?MQ7"J'GJ2:Q:\1N"CR2Y/+#[3J9"X M039(W*.]N_NSK%ZU5KZOG-@+_M==C6I[ZLJR],G1XZF\Q7P5(;J,<6@6N0NL[\;!X+[+GH=&CZ;Z6,)G45?!XJOW' M':[R)^$Q.QT]1$SEJ44%IV29%K3:YEZ/@J" 5L:ERWOC5W=J% RDA_/_NJ+$ MQ!9W;N4%RAGP'DP1'/[23)0"TB.O/5]%#,1[3SD50@4U3_TCL@7I =*:!.I#>))CJSQ,2QK%)L;X+E8]+& M]<3LJ0RI;^;%1.TU0R>GG;S7G>9SN+F5%X.TI\M#'>2G58)/;JL)]A3O\SH' MX91SDW4^FXA\5[B2.CKDX=,AL^1=A_]@:EX_WW&(<1D7>V,3*9KSQL"Z^B#@ MO6 BM]R-Q^K?N0LRN-I3P(OL+C'P[9G:T^3,/38*R*;A*WC%OX8":KA& 851 M0-],;,U(B*'R,+M\J'B*ICQ M;:$/3B/A;8C#9 HH.S0!#HD_+(6^ ZS\G:]Z"IW"#M>ATF^_7_EGOV>A@*;E MP%S8E3YI6AGT8]CI RP9I@9CG5ZW//R%;A][>&P8/3OHVTT!]LMM3]$XHG )JVKBX83DAW0G_]."WNZD_U6+_<^<5Q@E6 ##J M'B18XG(8^B8#AR==*DI@T58;5TC.LO8WEXRCY]W7.&6>2]C>\][3C%[C:-'0 M$?8=J\PRNC-[L=MDX31JYODE<<&FH-8FAD%#/S,A.6[3DK(-(_S961=S5%KJ MA*_69%7HRHKCBEUF^.*XIP731).^I_JC@Z8P1I8F]<0(P5(N(-8;U_P4=18! M?'\'2;RF]M%L/X<"XJ2 \!T;U*RAMR"5D=ABV]3(4UA2#7SKF80D!01[IT95#M$!3=9^F,F*P32V9Z*NC55#/T M%)?OI?>P&,< F/']GZJ+=JPIH+?W]Q+:25 "MD]%N\GI]M*R;W](6"+D?,K$ MR'B@O9K.!1&+C^781561]QEEHQ?U-6;X 8R/^ZD,_3\(F"IVL\BYPP=/FJ_C MS.;^1_;7(I&BZ238>(9J9 M",-!#>V3I1^DY)=;]'3W&K:R3O8.?B$Q%^8ZYG+G7W.+"Q2,_Y2@,D #--0: M^L6;[_K4-;3PC,91VAJ6S+S][ZL M_;(3$A<(Z1^">#D>S*H46,'*X@ LX[3T+Z%,-+$,NE886.$AMC^5,&$Z/#HN M[#+O8;HZ,=K>ZCIB4E=9N2Z1(Y#S<[=>_G:X84APYM-(.6;A7W\[ MK+;U,F&+ KJ73""-RCS1/8M\WPU!!Z(D/[3_D)&&HI[$:K.+7RF/84!U-;@^ MPERMVX9IY3EX6C]\=C?OPNL;UJ(5#,"P:/S]/H.R'MP)@-R*44 "+J3[C!&' M4PM4W;B0__BC=P+;>.!';? [J23],QCRXB8UT9W[^UF\1J; - !:6%MGCJ" M&&AJX/C*Y=_. E$]_'/UW(L)Z9QR"?$\&+BV[L2UZL+@ 1-8/5'P0L**/L 6]G[N>8@Q;M^MSN4+]Q]E['OO GUM*BLJK]59H(9B2]G@<'#Q7MDQ>QMDJTP M^ZI \#AKH-O&.XBH[^L MEUDX+/0Z#T?L^0'Y=^Y0N4=A-UK/,>D'-G\&YHP/Z/=B(+M!7)+] ](X?%H' M=O&'FGV6_,Q^':FJ%GEYI*8!E1^\[-Z]VFDI-M2XVM6H%=,\]/"]*.O2FG/G M& PF%LU1;%4\G?B8@.9#$UM0V?)/#Y\)WUZ1%+!MP]$M=%9ZNNELXQN"]'5YI*=GNV#NQ!PZ7J587A-QN(9M00&U8 M@@O)813."8^_W)H@ 9]O:5_K"M,:V&?-)VCIC295/>_5'M:^^:.K2$QELKK* MO3=G='_Y):]%MX:*HE+L^4)ZLEX!-;>EL$VF3]CJ\70WPY7NWR,-&T9<'T:+ MD_G,R7S.W9]7C<_=1CJLKZIPV?5"N'F7>(82\A#%"2I^."[QH*+&EXUBK.F( MREL/I;6BUU&#+P&H8(_E &^P>1$!M0_"#V.IU/$9VT+_2.IB#T')N[T3H_$= MT;,:5CBL'9E_1-3L0&4U.;ZXE'XS+2]3R.AL-8_U^^,6Q?*KFO>S&.,_6&]6 MOASOS#7#9].03N3EK&]5^N[BHZU>A62^:!,D>/ZJS)-R8BO=+YS#RI6-K_T\ M%>RNWPZ4=C<#L++I#PPO^2B\B>B=$A"GW)@F?"$UX]"/ H*L2;+ZQ\D&/I2Y M!U9CB\"G$MC*D=\0O<\DC+YQ]1^^HH""Jβ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

    X<(U=&Z"T5P#)@X:(YZI8:-= Q @PG[L$L8S".:_(,X+BIM ]< M)H6Y6$A[5K3+V/B+![U8"'LH]L7FM3E#8*XV(Q?X44RIBM,4*F0)>;(#S$^XR2ND'#':Q069:J(O5R--.KRZ%IEKGE:;6E8%= MA:G44\832&*3M,@(A51R!BE1/&6)3"U=V.,D9E]RM@2!;"FZG3,= ,7N,.D\ M45U-^T[*-R>D=#X1.BZ(IV.? P06/=LY+N#S YR1)Z>I7-NEH5'ZO,YE]?;K MA[Q/D&H"5?IFUBHB<8!%#+.4!1 GJ=!N8B(APS'*1!1E$7FLNWP MDC>M*-H33SCH".2FJM9@VBGP'! Y;BU;='8L7("W?X4?WOG3;5<9/6F\-=E% M[8 K&,^M@_/[$W:>OSYHXR.KZI)K8E7>='+Y)+_*S8-MQ1@H%OLV3Z*ZZ79/% RIFOI2/H5W MV"UY F':'F@B&&[;&@L)1SNV3;"^FK0\)Q M0LMV/S@I\%YG@]-O3 QHY[=2/*SEE?HTB)=O"B";C%)M27Y]?/(74Z]N15,N M*8ICR$C$M1N2)I#*,(,H5B%)*Y'X,^;HPH9M/ M__REX<\';5JOO\GUU_84MEIE M#*4XC1*8T3B!F.$0LDPI&(DLCH,@BQ/L=$)Z'CLSFSW]!8W=3->9Z-K9L.4P M-.6$S1V//U/F!Q]/-NU,9A8U;GZ M>V[E/(TZS=Q=W4L3#]$5&^Z+"Z]BC$A$N2F216.(J7':XDS!!*4BC4,69=CI M?/DPF9G-TY8H6#?EXM8Y9?EZPM;L"$AVUNA\T=VLS$[JAN"V=KG'6GCC(GDR M#$>(+*KPXX(^5^033T_/(3#12GK[UF3158/XQ546")Z).(!1*D/394I QBF# M 0]EC*E@*":N*0/'B,VLK"UI4!G:%Z!JJ%^ 8A @^U.^Z3YW[(LP"B%2"8E# M8N[/4@IQDF!M\P2%8D_::7G!+08S;)45*+)X^<$OI0KLC)=]Q30S[* MHHNDL\P$V;XP\W+P\ZA.1IJRPP7=_>EO-4[*+W/,H'@ M=[*[BV\CYC[(^DI=T^_;%,%(,A(G/(2,(0XQ3B+8>%JQTCX7S5(A4J?R 7,P M.;,.7EZ]>F<2&=8/S8+XT>Q%3260NBYS]E";PS;3$,E$,K2-$=;FL3X2\0)H M=LVYK6F!^^63_JOI@VGJ/CB7B)IA>NW6WY>>-#>[L_Q\3:A9-1^@WHI?)5W7MUP[29U30*(0D00IB+,DT?_+FE8K%*:4 M,I1D4<8CJUWR,0(SFV%-$=YN23J$ AW"8MSN^9#0S689X7;4IB22')+2(=#I M3&FG!3@]E=I30-.()*.!3(?>6RZ :83K)X%+8\]-#5A2^48V>??-^J@G\*.> MI5WJ_?MM7;<821*J&$...(-8!C$D*M3_2V,1$<8P2;!; ),MZ=D#FAI&P) 3 M8%AY4E?B_=22>@X0VSED\P#G9K+\838A^LE5?&_14-:$%XZ.<@5D/UK*>82S M#_(_TO*J;!*0Q5]-7H-V@YI#G54F!0TRDJ0N\Q:%F!>UFV)ZS3#UB/(NI\SNH#IW..6S5]4R>@ MY0 T+)ATSO88=I:#UU,2^S]_/4KQI8YA3T$P\:S*C]+9]%V6\DA%6$2(91"G11B.-.60J3"'B*,,14@0SM*J+ MFJ[MC(8]:2?;\?]S]Z[-;>/*VNA?8=4Y=HO MT^0@?Z/SI?G'EV<_;Z1:K>4=_3$KJ&"E2BDB4FJ7)%*,:)46*,\S065:DHR# MYA^$4VWD<,?(WT2_Z,AQ(S>_1NN=&GKUF2^'=E6[L[%VI&?7++U$C5W \J1P M#\[-S;W.XX"YP68:Z &XM9;1+T:E7Z]J+VETM;T[\BHRZNY^^U+GJXA9K,!2JN!0ABJ_"J?8M"5;P0$]*O,*+\%W7G*=N;%<('_1Q^;PDXDXXS+-D';" M7&\BF4"$Q@0)GDC!M =F.6@3>5K,R(YT1V6S-E0W-E^EH[S-E7&0BR>[FE?* M>-/UDPULZD]#!R*?Q,_-!UZ."LR?[0"QW#]&8L : S>C@HTU/BEDXD'&?88> MCR[N_;3O\3/;[GM(+6&XI++BS!PSIS%#F)($L2R12&6\XF8.C,QSV#'S2Q&C M'R>S;:@8,,M3CH/><+<$.=(\$3'QP>\[ XP/:LY^\ MB KY^OY^^WYM7^37#UL/)N3#&XR\LKI,P5KP6MZ;UX 6OUK*U=/FQ:R>_CD8 M %3Z5UXP0("A?4 L?#F43]MZ*87RB[N^!H/R:3[-&A.[='MC/&:8EC_=ZM8FRZG2J" M*DX5(H)SFB6J3!,GIIQ7MV3L@L#=8INW8IMTCH[%5[7ND=QK.='\M8N?OUM\ M\6_Q5&&>].)I;U=18]Q55)MGJ5!VG:S;E?UGT]NZ,_*JX[-W=M:)KI]@7%RH M9_7:4^8NMN/?8SA=J,<5;*9=,(4\BPS64LRW'R@W?:[/=O,D8II796PZVIA^ MN:F4(\8*B;C >K^9ZO<[EH]T+KZLGNG")HP9(2)E@J"\3,TI M;,41S1A%I2%HY:RL]+*$++N7 D9>=(VX:"V9]E$UP]FZE7T5-=25L$5XA)'; M$KS$B0JW]LX9$6CE'=U^TG5WSKB7J^[LYR[E(_N=;AN2U1OU:;6\ MOY/K!W-N9 F!]CQZ::FP,AK MMDN6M5?(_&140OJ.#Y%1RI=MS!%EQ]W4B-@!-T']L-VUL#6<8N/P&OK"$9Q9 MS%'\*Y&*P< YSR<&O(^??_JTYYN9R227B4PI$E5B>,'2"A'*,T2$JM*2Y!G+ M**1(KW/OD:OP[LPE_MPY71#YRBPA]!L/-2#]'>W9YRO3;Z M;;:;M_1QKJ.:^;^T,O6>]'I9]ZK7O(LG1H8G99'F0L0H%Z:37-$$T3(G^N41 MTQRG>9YF0 [[B_09O9"GUBZRZIE2V9V"5U&CXI4]%*KK;&LU0PQRO_0YN;TG M)D0?]@Z8!'B?OM,0<(5K1KU(FZD[5$- =Z)M-G:VNFDP M=I+JH,^5URHUO('1NE$J4JMUI*Q:T;S1*PB_H.-#<$QYC0DM,"-VT!K;:-,P M$D9?NJC6&D6M2J,TRL+0"-\VZRC_M9IH8?#TM-0";^3)\]\&GK]+:CRCB4@_ MK.7_/,DE?WZW>J#SY0PG2:[R,M5.*\\1EA0CQC**\K*4!J4&YV:S6IP<&W*W>R"^22S,0Y$X_ M.&DFP&QF64:+6.44Q97,3 8Q1E26$N4L*5.N""_S!.)RX"J,['CTMZT$YA;A M*#JF($?%!IBIM+J80NO3A)F65$,H1$YG>]PA5(!93@AA- MBKP0-.-2N;B:LQ)&]B16IBG@V4L%50V?1Z;??02Q%^8=/$QU7OR#YO2M;7UQ M9UWKG_9K^OQ])UFR@V:U*W+X@_ &U,^KY9>GA4QBEB?7Z_6U6#UNI?BPH/>N M':CG[S#RJC*DM49R9$2CY" KW6CAWG+:@T/_&@L' 6RA.5@?_6E4"#3R8=A& MKV;3GMM.UFTZ;%JWW=3ATQX\X?^+/M*EU$M@19>;'7%**5*9850H82)L3A') M4J4!+&*>EY1PY11AGQ,P\OIL)496)(!!^Q06_8LPA(6PY7=HG ]/^"DK 3SA M%UKKQQ/N^$AA/.$]EO3RA)^Z;CJ>\!ZM#WC"^S[G.U[FY.SAYH0[E5(PG!8( M$\$1UJ A4B48J;3"21Z7-)6@NI!>:2-[D+,3MCTS!/W(N6W%@^$!\S<70.$Q M%,7!Q!?ID33RFQ,'LXWDC+A<%S@#%Y[[^Z$$/( S74#UT.Z[@Y'= M([@"@*%C'^EW)/X<)_G'$#@?X)^XU&//8 L26$^1*WO>?Z1;Y&KTV#[O2:PV MMC9K^XTN;W85K_.U%/^0\_MO4EQ_EVMZ+W_3]]V^T]YNE_N<42D34K(29:I* M$*9*(%I4VOO0DJ_R?Y@GVGBB\OI;3G5^\OJVG3DM^'JW@J12KQ^;M8K61 M=ZO?EX]S4Z;Q@HO ,:?B<*N1@Y5:@\BJ$.EXY6[^8(>U_O[Y]F.GI$C[DSMW M9CU7E(8S+H$!@KW^7;$9A: !:+U74L;E_I-E9P#&=M,TD,O\CF?J7I9F04Q1B9*\*)-829Z1#$*H<'!WT&+WI51H.)0B:B7#CE8. ML7 [1/&V$+A:K9BKZ.T 113X;.2D_H%.00[O/>EYQTFS7IYLG/[0!7-^.J0- MUTO1=I-]D=_E\DF:">'-5ZNB,JW*0B#&2G/BD.:(931!0@E>)B*N>.N%/?@*"VFT5CP4@;)'7&YV.&A:V7?-JH\E5 MM-WD1MP(]7NW'T #>\1<9 M[/&RCSH6-Q(#O_7/6A3R]7\L9/HXX*RA)P."\Y_VY%]Z>GQ:_ >0$Y$^ M%9=GC0:DHD(8[Y7+VXNER&D/Z'Z0:!C_L%[.\I^NE?EEO MVKGKMZO%G#_OS[:94$DB8H(8X1G".16(4LX1*8L\RV.98PSB>QR0-[(?,L.] MFRFV6H$Z.PF+3(;P.!@<*08:D31IZ M.)K^,N1PO$WX\%+GY'=0W=V04>_IA#I0,,V;JCG MV_O.@/![*([''--!#3S^\$5YHI$1%\$5?(*$GS:O-%#B(NC.SY>X[+83L^>? MKN6ZV]=RV;*MS<>E]O+S55W2M>TK-:WR(N4DSE"1I]H'QS%%54DYDC(5!:." M)AC$F_?36#:R-[<"+RQ8_^DP&YNY_S6?,? ULS0CRHFLR5N#T5,O^X";=L1: MVN>%U(K)Z,O-'Z R2G^T'?(U8V,(>^D[65,C=D ;.5T_Z M'5,S^YDM87U6/E,D48(:0J**FAG"68&J6 A$2E*595Y6E0!QBSA)'=^=6['1 M7JZM';U>+%9_V8$(QJ\WH[#-'AE:<^L&K=NF)#A@T#S\,5:C9KE ]@:*J-UD M3AKM@F!X&8G"+O9S'Y_EUE3QW*Y7W^="BC?/VEN)C\N=([OFV_GW>N9F2JM$ M0T"1Q(:IG*E"NP^OF]2X=R6[#6JF*WS+T]F MTSQ?_AJM=F]FNM,(YD@ (+MYDW&@@[D4@YHMX+OMHO9'B]H^GKD>1@WL7N M!/(Q ,&3.AHX("^]C<<=+LO+K=2'^7*^E980YZ..EVM&G+I!J9[0THV3S"R_ MY4:^R >IK"I2PBL4"YJ;:5 *4:884E@F5:6XR%,0EWE(Y2;,V-7*-MQ">W6C MMH6N&6K453EJ=/;+WP5Y>+!DWM2/Q#^S=\'3F"3/%Q+)P$F_(*J]2@8P)*CG MTH%!97AZ[ZW>P-I&D07=;&Z4G;-E&<$&+]HF:@0^KM9S?+^L^<-XEP-0;3OO3HLY[B/_]M-D:Q71\>*/N MZ(];XU_T+[;;]9P];:UO6=U2T\JY:T8J,(LY%PHIJ4,S+"J%JJ1(4,'32G!! M>4) W):O8L7(;N:FZ0SOEOPL5IN-G8]E%N*6_@#VBKW.PW9S:3_](P0F0X8* MMG245UL6M:8=O*OH<_W\M8FF(GU=_[YCI6&LJ>TGI=CLLNY[%JA9Q:1^ M3U4,J2PIS=!6CDB2$Y2QDDB2$9%AZIP/=Q X\@O':A ]6!4B970 )&5=\'+( M: =& >:S:P!JZ9$5?]6I6.KP?P7&!9";#HR/7RKZ T;U99I?[3)=4 M!EAUD$.&7 >G.GR_MF[ZB^2K[W+];(\&7+D-3UT[LL_2(C4!*!?M<5PGB8JW*VNSDO#$1/V&>D%Q_AR1M.1D#89TZ7<;#WL%T5[":'@HO 0!"Z;3Y# P-;S%WI5]%.?EVL$K2*R\?>0#LN)Y&3;I @ M(+SB:SY$I>9<1K*=IP%S"3V8N3F",#C MEO\A *W4@ P@[L8%6NL]@B9=X<,&OUS7#E=XTH??/=S_U^HO0U?\=KD1^F>-7$HUWVZ R8S^ MFXSW%3V4&[6"1TD#N-D8:G98O[!IQX8Y&7XT,^X'0Z#O/5#XI.O M#YB7Z\+S+K!ULEEO#9/,9K68"ROBHUZ+&UMP([)$YE62HC)5"<(5IHC0HD22 M%06-XUC(V*GSY;R(L&2,OO0.AD98*2 R> :5_R04R%;;FCJST86@] M8RX@]7FYV7[93@_S8>G-?L-Z,YIG+ITNB=FO^T'>"G[XR"AR^8)57"!,M(>A.),ZCLEQQLN\ M*E7FQP-YH68C>Z)N1Y/+D-M-[Y3;P4*%D9^BF^=ZE6<#\W#'CZ6?!VS32P06 MKGYD- B#TTI>JMMB/$'MNW@FF M0N=^.?^7%#/)59Z2(D4E,3GR*BD1);Q :1;'BL6]B8CN0 3= "V< M5CFI5_F1+H =BI5G%[9>]&T$N L)=7SSN)ZOUH;A<;YR+>OUQ-W-CXX H^]Y M4CUX\2^M2-1J-VPXIN5Z*[B#$S>;I0>Z&(=[1'YU?SABE528Y1SG502;. MRA)50F2HS(I"L;3@*4\\?-KXFD_C!W>;N"W]X;_)G> Y>N??7N.Q!,O9775< M:-35O^$]B'9SD,S917?B:V/$U7Z;KNWH?F+4;-](H(^7(0RM\&MG%4=Z Z9 MR+$DAQE 9;1;I#=3XJ\TF^*$F5I89JK8XFJE!IV]#+-,4]R'*>7S*$Z M+7;DPP;3\SJO^V=W/.7 [F='^-R<#I5=*C"*+40,*M'&E%U1NBK M3JKJ!V)H8-7 U9Z%;&M#3+=]OM7?FZUV4N_;DNHWSW?ZCC;!7V":Z_TP03%C MVE70@J&*E%SOF7&2QZ6DJ02-K'.0.;*?:#6XBJP.-I38:7$5&2V\&%M)TQ8*ND-P5"T(N-37/30ABF62 ML6YH\U$'+U+,DEB(DB8Q8G:,KF *L:(JM7\0LL(4IPD'M9V=%S6Z,VCW"QLC M^:H.&S;1W JWPT_J?P%./.G!SM4'A$ $MO3W8'RMP:C%1K7L=-KWO&].]\L/33GR7]>QP@_?_BU&CB MHZ)PYT,U#[R5N.<"Z% M3<^C-FCX2<*SX:M\R4/J\+&>7;)I1T!T7_\BIGF.DQ3E/,L-PZ9 I(A+1)1D M+$EDB4O0,(9AD: %[QMNU16M2[WL>;/LO?-\#B"ZK?^PT,!\P"XAU@BW$4[M M&$8):=QM#48;,BAP8M(05P".*4.[W+[;256B]7] M\SZW%*<%+3.!T4B M.QO&+$5]X=/"3CGYJQGGB&@S%E49QKSOEC%/7[UJKKQO!O/2;:2_'9$P4U/U MK^T_3S26%_!U<'.0/]E#AGG8 *-T.]R('4/L]Z-CRB@)NPFA?^VQMP"-_ST& MVL(?0;!1M1ZB8>\L(>>S]WJ7O'U^_R#7]]I!_K9>_;7]9O2DR^=93!).32]V MF9KJW91GB"6X1)0F2>N'[]LE_EAOC33,M^N M-MO-9[F=E0G+L[Q,41$+,\>EY(B57*""8Y$D7&08$Q@KY4DY(Z_-=Y)M;2+0 M3@+E1JC?_O$E/+!-XP5&0W>*VMZ/K;U6GITD$'YO>,:DP!O"EU)>91=XQM1S M6[]S'_?@5+C6:IH?&28(1)F6"&!<,4<$I M3U11)-2=F;Y7U,BKU(AN)@[MA-O*'@#U0#]4_7=ZH'.EZ%8&9SL["5GZ+_#=!P-3I8<4#6X7>'+V' XE4[[P?<_ M^.))F.AEM1)_S1=Z.8J2)56A8PHA4X1E6B :BQ*515Q(D2LA8@(YO781.O+Y M=6?,(VW&/"Y[WK[^V+G%'Z$1@;FV$S,O38'W+SL5HE:'\Y59'DP,[B8'(V-P M$#DQ'X,[",>4#(!K+TAA?]:FU-F=6D[+>DU4GJ59A;*LT$$--TQM3"1(ZHT' M5D+&- .5)?;(FB1YW<'B?L1^*X=S N9KSXC M:?ID=;_))S/5 Y=XCX)="KH6M^N5>.+;?U!S\+A]OETMYOQYQDJ6)C+/4:%R MLT?)E-Z>Z-6=5A7#+,FY2$''"+W21E[0K3#P%-@>?!QS*Z&L!F9%&K%1(S=J M!9N)A$9T]&?S_W$&5;M8'6YB;(^LJ:?&#IM]8G*LPT6O7V^\CRXVLUP47);& M+8B"(%R1#-',%*U)GJ28T$2_[F$#+D;2%++"_*9CV'G>T<*V[,Q?[B%>K]2X M^[3Y9J:4I=/AJYO1[/2I)4W[Y[D9QT*W/TE%]_E[ZOE]MMFQ@E. M$R4KA.,X1KC@!6(T+5%%$BI*Q4I!,"0$]%5D]$/L-(=Y:F]$W5SQ%#C!?&VM MT56TTRFR2AT0,6U7$9/1+9UK)_K?DJZCFV5 GLY+,0GD%;W5F-3M70K62[]V M\?W@0YENOS]:5CKP'*:C"T?V'MK\Z+OE>5"K]8/-WNXKRJ\BJXO[]*5CL_M= MQL46P_S "6-K LJP^\A>J[RF*1W?;;(!2F<-ZWFFPEG#:ANPS.?,*7D?3A8;6T>=+FV#U.B2)9F2(FB@1AG$I$ M*#.S92J6")$G"8QZZ4C"R,NFEE?GUZ$LH2^Q< M%+[(0MI:ZQHV0;3AK23"Z MSI?WGYB1\XQYQZ2;YSXX<5O+35VW_)LY[MQ\7-Y:\MM9D7 NRS1#DN84X:I2 MB)E*@S@G-$_3DG,&2SL$56_D]?U;TUWBS7P2^&$XYCA>#6)@4N3R5I%&XZNH MUME0-]=:UP42*Q5]6*V5M"-J YX8CH/P:W>$G%;NWZ/YHQ?88'T>_5+@.X-] M9&H)T1QW!H=7C>P"]\(9R.EN!4 1NY]7WV@N\N-5D>X'3 M)G3W F<^X=O(="V$?E ;,^>5+OZ_^>/;E9 SIG3D+U2%2FJ(DUA"$,DU+3R/99/B-[$@+CXQT:#O32:#ZEU0X\V'+R]=RCVZF M/L,N:&8Z>=N)>YGZ3#MN9>K]M/>4N-6#_+JE6_LV_&0>AW[OU07C,T%E3GFN M=P3$D!RRLD"L2 M4\"KFAC2'"NB$N//21G^[68KDG?"HE3Y<'N^!G%OX'@P/ MZ*O1&PJ?(6_#)H8;\-8C:^KA;L-FGQCLYG"1WT*O:RML:<6G.=>!L+R^7\MZ M-M%OZ]5F,XO3-,&5*E$J4KW8A5"(B%2AN.**,/U2EG$!6>R#$D=>\$TU25T? MM*@UB.A.A:OHWB@!6_3#*+HM_*#8P!;_09%-(SRZ[L#R6R\L8 ?@;&H@)S L M;U)'X&S^2V?@?J'GR 2E)-_>+#\\F1.3MW3S[<-B]=?F^F'UM-S.9!(3@C,[ MM%$[@SPFIDT2(R%DEM,\+D3E-/O=2=K(CN /O9O9<"-(?^.552"2/QZU/OIG MKE6)E-$ELJU+\^4]<'9"+XYN[B 8.L 8WHJ-]'N_%AP9R9$5?175P@,.2'"Q M,=1;5J5=?\-,",R8F8>25CE#6!:& MRUAE**F4XGE:\@*#%OUY42.O^+W@IAHX0MV>(BB;P5G W%9W&!A@2[N#@!5Z MU6DK"LEK,&19,&J#LX(F9C<8,OB8X&#P"M\6HA7_Y[?50E^Q,3,0ML]Z^U!W M'-ZNUO:4>[M=S]G3UA:WK(Q@,_1OM3#ON(_Z9:B_/MM9GM"4<"4127)3:%HR M1"I"D:PRP7#%<)86LWHZIMZ8K+>.J;\@RD&6QTL5G5?*&WD_7YJ9,Q&C"U-6 M!>U4"O,8RKP2."Y0*I49)U%@1$6<(2XR_3ATL)6+LGD,[Y?BYWX(K8* LT3Q MVOB[>?+I$04&=%8G4P;5-HLW:D5=O4RY\*%F4:M:R#ZTD% %:U@+HM3$G6TA M@3QN@0MZ=]^0E&W_T9" 7M< M?>D#Q"-(=3(S6*3:+VWB<-7)]..8U>TRS\"5+N3&CNI:BG?SM=[HUN1?;7?# MQO[Y17*I V?M=-HFA[O5F^9?I9A5G.2JR',4BR33+B$GB'":(Y:7!:8)S10# M9:9"*#6RW[ :1.N="L X*03J2E2,%[%$):\4PK'2@!-3Q!N71)0EQV6%(>1# MDZ/N2:[_"E [!J03 PCS\U8[9 =+FI[?6L%HIV'=R&9J!YI*O[J-K=4K8"P: M$*50D6@(E::-0P.">!2%AKPW[*VT66]GO\^7\X>GAZ8ZOZQHRE2:H[+(!,*L M8(B6>8D*'A-5QEF69D[#@([N//+[H9'EYJN.S>YW.!<9 _,:C9B ?0AGE>]; MS/JBSD+6/^T7\?'])EF)9\UHE]/Y#_@.0CTS:M60^2H( M942@M,@P+4F:5!4H NL3-O+*:47;MY36( MQJ5"@DK&4LYXE8'F#@4##!X430.86P@4"@:8DQH8IAV4/=K%PK$'14_.(^UB MM/-HZ L9I3\NO^NMKXTXWO]XE$M1-YE\K#,YXLW3]O-J^]]R:P@89G&5R+B0 M!*4L%Z:+RE1.Q!CE4JFB2E6E2G>":8CDT:LH'K60R,RVV,K[.8_F>]T ;,L@ M+/L]P*@(P=Q!1XNHJT;4ZA&QIVVD-8F>Y=82=8P%&8"O>BSH_.BK T((H[/V M@:&7W1ITP^G(KGWL/."^]KJ!-S]F70-[H_;5+^UHK3SG29J5"1(99C4/'E7Z M#Y7'>N.6DU0I)^H%%V$C.]5]"?9*=:JO7 9>P7%SS7&&00-X5.0/A ]%YJ"% MX1@RSXN:FB!ST.@3_)C#UWA/T)DOM<^02_V7K0G8FK_>L,7\OGYY"-, M[RO--!VA_]!_8TA*O57(- -.TQF2.?Y&\W_79:>LEARM=J+!(W8&\7/- M @9%!9H)M,*C1J3=3%WM?KH9!L=G%(^KN>'&\@Q*G'I$CRL$)\;U.%_JYQBN M.5\_T<6'U?J._I ;2\%]]XTNZ]X8^V_-6/-95I D+WF&$L8YPI)@O=,J4L03 M+DN597G,%<0_N(L>NT+ *&));46=,MD:V=$C?8;G_0!XNOF+<5""N8U&ATBM MUI&5V QVWFH]HJ:[S?[[5?0V=,TKW/Y ?@0@>%)W @?DI5?QN(.G&^K@(NZ&78Q0L1_VH10Z_+PYM.NO9.&':VOTY^"DYA89I2[A_O?EX]SP[0) M9@@]>X.Q%XN1&]W-'TS9P>^?;S]VB$+=N4[.F]^_DH)9#EQ0/49'?P9G#1VT MT(LDY?Q=)^-+&32L2YTR_.'7GR?QXC4@5<%+K@1*B"EXT,$S(BD5J,CU]ELE M::I?DI#7X'BJCNTEZC<0;11R9$&:X FYO:A_#MQA/FJD21(CQA+CH_P33I%X MS1AG?,#'G"41)/:RZ9==D9PMAKM>+%9_F78IO6MZJX7/MY\,_03-$I5(Q5!% MTA1A)0K$RDH@7J8DS4F*E4IG2WE/MU+<.2:A700[>0A2>X@C\>X.NI5M=_[< M2H\6SBP>[C#V.]RPJ%Q:6MN,@]ACHU6(:AVB3R-@ \@PA\;(+[,< BM82AEB M=V\JV>E&TZ60(78=I(Y!%WH2'*W6KH=!4QJXTY8PY(E 3'(!1E$D#RM.1)<$B.:)0\;N%9L\*_2?&TD#=JS_GP M<:GC/OO*VGQ<=M+I37L#7=RN-G.CS QUCNR MB@,+:0(_3#F7QS_FVV^&1V&^O->OG-.T\[."B3*EO$"X( SA*E&(I$H@FA=I MH629QDH!=N>7ZC/-IEUK9^@B3!%#]-=>JXWAG6/R&UTHXQ[DP^-B]2SEQF[M M3:&IK%M+3)>).5,',G5Z/R,W3STJY+[SX>K>$ZU)U%'EZO10C?T$A("-*A>" M$JJ)Q5>-:1M<+@3KJ/GETOOY^<+/=S!NW9N^/NN&B5)E^6L8E8F7)$2^+JLRS,N9Q#!T4<:>V!^H Q\S"H#5S0F,!Q;,,?3B-%Y9VV4P!)QN"A ^^>A3.#"GYJ)Z MW.6R0CI;M5$?$-U*_:U;;NF]O%%_7VT[Q):[VHY92G)2%46.JD3JS8N(%:(5 MHRBO!)$J(X4J2I\B.9@:([NCO0;F2.:[U6''4[DOC/.KBP,"[N:@QH<1YJAV M]6P=A:ZB0UQKI79TE_MZMO!%:GZP!"Y RKQ*L5E?D"=*QSSO)N?0_LBM]0T MY;VG:T-COFGXO$2&E:H2BG#!S 27(D6$Y@5*N*!9GF8XCD%;H=-B1B]GJ(5& MK528ZSD#C9MKN=Q@F.LXLG6$2>S]-@5:]V>$3+JN^PU]N6X'/NU1K/F[_N-A M]??-]>/C0NHM5//-*Y)4%2P52"9)A; 9MEY17*"TK%A1")65I5-.OT?&R"NR M%AK]??.WR,HU6W5 A>$97/I79"!K866^]5-@AXUK$"R MWZ3>DL@SETY7!-FO^T'9X\!'_=[WGU;+^SNY?C LW6WK=DIPG!/M2!0QW(*< MEXAF1")*TC13JH@5<2(=ZY$QLE\Q$I&^[B$2EAW>:U33*6C<7O87&@QS+=96 M(RVJF? ;@='O=/NT#ISHZ#$LT.O^E(1)W_4])KY\T?=]U*,=5OQO.Q'C5JX^ MRY5)JGY8PEMB^VXR\J+3LI]J1J]F)@RZ?7\3?=;_=3/$T8?5:KMEMN\AR6 MV&XC=YV7&,L89XG>0*M<(2RQWD57-$9%49*2EDHP!GJQ#DH<><5WY;=9ME\: M%7[UIIT;QM'M+1P4'=C2OQ@8> F"J[&A*@\&Y4U;<.!J_E&=@?.%?D[!TL\8 M/[.6W_1M;:6ID6)Z!5H:O/^2XEZV#0372B_$+Y(OZ&8S5_-Z:/OU4ICV%RZI M$,2(%G>D$?CYM;>BW(81ZLIL Z4'/GR)JFIAVQ9F35O8H. M6IZHT3IZJ;;-MP9M=!H#SD ^,JAJD[K3,4!]Z7E'D>'GI-N3VENY*VN=\UF5 M,!DGE>EY-X,"61PCF@J%=+"6I#IN(PD#,8:>E#)RA&9E1+_H=2E6BP5=;R+] MLHLV1CRP3?,T1IQ4.(]SAGA5% CSC.N7DM<3.>;UY M-+_>S*2268P9006N*,*4"T3+*D9E17E%\RQ3&:+M0(DOG2=ZW?]$X=YS2H1#>>-)=)[6NT_Y&([>%I,*]^;>-E]\ M._M[,3?EE[OSNR(5$A-&D21*(HQ%AE@54R1DDI4L+O-". U%'!8U=LIC)SAJ M)7L?>_;@Y>9ZPZ S''X >##DSU@6SA>['."IN;!'C#X!._UT!7PI.3[M=VB M7R_IXGDSWX#SD>>N'WE=:K&KI5P];0Y3;:T:[JG'L_8/9QU#F [5QAAEBM$E'ZK)@6)*\[S,DN<.IJ@@L?>0=6:1#?YIOFR%$39%M++*LB#%#C&1ZUY*R!%5E4J \+;"(*Y$5)0'- MJ#XM9V3'VDB-]F*!5#AGT'';HP2P&>86C\T=H1%BP*I03#1GI$Q+---OZA&/ MS,#'_59H9Y2/'5.;Y8)E2J4HH::X2A8EJEA:(IJS*I,J40J6J7MQ_Y%79)-6 MMV.Y8&OQ)0YN:_ "ZV!KKSL[*]",W0$; JVTEW>?=(6=,>WERCKW,<\RI;8& MRE(JM\3SSTU5Q=L[VU M[-/S>I[(XVJ]G25E').JPJ@LB@QA'%-$&<5&M6 W7]B+3[]?"V4US$=Y&.SL8%PLZCFAU9?7?D+_9>\>>F\ZR5)W,:M= MMDZ?]1]=>+N68KM^6(H/"WH/'5MX&CT<"+D M8GMA*^J\J=&?1G+@ 84GK;IH..'A'2\[!MO7GY R^NZ^EADU0J$[_%.XN.[S M+[06NML_-'2$<[9>BX+M_4_)F/@$H,?,XW. O@]?.GSD! ?1YLUSYZ8,RQI7M(X!LV^ABHP=C*R,Z#B%"?7YLJP#7?^ 99B M\X;=S0^,"2;,183'\8+I'3 P@H_G6R[/NH=R)N;<[!WLGZ_Q^7 M34I^Q@MP'F\ 1B=,WOAP 'G^AI5'MP.X^&0 W6P-EQ,< MD#=UEM#-_!-Y0\<+/0H7[:&XN%T;2H7M<_/B49QQG&*%"B5BA/.,HRKF.9(D M+F(FLXI63KOXLQ)&7O*UR*B5"2B;.PE'_U(.8B1LZ;ZPSX>6\*2A@$+ 2PWV MJ_@#&PZKZ^LSJK> [^2%TU7J]>E]4)+7^T$/[V&+&=ZN%@O)MU)\T%J]?=IL M5P]ZR5XOQ1?Y,-_:652_K;[+]=(^[\7UT_;;JJ:YLS6 S_6?^T)]3 6CAAJU MP#KVP&69(2)H@LJ**XYIEB7$B6I]- U']EYU]VTMGP=11'> ,1GF,#E[SM1\.S.L./)?K[G.Y._]$STR #^_[4? MG=_[HS,I9*7:+8#).CW6S\+,GK15?1'?/6;C:R-^L/S6G>5WOS,PHGO[_A;H MC30FS+UOM%$$3_=&'!.W@S?JJ()\!P(T! :;&_7)G.7=J+=K*>;;F'S @+G'$P2&+O"( MKFLZ6BF^UF> -\:#S.^_;7%3DF8YPHG(4$5HC!2.\UCEO*2%4WUO.)7&KIQI=(P:):.=EIVAHD;/ MZ!>CZ:]7D58666UW0WFB6E] 0!;F83D$S9,_ IA#"HB^S[E&F,< "(0G?QQ^ MD>\4BP(6V@8%KC>6#2-INN U*#('T6K8.WNSS*R?I&@+L740W)1BZWCYLT:G M^:%E4DFEXE5E1_JF%.$89XAD--5O,R$(+KBBB00RSP#$C_VJJI6).MI!;Q0\H']8:#WO#,=E A$_-;N,!S G&&Y^[^#F:#W2^_CM=/,EZ MVG MNEI;7E*];N@]NWQ_G^>YH\/W0"G3 15F'!$8D,&GN *55E1H$*6BJB$ M)EB!^IH')8[LA%OY5Y'5P"[;G0[>4>,PCFY.,B@Z,,=W,3!P]A!78T/QB S* MFY91Q-7\(VX1YPLO&-W2\4G[=!_PVSQ\H_&^SO4)4PAD58E MPIFL$"L2B8J8\RK#6<5+)R)!%V$CO]SVHJ.];/UMUY*!+[1>Q-Q6?R@<8.O> M"P+P8G>Q+= R[Q4UZ0)W,?KETG:ZQJ,/?;&X6U/#L-4AJ6\'T[NVH_?<8^P# MR\4B:F1W6?8!_+R] /2OSY"V X\?SY@=L #5U3B_1O6^&T_7K^Y@WD';NLOG MO9:@'2IJ2(#!"^_%E1,LM_U0VHVI-^L218-6W4N;G=;:!>;"5UB/I>$7VAG+ M?)?7R]M-N:C.F/)B*9W[E%]@6K-UW"A+T:+D^D;]MEJ)FW4SW^+=ZH'.E[,8 MBP)GC.O@E F$JQBCJI QRD62$A(GF%!0\LY)ZLAKLN$I6:FHU<+\W>BA 8P: M3:(_:UV P:L;JFY1;'"L8 LZ$$S@ !=D=J!(UTWFI"$O"(:7L2_L8C\'HCW1 MPVIII]?8,^6;I^UF2RWW[*S()*ED11 33"),DPI54I2(J)23I(A+GH%89'ID MC>PL:LG1QHB^BO[O^&]QG$2/=!U]-WK\9Y3$^I^BA_EB85YR=E#AIJTC_Y<4 M_QGEV=^2W>_-R6:>_JUZ><%\LS')U^'IZ\TX!2(/1 &+] M:SHT#L#8HP<"GZ+2(2P@?5/A,/$K!/7Z>@";EMQL[.\_&KC'A*U$;M8<=@4Y M7@,_O.CX0S,#\+MFV^_A04?< M=L1NE102)X2BB@N!<)DQ5+%2!P\\+TB98E'&[K.\SDD9/?=6BXWX7B3@Y7@6 M&X<((83%L&6Y,]:*C-Z&-1D0"(0PW;,)&@X![/T_9%KOB__LQ=.]\8?T/WC5 M#W[8N[[M^]SX3-K+SV8FVO?=UTVZT6&TVT,DZO8"Y'4"$@@&8^6@)M_3[2LZ_&T*G MJZ9_-_JD@=BQ\_[R1>K7V88N?@U:R39H"Z(@B*RL8$^9+ =/5\LQWI1/ U7R$B=L* MOL12:!RQ,]**&J-"Y]"&X%4YS>U?J1+GT+CSU3/ MEMCV_0^YYO.-%#,5J[+*2(9$EIA1D5F&J*H*Q)**%9F.\7$.2CD,2AS_O6KE MU_0U)D% ]0.RQ!B=E 3X%3N HO-[-APVL&5["(L5'C72HYWXH*]7-TO#O6,' MY$W]HG4S_\3;UO%"C\W\V2KT&\Z?'NI$&ZM/I&3/^^TR M?!W."$9"#>PW:L#J%I/K;HO)5=1J$M6J1!_& PQPPC 2<)YIAV\RHO; T[R# M.E^LW;K MY59;.:,T%K3,=< E5(PPP7J34^8%*@F7/%8\(6Z\#OUB1O:CC5SS189P[YX% MQ<$=!C$5YOQ:*[7,JZB6&GU<1HW<((9#F(=# .!)/^P'!)"$>,B^?B;BLU=/ M2$<\9,$A)_'@IWWJ/>3ZX=.*MJ/N"5%IQ1A%26&*407!J,IBA@KMA?*D5"6A MN7MYQ\&]QZ[FT,(B(PU2KG!HO(-3\3<)YDEVUGA581R:!2FZ\#;/,]@9?&C M@HJ3^O?73QQ>,F&YQ$E=#ZLC3G_$<_*9*8%\8VC-N\GU;L/(F^?]9VYKED8[ M$+'94WY8K96<;Y_T\_RXK'FN_B$-*984U]_EFM[+=M=YN]:N:A9GJB@*';@H MEC.$4\(18Z5$6.)<_\7D?4')EZD-&+O*PYPS+?1>Z)?Y,GK:B$B'F76=ZOFT MQ<_Q8-T.KW[FQP5SQE9+9-5\49C2[7!CSU'W@XU!D;7HJCT[NXHZ5IDI,K5= M5U%K6=28MCMDBZQQ :?$O=)C"35E;FKUIYU2]TH/YVC*W6OIX1'!_J[_>%A] MD=OYVJKVE7Z?+^\W9K_>UBQ+7A0XR5%94H$P$P01P1.42UR5,1,XR)&R!*',;-(1X.B@;,*_<#X1,W#R,""*6#(N,777M^56 A MM[.=O5'X\%VF"\R=+3J(U=VO\BU^4&;0N]WRS]F3^2*8>[]_>%RLGN7Z=[KE MW[3 @]]K#ZLUF1&.8TQ2J?T?2Q$NC/]+<()BD3&2"RQ4F<'*)'Q5&3M;4TLQ M!^>R5D9N_M_H?FV*@QXIL$_K L#= N1I8(0YU4:GJ"O4>HNKJ-4K:A4[^-!5 MU '__1[\WRSXMSW@>]1]7(I;L H1;T4FKB6Y%+#CJI.+[W@!<5E+A6L+7O9# MF>*D(%E!$Y06TLY%SA"E"J,XPTJD*8EEGD+<7(^LD?U8S6S6B&XX2F'.JP\G M-^\4R'J8^SEE>/2GR^ O/S*W?OM"LKB=D30]?5N_R2=YVP8N\5O)GU;+>W.^ M:0F>XY/-'NOBX_*R%=EO%])8NSG)18E0D58%P4N6(I%6% M9,))Q52.&7;*4P319F1OH+]0.6SU7X:MFW^8##%@"E:KA6Q:P2AV%36J/5]% M_RWI.KI9!CQ*"P)!("=SF2Z3NJ$@L+UT5&%NZIE9X=^D>%K(&_55WEOZ._FX M6IMQB1^7:K5^L+OV-\_-+^_LU/.D2,I2D1Q5 E<(IRQ&M)()HJ42"25ZCP9C M[O#0862WU6ID-@2-V&BG5-31ZLH>G3>?^-.J!F0#\GD CDF,<6$%YB%&012> M0?#')%02P$.#:<_Q_2$Z.HJ_X%9^[NSCDM='6'31D(Q8\ISK;;V7,Q+N5L>G M_YWDP(S1%*>I2I%B*C$U:P15!2&(Z5T8X:F*93O;/Y M6ULB_)TNM-S_J-L'HE6;_OOR]8^:3.+6_,6D?FMJ(F#.-\ S>JJ9Q@2[>,Q+4COE9+I-PP'X MTKD&O+-'YO*+28AN[E:W^OO]3=__JUSKF/7Z?STMYZOU+=5.WL2KQM7?KMOF M:>--FF1417"BP\04B9SH$))F.:(DPV:,1U[&E)4T=Y]7>IDN(WO76CFSD%OU MHEJ_Z#JJ-8P.5(QV.M:=2X HS38*&._Z*TZG>^^T0@0G0!Q=8C] MQD,+>)+8 G5]#-1U U3T9ZU.Y))^O1@\0"@W'HA^H=OI;QT_^-:!P(2%;'YP M](9HP%M.%Y+YV7H0@GG> N:6A9S/WC5?IKKZ^?U2O*-;.>-%A5E&!(KSU"2N MF4)$8COM(96B% D53GF?LQ+&/NAL9#:-"]%[PY&NQ;IYAO.X]#O/(-8"0R>H MH<9&D.&M0NP.$/PGE^[];B>KV^%O4)N_TN M.?+['E\Y\MII10$6S!D+^U?+Y<;!ELJ)@5^1FZT@ZM[S)GE1]IZXW614O>=- MZ5+T]GS*?K9G"O6!=W.2)@7!.4]35#&9(5S0'#&>*)3K'4NB)(XE M!I4CG)4T\A)KY4+.?8?1<=OA![$9NO*ZYEZU6;!P,\"<;0LU(.BLG&F' @V9 M>S0(:/ "S]*B\SG_3^V ^%DA]$:>,X98(G5,B46%JC2N4%[PJJIRGB<*5 SI M(G3LG7Q?>4OTIU$CLGI *X5<\'1;[J%1 N[@+P<(7O@#L#A4I8^+R&E+>P @ M'-7R0*[UI&%$OOY.YXLZB=T9%_1MM=#WVS0E*[N![XI46*F* M(\ZE0K@J*:)9FNEG0BH2)R6C%:A]PEN3B4IUEG(;S:V">^:%_X!Y$W^PW5S, M)!#"_(Y6*:IUBGXQ6OT:[?1J1I'NIH0UJEU%+>)_MNH%]$D70Q3(4?GK,:GW MNABNER[M\AMZ%REJH7?T1T/Z_D8NI9IO9RQ.1)[&.=);&(:PPA(Q5F4HSN.< M2Y8S7C@5Q0S(&=E''9+]-UYJ2W] N?[/H>3F?@+8#G,NC6/1$O=<_HW0@%3^ M V:%*[([*67JRKD^4T^4P_5^W&\@T*E.T<]/9G-TH\S?-S.1)PE.8XGRBE"$ M:8X1B\L<)9DBE& L=0@"&0XT*''L$*/IHN;=+NI'VT6]M&J8 E3S,W"6SC"2 M_0M[%'R Q^KG&\QK#:(;97\.#@ULY%!0B+S'#UT*%7@CBQROW D5KYS1$N&AWC[_'$_-\06D]Q]H\N&@JDSX.T%]=(7:<92M_WY M.A9[H@O3.[>9<:4=,*,Q4I7A;H_-8-=882330B2\%$55.4UI^RFM&[WXQ#04 M,-M0P+LL<;23%NE,G;Z*_FHYWVC#^;9N5=\5JVG=HZU1WK:*/$NZAG:*_%2/ M(!1UX,_ZM0&>X3GP"@[0"M8&1QV+FP*_K;9Y3SIXT_W:'5$-[DR/.K9'UO@) M>0=?XYE.14HXJ6T_%V/A:SQ6,)WAJRCI6\6]F=\OJ1&T^2\I[NTQ8> MQM#M3148&>A>JA^4$?+ 'N#U7L/2YRX[ML9@N/Z;_=+/=,_S=;DYE$[(9-B M:E).FUE5EKC"5*$T,2W9+*6HHAE'1:I4K"H<)Q04VI^5-+(G^+P[0%FUDJ-- M(QJ8O3F+E6-V)@0"P.S+SOB=T);G(6"H-FA8J)S)63G3YD2&S#W*>0Q>X-7$ MX1FCM'&'_C>]NVQH]G0 ,J.E2%B>*E2QBB.18'C#VB4!SZO$]4^_3P M0-?/-^JKWOC.U9R;(9J;3KO0V3QGEI8Y9,T8PPI1P1!6N M$$DS(F6L.&=.B]9'^-CYH5H;D[3MZ!/M%8I:C3SJF[W =@E&QX,0&&K^=.A! M0L3Q4/0, .C"0SM_.#H#]R ]YPP+/.S]C#H\KR'7TA59SUVM8R=] F$]TMPT< M*)TV(5!X].+FDP9%IPU[&0J=^91OJ?)W[:!7Z^=W\PU?K#9/:[GGO2@*EI0Y M+Y!@J=FE%#K6P8JA,H^YR/,\5CEH2&:?L)&76BMZ#J]2[@'(;B_98Q[6:8@HT+.0KKM*#I M)V'U&GQR$%;_%7#N(I-!N;:5@8OG6SH7?]^\77V5"\FUM_C=$DIT F%'5B/( M/4=>LX>IQ4:GR"@5?=_\S68>Z=(,*JFUBQKUW)F10/CUK_,QH8.M>D_4 N\[ M?/'PHF(""9J,I,G'_"Y]D]?UGDE0N=FLUH=A1Y-[W=RMWLC:<4EQ]]?*C$'; MS 1)L5!,;TKR@NBX@*>HH@E%)>9I,U]JEV]WI#?*ZE#_ M1LQ$SA)!E$(BS14RPZ(0BY4TAS]Y7*69()S-EO+>-*3@ WL;'PP".1V0Z$E]CP\H+UV0USU\)M?)[W+Y)&_EVA(8:OMN MV&)^;Q=>HT/=[X\E*YC !2J%T)M-0@BJB"Q1FL>Q)%4J1>Q$*@B2.G+@M]LP M]3;(7P!:OR,9#0J8!VDTN(HZ.D1[)?;[RGX>@0M@@DQ_&P$NSSEO86 #3G4# MFM\_O\WU9A-.:@/:=SB3#7JQYT;YH*[ZW8,(R%JE"*I=X7DX(C@D6" MRJ(D@N(X+4M0C\(I(6-O@ZW(J)49_5E+!=;9G43'<;]VH> M4#NO4R*FW6CU&'FTK^K[;(!!",W,WS:,YU+D%4DYJJI"(LPJA1B+,R1884B0 MBS27( ;1'EDC+\TO\K&=)6JV034U;SV/W'OP>!]R;NLU$!ZP9?MR4$(M]VJ$ MO8V#>6/,2G@AZ?6F)9PVN7=>PIE+_);V!SI?VY.63W/*C,>8RTV3;1,WRR^2 M/ZW7\^7]&_WJW^Q?])M9*FD9%U6%$IRG""=5B8B9TU5DN=ZGE"HO.6B(@J<> M8^]=Y-+2"K.:V35:[23#W( ORFXN8@+L8.ZC(^0J,MK5YZ^=LM]P#N1"XP,Y M%U\M)G4\%T+UTBE=>CO?]H"M_JK-V4+6DV _S)?SK5;ANQ3U,,(9P5Q0,YPI M21A%N)(Y8IG($.%<%2E.2%F!RH@')8[LA/;RA^80>P+FYF6"P@#S)T<(:*]B MI:-/=?*]F18ZRM10L/W!^@J&Y$W<7.!H_G&'@>N%O@Q_;+NG!;/>YNNCCI>T M#_H[7<]-^>$7NM6;D+S@I*!5C+B03.]4&$>,Q/IO>57F"2VU7P"='K@*'MD] MM+*BM?.81#!T;AYB#$!@CL)HT&'TNXJL$E&M1:0#N1U87X+,6?2U/!C9GZ/8 MB1G_8& 1( M2DST+H<72'N,&,5*<%;&"189@]61.$@=O8JDU<'63]WMX:A6B3WWPP'.[[@:'2NDZ2)PVD^L.P5$" M%W!IB'X#V]80KM7@Y.W&3D#TU\O7330!6@M.0]7O!49""9BR T21=!K_V! M&@A.RWC%WH%>H_O;!OHO'7M.I(E7^(X!0RK"DSQC*&6)1#BE"I%2)HA+05D1 M8U%FY3A3(@_T&-FG6%G33H@\A-DMN)@ /)BK\9D.66/]NK,A3\(S^63(0RU^ MTKF0)Z'RGPIY^G8>)6EFS,)\>2^7A@G)E.%J4?.MK8;[M./LBDN9D43[K*JB M%<*R8(B(O$)*9J(D:5IPYD2"[BQQ]-BGHT)TO;1TKJT2OD1H3DCV.ZA1\(%& M/:\%#: N+31$?C5I :""U:-!S.ZM17.ZT71U:!"[#FK00!=Z.D?C8/\QWWY[ M^[39:L^\;I- "C!W]Z*C(P1VK42?Z M2^L3M0I=13N5KJ)6J6A7[;K3:W1 @=YW5&#]W?$( ,-=M#W?].?OOZMN'C[;X3ZHODJ_OE_%]2?!3ZRSA7-N-0YR[;HBO]SND4/>C? MZ>^M>)GHW T_^VVU$G_-%XM9125C!,ZZB M$Q4YG4&JK5GASJ9>Y6D$.M&:5O=)S\%>Y;&\/#U['24NX![<;U=G3.\03Y3IP'R6 '"S>_?(&%,,]9 M&_=VV#@__L!C$T*2!G;N/CU3X+%I)^D!3WS,LU?PQ,;!+M_.$G^^LT?JNT0T M2S%EI"J1WFXE"%7%^Y=^D>%K89J9S>V2K MX<%;_AG8B.@!O=LZ'QG0,(QG98/&MAOCHV6YZ!Q."B^ MS&"8 S&RS/@@+2W:B;O,0L#)[666^AW+PBR&G;:>MZ?W*/7$9=.=DY[7^> 0 MM.=C8?JE/LOM^Q]\\23FR_MV4[.KH^$B*6B65B@E(D.X,.-5>)DBEC =(7$: MYY43_XR/\.G.%]L3"U-^\\M.G]VIQ:_>XX] 6+N%06,A"'-?@<&[N/?*!861 MVK!Z1;]J1Y8+*$/-64[W\ A>KCE?/YGL#:-;F[*_7BQ6?QGVF,TL)3@NQ/=^(![_L^O!Q" MFT 8P)Q$:WPCU5;&7(;]8J4DN?]#ZG=K<[8\P,I)G*A4ERG,='6&F T \V)<14\ MHXRG25Z4>97D3C77;N)&=BCUTV/1]&X.& MGVS/&+[*SQVTE6QT8;K7/B[?TL?YEBY^EP],KF>YP)06N>G?4R7".*M0I:H" M"5D0GF5Y7!(0ETVOM)&=P5ZV[:9$'Y=1(Q[F"?H10##?01#] M6198TH7QK5__2;E]I-Y:EK.]8^YWLNF M+"M3RI#(.4=89 5B56KX:8J"YZ52K)2@UXW8R,J-6L'1GT8T\ #U M+%1NJSH$ + %[6<[O/QMP+!0E6KGQ$Q;5#9@[%']U]#G8CO_E_V6W:@/\Z7^[LV7]V]7F^UF1M*JI!5GJ,JK"N%"2<02*A#+:5Q4J7;Q M:04*UWJ$C1VM=42;$B)AJ+7FF\V3]7=<:P",VOIP %%SC+5 M6.$!8S8'$T.%;'VBIHW8'(P^"MAQ6<*%(G%."*2A3[B)TY!6_D^;);=P'E]L"#PT";*'OB8IM@T0M M=(1]&<3*T/3$?2)?AXO8 82SQ,,NUUY0I]])=71.&JE2I"PX12S+,H3SW*Q\ MGJ,L5Q23E"Y*S))%ID90$ ML0*;2=^,(IK' L6YB&,ADP(7%-+4Z2H8]%J?I!_3&3*WA3T&$+!E7FMP8IIW MITZ_'NAMCO_"CO"&6!YP=+>3V,E'=D/ .#6J&W2]G[]H^V;J\8\?%JN_OCX] M/BYLE$$7^Q$6FQ=M+8F(,RS*'"4L3A$NXP11B@52,DXRQ515Q2"J/T\]1MXD M=+N*NOK4LT^-EM''I9T,!Y^2XHN\FQ>: $^84SIHT&K1NSI$M:/6J)U#%X(3 MR&_Y:C&I&[L0JI=>[=+;753I]D6:Z7#:F9X%RLGJ5\ M4X]&,PSLF_TK690DYH8&3Q:E1)A7#)'<4.5D9:G.SPIMO1"2^ LE,5-B-5POI@$*SG&2!ZXF9G."C'7 M]_#T,$T ]%]2W.]3!T5&]:>)'2M;(BSS!!'#M57$&!.A:)I*4$[UI)21?<9^ M]+R M_H?Q '(SHU5.;8 MYXFU!G7 N-0W>%S/-S+::00\073 T/&T,"PRP)/!!I2=],XYX$CQ,\#>4(=] M#A*G/=ASA^#H$ ]PJ7]L;/XS$\Z^TT5=\;#9KN=\*X7YA8[-#_^A\\E;2\[^ M<]-.J/W(88;JY1*.%Z>7B6MTK^Z>=IMAH;5W:>F>3_3T\ M[I_PF;MO*'[.)PG?J5S5>9>.@N8 =/?$ZH_4_&T'_WAX16U4U%H5_=+:]:OA MR6T)4EK;[.39J+8N[)YH^J<2<+,UH?*3[^*F?S"GMH>OH(4'44QODO]N]4:: M HUKI0/%_Y9T_4&O[AG#O"Q)HE L>&'(&#BJTJQ E4IY6K$LJTKW*55P^2,' MR'??I,;;" 0PJ'B@V._])\ &YKYA%3W:BQNU(J-79!0;%TL 2+@W'S#DN/9E.XSXLY+'*W.XV\OK4"Z+?KZ]NH42'JZ."VV!T!Z5_GX;& +?$^& +G M"&&F]C"'Z!LURYJ+_6IVO/TD"QEF:KN&@5=Y'(O>RN7&%. 9DNY=^_,^RSBC M+",J3V)4$(41+KG>8,>B0K0J2)EE"<;!"L?C\6$@+@R8&G]2"R,A?3O+C+>F\\ M&969BWE=9C.GSWM/5>32M,?9@:KSS3_O]'V:DZL89WFI"$59+%*$!4T1PXE$ M:263LDA8G!'0(/,>62,OV0/)D1$=&=F>YWQ]F+D=&P1" K9RO4'PF5 X9%ZX M281G)4T]<7#(Y!.3!0G) Q/NTTMR(]Z_D[F+@MU@LMA2W2O9&UM.@7(^_\F$3_ MPOYC:T*7]G4$Q!MR6LS8AW)6J#E77N_"OJ@+I[6HQY\_[+!PO1,JJHD1Q MS 3"5,:F_9\9#J(\2WB1YM)IU)ZG_)&=YF[BGM7HU+R]:V@:Q -CA\S(N,C! MG*(K:-&?M4I.E&E!@ 3D5<8%U"_5,@JPL!2,/RR]61F/VTZ7J/&W^2!W<\%M M/"-F_?6R/'5OGC;SI7Y!-&VP&SNRA^5YEJ4R0V5%34HZKA UA: BDQG)TXI+ MZ933<9(VLIMN17D-->J'R3%2#64\,/QTM!L>.;K8$RH<[)4U;8SG8O91X.9T MD=\2OEV;)H;ML^%QVAIZI_]YFC^:F[]\LTE2I&65,J0DS0P+$T%,%1G*1)RP M3*E2_Q*RFET%CUULTJA1\T^T.L#6MS.&;DM]#&1@J[[5X,HRMFT/L='_6+_[ M1XD!?$$(Y"J"5%5EV&5+0S:;"X((3R2*!2ED7/(D*4 YYJ/Y>91\KF:2]&4B) \+BK"4Y3S3"$?1H7U9*+S.K MVL;JCS"<2DZ'(C1QJ%+SZ1_ (X)QD7 $2&6W66=E2B3\ -WA -Q_WDME=,]6 MTP5FT/0KIM\7>1,7ZF)L);5V%5:2]'D /4#'^O6_]I;?/_8D!FTE7FNG=@_# M2V$^:JZ7"W/0;;J"OK[?RF_+]^7ZO[9TK@GPIJ/@-_JCQ7>^?=K8%L>XC#VR M/38L!2U/@=A*@]YPS)99*#5C0QU?="76[^;+M:;SV^*Y-(GV59AAZV\NCS"R5ZD) M!Q5E4UWZK7RJS."WSP]WW:8U]MZC1QG#/L*/'F">P%8%S9["4QW>L*1.]MTS M[&16/"Q:UU8MGG;,>]^N-\LGN?HBYY7!K[^7S^L&S>0VG:9/=AD4^2W2U><;/D]W)5ON@Q7^2M7L[IH_SZ%ZU*+FXWFU7)MIOJ MD'!IFA<;@UK.YU4%06UQUOIFF8,ZMYZ^)/-^P%7?[, M&G#(X=[1_=DRZ37K8PSM>4L3\/=FUL" M+# 12<%0P@K3GD@R1/,D1(D@.IB349$34-/!4Q(CN\:68(T1[U:"?$8O=J[M M.FEA[@DH*-C17);%D[,X0V!2@[\LX+'1]CSI.67L5HBRVL#-(I4HR;!$>89S MA(LPU5NJQ*![,,YBE5-.0/'-,,F)TL1N@N==1I3<9T31E@U/B6-[3=J9KE_] MP$QY(%GL=E U_G+#3J0=.RML3_#GR <[48!U)MCIF_#KC ?Z^L>ZDT*Q/P/_ M5"[DW48^#7W/EJ.,^#'3U^!E?=#ZNMMYRW 05"QX.LT'".MTK&\S_F3G^P!A MNP?]D-?@R3A?3.N2YLR:Q$52Z(4+$1J%"-,XU-MRAI%(HZ3(HC"EJ16(WM&X MH^^GZ:9<;TI.YRT6Y!,H6$,(-T%@Z45B57+[[KC> W#I)IG^4D:U%$Y>: M>@5+UC 0_$97_Y2;H.(B>%/B_*_I;@3>F9+5>T0 MZQ+!6ZYCPI44.CIL6\:4;,4$Q)BI!$E.&, X)8B$M$",T MC6E.XIQ&D+W>N.R.?:MNF@.:'=!Q,TC8QG#D*;/;5/X\$P'S:RW?08?QFV#/ M>M#EO2UH;KFO)J_#?] (T'2*;#>W0[,*WM-.HVQ/^^&1F9UT+SV-XH_WX1-1 M=;SL_$Y7=?V#:4K"KP@755 M@?Y-AQ'WU87L>E=H40,XS2(5*Y*S%)'$P(A**1"528$X%520/*%4RMESU7Y2 M;P16&\O;T*GXA_BP8RGLW9E\+!<+$Z4M55"/$OQ2+H*U$:$'_N^-IY8G@B6Y MGM5<1CG"1&2(AF&,HD+AE$99'HNXF=H/^JO^5Y_85@;["UJ]DOQ+3:CE_?C/ M.$7 (P?#7U,=V!4BZ$@1L->@^UPC25")-,^]3SXNH2?C.]I[^>GGHZ3J_O)&7"+/?Y.RX6!K-'KG5SPUP>Z,30_ M+K<+\7FYN5NHE?F-^/UYN6C\4A$62H@H07D1I0C32,<0N?YG0C.J6%(D/ )U M&01S,'8JIXX 5R9?\[GF)%"&E:!US-\&.H6#[;/:&OIVOLSH\.5$X_4F=H;-ZCIV:^T"N^>1LL[]]VB,E M1)C)D(>%@4T7""=1B!C.!)(YEE&B2)J&P SRLW1&=C2&*C3Y^[P^[)R&!REA MKL$0/+C.'07E84 L;TG-$O[O=JT-WY3B:4IU M+N)RM9X1$JDXISI(X"1&.,^4WHVR&"D5TC!A(A6Q%;8,A.C8YMHA!0"UM-58 MOPV/I0>809^V+;D)# _H;H&J:LR1=01 ^QQ!5VX0GWYT!L/T! K?"^1I.]9T MZ)U Z0X@.Z'O7HG3>:].4[AW!1 JBV4:B10)DH<(QSQ'!1$*Q2QF(E.12GCJ MA-?91W6"W)CZP&:I@BX7_ZL]H[$H<[A"IY:'9KXU!3SP\J$D=P10&Z%](X'V MTGP;1% ;-5Q$!K5ZV773H\J%.39:U.Y(.RJ3/?KAZ7F^?)4K$]"MI/DI7;UV M'VH:,80XTVJA$@ELO$I>$$2YBLT_553$491PT/',=>R,??V_?'JFB]?_M:[+ M:1O2ILI*UOR9ZMM-V>2PK>F+WI^NJY1RZ,;KJCFQW9]-I6GH-J[B*^C2K'+/ M;X*6M^" N<,G??? \*,F;]O"JYB9>/?H0W&GFTPOH[KYRB_R93DW1OUN)46Y M^4BYN:I_W8&'%#F3G".]_2P0%H5"1&8A2I@*2:+27(8@".5>:B-[NAWMH"8> MM-1ACJQ?879^RIL:8&[HH@9& !*Q$M&3"^FG-:F'L!+[V '8O>1FWQ^4DEP' M6Q]^\"HWUM34W2], H[Y?R<#YXLTFS>^V67G'/[@('\R46$' M;]2W-5OC-9O^FEXK T=4N"?O.@:'D_KD$55\[,G').5PU]"40=!'N52WO&J, MMMYW2_N5SDUQVBPO1!:F*D1= .X>O"N([>+ MA^MU!;MT (G=>^5@-])T%PX@R0ZN&V!OPNL#=S"EA%JAF9@LH#^Q32;^#\Z@-F%>#*"+XT_#BJ1K> M0EJGPL"^<2>K"K00KEL2:/.X(W[+OI2^2OEL$5ME(G),)$&"X@)AK!0BL10H M(T4DTBPA&',0:,MY.N.'*SOHAIHL$)/E@G;L=GP>9 9'($?BCG#\-""5+Y25 M"U2FA5;I%_4$3V7@<XZ.3&X2IQ21&G*$99A@5B:8I2$*LMY MF$1"@1(-+Q$:^U:^)AOLZ+K?PE_2E)VY^I ?9J].HL/OU@?D\G6=?HG,M#?H M \*>7)H//>]FM&T\_4!?33#]KCK"W,QHQ(7(A412F?*$.(I-'9Q K& 13521 MI3$("NT\F9$-=K=;>ZZIPHST@F;L3/1Z>6$&NA.U(7@3-"3]66>_2)YL\P*1 M22VS7]!CNQQXVK&9@PZ;M_J+WP&=->$&"JNSLU(,"8(:ZDWU'<8P. M#OU2^>K><('*M)T;^D4]Z=HP\#C\\,@'3W_84"_U $\-C$-@&/@W^_.A* MXUAF-+:ZG1JD-++Y:;IH1SB8+]? 4Y[+&N*)4H+D&#']7X33M$"448)DRN,T MU?OL JO99KFA\RDUM*-GK:%OYI5@,9J>[*("+]+#O%679%#3#'YIJ%X&UP!' M!H.2>8H-+M.9-#H8%/=9A MO@^5@$/] VT$JHR:NEZ]H2\8U^LV MBZM&C9*0O A%-%O(1]/Z[)N]"[B&)RN#*&J#..',VCCV' ;\.UW90M=Z4;J* M,BEQC%%1B!#A*,D14331P5(:8L(8UK^$.-S1M>WND=]2S7:N>2KEP7QW1V]+ M%>SY:H W38>JEC7TR?!F@K6V9U7+GL>XS8>6/*T"5[$RZ3+A0VG'ZXB7,1W2 M./^AWU_^I8U_N3*?2KF[X<\3SO/(I-^SC&AGEC)$2<%0K%2:Q#S*(F75/:J7 MRLA>JB8;=.D"4@\OJJ;? 7D3&.99SL@Z? (,$!J08NE#>+>L2LB$P_(GAV3J M39F\^/)T69)#_!\D1@X^[%P[+5IB5.@D.3\/J%\M7%M8%*M,F8?6+>I*# M-?"XF[%^K,M'3;U_$\.%><@DE@+EF J$BT@OLB**D4IC P^;8A6",(U.*(QL MH V]"MX"9I"GNK SQ:LDA!EA5[@1ER3U*,2(@3I)?(I.#Z M#UY87<= "8]MDQ4G074R$93[ RUJF FV%3?ZMPI2] =1J\5F?"1E FS8KN=Z,T$A01%.N.&:4IW:'EC;$QKYA MJ7,U-&UHS5:OANS"'E]RPUSD7N3Q<:EM)/1UL=%':MJ+"PNA3RXF;-YQ++U< M+<66;_Y!3=^-S>LMYZLMG3?_+.7Z;KW>2C'#N"!%'*8H3=,,89J%B!!*4)Y( M&49*A@J#\ECLR(YLW@W5JH[XKQWIH*QH VLT[=1H9_G^E0,\BM"+AZ"KNO/@ MAQ\;N1"FH5#-5="R%31\F?M2OI)T+2M%[MD,[OH5"2_Z!.G%5PVH'=%I2T)! MBCBI$(6][>97JIX\]=7I;]IIR;G^PN1RNVZ/RK%D(2=I@N)$1"9*B%"1$(DR MR;&DF,BA-;*1UY2#+^7C]PU:*J1W5<$O7^Y__UO;L;=J MU%LMA)V6J# WT*=).Q?@23\P\Z^)WM32KX,_:\+!*+L&"P$]&7X?I4F-WD+D M8X.W>>7MF[?K4.19KC:OYB1XTW0,KDKW9KDHTBS-M9^(98JP"!DB8:@=B,), M",49PZ B]4FX'MD!M71O*GSVNK!V5V;[=NW<+T^BG[-K_-.?HJ.9@W;M4R:@AJ+9\_ /P!>E.#X-N)?P8(W_)%U\/L MQCJJUD,/='6_JOH1B0H8\D&N*D2T66Q@5E+&42A#@;#>H:*"YA3)5$6QS&,5 MVK5>A)$=/3AL/LN_6@?:-P=KPPZP3M-2M;8' MW+X5!G,2>UU]K76E6= ?6E ST<"(:C9J_$*?!]@0N;T=8%L1G?@ &Z*(TP-L MT-O7;7.K8&==.:M/^@=W&_FTGF4%88I)B80J=*@1A02QW.0113G-,YY(3IQV MI^>(C>PW=MN7#NW@3T,]J,@#LVY[U0;;#UZK#,=M'%@/SENN/@$][Y3.DGJ3 M#4Z?T)?V);WO.&;1&Q?Q*UV;OEQ[!.E;IOT(E?T4?[=7*\9 M.)V/M%Q5GNJ+7I,_+E=FU%E*,LG2*$1AC+$YY8H1RVB"",$JXSR,: :".O[) MY!O9B;6LH(:7H&*F!H,R[$ @TG]2#=K6+?Q<7(^8I&"D0)48AR#P'5D#]AIT MGVOD#2J!;]I6LAV9FYWT1DL=-&+?!#O!;X)6]*#W.QL'0/?GG%A?%2,_F733 M5JK\9,)?6(U_5C8=*W/:(9LSS8.SS-\D-4EVXMZ<@VY7*X/)O!":S57[3RUD MN:X+RE024:58A%@A%,(Q,UT*]!^9D$2$+ O#* )5]/CB;.1%=^_PJNN.FGIU M'MEEQZUXS]_LV"V;;Z)SV(+G2=WPHB7?JO%5[.2-KVF+I'RK\Z2XRCL!.'#N M@UQ6:(]FH;A]VMB"YAZ]-O:)Z8?[H,:D/(P?^[MQ#\K:[W"N%!-XSNDD(0@> M]X(L3M"XQV--!HM[08@N).ZE1QQ/'^AECQ854-,PRF!.U)#Q9RN##+F6PTYWB.ER5 95: M>L<1% 6]#;Y&1U= L-@)[!V398#L&X&TV"GC,FJ+Y?ON!0[+U7V+'E[YK]9K M?2S7G,Z-L_J-;K:K;Y9-FTK#5,>,LHRBE)E"K;T M%A(1@06*"I90SO)()0FH94$ON;&=TT%A9@O\^ KL4="O,#M?Y$\-,)_3T@UJ MPKODX-<1ZC+M9/35L:"?V+1-"ZP$/^E;8/>6FY6W*';=% +)>1$97/PBI(G> MY*@<%9G*$"YBE28"LT*"XI$S-$:VYSTRHJ$9-$2!.YASJK$SXBL%AEDN5%:P MN?9(X\E&SU&8U#![1#RVQKY''6#I/CP]SY?U'?CC2E;WXU^EN=;6?'^3JZ?U M3."4JXBF***A0C@7":)82E3D,B"DEC'$KFT"AJ\(TTY9PN:A28MUEC$N0PCK!U/AS'U0%N%,8T%%G1*.[#0DRNMI:F_09B(4;6F-WZX44'T%"NL;:F M3KFF>E,7M7CL,SLHFJ=5XS*=2=>,07&/5XSA%R:N0FP*)^[U\F7 6K5]?-[6 M[45XF"HE0D1SDAG01U'G_!+,'=OIGYTZ: M7FX_XZS9+2!O.@^PA<=#=>6N?O*^.X4UXS]!6>203M^ZL/$B?_\:I8E#ZO56 M7#A(R!7^HYR+NCJF_>O=T_-J^5*?IS4'#T48TBPJ(I0E48IPS+6WCL(()8IS M06,=B<-R):RHCKS#:PE7>9"L_4?980.*"&*C23L/ZET_,*]XH)K=/[H,@5_6J[I%OMG2^?SU@98"4)4[,,S(3D13 M1Z:.];/^?XNZH7'@J:^ MHOL+TP)/'CRZ$%7I4.=',W.#QIE!UU"T0#A/F<'YRI&2M%"$"BGC?+:0CP:) M^)MEVO9/()>5/RUJ?WHBG;5O;5C9E6"97B?F%&UYMD#+NG/!SZ)$FQSUGX#- M,8]&1^F"T\C9_>5-T'Y+!V_LVF" NU_\+),#R>O_"=B%?$MNE0/_6M\4K%+A M)YK WEJ(GX'/Z:HM?@9ICX*UGXXOM[.+SW)3=S'_M%RO9S'.4IKI*"HU/7\Q M9AA1(@12*<^33,DL3.5L8_#6[$X6#D8'[?MW-.R/W>1&;^L,,=CF_5 #(@XQ MB:1$I,K3XF&HP\I"(>_EJGS10<>+;%L,&G"_]\LG6BYF!>0U3U=E,EZV@Z=8Z:M?6J[7DJW36F8]I"VNO M5==)V>W5 \)3H-Y]-W=9XD'*U=]7R^WSQ\7>MBS3GWJ&&-D!-90#0SJH:-\$ M'Y?+S6*YL=QY#ZF@W[UXE![F//H$#_[TZAPL973*9.H;=[(L)@OANAE,-H\[ MF.'RJYQ+OI&B:4#RF3Y9@\:NC-+(![D@'= \:ME@N$!\X.0+J MJ]\6O6H!>ES6*J"#FK8G[$M^P)VS+SVX70:[Z@-V+6LC8^]]:>\ TUUDVLAQ M<,-H]8([>+Z4AR#7ZWT,&K(\)[)(#+J+]EBID(BED4()DR&E>4$SED)!\B^3 M&]MM5<2#+_>_M_D(51J"X0&>F&*I0,NC?F]J ?JQBNX)YOW:3W% V>:N $/2GG'VW>/9G_ I@L?+DD]$; M>$_'S711_.0:/M@23$_=-3V!F89?[^AS:1)P3 ASS^;E8WV7,*-)F.&<,$2X MH AG)$0LCB-4$"8YB5A"4@I)$NHG-TG"D- L0!,2>G5DMX7P)SELP31T._NH M/4V?&0DVHGG+2>@E-G%6@HW@IWD)5F]=G>BG:52@"-^7<_W^NG8LNR9PA.O_ M21[K<#^/$2;8)"+$$H5%%N&0JRQDL/9ZEH3'/D.XN_WU[M/=M[L/7X/;S^^# MK]_NW_V__W[_Z?V'+U__Y_\@<93_G^##__?[W;?_<,X2[->KY8'""-J"'I$> MUI(U\= H_?& POI/.NPG^U:IB%;*Z$E0M'O?,<.IU#M=^R;: \D_#1]!Q0@PJ]%*H7;.P[>:8([#AX;@Z4< D7UE&MF0G#:I"*"$ MD_PAR+N.+D/J9^G\XW8AUA^4DMRD7G[]BSY_H1O98CZJ**0L*E".<8IP&FMG M(;7OR F1!1-)7(@,Y#&&:8[M,+055.2#'?W $ _N7^1J8:KZ3>L8^2,P7%6_ M ?H-"ZU:N@V_N@)Z#;":QNCP8:\!7T[$@N*T/L1>!2"$5-AAE@>IBE.DE#%5IE1M@1' M3Y3JD \,_6#'@&/QQ* *[7R%3\7 ',5U.H%WW;44U%??W2%RTW;>M13^I/>N M[7M>P6#KIA'G84O3+*&JR!42+!*F':A -(D4X@E3+(ZDC 7(,)IR/.89V'!17M7_*9J/KSRA=[VOH5J M[;SRN%^ERT6L'[RWEMVUSVNVZY4V+CIO'P,_ SROA8(L\7EM1G(-&->;>V6: M3U>'87+U4G)-:3D7LYBD&649045D;JYHFJ%"A!'")"]XG(@HE*#N I=)C1XD MKC<&$_/1D [6FB T(KRH(]M8T(?DT"BP%KJB6IU/MW2#KWT:<(C_AH3S%OE= M)#1QS#/7)W,@>HJ(8O-0DFP9/$V'CGIL)RUCFC?0[>913ST[#L/_H9@0U MOC4*[3G6_C4@9GN4Z@T_MH^&:\[ ILD^^+JAF^VZ.2F*>*RWSEF*0A;I"(J9 MP[8HIBA-0AU)%04O,@'+$#A'9NQ\@!W1H*;J>*YV04=VONYZR6%>RT%HATO] M/IF\7>&?)3+QA7V?H*?7\[U/NR;I/2_7Y69=W]=U"M 24J1$L0018DR4DQ31 M/,P1XWDFI6)Y&H.NTRX1&ME('U;RV739$ WY/;@Q-%'O@I[LS-2']#!#;2DV ME^=^:_)LQ?*6F'>!S,0I>?W"GB;C#3SO9K$MB&C/M?L1Y/OO:ZFV\T^EDK,P MY5P648)2DG"$<9H8U'1MU1FE!!>"QRF?Z;?8TM:NKV$'\O5WF;+?OK2@PZK. M+)E7F27E/K.$-L;Q5]L$HFT:LJV8#.::2YBCN&IZHBR1G(4")9F,32/*TA5[$RZ3KC0VG':Y&7,5T/TI^> M5_*[J6)_D37J;(TC=8RIQF01ZK@R0@7/(H3-?E#'H!&B84YYF%%>Q*!-H2WA MT0_9.VPT*,8-IC'TM-U2D;9G[_[5 SV)[VJF9N%F$L@YJ.S>#NHMR4Y\; ]3 MQNDA/O!].$Z5 SK5=)A4,.@I&.#4)#!3_E&E?&%)O0F"U !NU/5H4:WA/-"- MW'=:CZ10*'\VS_5&G%!P.'EXGK98';2T M:@C= M=N"1[:DE UMQ=E+S*$]ID7%$BS!'.$E31&1!4%ZDA$592N*$S^HSJ*\;NMJ, M)_LQ$; &;@(F'\O%PF0 +)53BL9.+233&^X"AP@STS,B2K2",E:@6,4\$FF4 MAWG8J.7#PC(/UUTI+0D'E4ASR7.E,NP"$A?Q8#YV\%,'QR#'/'L*/W;#3AIY M' MS''2<_!X>;U1I$;\OQ&K^^OA5\NVJ+I%^VMB&'!<'&-E+:I)2TS2N84_6 M/@RY+/=P).)%9.#9=Y4-=5;FX/9IN?5Q\6DEFE- M'8 M+KT['7;: /<'2&=#S[KM?>X6?&60D=[+^K]W"TW'+ ]KO<>2Y8OIUSJ+E7"FI9"+X,*P@]"W,:Z]5F]I7+!=4[2=,HB=/UICFQE@G'/(HYBE2<(YSE#-$T52A*148Q M%BD3Q"8HN4QBY)"D)69GZCV:Z#=L/_*!#R8K.AY/\(?%Z+--_7;'+O6_]C;9 M,_ D%C@L6&MO%D\ZE@DL%X_?Y.K)X!?^1C?-9N*+?*Z+$];WZF&E%ZSRF^5Q_+-:?S_Y!T-/)8X>-**KV*(:]F9MFS"D_)."BQ\C>M:BJ&DWM\(4Q2[GF4\ M+#(J8F1*HA#.)4&42(H8X[F,]*9$"!"(ZL'H([NGEE; #;%]R87^=].[N,Z[ MAI9@=/5CYWV0FYG]@YI" MR#9TC42:TD*'"Y$P?=E2F2&JDA3E*BT$)43B!!0X'(P^LIDUM(!F="B_G1DY M2P4SHX;,"&DW9P7P9#R'8T]J/&?%.C:>\P^Y&<]A1Z(6,/BUV[B.Q(172Y:@ M^H_,&!1.$I2&(L^37&^5%:B$99#BR$;6= [KM#@,YM4!T=RU;=BP#NV,TJMF M8(9ZU#3L9M=#[769^ M]4@73?%6L[+H/7B6A"1#1.'(>(,$%5*OL8P2GBN"LS"R0DVQH#6R"]#$ TT] MJ,D'7?J .ZT!=?7;O&U^_'H-0+?F3L([=2KJD\QCCZ*S M9";O3M0G[+F^1+W/.X0?A[%-713).$0)YZ850*;TICX42(F0<%(4 M5"16=CM 9V2SW0?9]88#=+]!MN&\1)4X%B& XTQ_[BJ5$4Z2D(\\O;I)';*&H]#O?&(>*<[:F' M-HAY%?3EIV7-TNV/H.(+CC%&<($D$-X"!EF*OS.#/BL-Q<(NNT)"O3#$'#J9-#G-7T4D^V!5#.1QH?:5SN?ZF7[Q= MB/>EW@1M/I8+NN MZ77UYSZC_7VYKI+<38^\61CF42$*C.(\RQ'.>8H8S5.D MHI!D19REN; _\KJ&D['/LAM2P:Q*V*L9"W:YO?=.<1NVYNPEV#XTXXE0_B'Z^1T]'IV4PCT'-=DJ+?'9V\-:&/N<3QH>.X M^)2#-_AW2>>;[^_H2GZ5CV;:FJ^%:N:QW@4C+)A .#8-6?(T1)A*BGD< !#=S6V< M48$G[S$@4J\/N?3N=)YD@/L#?S+TK"/*-UU_UY&-^<^'_]KJ$&9N*J:.D:EY M2@CA(4F@2SLP MQ)NC8G &9H_:[/R#+V7 W(*['EQJ)0<%]%9G4U)64@T*?*:P%BCB6A3V0VWDB8RI' M<;OP[H0H;OW<'Z*X#3P+!V2M$H@>Y$HUO1@ 4*QG7AW97]2)=(;D9A5WMVD?CU&O&).XEQQ.Z!GOG M'^7F^[OM>K-\DJNJ"N*SW.QPEID,:<82E!&2("P3A0HF"Z1(+(HDRRC)K,)S M ,VQ3^<.$8=N@B%L F?=61[-^=4(\&"N5<9?I3E%;\C?U*5%-P%56L'![7R^ M_*M:N4UI\[N5%*7)I%W[Q#%VT(:W%GS#%"?NOF>M@M/&>_:ONOD,,Q!=?W]8 M+5]*(<6OK[^O3>/0NRJ]JEP\WO)-^5(#O[-UQ8>W%0LYVW&5=Y,.>C M>:DO!%IN O8:_&(8TBK\6[#C*=@S%?S9LN7Q;-!=)YY")]CSR^,N7/D9@V%;Y'R)-<][YG M7>_W5N6+'M*4][70#^O;A?AW*1X/C-^D.LZ7U9$&;'F[@L*8UUPM4QW8D1H$ MM>&KN\+M.1MEL?.@(6_W9.Z<3'R-=K7*3F_9KA_2S0;-95X'I$?(-)8Q1%@N:*&4@V6 ]A@^&'WD1K*Z*KX N.M*%G8MQEQ#F-0#"P7L. MGY7!5]/AP\&G[3I\5K"3ML/GGW(],M=?KHY>/_QXEHNUG,F891%);!;*N.!)&"&]&(8(RZQ !==_RR)S'EX4PA@S M8'E\,TE&7HDK\H@9^D'3'"&H0*8?98VQMVAE"JCA[Z9J!*!_N@E>987OT\AQ M$U# %?B;J]72I_U+3#O,>]8S7I$.'IH9O^W.^$Z\0\_^'PKS&ZG9NZF MZHT0?&Z^@2^=;\!78L!/HW]/KO_MY)ATD7GSZ3I>SMZ>(=<:C.=2 M ]<FG M\L78.>J=?MU:8!XFY"__.=X@C+8B$E1R3#.J[F.$6,*X9X02A/ M%&$J!$$O>>!I9%?DHT&?#\W;>:2)]0ES5C5SJ.(NV+/7)JT8IG@5=W8XG:*% MGT>E>?)S/CB:U 5Z5.&Q=_0Y-#Q!_=N*FJV/WB%5=ZR6N>F';XWLH1IBW5V< M9=;*&0'[W7Y;#*>?\:*C)TLW/B]#--+_PA%L \?M:WJL/ MZTWY1#=R/2M$%&.>4Q2FIDD8+S+$TD@BB=-4DJ@(:6S5-?O\\&/O,-;58KXC M!UO0CS1AMS:[RP>S-\-%UIY0<.'4[J4C3[M;-BSEH KH@\%@0T;(+(G:[>A M.*D+ *C@V"] 7G7,E%PN'C=-KVN#2MM=?%LMC M1_HS1";O,W]9T'/=XWN>AIFID.7LPV)3;EX_EG/Y>5L5S(>8)(7B*>*Y2!$F M*D&$B1#A+%=1H5(>*2N,WW.#CVR2-;G T MJ@G9V>%8/_=9WK70PFP,(9FUH M?1+T[#3U:[5EZ;_L#>KL8).849\8K?'T/N. ._*I_*?\S9SDF-K@MN$7X1&. MDY"@*"X*O:C)"+$PB1#)1%8P%D42Q]:@(^:9)!33,P1 '8&V?UT6\_ M7J0$+EQ' KJ@C)R5% QA]T M"XW;-AKWZOS-_Q>YWJQ*<^?P=;/D_S30K.OJ/K_)XSYN?D%R'N:)P5;%QOUD M(D=$*USON=,BC6E(& =51'KF;^Q6)=CMJ;^.9NTDW-2*H]W@V- M1>;:4C2S/;Y7;>7\C.6<<)+K6##GVC<75*(BHS$2-(S22(9<_PL&,WF>T,A. MMFE&4]8Y3V)?@<8;^L";BHOZLG."/K0 \V9[BC=!=0*BU=!2':.:[KQ6$O%[E=>-[]H/);I )9V/\+*,6C;LNNFR@0**NI^CT7=I?=X;.K Q.3'JNZ*.G?L>L5HCF6UJZ78\LT_ MJJ*7S>LMYZLMG;_;=:UN,:$HCI(T2R2B3%"S_\.(2!PAA1G%<:+]4P+R0I9T M1W8[%5F]+?BK80-8AFNI.SN?,X)&8$ZF82!H.0@:%D9 RP+*ZJO UY+JM)6_ M,%6+R/,0D'B.=S;GI/BBIO;@^$FOKL] M)\KI[>W9I]Q6S5^WZW(AU^M;_E_;/-7W74WF3?<+UW)Y$,D4P3O;>/ M8X:(@;)AE"1DX+[+$Z+/>D[D("-Z$ ^>#;SO-2^-IG'HT^[<;RO&@G.\D+C_EJ MQ-*I?+)_D-_I#KA_H:]7B3_ (YYE) ZE-CN1AJA@28Q(D48LQ9P3#.K1 M * ]LDGNNY((>="@Q? 1;.@/ S9E^+BV3\MEY=H9\4@J@QGXQ1XNE;8J'H*' M 7UY:.8R*/EHK5TN4W[C1B^#*AEN^S(\A"]'4V$0W3_+%36([)]*RLIY=84V M8UE(,AECQ JI$,84(Q)I1R-)G&:4"YH7H+Q% .VW<33+JG?98KE 39.88+YG MZ5J?"3A=H\N)Y!!8SF>BY3?F/7,ZB28=G.$BP3R5!0JYR8?-$\T2B,,-Z!XC3%+&0"E2$$58B944:1\TD?5A8MN:<>(I:OD::(*E__"93 MP_*DB(B($..7$ MK+\O_S+;^4!'&"8S71CH+6'^ME[.2V%0ZX/=Z665RZT^OVF6T)0)U^LV^U YGD-60?RPZ[4:[]C&U5;,"=FJZC@3YORPRNU M!B@B'TM[;L7E?K4(*SQWT41O03IHP.D*U5WD/"A@=QK ;6NX/]0Q)SV&X"RC M.).QWNHE2::W$DIPQ!0U*L7.X6LOYKD].<(QV611/@=<9 I-&4Y<%/ Z1>IYT,[M_R/+QNVD4 M\:('?FQ ;IJZZ/7]=J.W/ L#M_J^G&_U8_L>@'=Z)[3O^!S'IC @IDB%!4$X M+3BB..5(2L'UAI]%,:PYD1^V1C;OEDE$:R[U'M*P%VSKMM%FAU__2&\5YWP[ MKQ9(:/MM3Q-DYS2F5SO,T;3\!0V##:K5#KYC'728K-KX+'@Y+^NTKC%:F/I5 MF"=WYHFI25V@7T4>NTW/HSL>?B^?GDP'8QTKU83OUNNM%#,>44H+F:%,I$*' M.8EV*#%+42YEIGBA-Y=VR'D#=$9VAC758&W(WC2>\"8H*]+!+]H;UC\"MIFX MI#/+4[#K-0$\WZJ5\+56PM=&"355CV=6_6+Y.HVZ0&7:=\3< M.@L2T[F!_/5U_T@#5U2EX)GCJ+A^HN8,:QY%F24<1$ M%&M/$":($A(AG!0BIX79\'"'?JU3\6]E5U'@BIZ]!FM-X_99Z&V!&Q?].@Z=R/C>>QAP> M'_R@V8C33?";UNOW__D_HBS\/TEX$U2MS\SC[R6OX#@/?I7EVQ6D(R(C$N$0Y/V$4FE_0'G*$EPEL@HB4DA(&D?W<&GR.)P!Q%S@ 8; MS]P. ;_&@?;R;%,'0[\9#-DL&J2.\1&GDXYDZ'\H)[>:B;NRLRXO$,%.K2=X$ MAFB]G 5[LAX+#8)'.M,6'0^*>E"$.OC 1ZN9'_:',!&,BCI1"651$ M".O%$%&6A"8%DN*4T#Q+0, <3ER,;.7ZTR$C8VY6NH2OJZ-HZ)H%^ 1QTQ!_ M0\#-KNQOA;=9\?!SPVUVU70UVN;!8*[@W:IZN]SL;E7U2]G7)$B$2Q%6:$*<_V3H"*1%(61%)P4:9KG M(*2"JSD:V4^ /NY)7]Y@RJ_E9V(\3YL]7/R\5+ M=31:':.NJ[U*]_]YT1:(ZL7+(MS&N.<,!!LZ;3LC^QYNQUNFC4QH-VN*G5)4J"6JV"U9ZNZ M:GO5RR7TJFWBN;=S[#_OC+I?NYUMD;.3H;UE,TSKGV[T7&Z"/=\WS6U:->T= MWOVM#6^CJW\1G_, MXC3"/*<4*9%PA+&BB(8919E@"4MQR.."@>HK+].:XMP]X%WZP7RYAA8Z]NC* MSEE[T@#,LQX0;2&+?OFDQ?^;]JJRBIXU S?![::.F:I68YNE=L-^(?4MI/>7 MZW61TM3Y7D,BG\GY&GS%%3/[5HB5@0ZM__-)1]+1C(J$1*G"*!:%:=FCF-ZO M$[U]YPG)4U5$>:Y@T-EGJ(P<"380TPW%F_8O@:$=W"\L, JK%B2XT*B M+"D, &@>(494@;(HC*3B29()4%:U%=61S;9.BKL:_\M.@8H+0J,LTQ]AQ!#F M+$24Y7I3'6)*B6!*ICDDFO&O0->X9CFE&BTO27TK!WAAVC1-ZA#K5.2.@I@& MDMC71:H5S6DO52%J.+E@!;WLV$U,?S+?JUK#IZ=R8XX6OD@#*ELN'G_3?SYM MGVZ?EMO%IOZ]WJ#-(KW9*4*N/44B=( D<]-7C!8HI'D4,JH]L035 H(Y&-D+ M[ZB;#5+#$;#+&%BG=EYD5$W!/$K+2K#GQ<"\M)IKV EJ?H(=0Q[[D;GJPE=G M,C#]:7N4N:KGI%N9\T!N_NBWY4MUP'FW^&J*]DQ3YH7X\&,C%T**H]9IQ_B1 M7Y;S^N)K9-_5G*W MOKB:U E[5N6Q:_8]_,35DTW13*<\^ZB,^\,/N>+E6CZL2EXQK!J/(/(L2AD6 M*)8FXUW(%+$\52B*TBBG1+$L 46@TXLP\C*P0ZYH<11:/NIRF(J;B\W<2\=?6ENP#_&G685T^0 MMXK,ZSEQK,WL-,5H6X8GB0&()'HI(E0O2HDDB,5QC+C(PB@22@ 7I3,T1EXU MVE/"Y]7R6:YT_+DQ+ "K),]HQLZ17RDOS-,>=*@9H5MZCS"^ZB'/4)BV%/*R MB"=5D#V/.M\1F4.'=M :M[ >6VU>,\]>(G7Z=,Z[L.[RH"7W=4'.P- MO&+"Z^4&2$1_]QMV9*>^X@ IX\PM!^Q]QWTJG>W^;[,,6#L))NFWY3?XL^(X\(JR/(X2?>W;_# U M[5[,JR)/]E=^1W?TOXT/N5>:>+F1G\QW>K?0^[;'4I-IT*8/39E%E"=*4$2* MF",)O2L-4^H8BK8Z?[9^SB\T^?=8EWJ)[^MQ,-R7O)2KA]62^[0\W-P MH-$MLJ(??%O1"NF\Y:+:"AA6M/\S 'C@;J##&NJW5>_*@5HL2"]>.X9:B^W4 M.W1X],FZB%H+VNTG:O^2>V=1O7LY:@IV#K4J(2HE>F> $AD1A&.N$",11@)3 M3#B.TE!:U>^ *8_L$ZH>>>8[/VYW".].:*=(NU5[%/7 O,).,Z>-!T=&" ,+ M[[&3H!W=R;L&@M1QKD,@; !75)^5'MR@P!Z4%/$XX0HKA 4-$69,(DIQ@6B: MA9P4(2Y@IPUGJ8SL)?8T@[(#MXWVW4P#O7EZA%[KGE>8G8>X6@TP;]#10$OO M\CFT PY.CS#>L&W.T9@8KZ9'S%,,FKZ'W2ST\W*Q;'MAU1N%#S],9HC\K8)U MGLD\C3,:)RA)TQSA(LD1,_"W,F4B3B,EM0 SVB[A74E^0_MOP9\U>8^[/";%"4-_M"DS7X5T#RV7U?]5NY7 S #[PI_0'C8N*%* M +3,]:8,MQZY5R@%UA#72L[>#KC](TS7\M9*DH,>MW9O.#:U-;DJ]7U#F^P8 MLSRF:1HA06FB Q,E$(LSAD0B,F+N!' $:VI[0F)D-W4(0N""*'Y&*UQ0(7@A M4!@:B &B%5(448*RC$:8A3*E"8: #5RI%3_( IYT8Q>:72U7U&_E4+NH&E]K\L$6!2EF9;&M(>3?6*>'$3V/NP(E5NU#_M-;KXOQ5V%=EB= MS "G;$3F39Z;R@?2QZ4>YI M/-D+"K(S30]BPXRSZ6I84PSN+*2&(ZOVR^0+ O4"E6FQ2OM%/0$5'7C<-<_G M18^R7+U^EIM9QL,H(RI&-$LR'L%7G M!%:-Q:'5C84=N9 >SHU_=NR\K M#JJ;'K?Y'!E)I"3F<"'E1(<):8)H$<9(AI(P MHD3,<@QJO+8;>NP+&4T(V$UM+[5=5. F"\P%&1HC7)&>LNZK;=E^X&E[D9T( M=-)@[/0)-^OX=;LN%W*]?K=\8N6B\I?[M@5W0AMAJ4JZJU6XY=HV5]+ -W6Q M/M=K[6YKO,]]%6S]QBR)%2URFB)&F6F$DQ>(B#1$811EV@YYP:,"8G2C='B_Z32C";KLMY59K0!5@-"% M*&YD:,KW@[T80R5Q8&@L^,!>B,[\0[UJIL5 M%,=D0%EVWM>C"F"^\UCZX,^:]#@EJY9B^D(N&: V+6")G>@G."66KSF<'GV6 M?[W3;J7R3 MX(:HC6SEFGQ0TP]:!H(=!X"#DD&E69P<^50%S-I[M>!R;C2H#L"QD4^UN)T: MN7TDL+,B6RE[CXH&!YGNI,A6GH.#(NN7W *8+\M7.M^\_GU+#0RQE.L]CORZ M!HZ?145.5!%1E%)2Z*TLP8B8& :S-"HDS7D10"O:H Y@$LX<4UUSRB0T[;2^D8:NTCO;4#$AL2_B \V M^"( M;[I^Q(;9JJO$( "-?J&<4#,N##D95$:_2%U\C($GW4$QCFKEOTAML27?2-'4 MTA_^H//D'L1*4M,L,T,I"Q,=?],$,2(9RHB.OUF8"4; @!E7G*!U[EH+Z M$:/UHQ]VWQ@E>/"J.X\X']?S-#D&B#XPT'M@YY7N5I)454&M+WQ MOIB>$]_TG*^-'3ZS*QT>#79 H&.-H['BJY2-XWC%B\(IEVX3FN6TFN3), NII<#NZGF@Z8&?=/E77 M>Q[NA=!T9^8^]7)PKNYU8-A*)60Y^[#8E)M7D&:91)L,D M15DJ!,+$Q/UYDJ T93QF*LHSNTIU.W(CKS$U T'-06UX-_6&=MUMA6;GW"P5 MV+]P^%<+;%6X5B/6_@4F:,\^7P]4!\7Z+_M8V'+X25P&3-36'P#?@I^QW8K_ M_+9\D$O3/>WC8I_P8GG(=N'UT9-]_G-;5^T%WY;!PX?[@Y:'-\''Y7*S6&XL M^U3VJ6'XO,V#!F#&:2M\\*?7Y!\+69W.X2Z-.=E!W(!0W9.XH4>OK!S=8U3N MSFZRC-(\S@F2L4&D931$-%&97G=)IE(:IW$!0E_HH36RS>XH=]!4KT"+OZPR MN^,N3XJ F:ZK#MQK,B]+Y[M$\PREMZG8O"SRQ0+.GE<<+ZWEHW'0[Y=/M%S, MXK2(6"0BQ(LX0I@3A0H>)Z@(&B"NCOZV)?1-:UU\&=-#FBHAXJP M,TUG\6#&:"\9_#+YG 2^+HX/QI[VDOB<6"<7PFU8JY\/M_^,:0=L!G#A/5DWY9$)S5\F"*. M/0+P[6M;Q+6U-.*Q'B")1 ZL;& MV&MXI]/9(5STI^7:N3D<2,^6*__HV@.&"!W%[>H(^\"F)^D3YZ(;[ZWB0$R\ M4;B.LVIL..:X#ECB@I!""*$Q @S_0>) M.$>Y4&DA]-9"3Y:-J^HC,K(C.B!;@Q$"]Q6]&NIW,K[DAKD0)Y&MG8.-3'VF MK]_OF+W^U][D>X>>Q*!MA&O-U>I9QS(4':$LMK*I[35CFU:XS0U=\\M]+GJ> M)F&N0E04-$<8]5=2"#B]U>^GVRKI]P/50 M#Z1HNX!B+/7!?(!/S<%K6QQ4X*O*!4)ZVGH7!Z6<5+ZXC.'J@@STO!0?Z&JA M X_U+>?;I^V<;J0A6/)2.QY6T#2F$B6A3!!.#)(2IB'B-,TCR;.4"] 9R##) MT=U-S4 @&PZ@SF109;8NQ*8B!@E. M[!AL%7#J#JS?=#SA,%?_=^OU5@^X76D2#W)5+D6=#+#/7*T>N_V+KL3?5WIW M/\.$12(E%,6Y2$W[A B1F!5(QHG$7/$\RD!H3VYLC.XL6KK_CV9'+5=/5$]W ML*Z2Z+;:.Z\#@_.K;>:7;DQ,>^YQE:).SCVN&\VUMR;;W.U:3WZD M7#8UZRD):9$E#$6,Q@A'!ED[33,D$Z8*1H5D$2BZN41H9#=ER'9Z:P9*$PXH MH#)P4%%V[L:'^#"'4DF^)VFZZVK1?=?Q#\GEK; \PXU M+;\N_])6H/<]_RCG_]0?=@,7$\5,LB3&2"K,$#:@U50D',4%$6FAC3:W:TO1 M0V-D2ZV)5KOTABR@MN&"5OIMTY.L,+,\%=,%/NB"O(#JC.OE=JNW $PSK&:B M7Z#>*H@+KTY7U]#/^T&EPL"CCL"%W9Y6NP._$&/,%$GT/H;%YJ8V- <);&M'B# M?6*>H SV/NP(UEXAT.R^-V-GL>1Z*4],)PHB],IN&FA'-,YEEH5A2D'W&X?# MCVQ^-3'G^XDC5=B9GKN ,)NSEPV.YGY6!%^([H>#3XOJ?E:P$V3W\T^YF=/# M:LFE%.N/FIEJX ?Z6GQ0"3F"HDP5 DO%"D4J!7"14JC M[W'YJ@)K^J5 6#54;X+[72+1+=^4+^7FU9_-#LKJR7POTYG4D@?%/3;JX1=*A RI@A@47B$0"_66.,UI+A(B9":L:@"&"(UL MW4UE:$/[)JBH:PT%+7UHE>P%=?5;M$\EP S:77Z'FMA^X:ZHAKTP\,1UL/WB MG5; #CP/KWTU97S:]6[I?/[Z0$OQQ_H,U!:X)!8VZM@[SDYI:-!R%1BV@I?U M_PXN@;?9%\X"==AOU^.J#V;ICIH;H>K632-.Q;A 4I/5Z+JIH%NZZSB"6Y3_ M66X,@%3EHH04O[[^OI;B;K$+^)IXK^SL)A/,TCAGRB3V&A#;J$"DT!L!(2-& MDIRGS ZEWYV%L3V1 6)3\^5?33"\3Z.G.U: \'@.:K;;*8RK/)@?TKS4('8M M-P%[#7XQ#.EMU=].-Q'E2*< [CKQM-5P8/8B[@HXW)U>,Y'"'=UMJ.:G: MW"[$'_)[R>>RO<#)8IYAE1=ZSZ+TGB5)*"J2+$,B441B%HY',R'[G MVXHNUL_+U::!QWAIB-?=9TU-!^"FZ[*N^AV+/PT 3^(;DH&F&;1$7:[X+@L. MN.7SH@"WB[ZSBO!TUSW&+%=Y+$.1(TJQ0#@DTC26SQ"+H@@7D>(1#V&90,-$1_9054WS2U73 MO%3!=RD>S7*^3Q,"7A1:J=$N#O*M')CSVA.J>S;>!%^W[#\EWQ@ T-_H>F/J M,>6F#GY6VLT_ROI@E4FU7$G3+WKML]$]1!O>,HTL2$Z<=62OA-,,),"[;CZD M*M(T>SV]J].[=SUJ7:7Y47\0Y>.BOAOEKU508/8=5=%&]:]YM:#LP;7TEW6O MOM$?#SIT,+_8;%8EVVZJ,L_E S57K#-&0KT_BRF*,QDAG(89*BAE2.881XDL M4ES$$&[7?%RM)YU7CUOER;>XFJVV?JD4)>"-+L-FS'] =_T"?-^VT M1SK\35(C(5.VD.E(%>[%NS )MHAHM MVDW0"!=TI3-K>2V?OX7Z3:;%TXH_+>^3A@YO,BW',%=1RX*XZN%R"F!:?N!7!3PI+G'Y2?A""R?Z9/>E_Q& M_W.Y>J=M73N'5?.1,:QXQI(081+J>#_1H3ZCL4"BH%F&$ZDHMLI^[*4RM@$V MQ!R 5RXKIM_ZO(D+-$!K24%X*X.27 &X,"-19>J MY-6J>[_5:VVGHOK2*GZ$.D8+E<4TPB@6"B/,98A(1/2^+4L)39,XCF"KI1^V M1C;P+FC9,3\JLX;#H07 MIB;&BO"IR%,\":^C7XNJN8;*Z%>:(9BK'!=9.*(.YGU'8'-M9 M5=@<0'\TSGQ8>J\WUS+0UQEF4,7-0<^=[NVSR<[K/M>PW8+C-)S?=-MH!7\: M[H.&?9\.@0@L3Z+<>,HC;KNBH3_5125L[+S>N,6J7$T_BK$+E#V("W/W M^ZJ2BN)-L*/I,4NC7RA?^107J$R;^= OZDF.PL#C\$K7,[5N?ZP?I%S]?;7< M/H-+7"V'&]D<+Y9@_K$.##-!Q8U]*:NMDOIM=B3]P.S73C4CU*H")7T4I7FF*]&D*I"J944 MMPOQ:1\)Z-_IJ%CLC@=G&54YXSE&<:YBA$.]J+,XC%"D8TR>AES$"0B4=10N M1_9!+1UPI#3.E-B%$V^N:,>]9X??FV#/<=!EN2X5:39AIK>&24[ML!TT?-]8 MW." 0YI1%>LI(!J'QTG#J5'5?!R,C4O,$2%S^!JXJ1)2@97>>*58;[SR M&+$B92@B(8X)3546@E#%K"F/[' ;Q-O'Q\V'537T[=/&=A]X^-;8)O_X MN)*/!FY+DUPNY'*[/KJ% P#IGY%Y>%OG+B[07*^4%+1C.R^4T\;L:*C)]E_G M1>ANLRX\<65#0)/H6G?&:#O.W+-Y^5C-D6D+:AID?"N?]"/WZJO^Z5K5%25? M-W2U>:_GMVJ\S6G*4D(IRIA>G;'!R6>2;) MO=FA5W7Z;H?HA[FW:9CH5;$76RKZI>(0#LWG'WY(OC6P!._T<(_5"4\3]ML& M1SUCC!TJS>?!CG:P)PZ(C?H48!$I>9(=&#==$-OC'L=6.+?XJ6_@Z:(I"_$. M8BN;YQV2BMJ"HOM%N]\6,LP5C:F.CW)E#C,21$RX1'*J"LDD#U/[MD(GPX]L MD[MJ-$T0D"5SJH5^Z[M>-IC-=<5R 18[,\OV63]7R>F6Y6,UC;!,GHM2]&;N MG+XU7:;.18X/,G,N/^58#K]<5&"'_R@WW]NQ=Y?CGS7;=;[ZC!0A46%$$5%) MAG"62T1BFJ!"I'D1\C01.)HMJ@VVL-M265*V^OJ*^NOKTK?^^#[)]?K? DT0 M-12#YP920P?9HNTFOJJC*&!)O;5RBU#FI$ 9X0SA7(1:KU*A),M)EA*)TP)T MZ>=3M=-\G6O.\]K3HUH MS/,D-WW8>)1I.U-A@2C1%L=9CE.*928C4#,V1SY&-LGF>K<)>#JL@*]UG91L M9\83J YX%M(P%#0<57DP#4\'^3![KCRG WI2C;_+827=D M1$YXI*IR?OU+^A'A<7F0=-)3 \Q45TGN-+/'@T8SHQW[57>3%Y@H19*7'&8D MS?1\NPR60F(8,TI%+&.&XLQVA/LIF>!^ MT>[!C'49(7,#+3-=,EMU,E#D([ M36Z_+)/'N>UGB,P^M?VRH.=FMH\\[6QN:"5POUE+4=?5>D66'X38S8U=\8&7 M2AA1WKW:M;1((JBLB@A24C+(BRPF$94HH5:[UH)V^ RRYBQR!%(XV!/& M*!K;$"&PL;8;&EB&7( /8^BX& 2V MR2^B&:NB+(NOXJ$=Q"I3G#-."8PCQ"!*4@++*"]A2DH<1SQ&>6R5;GJ95&#M MT!+68=7-CC2H.]J64ZHNPV6F%_R 8*<&]O+OJ8*OU^2W'RIU531?PZ,N$YIW M2-15@4^&05U_P[$5#UF*^IMZMZTRU/_XLAO/O"@*GC(I(EB(@D DDQQB*0DL M2)8D!>9Y0:W*FT>I66UF^R+G3]-G3X^#E3'"6)H(2/0L ,13"K&(E0+,J" D MYD7*C 9E^0?+7O,%!\M,Z7F#P$[O-62A?FQ7^=S@L:?ML3V/B8B^NNR,TIJW M68Z)V"<];XQ>FKDGF;*HVI8Z[__SN=J^?-Q/;+K0%DM2HG1#*F"2105$*!/* M/$H0E"*/TP)E64&M^M'.QGE@G?/[JK*UJN;[:(;ZZF?\%):Z;WI[,YV:T$H# M6G' 0)Z?O.F9ZX=X[3YHUGS_]VB-YOHYO'5+2E^1(<+_%[D-]X\2'7LK)M MM6DTDDXM^/JT7M7KS:=UV_V[F[/!8Y0B'#5>N;[QSV-(!6(PSM."YD(4**=V MM6)7:096%GL.0).DTO$ >B8<)P29@&EFV'F&R$[M3$?'H83*6%YO=5'7*OD_KZ(,<648 :+G"G=E<2O1V3S,%K/"> -P?Q8/&9?<%S@IVZ?6>?*#Q'M=LN1=/[;2%R4Q;5]Q.F" M<[:-N"C.4;N(R\\Y&-%]Z:Z^I7EJ+F\>-J*QW?48B(64N>","%C$(H)(<@)Q MF120IT6).)()C5-C(WJ<5N"]MJM1%CUU0';D+;)T3% S,*7]86&W*7 (N=$6TFZ*@1?66)^8QH,UD.C&C#5^P4F1ZE_:G: M=@VNE DA=*I3=TU1YHSC@G(82\D@2E-E2F>,P"PFDA1"2)88]0<<(Q)8=>W) M:K-3.(R>OXC.N*;R);.=BK(6UVK^_#5Y)HR?O[CT;-/GKPDW'#Y_]5G'"Q9= M;_QYO=H-16I;[.JV OA36C+BX6FEGQ(>-K[;5]N5#M12;KC_=2U/7F"$>0QZ3'"(2*;> 1@DL4SW. M+4,D3XT&DEU8/_"V;2F"AF3?Y]!P$/DE0,;WK0;U[8I_%9L?%1/UU_62OQ-/ M&\&J-LURQ6\?=8NR_VI=*!X7,A$TADG!=/X29Q#'90'SC&4RXXAGPJJP(#@Z=W8;7[-R $^QN3;!SZ"XV079OO<9<>)BY M\]@$F$[[D$U9S#Z2KBR)>['^+-:W/QZ:*6N6LRTNO1]8>^@*BOOW=^"S^O_; M'\H2>A"@G>8W:=;%132NQ]Q] &&G"_Q@8!6,OR:D4T#^XJ*S!>6OB34,S%]] MUK&ZKD^E^=94?R8LPIPG&&*9Q1"E2!O>!85Y+'.422ES9G4Q?+A\X,VYSS?[ MHR%GF>UW!(79.>TNH-VF,Y?-OB3KK B^ZJ8.%Y^WN.FL8"<52.>?LG=DNUX> M'ZJ:D>5_"+)YO^)ZV,$"L01'D1ZOG0L*$4XR2#$O8%FP&$NA_K\P:HP^1B3P MUNK[^[5T@28,%.5F3(BY9WL1H>ONK0^Y+4U>%Y&M7-UK,CGYNQ<7G3<2=P$=X=[WH:UP(USU[$']OP-VLS5 MX _-(FAXM&ZO-^7KF)W+LV%NIU0"P^W0V,\#3-[Z_TWA9>8V@1Y@.^TFZ&-1 M-X7Y^VJSFYK[C?SU1JR$K)J.80E&"8MA6NK\'$*5U2+5/W+):!I%$:&E5>N< M"W0"*[E?-^NZ!L\#VF!+_@*TI6ZGO"XA9::6/,AOIW"&!(&B"'J2_G3(%9D\ M:8=+5&;=]U=$/=[1UQZW#YOI$ !Y-'+!!X\'WEY-,$B1,8]W]6)<#V\Y2&"W M0:XR;Q6H.F+7*2[5KS%;&.J(Z6'4Z?BO'(-,[+O@STMQ)^\W:_[,MA]7S>! M'2=L@RTBRR,97\58IS9&Z =N8\^+16 M9MTWL7ETC$M=1<\P5.43$\OH54=:%X)VQ,& >H"8EJFLOL)<5^G-&_DR%?\D M&&;\HN,@FDV7H/EUNV;_:CK[U+?/V^_KC3XC%V44QUP6"21(:0"41@2612FA MSOK(8RJPR(W2P^*@UM1O0-W0!V3' /BE6G5_>CFQR05',X7@#QW+ M(W<'S-<6F)8TV-/V. #'2$9?(W'&B!>B_AVEF[U'DL2>UC,MO!D8>UV[E&!XDT_ M]R=4I>+;('WFS]-XQ;K%M^.]X\IE6Z!OA@=W9TW8UOD]QLC6[)TGO;G#W9#LK&P09 M(V4@I7=3^Y32*QG9%T6^;%Y??L6?83UHA+G(6($RGA"8QBB&B!<$DK*((68D MPV52%@PG4RWK ;U7,JW7@PZV7FWK(93NQK4C0'ZLZP'QL.;U&2D#VM=#:J]N M8)\1W<3"/O>:0ZWUAVI5;<6GZH?@'U=JO0?=!:F)0>DJ#6T_#),W;Z7:>/K* M_8/Z)2U(&=,L*0046:+T Y,<8J438%DJ4R"3@B3<*.H\E9' BN/;=[$11!.T M*$.>@NNXLI@3+3LMTC(%&Z[ GJTVI'D#>LX.,L!O0(-LFRJCV9L)8XLZ\)FP M=BL2#XNY71VY!Z!&B\RGK#]?!;H'% [*TWVLY[5L]G;%NPJ^O5L3E8(5449@ M5I!"E] *2,L\AR7%24SC)$Z%446[/>G RE\GKN\K2S^M:\NA%A88FMF(89"Q M4_27:VYU4E+'1Z#9P_;RARW'/4?X9RC-'0'$L$QW; 77%,O6C-6%0_5;\E1M MR5+'B)5]^T0JK@@VK+17H&?'H\8AM=FHW5CU->K9H1L=W-LFU8Y\8N8*:TY<;9398>PWH !@ M8^]F@'9W/7\P8CUR,W/"I1_P3G,N/:WKX*XW*W?1_,'(]S:E MHXB4>B1)#GF:2HAXEL&RR#C,">>$4Y%S8NZ/CU&:)1&FKZ48$+?+A;D.F(&C M[0L&%P-K!@0LW&!?2+CYN>Z(V/FP)E*..JFC"\SGA9K(<>!F&KW@H+&^/C\] M+9M:.;+\?24>GY;K9B!7G]CZ5>AR8"50_P=?=#-$I5X_K[<5$VOY1=35PZK] M@9:R3#"*.,P2KJR^1%?%T3*#><8+D99Z,JO1= OOG 7/%6@I@U5#NAUBO2-N MH0R\?@T#]?E:&%O>? ZX!$,V0<_6#=AQ.OBSW6?YO/LL7U[_LUCH]-?Z/&YG MP,R?R>[@" 'EZ$'CE>!\!U,(G X.LB $)@10;QG;/ L^.%/[=*T:1@E#B"6# !HYQEC.$DYC)9J,]-U_-C."3K'47USQ=MF;E$ MHR_#:1&!]@*1BU/4$1ZZ %2"LUD]!E9ODQL_FCR5<'/1I"OO^6F13^3[?-& MW,ENQ--Z52\*C,N$)@CR*,80Q6D&2Q$E,"KRHBAD1$AN56)Z2B*PMGPG:K:I MVK':RAQ1\#6-D,C*4C^>P<9L$T^3V&[CMK2TG'MJ@6Z'+HOE::^>(3#K_KPL MX/&>''G2P8U_W]A10NQZH^_,J&[ ]KW85&NN6JK@J2%KX=^9HF?@40? Q&XW]PSLAQ$,O:Z. M"7 ?"B(+[S8 5&Z.JQ?([-Q12]E'/4W3M>9S(BVE._ /;=]UF0))U$DN:O'K M6JV\TFM^6I-5/Q-)B%3D+"6PC(1V]G17+YY3B'B<9!DK,X;-KVE&2056C#UM ML"<.&NHV8P]'H3+0A]X L-."%V5WFOTX"H+-Z$=?8#A.?K3^05A.>S01;WS8 MX^@*,\YZ-)'D<-2CT1NNA2!-W?8_R$;IP>U+X\B1Y8(2FM-0 M9C*!I8R+-.$R4IIJT=I"7[=DLS7SM7<%PAR7&,L(PR31 W\CRB'.2 XSP=,R26B)J>@@?+_B\P+8 M$_0 GUAQS\"9>;'3H;"\*-(5%V3#NSS'K9);\%UWBIX-T/'ALV1F3$YOE3)G MBHP%(06'"& M(%? +[YCYFY[J3+KX*QOT[;;;\58 MF^F!4+#9:8<]8N^&B.V\OXZ78>C:GXIP@<"3XK B/:LZ<0'E6,DXK>&:VO=; M53.Q5+\JL7ZNC\H]>G^ (I**(BTARV2L; K"89DR"?,R2I*4Y(@D1JVAK:C. MN72$.[F8$*(/CE\WHK #8LRK6#T\#'# &2R]W7 0LGU5Y.KJ 4VGYF#%E)?SR(T66SFC$(+^4ZS"VU>GCB9XDY^J%9DQ2JRO%_7 M55,91^NF3F(1840SE!/MT1+=G[:$)B[ 'ST?KN,MQO T,]%\HV3MN$T%R'U&AH'$OB=GC)%\G7D:!B!Z)WVRRRS)YT_LG!&;6\I<$/-7I%Y]TT^"M]7@GWU7UT[HFRU\W MZ^0$-,S=@QPX8 M\K-/:KOI',H ^:C3X?&D:28P,JM&F@[8L>;RL*+7.2O?OI/M/];/2_[Q\4D9 MPN^E%'K:BU"/?-'ST0,L4 MV''5//C%RZ@[/[B$'2-SC8F?80?16N5Y(B%)[UD2WU6Y>0(S;&& MO#3+MX=TE*>LR+(,9A%G$"%,89EE E*2\"RB7'([)V^$UHR63T,;T)=NGTRT M=$Y1LS5M)F'A;LM8PC#!=KDHH'=CY932*UDG%T6^;(Y8OS!H3(ZS=4&C M+[@9'F\UO[JYK/[07ZI:Z;YO:J7;OZIZD8@TQY1',,YT!X:,4(@EC2%*4TPH ME1$75H;'"*W .NJ ,M"D@:8,_M"T+8V.,<3,C Y/.-AI*T<(K T. ^$\&1QC ME&8U. Q$/C8X3%YQ]"3TY!A*:MV[=E^]<:NK9QZ:1*LW+_M'NFKHVS_)AG\@ MU>;?R?)9.SG/CTW;DKJ?/J"'%,<+(B-!HYS!)$X)1(+DL&120![GE'",2)Q8 M360,QVI@=;*;N+'5PYOU0*D703:V\Z0"?BE#Y^>GP-_2=](,P3>:(S#D&@S8 MUN[4\+F^^4+#^PW0W(.&?3#@?S!'18O@T0,+CK(O!RX2#@NEMF[Q0K1[V_8+>"+G>B/:Y;^0OH;4Z#NR3<;NY*+1A#SQMUC^J6JLDG895M7^WU>Q:EU &^W9FY\-/\D7L#HCN M8_RBV?X;T-H![#D?-B?K/E?W?,/]#3CD%O3L>BWA#(VIOXK/8)S.72 :&O(S M]:3!23JV 6E/G_K;^I8U+7&/+S<6,D$TQ4B9]2**($I0 4G.2EAD"2E+%(NT MX(N5>&C*8HWTR%6:1MH M]I@2-E&*;15V\I4/RE M>QE<15 ,^7J!Q2W2; = M:9T&WQ$/43%I+:FO'A=7Z\.M /[\@.J@ S( MZLLYW@^.8HI3_0*&Q>A%B^62\UV]N,EZ1"R!,LZT3F8"EJ*0RA4O21*G"!?,*D%VA%9@'=Q3!JR? M<[C9D;8TS\8 ,S/,/,%@ITEW".RH@CU9GZGV5V7SED]_F=+,2?-713[-C+_^ MBH/)]8:L_O6FK;.M%W&<9ACC$O)2MX45B$.<4@EQEF>I,J]$FAO=K9ZL''BK M:E)]M;!-BL>!\ 8FCJM(=MNND>;--6GLCM-SG(\>E@ >Q_;CZ(>JMMHP^KCYI7[RO'<62Q 7+E4.!.=:N10YQ@214AUB$*$ES)*PF MY(S0"KPW&E*#H^NF'_)B.>]A!"PB45DF.(814=X7*C"#1(_)BV(L<$&8B)#H M@S/?YL/L,#;SS06ZNOX_NYDX3]I^:EVPY1&F_J TLP8\_9KLU)(B"O94=="J MH7O3QZQOE\OUGTU?>7W%\%89H]6VF5L?H"K9 !?8S=&*,T[?^.ZR">#. Q> M<5.=?Q?\0=<>[P>6=4434ID*/.,Y%&6L5$&IE +.E051Q!&*:"+*$EM5JEPB M%%AI=F3!@*YCU[]NKSSM6 MG?7W^A]73\_;^I/X(99)E\T;H312!W<.>8+4OHTR!,LBBB#F(LJ9*$E,K+(J M1V@%MW<4*9!8UH:-0&.V43T);+=7]TE#ND>(IGL#.OFOYWO;EW==%]%7*=<( MI7G+MJZ+?%*B9?"*@Y_^9?U"EMN77Y^)[C@N1/UV_?A8-2=[?IM>T6[B,NT+"3)H$!I A%".2SCM-3FN2A10D1L-J[.G87 N[WC"3SL MF+K1#<)[MFX V3&F_J)A35NNW16V1:C #7^#F$)P5.U42@_HKP- WPX!O1T M^G8'Z-N9 +6X30D.K-NE2B" [<)!D[ 9C1NYK3Q?@&F2Y >1J&DK39CK_(W\ MI=,Q5W4_2'J1IS@M"4_T,(@2(BQRB*.<*.N-8LYD7N19YA" .4]MGMA+VT![ MT%C)8=[P*5!FMMP$N2?T6-<]C#J*X)>.YN7D?;?!PA>%\CE0^)3(_(.$+PIZ M=H#PY:>G%LX?#8KI)S:\-%6\>A!M,X=V(7@1XYSGD-%2V6DBDFH#\Q)BA&5* M"IX6PFJLL"T#@:VT86UYJQ!K?:99CR_R [:9$@@)H9UZ&*)W MF.FZY*'P29 M;NP*AOIAW9P1&L)%WX]1?>>J=$337!]^9+6.GJ 3C"]TJC;__2[!GW4WV3LJ* M*0H?5GMGP4#C&"T4VI#1],&. =!S<*,VP'J[6IOVG#8#95QK>,?#3D=UC_^-]JG4X#,+[?^&:KS[+-K03M-[7=2PXW8YT)<[OB MWS:$BT>R^5??HRI)$<$XCV"9)P(B)C@LLS2&A!-[LUM M11GL25M"'&#Q;YYN@JY+ M-GK=,_+Z?'-Q.#7%1+=YUW_9#53.RO&_F7GU0?U8O,I2)(A4, M1J4N72[S N*4<(B+HD0%IW$J"A,E-$HEL KJZ8*6,&@I@X:TV689VJG$IRHG=HT&8PPYZR(XX19 MA3DM&0B\B=6/I+2,9]HB:!C5#(B+96RSX>0&['CI<]IW[-SH?@14@'M2\1N@ M.=)A3Y\Q3D:Z_\$M9;. MI6_B#)^9_&R2*F.)91',.4"@11A!FDA C(<(8R+A@GW&Z@RUDR MH1/-]#T1;#J:ZC* O381;7J?#U4_23//HTAW"G+_TVN[2)+Z>Y]C&EH!SJ*O M?@;U8J<-IMQT7!B.V3LRE6BZ,W:5Y))'>EQ+ ;$L8H@PBB A*5,[FZ9QS(H$ M4:-*7&O*@;?XI<&[-AG3M@!.PY"068Q;U**.#<;EHN M_K3 <@#@:L>1KSL8%Q1&;V6L%ISOGL9%SH.;&Z<%W*RD)A5=3]G;]<(=_L)S M0B+"=#XL3R%*< G+E$0PQRC%99RC/+9*UQ\C%CPQC5<;/:5<_]Z?R$O;(D;] MQJ%3FYA1V,P,)U]@V"G/CNJ9SMN^>Y>8R.?):!HE-:OI9"+TL0%E](Z#&76K M<(KOO_[^JTZN[W(!!,^%2&D!:20292,1#$L6(1A%)6=$%DE)(F-KZ0R!\%<[ M,5 404/2XF _AX6!P3-10KNM>2B<2Q+(.2DMK)2)TKH9(X:?U,[2&)%DU* X M]]Y\=L,(UP?FP=AS]AD=;ZOMR^U&D+=K+A9Y$@E$4@&S)*,0I4D&L>XWG9$T MRAG.*8V,6DT?+QQ8+VA20-,"FIAYIL:![./Z8(I$=GK 4!BK#(QSG#LE71PL M-%N>Q3GVAZD59_]^:G)3>TFJTW:*C%*4$0)QK&.&(J>0YI':%25/$2\PE69E MJR,T9DYLZB[X)Z0U[=&YOF\\R&RWA1S$G9#0="*0AW2F_9JOE,QT(M3E5*;3 M1QTC]FNY_9-LQ.V*]__Z3K<56C=C5W7+[UW", +[GI)F%8-F4VQQ5PX!_"*PL[P!Z M:'2N\.X_!EPTG?P-\JCM[P!LA?=U+6!,=]Z; ELX3BX/K!=PND_HMI">7+3B M?Q=+_F&]^4J68B&EB%"9I##-B;)WN?*,"2TI+'%19").!$=&;?ROT D=W.)+ M 9[WU,%2;XSOBG[3H[8FIJU[K\%E=$?@ P3;&X&]Z)KH#=!DH:(+OWJ3W2K< M[P,#U^"^&Q:VH?QK$EX)W%]\?HLSB MRM.!@<#:[)L> @JV+A5@+F@:Z+3 &-DINSTSL.'F='K<#= ]S'_9\01ZI@Q3 M )VAM%"1@2%UTYU!H+53K!-P&=6X+NO.IXHG2'V@HZ>L,R'+[(MX4K^H[T0G MKJT?-N2QZWT>"5$(0F.8,\$@DE$)J<19D].L#,P<%U%BG6MV@5A@I=R0!GO: MH"/NV"Y^%#9#/]03&):NIS,.;OEF5P3TF75VB=3\N6=7A#Z;@7;M'0?;[*O0 M6:F*[7OU$[@GFVW%JJ2G5SI;Z1E7JVGN9PIAC*HHT MIDEJ?J-J0C'T1N]9 $_JS\'3D E =EQ86!)&,!I88;[!L=SX.UPT>7! ']P& MP\7"I/*-CYL-9?C[\9539B/TJ(%DM-!\%I&-7 GVL:YVXI=\:%% T83^UUG+9=@?K'F^4E.U%P?3/:FBYS?JQ M'.R[L?*"EB\]%[AE;*9^M%.1\MZAUIFA5^I9.Q7 RUUL)Z]LW\^MJ:9Z_]>& MM364ALW;#M\*K/ ,RQ"OB3:N4:9)9:<9&CK>JRLO2^#40>UHJ=G:I9T78=@; M[<(3CB.^+L=XWKS\1OZYWKQ=DKJ^_:NJ%Y*@LD YAWE.(M]& U5ZFKBAAW0\ /^T!Q9AFEL<#8[^P.A9[>5O0)G/U_, M'@)?\\8L*,\[?\P>DI-Y9 Y+N"F?/G)\NSJA]*ZJV7)=/V_$+:V;\>6+!)6, M%AF&$<$11!'*(2TH@6F>9X3%1.:Q5:J2%?7 "JCGI7%*3O?1GA^UASJ.+!60 M'=9F*B@8@G9*R"MXUDK("01/:LB.]JR*R F68U7DMHAC\[=]3>!N(N.>R((K M')TMIMW6-! Z0ECTKD::.>IS'K_AP5\WA;CC_L&G?8MVY=B#2G+$DB M2+!((8J3#):"8G6VRB+F:191876V#AA6^D7?A]W)W^O6 M8/ZZ51M87[S<2>7@DQ6K%-5UW0R=??_75JQJ;5M_JNKM(H^+M$QH#LLR*2%* M!8(T204D7*JC,B<)CZ3-=O3$5^"=?-+1MV$4KB54K+:^Y W8<:OO$W?\@IYA M\,>>9?!^]?S8++FVS>GR]2'-=,HK?!X[=?0Z7\9^7JY?''T-V/7$U;P3>?U" M>3+"U_/R;NKZS7-=K80>KO=(%2&]_I==LZ*/7'%0R8KL AZW[#^?JXW@MRL^ M\)/4WZG?\L&?]#$\+%"!1<1AR26%*!$9)"6BL,@)+CGA:8JMXJ6!^0VLWH<= MS4C+Q/^QT\JAOY>9MOZ)OH*=%N\9!P/.E2K?]T\;,M_';GOVF]#N\!-V$MP< M_&&(\.Y,>'O2]J&YG?44F GZX]-A+K*.CG,?&&NI_Z9.L&=%_4[S^+S1XUC? MD+JJ]YED-$UIKOY/SX='ZAC()<24ZN;_+$8)3Q!*C$::N3(P8SK@/II[TRN0 MGCV@3, =@Z#AT-)9M\7=T*$/B*:ETV\%7M!D/5=0? 4,;,G/&U1P!.>M>7_'X3[/MJO5P_O#2&]ZX1240S*8I2::B,081D 6F6"1B)6,8I1A$B M1OVR#.D%UDH[ZF"[(V^G;Z[A9:9>/*)@ITWV .PIMWY[B&8BAF)ZT@_7J,VJ M#@Q%/][]IJ]-ODO7_4A.9C$ODEAD>2$9)(AG$/%<>:D(8<@DQI1$G!(L%EM] M2VU]FWZ6H-5VWY%UOT]O_)5ZP,;__!]E$A?_%XB&'>?K]O-H6E^X3\;(^;]. A3KME')?-_T7Z>W&M=M8\*/W+9/OZ>XV7$]KO8=,7B^X;."2Y2E& . MLRA.=19-!G$:'\2NK46 M#N"C OFZ*#A+8]ZP_YB8)T'\T8?M*X'NA=C\NED_/S6_WZ84J=6'7[:KV\>M M:6G0E64"ZR9-'33D0;L-!PPH%W[[O%F!V\?ULVG+;Q-@QO>D9TSL=J8'.*SJ MCPP%=2I(NK;V;!5*AD(.2Y9,7W$-+4BA=C__HGR:U;,X&)_V32W91*H6.,DP M%ZB$<586$#&D$QI*##.&TZ)DHB#2:ER9$=7@88:6!] Q<5A@2U^ 9J0+U5GF M()B!:AJ%\ R5;2S"!TH.00D+J;V%)DQHSAR@L(#A-$QA\_+,LY>'$=3GQ[9 M^4M5_^O#1HB/*[6=1;W]0K9BP3.<2!3'D,DL@4C_6UGR"*91DI<48V7;VS59 M#LUQ8+6E24*I:(*J(PHVBNI,8W6-/YN9&G7L\ Z52_K9,5 W8"4L1^6-HV48&O.% M@66(['H*[TR)N'.FU_Y$2;-.J;"3_7*Z_;BJMYNF^5WK,.:XR%*41C!#3%\ M, :I4/YX&=-$IHS$(C4:$S!"8\:$HT_KU0-4:SP"S0?8,U*[.MVGB)FZV)-P ML+0;CR'XY@2!@T=]44AO_O,IA9F]Y8LBGOK&EQ^U#W^WEW[:0&H-JIV1]*Z2 MR@<7BOL/JWUVFV$TW&[5P#NW90;LN!EX+&#/C_)IUNOM:FWJCSJ =SUB'@XW MNYUN"YG:\SX3 MVA< JQ6Y*:+>+N!L$P .^X@D.KY\_KU5M2?]_9%1^WXG%? MXY 5+":HP9T+B%))((WB!/)(UK"K\HV&F&CBS86_8-8>O^1 8@6'1N]@:&6\OF"Z!XZM!L)-QH M:^;Q%>;KR6PDR4$S9K,WW/R4*[,NADW//E4KT9!>H"RF.2JQ0CDF$*$RAZ4@ M!>11G.:89#G)8AM'QH6)P#KN^A 7\(?FI?V16[HZ3J";^4*AH;13E+Y0M/:6 MIL#@R9UR8F%6?VL*2,<.V:2U'!.MF[#B81"G3^Q\Z:+?]1>AYW>H175%':;!I\.W FN9X95Y M3](\@'0DX/4 D;ML=CK@VX8TPS&LQ+.*[YR7Q"E^<[34;/&9\R(,XR\7GK#; M"7I>_/O55NVS6\XWND)=_>O=YMOZS]4B29$4%,4P+TD&$ M4V^W>TS]RWZ/C:TYRV8S$*K?=2:/.HX+^?;X\-OJJ7J[JOF&?UB2!ZNQ(2=O MASZ8FFD;WZI'K<9_^WS_$;Q=K^I*R2NXY3"14\&O'U339;;;56/B@C\T;4_W M$N."N<\<.5URWMDC%T4ZF4%R^4DW9_;+:1O:6,@TY32#7" .49'DL*0\AC@M MD@AC6J32*@7HE$3@W??%O3'O&3C,?,EI0MIMMR^!^_%>EL63)W>&P*P>VF4! MCSVOD2UILFNKZ2Z\UC8ZN^>>G^V9"U]1S]7"[NZ_?W33'>1Z3 M4@^7+TJEV7A60D+4/V214A[A.,/2:,R\(;VYH'LV3YKDH\B*!RL83$$680%+P% K. M"$ZB(F'8*) XA8D9+;L]A^!.@K:3Q[!=D>82-.G-#8L6^L'U QAHTAE@M5.O MEBC:V'3^@+70QC, [*:BOWVO:B"6[3W,(WG1EZ_/NBR3U(" 6FD1!2O5O.@? M]U;CNUT#L6+DJ7[6[B-0T@#=PG8C -\/QE,F%U@WGVW8Q*Q:L>5S<_W#R98T MK;NV6N#ZWSR=!A-Q'CTB7->>[]R8*/W!83)U+8<3YO?5$ZGXO?JE?B>U4'2/ M$UX6<5EDK"PYQ#'.()(I@B1!!8QE69:28,%2HT$B9N0"GQHM??#4,Z W6+5/ MY;(I?S2$S^ D\ J*G<[O\-C1UIK_)+7-*QX6"MPK+FZJ>AH^=GK46-Q1C7E] ME?ETH[%$!UK0_"T'?7>_$7IU/9!0=XQ:Y#PC499Q*,HD5I9R44!*HA+&3)99 M+',F$J/1@><6#ZS+.FI ?8G&T0!DN5S_J?/C;';L,2 &^FJ"F';:J9>PIS1! M+ NU,T$\-R5C+*:=/KD@QZCV.'YG/EUQ@=L#S7#IF8E#& 8S@@:5K^V@O 4J M$AKEL6YV6I80H91 BJB$I!0,:_08;7$:ENO-8[W6W/*JG_Z.7 &FE #;PS;E1X6=1QQ>%% M2CN%<"[+WUAHAVS_"X)-2/H_7G'FW/\+ IV6 %QZ<-H(T68&73NB].VZWM[) M?BA=FP&M/N^JUE?_[5_7"\YB1O)(P)2P'**82(B+-(4Y*>.$$I&3S&K"LR,? MH;?MGAQ@FI[;O$];<,W,@AD@L],!N_F< XYNP!##MZ,8.D_6=$3 \\1,6RY> M91*F(U27)ERZ+N>FK&X9>WYL+B%YJ*RM#[9^%)_6=?UAO1'5 MP^IM,]"!M4PLVZXU_)_/]58?3I^%8O8;^6N1T5+PC!T M_()?-,=_TQVR&J9!SS48L WV?-\ Q;D.)2G>_:G:@,!Z4L,A.)Q510>$^%A] MAR3EIMH5!X_K53-#K&F^7-\^;[^O-WI@\J*(922RG,!$U_&@)"*0TC2!)1.) M2"F526DUV'.$5F!5VU)NQ_K=@+HA#LB..OBE6G5_:ME=8@P^,\WI"10[#=CA M\;7%HZ4+]H3]J2\#Z3RIH3%*LZH3 Y&/U8+)*XY=9LB*OWFNECI&H(-#'Y6^ M6?]H;W[Z0CU$:)0*Y5&65'N4F*@-+@6D0J2R9*G(,[MN,E=)!M[L.^)-6)1V M_P6J 1^6+62N@VBVU_U"8[?E->T;<(C-D'Z "D!S<7WU=KE.<-X>+L8 G/1J M,7_3=<[O2MS)M\ICK+8?"&MZP'P2NO'+N[7N +.@A!-)4@$)5KH!%1&&F!8" MRBAG2)W]#-/<2BU<(1A8*6CR3=9XPP#H.;@!+0_@CY8+RQNHJR@:Z@6/V%AJ MA:FP.$S\-9/5V\3?*^1FGOAK)OSIQ%_#]X*WT;S]JZH724E25-(2XC*+(&(1 M@UCF"#(9<<)(D:38JK;?DGY@53%H^[B\U/91LQ&N;68#LIGJ" B=G28Q:98Y MCEK(-IE#V>?OD-E0_UF;8PZAF= 7\V 9QS#S+KA1?UM_$5K4:BD^B^T^,O)M MK0OO[I4M5''!W[S\7FNN=CWMSE1RBH31A'"F2Q=TKB]+8%D*#'.2*U>'\H@* MJ[$E(9@,'6C>LZQKBC8]TWJ.D:X4TL%.]>?ZOYHBTJ>.M#/:AB6 M?N6/91F7/OQ..WZ;P/)!4%K_==.N_'[PJ7[1K*OO^;=!VT^[4FG[Z'1 ?'V% MIT.P.&]\.B#()P'JD+2F]Y8:W&ON54%1,CT@.H5<*7.(>*XT?,%+R$E&!>=Q M@NRR*Z\1#*RM#_LR#1FP[G9@#*&9-O4)C)UFG(;)I-958X(&:&1UEMRKM;4: M$WZLR=7H>TX%7&LF!*\_*&Z;,/E=.P7T_5]BPRJE@'Y?*7MTNQ3\=GLO-M6: MOU_Q19)PGI8T@U&F%4.*$"R5M0<+2I)(YE22PJC;E3L+@57%CJ3.'-A=<&G[ MK6$5Z(^K++CFHEIT?-J5B;G /JY,Y@'33KWT[ #-3WLK!CJ.P(ZE&["'^W8+ M6K: XBLXH%9E;(&!=2UV"P*P;6GP M?S(<)G/QO8">V[!U[4'5Q2>?\V&N2C:I=^WABK.WKCTKT+G.M>\*^-Y?T"TYC6:2%LBQR/4=*(@(Q MX3G$+$\1Q0EGU,CO\,!+8#MCQT5O8'1\@(UF!'#!ED3_K>Y%(Q1/;2Z-OE<: MVB46Y^3$+V-@@8I <]CF\\R'MH5Y M,A_J;G9*>/3M3!8_>(W:+A-)S&?$^,'BP)KQM*3=T5-OMHMOU58W4/VXXIJ# M9[+\1[7]WCC0VICZ7CU]6[>)_%T: 2D$30M?',A?#!<_Q R(P2G8'@A- QEIF@JACP2^U["#PI?YK M;W&Z4)Q%R4R HEAX.*SN%HOD T:49=/AU? "=LR YR==1]CR MXR^X[H:#IU"[)?%9 ^]NP!R'X1U7<7"?/ZZJ;466;1Y:GP@M*151&NML\@(I MIU@GDJ1_V&D+YI!_Q^ M_2[$MLDEJV3%FJ][U E2@P+/,T@S%%68ZER)+47+E,X22P M$AJV.6_9/)[D"SI.0<,J..358B]/^AP&RFTND.V4H .FTQJ?3X+90K7.!;>; M"CZ%L(D8NW\-#PZP-]A&M?TD O.="CYP.#@]O"SHYAF_KY7["$*9HZJ MLVQV2K@3Z]T5L:S]R[/L>W(?#]>>U3L\*]:Q\W?^(11#N"@/04P?IY6V_) MJJD.7M-E]6!M/9VB9&(339+=TM+9B;TC-DT^&V-DDIQN)H:-O)8VPD5IQD_^ MT]=F/,\O\GQX2E]^S+60AS>MJ:JV9+G LI \+1C,,"T@(@6' MM"@(1()0/6\DS]/8KA;G+)W0<>8=5: ;D\-J!5A+V+8NYCQ*9J>T!]GM5,E M;$T1Z"CR%;$=ZDE&A?)6$G*>RLQ5':.BGA9FC#_NVM*:;MLN0]L%DF5.HXA# MM1VY5K*.C,_6S2>\>VO&O%]YYO;*)R*=-DP^?<2U7EX70WTC?[5]Y0?SM3F3 M"58>9HYEJHZU$D.:I@AF,A*ISA"DN96;>8E0\$N0IM90T34M%[B*C-FF\B&O M[7U(+^H\PQZN2>BM./T"F9FKT,>%/2TWO_*\X\R7RQ7LMX_ZM/BOQLEX_]>3 M,H/%?PBR^:8^@U@@3N,LD0)FI5#F*D]C2)A@L,@2D@NA#D4[<]61C\";7?UV M"LLA,(YXFNF &5"R4Q$?QKI:W #-"--I)T/N;H!F##2<>9P4,PT:7[-C'+F8 M=YK,-*A.YLM,7,Z^\N6C\LC5DUU__]O-YI-%^I U-<&8B08@ZF.LB M.A7#C"P[6T7,==&&93$&3[L=FTWV\Q?1%WO<;]8/&_+X1>BT146I32"ZD\<= M*[^MWXC]6WP1QYP7)"-0)CHCJ(@BB%F2PJCD11$Q$F?2J K7+UNA;_";$H'- MCIZNR=5LWJ@_ZQ@%JX93?P'XM*-SP)%,^T7!AL[#7< RPWXII[WWG3/7L[ 75+.$/XI^J5#_#5[$T^C0_L&$(#)D^&)A'7\#PN8YS MT+!^TSYC.0'?WB])S:3U2FT/;+L;*'MZZ(-0]L&3[NW%/M- M;+^ON?5NO/!Z:+]BV&"L)6V^\2Y)?'W7>1#6;LN=D3/ !KLBUJ0N:L=KSMY' M[8)0YSJI77ITMC2+/]>+2(A"HIA FD4$HC)!>JH(A6642(EYE,=VX\>C,,S?I,AL_TP"EJV!93E*ZOIY#$><7\6.]_"$V78L6$N$X MC26!>5I2B&*90BQE EE6D*1$69)Q\P+.P[6#7_>VQ"Q*%X]D']UX.*RPN/N!DT[;U M]Y/ !&5", 996DB(A*"0)F4,<1&EL=KR2)BUR#FW>.!=W@\$^+M86O;K.T# MS%1PEB&@3^'*6TC/9=%/":?';AOC/"N,7X MA@O-%]@[P_Y!-._0L M(>I/2(D*JP2?BY0"[ZDWZ\UF_:>>J@Z>FPG7RVX"-FNHVYT[E^$R.X2\@&"W MY>X/9D,U1/?SO_V=3%[N8W6MUPF:P7>J8?'0<=+VWKB1_UO@YFHYH>@$4+7#T??X-CM8&-< ER< MV4CN=,(:$9CMY+41=W@B6[UGO]'OA=C\NED_/WVLZV>UL3ZLK/?WR!*!M[6F M#!K2H*-] SZLU]O5>FNQD\<@N+Z!/4EO>?*."!Y@JQK(Z+1#Q]:=;6,:"#?< MCR:/.W:Z8NSY\;E)TG\GGC:"58U>5O^^%$U:YXH/+[+4L?\D-MN7>_7+V*J_ M>_^?S]53VU>-Q9G$J80YBG.(TK2 I(@03!->2,D(0:AYRQZYE7RU?W\3,B)\58CP#KD,4;L&,2D-7Q#7O/ MJ/HWS>I-\\B.6X\]OSSCYZM)F"^VYNTJYAG,DS9DOM=_G4*F;ERIKK7^A]!S MO02__2$VY$'T@TSO-Q43BS0I<50F&41Q7$"4)P6D.D.)D%+F.4NIC&8M:S+D M>Z9 O=ASCGJ8RR_ 0_29V4*=?_K:JF+#^%[QHJ6_*N%55O M%=T-6>KDC[_^/_&R8#K) E,.&4\I1(*5D# I8")D*5E1YB2-[$JJCB@$UOQ= MN5%'%#14@2)K6U5UC,NX"O8BK9VRM!;4H;+J@C 32JN.5YRYMNJ"0*?%59<> M=#,&/U6$5LMJ6XGZ ZDV32WD?@;[+H4PC@J44Y+#K$QSW7PZ@03E'/*$))C$ MB5"+V]AR9F0#;\@!$W;&E2%H9K:1?RCL=NN _@W0'+0UV6#/0Y"$2CNQ/9D3 MAD1GM0;L@#@^S"W?MH^7?UZOOCPO11S1+-9%9)O'U99_6)('TVCYQ04"[VY% M%VK"0%.&\8&EKNOBJI5VQ,VCYI>!N!XS]X*!W;8V$Q_\H;GP%#6_*J53S/SR MJK-%S*\*-HR77W_8>X78KYMU72\027C*2PK3*,T@2I& --8#FV*:820IC9%5 M]N(U@H'W;T,#O"6;S4M3-6R1LV4,F=D)[1,(NTT\6MZECNN&_"Q57 >"AB_8 M:LG]++59!\);E&$=ON=:SUYD73J;\+KHL<])7XG?PB:K'Y(>I%45!" M2!'#3'>I4SM?0AKQ$I8LQ4E1LHAAR\[Y5VD&WOP]8?"@*=O625U'S&SC>\;! M;N_OB"NKO$>CH7_3I*FL)>AY\%GE9"RPMX*FZQ1GKETRAN"T3,G\53=E\.:Y MUOEN]=OU(]4&7*5L#<'6#RO=*?,C5]0K69%]&2C[S^=J(_CMB@_\!/5WSX^" M=],\VB?5*J+ZH=_4C2]E%G-40EYR93WD-(4D;Z9-*>Y)V2FF6+V>FU7ZV[V&G%GONP8!]W82X%P ,)>C+1'L9FFOX@12@ M$V,W)FAG67TQ^-#6ZG5.Y#WIYUE8GE7!S_D1CD^(66D[COY]?%JN7X3HNJ<. MZ/8COF22EV51YK 40D DD@B6>5Q GB!"\HC$)N6^>E6Y@@]LP MRT'!5S$ST\Q>D;"\L^E(PTW7!OD@+.Q]B)JQI+YF#U^E-^\\8E/Q3V84&[\X M.27S5U*M/BG_]2VIOW]8KO_\N^ /XN.J*[7_K 1=K[9*Z&7;2U.H']>VJR*E M-!:8QQF,XDQIB(P*6%(]"BJA*"D3&E%BI2&\B^SR!#63X!?-YM_4WE&< M LTJ:'C5S6_[EA6'[(*>7^>,S0F?S$Q!S?XA[)28QV\0H.#8*WC^$S4G\/1: M69K381Q)T?2PN&-^)E%6W!?Q0ZR>Q6?1;] 2QTE.RABBDBBO'.<1Q+J+4IX* M6K*41@@CJVS*/U\_@%';T!G?;Y3 MAV$SRH>5G#&>E9"5>0&1.HX@U6$ R00O)4DY*ZQ.H(/50UOG36M<3DG8YH M6(3-1#-] =)R"79L@I;/F_9_!UH=RM/^@/VKSM2[TCM!!UT/_J[M.T&R<*]U[YZT.@!"V_4>U M_?[VN=ZN'\5FUXM5WTNI_^/?R%\+*F@AHXC (LX2B#),=#R8P22F-,]CR;#9 MR36!AWDB&[9C-.VA%"4K:$HP%"3*(,I+#G$:I["0)>-I)..BB!<_Q(:N?Q(P MA[R8G_KKK7+[-ET0A;Z 6CR8S\N9@J^9;1\8,[=84].4K&<'_*GX 3U#NNBT M#WCW/ '%E,_)ILZ(>!MQ:L_!S+-.G2$Z'7KJOI1K.>:[M9[4O& \4NX^3F'* MBESITP122[+6\J MC4-AY2'K$^HINX5F+J,\9/^T>O+H[QV+)M>K!_4;?'PGZ+8QR9IYX0GCB2 9 MQ$46*?>\B"&-\@AFA=H5#)>",VQ5(GF&2.!-HDE"31-HHF8SL,T!,CM:IXIM MMY$:B;_926Q?ZC@BDJ_"QG,DYBUC'!'RI&AQ[%G[\^E6F89T@"9F?D =2G_]A'*6R3(N M;2:.U0EUEG6G(^IPI=G.J+,"# ^I\P^\?K' E0DLBQ@KKS3'#&:YU+V>]$@Z M7$3*2^4BQWD4\^35:@:N\!YX6^^IZZGVA\.A7J^$X-KW-#NK?]*O9*>H A44 M7!]>]7/6%1A^AY^PO. :Y_]MJPP,/TG(8@-3%EQK7 ^7VS>PV#PW[#[CM;VS@[S>2EVO4YRYU-48@M-25_-7[1VZ3^*!+-MX31,Y0#)B$4HH MC+"D:N]3#&F","SB7$1I(01BS-2E.UH[=$1%4P-]N,XBDG(.ANN^W03A+.,F M%G)9N7@7)'!R\H[7FLW-NR#$T-&[](CWWC"?Q7;7D(QP65"F]E&:L0BBC"-( M\B2%M" HD7J8>&IU#VM&=KYCM!NYZV?K?Z3L]NNU1C*ZHT2(+F]V MR++MLW0G/U5,CPV_?=@(T0Y9 M2$B4"BHAXE@=PI*5D$K"(*W0?"PR.+SBHM;=MXT?.PR[8S%'I55\62^7']8;G0&^R&F> M4!XCR 7&$"59"4DDF?(_)(W*5!E4D5'3:1NB@75?SP*H5J!G O1)1']H/D#' MB.6MKQ&@9O:2;YCLM*$/A*Q-)1N1/1E*1B1G-9-L0#@VDJS>=5,9=T]BHPZ. M+N7VJ/N]CH%H1?6%;,6]4+\L=,<34,]9IL=:@VVF6D)":*=F]NA]:M$[ M&0;2LP,T/S>@X\CG#'0W++S-2;M.Z[CVM%?6TDZ^;.WD^J^ MA8#,*28\A;'D6AG)$F*.61V@]<)5R;S-*[A$9^81!5?$/9U*<.T%YXOBIL^*G@O\66P7-(Z3 MA(D2IJ(L(2IP#&FN-)K :4YD@;D05M[9T?KA(]=MKR'QEVX\9VD>'6-AMBC];;0+=M6/\:'LKA<]IZ3VM_%[L'J M>QV3=%1/.2)K$Z4X4Z4[,T@Z4Z9Z'$,LKSC!:L M**R:15RC&'BO7DG9]91/7]VME8KZHO9Z(F!0YQ"6)E%]!,TBU7\$+D@B:HB0C5N,'+I,*O,G/ MI8).3]+M83+;['Z$M]OE9^4&+57P1_>_0;*PKDL;+M&T)_3:>:%' AND<1Z_ MX;:C]72"/ZOE\ES.8(%+GB$101'E5!O6):0L*V&9"R(3'DM26(4*1F@%WM,] M9;MM/(:-V3[V)+'=1NZ)AD^?-!#/T\X=HS3KUC40^7COFKSB7H+ZK2NAT[U( MNS[C*2M+*1()@S(7>9)'$9)%;AGBFXR,4WRO+5-=]@AY <>(P7C4GJLUCU#9/9ZW[U([_E%MZ)/J0:(AY_73I?6W>$TKS[][K()YO8X!77IF!- MR_3;%5?*H9L@O6Z6CZZY[2LX093F-H?H?!%&>24AI(6">I1%/:80% MM7(JC*@&WMT=#TT=Z)X+T+ !6CXLF\[886JV^[TC9:<'O(#DT)+*0FAO3:A, M:,[<=LH"AM-&4S8ONRF/HXR(S\]:(=W)=]7R6?WIU^]$_;+NGK?U5OU\E/FW MP"5/49&E4'!,E&D0,SV?$"O[0!!9H!+CTFJZC"7]P JE(PM^J5:@;FC_S4YO MV,)9\$*BLHQ@7J:)*WG49AU*C]__Y7*D#1+#.>3]S9[5(4Y+27%)8Z#MDI%2[3KM',(V+ M!,=)A!DWNE(R)1A8J;<<@'K'@D4IC0EE)?OOEUW$GMCA.VK5C;=>5E?]5D.'#(:?' *J_C"?1,Z0#NCBUM.!PS9C[% MR W+<1TY"XQV2M,:0<]7?9,A<9JKY$9QMOE+DP 9SFF:MI!KF&Y;;9JPW[TB M]O5IO:K7FT_Z!Z#(-BU&DCA/TYACF.6ZTILJWYH6A,&2%D*D"8EI;I50>Y5B M\/!<3Q]H!D#' >A9<.IN>QU&TZB<1W!L(W+3<'$(QAG*ZBT0=XW>S$$X0_%/ M W"F+TX:Y]$UAM.+_O:\W%9/2_%.+"OM#.I.$_NY?/6G:B4^;L5CO-\CWS T'&-;@ M#\T?:!BT5C#.'\54\\P!M:U*"H>RZSB+"0#YG6KAPLAK#+>8 -B%&1=35G13 MB;:3EN[)2T-_.''IL[+8OOTIEC_$;^O5]KLRK&A2QD)(2+**.H\K?K1UU!V1K%^R/AS\%Q^[S]OM[HRL1%68HXYTD.TS1C$#&10$*S#-*, M15;OA@+P&5ML-.4@U7X ->+\!J]TE(-DQU]^ODAU[[I>J(;^OX2GP MG!/W%-MN:Z!J:$YIJG8.-,OM[ ,*UVW=M4W;P=+.1O\X M#LO$)FDCH@;IBG:.WBNV01L1?[SOV=B+;OM_[V%VHVON-VM%N+;7GSHVFCB0Z'EPF"QC@:Z9QO",F%N;ZXX''0#KN ] M&S?-3:B"2B.WX\6?&K&7WY,^L2 \JV*Q!^18PSBL8)^Y]7;]52P%4]OR-Z6Z M=$.5QZUI8M:Y=P/;"-JU(BN=1-@2!AWEKG&Y>9;56;G'M[H/D>TVM*NT5DE0 M8R(YY3B=77"V%*8Q<8892J//.>1]Z_NY._EV(Y03_X&P)K/IEC'UOG+I/PA= MS*T-@XTV$#Y5C]5VD11IG!2T@%%><(BX*"$F>M9\JJ_2<,HX-1\Y84T^\$;= MT0:R)7ZC#?J&/%AJ^A;)T/;0CF_D\(#9;7/-BAZYT#(#>FYNP![$#SV(/4O@ M4W 0+?++@X+IEFT> %2[_'-G3$:ST>U7G2\WW5GB@TQU]U6F='M;[&G-VQT?@3II.JVV@YOJA?KMR[?J46CW_K?/]Q\')5-U,Y&[^E%QW1E] M%!R* M@%O*P:AP/C,&SA.:_\)_5."S]_7C;SB$ 6[Y/Y]K75.N*RT%O_LA-BM=>[Y+ M)].C4+[>??C2];=*HYC'.)$PH2)79F>:0"P+#*,RQ;E,)6',:'.[$ \= NBX M 1T[8,?/('=361;PG;]89CT_&S" 4$Q-$M$.#M M9VCG_COB,.K\VZXYG^OO*.V!X^^ZAJ/;WU#K+UAVJ5=Z@L3'53?%HSDBZ'%* MUQ=]\5A7BA>Q^5$Q/=BJ6O-!)4=35[_(2)32'">0Y @IS5ZJ?XNS$F:IR%+= MS8D*8C4C(C##H8V_[9K]ZTRBK678(O17,PR(_$3?PO)TN?_X]N9\F[WEX*;K M09)J-:%6%?7M2FN9QZK323J/;\&SM%"(YC JB+Z25QXZ30H)4XDQIZB@D:#& M?ODU:L&39@;D@:(/!@R /QH6;+S'J^ 9N-L^(;';[[.C8>$\^T3%S5N>AHZ= MBVPJ[:A/?'61^9Q@4WD.O%[CEQS+"+;?Q>93U;9:4A3.C?QAB1 B8A3F% F( M*"HAY3F'490CD66$\M)JFJ$!S< :K^% -^.&_32- 3N6)04& )H9.)YAL=-Z M+2(#ZN&'*%G(ZZNVP(#BO-4%YA"<<&8.M:'70Z2W[=;!G6C1QWRK*Y#K&9ZO #F^.DXQZOGGB#5T\? M= SXG&9L**NW^<;7Z,T\\=A0_-,9R*8O.OA+NZ74[EA+/?BM_KI>\MO']69; M_5=KV<9YH6DX MV?E3%D*/NE0FZ\SG55E(=>!8V;PW>MAGWQU6]W30_J[HQ]KY])ZN[IV8" M[K\+?1'Z<=4&N(^F%_RJUM^^4Y;/KH?W0L9YDJ4(P2QBRH/CF$*:B10B]>>$ ML0*Q8IY^/KXE"ZSC6VZ:'CY\O5R230V>E,W7]/.9JYV/]Q^#F4GYT_ ;.-MN M6JN@;F;!0%K0>M);)2_H!+X!W>](_8Q:H6_ R4R91G"@)1],/?@)>@R%^IRO MW9'(NUS_/?H7A?JH>#EP(?3SJ ^?G]G6'0 MX52D\9-@DC1VFK@7Q..5ZD7NG>H1#E>:K0#AK ##BH/S#[B9JV_7S:9C>I>I M[:7SG47=_U1HB8H\31$DF53..TX$)(E D#$<$\HE*XE5,Z$Q8N&O.W>D8;6" M3QUQ\,O;C_>65MTH9F:&EB\DK&\Y=U0;NZ0'P7]2@XF GJR!45*S'M F0A^? MF4;O3!I1W PO_:;.R)HT5';-]#SFVAL+OO&-S\J\Q^M@:G M3D.W7<;A'Z'N=?FU^ M(?"XI[ M(R1N=P23H+&['C"4=?1JX-H:\UT+&$IS<"5@^HZ;#?99;-^2^KM:\T?%!7_S M\GNMXQB[\J5;I59_-+D CLVP"2LYA3[OQ?JS6%L'/X>OS1#^ MO']_!SZ_O[.*@!Y(9A0#=17*/@K:R>,_$'I.!-=0Z,%:LAB>EZ=27M\*S@+:;83+LGEK MA')1&K=V10?Z)P !PV)SC[@9KZJ@Z;:BD]ZDM5'Y<6L'BH]@5 GO1[= MP;47.0M\+;=W?N3[MY_/T;J1>C\DN?5MEJ"[7?U-SKI?M,R:&<" M^_Q49K;Q*WT .[72,@D;+L&>3=#P>28EH^45T(99H+D%';MJXX =P_ZLZ0 H M>C*S?7(VJ_T= -)CPSP$"3L576^VBZ];LFT2*[XRL2**4'.DQPDB#),()HSG M$$F$("FB$N(B2O($BS(51@&$BQ0"J\N>E%4+N,MPC"LS+T+:J213^8Q5R549 MQA2">GF@#-1_[17!Y75GVHWY?4'W:R?=X)N]TE)G_9CX/-<,(HY3'.D M+!G).:0T0PJXDNCI0#KFP]MU@[[MUTW[7>T8 !'1.R,W4 M:C 8[93MB8.UOP+OINL.>+D!#3?^E+ 3")Y4LQWM616V$RS':MQM$RU)75>R8FUZ^2YN^$[4;%,U">.+)"M$*8H$EJ34,_!("K$@,10I(85, M4\;TY 9S_6[+0/!4MD,>+$O0K>$T4SDA0;+3.L?D;_[_YJZEMVT<"-_[*WC< M!<)"E"A1NA1(BBT0($"#8(L>>@CX4F,DE@+92=?[ZY?4(W9L2R(I2MT"+=Q$ MXLQ\,H>K?AEV? JP3#CBA:@\94)C$4D+,,88L4ULB M%E&)0IK)!%L5<(P)G+MFO MFGY8W-(5]4;&GZFJ-[O/\9 W?Y#BY4E^S:\+%0#UYH+;9F\H2%*F_D(2I@+B M,%2^((PHC#DB:4"PS)$=68>5^-FSM8TR>D>_5Z?GA8ME+SU'O,W\QWPHVJ:# MO0)H?TK8"0=?1WGMA"][WM8)F)-#L6ZCN,9)=>WJ=9&7U;IV?OML+*5)B&7< MO ?2W4MCR% 8PIA&$0YDD')NU=%O0-;,+JHRL)/Y Z4S+;P#QO(4N_I(6CDU&33P.1\5N\'N5KP@V>2_6'P"AF M&<0D(3 +6 )3P00548Z$W;P>D#5[5J/G:)E3F#&$F=FD]H2$;>K"$01?!^EF M""J&)/T?CL<-A1(FM]B7FMZ^/C=[5<,JT^[ZF6?@+=V!UXTN@JI=F,+TH"6L M>8GIFW7#\\S5,,M5FQVH?5I">_YJMDPK4>JY;CK5R[58]=Z#-UL1%X+.;X/6.MSS#ZM[H!3K%+@[: MU@.E&[@=Q]AZ49V,CZY'E:;IVJFC M]P[Z#(.FZ1.-1KK;T[K5J>YC_VNOE463!6NXAZ?Z["#:>8$W_-HS($H7T"H# MK@O0J5,3X'Q?!C^+KA5SXNC6QL+Q^_C14VL+5T &>UU8#[I<\PM7>]]UPW > MQ(46_?GY25X7_%:-7.BL:;5J^X2VQ[1#DF$2401%EF40!R2&C%,)E:?&:1 ' MF6$AA9&TF9US+;[F4/T(&A7 H0XV/-UCL!DX79]@V#G9$1R,7Q9*)W-#.8>KQL4$6Y!HWM.<]N;CI31.H $[X:D_;(;/C=LB'EVNF M G2?28*)$#FD,*^ GNW[[E?"U+H\?<:L?F^Q)V2D-$/Z=0&,*-4^E"L?&L@$ M(I[' N,@9YE5_XDA80O6W&GAKM5T9U R]&F>;+?T4D=FMR_OYBG=-S'1>Q'< M&5&_J>2MW^C^ K>!>]SHN-_7\%[>?7[9;,NUVM%'2$8B4W,Y9F$,L<025$JW6TSO Z%/]FKHL)."M)G;DT[W &<2& MGN"PF]IG2NH5$)_]&F]'NNT#!&>^[2,P+MZ@N#AX:ZG]X)WD^Q>EWQZSXIAY>_1Z!U]VIX]*?LV_;9I:W[JM8U7M5+C9T'.E M"!,9YQ@RS!*(0\Q@RM2G1$HB,YS$&3)_+3$B;&:?=O?U6T.+"QZH"A= H3[Q M5CYX'22XLL?-P)UY1,/.I=6"89E#);IK-]6T<&W!&&;[L@?#PKUY!,7-Q4T$ MQ\Z5&5H[Z,[&QEC.I1E:\\ZMF=[C6ON@MGIWLB/1J$E,Z/K]@?#+E^U#6>F4 MP=_EE=Q?+.X)Q5SMYQ*8!XA#'.$(9HQD4. DR23.",N%79G$!&UF=H[[Y@>\ M7*_+KET$H&_ZZ.:73()JKQ)X*=2C4'[T%]C4V;#][\!S8YQM2<:4QV48("[U M$"PCR!K O2C0*G9QVI;B\OB1'"CHLS+$ T[>BDBFZ+)PO8D'V$Y+4WP,VN=" M#[\S-^K3IP_=3]0_.C/VZ<-_4$L#!!0 ( '")IUA7(R@ .?("@ 5 M ;6%S:2TR,#(T,#,S,%]P&ULY+U9DUO)D2[XWK^B1O,Z+L6^M'7W M-:X2[;**O"35NG=>TF+Q(-'*!-@ DD7JUX\'D'L"F4@@#DY08R:QN)[PY0L/ M=P\/]W_[']_/3G_YAO/%9#;]]S_P/[(__(+3-,N3Z>=__\-?/[T&]X?_\1__ M\B__]G\!_._G'][^\G*6SL]PNOSEQ1S#$O,OOT^67WY9?L%?_C:;_WWR+?SR M_C0LRVQ^!O ?JW_V8O;UQWSR^Y^MO<>_^GU9]>_=7%9--?I,_R/_WO7]]^3%_P+,!DNEB&::H++";_ MNEC]YMM9"LN5U!^EZY>M?Z/^"B[_&M3? BY \C]^7^0__,>__/++6ASSV2E^ MP/)+_>]?/[RYM>196$S.9G],L[,_U3_^TXL9P8$(7?W#Y8^O^.]_H+_P]10O M?^_+',N__Z'^,Z@:95*RNMS_O?Z'?[I>]>L<%P25%9=OZ3KWSW).#E9??597"SG(2U/+/N/1WV&X$KP@BE<*6&#ZX^?9MS_1ATD10M:?5&G(E23N M+;>6RGYT7^ZX3_1W3UC(M#<<0@I)@O(^@*==0;1;2^+)3(MP$-DW5[M-]4UM M/ING7V;SC',R&9?+A7FZI]G;8+WX&W_Z&N;T(4A?)J?Y\E^7^>RLA:Z6LP:2 M6ZN%R/W#+\1UP?D<\]NU5K8RM^)L28845W^SA<;_UWF8TQ=/?WS K[/Y\D0' M56S19"2](!-HLH H#$(,7C+N+:KDFRC_SL([X4#TCX-#Y-D))-[C?#++KZ;Y M)1V^52"&HPIT5CI!7#!B0$L%27N79@N M)E7P%X#F2EGC78&8R8M2.4CPCGYI0THR%*L2=VU.ASLK[P0)U3\D#I+HR*AX M-5U.EC]>3T[QM_.SB/.35(I-UCG0CF<2AI(0/2*4Y+T63JE4S$%HN+OB3BC0 M_:+@( EVH?T/^'E2A3!=_A;.\$1;ITKF 2I6B7Z2@9<^0HHV"!:<5XDU0,#M M57="@>D=!0=(L@LDO*$@?DXF;"7XCR1_?#$[GR[G/U[,,IX$YJQ4)H!QU?/! MS"%B)@.GH[.!0G 6#PLC=B!B)YS8WG'23LY=P.93^/XFD_@F9;+.3EQ80L>+ M2Y99.@<5"0D=HW.00JCL"E?1L:*E;@"8+"1R^=W <*M.>@/&" M?OIN_FGV^_3$V* L\XEH=AP4@1F<5>1.!UT4DYQQ; B+ZX5W2UVQGP05>PJT M)TRLCL9W\_?SV;?)--63T>B$TH*,FAPJ,G007+3D4!'$=58NB-0.&'=6WPT= M'6%'9YAPY$CC%(1;YX:>&B M;EI[-WATG/!L)-:1P5&MWK,YAA7=4GL;62!1!$[$V\@A8*0#T9O$E+9>RL,. MDINK[0: CE.<>XMN9)77.]'3]U]FT\L,# ]!!-0")$H#RA2"JTX2,/F8DA0I MFL,RFG=7W$WU'::MW)QQ]G<79Z(JR/VB@.)7L& M*BC"+2<8.R.0^!?.F\-T?VNYW13?<=IR?^%ULNE??4]?PO0SKO*MUK$HA584 M]2I"K4(.4:8,4@<9&8H@U&'>WZ95=\- QRG)@T7913CPXGQ>Q;6^@:N0)AV< M+TY0=]1%0QM#U?#PC&;G"%9)[G"717J_G6&$N**XH MOFKA2]Q>=C=$])_%/$"88]UM*^^&B8[3EDU$V@P6__:G>W)\2[^QYU/L=[^]?/7;QU\X/%TN+G_G>NL]A:Y]#(HGD91NE:J=%)(B MWI(DZ!L)RAA1=,!8U$,7Z =QN:)@G/?C@R'ATN@T$/>(I] E]223R1+?3KYA M?D-:F7Z>$!//%@M<+I[_^#7\UVS^XC0L%L^^3Q8GWCF5:G:W<$$,:0K3G%** M8K5LLO/*//R2&*%*0;>NII]X"XQBRFQASSR?2#X #G=PNUP M&,R&T<_TJQ*YZ>ABG.SA?WA+9F2DAO M0\D2F.&L]B>QX+#4M^A&D\MA@[-E)]3LNN(X;5Z.CJ)!%-#!T7;EEU+0CF_H MIXN3P$TN2G-P23JB&SUXXPU(9E5D4>?T8([IH(#PBHIQC5-#;_U 7< D36\ MKV+AF$/4=M4$2U $+(TG@-,/G%@JW!G:6*VCO-L4=!+([:G/63/A=@.-B]3J M-1,H119D7Z.)AIB(Q([BY(U%5I*1*/#!&\[]$7*'D'&!$ F,5[6O<*#_M79K'J)G7 >G/:":R;X#'+V9?B.J M9_,?Q,*)TEHK5I$O?";::T\OQ3/D*#AY^BG8_%#WS'UP.K]CC96[8= MX&(MC7?EY63Q=;8(IW^>S\Z_OIFFT_-:DDB_FV;3Y61ZCOG=5USW^KK< 4(9 MXBZ0)76:8R)^'_HS='^/M$^U([3IW- VW0X/C=DRG#:!!IW, M]91>+&N:X\WT+88%_C:;I@MND,N8&">1*+*&*NH$@1<#(7FM2Q#)N=8.T<,4 M]>!*-XGS&PJ^ POS\F+9%[/%*[MA7Q][H44 \/H&\[CK%F.A]RP[3R]^GX1 M'?YY-LN_3TY/3W+))B'6FO-4?Y"9-@H3$!236BF7XX,O=/;+ SV-QAZ\Z"9@ M&U0Y7<#OBG*#"9U"!"GJ 1Y- 2]+?=Y0:$\AS]:T]HN>!)?F#[\&@,M>PNS@ M,+MTY>IT@#/\%+[?L*=1&ZQ7+3KH6!OI.* PD9P[GA@)J$B='^IH>8B[?)^: M<1KK#^@['RCP#J!S(P%U(T(4F%.6/H-FT==W"A0(I(C@,6;KB@D,'^I;?/'8@, YG Q=X"5-?TGO"1E!9=D$ID%9>L9Z5*&E /CB6=)+ V2XQNI MR_Y@A1A/DF0'^;RWDQ GIY/E!!<4_:WZ:7R9G9+4%S427/ZX?ELIN+/%DM%C MA&95N((0!4(RO!CRY%5QK:_(=Z6MDWK MTV*O@912 >&Y@9?=Y/I5@FC?(E0 M=,U=IJ#!R6\+8FKJ(:#5E>%8<-H?SO$#E%%!Z"Z+"QY'W[4JI*K3I/: M>1&#!RE%G0?.'81<2P8J3C7(5"SH"V"LC;1U/0)B]:/_%^E*AQC[J! -56 M%1U@ZS*4_(#?<'I^M4-2(+\P%0=,:.*"N]I((AE(6")&J8-I7BVVF9)Q[[L& M0E$#H7>1_2/S.C^_M0O($UC%FC=^ZT2RF'6I%4>&(@QEBX28$O'&T3/!2W#E MH4YQ>QYQCQ,V[L78<"=>8Y5T8*0VF%ECF$"C$@@9;1U67(L(E(6?8;LJO)=I&%$3EFD*S8.K(4P3.C MP7J%T9825?-4Y",D=>,N#0>MEDKI &-WS^8;NR4('83*#DQM$*RJ*7LV\D9MRKH*#AJI8P.CK7[$KIZJ/2^3N,BK2V7\TD\ M7];$[*=9M;7$+U%!7_R\&LN$B^N QEOFM3,.LN6TJ[2.=*@+ ][97"Q3G(76 M56MM.1BW2.DHZ!U1Y1T _OWENBLQK-Z=WYSS$ *Q@T: =8K5RCX.WF0.V9O( MK7=!V=:V]&&*QFX_,AY6[I65-U-FK9YR $* M"J6]2B7IUH]W'R!G[%*(;@#82F4=H._3',/B?/YCQ2_&R>(3*[QYU?DV6L9-D72$NR;*>CKH_!IT4_Q<;U _M2NPR'G5 M[3JM7XD\3M6X^::.,-Q8@1U \KYP3XQ4285" I)U MEE()=30&=\ T$T4&K47SPM[[5(R;).H(<@%J:0:S(X_1>K_2QQ=<3A(%);>8 M:353Z_821QFP]0!7QYRV)0K3(3$.#+U>!\_1I@+H%!>:Y:("-C](AI^V]>ST M=/8[?1K)57TY.X_+T4Q3R%P[.1W8QS=BSH&4U87M0VW,_:T[]_-5R+-J_35>YROQFR?2!-4E$I5 M?Y3XXKK4$082DG)!.YDC.1KELHVSLS/? Z!M /1W$#+>Y6@]R?W:^_#*; M3_Z!^20ESD,BI]0S0TY);;#G8JQ3J'1,+C#&5.M2P(?'2I,QD\]<3VZD9.X,] JCV4$.G@+IY MKX@^(J\=\:7U'I1+#$*A6$<)DZ(P+BC1.MWQ"$ECIXQ'@-:^"ND 7S?NK+<> M\)[.=9U%!AMBJ878 6(I%@(/N99"2LY:1T([D#5V6G=@G+563%]8NW?.>\V< M*\*"MSJ#8L80*XZ#]B%QY-%9WWQLY79RQL[?'@];!RFB1TQ='//!<$U'?7V] MG>OK;1?JKE! ]!<9/->A>>)B"RGC)F./CZ4]%- CCFZ>Z8JGXK0F=U%H1WO" M*O"9MHAE02@,+)4P1/W\-GK&[69V?$3MJXH.8+6A-&O-TPD+)>7@'(A: : B M)SLK!46WQBEBQ&7:),,7TJV)&;DAVN"(:J.%9G :_I;HXR?Z\==7OWWZ^.[U MN_>O/CS[](;^M-D-T9;/#W4[M LWC6Z&UI4\5X"\;M(GO"HY9R#3<_%LT'OK M@0N4N9 +'K#]T*V-I!Q>Q;-J5?*:=F%]EU0_^;?)\LOE^/*K5L:UM2#]+]=" M)6%E*8XYB,9&4"4Z\ HY6"V=TLER^L/F93U/)G/E-DQ>W>/C_-LDX>+C[#2?1),='?46B'(+2H8$0<8,M;6)T>0%&-DZ8;J= MFG&O>H8 5R/)=X"A/\]GB\7[^:Q,:L,4[521 I(T#)0C)]$'^J76R5O%,?'8 M&C0WEA_WKF8(E.PKVPXJMRYFYTT_O_K^%:=D(:\$XDQ@L5@'7-G:!J=V+\FB M .F"QB:S3M1MFX#E$C&-PM*&VODPZ0 M]H%40P34"=@OR><[G:W&(5TR@TYX"G$#F-HG0&4>(804 $M*A;DH*4QM[GX_ M0-"XOM PN&JG@2XJJ^X)Z<3XZM5Q#;I@[:;$. 1#8DI%6YF2B%JTGD1UCXAQ MW:-A@'.8I'MRDZY?,9T4[F)"K:$& J \4^!Y*I""LB2I*)5K?7NR@8QQ*PD& M=8WVE'4'NTY61VDGAP0>%-<5/7!GR'"Q:Y0OY$\&VOM#< MC;*1:Q&&P-, *NG "MWEZGE83!(Q$8-(]?6/R61*8V'@>/;DFPJ3,A:N4^MZ M](V$C)O['$+CCX#JZ>+O$$,O)Z?G2\PG):O5!!5 4TOGBXK@BD/@T3I,V3ML M/H1X"RGCYCI'P-$^*N@ 27_#R>S;Q1)?,;?SL\BSM^5>P6$%^R]G"S2 MZ6QQ/E]/3[R2I F%EQPL<4WQ@U(43CCG-'F"UC$;,?/F-0=M*-_-WOU4U2\C MJ/0G O+:WF>3;$E:$3=1TR[5!J*( KS(5C%G;6H^(?5)!(Y[#(^!H#U!_'1U M]HO5"W'>+]X6)09R3PP4'1.=4ZS.-/<.L%B??,D%F\_!>"*)XQ[W_>*UB4I_ MT@+J%^]^??_AU5_H[[SYSU=OWWT!JZJ5) ]54J#"0^U/ MN[)T4FO@R87@ F866Q+34W)']P6?HNV'4W)/D6\'Q^2VAJ&;FH62H*J:IOG!UJ$;V_BM^V9=/Y@1 MM=6!RQ!CJ$-(-0F)U[K-D'4NT9#(6X-P%$;[K,P^!.S]X^7_;YOJ)!?FLE<9 M@C2"7"H4$%"76B:$)0A=4#>O@R.7BO8/^#&WZ)/0U_'6K$V&IY@O;EW? MGY(TGB8'7;@QTO-:F$=Z\MJ#5Y+7)YLB,H'!Q-9WXT/Q,G(-[3_-ACLJIOJ9 MD?%0#_H78?'E]>GL][]@_HQ_#I-I_)%T;JF9()F%6+!=,K6OF'R"GS\>%AP0ZK63_$_7OODJ^O7O] M\=.[%__S+^_>OGSUX>.K__77-Y_^3_O$XL95!D\L/LY;^T;>#_29+RY+S5$" M,[: 2@316 C41E%?N.'*%_9U$+;$YF--'R2H$RSMH>EMH#E8[!U@Z X/+V=G MY!:>.!M051? ZSK'BLY\")KB*.N9$4Q9]-BZ/^A&0CK!S.&*OENB=;#4.X#. MC:YNOV*]5#XQ.?J"Q8'VDDRQS1I"L@X80Z&D$:*PUK=_]X@8N4ST<,5N[YVW MAY0[@,F&5FT7C(@BE#=!0Q+KZ18./",!43R05!;UP;]N#)>MQ(Q<%=H<-FVD MW@%\M@PDO6 FZBS0%PU:I "*Q0"1%0,H$S*G6!&NM8?\($'C1O3M8=1.^CU MZ?&)GQ>,!1Z*-8E!8MY!38B =]F!-1FM,8''TCI-M#-QX[87&@!B@VBE [C= M',V8V@/I ;R[@ U5T'' M6^)E505Z4@1'C9[B"^O(S/IHP%DM(>>8"H]*<#_8W+HK*CJ9C-4P?-]/P!U MA(QB]>[P):[_^V9Z/SWV879Z^GHV_SW,\TEA!KDP!8SP85W12YM* M.:&45_ M(G7K%WQ/)+&3.']/1-Q_DSZ8>CI WX/-W)G*C%G:F"[6MEJH!= )':%RX940 MM"];/_,[N*_^D&6SPP'A*2WVGZ*5O1'V%>>36::]-%\V.@CO30#61;JBHR0! M\?HJTI$#F!B=Y]*)PEUB)K1^R[?G*.8AJU./AJD#-= -DK8/"^#"&L?05YEH M4$G0QM E@[8%(Q99(LN- 778R(8ABP&.AJLV^N@&7BLVUC-R7I[/R=Z^7R^P M8FGUA^^^KCHAO?J.\S198#Z145NG18"85A4U+E' PP08JZ- S@++K8_)IU,Y M>A_CXQJZX338@=.VA%_823ZOD]:?9I_"]#G.I4B6V M29:7;7PPUSPG3A)?A#TBB7TR6>#%F9KW):S>CS]/55U9'TTD) M5M,_]G6:7P&5K2)UH ;4T41C4^:L]67'T#R-WD1SC/TP/CHZL/FWGZS'XK7) M6,"+>J\D!$+P(:Z**7> 6B.^ZY4."*,69]C,A^GO5/&0OT:.AOE_@]#$/9:CGHS8:H:*5Q+\A22@1 MP)7:'=A:99/SW+G6N;E1GR0/VD)P]-UR5#CTX]@/\ HTFJ!,<0H,YR2(D!*X M2!Z;,5S&(B5CI745RDBOB?D_Q>W=R!#HP/5Z\$X\QJ"T-PQ"- B*NP#>>@W> MR%!TH!_U "^!#ZQ4^*>X_FNFE@-O %]-\U"%"DEQ%81VP*/2%-@:8B"$#"4' MXT,R7LA!TM)/+U3@_SP7>/NKH!,@;;\7#P&S%8J#TYYV153DG:O"P9:0E791 MQ]@:3X?5*?!_BENW-@IIBJXC-TI]]O$OK]^^^]M #5*OOGZ4QJB;>6G?M^#2 MN;INWQN]2*@)(YSKB^Z6+B*"$\8QF;T*I74CGH?H:9 'K=]\/Y]]FY#DGO_X MZP+SF^G5*,1G:3GY-EE.;LSC]"%2G,0UI$A.HTI)0D!!F])%;RD,PAB:3Q)\ M,I6=5"$?BJ -Z=,AU=6!HW\[0>P-MYZC :]KY8/BG)Q)LLTE%!6CT09CZZ*^ MCGKU#JWM!W/S3Q%]![BY=<%U.8D%;['T:?94:=;V_I:9"#XEDH$-D5P#ID%( M6;(1L23=.D\R!!_CECD?&<6C Z&#S? 2:>6TGD-$/S_%B_3/L[.:'?W'NLS! M91-)S (*3YG"<^;!*5TOWVR*W"K'4^L*_%WH&M?DCH^>V<"J[ ">6^INA K6 M9*W!9I(0G3CD&"%&J&&?+"@PRM93#P\HDQK,7G8'P0;JZ@!T*VDMB/#7L_G+ MV7E.^'^D. M@,U4UP$,;]KM=^7U9!I(NM//+V8+XH5SS[WR AR/CD)#24(*20"+41:GI4B^ M>37I _2,^VJD.Q@V4UT',+R?>KV2VD4UX)7(M [,,5'W%D6#"C4%@CY+<%X$ M:S66+%K[B;M3-ZZE/')H,Y#2NH3CI7VGC8^3;ZM.$2XZ[Y*PP&1M.AQB A^9 M@,0Q2KM87H;3#P*O0,5=&A]S4"P>S/]1D*?S6G+GF@5O>-& M0L% 6S77M]&&<6 JR2)Y'>K;.OGX($&]O58_$M#V54FG"%O7\JPJ/I?/%@NL MOH-P/@=+_DAV=4RC)7FEZ$'*Q!/7 6WS2M]=Z.KM%?N1\':@@OHI'"2W)"'F MQ6N2[=O*V_OP8^5.G["@4!B#P&W,H*)Q56!DK0/G4A7AN&N=:=E*3&]/TP=! M61M5=.FHO;P@Y,67,/]<^SZ8),D,:Y#:4B"DR!.@D"A!VA#QGQ5=PCE(VUVR4X1F)3+"OPMA0H)I-;:B1FTSIM M]RA1O3WU/G)4NH]JNCQ>7YU]/9W]0+QXQ?YV$N+D=)52.DE61:VS!?2<>",/ M%5P*Y$0XVF="L6!LZQG"3Z&OM\?51T)@(X5U"4;:7?/SVSR50(ZM\89BH1H? MV23 V]X9=P=2#=-N@W6 M@_75 11WO]4^$2D6 M,N@*;,FI1O0>'/( WCGCA6<"<^M$\N[4C9M9/G[Q_A!*:S:\MSD6-(J^^@9MZV#DJ=3VDQ^GG"<5N;'R.JRU=)1X/?02KJ$W7/SQ>3*1(WBU4SIBK>BS_) M)]Z3JQN)%U,P1V"*)*>D(M:0>TA,>W<<.HUNI MJX!.F]6#6PY>$FN<';)9EYHE_$!7F-N)J;+ M(+D9"AXJ4]U;)1U@ZP-^O7 LWI7;C'!I*;1"15:[%@2M!%7(B,>("5D1=89B M8VQM):;+"'@H;+5123_NW*+'_-Z2NT@@MR:%GS MSI&/$M5EH'L,9$;1L'095"X(T5@%3 AKC9(%^0 C M67:DKLN0>"B,#J2T#D+B5Z5@HLCMU??T)4P_XP="^[MI9;;^OUX(?0NGZ^UY M.>INE1N=YMN_<>-OGBA=4+)<@/[/H%:T03#.09+.6\,5EM3Z* ^0!$;UVI?GM^3TJ1FY;W$;[ M]T+_PX3=+-QI:CL^GI^=A?F/6?DX^3Q=#4>;+N_+;Q]3LN.7&UB6?7@8WM @ MRS)KQ\"R^N2*\ #1R0 Q\>RME5'PYNU+!S,T#TKV$PGS.?WMOY\89V-TM2!. MU MRRQM_58#0[0;G8U,S[;%KJ E5+8R\ +)&4-!67 0O63 "H^B6#JV;.O(^C&: M#J]DV/S]EY-%.ITMZ'B^ACW37#$E&(1,,E#$+P2?Z.07JF"Q.O/F#5*?0-ZX M!JDI=N[7-@RCI#YMT\V6I'N8HWL=30^S0%NI:61T+K__XUJ9UY6FB5L7Z"CC MP08ZRK@"KT,!+WPTD=UO).?P)^KU/7\/6:D(MCQ92D *49QZ\TQJ, M,CG%PHS)K>]C'Z)G[*;+;3!Q_U%Y(PWT:3@VM)C=PWYL:U1[F!EYC+9&UN2J M)6,=&G#1CV#R#SHZYO@U3/*S:5X1LJ9@ [H\2@R923J6,JLAO:73PPO07K!@ MN+21M2[)/I#D0ZW2?<5<;PGG;(I:.Z"CV]9,/)VJ1B PST/2KC@?6SL\#Y S MKDTZ)K(VSZ<_7$=]FJU5P]X;_?[WL%EW/]' 8#U(52-KM5KCAHM<#.,L9$A< M)SJ!3($H1(1D-:MW;F'*1K7HAR@_;L&HJ'@^[01MZQON+"U+V;3 ME>CV]W5V^6R3BZHG4M^)-V2L529R#R%962\C#'AO%!CNO4+!!:;6-S\C>4-5 M8R<[J.EZ3T4O=:+#%6((M;F518A%%S"8"NV MOAQ\"GWC6JZV^-GP#FH8/?5IGNZVUMG3-&WZ3)-\]2/4-3))?Y[-\N^3TU/2 M]]TE-QQ].1&()(7[DL< *FDZ!%W0$*-QAF?FM&J=27D2@8?GMK>M<(W\HEDP MCDU?1<+K8)T,XI'0UG MH'1P]0<%WD@&7BE3BK728.N"A0?(^:E,S1-0<]?4M-)(GR:FYMH0/[S[ZUIV M%/ZLTFTW.W3OE<%^]*M-DMI/HWV8/+>3*804/'!6NP(@,S5"YQ"TT!A<-EZW M;NO?/L^->-V+_$ZZU1JI74JJSNG-H$19Y2(">$ON?M;1*M_:XCY,45=Y[J=H M?U.>NY'@^S0NEX/=VMSBW_M0JXO\ARGL)'L=BS$V4J1M4HVT7100LD/0-B;I M3$J)M3[\>[C+W^[>BZPM1R< D].@>.U28)('F8S55B&Y_JUKJ1^FZ.=.9S\% M7QMO]-MHJD]#=F=[* A><,@JU1;@):!O?4FP*VUC5V\/ MA*;[E=P#J*I/"WBS:.O X'#;IQK790X=!MZ?GGCI1$[SC6'&5Q5S/#CK= &M MZI4,XQF<] Y*489TR+(JK+MKUXZARC[-W$N,>_INL9$[=G?]9N%G M7&YZ?T 'D(S:05B5Z;$2P#.I(1M$;K7*MK1.7FVFY%#K<_NKUY#4,L2D2X'L M0WU@D25$9QR@K2EAKB.I<% &.[$>#?1_UTJT$'F?5N!.5JB%O[/Y:^TS6$-[ M/:OE-AX#U\4G5D:.*H!D)H-2T8(+5H)V*=(Q)$7&UEON<:J:)*,>.?Z4"CPD M)B&QP$'Q%,"I@,!8$"&@BE&T#LAV(&MHGSR3?ZQC=\ M,R6AG:^Z (=I_@OFS[=;S>[ENNSZ\2;^S5Z<-'."-JS^;,/JFUX\99M8=@&L M]^3;1J7 H\Y0N'>N* )L\VX!!Y![N#OUY*5OA &TNU*0JQ<9!51VM*%3YA # M*UE1,%!DZXG3A] [MF-V'$S>]]Z.I.$^3>KE%+L7L[,XF8:]VZ5L_$X#0_DX M?8ULXH:%:KQ?+W-60]86ZP3J)>222,;'G(&;5?]*'L'K9.LP*R;:&AD@-:?OB[5$SZRC!Z2$O6RF$("7U M]\J9PC!EV=K W*;@X%9P=79,'6+[5H1KD#C:W" MO2LEORLW%[MHP+6JE%E-S(F5G,OI.M1,/WANN-11 MQ^8=K ^C^."@;]?5G]]<_7H#<1>MEZ& ,[5;=*)SW2OF:1?%.MF",]>\N^6! M)(\<^AT/G_>BOR.JND];^8K,X.P'XG.<8IGL5Y9Z[QLM/*T'Z6KU IGTBZN% MJEXOE[J^%>).<$,';#&JSN]T==!=,2 ,0Q>,*8:UWL@/4W3P*(,;$*]/6F_+ MN+YTO8%M5J)BUKL:A?":53%UB+T&RU5B7HLDFP_]? I]([\];H><>Z,*AE)2 MGP;HM]ET=E7Z/UOL98#N?:.! 7J8KD8&Z.8B;Z:T-K[Z7I5_H[T&4Y)S2_B) MA9!DZE&BFEPBWE^E@GV]T,V:Z<22D1E0UL[Y3&=P M3E@ZZX-.M<4:G?E#W"7N1-W(8ZZ;8F?CC6)['?5I@]:\?0K?]VW.>_W/FS0[ MV$)-L^:\%]_?<)6"#JWGR"&Q2)"1)8'3',F99CS%.I9/M'_.OY6.A-:UWP]1,_8S7G;8.)^@X)&&NC3<)"O M=C997M[>U^)WLI0XW7<6RD.?:V!8=J:VD:&YL=ZS.^MM@%E)#$4) 7()$I2N MEZD1Z2SA7I&[7$31 \0;NQ/8(/AZ?+&;FP.%LS M=WH,<71BL(;#UH9X;"B]]6G4/N+GRFUM 3>EA;[.)[5G[M?9O#*^5Q;]P0^V M2*;O3G$CTW:QXM4BUU5\N@;ALAZ1$>ND"@'14_@O46=-P7\6MO6%^#9:#K[! MN_/=C14PQ:"I&$^>D^@7 M[\J=!7ZL?[QQ:U-R$C$;<*5F9S5CX*7QP)A@#AEZ$9H7;^U$V>@OZUJ@Y%Z! M4GNE-#->^T/M-=G?<+H>VGX28Y%1. 92^+ NK8\6)81H)6/9V]2\@N7F^CO! M1OQDL-E;P!V XST1/5^3_@'3:5@L5G9_I9'\7^>+531Q8]#QB:!@1-3:/VU8 M!"6M@R@#!^$$)T$EEU+K4O>K@3R.1/!K)!%=4!$/^ZP'?EU6(Y.0M+7)SD M3+8UD%&57!M03G.RMBR#-ZI-6$)@B.L>S-42995;3V+;B;"= MP&5^,G"U5TD'.'L1%E]J&I;^4\N8OX73:UZN@XFL#(^\:+"EU'FQQ)[/(D%* MW&063"RA]37F3H3MA#/[D^&LO4HZP-FG>2XB\WCR.DK@EO( MV2HZZ[V'J(@I9AU#5(ZEW+H\92?"=L*9^\EPUEXE'>#L:GKMO7Q(JK.3;(!" MR]9!U_5MJ6? A2G&:*T$;YVDVD;+3FCR/QF:F@B^ P!MG5-SER]5N,XN9@C* M8&W2'B"*0.>^MD*P[$5JGO7Z[^SZ><54VLNWTS3Z7E>U3??9G_S+550SH84ZZA=7H?N M2HJ6>2VNUC(JS17GH76B?@ V=@/PSY;,'UO?>T/^&\[CK)4[B-/%^N'0*DRJ M[Y3FN)S,<>5XU,=#EWD?K\5J1F&@H*BV/-3@*40'XH@<78K6I6X^6G)'VG:# MY\]V33"(9GHPLY]!$\AT@Z'ZC^KL,E81*2=H#/JOZSAH]N)(H)O=%^T0"\[%UU[E'B=H- M4S_;I4%;78P(KM6,\8]?)E^_UA+,:?Y+F&;Z.Y]7;_KIUZ_Q?O04BT =F0$K M-.V;7"@0+Q1"*9,2)A%C]'=@MF7\^]/6W0U)/\NUP-""'QM3JX=Y+V:GIYB6 MF%=#+RX&753N/N#99$F__VGVYQGY==-57?KIL_/EE]E\U4=PLY\IK?#.UU2C MY752=: @*P@Z_46DN)TS9^Z^N]N"O"&HVPV?/\MU0A]*'!O%M^9DW1UW=#,B MNA$+%8W$102R]IEBH=H8BJMZEY="]#;JI-E.&'WZVKLA\&>Y@CB& CIPZS[6 M!SEAGM_/9_D\+?\6YO,P75[LFI,B@RQ:?$2%$P2"&K*(@J49L_;[M M08)V*Z+]V>X@VNF@ T ]RV2,EY/%I3-Q=W\8[83-S$-8[P^%$)67("@,2EJC MX'?=M\/?,CQ,TFZ@^MDN(%KJH0-8O<7/X70C(T(:Z05'D(D3(Z8^>L_! D70 MEGO/;1:M7[=M)68W*/ULEPYM9-\!B%[/YCCY?#%^A/@@,[L@X=2"3G(H5[\\ MO5G?>8/1$)+SQ8%5N9:4U^'I.CGPY$XJCUZ1(]FZ)G)?8G<#X<]V<7 KF^*5>:-2Y"34+O3DBML4S1Z=]K;Y3H&)U,-7*'5 L6YF]*ZT?G.Q*VVX8 M^]FN! ;13 >(>Q7F4Y+5XCW.5_U8[[+C9;#:2@-,RE #8@,.C0=GMGNQYHJ8<.8/4;_GY#4//9E'Z:\,;SB'O\.2>3=AQ\;;JI4C2T M8VJO=*,((-DH4UIG+9Y*XV[ ^UEN$XZBJ9^Y&<:G6OL^8"N,B^\?K1'&)GZ& M;X.1.=,AB0 ZAEK=8P609Y_ Y<*+%LF9YO-1AVN#C+<< 9\=&2K!:CBZ8?@',04-1CFG#>FR.!;-P%Y*HW=ML9X"G*V MOM ;0E$='*];*^!OO+;@&*,D>$3Q*(IEE9 'FH!)8*'R)!3Y),E MMZ$H@:V?P#R5QF[;;!P"O4$5U140[\9'U7XGVFPO)Z?GM:#@-INA9-I5HA8, M^%6E)XDS4#B>=<1DHR]6MC9^>Y+:;>..-K <3FU=H;,^T7Y].OO]X_E7B@_6 M52W7C007=]BL:4F(36^#LIB-;5V_NR>IW?8&:8/.X=36 M9^![^33WH.CV_D>:M.9_D+)F#?HOGB9O:L8>-4-CV'K$@M),@K=,0THR>>], MMJQUC<,#Y+0S35>+K&_AEG= +;)(DED'PF( )6."&+V$)(24&HUE<;B3\F': MQF[AL-33R9GGBB_!U0F?. MY!^8W\_Q:YCDJS8<*SHV8,]J%G@Q%HP3%$IJ79_0A0(6/5J!F4O9? CB822W MLV4WEKFS61A*ID7Q4&+@H)3/$+@M$"BLB24E'67SHL?'R1IY_.,1D;;=RK71 M69\&;M4JX+I1SO[6;?.'&IBV'2AL9-?6;1.NP".,2FLRUE8UGA#WJ;@L.=-@61%?W&3^*X!G) IAJ4 '=.J/ML/Q*/4@#Z89#P* M?=<4;WO5M,MRXQJ3 ]1[^_U2<\GVD @@IA:5JU5F8XYI>=$7W?W5LDZEOXA,Y@-YJ(^O079%;]T!H0_FX:?T&T!Q1D7V> M;#L\HMG_M-O]XPU.P#TYZ<3;]P:SS\X"^42^]DQ3$)2UP+V/)63-LVAM$D;V M]O=<_N8S:F-R-)Z<51;J79NMW>SKV!8IHK F&-$ZNWHHS3]WG/ 4C-XOW3VB MMOLTM9?7Q^'&S?$4E_N;UX<_V,"D/H'B5O/DMUVQ7X$PY1BY*1P2H9""U63! M<8% 1[4WD4656?M!#X\0=80J#Q1!ZV@4L"#J?:Y-=7X' T1,S*&6I7DSTT95 M'L--D&^*E3V*/9ZBDX:MK1K?%-UNXG600=K^L28W1SM1VL@0_7DVR[]/3D]) M\W<7WG RAJ*+UL6 SK7)F6$*G,H%8G"R4"#@16[="NQ)!+;+S-[H:7AWV3NQ MD3,\9JL1:B@/RG,-@7MR&8K/2 X#LN;NV1YDCFO"AD/9]CSM,!KL(3ESP>+L M(19?GR^K2,_J#,A_K/3\ZOM7G"[N)J9*%CHRGT%PYT"%Q.CHX 88LT+R0I;? MM][1+>D?-U%S?%@?7>=]AAB7@M__"+_SA0;G]D,TC7)8DQZ9BT&"R?6^72#A MC:?:-IP+)[- GOD_QV%])?KK-F$YN%0\^:CDG9))1S+I*6G@FC-K'"OD,0]V M*-\CYV7ES)TM*96.J5>3 @33:(1F6?6MNHAK>J:TF^H_@Y+"]O5)X' M"J03?OR"N'QQ:T[D7:_3UA'<(H-TK%X)DA "2@8L4K3NM:&?R\=@/8[81V=6EZSY8/):*^CP>5_<:O\VF+>LCMWRN58GD+M1VZ'>K,&ZXTC=+X0^J+7GJ4@TK30[BLI']O-]M MOE8TW2;P"L(R<*.]2. Y&E:!'3N(%Y:B2=+DX0\V?D=SG/3(LY3FYYCOFU9"!GFKZ>(7ER!DT=H< M)(?$9>V.5"N5M SUXA^#$DJ[W+HCZ-,H;.<$WE_WS@;1)3HK0JX-Q2ABR\Q" MD!1+H8%.%]6G17F(\R+.+39VUS;0TBU_C M&& MH6A()>,@V) @8U3>I:2B:.T\/43/V/'EP4C8;C0.%'X'^=EK7BXR?63XUK,E M/^'\; -_+"?M9"T+J,\J5-(4#YLD06/17#*T0K3.[#R5QG$SLX,";@ E]7E6 MW4EXMG/ '_IF^T3M<=SPU:(WEMH /\F]T"K;]< *5:0"[S,#IUQ@49KBF[>C M>YRJ@VXS:T?HV;3V2;U(W]U8ZG)K?-KPMM'*9#C&!*$80^YB#!0)1PY2<" M^A[Y ');A@0;B'@S_4@(6#796A4;UU>UX?3];+'*'%XU;+WIR$J>TNKA;G:@ M7-80_+.Z%[TR3NAG$RL)P1P3B=Z^ 2!"\] Q]XX2'%J'WK]VQM*!\[^!D' M]"-HO0.LW\I>/L;JV]GB;DH354!7;*XOY1)Y>HR#\TY#)&(I-HT82 M/&X7X?%-^O!Z[M/!?GZ^F$QQL2!^(YU9JYEE^_O2#WRM@=N\*ZV-/.0-RQ$D MU_>SZ;_/)^N#_0J'.HCH<_&@8YW@'+.@.*]$X%R+5(1/+K1VZYY&83NC>'$S M_@_,;S(ID@X'7*^Z6"U+P+YQ@5V[VRX6M*7O-D5&IQ,%HAY2#K1YK#(0@LB M4FH*B)EPI77#O\8LC.L'#XC/[7;R^*KOTVY^7!(?S\.BUM>=U<=UUR7E^XW6 M>>A[+4;I[$QOJ_S"U4G]KMQ<\@.N#ME55>*J! M"RE!!2;H0'<*)(N6L<0C\ZTK&@ZCN)UUO>PG?UM5*P6^^[J>,;KVA^Z6!BF7 MG(D42Z;@R,D.JC;6U:R6DCMN:)>Q,-RPBGVI'CF7<#R4;K>I1U%X5U'59HX_ M((EUDDCN*][_.IV0J'\/\[R%?1ZL22$%B"Y9.D5XJ/4I?-6M6B6FA,/F;07; MLC!R3J%?\ \)A:YVPF^SZ3?BE<2+\S*;G]6W:BMIK%G>S*W'5+BE8-.HZ&O% M% >?+(=@22/%2BG-<*^:]Z%XY.Q"#S@?7-%=P?IZ5U^(<[5Y;QYI-1F^1D"- M$+Y>!_,W-K660D>DX\WE6NJL GB-H3[0#-*C\X:U]@';Z2CP+;G1I76KY*%&-7S)N7>\.^J.Q.J#P$$JDC9A*!N<\ T?F7S+% M!#8O[M^/TG%#N;:8>N1%XQ"ZZ]-R?<3/J_EAT_QJ2@M]G4]JG_"OM;?4]/,! M^:X=/MLB[?54ZAL9N(MUKY:ZSL+RP@PS$DJ2IK:_J57,*$#G;'W"A*HTS]%L MH:6AMW=GA3?3E8=;E?7\Q\4?WLA:B!!5R@J0A>K4"EFW@X*BT:;(,PHY7/3R M)%+'-6A-,/2 9S:8TCHU9#L-D[_18&_SJ.W9G5';+W$9)J=[F@:7,*H IG'&^@ ^UU8\/G(G6==K;J3G4]-Z1].TKMPU# MX=?O^^:W9\37T^]$!ZFMB[E;$;\Z(\I6V#M MKH$>1[4=)(^N&'_^XX+->@*]GN-_G^,T_7CV?;(XB84'%Q4#:>JD6BP1G"6? MVCO-973,"]4Z*MR!K'%Q.!)@ML&VD?9Z N0FAE[.SL)D>I*B]&AJNP=RR4!9 MF^N($ ]:RFRT\CG$UE=0.Y#5"2!;06$;U!KII5.H+:YV[*]X%G%^PB47W* % M65($56K+:&$XF&"8<,(G&08[JA^@JQ.PM0+##F [2#,]H>WYCZN?_F6"Q$6N>.P4Q"*_J6:!MZU3%;I2->VO>W7G;2H<] M(?/F;KO/W\6^#I&D9$T Q;(")5BD;2!-O@=J!&.@67N& E*!2T[23YQK7?OF<,O"%^2G N>I;1IM;W?0^0T\EA M.PJX]M%(I^"2%ZQD*9WCV8(@LP]*NP*!,PM,!8F1?E3J&."23P#78'5AXX)K M'XUT *Y-3_4^3!9_7SD37C%F8TI@?'04"-5NZ2%G0$W.K M.D4?1NFK_ 7HZ M@=>H@4(S?76%O2$V3(PD),X0HDH*1'!)!&E]T:U]LH?H MZ:]'PGY:WPJG U70 9Q>A,67UZ>SWR]>&5_88]287$ .J<9"BL4"+MH(F",S M6@F24NM1-!L)Z05 A^KY;L_C@X7> 7+^%N;S,%U>QA[9*&^R@74/R3=4+''?^K7_+0)ZZ4S1&"G["[D#A+0X_-].IOAFB6>+DQ2MT4YY*"[5 M##:)(<@B02=O#6>AB-3Z;7E3!L8MA._#$1L/$1ULAXO!I)(ZJ3Q-KQ 3,;4GL=P+$Z(22N^I\ZY_Y; M.+T5^E\S>&*23#KE "+3/E>&&_#U%C'HF)71@A?1NIO\SL2-7/_4%A0;W,3V M&AH1>JM&GK_.IOCCUS#_.RY?GT_S1GXPQNBLH4,%/4F-80:?!4+F2+NV>"UP MMWF0.RPVKN'Q<;-K T(G-:"'ALX[VL'L]7;2MH)&W@IWAB+6H%)*,BC MM1JBQEJY*G66.7 NPDZ@>62A<2. 0'34L =>$;7T?Q:9B?,2^=Y+I"BTW2\ MBE6E7O4@R8\,7HDLATNKKFG8"3OZY\).$WEW@)>MTCE)PAD>C02OK:U/'R-X M7Q1$FSR*K'A1LC%PMA*S$X+,SXF@-AKH $HWHMN'9$4VTX7HJIB;).*B5&SQ8,H,<.T'EMJ&_P=T)!IBM**-#2>D_N*OP,,70GGX:VYVHOOXNGD\[K'[8DK MTLM -EQ'%<@GD Q(5 Q\TI9^$;ARK<=;[TGJN#;P"#@\A@H[0.K#DCPITB%C M%/+J^K91"?)/H^*U-Q R+4B #%O7^3Q,T;CYB"/@KJ%"_CF>Y[^?UP8LRQ^U MM<=_GT^^U@J7X[W%?V#U$1[>[RJ+X5_97TM;&T4(1O:?2I0^,9]'90K)* H: /+ M/,C6O05VI:W;-_)/0S0P7; QHN7Q\@"F%1 P4U MFM_)4G*66W1EI\J(7? P9NGA RPG^=3"=GYV<7A!N# M(12>01#HR9T+"-Z%.B[)2FEJVXL/W&X07 M7;*KTT&9S1I45 )\'7+-DSGM,TA\*N4-M3+QU [6V8 MYN?G)%4*_NIMU)NSK_/9M_4;R\M''\Z&VB(%C"VU]8"2$.NC#^><4(:[PD7K M=Q./4]4IT/8%PMTT8ENM=("SVMG^G#YW):D+-F+R*MOZ2+?>IBL4&5RR$AS# MI%!Z%7WK3-064L8]*H=&5 OYCUTD]Q+/9O69Y$HIJWD<%TS8&$1VWH*L+5&4 M)??!Z5I!PJO[=4QVU;8=Q[BZ&PT4ZH8R/C]?F<*#^?(]G-=Z5, M$M[%N2PY).,T2*$IU$0NP0NO0>>2D'F>E7KT]F&WI<8MH1P4*VW%W,&I]&L@ M<4YQ_N.FI"Z[Q3EM)#,&F*O#+X-DA'\?09.?2!ZD<):UOCQ]@)QQBRN'/IU: MZ:$#2'V:A^FB]FI?*>] M5J>)@3V1L"O0]E3+WDC[AO,X&[O*Z+?:>:+6F@Y=4'1WH:/5#CW(X?!E0E:) M0G91@>5UFHRQ'KR5!MG[+, MQA"S2:UKPG,_9;.+L,I60L4A>;@6=/8G3:50EZ M2)I\#I\26:_F346?1N+(G5R&@LKND#Q8;QW \GU8WKBG(D0D)Q*C$X-1E.WK M:$VK$M1!GH9QB[YYK]%;!'0+J<-5?3<#9,INT3#R2]$C0N<@Z?=0@[NRRRM^;_F-K/A/DV6]SWDSS9-ODWP>U@.2F&9::6EJ/1R"BHX\ M7ZDS8&+)*!N%BCMU@'P$ !L7'^>*ZVB.P.$"[PTQ?YLLOWS T_6C_R^3KY]F MKTA>R\L9(IX+X1C%]=K5R>T<-03T!E 8R1(QF'=+E#P52P^3-=XYTP #\&I MH39&!MJ++Q,LK[YC.J^7-NL2J?F%A77.,@Q6 D=97]*RNONTH-U'AI:5PAVV M>"SV D= :BERF?MY=]!0N39[V&>KUXMD'$N%,AG*-*K.GB!0\C1@?#&>T-1+PKV%W@':/GXA03Y/"PPUT)OG"XN=//_L?>F74[FR+KH M+XI[-0\?*0KZ= M9"96*.)1*"(4PZ(:BNNR@=]^7?_.A_"K?F^]X^MMSW)-*[@14;+"Q1P3!U=X M#0)5RU+D# :CTUA[HL36N?E#[&/DM]7#8;7=3F%L&7> \X^X7"VF:87YTVJ> M_K/.5__XZ<_+C#ZN9+T< *-1M9,B@D^V@$W>NB!-1MVZ)NY1@D9NV3 Z7N9# M"6_L>H/=[J2W5SE? E%J'R4(7KL+"Z?!"\FA)E&PP'W"[>+@HU)*WNZ5>]D\ M:_PDU_;@BW>>.'"CV^0EDT,%-^NZ\:MWWY2/6!'EBVUH=3T24S%M."IV) JHX#KZ4 M!+DV=Q!*>.E;=TJ]GY+N']>.@U=#,8RMJ"ZW\&E^ODBX7&?:Y_.T^H@_<':. MDY18X8R3X\WJ'$M4$@+3M"LR(V1B2LOM3M /**44+LI\\2W,$EYW97WU]W>L1N/GZ3?Z%=H[?7=90JH_HW\PG6<^T2JK MS(LAY6LB[;L00[FEXR.0ZR)T#J%U?*05[=V'5MHHNE%$/;9JW&SZWKUN'*[/ MN*B-W L*XB""2-R2\: 5.)LD6*<4(UO8HC,[Z,VB@+ ?A_MB0VHQ; M_75Q'%[/%[\3$6FU?#/[(] 2TW!&3OM?\\5_:,,ULCZ)7$LNG0>=90)EC(80 MZE^=S"8HY5S:K9QAWY7'J2T]+<0&E48'%_2+_ /)+%T2UZINGBUQ@EYS3GXY M1.'IL"CIP7%/K).<.9^<2;EU1<-=*G;"EGVVV&K$_AX 1%S)T[/U>]SUN+97 M?Z>S\XSY-;'VHC/-6G;ORZNPJ,;!DL[3.C3YXEOEZT2G4C-.'7"E3;WS(X2L M$&)R+'D1;<+F_:I;$+X33-WSA^G)A=P!LI\,KS\47;^87?BF-MTY7X?AWZ^^ MXN+SUS![_WW]'OZO>J70%7)QJ4RBP&Q*+B!F->.;V:=5F.7Z M@#K+KS8\W.+ZFUE:(!WSW_'B_S_.S\[(;:B'?8+<2",+ V=B :6)/2%R07^D MF#379."U;JC1B/1NR]?WP=F=IE0CB+4#N^9^-3')TJ(N5H.1M0T7"@?1"P,B MH-%<"FUC\SK.>RD9%VNC@.)N%YAC)70PSKZO#0W:^V(U(-HV?Z63_&:Y/,<\ M"5)*IZ*'XB.=X\@3Q*(+H/>(6N4896L'<#?*QJT1[1>-1TFP6RWX88'X]W19 MKYIM=D[J&!3IK 1IE"?;.U<'@=/-(S(Y"B8$HUMW5]B;R'%[L?6+UE9RW1^X M_@*X,_P25IO?'0BZ%V[EA2CE-!?Y)47C M-LSM&)2'2.Q8!'X>VHYT"45QSH*WM7%*3,2G0%^))()DB6>+K3V_(^S(P3KJ M]@N[O21TI!WY:I9["21]Q#2?I>G9=+WNO-31P/1O\N\UKHWY'9*HZ,/Q,FA] MNLC2@92-$&IJP<,3Q)Y0!&6, [)'4ZW!"%6QUE02*PPS]3FV^0/F8+&G[;>4 MVR*XVG-Q#&MW&.")-JX$"O#:)DA>25FL#2A:YT?M1EF_D:,]4+*M6 <02@>>6^DS,!55J!4(:/$J-HN(DNCKK937)B;?K34Z4+ZB5)WO8N,K&:.G460:T7UXWKC"W=ICW(G!<37@2R,Q/ M);^&#=';V707VQ#<>/+_ _EAY)&I4DCY2ZL!>4WMEUEGWGJXP[V$C*OXQH#; M\?+H E:[LV[CKUTQCT.1#&H;71%6'%_[V9!P;-47?S/A+L0HFN M8[$U\,0T#FR@400X)B3@$2; M=,FQ*%N'%?17;^#?3K__OWL\N8(RZ^OS^8_W\S6 M1:B5D-,]'>Y&R @OA0=P:/B'02<98\(ST-)6CYXS<#YFD-[YDK-Q4;1N'S;< MP^ 3'+[:M F$+BT8Y* Y*(L% G,:L@KT(\5CY*UGO.U(6K=/@_O@Y$XIT !B MZ3> M>T.(^8Y[8E&&2UUVZZ3XZ#+=)@\<8MHTYFH'>N9CC9^\+W\N+WH]OH_DCWK^>+V27@[#7%Z-EW]HJ.@Z0B%]? U 2IQ!,?-.BLW!(&,'.#6 MEL\1Y([8Q+,A8K9;C9U(?!T@E9B8B(EO9C]P7;WR8I9?3V=AENXP5&7DR60- MSCI7IW48\#Q;8!Z+#"J:V'SXZ\[$=?MF>XRG-XQH.L#09(N)DW?Y!(;0VY7 MVD9^F1T&&O,3R&ELZ^W/V70>EXQ*/1EGW6VID=]$!P71 ,P>&SH7G%H[+$^?":>B4L07L(75:022 M3 ".9(YH:Z//9 IXN1.*]EEUY,?*X0$UF C&QM;&F+WBUXNTFOY8=T&[8IJT MVI+M4"!ZJ8_YR1>EV=87ZQ^G!9*3EQ#G4B_@%3Q#/E1&WN;>BO MS')3(W;DM^R$H(.6']]5;";]^4E%T87)OOQ:_U?[R?T(9U7_7@_CJ3\@77_[ M&S=^\UKM*YVR*@R\TF0GRDAV8E$,0N5N,#GEYA'Z)H2/6^D]D'MY>I%V@F/: MU_9N5B_#8O&+./SO<':.$ZZ8S<%XL)%Q4%QE<-H:R#8I0?:)CJYUBX&="!O7 MZ1P!,/= MJWTND@)OLVT23).1.T8),$,J) \!!$EN42"A6221M6ZO/PV!>.Z MI>/#[ AY=*+B#N;?Q-F4HJRC"TQ]VW/"@0]T>%S41;G(>?3M0VY'$#RNQSL^ M5D\G[6:)NTTS*]H0&O"1'*F@"NB +6,K3<1]U^6N]3-!V=P[C)%ZWCT>Y?Z;=? MMWZRGB:IA4,F3 :/M= NDD'M/;'$&:5#9A%+;%TH>Q"AXYJ#3?%T)\MQ<,&- M>%/70?,?ZS/R>J)S"3(75U^F'8M %JHEQ<\C>.,54YDV)'8:F$B?>@-I]+=K ME-U:<.2\QN$%.S^6RSU 8S/3V O.E":*8PP:E%=TAHS+4#1/Q=L4?6H&CC%' M3A\AK&UQ'\"YD07^QW16!\!N"#<\Q5*\!^0\UX9\"=RZ_"7IX VBRFZG(H(G M1'YKT9&%?HC(YBWXUX&[]H :7)\#P;S1D6O + LQ)$0(=6IZ](67F+GRJ75> MZB/DC)S=?+*+H[5D^@79[_,Z2W.269%>>E.[O3O:3.UO([4'%IG%'))4OO5\ MH$<)ZM*NW5_LN\'I !F,_?CXU_3L;/Z3/F>^J+\VQ>5&]3I&.I>3Q6\RZ5\5 M;$T,KY%7Z8-V+#!9=AM"^M *72+C$ G.6[-S;$RLLV!KW^'O2-S9; !YION< MUSFHF9'V9:$^DP&I6%B#OAX;Y/'_]Y@8B,_F"F).N] M#$;LIC8>6V;<'*>A]$?%01 MM#".9:(:]U WHNU'2+71V!R )/'MH(>=^MRR%*:Z$ 7Q6O7/4EW M.?,UDZQ.K&/GSP)=:FG-X[ MLO(Q"&*/DV!UM*+P5&+S*54/T=)/.*Z!*FG"\ Z 53%!&K1 H@="VE=>0I^ISICV0$STS$LML3\1-)*8^0T$]T[@B(M&1S!RID MPY47L_QN/EO<8-$GDLSY90954:HJ[AU!$U#H@PS!D@EY'CGI+43_MN^_# M]\Z0]W: M^Y3.OT\Q?_KO>K[H M;0KZ"6 V5T-'L+H#H+Q??<7%BY06Y[3TIDDS7Q .U'!BS"IM3Z3>])HKI, MK&R#M;8"Z0!A#W#KJIMS;7AY\W@:)94E)*P%1J=]#"P;G:8U;;7$S07KK6$SL>(>?X<6^;C_X8 M?OY!*%Y,P]GR':YJB'B)BQ\USJ8DH@T,&.UOAX^X@N*;2Z."ZN]K17_/%?][,UFV=EUM;2CQ)K@6'4!@YOREI<$QR MT%)PKUD,S+3.J=N!K'%CH(,CK)$\>H)8M1677S'_:S[/6UNRHL0B:3(%8'NFHGLW.\5)=6@[**052R MMM5"K3%PM-N3;-IA:=<)NH,%10<'S;X<[K.!ZCHJMXG!7S?!'/O"#D+L2TCLIJZ8"41T6& MKNT89 2?K0]2%N-8:U/A2)*/?C:^6&8]EV>)EV%=G;EUM@YX$G3*5"$#,'I' M?\U2(5/9LO;OQ?<1,JX9?DHTW7E'/EHN773))W5[/?WIS6S=*>=R,PE9$CX' ML-S624^U>;8@8Y#I7)C5+D71.@_O$7+&M[:7PI=J*SU/)(7F8P1VL!' M3#C]4?,4+T]$("M1F%KW;&OW?1')C.29@Y49HT#ND+7.QGNBN-9^N=U$]VLN=J.(FUAT<*TS91ZF9MQDAS'Q MUDA"'6#MY7RV9L=?T]77E^?+U?S;AF4WML2DT85Q#R7H6FJ?$\0@/7!OLB!; M,R0K&H-N![+&S7L8$WVM9=8!##=LNY%S'9T5064PNH:&+=?@2JDEV98[(8H2 MLO5C]#8-XR8[=&"V'2:-#M!T>V+2U9$P.FBK23-S0QY,6)?ZUW99@65M?)9Z MNYUM@_R&>P@9-XEA3%P=+Y<.P'6#/7\0>_#L+,QP?GZ5"!ECS#KR6FX99=6\ M$9P7''3FR3&A9/"#F&@/D[03X/P_$7 M9=47]*[B@(5%I3W1G45]I?<&G#8% MI,+B"K,\86NE=I>*W8*S[!^.L$-$TN>CTCKP=^W>O N+B]*E(YZ6GOK(!@], M>U'=Z)EIO>;US+22H\9B#: 5",HH#BY6I2)$?6I4HL36NO\V!<=W%<+*M-F7 M]I*H<1^'CL# MW=Y#+=G?9];GUC&]+!6?ET_A##\3R5N_T$[I[+Q4>V5TV"Z'45*2"V.9MB!R M?3I$Y2&B51"*%89)GY"U[E;05DE5%BXK#^EF_WVZP+1Z/9V%6;H\-\LMWEX6 M=7^>_[;Y+N:)L)E)3MZL]98.$J.KVC$3(::L6 IUSECK!_X6='>EZO9!TIVZ MQ%,+<>PRZJL-KS?VH@X-HNWBZ_GB)5$R7;VM-2:R$.-,\&"#(X>$2U+O-;TI M.EY?]+W38;?ZZ5U6&_>ANP&6AN'K_D#Q%T"9X9=:GO&Y79GTK:UM'8B)%LPJ MGCT@^2VU-V&=*^01D@]!2Q&C:1Z6?Y2@<9^YAU!-1[.]F7LW3-Y--JE([3FP ME-:3ZP/4DT!;42+(G(/>'L,P>M[-8,_7#?'3BN7]**+[=O1N/DN;37ER.UA- M1DL6;9UP)L'5BXHO/$ZY@>5]!:E41H78'X)%%=>7S[8& 'L^H( M]G?P'-/"A?V(M<$FR?!]>3U=IG#V7Q@6DX*:DWOBP,42B!$^0;1! _DMJH2@ M,)?61VVPS8R+W\:@&R"(<3P"_B%'X1U=6Y]_XMD/_&,^6WU=3J(JNE3MDLG+ M(F7C8DVE0Y"FL!*%U"DU;PLVP#[&#;/T?P".DOL_!/N??\[KL5].@F+)R42; M5;J.$%BWB!1DT3-;3"E,&-GZ>:TE_2./Q>L>ZP?)^9^"<<(K7NR^Y,2T:?\A)1U[M&^N=S#R (K^<7Z8K/\A2'\]/U]<;%X8EAFY28!: MB=KI7H 7*8$OF2=FI0M>=PCTJPV,W$:^>YP?)NENGB)WW/G-';\H1$3=2-&Y9R#"('5%H/6GD>Y_C M7"J<%<;I9A$UA3QG< P%,(Q2"5.?>EO7CA__"CI8U=/3%P_<]C^&3) 1W.M>'[Y1K"1DQ&+D![S!ENHV$=L,^V=U'U<@% M,:>T HX62@?J\RT=D/GB=O+]U22HJS>9RR?WZTQ_(Y/E:$&$$.B2P @1'8\X1\ D%UH/4>V^73+X?6>^D%62VQ>%9G-7J(@BD0 M]5'%EA@9;QUR.HK@L?,;AD?4'B!N*]YGA.4[CX"84G"2;BCE?'T@20B>6PY! MRO>B@YZN 08JB;],Z#-]Z"CH4ID9GG M:2S=V\<+;<=@/4B(SPFDUT]R3D2RPBR"MH&.(>;Z3)$$<)V)DUZ&T+QIP/Y4 MCET.T"]0#Q/D,X+J]:M:"2X*)3V@T*)."*"[PGD#UKIDC N*;<\3/1E2.WDC M[1BHAXEQ[,?11W;W\).:PY"-5PFXD9H,&\W 1[+*-:K,E$PFL*U9/0^\@QZR M^KA/GB<$X&GD\XP4Y<0;JX4WH_;]X=/H853GQTTJF:OYY8 64>[/'I#0K^#MU+)Y-1,".YQ*08 MK9#D'@=!>LR3"E.:G.-@& N\=='X2)-1U@?O T\. 5IK M&8WMLVYX=7GI3QQ7RNL4:\]O.BK,:J#-."#+EJE4\R.5@E M'L:%QR;17_WT^_5Y]D>NQYG4"7G9)<&\T<%;(,?;>T59J!RW'HPMU"E[9 M[Q:[?YWG/9KDZ+NL ?,[N-%NL?$VTR9$L).)U".KK9&4LPYBU@***]:'XKPV M9DBK\#8YSWLRR3$W6BL9-8L[-'4#/RSFWW&Q^D5>T]61FN'JNF?*?;]PA&-X MU'H-7,5V^VWD/%ZN]^$LD#*[L>CU;-9B2*=A &UM(;-)"/!9UEE+5GA>+2?5 M>BK6DT0=G8:ZX??[\N!2G]ZBHPDFL=S:-]Z5 MMG&]R;:XN9.1.H1\.KAP']S-;[_6H<"_I\N)T(&59 J(4*\(P24XX1E(5P1W M":-NWBIF![)&;OHR"![N#,EI*YR>\58W]/N\IB-.K'>)CF0$9-4M#IIL5F4" MQ&2RXUE%FUO7V^U 5J?:[5 H[ JU ^72 =3^",33&2Y^W=S.'_@MXH+L5"T5 MXPQLB!:4L@:"1 1C71#.95M\:U_B$7(ZA=:AHI\/(X<.(/7;.7%R.OM".[G\ M\LVW[XOYCPN'^W)3,J-!G\!K\K!4L@F")[8QAA8-P\ADZQ3-G0@;-P@[-,S: MRV;LN-KM=_[-C*F+;;C$I3 J@2F"SDW.%IQ.%K(OB-)(G]R6_GH@IO;P&N,& M8H="2TO&=J"0WI)7OJ$\EAAB'9R>;"!#,T8/448)FD?"/#=D:3;/8[Q:?=S@ MZ]"JY4 N=X"/E_-OW\_IX[;OW50L=]Y$,$S7^%\F1C"N(3L?N*_=.9JWTWZ ME''CJ$,CIP7_.X#16D]^G9_E>VY4EYADOGC(6M4!A\CK5BR8X 7+PAJM6T^Y M>82<<1-5!U=$C>0PMF7S8DIL#:6RZ-_X=9K.\'(7TN7@O8H@LLF@?.'@DO&$ M@5*\BTHDSW8R;!Y<8MRDT4'MFC9L[4#?O#Y?S*:K^F URZ^G?]>O+G<2&!IO MK:U]4F)E3HVGU?369'6=LZ.E:VWF/$S-N$UNAM8VC:1P,)Y^X"+.VR0H?)O/ MZB- E; Z\RF6,,/(0"6H#&DXJPK.VF;AU88MV/,H,JF M"5,[T#4OU[LX3W4;;V;$LB\DI,,5QVA!)KI9592ULR@Z2+29[%*NCTC- M[>2'Z1FYZ%R'Z:J'(QB8P(S/1I"OT_J9^#%Z.GV2 M&5AM[BN(L>M9_YQE_(%GM)M<'P[^%Y[EU_-%K36:"&,YYTH!,S'3$2'?V:4: MD%%HHG8L2[F;O_GP&IV^Q!R'D99\[;/Z]($TW'=A41WL'WB1<=LPP7C[DX=+ M)7YT#R=+&A:1<$67$G!9:CO2(H N) U6FN@(>B6%DR65G3QI. M,7-HZZ:J. M M)T28=$GKD**DCG9;+8?!C./R1I>!_<')PTO(]\.O )=DE&-*E8;96'+(EE M2I)O[J.E&SL*2SSE&=G)DO2?7=+P7G@X(&EX'^'TC+<;<<=DK!,J><#,&;', M&/!:%6 "G4;!;>+\5'A[3DG#>T'A@*3A?>0R]K/T(WEAF)DV="RA.#)8540/ MY-4RT.A%X@)-D;M-(3HRX6[4+."]9+ECPMT^C.U9%5T[.,26(HTLH'(=@"!= M 2=JR:T@)C$=@S$GTT3/+:P_R,5WF&@Z -O->!P9HDF3>RN!*:'J7(T,@>NR M?GRW@:4B;.L^;#?7[U0['2C;.R7-!S)Z[!OK9BWVO/QK/L_+3_.S6P';2?)Z.INN\&UMI;O]>T>T>CEVR09/-$UWW>CMIMY]/Z=G M9X39.\O>[5SD B,$!P4AIW4:8 "G,X*,5@K+K5.V=?^3O0AL]Z;SB#@NG&4= M?')U3A/65PGE%:-#*4Y26>9M;)V=L#MUX_J+PV'JX3>>IO+JX')]9#^_ M_?HC_._YXN596"[74>1 7C&S@H$,+I'/K.A2,8P#=TH[+"ZWGU.X!WF]O/JT M1Q>^7<:I>6UVB-R!9756.#-TLA,Z$,&2TQ1D8*%UJN&> M)(Z+R,&@LCLDCY9;![!\>4ZN^S=B67Z??+Y\U5)TTYTL"G\AI5U@K M()"M&_*DG*U,.C8OL'Z8G&[A=CP,MDM(&LED[/#/7D @A)/ZMMRDH&JWI<8JZ$%BQHWCGE(!M9%' M!\#Z$%8WNPO(*) E 5@2 V4Q0Z@)(S8A8BC28FIMX-\B8-S ["D!=#C?.P#- MIWE9_0SKBO'++W^_2-JN)V'=,?JJ$9>WA44--N?:D0#)U5&U#$IJGX.T7LOF MP8M=B1LWD'M*L TCKPZ ^'D1,GX+B_]T 2U! M%>W!J\*!CH_0LG!DKG74X!%RQNUN^J+\VO6Y51WQ(A>@O)9,>#UQ#T,X!8BHQN>C]=I^(!P*<#ZW0)3(. MD>"\-3L[4#)O9AG+'L]3/@6/*,DC38B@,"OR*9(!F3E*YKB*IG4/I3U)'#?T M>:)K;DBQ]8_*>^U197U1QG%P+M52%N7(@HQTJ(U$QYB(JGGKN /('%<9#@J; M_2!ZM P[@.F=L(N4H4:+'2@ZPJ DBQ#H) /9'-%XR4S.K1M_'13T&@M@QPO] MJ<#7/A+H $&/7!)OK]*(T<;@,^ M$8V?Y768@/H&W3N\[L21E+ \60DZDQ&K.)VB$(,%&J(N?44IZ=HZA9H M!^-@=ZCM+Y2^0?90H1\WY)6[4, SE^MSF06/=%*MS]:GS+S4)[Q+EOTSS;_A^ M4:49 M,]EGI5L7;0WQDG.",L+V:#GR-6-0>(UABZ3 1[H.35!!D2&;16[MC3[^@#"H'KHV M6EA*)&C/P,62"-&T[X 8 6.*"K,HJ7GC_T/H["6%JB>-=)@0^U=+=RS<*QLD M!BY,K+GX6-5OL!F\J2,X6#11D_9-L;63?BBM7;\&-D#1?K!M(])G"-V)SLY@ M2>04BF1H5V0V>Z9-'5:K=9*.;I<3I^WK2!*$!99%J+YE N^M@VPQ8DY,.MUZCL0Q]([[/M';(6@KWO%?S=:IUD\P M^1VN[FZ3,G,JJW"K@>2V@]8?-R\J)-"\B3R MZ4&C[K"G*T8J*S2C^P&\K+>%U@6BX0J,%R(R+@J&]K;V[O2-JS%/%^T?3&;/ M!(\3%A)R0XXT+P;):G$,? X(I.,Q\9"%;-Y"I)EZ'-#/&PH5!\!O+Q$URRX8 MNJWOUOS!5JU[[WSL,.UY'Z=^E!:\FAL7&2&P!"0MF#2OTS8CB)BR%MY$)UJW MTNBU!2_7Y(+1\2-#0=MJOM*)Y+8:*:*$J,E(:=[$_I_9@G75P MK^[3J),++C7W=>Z(LK72Q)'NKC=$L*Y@M+'HUFD=_\06O'LAY(@6O/N(JV\D MWO]>'J.TNI8\&9_H/"<&4:,"\NV#*UXH7EJ_E_]C6_#N!94C6_#N([>Q6PAL M.N71!7,W;T$GIGURA)+::]%J8EDP&J)*+M%%(_UV[\L'XBT/K]$M?HZ7Z[P] MDSM08;<;*Q:G3=#>@N2UTT*NE20N$G\RV1M)IF19Z_+L_1M:=M-F]Q#X',_W M#D!S!_1!5W C$M0S*6/RQR'*&(A^&R*I8Y=SZVC:09JGFV:ZQT#G*.Z/B)[E M8C7Y2*RY&+$!#'WJ#;C0WZZA1BHF47)VPUUZXY01#'2@C2DL$1RO;2N=ERP3-[5O_U[[#V]@MA=L M&C0PVT>&'<#TCK]G-,;B/0>4J?;#Q-J+JP1(.3-GZ59@I34&^XKS#2[TISSN M?230 8)V*DGWV?CD% .G:\=XI-LBHJ_M%(1!H;5U^'\;F)W^C>PP 74 NLM9 M8H_L[2^0V^WSQX'HF<^DB@/ABVM&N>M@'NC@='=Y.U)S$KQ1 <[U)"K MDDG2.7<)F,9B2_2,N-H:FH]2U.VC22/PM1-'!UKQ$7;5P5)O9NF\4O5Y_A%G M^//]8EWKDB=*!"L,WC(Y1V^PS3!HPG$%_7 M(-U2\Q]P,9WGW[#,%_@._UZM=QW.-OM>UK(LH:3/,4KP)7%R[ABI_TRVD1-% M)#*C$Z;67:<:DM_MA,6AX3RLH#O ^%$%6K;H[+)6P".K_E]M:ZC(MXS>Z()1 M2"Z:=\(8NOYNC-&-;5!\,E$V@^W0V?V7;NO\,;?U]?FJ)AO?,*]>_?V=#G/C MDH VM Q31S GT8I/D"7G;&^0.)9UO'&Q<0S)91( 0QCJ3H*&5Q)@DRRY"/&++0\8>OJ M7+28S!&",E,!DYV4'6@Z,- MD%_K;&+*)(NMI[$?1NFX<8F>X;JW',C M5(T2LBRI*,U5A*(4 U6, 1<"UA[YF%&(S'+K)B$C]4NY7/8B3%L]?4E\6^SA\ON%HYQPQ,#+CD=(*3=1&XT^.B=$JJ@WYZJ\("K M]L "(R/A<'G-&S-O; "\F\\NMI%H&Y=%ATP4)^@4L!(U*"D=.8,7X;P1_+M XNALO[\NU59H[.P6:;-6AOZJB/6+M4V$*F%WEJ MTI*SEENGGMXAHI?F#>VLB>/XW!%0/L[/SE[/%S_#(D^D<=XHIFN$LC;FRA8" M6C+5LZ3M*)98:/VJ=P\9??@U!PKV 9@W'T8"1\7Z?^DI&\:#-QYI)ZX@1.O\Q>UH3Y M6?KU>1%FR[.U3/Y%E_#;.M@>F?)T019 '6WMC4)F=PF23"=N ME+6C:?X;4[ M=7VDL[3&5&.I]*1_7*ZUY#X 1DG4%H;@"MW>H="7)@F17.ND[3X&H RF?_;A MZ)'ZY]4L#Q6Q?TLN/^+']W]>1!\#K82!P#<-<7HV74UQV:)9^@&K-(C['[NW M1D\#ZT67UU-,M% Y6L)=KCUP&%.$NX"0HF0YJF2%;=TK_38%Q^J4"[:^_[Z> M/37[LO[P34G,9UQ\F[B@L*A4Z'3)5,>[)W!,&0A:2%-\8;&YJGF"I'$MH"/D MOZU\6K*^@]OI]D:VJJ[J0\C\?+;Z&%:U BL1IR=8.):L%(14!\;*)(#L/ \Z M1Y.#U#'9UO5T^](XKF74$&N#"F?L"-_6$:I[>U_^7%Z\P;U(Z?S;^5G82@F9 M:"Z=84Y 2:Z6:=$YN/QA M5=I\$NA@2*,$H,_$39,YQ!CJ>&%C;:WJ"*%UOX]]:1PWM_946NU8X70'OEJ6 M/W'*.DT'"#Q#3CRK8T&EH+\Z+ *=X9JU'@-REXIQLUT' ]#>#![[XMM2N>]P M]9)\H%^TGW^'LW.<9$N^KS,1K&*TEY U.)="K687116#UN>=[K@G%AHWY;35 M==:2FQTHCU>E8%J]GUT4_;X,RZ^OS^8_:YHVF7J30JX$.1,*DC02E!7E(G[B M/*LSF7).L77:Z*,$C9LUVE"EM&-[!QA:'X3KI@0OOX;%%UQ.1)'&L>#)*=7D MF483(""WH$,1/BB)VK?VW.ZG9"?4N&> F@:,[K.EP]-AN^O.!?<%1'X+9V&6 M\--7)'5<&V%.RS2M:1HT@GDL42<)>#;EW##QT10X8YG,)Q-%!J5]373U' IZ MHY,W7L;VX<.6\=%'?=Q)5=N)>0'25W5>YR3%0D<^2I,DF071R]9I H\2U%5L M=!_9/VZ8'\/V+AHQWM[.Y1'^=?$VN9IDEM'(6"#99$G-)PE.20>,9Q,P&*U\ MZU>$QRGJ*N[9#D=',;X#<^R!W;R;7S3KHPU);H1SI8"QD:R&4'M(6I:@) R" M%^7)=SD-DJZ)ZBK8.0"8#F1_OWB:2),]Z5AR@&PLQ>KFY4)#F0.794?K'N,D_$Y#6U+GC%':KF99^M:.\J7CN<>3>0,/L%\;4ELL?6!??D M-1D-*.K,360(/D51F]^*)+F(3+?N"=20_*[BQH,:EP.)])\9-KSBWQ]A=;Z@ M_Q\Q6O@@+1T$"7?CTS"Q0>ED8#(;\)8,WCH%$)R4A4S?++-44AK7NE9W^-S) M*X9^"+_6I;?W-_@4*)WGL8#E(H"R4@!=/!Z\3T$EC,Z&UL;#X=1V%57G4$$QS$R0$E;5"8J<&@D""<,;=B1K=\Z?>E06KL* M4@X.RV.%]8Q >=64T_)(AH MGAORUOTUE:8M%A8 51W&1+H? O$5K)3!BARYQM8]UOEL:M Z*G0M[=PQDX1?71S MG^>_X84YVE[8N4#6:/[K]U58/(0 M3)V"Y\](GTV,"%:Z:(!QQNI,H@@^Y #:H%7,.V=RZS3376GK*G)X"OVUES Z M>&M\=%]_SO*F:FT]"HM^=9-AZZ- +:4"(VLYN*B#N#P6\HEX"EY93M[Z*1'W M$*%=I:X.!K\F8MH?B_X"BS/\4NO//@^>,!%3<#YE#RIF18ZXT^#KD$R53"I* M"1Y+ZU#F,0D3_AG J@6K^WS;>+_ZBHMW\TUGDM6F4^SA[Q./?EZ#-X;=Z6WT M3O#[1E2U'FOY,GR?THTR_1_,'Q;XO5I.L[PFZ>$6NY:\/Y\SI%0,D/6D()A@ M@:$P$E5F+K:.81Y)5F]F9;[XMA;U18>WY(6RVB3 M"YK(W;$ MZ )85E)F.F?5O"SU2:+&?5;N3<0EX=. 2_XV+Z8]U\Y;&SDU$/Q](#EUA MZN5\MCYSG^E?;CJ;1IU8RB)!\$BG+R7Z*F<+!=VZ\5,1JK7%]1@]8ZNR5E)_ M$$Y'BJ #.%V68OXOS%_(K-PTM;79B'6[05+B9$[&>MAJ,J,4UI<@I!"\=8#B M7D)Z ="QM41UCJ%R14-0CGP20;89A&5H9"J,N]85 M8(^0TTMWX2&NME92Z !0K5*O%5,II!B 9RY)M4M-1C7!TY M"O3VDD$'@+HV1S;SU*XK['CV7KG @2G!R'10##P*"8P%66=*^]!\P,O#U(R; M_C,4E!IQOPL(9#D,-.-\!@E[]]WE-CL?5UWE^,_N!R]7Z-752R.G1Q APT0H@+@F(J4A M(83,B$:9UA6R#Y R;AK.4/AIP?<.X/.1"%],ZSC:Z@C?. :":1.9)6:0VJ1] MA AE QJ<*2Y?_W@WO7R( MF^4;^S*%2Q.TA)AC!%6(N_'J M]<=TF?#L+,QP?G[+#!2*">?IY%BQR?Z.Y$$ =](7D9SWV+QS]Y-4C9M0,YA? MUU8:?>'KQB:8RDFI6J@:Z@2R4CU4'0L(\C9-S\F1.@Z$"> M]SFB_/(-_R/^P-DYALV;_>4CQHTRV,N6 %?5L'O_TR,R=,8@LT'BS^C<;91/ MM"'B(Z;YE]DZWDH7]!:%5VD=(7 IPGK20:X=6GDMF]<<#!V'$J,(-K2^V_:A M[^A7T(T$_IJNOKX\7Z[FWW!QHQM1<4XSJR#AVE11";PM"EB6K#;NCRRTUL*/ M$C3N,\%@N+GS2MI,*&.7F[Q(:7%>F1/#"I?$KA=G9_.?M0_I0 LLF?,LY8[=R!]99-S@_N" :6.@V/ MP,O6R=QK*XW-8"UM2(E@(-3A\8)T/I88=,@G=17VZ5P]V&M&']@[1$1]EDKM M'49H,=_V^$7'B+V<9/KM7O@NG!"7G#QFE:UUR=,I( MRO;'$OMG7]8)?K_]JMG3%QFOJ&3.*&JL5IG:WUD '7D-C,QB3?X9\:&UO;@3 M8<\HLK(/CN[FH;064@<.RQ7W-@,./^!B_5XP2_@^GDV_A(N4TN]8G[\_3[_1 MK[POG^B[RT+\I)]]6H7%ZG>R%]8%(MKDY*10H'GRH!B9)BYZ^L.QZ*,HVC7/ M96F[@[%K)YI#[$XNPVCR[@#MEQOZ3'Q=EMJ6\5_S>7Z_^(2+']-TL25T42LD M \HP1BY>[2M UDT";FJ"1V92A=8YQCN0-6XPVBX]5"%V!P.^\'M -F,_5IRLYDG&4"?R<#' M4/M";>KD&-<\"-H+?3>!0I_ <<,@Y1 5%P[1JJ>\F5T6ZAHWA\AU/A"31P1, MQMI8[$LX>S5;D8]_4=KK/?=D&Y.V5AF4,G66.K<0K29F<16DB8_HH26F_^?+ M_,?_2Q]]H8+HBVO-<\^"XSYT#'>A'F,#_F=3^-B9NKC:,XCA;7O 'OQKX[?IO_I \BA?;7].P_T]ERH\V2 MF2K!&F>VQ?_ E7'_YX\G\,,%-6_+M0ZLU+OADS_. MSU;3[V?X.YY-?^"B:L(;^G'Y]BJ+D DLIC@!HMZE"FF[@=4K+WIO=4IU4-W@ M0;E=J1WW-?.$COVP)^N=4)!CG0<2DZHI5W0#69D+ MIL3,=I/D\8.F&]I[RY'K!\VM!=\!X"^3!>>_PMF-U\+;"5N%%648]\!<+2TH MG(SGHCTYV)@,2[R&9MKGUCU)5V]Y=26VE0,E,"6TE$[R_I/,3YM"=!';M1/0/R22YKF5Y^;7R>CF=;7W&. 5!3U$S M;MW/7KP:(RF%#-0<+:ME>L=N.+01-&R91IW?UD%[IZ\[(: MH6A;TS874?<7//$C\UIB*HJH7?\D V=U .M0.-1"B=BZ1V+'567MY;_75;Z/ M, Y&UO>UL[1..SD^TOWH?K9/:,[KL[N<>"$LSRQ KI4HJIY.K\D8XI*E;(06 M<3O[\(% ^$'+C^MC#P:Q$\FC=XUV^Z[X'\P36?,:4D:(BI/IS8,"9ZP!E*7$ MPNC(-<\(V8_"<7WI<77><>+J9_K,XXI=LSJ1DRD0:&5E'X++MH#-(BFIDI.Z M=42R8S=ZY%MV'V$<>O1LOM1>)2U]@#_+QY+'7(A MD_4@ EKRFTCYNMJ^+[N8I+>)8XX[&66/K3*N>3\@&&Y98C\#J .9W !]2YHL;F[C.)K9,10'.TQ_*0?D!TB'3GK5G= 5X^WMV!"J7(FC&6 Z?+7^4"0>H$26KBB58Y86NPW*5B M['20ID@YDLEC)_4^<(M?/_$F9G)!YX$KMGZ(K9MA ;0+0@=IM%?N& /Z[;B3 MA(8Q9=JSM@-U\G8^^_(9%]]^Q[BZ;/@@L^+2%@V2)00/*.^VD([;Y MUI[E/63T9P4?*.3M0=='33"_+N"XM,UL5[ MPAKP.9,9I^EJ]J9.U,W)&F[(BT Y!-#N(V:<5Y(3X>IH[G< HP>FPE]U/&+% M* P-/PX1>,\@@P/J(9RZ !5F^-QCY;5&HLB M)P&2B#7;&P-X)"V;!'+M>2DQF&&4TX&77O.V>B=33D=ROP,87739?UC51F;( M5I1@D;Q9%>CN=CR0U2B,R>34LM!\5.SC%(W3*^\$RJF='+KHD;P^$YNNNY>; M*,73>; 1-$K2L%HQ<(9T+3'-\RP,J=C6K_WWD#'.9)_A$70LQSM01IM1(G_5 MMH"SU:^-9_'R+"R7TS+%?+4M96/D2@.*&E#A9/LYFPH(GQCF%(63K:LO=B1M MG($^PX-K",ET +B-PJ7=%:2=S&?DQ^(#]4LAVTC[H9L\('D=N0APRDK0Y'1X M'V,RHK7VVH.\<68 G'B!'9**5%J0O=8QV<>3; MDL9.(GMI8Y&:;1ESY :<;-L1'Q=IKJ//79EQ=?%KC. [Q2 MJ@Z-JLT/$Z\N18H>0C UY4\7F;5A<;MN^P%,/+C$;JAX1O'OAASMYYJZ/3Q@ M>Y[ A&6'P@L!MA0R]IA1$ CE8#!JZ:S/P0XP;>1IPG8#UW.-?#<52P^C'#9Y MP1^QG,_RG2B9L\IG90M$C;G.22$#3P8#207G)%K'FMO/GR[3V7QYOKA1O\D].E0U*;]VK?&: M$9:4!Y&<+@EE0=[:_[B?DN.;T,?5FQE]UGF]DB]2)'30612NH7A'AAKFVLJI0$WKA)BUU2FHE&-ZRA*YYW-[DONA@IJWX=K8 O^(/^9G/ZX::3N+ M,>BB@:UUIB:_+$CB SK-0F(J1ZYW$OCMSQU[BD)K@1_!M;$%_O^%[V%&_*]X MO6R=JVQ4TA@'.=0$(HYUV&=FD%D4BN?"<3M#X@&IW_/A8_<;;RWZ8_G7G6EP M[9USSIWSQ(GHJMXB;04Q^$!8YG0M6FTCMNXI] I/>F+UL;D8?SN!#97F:O> MYY!$!N,$$CMXJ,6O$G+113#DJ7VWR=&STYN*\QZ(',+;#F!Q,Z7^YN,C"[3I MY("8P[R(FJ]+^8Y9?A^[1& MZVL6ZG4?W^6$H2E<) 0R,6IG#Q4A,D3RR)2TC.G,FY>)/TY13Z9,.[732 +- MGFJ:Q]3;S).]YW,:1=)/,O7U@6!J<9Y)30YJX9+,&A9J)6Y P!*=4-H6[EMW MZS]=$)TN3-)]R*"$:N-[62#Z$,E*%X)+]'146K_-/9<@^CYRWR6(O@^K.[!9 M7M*2T]7KD-9/B.O0GT.4M>I&!\K1PEV M^\7V."YWAY/+T($H61@RSSB1%)EPP*KR CN7:J8 ;OI .&FOZ#K 2F&J/F48)Z M@L\A\KX[&Z01\SM TI^S)9)7A[EJY,T6"K$@UZ"BR#63G%D&43D#MBCNM>:* ML];9;/>0,:XSW1PUQS*Z ZR\Q=6JSEN]X,UF#VC1^N(EA,AS[>KDR!T,AN"/ M0J.Q0J;F323NH6-S2G.T3+U>A.U$HE!R::2(>(*_",[E1! MITNALLZ+UA75]U,RKA%SO(2?@,P![.X -(^;8CXI'FK2MRFF]I 7 B+S#+*0 ML;Z^O"U4X%X^B T2$CWA3-P*NB0*2@ M'./1DH9NK7SN4#'N534 :HYD=&=0N167($*5*\: 9HF#0I,A"F\A*Q.0!6V0 MM_:<'J*EIQ>D!A9."XYWBIRW]=%EL3E8,JL42F20 J?C0'RA@Y4-B&!\5-E9 MFUNW)'J*II&OK2:2WP%.!XMA[#2[-W7^6'U2K?1?YHGI:#VS(A+9BGQ%E^K( MDD"7K^(VV\ -W^[3\$">W7V?WA\B#A?>O"4G.] P]Z2:T^T<2TX,L/9K4ZI( MB(J88KE2GM-9X7R(E]<#BC8&F^_2^CXZDLO=X>1&NJJW*NOB:TX8:B!E&B!R MQ4&4S*VP2AO7NLOTLRG:V$O&NQ9M[,/PL>^:=_ASZRJ^K.^_S$]FKO;RRT ' MJW99)UX%)SF@$LXJ5;6OVNG>>6JEGK!QJ##G0W%V;)A<9JY?!0ANE*Q@MD9( M9R 31^@^S1%"81:X"9X7ETO8S@-ZH@+@GD5Z"N^V $]H*.5_]] M/OV^O1%4M5.Z\I!2)/Y@'?C F0)OZSNI2X[9_=3&?:OT9*2VQ,;1'!T1&LO% M:O*QCHE?6V!D?!E&:JUV%E/DVRF$&%V-,:OH66(QX$X1-OK4&Y8I_>W:*KVU MX#A==%N[+8?SL ?!7[XG1(*YM@@F9EF+#@SA5=O:ES7P@#D7NU-H;!?1CVEC M'B&L;7$?P+F1!?['=#;]=OYM0WB.1&>)&71."$HD\K<8:;\$' MB?S6HB,+_1"1S5OP;VS!A[]O$%Y*?4)2#)(5Y&B[X"&(*$&B%MX$EE4H+01_ M<]%QG(9F@C^8?QT$H_X=%M-ZN7T,JXW6$X*%:#.0;4-_<&_ L75AD,209Z.;!D&M3QY $A09J :)$8Q67K;MR MW:5BW##4<5)]!"('L'AL[_'%&7W0C&C_+2S7>]BH0F-J\2 &*'7:HTHRTQV8 M+&TI9<.+CZAVZSCQP +](. 0H-E/146R@TH&JX(E"RE[\G\9 BO9%X^YY+PC.O9;>-P( M95/4#,CQ#BZ>UTBB"&>OSV=Y^:H43+5\]M//\/W& =$NBA2Y Q29K"U+CEKT MB4,6M2HZ!A-UZSYG.Y U;J"S$<2&$L.ST5/O9_C'?+;Z^F9&*^-R]0$7TWF^ M>A,*.81 ^T0>0.WHV"RH82>#2H_3?]^ M>,>L,%4\F1@F> E*!0V^=DHL+O"(Z'S>=A2/Q>1CY(P;5Q@%DG#;U=J^.=LVGK)TFT^XP?G< MF[?W)*UN0K:_S1>+^<]:11.^TT]6OR8J*:.4%L!J^:CRR9"*+HHTMM2Y1NX] M;]V2?1_Z>DJ].A 0.^2#-Y'.V!?H?1M[D1+)B*3U&L.*%/>;65I@TG[?+'MQ MW>/+^7*U?(>K"=>,8\VW=\994"61Q^,-0M'>FQS0JN9EEP^0TE.J5QM%U8+G M74#G)FM^H^.R_$2TA/Q^=M- Y1,GHM/*1N!8)X.;0OM"(ZHA882PN3@Y;#+Z MP[3UE"O6"EP#2*4#M-VGB?^*DE9+(]B^,NI-QZTLX]9/24!-$&5,?RN@.XW&8+ MG0Q\\6U^/EM-G+RS-1;_>)93F&VDPQJUQ'RB@)OKZB::;JA%8E>1XB MD/4(2>-,=A\:2ZUD\!PF3/Y1O=WU@,YYN=E1I-G4R:<6:#Z)&Q<37'IM19Q!6$2=(_T*4(D)**I/'DC'X(0=! M'$+S^+'4(Q'UV,2(P878P76ZQW[?S-Z1)OC\$\]^7+S/+B?)>O*>LP6F(BEZ M299G#"J LCS[S(-$;![I/X;@\6.TX\'U2/$]-ZS6P_CYYWPB+9FP*4<0P2$Y M1U)!J.E[4GCKB<#LJ!X++VC+/D MK\=<0*LZ(\U(LI%'U9I7E(X?(QX=E'L+[#G"\O7\?#%)W/H8B:4RK0V7&" F M6R G'Y$[P;'Y6(^#"!T_4#PV*/<6U^C/^'=W^.M%H0^_V@VZ(K57&3!+4OPQ M&JCYT+/]4TN-'Q)N!)\!.-N9[IH(6X@!4H!=)UYI4KE> MZ/6@:"6]]H3SYMTD;ZP_?A!X0$VS%W/['%GW?O45%^_FL\TXT+?3$.LC&RG/ M(P)S3W]H@V#,CBFM4NIY9:4[O+^]1?4D*.&)8DK M2677CMX.V^GB H$/( "" #),4M LE6B243!3NN9G+U%U4VN%L?+8$I4520/G MUIMNLN#*/T?S[V]N9O/N^HY]][?EI86(=E$N+G)7>2Z1)2R?SHE9GQ,NIG2+ M[9ZDU&[&8Y6C*'FJ-)8Y8]VO.=TA7ZV;U!H(4L/RO@%3]A:V,HEAM:>+L9VL M?GLW\/C2D."#8QA%SG,W/MB7]1%^"9P+$;3& W39W4M6W7S5P":LM%AJFZ\/ M$W"'(RC/A?V5:S/O*0S//?R (\AY3N'LQV"%62(H60X_4C8/(^MEK+9_HVX6 M:4C35(BOM>'Q<>3C9 8>XFTCX7L;@2 X1)OKQ1D1B">FP3GD\$ND#BOKF/:J M%T!V?:5NIFA(B!3C;0.GU2OOIS#SJ9@@&@#5@E6K#6WVZ11/1A!@$K,Y#:=R&Q@B.3(R M$*F=ULZ4+C/<2U3=0L.A,P9%1=( QM9OH98/!&:O)N$Q!R^#C)8)'1'5)$'@ M("1R8(L1MLR&Y#GL<0 O>P]5O5!FSA1EA8729M[\;9R.?MK<@>BN,'AF)^&_ M8KC*3D%N3K14+CN=+O[=286NQWZL2-%KD9T6*X#=0,VK#=1L #4W+& L/2(X M292]=60-^&?$A."TQ=;1TMTB3R#W=-MX\*=GRUX-8.P]-EPA3)R%$$>!XRI! M604GGL=H$\7E3>:1Q-8NGGT>-#XUL<\AVP8.^-6&WL;9Z&JR%&ON<4J4DQ)< M$109X8A3A9%.,B)"&>-8:PJ[*8S0S92<'?R.@4%77"9-(FO5"TDH[+S$"B6> M%+@^Q"%+24!*B4"9#$G8TL6NVVBIBZX2I<006DT]3 M6%M?\-\;\NXPUIA&BA13L!<2"7(*8Q0BEDY'D20OW?UB%SWMN5O'27TKG$X4 M00-PNO^(.3=G7H^AB4RYE QRVA#$@Y/(@*8AZ:EP!D(AZDM[59LI:05"ITIZ M2T^+$]A>>?K/5Y#"XA[MJX\3.QUURW&[GL8D(D,^6H>XY0:\33#5CA*EK*!! MVUXOF_=, =KX\=KOR9[S9"LC@=H06M']^V3V(_I1&L6P'I^(C6,82,<,ZSSY M,G<\YA3YY T&;]!ZJ4O :!L!]2:*%1!J5YK#C<#D?3>-WL[6,8)+Q)' #,0( M7$",D"L[9.Y3JR/3TF'A32]?IR=&'GZ](D#*B'0#2$[@;Q..3+Z$OU6?C_D_ M6.= O/"$<IUD(&30!J ?][5;F MUQ,MD\^C'K0$\VN90(9KDZ>!2A8P6'96^GW.1D*:!- Q@M[=5? (KC< G6., M^BF2RG^N)1)QK CZIDX@:"MZO4TH7[R72B[!64E6# V4K M1$M)K2DHYM?CG],Z_W<9HHK&1XJ$@8.'"^F0,3JA$$D4)#]MPJ4[UFVCY?RN M0)*]A_*IVQ+TG_ M^25ORV"Y&@:.QC_8>-<-V8:V9_WJ76?7C?_):'(;-71I-=_,CB^ZV2C3]]Z. MIG_8\Z4Z7&$,!N"8B]Y<%0G)T0#A=CG7F!\"!K+%1@?(ML&7*8M M18[)1F.)UBA*:?-;.X^L!RZ2!*&%9\:R5+J'S\LJ,#X(!OT*C ^129/(6B<9 M*0<-9!!%J)0GTSB=NX^9/(8'S*$5A,/DUA;4/-HY3:)\446/<8 M02\)1U8ZAY2/&'-J<-3E)Y><98'Q05(_I,#X$!$T *21S M;G.HI69(&Z=S+Y9@P/@>6W'>6CNU^\Q/BP>$4YC M27CN=)$[$@1-\T1OBQCFF!!&.5>E*[JVT7)^F>O3S[LBS69Q/EO' M&3$WFP=[RRS!B%,(9@PF 3D(,JR6/MKB/2QVD-,>C(Z1^*8;M +L;P])]UKP MK/8C*=6>XH 4IP1Q0_+QS0PB(28=G.%"E)X.L(^FNN'>\V#J-$$T *S3[K>- M5B9%J?+#D_S:FR5D672(>2D%XT%Z73YS-72=8(,%]J4S$,-(N"DXW]XQ?[YW M0[TX BX9!$V,28\\L11Q#1NS2>5N^MXG02(5:KC;W>UTM1)O#@Z3K0 M)+-6 MIR@?7%KQN)BGNYEWZ97W-] &W>6AV#!9%K"*1@1@? M2B/T996L' 2#?B4KA\BD262M0M\\\L!I39#%(=X&,@+C"!VKR*%>78NF6 M4V=5LG*0G/N6K!S"] ; TZM*PLADE,@OU4Q^#8D%LLXS^&.(Q$C.M2W?NNQ< M2U8.DO\Q)2L'"*,)?.VX'%<^-Z[G'D42\\/=W'T+\X 4U@83)IQ(SU%1?.XE M*Z<<@<7DTQ36-MRB)V)EE#X@[RC+#5 C4TFM"@C[8'/1 M< -P/KAEP^-+R-3_8NH=>ER_9ZX];WG#@435J68XA7,-%"_@1++.@9-M-)PP M D>DI843A@ M,R]>. 2-!0?Z'2#;!GR=V^CFW;]N1O-?V>!TD\5F%^\_K&40*L,!&G/!*N,0 M.BLLD'$R$*84\[%T8?!.@LX.C,> HAM*0@W [=$>UH-6HC4ROS *.M^LAI20 MI:"S$GME' '6I=*YK(V$U(5704%WI;G> '3N^49KO_N!,P[NT?@F@![F9QWY MXJ(;CQ?IE>6EPWKP'"8DUX @PU6N#+$4&1P8$LI93T/P6):^XRE">%UH%@!0 M5UN:#4#XM)#68K,&BBU,.Z^>3 M< -P?ISV> ]"Z!'!OEF^N;L 5G7A4YQ_3M_L7W&G ; MDTN-G:""&%7Z$F*(?9R?IWHD#+O&,-& 7GR==_[/[]T89#Q;GIRWI]E%-UU@ M8#Z?CMS-/-N;;]WF(^Y2."E3P YYG&?DANSLX8"1)8QS1VQ@MK177(;RNMBO MC\ G =RSP^%H)?BQV#Y$(M/YX%QS7I[LH[>NO],<[)]-] U8_!+,O]L\3S%@[1FB+L^==28@$R#H MM]ZI$%F@+)3.NA7=0-VZL^84H1XX&M",0H'<2RGW^G 6.9T(PD$D MFK2UHM\LT#9]H<&*19K3A0IP.-$7>C<)0UVMO[Z906-]%BYTN?I812>;&17!02?T_J[]SXR>_WKWI^6*2[)G?/ %D0) MAD-$BCR&WB:D,1>!"LY3*#U+Z% :*[BO=?W$Q*Y6N_0>7_N"EC 6$TBJG\VVEH-DS:2:+O :?CY5 16-FUN?S: MW4S"[Y,1>,:K^\7 B3#>2J2$I\ ;G:NEI8/8*X2D!3"(\'W>V.:EV\/""7+K MBC&Q3=MR=S4211)*6I;'-SF(?20$W@)X0Z0*&KB"L2G=VTLQPR823@K.(DC$!\;AH0.$C8C(YB(=U[8XF?M^$C=6XGB&"G*TQ:Q\2G.[RX,+Q4) M20J*D9$%S"J[-AY2;;DMN.V5W:3G68LT%.PGW9A+ SVZN8RA\)73Z M-RK B3J72X%1K2VQ*$J;6^2:?!O*'=))8Q*$H$F$@2Q*HY=+(=(8N$K(2VD0 MU\PBD]U3:8A3A&J58BS,D1=]N70(PDZ^7#I$>&WZ 8NDMHY*"ZLM2B$_#''. MY LYAU(4P43*HTML^'/^#"^7#I)_S\NE0X31**8>)L<)2UYXXI!@2N47(A+I M/&8X.259 -]$Z6?P(L_A28H=XP\?HKX4BZ7#I+;[LNE0YC8IFVYBZL,\3A/K$..:XZX9QH9AQE* MBN@@-)&R^#/H%W2Y5/CD.DXL#4!L;]+889-L[MXJ^*)Q'>;(^5S.F83 MT?_$\"$ VT=IE,^"AQFD5YLR2*M_LHZQ@>/:?3ZC)%(F)T$462[X)< M3,@1H9%G,7G, R?%J\.'W5$;[D5MW ZH3B>"Z*6IU/U!Y;!*!*; ?SF[E *; MP$2^OPJ+CG0!::<<8B0%@HUDNOA(N.?85QNNU$M6KQ* >F%*]F'R$_Y]-_UU M"7N1@2Q*BY-#G-N 7 H4X40"ME%B;4W#6G6[D3;L1L=!YH7IS0-;_NPR"A>L3AYIJ2$ZY"KWBQ<*":*3H6!9=/$ZSRH;;:/@ MZP7KW3"0>V%Z>3'-$T'FOR[&%EBU]*5_Y.SAI7;>@#=MD0TX(AYH;F4O' I> M1VE#I"D]0R*M_,;:J'![P7I7!E(O3,\^ ,8F5Z/;?[PP/]^^V\EO71?^/1J/ M+[6T=#%R!YB0$/<"G ,5%(HL:F^DHU:TK&][-]A+[^3?>M<(Q!K0OUNZK6*, MY[?"D9%<):XPTMQHI"/5DE,F5?&KPX-0J_[#4'N48!H 5$EV+K0K]PFZ[V5> M>I^[F)* *('#C;L(#*%&(464S^^0M6%#E6@-MJE>*J#_PU2@+2C5KC(;0$BK M?W+;I^O6YB07!/,A@9$1X$3B7'IE@@,39)D'&0K+'PV[W?,DZQF([J5"YC]$ MA9I&S NK-[C_-VN9B62=Q5(BGV?22;_>L^8P@X]R!/CX*) ?'$/7@X@B(5C0H\"5.^,_;PNWHYI1 MGXD% M$/4R5>TN!73O9PN3=!E"A#T0CI2CX"5P^,6E;):DL2!$*A4=ZF'QL#MK(W1[ MZ2I7"%DO4^WN&R&LA/ "3GEJXU,/02/-4K;K7%JAM,?<[?/?SK,= MT$%RV]T.Z! F-F!;WH\R\1]'/Y_ZM*]__6?6+.B456LUQK M1#C8<] T8RU'A+G *0_!%Z]@.9#$NK9O,*CTA^3)7YIV^CWZLMZ*D,3B1/,**Y W@W"<_$"2Q%@&XY1@IGO+Z.K[_'8[U'%)B$ &6POF M7TE@& V(695R^;F/JO33FCTDU;V$?TZ8E91- U#[./)YFO?DZM45!%F+#H2K MC3@5#($0' 6%51AY' ^MGG+KN M.?K7:J/!YGJ!N$JY)0TS"%8P<.H332#&9X$-U=[HZ/ZU@]FOVJG6X\32@/5: M7_+MT-!_QFR=8W@%T+97\?=93#?CCZ,4+Q6SG%@J$/-YUEX>+ND@GD*<2R.Y M#:)\+' *O,.B@J5*2Z_ M<%LDEG"TPH/7'$U^S!BB!"?"1)1\I)%3[T(LG>AY2$&Y,L.O\\[_^?K7(B&S MC)2)P2EB'E R&! JP+'Z M%02P2+0MMK#:T.*6%2>"+:AZKID$%]LJFFO#(PJ)NZ")! >A>#7J-F):J04\ M4=R/852$]PV Z#[]ZRPPQR+!D8W<(^.+"1(O@-*/*((=%0-SG&C,M("@5B7LG@#_]!I# JO

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end XML 124 masi-20240330_htm.xml IDEA: XBRL DOCUMENT 0000937556 2023-12-31 2024-03-30 0000937556 2024-03-30 0000937556 2023-12-30 0000937556 2023-04-01 0000937556 us-gaap:CustomerRelationshipsMember 2024-03-30 0000937556 us-gaap:CustomerRelationshipsMember 2023-12-30 0000937556 masi:AcquiredTechnologyMember 2024-03-30 0000937556 masi:AcquiredTechnologyMember 2023-12-30 0000937556 masi:OtherMiscellaneousIntangibleAssetsMember 2024-03-30 0000937556 masi:OtherMiscellaneousIntangibleAssetsMember 2023-12-30 0000937556 2023-01-01 2023-04-01 0000937556 us-gaap:CommonStockMember 2023-12-30 0000937556 us-gaap:TreasuryStockCommonMember 2023-12-30 0000937556 us-gaap:AdditionalPaidInCapitalMember 2023-12-30 0000937556 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-30 0000937556 us-gaap:RetainedEarningsMember 2023-12-30 0000937556 us-gaap:CommonStockMember 2023-12-31 2024-03-30 0000937556 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 2024-03-30 0000937556 us-gaap:RetainedEarningsMember 2023-12-31 2024-03-30 0000937556 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 2024-03-30 0000937556 us-gaap:CommonStockMember 2024-03-30 0000937556 us-gaap:TreasuryStockCommonMember 2024-03-30 0000937556 us-gaap:AdditionalPaidInCapitalMember 2024-03-30 0000937556 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-30 0000937556 us-gaap:RetainedEarningsMember 2024-03-30 0000937556 us-gaap:CommonStockMember 2022-12-31 0000937556 us-gaap:TreasuryStockCommonMember 2022-12-31 0000937556 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000937556 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0000937556 us-gaap:RetainedEarningsMember 2022-12-31 0000937556 2022-12-31 0000937556 us-gaap:CommonStockMember 2023-01-01 2023-04-01 0000937556 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-04-01 0000937556 us-gaap:RetainedEarningsMember 2023-01-01 2023-04-01 0000937556 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-04-01 0000937556 us-gaap:CommonStockMember 2023-04-01 0000937556 us-gaap:TreasuryStockCommonMember 2023-04-01 0000937556 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 0000937556 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-01 0000937556 us-gaap:RetainedEarningsMember 2023-04-01 0000937556 us-gaap:FairValueMeasurementsRecurringMember 2024-03-30 0000937556 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-03-30 0000937556 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-03-30 0000937556 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2024-03-30 0000937556 us-gaap:CashFlowHedgingMember us-gaap:FairValueMeasurementsRecurringMember 2024-03-30 0000937556 us-gaap:CashFlowHedgingMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-03-30 0000937556 us-gaap:CashFlowHedgingMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-03-30 0000937556 us-gaap:CashFlowHedgingMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2024-03-30 0000937556 us-gaap:WarrantMember us-gaap:FairValueMeasurementsRecurringMember 2024-03-30 0000937556 us-gaap:WarrantMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-03-30 0000937556 us-gaap:WarrantMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-03-30 0000937556 us-gaap:WarrantMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2024-03-30 0000937556 us-gaap:FairValueMeasurementsRecurringMember 2023-12-30 0000937556 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-30 0000937556 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-30 0000937556 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-30 0000937556 us-gaap:CashFlowHedgingMember us-gaap:FairValueMeasurementsRecurringMember 2023-12-30 0000937556 us-gaap:CashFlowHedgingMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-30 0000937556 us-gaap:CashFlowHedgingMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-30 0000937556 us-gaap:CashFlowHedgingMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-30 0000937556 us-gaap:WarrantMember us-gaap:FairValueMeasurementsRecurringMember 2023-12-30 0000937556 us-gaap:WarrantMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-30 0000937556 us-gaap:WarrantMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-30 0000937556 us-gaap:WarrantMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-30 0000937556 srt:MinimumMember us-gaap:LandBuildingsAndImprovementsMember 2024-03-30 0000937556 srt:MaximumMember us-gaap:LandBuildingsAndImprovementsMember 2024-03-30 0000937556 srt:MinimumMember us-gaap:ComputerEquipmentMember 2024-03-30 0000937556 srt:MaximumMember us-gaap:ComputerEquipmentMember 2024-03-30 0000937556 srt:MinimumMember masi:DemonstrationUnitsMember 2024-03-30 0000937556 srt:MaximumMember masi:DemonstrationUnitsMember 2024-03-30 0000937556 srt:MinimumMember masi:FurnitureandOfficeEquipmentMember 2024-03-30 0000937556 srt:MaximumMember masi:FurnitureandOfficeEquipmentMember 2024-03-30 0000937556 srt:MinimumMember us-gaap:MachineryAndEquipmentMember 2024-03-30 0000937556 srt:MaximumMember us-gaap:MachineryAndEquipmentMember 2024-03-30 0000937556 srt:MinimumMember us-gaap:TransportationEquipmentMember 2024-03-30 0000937556 srt:MaximumMember us-gaap:TransportationEquipmentMember 2024-03-30 0000937556 us-gaap:PatentsMember 2023-12-31 2024-03-30 0000937556 us-gaap:TrademarksMember 2023-12-31 2024-03-30 0000937556 srt:MinimumMember 2024-03-30 0000937556 srt:MaximumMember 2024-03-30 0000937556 srt:MinimumMember 2023-12-31 2024-03-30 0000937556 srt:MaximumMember 2023-12-31 2024-03-30 0000937556 srt:ChiefExecutiveOfficerMember us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-04-01 0000937556 srt:ChiefExecutiveOfficerMember us-gaap:RestrictedStockUnitsRSUMember 2023-12-31 2024-03-30 0000937556 srt:MinimumMember us-gaap:RelatedPartyMember 2023-12-31 2024-03-30 0000937556 masi:WillowLaboratoriesMember us-gaap:RelatedPartyMember 2023-12-31 2024-03-30 0000937556 masi:WillowLaboratoriesMember us-gaap:RelatedPartyMember 2023-01-01 2023-04-01 0000937556 masi:WillowLaboratoriesMember 2023-01-01 2023-04-01 0000937556 masi:WillowLaboratoriesMember 2023-12-31 2024-03-30 0000937556 masi:LeasedPropertyMember 2023-12-31 2024-03-30 0000937556 masi:WillowLaboratoriesMember us-gaap:RelatedPartyMember 2024-03-30 0000937556 masi:WillowLaboratoriesMember us-gaap:RelatedPartyMember 2023-12-30 0000937556 masi:NotforProfitOrganizationMember 2023-01-01 2023-04-01 0000937556 masi:NotforProfitOrganizationMember 2023-12-31 2024-03-30 0000937556 masi:LikeMindedEntertainmentMember 2023-12-31 2024-03-30 0000937556 masi:LikeMindedEntertainmentMember 2023-01-01 2023-04-01 0000937556 masi:LikeMindedEntertainmentMember us-gaap:RelatedPartyMember 2024-03-30 0000937556 masi:LikeMindedEntertainmentMember us-gaap:RelatedPartyMember 2023-12-30 0000937556 masi:LikeMindedLabsMember 2021-07-03 0000937556 masi:VantrixCorpMember us-gaap:PurchaseCommitmentMember 2021-07-01 2021-07-31 0000937556 masi:VantrixCorpMember us-gaap:OptionMember 2021-07-01 2021-07-31 0000937556 masi:ReimbursementFeeMember srt:ChiefExecutiveOfficerMember 2023-12-31 2024-03-30 0000937556 masi:ReimbursementFeeMember srt:ChiefExecutiveOfficerMember 2023-01-01 2023-04-01 0000937556 us-gaap:MachineryAndEquipmentMember 2024-03-30 0000937556 us-gaap:MachineryAndEquipmentMember 2023-12-30 0000937556 us-gaap:BuildingAndBuildingImprovementsMember 2024-03-30 0000937556 us-gaap:BuildingAndBuildingImprovementsMember 2023-12-30 0000937556 masi:OperatingLeaseAssetsMember 2024-03-30 0000937556 masi:OperatingLeaseAssetsMember 2023-12-30 0000937556 us-gaap:LandMember 2024-03-30 0000937556 us-gaap:LandMember 2023-12-30 0000937556 us-gaap:ComputerEquipmentMember 2024-03-30 0000937556 us-gaap:ComputerEquipmentMember 2023-12-30 0000937556 us-gaap:LeaseholdImprovementsMember 2024-03-30 0000937556 us-gaap:LeaseholdImprovementsMember 2023-12-30 0000937556 masi:AircraftAndVehiclesMember 2024-03-30 0000937556 masi:AircraftAndVehiclesMember 2023-12-30 0000937556 us-gaap:FurnitureAndFixturesMember 2024-03-30 0000937556 us-gaap:FurnitureAndFixturesMember 2023-12-30 0000937556 masi:DemonstrationUnitsMember 2024-03-30 0000937556 masi:DemonstrationUnitsMember 2023-12-30 0000937556 us-gaap:ConstructionInProgressMember 2024-03-30 0000937556 us-gaap:ConstructionInProgressMember 2023-12-30 0000937556 2022-02-14 2022-02-14 0000937556 us-gaap:LicensingAgreementsMember 2024-03-30 0000937556 us-gaap:LicensingAgreementsMember 2023-12-30 0000937556 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2024-03-30 0000937556 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2023-12-30 0000937556 us-gaap:PatentsMember 2024-03-30 0000937556 us-gaap:PatentsMember 2023-12-30 0000937556 us-gaap:TrademarksMember 2024-03-30 0000937556 us-gaap:TrademarksMember 2023-12-30 0000937556 us-gaap:NoncompeteAgreementsMember 2024-03-30 0000937556 us-gaap:NoncompeteAgreementsMember 2023-12-30 0000937556 us-gaap:LicensingAgreementsMember masi:WillowLaboratoriesMember 2024-03-30 0000937556 us-gaap:LicensingAgreementsMember masi:WillowLaboratoriesMember 2023-12-30 0000937556 us-gaap:OtherIntangibleAssetsMember 2024-03-30 0000937556 us-gaap:OtherIntangibleAssetsMember 2023-12-30 0000937556 us-gaap:TrademarksMember 2024-03-30 0000937556 us-gaap:TrademarksMember 2023-12-30 0000937556 2023-01-01 2023-12-30 0000937556 us-gaap:TrademarksMember 2023-12-31 2024-03-30 0000937556 us-gaap:TrademarksMember 2023-01-01 2023-12-30 0000937556 masi:PatentsAndTrademarksMember 2023-01-01 2023-04-01 0000937556 masi:PatentsAndTrademarksMember 2023-12-31 2024-03-30 0000937556 us-gaap:TrademarksMember 2023-07-02 2023-09-30 0000937556 us-gaap:TrademarksMember 2023-10-01 2023-12-30 0000937556 masi:HealthCareSegmentMember 2023-12-30 0000937556 masi:NonHealthcareMember 2023-12-30 0000937556 masi:HealthCareSegmentMember 2023-12-31 2024-03-30 0000937556 masi:NonHealthcareMember 2023-12-31 2024-03-30 0000937556 masi:HealthCareSegmentMember 2024-03-30 0000937556 masi:NonHealthcareMember 2024-03-30 0000937556 us-gaap:CashFlowHedgingMember 2024-03-30 0000937556 us-gaap:CashFlowHedgingMember 2023-12-30 0000937556 2024-03-31 2024-03-30 0000937556 2024-03-31 masi:TwelveMonthsAndThereafterMember 2024-03-30 0000937556 masi:BowersAndWilkinsMember 2020-10-31 0000937556 masi:BowersAndWilkinsMember 2024-03-30 0000937556 us-gaap:NonrelatedPartyMember 2024-03-30 0000937556 us-gaap:NonrelatedPartyMember 2023-12-30 0000937556 us-gaap:RelatedPartyMember 2024-03-30 0000937556 us-gaap:RelatedPartyMember 2023-12-30 0000937556 masi:TermLoanMember 2024-03-30 0000937556 masi:TermLoanMember 2023-12-30 0000937556 masi:JapaneseLoansMember 2024-03-30 0000937556 masi:JapaneseLoansMember 2023-12-30 0000937556 masi:RevolverMember 2024-03-30 0000937556 masi:RevolverMember 2023-12-30 0000937556 us-gaap:UnsecuredDebtMember masi:NewCreditFacilityAgreementMember 2022-04-11 0000937556 us-gaap:RevolvingCreditFacilityMember masi:NewCreditFacilityAgreementMember 2022-04-11 0000937556 masi:NewCreditFacilityAgreementMember 2022-04-11 0000937556 us-gaap:RevolvingCreditFacilityMember masi:InitialLendersMember us-gaap:LineOfCreditMember 2022-04-11 0000937556 us-gaap:LetterOfCreditMember masi:NewCreditFacilityAgreementMember 2022-04-11 0000937556 srt:MinimumMember masi:NewCreditFacilityAgreementMember masi:AlternateBaseRateMember 2022-04-11 2022-04-11 0000937556 srt:MaximumMember masi:NewCreditFacilityAgreementMember masi:AlternateBaseRateMember 2022-04-11 2022-04-11 0000937556 srt:MinimumMember masi:NewCreditFacilityAgreementMember masi:AdjustedSecuredOvernightFinancingRateSOFRMember 2022-04-11 2022-04-11 0000937556 srt:MaximumMember masi:NewCreditFacilityAgreementMember masi:AdjustedSecuredOvernightFinancingRateSOFRMember 2022-04-11 2022-04-11 0000937556 masi:NewCreditFacilityAgreementMember us-gaap:FederalFundsEffectiveSwapRateMember 2022-04-11 2022-04-11 0000937556 masi:NewCreditFacilityAgreementMember masi:AdjustedSecuredOvernightFinancingRateSOFRMember 2022-04-11 2022-04-11 0000937556 masi:NewCreditFacilityAgreementMember masi:AdjustedSecuredOvernightFinancingRateSOFROneMonthInterestPeriodMember 2022-04-11 2022-04-11 0000937556 masi:NewCreditFacilityAgreementMember masi:AdjustedSecuredOvernightFinancingRateSOFRThreeMonthInterestPeriodMember 2022-04-11 2022-04-11 0000937556 masi:NewCreditFacilityAgreementMember masi:AdjustedSecuredOvernightFinancingRateSOFRSixMonthInterestPeriodMember 2022-04-11 2022-04-11 0000937556 srt:MinimumMember masi:NewCreditFacilityAgreementMember 2022-04-11 2022-04-11 0000937556 srt:MaximumMember masi:NewCreditFacilityAgreementMember 2022-04-11 2022-04-11 0000937556 us-gaap:RevolvingCreditFacilityMember masi:NewCreditFacilityAgreementMember 2022-05-16 0000937556 us-gaap:RevolvingCreditFacilityMember 2023-12-31 2024-03-30 0000937556 us-gaap:RevolvingCreditFacilityMember 2023-01-01 2023-04-01 0000937556 us-gaap:RevolvingCreditFacilityMember masi:JapaneseRevolvingLoanMember us-gaap:LineOfCreditMember 2020-03-31 0000937556 us-gaap:RevolvingCreditFacilityMember masi:JapaneseRevolvingLoanMember us-gaap:LineOfCreditMember 2020-03-01 2020-03-31 0000937556 us-gaap:RevolvingCreditFacilityMember masi:JapaneseRevolvingLoanMember us-gaap:LineOfCreditMember 2023-02-28 0000937556 us-gaap:RevolvingCreditFacilityMember masi:JapaneseRevolvingLoanMember us-gaap:LineOfCreditMember 2023-02-28 2023-02-28 0000937556 masi:JapaneseGovernmentLoansMember 2020-06-30 0000937556 masi:JapaneseEquipmentLoansMember 2021-04-30 0000937556 masi:JapaneseEquipmentLoansMember 2021-05-31 0000937556 us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-03-30 0000937556 us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 2024-03-30 0000937556 us-gaap:OtherNoncurrentAssetsMember us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-03-30 0000937556 us-gaap:OtherNoncurrentAssetsMember us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-30 0000937556 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-03-30 0000937556 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-30 0000937556 us-gaap:DesignatedAsHedgingInstrumentMember 2024-03-30 0000937556 us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-30 0000937556 us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2023-12-31 2024-03-30 0000937556 us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:NonoperatingIncomeExpenseMember 2023-01-01 2023-04-01 0000937556 us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2023-12-30 0000937556 us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2022-12-31 0000937556 us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2023-01-01 2023-04-01 0000937556 us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2024-03-30 0000937556 us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2023-04-01 0000937556 srt:ScenarioForecastMember us-gaap:InterestExpenseMember 2024-03-31 2025-03-30 0000937556 masi:SoundUnitedMember 2022-04-11 0000937556 masi:SoundUnitedMember 2022-04-11 2022-04-11 0000937556 masi:SoundUnitedMember 2023-01-01 2023-04-01 0000937556 masi:SoundUnitedMember 2023-12-31 2024-03-30 0000937556 masi:SoundUnitedMember 2023-04-01 0000937556 masi:SoundUnitedMember 2024-03-30 0000937556 masi:SoundUnitedMember us-gaap:TrademarksAndTradeNamesMember 2022-04-11 2022-04-11 0000937556 masi:SoundUnitedMember us-gaap:TrademarksAndTradeNamesMember 2022-04-11 0000937556 masi:SoundUnitedMember us-gaap:CustomerRelationshipsMember 2022-04-11 2022-04-11 0000937556 masi:SoundUnitedMember us-gaap:CustomerRelationshipsMember 2022-04-11 0000937556 masi:SoundUnitedMember us-gaap:DevelopedTechnologyRightsMember 2022-04-11 2022-04-11 0000937556 masi:SoundUnitedMember us-gaap:DevelopedTechnologyRightsMember 2022-04-11 0000937556 masi:SoundUnitedMember us-gaap:LicensingAgreementsMember 2022-04-11 2022-04-11 0000937556 masi:SoundUnitedMember us-gaap:LicensingAgreementsMember 2022-04-11 0000937556 masi:RightsToPurchaseSeriesAJuniorParticipatingPreferredStockMember 2022-09-20 0000937556 srt:MinimumMember masi:RightsToPurchaseSeriesAJuniorParticipatingPreferredStockMember 2022-09-20 0000937556 srt:MaximumMember masi:RightsToPurchaseSeriesAJuniorParticipatingPreferredStockMember 2022-09-20 0000937556 masi:A2022RepurchaseProgramMember us-gaap:CommonStockMember 2022-06-30 0000937556 masi:A2022RepurchaseProgramMember us-gaap:CommonStockMember 2024-03-30 0000937556 srt:MinimumMember masi:A2017EquityIncentivePlanMember 2017-06-01 0000937556 masi:A2017EquityIncentivePlanMember 2020-05-01 2020-05-31 0000937556 srt:MaximumMember masi:A2017EquityIncentivePlanMember 2020-05-31 0000937556 srt:MaximumMember masi:A2007StockIncentivePlanMember 2020-05-31 0000937556 us-gaap:EmployeeStockOptionMember 2023-12-31 2024-03-30 0000937556 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-04-01 0000937556 us-gaap:EmployeeStockOptionMember 2024-03-30 0000937556 us-gaap:RestrictedStockUnitsRSUMember 2023-12-30 0000937556 us-gaap:RestrictedStockUnitsRSUMember 2023-12-31 2024-03-30 0000937556 us-gaap:RestrictedStockUnitsRSUMember 2024-03-30 0000937556 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-04-01 0000937556 us-gaap:PerformanceSharesMember 2023-12-30 0000937556 us-gaap:PerformanceSharesMember 2023-12-31 2024-03-30 0000937556 us-gaap:PerformanceSharesMember 2024-03-30 0000937556 us-gaap:PerformanceSharesMember 2024-02-28 0000937556 us-gaap:PerformanceSharesMember 2024-02-28 2024-02-28 0000937556 srt:MinimumMember masi:A2021PSUGrantMember us-gaap:PerformanceSharesMember 2023-12-31 2024-03-30 0000937556 srt:MinimumMember masi:A2021PSUGrantMember us-gaap:PerformanceSharesMember 2024-03-30 0000937556 srt:MaximumMember masi:A2021PSUGrantMember us-gaap:PerformanceSharesMember 2024-03-30 0000937556 us-gaap:PerformanceSharesMember 2023-01-01 2023-04-01 0000937556 masi:MasimoRetirementSavingsPlanMember 2023-12-31 2024-03-30 0000937556 masi:MasimoRetirementSavingsPlanMember 2023-01-01 2023-04-01 0000937556 masi:MasimoRetirementSavingsPlanMember us-gaap:ForeignPlanMember 2023-12-31 2024-03-30 0000937556 masi:MasimoRetirementSavingsPlanMember us-gaap:ForeignPlanMember 2023-01-01 2023-04-01 0000937556 srt:ChiefExecutiveOfficerMember 2017-07-01 2017-07-31 0000937556 srt:ChiefExecutiveOfficerMember us-gaap:CashDistributionMember 2017-07-01 2017-07-31 0000937556 srt:ChiefExecutiveOfficerMember us-gaap:RestrictedStockUnitsRSUMember 2017-07-01 2017-07-31 0000937556 srt:ChiefExecutiveOfficerMember 2023-12-31 2024-03-30 0000937556 2024-02-01 0000937556 masi:GPOMembersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-12-31 2024-03-30 0000937556 masi:GPOMembersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-04-01 0000937556 us-gaap:SalesRevenueNetMember 2023-12-31 2024-03-30 0000937556 us-gaap:SalesRevenueNetMember 2023-01-01 2023-04-01 0000937556 masi:JustintimedistributoroneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-12-31 2024-03-30 0000937556 masi:JustintimedistributoroneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-04-01 0000937556 us-gaap:AccountsReceivableMember 2023-12-30 0000937556 us-gaap:AccountsReceivableMember 2024-03-30 0000937556 masi:CustomerOneMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2024-03-30 0000937556 masi:CustomerOneMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-12-30 0000937556 masi:MasimoVsAppleIncMember us-gaap:PendingLitigationMember 2020-10-13 2020-10-13 0000937556 masi:MasimoVsAppleIncMember 2023-01-30 2023-01-30 0000937556 masi:MasimoVsAppleIncMember 2023-02-01 2023-02-28 0000937556 masi:AppleIncPatentInfringementMember us-gaap:PendingLitigationMember 2022-10-20 0000937556 us-gaap:IntersegmentEliminationMember 2023-12-31 2024-03-30 0000937556 us-gaap:IntersegmentEliminationMember 2023-01-01 2023-04-01 0000937556 us-gaap:OperatingSegmentsMember masi:HealthCareSegmentMember 2023-12-31 2024-03-30 0000937556 us-gaap:OperatingSegmentsMember masi:HealthCareSegmentMember 2023-01-01 2023-04-01 0000937556 us-gaap:OperatingSegmentsMember masi:NonHealthcareMember 2023-12-31 2024-03-30 0000937556 us-gaap:OperatingSegmentsMember masi:NonHealthcareMember 2023-01-01 2023-04-01 0000937556 us-gaap:OperatingSegmentsMember 2023-12-31 2024-03-30 0000937556 us-gaap:OperatingSegmentsMember 2023-01-01 2023-04-01 0000937556 us-gaap:MaterialReconcilingItemsMember 2023-12-31 2024-03-30 0000937556 us-gaap:MaterialReconcilingItemsMember 2023-01-01 2023-04-01 0000937556 masi:HealthCareSegmentMember 2023-01-01 2023-04-01 0000937556 masi:NonHealthcareMember 2023-01-01 2023-04-01 shares iso4217:USD iso4217:USD shares masi:reportingUnit masi:segment utr:sqft pure iso4217:CAD iso4217:JPY masi:plan masi:executiveOfficer masi:distributor masi:customer masi:patent masi:complaint false 2024 Q1 0000937556 --12-28 http://fasb.org/us-gaap/2023#OperatingExpenses http://fasb.org/us-gaap/2023#OperatingExpenses http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent http://fasb.org/us-gaap/2023#AccruedLiabilitiesAndOtherLiabilities http://fasb.org/us-gaap/2023#AccruedLiabilitiesAndOtherLiabilities http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent P3Y P3Y 10-Q true 2024-03-30 false 001-33642 MASIMO CORP DE 33-0368882 52 Discovery Irvine, CA 92618 (949) 297-7000 Common Stock, $0.001 par value MASI NASDAQ Yes Yes Large Accelerated Filer false false false 53085556 157600000 163000000.0 4700000 4800000 330700000 355500000 506100000 545000000.0 11400000 0 159800000 168400000 1165600000 1231900000 70300000 71400000 57900000 57300000 415000000.0 424400000 169300000 177700000 119900000 129400000 124000000.0 112800000 222700000 232400000 396000000.0 407700000 107100000 107200000 109900000 89300000 2957700000 3041500000 203100000 251500000 65200000 62600000 70000000.0 87300000 165900000 162400000 504200000 563800000 841400000 871700000 106900000 111700000 140000000.0 129500000 1592500000 1676700000 0.001 0.001 5000000 5000000 0 0 0 0 0 0 0.001 0.001 100000000 100000000 53100000 53100000 52800000 52800000 100000 100000 19500000 19500000 1169200000 1169200000 794900000 783400000 -75300000 -45300000 1814700000 1795800000 1365200000 1364800000 2957700000 3041500000 492800000 565000000.0 251100000 280200000 241700000 284800000 159900000 196300000 47800000 50500000 207700000 246800000 34000000.0 38000000.0 -9100000 -11800000 24900000 26200000 6000000.0 4900000 18900000 21300000 0.36 0.40 0.35 0.39 53000000.0 52600000 54200000 54400000 18900000 21300000 -35600000 -22800000 -700000 2200000 4900000 -4300000 -11100000 -8000000.0 52800000 100000 19500000 -1169200000 783400000 -45300000 1795800000 1364800000 200000 7200000 7200000 100000 5300000 5300000 9600000 9600000 18900000 18900000 -35600000 -35600000 -700000 -700000 4900000 4900000 53100000 100000 19500000 -1169200000 794900000 -75300000 1814700000 1365200000 52500000 100000 19500000 -1169200000 782200000 11500000 1714300000 1338900000 100000 4300000 4300000 200000 12200000 12200000 7300000 7300000 21300000 21300000 -22800000 -22800000 2200000 2200000 -4300000 -4300000 52800000 100000 19500000 -1169200000 781600000 -17800000 1735600000 1330300000 18900000 21300000 24300000 26100000 9600000 7300000 100000 400000 500000 500000 -22400000 -34800000 -23900000 7100000 -7000000.0 5900000 700000 -8800000 600000 1000000.0 800000 2700000 -40600000 -27100000 3200000 -16500000 2300000 -21800000 -5800000 -8300000 -13900000 900000 -5400000 8300000 45800000 400000 8200000 8500000 10600000 9700000 0 -7500000 100000 400000 -18900000 -11100000 64000000.0 44400000 92300000 72400000 7100000 4900000 5300000 12100000 -26500000 -35200000 -4600000 17400000 -4200000 -28500000 168200000 209600000 164000000.0 181100000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. Description of the Company </span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Masimo Corporation is a global technology company that develops, manufactures and markets a wide array of patient monitoring technologies, as well as automation and connectivity solutions. The Company’s mission is to improve patient outcomes, reduce the cost of care and take noninvasive monitoring to new sites and applications. The Company operates two business segments: healthcare and non-healthcare.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s healthcare products and patient monitoring solutions generally incorporate a monitor or circuit board, proprietary single-patient use or reusable sensors, software and/or cables. The Company primarily sells its healthcare products to hospitals, emergency medical service providers, home care providers, physician offices, veterinarians, long-term care facilities and consumers through its direct sales force, distributors and original equipment manufacturer (OEM) partners.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 11, 2022, the Company acquired Viper Holdings Corporation, the parent company of DEI Sales, Inc., d/b/a Sound United (Sound United), via the Company’s wholly-owned subsidiary, Sonic Boom Acquisition Corp (Sonic) (Sound United Acquisition). For additional information on the Company’s acquisition of Sound United, see Note 18, “Business Combinations”.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s non-healthcare consumer products and home integration technologies are primarily sold or licensed direct-to-consumers, or through authorized retailers and wholesalers.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The terms “the Company” and “Masimo” refer to Masimo Corporation and, where applicable, its consolidated subsidiaries.</span></div> <div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. Summary of Significant Accounting Policies </span></div><div style="margin-top:4.5pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (SEC). Certain information and note disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) have been condensed or omitted pursuant to such rules and regulations. The accompanying condensed consolidated financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments, including normal recurring accruals, necessary to present fairly the Company’s condensed consolidated financial statements. The accompanying condensed consolidated balance sheet as of December 30, 2023 was derived from the Company’s audited consolidated financial statements at that date. The accompanying condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes contained in the Company’s Annual Report on Form 10-K for the fiscal year ended December 30, 2023 (fiscal year 2023), filed with the SEC on February 28, 2024. The results for the three months ended March 30, 2024 are not necessarily indicative of the results to be expected for the fiscal year ending December 28, 2024 (fiscal year 2024) or for any other interim period or for any future year.</span></div><div style="margin-top:13pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fiscal Periods</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company follows a conventional 52/53 week fiscal year. Under a conventional 52/53 week fiscal year, a 52 week fiscal year includes four quarters of 13 weeks while a 53 week fiscal year includes three 13 week fiscal quarters and one 14 week fiscal quarter. The Company’s last 53 week fiscal year was fiscal year 2020. Fiscal year 2024 is a 52 week fiscal year ending December 28, 2024. All references to years in these notes to condensed consolidated financial statements are fiscal years unless otherwise noted.</span></div><div style="margin-top:13pt;text-indent:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> amounts in the accompanying condensed consolidated financial statements have been reclassified to conform to the current period presentation, including certain balance sheet asset accounts in the consolidated financial statements for the year ended December 30, 2023. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was no impact on previously reported total assets, liabilities, stockholders’ equity or net income.</span></div><div style="margin-top:13pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company prepares its financial statements in conformity with GAAP, which requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Significant estimates include the determination of standalone selling prices, variable consideration, total consideration allocated to each performance obligation within a contract, inventory valuation, valuation of the Company’s equity awards, valuation of identifiable assets and liabilities connected with business combinations, impairment of long-lived assets, intangible assets and goodwill; derivative and equity instruments, deferred taxes and any associated valuation allowances, deferred revenue, accounting for pensions, uncertain income tax positions, litigation costs, and related accruals. See Note 24, “Commitments and Contingencies”. Actual results could differ from such estimates.</span></div><div style="margin-top:13pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Combinations</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for business combinations using the acquisition method of accounting in accordance with Accounting Standards Codification (ASC) Topic 805, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which requires that once control is obtained, assets acquired, liabilities assumed and noncontrolling interests in the acquired entity, if applicable, are recorded at their respective fair values at the date of acquisition, with the exception of acquired contract assets and contract liabilities (i.e., deferred revenue) from contracts with customers. These are recognized and measured in accordance with ASC Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The excess of the purchase price over fair values of identifiable assets, liabilities and noncontrolling interests in the acquired entity, if applicable, is recorded as goodwill. </span></div><div style="margin-top:13pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for certain financial instruments at their fair values as either assets or liabilities on the balance sheet. The Company determines the fair value of its financial instruments using the framework prescribed by ASC Topic 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements and Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and considers the estimated amount the Company would receive or pay to transfer these instruments at the reporting date with respect to current currency exchange rates, interest rates, the creditworthiness of the counterparty for unrealized gain positions and the Company’s creditworthiness for unrealized loss positions. In certain instances, the Company may utilize financial models to measure the fair value of its financial instruments. In doing so, the Company uses inputs that include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, other observable inputs for the asset or liability and inputs derived principally from, or corroborated by, observable market data by correlation or other means.</span></div><div style="margin-top:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recurring Fair Value Measurement</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On a recurring basis, the Company measures certain financial assets and financial liabilities at fair value based upon quoted market prices. Where quoted market prices or other observable inputs are not available, the Company applies valuation techniques to estimate fair value. Authoritative guidance describes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value:</span></div><div style="margin-top:4.5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">●    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1—Quoted prices in active markets for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">identical</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> assets or liabilities.</span></div><div style="margin-top:4.5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">●    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">similar</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> assets or liabilities, quoted prices in markets that are not active; or other inputs that can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></div><div style="margin-top:4.5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">●    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables represent the Company’s financial assets, measured at fair value on a recurring basis at March 30, 2024:</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:41.506%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.812%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:19pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total Carrying <br/>Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Fair Value Measurement Hierarchy</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:20pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:22.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;text-indent:22.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.7 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.7 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:22.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;text-indent:22.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.9 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.6 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative instruments - cash flow hedges</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;text-indent:22.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative instruments - warrants</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197.5 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176.8 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.7 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative instruments - cash flow hedges</span></div></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:22.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension benefit obligation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Includes accrued interest.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables represent the Company’s financial assets, measured at fair value on a recurring basis at December 30, 2023: </span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.795%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total Carrying <br/>Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Fair Value Measurement Hierarchy</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:22.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;text-indent:22.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76.0 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76.0 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension assets</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;text-indent:22.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative instruments - cash flow hedges</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;text-indent:22.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative instruments - warrants</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200.4 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182.5 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.9 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;text-indent:22.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative instruments - cash flow hedges</span></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:22.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension benefit obligation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.2 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.2 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Includes accrued interest.</span></div><div style="margin-top:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company invests in checking, savings and money market fund accounts, which are classified within Level 1 of the fair value hierarchy as they are valued using quoted market prices. These investments are classified as cash and cash equivalents within the Company’s accompanying condensed consolidated balance sheets, in accordance with GAAP and its accounting policies.</span></div><div style="margin-top:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has certain strategic investments in privately-held companies (non-marketable equity securities) and companies that have completed initial public offerings (marketable equity securities). The Company’s marketable equity securities, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">whose price is based on quoted market price in an active market, are classified within Level 1 of the fair value hierarchy. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity securities are classified as current, short-term investments, or non-current, recorded in other non-current assets, based on the nature of the securities and their availability for use in current operations. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in the fair value of those equity securities are measured at each reporting date and changes in the value of these investments between reporting dates are recorded within non-operating loss. </span></div><div style="margin-top:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s pension assets consist of Level 1 and Level 2 investments. The fair value of Level 2 assets is based on observable inputs such as prices or quotes for similar assets, adjusted for any differences in terms or conditions that may affect the value of the instrument being valued. The valuation techniques used for Level 2 assets may include the use of models or other valuation techniques, but these methods are all based on observable market inputs.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also has investments in certain derivative instruments, which are measured at fair value and classified within Level 1 of the fair value hierarchy.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Non-Recurring Fair Value Measurements</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For certain other financial assets and liabilities, including restricted cash, accounts receivable, accounts payable and other current assets and liabilities, the carrying amounts approximate their fair value primarily due to the relatively short maturity of these balances. The Company also measures certain non-financial assets at fair value on a non-recurring basis, primarily goodwill, intangible assets and operating lease right-of-use assets, in connection with periodic evaluations for potential impairment.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, the Company did not elect to apply the fair value option to specific assets or liabilities on a contract-by-contract basis. The Company did not have any transfers between Level 2 and Level 3 during the three months ended March 30, 2024. </span></div><div style="margin-top:13pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Th</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e Company considers all highly liquid investments with an original maturity from the date of purchase of three months or less, or highly liquid investments that are readily convertible into known amounts of cash, to be cash equivalents. The Company carries cash and cash equivalents at cost, which approximates fair value, and they are Level 1 under the fair value hierarchy.</span></div><div style="margin-top:13pt;text-indent:13.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable and Allowance for Credit Losses</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable consist of trade receivables recorded at the time of invoicing of product sales, reduced by reserves for estimated bad debts and returns. Trade accounts receivable are recorded at the invoiced amount and do not bear interest. Credit is extended based on an evaluation of the customer’s financial condition. Collateral is generally not required. The Company records an allowance for credit losses that it does not expect to collect based on relevant information, including historical experience, current conditions, and reasonable and supportable forecasts. Accounts are charged off against the allowance when the Company believes they are uncollectible. The allowance for credit losses is measured on a collective (pool) basis when similar risk characteristics exist. Based on the risk characteristics, the Company has identified U.S. and international customers as separate portfolios for both segments, and measures expected credit losses on such receivables using an aging methodology</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:13pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventories</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at the lower of cost or net realizable value. Cost is determined using a standard cost method, which approximates the first in, first out method, and includes material, labor and overhead costs. Inventory valuation adjustments are recorded for inventory items that have become excess or obsolete or are no longer used in current production and for inventory items that have a market price less than the carrying value in inventory. The Company generally determines inventory valuation adjustments based on an evaluation of the expected future use of its inventory on an item by item basis and applies historical obsolescence rates to estimate the loss on inventory expected to have a recovery value below cost. The Company also records other specific inventory valuation adjustments when it becomes aware of unique events or circumstances that result in an expected recovery value below cost. For inventory items that have been written down, the reduced value becomes the new cost basis.</span></div><div style="margin-top:13pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment </span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost. Depreciation is calculated using the straight-line method over estimated useful lives as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.736%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.064%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Useful Lives</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and building improvements</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 to 39 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 to 12 years</span></div></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Demonstration units</span></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 to 3 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and office equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 to 15 years</span></div></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lesser of useful life or term of lease</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery, equipment and tooling</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 to 20 years</span></div></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lesser of useful life or term of lease</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transportation, vehicles and other</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 to 20 years</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Land is not depreciated and construction-in-progress is not depreciated until placed in service. Normal repair and maintenance costs are expensed as incurred, whereas significant improvements that materially increase values or extend useful lives are capitalized and depreciated over the remaining estimated useful lives of the related assets. Upon sale or retirement of depreciable assets, the related cost and accumulated depreciation or amortization are removed from the accounts and any gain or loss on the sale or retirement is recognized in income.</span></div><div style="margin-top:13pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lessee Right-of-Use (ROU) Assets and Lease Liabilities</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement contains a lease at inception. ROU assets represent the Company’s right to use an asset underlying an operating lease for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from an operating lease. ROU assets and lease liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. The Company generally estimates the applicable discount rate used to determine the net present value of lease payments based on available information at the lease commencement date. Many of the Company’s lessee agreements include options to extend the lease, which the Company does not include in its lease terms unless they are reasonably certain to be exercised. The Company utilizes a portfolio approach to account for the ROU assets and liabilities associated with certain equipment leases.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has also made an accounting policy election not to separate lease and non-lease components for its real estate leases and to exclude short-term leases with a term of twelve months or less from its ROU assets and lease liabilities. Rental expense for lease payments related to operating leases is recognized on a straight-line basis over the lease term.</span></div><div style="margin-top:13pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets consist primarily of patents, trademarks, software development costs, customer relationships and acquired technology. Costs related to patents and trademarks, which include legal and application fees, are capitalized and amortized over the estimated useful lives using the straight-line method. Patent and trademark amortization commences once final approval of the patent or trademark has been obtained. Patent costs are amortized over the lesser of 10 years or the patent’s remaining legal life, which assumes renewals, and trademark costs are amortized over 17 years, and their associated amortization cost is included in selling, general and administrative expense in the accompanying condensed consolidated statements of operations.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> For intangibles purchased in an asset acquisition or business combination, which mainly include patents, trademarks, customer relationships and acquired technologies, the useful life is determined largely by valuation estimates of remaining economic life.</span></div><div style="margin-top:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s policy is to renew its patents and trademarks. Costs to renew patents and trademarks are capitalized and amortized over the remaining useful life of the intangible asset. The Company periodically evaluates the amortization period and carrying basis of patents and trademarks to determine whether any events or circumstances warrant a revised estimated useful life or reduction in value. Capitalized application costs are charged to operations when it is determined that the patent or trademark will not be obtained or is abandoned.</span></div><div style="margin-top:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Software development costs are accounted for in accordance with ASC Topic 985-20, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Software - Costs of Software to be Sold, Leased, or Marketed. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once technological feasibility has been established, qualifying costs incurred in development are capitalized until available for general release to customers, and subsequently reported at the lower of unamortized cost or net realizable value.</span></div><div style="margin-top:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangibles purchased as part of an asset acquisition or business combination historically have included patents, trademarks, customer relationships, developed technologies and contractual licenses. In certain circumstances the Company has also acquired non-compete agreements tied to certain employment relationships. The useful life for all of these is largely determined by valuation estimates of remaining economic life. In connection with the Sound United acquisition, the Company acquired certain trademarks/tradenames, which are intangible assets with indefinite useful lives. These brands are expected to maintain brand value for an indefinite period of time.</span></div><div style="margin-top:13pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Goodwill, Intangible Assets and Other Long-Lived Assets</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is recorded as the difference, if any, between the aggregate consideration paid for an acquisition and the fair value of the acquired net tangible and intangible assets. Goodwill is not amortized, but instead is tested annually for impairment, or more frequently when events or changes in circumstances indicate that goodwill might be impaired. In assessing goodwill impairment, the Company has the option to first assess the qualitative factors to determine whether the existence of events or circumstances leads to a determination that it is more likely than not that the fair value of a reporting unit is less than its carrying amount. The Company has two reporting units, healthcare and non-healthcare. The Company’s qualitative assessment of the recoverability of goodwill considers various macro-economic, industry-specific and Company-specific factors, including: (i) severe adverse industry or economic trends; (ii) significant Company-specific actions; (iii) current, historical or projected deterioration of the Company’s financial performance; or (iv) a sustained decrease in the Company’s market capitalization below its net book value. If the qualitative assessment indicates that it is more-likely-than-not that the fair value of a reporting unit is less than its carrying value, or if the Company elects to bypass the qualitative analysis, then the Company performs a quantitative analysis that compares the fair value of the reporting unit with its carrying amount, including goodwill. If the fair value of the reporting unit exceeds its carrying amount, goodwill is not considered impaired; otherwise, a goodwill impairment loss is recognized for the lesser of: (a) the amount that the carrying amount of such reporting unit exceeds its fair value; or (b) the amount of the goodwill allocated to such reporting unit. The annual impairment test is performed during the fourth fiscal quarter.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similar to goodwill, indefinite-lived intangible assets are not amortized but instead are subject to annual impairment testing, unless circumstances dictate more frequent testing, if impairment indicators exist. Impairment for indefinite-lived assets exists if the carrying value of the indefinite-lived intangible asset exceeds its fair value. Determining whether impairment indicators exist and estimating the fair value of the Company’s indefinite-lived intangible assets if necessary for impairment testing require significant judgment. Qualitative factors considered in this assessment include industry and market conditions, overall financial performance, and other relevant events and factors. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews finite lived intangible assets and long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted operating cash flows expected to be generated by the asset. If such asset is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount exceeds the fair value of the asset. Long-lived assets to be disposed of are reported at the lower of carrying amount or fair value less costs to sell.</span></div><div style="margin-top:13pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Defined Benefit Plans</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains noncontributory defined benefit plans that cover certain employees in certain international locations. The Company recognizes the funded status, or the difference between the fair value of plan assets and the projected benefit obligations of the pension plan on the condensed consolidated balance sheet, with a corresponding adjustment to accumulated other comprehensive (loss) income. If the projected benefit obligation exceeds the fair value of plan assets, the difference or underfunded status represents the pension liability. The Company records a net periodic pension cost in the condensed consolidated statement of operations. The liabilities and annual income or expense are determined using methodologies that involve several actuarial assumptions, the most significant of which are the discount rate and the expected long-term rate of asset return. The Company’s accounting policy includes an annual re-measurement of pension assets and obligations. In addition, the Company r</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e-measures pension assets and obligations for significant events, as of the nearest month-end date on the calendar. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of plan assets are determined based on prevailing market prices. See Note 21, “Employee Benefits”, for further details.</span></div><div style="margin-top:13pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for income taxes using the asset and liability method, under which the Company recognizes deferred tax assets and liabilities for the future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and for net operating loss and tax credit carryforwards. Tax positions that meet a more-likely-than-not recognition threshold are recognized in the first reporting period that it becomes more-likely-than-not such tax position will be sustained upon examination. A tax position that meets this more-likely-than-not recognition threshold is recorded at the largest amount of tax benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. Previously recognized income tax positions that fail to meet the recognition threshold in a subsequent period are derecognized in that period. Differences between actual results and the Company’s assumptions, or changes in the Company’s assumptions in future periods, are recorded in the period they become known. The Company records potential accrued interest and penalties related to unrecognized tax benefits in income tax expense.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a multinational corporation, the Company is subject to complex tax laws and regulations in various jurisdictions. The application of tax laws and regulations is subject to legal and factual interpretation, judgment and uncertainty. Tax laws themselves are subject to change as a result of changes in fiscal policy, changes in legislation, evolution of regulations and court rulings. Therefore, the actual liability for U.S. or foreign taxes may be materially different from the Company’s estimates, which could result in the need to record additional liabilities or potentially to reverse previously recorded tax liabilities.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that includes the enactment date. A valuation allowance is recorded against any deferred tax assets when, in the judgment of management, it is more likely than not that all or part of a deferred tax asset will not be realized. In assessing the need for a valuation allowance, the Company considers all positive and negative evidence, including recent financial performance, scheduled reversals of temporary differences, projected future taxable income, availability of taxable income in carryback periods and tax planning strategies.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are highly susceptible to changes from period to period, requiring management to make assumptions about the Company’s future income over the lives of its deferred tax assets and the impact of changes in valuation allowances. Any difference in the assumptions, judgments and estimates mentioned above could result in changes to the Company’s results of operations.</span></div><div style="margin-top:13pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition, Deferred Revenue and Other Contract Liabilities</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generally recognizes revenue following a single, principles-based five-step model to be applied to all contracts with customers and generally provides for the recognition of revenue in an amount that reflects the consideration to which the Company expects to be entitled, net of allowances for estimated returns, discounts or sales incentives, as well as taxes collected from customers that are remitted to government authorities, when control over the promised goods or services are transferred to the customer.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Healthcare segment</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the majority of the Company’s healthcare segment revenue contracts and transactions contain standard business terms and conditions, there are some transactions that contain non-standard business terms and conditions. As a result, contract interpretation, judgment and analysis are required to determine the appropriate accounting, including: (i) the amount of the total consideration, as well as variable consideration, (ii) whether the arrangement contains an embedded lease, and if so, whether such embedded lease is a sales-type lease or an operating lease, (iii) the identification of the distinct performance obligations contained within the arrangement, (iv) how the arrangement consideration should be allocated to each performance obligation when multiple performance obligations exist, including the determination of standalone selling price, and (v) when to recognize revenue on the performance obligations. Changes in judgments on these assumptions and estimates could materially impact the timing of revenue recognition. Revenue from fixed lease payments related to equipment supplied under sales-type lease arrangements is recognized once control over the equipment is transferred to the customer, while revenue from fixed lease payments related to equipment supplied under operating-type lease arrangements is generally recognized on a straight-line basis over the term of the lease and variable lease payments are recognized as they occur. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company derives the majority of its healthcare segment revenue from four primary sources: (i) direct sales under deferred equipment agreements with end-user hospitals where the Company provides up-front monitoring equipment at no up-front charge in exchange for a multi-year sensor purchase commitment; (ii) other direct sales of noninvasive monitoring solutions to end-user hospitals, emergency medical response organizations and other direct customers; (iii) sales of noninvasive monitoring solutions to distributors who then typically resell to end-user hospitals, emergency medical response organizations and other customers; and (iv) sales of integrated circuit boards to OEM customers who incorporate the Company’s embedded software technology into their multiparameter monitoring devices. Subject to customer credit considerations, the majority of such sales are made on open accounts using industry standard payment terms based on the geography within which the specific customer is located. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into agreements to sell its monitoring solutions and services, sometimes as a part of arrangements with multiple performance obligations that include various combinations of product sales, equipment leases, software and services. In the case of contracts with multiple performance obligations, the authoritative guidance provides that the total consideration be allocated to each performance obligation on the basis of relative standalone selling prices. When a standalone selling price is not readily observable, the Company estimates the standalone selling price by considering multiple factors including, but not limited to, features and functionality of the product, geographies, type of customer, contractual prices pursuant to Group Purchasing Organization (GPO) contracts, the Company’s pricing and discount practices, and other market conditions.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales under deferred equipment agreements are generally structured such that the Company agrees to provide certain monitoring-related equipment, software, installation, training and/or warranty support at no up-front charge in exchange for the customer’s commitment to purchase sensors over the term of the agreement, which generally ranges from three years to six years. The Company allocates contract consideration under deferred equipment agreements containing fixed annual sensor purchase commitments to the underlying lease and non-lease components at contract inception. In determining whether any underlying lease components are related to a sales-type lease or an operating lease, the Company evaluates the customer’s rights and ability to control the use of the underlying equipment throughout the contract term, including any equipment substitution rights retained by the Company, as well as the Company’s expectations surrounding potential contract/lease extensions or renewals and the customer’s likelihood to exercise any purchase options. Beginning in 2022, for contracts that contain variable lease payments that are not dependent on an index or rate, the Company classifies as operating leases any lease components that would have otherwise been classified as sales-type leases that would result in a selling loss upon lease commencement. Revenue allocable to non-lease performance obligations is generally recognized as such non-lease performance obligations are satisfied. Revenue allocable to lease components under sales-type lease arrangements is generally recognized when control over the equipment is transferred to the customer. Revenue allocable to lease components under operating lease arrangements is generally recognized over the term of the operating lease. The Company generally does not expect to derive any significant value in excess of such asset’s unamortized book value from equipment underlying its operating lease arrangements after the end of the agreement. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from the sale of products and software to end-user hospitals, emergency medical response organizations, other direct customers, distributors and OEM customers, is recognized by the Company when control of the performance obligations thereunder transfers to the customer based upon the terms of the contract or underlying purchase order.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue related to OEM rainbow</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> parameter software licenses is recognized by the Company upon the OEM’s shipment of its product to its customer, as reported to the Company by the OEM.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides certain customers with various sales incentives that may take the form of discounts or rebates. The Company records estimates related to these programs as a reduction to revenue at the time of sale. In general, customers do not have a right of return for credit or refund. However, the Company allows returns under certain circumstances. At the end of each period, the Company estimates and accrues for these returns as a reduction to revenue. The Company estimates the revenue constraints related to these forms of variable consideration based on various factors, including expected purchasing volumes, prior sales and returns history, and specific contractual terms and limitations.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Non-healthcare segment</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-healthcare segment revenue is related to hardware and embedded software that is integrated into final products that are manufactured and sold by the Company. Products and related software are accounted for as a single performance obligation and all intended functionality is available to the customer upon purchase. Non-healthcare segment revenue is recognized upon transfer of control of promised products or service to customers, which is either upon shipment or upon delivery to the customers, depending on delivery terms. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company offers sales incentives and has customer programs consisting primarily of discounts and market development fund programs, and records them as contra revenue. Estimates for sales incentives are developed using the most likely amount and are included in the transaction price to the extent that a significant reversal of revenue would not result once the uncertainty is resolved. In developing these estimates, the Company also considers the susceptibility of the incentive to outside influences, the length of time until the uncertainty is resolved and the Company’s experience with similar contracts. Reductions in revenue related to discounts are allocated to products on a relative basis based on their respective standard selling price if there are undelivered products in a contract. Judgement is required to determine the timing and amount of recognition of marketing funds which the Company estimates based on past practice of providing similar funds.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payment terms and conditions vary among the Company’s distribution channels although terms generally include a requirement of payment within 30 to 60 days of product shipment. Sales made directly to customers from the Company’s website are paid at the time of product shipment. Prior to determining payment terms for each customer, an evaluation of such customer’s credit risk is performed. Contractual allowances are an offset to accounts receivable.</span></div><div style="margin-top:13pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shipping and Handling Costs and Fees</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All shipping and handling costs are expensed as incurred and are recorded as a component of cost of goods sold in the accompanying condensed consolidated statements of operations. Charges for shipping and handling billed to customers are included as a component of revenue.</span></div><div style="margin-top:13pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Taxes Collected From Customers and Remitted to Governmental Authorities</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s policy is to present revenue net of taxes collected from customers and remitted to governmental authorities.</span></div><div style="margin-top:13pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Costs and Other Contract Assets</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The costs of monitoring-related equipment provided to customers under operating lease arrangements within the Company’s deferred equipment agreements are generally deferred and amortized to cost of goods sold over the life of the underlying contracts. Some of the Company’s deferred equipment agreements also contain provisions for certain allowances to be made directly to the end-user hospital customer at the inception of the arrangement. These allowances are generally allocated to the lease and non-lease components and recognized as a reduction to revenue as the underlying performance obligations are satisfied.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generally invoices its customers under deferred equipment agreements as sensors are provided to the customer. However, the Company may recognize revenue for certain non-lease performance obligations under deferred equipment agreements with fixed annual commitments at the time such performance obligations are satisfied and prior to the customer being invoiced. When this occurs, the Company records an unbilled contract receivable related to such revenue until the customer has been invoiced pursuant to the terms of the underlying deferred equipment agreement.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The incremental costs of obtaining a contract with a customer are capitalized and deferred if the Company expects such costs to be recoverable over the life of the contract and the contract term is greater than one year. Such deferred costs generally relate to certain incentive sales commissions earned by the Company’s internal sales team in connection with the execution of deferred equipment agreements and are amortized to expense over the expected term of the underlying contract.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">T</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he Company recognizes non-healthcare royalty revenue associated with certain prepaid license arrangements. The Company recognizes non-healthcare revenue from the prepaid license arrangements based upon sales-based royalties when a subsequent sale occurs.</span></div><div style="margin-top:13pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warranty</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generally provides a warranty against defects in material and workmanship for a period ranging from six months to forty-eight months, depending on the product type. In traditional sales activities, including direct and OEM sales, the Company establishes an accrued liability for the estimated warranty costs at the time of revenue recognition, with a corresponding provision to cost of goods sold. Customers may also purchase extended warranty coverage or service level upgrades separately or as part of a deferred equipment agreement. Revenue related to extended warranty coverage and service level upgrades is generally recognized over the life of the contract, which reasonably approximates the period over which such services will be provided. The related extended warranty and service level upgrade costs are expensed as incurred.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the product warranty accrual were as follows: </span></div><div style="margin-top:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.391%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.791%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">March 30,<br/>2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">April 1,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product warranty accrual, beginning of period</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrual for warranties issued</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in pre-existing warranties (including changes in estimates)</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements made</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product warranty accrual, end of period</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.1 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:13pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Advertising Costs</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advertising costs include certain advertising, marketing and endorsement licensing fee agreements. Advertising and marketing costs are expensed as incurred. Licensing fees associated with product endorsers are expensed on a straight-line basis over the term of the agreement. Advertising costs are included in selling, general and administrative expense in the accompanying condensed consolidated statements of operations. Advertising costs for the three months ended March 30, 2024 and April 1, 2023 were $11.9 million and $14.4 million, respectively.</span></div><div style="margin-top:13pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation Costs and Contingencies</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records a charge equal to at least the minimum estimated liability for a loss contingency or litigation settlement when both of the following conditions are met: (i) information available prior to issuance of the financial statements indicates that it is probable that a liability had been incurred at the date of the financial statements, and (ii) the range of loss can be reasonably estimated. The determination of whether a loss contingency, litigation settlement or contingent fee is probable or reasonably possible involves a significant amount of management judgment, as does the estimation of the range of loss given the nature of contingencies or any associated contingent fees related to a settlement of a legal matter. Liabilities related to litigation settlements with multiple elements are recorded based on the fair value of each element. Legal and other litigation related expenses are recognized as the services are provided. Contingent legal fee expenses are recognized when probable and reasonably estimable. The Company records insurance and other indemnity recoveries for litigation expenses when both of the following conditions are met: (a) the recovery is probable, and (b) collectability is reasonably assured. Insurance recoveries are only recorded to the extent the litigation costs to which they relate have been incurred and recognized in the financial statements.</span></div><div style="margin-top:13pt;text-indent:11.25pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Translation</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s international headquarters is in Switzerland, and its functional currency is the U.S. Dollar. The Company has many other foreign subsidiaries, and the largest transactions in foreign currency translations occur in the Japanese Yen, the British Pou</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nd, the Chinese Yuan a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nd the European Euro.</span></div><div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records certain revenues and expenses in foreign currencies. These revenues and expenses are translated into U.S. Dollars based on the average exchange rate for the reporting period. Assets and liabilities denominated in foreign currencies are translated into U.S. Dollars at the exchange rate in effect as of the balance sheet date. Translation gains and losses related to foreign currency assets and liabilities of a subsidiary that are denominated in the functional currency of such subsidiary are included as a component of accumulated other comprehensive (loss) income within the accompanying condensed consolidated balance sheets. Realized and unrealized foreign currency gains and losses related to foreign currency assets and liabilities of the Company, or a subsidiary that are not denominated in the underlying functional currency are included as a component of non-operating (loss) income within the accompanying condensed consolidated statements of operations. </span></div><div style="margin-top:13pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivatives Instruments and Hedging Activities</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company addresses market risk from changes in interest rates risks through risk management programs, which include the use of derivative instruments. The Company’s exposure to a counterparty’s credit risk is generally limited to the amounts of the net obligation to the counterparty. The Company established policies to enter into contracts only with major investment-grade financial institutions to mitigate such counterparty credit risk. The Company also established a policy to further monitor the counterparty risks throughout the life of the instruments. None of the derivative instruments currently held by the Company were entered into for speculative trading purposes.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All derivative financial instruments are recognized as either assets or liabilities at fair value in the condensed consolidated balance sheets and are classified as short-term or long-term based on the tenor of the instrument. The Company has elected not to separate a derivative instrument into current and long-term portions. A derivative instrument whose fair value is a net liability is classified as current in total. A derivative instrument whose fair value is a net asset and whose current portion is an asset is classified as non-current in total. For a derivative instrument that meets the criteria to qualify for hedge accounting, the Company marks the fair value of the derivative instrument to market periodically through other comprehensive (loss) income. When the hedged items are recorded to income (loss), the associated deferred gains (losses) of the derivatives in accumulated other comprehensive (loss) income will be reclassified into earnings. Any fluctuation in the fair value of a derivative instrument that does not meet the criteria for hedge accounting is recorded to earnings (expense) in the period it occurs.</span></div><div style="margin-top:13pt;text-indent:11.25pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive (Loss) Income</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive (loss) income includes foreign currency translation adjustments, changes to pension benefits, unrealized gains (losses) on cash flow hedges and any related tax benefits (expenses) that have been excluded from net income and reflected in stockholders’ equity.</span></div><div style="margin-top:13pt;text-indent:11.25pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> Income Per Share</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A computation of basic and diluted net income per share is as follows:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.391%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.791%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except per share amounts)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">March 30,<br/>2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">April 1,<br/>2023</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.9 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.3 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic net income per share:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding - basic</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.0 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.6 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per basic share</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.36</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.40</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Diluted net income per share:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding - basic</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted share equivalents: stock options, RSUs and PSUs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding - diluted</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.4 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per diluted share</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.35</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.39</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net income per share is computed by dividing net income by the weighted-average number of shares outstanding during the period. Net income per diluted share is computed by dividing the net income by the weighted-average number of shares and potential shares outstanding during the period, if the effect of potential shares is dilutive. Potential shares include incremental shares of stock issuable upon the exercise of stock options and the vesting of both restricted share units (RSUs) and performance stock units (PSUs). For each of the three months ended March 30, 2024 and April 1, 2023, weighted options to purchase 1.4 million and 1.0 million shares of common stock, respectively, were outstanding but not included in the computation of diluted net income per share because the effect of including such shares would have been antidilutive in the applicable period. Certain RSUs were considered contingently issuable shares as their vesting is contingent upon the occurrence of certain future events. Since such events had not occurred and were not considered probable of occurring as of each of March 30, 2024 and April 1, 2023, 2.7 million weighted-average shares related to such RSUs have been excluded from the calculation of potential shares for the three month periods then ended. For additional information with respect to these RSUs, please see “Employment and Severance Agreements” in Note 24, “Commitments and Contingencies”.</span></div><div style="margin-top:13pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Supplemental Cash Flow Information</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information includes the following:</span></div><div style="margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.391%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.791%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">March 30,<br/>2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">April 1,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash paid during the year for:</span></div></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.5 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.0 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-cash operating activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROU assets obtained in exchange for lease liabilities</span></div></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.6 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-cash investing activities:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unpaid purchases of property and equipment</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unpaid strategic investments</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-cash financing activities:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">       Unsettled common stock proceeds from option exercises</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Reconciliation of cash, cash equivalents and restricted cash:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></div></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157.6 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174.1 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash shown in the condensed consolidated statements of cash flows</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164.0 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181.1 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:13pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted and Recently Announced Accounting Pronouncements</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes to the accounting policies discussed in Note 2 to the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 30, 2023, filed with the SEC on February 28, 2024. other than the following update: </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the Financial Accounting Standards Board issued Accounting Standards Update (ASU) No. 2023-07, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The new standard is intended to improve reportable segment disclosure requirements primarily through enhanced disclosures about significant segment expenses. ASU No. 2023-07 is effective for annual reporting periods beginning after December 15, 2023 and interim periods in fiscal years beginning after December 15, 2024. Early adoption is permitted with retrospective application to all prior periods presented. Upon transition, the segment expense categories and amounts disclosed in the prior periods should be based on the significant segment expense categories identified and disclosed in the period of adoption. The Company is continuing to evaluate the impact of this standard on its consolidated financial statements upon adoption.</span></div> <div style="margin-top:4.5pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (SEC). Certain information and note disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) have been condensed or omitted pursuant to such rules and regulations. The accompanying condensed consolidated financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments, including normal recurring accruals, necessary to present fairly the Company’s condensed consolidated financial statements. The accompanying condensed consolidated balance sheet as of December 30, 2023 was derived from the Company’s audited consolidated financial statements at that date. The accompanying condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes contained in the Company’s Annual Report on Form 10-K for the fiscal year ended December 30, 2023 (fiscal year 2023), filed with the SEC on February 28, 2024. The results for the three months ended March 30, 2024 are not necessarily indicative of the results to be expected for the fiscal year ending December 28, 2024 (fiscal year 2024) or for any other interim period or for any future year.</span></div> <div style="margin-top:13pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fiscal Periods</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company follows a conventional 52/53 week fiscal year. Under a conventional 52/53 week fiscal year, a 52 week fiscal year includes four quarters of 13 weeks while a 53 week fiscal year includes three 13 week fiscal quarters and one 14 week fiscal quarter. The Company’s last 53 week fiscal year was fiscal year 2020. Fiscal year 2024 is a 52 week fiscal year ending December 28, 2024. All references to years in these notes to condensed consolidated financial statements are fiscal years unless otherwise noted.</span></div> <div style="margin-top:13pt;text-indent:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> amounts in the accompanying condensed consolidated financial statements have been reclassified to conform to the current period presentation, including certain balance sheet asset accounts in the consolidated financial statements for the year ended December 30, 2023. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was no impact on previously reported total assets, liabilities, stockholders’ equity or net income.</span></div> <div style="margin-top:13pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company prepares its financial statements in conformity with GAAP, which requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Significant estimates include the determination of standalone selling prices, variable consideration, total consideration allocated to each performance obligation within a contract, inventory valuation, valuation of the Company’s equity awards, valuation of identifiable assets and liabilities connected with business combinations, impairment of long-lived assets, intangible assets and goodwill; derivative and equity instruments, deferred taxes and any associated valuation allowances, deferred revenue, accounting for pensions, uncertain income tax positions, litigation costs, and related accruals. See Note 24, “Commitments and Contingencies”. Actual results could differ from such estimates.</span></div> <div style="margin-top:13pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Combinations</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for business combinations using the acquisition method of accounting in accordance with Accounting Standards Codification (ASC) Topic 805, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which requires that once control is obtained, assets acquired, liabilities assumed and noncontrolling interests in the acquired entity, if applicable, are recorded at their respective fair values at the date of acquisition, with the exception of acquired contract assets and contract liabilities (i.e., deferred revenue) from contracts with customers. These are recognized and measured in accordance with ASC Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers. </span>The excess of the purchase price over fair values of identifiable assets, liabilities and noncontrolling interests in the acquired entity, if applicable, is recorded as goodwill. <div style="margin-top:13pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for certain financial instruments at their fair values as either assets or liabilities on the balance sheet. The Company determines the fair value of its financial instruments using the framework prescribed by ASC Topic 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements and Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and considers the estimated amount the Company would receive or pay to transfer these instruments at the reporting date with respect to current currency exchange rates, interest rates, the creditworthiness of the counterparty for unrealized gain positions and the Company’s creditworthiness for unrealized loss positions. In certain instances, the Company may utilize financial models to measure the fair value of its financial instruments. In doing so, the Company uses inputs that include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, other observable inputs for the asset or liability and inputs derived principally from, or corroborated by, observable market data by correlation or other means.</span></div><div style="margin-top:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recurring Fair Value Measurement</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On a recurring basis, the Company measures certain financial assets and financial liabilities at fair value based upon quoted market prices. Where quoted market prices or other observable inputs are not available, the Company applies valuation techniques to estimate fair value. Authoritative guidance describes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value:</span></div><div style="margin-top:4.5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">●    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1—Quoted prices in active markets for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">identical</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> assets or liabilities.</span></div><div style="margin-top:4.5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">●    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">similar</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> assets or liabilities, quoted prices in markets that are not active; or other inputs that can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></div><div style="margin-top:4.5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">●    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables represent the Company’s financial assets, measured at fair value on a recurring basis at March 30, 2024:</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:41.506%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.812%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:19pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total Carrying <br/>Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Fair Value Measurement Hierarchy</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:20pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:22.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;text-indent:22.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.7 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.7 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:22.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;text-indent:22.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.9 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.6 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative instruments - cash flow hedges</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;text-indent:22.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative instruments - warrants</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197.5 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176.8 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.7 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative instruments - cash flow hedges</span></div></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:22.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension benefit obligation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Includes accrued interest.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables represent the Company’s financial assets, measured at fair value on a recurring basis at December 30, 2023: </span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.795%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total Carrying <br/>Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Fair Value Measurement Hierarchy</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:22.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;text-indent:22.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76.0 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76.0 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension assets</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;text-indent:22.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative instruments - cash flow hedges</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;text-indent:22.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative instruments - warrants</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200.4 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182.5 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.9 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;text-indent:22.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative instruments - cash flow hedges</span></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:22.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension benefit obligation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.2 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.2 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Includes accrued interest.</span></div><div style="margin-top:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company invests in checking, savings and money market fund accounts, which are classified within Level 1 of the fair value hierarchy as they are valued using quoted market prices. These investments are classified as cash and cash equivalents within the Company’s accompanying condensed consolidated balance sheets, in accordance with GAAP and its accounting policies.</span></div><div style="margin-top:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has certain strategic investments in privately-held companies (non-marketable equity securities) and companies that have completed initial public offerings (marketable equity securities). The Company’s marketable equity securities, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">whose price is based on quoted market price in an active market, are classified within Level 1 of the fair value hierarchy. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity securities are classified as current, short-term investments, or non-current, recorded in other non-current assets, based on the nature of the securities and their availability for use in current operations. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in the fair value of those equity securities are measured at each reporting date and changes in the value of these investments between reporting dates are recorded within non-operating loss. </span></div><div style="margin-top:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s pension assets consist of Level 1 and Level 2 investments. The fair value of Level 2 assets is based on observable inputs such as prices or quotes for similar assets, adjusted for any differences in terms or conditions that may affect the value of the instrument being valued. The valuation techniques used for Level 2 assets may include the use of models or other valuation techniques, but these methods are all based on observable market inputs.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also has investments in certain derivative instruments, which are measured at fair value and classified within Level 1 of the fair value hierarchy.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Non-Recurring Fair Value Measurements</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For certain other financial assets and liabilities, including restricted cash, accounts receivable, accounts payable and other current assets and liabilities, the carrying amounts approximate their fair value primarily due to the relatively short maturity of these balances. The Company also measures certain non-financial assets at fair value on a non-recurring basis, primarily goodwill, intangible assets and operating lease right-of-use assets, in connection with periodic evaluations for potential impairment.</span></div>Furthermore, the Company did not elect to apply the fair value option to specific assets or liabilities on a contract-by-contract basis. The Company did not have any transfers between Level 2 and Level 3 during the three months ended March 30, 2024. <div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables represent the Company’s financial assets, measured at fair value on a recurring basis at March 30, 2024:</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:41.506%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.812%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:19pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total Carrying <br/>Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Fair Value Measurement Hierarchy</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:20pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:22.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;text-indent:22.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.7 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.7 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:22.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;text-indent:22.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.9 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.6 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative instruments - cash flow hedges</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;text-indent:22.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative instruments - warrants</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197.5 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176.8 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.7 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative instruments - cash flow hedges</span></div></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:22.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension benefit obligation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Includes accrued interest.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables represent the Company’s financial assets, measured at fair value on a recurring basis at December 30, 2023: </span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.795%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total Carrying <br/>Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Fair Value Measurement Hierarchy</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:22.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;text-indent:22.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76.0 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76.0 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension assets</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;text-indent:22.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative instruments - cash flow hedges</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;text-indent:22.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative instruments - warrants</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200.4 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182.5 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.9 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;text-indent:22.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative instruments - cash flow hedges</span></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:22.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension benefit obligation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.2 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.2 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Includes accrued interest.</span></div> 81900000 81900000 0 0 75700000 75700000 0 0 1700000 1700000 0 0 22900000 16600000 6300000 0 14400000 0 14400000 0 900000 900000 0 0 197500000 176800000 20700000 0 0 0 0 0 32100000 32100000 0 0 32100000 32100000 0 0 87000000.0 87000000.0 0 0 76000000.0 76000000.0 0 0 23100000 16800000 6300000 0 1700000 1700000 0 0 11600000 0 11600000 0 1000000.0 1000000.0 0 0 200400000 182500000 17900000 0 3600000 3600000 0 0 32600000 32600000 0 0 36200000 36200000 0 0 <div style="margin-top:13pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Th</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e Company considers all highly liquid investments with an original maturity from the date of purchase of three months or less, or highly liquid investments that are readily convertible into known amounts of cash, to be cash equivalents. The Company carries cash and cash equivalents at cost, which approximates fair value, and they are Level 1 under the fair value hierarchy.</span></div> <div style="margin-top:13pt;text-indent:13.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable and Allowance for Credit Losses</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable consist of trade receivables recorded at the time of invoicing of product sales, reduced by reserves for estimated bad debts and returns. Trade accounts receivable are recorded at the invoiced amount and do not bear interest. Credit is extended based on an evaluation of the customer’s financial condition. Collateral is generally not required. The Company records an allowance for credit losses that it does not expect to collect based on relevant information, including historical experience, current conditions, and reasonable and supportable forecasts. Accounts are charged off against the allowance when the Company believes they are uncollectible. The allowance for credit losses is measured on a collective (pool) basis when similar risk characteristics exist. Based on the risk characteristics, the Company has identified U.S. and international customers as separate portfolios for both segments, and measures expected credit losses on such receivables using an aging methodology</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</span></div> <div style="margin-top:13pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventories</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at the lower of cost or net realizable value. Cost is determined using a standard cost method, which approximates the first in, first out method, and includes material, labor and overhead costs. Inventory valuation adjustments are recorded for inventory items that have become excess or obsolete or are no longer used in current production and for inventory items that have a market price less than the carrying value in inventory. The Company generally determines inventory valuation adjustments based on an evaluation of the expected future use of its inventory on an item by item basis and applies historical obsolescence rates to estimate the loss on inventory expected to have a recovery value below cost. The Company also records other specific inventory valuation adjustments when it becomes aware of unique events or circumstances that result in an expected recovery value below cost. For inventory items that have been written down, the reduced value becomes the new cost basis.</span></div> <div style="margin-top:13pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment </span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost. Depreciation is calculated using the straight-line method over estimated useful lives as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.736%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.064%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Useful Lives</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and building improvements</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 to 39 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 to 12 years</span></div></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Demonstration units</span></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 to 3 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and office equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 to 15 years</span></div></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lesser of useful life or term of lease</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery, equipment and tooling</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 to 20 years</span></div></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lesser of useful life or term of lease</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transportation, vehicles and other</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 to 20 years</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Land is not depreciated and construction-in-progress is not depreciated until placed in service. Normal repair and maintenance costs are expensed as incurred, whereas significant improvements that materially increase values or extend useful lives are capitalized and depreciated over the remaining estimated useful lives of the related assets. Upon sale or retirement of depreciable assets, the related cost and accumulated depreciation or amortization are removed from the accounts and any gain or loss on the sale or retirement is recognized in income.</span></div> <div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost. Depreciation is calculated using the straight-line method over estimated useful lives as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.736%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.064%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Useful Lives</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and building improvements</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 to 39 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 to 12 years</span></div></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Demonstration units</span></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 to 3 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and office equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 to 15 years</span></div></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lesser of useful life or term of lease</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery, equipment and tooling</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 to 20 years</span></div></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lesser of useful life or term of lease</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transportation, vehicles and other</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 to 20 years</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net, consists of the following:</span></div><div style="margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.391%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.791%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">March 30,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">December 30,<br/>2023</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery, equipment and tooling</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173.1 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169.7 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building and building improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108.1 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92.2 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.4 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.5 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transportation, vehicles and other</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.5 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.0 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and office equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Demonstration units</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.3 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.1 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction-in-progress (CIP)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Total property and equipment</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">692.8 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">686.8 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(277.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(262.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Property and equipment, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">415.0 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">424.4 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________</span></div><div style="margin-top:4.5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">At March 30, 2024, property, plant and equipment, net, excluded $11.4 million of idle undeveloped land classified as held for sale within the healthcare segment. The sale of land is expected to be completed within the earlier of the next 12 months or upon the closing of customary escrow and due diligence procedures. Any gain on the sale of land transaction will be recorded at the time of disposal.</span></div> P7Y P39Y P2Y P12Y P2Y P3Y P2Y P15Y P3Y P20Y P1Y P20Y <div style="margin-top:13pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lessee Right-of-Use (ROU) Assets and Lease Liabilities</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement contains a lease at inception. ROU assets represent the Company’s right to use an asset underlying an operating lease for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from an operating lease. ROU assets and lease liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. The Company generally estimates the applicable discount rate used to determine the net present value of lease payments based on available information at the lease commencement date. Many of the Company’s lessee agreements include options to extend the lease, which the Company does not include in its lease terms unless they are reasonably certain to be exercised. The Company utilizes a portfolio approach to account for the ROU assets and liabilities associated with certain equipment leases.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has also made an accounting policy election not to separate lease and non-lease components for its real estate leases and to exclude short-term leases with a term of twelve months or less from its ROU assets and lease liabilities. Rental expense for lease payments related to operating leases is recognized on a straight-line basis over the lease term.</span></div> <div style="margin-top:13pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets consist primarily of patents, trademarks, software development costs, customer relationships and acquired technology. Costs related to patents and trademarks, which include legal and application fees, are capitalized and amortized over the estimated useful lives using the straight-line method. Patent and trademark amortization commences once final approval of the patent or trademark has been obtained. Patent costs are amortized over the lesser of 10 years or the patent’s remaining legal life, which assumes renewals, and trademark costs are amortized over 17 years, and their associated amortization cost is included in selling, general and administrative expense in the accompanying condensed consolidated statements of operations.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> For intangibles purchased in an asset acquisition or business combination, which mainly include patents, trademarks, customer relationships and acquired technologies, the useful life is determined largely by valuation estimates of remaining economic life.</span></div><div style="margin-top:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s policy is to renew its patents and trademarks. Costs to renew patents and trademarks are capitalized and amortized over the remaining useful life of the intangible asset. The Company periodically evaluates the amortization period and carrying basis of patents and trademarks to determine whether any events or circumstances warrant a revised estimated useful life or reduction in value. Capitalized application costs are charged to operations when it is determined that the patent or trademark will not be obtained or is abandoned.</span></div><div style="margin-top:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Software development costs are accounted for in accordance with ASC Topic 985-20, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Software - Costs of Software to be Sold, Leased, or Marketed. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once technological feasibility has been established, qualifying costs incurred in development are capitalized until available for general release to customers, and subsequently reported at the lower of unamortized cost or net realizable value.</span></div><div style="margin-top:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangibles purchased as part of an asset acquisition or business combination historically have included patents, trademarks, customer relationships, developed technologies and contractual licenses. In certain circumstances the Company has also acquired non-compete agreements tied to certain employment relationships. The useful life for all of these is largely determined by valuation estimates of remaining economic life. In connection with the Sound United acquisition, the Company acquired certain trademarks/tradenames, which are intangible assets with indefinite useful lives. These brands are expected to maintain brand value for an indefinite period of time.</span></div> P10Y P17Y <div style="margin-top:13pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Goodwill, Intangible Assets and Other Long-Lived Assets</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is recorded as the difference, if any, between the aggregate consideration paid for an acquisition and the fair value of the acquired net tangible and intangible assets. Goodwill is not amortized, but instead is tested annually for impairment, or more frequently when events or changes in circumstances indicate that goodwill might be impaired. In assessing goodwill impairment, the Company has the option to first assess the qualitative factors to determine whether the existence of events or circumstances leads to a determination that it is more likely than not that the fair value of a reporting unit is less than its carrying amount. The Company has two reporting units, healthcare and non-healthcare. The Company’s qualitative assessment of the recoverability of goodwill considers various macro-economic, industry-specific and Company-specific factors, including: (i) severe adverse industry or economic trends; (ii) significant Company-specific actions; (iii) current, historical or projected deterioration of the Company’s financial performance; or (iv) a sustained decrease in the Company’s market capitalization below its net book value. If the qualitative assessment indicates that it is more-likely-than-not that the fair value of a reporting unit is less than its carrying value, or if the Company elects to bypass the qualitative analysis, then the Company performs a quantitative analysis that compares the fair value of the reporting unit with its carrying amount, including goodwill. If the fair value of the reporting unit exceeds its carrying amount, goodwill is not considered impaired; otherwise, a goodwill impairment loss is recognized for the lesser of: (a) the amount that the carrying amount of such reporting unit exceeds its fair value; or (b) the amount of the goodwill allocated to such reporting unit. The annual impairment test is performed during the fourth fiscal quarter.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similar to goodwill, indefinite-lived intangible assets are not amortized but instead are subject to annual impairment testing, unless circumstances dictate more frequent testing, if impairment indicators exist. Impairment for indefinite-lived assets exists if the carrying value of the indefinite-lived intangible asset exceeds its fair value. Determining whether impairment indicators exist and estimating the fair value of the Company’s indefinite-lived intangible assets if necessary for impairment testing require significant judgment. Qualitative factors considered in this assessment include industry and market conditions, overall financial performance, and other relevant events and factors. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews finite lived intangible assets and long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted operating cash flows expected to be generated by the asset. If such asset is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount exceeds the fair value of the asset. Long-lived assets to be disposed of are reported at the lower of carrying amount or fair value less costs to sell.</span></div> 2 <div style="margin-top:13pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Defined Benefit Plans</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains noncontributory defined benefit plans that cover certain employees in certain international locations. The Company recognizes the funded status, or the difference between the fair value of plan assets and the projected benefit obligations of the pension plan on the condensed consolidated balance sheet, with a corresponding adjustment to accumulated other comprehensive (loss) income. If the projected benefit obligation exceeds the fair value of plan assets, the difference or underfunded status represents the pension liability. The Company records a net periodic pension cost in the condensed consolidated statement of operations. The liabilities and annual income or expense are determined using methodologies that involve several actuarial assumptions, the most significant of which are the discount rate and the expected long-term rate of asset return. The Company’s accounting policy includes an annual re-measurement of pension assets and obligations. In addition, the Company r</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e-measures pension assets and obligations for significant events, as of the nearest month-end date on the calendar. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of plan assets are determined based on prevailing market prices. See Note 21, “Employee Benefits”, for further details.</span></div> <div style="margin-top:13pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for income taxes using the asset and liability method, under which the Company recognizes deferred tax assets and liabilities for the future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and for net operating loss and tax credit carryforwards. Tax positions that meet a more-likely-than-not recognition threshold are recognized in the first reporting period that it becomes more-likely-than-not such tax position will be sustained upon examination. A tax position that meets this more-likely-than-not recognition threshold is recorded at the largest amount of tax benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. Previously recognized income tax positions that fail to meet the recognition threshold in a subsequent period are derecognized in that period. Differences between actual results and the Company’s assumptions, or changes in the Company’s assumptions in future periods, are recorded in the period they become known. The Company records potential accrued interest and penalties related to unrecognized tax benefits in income tax expense.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a multinational corporation, the Company is subject to complex tax laws and regulations in various jurisdictions. The application of tax laws and regulations is subject to legal and factual interpretation, judgment and uncertainty. Tax laws themselves are subject to change as a result of changes in fiscal policy, changes in legislation, evolution of regulations and court rulings. Therefore, the actual liability for U.S. or foreign taxes may be materially different from the Company’s estimates, which could result in the need to record additional liabilities or potentially to reverse previously recorded tax liabilities.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that includes the enactment date. A valuation allowance is recorded against any deferred tax assets when, in the judgment of management, it is more likely than not that all or part of a deferred tax asset will not be realized. In assessing the need for a valuation allowance, the Company considers all positive and negative evidence, including recent financial performance, scheduled reversals of temporary differences, projected future taxable income, availability of taxable income in carryback periods and tax planning strategies.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are highly susceptible to changes from period to period, requiring management to make assumptions about the Company’s future income over the lives of its deferred tax assets and the impact of changes in valuation allowances. Any difference in the assumptions, judgments and estimates mentioned above could result in changes to the Company’s results of operations.</span></div> <div style="margin-top:13pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition, Deferred Revenue and Other Contract Liabilities</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generally recognizes revenue following a single, principles-based five-step model to be applied to all contracts with customers and generally provides for the recognition of revenue in an amount that reflects the consideration to which the Company expects to be entitled, net of allowances for estimated returns, discounts or sales incentives, as well as taxes collected from customers that are remitted to government authorities, when control over the promised goods or services are transferred to the customer.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Healthcare segment</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the majority of the Company’s healthcare segment revenue contracts and transactions contain standard business terms and conditions, there are some transactions that contain non-standard business terms and conditions. As a result, contract interpretation, judgment and analysis are required to determine the appropriate accounting, including: (i) the amount of the total consideration, as well as variable consideration, (ii) whether the arrangement contains an embedded lease, and if so, whether such embedded lease is a sales-type lease or an operating lease, (iii) the identification of the distinct performance obligations contained within the arrangement, (iv) how the arrangement consideration should be allocated to each performance obligation when multiple performance obligations exist, including the determination of standalone selling price, and (v) when to recognize revenue on the performance obligations. Changes in judgments on these assumptions and estimates could materially impact the timing of revenue recognition. Revenue from fixed lease payments related to equipment supplied under sales-type lease arrangements is recognized once control over the equipment is transferred to the customer, while revenue from fixed lease payments related to equipment supplied under operating-type lease arrangements is generally recognized on a straight-line basis over the term of the lease and variable lease payments are recognized as they occur. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company derives the majority of its healthcare segment revenue from four primary sources: (i) direct sales under deferred equipment agreements with end-user hospitals where the Company provides up-front monitoring equipment at no up-front charge in exchange for a multi-year sensor purchase commitment; (ii) other direct sales of noninvasive monitoring solutions to end-user hospitals, emergency medical response organizations and other direct customers; (iii) sales of noninvasive monitoring solutions to distributors who then typically resell to end-user hospitals, emergency medical response organizations and other customers; and (iv) sales of integrated circuit boards to OEM customers who incorporate the Company’s embedded software technology into their multiparameter monitoring devices. Subject to customer credit considerations, the majority of such sales are made on open accounts using industry standard payment terms based on the geography within which the specific customer is located. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into agreements to sell its monitoring solutions and services, sometimes as a part of arrangements with multiple performance obligations that include various combinations of product sales, equipment leases, software and services. In the case of contracts with multiple performance obligations, the authoritative guidance provides that the total consideration be allocated to each performance obligation on the basis of relative standalone selling prices. When a standalone selling price is not readily observable, the Company estimates the standalone selling price by considering multiple factors including, but not limited to, features and functionality of the product, geographies, type of customer, contractual prices pursuant to Group Purchasing Organization (GPO) contracts, the Company’s pricing and discount practices, and other market conditions.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales under deferred equipment agreements are generally structured such that the Company agrees to provide certain monitoring-related equipment, software, installation, training and/or warranty support at no up-front charge in exchange for the customer’s commitment to purchase sensors over the term of the agreement, which generally ranges from three years to six years. The Company allocates contract consideration under deferred equipment agreements containing fixed annual sensor purchase commitments to the underlying lease and non-lease components at contract inception. In determining whether any underlying lease components are related to a sales-type lease or an operating lease, the Company evaluates the customer’s rights and ability to control the use of the underlying equipment throughout the contract term, including any equipment substitution rights retained by the Company, as well as the Company’s expectations surrounding potential contract/lease extensions or renewals and the customer’s likelihood to exercise any purchase options. Beginning in 2022, for contracts that contain variable lease payments that are not dependent on an index or rate, the Company classifies as operating leases any lease components that would have otherwise been classified as sales-type leases that would result in a selling loss upon lease commencement. Revenue allocable to non-lease performance obligations is generally recognized as such non-lease performance obligations are satisfied. Revenue allocable to lease components under sales-type lease arrangements is generally recognized when control over the equipment is transferred to the customer. Revenue allocable to lease components under operating lease arrangements is generally recognized over the term of the operating lease. The Company generally does not expect to derive any significant value in excess of such asset’s unamortized book value from equipment underlying its operating lease arrangements after the end of the agreement. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from the sale of products and software to end-user hospitals, emergency medical response organizations, other direct customers, distributors and OEM customers, is recognized by the Company when control of the performance obligations thereunder transfers to the customer based upon the terms of the contract or underlying purchase order.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue related to OEM rainbow</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> parameter software licenses is recognized by the Company upon the OEM’s shipment of its product to its customer, as reported to the Company by the OEM.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides certain customers with various sales incentives that may take the form of discounts or rebates. The Company records estimates related to these programs as a reduction to revenue at the time of sale. In general, customers do not have a right of return for credit or refund. However, the Company allows returns under certain circumstances. At the end of each period, the Company estimates and accrues for these returns as a reduction to revenue. The Company estimates the revenue constraints related to these forms of variable consideration based on various factors, including expected purchasing volumes, prior sales and returns history, and specific contractual terms and limitations.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Non-healthcare segment</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-healthcare segment revenue is related to hardware and embedded software that is integrated into final products that are manufactured and sold by the Company. Products and related software are accounted for as a single performance obligation and all intended functionality is available to the customer upon purchase. Non-healthcare segment revenue is recognized upon transfer of control of promised products or service to customers, which is either upon shipment or upon delivery to the customers, depending on delivery terms. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company offers sales incentives and has customer programs consisting primarily of discounts and market development fund programs, and records them as contra revenue. Estimates for sales incentives are developed using the most likely amount and are included in the transaction price to the extent that a significant reversal of revenue would not result once the uncertainty is resolved. In developing these estimates, the Company also considers the susceptibility of the incentive to outside influences, the length of time until the uncertainty is resolved and the Company’s experience with similar contracts. Reductions in revenue related to discounts are allocated to products on a relative basis based on their respective standard selling price if there are undelivered products in a contract. Judgement is required to determine the timing and amount of recognition of marketing funds which the Company estimates based on past practice of providing similar funds.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payment terms and conditions vary among the Company’s distribution channels although terms generally include a requirement of payment within 30 to 60 days of product shipment. Sales made directly to customers from the Company’s website are paid at the time of product shipment. Prior to determining payment terms for each customer, an evaluation of such customer’s credit risk is performed. Contractual allowances are an offset to accounts receivable.</span></div> 4 P3Y P6Y P30D P60D <div style="margin-top:13pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shipping and Handling Costs and Fees</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All shipping and handling costs are expensed as incurred and are recorded as a component of cost of goods sold in the accompanying condensed consolidated statements of operations. Charges for shipping and handling billed to customers are included as a component of revenue.</span></div> <div style="margin-top:13pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Taxes Collected From Customers and Remitted to Governmental Authorities</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s policy is to present revenue net of taxes collected from customers and remitted to governmental authorities.</span></div> <div style="margin-top:13pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Costs and Other Contract Assets</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The costs of monitoring-related equipment provided to customers under operating lease arrangements within the Company’s deferred equipment agreements are generally deferred and amortized to cost of goods sold over the life of the underlying contracts. Some of the Company’s deferred equipment agreements also contain provisions for certain allowances to be made directly to the end-user hospital customer at the inception of the arrangement. These allowances are generally allocated to the lease and non-lease components and recognized as a reduction to revenue as the underlying performance obligations are satisfied.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generally invoices its customers under deferred equipment agreements as sensors are provided to the customer. However, the Company may recognize revenue for certain non-lease performance obligations under deferred equipment agreements with fixed annual commitments at the time such performance obligations are satisfied and prior to the customer being invoiced. When this occurs, the Company records an unbilled contract receivable related to such revenue until the customer has been invoiced pursuant to the terms of the underlying deferred equipment agreement.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The incremental costs of obtaining a contract with a customer are capitalized and deferred if the Company expects such costs to be recoverable over the life of the contract and the contract term is greater than one year. Such deferred costs generally relate to certain incentive sales commissions earned by the Company’s internal sales team in connection with the execution of deferred equipment agreements and are amortized to expense over the expected term of the underlying contract.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">T</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he Company recognizes non-healthcare royalty revenue associated with certain prepaid license arrangements. The Company recognizes non-healthcare revenue from the prepaid license arrangements based upon sales-based royalties when a subsequent sale occurs.</span></div> <div style="margin-top:13pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warranty</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generally provides a warranty against defects in material and workmanship for a period ranging from six months to forty-eight months, depending on the product type. In traditional sales activities, including direct and OEM sales, the Company establishes an accrued liability for the estimated warranty costs at the time of revenue recognition, with a corresponding provision to cost of goods sold. Customers may also purchase extended warranty coverage or service level upgrades separately or as part of a deferred equipment agreement. Revenue related to extended warranty coverage and service level upgrades is generally recognized over the life of the contract, which reasonably approximates the period over which such services will be provided. The related extended warranty and service level upgrade costs are expensed as incurred.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the product warranty accrual were as follows: </span></div><div style="margin-top:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.391%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.791%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">March 30,<br/>2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">April 1,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product warranty accrual, beginning of period</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrual for warranties issued</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in pre-existing warranties (including changes in estimates)</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements made</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product warranty accrual, end of period</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.1 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> P6M P48M <div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the product warranty accrual were as follows: </span></div><div style="margin-top:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.391%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.791%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">March 30,<br/>2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">April 1,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product warranty accrual, beginning of period</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrual for warranties issued</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in pre-existing warranties (including changes in estimates)</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements made</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product warranty accrual, end of period</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.1 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 8600000 10600000 3100000 3800000 -400000 3500000 4000000.0 700000 8100000 10200000 <div style="margin-top:13pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Advertising Costs</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advertising costs include certain advertising, marketing and endorsement licensing fee agreements. Advertising and marketing costs are expensed as incurred. Licensing fees associated with product endorsers are expensed on a straight-line basis over the term of the agreement. Advertising costs are included in selling, general and administrative expense in the accompanying condensed consolidated statements of operations. Advertising costs for the three months ended March 30, 2024 and April 1, 2023 were $11.9 million and $14.4 million, respectively.</span></div> 11900000 14400000 <div style="margin-top:13pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation Costs and Contingencies</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records a charge equal to at least the minimum estimated liability for a loss contingency or litigation settlement when both of the following conditions are met: (i) information available prior to issuance of the financial statements indicates that it is probable that a liability had been incurred at the date of the financial statements, and (ii) the range of loss can be reasonably estimated. The determination of whether a loss contingency, litigation settlement or contingent fee is probable or reasonably possible involves a significant amount of management judgment, as does the estimation of the range of loss given the nature of contingencies or any associated contingent fees related to a settlement of a legal matter. Liabilities related to litigation settlements with multiple elements are recorded based on the fair value of each element. Legal and other litigation related expenses are recognized as the services are provided. Contingent legal fee expenses are recognized when probable and reasonably estimable. The Company records insurance and other indemnity recoveries for litigation expenses when both of the following conditions are met: (a) the recovery is probable, and (b) collectability is reasonably assured. Insurance recoveries are only recorded to the extent the litigation costs to which they relate have been incurred and recognized in the financial statements.</span></div> <div style="margin-top:13pt;text-indent:11.25pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Translation</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s international headquarters is in Switzerland, and its functional currency is the U.S. Dollar. The Company has many other foreign subsidiaries, and the largest transactions in foreign currency translations occur in the Japanese Yen, the British Pou</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nd, the Chinese Yuan a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nd the European Euro.</span></div>The Company records certain revenues and expenses in foreign currencies. These revenues and expenses are translated into U.S. Dollars based on the average exchange rate for the reporting period. Assets and liabilities denominated in foreign currencies are translated into U.S. Dollars at the exchange rate in effect as of the balance sheet date. Translation gains and losses related to foreign currency assets and liabilities of a subsidiary that are denominated in the functional currency of such subsidiary are included as a component of accumulated other comprehensive (loss) income within the accompanying condensed consolidated balance sheets. Realized and unrealized foreign currency gains and losses related to foreign currency assets and liabilities of the Company, or a subsidiary that are not denominated in the underlying functional currency are included as a component of non-operating (loss) income within the accompanying condensed consolidated statements of operations. <div style="margin-top:13pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivatives Instruments and Hedging Activities</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company addresses market risk from changes in interest rates risks through risk management programs, which include the use of derivative instruments. The Company’s exposure to a counterparty’s credit risk is generally limited to the amounts of the net obligation to the counterparty. The Company established policies to enter into contracts only with major investment-grade financial institutions to mitigate such counterparty credit risk. The Company also established a policy to further monitor the counterparty risks throughout the life of the instruments. None of the derivative instruments currently held by the Company were entered into for speculative trading purposes.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All derivative financial instruments are recognized as either assets or liabilities at fair value in the condensed consolidated balance sheets and are classified as short-term or long-term based on the tenor of the instrument. The Company has elected not to separate a derivative instrument into current and long-term portions. A derivative instrument whose fair value is a net liability is classified as current in total. A derivative instrument whose fair value is a net asset and whose current portion is an asset is classified as non-current in total. For a derivative instrument that meets the criteria to qualify for hedge accounting, the Company marks the fair value of the derivative instrument to market periodically through other comprehensive (loss) income. When the hedged items are recorded to income (loss), the associated deferred gains (losses) of the derivatives in accumulated other comprehensive (loss) income will be reclassified into earnings. Any fluctuation in the fair value of a derivative instrument that does not meet the criteria for hedge accounting is recorded to earnings (expense) in the period it occurs.</span></div> <div style="margin-top:13pt;text-indent:11.25pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive (Loss) Income</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive (loss) income includes foreign currency translation adjustments, changes to pension benefits, unrealized gains (losses) on cash flow hedges and any related tax benefits (expenses) that have been excluded from net income and reflected in stockholders’ equity.</span></div> <div style="margin-top:13pt;text-indent:11.25pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> Income Per Share</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A computation of basic and diluted net income per share is as follows:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.391%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.791%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except per share amounts)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">March 30,<br/>2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">April 1,<br/>2023</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.9 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.3 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic net income per share:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding - basic</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.0 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.6 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per basic share</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.36</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.40</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Diluted net income per share:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding - basic</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted share equivalents: stock options, RSUs and PSUs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding - diluted</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.4 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per diluted share</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.35</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.39</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net income per share is computed by dividing net income by the weighted-average number of shares outstanding during the period. Net income per diluted share is computed by dividing the net income by the weighted-average number of shares and potential shares outstanding during the period, if the effect of potential shares is dilutive. Potential shares include incremental shares of stock issuable upon the exercise of stock options and the vesting of both restricted share units (RSUs) and performance stock units (PSUs). For each of the three months ended March 30, 2024 and April 1, 2023, weighted options to purchase 1.4 million and 1.0 million shares of common stock, respectively, were outstanding but not included in the computation of diluted net income per share because the effect of including such shares would have been antidilutive in the applicable period. Certain RSUs were considered contingently issuable shares as their vesting is contingent upon the occurrence of certain future events. Since such events had not occurred and were not considered probable of occurring as of each of March 30, 2024 and April 1, 2023, 2.7 million weighted-average shares related to such RSUs have been excluded from the calculation of potential shares for the three month periods then ended. For additional information with respect to these RSUs, please see “Employment and Severance Agreements” in Note 24, “Commitments and Contingencies”.</span></div> <div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A computation of basic and diluted net income per share is as follows:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.391%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.791%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except per share amounts)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">March 30,<br/>2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">April 1,<br/>2023</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.9 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.3 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic net income per share:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding - basic</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.0 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.6 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per basic share</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.36</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.40</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Diluted net income per share:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding - basic</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted share equivalents: stock options, RSUs and PSUs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding - diluted</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.4 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per diluted share</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.35</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.39</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 18900000 21300000 53000000.0 52600000 0.36 0.40 53000000.0 52600000 1300000 1800000 54200000 54400000 0.35 0.39 1400000 1000000 2700000 2700000 <div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information includes the following:</span></div><div style="margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.391%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.791%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">March 30,<br/>2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">April 1,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash paid during the year for:</span></div></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.5 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.0 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-cash operating activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROU assets obtained in exchange for lease liabilities</span></div></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.6 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-cash investing activities:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unpaid purchases of property and equipment</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unpaid strategic investments</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-cash financing activities:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">       Unsettled common stock proceeds from option exercises</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Reconciliation of cash, cash equivalents and restricted cash:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></div></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157.6 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174.1 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash shown in the condensed consolidated statements of cash flows</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164.0 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181.1 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 11700000 11700000 8500000 11000000.0 5700000 5300000 20600000 600000 2700000 700000 200000 1200000 100000 100000 157600000 174100000 6400000 7000000.0 164000000.0 181100000 <div style="margin-top:13pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted and Recently Announced Accounting Pronouncements</span></div>There have been no material changes to the accounting policies discussed in Note 2 to the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 30, 2023, filed with the SEC on February 28, 2024. other than the following update: <div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. Related Party Transactions </span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s Chairman and Chief Executive Officer (CEO) is also the Chairman and CEO of Willow Laboratories, Inc. (Willow). The Company is a party to the following agreements with Willow:</span></div><div style="margin-top:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Cross-Licensing Agreement - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and Willow are parties to a cross-licensing agreement (Cross-Licensing Agreement), which governs each party’s rights to certain intellectual property held by the two companies. The Company is subject to certain annual minimum aggregate royalty obligations for use of the rainbow</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> licensed technology. The current annual minimum royalty obligation is $5.0 million. Aggregate liabilities payable to Willow arising under the Cross-Licensing Agreement were $4.8 million and $5.6 million for the three months ended March 30, 2024 and April 1, 2023, respectively.</span></div><div style="margin-top:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Administrative Services Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - The Company is a party to an administrative services agreement with Willow (G&amp;A Services Agreement), which governs certain general and administrative services that the Company provides to Willow. Amounts charged by the Company pursuant to the G&amp;A Services Agreement were $0.1 million for each of the three months ended March 30, 2024 and April 1, 2023.</span></div><div style="margin-top:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Lease Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Effective December 2019, the Company entered into a lease agreement with Willow for approximately 34,000 square feet of office, research and development space at one of the Company’s owned facilities in Irvine (Willow Lease). The term of the Willow Lease expires on December 31, 2024. The Company recognized approximately $0.3 million of lease income for each of the three months ended March 30, 2024 and April 1, 2023. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net amounts due to Willow at March 30, 2024 and December 30, 2023 were approximately $4.9 million and $4.1 million, respectively.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s CEO is also the Chairman of the Masimo Foundation for Ethics, Innovation and Competition in Healthcare (Masimo Foundation), a non-profit organization that was founded in 2010 to provide a platform for encouraging ethics, innovation, and competition in healthcare. In addition, the Company’s Executive Vice President (EVP), Chief Financial Officer (CFO) serves as the Treasurer of the Masimo Foundation and the Company’s EVP, General Counsel and Corporate Secretary serves as the Secretary for the Masimo Foundation. During each of the three months ended March 30, 2024 and April 1, 2023, the Company made cash contributions of approximately $1.0 million to the Masimo Foundation. During each of the three months ended March 30, 2024 and April 1, 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company made various in-kind contributions to the Masimo Foundation, mainly in the form of donated administrative services.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s CEO is also a co-founder and a member of the board of directors of Like Minded Media Ventures (LMMV), a team of storytellers that create content focused in the areas of true stories, social causes and science</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LMMV creates stories with a multi-platform strategy, bridging the gap between film, television, digital and social media. The Company entered into a marketing service agreement with LMMV for audiovisual production services promoting brand awareness, including television commercials and digital advertising, during the second quarter of 2020. During each of the three months ended March 30, 2024, and April 1, 2023, the Company incurred no marketing expenses to LMMV under the marketing service agreement. At each of March 30, 2024 and December 30, 2023, there were no amounts due to LMMV for services rendered. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2021, the Company entered into a software license and professional services agreement with Like Minded Labs (LML), a subsidiary of LMMV. Pursuant to the software license agreement, LML granted the Company a perpetual, non-exclusive and fully paid-up right and license to integrate LML’s software into the Company’s products in exchange for a $3.0 million one-time license fee. Pursuant to the professional services agreement, LML will provide professional services to the Company, including the development of custom software intended to support the integration of the licensed software into the Company’s products, as well as future support services upon the Company’s acceptance of deliverables.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, the Company entered into a patent purchase and option agreement with Vantrix Corporation (Vantrix), an acquiree of LML, for certain patents for $0.5 million, and the right to purchase two pools of additional patents from Vantrix for an exercise fee of up to $1.1 million. The agreements with LML and Vantrix include sublicensing provisions whereby the software and patents are licensed back to LML or Vantrix, respectively, for further advancement of the technologies.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains an aircraft time share agreement, pursuant to which the Company has agreed from time to time to make its aircraft available to the Company’s CEO for lease on a time-sharing basis. The Company charges the Company’s CEO for personal use based on agreed upon reimbursement rates. For the three months ended March 30, 2024, the Company’s CEO did not incur charges pursuant to this agreement. For the three months ended April 1, 2023, the Company charged the Company’s CEO less than $0.1 million pursuant to this agreement.</span></div> 5000000 4800000 5600000 100000 100000 34000 300000 300000 4900000 4100000 1000000 1000000 0 0 0 0 3000000 500000 1100000 0 100000 <div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. Inventories </span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consist of the following:</span></div><div style="margin-top:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.391%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.791%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">March 30,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">December 30,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232.6 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229.7 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244.2 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285.3 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Total inventories</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">506.1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">545.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consist of the following:</span></div><div style="margin-top:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.391%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.791%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">March 30,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">December 30,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232.6 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229.7 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244.2 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285.3 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Total inventories</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">506.1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">545.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 232600000 229700000 29300000 30000000.0 244200000 285300000 506100000 545000000.0 <div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. Other Current Assets </span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current assets consist of the following: </span></div><div style="margin-top:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.391%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.791%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">March 30,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">December 30,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.1 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.3 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease receivable, current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid income taxes</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.7 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.3 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indirect taxes receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract assets, current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid rebates and royalties, current</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Total other current assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168.4 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________</span></div><div style="margin-top:4.5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">    Restricted cash includes funds received from the Bill and Melinda Gates Foundation. As the Company incurs costs associated with research and development related to this project, on a quarterly basis, the Company reclasses amounts from the grant to offset costs incurred.</span></div> <div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current assets consist of the following: </span></div><div style="margin-top:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.391%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.791%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">March 30,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">December 30,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.1 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.3 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease receivable, current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid income taxes</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.7 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.3 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indirect taxes receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract assets, current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid rebates and royalties, current</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Total other current assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168.4 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________</span></div><div style="margin-top:4.5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">    Restricted cash includes funds received from the Bill and Melinda Gates Foundation. As the Company incurs costs associated with research and development related to this project, on a quarterly basis, the Company reclasses amounts from the grant to offset costs incurred.</span></div><div style="margin-top:4.5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other non-current assets consist of the following:</span></div><div style="margin-top:4.5pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center;text-indent:-9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:70.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.811%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">March 30,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">December 30,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-746"><span style="-sec-ix-hidden:f-747">Lessee ROU assets, net</span></span></span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.1 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.1 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative assets - non-current</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid deposits and other</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.5 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Strategic investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investments - fair value</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Total non-current assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109.9 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:4.5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Excludes accrued interest.</span></div><div style="margin-top:4.5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Restricted cash includes cash held in certain subsidiaries in jurisdictions outside of the U.S. such as China, which may be subject to transfer restrictions depending on jurisdictions.</span></div> 53100000 58300000 29700000 30200000 27700000 29300000 23100000 28600000 10300000 6800000 7200000 6700000 5000000.0 4800000 3000000.0 3000000.0 700000 700000 159800000 168400000 <div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. Lease Receivable</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For deferred equipment agreements that contain embedded operating leases, upon lease commencement, the Company defers and records the equipment cost of operating lease assets within property, plant and equipment, net of accumulated depreciation. These operating lease assets are subsequently amortized to cost of goods sold over the lease term on a straight-line basis.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For deferred equipment agreements that contain embedded sales-type leases, the Company recognizes lease revenue and costs, as well as a lease receivable, at the time the lease commences. Lease revenue related to both operating-type and sales-type leases are included within revenue in the accompanying condensed consolidated statements of operations. For the three months ended March 30, 2024 and April 1, 2023, lease revenue was approximately $16.0 million and $20.0 million, respectively. Costs related to embedded leases within the Company’s deferred equipment agreements are included in cost of goods sold in the accompanying condensed consolidated statements of operations.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease receivable from sales-type leases consists of the following:</span></div><div style="margin-top:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.391%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.791%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">March 30,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">December 30,<br/>2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease receivable</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.3 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.9 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for credit loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Lease receivable, net</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.6 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion of lease receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Lease receivable, non-current</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.3 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71.4 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 30, 2024, estimated future maturities of customer sales-type lease receivables and operating lease payments for each of the following fiscal years are as follows:</span></div><div style="margin-top:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.391%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.791%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Future Lease Receivables/Payments<br/>(in millions)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Fiscal year</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Sales-Type Leases</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Operating Leases</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 (balance of year)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.9 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.5 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.8 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Total</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.6 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Present value of total lease payments</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr></table></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________</span></div><div style="margin-top:4.5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">    The calculation of the rates implicit in the leases resulted in negative discount rates. Therefore, the Company as a lessor used a 0% discount rate to measure the net investment in the lease.</span></div> 16000000 20000000 <div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease receivable from sales-type leases consists of the following:</span></div><div style="margin-top:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.391%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.791%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">March 30,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">December 30,<br/>2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease receivable</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.3 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.9 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for credit loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Lease receivable, net</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.6 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion of lease receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Lease receivable, non-current</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.3 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71.4 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 100300000 101900000 300000 300000 100000000.0 101600000 29700000 30200000 70300000 71400000 <div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 30, 2024, estimated future maturities of customer sales-type lease receivables and operating lease payments for each of the following fiscal years are as follows:</span></div><div style="margin-top:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.391%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.791%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Future Lease Receivables/Payments<br/>(in millions)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Fiscal year</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Sales-Type Leases</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Operating Leases</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 (balance of year)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.9 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.5 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.8 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Total</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.6 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Present value of total lease payments</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr></table></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________</span></div><div style="margin-top:4.5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">    The calculation of the rates implicit in the leases resulted in negative discount rates. Therefore, the Company as a lessor used a 0% discount rate to measure the net investment in the lease.</span></div> 22900000 8500000 25700000 10200000 19800000 9400000 14400000 7800000 8000000.0 5600000 9200000 9100000 100000000.0 50600000 0 100000000.0 0 <div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. Deferred Costs and Other Contract Assets </span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred costs and other contract assets consist of the following:</span></div><div style="margin-top:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.391%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.791%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">March 30,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">December 30,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred commissions</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.3 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.8 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unbilled contract receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid contract allowances</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.2 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.0 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred equipment agreements, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Deferred costs and other contract assets</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.9 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.3 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred costs and other contract assets consist of the following:</span></div><div style="margin-top:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.391%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.791%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">March 30,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">December 30,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred commissions</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.3 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.8 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unbilled contract receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid contract allowances</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.2 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.0 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred equipment agreements, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Deferred costs and other contract assets</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.9 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.3 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 21300000 21800000 18800000 17000000.0 16200000 17000000.0 1600000 1500000 57900000 57300000 <div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. Property and Equipment, net </span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net, consists of the following:</span></div><div style="margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.391%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.791%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">March 30,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">December 30,<br/>2023</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery, equipment and tooling</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173.1 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169.7 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building and building improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108.1 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92.2 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.4 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.5 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transportation, vehicles and other</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.5 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.0 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and office equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Demonstration units</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.3 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.1 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction-in-progress (CIP)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Total property and equipment</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">692.8 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">686.8 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(277.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(262.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Property and equipment, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">415.0 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">424.4 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________</span></div><div style="margin-top:4.5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">At March 30, 2024, property, plant and equipment, net, excluded $11.4 million of idle undeveloped land classified as held for sale within the healthcare segment. The sale of land is expected to be completed within the earlier of the next 12 months or upon the closing of customary escrow and due diligence procedures. Any gain on the sale of land transaction will be recorded at the time of disposal.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 30, 2024 and April 1, 2023, depreciation expense of property and equipment was $10.5 million and $11.8 million, respectively. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 30, 2024 and April 1, 2023, $6.4 million and $3.0 million of equipment leased to customers was amortized to cost of goods sold, respectively. As of March 30, 2024 and December 30, 2023, accumulated amortization of equipment leased to customers was $0.4 million and $1.5 million, respectively.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The balance in CIP at March 30, 2024 and December 30, 2023 related primarily to the capitalized implementation costs related to a new enterprise resource planning software system, costs related to facility improvements, the expansion of certain key manufacturing facilities globally, machinery and equipment at the Company’s corporate headquarters, as well as on-going development costs associated with a new research and development facility, the underlying assets for which have </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">not been completed or placed into service. </span></div><div style="margin-top:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 14, 2022, the Company’s wholly owned subsidiary, Masimo Canada ULC, entered into a Purchase and Sale Agreement (Purchase Agreement) with Ke</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ltic (Prior) Development Limited Partnership (Vendor) for the purchase of a property in Vancouver, British Columbia, Canada for a purchase price of CAD123.0 million, plus GST (Purchase Price), subject to certain adjustments. The Company paid CAD21.0 million as a deposit towards the purchase during the year ended December 31, 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The balance of the Purchase Price will be due and payable upon the closing of the transaction, which is currently expected to occur in mid-2025.</span></div> 173100000 169700000 150500000 151000000.0 108100000 92200000 54600000 66200000 45400000 45500000 39600000 37500000 33500000 34000000.0 18700000 20400000 11300000 11100000 58000000.0 59200000 692800000 686800000 277800000 262400000 415000000.0 424400000 11400000 10500000 11800000 6400000 3000000 400000 1500000 123000000 21000000 <div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. Intangible Assets, net </span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets, net, consist of the following:</span></div><div style="margin-top:9.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.163%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.016%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">March 30,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">December 30,<br/>2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Gross Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Net Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Gross Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Net Carrying<br/>Amount</span></td></tr><tr><td colspan="6" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intangible assets subject to amortization:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired technologies</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138.5 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18.6)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119.9 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174.7 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129.4 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized software development costs</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.7 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.8 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.9 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.7 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.1 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.8)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.3 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.1 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.4)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.7 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-compete agreements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licenses-related party</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.5 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.8)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.5 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.7)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets subject to amortization, net</span></td><td style="background-color:#dbdbdb;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">489.7 </span></td><td style="background-color:#dbdbdb;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76.5)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413.2 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">552.3 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(132.4)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">419.9 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intangible assets not subject to amortization:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222.7 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242.4 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-672"><span style="-sec-ix-hidden:f-673">Impairment charge</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total trademarks</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222.7 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232.4 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">635.9 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">652.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finite lived intangible assets have a weighted-average amortization period ranging from twelve years to fourteen years. Total amortization expense for the three months ended March 30, 2024 and April 1, 2023 was $13.8 million and $14.3 million, respectively. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total renewal costs for patents and trademarks for each of the three months ended March 30, 2024 and April 1, 2023 were $0.3 million. As of March 30, 2024, the weighted-average number of years until the next renewal was two years for patents and six years for trademarks.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated amortization expense for each of the next fiscal years is as follows:</span></div><div style="margin-top:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.789%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Fiscal year</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Amount<br/>(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 (balance of year)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.8 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.7 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.0 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Total</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413.2 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indefinite-lived intangible assets are subject to annual impairment testing, unless circumstances dictate more frequent testing, if impairment indicators exist. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the third quarter of 2023, declines in the Company’s stock price and certain worsening macro-economic market conditions, including continued slowing in demand for consumer audio products, contributed to a significant decline in the Company’s market capitalization, which led the Company to conclude a trigger event had occurred. As a result, the Company performed a quantitative impairment assessment, which resulted in recording a $7.0 million impairment charge for indefinite-lived trademarks in the non-healthcare reporting unit. In conjunction with this third quarter interim impairment quantitative assessment, the Company concluded that both the healthcare reporting unit’s and non-healthcare reporting unit’s respective estimated fair values exceeded their carrying values. Furthermore, recoverability tests performed for other long-lived assets with finite lives indicated no recoverability issues.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fourth quarter of 2023, the Company performed its annual impairment analysis by first electing to complete a qualitative assessment of its indefinite-lived intangible assets. Based on this assessment, the Company determined it was not more likely than not that the fair value of the indefinite lived intangibles within the non-healthcare reporting unit exceeded their carrying values. Accordingly, the Company proceeded to perform a quantitative impairment assessment, which resulted in recording a $3.0 million impairment charge for indefinite-lived trademarks. For purposes of the impairment test, the fair value of indefinite-lived assets were determined using the same methodology as described in Note 18, “Business Combinations.” The estimates and assumptions applied represent a Level 3 measurement because they are supported by limited or no market activity and reflect the Company’s assumptions in measuring fair value.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fourth quarter of 2023, the Company also performed its annual goodwill impairment analysis by first electing to complete a qualitative assessment for its healthcare and non-healthcare reporting units. Based on this assessment, the Company concluded that it was more likely than not that the fair value of the healthcare reporting unit was greater than its carrying value. Accordingly, no further testing was required for the healthcare reporting unit. However, the Company concluded that it was not more likely than not that the fair value of the non-healthcare reporting unit was greater than its carrying value. Therefore, the Company proceeded to perform a quantitative assessment for its non-healthcare reporting unit. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When a quantitative assessment is required for the impairment test for goodwill, the Company uses a combination of both an income and a market approach to determine the fair value of the reporting unit. The income approach utilized the estimated discounted cash flows for the reporting unit, while the market approach utilized comparable company information. Estimates and assumptions used in the income approach to calculate projected future discounted cash flows included revenue growth rates, operating margins and a discount rate for the reporting unit. Discount rates were determined using a weighted average cost of capital for risk factors specific to the reporting unit and other market and industry data. The assumptions used are inherently subject to uncertainty and the Company noted that slight changes in these assumptions could have a significant impact on the concluded value.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimates and assumptions applied represent a Level 3 measurement because they are supported by limited or no market activity and reflect the Company’s assumptions in measuring fair value.</span></div> <div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets, net, consist of the following:</span></div><div style="margin-top:9.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.163%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.016%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">March 30,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">December 30,<br/>2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Gross Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Net Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Gross Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Net Carrying<br/>Amount</span></td></tr><tr><td colspan="6" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intangible assets subject to amortization:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired technologies</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138.5 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18.6)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119.9 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174.7 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129.4 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized software development costs</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.7 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.8 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.9 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.7 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.1 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.8)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.3 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.1 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.4)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.7 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-compete agreements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licenses-related party</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.5 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.8)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.5 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.7)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets subject to amortization, net</span></td><td style="background-color:#dbdbdb;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">489.7 </span></td><td style="background-color:#dbdbdb;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76.5)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413.2 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">552.3 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(132.4)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">419.9 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intangible assets not subject to amortization:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222.7 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242.4 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-672"><span style="-sec-ix-hidden:f-673">Impairment charge</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total trademarks</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222.7 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232.4 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">635.9 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">652.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 184400000 15100000 169300000 209200000 31500000 177700000 138500000 18600000 119900000 174700000 45300000 129400000 45300000 5000000.0 40300000 39700000 7400000 32300000 48700000 6900000 41800000 53900000 15200000 38700000 40800000 15800000 25000000.0 39200000 15200000 24000000.0 19100000 6800000 12300000 20100000 7400000 12700000 3800000 400000 3400000 6300000 2600000 3700000 7500000 6800000 700000 7500000 6700000 800000 1600000 1100000 500000 1700000 1100000 600000 489700000 76500000 413200000 552300000 132400000 419900000 222700000 242400000 0 10000000.0 222700000 232400000 635900000 652300000 P12Y P14Y 13800000 14300000 300000 300000 P2Y P6Y <div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated amortization expense for each of the next fiscal years is as follows:</span></div><div style="margin-top:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.789%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Fiscal year</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Amount<br/>(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 (balance of year)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.8 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.7 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.0 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Total</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413.2 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 44800000 56100000 44700000 43300000 43000000.0 181300000 413200000 7000000 3000000 <div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. Goodwill </span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in goodwill were as follows:</span></div><div style="margin-top:9.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.063%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.793%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Three Months Ended <br/>March 30, 2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Healthcare</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Non-healthcare</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill, beginning of period</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98.6 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309.1 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">407.7 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill, end of period</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.6 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298.4 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396.0 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> <div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in goodwill were as follows:</span></div><div style="margin-top:9.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.063%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.793%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Three Months Ended <br/>March 30, 2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Healthcare</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Non-healthcare</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill, beginning of period</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98.6 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309.1 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">407.7 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill, end of period</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.6 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298.4 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396.0 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 98600000 309100000 407700000 -1000000.0 -10700000 -11700000 97600000 298400000 396000000.0 <div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. Lessee ROU Assets and Lease Liabilities </span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases certain facilities in North and South America, Europe, the Middle East and Asia-Pacific regions under operating lease agreements expiring at various dates through January 2032. In addition, the Company leases equipment in the U.S. and Europe pursuant to leases that are classified as operating leases and expire at various dates through November 2028. The majority of these leases are non-cancellable and generally do not contain any material restrictive covenants, material residual value guarantees, or other material guarantees. The Company recognizes lease costs under these agreements using a straight-line method based on total lease payments. Certain facility leases contain predetermined price escalations and in some cases renewal options, the longest of which is for five years.</span></div><div style="margin-top:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generally estimates the applicabl</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e discount rate used to determine the net present value of lease payments based on available information at the lease commencement date. As of March 30, 2024, the weighted-average discount rate used by the Company for all operating leases was approximately 4.2%.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The balance sheet classifications for amounts related to the Company’s operating leases for which it is the lessee are as follows:</span></div><div style="margin-top:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.408%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.794%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Balance sheet classification</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">March 30,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">December 30,<br/>2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lessee ROU assets</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-713"><span style="-sec-ix-hidden:f-714">Other non-current assets</span></span></span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.1 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.1 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lessee current lease liabilities</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-717"><span style="-sec-ix-hidden:f-718">Other current liabilities</span></span></span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.3 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.2 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lessee non-current lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-721"><span style="-sec-ix-hidden:f-722">Other non-current liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Total operating lease liabilities</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.8 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.0 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 30, 2024 and December 30, 2023, accumulated amortization for lessee ROU assets was $53.8 million and $48.9 million, respectively. The weighted-average remaining lease term for the Company’s operating leases was 5.4 years as of March 30, 2024.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 30, 2024, estimated future operating lease payments for each of the following fiscal years were as follows:</span></div><div style="margin-top:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.790%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Fiscal year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Amount<br/>(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 (balance of year)</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.9 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.6 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Total</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92.7 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Present value</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.8 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________</span></div><div style="margin-top:4.5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">    Includes optional renewal period for certain leases.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 30, 2024 and April 1, 2023, operating lease costs were approximately $5.8 million and $5.1 million, respectively. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 30, 2024, as part of the Company’s on-going rationalization of its operational footprint of the non-healthcare business, one operating lease was identified as under-utilized and considered temporarily idled due to the inability to sublease the property timely while having three years remaining on the lease term. The ROU asset had a net carrying value of approximately $5.8 million and the undiscounted future expected cash flows total $1.5 million. The recoverability test failed due to the undiscounted cash flows being less than the carrying value of the ROU asset. As a result, the Company recorded an impairment charge of approximately $3.9 million during the three months ended March 30, 2024, which was recorded in selling, general, and administrative expenses in the condensed consolidated statement of operations.</span></div> P5Y 0.042 <div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The balance sheet classifications for amounts related to the Company’s operating leases for which it is the lessee are as follows:</span></div><div style="margin-top:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.408%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.794%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Balance sheet classification</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">March 30,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">December 30,<br/>2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lessee ROU assets</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-713"><span style="-sec-ix-hidden:f-714">Other non-current assets</span></span></span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.1 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.1 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lessee current lease liabilities</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-717"><span style="-sec-ix-hidden:f-718">Other current liabilities</span></span></span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.3 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.2 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lessee non-current lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-721"><span style="-sec-ix-hidden:f-722">Other non-current liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Total operating lease liabilities</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.8 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.0 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 75100000 59100000 19300000 18200000 61500000 45800000 80800000 64000000.0 53800000 48900000 P5Y4M24D <div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 30, 2024, estimated future operating lease payments for each of the following fiscal years were as follows:</span></div><div style="margin-top:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.790%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Fiscal year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Amount<br/>(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 (balance of year)</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.9 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.6 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Total</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92.7 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Present value</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.8 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________</span></div><div style="margin-top:4.5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">    Includes optional renewal period for certain leases.</span></div> 16900000 19900000 15600000 11100000 10400000 18800000 92700000 11900000 80800000 5800000 5100000 5800000 1500000 3900000 <div style="margin-top:13pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12. Other Non-Current Assets </span></div><div style="margin-top:4.5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other non-current assets consist of the following:</span></div><div style="margin-top:4.5pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center;text-indent:-9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:70.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.811%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">March 30,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">December 30,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-746"><span style="-sec-ix-hidden:f-747">Lessee ROU assets, net</span></span></span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.1 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.1 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative assets - non-current</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid deposits and other</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.5 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Strategic investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investments - fair value</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Total non-current assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109.9 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:4.5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Excludes accrued interest.</span></div><div style="margin-top:4.5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Restricted cash includes cash held in certain subsidiaries in jurisdictions outside of the U.S. such as China, which may be subject to transfer restrictions depending on jurisdictions.</span></div> 75100000 59100000 14300000 11400000 7500000 6400000 6900000 7200000 3400000 2200000 2600000 2700000 100000 300000 109900000 89300000 <div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13. Deferred Revenue and Other Contract Liabilities, Current</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue and other contract liabilities, current, consist of the following:</span></div><div style="margin-top:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:70.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.811%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">March 30,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">December 30,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.1 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.8 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued rebates and allowances</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued customer reimbursements</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.4 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Total deferred revenue and other contract liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96.4 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113.7 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Non-current portion of deferred revenue</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26.4)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26.4)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Deferred revenue and other contract liabilities, current</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue relates to contracted amounts that have been invoiced to customers for which remaining performance obligations must be completed before the Company can recognize revenue. Generally, both healthcare and non-healthcare segments record deferred revenue when revenue is to be recognized subsequent to invoicing. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Healthcare Deferred Revenue</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Healthcare deferred revenue primarily relates to undelivered equipment, sensors and services under deferred equipment agreements, extended warranty agreements, and maintenance agreements. Expected revenue from remaining contractual performance obligations (Unrecognized Contract Revenue) includes deferred revenue, as well as other amounts that will be invoiced and recognized as revenue in future periods when the Company completes its performance obligations. Unrecognized Contract Revenue excludes revenue allocable to monitoring-related equipment that is effectively leased to customers under deferred equipment agreements and other contractual obligations for which neither party has performed. The estimated timing of this revenue is based, in part, on management’s estimates and assumptions about when its performance obligations will be completed. As a result, the actual timing of this revenue in future periods may vary, possibly materially. As of March 30, 2024, the Company had approximately $1,508.3 million of Unrecognized Contract Revenue related to executed contracts with an original duration of one year or more. The Company expects to recognize approximately $395.8 million of this amount as revenue within the next twelve months and the remaining balance thereafter.</span></div><div style="margin-top:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Non-Healthcare Deferred Revenue</span></div><div style="margin-top:4.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, the Company’s subsidiary, B&amp;W Group Ltd. (B&amp;W), entered into an amendment to a licensing agreement, whereby B&amp;W received a $20.0 million royalty prepayment in relation to sound system units manufactured under the Bowers &amp; Wilkins brand for various high-end car manufacturers with a total commitment of $35.0 million to be received by September 30, 2028. As of March 30, 2024, deferred revenu</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e was $14.6 million.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in deferred revenue were as follows:</span></div><div style="margin-top:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.789%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Three Months Ended <br/>March 30, <br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue, beginning of the period</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.8 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Revenue deferred during the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Recognition of revenue deferred in prior periods</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Deferred revenue, end of the period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue and other contract liabilities, current, consist of the following:</span></div><div style="margin-top:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:70.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.811%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">March 30,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">December 30,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.1 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.8 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued rebates and allowances</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued customer reimbursements</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.4 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Total deferred revenue and other contract liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96.4 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113.7 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Non-current portion of deferred revenue</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26.4)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26.4)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Deferred revenue and other contract liabilities, current</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in deferred revenue were as follows:</span></div><div style="margin-top:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.789%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Three Months Ended <br/>March 30, <br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue, beginning of the period</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.8 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Revenue deferred during the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Recognition of revenue deferred in prior periods</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Deferred revenue, end of the period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 63100000 63800000 23000000.0 37500000 10300000 12400000 96400000 113700000 26400000 26400000 70000000.0 87300000 1508300000 P1Y 395800000 P12M 20000000 35000000 14600000 63800000 8400000 9100000 63100000 <div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14. Other Current Liabilities </span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current liabilities consist of the following:</span></div><div style="margin-top:9.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:70.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.811%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">March 30,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">December 30,<br/>2023</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, current</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.6 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.3 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued indirect taxes payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.6 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.3 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lessee lease liabilities, current </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax payable</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.1 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued property taxes</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued warranty</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued legal fees</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.7 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.9 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Related party payables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued donations</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing agreement, current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Total other current liabilities</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165.9 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162.4 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">__________________</span></div><div style="margin-top:4.5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">At March 30, 2024, other current liabilities included approximately $0.5 million of refundable deposits during the due diligence period related to certain assets held for sale.</span></div> <div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current liabilities consist of the following:</span></div><div style="margin-top:9.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:70.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.811%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">March 30,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">December 30,<br/>2023</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, current</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.6 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.3 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued indirect taxes payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.6 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.3 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lessee lease liabilities, current </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax payable</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.1 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued property taxes</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued warranty</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued legal fees</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.7 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.9 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Related party payables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued donations</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing agreement, current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Total other current liabilities</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165.9 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162.4 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">__________________</span></div><div style="margin-top:4.5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">At March 30, 2024, other current liabilities included approximately $0.5 million of refundable deposits during the due diligence period related to certain assets held for sale.</span></div> 34600000 34300000 29100000 23900000 27600000 26300000 19300000 18200000 10500000 16100000 9600000 6700000 9400000 10200000 8100000 8600000 7700000 9900000 5000000.0 4200000 2000000.0 4000000.0 3000000.0 0 165900000 162400000 500000 <div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15. Debt </span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.791%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">March 30,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">December 30,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term loan - current portion</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.1 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.3 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japanese loans - current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt, current portion</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.6 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.3 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term loan - long-term</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268.1 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271.4 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revolver - long-term</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">565.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">591.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japanese loans - long-term</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.8 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.8 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt, long-term</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">841.4 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">871.7 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">876.0 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">906.0 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit Facility</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11, 2022,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the Company entered into a credit agreement (Credit Facility) with financial institutions party thereto as initial lenders (collectively, the Initial Lenders), Citibank, N.A., as Administrative Agent, Citibank, N.A., JPMorgan Chase Bank, N.A., Bank of the West and BofA Securities, Inc., as joint lead arrangers and joint bookrunners, and JPMorgan Chase Bank, N.A., Bank of the West and BofA Securities, Inc., as co-syndication agents.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Facility provides for an unsecured term loan of $300.0 million (Term Loan) and $500.0 million of ongoing unsecured revolving commitments (Revolver), with an option, subject to certain conditions, for the Company to increase the aggregate borrowing capacity by an additional $400.0 million (plus additional unlimited amounts if certain incurrence tests are met) in the future with the Initial Lenders and additional lenders, as required. Debt issuance costs of $8.4 million were recorded as a reduction to the carrying amount of the Credit Facility and are being amortized to interest expense using the effective interest method.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Facility also provides for a sublimit of up to $50.0 million for the issuance of letters of credit. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the Credit Facility will be deemed, at the Company’s election, either: (a) an Alternate Base Rate (ABR) Loan, which bears interest at the ABR, plus a spread of 0.000% to 0.750% based upon a Company leverage ratio, or (b) a Term SOFR Loan, which bears interest at the Adjusted Term SOFR Rate (as defined below), plus a spread of 1.000% to 1.750% based upon a Company net leverage ratio. Pursuant to the terms of the Credit Facility, the ABR is equal to the greatest of (i) the prime rate, (ii) the Federal Reserve Bank of New York effective rate plus 0.50%, and (iii) the one-month Adjusted Term SOFR plus 1.0%. The Adjusted Term SOFR Rate is equal to the Term SOFR Rate (as defined in the Credit Facility) for the applicable interest period plus a spread adjustment of 0.10%, 0.15% and 0.25% for the interest periods ending one, three and six months, respectively.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also obligated under the Credit Facility to pay an unused fee ranging from 0.150% to 0.275% per annum, based upon a Company leverage ratio, with respect to any non-utilized portion of the Credit Facility.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to certain covenants, including financial covenants related to a net leverage ratio and an interest charge coverage ratio, and other customary negative covenants. The Credit Facility also includes customary events of default which, upon the occurrence of any such event of default, provide the Initial Lenders (and any additional lenders) with the right to take either or both of the following actions: (a) immediately terminate the commitments, and (b) declare the loans then outstanding immediately due and payable in full. All unpaid principal under the Credit Facility will become due and payable on April 12, 2027.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 16, 2022, the Company entered into the First Amendment to the Credit Agreement (First Amendment) with the Initial Lenders and Citibank, N.A., as the administrative agent, which amended the Credit Facility. The First Amendment provides for an additional $205 million of unsecured revolving commitments, increasing the aggregate amount of the Revolver from $500 million to $705 million.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowing rates, financial covenants, affirmative and negative covenants and other restricted terms remain unchanged from the Credit Facility. All unpaid principal under the First Amendment will become due and payable on April 12, 2027. The Company was in full compliance with all covenants contained in its debt agreements and Credit Facility agreements as of March 30, 2024.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 30, 2024 and April 1, 2023, the Company incurred total interest expense of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$11.2 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and $10.9 million under the Credit Facility, respectively.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, in connection with the Sound United acquisition, the Company assumed three outstanding loans as follows:</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Japanese Revolving Loan</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the Company entered into a secured revolving loan (Japanese Revolving Loan) with Mizuho bank, which allows the Company to borrow up to ¥800 million (approximately $5.3 million). The Japanese Revolving Loan is an evergreen agreement that terminates upon request by either the financial institution or the borrower and is collateralized with land and buildings in Shirakawa-Shi owned by the borrower. Interest accrues at a rate equal to the Mizuho Tokyo Interbank Offered Rate (TIBOR) plus a fixed spread of 0.50% per annum. In connection with the execution of the Japanese Revolving Loan, the Company incurred debt issuance costs of ¥7.2 million (approximately $0.05 million). </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 28, 2023, the Company and Mizuho Bank executed an amendment to the Japanese Revolving Loan, to increase the maximum aggregate revolving loan to ¥3.00 billion (approximately $19.8 million). Under the amendment, the facility accrues interest at a rate equal to the TIBOR plus a fixed spread of 0.75% per annum. The Company also paid an upfront fee of ¥22.0 million (approximately $0.1 million) on the incremental amount of the revolving Credit Facility.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Japanese Revolving Loan agreement contains customary affirmative and negative covenants, such as financial reporting requirements and customary covenants that restrict the borrower’s ability to, among other things, provide collateral for obligations borne by the borrower, and determine the eligibility to declare, and amount of potential dividends to be paid during a given fiscal year. As of March 30, 2024, the Company was in compliance with all covenants under the Japanese Revolving Loan agreements.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Japanese Government Loans</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May and June 2020, the Company received ¥1.48 billion (approximately $9.8 million) in non-collateralized Japanese Government Loan facilities (Japanese Government Loans) as part of its local Japanese stimulus program. Interest accrues at a weighted average rate of 1.33% and is repayable in installments with various maturities through June 2035. The non-current portion of the Japanese Government Loans is presented under long-term debt and the current portion is presented under short-term debt on the accompanying condensed consolidated balance sheets. The Company incurred no debt issuance costs in connection with the Japanese Government Loans.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Japanese Equipment Loans</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April and May 2021, the Company entered into collateralized Japanese Equipment Loans of ¥150 million (approximately $1.0 million), payable in installments through March 2031 with an interest of 0.58%, and ¥80 million (approximately $0.5 million) payable in installments through April 2028 with interest of 1.2%. The non-current portion of the Japanese Equipment Loans is presented under long-term debt and the current portion is presented under short-term debt on the accompanying condensed consolidated balance sheets. The Company incurred no debt issuance costs in connection with these Japanese Equipment Loans.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 30, 2024, the aggregate maturities of principal on all debt for each of the next five years and thereafter are as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.790%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Fiscal year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Amount <br/>(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 (balance of year)</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.5 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.6 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">809.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">876.0 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.791%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">March 30,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">December 30,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term loan - current portion</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.1 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.3 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japanese loans - current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt, current portion</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.6 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.3 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term loan - long-term</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268.1 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271.4 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revolver - long-term</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">565.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">591.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japanese loans - long-term</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.8 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.8 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt, long-term</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">841.4 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">871.7 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">876.0 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">906.0 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 13100000 11300000 21500000 23000000.0 34600000 34300000 268100000 271400000 565500000 591500000 7800000 8800000 841400000 871700000 876000000.0 906000000.0 300000000 500000000 400000000 8400000 50000000 0.00000 0.00750 0.01000 0.01750 0.0050 0.010 0.0010 0.0015 0.0025 0.00150 0.00275 205000000 500000000 705000000 11200000 10900000 800000000 5300000 0.0050 7200000 50000.00 3000000000 19800000 0.0075 22000000 100000 1480000000 9800000 0.0133 150000000 1000000 0.0058 80000000 500000 0.012 <div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 30, 2024, the aggregate maturities of principal on all debt for each of the next five years and thereafter are as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.790%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Fiscal year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Amount <br/>(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 (balance of year)</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.5 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.6 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">809.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">876.0 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 30500000 16600000 16600000 809000000.0 1000000.0 2300000 876000000.0 <div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">16. Other Non-Current Liabilities </span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other non-current liabilities consist of the following:</span></div><div style="margin-top:9.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:70.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.811%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">March 30,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">December 30,<br/>2023</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lessee non-current lease liabilities</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.5 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.8 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue, non-current</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.4 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.4 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected benefit obligation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax payable, non-current</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing agreement, non-current</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indirect tax payable, non-current</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.4 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Total other non-current liabilities</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140.0 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129.5 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrecognized tax benefits relate to the Company’s long-term portion of tax liability associated with uncertain tax positions. Authoritative guidance prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. See Note 23, “Income Taxes”, for further details.</span></div> <div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other non-current liabilities consist of the following:</span></div><div style="margin-top:9.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:70.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.811%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">March 30,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">December 30,<br/>2023</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lessee non-current lease liabilities</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.5 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.8 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue, non-current</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.4 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.4 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected benefit obligation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax payable, non-current</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing agreement, non-current</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indirect tax payable, non-current</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.4 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Total other non-current liabilities</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140.0 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129.5 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 61500000 45800000 26800000 24400000 26400000 26400000 9200000 9500000 7100000 7100000 4500000 0 0 8400000 4500000 7900000 140000000.0 129500000 <div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">17. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Derivative Instruments and Hedging Activities</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivative Instruments - Cash Flow Hedges </span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s cash flow hedges are designed to mitigate the risk of exposure to variability in expected future cash flows of recognized assets, liabilities or any unrecognized forecasted transactions. Since July 2022, the Company has entered into various interest rate swaps that are designated as cash flow hedges on a substantial portion of the Company’s outstanding debt. The interest rate swaps reduce the variability of cash flow payments for the Company by converting the variable interest rate on the Company’s long-term debt to an average fixed interest rate of 3.22%. These contracts, carried at fair value, have maturities of approximately three years. All hedging relationships were highly effective at achieving offsetting changes in cash flows attributable to the risk being hedged. The Company used a regression analysis at hedge inception to assess the effectiveness of cash flow hedge and periodically thereafter.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records gains and losses from the changes in the fair value of these instruments as a component of other comprehensive (loss) income. Deferred gains or losses from these designated cash flow hedges are reclassified into earnings in the period that the hedged items affect earnings. The Company does not offset fair value amounts recognized for derivative instruments in its condensed consolidated balance sheets for presentation purposes. The following table summarizes the fair value of the hedging instruments, presented on a gross basis, as of March 30, 2024 and December 30, 2023.</span></div><div style="margin-top:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.793%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Condensed Consolidated <br/>Balance Sheets</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Balance sheet classification</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">March 30,<br/>2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">December 30,<br/>2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts, inclusive of accrued interest</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></div></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.4 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.6 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts, inclusive of accrued interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.4 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the gains (losses) reclassified from accumulated other comprehensive (loss) income to the condensed consolidated financial statements for the three months ended March 30, 2024 and April 1, 2023.</span></div><div style="margin-top:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.660%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.607%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.793%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flow hedges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Condensed Consolidated <br/>Statement of Operations</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Three Months Ended </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Location of gains (losses)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">March 30,<br/>2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">April 1,<br/>2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-operating (loss)</span></div></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.3)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.3)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the changes in accumulated other comprehensive income (loss) related to the hedging instruments for the three months and three months ended March 30, 2024 and April 1, 2023. </span></div><div style="margin-top:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.792%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">March 30,<br/>2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">April 1,<br/>2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.8 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.3 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount recognized in other comprehensive income (loss)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount reclassified into earnings</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.6 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 30, 2024, the unrealized gain, net of tax was $4.9 million. For the three months ended April 1, 2023, the unrealized loss, net of tax was $4.3 million.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expects to reclassify a net amount of gains of $11.8 million from accumulated other comprehensive (loss) income to non-operating (loss) income within the next 12 months.</span></div> 0.0322 P3Y The following table summarizes the fair value of the hedging instruments, presented on a gross basis, as of March 30, 2024 and December 30, 2023.<div style="margin-top:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.793%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Condensed Consolidated <br/>Balance Sheets</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Balance sheet classification</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">March 30,<br/>2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">December 30,<br/>2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts, inclusive of accrued interest</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></div></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.4 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.6 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts, inclusive of accrued interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.4 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 14400000 11600000 0 -3600000 14400000 8000000.0 <div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the gains (losses) reclassified from accumulated other comprehensive (loss) income to the condensed consolidated financial statements for the three months ended March 30, 2024 and April 1, 2023.</span></div><div style="margin-top:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.660%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.607%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.793%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flow hedges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Condensed Consolidated <br/>Statement of Operations</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Three Months Ended </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Location of gains (losses)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">March 30,<br/>2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">April 1,<br/>2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-operating (loss)</span></div></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.3)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.3)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> -4300000 -3000000.0 -4300000 -3000000.0 <div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the changes in accumulated other comprehensive income (loss) related to the hedging instruments for the three months and three months ended March 30, 2024 and April 1, 2023. </span></div><div style="margin-top:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.792%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">March 30,<br/>2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">April 1,<br/>2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.8 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.3 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount recognized in other comprehensive income (loss)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount reclassified into earnings</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.6 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 7800000 19300000 10800000 -2700000 -4300000 -3000000.0 14300000 13600000 4900000 -4300000 11800000 <div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18. Business Combinations</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sound United Acquisition</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 11, 2022, the Company completed the previously announced acquisition of Sound United, pursuant to a Merger Agreement dated as of February 15, 2022, by and among the Company, Sonic Boom Acquisition Corp., a wholly-owned subsidiary of the Company (Merger Sub), Viper Holdings Corporation (Sound United), and, solely in its capacity as the Seller Representative, Viper Holdings, LLC, pursuant to which Merger Sub merged with and into Sound United, with Sound United continuing as a wholly-owned subsidiary of the Company (Merger).</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sound United is a leading innovator of premium, high-performance audio products for consumers around the world, which operates iconic consumer brands: Bowers &amp; Wilkins</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Denon</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">™</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Marantz</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">™</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, HEOS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">™</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Classé</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">™</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Polk Audio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">™</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Boston Acoustics</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">™</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Definitive Technology</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">™</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The brands are linked by a commitment to the highest production standards and a focus on unparalleled audio quality and audio performance. Sound United delivers significant competitive benefits through its platform advantages including global distribution across online, retail, and custom installation channels; a cloud-connected home ecosystem; and a state-of-the-art research and development function focused on creating the highest-quality consumer products with world-class industrial design.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company acquired 100% of the equity interests of Sound United for $1.0575 billion in cash, subject to adjustments based on Sound United’s net working capital, transaction expenses, cash and debt as of the closing of the Merger, payable by the Company in cash. The transaction was primarily funded with the proceeds from the Credit Facility. See Note 15, “Debt”, for additional information about the Credit Facility. There was no contingent consideration resulting from the transaction.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of operations of Sound United subsequent to the acquisition date and the acquired assets and assumed liabilities, including the allocation of goodwill and intangible assets, are included in the non-healthcare segment. For the three months ended April 1, 2023, the Company recorded revenue of $216.6 million and a net loss of $3.3 million from Sound United, respectively. For the three months ended March 30, 2024, the Company recorded revenue of $152.4 million and a net loss of $11.6 million from Sound United, respectively.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Costs</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized no transaction costs related to the Sound United acquisition for the three months ended March 30, 2024 and April 1, 2023, respectively.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Purchase Price Allocations</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purchase price allocation for the Sound United acquisition is final. Goodwill was calculated as the excess of the consideration transferred over the fair value of the identifiable net assets acquired in a business combination and represents the future economic benefits expected to arise from intangible assets acquired that do not qualify for separate recognition, including the assembled workforce. Goodwill is not expected to be deductible for tax purposes.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The measurement period adjustments resulted primarily from valuation inputs pertaining to certain acquired assets based on facts and circumstances that existed as of the acquisition date and did not result from events subsequent to the acquisition date. </span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the final allocation of fair value of assets acquired and liabilities assumed.</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:82.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.791%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:-1.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Sound United</span></td></tr><tr><td colspan="6" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Cash consideration</span></div></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;text-indent:-1.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">1,057.5 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Purchase price</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;text-indent:-1.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">1,057.5 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Assets acquired:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="6" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.6 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Accounts receivables</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Inventories</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238.6 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Property, plant and equipment</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113.2 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Intangible assets</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">649.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Goodwill</span></div></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318.0 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Long-term other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Total assets acquired</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;text-indent:-1.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">1,547.3 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:13pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="6" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Liabilities assumed:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Accounts payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(118.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Accrued liabilities and other current liabilities</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(148.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Deferred tax liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(145.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77.0)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Total liabilities assumed</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;text-indent:-1.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(489.8)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:13pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Identifiable Intangible Assets</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the components of identifiable intangible assets acquired and the weighted average amortization period as of the acquisition date:</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.792%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Weighted average<br/>amortization period<br/>(in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">April 11,<br/> 2022<br/>(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Trademarks/tradenames</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Customer relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">17</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Developed technology</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">8</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156.0 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Contractual license agreements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">15</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Subtotal</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">14 years</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">387.0 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Indefinite trademarks/tradenames</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262.0 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Total</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">649.0 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the fair value of the identifiable intangible assets, the Company utilized various forms of the income approach, depending on the asset being valued. The estimation of fair value requires significant judgment related to cash flow forecasts, discount rates reflecting the risk inherent in each cash flow stream, competitive trends, market comparables and other factors. Other inputs included historical data, current and anticipated market conditions, and growth rates. Contractual license agreements have a weighted-average amortization period of five years until the next renewal term.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intangible assets were valued using the following valuation approaches:</span></div><div style="margin-top:13pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Customer relationships</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of customer relationships was determined using the multi-period excess earnings method. The multi-period excess earnings method involves forecasting the net earnings expected to be generated by the asset, reducing them by appropriate returns on contributory assets, and then discounting the resulting net cash flows to a present value using an appropriate discount rate.</span></div><div style="margin-top:13pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Trademarks/tradenames</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of the trademark/tradenames were determined using the relief-from-royalty method under the income approach. This involves forecasting avoided royalties, reducing them by taxes, and discounting the resulting net cash flows to a present value using an appropriate discount rate. Judgment was applied for a number of assumptions in valuing the identified intangible assets, including revenue and cash flow forecasts, survival rates, technology life, royalty rate, obsolescence and discount rate. </span></div><div style="margin-top:13pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Developed technology</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of the developed technology were determined using the relief-from-royalty method under the income approach. This involves forecasting avoided royalties, reducing them by taxes, and discounting the resulting net cash flows to a present value using an appropriate discount rate. Judgment was applied for a number of assumptions in valuing the identified intangible assets including revenue and cash flow forecasts, survival rates, technology life, royalty rate, obsolescence and discount rate.</span></div><div style="margin-top:13pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contractual licensing agreements</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the contractual license agreements was determined using a variation of the multi-period excess earnings method. This method involves forecasting the net earnings expected to be generated by the asset and then discounting the resulting net cash flows to a present value using an appropriate discount rate.</span></div> 1 1057500000.0000 216600000 3300000 152400000 -11600000 0 0 <div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the final allocation of fair value of assets acquired and liabilities assumed.</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:82.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.791%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:-1.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Sound United</span></td></tr><tr><td colspan="6" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Cash consideration</span></div></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;text-indent:-1.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">1,057.5 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Purchase price</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;text-indent:-1.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">1,057.5 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Assets acquired:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="6" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.6 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Accounts receivables</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Inventories</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238.6 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Property, plant and equipment</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113.2 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Intangible assets</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">649.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Goodwill</span></div></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318.0 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Long-term other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Total assets acquired</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;text-indent:-1.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">1,547.3 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:13pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="6" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Liabilities assumed:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Accounts payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(118.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Accrued liabilities and other current liabilities</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(148.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Deferred tax liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(145.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77.0)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Total liabilities assumed</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;text-indent:-1.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(489.8)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the components of identifiable intangible assets acquired and the weighted average amortization period as of the acquisition date:</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.792%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Weighted average<br/>amortization period<br/>(in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">April 11,<br/> 2022<br/>(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Trademarks/tradenames</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Customer relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">17</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Developed technology</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">8</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156.0 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Contractual license agreements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">15</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Subtotal</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">14 years</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">387.0 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Indefinite trademarks/tradenames</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262.0 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Total</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">649.0 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 1057500000 1057500000 82600000 108500000 238600000 30000000.0 113200000 649000000.0 318000000.0 7400000 1547300000 118800000 148900000 145100000 77000000.0 489800000 P10Y 6000000.0 P17Y 196000000.0 P8Y 156000000.0 P15Y 29000000.0 P14Y 387000000.0 262000000.0 649000000.0 <div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">19. Equity </span></div><div style="margin-top:13pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Series A Junior Participating Preferred Stock and Stockholder Rights Plan</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, the Company authorized and declared a dividend of one preferred stock purchase right (Right) for each outstanding share of its common stock to stockholders of record at the close of business on September 20, 2022 (the Record Date) pursuant to a Rights Agreement, dated as of September 9, 2022 (Rights Agreement), with Broadridge Corporate Issuer Solutions, Inc. as Rights Agent. In addition, one Right was issued with each share of common stock that became outstanding after the Record Date. Each Right entitled the registered holder to purchase from the Company one thousandth of one share of the Company’s Series A junior participating preferred stock, par value $0.001 per share, at a purchase price equal to $1,000.00 per Right, subject to adjustment. Generally, the Rights were to become exercisable in the event any person or group of affiliated or associated persons acquires beneficial ownership of 10% (20% in the case of a passive institutional investor), subject to certain exceptions.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 22, 2023, the Company and the Rights Agent entered into an amendment (Rights Agreement Amendment) to the Rights Agreement. The Rights Agreement Amendment accelerated the expiration of the Rights to 5:00 P.M., New York time, on March 22, 2023, and the Rights Agreement terminated at such time. At the time of the termination of the Rights Agreement, all Rights distributed to holders of the Company’s common stock pursuant to the Rights Agreement expired.</span></div><div style="margin-top:13pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Repurchase Program</span></div><div style="margin-top:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, the Board approved a stock repurchase program, authorizing the Company to purchase up to 5.0 million shares of its common stock on or before December 31, 2027 (2022 Repurchase Program). The 2022 Repurchase Program became effective in July 2022. The Company expects to fund the 2022 Repurchase Program through its available cash, cash expected to be generated from future operations, the Credit Facility and other potential sources of capital. The 2022 Repurchase Program can be carried out at the discretion of a committee comprised of the Company’s CEO and CFO through open market pu</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rchases, one or more Rule 10b5-1 trading plans, block trades and privately negotiated transactions. No shares were repurchased pursuant to the 2022 Repurchase Program during the three months ended March 30, 2024. As of March 30, 2024, 5.0 million shares remained available for repurchase pursuant to the 2022 Repurchase Program.</span></div> 1 1 0.001 1000 0.10 0.20 5000000 0 0 5000000 <div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">20. Stock-Based Compensation </span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stock-based compensation expense for the three months ended March 30, 2024 and April 1, 2023 was $9.6 million and $7.3 million, respectively. The stock-based compensation expense amounts for the three months ended March 30, 2024 reflect adjustments for the expected life-to-date achievement of certain PSUs. The Company reassesses the expected achievement of such PSU awards based upon the achievement of certain pre-established multi-year performance criteria approved by the Board at the date of grant.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 30, 2024, an aggregate of 9.7 million shares of common stock were reserved for future issuance under the Company’s equity plans, of which 3.1 million shares were available for future grant under the Masimo Corporation 2017 Equity Incentive Plan (2017 Equity Plan). Additional information related to the Company’s current equity incentive plans, stock-based award activity and valuation of stock-based awards is included below.</span></div><div style="margin-top:13pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Incentive Plans</span></div><div style="margin-top:4.5pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2017 Equity Incentive Plan</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 1, 2017, the Company’s stockholders ratified and approved the 2017 Equity Plan. The 2017 Equity Plan permits the grant of stock options, restricted stock, RSUs, stock appreciation rights, PSUs, performance shares, performance bonus awards and other stock or cash awards to employees, directors and consultants of the Company and employees and consultants of any parent or subsidiary of the Company. Upon effectiveness, an aggregate of 5.0 million shares were available for issuance under the 2017 Equity Plan. In May 2020, the Company’s stockholders approved an increase of 2.5 million shares to the 2017 Equity Plan. The aggregate number of shares that may be awarded under the 2017 Equity Plan is 7.5 million shares. The 2017 Equity Plan provides that at least 95% of the equity awards issued under the 2017 Equity Plan must vest over a period of not less than one year following the date of grant. The exercise price per share of each option granted under the 2017 Equity Plan may not be less than the fair market value of a share of the Company’s common stock on the date of grant, which is generally equal to the closing price of the Company’s common stock on the Nasdaq Global Select Market on the grant date.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2007 Stock Incentive Plan</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective June 1, 2017, upon the approval and ratification of the 2017 Equity Plan, the Company’s 2007 Stock Incentive Plan (2007 Equity Plan) terminated, provided that awards outstanding under the 2007 Equity Plan will continue to be governed by the terms of that plan. In addition, upon the effectiveness of the 2017 Equity Plan, an aggregate of 5.0 million shares of the Company’s common stock registered under prior registration statements for issuance pursuant to the 2007 Equity Plan were deregistered and concurrently registered under the 2017 Equity Plan.</span></div><div style="margin-top:13pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Award Activity</span></div><div style="margin-top:4.5pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number and weighted-average exercise price of options issued and outstanding under all of the Company’s equity plans are as follows:</span></div><div style="margin-top:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.391%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.791%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Three Months Ended <br/>March 30, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions, except for weighted-average exercise prices)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise Price</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding, beginning of period</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87.79 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126.49 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162.00 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding, end of period</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91.51 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable, end of period</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.43 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stock option expense for the three months ended March 30, 2024 and April 1, 2023 was $2.1 million and $2.4 million, respectively. As of March 30, 2024, the Company had $19.6 million of unrecognized compensation cost related to non-vested stock options that are expected to vest over a weighted-average period of approximately 3.1 years.</span></div><div style="margin-top:13pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">RSUs</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of RSUs issued and outstanding under all of the Company’s equity plans are as follows:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.391%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.791%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Three Months Ended <br/>March 30, 2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions, except for weighted-average grant date fair value amounts)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Units</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Weighted-Average Grant<br/> Date Fair Value</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs outstanding, beginning of period</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105.87 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126.36 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157.76 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178.68 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs outstanding, end of period</span></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104.94 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total RSU expense for the three months ended March 30, 2024 and April 1, 2023 was $7.2 million and $4.2 million, respectively. As of March 30, 2024, the Company had $106.4 million of unrecognized compensation cost related to non-vested RSU awards expected to be recognized and vest over a weighted-average period of approximately 3.7 years.</span></div><div style="margin-top:13pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">PSUs</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of PSUs outstanding under all of the Company’s equity plans are as follows:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.391%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.791%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Three Months Ended <br/>March 30, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions, except for weighted-average grant date fair value amounts)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Units</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Weighted-Average Grant<br/> Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PSUs outstanding, beginning of period</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190.04 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164.19 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250.73 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250.73 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PSUs outstanding, end of period</span></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170.69 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________</span></div><div style="margin-top:4.5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">    On February 28, 2024, the Audit Committee approved the weighted payout percentage of 28% for the 2021 PSU awards (<span style="-sec-ix-hidden:f-1033">three</span>-year performance period), which were based upon the actual fiscal 2023 performance against pre-established performance objectives. Included in the granted amount are those additional PSUs earned based on actual performance achieved. These PSUs were originally awarded at target.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 30, 2024, the Company awarded 155,156 PSUs that will vest three years from the award date, based on the achievement of certain pre-established multi-year performance criteria approved by the Board. Estimates of stock-based compensation expense for an award with performance conditions are based on the probable outcome of the performance conditions and the cumulative effect of any changes in the probability outcomes is recorded in the period in which the changes occur. If earned, the PSUs granted will vest upon achievement of the performance criteria, which include a relative total shareholder return (TSR) component, in the year following the evaluation and confirmation of the performance achievement criteria. The Company’s TSR is based on the Company’s common stock percentile ranking relative to the constituents of the Nasdaq Composite Index for the performance period beginning on January 1, 2024 and ending on December 31, 2026. The number of shares that may be earned can range from 0% to 200% of the target amount. The fair value of market-based RSUs is determined using a Monte Carlo simulation model, which uses multiple input variables to determine the probability of satisfying the market condition requirements. The fair value of performance-based PSUs is determined using the closing price of the Company’s common stock on the grant date. Based on management’s estimate of the number of units expected to vest, total PSU expense for the three months ended March 30, 2024 and April 1, 2023 was $0.3 million and $0.7 million, respectively. The PSU expense amounts for the three months ended March 30, 2024 relate to adjustments for the expected life-to-date performance of the PSU. As of March 30, 2024, the Company had $40.4 million of unrecognized compensation cost related to non-vested PSU awards expected to be recognized and vest over a weighted-average period of approximately 1.9 years.</span></div><div style="margin-top:13pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Valuation of Stock-Based Award Activity</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each RSU and PSU is determined based on the closing price of the Company’s common stock on the grant date.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Black-Scholes option pricing model is used to estimate the fair value of options granted under the Company’s stock-based compensation plans. The range of assumptions used and the resulting weighted-average fair value of options granted at the date of grant were as follows:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.391%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.791%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">March 30, </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2024</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">April 1, </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2023</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2%</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated volatility</span></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.6%</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.7%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividends</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average fair value of options granted</span></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$59.60</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$75.08</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value of options is calculated as the positive difference, if any, between the market value of the Company’s common stock on the date of exercise or the respective period end, as appropriate, and the exercise price of the options. The aggregate intrinsic value of options outstanding with an exercise price less than the closing price of the Company’s common stock as of March 30, 2024 was $169.8 million. The aggregate intrinsic value of options exercisable with an exercise price less than the closing price of the Company’s common stock as of March 30, 2024 was $167.4 million.</span></div> 9600000 7300000 9700000 3100000 5000000 2500000 7500000 5000000 <div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number and weighted-average exercise price of options issued and outstanding under all of the Company’s equity plans are as follows:</span></div><div style="margin-top:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.391%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.791%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Three Months Ended <br/>March 30, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions, except for weighted-average exercise prices)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise Price</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding, beginning of period</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87.79 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126.49 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162.00 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding, end of period</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91.51 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable, end of period</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.43 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 2800000 87.79 100000 126.49 0 162.00 200000 44.11 2700000 91.51 2300000 80.43 2100000 2400000 19600000 P3Y1M6D <div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of RSUs issued and outstanding under all of the Company’s equity plans are as follows:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.391%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.791%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Three Months Ended <br/>March 30, 2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions, except for weighted-average grant date fair value amounts)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Units</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Weighted-Average Grant<br/> Date Fair Value</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs outstanding, beginning of period</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105.87 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126.36 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157.76 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178.68 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs outstanding, end of period</span></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104.94 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 3500000 105.87 200000 126.36 0 157.76 100000 178.68 3600000 104.94 7200000 4200000 106400000 P3Y8M12D <div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of PSUs outstanding under all of the Company’s equity plans are as follows:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.391%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.791%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Three Months Ended <br/>March 30, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions, except for weighted-average grant date fair value amounts)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Units</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Weighted-Average Grant<br/> Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PSUs outstanding, beginning of period</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190.04 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164.19 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250.73 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250.73 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PSUs outstanding, end of period</span></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170.69 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________</span></div><div style="margin-top:4.5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">    On February 28, 2024, the Audit Committee approved the weighted payout percentage of 28% for the 2021 PSU awards (<span style="-sec-ix-hidden:f-1033">three</span>-year performance period), which were based upon the actual fiscal 2023 performance against pre-established performance objectives. Included in the granted amount are those additional PSUs earned based on actual performance achieved. These PSUs were originally awarded at target.</span></div> 300000 190.04 100000 164.19 0 250.73 0 250.73 400000 170.69 0.28 155156 three 0 2 300000 700000 40400000 P1Y10M24D The range of assumptions used and the resulting weighted-average fair value of options granted at the date of grant were as follows:<div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.391%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.791%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">March 30, </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2024</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">April 1, </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2023</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2%</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated volatility</span></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.6%</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.7%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividends</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average fair value of options granted</span></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$59.60</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$75.08</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 0.042 0.042 P5Y10M24D P5Y10M24D 0.426 0.367 0 0 59.60 75.08 169800000 167400000 <div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">21. Employee Benefits</span></div><div style="margin-top:9pt;padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Defined Contribution Plans</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S. the Company sponsors one qualified defined contribution plan or 401(k) plan, the Masimo Retirement Savings Plan (MRSP), covering the Company’s full-time U.S. employees who meet certain eligibility requirements. On April 11, 2022, in connection with the Sound United acquisition, the MRSP was amended to allow for participation by eligible Sound United employees.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The MRSP matches 100% of a participant’s salary deferral, up to 3% of each participant’s compensation for the pay period, subject to a maximum amount. The Company may also contribute to the MRSP on a discretionary basis. The Company contributed $1.3 million and $2.3 million to the MRSP for the three months ended March 30, 2024 and April 1, 2023, respectively, all in the form of matching contributions. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, some of the Company’s international subsidiaries also have defined contribution plans to which both the employee and employers are eligible to make contributions. The Company contributed $1.6 million and $0.8 million to these plans for the three months ended March 30, 2024 and April 1, 2023, respectively.</span></div><div style="margin-top:13pt;padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Defined Benefit Plans</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sponsors several international noncontributory defined benefit plans. In connection with the Sound United acquisition, the Company assumed sponsorship of several international defined benefit plans and post-retirement benefit plans. All defined benefit plans and post-retirement benefit plans assumed by the Company were closed to new participants prior to the Sound United acquisition.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The service cost component for the defined benefit plans are recorded in operating expenses in the condensed consolidated statement of operations. All other cost components are recorded in other income (expense), net in the condensed consolidated statement of operations.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s net periodic defined benefit costs for each of the three months ended March 30, 2024, and April 1, 2023 were immaterial.</span></div> 1 1 0.03 1300000 2300000 1600000 800000 <div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">22. Non-operating Loss</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-operating loss consists of the following: </span></div><div style="margin-top:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.391%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.791%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">March 30,<br/>2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">April 1,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Realized and unrealized foreign currency gains (losses)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.0)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total non-operating loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.1)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.8)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-operating loss consists of the following: </span></div><div style="margin-top:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.391%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.791%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">March 30,<br/>2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">April 1,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Realized and unrealized foreign currency gains (losses)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.0)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total non-operating loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.1)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.8)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 1900000 -700000 1200000 800000 12000000.0 11900000 -200000 0 -9100000 -11800000 <div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">23. Income Taxes </span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has provided for income taxes in fiscal year 2024 interim periods based on the estimated effective income tax rate for the complete fiscal year, as adjusted for discrete tax events, including excess tax benefits or deficiencies related to stock-based compensation, in the period such events occur. The estimated annual effective tax rate is computed based on the expected annual pretax income of the consolidated entities located within each taxing jurisdiction based on legislation enacted as of the balance sheet date. For the three months ended March 30, 2024 and April 1, 2023, the Company recorded discrete tax benefits of approximately $1.3 million and $2.4 million, respectively, related to excess tax benefits realized from stock-based compensation. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets and liabilities are determined based on the future tax consequences associated with temporary differences between income and expenses reported for accounting and tax purposes. A valuation allowance for deferred tax assets is recorded to the extent that the Company cannot determine that the ultimate realization of the net deferred tax assets is more likely than not. Realization of deferred tax assets is principally dependent upon the achievement of future taxable income, the estimation of which requires significant judgment by the Company’s management. The judgment of the Company’s management regarding future profitability may change due to many factors, including future market conditions and the Company’s ability to successfully execute its business plans or tax planning strategies. These changes, if any, may require material adjustments to these deferred tax asset balances.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 30, 2024, the liability for income taxes associated with uncertain tax positions was approximately $35.3 million. If fully recognized, approximately $32.7 million (net of federal benefit on state taxes) would impact the Company’s effective tax rate. It is reasonably possible that the amount of unrecognized tax benefits in various jurisdictions may change in the next twelve months due to the expiration of statutes of limitation and audit settlements. However, due to the uncertainty surrounding the timing of these events, an estimate of the change within the next twelve months cannot currently be made.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company conducts business in multiple jurisdictions and, as a result, one or more of the Company’s subsidiaries files income tax returns in U.S. federal, various state, local and foreign jurisdictions. The Company has concluded all U.S. federal income tax matters through fiscal year 2019. All material state, local and foreign income tax matters have been concluded through fiscal year 2016. The Company does not believe that the results of any tax authority examination would have a significant impact on its consolidated financial statements.</span></div> -1300000 -2400000 35300000 32700000 <div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">24. Commitments and Contingencies </span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employment and Severance Agreements</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2017, the Company entered into the First Amendment to that certain Amended and Restated Employment Agreement entered into between the Company and Mr. Kiani on November 4, 2015 (as amended, the Amended Employment Agreement). Pursuant to the terms of the Amended Employment Agreement, upon a “Qualifying Termination” (as defined in the Amended Employment Agreement), Mr. Kiani will be entitled to receive a cash severance benefit equal to two times the sum of his then-current base salary and the average annual bonus paid to Mr. Kiani during the immediately preceding three years, the full amount of the “Award Shares” (as defined in the Amended Employment Agreement) and the full amount of the “Cash Payment” (as defined in the Amended Employment Agreement). In addition, in the event of a “Change-in-Control” (as defined in the Amended Employment Agreement) prior to a Qualifying Termination, on each of the first and second anniversaries of the Change-in-Control, 50% of the Cash Payment and 50% of the Award Shares will vest, subject in each case to Mr. Kiani’s continuous employment through each such anniversary date; however, in the event of a Qualifying Termination or a termination of Mr. Kiani’s employment due to death or disability prior to either of such anniversaries, any unvested amount of the Cash Payment and all of the unvested Award Shares shall vest and be paid in full. Additionally, in the event of a Change-in-Control prior to a Qualifying Termination, Mr. Kiani’s stock options and any other equity awards will vest in accordance with their terms, but in no event later than in two equal installments on each of the one year and two year anniversaries of the Change-in- Control, subject in each case to Mr. Kiani’s continuous employment through each such anniversary date.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 14, 2022, the Company entered into the Second Amendment to the Amended Employment Agreement (Second Amendment) with Mr. Kiani. The Second Amendment provides that the RSUs granted to Mr. Kiani pursuant to the Amended Employment Agreement will vest in full upon the termination of Mr. Kiani’s employment with the Company pursuant to Mr. Kiani’s death or disability.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 8, 2023, Mr. Kiani agreed that the valid election to the Company’s Board of Directors (Board) at the Company’s 2023 Annual Meeting of Stockholders (2023 Annual Meeting) of any two individuals nominated by the Company’s stockholders in lieu of two of the Company’s then-current Board members would not be deemed to constitute a “Change in Control” for purposes of Section 9(iii) of the Amended Employment Agreement.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 22, 2023, in connection with the Board’s unanimous selection of H Michael Cohen as Lead Independent Director, Mr. Kiani voluntarily irrevocably and permanently waived his right to treat the appointment of any lead independent director as “Good Reason”, to terminate his employment under the Amended Employment Agreement, and his right to receive contractual separation payments on this basis.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 5, 2023, Mr. Kiani, pursuant to a Limited Waiver (Waiver), unconditionally, irrevocably and permanently waived his right, pursuant to the Amended Employment Agreement, to assert that a “Change in Control” has occurred pursuant to Section 9(iii) of the Amended Employment Agreement unless the individuals who constituted the Board at the beginning of the twelve (12) month period immediately preceding such change, as defined in Section 9(iii) of the Amended Employment Agreement, cease for any reason to constitute one-half or more of the directors then in office. In addition, Mr. Kiani agreed that, for purposes of determining whether such a “Change in Control” has occurred, any individual elected to the Board at the Company’s 2023 Annual Meeting will be treated as a member of the Board at the beginning of the twelve (12) month period. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of Mr. Kiani’s execution of the Waiver on June 5, 2023, which waived certain of the “Change in Control” provisions in the Amended Employment Agreement, the Company remeasured the expense related to the Award Shares and Cash Payment that would be recognized in the Company’s condensed consolidated financial statements upon the occurrence of a Qualifying Termination under the Amended Employment Agreement, as amended by the Second Amendment, and the expense was determined to be approximately $479.7 million.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 30, 2024, the Company had severance plan participation agreements with six executive officers. The participation agreements (the Agreements) are governed by the terms and conditions of the Company’s 2007 Severance Protection Plan (the Severance Plan), which became effective on July 19, 2007 and which was amended effective December 31, 2008. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under each of the Agreements, the applicable executive officer may be entitled to receive certain salary, equity, medical and life insurance benefits if he is terminated by the Company without cause or if he terminates his employment for good reason under certain circumstances. Each executive officer is also required to give the Company six months’ advance notice of his resignation under certain circumstances.</span></div><div style="margin-top:13pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Willow Cross-Licensing Agreement Provisions</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s Cross-Licensing Agreement with Willow contains annual minimum aggregate royalty obligations for use of the rainbow</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> licensed technology. The current annual minimum royalty obligation is $5.0 million. Upon a change in control (as defined in the Willow Licensing Agreement) of the Company or Willow: (i) all rights to the “Masimo” trademark will be assigned to Willow if the surviving or acquiring entity ceases to use “Masimo” as a company name and trademark; (ii) the option to license technology developed by Willow for use in blood glucose monitoring will be deemed automatically exercised and a $2.5 million license fee for this technology will become immediately payable to Willow; and (iii) the minimum aggregate annual royalties payable to Willow for carbon monoxide, methemoglobin, fractional arterial oxygen saturation, hemoglobin and/or glucose measurements will increase to $15.0 million per year until the exclusivity period of the agreement ends, plus up to $2.0 million for each additional vital sign measurement with no maximum ceiling for non-vital sign measurements.</span></div><div style="margin-top:13pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Purchase Commitments</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to contractual obligations with vendors, the Company had $267.2 million of purchase commitments as of March 30, 2024 that are expected to be purchased within one year. These purchase commitments have been made for certain inventory items in order to secure sufficient levels of those items, other critical inventory and manufacturing supplies, and to achieve better pricing. </span></div><div style="margin-top:13pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Contractual Commitments</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company may provide bank guarantees to support government hospital tenders in certain foreign jurisdictions. As of March 30, 2024, the Company had approximately $5.1 million in outstanding unsecured bank guarantees. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In certain circumstances, the Company also provides limited indemnification within its various customer contracts whereby the Company indemnifies the parties to whom it sells its products with respect to potential infringement of intellectual property, and against bodily injury caused by a defective Company product. It is not possible to predict the maximum potential amount of future payments under these or similar agreements, due to the conditional nature of the Company’s obligations and the unique facts and circumstances involved. As of March 30, 2024, the Company had not incurred any significant costs related to contractual indemnification of its customers.</span></div><div style="margin-top:13pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fee Agreements</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2024, the Company entered into a one year alternative fee agreement (Fee Agreement) with respect to certain on-going legal fees and costs charged by a vendor. The Fee Agreement imposes certain limits on a quarterly and annual basis for actual legal fees incurred by the vendor that are payable based on work performed related to litigation matters against Apple (see Note 24, “Litigation” for further details). If the vendor is successful in obtaining a favorable judgement for the Company on any claim or counterclaim after exhaustion or dismissal of any appeals, or upon settlement resulting in monetary consideration to the Company, the vendor will be paid a success fee equal to three times the amount of the excess of the annual legal fee limit within 60 days after entry of a judgement or the effective date of any settlement. Amounts due to the vendor under this Fee Agreement will be recognized when probable and reasonably estimable.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the potential separation of the Company’s consumer business, the Company entered into contingent or discretionary fee agreements with various service providers, advisors and consultants. The Company is unable to reasonably estimate the contingent fees due under these agreements at this time. Amounts due will be recognized when probable and reasonably estimable.</span></div><div style="margin-top:13pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Licensing Agreement</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 1, 2024, the Company entered into a <span style="-sec-ix-hidden:f-1093">three</span>-year licensing agreement for approximately $9.0 million, plus applicable taxes. As of March 30, 2024, the outstanding obligation under the licensing agreement was $7.5 million, with $3.0 million payable within 12 months.</span></div><div style="margin-top:13pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Risk</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is exposed to credit loss for the amount of its cash deposits with financial institutions in excess of federally insured limits. The Company invests a portion of its excess cash with major financial institutions. As of March 30, 2024, the Company had $157.6 million of bank balances, of which $8.1 million was covered by either the U.S. Federal Deposit Insurance Corporation limit or foreign countries’ deposit insurance organizations. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s ability to sell its healthcare products to U.S. hospitals depends in part on its relationships with GPOs. Many existing and potential healthcare customers for the Company’s products become members of GPOs. GPOs negotiate pricing arrangements and contracts, sometimes exclusively, with medical supply manufacturers and distributors, and these negotiated prices are made available to a GPO’s affiliated hospitals and other members. During the three months ended March 30, 2024 and April 1, 2023, revenue from the sale of the Company’s healthcare products to customers that are members of GPOs approximated 55.7% and 51.0% of healthcare revenue, respectively.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each of the three months ended March 30, 2024 and April 1, 2023, the Company had sales through one just-in-time healthcare distributor that represented 16.1% and 8.9% of consolidated revenue, respectively.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 30, 2024 and April 1, 2023, there were no revenue concentrations for the Company’s non-healthcare business.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 30, 2024 and December 30, 2023, one healthcare customer represented 11.3% and 18.1%, respectively, of the Company’s consolidated accounts receivable balance. The receivable balance related to such healthcare customer is fully secured by a letter of credit.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 30, 2024 and December 30, 2023, there were no customer concentration risks associated with the Company’s non-healthcare business. </span></div><div style="margin-top:13pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 9, 2020, the Company filed a complaint against Apple Inc. (Apple) in the United States District Court for the Central District of California for infringement of a number of patents, for trade secret misappropriation, and for ownership and correction of inventorship of a number of Apple patents listing one of its former employees as an inventor. The Company is seeking damages, injunctive relief, and declaratory judgment regarding ownership of the Apple patents. Apple filed petitions for Inter Partes review (IPR) of the asserted patents in the U.S. Patent and Trademark Office (PTO). The PTO instituted IPR of the asserted patents. On October 13, 2020, the District Court stayed the patent infringement claims pending completion of the IPR proceedings. In the IPR proceedings, one or more of the challenged claims of three of the asserted patents were found valid. The challenged claims of nine of the asserted patents were found invalid. On appeal, the U.S. Court of Appeals for the Federal Circuit affirmed all the IPR decisions except it reversed a finding of invalidity for certain dependent claims of one Masimo patent. From April 4, 2023 through May 1, 2023, the District Court held a jury trial on the trade secret, ownership, and inventorship claims. The District Court granted Apple’s motion for judgment as a matter of law on certain trade secrets and denied the remainder of Apple’s motion. On May 1, 2023, the District Court declared a mistrial because the jury was unable to reach a unanimous verdict. The stay of the patent infringement claims has been lifted and the District Court scheduled a trial on all remaining claims beginning on November 5, 2024.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 30, 2021, the Company filed a complaint with the U.S. International Trade Commission (ITC) against Apple for infringement of a number of other patents. The Company filed an amended complaint on July 12, 2021. On August 13, 2021, the ITC issued a Notice of Institution of Investigation on the asserted patents. From June 6, 2022 to June 10, 2022, the ITC conducted an evidentiary hearing. In July and August 2022, Apple filed petitions for IPR of the asserted patents in the PTO. On January 10, 2023, a United States Administrative Law Judge in Washington, D.C. ruled that Apple violated Section 337 of the Tariff Act of 1930 (Section 337), as amended, by importing and selling within the United States certain Apple Watches with light-based pulse oximetry functionality and components, which infringe one of the Company’s pulse oximeter patents. On January 24, 2023, the United States Administrative Law Judge further recommended that the ITC issue an exclusion order and a cease and desist order on certain Apple Watches. On October 26, 2023, the ITC issued a Notice of Final Determination finding a violation of Section 337 by Apple. The ITC determined that the appropriate form of relief is a Limited Exclusion Order (LEO) prohibiting the unlicensed entry of infringing wearable electronic devices with light-based pulse oximetry functionality manufactured by or on behalf of Apple, and a Cease and Desist Order (CDO). The LEO and CDO went into effect after the 60-day Presidential review period expired. The LEO and CDO are currently in effect. Apple’s appeal to the Federal Circuit is pending. On January 30, 2023, the PTO denied institution of IPR proceedings for the Company’s pulse oximeter patents that the ITC ruled were infringed. With respect to the other patents asserted at the ITC, the PTO denied institution of IPR proceedings for two patents and instituted IPR proceedings for two patents in January and February 2023. In the IPR proceedings, one or more of the challenged claims were found valid, while others were found invalid. The time period for the appeal is pending.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 20, 2022, Apple filed two complaints against the Company in the U.S. District Court for the District of Delaware alleging that the Masimo W1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">™</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> watch infringes six utility and four design patents. Apple is seeking damages and injunctive relief. On December 12, 2022, the Company counterclaimed for monopolization, attempted monopolization, false advertising (and related causes of action) and infringement of ten patents. The Company is seeking damages and injunctive relief. On May 5, 2023, the Court ordered that the two cases be coordinated through the pre-trial stage. The Court held a case management conference in March 2024, but has not yet issued an order to address the scope of claims and counterclaims for trial or to set a trial date. The Company intends to vigorously pursue all of its claims against Apple and believes the Company has good and substantial defenses to Apple’s claims, but there is no guarantee that the Company will be successful in these efforts.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 22, 2023, a putative class action complaint was filed by Sergio Vazquez against the Company and members of its management alleging violations of the federal securities laws. On November 14, 2023, the court appointed Boston Retirement System, Central Pennsylvania Teamsters Pension Fund-Defined Benefit Plan, and Central Pennsylvania Teamsters Pension Fund-Retirement Income Plan 1987 as lead plaintiffs. The lead plaintiffs filed an amended complaint on February 12, 2024. The amended complaint alleges that the Company and members of its management, from May 4, 2022 through August 8, 2023, disseminated materially false and misleading statements and/or concealed material adverse facts relating to the performance of its healthcare business and the success of the Company’s legacy Sound United business. The Company moved to dismiss the amended complaint on April 29, 2024. Briefing on the motion is scheduled to conclude by July 26, 2024. The Company believes it has good and substantial defenses to the claims in the amended complaint, but there is no guarantee that the Company will be successful in these efforts. The Company is unable to determine whether any loss ultimately will occur or to estimate the range of such loss; therefore, no amount of loss has been accrued by the Company in the accompanying condensed consolidated financial statements.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 1, 2024, a purported stockholder, Linda McClellan filed a derivative action in the U.S. District Court for the Southern District of California against certain of the Company’s current and former executives and directors, and the Company as nominal defendant. The complaint alleges, among other things, that the defendants breached their fiduciary duties owed to the Company by allowing or permitting false or misleading statements to be disseminated regarding the performance of the Company’s healthcare business and the success of the Company’s legacy Sound United business. The complaint also asserts causes of action for violations of Section 10(b) of the Securities Exchange Act of 1934 (15 U.S.C.§ 78j(b)) and Rule 10b-5 promulgated thereunder, aiding and abetting breach of fiduciary duty, unjust enrichment, abuse of control, gross mismanagement, and waste of corporate assets. The Company believes it has good and substantial defenses to the claims in the complaint, but there is no guarantee that the Company will be successful in these efforts. The Company is unable to determine whether any loss ultimately will occur or to estimate the range of such loss; therefore, no amount of loss has been accrued by the Company in the accompanying condensed consolidated financial statements.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company received a subpoena from the Department of Justice (DOJ) dated February 21, 2024 seeking documents and information related to the Company’s Rad-G</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and Rad-97</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">® </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">products, including information relating to complaints surrounding the products and the Company’s decision to recall select Rad-G</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">® </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">products in 2024. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company received a civil investigative demand from the DOJ pursuant to the False Claims Act, 31 U.S.C. §§ 3729-3733, dated March 25, 2024, seeking documents and information related to customer returns of the Company’s Rad-G</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">® </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and Rad-97</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">® </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">products, including returns related to the Company’s recall of select Rad-G</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">® </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">products in 2024.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company received a subpoena from the Securities and Exchange Commission dated March 26, 2024 seeking documents and information relating to allegations of potential accounting irregularities and internal control deficiencies from employees within the Company’s accounting department.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to each of the subpoenas and the investigative demand described above, the Company is cooperating with the government and may expend significant financial and managerial resources in connection with responding to the subpoenas and investigative demand and any related investigation or any other future requests for information.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may be involved in other litigation and investigations relating to claims and matters arising out of its operations in the normal course of business. The Company believes that it currently is not a party to any other legal proceedings which, individually or in the aggregate, would have a material adverse eff</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ect on its consolidated financial position, results of operations or cash flows.</span></div> P3Y 0.50 0.50 479700000 6 P6M 5000000 2500000 15000000 2000000 267200000 5100000 9000000 7500000 3000000 P12M 157600000 8100000 0.557 0.510 1 1 0.161 0.089 1 1 0.113 0.181 3 9 2 2 2 <div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">25. Segment and Enterprise Reporting </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reportable segments are determined based upon the Company’s organizational structure and the way in which the Company’s Chief Operating Decision Maker (CODM), the CEO, makes operating decisions and assesses financial performance. The CODM considered several factors including, but not limited to, customer base, technology, and homogeneity of products. The two segments are:</span></div><div style="margin-top:4.5pt;padding-left:18pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Healthcare - develops, manufactures, and markets a variety of noninvasive monitoring technologies and hospital automation solutions and therapeutics. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This segment includes the Company’s core legacy hospital business and new Masimo-technology-enabled consumer products that are distributed through many channels including e-commerce sites, leading national retailers and specialty chains globally.</span></div><div style="margin-top:4.5pt;padding-left:18pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Non-healthcare - designs, develops, manufactures, markets and sells</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> a broad portfolio of premium, high-performance audio products </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and services.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income from operations for each segme</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nt includes all geographic revenues, related cost of net revenues </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and operating expenses directly attributable to the segment. The Company uses gross profit, as presented in the Company’s finan</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cial reports, as the primary measure of segment profitability. The Company uses the same accounting policies to generate segment results as the Company does for consolidated results. Segment information presented herein reflects the impact of these changes for all periods pr</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">esented. For the three months ended March 30, 2024, intercompany revenues between the Healthcare and Non-healthcare segments were $0.6 million. For the three months ended April 1, 2023, there was no intercompany revenue between healthcare and non-healthcare. All inter-segment transactions and balances are eliminated in consolidation for all periods presented below.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selected information by reportable segment is presented below for each of the three months ended March 30, 2024 and April 1, 2023: </span></div><div style="margin-top:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.952%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.376%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">March 30,<br/>2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">April 1,<br/>2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues by segment:</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Healthcare</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">346.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-healthcare</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153.2 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218.3 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue by segment</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">492.8 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">565.0 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit:</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Healthcare</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-healthcare</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.5 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.8 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241.7 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284.8 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">____________________________</span></div><div style="margin-top:4.5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Management excludes certain corporate expenses from segment gross profit. In addition, certain amounts that management considers to be non-recurring or non-operational are excluded from segment gross profit because management evaluates the operating results of the segments excluding such items.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s depreciation and amortization by segment are as follows:</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:70.454%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.829%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.831%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">March 30,<br/>2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">April 1,<br/>2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total depreciation and amortization by segment:</span></div></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Healthcare</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-healthcare</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.3 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.1 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total depreciation and amortization by segment</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 2 2 600000 0 <div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selected information by reportable segment is presented below for each of the three months ended March 30, 2024 and April 1, 2023: </span></div><div style="margin-top:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.952%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.376%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">March 30,<br/>2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">April 1,<br/>2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues by segment:</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Healthcare</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">346.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-healthcare</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153.2 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218.3 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue by segment</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">492.8 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">565.0 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit:</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Healthcare</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-healthcare</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.5 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.8 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241.7 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284.8 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">____________________________</span></div><div style="margin-top:4.5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Management excludes certain corporate expenses from segment gross profit. In addition, certain amounts that management considers to be non-recurring or non-operational are excluded from segment gross profit because management evaluates the operating results of the segments excluding such items.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s depreciation and amortization by segment are as follows:</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:70.454%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.829%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.831%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">March 30,<br/>2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">April 1,<br/>2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total depreciation and amortization by segment:</span></div></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Healthcare</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-healthcare</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.3 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.1 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total depreciation and amortization by segment</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 339600000 346700000 153200000 218300000 492800000 565000000.0 211400000 214800000 44500000 77800000 -14200000 -7800000 241700000 284800000 10000000.0 9000000.0 14300000 17100000 24300000 26100000 26100000 22900000 false false false false

    J].W#R12I/\LS&'%&KN@1Z1]Y M$.(7(L$,C5-,*2>'W[% Y>U+*^A6,;PJON^1MP6[T:7KKP\ M:_KEPOZ ,>\29(188/H($31J42G F"E^8IMU-# MQOPL=?*SMV;%J5GYV[9[E&T\[$LQJ9SJ>N6N!,/&_6MC&E8Q+)D!D(LX,PAK MXY$-Y@%T=;YE\=MPL:;ULY)OG0BI#\^>:>6B/85&("0SWI<3, 6LD;1T+QJX MB-5CU[\[-IJ5> I^_:-#?ZE^OU55UE@H-^JIHE/X^T\?K;-:6Q4E4]L%5Q8C302)^=1]G'V,*C](<,U>\,="CK(#@Q4J"'$ H*$3 )_4TE#L_:CG?R6Q(48&G1C=]4">L4R/\#-K-Z_11 M%FCM+7'W7]!34,HWB'SK^[RD+=>YP#,4@9O??+LO4 =^.N'GE$ M[1>MS;1PF[_R2-+V"YR(N*ZH'ZXO@-5H$!?9SM/7LF:/H'@1&C@20^*E]1KY M]C5QTB;HMT,#8MXMBT!X@O=3MNPHXL"G0FO?@B;/V#^7D(;9*$TRB7_NO_?B MB+RX[WQ&\9E%$A#!2'42/[_IB"D)8# VQP/^&#X6)_?:[!\(QK$H,;O'(SV<4/A//<,Q?XL?B)+.),23LSUIP';(B@]3F#\D\V_+"+Y$FTRQA0R5D MB[&MQG*D$B5.6GQ)[8]-?7Y6P;=X0*@CINQAFNHG,.^7RC.$A8/)12T2O2TR MO,U3O7.\+5-U;-@3]6XVQ?:RQB(566/U0MGB7 G?5_(+[=;3$5[N!<9)Y2O. MV' ;*<[YM%87$I');/%E?O6N\*(O;=/QE4=7:$Q[6@-+TOVKCRU$'Y\3>,_X M^-X]8N Q^_>%4ACN1N_>-\EL9.\"L$?"GC8X"NH#7^Y&:036?Y'I@N9G? M/VPN*%B4$'4G'B[9JJA$7L>D*W#^MA07$6#7)/UZ; 4_AH-U62*3%O9>I)/D MI59F$'6_Y M9SB_UG"#7T,\@VQ Z)I4D@T;Q]PV=GJ7462X!"Q+Y'TU9P8PZOGX$, 1D=$% M#G!@-,AO),"FG:-RMTWY$) J'D!P#U\EX47E3!F%N,PMX +MC ],1>I_*F.T M^.(!_?0+I'+=92W MF-MERCKR=9:;.OKU$M,/*4LXT-T!*1T8#?2!Y#KR'^45HW3*\V&?YIH@F^-; M4H-].E4G[_M-\QVGN6T[-D8UO4JLNU=,?3K6W MCU7(W'OBX(<'?#>- D0_.O=8["%3OUB0SV\2,9^&A]RJ\9C],>-=J"Q%;VZ(66YX@TV3]W*WFF^RD/$,,(E:A4FX(]KE($0TH7&NSGD(< M-X^-6\#'M;#+[4YRDN8)[=;W+_?>9Z"8'.^3\7+PRSB>@>9[K^0(67IZ+/8C M_&KZMEF5X@:6-JIJD;00C13NHNEII.,.W4I"?D(>)&*B$JU8N+FY:#JY+>IK M7CWQ<"_O2\?8/:\@+H7Y"+,G3[Z$93-R2M8/_HL[EWZR7@@PYW)#=TVS"3** M8IZTAOZXS,74W[PF(A$.CTWX*+!^YNDYTIOTZ4;2/+Q]Q=MP[:EU2389]!,\ M0.2%,NX0_?C]?/?X5#4'W)^1JZTMXV)I0 OUW+^:D1B<]>,B\Y_N"*L,7>B M1Z']$(73\'7U&Q[>*%P')Z0K-VT4C2@8,7 LPR7#QVC<^M0OQ]AL5!NL,FP7 M9EU44!_PE>WRI0GSPQ+'&U*C,X8V8.G\"LTL(U*' APF@S[W5NL@RX MP0=:4\= 3?WE/(1L5/[UUI62+L0?.MHW/>Z.IF;,]54K4D["2=\I(: MP4O B* 0_0P/8(DL-_J( \%Z.VU((;6B_!'T]%5+(<^MGV*'&76<1Q0V&;6, MKX.D,%8O&UORQ+)#RZ_[EKO;!?P7V6A(PKD(JTNE=O@0?D1,5(7AZW M3"^^B$5DE$Y:QG#-%_F4[ZB@6HUQ,S:VCB#U8>Q1#$-&"$=_Z\^PMI,(&!"&9"K&;F!5"-/J?"V7F]W*6ZFQ9Q!U7LX05>-1=Y(^UU,TY\X&#TWU]?%; M/HBM(WXX_U>#G@$'P3T]/VZ=@GRK_KC+DO]97*1$ZLF61SBF'E.AZLZTO)59 MAP>P8Z,4-P=%4* MW#@S=('XPF/E?P=E] E8Z\N7>M3D7/=1N4-HXITI/("S M4=Y8\):ZD*K 2-I<3=/="&71](3&$<6/1M?/WAB33EXBSDR7_U4$G(3%<%Q/ M$;ACF\1H3F58WB-ICM$7?*DII#37>"GW!LU5"6>$[:?66WJZ?'BUN!"'^.,G<;(FMH M?*E0/I[4UP3?DV^C+HVEZ">,:3M#G68,&IVN/;LLD*V.![A4/4^53J22*M77 M(?I_23N3ZG3]P71W3;/G M;=[64E5V'=U<-2#":TS^UI;O9T</[%L)(H6N[)?/;>D$[J8-H%UT/D=A[HN3X0&0 M*&MBA5!I;JE4 MA-R!ZQ6UT378)J]YUDW [ZH6/AXE70K6O$2\0*'\+VUTDX20LWE-J *8!'(_ M;I$.M4'.W<8I+*]5)DBS441/^ -KG7P=R>ZI4,3*OO&S\GSPA&0H2)$!:D P M$VV2?VI>U>+@K:O%83.Z:\^[+;QOY_84 0$AZB3G*0GB M^/CGZ,I-_P-[9):#;BSHD*V2$PN#UBL?'-,.0L:9=ZSF0K2-?D&FN;00[75$ MYCH.C2V>$1N<'QX![@'W0!X;Q9W_R%(9E0__=J?I/[)0+#A_/. &'C!T_!6C MX[L]#/INV)@4K MLW& #URJW(YV,&JL7ACXP/8B-CADZ:&&?;A"M?G+(]: M)0L;#$)\S3X/=[SKOW!!N&M7\^CU6 )N_AL4^[V0<'+4X#/C(X8:R@RQ_9.2 M*94>W"7/U1(\M5,+>MK75V8$8&R=#-VX'4E%^O",C=>)05)DQ:].'"V;8H[]N LV]"P*S7 M%=F&'@P+292U5Q-^3(U5[&9;BHOUZ=WQU_A]_#HE9E"TO"'\E1R1%4K3E.\JWB#45!+PG91"X8^VNBD'Z M?Y;TE_G7&:R?OZC9P7#DY7GDH](5AA5&*I3W-O)NDE%1NXYR>G[5$.1;5XI!YZ[E>[]3#W3:7"_+?HNI;A*AO7N]3/Z5<^IY/>$HY[#<7 M%@!Y,-O'V(GI:?'ST!3FU8F: ?,'2&L9YWMX>DP=^&=_JO15NY5J&Z4I[A"< M0**]%_'P<2&Q@8Z2^]FSHM,B6SHZV["IJ:FW-G?7UN_$YA65%>7)!F>DIF;0 M>.<79%B1O'U5+0 X^[-QZH#QSKC;S).A&9F1D9=T@X<0G2UR:*[N"\7KPW;I MA:%P51X5EC\D3'F,A]S8.X_DB:POZ1 B_^72?_$>-S\G@I]2H&_?R5RUVE]\ MH$0E.V%PR]A MAH!)VI,98GH%FRUV&-."[N$Q);4K-+I^(!<[S#?+J.YG46+].F&=_=3:P]Z& M3]QHW8GZ,$>4?DP]AGO85JD>DK[:P] 4JEG8B3J MPTAZXD:V)I M+4,IW\H^O7MLB"_59GV);G$FR/V&0"EB8^T6/7&H[V\5"J(RU901L&8=HB@5 M^ ?S-0]I;.GF*!5U(7C]][ M @+>U_T3 9B5R/%OANT9W\<#T-G$Z1V;6X?_'F'OWRJ8C8W#=B-@:-_@10+0 M>HP 8[<;0X@:H/%;S^">+,X]DUA37Q$FUM1G@>AI"P+(=E.5(CQZ4L//]FVDMV+B/]IN2SE!K:8*7:E6'3=1)AC39 M+32O>C0/-![+X@&+#JU&8RBJ[_XO#GIUF^-F)/4J]".^SL;1.KHX9XP)\W#BJ[91_OIDRTK\+/<(SI[M18/F7.YEM\);D;2]4:RBQ ^K C\ M\V82X!**Y.#C&O/2_BZ9::_TQ&E?IXP)U)$5Q,VB18HX[;44;W%LTK)T+WKG M02*GR,MVY[Q=@88T41__-K52RK_*.12RQ(DL01V.1@_VQW0OM0AX!*_#DS>\ MU+.R6:&GO>> 5EM]?I1B#4+:B.9T^>O1PO<><VVB>:73,[VH)QQ&B!5\IC%C5P2&(.+\6 M#[C6@ID6JP>YX0&@X[EMH_6Q*/*,CW@ P2>%^=9K&4E*:F"!$Y!V_L;#@/?_ MXV#*^XCTZL!9J)GSULQ@9 A_7;W#)?XZSQL<^3KPY?MZ6_YR]W@C"[[WS-)- MD7YB\;WF5KDZPQ[!$?HQ7EM$G>3PO&I4GYM%M0,ZBA]QE'8T<.\)5'?ZJ_/Y M\#WY!WQ53S=?:#%JA?2Y[[NA#+Y[#X03HFK?EUFN<\X\,_[0S;V&]T'/C6X) M^:I7R"=,PO]H)V.#=![5^C/JR?*PVH2]2)#:@[M5^%<[)7X]Z5@ZM]&DB;-] MLKFQ,PEQ.=KQDBR=E.R$N_TQPZ.N2*G\5.>>+N)#.=6/:;;*D=<%=VVMLA,P MR3ZCOJRHD(/7A7GH]T:MAG.3>@*F?KRU1V6:]J=ID;2M3??V2EUQ]2-15@SI M]H<,K5==*C=<<:/*P,6G[N?\<=XUR,P9UV0_VD'O3VDO27 0-6?F=[#T(A6Q M.7-/8;.5O]9&+1&AI(9+9P%TTD]=/Q .0 ]N@@SN8]I8K1WT)S/9/*J7T,)!O*TO(D_-IEN2#< &'5)W,5DWC M2*B#LA;9HTCI\#MW%&_\'))@]><8)&X."F,>A]/[.$XWM-PS)YAK*-),@WT/ M_9)"+Z64;H@N1&E8381%A'4W?XU8H6);K?:6['_?AW@^JJ2]XGG1@#6M5_O1 MF0VDMWYW\>:&[EU2.I_"F;<,+XADB&D\@$^JTF@-9YQ)(I:A;[VQ!KVTG-E9 M6IP8;$+_!$/&.X763@,*2RNNQV:DD0[WLNBE#)*HMK\BSCF-_]4#\=]*->V1 MX%ZB/SONK$ P;?7F%LI\.BOEW941)N>&A4SVL)U- EXZJ9=BY9[EMP]*6ZZF M*%T#_" @(#O(O*BOH#(*L]ER=IXE4E$_I%HD>/\>U5#'%ZE/Z[B.+:X<7MVG M'(],IK80V<=ZU"7@1@VBNS8GIAC\ZF'SEFFLZ&K,N-B^J^SS7M#$W-7&?*=^ MW?@XF?.HYR(6GBJ]A;FV]9:!58UQM^H*,I3IGCL-D%@L"1&#WE\S*K(==R_Y M<>IB=D[4)@4?OCT]7H9U8/=8UP*5+]>@HPAK;7+7&!KJSK7FSU,T>X>]%?^" M.+YK[6]]P_WW_?$RMQV">I5_=/,KBO7[E;;*SVUN.G?J7\NZO<<@5 MB:?K/OQP35HVLICX)+]?S1&^9A1/"")R;9!_NCEOMFB-E^>7I%9 M=F L;RO<5\>Q13HKS]@T,I-!,,-;6)?Z7822OPQA 77_+^[I_0]V-GRE18U! MX' \('D)Z.Z=$XBLD,,1Y A078\W#GO7+P@)7UHSZ2W9/,A!2O^DNN%FJEUCK<;7RE[ M3/-X(^KB+P7NIJYJY=%HY8D>N!+*(_1TFZ%2B?Y2I&Z.-),HJQ-IQ>U /F*. MX[ADO1EUR=:=0LO#7TCN8"9J#$T?H-'$0DGU!'K4P>_4/DCJ4[3A3"\?1%Y!86%! M2NQ-KA]!9-!/I$67V@^HC@O76!2,.)]0E(?S;*S7Y2H_L*\WTQ(0\0 MI1'6^X6!6;=L5D/LJA0I#?KIJ;6UC=N(NTWLJFXAF2G' X24 MJF"[> !G@Z:$^'IJU^O<"1*B&!F(?#8EO.0^=<38#3&5YZP;3J0OT1M.X3] M2/ MA$)1@WX#W3+JP_.-JZYVWQ*^2/?IJI9K'LZ.3J7%IES&]4$17M*S7](E@&Q#N_3BROO..=+G MGTL-MJK:8TQY[BQ=*QHT^WYA9$J>%D@$R+Q_.YYQ_/V7A6,.6H%ZUWCG):=/ M&",9LN3.OB$>K8FF7+8145)1?9B-9KUQA!#NTZI+ _ M2M)8GLSD'<6&-Y_NW$7$RO7'3!JD<=85ZV4GTGF;619V"' /9I]K5?4B[->E M7P>U_I1XI8YG[R9J>2^$U:B1])#6;PNCEQQ"3KZR.=M5KN_A*\:?%.N.._$_<+?[!@$(UN#MDK.,R M=V!3S<.E3(R2,C_/$?6Q0U'3_U,A=-_ /OJ7 Y]K?0@A&27& /W>4\&KFR8\U9^SFBPE[4?H$4181 MYD5X:?]F@6AN/-G9ZQ+Q::NY 2P-97'*#9(],\Y4?V_N5#-/U,;-\8";.YE1 M,\K4A6SB%,5"Z 5W&0@-Q,(A:I[B2CN]MWI(J7$TU[*Z<4 $@N.8?-7PL+G@ M1\P-S$PA[CRC)RNZ2!2TYE^_$N#ASJ+?AQ>C*M_5C"Z4LE! ;KZ( M+" M XCF.HF?8*[E(3O.83_[Z3;_[,EWFU#[HRYNCM_ R3,/#[:5F'4P'W?2P^7I MO=U:A.R.@E>_FA:9V+Q*U-?OLWB@(;W=%R-63R1@R-[[\U.X@^O*Z0T48SI' M^N7!3[1 !K(Z(%99-24=)6Z0LL;Y AGY!U1R)26B5WY>0S3[)@=-E]3@8U6 M=OA#^BY4J<2#UDPMS-T\GQHZ9[O@*?SH-9-/ONY3/8&<6^9W[#T<"PG66N4? MK>C@;_Q5('4(=^8*3?-B@LTF5PNK9^3L5TU!ML TT98Z#K"IL>U3=8U1&2&- ME7HV\NL*4YS<-%M_$!G [=5$HTB($2_';-X2ET%-8 3R?3S2:"NK#(LG)T.U MV*/5.BM/P14NR6(AE!+ZVLKSF(>,SULU>RY3G!*3(156O_+"9_Y+DW+!YQ&+ MLY!UYGI?C8JVSMMSZ5$M(IFQ-XN,"1BZF3Z3Z_TX-4VLLMX5^^-QS80I608! M7B*]HC0,-L^"OHV K0J-B^XPP0ZL!M,/FWN-DKV" H;"2S&)Z?K:G[88'_X1 M*JG#V<% [ *M(,;OJ$&"1_A11[N+P)Y,#+N+:EN\CD MC4QJ(6QS@%2>6*,B1IBR'R02G$5C+\C*JM]'TD!\X3DJ2X1?P-$4O8[W@K[( M5\1V_9OID_'@++JN3.;,#O5EZRGN1DL?GX*IC-)GW;?N+H[D!!+DN3X4I.J'KL"Y8]IIGP_=E[/0YB'XMY/,OZQ_BGB)$"2R'Z?%W OU MO)6:EP<.,3Q3C]3B%QI@UWYIX=YRSL+*=CEFO9 BM5BH/C]FY(ZF)7" /1;YOX '!$%XT;Y%4O\_.(K._8UXQ.GD--V+/5SSCO:]V[))3 MJ7YR$:@3DY# 6Q!XX:1JN)CVX'BJ3:Y+E'WC6-4.KFJ1+5C'PTJ&C)!KCP M,U]&,7=7W#8 @^)'LC;;YJ'#,M9WI.#;1:$'RLP9 1US\#=>O2*167>YJ;HY MS&O3*;]BGUTESKEZ-?"KO"J ^2A6)[6*LP'V'I=MV-R W4I V0].OC@\UTE= M.6X?D0F[#Q]P&^RIUASB#RYVV#[-\2 WU K5C'D508#4:*=_K82\>," 9S&% M"N01>.56C=1HP3@G4LG;P\U)L"\Q!!K[IO%VP@UO=O?@+$9T5Y M"028I/FK-E": )GG,(3CWL+>#ZC9AQ;A>AF1%$7BQ3E5@M4G\[%H)2R_22&G M"%T+'N#FSGB>DE^D(!9XV$D.+PD<%(D M^A*9,.(U=?-\@,_4:;+U^AUD-[6 MZTMTR,SI#)+UDS0Y"N&F!T5Z;"X)\/? MVX3; ^G=K))WM2Z$?BC\0,/QBNK(/3"SPH.2P='_ P1IT0:)PCY$O_P:=9)T M%)F4'N>=CPYUQP,>Y> !'WQ\0R!V!"0F4#9$ ( #\B%X ,6IW3'L!O\">$IL M:,M@_E$U% ]X+PCY+BDYO#,3X7B"?9@YC/.1 )Y AJT:3[[C 72XP>',!I'A M+ST[.*=N/.#Q07:'@S(T-5'A/FJ+3]\K>U^)7(A+!LSC;*N)[&;D03;*E[X: M>4Q[VW>J*]*ZY#***6[&/BTA[#*__6JPH#59Q]KEQ<>Z &6)1I_C@.B_KW.= MA;">RCCXQ:QE#*_UCWUA %K88?)FT/LD!7Y\>H.V1XC%_-3^\$]7D!I!!S6BU1!2_0B^WAE( MS9R\5-CZ]0[RE!]FL3>\Z!1>O N*CLDH&D=1NS'-K\V]:ZXE/VE7"IG3BXI) M?U._7Q,G_['0;)/$6?SB[)$L>7!IRT(P[[^H^,+)_H969]-H;;-$KR*+6YGHX@JO'*CY@ MLZGR?%:2YRXH8#4HH&I!S^0!'I!A1H(::BB]8.%[]3#)\%^7&7]>-$!PW)<) M"ITRB53" R@M1P@&O [LPED/0=@/8(; )\: I9M05C_)3@Y+M$M,1;RYRD\CZ5FRB:[Z$ I\^^Y>X. MOY(IM?T$$*7G87NX@U1#W0E6Q$U!ZSSSG[HG2FG%/EKBY7>R9T0E! I[4_<> MI[F:C'W9^ C_RIH&(.,GSG8D1I8.%PB^L6%C9T=GGQS?_/*G;J3W 'W)#M,4,4'D# W5,0##F,ABB< M^M_N#CP7 '+4V@1'@.] ;^7I6TPPTL,-1HL87S)RC=MN,>#<^KJCFGUYI-^H M70O8.S>X4?_331"%,]V+HQ2MTF''M$JI>U"U#_$-GOC&3,6(*SXS"YYNT/U/59 MP4(.I=M@Z&[YSI^Y#.J-?I24=[ M%5.& ]/TU*.IMI:)YR;2F%]:?173J@[K8BW" V274Q]H,.316-W)?D<4BNC MG_=XVA%EY9@]">M-^@$R[A8;T7*D"(;=VD=QZM>46>_?(D^=K+8LY"A1L!G+ M*@KA&981\EK$3DQMY+\F&/*9W^")& &MD3MO2#WVNP272]$2D!2?GOQ:?/WZ M?LO\+%3J]7HJ(X!E***BA%Z-SY*E38&3X%1N_5GMP'9S2XM(\K1E9F3M"><, MI3;D6IP91?S7>D!Y&-*6*S_>&/5 M_S@E]*]E71-()@S;HH3Z P]8^&P)/)8GDK)&'_\"*5/'.,IZPD%SFH:<%##V M$LY9O2KQ;QN>OSG4N[!OU<1IR1VP/2?Q3N*T9.)Q#;O43CBZW(X1X)/,4T<\ M((!O^J><19;JVB7S]WIAI^WJW?J^]#EH'5/2NV:EB?K5T",^7\_*7?;7.;8&J\MFCF"(",?GY!"9C)69F#0+3T3&9; MA-;A ?X>+R8>49,V%L9UUK@\VI96HWKY2;==3I"@-W87?A$."F 9P:>2GIA, M@L%)_$%5*MKE9[1E'[YD6Y-U15PN4*K:^OS E?FI H>=:R$*PA?:GT0W$"O4 M"]U$#% *F6*BXGSKV2(,FBEKR4$M#8>.CAF-$%>/CQ$4DXTT[_+O:("KO!/ M@8: "G[HRT:076=PP&"J*,-H!0/^"4TWN/HBXZ5C>:"+Q?JB_XH*.K/E5#K M*DEE;+NA2D:<#DSW9_IV:2AD_AZC,Q8/P'E ;@JZM!U3,YK5B<]5;BY(\*,X MGSE&Y+Y-209="3]*B_-2[6MTW_#Z4A7/(T_04$/@O]2S[GTF27&7-74PL\\BP>0P6D,)8_%<+/,4E$':O.C109>-9MT;IR-Q_K_ MN,]-'-)K\ DVZ8TS8;X,+=-/X7)N=D5&91^3SWL5M73G3=T_8CJ;Z:V:6N6F MT1DS54L3C^B[=?:9^SW>$6*>E/$ORJX+O6PH?J]";31FV _QU!N.%2"@'L.VY1G%>GCVV9O2K]X$DJB]&=$_UX,'E$D6A1?2 M.TI(BEW;N]KS,9'8@:0?>!O#Q'-C: M?,W,?(;?VF (M@-C&H1);S[\O/$-E@#L>;(GLA*EY=A4]M2LC@E1[%"RM6Z1 M\B$[RL+1)Y5;4; 6>GE[W0*$3_K.C$T TQYF$E M.DUL< 3*_0)VJSD/#S "FGH&&-:$?UVYQW:*!ES0G=$OOA]Q:>^%]+ !^:UD M9KZ6,*95OA;;_SF74S 2[Q9/*4&M^7WHRZ%P;12-Q,OKPD9R57Y!_DK<@"NC M":/JRJS^1O*6(FSH[V=D+UZ M,5A3CUL5C\YL[=5=U%2WV!+O_N1TG6IH*CH MT07 %?(<])SR[T:'XDYT=OMW'0M!8?*#A='(9['IX&9-K">>W&%;+6ZU[?,60) M#'Q[]Z[ DMAC7[./(O_:@OZL*7!!OCA4[G?#P9PN169H?;[&"2_4:U-VH:5C M/M.\Y"R;.]F4"Q8C#B1B7B(/8_RAZ@YEX"ZY[*,XG,,G8>QFO5H^&S(HICR" M8]-K<2BF]7HMJ-1"WVQ\6-P>G="X(/^?3X+M7R( D6QWTVW0"GBH.5T>M/!A M._,M6O)E/LO]4?%B$P^0E7'5\RMN>[:1O.5Z?ZB5+L>I.DA;:Q%TAH#+?IO@ M2>S?"3A*V:)8.GP[=55S6$0.$XM 5"HPY@&MR&V.ZMUXU$HJ.\*O5'M,QU)0 M>O5"?6HWB<^R ?WBD)I ODR@94YH/\^%S3RYJA.87XG32M^6N#ME4=KN[JCE MZ&>A)9%8\JY;GDFGNH#=[0&R,/51HB1HQO!;C>/B6Q1-X'NR/J MIWZ]QV/@;L$.VEG^FR.FSA%W!1A%3)N@SOZ6A,Z?P[#DXV8LYC)/8%@"#/V\ MN4?,.A@$_/-_%HW@7-(FW(^1&3A3=+2F?TGY[B*LKI]=(3'O%A>2?K7,%83/8].^FR4 MRE9$3_S4RB8D.5WQTU(1J$K19DT0ZS_M2^>5OL&K?N N#*^*;])<-5!B4&E[ M:D0K-]0?2* MFOJ"<3JF]4OG # _W5&=\/;WZ]P8@.CC)\@GDV:MED$OTPR\.V MI0H5/IDQX7P1=^IU5HU.E7"U][U+X^VQ"ANF?%-/?W8FUC/_ M>D]//&!>$[IF-[ 4CBQGB*L5=C1QX(]"WPBVWIA--.B?:W9N='&2*[R2Z5'; M<+58[WQ%XMN;[!X\;FL0@C2>$B.U&2B.DJ8J%;8\WF_4L5O--WJR6.VA5G!5 M[CK''#9--EU7CQG3G/K!O=#8%!O-*@56"R<"7P5B'.='"07C+),L(/-X $%P M65T$P:V?^279+5<"^&LB!#'L?B1X0-NY"MCQR1$10I7A ;^8)Z20+VF^O#Z] M* Z_[X5ACDQ*/HMB^:4"SAL1 Z'LYRBY(6L\3X/X\PM*@R5%RONJM02 M>7;+?_:0TP11ZE3(N:)B_(*VZ,*\.7(GP.0B*MRICQ/NT?!Y^GI> G7*BH_( M/'#RIK]<7Z7&(Y@3?CLF1Y7N&O$TJ?QK@-2?C[NQ/#[7%F".$=H&G2T_'ECD M6]K<^<3$J(X'9$L-?T, SPRKCM+9X %#8Q^+V)1ZW*#IID!"V)_^ZWG=C-D6 M;I;R*'KI)_6\/,R_0GQS8:=C=E\/M^R;^>'4M^Y& M?B<#T$FU:>&(TQ_Z+1^UD$R&6BNBFBF4_2 MH 8$N-.'!S0\V\'V)6'%(7\A$D2V>93#_4X9):KOV:&.PXZ?SV%7ISS6#,R]W-@7Z8/P %U($QGZ*99L M*RU$J8>V+O,PI.:=V W]AV):0_7KP.]P[#$:8I/VD;?:2=+_&B1^KH<563P/ MU'%XW_)T200/ ]EY&SEI[IG5/GW5]E8KQ<(:<6^4.1569]RO[GU_IO:I1FM MY^%.J>_F>L6C=GBS1'7'W+8@M5[,_=8!0SZH)O0B6@E7PX1Q@,O&&S'S(I31 M'>UG9*\9"@FU9[\R\ U*O4##V19Q7B%\+?$@-=G5(.OBVVLR"M37'$V5 M^T2 BE4O!O2925X?U5OC[,0R<1N8+-'%'9KNZ:;NA&7#6M[?,G_.FGO#9T!,JGR;_ ??$ &\LB MKJ1O0]U'5B76-UP7M$ 21GG\YH3%^/[JP .+0TY><%J^CW+& -8+5H>@P!)T M;[7M>JSBI?@CJ?4)<1UFR>=W,.K^#1N-N:_#-D \'^@%B#';(/ GT=;Q1.Y8 M^V$'3L,WRF]$8[T049Z07MVT;CNAP&3',067=!^CCN\Q(E$K7': M^90WMKQ(3^BK(&QRP"7EPQ8WFR 3_;=PG* .SY#8HPHMZ3(P\=)V8JQ:/H#A M%C++.\0I@ 78-HQW_$NI3$JS]S3EE*"1.Y(4QG66\.\3;<^SK4\?&6K$E$3?_1!-0 M@V6X$M#T%M"81R=ZVEOB#^(\MY!_/J&H%8+R+UH7LVY!EGMC?6P2 \O-,2E9 M>276$QH#>E'?#N(/1P:5[/F%>43%/&+DN:OO N(GY7YNR?# TO.$1;NQ7!,>%;KKA"[RC>8$73W"K_$;4Y5:UABB MR[8T*V=(M XZ+]N>GO\R#_QN75K%<_F%Q][@64?.W1, D(_!D]T2Q'3?P5H2 MKPT(E?]] BT7A16<+YET. 'PX\K'/08G"BIDGWFF7BU.?@"I>S5I[CS%^+TJ MH_.@[(LL0BJH!?J^G1:\.%0;RW4ZFJSV]T5N9MN@;TRW[T'<0"(S;:F)!O,W MX?1>RC=*?\YZ)]@*U/7*I&;G0(50M$C-XYGO%7VY_2)Q/)8OXPEKD'?]9\!D M) 2R5=T0BVJPQ]9B:!U8IXMV=U2LU;*-#:UPV">2[E*4<32722#MFIOCAH@:\$_&;56:$)HQ-2 MW6<31 M.WG8, 7P+L#]+*\_M>>*3<_XO"XTK*'!J"$@748;S'T^(>YVC02*Q.(5;.#U M%W7$]ORH74-]XO(B>;:]K,2DL_%Q-BTO>H]4!X*')WXA@WD@5UYFX5+-9W D M&%6^/M\WT#R?IG@9D8%U7A?=NU%VE_F2\?=CN4VXW#;4GHN9U E,$6\@O$? M+HTG@)<'4:T*!2JS6K$?P<_EFHD(0P0KG2BJ\-;J+<8_[02@Q'K=/>5\]0L6 M\K0=WK-\)2NBIB2/>\=UC&QNSX=RN3+?LCG8JU&_"KB05^ @5L.?,=84+<&: M-974WKNB)8)+<5!99PCI&BP\@]O&WUZ@XH"^20RXJJ7 ;S$\0B^JI?!&F-*= MSYTO]4E]E)Y'A4YVI<(L4#<\O_X/8,KI@[3>0QVP77'_H6/%T5+2YQLJ,"F0 M:_^P7AR)S02&]]K':9.['XG)EB OY(.N#CPFS4M'UGLQQ1+@OSN1U]$7[CS9-O7'JLN84R3-KJS1AF(ASF4N^(T[?'OZ(#_3=L[_#=< MA*X'5N+M=6L;2U9^GK'(=.FVE$Q"9E"FDGA=09&?:#%2Q&.%!C!PRSFE/SEI M=527:N^#!J&I@-:O^\&"'WIH[&U-OHM%,#H4%LYG-PI[0,WKE9BO7BM#,Z,F MGX6#E>Z9Z#Q,>"D*ZJ"OK2LD77[)ZI'7YAOND9G[86(1L6(O1_'R*OBOA56* M'N*]TF>,4^O:B^=NRKWH V4B/D[SEI%I&(G?+*2E3_VZ!JYZ^4PO\;S^Z(PK M69R2R"7Y489 @H2AB+\V]WS8:5Z$33Z(?,X3,\[*+C7J*^IC&=,V=-=?XK%C M7U2&O/68O,==+TE/"XWS%OAC^(9PZ3\%219]Q%^=:#60R/NS#J-JVZ1UL#?\ MZL]L7>K&362_& ^]>5_E"4*RX9*7TK-[ZG)>/6?M.'5+&++9$Y-Q3\H)XU?Y-F MZ^O$T;%6+A2,R74&^KXM%'$^1NR$.-;GOIH?T$0$_?Q4H:;/\Z;=A&/-^^;U M)]>NZLD/7"08YKR_2=E\/P%L0>26[L&[XM$O]H/1TS4M'=Z;&H+,=#OD_/SG M$A_%[8T?=K"_66-H>5'>TY!2GIW>J:W#J>X>'\.N?:5%P R_S5__I;_Q'QQ) M#0T3WBW$0R'8"4 $BGU$@3>*,_,"A)+;U]MRN([D>2,<+RX9[_^'PTYITCZG M66 4CA9=.FAY I!").GJ\R21#^H.F,V%ZW\9D-IP!9L;FB3Z7$TE\0C#Q#HJ M"/!]:*9*24FH03U>??,+1;L4X;?MPQI1!+I\ES0?NY;A@S5I/CB3S>),G5J^ M7I0!.[=V-25O'P_%LU(X#7(//JZH,'01 -CUWQK!XE68]"W"HNE( @W:SYE2 MS?$Z@/NX0BNNB O0G@!^;MHYD9W)]5525)'^"%]15&_GO,1!<^L[23L[_O@U M>IZ2RU\0$K%5MV;A<;UMYAAQ_J]F#3B;C2X#T4/[^[$)0HF#YC/S5-; &Q.V=52DEH9??'YKT[\7@]UK9^>+/ M1F;_'L2WZ\UU\0N-8Q.4-S.MXE0/Y![.ENLV[Z,&]9F$QK0>7A8^XV6)\R!4 M]H__PWJMT_"Q+^C;T('?(CP.=,^5X65VG#-DU\BJ?]A.;([!7_;GBLONF^QB M2[8K9)WQ+3H*X=>6>S3X +<(,4GJ/U 7=>"S3"FQQPT1 HQZMI)>S7&?U MN58_9-]KX)_HR7._G"",SMW!WY9]2>7/GF&JP_7UNT+RN M(^>9IWLHLHW.'/=/>H'?08?;R-+&P4= %5@R6=?$=)6?C$J$V'L0T93E3'-\]P1 B;_6M EQ MEHSY-%$HK'@6F;)<(45LM\#5XM(07E-B!G>VFA/D:EVNFM&+%WE7J$GV7E,< MR.3Z1&G=U3/,1&C)9$XLBOZF;)"FRJ&D;OU:LJV8$UT]K.$[SSB*5,TYY_W6 M2]N(]"@MRN;W*LNC@\3SWM[.B&@9RF&9Y4I3]G=K#+C.#6J M#_;*C7WXJV;FLO);NT#SE:)^;>2-.S+?.@3:<-;^4+^L-BE( M9>.<*PO"]&&?(:9O5'<%:RKS%F MO>^_;I(D)8S+[YP+DZY04F-011_'[>62:34M$>;"62*"/YN)1)>;*V,'V MN"<0!AGX\Q>B][B2A@V.K+X/[WZ!4HUT!2P$U+#_QY&0 ?'NX2IDKQ.;#$K0 MZMM"PP/W+EA45I@>@?J4O8EF6%S[>;'$>.\A0#N'(2!CE9#R:/KSV@MV\-;B MNU?,ONMNR:&K8.4M^5#$< ITN"9AWF=PD\;/HP>7/KG74U*BQLDXPO0HR\H( M? "U?E*,=Q>!KW_+^MK@T8*"S,<4*'89GL#R4STHG[YQ-:3H09CB^8"$L4G% MG,P<+D7 L"J&MEDY6EZ!5 [IZKF1=PH5O* AYD]\5>8D6B+C;XJ+K I'RK"/ M7$@9L?9U+_'M='+6)A)2SU*HL/CF$<5&<7&?%$$H:"O1<;)D1U::J>[")BFK0PY9??\/GM3A('/4C N6K;C;^^-BMQ$C>$^[!/$ MG3"W@_R.ZJ/(W2\N?!'CCK9&=Z5-PP64J/1?%+&-XD]4G\"?;;X]X39]- :. MQYDC&/PH2%REZWB76&A<#;JB>G;ZGZ%&M0ZZ[^]3WY*8;%%&RT"42,OS+,5* M^:.\R/$OZ2K_\^LLC+"\WNA,B9U6-+)JQV]7@D=N7K@-^B-%<8>!+_]9X!58 M+G_9"_+0RXX M"2_=D1D-92X_=FZ/"]:$(-]OJK$LBM]A$$+H _K*EE01N;ZD\XW8]>Z="F6' M;'6O-9G=JA)R@XH-V0Z>0N8GE^M!=6RO+LGP$Y'F+H=%T"0K+6)>28Y97["3ZYV;8#Y/@,0K@KP/PWKE,*WBE-RZT+0H@E" N53%/(Y>>[W7W/W@]GSK =S275ZS4;QUCQ^R MNQ$ - +2!$#LGMU%LAT@,;^G1U=- M/D6^+;37RSE8>Y!G'Q?67^U!RP-E'/(BH+;LZ8)%6RMF*GP]A&*T)S7 M12G>QD$'DF(WB _!*(C3S1P%4IMBS$'3SA5P8N=(L2"&7_K%7Y M=?YVP+-(ZDL"!>YS!(22W,'B<7KBIP ZN=?MH MHT@''^K;8'[%*U'TE!E\"_@COV6?FY.;F9L:77PISR'/)BXU.RF=-S@]-9W. M;NG-2RO#:+[T*/6R$K+"BQR$;/D?AEK=!77F5,1D!H#\N==75BTS/R/!>(O$ M"O-Z;)]Z\?,=)F$'9X>&K^3WAX68+NL//^7,#5.[-JAP]TG'/4*IQQ3LEQ'X MIKB(LDE=1=ONA-0P9#E2.ON';O1TB]NUK1AX+UN[. \Y&,XG95VSO6M^KS#Z M+"49@C!1_LJ%; M.$!UZ&99W=@E6_16?O)<7)SV3,!V2\<.6PN.S>V*E/5]:!$&N67:PQ:E]L%D]$?LQO!83&F\R1DJVU=8%%#R]D/6Y89_DRAGR ? C6NIVZUOGD'%DB M<72#*15XX/[:X%D9J\IC#-2#[CT#".C M:A>[7ID(#)\"JIP7$M255O99C;]2+[!TAEFAA2PH]B_=MLW^;-4=\5"1I 1Y M9@S>KK$0^>SZU71XGG>\DE> +$=)_ 4(K"KU>V\*:N$U9S8TUTCBWM<)=%Q M$-)*HK92@GF1+2J(<#/_M'(4EN1$[D;U&LOSZ$'AH-:^2R,>MR[^4_OT7^\' M24L9BL?1!@@&^+;<'@*'-:\Y/9BG94EXM+0%6W_G=@+@#" ^\)YH"_3>@S@[ MR9M:%E$9L-0@S+R?,QC$CLW/J&OO93/'L?'H2B:J/0R>04[;(7X=ZB6Y61F9 M0-S[$T *\<[QU#.O'!SWU' *<,%"?/)8R(EY<5B9Z$=.'E!;5]6Q*H3M]?:W4(CO*A'*"/$*#JL9NT!;$.:S!&YL(BA\Y\]3X M@F)&#)#6HK)'#<500CKEII(+M^BQ$L-(96BS&114X_S4>C+.X=@H4/^6?'D C>=#MF_#-@[>1>U>FP$NZF%C>:\NJ8@-)2:]?/1B M1TA21-(CB)"X^P/5?J0)1^U:%4R*ONYQ04?/4#]E>=R"W5M 4Q?:\MC>+]QS M[010ES8$P!@P/KCG,>4S&[/K1D"6T7^WQ^-OO>?QB(SDY:3%#'C!?3!35KYE*WLP/>0)-1^YPJ]NF^^W;@">]K&FS:O6@T>*R-Q7SJ>Q!G&.5@K&ZG0"N -/N'FN@';<=R-YZJ.[(3^X MY@&J=2,?6N3K=5_)U]2_OE+LIY/JY;'H+S$TN[?L9WCVN+77E9#Y%E[(-+=U MGCZWO(>S%XF#D_.&C/JB%+4A69(Y29R$MD=KJ:*I9=ZN+LQ"I>".$P#T\ 0 MQ,F.H#TD2EV8+]$GRFECD).3VGW%>)C#9"PWQGH(K>B1I)J 4WP<@N)_A3*G8L&#K2H@DO?K M9K3X"8 &I[>W[*NOH2/"J.VI-[BIKFYM;]6^CP-:G&^\SIFCGYU>=#"CD*ZN M\_7-0Q6:B9\RT/'-2:>I]#I6$@GO;BWZ@&_VNSFZ$/CC,3._]G4*U#HV+:#J MH#NB7.1SY Z#IMUB_4>M=UQ9 C226Y:C XZ,T9^[YDO1_H;6LHITL>E9[9:. M*]PF>8ZY I\C\R/+DJRXN7/R+NB.& MXHS>]9LW<7)FD-R2I"XLI% 4.'M1^N*J:\->Z[^FRSR0RGGQK,IE;,H/+G,W M^^OZ(PJ+%S8.AHKBL@+$X-P.*UL2$R+ZW!7S0M4+"-V-Z+8/S0.-5 8Q!V?T M^^.Z*V8V)QNR6ZN*&[X?+%WGL)B+MC7N\]FV(8(F-!Y,FS"CZF$NJ"YF$^!B MS>YDP?6)KJ0RJ1 !H_AB66627M^D[PNOM.L=DQZFVJ;@))ZUKO/D0*&R%N/. M/NY/2A>1K*@+WWH8[;:UVCB-8UC,\T4&+">!C/]&-\C3F'8KWM+O?KW-^R/. MI?[;=D0_XC@PQ<@^6EZG F,)K1I-$E.VR5%RKK7L^VI<=K4J[EQ7_=NDV[<0 M+5*0A0QLBC\&Y#,S)]RX?7#P]?61K$E9\$=.K8+P\9]JAV#D2'KZ6PJVUSZ/ MOT^[_Q$/_F=H0Z=!$P9(EVU^B(H_'ME5#E$-"%VA>X0MVCS."7ES)^T-#:Q4 M)JN6[V!14YIVA?;FP,@/);%^CO3SD4H,#R=4\'BP\_?R2$I-3X].)ZE56\K* MSTKB#W-(\GG,$.;[SMPJ^"5/1)QJ=I@266'FK9)SIY?F)O;> MUEY N!=IC\-TL7X;D;VF<.F/"(=)XF()GM4K,<\Z8L863@ )(=^UX)$9 MW1?Z#EW?3I7=CQY48[ZAZ.\MYZHSI,BA3/[@"EB^S)[+\\-8$]>#SP[<>!0R M:$V5:7W_H;<7H?^EE,@90X.S)@G)@+N$L6<6?L6%XP6C,I:CS+X1C-G-8WZ* M-AE-8I4BDNM >.0W 25=:;'=7D82QH)ZN[6[_)EC?E"/WV;>;[/A7.LHCQE. M .*42^P5#U/R^.P#K+ AG7,KIM?2,$XLR+7CUKJ;-SF&-,0&FBCH[IYM%1#9 M9:,&,A#.5_$O:H29 -[354?-3K#V0+*\3@!38G(KVGF-]]9$&;K%% HM:YM$ MQQ$N*[1ZW IY2,B-4!(V$6+R(D,S_%DMHOPS[.& =)T LA;0E-@:W/.]%B$A M)1>S /]'&_4VX]E9H;:IYHMJ)>4^P(^SX.4L M_7?;P]@$,/F7KL,#(3R^H$45E25&FC&@7%VN-_,Y:@WIET7=(4_VI'(L-U17 M4OE6JXK1DX:>+PL_JK9SZ@ZWSWM\X"2 $@=XH,4MW_#ES9;(-+3Y@ ]E]3@P MKVJN;>AI/C\'1+1,PIH,'#$C1?2B4(,^_+G3=*N&KJ+4.>/\CR8HH!LAKBBM)@P8-HQW U4Q MHM8;K)33Q]\.\3;D)]0(W(RS8-[/B1S 8ZS=7ZT7/)QP1 XY2KW++?+@F]U4[?6H=LR#CM#25U\6TYEMK:.F%&%9UFWA"W M14?=!T\M/71^4+3I".BI2XC^ ]Q;P%H!DM$?6##V M$B+2%R1R\J1KQ3*]* SJ?F;@62SP(BE>+XS=&OBM;^7\:ZH+\/PF_'?;_QZE M63Q%'#Z8H1:"8R-Q%W44I6,OZ<*D,FY;Q1I>LYY"@DW"FQUEZ?GDZWQ'I'PI&.N(11'FHNK;N*5' MH08+-YCF9-=@_>?.@P$$NSU/]?O3.:F-HTJL^SZ-//HE%6G]MNF#N(W57,) M!NF\F/9^LSAXI6&HET9K0,N>3[2.MU./QS""A\CVW%F._L/^2Y*=K^EWG]E/ MDX)H'4#?Y-I'-61780%R52)->OZDR+<[+>KM83X!6>Y)HQTA1?[7DU?6)%A- M_& PBKB7HZ6L:W((4+W?(UF6X!&AIC0:VA- Y@E V\,E*"[BRQ['O-6L#Q[X MX9V:@\16!3^5V8'58(T@_)/6^0DCYDO.9EF>M/&#ZZ*1;V_C,9ZX&$3[H/5X M_[BD*>U\W7).M<46L$(E1X5*#FJ&5RQ.UX\".T2SCQ%C-86O\A$0)D>VU?JN M%\.7"FS'HP;%;8T7DXA\^'+IG#-FTX:THQ\P%0K*<%@MK+_91; M 9W!\$WBAO9WYU%X3^PCQFVSH?>FL5)&O$\*Q2P5J1(==P6B]3$93N:&Z:?S M T2K+F9CT$+F?QTV6FT )<'M)/1. ,*],5+!U^Y[CJ^_]9UX3?0QSL1/6R@" M.=&D]:U[*;-Y0S(I\B+[4RZ@S =WI=X!)XE;E*$9?7*3'R _N'#F5GA3WAK3 M*@5<0JLX1CFZ.M< _>8^D]?>%38R:L]\3;/TB%*VT2_UAVPCY&]'K?S#!T7; M\&B6:=QY;+6D7FGZY *(!E9T MG;^CN_1$ONT)PO9A[YKA".T?QQ3*X9Y:'-R#W(%O:^,T3@";\3.$V_K0DF!L M>^'1$(*'C'=\YWYX>.-0](3:"F#QW^A6&S&.%C4<4@!*">FZ\@;R]=W:7P=1T/\#_PM+WE\%'W&*]F; M;L^E2;5RVNF+L"M&(K/'[URE^Y3[.6HD.SRS/UWL6P!\( M@]34**":!';K=ASJ+VV/(UF@."SH]ON-_:1XOG+:'K^HNHJPO( M8FA63J2BBI[L#O0*W'&\=IA#Q&KM&<+/ZB M4;,0:!39;QO$:_8.7=:!SJA@'R_FJ([3^4F#OKZBOBX>2\?O]+=RYBX:1A!& M?&-R/HP_A+&XY("R18M%[. MJ>7LB/D<';59)WRP3>7]D+\Z@/>%TW[+1AA=P[L**(3F**C'%@VT';%YM2#5 M(11F'K"ZUI!6X:UM*LV[-LX]J)-<\=W%_Z'EX@49PM#< Z<_6_!'YM3W[18, M/3RM/#S)(M^3E)65L,>^+B4F]#KRW&I&8[9W1M-,6Z5_R>O_1\#E?Z>6>OW3FHOF[50Y/\&LWA"?[ M'*KMY&*E-YR[#^3H&Q^[O%<6O6(15Q0M*&S@'Y0;S,32,YV6G;Q6^E*V/93/ M:^/%L[!T@Q9#34&#(=$X0D#,]1^J_O_';MR;A&S3$ QW]6GIA16< 2.-AY(& MXY!G3I=6SE39R,6?C7,0NB1DS]S8L,$WWV#U-!6CZ&DQ3:[G#K9Q](GQ]ZUC M"&,W>O^ZF#P#\ZGW4B_]3N.H^Y.?[@:XZZOS MP46!T1NO8$(/(>V5'.0!DWW5JF6.BI M^ZK!OK; =Y9#P$1P(.[U[<\*7]Y]RK.+M;R>@7=<>B?')->[(5_7ZY]$E)D% MBKS_.C_RT#.TH&RX1$?ODJE8G-+[(8,;Z?G-E)_E""6EP-V;+WV%&H*:?H@4 M<,QOO:P/8'EM\Z&3O]^2CST]R\2:[1K7Y7NU"1.I%9087./N;K9#7F'.\RTK4E*X^[H+#/3IEPN&%E'*BQTCAA\! MCQ\$63O%U)T ZE@4IF8(68-JT#]S^8>=07?6N)5_X/3A7<%ODHR?1D-F)=H? M3$H?[8G+CJ\"^VOXYRP8I'SR^=RTF?SM=VZMLIWV@.7^/:HO^@":Y:W+."3> M+3_<#,6TK<#AS#X[K(Z'+*P"5@=*I>Y@[D.\G &<.D(?LCX:!%2+N8]]3 M1^BW80H0;:Q K[TX73?H??)64Q=Q; W@* ME-\NN*F3;RJ]C LC.?I]P[9698IVI0CC"+QN.;C^GT8IS#K" MF&;KP@;'[I)3FL )6(E^N5SX<')B;[9OY&N)Y.5M/: ]2UMA_Y',2V*F@8K5BH\ Y"T%0'B2$*C+99DOJ#:OB_ M!?96K$E>-H-KZ[3[N>\=]#,SXO6PO" 9IW("X*-LA2=-FMG;E EIE#0JZG\= M2GYSU8JV9*,PZ%GO2**WD0BX.MSSUKQB_%E)_XIU&S;*9RXZ4P&!WL:?!BYA M*(\LMU@GP5W[P7"0A7UK36J3^>9MJI E61/+ZF_NN9/I T">NW#L4W@%WQWZV]?\4@"C &T17 M[9H30%S&5A6CX?Y;5E3QYL[^SB*J81H.!"[5C.P^+&)EZ@KZ-PY\1N[\%Q!2%QAW-6<8- U=XMU&5/'98VEELK9%2=\4?%"Q+IR: M=IQ@CJ!0SNVQ?;9#7E/W?.OC]F>E(*V_L'AS6/\LE*-*O-LXDEU7[E"ANKBO&LW?$$-XF2CN M*M5XQC,0[U%W-H_Q9&V I@?DT:J+V!/%)-((?=D:WS[^K\>2G/%_JVPV##L![!:A42GV29_[ MO+P&QDW'[8;R]Z&ZGJ./"MET)J@K.BOO/X%M7G[5B2&,*_? &V0N8/3T:^PT M*%[V$H=)!'&GRZ>9%@;UW"^/*Z8-S"-W@C/"[#7N)>M4ZYW3,A L+(TG)$@G MFG[_ 3N$ 1^A3M83%MT[@D<#17?73@!ATWR-CPV#XS@?C6%'GWE^SO?.D36- MNX_\>@%_*#TN*E!.&A-N@/S6OTHE X1M0+4>W4)O;X64=MJ9!^YLSKOL?OBX M PUW0O%T=75 Z5(_:C*VW%=DC[ZYJBIXAF :&Y=E_Y[.H*U WYH"A#H'6;MI MZ! OIYP^.(/BF87+81_1YX/2TY-+C\J26')F[G0XWO\@KG1CZ(MSTE&$H$E6 MAZ-;WL8,)=WZ/J[.Y-:9/T7!GK*4,1M%5>/ ;S MZKNFQH?<& WM:K=K?&=A/YO%K%90 X-;%HUD=@/C<_4\XKA-@8> M6H??IW]$BONKM#TNRNB4CA"CD*<>]WARRD#%T/#CH=OV#%A86D^>ZX4+<\-PG:WSACE/DOT\6.M'LT'@ M-5>N^W8?! H(/<6^$9:R]1[MU@ :,.K8C$EY[X$ 88,V(E8]E,0NX7#%;5,U MB ?BH@9#"O!%K&"TZNH=&\L7P-%:*GC\[3;F>.S71E+/>96%<']LTV%_Q>H9 M\>OA:I -8'QX89+]]>'\M)PW<5DS:IP,&1$:E#F$L[7XBW_WOXT"S4N= $AH MNH==*)?EL%\*"CASPNRDTI,OAC^(YK*)=W;2A,"N6ST5+!?)C0NYPM@E3S)0 M?L50CQ9OK#3_<+PK>W?PSCL,?WW>L, :4.#W>H:7CA#OD?NG\1YJRB7G-[@] MD!!\B;*J$;D&JK<@QAD_:41]1<-S2\F MVMV*3I@X,!&+OG@5?YR!H;]"6?9R)P!2VC'<(]XOC1UOKNJ"._W?C*%-P3/6 M\83>W^\SCL!O%Y(L ]_U*B?5\0 ?I+Z(C+O7&I0Z_J RB&E209* MKG'0N]&Y*X"K,DKE2%^R=%;?7&TY[(G5?F80(U#F%1UQ<>!Z;U.6,^F+QM'[ M;GT37VLMGBTQWQQ'1*B\.>GB@-6TJ1?YLOR$:@%F/6T+VS\2'^@?6_YB JO%^O!S*QF<(K4V9B? MP#*5>.5M.>VQKJ#'M\O G/+Z,LR>Y)HRSE>LQ:#DFMSF@GDRXIK2_;'1?#\2 MB3C/DI2<\RM292NF9_(':YC>[7("@<,ZN6%28.>.:<_-QM)M$_:T1O4_I06EQ]+ M'VV7S_[2 M5MZ-@;54Y&KM4<6V0"_K,V=@5%TI[?Z%&?N'4;6-E6FE@]=2S7;F3XOLH7^6 MR9X H7C?"SZ]QKI$W%\I_H)O$@-/E[*XI-"MUZ]YO/7M@*=O^LKSK(G(2WR@ MZD./C^-<'S59D<:]X&F_+%[L#(.%\-I#EE*]^LK2CYEVS"?5WD3G"YY MER<;\^[F4!_7>S";M][$6(H*WJ!2XP4*6WM=?P)(V6P:SP9W*I9?Q\S[C;*) M7Q]MQOJN,S#=#^>6_)#*W!J;[D5]):)?G5KCO"M>)@VXWRM/,A0K-/JL6&YQ M]%MQY^7\QO7#^?HJ 0/*RE'^?83-R/+(U;YTV /B"E)*3GHH^_:K&3/\(C)_ MS9?,$90UK2.*;[$5B1:\*WA;/40(G#@?:1U6QVQXQ9HK@BQ_6[VTER2ZD*3D M*L=IO?"\LTP[>$;*R&D#J^'0LE$$#YY*&-E1O%T8X,ZL&9/A*BX6H]_IZYNU MK[P6L:^G1/B=CRQ_5G:\= ^-*9OR&N^!A,CDVH!UD0[=RUN=Y:5U2T7S%D** MGL*VLG)0/X;HN/,6G.*W9^.=%G,^W$ZP<[M"UJ&2)X,'7Y9_EQU%> #;7'#' MMI6Q=I*BWW@:O5Q$[I .^'U7'()SWAQR%HL:V;^Q790>6>A^(;O=;A M(-2DP0!-^CR?&F5^-5^1\*YR+RE.<.?\SQ=C2:O2V<)\*II1WQ=*AV^.S._< M.1K3RXZL#2Y+7,PIR"C(B;4*,QZ/OO^D0_6TP[;MGS_G_R>7JH 3W;_FO2:W M*(1M.5AS7(B#S!'[N(QQ4$I*#^YOM'2Z'K*]U9?7%:NDZ:XRY'QW(S'SR?N. M0F,\)MB6_8./$ B?%<$<8XC1G/[7\_.2U,H8C>BF&,]6J]J"SCKU8-;);E/3 MQCV7CBH>#7[]2L$2;/0^()S2N]08:)A-D9; MEP7W^Y5B+^[ODSKGMS)XZ'"G8U1W:A=NKWQTTX=TCG)J!/_%XKR@TA*V[ZG7_Z:;F$K;7@@D[M@ZNQ51\^ MQLE>OIPH_^X. 1LD_=8IYW_;JFBTQ18]NR3@#NE&HL-&1BN(_-A84K:/'V.TA'*]J!G_^S'*"1 MJ88D3=Y'5MIS*%H$<"9O.IQFGRN:\#^>_%UWX[?9I?&[2%:SN$.^7?TK$3G1 MY>PQA_$[$JSR:A87#P75E%Y]4K2;YOLU5RV^=V[TRHBT>K*-F773&TUV;R'A:, MSK_._8H@S,^_A.G0C\>:8V/DU?#X$+W-? =W;HM'V+QQJ(GU16>:)H;/QZHOQEHNK1PNT9:<$BX!58M M\5#+#L;XZ".Z5I.44N3QM^4SR?2?AWS1/W1A*ZAK6RZU%C!98O4.WB-0R4$9 M9]_,UT./ZN_M1S[S.,[)G#1@\M8*$!SS&H?!@N9DRJ9/\=9[?W@.! ^DWYT M? ^:_I)4RZ+%8S"B8WA%L225*5P]R?X.H0.D_9@'D&AKY>":;.#D?0]7&O3> M,ADD_ 10M%XF?202>C1!BJ,![WS\ 5NVQZI,)7)43Z.5IXM&/N[V%)"9U;GH M?HU$&"?=28A/*I>K9,\H(JDRGOO:U1IW(+=@WGI_QSF:991A]/AF$V6W'6@B MM<;U>"EU,*(SW@OLXU5=X F3V\#,7="L[WH\H"Q]MNFY55@.=_$''T^8:XU$ ML>B_( KU;*(3#D!'%NCEG<"77#.^Z@%]G4[OG?)=R:H;2W,RD/Y )9G$^'4D MGU=Z5Z:948PN(%H&O^^W'AT_QKA+?/B8BZ$I ;4ZC@Z%3+/&G !R$5XSVF.) M'CT8:>\7E"(\/[K]5Q$##VNN \4&*HC2A=9B"M__&]&CYDE$[;;8RM.121/4 MIN4^KN6=5'N#1-70A%NA58B/Q%7?0(KP:Q8ZSX;CKB[AAB::YJ=4*)-KH>ML M'HQ+Z^L^KK'>LL\^O(IC!+:T0TGD23M -V8:(;K?HSB4J+G9XBNQ8*OL]3$Z7:M3.=&WNV7@3;9-D.F=>7NIH*?D?,;[ M'9^9K<\0>)F,SN.SCM:HQS\5\%]1=N"PA//"ZJ[><;R:?J/^L. V*C(PI,5M(\Z5DT7N:SLDKP&3XZ=D,S/HT<^"'R=T8ZF ;W%+K>P4K6[\T M.D.24+RC=OA[D_)?FVN[=7_=?,Z/LD**$U25/KDHN4_^P M)E-TJ]9HT>*5!/8?-(Z$-]A3'BK'M1)(NYO.'7L3IZ1=6"UG/NBOI-W!NJL7 M,WS]_D+:S>.[(M_7URJ0NZ.N/FGSG%5_. MP!Q=&^JB)J^-L<>U?,[U=]'29@I?C=2X-?;JM&/A"/KI=JL_5@$M-&-!7\?# MRK+W_T[FQ'#:!ONB> ! O,'41G.$V_WZ@45J-6EFKDF:_K[=A8N'MLY]ZB,[>YK=*& MB>4+J[#(0-?Y@MOUED/:*-NV[[L$NK73\?\I3M)G[?]$X^M50_PW#B"B-J"+ M,@U5Y0;*P^;6NT157KWC<9FF[]S0#4%#9JO1N4VD23$J1N:U^0-W;70>&W,K MU38+X;5K^00@OKZ( ^.UB6Z7;+JC=M5-CE3VP0F 0I]R2OG%_K%4W?9+UYJ0 M[C.^(K%%(=VV9.Q#2FT 0@+O B'!T(%7[.B&8&_0;LZ*^=>#=8DCP577#U); M;27=US.OL91T[8.GI%H$[;4*_1A;BN_]?)!V%FE]6M^G^&L!/R(F\"93K [O M]5$>$^1VE1!N4OV-'V\).=1E!U]32=%MY.1 M$]!Q#[_197^$32> 10UM735L,3QNF/L1C=ZP'O;"H;>VOJ8N39.NMBYE:V1M MI!UOL)()1Q(?;8$ H./+&V%"J'?WGX8:A$\ @O"U.%F-$\ <'"6,PQ2=S@]Z M*_=[+LN_RCOHN6*OQT")GX&N:\=NMU#&M^#:5BD2D2VPQ9TW672V7D"BZ M-GI\%&U%HT?[%!IMI%?**Z(RYTQ]5!R#H3="&^4E;QQ7,\.G4W)C5)=$[X]G M>7Z]KHM#Y>!NI/A7\C$T^X5"R$>-JE"S _FAN-2A^[Z,ZYM-6:FRVH,XUDWX MG$R>#)D@0N;&=GD Y(!UVP)ZB+$/49"R;=4(NR0;U[,WQDVJ=Q MA+?R"" PVZTO>/S0HS S^H>?5E,&TKNU-Z?-ZHARY2_)LV/)9A1L_Z"?M3R# M'I(V/Q_OM2$7V; X;#Y?2=KH6NA=1>G1JEQV2","3BM0ZG$^"JVHB0Q_\60Q M[W,NF\-E@X9")V!N66WTMQVI:MR=*8D)Z=8E?LJV/7H48[17K_M=(N\%H9DW M35XE<5.5_)9>%@,)E+??Z,1PN^6==QL=-'KBF@(;GZ2S.9#MAC[('D#461#5 M>XTHB9G"SM>(>-3X&ZI=W.&7KC"T,_%D%G([1,DVB7E?SMQF:%ZE9XVZPNQ? MZ7[U:PTA40#LE)JR$9IWK8N;\) +-N:R6WCT^E6'G7U4:NS,],_DOWLN5H@G M_)9""B5;2^N$>9[1S]2/^<']%\C6T\\H5E3A%.4>V@#5TMDOR%0RAE/V5MW( M,7.TOV$V&W$-//89LN/!M3!C7KU,X3I1HSYH-+R1'%N9KL]KWM5.TF>37-*NI8*.#ASBIHLW*P+BS,BP4+<>W3B(I@8S89 MS2=4;BP5JO&NRP"]CCJ M_B3B%?+^D>?KF1, TN^YL&:Y?D8IMLKK)0(B@^/Y82K'KX^RZ9[6:U8HJYR[J!YB!8 M/,9""#>!->V/J\RYXW=59=TW0D=XBS)=.+UIU+ P MWX8C?;0?EGG5X1U7=ILGJAD.]K,494KWC(51B.9754A%^CS+B[.W7\CO.6XN MNEHD0M>79J@ ]MR(S/FOU>\!Y 10[Y#P< MNJ3-AKTMKB:M1?_78BU$L=G'9 MD:JI:5BX1\HEDKZ!N;UZT%657_C34HD:CSC:A5X'M^A1': M(#_* !R.M7\BF-+YPU%*6BVKZ<3@A![3G\H2\7.1YPJ8V'W,5"C_2] M];-6O22Z91NBLR9,KM!\7UJ/,V=Z]2[MV#?&7:G54^_6_#0;^7Z ]G5[_9 CVVZQ' IL]6TA*RDE0 M1B1BK2&$0!0^ZY[.3P@6NUQ,XU2K[48CA*,+A=R:+50!WTQPG.+ M&H>%W MN-/O69T)&R,LLH,@DWG(5A@P!&N+CL!&KO%]WM5;_3"0/S*C@TD-#5,>/U_Q[SM,-C M ASBSV#'X''[GE:>U$URW>"(:@-3JXB%*V;QE0??I].BWI9]2T_EGRITY3M7 MUEQH:/**4(\\J?&+RO$ C1Q1J<%=QC:L)N0EY<- 6(>-[O)WH=*UW_UX1\V" MF>'2&N0+/O:B-JD&9C>][A469N:I@>C EF*/G1DI>X(AO6E&'!NV-LN:.9Y% M5\F_3T^&?.$VMY0MT-TIONY[N*P'&YP29NOV70N>P4H:Z,H-3L_=_>D,@U/$ M#E'N+:^&.T:PZD"(Z@/,"-NX#7 M(9U9*>=R(@/B3@#O6 :K?\H['0OD$:%9QCD[ M,Q(@S)**O'T8)_#C]QR@&Y_2HT=D)_'/+V8BO?!^K+9VA]Q>P;:W&]9WZBZ5 M[-KA.H3S#-,.7W[^ZO&^X8>N68^*2-N".^0#B>HJ'"N:JGNZI&<#IXK:IF1^8IMKYNU=]I[3E M.O_Y>S.3\7214V)KS5,7QD-C7(BH#2C."!(]FG;?FX+?9:5Y%7A<"C@!?'<< ML3ANOJMX-(M*7\Q=-'_HYQ&S00U266&+FG7%\!^Y)>E5MM-*$F/>^!Z9_Y/8 M$"@ V?QZ],)SN;G4-;I\FI$+(&^B[/%72%*)AN.4F[W#/2< =N;WWMZ[9)/7 MMEECCNGVO6TWLYU=&JD^-.OM0^+5,XCKO-@T1'21#1L #IQJ8 L"[U\AW.H" M^C-P D0K.N:?W,/@C>2I#XD)%V&0"]A3FUN'D5&$WUY"[6;9TU-.^ZFIN:G MZEPZJVH;$5LC3:!G_F$N B-\\7C"-@/GA;VUP:E[T.<9TA'P&B&^\> -GXB9 M8\5!E9&(AAY';E;43Z2;QZ"BY"7+4;+WM4&;^*].@Z/;O%YY)Q"#TFAL.]&T*ICO4N680:1.<25*PL&UN0,)?IM!+7F6-&J MR=^@6%S5RDP3)9D96)L.&A6S28GE/_\0-6U<5*[UQ/M-UL.GMQ_8\]P%.)J; M_03B35Y?7[_N_/7<[>HC.[N?(GL5>P9B'MN%!GL5'E%HSP;54__TJ=2BQ_%*X*=W=Y!. $/Y?(.7\:=CJ7N.?#]H*"N]MYYT 8";> MRSB\E;/'^[^2_X^YMPZ+F*$'F/K-\/[VOMQG[W/.][K./M?[_C>YGO6LYU[W M_;GKLW Z9+4^\^N/5J__6PYM^2IA81(BZC-4C($:W29 M5WBPI]?4O;,.#9]J>)WHZ&:MBL[_5B06<$<[WHS ];(P]KVE4S2(]ISIJZ[^ M/,C7U7)3.@>J1T+-*LY<,L@I"I._TAP?'AH;OLM/;;.PXRX^8/#5D890^9Y[ M5/:A3*0L*FVG/ :B+N4RH*,%NE'CS,*3FG7SJ$A];Y>@QWQGA> .Y4>$F'+? M*(F%OW +U/P!*^IBL*$2$;-?%\T:8RR7HQ*DI!TLJXVHV+([;F.Z!:4_9D[Z MNZO?'T(/_\LL3T>(0(#@['T!@M@V)9@G&G-9I&02 =:7ZS!\5 P7^QZ"%$-G MC ,_S8@GV.H+K V6[;RP<&=0/FNAK'!!!Z)PEER^//3;2-4*N-M"T S)19JN M\WE"\B5@_C!O+6C^O;N>5FKEZV=UISPC]7W[PD^L^^MR/GK:6H52(M,ZO@'. MFF!'L+FX3V+/S@P1 ==YYL7DUKYD<%HRSU]7F;'PFC9(\;@R0;$K7W)/5//+ M]21R;E:.?/M^H/V'XBS!+_D M&Z27GLJ,P T&.^5K&@R+^J-1O2])0QQ2_YX^97%#X+KNM!,!#40 N9),+I)T M1_V_H_[1)<)E3R+ 46G_(A$0<-(,BMY<)U>E&1,!OZU]D-BV.6GM,X@ P1X< M2<7',^,N&H>1%__8K_*&_03E-\7>!+U![),6^080T[%&CO8PT/PK%[L/2CZC MP;*8;#KHB(!**&;*D7R>B,^M7XOB="5QR1O@K] $]-;$9R7_=&$B0-SOKO79 M_.LQ@@[A\^/TL4HOOO0&Y*DHOA59\V^XX&!!QE/@WRYZVCS$(RW@^<^$ZZD> MZ2':!K=CN6C3(MOH7Q?29]]\?>HF%F-(F9WUC=''E/!P-WHGHC7\<,639:-M M4'I@W-ADTY,]KA%+X;/DEJJP0%*2G'$/S1UR0(9/UKOPW^&1'D)M-!N2_&NL MD#%'M2GY[:)1QQ^#QF,-8KB%,-,.YM".SUN1A.2!6SV:#J$;*WIR;$%[E><4 M'M+?XY;0[U4VOT="2GC?M?"W%3T-Z=TRX %" QZ#!=L7+1/&]EW+4^)V8"0X M5DBN:II P)16[WDPX*$SS#8?7;T=\9PK"S]7C:2I:M[>7 MF\56NKF +1.6>NF;B/75;D1,1/O#3;U%C#;J4X8LIRBS&4D2OQ!:HZQ=TP/M MT%7CU+92MS A=*$D,]%QN[]Q+G+ 3;2WE#D(%:&YL35OTT#@O< M%@N\(M42&4NFFZYML&^Y2"7XV?)JEK6>YPE :M[]>4B:Y\])K;3=B3"% CU, M#J36V-T)/>656FA$DN LY AI8AHCP=>KS"0?(1_US2N;(\^> M!&,0#5.O=S7K(4'PZAO/TT-2(ZZSE,BXJS41NO4G)Z7D_N4I,E*>^;- MACHF@5V8 \^U@UM/@K+\5.V9FI-/RK(Z#^Q,J>"_:3 4E\L)MIV1+=:7B+7B M>:$IBW4@%S^[_*/.^2_@(1HBP%\2K3,&;*-8K.GK+M9#/6&*'M-?'K,[E>/0 ML\62O7GPG#(F=J/$H=284[#D^^+=L%Q]!7*,@8PE"[,B<"PG+40G";K2^=6V M-D\DDAL/DL;BE93@ 3G,5=\<"+DKTOD*M XBV:M?TKO-M]QB+SHX"]LWI=XB MP9$)V*\WJ GK"31G:B:H$0&=DN 0 VXB(!!G/^V-;J*%E B>S_,ZWRTB]_RZ M]<6^YETC%#64%JG5-8H22&QR >D"506_M.NT7.(67-8 M>XEJ!]RM95MEI;:Z4* T:X\(T,,5?V[6Y(IC*6?-R?@.T0/KG"J3^D!O6U4@ M7?HA_FU_[3DU]N_BG,_(VKSGX3^-TO81 82+LEL9JK.;J0O6#9V+6EWO5]1Z M)FH[BK.Y%[0T\!THE4?[?&UAC4WSO$[>[AZ[RWFP7F%MU$V(V'M*TF3=?SWZ MY'_]:+2C:ALH=!:4R"@*W*X]2*<3M/D\)<+(5L=9+G6.I6YQ?W=()SXNTN9' MYN/"2MVRVR7Q9V6OCXV%DCRB+([?0E3]P(V(=0)6[*#1S&VUBU5Y@IE>LN7I MXR#K,YH?Y\>3,FY]?'#6X4;;<.C-2^/23ME,12])ER["X/@*O1-H7B,N'LZT MF541#+IJ<;H9N\EU*ZCZ^F 1(>IO/XD Q=BRI\V0PU8S1G(5_]'A,2MZI T3 M/3KWYL=(1UT;UH'#S:*:3'9/='80PU6P+XG MA(_VY"N.]!O?=J M3ET*T1 M\]9NAZ7%[//DYZW[AX.@46=PN;E(043'R8,7"X(BEW3F!4TI9&[JC0QURL;F ME)3^G#'1UM%6N@]H$]X2$J,@-_"G+OWGP:+_E\8<4V[3)?Q@SP 1T-6R,"W( M;3/;!$[J*<.":32$S45:.:SM&0NKMG>%]P!2M-AN!(=R[M;.NA\8Q;5XS8=O MW&R^\2X18'\,V%T+84%A:\Z-C*_G/% (I013'%OXT;[\&==I1K^]LYJ2S;RR M]NJ%5]N9Z^)>.YEIT2L$1'EQ,/%E6A\R[B!EHQ=[*,L@>SR>P[9<, MS:SXZ IUQ$D8]BJ3*['KR)5"'>1-7 MX$?:(J76&[#,:@X68\S$!$6PM/68XY8G=SAV5'W W&Y+I*O@/C=&_F;?LZ"O M)?,Q!GZOP0OX!DSL$.V:'7<8#2'^A2)6CGX;N3B!UEH''_9YS]9L#>7Y,34Y MB0V/J6OXQ:Z5!86^FJ!,YH-/G&[[.?0&*X%D_#/W9+\"@?;B.$\-P;G77L(V M92=)>M!0R&%8(YA" ?35765,K;X@B_/:?F9NO:.]9E$1VZV'=OH?O9,+?!SF M[XO+78KHRFDYH$,NG\265JJL,;M7W@O13L,N8B 2Y8*]$T%K?7:+5Y[?.?4S MUC&K5ZS(^*3Q)9J1FS,_P7Z9NL,2:_<("+3"=-EN[<."71B23-1Z Y//DK_* M""$Y0UJ$7;27U_"7$483C%IN80%;+991':'?X8U1C4.^ B/14\)=R$'WN W@ M##0?5:^787 8W@4MK'[J6\OQK'!L> VQD82J(B!]V*>\5U-NS!_S36Y.^0XP(H(XA814+')*@,Z35G\_.428@S3_N\7'(3(-C$_5I3-RA2=M'4.!9 MWG2U"Q?7G>+*.X[7GI#-L,E?'B)N3_):3U]:_3G*W&WX%-4#MT'T0A^ZMSR/ MOW+OD^;9BO'4%=.O;B$)KO[Z)",6JAU&?9E3?6',@MQSG/T@^K$Y%IW&Q:\93JZDUQ[&1I#Z%EW MPM;QDZ^7?U3@T4_RN'/6-$H146)->8D#;T5KR#V37[A#C![A =4.A),]S%%]PG6B!^3&-T$E# M$&3.=L,3Q^?#/K[B+%XU9NY]H5[D&R6YIK@P=&;;AV"8N'1@Z#.UUA-6N=MN MY86R#9@QID(X7ZA(P@_0AY?D5Q3(VY:GIV9D3R8ZK2Q^7Z+4:+FT*#!T@@WK M_FJ&A G_\KR0HY*2:%AD89]I-W/.GH.C1G&UW7R/H5O052<6YM^!/;TO^)%)4!;*,D+!QK>%"V+MV4 ML>FFUWC^\U2*CN<\2(;?UVVO/O:DX#?:NX-RYSN"QSG'=2ZVANL+^^N1!%KM MM]4QUL-Q:$$SGT E"E\:ABBFOG*6SJYT WBJ4.?ABX>,7PU%?C_W^#GN@R#X MUHUC6/]1RM(5\M7'SA"N,M=1QILN?!L>W)5090(NG-_OU(1& M];YGAQ4%2L M0LO?O_GN9*!#:!0\ %;T$<@;YS0YJK)*4BFG3XZNE!$!T>'#/=PKCMT'%Z<3 MYQX6G!C>N]"R%E8K\M_G]VP,A^!1$@ M7<-V9X;P M$I$Q"N%&P&FV\^Z*K6K@'?S)DL5/R*3-6B5<_*#*GFN?W@%&\Q M=\"SI_JDT;7^4-(,[]E*(CLG4#X@3ITF@ C G:]U(2,2(N!?0A(NJ$P)W5?8 M:YB(X-?Q8,ZM:SW!4!9G6KH7[]G2\U-7UA>TE#4NWGS%>KDY#WXRDOQ/_YE? MT:5WFK0H&7\ ,S)$P+Y>)LE+"*]'A]2@U9% MA]0D.>B;B]Q _$@J#PNX3_\X_%K>YU@^YFT?"?!M6-M/EFTMPC-&:]@4O\?F M@87SF/Y0/CA68_6*Q_=7>[:O6@^B#VS!2D0 B.1/(D5Y6>M7%!^3WMFRR!B? M64N;[<\),/V\E]M>2^U@FNY/67$3FD^.5:W7#@4^.&.]XB KUCMSZ&T5J%#1 MKY4>QC!" 9I&WE^82U-/S62>2B,"P.LE7/VCTTGV)#?R=-.!C!O(UXV_:8V@T/(:U54S MT6 YH,IK+EY-7[B\REWBZJHA>6L+Q1@TY**F9WCQ[5LJ"@T*O\=U&V#6(I803O249D5CX]IYHT025O\>DA9#;G M!?//.W9/*"I'*H$%?'^.NFR['JR/!T\2 <(R*GNL0M>7A8R_U3R_ZU(::+,W M/-*F6+97TQB:$^^&HOX0\KH]KO_Z2\J?!(S+KG=M4\NLC3Y-$2,/[B5RU0XU MVVX=*1VT(*,7Z3HYL>;6PYG.)?W]3.BK U7>UVG'/=Z?SI1C9=[W5TWP6B-E.\.IZ(-D$]ZC*]@4&7ZNXU%F+HL(TAP.L4* MNIXID7_XQ'L89M+[ZQ.GE5BH6O$5^,A,[KR$34*\M'R4Z;+O*+5O[=TMK]T= M1X)^K14AJ.X83F>LAV9B"#0XJKK^_F5FN+Y@$HS/U&H^>\FT<%)+%S42C,:G ML4RB.TB:3KED0FYI]@30#@-;G/)IP:]6%AZN8((6US=$LP(V^7)N#%Y;>S F MK] 6-7GW@"G"O32\&/M?!#"+4"+@S-/5YGJ?O7WXY(6!_>=8_KF$M;8TC9M* M-3.Z;AG[K;J#E7=Y'=2_^G6T/!BW>940=R? M_U10-#XZ2 M[^-0W'D$'7E)X'\XWTL1O&^8L4?+3$.X"FF9M)$LG$]>FYZQ6\AF,AO!F\9\ MNQ%!'5$:O8[H-TG29+[M:9\<&T72(CZ31]F)#P0Y>KHJ]($,] Z.0LLWN]7' MW%+6D#-6T+C1 =)1T+O\34M52H6Z[>Q&:WN[!_=C\G+48Z'K M$OG^=9B"YH)M7U3'5'6TS;!OHS*5PI3#9)0/L0E\F)2+CZ7:H!LG<\ M-G,AL.6Q2]*'333+V0OO"I"G[T>APZ.],H_O2'\);?[.^2&!->)%KX6EIT4F MW6T0R83+TKE^T*;3$189'*+5*=.YK*FK,=3 )J+#IB,<=DY.1%6J/5I6@[)5 MHZ_>ZJDL@)Q'5?A'&9$'SLYX@#83%V#-II%WE5E-ER7K#J/+)DD8\<^$@%33&3$HT/Q MV]K8S>S+S^!K&YQ(#O5G=W["WM1116[VS#\NX'X*$2#10]JCVS?(>Q3-C$<) MDD-[G,RDH=>RZT2@<] 5!'Z_FAQ&-/T]0F1Z#[ION-I# M4$7%S7R!X: <&B-T?O77<]Q*:TYH-HY#K?,=%RYS)JFDY3X$0U!EX-\(%UV@ M<>R$Q!PBX*/8MX*V$(,O]/0+Z&9\G\:LK;_-\MVI;Z5(9VW-?-8B;57E]RU- MO)!ZQ;7 MJZ@_L@EP3"MHC^+#%+G"=;EO1XF%Z1F6DI8O@QRB.SH3+S$_IOK, 1ONS/>" MJ#$^_U')806#1TT3Q=[5I?"-D9NO*7+$,;YW*CND-6N_OA+MYZ!V(V%;N>W M271T*P-&R/V/J7_H;AA''W!+(K;>$XS>K74K-*#"[AN$7HA+!_(MUM%O9GA=@A]O7=/,WI0^ M@\@=3LK0?M]8FN#+]KI8'6RQ'(O*2XDN6=7%5E?W5EY5434' #ZY:YVQ-'%B3+$&/EBG.AL\L6E3GFC<=D/N>\W$ MB6K*3T[AH/GZB(V!O$_87/3MCN2"BCCA\+VFH(.V,[F%>"T;T,)(SXT/A.2? M-B?L1AZ['8B[IJ9#,ZMO+9M9C;!3']3ZHIKVD9$G*_W0!0^<\-Y< MEK/'\RZSSWH28&C$#!3D(*80B^YO#W&\BE_"8PZGQ\SZUFN2N+G2#^GQ#H29 MB;,2XOZ'WJ]-,W>( "^9<994\;25\>M^G[;72X#6\A<1:DYMWO2D-U(1RJE^ M 7>"4>=Z>I.:AHT'2BVY*JL:O!W6E]Z%=N]LC-31L%%9R=\NT1\:_>GBZM2F MH%VEKPB2S-:\]GH]OS'676-*#I_F>,UGV8,9_NK 5;9[,KO"!<..\HFNI5Y/ M3'\WW/W\M"PWW25.8#C[[407L^X5:9-_US MAZGU"N0IG2@CT<4FS85EF3F19QLZ+2#=;.%'JR$ZEG:"D2@/>++DQTMS+/I3 M#VF*0G:W*;H8*JN< P5-MPKVDIG0%=.J#H('IV]%IGHQB[ IZOYHE[TF?:>V MMN_J[\RUYW$!:XTKX?ZHY,EG889YAX50<(X3YX-2W77?PIA.=2W*2&/6J(** M*/%(Z@KXBPHQ>!E\A%G12F0$BV('CYYF/%=;OJ#5(S-G;_3Q& MD:IWO'(]_ MLL><6],IZCS]A!" JM=!<(?40 ?O=@?KMBI+A_" I")O26O3?*P!0VD;:WAC MZ25%]J5IJ<'+6BV%>9S?&U^+O]0?! !H 6J[#K[>[< 9:"O^,+#0#IG*CT42 >0W^5>1 MKV*( %/O@2&5-WE6;9BJ8T-G8'>^7L;['M8EJ<-,BLM>>D^=_CD@AY<(V;J, MJO=R;6C#>AE _%K:W.*L(3WZ9@\KK(LQB[VC'I$WXEGO2<]\%PN M8D!;!(B",LU4O"IPO#0EPP'1V"NFP-52559_7*\$?8#+V-9E]JU7^S9-?A"^ MP3?K"9,QSG(9&70_%]2RCI/GH0C*" ^]_+:Y=TX@QNF<@*;%9EFQ1I^6//#B M-U7JE(AEZ7GNG)2W1IRTS$^1"Y?VMI:<:A)?U#AC7-K[)9EX44WQ$9W%K#L+ MJ"GV/YG>91@1<+<0>Q/TR92 M66"2?-H@]?H1G:NTWI"WEAAM$<_[$JTFP_%=@0-:@S0]Y:BW_%48PXQ_++;X MVZF/MJ=( S:CH973IAUQ^;/9EH0S%7ZJ8!]_!HB+319A>\%+F2(P._I"0&\2Z:H0LZ &5)DMM-2Q>A^^B34OYYA0 M5-C++ZM*M'EZ#CBNM-6A_$,<+R/ZS+(B2O$JN;H@[1_1BBD-_Z)_\4E](D 0 M"JL^P?U\>;D"T8F(&NU4N= B=_;A\:2F&K:)K290Q+/4M/#4TWQ2H<=M-DYL M?M!,)Y.J:_T67B&9X2C? WPOP35)$EXSS;^3/ M36?G2?GCZ"L"*B2+S[L>OBX?]"YT]?J="] ,"D/@ZY0/WI) 5OTS($:!W(L_ M=/\W.1K'$"["21[PBTGH?A9C!Q%0"U<_BKVX_ZE1C1/174K>,2+>0= M0X8H(2<;B0 L-SC,=!]V""8"_.Y,DI_CU&\U7,/O3#>^\@7B%#X3CN]! _4P M#^'83#-\R\3J)C3--[X$0Q.((LSZR$!W]');YJ#\X8<#+3;DPIK^WR[NW+"0 M6W3/1]?E^NV&J ;++.?1@V3Q1?WV%M+D,&]G<];G'S,ED3_DD M?V96Q[?I'0J\.%&YM6_;NEJLSQS.?-UI?SZ\)*#\^;)8H/[/ZH 6)O7Z]S]W]/E"L^G;K MFWL: Q,/JJ7,1-0U!_,EG]EF"N1%-J]E@A8 :/UMO:S ZJD0N1Z/ZXY986DVP[?"*?=OGS^LJG!XZ< M6A[!_CH90U@W12JHM6?AP[9R[N_=TBOZT0:X82$.:P\'!ZX9. MQ @&!4X=N9 M)! Z&!:1 M)G@+TW. VT-F7QLC[T#F+0L1LQY&5-EU ? Y,T>X(E$:GG^.% M@?:8AN6]: W:ZEUS4F*<>K#H V8XZ(&RC;AK\9>$<<^]B?,1G_UB:84(,(>+ M?5,U23QETGMM(L5ALDA?W"I)">A7?$DY#[P,']J?1-"S>\K@/VB"FL2@:U:!1Q0#UC%PUCI@3(,#3A";:13MRSFU2OOYU>XS@%2 M]F,7IUH26TOO91<:GO>^#NDQ^=T]_PQ,#K2!IIHN#(V++W/7];"-5R<^W743 MO._K#+TX>1=5L\!]YH+?MLT:[ITJ-,VQT?ED48NXD0<];8@,UW5UOV>9!,', MO![LJZVL17!-W0#DMEWY.)\C>M+SW(5$#Y+'F/ZUTC^PD^9.V2T#W^_SY^N" M=$%JI:>/D0^5V?<>CA)W78X>*3![A0=6@]&%F MOBVCJQ%-#\*=J0_QAAS!O(H!& M1?C#*D\'GN0O>F.JO'8:%(=RH&Q,&=)P7+.7@"V7JAIS/KWSWK1ET+"LBJ@) M=7[%D,9YZL\1OI8"+'J#5^:Z+-84VV-GM&H;-,88C8B \FM$0-C%X5N^^YZM MSG%3"+^+=8E3O0_A+0FVA_%ZS:9)#IH_F5R[>49Z72;[1KJ7_KKF[F^ABB1_ MD ?&\63F:A5!HX'FJ.:,<+?EZ9UEQ_YPO+D\U%.F%E&8<^\+N'[OA70@IAO^CJ?N;,V^F@J#] M)]T8 A^N14;<_IJMU,X$_VS&>'=WL/%B2#1_K3>L\G9.>M1+>2HZLR:')Z>3 M.DI5S_89:]_D)UFL3V0,.-U P@AGO-=\U&0"Z<((1DGN"A'-&@,6RURW#N@K M*;7+M%^DB_!)W=\]?5O\9IB.(XA5C%/1A)]*U-#\S=BTUIW(QT_,F0TI6$BX0.NWYV@4A^-H M\$VN)+@@.K9?4&=S 8/<+1,O=]!^*"X-'QB3A.>I92&S!8G]6TC$201(^C'L1O3T!">-;?)7_!@HE_2V'C);$7H_D"^O;.5X M>-VLT]Z89-_"TM[*6%@ZKODR*5V+;]1A__3M[G.V#_3D(G2.UG#_M<+0I)5Q M(H"Q.I!*='*M.W'&\,U3\%FC;,$&G-8Q4[Z;K3_9DSEO("@2T_613D.V==SC MU$'6[S[.:_J.5)WXL\BZ$"XUC)6ZB6VI[9<^-! >NG>GN,<]T$!/N],SE@'D M"@YK>!D@\N3)\WX&QX&I:X=R_<^^9@YV&Y44DI#W^?\+'$=')4W*T-EG]!<< M80NRQ6*/M(MK%9[X-*[Z=O ]#0]%<6UZ%M2@^,)T5#BR+'-H(9Y\ X_Z%4YD M>)H%Q[O*D^.4!_:_NA#OH.WDLHXW"X$N@QC=E6;%D)YYB9[/7MMLE)7!0OTZ M'7U)5,/&5Z\XE&BI6^308UM PROO+[27JBIQ^US2UI%RT!*KPLB-)R>G%*10 M*SUFS\G)2>#VLK7U2+8-"0E.L@@X=2OLB>*S6'GJG,^E H SY&NC(<.2$DQ5 M2,=:Y*K+]6S@CW"\HS%KSY_?V2>D$8=;\'U0+CLC>%YPT1RS,KI M;RL\>L*\4=*5+#JS_7PLOBD@66"4^;P$%")5)*U 5V% M\]UAK@\,I(ZSN/63( M*^BZ,W; ,SGAZ/G-A!*B-?=$FUD]_-@\.?5H\B^=B=5/P%E9SU%1])8EX6D\ M=7S.S?#4M/.G33[>B\RC;12V+#GJ;G'X!0>H_=IQ='Y)BJ;*%58XA)M*A!W33XBC2BMD[$ M0<,D>];XV>&1IV/ZZ^2H=/A$(")R= Y2=#&0]ZK*>HHZ9R&T0]I#%\NT!@9E MN6NTODFIZ?2]TM64I63VNWGQ84,NC^!=5U9Q$;+G?')+&8IK7)S_&FDXE,-2=N&&;E0;6:A$L MGL<&W/EQ:!?O@'@UZG<_P:_OX8CI 8L/0T.'H=_^J?RI3X()GD(I</O,/W[*&U(^L*[*4<#@0 M"6V2+E.0CZSU3'3QZI]#KK)+M2B"[C((5,[<,26@IU+=A4/4FK'TKW )@6N%^A.8 MFKT.O"O^W90;]C%.%6MO.BT:0V?!EU,<)4+!EE%A,Z>S'=E[<+XNU&31I,[C M]W*H?#WHK(IOUN ^?Z@QCZ*ZTKSSU*OQ>ZNF7#KO9K,VJD$VVM?D&@/,DKHX M+1R8!*EV*SYNPQPE^=:/S1GT+-P'?I^"1& +/?49&Q(.YJPZ7XSK-P[^G!.. MNWJ\3GLC/XS*SJC_=55"7NHV2O3F[LBN7TDP\ O&).D24V4@IF;7B=^H)O 0 MAH%Y9>IN*IAL,:]"IZ%S=7BUVKGS-99 DOF#8U#E<[OUB-I=+2XD_>.32W@X M%B5]F)PD:IK')[9#1EY]T7EGB8!![.B!:X?BH'O4]-K)^!5):;_NB@PBX&W' MSC;HTX'D%G7%QYQ>\PJHFD-"%VO>>FPNS!L<8K[X[1SG]_5%@.W0XI):9,[# M>663%?2I'W0GER9G?IA42N.7I):I(GB]O2FT:^#T[SI69K,J*L#)A9?6/+74 M>+14*Z1;IYPE_W*+_IT1I5S0$F2H?7'G8K6%:P7X M)');A*1^FO^1V'@(0-(EJ8CU)N9[B*TQQ/Y=@@Q9>\^?^=-U8="-$!@6$N<' MG2,9+M(B410VD9?% ?N'0(D(]#O<'8$I/.AUZSZ)TH7N6 T84Y5(/2BX$:V MP1Z/+I$9FPU^^',,T4^3V, V]39%W?7Q9Q)8S%OZMXB#_$$X<&MMAF88VGGR MQXQYJ@UA#H?8'ZFVK )Q*YZ80:G&QV2_?LYEG9&5E9F5F?Y\/IA5/E:4)\N$ M;!FP'__4P_27EUHJ)D%"28+QA5EW,1!4B.EK?8D6FKW9E;F-O:7?1*!2X-IX M2'C\&F_J]Q*E9QT.-;XF$WDY'UO.*HDV^$ M#]S22ZD0[&,5T>'7GX"7N54A7D"_'4MZRJ8-Z)]VX40;0\_"Y@7Y'Q>ZVX_.%.1<"/,CYM"9]*P MT,,W_7R*POC7J=N>]B^*:RZNIU^2BMF3:-LZ.0UND&)8EL5L:; MY-J#/Q^#+0+402]/! ;3+Q*C#Q;Z:2ZZIF8DK/3MD)/P\/,P\.C/(JC;L@*3!F298TC=K MO5Q)\ &X6>@0V3\ZO]+/!6V!81#[,Q6M*_;.K@N4:^G&UW*YSN:E!>AJO6A7 MN/GFX##"E67/M=CHXL,/TKY\P%C3]D<'OANEZ=7.U;J5AFQ1(#*5R!\ M#G=XT()MPYK[IF/B/!?$6?I*RH@ +2M9N4/EA(Y+A5EO8^$<=!Y/7L$I%Q.%#@M4KG/Y0]EU/8K+UG\H@K8F\Z M1Z+@V]W.R:H:&7:61CIS)F=8RW2"Q!SG$#0VE0A@0M8!IS8[F(?0U?D%RQT9 MODNN-34BBS]=EG!H)EU%WD3NHE!PS,?P61* M3M.0?.%@3 Z_VFF)>3;@%G!_!*'NM0N^7(!KP0&G?9&/=Y'3'$8^^7A?U)M\ MCZ07@LQ(PC9Z=#5#[>M53,W.P&.)QOYC:"]?+_M6Z)TB*3CFJ835)QIX5B$? MHA$[RLCA28Z@'##N%![>(!@S2FOH/7KN4OO-L-*[4"J,7MX66"?2%C&NDZJ3 M()>+3*KU?S$,>--43]GY*==NIYI7A];SM MA(A!GR6\J _0E0*26,"'3ESA& M+,I8)>T-\F62(-T(/K&HR1"_R1^&<<57]2/_,B[J"B("/NKAWW-T\^.TB( H M(@"[@#E*X5\C6YA2]'SF$36;$6+_*R,CF9J-A[QO[/Y$/4T>^+8WOX6%)+! MC AXLACR3LQL+6FHN*1I5N240&(IE>G+0K[C72H#6>FMTKV*U\V:TX_(Y:FD M]BYS5+C$)\$3,FQYNV6/V!*7$R^'!_E(B=%26>;GW?9RJ M1P__YVPOM%6I6X60A<.YW)*BX+D&>SS\S?AHT([B7 M&,BI(@(*J&2JU&\S/Q?-#%7$-_9E*+?2DZNG2>>#)Z\-B#PMMWI((':Y\/UF %5+35+X5V>W!;68&A_)R^H"@-*_G<@9/D3 M]"XXR!"T!&N@B01>%GO=UZ0XF02.__94<*AL1>?*R,P@$R_&$$T7W->A6.:. MXF",/&;?S15R7,3T**5V;J8,P_1]*C'5',V@JDOA;E_;E#CNG4EEQ$+WU;@% M+J@C[K/(7O1HJY&[N%+BGEFTLB#RH;D"V7*J_<&V!2 V J7'=VMM<,VBMQ*> MA3J@86&2Y5SCR4DV<[[(EZA/PM%RVJFHC 3(*'6)_%++I6;_>U'DX[# @?^7 M"J/_+M;HH\[G2MP[4R",Q;H05B(V$V3&79JVMO]IY^^AY] M7\,FO&_K.N2BVH5VG>^T9%*C@3\\\_^L:+G/A7#U],@26Y\IP%NKOE/4VAX3 M:)H0N=AW<:T+5H2Y]BIDD$\F)V)'-+J/\'^@<#4A;K7?J M)!"7CFEF[3"^.<8L5!UHEZ,3([Q!75>^C%^9:Z9*T.14=MQ:S[8 .F\=/BXE M81_#9_]R]Y2[DZED'45-&87!"=5*12# 3[QC<(F6QM M<"O]DGWZB[X3[[N+LV]<;R6-L,#\AWK):,(%3$D"HH8 W>-\H^G@F+F\'C,$ MM+N\GP@%G\-_>BRS4Y0,0YTT%/*(H4ULR@X2X".#7.X_-3JJ 6<-B0 &YB*9 M:SNP-BF=JY-6=1)NN&IOH'K.U;5#3+7 X$=[?\M^*CZ.0*B#-!QTXQ( ._)4 M=O:UU(S#G(&":XVY%W-Q,>$" I[W&9NW?6KBX#OZ:4P_#]982=H*SO:2"/@$ MX@*N*)A*Y[@?>D<8:>L5!!JT*;EB53D&)I1L>G.Z_W_L,I[5\\!;T<,U-35A M>.D0VER;M;4LY\"AU'Z][A,1 ,+,K..' A6&M_32C5EGU'PK%.1[:R4TM53K ME_ 16'1+1=#R,)>$UVLP&:.XLJ1>FU\9YX*R( ^81TA8IY(Y4SSCT(4(H".# M&1L.-8&.G<660R+ E 1G&J/SOR!FA8D +ODA%-/H?OQ7YSL?D\>_%UKMKO-N MC2*/9:[RJ.Y\YPX,-*.LF-+#+&/EO?J=J#>9;K,J]GUY"S MI#G@L+R2>G+K\B1-9<^NX=L1%NZM8F8K5> 'B4/O/?=8^DA\SL*TY@=7HU'[ MX4@EX&P'M<<2OJQI8GNYFO*QQ"(;)N=\ 7/O;D>[ M].J;7#L9A0(< HG=/6DR/%WK:D4$^.Y@5L^7%RZ-4/#7]D(T?W;NOFOU1>=< M!\P.7XF!DN0F'^VZDA&==^X6\(?T!*A0I72G8K6[KML-;;T[HKW^=N0KEM_' M037PS0F.>'E#MR7.%\(TK!ICXYPY=D/)C0;'Q)A-P1/?,4+I-5#Z(HV]:+4W M/B.=L5+I'9(1PBCY1+\)"^G!2HJ24PFZ@$_:_C=]5D8&1RSL<1PF]DFP(M&A MNZD3B?1V#G@8?(66.\2(?:RQW\Q)N_YVSC$J*EJ[IX"?KU">(2(!;/XRE.HG M1ZE.FM[!3J.].^F'%HF 2M':YL-5PV##_;0$^3FR#SL 1?)IYP@ N+X"7=.*D#13B%')7_( M?]H!W,AQ4+AKOE.X+7*P._QB %\@YH#[BLZHUQH7>5Y1X%*\C0U]GAMDL_+T M$M1-<-"_QBG-J_ S%3EAE/N'0A7SF7;FW(E*:(+"%@XY<')*8T'&<,?$4$3U M>03,?HUD6/RGO7/XIV,YFVOA\%5_5*/O@WM'1R@Y\O_5C?X7H$A@YK;O/ZCDV)J8L2@#QD5\N],DHC'44^O'B+.=+.]O8:/U=XYW M3!PK][0E33(PSU5#5\-R(?;ZSS -\P1159[,QR0\L?KOKW#4N1=)!%!G[@$B^ M://R.H/]AZ%3B/E\G0B'R>+OIICC.LJI;SC(3R3H=PSROTF=?(3%+A_P%=/8 MX)S1A&+:$MWDYA69H='7(=>05K%Y*'QH\L1<+&=Q7OQIUBS"K2^ZQ]E9QT[9 M'64Q_M2-7,%"!+S-LP>B,[>_[A='Q2;99AVB'=SW<'DAC\T2;LTN^S6,?VP/ MINQO[BN_XNVFJ7HYI14I;+-R'%5'0@40W[\OZI$#Q?&:YJMA"!JN]"7B'Q%J M/CDK^40 ;U_*E? (H5=K)EE17):.F/@^(/ZP2:Z2 M%C]D^NXP[M%!]LCJ9D)8Z1;0&GS=XASP@]F,M-5#_U=3!G)WPQ60E<=CV-IT MAP&GH1 4W.%?UIW8)!$!9RRF-7JA_-!07^A\F*T8J-/'9%U[<\AS/F-TBF?B M8_!.YYNUV"2.F8TX19K(F>:^UY<>D+->G_X0L7Q'VK)!YX)(B).!X.'F/B$? MZ(XQU;1_J'\I2%DP%;>+[39 M^6@EQF(_Q9K)QX.)T<>5-2.W15?'8HNV7%AD1T2H;[A/5Y:/SYC1F#>?2I5/ M1W@U6FMPH(N>-6CU^K4+]UDFQ7E4.8*0!;I:N52N-U,!LB<^OZE_+?X&.?!! M$B]=,BI-G;1*+SY!&/K">-HA+5]"JU^5?. H 1OA M)LTTTNVV9[??.)DEIP2D3'[D M9CC##'YB))TTZ*Z!"WE%#CI(]JQ?M#N>_CQNZ>SOX1/D?KP8[?I)C MNKW2!NR#4+85T?PH>,^55=G M!E:-&BN#!:%GBUK[6NN,&!_/]O)M \N)@%YP(R(27T[:8F#CXBKK(B%Q11&; MHRI5&OG=F1%H2FAM]RUJV,Q\"K3T- M#]=1A7>V1U]_3>&,EGK>M#+K'3:\@!U0( MM<8C.([M+S1..,($=HGE@6U%3TM7XE>L3/F"O*W8Y-#[@LXQ;;5E6:5EY\1P ME7SQKY1S^HDO=?R-4I\YBIEQ,6=2Q^(().AP#GJG*!J-[)D9 IISC*[#U'XB MIA\^^^SS@ ZH\6(,QW;K AR&#/$*._3M8'SQUV35?^LQ8;\/')F)XR[- ?;% M;></Q^Y[F-I7RYS3X8(R'%K;N\>&NC0Y!>&5,,M+*W,WVVF M%6P6)#$)D\8R_A5&##<#-V((^7XM)#>408A?E4U7,JO"VLLM5H..X_E/);^T M*4,:&BT-5FJ?B_VH,*SL[=(2^?Z<6WQY+&1[U/*7A)9_8_Z%84 .1%O:P_M" MEA(L/*""9%!ONA$796#IG,W@E!+5^1APAAQY]KD@R>/>,VH(\X! @;-P?JUT*=ZEO:5..M/MH^IEL5_ILX?73#>")J>D M@9VP^$2'E/B<$L1UMVG'ZR,*$RT@.!9$):M%"W?B2+ 1$Y:7Y#(6J&V5 )/N MM]_P_Q(_S1$H. %^GTB#I\,L>4 " ]<1?2W@/9,&+)1T#RL^I@UE^[B2Y?+R\@+?D:I3OS+Q&KJ2!/*NV\U)6)=0.<973MA9$]+3H-;> MUC]4XZI9+NKMY!:G[.#%^<5@ K4RG_UMOL0]F6HGS>%RD8$K@C0%=2+@5Z'X M#P\YU]+#<2KDTKP@ MB!B\?*=3_DP,[T]^TEW.;MW#S_?CH15)F>8PJ/XM*Q MR=ZCKTYY?908^3 )>]] ]%=.FG:9YS[*L"2(5?B+@3@>> M+M$0**I9KTJ48)N2_.G1X&P."16.[L9WY$92WN\SDQP2=D8*E%UTZ[GM$8;./?E/I86?/^[5P' MUQ"9/6G@#_27*J0)0B =:X4+-#I5K,'1>'Y<#BJ\/D#O)"9[4URF:O7#9C%) MKEJTAJ->GDR32=TETPH9ZO[E3EF@P.W5\< ;88O0+=#SGYM=LB75#YTR6YEJ M=GBU^]?K?G@EM<1EM'Q_R7NMJW;TI%A0INSWEO K/R=!=4_P3$CN8Z-+^EAZ MCKT;$1T%,"QS)Q$P#'5T0V8ZZ,7VX7GKOOQ(X?-SN!IXZP"NPT>!EXY^+'68 ME+>P@DH 958,[G"4Q06"!OM]I7/#JBX_4>X/B#(TA&%F(FS%0W:@E$G!0U)51V=H>I5GUCHL\$#MK*H A:Q$Q976%1M ME!44'\/5EU-4%^C161-=N;#!MP/X7$LR:S$ TH1 ]%0@AD"0E*704SOK#"W@ M.8'C(?Q\K^5><-Z5>MQY6;NW)H+K2[_B)>#L0\920C@T3FUN_(6.;ZV[FUN$ MT6Z-#>VT1,7GYGEN+)#C-J4,N.RYUZ9-IIDECS:+B\V#TD]3P#>E91;O"G*Q MDA$X]X,=5 M8G=I=#=I3+8BD"2D &Z4=K5B'IG)\NI[OUO?A1Y<#0#!],>UT*Z,ZJT2]?TD M'#>XDA&=A>;?'_4>913LA]2XX]B7?HXB$8'8D3K!CWN9/3X!:Q*1P;F1 -OD MFM4!X_(BJSLJ0?1>.JC;T,>1E,\: ;YMN"3K'^OKK@UUUBV'.O4$KZJY0HS_ M]N8BOYO] ?NXJBX]U6NDQ@+$,\,&N#;E<#+I_)>0R.%&0A/^*?,_-3%_:PKF M?[*:L'U#/5THY4'I)DWESW1]LS7HNWM^-;$>P[1/V@EIZXQMRL4L#=MLC5NK<=MQ#GU*7*L+G;TE3%%ZC* MFDWY.I1M?"JSK/3"D%8P749 <7&MCMZI6,&TA\)9S?UD.HF=HO\R.EBNQM5. M!^83V'&?U^YNR;M=;?%#3K]^;)Z1K"UIF.]^Q\5(75?Q'$,__^B4YO_'W'O' M-;EEZ^.QH@(B"C8$5$"D2Q<0(B*]A%X%1)IT% *: #D61$""]"8@-?0.H4<% MI/=>0D=*Z"V!%'X)^9SYS_R)NQWO_O=>ZUGK?6LM0P,A];K M^2A4Q%IZRJ*.&) NJ!.B:^_ Q"I1T:437$+2%8&C1"I0-T/K6?:XC7!3;]6G*>>:Z;/UG\@%DN5HJ0#Q")*0"IQ/VWMU M $@)LZ1,E/+4J 5:U-R- X"T0!L=\5H&R>)UU.L\R?0 T)I2Y&/HY=!&^"UO^6SM!+->4,Z;HJH++JM.2.+0.'[B M4E$1OV"T&?)+Q_")_$[M%PDJY4_NF^Q(/*1D#*O] G0L45-L5&H7L4FSP M+SE^,D9)#$&]=["VFZ9[%7[&AC8MR](1I5)QI_7X=F9LEOCK1TPP4GH@3]TM M/<T/2[1XL+I%MC(+&>6Y_Z+4$V#?;@&7:TD&L.G$O@/ VL(2A7CM+?#S M1__G"41_TJY^UT@7S@WF$LOF^7J=4C1[+E_U)[@S!ZW/0)O53]D=27RVO#JT.)8GN6 _C7@Z/;H3 M\P3TSNZ-79<631KET:%_2)"JM4&MEZ[6!0L3OOH(@L,OY&PL"[PO)W;KAD3' MV EY^X[61"F+\J99":5I?7[^G!OQ]P.8J2V(*1ZP>.#,WQH>1+,%GUA>V1EQ#VN]&0^>4N; M_@U_B#*KDJD#@*^'EPII>QO5B(IE\KS8:[V?XMZ_C;#2T_X2Q..H\87QRDI( M1'.'[KT7[<4U&WJZ6D85F6-?[,0Y9*LG[/(NK^E:GXW$GU5+HB?)3=E;+YHL-_V"\WP_%E(-T03 B[\-MR!;$0$O M91)Z/[&\+0M=7]Q, "%DQA62%E0=!$#;/43@$%3_76KME&ILM" MO+SZC97.#DK-M78FH\\5IFI[L':^(L0F1D"^ VNID*R8D&7X--\%,VQQ[S/D MYU6@1NX._0=[R958X^NX-,/L+V#'Q/6,O+'SJ\$!IHRJ,HE3+YB)HQ+[3@:; M!P"6IB=E/MV)2C#0Z ' 8\OAN;29&=W)^4<8:3-JK=DKP?/W@5\@W]=6T7/Y MU"X_G-W"80ZBI>&VO74&"<_V<&7SQ/PV<.:2.I$.?VR92J/R71'XA@UK G M:^R^'I;3*K[M0*FH^A3?+^FN/* E2 GVL&.BHF&46%H-'F2R066V!:N=)W&M M]6%\.#OSJB>F2'CBS$2&Y.![R6D;((;B*F'"HZGTA,"^Z:R1Y-??B>^LZ4UO MBW]LAT+@W0ZC/VEGFT:D_(K$:SLP[2D/ATU'49[ZX\-0R\M!:45,@>YSBW=> M&#,ZG,LU",L+N/.RT,6YX4+[S8;+V<4 F9ZGDKR< M;\&F ACLV%UV,U))IMZ:^U09=UA9]Q4S]Q4=A@N\]0;Q!I9:NK@!+B%.YZG% M9_U& 1&:GP=MLBU"\Y)R/1-L+9NQXB.C:;DE'LWKR2>(;X+G&_-C93Q_9*^^ MG&?N_>0I@!5W0\7.^=I?:@CY=)WTP?[![4V]8TF>(_#7?U#R^T]+/SKTWQXA M&T20I:@VKT9T\=*ZU/.O#(]' MG_\\6BAFIIH_='E@HI$_-D_7NK MJXT@W"ZFE!5600'%<.FA.3/[Q8YK* :M@:8F261I);[8.#7W&.^TY(V2>QUM M7K=#(J,OOWE#<5*T_GZH[3JRYM)P\6N&":R%H]U7\O%)FR2D1T,FIP #$S9] M'WGQNM&X!T)D.B5_-N0)7,0J5-'&9O.V.7F91?_0'/[KGK+<*QQ\@_2Y0D N MO?-;-2@F"6('S41E,GH[Q//U5FO*+ ;Y]!B4YZ[PB=LE:?F84F60]<1ZRN^' MZC4@X[4&]7_^?4G_E+!94# (F!6*C00/),%.XY M%7O/8R4N%3D@$9\D(#@VP0HI2A'E8MC>WB#? G(S7_>X<'2_:E6%C0P&K?G[ MZK.8!0SYD=\.FUML^,T+6$+R*ZOF<\4,A+[I$'',T(\=07=R>+288-]5YF(5 M%2^>R=!K)2]!]>]K*?VO7 MJ/.9\QEX1]LGFIXN)G.L>M6)C1!@P7/#J][B1T'E:-P]>\,0)X-+URE]-P;S M_]%V^DNVM"19UQOM/EX6F#?9E**C5=73 LNT+,"+D\-T2I2>+#$C:HM*NNQC MU7F4R\715MJ 0CHA8"H)25Z61[_TRT/W3BOJ(!\0='#-W4%4H^)J7M!%'X2] M"WN8=Q5X\)%33<+C+=5K0JW3=[TE8^AC!Z^SD(&RNX7TWYF4NV[M$J+:PC;]1 W=V!EO]4R9_C;=G3"L"7'P MC^>9R\Z'1\Z,OER)J? \VXF^6UG-,C\24UTV,O;">)M^T&)KB'O_@YGY):/+ M-O3],YL,1?+7CP]W!>+]6HH$%1D>*[']D,3X1K1=\MA CY1#[;1,+[M:/[YB MZ/7^.CQ9EK-W]+Q X@,FB?*S"7:S^]#DA+>11;/N>)! ;Z)]BO/;R&)WHKIX M+P$XKEC*QI:RP+XHIP[L35SP[MMVH8D'?@52D,T&",R6<^L!%;D]^A,AQLUBS\ MWE]!S"QCRYEX:?C$-_;NTV+3L$]M SJ(/EG)1\=<+ZU&K55H%#=OG(J W9$* M_E&?D)QH59,]6A,_9U)K.*I"Y,6W[XST(-3:ZN8V4 M]K=(;,.FDC%Z^Q^+#P!!!X#!?0H(6X#'GP=_4@/>@^924(GLG0. GLNN&%E\ M0?LERZ/RGEB2LHF8BU:*W]0NU5-4\4#* M[:9)?B^^5T#LM)BI3"C+NCL5(LHG)E"">*F:XW_MQM@KA#%9'FV:_&*NFP.G M;A ?U< (<6(*R\8>;[%^,$_4T^J@R[+Z0Y](XFGR#^ZD_]:6%7__9I_Q$QIY M<)#,7;(\&][Z>W/[D^OP99&'\WW@ZIN26R M02*>/U$_KSAE_45G0$1#F?J.ZALH*X6V0A&X^V3C7ES,=138 GQF\RX1UP03 MJ(IZ$2]%U3&ZA7Y+J:UYL5039DG)Z^7=+;\D2VG99]S5) MCQ*E(3O7M_I=*(5,.0H,^\DOTF/CAP/$[47Z^:RKYN5IC*(,1K#CW4F1=WH4 MCCR6."S!%??OK"'\RX5K70U:# 4@!K>O]UQHNMH"*27JPD.Y+%TI)>K.M<@> M9Z(@)Z\S2!MJ?'ZE)_\(/K^6M+I*TT&]YL7JA$W\]EQ4A!6\.VX?C,0'(P=3 MFO8%G!0&R;KXSL_;H8M)](P!G^/FYMOOC7VT;YXAB2\3])A!D193G]L\/&3R MV:A\K1@VO1L4SD:4"@DC EITA=]1^!!7_I-8KX<+%AE%X"U^4C9 WT9Y8=6K#1.\EE,"JVB1U6]L>C4L(J1E]33Z5XY8_LBB4-?PM*C6(FR.S-_ MWY45LT3>Q:?&AX-*#P#ASK"[.DK+L*CX]NJ^/:NPIA(I\4S)+3._H(O48G4\ M2:J9O5G[T5F4+.G!/QV;A",)///)O5FPN%5HP:*=,;= J.F)WIIBWH57=E9M M*R.\*,79SQ^RLOBTM<$<' ];6R_H%HGO4=2__=1/MPSYU7#G]4IS$5IKC^^Z M]7GGGAS<<^ER28B^PAAE/P?E<7F,?)X$A[B,13G,+G6#@<$ZM!9AVHGDQ?V5 M^_4WV_/]X);;BM5JYP_?+7R1'8:M:488QHNO8T9F3X6>?I([$@?R^>'ATYT5 MH/)TYM5,HN-CKBM*@U_G9L4]R.9%U4]\<0TXA^D%;;+.P^I\X R)4.41\UO[ MBC8_GO#3LXV^A#>,=CD'#$>/!7AYC(GJG;>C^7'WO9Y-$65Z/_YX>C$H E?^ M5*"7%>G)%9_)T?*R%(Q+]%T(?*)!G<&Q1(08'YP013<6_2+52C^RTFMVV^1= M*OI;V:S>\2-IEAK61?NF]6TIV^E74:.N+O-R>SO=G54N=\]:SK*/\%^M@O=, MG]RY4VJ,KOV2E,RZI9CK82DF4_>!9T#AVX@Z!/P:A,"O8>M&GM^&G!MIUY1\ MB8A:7.EW?JM?[+Y'1AH)WMD*"[).8ER].R)CU%#7;3!-O(Q.Y_8\272UYDH# M)^@.:'N>B#W$"L^5>ZN%Q[^04E+#$)<19#%Z M@;2SFNJ>R;[X38*".EYAM25U0\&BY#/#NLNRI*AR42,M]0#0=0 H *[4#,3+ M%('9U>@&23QKNHO=G$;ZY@L3:\ -;.E0AUZL1\G2TNHV,UT 7]_,+!=@27JG9"DC MEYVR>QUSX6^;*OR[,F /V??">QU@>T_.S<\D"RF&7D4C;3(VD KT?++(KG1- M=[ZRUVYP5Q_]#EBA_UK27[A*X9/\C=Z9C]GO'B0-4FI$_")"5G@( 9(U$+\] MF0. ',J%ZEOME;$T;DUE%DPZ0)6#6S:J,66 ];[3?D>?B,^;VD_>@E^JUIY MM::_\._Y-O^\5M-9( (OE&RO@LG2T8R)*H\LJI4. /R2EC: #=VF'F]XSXIS M73?UUYORQW]SE);_07=%WOI84U,K^=];*(17U&M->':>LT*1G9,/@Y&;%/7YMNM+FJ4W&Z.H@\<@KI'$4JPX'QR,6^Y>W M$'%U6M3\&>B07#"[(:5N ^JG2IM+7/#;K^#.PI#T*KW^QV!9.W3\P_S8GY;T\-7>+M MC(R-Q%L^\I;/MKNZNRSQ@\C;&4\79PPS%Y\NBI,F7\?&G@H_ ;]\(TA/UY6! M4@OU,\_/2>+,U_VD*W>D8P@-V,>-=>POU ,WLIUK]8* 8UHR"YU8!95[7BH= MW!\D1$=HV7T9OE\-$?VH9D%QCS/]IQ0'^4N:,OGH4?\V!*NK?4"@7EY#6C.A MTJ%^%L3N=];*J.[OV)&XM[VY"0.#_.4I_M*K*3:WO MAKH"%DX$@\?+DL8QHL8)1^RG[1QN_U ),'[O?_STC011Z\G-PXSFZ(6\[@:LG]+VO/MD MFRWU*-%@L";%[TZ./WW#&C'M/3IZZ[Q*)[>"G5!SJB O51^EPU"2SM\S!F11 MSSW$Q!$0OU*HFU""FJ(^N'9OV3'K&>;[S+'KP$ M%4S41+R/.37?\E[F+>548V!_>*B2$W&:V*_8O2A"E3C)P,&B X24$6D7]]J9 M[NF-*3*ZIS_6V"<_/*H=]7WZI8*#A;*> :V('5N_U4:X5M;2]=>]);#W(>=&U>L0T1S[4&^FI!,E M8Y(0!"5I!JI+"Y%^;0Q/O!Y'$B?)8+M3M=TQ- /(>[ :Z :S !QD%C]%8:BN MK6,?2!J'NB^2#9>^0W;$>QFRQN]1V9ZY-E :U(AOPIHCT[B)&G#8!@H_1"G, MEBOI;;7DY4:40.&"(0@5_4-P, ,#LR$&S%)SR'^Z8/-QB!K-[?6P' QPOY&( MQ;."%[]R&CT\ $PKDN\H0]2@1!\2B1D'@+(#0!!T("%W&CR12,PF3E)"-VL@ MLPW)A4Y2'VP"5H9= N=?R+&![1P AA+W6%$ZAX8^I6,W5B/#:F'C ,"7[T_^ M4DS&>GM0WKOT8=6#*IFXXA*,A=%K2TFD;OF_4FJ"X5%]!!AWQI.<2 M5UV=:6MBG,1ND4A2L*_&R'VM,/P+NAAF.1\B-.Y2*'0RD'@H-$[C40YS90K+:"8!Z?-?XT>8 D5+MS2O M1_-*.)Y405P(\9=_*+)SQ#(GU?5>2,H0)$+]"UFJ29%OE,D0'J&WH]LG(M+/ M6%I:>JY'J[M'CD-=SU1/+9"\2J+WN+= 6O7[ M=]NT_KD9+"7D=?6MDL "W M8QR4:/S,/_N>-R>/'4>IE5W;#VNFMA;[0M)B;44<[RJ5R,?%]T$'Y429+IJU MC+JC/Q0?DWOQH"]OZ3Q@HOK8*X%5/THLYF\*V_ZW\]W]R6_RH A)WFY&YO\2K?4O!,O.D)A*[_;-"S58#G8=G9[5LW/+!+0(XU69 MZ:M>>=@.@SH&$F0WXCFBK$@^ZFT"WJ<6 M'\8%%_G(.-V*X,@0S8OC<=A->')WZ8850V'/]]&]#[P?K#Q?ROUV4)V<%".A.R24XW-U@Z'JO"_69]*\F3 MS_M:LPFC_"T=[YW5"UYS=EF?FX3U= 9D0\>>YW3'\UQ+BF \QTU&CCF_Q S6 M%59@>[&F$0< /TISMO% -HI@H/KYV(6=A%M;I+&(=;8# ,U9,HR;F!FAN$NJ M?F&M]M,? +Y%R-P%-@O,#F]N,0T]IIX'ML$.C5E6#&<[AG>9^ZMQ9B) M7HU1U$Z?"IC,^-#"+J[+37FX%[\4)[&"X3027PAXPVZ9OV&"&R]F;4*9 ME;1\G.8!P%/@P0'@%BP>'\\=>X8XW]>U#1>[G'ZNSP#IM9I;TW?%WE!9?Y,7 MZO#20%QA=;4@V]^/YIV/>WBI<4NGR@=,0#1IEUC2(2'%,Z2NW%,? M(A2?6VUY!P[UIEM56+O.ED%>[_OBX?#-,3N"Z$7OWQ[NG MXUQ/(BXJI07(<[$_5YC,_KZD=/WU*1GBP%=N^SN*YKWA.4G G+0=8^J$V/C2:7[R],W0TKYU'$0ZWF;;F M8W#1!\KZ;-Q.Y1M#66P2@A3G!G6E8^=?=7H%VE5J[&.?4KURP\PH 9@/[(8 MHWKR[D_>STK;58-$=3ZZT7\I8>!CV@?@EY\=H<(=.7 MX@YU$0OM50H_P[5S>WZBTO1:C:2#C/CB GVQ:I'E:+ MK-S>;^XK23@ D.5W+EG-.ZWI+LZ%92H#<11OQ SY4W]83BN0_,T+;);[0E1. M\F>3'0I9X8GT4OPCU0%9("X8&XQ[LS:BV)E]&K*V"JR''>: C/B,4RJ(3-L> M .Q9UU@WBLF_T!/:^= !S 22S_F,&58CRQI#K0'[0D>I> 9%2SJV#NP UV-= MWE%EDB2=)Z*D6AGZ\#.SIEI?'84-3L,1C+TFBAPBJ@: 9]>Z@O:J,W]D?A0J M4I0D\ !/"ZC,!IA/::D"6X1U?E04% M>2DOV+/L6A]_4\^*>)MUYJH_1XRAGKS8TUT>S#')?V[P_>D)(8>23Y4P69E/ MI#X B$S\H!HL["7&GY6:2_28=PU/ )[O<8K?J!4:Q3AH)^\M43>"D.)\W#R1 M)^4UYS3+?+%F2^44[RO9IHEB-&)O$OMT,4O>UFPOA;5MX>_O)?1FR'&WYFWJG_Q[M7@L!KI>W+Y7& MOR%42L[=TAR%VA BQDM%%DKMEZM:Q7MPW%>RF'-EA9*&(JA/J;;3VX&'K53) M,TDZY--B)LZ4*>X+X9PV>'))PT\/ -W8[V;OAEEMPC_.#(3A,_OC#([MMLJJ MM8,>%GB_"Z&Q2GULI_.8$BBU^8=*U,L2-G6?B7D?N]<*N^-%$YB4C9]&>AW) M>\D?'U_F,6'U?23K,>*C0[#'R1Z&[\@BX<\&+N#5S)\DP?XVV#>(Y_S^79([ M:RO6]L6GTK/'Z"(Z9F>?/BM_Y.1AN[?LFA_HZ0VQ_U\[]ZR!X"I2W%G4IP. #RUD^/@ F6&FN M@4*>PM#$ M"L,LC]WAI83(4?>>FR 0#=]-9VZU+)&/)84%>MK?'KJ#P*ME&_]9_(>!=-AZ M4?N'*L2>AF--R\?,Q%P?"_"M1?N0W6P1=PGO-V-,9Y,_-0O%ODO+R$'W=6P\ MD!,)45@!?Z# P3G$[R>!;_9Z/@1;*)X9E-OQ1]C+#3(+]^-I>JJ%=6K$L7)6 MCW>QHZ72:L5]][L. &=[M!4]M7G;E"BY$'*_5*S],R(-J7G[PU!HD9C"!J8& M_:!".A/ED3M4T\GO+ MU9WT%JQGT[5&*VNNZ8]7,!Y^BHY9U6!3VH>2AGPT^/RR#<8;\$AAS=O:NDH4 M=\F6_B_!5 ?@U&WS:^:?#P!A^=JK'WPO:*ZRAC$'#1\ KF^=:WNKRW$1)* Z M8"+:BAR(XBB4K+OR\97NPFE3Z$E;RGYI_N?>/M-\G+;YYG[4#\YO9VJGANX* M3'M/;%S[@1<^PLP(#..I@.0EPT^NM*=H%&9&9D&\-/@3I57/T?&&6<0FG!C4 MEZ.J"';9;V6]*F@TE4T72[I!,F])\+:B0P\F^MUVRUH17T-8HTN^]>.T(:2W M?EWVEA>N =C[AC1J;:E7!:7="^F,^K96BGN:VFDASUZ#$)4T+'"^])W%D2NP MQM&LOH7=<>?XI*C%SE)N-+.L>)3&QW:'H[ !8._HE\$4I;G%#J[:3ULD_.(: MFE<9:*M!KTX2D]GIJ0]#7,Z2^436\2A\-S994C_4 '%Y_@# BLO'NX I3H?T M1BT2< 4UK5C9BQC02&?_<@#XCII.V%%Q7_=)Y6WQ360.5FL4Q@9O )=/U*S&ZS9W?\71;0B[>\WLF?9-,'LL9J=BN!#+KD;ZBO55 W!:DSFXI=I'KWRJ:764$C.38!&^.=-YH32]K@BWIS M+5'^"N>NZUYO1MTXZ_.:+3,XK8TYB;+2!:0^4 M&;;O+BE-JX8Z5H=ZMVHE/WQ]MX'^/@!RY-5@Y^YBQ<2:2?SWC4J57F=/M^J> MIHD+S6R7/(%B3Y3Q$!T\2NG_"F',QAP SGQ;"L>XS*N/XU^?\AD/JY2<2:XR MCF4\Q\L]D[,>;QT:R^!+'[7F9FJGI\7UL218BS?8FY>2'9!+&3J_F'2!;4#( MPV^K$&>IL;TB)F!I56507'P^2_5Z2K#E-NKQW!WPV9LO2G+BZG".DC&O,\// MLVY3*E\\[OQ'^NW/;AX8C2+PZ4!I&K>X<'N%GS.VM)?S??%R'#J7(Q'JMUP\ ML>+@9B,-NUEJM2(Q)BIX>#-C6^#-;*;O1\F#9.2UCC)6C;Y8D8X)NG -OCHV MQ%=XGVN1(S]#M(*0QL\=+BNG\7"G^,K2H)HR)B0GA>)\S:^5IV5D$0H(9@I. M?P=_PZH*DI=3!%UM *DJ*I^755<_KG*TD>;<]ZRLNV< Y$?O^\BG%O7[/R$F1GOM2JMDR,FNE$3.Y\KF729FC1&OLG5(=D?/?_?+4.#)_>WN/ M-_7EPU3R"+F>__7L*7&$"O%>IZJ>_/$0=09;W4(I3LGYO]T2U(N^ =O75UNJG38\R&@5XQN M/64?8KW@([L:<%$^9#9,(' IMU_+-^V]/+O CYS6G'-)FPK'[G)T':4T)GZ7 M_PO;_L@!X/3;I;5MU+2Z'EZ1>'+M M@_?$0P?"L5D!?9JJYJ>O;+3&TIYX>*[Q++_T#O*V M03:>B1&4WK''Q;WK?=:CI$ R;>S(&TA ?B76N/KG:)0*Y X H392* ME0/AKD $,QVJ3)J9NGD:D>BS\R5U!8U\5/\Q6$NUU ,^G>8/6K+?I,KZ\G>K MI1R^KE9JTD6F32TIOSW$#,2$,=3X$UV#L_]0W/FR@"MO^_KP9%W6;NNX&M!@ M_<1?3VP(#86$NE]+Z;)SN'.=+,BR./_KI:4I- U7!19ZIG=A5I+@80)5X@,+ M7QS1^?YO7_&#GCE[Y=ZZP1$2X_^$$BQY M]P]/_O^[BX(G?SZ74&%+,C,70\H(/[5(3<;MC =%K)B]SWP=D]1@45@Z#!BM MRYX$^]NE9&#XOAIS3;XR4[Y$I?/\.E>XW5+ 59V8#&82, M-([:IA66"O=^$,(/23.9M/?F:'M+5^=JP">C_#0$6U<>(!4*U3&]'W1,M@X M5W^24">P1U&$W>!&^90A.IYD 9"4;2V=J1 H4@2! .?$J1A36! J_ZKT4+\F.D>R#Y9.P).R: M+O-==LSM#-8ITA!^("&'-<_G&8EUA;CO-S^PL[-VEXRW]WA(HFLCD G_007* M5VNDC;4^H$QI?M[)% )LE Z7C[)C-JC'+)"M[].=)/--+T=O/E]RL!S;3PEUIW-X@)\<_P:XEKI^;S7EX+*E;-CBR[9/4\/5MTXZJ-2S22 M=7IQ8=KC>#:\3&R7 T/]+T::_;DJWY 5PP,H8/I@C:2?/U0'@> M:0B(1AR(B#@!?,!N4*DHF/C]_N2< ^U8J7H&&=216%@"?]QX 4OC3<<2BX^H& MHDHIC$2+=\O!94K6FM$[ED,R+C2>"D(QRH-L1\CV_;T# -]*='P0H:Z6:OET MLE$F-K\M\0/4.)==Q?\&_MH:V#''R3V"6J59F\LB-<,S/(6'U[Z>WH'"'Y@E M_:%%$<-*X+.T. "<)%G"KD'/7+XG4C4_53OV55>H=T$EIZ-Q568"4IF>A?<3 M[H.=0K_ &=U38H,S2'ZJ.$UI%?/3=9X@MON\RG%^'1IVV?)1Y$2;I7#T;H1I MLO&RNB/C]CN]H.F0%$8&3 8/%]N"XB&&] JJ^90TAJ-AF6N(86(J=\6U_9!( MUS52/VL<<&9?CKN1O3#G74(2^(0-@'CZ&B5H/O-/'14.*90276LC_'"26CQ9 M%XJ:VY7+/' YF[' ET&RO!2)E*JVDSH&UE[0SM?"FMH.["ULGV3-UK&7MZ*4 MH53XQ9%4@?W"$A4WD_@UT2^>SNCAT'*^%L%ZD?9-8IK;RW?SH][/D,^JTB&O M 3IZ!N5)6;&F-W2:V>ST3,BOJKOR/\L#T6\+DZ@)0 <2T@\ T7DC\(L9"4 _ M]$JE'5?OZH=^QE&JQS\\YVBE[[G;[USH!QF5A=Q\?[2H28^IIY$RU(7@_QI* M7YWPR4-PV>5'!:&R[&LZO"B1^"DX& ^OA4/L[5L@U1I-RQ].[K9I]VOW5[MO M=?<]V=UN%BK+KF^W>.SM:7^JS M@G,8T9S="JO/YWC(+($&^0Y5#=6!S@EI]%5A64NXTQP8$4F(S(B2Y"HZ\MS, M?LXMB.Z;2\A>\'N@@(^H5^*WEPG9*5*(?.C5LG='Y6S*=L?'PAE-\IU:]'N\ M\Q9&IHN9Q5X7O;"/D^,Q\B//UXU84WXGKOC(&[2) Y=BW&A<'-V'LBPND*IX=Q7FL>H5 MSW_):<6+7^>9\[5VM^B%PKOW.&CV[I5I%-V_W*@J*ZO.7B0:%'*:LMN^X7\@ MF@B#K6M1K.PRH/G:11ZIS@K/ X"EMN; Y3;5-XKP MP$@9;KTJP2I6\&K@I9_AL=>HJ3L3%V;WM B3,E+]LX(3L&(?D<:X/?4J]&='39S,T2=L6<[LL5+M[8$Z\XBIC(_+:S,EU M5>9D\YY*V7C-0L;']\;9E,_'2*KH4CG7@D83'9WY0BJ0%]O0N$>1H^@X18G( M4:E$YQ]V')];)SW/GJSU,K.E#4^.UX;<@PNSJ;(+/YP4>7Y#FU^Z/I1-8>[: MN/YJ0^.WY.=GLQS;L((B*G->#N M0+]:P^V? 7$-,$=492Z,7*E\#@>KGM=(3T5UD0')7S@7@T1L[T2E9M$.'RUM@:4[P=CK!I2BQ$>&.MW;YCY!(^Z#7A0=E/XGF_%Q<(B9S/5=)7"*95 M-KW9%,9[I,-#O6#UDJ4AV0Q20W9VPX#K!CDN^'9\5T+/)LT;QX]GGZ./?;4I M70UFS0:#5,$6*<>O)%R7-77?M]#1T>GN_:JH>%RD)+R@05U55?V\+$@==)17 M4_8X/7/V7X,C5X'CVN**2DJE0?JIS)/DMA5OACQ%%@ MLW\.7 [Y_##"-]3R*YEGL.E$ AF?3 C4''HH*76H^A-A'$"RH-VF!,"7YM-'8&T"E5E)-FH=TSA\ M_Y#D:U_M2Z.&XSWHN'3&CQH/V[7%S9C?"W*]?WC*9O,.)>EPY-\/6W ]9%3F MY]FX_X#D#FL[)HUE==ME_AHX1 +5DFX@B)=W.IHP+L@M7/(&,1\+:I@LQ)NR M,*O/])'E@BW9V"-KJ$(4[!-R$_DKB_$NKI"BN0LQG MO MOC(R$G**OFF2U]>2EV*I%_]Q =#Y"4IIH:'7O(.;,\LCD*?-^0V$3T,Q 5^9 M&9Y_%Q3U9BT70PNW9CYGU&IS,S+0*Y;3T KJ3]\A+\KG7\HTKNH1RK$MNYZ; M6!S?4+)U@OK:.G9&?S$3C-=L-HU;K(G[V*33%JZV7:"G;0!BUWGHIZ:=PGF5 MT@LK)?Z?LS'!P/72M6A=)D1Y+3>!>?0*.%,#,2KU!B6E'Q"9T@HZN[RL1=9?HSE_HW+O4?Y>YFS:BQ/$ITEF6+S9.5.X3WE_JU*_ MX(C_ 'XFI?1#P0&@)[$Q#X>AU^BW+=RW+1&[G*9DDP%)7/-IZG!:0QI#[!YG MQ*>3V%+9G>'UPX;G#XD:M#\A6GX5Z<*EPN_[)$_4Z<7Y]*V9W0ZY2L_OL@> MIK@5C5[&A\HH-@@BDC8Z%+$J_0JSF[RQY]\2/'Z,/Z['!:O@*'>]$4D M38+W:C[V-JEZ7PJWG#"V;-C6(\L.U.2Q?^PG&1XZS7I *MG,\0 MJ\+M;65B ZXL%:YPW&LQEOCL'D+-8CK.=_A,VPX%\K\^D/,8?(*^OT[ED<&W>3T^H;IM$'KE[YI&LEJ/?VG%Z( M]&#ET"\]"O(Z"=R7?O29T\$B+KDZY5RTQ;D\]2K.>#/#WQ! I6-XAVD@,BN_ M_'G0R$5OGQ&HP034/F>,>M"-D3_4828)U=05EG& A9D,\^SD)7,FF5:2,WZ MF6+>+?UQ#L?_O)#+"IS2-&]Y;6S?DOA#IZOJ:0VS^7JU>,M*H6_JL>6E+^EU M*_ U1 H"WG[BZ?H3)!-'0-MM3 Q3Z\>,^^(B*\#-7B0K%X"D3I+;8]49 MDAXPIG-"+CZMTS&L8KEGM)+EA6NF?1%DIZ74MRB#&#JW\XD^H5B@DB4\"2,9 M*H&MC>!A[-1Y$D7P'F+Y\#B1&00';>PN.'](B)6UC,U M$%2!<-^U3K!52O&@DZ6).I]S)Z#I^V^P[+W]L_X283%E<)VAO(HP6(S3+O2N ML9&5"X?Y];O%A?9G2ZGQW$-\^ M@O]QQNV$XF,/9^/("/&SDRXW.1X\R=2/Y*9Y=%:T=X;KNF*_0*ABN!CF\BY> M#PD*#&35WP+.LEZ7G$JL9EEP)JVZ-72*.1N']I'B<]C[3$9OR%RS;-7*#'T@ MPV7:E-QU;'C%4\OSGT>R_VW5L@X]O>6H]6QXCEDC205UP\T?A!5%2Z$D>4HV M-FY_:,J)SRW;7^/18JE\^1XO73$$+I8P\*W60N4$-G*21V:G<-6\U5%33&C# M4:8]]57I+2U0.J*R5M^C8RLMV^+ZRX(X!\>=04-M':X7-Q00:>V.CH%YD>&G M;T%KUJY1JC'X_J-3\>RBV3.-*T_XM\=D!RRN\X(^S M-R[;Y_T8MSU]0AHLF2MMS7?KNBR#]N=>]J_[-%7[;PDR !K%H@;!:6X99\E,ASSEI'ARS;?Y:78%>@_K+Q34DG& M7:6.[OFX&QL\12KCZHA-=)ED;?G)\&7^3\N.VX$S3Z]FEB(-,_M"4QW2._)4 M&,C__"/FE[BZ !G<0,3G]Q4H!3Y:\:[>W_H. &<7L]!^LT9)GP3V>2?PG3D^ M8]7T#P+Z$M%T] ^HO^O(%4L6DVVG/-L_W&)'"9_W./M0=+7 762SS]:8ZXIS M[B(QY2.Z*H7]AUAVIHKF1\L[EU6,V-_/8L46VOIT9IZY/_VFTN:K>P>1><@E M93<7E='?%>@0B#"=WZPJY;09EQY&%8V6>;EFAN9%.3Y6#F0J+M/@3]93MOJV M[)0D*_<^F5\TUOAVJZD_)QGG_G6]'"=PBJ"&/:G O41G%E+SC%6B(T%UD7:B M\FF1CVAD9%P1WH).SXD7?!_,7:2__*D#D^V+TFZ&'W>C-*!8,OA/@Q!_F8B8 MUP<*(6*6$[H3/)K+N2^Q:M8Y!+/_6*=1,H&F7?LT>@!P+MGNZ00=K2-(*2FA MN^\7%0(HI^P8!=&/#)+H&PI[/6#B:M]?1NF @^OA\Q/T\:[\?OGH>+V!AI+V MXSW*+_"GH]34&3Z-%=Y?()&/IR;Q?[[G_V49SU]$R18SI2>PURF?H+W< A^G MY39AG1UL&VU1M/>>*.,5-1_.6LD41O^O5AQ9D!>A@2RC6WFHMWJ]*<:0)8*- M<6J4RPT6#-JN]^<:V0)Q*J@MIC2<*J'^MJ1E@5NV_\)$;$FY3,)8!&-_KOK[ MT9I2>7,]H-+JTI?--.Z52F[%099%4066)R9SY M)!$G6(4L@[QQK*G;3-.ME,8>U/)1%JNO![X]R7#S+3)B?52NCC*;;K ?!:,V#'S)ZJL\MITT,&+;WC?BJZ?> 0]1J\'^@&0CL4Y'FRA@]NS)+.CII9G=RN ME*@,#\6[BDH:A^YP<>PNV&\7WD)H:YMO8%T;T^S$M;7=B"ZKDV]Z?*,R>;1( M[+ :Z*[D"]4!"[)5>_TO+4=:;K'.D.HF,B#E87D/+(A.)#Q!&B]M4H^)%599 MO&:1&JJ@"Q?1]_1\SDA/+VMC8_F8BAV_"^F.OLU;?^+8K1IO&M@4<*)%S/P= MT17%57M_Y2MH$XHLV]9::2^.2N/ZN$ J;DD%J[Y)B'W,\J8 &?Z$:TOR2R*S M2J'EEW>@:6J15P4KMSJ F>6L,_QW@&\AWHC.7K_\1['X?BA.^OLX,/-1MNA+ M'I?HJ! ZIY5O?2]^^R!";R6G,7RY!%WWC:O(L_"2(?3_8=M0+CP\ .SYPH:/ M>DV3Q21PCZQE:LTAE.,T%4P^ ]DR)!48)=([UTJ)]'9/X,>>'!H;E7\XL('! MEN=2YW8O(0\6364JK])?08.JS]ML>9S1;>.9A6:2L[#QC.Q%Z"%"N535*SR( M-P/M+]U+?;U P>**%*[2KCK9F,& GX-9-TUP%Y#WZ.MD8-G"\2DZ-]_31(#& M3(-KH-JQ$'^[N6C5FS-(+WK^LDUVK53'S)3OM1BTZ3^,SQ_&GA5AHP$R;K"Y M8MBZ!<&;,NVF2__S ;QE*.T^@;L8?@)Y62CE*4E4Y@$47#]*2?;46EI:?,IE M[Y"=9;>0\33S1W9.3G:LI+VQBO'3$?N V%C_F!NO$TYI5E5]S/H<>I\B97'7 M/6ZM9DX0W]0BYRRB^]><9BJP8*V,=>+7S+&8RN6V'S"DTN36%0>-W#.96;L MPT-M",+)=[21I C=4G$>&J'>Z0TXHZ'2G$JY8AB8; MOW3=G#71-3ZC?-7>FR^)(A)?_2$@*?6G%-US]$0G-B-@\Q%@ 4-LH]R:_]F* MP0<&J_:U9;3IEV_!59N'5"JMGZ;\F I\JTB)P?_2*':_!?9-R7,>B]H3V)&9 MP+^+(U[T%/=9%F12%TD.P\%)61MWOB#7>!40^MNV)4(P?:LLG@LXU" M'3L-Q9;:[7,F0[.KEM:+G57,XI;,&E>,XZM QM$M'W: 9H[+':MQU"<5C.V; M-K:LV>JB+WJ\T_-/I='ZK8>,MP99IR<(/,@]D&>)^^6.\3:/^?K<09EH[NLK MN;Y&E;MJI:O-R?RDIC)]QZ22I8Q]GJT)Q] M$M^HFS50QJ9+V VD)YME+*/C:Q&-WT=D'Y6>1;=9\:SOT O[AE[-2(KDW*[, MIA#P4W[FZBY4$V+W+#?JII"&UE7!LP> YXYF49BVAZ+\;M!>T1,G%&SR(N.7 MX!?L)F>V;+$)/S+]Z4:G-W1+8\Y$3M]^=.A,C_3;VB7Y0.?W\M9:S#XO#HE? M,B&P8AZMMZS0)D71=SF/3Z#[7-N5+]GL@OD834U%V44$==59J$^%J;+(7#%+ M3IK-CN83J,0:C__B)<@P7_\(\A,B0$E&>F2QYGE1?!F+;%MM:]EE.*^NT5>Z M 19_5.-I!LZ3*9*XU,P.EHA5;XA+C=SG2.IXT,(+!E9B34Q^&?#_NGW+?\_D M%JK#TA)>37(T;S-QXA ?)D,\02F,6X]VNLVR)/435S57 M[]8+ EANEZ3\MO0%F@\VIF![]"B)GK[8!S\':Z_]NE[,7+@Q_\1QXFXLHQ+Y MMMZA%<74.D7$^ES@OF0?L])#^H]?HE0I(=?7?_,D_[OF+;^4M]."24[,8>4) M+:@H%XC7B\;I!0>H.;,_<]K&;F5.'?6,5/%C[8%9L;1KC+TA9\685^2DG4>R M,UQ;3YRT?\F7J4L)G?)?H?&1H_^85S^7X2 8HV9MK0'D"&K249?_V#A[.QUB MWW)U23(\(#FT*#3Y%MPP5>\%6J7@.#UY2AF4N&@S0]%77IVOO!\[:?QYA1^N M7"M49:(B_^P!BP2;ZYF"ZZ_Y*1)Y!TZ6R',P*32"T.PC/2EYK%H\@EF@(P\^ MLHVK692+S55Z'K]3N*[9JSE35>SL;_GN7L)S%<\ VG[E8\I\8NKJ'N\S'3[# M!L:>V(+3<.>$VOQ>=__ 9V'F\8R*E(2!@Q M*N?9,-(@C#V[#UI/G/3ALA@5U&7TBG1G]V>4YSA[7Y&\GLW\R1 2E@4!O\+^D8O_F@CQVCO/[V4][0=UQ6S.=T)472)#IVK+M M\,"WO))A+Q;M&%^-"^"5#XEPY3OX%*?9$.Z,+#U#7O_DAZ&70CE!8(<3R[1. MKCP7Z(87%)-83$])F,=@$S0FKO]@?J=S=LZY7Z?!\)J0)(G]F9[U%M7QJ6+81.%,_L7D-$0@=SW1S5S2ZQD40O=$7/'OUPY#A/-O?@33SW-4C$N3WP1^CP M8O_, B\.#4@_S$XO^KDSF+?1W@:>^T855I(>U]$V#ZK)U6:OX#V17-/NI[4 MN$QJ 1R^W#F<%VUC!&LD<:+KW)-L,;>C"-ZC6HO]4RY+^MB3\^JYH*O]9V:;R9Z^!#\_3I.3V2'^0G$?\_]@$_Q;@ M138$*MZ/,SFXKO!]56;VH7*?W!QU$Y<38@_1GQ9V9[S<%L&>R:W,U*BCJ+OP M-2+\W2S]H?U^QMNW6"C^&0K9:&9[\M- W3A3E(W-B103:[%:>R35QXL!]M&^ M60OFOJ'RI ]U8>3[C6&F!@U90G!!&Y9I;;1JD,"98"7P*P0XQNS3,DO1*)/. MEU;M3,W<2_]?==<9U?26[3.B(DI1*:*(T2LH'>E-0$2D$WI1 :6#@2!"D!HO M*(A I$B74!:$)"N]"(=I-<0(ET(A"9)()&\Q'EWULSSSSP5L*Y2AWFAP^K<^D.-)(^?1)_!$E]K$OF M.X;21 :N[[(4C :QEP7CVO0"K[Z7@]@Y:Z@F(68TB:I?A\U?=T13+&#&'3 : MV5Y>^&OXZ@?8-*5A+"ZP^@2VRV)Y"EGKMB@^,$#UVPJC2CXK'GQ\Q]U?<%WR RGDM?/(L[YT. M>BNX0NY5T/(ERJBB;'(B<(P*Z&58O*W$KG;><_Z]4F2U'.B^>QWXE*FF:04) M4SUA5IO'@,B3ZH#"SWEK,J\VO8/ST%#4'^B!2$XJ0/'=@5@YF_4.L?+BV^)H MNV2PV-1J476=%-^2+;]WWLG9@'KE6P;FJP9(-1KR>%>;M\#H3XG! M;$,9.U46U\4VL*=ONL+JTTH;?37OXX_E4Z*%[%>\4@JOQA5FM[?@ [T')=5. MSIZZP4!O]'#FST[KZR#E*JF@,=@SL/0K*.*[Z_F,F<\;:WJR XB+<4LH97K. M>(!PO6^.N[RW7VG &4=[K[/);2;Y0P-=N4NM=!3PZ$+6:E_\8)K)6+WHV,3K M3>6 D5HV5Y^&SE:-^>&HJ92K1]2KKW%H9,$YD%H2K[_&3POA/"TCZ5DOQ_ZB M?")*?(=(0U!=L&L9%$OFCH.OFW0\D?];^]B[-C0\(4LS0O \""J D^$CC%BU M^L,-:_"3?Z;MS-X8C-Z?[_7X@1CC$RI@XQ&]J^[@#5(&%>"HOU5(!;!3 33K M:J,-35\#N>XG)D,T4@2QCKRQE(T&L-IY4X[._L14*5.O(]1)>W MRAU,=-J3ZIR=[I-3E.^>%SJS<6F'"H )]N8@X*#S_K?ST?1=+ORTDG_ND=V? ML_8@-#I6P.)'09]*7@]01G L]81&X(&3D[#7W1A[ 6;NM.?;.@D1.&([:TZF M14BZRLB;G%?> Q7P,K/QU"&^AYSG$FA?,H;])[UU/3ZLI;>LK.]6DE51<@VK MN.#V206W0/P 5NFR$A*M5.+N).ASS$O^'OZ7W%>7$2A3J/%@9TULDO[H"Q4< M!@QZ06,!-YA"JH59^H?@L57FJJ!'5$#K"CE%?$A))[M2,$Z3P\CL5P-7_Z'R M2\RTO])1Z,=U4;W;#[VX::"T!.1!9'0E;CAXS'S!-S1ATK*G>' ">VF8AFJ: MS%;]L//Q*%S^LG]O=&!9#^&;=TP'2/^02P@R66#V^>67TAJTVR__F_^W!L=: M@;7NFR"SY^^WNCM4)]I#G?!H,KN]N]YU&W#Z+"8@3U WK-E.()O?I,\Z]AW\ MVN?N%ZRYCH9:]$Q)6TIA\"$P=C%[\W&.BJ![**+3@Z4HU+H-75M[H60.6S]< MDY77"17#P:V^Y!4F6N4NRY.& 2JJ1);#F.:_;01%)Z6D)[K7E^S6:3T M),_L2=[SA=R"E_[:RR&FU57F1,+2U(*Y%%EM^^+>J8/FCIMP@V5>Q"]J),W'(56WZG8-_:Q[VD'1AQ8IB5,?,=IF#7Z M Q\O\N>N-GQOGLL+!7MHN"P6AKKC7WHCBZ"V]X<&6];%)'.-*W697QGIFAS2 M6N'T(,M\'A6'^90J%\L#8[]!$M=*K&\1,F98K8GJ8#87C<9KGY[VN_3*E !L MI!"G3^LS/#V.9$ AA0P#3S56N1HRUF-@;:(]S$"5L%!CJ?)[^V'<>)6AQO6@'FW,#HY\*RRW'0X MG FUNKK\,CDA(5GP:D%!0;K&R^/^3WZQ2'#-C6_)$A#IO7'H8(W[E=JKL9G% M7]1%HKAD#B/U 0Q\2$_ 6;[=6MMM;9I=L#MV7[C*MZ<_ WU+/2$K >'E<[5= MM.-F\<1JW*G1!\0,Z+S;0'ZGB;;K5T)= 9FUM %$9!BX..^PN%U1.\WHRZF^ MN /99D.OC*NJ;-KZVQ;"@S4)W8^_]3+[*H6<,?9G29^\V:=M"JX&RU :"*$L_ZJ(6/+YL>.--4HHM=#WJT>T9AV,"KN6>L MZ-K:FY;4?(YJWKNW=;9QN[ MP%PR&JJ8.K_DF=09P6>HL$2\H(:^!I=ML[2+8Y1T[%-+UA]GMO3G6X?L40'' M/+% PA:]82FY;7TK0@-$,9C@;=G1&J8"X"*W"L]0O$6P;^C+@/7__5ZW?_L^ M[0O1E(DB%1!?Y&P+5EZF?*Y]!1856UR_YZ'Y+EC,<.G16A(SZ*[).#>9I](E M^UU$M#!DK8_Y"=A,STX(,?MZE6#\+4E:G&8)?_NIK<>_2Z7.']\B\Z,"3O#@ MEB:I@+X.]H]MJG"Q,5+F< H:SR4?8FIJ)R?NN/LV<^$E=\^(^M'F%]=BW\;; M"W9&M6?3L*" M48QRMF[T+XP\![&T4-:%A93%+09O'# 6)S)62EG)V<4QA MJW)0E#'4M;W#.5_P)HUF4V A_YBOXB\&&#$%H[SN,\I!-?[9U83;TVL>'V8F M/GJ2\YP]ZAQ5[C(E9L8B3:U6W#CKS$SC)?B^C9[B7A44LH.[V"C8:YHOA@G. M7^O-S'IPDU7M:ZL;IEH4X1D)G5Q&HKU^;=7D YO%(6Y>?]%\-//7BR%,O"Z9 ME,'&V6MIF2,FR^3$/?\KCS_ZMUH[F8AN$:^:"I-#[8?]5VU$0V/2LJD G8GC MMUAC!F6CN\X=R]+HT1G2>\."CN=_ED28JK-M)H7OFY#">^;(_OT0M^!='INU MV+7T!9?RZ:^<$ [C&9.644=XX.F[8,]S)W(VZMF3R\B[G>8 MWQ;Z$L9X\0N\_-S0T@S^<$VE=\*4!G/Q,\FR6,/NIABULX=/'UNIQ2B:_493 M:R@W LKL_]Y.L9./>+\US]Q8L;>,_%[Y>KDWI %(.;>GOU/^_C*N,>J[408V M_CU(KQ;AS0T7+B'(\*OQ.?@V$$LLWRL%LQU7:F-&5KH[1R,3F!8K''WBGR_- M7@UW>UX/ J@,-\&>[;&&G,?A+03( 55I_4$;1-#A28=^.]/L@@-&O_C*\Q,^(5 M?C9BG$0%M,^UC61I&^M(>W5:ZM*DU\%/TNOW4.MW*/0G4GPSB$I[0$H[_ Q2 M<1UK-% K^7Q(R#4;V-:@X:-O;B7$E:4A>)[\F.?NN;J'?!'"F0" M3+-*#I* MMY=6:<+T6.LD$-._>'?J+LK?22>]=2]E[N-E/7S.HS^::GJH_BWY,03QK4]%G M^9+3SW5F #/:S>P*N>[HQ/O[YT^E%X5J7A28'VH*^:'?E7KL<)M^]]+/"#). M+6SN'>^UN9W2PTP%0&P1!4AD,9O,]5RMAP]GO.:!IB M2#F\=C^ENNKV$BZX9T(!551?5Z6R]-#7V[3Q:X^?TS"2/]^+*%:7,1]."*B84$>Q\B[QWMJ[B.7727+U8;^$)1=5F6.;5W7SZZ$[AY1$6:H(HQA.X;GWC\1D95$RA<\(M69 MRR;(7PR3,87S'0?072HZH)] Q[]%0=$?4U7Z:!S6]&W1#&A/8=QCT+T]-.C! M^VH:HY!:HJ\H@*J"^CI#W(LTC7S,1^,B@YPN\)SARDZ855:D33% ;UIC^V"# MI"]NT#6LVF4[ZR%;EM+\&HN&!!.Y[J@;5*Q; 5VA\!U,BEU.C%3YRD3EQ.N$ MVW8.6J& -\]L?? E#W]*)/J7=%G]23,7;U $>/: [HBEYL&1V@W4E^9U6 JO M8&B133;&BDGPD?SG7O2AK'MIOKJ0Z=:F=A%K']/AD?O"3@^X@.)*B2XKPL+T M!RRW'ZPU5*RQIJRQS(Y:%Y83&6T)JK9XYH31F11Q'WLW"9YP=_QY#?6A!0D_ MO2!COI%=CIU+%$Z?2P-E9?1[RO9?[VE5"0WW;<%: GT;=TY@:RT6(=W1F0DT MZ,9 "+ZC%W8%WO XO#=@''!9FH(7-@VN](* M"34->/M\_ANM^R$<6ID1G*=N/J5W,UK\QW7*SUQ7&^P.$VH,Q?8>"K%2N>D] M)I075'3Q;;OOA8Y860N/N=/R@1Q/(^NA0;1-KZ]-J*L,Q-GIWYD!C52[;5VY(FVN M CFK>5W&A-^YW#/_9.Q XV8Q1XA[^).G@^L+ MJBNW&TGK_NE5D*"@M]B3RKED^U.7G[?R&"NK[?]ZLJ,S)C BOT"IBV*\I_F\ MT(VYHWV&\FG\E\+Z"Z"\ -:0HE,;F"X*QXM#:MR'+DJCIEM:&N)9'\3(,\.LZ9>*OQRM*)).$M*7NB&\O=I3PW[ 'DH9K6WQ%RS#"%?O M\WB82R(VQ/TA=5S3)T5'NI8GR7?TER./?QBTRKY1@VOMJOWTOD MX>H"VX(0+-'(]]KWY:#LB;C(@,EJGEB2Z ,H%8!"D@PSNM4)GL7MJJRP60$8 MMV)+-F>MR@-HPO+>Y0\%=3[L/C,#.OCB54<14E7Y4L#D)4*X+2[#45O^/W:GTMRA?0EE6%)H97 M_$&/068CAR5&'ETX_\Q>%U[U;/7SVU4\?%(^N&KE<_UDO>U[SU-/2GG4[=RG M;2::C-Q,V0U>3^O+B%Z/K]1@ !G.YN4C-RZ7(S]9<4BH<;_D-(WR!!C"Q$I- M?#!$_>T]HO+27$!1N[HYTL*5MV',3I\QYLO1(XPW@=6*8O\LO_T^KAJ4WOI& M9,&'QMD;0.8#PYZHJ+8JU43&[NGS5F$O_P#.;<*K9*.]Y6<-!=R$SF63;+LI M4;&WAYH:I)0N;XEXT::'_M] .AJ8;>FJCD"K=FN"']PNA )[Q5(F^W(/QYW2 M* V(A.TON)X<%BN*4G8[_\JA,O4]W5*GQPU+BC4I_%*.8L,'6E0 ]_8!9XC' MIQG;2[Y%-U<+MSL'B(WWP2]=\^"%A%G74K(85]2-P^),V@J^7C0+<:+U[]I_ M@>(-,+ W#IA&!;8@<+T$F'+]C)5UTI%*3 MXU$&"A5)SV;4^NT;Y4 *7V0PS%LUC='$G0KX8 D;RM#WQ;=N)66^&*4"6"S=;TU14"$'KK9=XK.J.S93FUV8 M6N-">U\XPVE2?<2V>E%6QQQ9"3*4??V;I6C[J/2P'?F,0[-E6YBPZ/G<>*=\ M^?V73"C^5#HR6*:W!I7V+?5NA;MQH+0K4)Y:7Z;HJ0:[.3!6W*Y9QD!C* M_?*U=_U>P+0SZE"BF_X'&U=4N'II]SUH6P7?$)43)PI+*>HRT'H>,&E M7R*F6E?H(;V*QG@+"E_Y8D8W\]+,.EOZM]K(N:L=G6X%.#=%0JF@X($.011P M9"HD%#PV[)"_'Q9F=;)#V6GNZ:+=94*I)%^D$9"F4K5+$+:\^Q9SB2 P/(2T M.QX *U1$%-/T-32W#^VI$^=M='W(S'SP\V_,7RIW;1K;4J\O@UU4Z/ MCVC+.WY"U4=Q66CNZ<^,I80$+F2Z(,YK4@1A@Q=Y[L.EF'8AFS^NW6CX4Y'P M&Q4: Q2H"%+NX=F2;']1K)X7UUP')RRM%8]@)OI*HM_F9*'R\YJ-3V6]]_F*:OSK\T+SLK:=105A>45%G4-&&A?;UCTFT ^- MX)'O"=%2[RU/C)@X/NIIX[_GF>2Z1"]@6-G)WCL*DZ("?CT[_65--9I<6['? M.63IYM\6YE,>59Y0*7 MN!$^^&J' U/8)B(H;4PANAJ#[=WQ<9\9GR:A4/?:V>>P]\9&S7T<>4V/"KU4 M0Z/G4*]X8[#KS-%N41?$CNN!$D[REW0;Z_(QTMAR;O/)=;')EEG"#+IUCD# MH"?J@MG^\+1Y?D5"_MZ%,^S:+$>%V<+;#-5!-+0Z[^(Z'Y:>SCTD8*=QR_ - M34H.Y_USR/3_Q\ ;&(V/I8A%JEML1,0!(>,"/8AW[=]D<3^\2#2@<8V-S-_0 M3@54!FD>X"3IN&(/05FF A#S=8V;_4#RN@0]6C.&_2&R$"2]JY0G:1U4@ $5 M0/2DATJJ&'_/5:)4#V@L3*#]KJMN?ID&DK?+Z'_7_;?=YO^)@4'(%)!@_/TC M37@$]U(!TSIT'\_9__DLMM3)_P!02P,$% @ <(FG6. \J>>#@@$ M0H/ M !4 !M87-I+3(P,C0P,S,P7VQA8BYX;6S;/[M#^B/P1^ W/!"Y)N;?_O#7Z[? MPNP/__/?_]M_^]?_!\+_\^NG]^!UP1_NY*8&KTI):RG M[R^!?6M!'\KRK_G M7RGXN*:U*LH["/^]>>U5W-0B#$/>/]7\M_Q0KA+ ,4HA2FD",$@*9 M"A54 0X2KL),2'%Q\Z$I)"F1"LE4IFE__[0^W=7W_IU]^^?;MVQ^_LW+]QZ*\^24,@NB7_ND_=(]_ MWWO^6]0\C0@AOS1_W3Y:Y8<>U,.B7_[/[^\_\UMY1V&^J6JZX89 E?^I:CY\ M7W!:-ZB?Y LSW'ZAWFS$4M_=+:FS69^?8U]?BZ*FZP6^%CLR Y;7YH/W^J>.C!EH MQ)@V=#K3/6!5?J_E1B\QC;5\,C3(Q;_]0?^T>JC@#:7WJ\]UP?]^>7]?2IXW MION36=:JSY>?/O\N[Y@L5_7V^[N2&_B7SSVI9CS'P?[@(%9]1#U+614/)6\7 M-LV%6=1;QOZ]H0^&#("6 _"3YJ'Z^5]_V7'N YKU\JBLO0("OK0<_']'D2GX M$UIKL\ 7Y7-I"^XN[4Z#*BUN(ZJB%6OD[0;3O?$+[S0OLY]#9],@"J+NXGBU\7$;TD[$9JM/X"B%++4'NX! M$?>^S9>N\SF7UZJ$LM=>[RFB@ A5',,Q(#+$,(T@2[;82'K&, M9"Q*,^%B!8Y2FEG[.[I ?K^7FTI6;MI^'!\[+?YSQ3W]PC2%-=LL\;"65VJ?PC5E:WFME_E?->M_7^$H#;(H M"F!(A((XP2G,N.1ZSRDI%R&+(Q8XK>/6I.=>T#M&0*' E=Z0E_W7>_B==US5 M[6&U7-YG M#=D4&]@Q -93[&P/J]:>K_/M]H&_.JE"*OWU)NAG[\G7[/[Q[N?BW*LOB6;VY>T7O]E_IQ M1:402NH=@HH4AQA'&%(98ABE<2!XBH3>+;B8 A?B,YN%CBQ@/5W .\)N-L$) M3SO[,!=*;K;"<&%\BY8/T#-R 7KDMKR 5Z>0<[8<4R#P9$6<2"]J4:: \MRZ M3!ICFJ7Y)"NI7[J]W(C7\JM<%_?FPNU-NU-?96&F_8L@@#'F&&). D@S%< D M8 %"H0P0#U9?9VF:@K_;\%+22KZ6[;_O-E?WLJ1U M:T+RFJXO6567E-#(B#H07M2CN@#PW+Q-&F.I,K)L;:EK6C]F86CK7_A#QM7%. N4"8Z&G:3>?(T3Y!9V-^R$W_;PY)51O5.@FK'@F#"(!89AYEB#"81"D@@,*8S1F M5O>>HEX,#4E73V$?$EN7X"Q!7=?^3L:6VD5[N^-S>3\JC+=U?)_"P@OV41'W M5^;CC[IIWAVM\M7[G.L=@U[6+V]**HK\J5Y@R3 ,%A0H3B!.BO7H:"A@K M(C**I8A":J-\XV1FUK\M74![PA> G[A6=T%I7!_]R>YZQM>+?;D3^U0T@8O8 MH@NS;J);%A#_";UY8;"V3W;2M2;*/&OL#@ZB*&ALSXFW%S$_=A+T%LCRZ8D1 M$K>TE+_JG89X5=R90XQFIB_+TFS##9GJU\?=,Q_IH_GL\ALM1?._:TWU*RP1XS@KP7%C(G M+3<3++E8-8/^IHG7K_4F[RW-R[_2]8.T,8XCK\]LVPP=T! "M#)7F@T'P+!@ M9^/&)!\W49Z$GF)A=D*"'0#G6QH+B0X8BDKR/]X47W_1;W<7Z5FP?Y21H=U9[31UF:_$.3;W?%UOE-H_GFYH:;5)+\3C]R MI3[K3RO5'K&TZ3MH%<4HBE3*8)!ED79GA("4Z[U9%C&AD-Z5$1*Y'87Z86SV M(].&35#V?(+[':.@V')ZT42+&UY!W3!K3$(U8-?U5-73M-F>OBX_&:ZGM V' M%V#+(Q@P":X&$]'S":ZW$S%D]0*TS/H\T?6+GK>37T]L+7Q"[!?,_9-DS^-/ ML\L?S496^UP;T9RB?2RJNI1U7C;NE_&LJH_%.N>/*QDBDL5) M-,Z+UD:BZY M*4\@2;CD<1*Q,'&ZY+8E/+-=?7-WORX>I02OI7_+\>]/"_/E1:R:I*5K^5156M H(Y58& :4Q2B)4,(<,) M@5$4*D9E*)+(R9D[17#N>!E:W0(]A54NFC@!5V_K)%Z6AL,C"HX&HZ,,Z@)T MM,&.^ 5HR'NT"9:"^K(%I\@M:P,LA=_3?=OWSLWR^R1Y<;/)_R'%.Z$)YBJ7 MXK()'NL("VU_!AD ^F\/=]K7>9JSIF(>2TX4S$BL_0Z12,AB%ICXTG$]-:?0SR1:'G6_W-2XF3EO ML[)0'J-7.+TG._KA[H4R(KU">SQMTB^9:99=[Y!DJ2FU01?7]/N W@=9KZ(H MBBD7"50!4Q!C',",11S*2+$PPH13XA2D>(+>S):WIPYJ^GUZ4N4IS.P,HTS' M0(Z+0QYBX_19^H@7ATJ$7(#ME^#CB2^!LQE^D)%IN7Y@O,R M3+B'54:0/ M#TT!%QP@' >Q@DDH.,0\SDSM&P$%CV*]1U-"94X%+[QS./.6KB,+Y([N!9!: MFPIEHBGR0H"?\@VH#,_.M36]SY;EF=E+SH'CJ9GA S:,@"&S8, M8(]@^%S' M,6A8O@ =TR:V8C"%+>,+QIE.Q72I(%-G_GZL"-.I\#J'ETXFY.Z0?'I82Q2P M&&GRU^7=IA9OU_3&-K3T\-MSAYR9$VY#%:(G*JIWK'?&][.]5!@1_[0+=K[D M;D;JM-#@B^' DZLU+MXD[^K(D(LY5.,B#7VH$T].2.2;K/&?S -7ZJ-6>)-@ M=2/U'XN'>A7&/%8B#*", F0"%&)(XS2$+,0109(23*T*D<["W=QWC\TZS)IU MF _7:_ITO:X&S]UWZS5MU^OFN'1+PO$_JN-5Y\:F:XE7]7SA+ M#MF5+SE;TY(R7V;6W+(ZYT)U-!G4.]'E!763[NXC]LW5SK$>=V?7>, *$Y 9NB!F7+"^B9W)+.=6.XO^Q-5V?WM*'8W" MW QL3($LN>&/[:;Y2AE+M:;YIJY6S'2'$S36>$<"XD1(2#(JH)"$R4 R) *' M>AJGR,UL)5J"9@GF6Y(NA25.HF7AJ'K%P,T(&-)@0+L_B -7"KR:!Q"7BAL^ M@9E8>>,\@!QK<-C*.UZ+X^0H"];DL)7H:6T.Z[O9R9DLG\_F8U9TEV]"Y@+'P69D3@-XJQK\M.-! M&Q>QBA"+B.F,RR*E_:",Q9"%80()#;D@.$E1%$P(=K,DOTR86L^$N50=E,,M M]EJ6M!6%SRX@?!!H.W/B$S>OI8.?MS2Y'(?*1]7@,<'G*QE\D.I+UPL>@\*B M6/#HZV?T-]KOH;2CLA((!1$1&!*F&,1I%NF?X@0R&3,<18JB+'9N<#1&<>Z@ MC=$ZFA-!LK,*7D5WLP>MXA_LA[@C[[F7D8VD/IL9C=);OIN1C?@'VQE9O3@Q M@;HLQ .O_];<"M2/#26Z[C,X5Y)$-#+%P'&L3%EPI1T(E2DH!$\836F&")[@ M18Q37<9Y^"SK>MW6 -W5#C&N)_ S4[]/< PL<K[I.E^#CAO0 MLP,Z?B[ UL]21=D'3/E,LK:"P5>*]3BQ91.LK03?2Z^V>VOAF-!M&:\F]KH/ M;VJ+R[S.O^9"?\D^:55=R8!B1"F"G*$$8HQBF&5I!%D:2D5DH#AQ2[>>F^.Y M#SOZ(DZBH^G:G77V&;,\,/F1YL'1'IX?-SHHDC@08U"BJY<$?!JKF[A<)*DK MZB\=66K-[S]'I*DK_-XB3YT)3UQ'Z%I67?G4UWFIAW^;;^B&YYN;]\:5J)K_ M?Y)9\E^4[O[U2^R6OYWE!\\YVO'TQ2V6]%(;[EZ_7G/G+#O-GT.RG- MJE+*6U/%[:ML/VPVBI49],WFX:XK/[:BJ8@RKA",$QY!G,8"TBQ#4"@ID) X M#D/BU#SH1<28V8;OA+H .Z':LW;S22\7; 0#/VU% [UL/U^ K7@F'J0KEZ'W MXT]$[#__LI,2#,1T;$KP0E\IRQN5'_Z+XGA!\\-_1]SO?EYTBGQ=);V,$,O> M3+WH1.U==+TL-V[+;U76J]_I?Q;EJX>JUF.7U>7WO%H)@C&-&(<\4=RD]2"8 MQ5$$8R(IY2$-,LYLEL7#P\^\7/6TP!=#S'+1. +$N#$_7SPW(VLKF;6I&Q=@ MS 3I-P?F1_^V,SU'!EW$)(P+U*OJB:>F>;"#^ZVNV13.),4LPX9 @K418 M* 6S)%#&WPQ"S@.5$.7B91XG-;MJM6$6D^N]C8!DYS?Y$=U-[9Y<+_<0S-&C M^K1PGKR"$4*+KMRG!7Z^NEJ\<49KV4K>F.7WS3J_ZZKW_"Z;8A-)%*DP2#&D MH6 0HR2$&1((,I9P$22$HP Y-YD]1FWN[=R ]H1>LTZ<>GV;P^OJ NR-[_;7ONS'3*$VDT+N.B,4!Q)122$F00I0P)242 M08:=&A2-$9O9])FJ7@ FQDJ-G&Y3]!_U:)O$L\\ M-M9V$=Z3H1DEM:BUL1'ZNN>,J/L#)Y5-KB&M;M_JK\.?I;B1O]%\8SZ\ M-%\3SH=48=Z#[ZP'[?/+X6HXWYURR#8,%YF-:#8_EYL6MW(=G $>+@OBBM5SI$,_H/"DPXGOL MJ;>Q&WFEVJUG=S\A1!8H'B+(4:*W%#*(((L3#B7'E"4,QXP[WL(^)S'S@F(( MFM.+EJ3KQ>L>'K87KN=(Z7K1.A1PAIN9X\)XNUC=([#PA>HQ ?IBJ:6VA,?M?M8^ZDKK/?V88PY%"P6YJ*!0T81@:;\<4CB3"*$?6WW3S$S MLQ9?WIEC&'-HV7<]VA;]X$\VG-UU1;OQ][?)/SD7YV_G?2+L?>/.&B[V]N;5 M]B^:P64VYK8P+; %/\G*#[/9M@7-95MM/:9[<.7[O,YOFN'TWETV,844DP"I MD$(24 )QIAC,,HQA0IG(& ]H$EFE$!\>?G8?I"=H3L"D 0G M.[_7C_1NZK6CN3MDFR-P\;1LGES1$4*+.IJG!7[N1EJ\,5/IFNI$-Z[?3#V= MZMWF8].I[V\RO[FMI;@T)V\WLFO5)3^6.9^-_,I:J@..1\Q^K%H[_*7&NBC,#"],6*^VY M;JK[HFPO"TW!Z'O#2^=(Z56$!IE>7O3F+&YKI!$E%62$2J18RN/,Z3!WE-K\ M&[4![0OP5=[F?-UUF2[<:Z^.(V=GRKWAX;S)&Y %6[HS.*)6$GJR:..T%K5! M5F(_MQIV+YU=E:5\G6LJ%5U?J??%YJ9)8&]+-K_;=&GLS[+=JZ;K]V/[_UT# M X*IHAD/8:64S(#ERY:-"D?9<>SN?#L"P#L MU\YH#4U[K6$DZNIGG*ASOMADVAFL%YX@-S,WG)D2].R:6=K#WTQ77\9D;^(N M0,LR^-+].TLCC!FA]5^!Q!N'+U5>Q#?$([5#O).:FA;]I&3)[S"E%>$)V0NCT9$V\)W>X< M+)SF/1FB_>3OZ4--,V>_4WZ;;V3Y>+D1SS=?B2(J%'$ 22"T.VJJ>M,@8% @ M%3",8T28TZGH"*V9S=.6\@60VUV:\2/K0B\.FQLW"S2&F9VE\82$FT79$FW[ M!,RX6[40SY-Q&*.TJ!&P$/FYLMN\,C'65U9545[=-Z70NMJEAVJ5KC*:"9DD M7.\U(P1Q''"8A4K @)-(!%&*HU"MZJ*F:SL-MR7LI.Y;\O8',^85QW!@6\CL M%'P.(-RTO>7 G.YW/+3%D(_50O884NPHNJ] 8UNRRX8?.X*Q%Y3L^O[4MD%2 M[[-,@IRL5BG3V(8)@RF6VB@TA=E5HB!/LQ#3*$8HI6[G4K:#&B AIV^3Y703:=[T:Y'99K0L&>?>6_M>09#+]R,9U^H_=8[!YZ9J$%Z MRFZUN 01A$+2"("J))$:Y.@'-*8A#!+]7\H$ $23NWUCA&:V8/N MR8(=74>E.@:0I8)Y$-M1V?8EGL%5/B67+ST\1F99G3PA[)Y^GGK^G)Z8[8XZ MK[AOF+.$WUUA<1F"FFE\1,T"!F:8!"]VH;HR1GUM\K M+TUT+9"S4V>_>+@I=MNV6.$GR!=IDV !SNEVGUYC1; M\*K8-,52_Y;7MWWQX[ZDZN-*9B)2"E-(D2(0DR359B#0OTH6"6T:<$J="B.. M4IO9 KR62FK$!"CE5[EY<&R0.8Z3BJA(D-XR1-(4)\*IJ0:;!)"E*&.2(:DB MM+IO@G ^U[2L%T;K.>7)F)F4N)M\8RK5F?M/_>4$[=@^P40LQAB%W)RXZB]= ME'%(L,:629PQH60B,]*!^68C7@3*GNX90)K>>;-!:+<(>0/%;?WIR8)OFB[H M"5]LFS8?KY?GO/)82>AIT1FGM>AZ8R7V\Z7&[J67:Y]WK>=)MCW1TZ?YY._9F7L?T%R]=OH'> 'T[X_)RF+I9(R\M M]!I&?ZP>>OO8_4!-] ;,_=-UT=L'=HXV>@>HG+'9W[M([Q(!$QQJSS6&89I2 M[6G%VH[*&$$:H"R*<9#&B5,BX BM);;W$_;R1X!QV,2?+^Z4W?M^5*C_HSD+ M\7SNUX]06GZC/B[RP1WZB5O]=X9=MA7M'-VKB?%CZ2_.C[.@8#0 ^U!Q@'^(O#6OS MA#6?"8\OWV=!M>?-G#G<-./W2:YI;7+:ROJQ26C1.U.3^];4RJJN MU."S5423+(EE!I7V8TQG$@HII1*F-(T1(V$<"J=VZ@ZT9S9R'2?@WK "ZAW= M"T!;;IHSI-WGX"?M>E:@OJ4;QP1E%\#M+-I,,+I9L1[!A@MP/43PFZ,I0[B9(,G%ZLUWR1],]XY7FMA-43XVA:DL;,C1 MEV>V%%N:H"?Z)SO]/R[MN)9[$=1-E_=E]%:,ZZ0T(W6&]+N=4G*QT\7C(RZB M<2<%ZO7J](,3BL1?:AC"3_*^BU_X6!8W);WK-M-)W7"K%^9-$'BKI[R]]&!I1"A) M,B@CHHT6#@AD+(@@%QA')! I5TZ1$,X73"?;@6#BO8$?_ATPPV(-G:J;!_D 33W?SFTU367A3=XW8--4F53N7 MU> P5_M*) YBF'&*M=T1$C+.*,2*"(91%@78J4>!'=FYSVX?[NZH]M[USGO M#]@Q!'J.'$]H[3"U/)#UCI3C^>LX,N#+/.>L3E+[.E:U([KL*:H3$'N'IFYO MOU"%R+X"F&61R)0F.$E22!0/34L&T^T^4U!F(.G,;% MM)7L+,0"Q%"&G$. T%(D@2, MQ9%3\<@16C.O$0TI@-R6@S%H[&RW)X'=#*TA"AJJIB::H7L!.OEG"%6R$-&3 MX1JCM*B5L1#YN4FP><5OJZ_7IIJ/%%V7OX_Z&U)=BO]\J)IF"O! MZ_.[@9W+KY4^D5:?]KBVUJU7M\:&&Z?#V'7CO;"NC:*?IF!GSYJ=77K12?#6 M3.RGENF?@>D;=0$ZYD''/3#L]]V_-=M-O-1>%_"=>!=@*)$Y7URJ,;@OU&?N M378VFS]$WS)?8-OV-/-&;VIYE4+OANM'0[@>5GO:G*D"]?:KS0#FI'K1[,<%!NSX6^BNJ2@$4L)A6G$B#82 M D/*N3&T)%$HR)(@=JK%.TIM[D/7AB38T73J/FF'E^7YJ"\4W R ,P#NIXPV M@ODZ%!REM>P9GHW8>T=N5B]-"*=KW;JVWD>?DIW+ZKWVZ=YIBM6*,Q5R@1!4 M2B__6' *,RK-)0T+ HQP'$;V(76GJ,VLU-TFJZO2,V ?#$L@(8'ER"SD^B- MJ[AW3";M.1>$PR'NSB"9@@3%,<1A%$&*]98Q$HSH?4Z($7=* M7+8A.K/9:VD_@GM3D_'1?4-CA9N=,^,;#3>#UU$'6_+^G!D7P3SY-%8D%W5M M7$!X[N$XO>N>=7,I1&ZL/UWC(/SZ.J_XNJ@>RD$NK64&SLF!9E;F'7V@&?CI MZ\]@QX-]6LYI.,;UV3L2CHH\ H+GZ#4G22>E\IP>?;&T'FM!ARD^]B]-;0O$ M2Q,R^UJV_[[;=+9BX"*L I;%'&$% Q8SB!%)8480AQ(E.$BC0)+8*5'7ANC, MFMZS 'X2'1,_FXLYVBUBZQTCKEU^+/"T6\Y]H^1F!78 O1X"U*_R[RT FM"T MQUYB;UUZ+$@NW);''H3]/CP.[TXL/$JK6VV&VKLF;9BZD)8XC2(B<0(#9 H/ MLS" 5#$"HU J'+ !3ASJCAZD,S,1L$0!4.JCK4=#T-CI^WG"^RFWWNRSA#> M,RZ3K_J-AXDL6[AQ5-"]BHWC3\\45'XL;/##@Z%^I9J_5I=?:;XV]T]OB[+I M0KUBDM$(9QSR6.D]>TP89$D2F48 / PXCIA"7L/')S(Z]_%F&UT):$\7J*($ M-X;RMBAL6Q"VB21O(L@KWR'D4^?0\C+D!Y@9-R-F$Q9^(BJ\Y;U):6JX!Y=/ M)K@18,'@[S,A7BK,>RJ;/U9 ]YE@.X=NGTMO8M)TL;FYEN7=:\GJWVG]4#9N MX*?^N+*Z4A_+?,/S>[I^MS$IDM??BE4884$QUUL^4Z\7)T+!3.A?22Q1&L8I MC]V2AJ8P,;-%U]_ZQ#%U>@J2=K9W;GS<[&K3(-NP PP_IF%KP]%C7S;W6^$Q M4?H,R7WE2D]A8=ETZ3- VLN8/F>L:2;HUX;_!]2 MO!.::JYRNBW#>N^F\/=]JV=F?7;:?LMA/6F^_&W)JZO8/& M&ZN$A3SA20J#P!2L83*&-!:A_HD13H*(Q;L\F6=M7$HA7- MY>PY#7=>9L+M3.T//XUNMKH7!PSDN0 [B='X\K2@O(\.B2]*+3M/S->UEF7%;%(7,5V\T0_7C MYSNZ7O>LKT*2,LI("B56VN4.90BS+(Q@JK]= 0X0$J'5+2!I:VAIH M/\+D(VQNF@TYW1SO"F,%RKA)]R"JF[%MB8&&&NC)G6_Z3L@Q(@3@A3*^ZIQZ;F)&<;_):OC<5?YX7=[^\,U_,?S3&H=-GX]V:PD K M%?!(9 F',/X\*9 Q("Y64J'G0>,KX3I:4PLFTM]%E![:=;GC38QQ:[= M=+\MRDMQIQFH:E/'[*M\*V6U0IR0B',%TX!&$!.J-["$"Y@(RA(A91!3IT.X M,6)S[S.[4W=SIDZ?$ =*.C$H7O!U#P3W/RT(\7QE> M8Z26S>VR$'HOJ\OF'7?__KV>H?7'VV(CV[/]58H2P6(NH4I3!K'4/Q$6(ABR M*):"16D<6IU%'1I\9M5MR(&&7G=;9N_2[^%PVI\_1SK74VYKP9P\^6,23'+C M]P9;S(<_)L;0@3_ZC'L0L=FO?Y7EXY5Z4S:Y\+M@Q_>6*3^VP\SWE>JI-\UW MRK)HFCZO']O+YN>7U,.PVO<^DUY<<9@466M%8+'@6A=QA_&U3N]-+5I=U^9V M]U4I15YW06$J8QE-$=:8FI#:( @@"6D !1$QCZ*4I=(IJN80D;G7A8:D^::W M1%W+4!] Q?*N]$Q9'5>)9V+.$">G:J%-W3] MJJCJJBGG^C@H89*1@&8AA@HK K%VQ"")F80\4"FG&4H5=XIN/TII;GW,Z_RF M75D:ZLT5C>D.G6]NY,:]*O-QQ&S5U ,.KKJJ2;;27[05EQ_!E^[?6>IIG)31 MF_H>H[.P#I\0=U^13[TP.=NTZ1NU:\;;K2!Z34T1$WHA15D*,<(99$&F8!B' M&6%<\M0NH_X4H9EUN2<+=G2=TTH/ V2GNS[$=E/= Q+/L-*>DLM?]NAA,DMG MC(X*>R!+=/SYR57$Q .O_T9-(&3]V&2DZ$UC*>7WO#*+T_.LE9542BKM D.& MHD@[QV$(J0H8I($B&FJ4$(;ZZI&6)Y^N/%A]T9]6A'33\+889%."^KZ4L.<# M?&M9-+$8/^4;OGX0YE.^>UKJY^XT/=?@'@M79Y]$:[+:CU MO98;L^?N& 0]AZ!CT12XW<]Q,T>S ^;[M[SFN4V&S%]1+D?Z2]?HF@;/@9)= M$PRB;J^VTI_^M!.^!M=T:*.94*Q3 03$&/ZRR;5G]?DOG1N>$LGC.! PR#B!F!DS M@%(.HS@C2<2B@%.GZOBCU&8V #O:H"$.&NK@)TW?U4D9!\U.][U!X7KT/X+" M#%L9*S&]-:8>H[5P*VH+L?>;3]N\Y'YG]59+46QD?XGP^D%>%W_-BW5S"G>E M_ESFAKG6Y;,Z;AA"G1< 2\N!_BW=-:_F3H19?N0T(]7ZD//C--::Y+*N0=+?]>]35J M2(PB@BA488(ACD4 M;.-88IDP*,DE3QRNG-_3F!FY=F1M&EO^$4UZIAPS[7JZ'-G!2U7UT672&52BO4W^N[=YJMLFY-4 MJS!-F4HC#@5I^K\%&:04Q3 A,I(D4BK-Y(064#:T)QS>3VCGU&8_-@&C\B;G M(&\8,&?&E-?YUPG%XZQPM3R5]P73.7'.E7%P._I@5U-@P(+WB&PM(R5Z:H2-;G7YFZJIM_!MQUW MCE$!9TR G=V9&\^SRT1MRS_MRO*8[F_=1:!!V+1[&_ +KMBZBZOR&(=P/DR^ M0A7.X&39:(;S(=L+>/ PY%G5\MLN;YKDMB3W2IF.[%BF$*DPA9A*!$VRE[9X M840PC@033D5+CE*:>;?2$FS,U3U]G!3 = 0A2T/D0VXW,]/7QNU$;XAN"VEX MKX9_7#*_)? /T'F)NO?'Q3U2['[D!>^IY2;"\5U;2%^;D$]R([]=E6T RDH$ M' E$$,0DUOL@(@6D@=X6!4D2"DG3-$[<^F!/8F/N&X(V=WK=Y$[GN]QIVE6/ MX9HS_7G+FMD5E(8Y#3^0#7O>TM+'9L+.<,R/K^/%P5A:NK$O!MIW V@_]="^ M&8?69UZZ!3+SYZ6/,?&CY*5; .60EVXSVM2^ -H*Z&U?E^UN:L6M9(0S050& ME39=$$N<09J($/* *(E4(%#@5./[ (W9G9*68E_NS+6V_SXF=C;E3$G=#,96 MR([:15/$T6>5_J/">"O*OT]AX1K\1T7<+[E__%'W@(+K4NB-Z6?)NZJ,ES MYUL(/>GJ?FS<]GR;I9$.VA*WUHJ&A-_)] MLM@%V$C'(@ 6L-DYV'[!<+Q=,+2A(0X:2A= TQ]<X/3*JBU$[ >EU\ MH_J;W]PW=&4%WA<^*DFZ ^*K9<1I@LLV?[ &8*^-@_V;$P__-W4N\O6#J3.U M\UC>?#?)?E*\U:*8FX:'N@LF?$/+C5YWJH^RO8MH7\Q!NP-]S,]@\!H&QBPV%0[ZI@$FLNVE8Z_X.59. M30O"MH[$2[4?=)UOF0B4,I/\&E!BYIO!3&8A3$1*D@@Q3#.Z^BI+5OPSS_A0 M .LY;\C)=A(?3)KBCSJ'EOOR'W!>''?WY[>8;&4! V&ZSCFU%@=T\ERTK28; M16YE^@&Z3DZ@TK_^#YI%6M^_Z M;*;+C7B;;^B&FWI)IASR)3,Y3[Q>8[=#9"+#EHJUBKC?U M'2,>-_;.PGMR1.SI+NI).,/QW!5P'^#,NFB#4DO5]L,_Y[+40]X^OB[N:+Y9 M99QJRQ%B*!(I(0Y2!&FL%.1QG'$5!AQ1,JE"F@WUF4V+(0L:NF!+&'QI24\M MEF8%JIUUF0TJ-PMS$"5C9#Y<_O4T6M,KJ;E([;NFFA7MEZFNY@++T3IK3H-, M,S-_EN)&6Z[7LLIOVAZ@S;%WJ (6QX) Q6/312M.8!8Q:BI$DRCF*0FH4[V4 MPV1F-AP=43"@.NE&X A&=N;A?,G=[, $H9V5?UPF3UI^A,BBZCPNZ'.]/?'T M- 7]K2C$MWR]?K_MYQ.FD=2[A10R(O1:+R/]4Q02F"0H21(SIV37PL03%3AG/$M5-#]VD=%;!HY)XTK[]\1=5O*/B/=>YXP].+KQ^+\OZ M\:.>S%K[]N8 []XLP+^5157I[;NBA!!JRK((B#,1:MU#%"(N. UB3I+,*3%Q MG-S,BGAMXA?!?<="XRS*GKYSG?0QU.R4TQ\6;IK:T[T #>6V$'I/VUPQ> TR MM)/27]'R,6)+5RBW$/Q .7*;MR:6&\YO;NLK]9>J30V\8K5VJ$W&X)OO;?. MMT5YI/*Z9XDJ220A*9"!G,!&0BXA!%)&9)FC 9.27VG<'+ MS&;BT]5?NIQD4'1<-3T5.KZ:>-QU$]>\[CAR+N)TSD38&9>%X'6S/ U3L%!0 ML]7F)H.K <)OA@AOF6OCHL&6/8_5D<_'R%?MY#,X6;:R\OF0[=5=]C#D>27J M-(%/Q2-=&SU>(9IA$J@01A'A$ >(098$&(J0,(XY"U,QI9_V$R(S&[!M936C M1V5/=%J9N2?86/HU9TKLZ,T,A?UT4MC)->,.2>.Y1MP3$B]2$^Z0D,=JP!U\ MUDT1[VB5-ZD4VTR*75NIZ^9_VRQ 29G"- Q@EA$"<4022 @+(>4QUEJI1!!8 MW2/:DYP[<(_?2O&P;G(3##^#Y"#GAFX..(ZK\#SHN"GT<3# EX8'JRZ-4_$1 MW7UY6\]N69R>T%X8+VN[Z"YZ:R7->\;TX2"*@L;\.8RTB#%TEZPWC1/>G+B! M:RO0?:1ZAWA=TDUE8@Z*3;5K2+W[)E/$J1 DA&D4*8BE4I"D&$&)X@2)($U# MYN3(.-">>X/6<@(:5L"0%]=&,O9H6NZZYL'(<9=U%)XGW>1GZ74[ 0!O[6?L M*2_@\DCVZV_;(0F:'*OI-";,_UHE]&8H! K;=:A M$I1"C(F$61QCR!5*94*5"H-X0MW=2B>>C+"YY_4#7Z\>/-&]"UQUJ8AU^>^ZCFC=7H*<*#-EG^2..W;&.(#!N M.?P([WAJCDD29SA& M,!,FF!HE(TUNB*U_9?UDE18)0@2'A MQNN/3*G7&,4PXRJF0:HX)8%;ANY!.B[?YTGIM!W5OMZKZT7)06PL;TK.E==Q MT>T$W=9\]:ZTHP)YB_$X1&/AT(X1,?GEAUH;L\N%)-?F5;Z/G9239% ML8P436% 66QJR9G>6EA (A4/,,T09MRI8,)IF@M>F;3)T28+JT.TJW7NF EO M@2-)B0B9]E]"9)H*,99 @E5L:EM3A1%#F0@="Q'X17*2T7L9+.W,HF=\'*^? M]H!IZ<]RF3)!8E]Y\Q84ETUYMX=@+UO=X=7)#I"2IH!^TQJ\24NY>JBKFFY, MM=>58BI)52Q@8')&,*)<[W@XAF&29&$24Q5BIQW/.+FYCR1ZXFV%O OP/X(_ M!@$"][0$7PTK_P+B/P;@+E^OS5:]JZM''^K;HLS_(<6_@*#_,*\JT^O&!)@6 M._Z=_:LQZ*T=+4^ .GM<'9:?6RP;TA?@R@*-*KPE.8BAAQN2]YOD\APS ..$J1W-43[+8F(($MC!A%B1,HHS*+8 MJ>KE:9*S^RXCJ2UGY-]98&GKB/A$R-49.1L_+.G0'T_F42^^P!L,X$ MVG]S8A$?^>V2-S>PVAQI:AO](V^3[YM&"(_M_W>[]R!608@SO.$YS]I/94VU3G MABHG *18Q1D1&>0RY-HS5!32B'&HF*!Z:XK#. A=>M#X@V]"_QG39>45+;0S2-)5AV-MD?!&X6^%1;V \C7QV?G5\'0L[?X=40^U$ZN0X$=^C8.GQK M0D+5KP^5]A"KZE5QQ_*V+HOV8HJ;C3F=?2>T77?(=/M!YW]:OMR/]SUPR[U[@!;DI_E M\@!? .4GV80O0=_[?DQO"Q_N'IK<)>U[EW7^C];8Z#U8P(1L2D%KKX%DII>+ M3*'B*N4Q(U&R&O\9KB/=T-EB=OX;\4+W<7OH'B)FWA-_<>]A]]! M<]8M_& 8]VS$S_7?/Y;\JKRNRC=5G=\U!NQW6=\6@^;VEKF)-F/-;"V:*"GP ML^UXQ]^.][6:?"SN_Y87P=;11Y[FXQ>T#/\ ?0>/ MH_C2K04/&@2.D)AF@P\"3&4(,@ $G_JS:%/$]F2TGTHO:I2F@/#<\D\:8V(G$5%S_6!8JKU<\ M0%$J40HCH@3$+.60!"8\QO0?H2((&6.Y4#CTRS%MH*-6T0_Y;7MZ\>JKJX MD^5>?1>69=1$2\- **S52"&]R4L9##)$PR@)4^F6DV]#=&;]>MUG.);RJ]P\ MR#;;LTF6]'C\+ZI.6OL>JB;7-5VOV7N]]O/GA5:"!)"0KUH0\S3&.JU6\ L ME0$,A11A&$B4*:?^J'[9F_NH>E#"X5/34$3_,& &_*7:9G=4#^OF6.-OTFQ& MI8"77[4GJ5\9]!;E&KRF=?.GYJ.II3*\3+;E<=6+3:'CB=6P M,/[Q4ZGV\+WCMTVL[PZV!A.]3,T.GWAZ+^_AA;D7J@3B$]CC14.\4G&S_D+F MJ\]2>T1Z'>G;W7R@=W*5R3#B*A*0IZ&VWRC1^RT4!S"0,0MP(L*$IS;V^QB! MN2UP1W+7TLD0M3.21S$9-W,^)'4T5&Y"6AN84Y*,W.GI5UOKH'_8&86C RZB MUJ?$Z17SY',3'2NY7IM@1[G1Z_KZ>@31AP=%SLP+1T2 M[Q"YZF^'SF\#=)[RT)=*].@U. GMRQNP([KL*N\$Q-[J[?;V--/QYNY^73Q* M.7 %?I=W3)8K&:.8A0F!B3(U :,X@E3@$')SAY3%::3W5R[6XBBEF0U$3_>) M-^UF$HZ#9&<%O(CNIO@'I09?6K(>=P@G1?.DWL?I+*K1)\5]KL2G7YBFMZ]E MF7]M[,"[C;8(38Y0I6U$UZ_^DNL_-8>1AQK]A#@E0:RU.DY)U);[9((HR+(T M"U&81(F*753['&9F/[KM60,#WIIEL.,.[-ASLPIG38&=X5@*6#?;XH3I_/V8 M?(#DR4J=QRO'LM6?T[K9O=U:72QL($.+_5 MW^(5CB5)(FWA5)P$$ M,("4LAD@%<2)42"*)K3MKGB0WLTF[OI6EI(:@0];M M:8S&+9)_R=ULCB$-#6U@B%^ GOP%:)!H\Q0,"UXQ<<@?]HK-M*S?\S%RR]*U M%GDTM_;T*,MEQ%I+]"2/U?ZM"<;M:0G79[]U\7!-D&'_2Q.K_U&6S8;S,;!:?!@>:^&H@*;\%I:$-?LHW M0!3K-2VKYD]-]>:?'8S%F?-@85V70]?-].X5>'[V =@BWS!RL?N]31O1'+9_ M60YM![N]'.K3C/K\Z+L9?3]XC:X(9Y)8;KGP@\63M<33D&X+3576J]_I]_SN MX:X[UR*,IE*R% 9*4!-@02##B$$3O)51%65"6!W^[8T\\R+0T;*S-/MBCUOI MLX1QL[D=&8\'=D>9']OZZI<&VU[]VV[+NS_>(GIW5(Q>BXX_X'YM_;JSV*;E M^8HD2:I=J=2T&4)0FRP,661*"'(6!!E-$*%6B?+/!Y[[ *PC!0PM^]OI)Z*/ MJ\4Y CD>/%G)XG0)?8CQ29?/3P9:[-+Y$/O#R^:#?W?/\[ZF[$&[SN_SJGX6 MEV69W'UT@+G/2EJZP!"^ UI^P3NXU*/*X0W@=VT8RCK+%%A5G)-RL8^/NIB M*=@G!1OF79]^>-JMSKO-5ZVL1;E7%YNE+(BC6&@OC.MM?!1DD D10&KJU<8D M2BBRVL:?(C2S.O9DG>]:C@)C=X_B0UPW9=Q27*8(^"D!/=UO'"6SZ-W%*6&? MWTNA-6=IL(+B(>FD#&-&828I(B2!*)8"2# MA$2894%FE0!S@L[,JMI0!EO2H*-MO[,:@^CT/LN3X&Y*>T1FS[LP"]'.V).- MC;[8#LU"Q.%^S>;QB6$2VYO&*S7,XO\DF[IKKXJJKO9BHZO=\B(E0D&&,,P2 M(2#&E$%*>0REWNT%&$4XQIE3I,1Y_,RL\\TITX%"&HYQ$6=B;K>D+XBDFQ$Y MF,\Q*$0R4Q"$'SA\Q4&Q4!%URGFW(SNS&6N8,*E5'_5#_86+8[40._CL M3)5_4-PLTA:/'0?+[$K\Z2(0182KMTFA46" M$X42)SMR%C*UYX_Z'EUUIHV M E7>9,-^SZM5BB,B:1;#2 4(XC!(($L$T;_&$:8B98Q:A8^>H#.W6]07"AN0 M!5\,8<=.L<=@LO2&SA?>T?V9(/?D8FA'I/)<]^PYE1OB@=7J8=TY2%5K(LR]3%\U)\ XQ8A@&$21WNMD+(.4ZY]2 MJK<_&4M#[;&X%9YUHN_RW9Y66K;G!JBB!+R4(J^!WGQ6KO]4"]UX#-T.)HDDX>#(<;K07-2>38'EN9*8-,LWT7)=4:.>C M_+O);6E^,2G\57>UH1*"@X @* )BJA)Q!1DR]]T1)A'F+,NP4S^-46IS1T]L M:?]2FQ\WAK*;01D'R\Z >(/ S6#LR#:I;ZE";D6EV& 4M.#OGY\MS$]T?5&P[2F[[ZM2&"P Q% M*61Q@F)$" I3:IU+,4YK]B,,E(*6.-A2!X:\0XS^";3&==LS!FZ:?5S\TYKM MC(-#+H(_/*;E&HSA\KHP^VT/%L]!TM$L@1-#+)<%8"?+DRA_RU^ M*IJAVYK1G_+J[]T7DK&81DF6PH!'TG3AH'HS)!F,%5*24L0#XE0&Z 2]N>-4 M.NK@"7E@Z#N67ST!FYVOXA$,-YLV@L,,[HJEF+XJK9Z@MFR153O1]^JK6KXV M3><_R:HN?/Z<2];/="TKDY'17&X,(I\08R0(F81QA+3&(J979A)D,"."IIS0E)# M_1;U&+F95;:A-CALFW)!>A0I.\WU)[^;_O97G UE:!YO[SBKF8*_[.3T>D%Y ME-@+W$">$OSP%>/)MR8<(/R5ZI4]__ZJ*._[W1_-4*"(5N0T3;1*XQ@RS@,8 MITE(E!014_:59_:&GUF%.WK $'38$.^C8'$6<)9L;NHY%&O*AO_ +-OO\<^2 M<]JVWDU>MXW\47%&]^[[;RVW73_*\9,=^O&GIJW\?Z5E;E;!3[26S65Y$'.. M%28P1BB$V-1DH4&:02X%CFF2Q:FP.DP\1F!VT]"2 X;>I"B"/43LUO1SY'0U M$PXB.J_9Q^3PM$KO#;_HNGQ,N.EK@BQ+!6"PE))3% M$,@?]*;M^IM< M?Y6_%YOZMEI)RD+%M3W75EV8SI4AI#03,(EBO1,+)%?<*5]O*B.SW]\N%X*^ MA['+VI"G(2@*/U04Z_.;$_TS;-=Y@(/$@*__7Q<(.VKC?;VZ)4,J\?]#?N MW>:CYJ\0JXP&F#',8$!,E1&% KUS12D4VL7!L0A3)L5J(V],KK&=U9B!2RL- M(ZVFUCWHP#M!:BJ:^;U/3MW)T@^:8&SL#]5)XGUW58,CND](&['&LF^6V MC^6 <:"GK67=8_NI^7#UU:MJ!@Z7;6PU'\1[7;!F)#7U*'_]("^%D.*:?M]/ MBDE"Q$5 0X@%8Z9D#()$91', A$%,B$J1$Y]L\;)S>S(O=N(O)1<[XWH=ZVM MY<3;_!.0V9[\^P+"]1[ -$AN" --^4G^D/+KU>M5F^Z2H?\>)FD_]#BG?"Q+RKYN[OLJIDW68'EU)<;L1[_7&^ M;AI%-;VHI=C%WPW^=E7?RG*%>>4CMOX >:H?.J$@P$,+5. M>A' 4 ;0"@%Z*9J$Q &OH!-D&"D\_+O>?!EI_)<[6 9]S]439F;Z18HQ+#,1 MQVH[+$1]0E3(:WE7;*HNW>(OF[SN4X\9Y1DAD=)KAA(F_BJ&+(DE))%D*14B M0\1JFS9*96;'[@E9\&#H.D0E'(5FW ![$]C-7CZ5M2$Y)7;SJ- .X18^A)\6 M4G%@PO_H*4SBE%"CH1!'7UXNW.$4_T]"&DX^//&<_T&;.EK)=QM>W,E5&' B MPU3". @IQ&&6PHRAQ!0")R3A*$ABIY.@I\//;%MZ8B!OJ#D>JC\%PO(\?+)X MCD?9O63OQB5S/W@^*("O,^.G@R][W'M0L+V3VL-/34UH;*KD?J1E_=BFGJ]" M0JF0-((QBF*(:1I!*F,.$0^R.$K2-$N=8GOV2'NMAGL?:> X5A M2KCVI)$,888Q@5*16 D<"!HZK7!V9&=6TT,[\_-/2@[!-_FDXTQ0SC^I #L. M9LII=)-ZOA."0T1?>H<_ H3%#GWL[2EY%SF7FTI>WI2RN8\UG;!761((;"Y* M%,Y,_U#M^I(@1I"A* Q5ED5)9E4/^BB%F6U 1Q+0GB9HCDY-E(E#J.UQ?"RV MV.=*[:;DO7#!S8(3OIYD! M8P].,"7MSN&:?O]('\VIX:!4!XIEDB91H)U_&6F#PJC>2\<2HC!*8DZUL;%K M@'>"SNSA%(:P":8 ]RWI"[ I-O!4<0\GJ"QLBQ\ W"Q,)[N)H/C8RVY1U\1) M= =[XP>":59G(A1NUN>T@*,V:.3UY2S1:1F>V".+QZ?&\ NI\DU>R_(0AVD&29AD4%"IHEB& M-%'2K>"T*PLNW^))-:<'Y5$A^.E#44M '&-OG6&ED78=4YI!A"2#F"42$A01 M*"0*<49P1*-TM9'U"T*ZO:ZOI\(Y,X9VF\XYOVZNZT;/"6Q8 3M>^FOQG[;L M@)Z?X]_$"9D5TZ#PEF?A2'[AK(MIX.SG8$PF]:=[<-@7TL[QILC^[ M$ #M Y,X0GI3F63:NU \@IE((\@ES6@4IRJ5R.4T^PB=F>W!+KVY)^OF4!Q# MQ\YO\""SFW+OBSM#N=L34GE:Z8]1671!/R'J\W7[U.,+)TSV-;6KNFSVY6T MV?4MW73I0'I+^%56M11_D_G-K?[W4F]^Z(W\30]=O]9KQ%N:ETU6P2K&H20H M"6!F"DI@JAC,LCB&BG*6D2S"<10[A6_\ $+-?74F;_+-QBACH) MK:!MZ#JHM:B[%.*MM!>@EQ=T H-&8F!$!D9FT C] Z07SS"%+YV/[%.D?XX$ MYADFT5O&\QR\33TO[P[B=[$&E\S$V_)ZA?3RB;(80X6R"&+,(DAB%L(P1E3A M+"0L2-V*W1REM%'G_(/7T*^YGIF^U!,7&E,@JM,EX?/T@KXLWWXUQDE?JS485^LO1 MV*&[VO;HU&'(F?6XXP3TK "A'=.Z !TWQG,=\',!+N],7TG[0U07\$Z?IX;,Z2!U @"3SE-=Z"QVK#I!^.'IZI37I[D ._-SI89^3!>J_*JHZJIQ M8]C C:FV*UZ:!9)$DL,H(Z9)F4"09EC!.&SZ+'*51=S%2SB/G9D-4+L?8D_W M0X,MTU27XLPYL/,ZED-V^F9T(JC.+HH?+#QY,6XY[Z0IU'=J\>\ MV=1Z)Z:=L#X'FC=T/SRTJ:81"J2,$4119LI$H0!21!1D 2-9K%2&A%4LXTE* M,YNMEG;C^C^E#EKR]@5FQO$:MT->47 S,9,!<*I!8R7L<"H.(_'ZKZSCIF=P*P=H[' M/'"Y68">AZ:H98-9SP88\ $,(^ GPXK'N#1W^3TY%@Z$%W4BW %Y[C!,&&%" MFL/_HO=T(RN]"_M:K+^:4N3%MENXHEA0HIV!,$P#4STRA%1E"4QQ&"8!"FC@ MD#@U0FAF"])3!EO2P-!VB/(? VGM$JKF M_[L:FX=:)WR2)O=BZY-"XU5G"&4<"%A0$,35Q=(2((DA#()HS#C M69R0R"F09BY.9S:*/KJVS#=+=D[7#X&]XT%0TX6W*4)ARN:U7(,MVUUKWN-M M8+;LFBEK&6Y:PW@,*9@;5%]Q K/QN>SE_]QP[]WHSTYP@A?ZJ7BDZ_KQMP=J M;O^E-"4"[O)F8U>]NC7'I/GF5;&I-;(KA;)$*9Y R4@"<1Q&D*:)@@'G&8JX M3+&P"H5T)3RS06ZIF1X$O*7GX*"YP&?AK\X$BINE[)@ .RXNP( /_S M N;@XBC[ MZS+[%L]/41BW?I-EU;/]]MVF"%+NVRYXI%1(HXCB#2?H?>,%(,*4DXY)R@6'L? MF<39A*+N-K2MOH%GEV3O.3#A[^U//YLUH6@BG?OZW;1AR#F(\#2\=CL];VA- M#2OL$.KI-PBUL> =#UWZM]<(0VN1_84:GB:Y=,RA-0@'@@_MWYU8F; ]/OE\ M*V7]OF@O_KI"F$$<<9O"D<+Y*"QXGM&PYP9,"[Y40//W&U B9 M=]H+-Z$V^5?YFM:T[P<6LH@'2G H><"U(J<<4DE2F(8!#R1BJ0I"MP"9PX26 MB8\9T#992?1DTS WL,:5V"<$;BH\5?H)L3'CHIT1&G-DX(4C8\;%VP^,.?'\ MA+/"RR;F0XJF1Y045U]EN3$91-MCS$_:$?Y\]?;3M0:[;9O=,"&KNFVYV-U< M9I1PI4("@S#6*[0(0IB1*(6A$$3*.* XL(KJ])R8[I2E8/B^N88\:%JCC5# MK&@J26!) $$7;:;5K0G'FIZMLVF%OR'0]=NXJ6"Z=C M8!U MO*M6"1(XBF,$M0]L2N5'&21!QB#',M'.L9 J<>L2=39+<]\P#;+=3E<)>985 M9Q@%7PRKH.'5T11YF"\[2[7L+#C>A9U;IL5N I:KK+*'V4O71=DQ],]1U60/ M0&\U2?9'GF9H7]'J]NWK=Z_>;*FA.%(("",PPQY3$D!(N##M0LCT/L-$C^5Z2=SP7%8'"CE)E3*>H12*A"5ZP4HR M2 5F, H%RHC,$(D#IP7+A?K,BC3@I=DC/^'&1X4L-Z@M%[2Y '1ZJO4WQYR0=L5]WFW$!WHG;5?"/RN^T8I\6;]("/C+L M8NOY:=&&R[O%T]-#5@;;+W..*%\9[[A\?%4(N8HP3F,N$R@C;EJ^BQ0R'J